gene	start_AA	end_AA	natural_variations
MT-ND5	17	17	P -> S.
MT-ND5	95	95	F -> S.
MT-ND5	99	99	S -> P.
MT-ND5	124	124	F -> L (in LS and MT-C1D).
MT-ND5	145	145	E -> G (in MELAS).
MT-ND5	146	146	G -> D.
MT-ND5	160	160	A -> V.
MT-ND5	165	165	N -> S.
MT-ND5	171	171	A -> V (in LHON).
MT-ND5	211	211	T -> P.
MT-ND5	236	236	A -> T (in MELAS/LS; due to mitochondrial complex I deficiency).
MT-ND5	237	237	M -> L (in MELAS/LHON/LS; due to mitochondrial complex I deficiency).
MT-ND5	250	250	S -> C (in MELAS/LS; due to mitochondrial complex I deficiency).
MT-ND5	253	253	V -> A (in MT-C1D).
MT-ND5	257	257	I -> V.
MT-ND5	304	304	F -> S.
MT-ND5	314	314	M -> V.
MT-ND5	331	331	T -> A.
MT-ND5	393	393	D -> N (in MELAS and MT-C1D).
MT-ND5	447	447	N -> S (detected in a patient with mitochondrial complex I deficiency; uncertain pathological significance).
MT-ND5	458	458	A -> T (in LHON; secondary mutation; does not seem to directly cause the disease).
MT-ND5	465	465	G -> E (in LHON; primary rare mutation).
MT-ND5	475	475	A -> T.
MT-ND5	503	503	D -> G.
LIPC	134	134	V -> VHYTVAV (in HL deficiency).
LIPC	289	289	S -> F (in HL deficiency).
LIPC	342	342	V -> I.
LIPC	409	409	D -> A.
ADAMTS17	566	566	R -> T.
NIPA1	45	45	T -> R (in SPG6).
NIPA1	106	106	G -> R (in SPG6).
OCA2	10	10	R -> W (in OCA2).
OCA2	27	27	G -> R (in OCA2).
OCA2	86	86	S -> R (in OCA2).
OCA2	112	112	C -> F (in OCA2).
OCA2	198	198	P -> L (in OCA2).
OCA2	206	211	Missing (in OCA2; severe).
OCA2	211	211	P -> L (in OCA2).
OCA2	273	274	NW -> KV (in OCA2).
OCA2	290	290	R -> G (in OCA2).
OCA2	334	334	A -> V (in OCA2).
OCA2	350	350	V -> M (in unclassified OCA).
OCA2	368	368	A -> V (in OCA2).
OCA2	385	385	F -> I (in OCA2; severe).
OCA2	387	387	T -> M.
OCA2	394	394	M -> I (in OCA2).
OCA2	395	395	M -> L (in OCA2; severe).
OCA2	404	404	T -> M (in OCA2).
OCA2	419	419	R -> W (in OCA2).
OCA2	425	425	Missing (in OCA2; mild).
OCA2	440	440	L -> H.
OCA2	446	446	M -> V (in OCA2; mild; AROA form).
OCA2	473	473	I -> S (in OCA2).
OCA2	476	476	N -> D (in OCA2).
OCA2	481	481	A -> T (in OCA2).
OCA2	489	489	N -> D (in OCA2; mild/severe).
OCA2	549	549	H -> Q (in OCA2).
OCA2	614	614	K -> E (in OCA2).
OCA2	614	614	K -> N (in OCA2).
OCA2	617	617	I -> L (in OCA2).
OCA2	652	652	W -> R (in OCA2).
OCA2	678	678	E -> K (in unclassified OCA).
OCA2	679	679	W -> C (in OCA2).
OCA2	679	679	W -> R (in OCA2; severe).
OCA2	688	688	L -> F (in unclassified OCA).
OCA2	720	720	R -> C (in OCA2).
OCA2	724	724	A -> P (in OCA2).
OCA2	736	736	S -> L (in OCA2).
OCA2	743	743	P -> L (in OCA2 and unclassified OCA).
OCA2	773	773	A -> T (in a breast cancer sample; somatic mutation).
OCA2	775	775	G -> R (in OCA2).
OCA2	787	787	A -> V (in OCA2).
OCA2	795	795	G -> R (in OCA2).
OCA2	799	799	Q -> H (in OCA2).
OCA2	827	827	Y -> H (in OCA2).
OCA2	833	833	Missing (in OCA2).
RAB27A	130	130	L -> P (in GS2; strongly affects GTP binding; cannot interact with MLPH).
RAB27A	152	152	A -> P (in GS2; may affect GTP binding; interferes with melanosome transport).
RORA	18	18	P -> S (in a colorectal cancer sample; somatic mutation).
MYO9A	85	85	R -> Q.
MYO9A	168	168	N -> D.
MYO9A	211	211	L -> P.
MYO9A	946	946	R -> Q.
MYO9A	1834	1834	R -> C.
ETFA	116	116	G -> R (in GA2A).
ETFA	157	157	V -> G (in GA2A).
ETFA	266	266	T -> M (in GA2A).
PEAK1	611	611	H -> Q (in a bladder carcinoma NOS sample; somatic mutation).
PEAK1	1035	1035	S -> F (in a metastatic melanoma sample; somatic mutation).
PEAK1	1145	1145	P -> L (in a metastatic melanoma sample; somatic mutation).
MKRN3	145	145	T -> M (in a colorectal cancer sample; somatic mutation).
MKRN3	239	239	S -> T (in a colorectal cancer sample; somatic mutation).
GABRB3	32	32	G -> R (in ECA5; the mutant protein is hyperglycosylated and has reduced mean current densities compared to wild-type).
GABRB3	217	217	R -> H (in insomnia; functional analysis reveals a slower rate of the fast phase of desensitization compared with alpha1beta3gamma2S GABA(A) receptors; current deactivation is faster in the mutated receptors).
TRPM1	6	6	R -> W.
TRPM1	56	56	Y -> C (in CSNB1C).
TRPM1	72	72	Y -> C (in CSNB1C).
TRPM1	74	74	R -> C (in CSNB1C).
TRPM1	99	99	L -> P (in CSNB1C).
TRPM1	364	364	L -> R (in CSNB1C).
TRPM1	399	399	P -> T.
TRPM1	473	473	R -> P (in CSNB1C).
TRPM1	534	534	G -> R (in CSNB1C).
TRPM1	541	541	M -> K (in CSNB1C).
TRPM1	611	611	P -> H (in CSNB1C).
TRPM1	721	721	R -> Q (in CSNB1C).
TRPM1	883	883	E -> G (in CSNB1C).
TRPM1	962	962	M -> T (in a patient with night blindness started in the third decade; associated in cis with G-1438).
TRPM1	1002	1002	I -> F (in CSNB1C).
TRPM1	1161	1161	Q -> H.
TRPM1	1379	1379	P -> T.
TRPM1	1422	1422	R -> W.
TRPM1	1438	1438	R -> G (in a patient with night blindness started in the third decade; associated in cis with T-962).
RYR3	261	261	R -> S.
RYR3	494	494	V -> I.
RYR3	693	693	Y -> C.
RYR3	731	731	I -> V.
RYR3	1380	1380	E -> G.
RYR3	2268	2268	Missing.
EIF2AK4	137	137	H -> R.
EIF2AK4	166	166	R -> W.
EIF2AK4	872	872	D -> V.
EIF2AK4	939	939	H -> Y (in a lung neuroendocrine carcinoma sample; somatic mutation).
EIF2AK4	1060	1060	T -> R.
EIF2AK4	1406	1406	Q -> H.
BUB1B	15	15	M -> T (in a colorectal cancer cell line).
BUB1B	36	36	R -> Q (in PCS).
C15orf52	189	189	G -> E (in a colorectal cancer sample; somatic mutation).
CHST14	135	135	R -> G (in EDSMC; associated in a complex allele with Q-137; results in altered intracellular processing).
CHST14	137	137	L -> Q (in EDSMC; associated in a complex allele with G-135; results in altered intracellular processing).
CHST14	281	281	P -> L (in EDSMC; loss of activity).
CHST14	289	289	C -> S (in EDSMC; loss of activity).
RPAP1	525	525	R -> Q (in a colorectal cancer sample; somatic mutation).
GANC	153	153	I -> M.
TTBK2	635	635	D -> G (in a lung small cell carcinoma sample; somatic mutation).
UBR1	136	136	H -> R (in JBS).
UBR1	1279	1279	G -> S (in JBS).
SLC12A1	272	272	V -> F (in BS1).
SLC12A1	648	648	D -> N (in BS1).
FBN1	20	20	Y -> C (in MFS).
FBN1	89	89	C -> F (in MFS).
FBN1	111	111	C -> R (in MFS).
FBN1	114	114	R -> C (in MFS).
FBN1	115	115	S -> C (in EL).
FBN1	122	122	R -> C (in MFS).
FBN1	123	123	C -> Y (in MFS).
FBN1	129	129	C -> Y (in MFS; severe neonatal).
FBN1	154	154	C -> S (in MFS).
FBN1	166	166	C -> F (in MFS).
FBN1	166	166	C -> S (in MFS).
FBN1	217	217	W -> G (in MFS).
FBN1	224	224	C -> R (in MFS).
FBN1	240	240	R -> C (in MFS and EL).
FBN1	366	366	W -> C (in MFS).
FBN1	439	439	R -> G (in MFS).
FBN1	476	476	C -> G (in MFS).
FBN1	490	490	D -> Y (in MFS).
FBN1	504	504	C -> F (in MFS).
FBN1	507	507	Missing (in MFS).
FBN1	541	541	C -> Y (in MFS).
FBN1	545	545	R -> C (in MFS).
FBN1	548	548	N -> I (in MFS).
FBN1	560	560	G -> S (in MFS).
FBN1	570	570	C -> Y (in MFS).
FBN1	587	587	C -> Y (in MFS).
FBN1	592	592	G -> D (in MFS).
FBN1	596	596	C -> Y (in MFS).
FBN1	598	598	C -> W (in MFS).
FBN1	627	627	R -> C (in MFS; enhances proteolytic degradation).
FBN1	628	628	C -> K (in MFS; requires 2 nucleotide substitutions).
FBN1	629	633	Missing (in MFS).
FBN1	635	635	Y -> C (in MFS).
FBN1	636	636	R -> I (in MFS).
FBN1	652	652	C -> S (in MFS).
FBN1	654	654	D -> N (in MFS).
FBN1	661	661	C -> R (in MFS).
FBN1	661	661	C -> Y (in EL; patient presenting also mitral valve prolapse).
FBN1	681	681	S -> Y (in MFS).
FBN1	683	683	C -> R (in MFS).
FBN1	685	685	C -> W (in MFS).
FBN1	705	705	A -> T (in MFS).
FBN1	711	711	C -> Y (in MFS).
FBN1	723	723	D -> A (in MFS).
FBN1	723	723	D -> V (in MFS).
FBN1	734	734	C -> F (in MFS).
FBN1	746	746	Y -> C (in MFS).
FBN1	748	748	C -> Y (in MFS).
FBN1	750	750	C -> G (in MFS; enhances proteolytic degradation).
FBN1	776	776	C -> G (in MFS).
FBN1	776	776	C -> Y (in MFS).
FBN1	781	781	C -> R (in MFS).
FBN1	781	781	C -> Y (in MFS).
FBN1	816	816	C -> S (in MFS).
FBN1	832	832	C -> Y (in MFS).
FBN1	862	862	C -> R (in MFS).
FBN1	890	890	C -> G (in MFS).
FBN1	890	890	C -> R (in MFS).
FBN1	908	908	C -> R (in MFS).
FBN1	913	913	E -> G (in MFS).
FBN1	921	921	C -> G (in MFS).
FBN1	926	926	C -> R (in MFS; enhances proteolytic degradation).
FBN1	984	984	V -> I (in MFS).
FBN1	985	985	G -> E (in MFS; atypical).
FBN1	985	985	G -> R (in MFS).
FBN1	1023	1023	K -> N (in MFS; severe neonatal).
FBN1	1043	1043	K -> R (in MFS).
FBN1	1044	1044	C -> Y (in MFS).
FBN1	1048	1048	I -> T (in MFS).
FBN1	1048	1048	Missing (in MFS).
FBN1	1053	1053	C -> R (in MFS).
FBN1	1055	1055	C -> G (in MFS; neonatal).
FBN1	1055	1055	C -> W (in MFS).
FBN1	1055	1055	C -> Y (in MFS).
FBN1	1058	1058	G -> D (in MFS).
FBN1	1058	1058	G -> GC (in MFS).
FBN1	1068	1068	C -> G (in MFS; neonatal form).
FBN1	1072	1072	D -> G (in MFS).
FBN1	1073	1073	E -> K (in MFS; severe neonatal).
FBN1	1074	1074	C -> R (in MFS; severe neonatal).
FBN1	1086	1086	C -> W (in MFS).
FBN1	1101	1101	Y -> C (in MFS).
FBN1	1113	1113	D -> V (in MFS).
FBN1	1117	1117	C -> G (in MFS).
FBN1	1117	1117	C -> Y (in MFS).
FBN1	1127	1127	G -> S (in a mild form of inherited weakness of elastic tissue that predisposes to ascending aortic aneurysm and dissection later in life).
FBN1	1128	1128	V -> I (in a patient with mitral valve prolapse).
FBN1	1129	1129	C -> Y (in MFS).
FBN1	1131	1131	N -> Y (in MFS).
FBN1	1137	1137	R -> P (in MFS).
FBN1	1153	1153	C -> S (in MFS).
FBN1	1155	1155	D -> N (in MFS).
FBN1	1170	1170	R -> H (in MFS; mild).
FBN1	1171	1171	C -> W (in MFS).
FBN1	1173	1173	N -> K (in MFS).
FBN1	1200	1200	E -> G (in MFS).
FBN1	1211	1211	Missing (in MFS).
FBN1	1219	1219	Y -> C (in MFS).
FBN1	1223	1223	C -> Y (in MFS and SGS).
FBN1	1242	1242	C -> Y (in MFS).
FBN1	1249	1249	C -> S (in MFS).
FBN1	1261	1261	Y -> C (in MFS).
FBN1	1261	1261	Y -> D (in MFS).
FBN1	1265	1265	C -> R (in MFS; subdiagnostic variant of MFS).
FBN1	1278	1278	C -> S (in MFS).
FBN1	1284	1284	C -> G (in MFS).
FBN1	1325	1325	E -> Q (in MFS).
FBN1	1333	1333	C -> S (in MFS).
FBN1	1337	1337	A -> P (in MFS; neonatal).
FBN1	1339	1339	C -> Y (in MFS).
FBN1	1366	1366	E -> K (in MFS).
FBN1	1374	1374	C -> S (in MFS).
FBN1	1382	1382	N -> S (in MFS).
FBN1	1389	1389	C -> R (in MFS).
FBN1	1394	1396	Missing (in MFS).
FBN1	1402	1402	C -> R (in MFS).
FBN1	1404	1404	D -> Y (in MFS).
FBN1	1424	1424	P -> A (in MFS).
FBN1	1424	1424	P -> S (in MFS).
FBN1	1429	1429	C -> S (in MFS).
FBN1	1475	1475	G -> E (in MFS).
FBN1	1475	1475	G -> S (in MFS).
FBN1	1513	1513	C -> R (in MFS).
FBN1	1530	1530	R -> C (in EL).
FBN1	1564	1564	C -> F (in MFS).
FBN1	1564	1564	C -> S (in SSKS).
FBN1	1564	1564	C -> Y (in MFS).
FBN1	1570	1570	W -> C (in SSKS).
FBN1	1576	1576	M -> T (in MFS).
FBN1	1577	1577	C -> G (in SSKS).
FBN1	1589	1589	C -> F (in MFS).
FBN1	1594	1594	G -> D (in SSKS).
FBN1	1610	1610	C -> G (in MFS).
FBN1	1631	1631	C -> G (in MFS).
FBN1	1663	1663	C -> R (in MFS).
FBN1	1663	1663	C -> Y (in MFS).
FBN1	1692	1699	Missing (in ADWMS).
FBN1	1770	1770	C -> F (in MFS).
FBN1	1790	1790	R -> P (in MFS).
FBN1	1791	1791	C -> R (in MFS).
FBN1	1791	1791	C -> Y (in MFS).
FBN1	1793	1793	C -> W (in MFS).
FBN1	1796	1796	G -> E (in MFS).
FBN1	1806	1806	C -> S (in MFS).
FBN1	1806	1806	C -> Y (in MFS).
FBN1	1833	1833	C -> S (in MFS).
FBN1	1835	1835	C -> Y (in MFS).
FBN1	1837	1837	P -> S (in MFS).
FBN1	1876	1876	C -> Y (in MFS).
FBN1	1887	1887	T -> I (in MFS).
FBN1	1893	1893	N -> K (in MFS).
FBN1	1895	1895	C -> R (in MFS).
FBN1	1900	1900	C -> Y (in MFS).
FBN1	1909	1909	I -> T (in MFS).
FBN1	1915	1915	R -> S (in MFS).
FBN1	1928	1928	C -> G (in MFS).
FBN1	1928	1928	C -> R (in MFS).
FBN1	1928	1928	C -> Y (in MFS).
FBN1	1931	1931	Missing (in MFS).
FBN1	1971	1971	C -> Y (in MFS).
FBN1	1977	1977	C -> Y (in MFS).
FBN1	1998	1998	C -> Y (in MFS).
FBN1	2085	2085	C -> R (in MFS).
FBN1	2099	2099	C -> W (in MFS).
FBN1	2101	2101	T -> M.
FBN1	2111	2111	C -> Y (in MFS).
FBN1	2127	2127	D -> E (in MFS).
FBN1	2142	2142	C -> Y (in MFS).
FBN1	2144	2144	N -> S (in MFS).
FBN1	2151	2151	C -> W (in MFS).
FBN1	2154	2154	P -> R (in EL).
FBN1	2160	2160	A -> P (in MFS).
FBN1	2221	2221	C -> F (in MFS).
FBN1	2221	2221	C -> G (in MFS).
FBN1	2221	2221	C -> S (in MFS).
FBN1	2223	2223	N -> H (in MFS).
FBN1	2251	2251	C -> R (in MFS).
FBN1	2258	2258	C -> R (in MFS).
FBN1	2269	2269	I -> T (in MFS).
FBN1	2282	2282	R -> W (in MFS).
FBN1	2307	2307	C -> S (in MFS).
FBN1	2335	2335	R -> W (in MFS).
FBN1	2339	2339	C -> Y (in EL; patient presenting also flat corneas).
FBN1	2385	2385	A -> T (in MFS).
FBN1	2406	2406	C -> Y (in MFS).
FBN1	2442	2442	C -> W (in MFS).
FBN1	2447	2447	E -> K (in EL).
FBN1	2474	2474	Y -> C (in MFS).
FBN1	2489	2489	C -> R (in MFS).
FBN1	2500	2500	C -> R (in MFS).
FBN1	2500	2500	C -> Y (in MFS).
FBN1	2511	2511	C -> R (in MFS).
FBN1	2535	2535	C -> W (in MFS).
FBN1	2536	2536	G -> R (in MFS).
FBN1	2570	2570	E -> K (in MFS).
FBN1	2571	2571	C -> R (in MFS).
FBN1	2581	2581	C -> F (in MFS).
FBN1	2585	2585	I -> T (in MFS).
FBN1	2592	2592	C -> S (in MFS).
FBN1	2605	2605	C -> R (in MFS).
FBN1	2605	2605	C -> Y (in MFS).
FBN1	2610	2610	E -> K (in MFS).
FBN1	2618	2618	G -> R (in MFS).
FBN1	2623	2623	H -> P (in MFS).
FBN1	2624	2624	N -> K (in MFS).
FBN1	2627	2627	G -> R (in MFS).
FBN1	2629	2629	Y -> C (in MFS).
FBN1	2652	2652	C -> G (in MFS).
FBN1	2663	2663	C -> S (in MFS).
FBN1	2668	2668	G -> C (in MFS).
FBN1	2680	2680	R -> C (in MFS).
FBN1	2726	2726	R -> W (in MFS; defects in protein processing).
GABPB1	31	31	P -> A (in a colorectal cancer sample; somatic mutation).
TRPM7	406	406	S -> C (in an ovarian serous carcinoma sample; somatic mutation).
TRPM7	720	720	T -> S (in a breast infiltrating ductal carcinoma sample; somatic mutation).
TRPM7	830	830	M -> V (in a gastric adenocarcinoma sample; somatic mutation).
CYP19A1	365	365	R -> Q (in AROD; 0.4% of wild-type activity).
CYP19A1	375	375	R -> C (in AROD).
CYP19A1	375	375	R -> L.
CYP19A1	435	435	R -> C (in AROD; 1.1% of wild-type activity).
CYP19A1	437	437	C -> Y (in AROD; complete loss of activity).
MYO5C	522	522	L -> P.
MYO5C	634	634	L -> S.
NEDD4	627	627	Y -> H (in a breast cancer sample; somatic mutation).
ANXA2	98	98	V -> L.
MAP2K1	53	53	F -> S (in CFC syndrome).
MAP2K1	130	130	Y -> C (in CFC syndrome).
SMAD3	261	261	T -> I (in LDS1C).
SMAD3	287	287	R -> W (in LDS1C).
SMAD3	393	393	P -> L (in a colorectal cancer sample; somatic mutation).
MAP2K5	427	427	A -> V.
ITGA11	1003	1003	M -> I.
ITGA11	1029	1029	E -> EV.
ITGA11	1093	1093	L -> V.
CORO2B	318	318	P -> L (in a colorectal cancer sample; somatic mutation).
BBS4	46	46	K -> R.
BBS4	165	165	N -> H (in BBS4).
BBS4	295	295	R -> P (in BBS4).
BBS4	327	327	L -> P (in BBS4).
BBS4	351	351	L -> R (in BBS4).
BBS4	364	364	A -> E (in BBS4).
BBS4	368	368	D -> G (in BBS4).
BBS4	457	457	S -> I (in BBS4).
BBS4	503	503	P -> L (in BBS4).
CHRNA3	23	23	Missing.
FAH	16	16	N -> I (in TYRO1; loss of activity).
FAH	35	35	A -> T (in TYRO1; atypical mild phenotype).
FAH	62	62	F -> C (in TYRO1; loss of activity).
FAH	64	64	Q -> H (in TYRO1).
FAH	134	134	A -> D (in TYRO1; loss of activity).
FAH	158	158	G -> D (in TYRO1).
FAH	166	166	V -> G (in TYRO1).
FAH	193	193	C -> R (in TYRO1; loss of activity).
FAH	207	207	G -> D (in TYRO1).
FAH	233	233	D -> V (in TYRO1; loss of activity).
FAH	234	234	W -> G (in TYRO1; loss of activity).
FAH	249	249	P -> T (in TYRO1).
FAH	261	261	P -> L (in TYRO1).
FAH	279	279	Q -> R (in TYRO1; may affect splicing resulting in skipping of exon 8 alone or together with exon 9; lower activity as compared to wild type).
FAH	294	294	T -> P (in TYRO1).
FAH	337	337	G -> S (in TYRO1).
FAH	342	342	P -> L (in TYRO1; loss of activity).
FAH	366	366	Missing (in TYRO1).
FAH	369	369	G -> V (in TYRO1).
FAH	381	381	R -> G (in TYRO1; loss of activity).
FAH	405	405	F -> H (in TYRO1; requires 2 nucleotide substitutions).
KIAA1199	187	187	R -> C (in a family with non-syndromic hearing loss).
KIAA1199	187	187	R -> H (in two unrelated families with non-syndromic hearing loss).
KIAA1199	783	783	H -> Y (in a sporadic case of non- syndromic hearing loss).
KIAA1199	1109	1109	V -> I.
ADAMTSL3	330	330	V -> M (in a colorectal cancer sample; somatic mutation).
ADAMTSL3	587	587	R -> H (in a colorectal cancer sample; somatic mutation).
ADAMTSL3	855	855	R -> C (in a colorectal cancer sample; somatic mutation).
ADAMTSL3	1315	1315	A -> E (in a colorectal cancer sample; somatic mutation).
ZNF592	1046	1046	G -> R (in SCAR5).
SLC28A1	34	34	E -> G (in A).
SLC28A1	140	140	L -> LV (in A).
SLC28A1	409	409	N -> S (in B).
NTRK3	149	149	T -> R (in a gastric adenocarcinoma sample; somatic mutation).
NTRK3	307	307	V -> L (in a lung adenocarcinoma sample; somatic mutation).
NTRK3	336	336	L -> Q (in a lung adenocarcinoma sample; somatic mutation).
NTRK3	664	664	A -> S (in a lung carcinoma sample; somatic mutation).
NTRK3	677	677	H -> Y (in a lung adenocarcinoma sample; somatic mutation).
NTRK3	735	735	R -> F (in a lung large cell carcinoma sample; somatic mutation; requires 2 nucleotide substitutions).
NTRK3	736	736	W -> C (in a lung carcinoma sample; somatic mutation).
NTRK3	745	745	R -> P (in a lung carcinoma sample; somatic mutation).
NTRK3	766	766	Y -> F (in a lung carcinoma sample; somatic mutation).
MESP2	66	66	A -> G.
MESP2	125	125	L -> V (in a patient with spondylocostal dysostosis; inactive).
MESP2	224	224	S -> F.
CRTC3	346	346	L -> S.
BLM	672	672	Q -> R (in BLM).
BLM	841	841	I -> T (in BLM).
BLM	843	843	T -> I (in BLM).
BLM	878	878	C -> R (in BLM).
BLM	891	891	G -> E (in BLM).
BLM	901	901	C -> Y (in BLM).
BLM	1036	1036	C -> F (in BLM).
BLM	1055	1055	C -> S (in BLM).
IGF1R	105	105	V -> L (in a renal chromophobe sample; somatic mutation).
IGF1R	138	138	R -> Q (in IGF1RES; has decreased IGF1R function).
IGF1R	145	145	K -> N (in IGF1RES; has decreased IGF1R function).
IGF1R	739	739	R -> Q (in IGF1RES; leads to failure of processing of the IGF1R proreceptor to mature IGF1R).
IGF1R	1347	1347	A -> V (in a lung squamous cell carcinoma sample; somatic mutation).
MEF2A	263	263	N -> S.
MEF2A	279	279	P -> L.
MEF2A	283	283	G -> D.
MEF2A	440	446	Missing (loss of nuclear localization; 66% decrease in transcription activation; loss of synergistic activation by MEF2A and GATA1 through a dominant-negative mechanism).
LRRK1	1803	1803	A -> T.
LRRK1	1824	1824	L -> F.
LRRK1	1847	1847	S -> N.
LRRK1	1927	1927	D -> G.
C15orf2	37	37	R -> Q (in a colorectal cancer sample; somatic mutation).
C15orf2	114	114	V -> I (in a colorectal cancer sample; somatic mutation).
UBE3A	44	44	C -> Y (probable polymorphism).
UBE3A	62	62	R -> H.
UBE3A	201	201	A -> T.
UBE3A	372	372	S -> P.
UBE3A	826	826	I -> II (in AS).
ARHGAP11A	605	605	E -> K (in a breast cancer sample; somatic mutation).
NOP10	34	34	R -> W (in ARDKC).
ACTC1	90	90	H -> Y (in CMH11).
ACTC1	97	97	R -> C (in CMH11).
ACTC1	101	101	E -> K (in CMH11).
ACTC1	125	125	M -> V (in ASD5; reduced affinity for myosin; normal actin filament polymerization ability; normal actomyosin motor function).
ACTC1	166	166	P -> A (in CMH11).
ACTC1	168	168	Y -> C (in CMH11).
ACTC1	297	297	A -> S (in CMH11).
ACTC1	307	307	M -> L (in CMH11).
ACTC1	314	314	R -> H (in CMD1R).
ACTC1	333	333	A -> P (in CMH11).
ACTC1	363	363	E -> G (in CMD1R).
SPRED1	31	31	W -> C (in NFLS).
SPRED1	44	44	V -> D (in NFLS).
PAK6	3	3	R -> H (in a colorectal cancer sample; somatic mutation).
PAK6	514	514	L -> R (in a lung small cell carcinoma sample; somatic mutation).
IVD	42	42	L -> P (in IVA).
IVD	50	50	R -> P (in IVA).
IVD	69	69	D -> N (in IVA).
IVD	199	199	G -> V (in IVA).
IVD	311	311	A -> V (in IVA).
IVD	357	357	C -> R (in IVA).
IVD	371	371	V -> A (in IVA).
IVD	392	392	R -> C (in IVA).
IVD	411	411	R -> L (in IVA).
RAD51	150	150	R -> Q (in BC; familial).
VPS18	913	913	A -> S (in a colorectal cancer sample; somatic mutation).
LTK	569	569	R -> S.
TYRO3	831	831	A -> T.
CAPN3	4	4	V -> I (in LGMD2A).
CAPN3	26	26	P -> L (in LGMD2A).
CAPN3	77	77	D -> N (in LGMD2A).
CAPN3	86	86	S -> F (in LGMD2A; severe).
CAPN3	93	100	Missing (in LGMD2A).
CAPN3	118	118	R -> G (in LGMD2A).
CAPN3	137	137	C -> R (in LGMD2A).
CAPN3	162	162	I -> L (in LGMD2A).
CAPN3	182	182	L -> Q (in LGMD2A).
CAPN3	183	183	P -> L (in LGMD2A).
CAPN3	189	189	L -> P (in LGMD2A).
CAPN3	200	204	Missing (in LGMD2A).
CAPN3	214	214	G -> S (in LGMD2A).
CAPN3	215	221	Missing (in LGMD2A).
CAPN3	215	215	S -> P (in LGMD2A).
CAPN3	217	217	E -> K (in LGMD2A).
CAPN3	222	222	G -> R (in LGMD2A).
CAPN3	226	226	E -> K (in LGMD2A).
CAPN3	232	232	T -> I (in LGMD2A).
CAPN3	234	234	G -> E (in LGMD2A).
CAPN3	254	254	Missing (in LGMD2A).
CAPN3	319	319	P -> L (in LGMD2A).
CAPN3	334	334	H -> Q (in LGMD2A).
CAPN3	336	336	Y -> N (in LGMD2A).
CAPN3	354	354	V -> G (in LGMD2A).
CAPN3	360	360	W -> C (in LGMD2A).
CAPN3	437	437	R -> C (in LGMD2A).
CAPN3	440	440	R -> W (in LGMD2A).
CAPN3	441	441	G -> D (in LGMD2A).
CAPN3	445	445	G -> R (in LGMD2A).
CAPN3	448	448	R -> C (in LGMD2A).
CAPN3	448	448	R -> G (in LGMD2A).
CAPN3	448	448	R -> H (in LGMD2A).
CAPN3	479	479	S -> G (in LGMD2A).
CAPN3	486	486	Q -> E (in LGMD2A).
CAPN3	489	489	R -> Q (in LGMD2A).
CAPN3	489	489	R -> W (in LGMD2A).
CAPN3	490	490	R -> Q (in LGMD2A).
CAPN3	490	490	R -> W (in LGMD2A).
CAPN3	493	493	R -> W (in LGMD2A).
CAPN3	496	496	G -> R (in LGMD2A).
CAPN3	502	502	I -> T (in LGMD2A).
CAPN3	541	541	R -> Q (in LGMD2A).
CAPN3	567	567	G -> W (in LGMD2A).
CAPN3	572	572	R -> Q (in LGMD2A).
CAPN3	572	572	R -> W (in LGMD2A).
CAPN3	606	606	S -> L (in LGMD2A).
CAPN3	638	638	Q -> P (in LGMD2A).
CAPN3	698	698	R -> P (in LGMD2A).
CAPN3	702	702	A -> V (in LGMD2A).
CAPN3	705	705	D -> G (in LGMD2A).
CAPN3	705	705	D -> H (in LGMD2A).
CAPN3	731	731	F -> S (in LGMD2A).
CAPN3	744	744	S -> G (in LGMD2A).
CAPN3	748	748	R -> Q (in LGMD2A).
CAPN3	769	769	R -> Q (in LGMD2A).
CAPN3	774	774	H -> D (in LGMD2A; could be a rare polymorphism).
CAPN3	798	798	A -> E (in LGMD2A; could be a rare polymorphism).
CDAN1	599	599	N -> S (in CDA1).
CDAN1	672	672	P -> L (in CDA1).
CDAN1	698	698	E -> K (in CDA1).
CDAN1	714	714	R -> W (in CDA1).
CDAN1	868	868	F -> I (in CDA1).
CDAN1	869	869	V -> M (in CDA1).
CDAN1	1042	1042	R -> W (in CDA1).
CDAN1	1043	1043	D -> V (in CDA1).
CDAN1	1130	1130	P -> L (in CDA1).
EPB42	145	145	D -> Y (in SPH5; Komatsu).
EPB42	280	280	R -> Q (in SPH5; Tozeur).
EPB42	287	287	R -> C (in SPH5; Shiga).
TGM5	67	67	P -> S.
TGM5	109	109	T -> M.
TGM5	113	113	G -> C (in APSS; completely abolishes the enzyme activity).
SPG11	1349	1349	F -> I (in SPG11).
B2M	11	11	A -> P (in HYCATHYP; lower levels of B2M, MHC class I and FCGRT proteins).
DUOX2	36	36	Q -> H (in TDH6).
DUOX2	376	376	R -> W (in TDH6).
DUOX2	1518	1518	G -> S (in TDH6; the enzyme is non- functional; expressed at the cell surface of cells albeit at low level).
SLC28A2	12	12	L -> P.
SLC28A2	142	142	R -> H.
SLC28A2	172	172	E -> D.
SLC28A2	385	385	E -> K.
SLC28A2	462	462	L -> F.
SLC28A2	612	612	M -> T.
CEP152	265	265	Q -> P (in MCPH4).
CEP152	667	667	K -> R (in SCKL5).
HDC	49	49	E -> V (in a colorectal cancer sample; somatic mutation).
HDC	285	285	E -> K (in a colorectal cancer sample; somatic mutation).
ONECUT1	75	75	P -> A.
DYX1C1	2	2	P -> S.
DYX1C1	420	420	S -> C.
TPM1	40	40	E -> K (in CMD1Y).
TPM1	54	54	E -> K (in CMD1Y).
TPM1	63	63	A -> V (in CMH3).
TPM1	180	180	E -> V (in CMH3).
CA12	143	143	E -> K (in HCHLH; mild reduction of activity; mutant enzyme is highly inhibited by acetazolamide and shows higher sensitivity to inhibition by anions compared to wild-type; the mutation affects the chloride-mediated negative feedback regulation of the enzyme leading to excessive chloride secretion in sweat).
PPIB	9	9	M -> R (in OI9; patients have white sclerae, normal dentition, no rhizomelia or severe deformity of long bones).
KBTBD13	248	248	R -> S (in NEM6).
KBTBD13	390	390	K -> N (in NEM6).
KBTBD13	408	408	R -> C (in NEM6).
CILP	327	327	S -> F.
CILP	895	895	A -> V.
CILP	1101	1101	D -> N.
CILP	1168	1168	V -> A.
TIPIN	270	270	N -> S.
CLN6	62	62	R -> H (in CLN6).
CLN6	72	72	E -> Q (in CLN6).
CLN6	154	154	Missing (in CLN6).
CLN6	159	159	P -> L (in CLN6).
CLN6	171	171	Missing (in CLN6).
CLN6	221	221	Y -> C (in CLN6).
CLN6	221	221	Y -> S (in CLN6).
CLN6	241	241	M -> T (in CLN6).
CLN6	265	265	Missing (in CLN6).
CLN6	299	299	P -> L (in CLN6).
CLN6	300	300	W -> R (in CLN6).
NR2E3	44	44	S -> L (associated with autosomal recessive retinitis pigmentosa).
NR2E3	56	56	G -> R (in RP37).
NR2E3	67	69	Missing (in ESCS).
NR2E3	76	76	R -> Q (in ESCS).
NR2E3	76	76	R -> W (in ESCS).
NR2E3	88	88	G -> V (in ESCS).
NR2E3	97	97	R -> H (in ESCS).
NR2E3	104	104	R -> Q (associated with ESCS).
NR2E3	104	104	R -> W (in ESCS).
NR2E3	121	121	E -> K (in ESCS).
NR2E3	234	234	W -> S (in ESCS).
NR2E3	256	256	A -> E (in ESCS).
NR2E3	263	263	L -> P (in ESCS).
NR2E3	287	287	G -> S (associated with autosomal recessive retinitis pigmentosa).
NR2E3	309	309	R -> G (in ESCS).
NR2E3	324	324	K -> R (associated with autosomal recessive retinitis pigmentosa).
NR2E3	334	334	R -> G (associated with ESCS).
NR2E3	336	336	L -> P (in ESCS).
NR2E3	353	353	L -> V (in ESCS).
NR2E3	385	385	R -> P (in ESCS).
NR2E3	407	407	M -> K (in ESCS).
HEXA	25	25	P -> S (in GM2G1; late infantile).
HEXA	39	39	L -> R (in GM2G1; infantile).
HEXA	127	127	L -> F (in GM2G1).
HEXA	127	127	L -> R (in GM2G1; infantile).
HEXA	166	166	R -> G (in GM2G1; late infantile).
HEXA	170	170	R -> Q (in GM2G1; infantile; inactive or unstable protein).
HEXA	170	170	R -> W (in GM2G1; infantile).
HEXA	178	178	R -> C (in GM2G1; infantile; inactive protein).
HEXA	178	178	R -> H (in GM2G1; infantile; inactive protein).
HEXA	192	192	V -> L (in GM2G1; infantile).
HEXA	196	196	N -> S (in GM2G1).
HEXA	197	197	K -> T (in GM2G1).
HEXA	204	204	H -> R (in GM2G1; infantile).
HEXA	210	210	S -> F (in GM2G1; infantile).
HEXA	211	211	F -> S (in GM2G1; infantile).
HEXA	226	226	S -> F (in GM2G1).
HEXA	247	247	R -> W (in HEXA pseudodeficiency).
HEXA	249	249	R -> W (in HEXA pseudodeficiency).
HEXA	250	250	G -> D (in GM2G1; juvenile).
HEXA	250	250	G -> S (in GM2G1).
HEXA	252	252	R -> H (in GM2G1).
HEXA	252	252	R -> L (in GM2G1).
HEXA	258	258	D -> H (in GM2G1; infantile).
HEXA	269	269	G -> D (in GM2G1).
HEXA	269	269	G -> S (in GM2G1; late onset; inhibited subunit dissociation).
HEXA	279	279	S -> P (in GM2G1; late infantile).
HEXA	295	295	N -> S (in GM2G1).
HEXA	301	301	M -> R (in GM2G1; infantile).
HEXA	304	304	Missing (in GM2G1; infantile; Moroccan Jewish).
HEXA	314	314	D -> V (in GM2G1).
HEXA	320	320	Missing (in GM2G1; late infantile).
HEXA	335	335	I -> F (in GM2G1).
HEXA	347	352	Missing (in GM2G1).
HEXA	391	391	V -> M (in GM2G1; mild; associated with spinal muscular atrophy).
HEXA	420	420	W -> C (in GM2G1; infantile; inactive protein).
HEXA	454	454	G -> S (in GM2G1; infantile).
HEXA	455	455	G -> R (in GM2G1; late infantile).
HEXA	458	458	C -> Y (in GM2G1; infantile).
HEXA	474	474	W -> C (in GM2G1; subacute).
HEXA	482	482	E -> K (in GM2G1; infantile).
HEXA	484	484	L -> Q (in GM2G1; infantile).
HEXA	485	485	W -> R (in GM2G1; infantile).
HEXA	499	499	R -> C (in GM2G1; infantile).
HEXA	499	499	R -> H (in GM2G1; juvenile).
HEXA	504	504	R -> H (in GM2G1; juvenile; inhibited subunit dissociation).
HCN4	553	553	D -> N (in a patient with cardiac arrhythmia).
HCN4	672	672	S -> R (in SSS2; does not affect cAMP- induced channel activation; causes shifting of the current activation range to hyperpolarized voltages).
ISLR	183	183	D -> N (in a colorectal cancer sample; somatic mutation).
STRA6	90	90	P -> L (in MCOPS9).
STRA6	217	217	G -> E (in anophthalmia/microphthalmia).
STRA6	293	293	P -> L (in MCOPS9).
STRA6	321	321	T -> P (in MCOPS9).
STRA6	438	438	Q -> R (in anophthalmia/microphthalmia).
STRA6	638	638	R -> P (in anophthalmia/microphthalmia).
STRA6	644	644	T -> M (in MCOPS9).
STRA6	655	655	R -> C (in MCOPS9).
CYP11A1	141	141	L -> W (in AICSR; reduced activity).
CYP11A1	189	189	A -> V (in AICSR; no loss of activity).
CYP11A1	222	222	L -> P (in AICSR; markedly reduced activity).
CYP11A1	271	271	D -> DGD (in AICSR; complete loss of activity).
CYP11A1	353	353	R -> W (in AICSR; loss of activity).
CYP11A1	359	359	A -> V (in AICSR; markedly reduced activity).
CYP11A1	415	415	V -> E (in AICSR; complete loss of activity).
CLK3	486	486	R -> C.
CLK3	607	607	Q -> R.
CLK3	628	628	R -> W.
CYP1A1	448	448	I -> N (in allele CYP1A1*8).
CYP1A1	464	464	R -> C (in allele CYP1A1*9).
CYP1A2	42	42	P -> R (in allele CYP1A2*15).
CYP1A2	83	83	T -> M (in allele CYP1A2*9).
CYP1A2	168	168	E -> Q (in allele CYP1A2*10).
CYP1A2	186	186	F -> L (in allele CYP1A2*11; drastic reduction in O-deethylation of phenacetin and 7-ethoxyresorufin; has a Vmax of approximately 5% of that of the wild-type and 5-fold lower Km value).
CYP1A2	212	212	S -> C (in allele CYP1A2*12).
CYP1A2	377	377	R -> Q (in allele CYP1A2*16).
CYP1A2	386	386	I -> F (in allele CYP1A2*4; increases catalytic efficiency of N-hydroxylation towards some heterocyclic amines and reduces towards others; reduces catalytic efficiency of phenacetin O-deethylation due to a high decrease in the affinity for phenacetin).
CYP1A2	456	456	R -> H (in allele CYP1A2*8).
CSK	45	45	P -> L.
MPI	51	51	M -> T (in CDG1B).
MPI	102	102	S -> L (in CDG1B).
MPI	129	129	Y -> C (in CDG1B).
MPI	131	131	D -> N (in CDG1B).
MPI	138	138	M -> T (in CDG1B).
MPI	140	140	I -> T (in CDG1B).
MPI	152	152	R -> Q (in CDG1B).
MPI	219	219	R -> Q (in CDG1B).
MPI	250	250	G -> S (in CDG1B).
MPI	255	255	Y -> C (in CDG1B).
MPI	398	398	I -> T (in CDG1B).
MPI	418	418	R -> H (in CDG1B).
NEIL1	242	242	K -> R (in RNA edited version).
CHRNB4	136	136	R -> W.
CHRNB4	467	467	M -> V.
CTSH	126	126	G -> R (in a colorectal cancer sample; somatic mutation).
ALPK3	338	338	T -> I.
ALPK3	433	433	Q -> E (in a lung large cell carcinoma sample; somatic mutation).
ALPK3	602	602	Q -> R.
ALPK3	663	663	G -> D.
ALPK3	836	836	R -> L.
ALPK3	929	929	E -> D.
ALPK3	1364	1364	G -> E (in a metastatic melanoma sample; somatic mutation).
ALPK3	1412	1412	R -> W.
RLBP1	226	226	M -> K (in FA).
FANCI	55	55	P -> L (in FA; could be a polymorphism; no effect on ubiquitination and DNA repair).
FANCI	858	858	H -> Y (in FA).
FANCI	1285	1285	R -> Q (in FA/FANCI; abolishes function in DNA repair).
POLG	3	3	R -> P (in PEOB).
POLG	55	55	Q -> QQ.
POLG	55	55	Q -> QQQ.
POLG	227	227	R -> W (in PEOB and MTDPS4B).
POLG	232	232	R -> G (in MTDPS4A).
POLG	232	232	R -> H (in LS).
POLG	244	244	L -> P (in MTDPS4A).
POLG	251	251	T -> I (in PEOB, MTDPS4A and MTDPS4B).
POLG	304	304	L -> R (in PEOB; also found in SANDO).
POLG	304	304	L -> SANDO (in PEOB).
POLG	308	308	Q -> H (in PEOB; sporadic case).
POLG	309	309	R -> L (in PEOB).
POLG	312	312	W -> R (in PEOB; sporadic case).
POLG	380	380	G -> D (in PEOB).
POLG	431	431	G -> V (in PEOB; sporadic case).
POLG	463	463	L -> F.
POLG	467	467	A -> T (in PEOB, SANDO and MTDPS4A; results in clearly decreased activity, DNA binding and processivity of the polymerase).
POLG	468	468	N -> D (in PEOB).
POLG	497	497	Q -> H (in SANDO; atypical form with spinocerebellar ataxia and epilepsy).
POLG	511	511	S -> N (in PEOA1).
POLG	562	562	R -> Q (in PEOB; sporadic case).
POLG	574	574	R -> W (in PEOB; sporadic case).
POLG	579	579	R -> W (in PEOB; autosomal recessive).
POLG	587	587	P -> L (in PEOB, MTDPS4A and MTDPS4B).
POLG	603	603	M -> L (in PEOB).
POLG	627	627	R -> Q (in SANDO; shows DNA binding affinitiy and processivities similar to the controls).
POLG	627	627	R -> W (in SANDO; sporadic case).
POLG	648	648	P -> R (in PEOB; sporadic case; also in SANDO).
POLG	737	737	G -> R (in PEOB; with absence of progressive external ophthalmoplegia).
POLG	748	748	W -> S (in SANDO and MTDPS4A; some patients manifest an atypical SANDO form with spinocerebellar ataxia and epilepsy).
POLG	767	767	A -> D (in MTDPS4A).
POLG	807	807	R -> C (in SANDO).
POLG	807	807	R -> P (in PEOB; sporadic case).
POLG	848	848	G -> S (in PEOB, MTDPS4A, MTDPS4B and LS).
POLG	853	853	R -> W (in PEOB; with absence of progressive external ophthalmoplegia).
POLG	864	864	N -> S (in MTDPS4B).
POLG	879	879	Q -> H (in MTDPS4A).
POLG	885	885	T -> S (in MTDPS4A).
POLG	889	889	A -> T (in PEOB).
POLG	914	914	T -> P (in MTDPS4A).
POLG	923	923	G -> D (in PEOA1).
POLG	932	932	H -> Y (in SANDO and PEOB; sporadic case).
POLG	943	943	R -> H (in PEOA1).
POLG	955	955	Y -> C (in PEOA1; can underlie parkinsonism; 45-fold decrease in apparent binding affinity for the incoming nucleoside triphosphate; 2-fold less accurate for basepair substitutions than wild-type).
POLG	957	957	A -> P (in MTDPS4A).
POLG	957	957	A -> S (in PEOA1).
POLG	1047	1047	R -> Q (in PEOB; sporadic case).
POLG	1051	1051	G -> R (in SANDO).
POLG	1076	1076	G -> V (in PEOB).
POLG	1096	1096	R -> C (in PEOB; sporadic case).
POLG	1096	1096	R -> H (in MTDPS4A).
POLG	1104	1104	S -> C (in PEOB; sporadic case).
POLG	1105	1105	A -> T (in PEOB).
POLG	1106	1106	V -> I (in PEOB).
POLG	1110	1110	H -> Y (in MTDPS4A).
POLG	1134	1134	H -> R (in MTDPS4A).
POLG	1136	1136	E -> K (in MTDPS4A).
POLG	1176	1176	S -> L (in PEOA1).
POLG	1184	1184	D -> N (in PEOB).
POLG	1186	1186	D -> H (in PEOA1).
POLG	1191	1191	K -> N (in MTDPS4A).
ANPEP	242	242	D -> Y.
ANPEP	243	243	L -> P.
IDH2	140	140	R -> G (in D2HGA2).
IDH2	140	140	R -> Q (in D2HGA2).
FURIN	547	547	W -> R (in cell line LoVo; does not undergo autocatalytic activation and is not transported to the Golgi apparatus).
VPS33B	30	30	L -> P (in ARCS1).
VPS33B	243	243	S -> F (in ARCS1).
SYNM	272	272	A -> V.
SYNM	330	330	V -> I.
SYNM	338	338	R -> W.
SYNM	567	567	P -> L.
SYNM	612	612	E -> A.
SYNM	761	761	P -> L.
SYNM	946	946	R -> W.
SYNM	976	976	Q -> R.
SYNM	1059	1059	P -> L.
SYNM	1067	1067	R -> P.
SYNM	1077	1077	S -> L.
CTSZ	36	36	P -> S.
CTSZ	129	129	A -> R (requires 2 nucleotide substitutions).
TUBB1	318	318	R -> W (in MAD-TUBB1).
PLCB1	907	907	A -> P (in a breast cancer sample; somatic mutation).
EDN3	127	127	Y -> C (in WS4B).
EDN3	159	159	C -> F (in WS4B).
FAM217B	95	95	S -> G (in a breast cancer sample; somatic mutation).
MYLK2	87	87	A -> V (in CMH).
MYLK2	95	95	A -> E (in CMH).
MYLK2	117	117	A -> V (in a lung neuroendocrine carcinoma sample; somatic mutation).
PTPRT	74	74	F -> S (in a colorectal cancer).
PTPRT	209	209	A -> T (in some colorectal cancers).
PTPRT	218	218	K -> T (in a gastric cancer).
PTPRT	248	248	F -> S (in a colorectal cancer).
PTPRT	280	280	Y -> H (in a colorectal cancer).
PTPRT	395	395	I -> V (in a colorectal cancer).
PTPRT	412	412	Y -> F (in a colorectal cancer).
PTPRT	453	453	R -> C (in a gastric cancer).
PTPRT	510	510	N -> K (in a colorectal cancer).
PTPRT	605	605	T -> M (in a colorectal cancer).
PTPRT	648	648	V -> G (in a colorectal cancer).
PTPRT	707	707	A -> T (in a colorectal cancer).
PTPRT	707	707	A -> V (in a colorectal cancer).
PTPRT	708	708	L -> P (in a colorectal cancer).
PTPRT	771	771	R -> I (in a lung cancer).
PTPRT	905	905	D -> G (in a colorectal cancer).
PTPRT	965	965	Q -> K (in a colorectal cancer; reduced phosphatase activity).
PTPRT	1096	1096	A -> P (in a colorectal cancer).
PTPRT	1106	1106	N -> I (in a colorectal cancer; reduced phosphatase activity).
PTPRT	1190	1190	R -> W (in a colorectal cancer; reduced phosphatase activity).
PTPRT	1213	1213	P -> L (in an acute myeloid leukemia sample; somatic mutation).
PTPRT	1237	1237	M -> L (in a colorectal cancer).
PTPRT	1247	1247	V -> M (in a colorectal cancer).
PTPRT	1324	1324	R -> L (in a lung cancer; reduced phosphatase activity).
PTPRT	1329	1329	Y -> F (in a colorectal cancer).
PTPRT	1346	1346	T -> M (in some colorectal cancers; reduced phosphatase activity).
HNF4A	136	136	R -> W (in MODY1).
HNF4A	264	264	V -> M (in late-onset NIDDM).
HNF4A	285	285	E -> Q (in MODY1).
HNF4A	402	402	V -> I (in MODY1; reduced transactivation activity).
HNF4A	453	453	V -> I.
NCOA3	220	220	R -> I.
NCOA3	556	556	I -> V.
NCOA3	1247	1247	M -> K.
NCOA3	1247	1247	M -> L.
NCOA3	1248	1250	Missing.
HRH3	280	280	A -> V (in one Shy-Drager syndrome patient; rare variant with unknown pathological significance).
KCNQ2	207	207	R -> Q (in a patient with isolated myokymia and no history of neonatal seizures; leads to a shift of voltage- dependent activation).
KCNQ2	207	207	R -> W (in EBN1; phenotype manifestations include myokymia in some patients; leads to a shift of voltage-dependent activation of the channel and a dramatic slowing of activation upon depolarization).
KCNQ2	208	208	M -> V (in EBN1; minor effect on maximal current but clearly exhibits a faster rate of deactivation).
KCNQ2	228	228	H -> Q (in EBN1).
KCNQ2	243	243	L -> F (in EBN1).
KCNQ2	247	247	S -> W (in EIEE7; reduces channel currents by more than 50% in homomeric channels).
KCNQ2	306	306	A -> T (in EBN1; 20%-40% reduction of wt heteromeric current. Ratio of 1:1:2).
KCNQ2	333	333	R -> Q (in EBN1; moderate effect; less than 50% reduction in current compared with wt heteromeric channels).
KCNQ2	554	554	K -> N (in EBN1 and EIEE7; decreases the voltage-dependence of the channel).
ARFRP1	108	108	L -> V (in a breast cancer sample; somatic mutation).
NPBWR2	92	92	G -> R (in a colorectal cancer sample; somatic mutation).
AHCY	49	49	R -> C (in HMAHCHD).
AHCY	86	86	D -> G (in HMAHCHD).
AHCY	86	86	D -> N.
AHCY	89	89	A -> V (in HMAHCHD).
AHCY	143	143	Y -> C (in HMAHCHD).
PDYN	138	138	R -> S (in SCA23; PDYN, dynorphin A and dynorphin B are located in Purkinje cells as observed in control cerebellum, but cerebellar tissue with the mutation has decreased levels of SLC1A6 and CALB1, both of which are markers of Purkinje cells; SLC1A6 accumulates and aggregates in patient cerebellar tissue).
PDYN	211	211	L -> S (in SCA23; the mutant PDYN protein is produced, but processing to opioid peptides is dramatically affected, with increased levels of dynorphin A compared to dynorphin B; these results suggest slow conversion of dynorphin A to short enkephalins; mutant S-211 dynorphin A is not neurotoxic to cultured striatal neurons).
PDYN	212	212	R -> W (in SCA23; the mutant PDYN protein is produced, but processing to opioid peptides is dramatically affected, with increased levels of dynorphin A compared to dynorphin B; mutant dynorphin A is neurotoxic to cultured striatal neurons, suggesting a dominant-negative effect).
PDYN	215	215	R -> C (in SCA23; the mutant PDYN protein is produced, but processing to opioid peptides is dramatically affected, resulting in an approximately 2-fold decreased level of dynorphin B compared to dynorphin A; mutant dynorphin A is neurotoxic to cultured striatal neurons, suggesting a dominant-negative effect).
TRIB3	60	60	T -> I (in a glioblastoma multiforme sample; somatic mutation).
PAK7	312	312	S -> P (in a colorectal adenocarcinoma sample; somatic mutation).
PAK7	538	538	T -> N (in a lung adenocarcinoma sample; somatic mutation).
PAK7	604	604	V -> I (in a metastatic melanoma sample; somatic mutation).
PAK7	704	704	G -> S (in a metastatic melanoma sample; somatic mutation).
SIRPA	6	7	PA -> RS.
SIRPA	20	20	A -> P.
SIRPA	40	40	D -> E.
SIRPA	61	61	I -> N.
SIRPA	68	68	W -> R.
SIRPA	77	77	E -> K.
SIRPA	81	81	N -> H.
SIRPA	95	95	D -> E.
SIRPA	96	96	L -> S.
SIRPA	100	100	N -> E (requires 2 nucleotide substitutions).
SIRPA	125	125	R -> Q.
SIRPA	132	132	V -> T (requires 2 nucleotide substitutions).
SIRPA	134	134	F -> L.
SIRPA	163	163	Q -> D (requires 2 nucleotide substitutions).
SIRPA	181	181	T -> S.
SIRPA	190	190	E -> Q.
SIRPA	201	202	VG -> AR.
SIRPA	214	214	K -> N.
SIRPA	220	220	E -> G.
SIRPA	222	222	V -> I.
SIRPA	236	236	Q -> R.
SIRPA	239	240	PL -> SF.
SIRPA	251	251	R -> Q.
SIRPA	261	261	Q -> L.
SIRPA	263	263	V -> M.
SIRPA	271	271	V -> I.
SIRPA	276	276	R -> T.
SIRPA	339	339	P -> S.
SIRPA	353	353	P -> L.
SIRPA	357	357	G -> S.
SIRPA	367	367	S -> P.
SIRPA	370	370	R -> Q.
SIRPA	389	389	A -> E.
SIRPA	443	443	Q -> R.
SIRPA	460	460	P -> L.
SIRPA	486	486	A -> L (requires 2 nucleotide substitutions).
SIRPA	491	491	P -> L.
KIF16B	772	772	K -> T (in a breast cancer sample; somatic mutation).
PCSK2	424	424	D -> N (in a colorectal cancer sample; somatic mutation).
DSTN	139	139	G -> E (in a colorectal cancer sample; somatic mutation).
TGM6	327	327	D -> G (in SCA35).
TGM6	517	517	L -> W (in SCA35).
IDH3B	132	132	L -> P (in RP46).
AVP	17	17	S -> F (in ADNDI).
AVP	19	19	A -> T (in ADNDI; probably causes insufficient processing of precursor).
AVP	19	19	A -> V (in ADNDI).
AVP	21	21	Y -> H (in ADNDI).
AVP	26	26	P -> L (in ARNDI; weakly active).
AVP	45	45	G -> R (in ADNDI).
AVP	48	48	G -> V (in ADNDI).
AVP	51	51	R -> C (in ADNDI).
AVP	52	52	C -> R (in ADNDI).
AVP	54	54	G -> R (in ADNDI).
AVP	54	54	G -> V (in ADNDI).
AVP	55	55	P -> L (in ADNDI).
AVP	58	58	C -> F (in ADNDI).
AVP	59	59	C -> R (in ADNDI).
AVP	59	59	C -> Y (in ADNDI).
AVP	78	78	E -> G (in ADNDI).
AVP	78	78	Missing (in ADNDI).
AVP	81	81	L -> P (in ADNDI).
AVP	87	87	S -> F (in ADNDI).
AVP	88	88	G -> R (in ADNDI).
AVP	88	88	G -> S (in ADNDI).
AVP	92	92	C -> S (in ADNDI).
AVP	92	92	C -> Y (in ADNDI).
AVP	93	93	G -> W (in ADNDI).
AVP	96	96	G -> C (in ADNDI).
AVP	96	96	G -> D (in ADNDI).
AVP	96	96	G -> V (in ADNDI).
AVP	97	97	R -> C (in ADNDI).
AVP	97	97	R -> P (in ADNDI).
AVP	98	98	C -> G (in ADNDI).
AVP	98	98	C -> S (in ADNDI).
AVP	99	99	A -> P (in ADNDI).
AVP	104	104	C -> F (in ADNDI).
AVP	104	104	C -> G (in ADNDI).
AVP	105	105	C -> R (in ADNDI).
AVP	105	105	C -> Y (in ADNDI).
AVP	116	116	C -> G (in ADNDI; strong accumulation in the endoplasmic reticulum and an altered morphology of this organelle).
AVP	116	116	C -> R (in ADNDI).
AVP	116	116	C -> W (in ADNDI).
SLC4A11	72	72	N -> T.
SLC4A11	91	91	M -> V.
SLC4A11	125	125	R -> H (in CHED2).
SLC4A11	160	160	A -> T (in CHED2).
SLC4A11	167	167	E -> D (in FECD4; interferes with post- translational processing; the mutant protein localizes to the cytoplasm).
SLC4A11	209	209	R -> W (in CHED2).
SLC4A11	213	213	S -> L (in CHED2).
SLC4A11	213	213	S -> P (in CDPD).
SLC4A11	233	233	R -> C (in CHED2).
SLC4A11	269	269	A -> V (in CHED2; affects transport to the cell surface).
SLC4A11	282	282	R -> P (in FECD4; interferes with post- translational processing; the mutant protein localizes to the cytoplasm).
SLC4A11	327	327	A -> V.
SLC4A11	386	386	C -> R (in CHED2).
SLC4A11	394	394	G -> R (in CHED2).
SLC4A11	399	399	E -> K (in FECD4; affects protein processing and transport to the cell surface).
SLC4A11	401	401	T -> K (in CHED2).
SLC4A11	408	408	Q -> H.
SLC4A11	409	409	K -> N.
SLC4A11	418	418	G -> D (in CHED2).
SLC4A11	464	464	G -> D (in CHED2; affects protein processing and transport to the cell surface).
SLC4A11	473	473	L -> R (in CHED2).
SLC4A11	483	483	M -> T.
SLC4A11	488	488	R -> K (in CDPD).
SLC4A11	489	489	S -> L (in CHED2; affects protein processing and transport to the cell surface).
SLC4A11	526	526	Y -> C (in FECD4; does not interferes with post-translational processing; the mutant protein partially localizes to the cytoplasm).
SLC4A11	561	561	T -> M.
SLC4A11	565	565	S -> L.
SLC4A11	575	575	V -> M (in FECD4; does not interferes with post-translational processing; the mutant protein partially localizes to the cytoplasm).
SLC4A11	583	583	G -> D (in FECD4; interferes with post- translational processing; the mutant protein localizes to the cytoplasm).
SLC4A11	584	584	T -> K (in CHED2).
SLC4A11	708	708	T -> A.
SLC4A11	709	709	G -> E (in FECD4; affects protein processing and transport to the cell surface).
SLC4A11	742	742	G -> R (in FECD4; interferes with post- translational processing; the mutant protein partially localizes to the cytoplasm).
SLC4A11	754	754	T -> M (in FECD4; affects protein processing and transport to the cell surface).
SLC4A11	755	755	R -> Q (in CHED2; affects protein processing and transport to the cell surface).
SLC4A11	755	755	R -> W (in CHED2).
SLC4A11	773	773	P -> L (in CHED2).
SLC4A11	804	804	R -> H (in CHED2).
SLC4A11	824	824	V -> M (in CHED2; deafness not assessed).
SLC4A11	833	833	T -> M (in CHED2).
SLC4A11	834	834	G -> S (in FECD4; does not interferes with post-translational processing; the mutant protein partially localizes to the cytoplasm).
SLC4A11	843	843	L -> P (in CDPD).
SLC4A11	856	856	M -> V (in CDPD).
SLC4A11	869	869	R -> C (in CHED2; affects protein processing and transport to the cell surface).
SLC4A11	869	869	R -> H (in CHED2).
SLC4A11	873	873	L -> P (in CHED2).
PANK2	94	94	R -> P.
PANK2	111	111	L -> Q.
PANK2	134	134	E -> G (in NBIA1).
PANK2	219	219	G -> V (in NBIA1; atypical).
PANK2	234	234	T -> A (in NBIA1; atypical).
PANK2	249	249	R -> P (in NBIA1).
PANK2	264	264	R -> W (in NBIA1).
PANK2	278	278	R -> C (in NBIA1; atypical).
PANK2	278	278	R -> L (in NBIA1).
PANK2	282	282	L -> V (in NBIA1).
PANK2	286	286	R -> C (in NBIA1).
PANK2	322	322	E -> D (in NBIA1; atypical).
PANK2	322	322	E -> G (in NBIA1).
PANK2	327	327	T -> I (in NBIA1).
PANK2	351	351	S -> P (in NBIA1; atypical).
PANK2	355	355	N -> S (in NBIA1; atypical).
PANK2	357	357	R -> Q (in NBIA1).
PANK2	398	398	A -> T (in NBIA1).
PANK2	404	404	N -> I (in NBIA1; atypical).
PANK2	413	413	L -> P (in NBIA1).
PANK2	425	425	Missing (in NBIA1).
PANK2	428	428	C -> Y (in NBIA1).
PANK2	447	447	D -> N (in NBIA1).
PANK2	471	471	S -> N (in NBIA1).
PANK2	497	497	I -> T (in NBIA1).
PANK2	500	500	N -> I (in NBIA1).
PANK2	501	501	I -> T (in NBIA1; atypical).
PANK2	509	509	A -> V (in NBIA1).
PANK2	511	511	N -> D (in NBIA1).
PANK2	521	521	G -> R (in NBIA1; classic and atypical forms).
PANK2	528	528	T -> M (in NBIA1; classic and atypical forms).
PANK2	532	532	R -> W (in NBIA1).
PANK2	563	563	L -> P (in NBIA1).
PANK2	570	570	P -> L (in NBIA1; atypical).
SMOX	340	340	Q -> K (in a breast cancer sample; somatic mutation).
SMOX	522	522	H -> Y.
PRNP	56	63	Missing.
PRNP	102	102	P -> L (in GSD and early-onset dementia).
PRNP	105	105	P -> L (in GSD).
PRNP	117	117	A -> V (linked to development of dementing Gerstmann-Straussler disease).
PRNP	131	131	G -> V (in GSD).
PRNP	178	178	D -> N (in FFI and CJD).
PRNP	180	180	V -> I (in CJD).
PRNP	183	183	T -> A (in familial spongiform encephalopathy).
PRNP	187	187	H -> R (in GSD).
PRNP	188	188	T -> K (in early-onset dementia; dementia associated to prion diseases).
PRNP	188	188	T -> R.
PRNP	196	196	E -> K (in CJD).
PRNP	198	198	F -> S (in GSD; atypical form with neurofibrillary tangles).
PRNP	200	200	E -> K (in CJD).
PRNP	202	202	D -> N (in GSD).
PRNP	203	203	V -> I (in CJD; it could be an extremely rare polymorphism).
PRNP	208	208	R -> H (in CJD).
PRNP	210	210	V -> I (in CJD).
PRNP	211	211	E -> Q (in CJD).
PRNP	212	212	Q -> P (in GSD).
PRNP	217	217	Q -> R (in GSD; with neurofibrillary tangles).
PRNP	232	232	M -> R (in CJD).
PRNP	238	238	P -> S.
PRND	6	6	S -> I.
PRND	22	22	S -> P.
PRND	26	26	T -> P.
PRND	31	31	H -> R.
PRND	70	70	F -> L.
PRND	149	149	L -> S.
RASSF2	144	144	R -> H (in a colorectal cancer sample; somatic mutation).
TOP1	326	326	K -> R (in breast cancer; somatic mutation).
TOP1	370	370	M -> T (in CPT-resistant leukemia).
TOP1	533	533	D -> G (in CPT-resistant leukemia).
TOP1	722	722	N -> S (in CPT-resistant leukemia).
TOP1	729	729	T -> A (in CPT-resistant lung cancer).
PROKR2	85	85	R -> C.
PROKR2	85	85	R -> H (in KAL3).
PROKR2	164	164	R -> Q (in KAL3).
PROKR2	173	173	L -> R (in KAL3).
PROKR2	178	178	W -> S (in KAL3).
PROKR2	210	210	Q -> R (in KAL3).
PROKR2	268	268	R -> C.
PROKR2	290	290	P -> S (in KAL3).
PROKR2	323	323	M -> I (in KAL3).
PROKR2	331	331	V -> M.
PROKR2	335	335	T -> M.
SLC2A10	81	81	S -> R (in ATS).
SLC2A10	132	132	R -> W (in ATS).
SLC2A10	142	142	G -> V (in ATS).
SLC2A10	231	231	R -> Q (in ATS).
SLC2A10	246	246	G -> E (in ATS).
SLC2A10	426	426	G -> W (in ATS).
SLC2A10	437	437	E -> K (in ATS).
SLC2A10	445	445	G -> E (in ATS).
SULF2	531	531	Y -> H (in a breast cancer sample; somatic mutation).
SULF2	573	573	D -> N (in a breast cancer sample; somatic mutation).
SAMHD1	123	123	H -> P (in AGS5).
SAMHD1	143	143	R -> C (in AGS5).
SAMHD1	143	143	R -> H (in AGS5).
SAMHD1	145	145	R -> Q (in AGS5).
SAMHD1	201	201	I -> N (in AGS5).
SAMHD1	209	209	G -> S (in AGS5).
SAMHD1	254	254	M -> V (in AGS5).
SAMHD1	369	369	L -> S (in AGS5).
SAMHD1	385	385	M -> V (in AGS5).
BMP7	198	198	L -> P (found in a patient with unilateral microphthalmia, optic disk and chorioretinal coloboma, mild learning difficulties).
BMP7	321	321	N -> S.
VAPB	56	56	P -> S (in ALS8 and SMAPAD).
CHRNA4	280	280	S -> F (in ENFL1).
CHRNA4	280	280	S -> L (in ENFL1).
ANKRD5	694	694	K -> N (in a breast cancer sample; somatic mutation).
MKKS	32	32	I -> M (in BBS6).
MKKS	37	37	Y -> C (in MKKS; in the heterozygous state; sporadic and in BBS6; in the homozygous state; causes both increased MKKS protein degradation and reduced solubility relative to wild-type and Tyr- 84 mutant; the mutant is immobilized at the centrosome even in the absence of proteasome inhibition; the mutant is also highly polyubiquitinated).
MKKS	49	49	G -> V.
MKKS	57	57	T -> A (in BBS6; causes both increased MKKS protein degradation and reduced solubility relative to wild-type and Tyr- 84 mutant; greatly reduces the ability to interact with BBS12 (decreases to 4% of wild-type)).
MKKS	84	84	H -> Y (in MKKS; may interfere with ATP hydrolysis).
MKKS	155	155	R -> L (in BBS6; increases MKKS protein degradation only; localizes properly to the centrosome).
MKKS	181	181	A -> P (in BBS6).
MKKS	236	236	S -> P (in BBS6).
MKKS	237	237	T -> A (in BBS6).
MKKS	237	237	T -> P (in BBS6).
MKKS	242	242	A -> S (in MKKS and BBS6; increases MKKS protein degradation only).
MKKS	277	277	L -> P (in BBS6; moderately affects interaction with BBS2 (decreases to 42% of wild-type); greatly reduces the ability to interact with BBS12 (decreases to 18% of wild-type)).
MKKS	286	286	D -> A (in BBS6; fails to associate with centrosome).
MKKS	325	325	T -> P (has a modifier effect on BBS; causes a mislocalization of the protein; fails to associate with centrosome).
MKKS	339	339	I -> V (in BBS6).
MKKS	345	345	G -> E (in BBS6; increases MKKS protein degradation only; proteasome inhibition results in aggregation of the mutant at the centrosome; fails to associate with centrosome; the mutants is also highly polyubiquitinated and immunoprecipitation analysis reveals that the rapidly degraded mutant is recognized by components of the ubiquitin-proteasome protein degradation pathway).
MKKS	460	460	S -> P (in BBS6).
MKKS	492	492	D -> N (in BBS6).
MKKS	499	499	C -> S (in BBS6; causes both increased MKKS protein degradation and reduced solubility relative to wild-type and Tyr- 84 mutant; localizes properly to the centrosome).
MKKS	511	511	S -> A (in BBS6).
MKKS	518	518	R -> H (in BBS6).
JAG1	22	25	Missing (in ALGS1).
JAG1	31	31	A -> V (in ALGS1).
JAG1	33	33	G -> D (in ALGS1).
JAG1	33	33	G -> S (in ALGS1).
JAG1	33	33	G -> V (in ALGS1).
JAG1	37	37	L -> S (in ALGS1).
JAG1	39	39	I -> S (in ALGS1).
JAG1	40	40	L -> P (in ALGS1).
JAG1	45	45	V -> L (in biliary atresia; extrahepatic).
JAG1	53	53	N -> D (in biliary atresia; extrahepatic).
JAG1	65	65	K -> M (in biliary atresia; extrahepatic).
JAG1	75	75	F -> S (in ALGS1).
JAG1	78	78	C -> S (in ALGS1).
JAG1	79	79	L -> H (in ALGS1).
JAG1	92	92	C -> R (in ALGS1).
JAG1	92	92	C -> Y (in ALGS1).
JAG1	120	120	I -> N (in ALGS1).
JAG1	123	123	P -> S (in ALGS1).
JAG1	127	127	A -> T (in ALGS1).
JAG1	129	129	P -> R (in ALGS1).
JAG1	152	152	I -> T (in ALGS1).
JAG1	155	155	A -> P (in ALGS1).
JAG1	163	163	P -> L (in ALGS1).
JAG1	163	163	P -> R (in ALGS1).
JAG1	181	181	Y -> N (in ALGS1).
JAG1	184	184	R -> C (in ALGS1).
JAG1	184	184	R -> G (in ALGS1).
JAG1	184	184	R -> H (in ALGS1).
JAG1	184	184	R -> L (in ALGS1).
JAG1	187	187	C -> S (in ALGS1).
JAG1	187	187	C -> Y (in ALGS1).
JAG1	203	203	R -> K (in biliary atresia; extrahepatic).
JAG1	220	220	C -> F (in ALGS1).
JAG1	224	224	W -> C (in ALGS1).
JAG1	229	229	C -> G (in ALGS1).
JAG1	229	229	C -> Y (in ALGS1).
JAG1	234	234	C -> Y (in deafness; with congenital heart defects and posterior embryotoxon).
JAG1	252	252	R -> G (in ALGS1).
JAG1	256	256	G -> S (in ALGS1).
JAG1	269	269	P -> L (in ALGS1).
JAG1	271	271	C -> R (in ALGS1).
JAG1	284	284	C -> F (in ALGS1).
JAG1	288	288	W -> C (in ALGS1).
JAG1	386	386	G -> R (in ALGS1).
JAG1	438	438	C -> F (in ALGS1).
JAG1	504	504	N -> S (in ALGS1).
JAG1	690	690	Y -> D (in biliary atresia; extrahepatic).
JAG1	693	693	C -> Y (in ALGS1).
JAG1	714	714	C -> Y (in ALGS1).
JAG1	731	731	C -> S (in ALGS1).
JAG1	740	740	C -> R (in ALGS1).
JAG1	753	753	C -> R (in ALGS1).
JAG1	818	818	R -> K.
JAG1	889	889	R -> Q (in ALGS1).
JAG1	902	902	C -> S (in ALGS1).
JAG1	908	908	H -> Q (in biliary atresia; extrahepatic).
JAG1	911	911	C -> Y (in ALGS1).
JAG1	913	913	S -> R (in ALGS1).
JAG1	921	921	L -> P (in biliary atresia; extrahepatic).
JAG1	937	937	R -> Q (in ALGS1).
JAG1	1055	1056	VR -> G (in ALGS1).
JAG1	1213	1213	R -> Q (in biliary atresia; extrahepatic).
SGK2	259	259	E -> K (in a lung adenocarcinoma sample; somatic mutation).
COL9A3	103	103	R -> Q.
COL9A3	103	103	R -> W.
COL9A3	402	402	R -> Q.
COL9A3	563	565	Missing.
COL9A3	564	566	Missing.
NDUFAF5	229	229	L -> P (in MT-C1D).
FLRT3	452	452	I -> V (found in a renal cell carcinoma case; somatic mutation).
SALL4	888	888	H -> R (in DRRS).
ARFGEF2	794	794	K -> E (in a breast cancer sample; somatic mutation).
CSE1L	842	842	C -> F (in a colorectal cancer sample; somatic mutation).
SNRPB2	19	19	K -> Q (in a colorectal cancer sample; somatic mutation).
SEC23B	14	14	R -> W (in CDA2; the mutant protein is unstable with less than 5% of protein detectable compared to wild-type).
SEC23B	18	18	R -> H.
SEC23B	109	109	E -> K (in CDA2; the mutant protein is unstable with less than 5% of protein detectable compared to wild-type).
SEC23B	239	239	D -> G (the mutant protein is expressed as the wild-type).
SEC23B	313	313	R -> H.
SEC23B	318	318	I -> T.
SEC23B	348	348	D -> A (in CDA2).
SEC23B	386	386	Q -> R.
SEC23B	462	462	Y -> C.
SEC23B	497	497	R -> C (in CDA2; uncertain pathogenicity).
SEC23B	524	524	A -> V.
SEC23B	530	530	R -> W (in CDA2).
SEC23B	603	603	S -> L (in CDA2).
SEC23B	701	701	R -> C (in CDA2).
PAX1	139	139	Q -> H (in a patient with neural tube defects, but not clearly linked to the disease).
FOXA2	328	328	A -> V (in Japanese subjects with maturity-onset diabetes of the young; pathological significance unknown).
DPM1	92	92	R -> G (in CDG1E).
DPM1	248	248	S -> P (in CDG1E).
THBD	34	34	D -> E (in AHUS6).
THBD	53	53	D -> G (in AHUS6; cells transfected with the mutant are less effective in converting C3b to iC3b on the cell surface after complement activation).
THBD	81	81	V -> L (in AHUS6; cells transfected with the mutant are less effective in converting C3b to iC3b on the cell surface after complement activation).
THBD	236	236	A -> G (in AHUS6).
CD93	220	220	A -> V (in a colorectal cancer sample; somatic mutation).
CD93	318	318	V -> A.
ADA	8	8	D -> N (in allele ADA*2; in about 10% of the population; 20% to 30% decrease in activity; affects duration and intensity of deep sleep).
ADA	304	304	L -> R (in ADASCID; loss of activity).
ADA	337	337	Missing (in ADASCID).
YWHAB	99	99	V -> I (found in a renal cell carcinoma sample; somatic mutation).
GZF1	97	97	A -> V (found in a renal cell carcinoma sample; somatic mutation).
CST4	77	77	T -> N (in a breast cancer sample; somatic mutation).
VSX1	144	144	D -> E (in PPCD1 and KTCN1).
VSX1	159	159	L -> M (in KTCN1).
VSX1	160	160	G -> D (in PPCD1).
VSX1	166	166	R -> W (in KTCN1; sporadic).
VSX1	175	175	Q -> H (in KTCN1).
VSX1	244	244	H -> R (in KTCN1; could be a polymorphism).
VSX1	247	247	P -> R (in a patient with retinal dysfunction).
COX4I2	138	138	E -> K (in EPIDACH; expression in patient fibroblasts is reduced to 25% of control values in normoxic conditions; the mutant protein shows an impaired response to hypoxia).
TPX2	464	464	T -> N (in a colorectal cancer sample; somatic mutation).
DNMT3B	270	270	S -> P (in ICF).
DNMT3B	585	585	A -> V (in ICF).
DNMT3B	603	603	A -> T (in ICF).
DNMT3B	606	606	V -> A (in ICF).
DNMT3B	663	663	G -> S (in ICF).
DNMT3B	664	664	L -> P (in ICF).
DNMT3B	699	699	V -> G (in ICF).
DNMT3B	726	726	V -> G (in ICF).
DNMT3B	766	766	A -> P (in ICF).
DNMT3B	806	806	E -> ESTP (in ICF).
DNMT3B	814	814	H -> R (in ICF).
DNMT3B	817	817	D -> G (in ICF).
DNMT3B	818	818	V -> M (in ICF).
DNMT3B	840	840	R -> Q (in ICF).
BPIFB2	20	20	A -> V (in a colorectal cancer sample; somatic mutation).
BPIFB6	296	296	R -> H (de novo variant found in a patient with mental retardation).
SNTA1	257	257	A -> G (in LQT12; leads to a gain of function of the voltage dependent sodium channel).
SNTA1	390	390	A -> V (in LQT12; results in released inhibition of nNOS, S-nitrosylation of SCN5A and increased late sodium current).
CHMP4B	129	129	D -> V (in CTPP3).
CHMP4B	161	161	E -> K (in CTPP3).
NCOA6	1060	1060	P -> S (in a breast cancer sample; somatic mutation).
NCOA6	1191	1191	S -> R (in a breast cancer sample; somatic mutation).
GSS	26	26	A -> D (in GSS deficiency).
GSS	188	188	L -> P (in GSS deficiency; 100-fold reduction of activity).
GSS	219	219	D -> A (in GSS deficiency).
GSS	254	254	L -> R (in GSS deficiency).
GSS	267	267	R -> W (in GSS deficiency).
GSS	270	270	Y -> C (in GSS deficiency; 100-fold reduction of activity).
GSS	270	270	Y -> H (in GSS deficiency; 100-fold reduction of activity).
GSS	283	283	R -> C (in GSS deficiency; 10-fold reduction of activity).
GSS	286	286	L -> Q (in GSS deficiency).
GSS	330	330	R -> C (in GSS deficiency).
GSS	464	464	G -> V (in GSS deficiency).
GSS	469	469	D -> E (in GSS deficiency).
ERGIC3	297	297	T -> K (in a colorectal cancer sample; somatic mutation).
TGM2	330	330	M -> R (in patients with early-onset diabetes type 2).
TGM2	331	331	I -> N (in patients with early-onset diabetes type 2).
TGM2	660	660	G -> V (in a colorectal cancer sample; somatic mutation).
PLCG1	739	739	S -> T.
SRSF6	145	145	R -> Q (in a colorectal cancer sample; somatic mutation).
JPH2	101	101	S -> R (in CMH17; affects intracellular calcium handling and homeostasis).
JPH2	141	141	Y -> H (in CMH17; results in vacuolization of intracellular structures and cardiomyocyte hypertrophy; affects intracellular calcium handling and homeostasis).
JPH2	165	165	S -> F (in CMH17; results in vacuolization of intracellular structures and cardiomyocyte hypertrophy; affects intracellular calcium handling and homeostasis. Greatly reduced phosphorylation. Increased myotube diameter. Reduced RYR1 activity and EC gain. Disruption of interaction with TRPC3).
JPH2	436	436	R -> C.
JPH2	505	505	G -> S (in patients with cardiomyopathy; does not affect protein conformation as shown by circular dichroism; a patient with cardiomyopathy also carries V-26 and C-513 in MYH7).
GDAP1L1	141	141	R -> W (in a colorectal cancer sample; somatic mutation).
SERINC3	437	437	T -> A.
UBE2C	25	25	G -> D.
CTSA	49	49	Q -> R (in GSL).
CTSA	51	51	S -> Y (in GSL).
CTSA	90	90	S -> L (in GSL).
CTSA	132	132	V -> M (in GSL).
CTSA	236	236	L -> P (in GSL).
CTSA	249	249	Y -> N (in GSL; small amount of activity).
CTSA	395	395	Y -> C (in GSL; loss of activity).
CTSA	406	406	M -> T (in GSL).
CTSA	439	439	G -> S (in GSL).
CTSA	440	440	F -> V (in GSL).
CTSA	453	453	K -> E (in GSL).
PLTP	282	282	R -> Q.
PLTP	372	372	R -> H.
SLC12A5	847	847	G -> D (in a colorectal cancer sample; somatic mutation).
CD40	26	26	C -> Q (in bladder carcinoma cell line Hu549; requires 2 nucleotide substitutions).
CD40	35	35	S -> G (in bladder carcinoma cell line Hu549).
CD40	39	39	S -> T (in bladder carcinoma cell line Hu549).
TP53RK	25	25	A -> T.
UQCC	44	44	W -> S (in a breast cancer sample; somatic mutation).
GDF5	373	373	L -> R (in SYM1; the mature GDF5 protein is detected as the wild-type in the supernatant derived from the mutant transfected cells).
GDF5	378	378	R -> Q (in DPS).
GDF5	380	380	R -> Q (in BDA2; reduces activity; impairs processing).
GDF5	399	399	R -> C (in BDA1; less effective than wild-type in stimulating chondrogenesis).
GDF5	400	400	C -> Y (in AMDG).
GDF5	436	436	P -> T (in DPS).
GDF5	437	437	Missing (in DPS; located on the same allele as T-439 and L-440).
GDF5	438	438	R -> L (in SYNS2 and SYM1; increased biologic activity when compared to wild- type; normal binding to BMPR1B ectodomain but increased binding to that of BMPR1A).
GDF5	439	439	S -> T (in DPS; located on the same allele as L-437 del and L-440).
GDF5	440	440	H -> L (in DPS; located on the same allele as L-437 del and T-439).
GDF5	475	475	S -> N (in SYNS2).
GDF5	491	491	E -> K (in SYM1).
PTGIS	38	38	P -> L (in allele CYP8A1*2).
PTK6	16	16	L -> F (in a renal papillary sample; somatic mutation).
SLC52A3	36	36	E -> K (in BVVLS).
SLC52A3	132	132	R -> W (in BVVLS).
SLC52A3	224	224	F -> L (in BVVLS).
SLC52A3	350	350	L -> M (may be a common polymorphism).
SLC52A3	413	413	V -> A (in BVVLS; may cause a mild form of the disease).
SLC52A3	457	457	F -> L (in BVVLS).
ZNF217	323	323	D -> N (in a colorectal cancer sample; somatic mutation).
RSPO4	65	65	Q -> R (in ANONC).
RSPO4	95	95	C -> F (in ANONC).
RSPO4	107	107	C -> R (in ANONC).
RSPO4	118	118	C -> Y (in ANONC).
MC3R	183	183	I -> N (associated with susceptibility to obesity; completely lacks signaling in response to agonist stimulation; coexpression of the wild-type and the mutant receptor shows that it does not exert dominant-negative activity on wild- type).
MC3R	335	335	I -> S (associated with susceptibility to obesity; in vitro expression studies demonstrate that the mutation causes complete loss of function; transfected cells show diffuse cytoplasmic staining indicating intracellular retention of the receptor).
AURKA	155	155	S -> R (in a colorectal adenocarcinoma sample; somatic mutation; reduces interaction with TPX2).
AURKA	174	174	V -> M (in a metastatic melanoma sample; somatic mutation; constitutively enhanced kinase activity).
GNAS	99	99	L -> P (in AHO).
GNAS	106	106	I -> S (in AHO/PHP1A).
GNAS	115	115	P -> L (in AHO).
GNAS	156	156	D -> N (in PHP1A).
GNAS	159	159	V -> M (in PHP1A).
GNAS	165	165	R -> C (in AHO).
GNAS	201	201	R -> G (in MAS).
GNAS	201	201	R -> H (in MAS, somatotrophinoma and AIMAH).
GNAS	201	201	R -> L (in non-MAS endocrine tumors).
GNAS	201	201	R -> S (in AIMAH, pituitary tumor and polyostotic fibrous dysplasia).
GNAS	227	227	Q -> H (in pituitary adenoma; ACTH- secreting adenoma; in a patient with severe Cushing syndrome complicated by psychosis).
GNAS	227	227	Q -> R (in somatotrophinoma).
GNAS	231	231	R -> H (in AHO; impairs the ability to mediate hormonal stimulation).
GNAS	242	242	T -> I (in AHO).
GNAS	246	246	F -> S (in AHO).
GNAS	250	250	S -> R (in AHO; may alter guanine nucleotide binding which could lead to thermolability and impaired function).
GNAS	258	258	R -> W (in AHO; defective GDP binding resulting in increased thermolability and decreased activation).
GNAS	259	259	E -> V (in AHO).
GNAS	280	280	R -> G (in PHP1A).
GNAS	280	280	R -> K (in PHP1A).
GNAS	281	281	W -> R (in POH).
GNAS	338	338	K -> N (in PHP1A).
GNAS	366	366	A -> S (in AHO; paradoxical combination of AHO and testotoxicosis; constitutively activates adenylyl cyclase in vitro; accounts for the testotoxicosis phenotype; mutant form is quite stable at testis temperature; rapidly degraded at 37 degrees explaining the AHO phenotype caused by loss of Gs activity).
GNAS	382	382	Missing (unable to interact with the receptor for PTH).
GNAS	385	385	R -> H (in AHO; uncouples receptors from adenylyl cyclases).
HCK	399	399	D -> G (in an ovarian mucinous carcinoma sample; somatic mutation).
APP	665	665	E -> D (in a patient with late onset Alzheimer disease).
APP	670	671	KM -> NL (in AD1).
APP	678	678	D -> N (in AD1).
APP	692	692	A -> G (in AD1; Flemish mutation; increases the solubility of processed beta-amyloid peptides and increases the stability of peptide oligomers).
APP	693	693	E -> G (in AD1).
APP	693	693	E -> K (in CAA-APP; Italian type).
APP	693	693	E -> Q (in CAA-APP; Dutch type).
APP	694	694	D -> N (in CAA-APP; Iowa type).
APP	705	705	L -> V (in CAA-APP; Italian type).
APP	713	713	A -> T (in AD1).
APP	714	714	T -> A (in AD1).
APP	714	714	T -> I (in AD1; increased beta-APP42/ beta-APP40 ratio).
APP	715	715	V -> M (in AD1; decreased beta-APP40/ total APP-beta).
APP	716	716	I -> V (in AD1).
APP	717	717	V -> F (in AD1).
APP	717	717	V -> G (in AD1).
APP	717	717	V -> I (in AD1).
APP	717	717	V -> L (in AD1).
APP	723	723	L -> P (in AD1).
TIAM1	678	678	R -> C (in a colorectal cancer sample; somatic mutation).
TIAM1	1339	1339	A -> V (in a colorectal cancer sample; somatic mutation).
RUNX1	139	139	R -> Q (in FPDMM).
RUNX1	174	174	R -> Q (in FPDMM; impaired phosphorylation).
DYRK1A	415	415	Y -> F.
DYRK1A	681	681	Q -> H.
TPTE	144	144	R -> Q (in a breast cancer sample; somatic mutation).
NRIP1	221	221	H -> R.
NRIP1	441	441	I -> V.
NRIP1	803	803	S -> L.
NRIP1	1079	1079	V -> F.
CYYR1	111	111	P -> S.
GRIK1	332	332	A -> V.
GRIK1	636	636	Q -> R (in RNA edited version).
GRIK1	862	862	R -> Q.
CLDN14	4	4	T -> M.
CLDN14	85	85	V -> D (in DFNB29).
HLCS	42	42	E -> D (in HLCS deficiency and a breast cancer sample; somatic mutation; conserves enzynatic wild-type activity; could be a polymorphism).
HLCS	183	183	R -> P (in HLCS deficiency; has normal or low KM values for biotin (non-KM mutant)).
HLCS	237	237	L -> P (in HLCS deficiency; has normal or low KM values for biotin (non-KM mutant)).
HLCS	333	333	V -> E (in HLCS deficiency; <10% activity; has normal or low KM values for biotin (non-KM mutant)).
HLCS	360	360	R -> S (in HLCS deficiency; 22% activity; shows elevated KM values for biotin (KM mutant) compared with that of the wild- type form).
HLCS	363	363	V -> D (in HLCS deficiency; has normal or low KM values for biotin (non-KM mutant)).
HLCS	456	456	Y -> C (in HLCS deficiency; 0.2% activity).
HLCS	462	462	T -> I (in HLCS deficiency; <10% activity).
HLCS	470	470	L -> S (in HLCS deficiency; 4.3% activity).
HLCS	508	508	R -> W (in HLCS deficiency).
HLCS	511	511	N -> K (in HLCS deficiency).
HLCS	518	518	G -> E (in HLCS deficiency).
HLCS	547	547	V -> G (in HLCS deficiency; 3.4% activity).
HLCS	550	550	V -> M (in HLCS deficiency).
HLCS	571	571	D -> N (in HLCS deficiency; almost no activity).
HLCS	581	581	G -> S (in HLCS deficiency; <10% activity).
HLCS	582	582	G -> R (in HLCS deficiency).
HLCS	610	610	Missing (in HLCS deficiency; 14% of activity; shows elevated KM values for biotin (KM mutant) compared with that of the wild-type form).
HLCS	615	615	D -> Y (in HLCS deficiency).
HLCS	634	634	D -> N (in HLCS deficiency).
HLCS	634	634	D -> Y (in HLCS deficiency; 12% activity).
HLCS	715	715	D -> G (in HLCS deficiency).
TTC3	1289	1289	K -> M (in a breast cancer sample; somatic mutation).
TMPRSS2	254	254	S -> C.
TMPRSS2	329	329	E -> Q.
TMPRSS2	491	491	D -> N.
UMODL1	173	173	V -> L.
UMODL1	274	274	N -> H.
UMODL1	447	447	R -> Q.
UMODL1	1027	1027	S -> N.
UMODL1	1068	1068	G -> S.
UMODL1	1115	1115	E -> K.
ABCG1	668	668	F -> L.
PKNOX1	265	265	V -> I (in a colorectal cancer sample; somatic mutation).
TRAPPC10	257	257	V -> E.
PFKL	81	81	G -> A.
PFKL	151	151	R -> W.
TSPEAR	166	166	A -> T (in a colorectal cancer sample; somatic mutation).
COL18A1	49	49	Q -> L.
COL18A1	111	111	G -> R.
COL18A1	1076	1076	V -> I.
COL18A1	1121	1121	P -> R.
COL18A1	1675	1675	D -> N (decreased activity for binding laminin; increased risk of developing prostate cancer; in compound heterozygotes may cause Knobloch syndrome when in combination with a frameshift/ truncating mutation).
LIPI	55	55	C -> Y (associated with FHTR).
LIPI	364	364	G -> E.
LIPI	431	431	E -> K.
LIPI	444	444	D -> E.
KRTAP20-1	52	52	S -> L (in a breast cancer sample; somatic mutation).
KRTAP21-1	15	15	G -> S (in a breast cancer sample; somatic mutation).
SOD1	5	5	A -> S (in ALS1).
SOD1	5	5	A -> T (in ALS1).
SOD1	5	5	A -> V (in ALS1; severe form; reduces structural stability and enzyme activity; increases tendency to form fibrillar aggegates).
SOD1	7	7	C -> F (in ALS1).
SOD1	8	8	V -> E (in ALS1).
SOD1	9	9	L -> Q (in ALS1).
SOD1	9	9	L -> V (in ALS1).
SOD1	13	13	G -> R (in ALS1).
SOD1	15	15	V -> G (in ALS1).
SOD1	15	15	V -> M (in ALS1).
SOD1	17	17	G -> S (in ALS1; sporadic young onset).
SOD1	21	21	F -> C (in ALS1).
SOD1	22	22	E -> G (in ALS1).
SOD1	22	22	E -> K (in ALS1).
SOD1	23	23	Q -> L (in ALS1).
SOD1	38	38	G -> R (in ALS1; mild form; ubiquitinated by RNF19A. Ubiquitinated by MARCH5; leading to the degradation of mitochondrial SOD1).
SOD1	39	39	L -> R (in ALS1).
SOD1	39	39	L -> V (in ALS1).
SOD1	42	42	G -> D (in ALS1).
SOD1	42	42	G -> S (in ALS1).
SOD1	44	44	H -> R (in ALS1; reduces structural stability and enzyme activity; increases tendency to form fibrillar aggegates).
SOD1	46	46	F -> C (in ALS1; slow progression).
SOD1	47	47	"H -> R (in ALS1; ""benign"" form; 80% of wild-type activity; ubiquitinated by RNF19A)."
SOD1	49	49	H -> Q (in ALS1).
SOD1	49	49	H -> R (in ALS1).
SOD1	50	50	E -> K (in ALS1).
SOD1	55	55	T -> R (in ALS1; reduces tendency to form fibrillar aggregates).
SOD1	66	66	N -> S (in ALS1).
SOD1	68	68	L -> P (in ALS1).
SOD1	68	68	L -> R (in ALS1).
SOD1	73	73	G -> S (in ALS1).
SOD1	77	77	D -> Y (in ALS1).
SOD1	81	81	H -> A (in ALS1; sporadic form; interferes with zinc binding; requires 2 nucleotide substitutions).
SOD1	85	85	L -> F (in ALS1).
SOD1	85	85	L -> V (in ALS1).
SOD1	86	86	G -> R (in ALS1; ubiquitinated by RNF19A; interferes with zinc-binding. Ubiquitinated by MARCH5; leading to the degradation of mitochondrial SOD1).
SOD1	88	88	V -> A (in ALS1).
SOD1	90	90	A -> T (in ALS1).
SOD1	90	90	A -> V (in ALS1).
SOD1	91	91	D -> A (in ALS1; does not seem to be linked with a decrease in activity).
SOD1	91	91	D -> V (in ALS1).
SOD1	94	94	G -> A (in ALS1; increases tendency to form fibrillar aggregates; ubiquitinated by RNF19A).
SOD1	94	94	G -> C (in ALS1).
SOD1	94	94	G -> D (in ALS1).
SOD1	94	94	G -> R (in ALS1; 30% of wild-type activity).
SOD1	94	94	G -> V (in ALS1).
SOD1	96	96	A -> G (in ALS1).
SOD1	98	98	V -> M (in ALS1; increases tendency to form fibrillar aggregates).
SOD1	101	101	E -> G (in ALS1).
SOD1	101	101	E -> K (in ALS1).
SOD1	102	102	D -> G (in ALS1).
SOD1	102	102	D -> N (in ALS1).
SOD1	105	105	I -> F (in ALS1).
SOD1	106	106	S -> L (in ALS1).
SOD1	107	107	L -> V (in ALS1).
SOD1	109	109	G -> V (in ALS1).
SOD1	113	113	I -> M (in ALS1).
SOD1	113	113	I -> T (in ALS1).
SOD1	114	114	I -> T (in ALS1; destabilizes dimeric protein structure and increases tendency to form fibrillar aggregates).
SOD1	115	115	G -> A (in ALS1).
SOD1	116	116	R -> G (in ALS1).
SOD1	119	119	V -> L (in ALS1).
SOD1	119	119	V -> VFLQ (in ALS1).
SOD1	125	125	D -> G (in ALS1).
SOD1	125	125	D -> V (in ALS1).
SOD1	126	126	D -> H (in ALS1).
SOD1	127	127	L -> S (in ALS1).
SOD1	134	134	Missing (in ALS).
SOD1	135	135	S -> N (in ALS1; reduced metal binding; increases tendency to form fibrillar aggegates).
SOD1	140	140	N -> K (in ALS1).
SOD1	145	145	L -> F (in ALS1).
SOD1	145	145	L -> S (in ALS1).
SOD1	146	146	A -> T (in ALS1).
SOD1	147	147	C -> R (in ALS1).
SOD1	148	148	G -> R (in ALS1).
SOD1	149	149	V -> G (in ALS1).
SOD1	149	149	V -> I (in ALS1).
SOD1	150	150	I -> T (in ALS1).
SOD1	152	152	I -> T (in ALS1; seems to affect formation of homodimer).
IFNGR2	168	168	T -> N (in MSMD; does not affect receptor trafficking to the cell surface; loss of function due to gain of N-glycosylation).
IFNGR2	222	230	Missing (in MSMD; affects receptor trafficking to the cell surface).
KCNE2	27	27	R -> C (in ATFB4; gain-of-function mutation associated with the initiation and/or maintenance of AF).
KCNE2	54	54	M -> T (in LQT6; forms I(KR) channels that deactivate twice as fast as wild type).
KCNE2	57	57	I -> T (in LQT6; may affect KCNQ1/KCNE2 channel).
KCNE2	65	65	V -> M (in LQT6).
KCNE2	77	77	R -> W (in LQT6).
KCNE1	47	47	V -> F (in JLNS2).
KCNE1	51	51	L -> H (in JLNS2).
KCNE1	58	59	TL -> PP (in JLNS2).
KCNE1	74	74	S -> L (in LQT5).
KCNE1	76	76	D -> N (in LQT5 and JLNS2; suppresses KCNQ1 currents markedly).
KCNE1	87	87	W -> R (in LQT5).
KCNE1	98	98	R -> W (in LQT5).
KCNE1	109	109	V -> I (in LQT5; mild phenotype; significantly reduced the wild-type I(KS) current amplitude).
KCNE1	127	127	P -> T (in LQT5).
SETD4	420	420	E -> G (in a colorectal cancer sample; somatic mutation).
KCNJ15	71	71	A -> T (in a breast cancer sample; somatic mutation).
HMGN1	1	1	M -> MLGRREEWQRQGSPVSRRLSARRGPQAPGTRLPRRH PARAFPAATM (in RNA edited version).
TFF1	32	32	T -> I (in a gastric carcinoma sample; somatic mutation).
TFF1	32	32	T -> K (in a gastric carcinoma sample; somatic mutation).
TFF1	34	34	A -> D (in a gastric carcinoma sample; somatic mutation. Abolishes inhibition of gastric cancer cell growth. Abolishes inhibition of apoptosis in gasterointestinal epithelial cells. Increases invasive activity in epithelial cells).
TFF1	37	37	E -> K (in a gastric carcinoma sample; somatic mutation. Abolishes inhibition of gastric cancer cell growth. Abolishes inhibition of apoptosis in gasterointestinal epithelial cells. Increases invasive activity in epithelial cells).
TFF1	46	46	V -> I (in a gastric adenoma sample; somatic mutation).
TFF1	55	55	G -> V (in a gastric carcinoma sample; somatic mutation).
TMPRSS3	103	103	D -> G (in DFNB8/DFNB10; fails to undergo proteolytic cleavage and is unable to activate ENaC).
TMPRSS3	109	109	R -> W (in DFNB8/DFNB10; fails to undergo proteolytic cleavage and is unable to activate ENaC).
TMPRSS3	173	173	D -> N.
TMPRSS3	194	194	C -> F (in DFNB8/DFNB10; fails to undergo proteolytic cleavage and is unable to activate ENaC).
TMPRSS3	216	216	R -> L (in DFNB8/DFNB10; fails to undergo proteolytic cleavage and is unable to activate ENaC).
TMPRSS3	251	251	W -> C (in DFNB8/DFNB10; fails to undergo proteolytic cleavage and is unable to activate ENaC).
TMPRSS3	404	404	P -> L (in DFNB8/DFNB10; fails to undergo proteolytic cleavage and is unable to activate ENaC).
TMPRSS3	407	407	C -> R (in DFNB8/DFNB10; fails to undergo proteolytic cleavage and is unable to activate ENaC).
SLC37A1	247	247	D -> N.
CBS	18	18	R -> C (associated with 1/3 to 2/3 the enzyme activity of the wild-type).
CBS	49	49	P -> L (in CBSD).
CBS	58	58	R -> W (in CBSD; 18% of activity; linked with Val-113).
CBS	65	65	H -> R (in CBSD).
CBS	78	78	P -> R (in CBSD; 50% of activity; severe form).
CBS	85	85	G -> R (in CBSD; loss of activity).
CBS	88	88	P -> S (in CBSD).
CBS	101	101	L -> P (in CBSD; common mutation in Irish population; loss of activity).
CBS	102	102	K -> N (in CBSD; 50% of activity).
CBS	109	109	C -> R (in CBSD; loss of activity).
CBS	114	114	A -> V (in CBSD; mild form; when linked with W-58 severe form; partial loss of activity; affects tetramer formation by promoting formation of larger aggregates).
CBS	116	116	G -> R (in CBSD).
CBS	121	121	R -> C (in CBSD).
CBS	121	121	R -> H (in CBSD).
CBS	121	121	R -> L (in CBSD; mild form).
CBS	125	125	R -> P (in CBSD).
CBS	125	125	R -> Q (in CBSD; severe form; loss of activity; when linked with D-132 moderate form).
CBS	125	125	R -> W (in CBSD; exhibits an activity lower than 4% of the wild-type enzyme; absent capacity to form multimeric quaternary structure).
CBS	126	126	M -> V (in CBSD; loss of activity).
CBS	128	128	E -> D (in CBSD).
CBS	131	131	E -> D (in CBSD; loss of activity; linked with Q-125).
CBS	139	139	G -> R (in CBSD; mild form).
CBS	143	143	I -> M (in CBSD; 4% of activity; stable).
CBS	144	144	E -> K (in CBSD; loss of activity).
CBS	145	145	P -> L (in CBSD; linked with Q-438).
CBS	148	148	G -> R (in CBSD; loss of activity; absent capacity to form multimeric quaternary structure).
CBS	151	159	Missing (in CBSD).
CBS	151	151	G -> R (in CBSD).
CBS	152	152	I -> M (in CBSD; severe form).
CBS	154	154	L -> Q (in CBSD; protein expression is comparable to wild-type; significant decrease of enzyme activity).
CBS	155	155	A -> T (in CBSD; complete loss of activity; severely affects tetramer formation by promoting formation of larger aggregates).
CBS	155	155	A -> V (in CBSD; protein expression is comparable to wild-type; significant decrease of enzyme activity).
CBS	165	165	C -> Y (in CBSD; severe form; protein expression is comparable to wild-type; significant decrease of enzyme activity).
CBS	168	168	V -> A (in CBSD).
CBS	168	168	V -> M (in CBSD).
CBS	173	173	M -> V (in CBSD; presents 40% of the wild-type activity; dramatically reduced capacity to form multimeric quaternary structure).
CBS	176	176	E -> K (in CBSD; severe form; loss of activity; severely affects tetramer formation by promoting formation of larger aggregates).
CBS	180	180	V -> A (in CBSD).
CBS	191	191	T -> M (in CBSD; moderate and severe forms; exhibits an activity lower than 4% of the wild-type enzyme; absent capacity to form multimeric quaternary structure).
CBS	198	198	D -> V (in CBSD).
CBS	224	224	R -> H (in CBSD).
CBS	226	226	A -> T (in CBSD; presents 20% of the wild-type activity; dramatically reduced capacity to form multimeric quaternary structure).
CBS	228	228	N -> K (in CBSD; loss of activity).
CBS	228	228	N -> S (in CBSD; has significantly decreased levels of enzyme activity).
CBS	231	231	A -> P (in CBSD; has significantly decreased levels of enzyme activity).
CBS	234	234	D -> N (in CBSD).
CBS	234	234	Missing (in CBSD; protein expression is comparable to wild-type; significant decrease of enzyme activity).
CBS	239	239	E -> K (in CBSD).
CBS	247	256	Missing (in CBSD).
CBS	257	257	T -> M (in CBSD; moderate to severe form; protein expression is comparable to wild- type; significant decrease of enzyme activity).
CBS	262	262	T -> M (in CBSD; moderate form).
CBS	262	262	T -> R (in CBSD; severe form).
CBS	266	266	R -> G (in CBSD).
CBS	270	270	Missing (in CBSD).
CBS	275	275	C -> Y (in CBSD; severe form; exhibits an activity lower than 4% of the wild-type enzyme; absent capacity to form multimeric quaternary structure).
CBS	288	288	A -> P (in CBSD).
CBS	288	288	A -> T (in CBSD; protein expression is comparable to wild-type; significant decrease of enzyme activity).
CBS	290	290	P -> L (in CBSD).
CBS	302	302	E -> K (in CBSD; 5% of activity).
CBS	305	305	G -> R (in CBSD).
CBS	307	307	G -> S (in CBSD; moderate to severe form; linked with D-534; has significantly decreased levels of enzyme activity; common mutation).
CBS	320	320	V -> A (in CBSD; has 36% of wild-type enzyme activity).
CBS	331	331	A -> E (in CBSD).
CBS	331	331	A -> V (in CBSD).
CBS	336	336	R -> C (in CBSD; protein expression is comparable to wild-type; loss of activity; absent capacity to form multimeric quaternary structure).
CBS	336	336	R -> H (in CBSD; mild form; exhibits an activity lower than 4% of the wild-type enzyme; absent capacity to form multimeric quaternary structure).
CBS	338	338	L -> P (in CBSD; severe form; exhibits an activity lower than 4% of the wild-type enzyme; absent capacity to form multimeric quaternary structure).
CBS	347	347	G -> S (in CBSD; protein expression is comparable to wild-type; loss of activity).
CBS	349	349	S -> N (in CBSD; severe form; exhibits an activity lower than 4% of the wild-type enzyme; absent capacity to form multimeric quaternary structure).
CBS	352	352	S -> N (in CBSD).
CBS	353	353	T -> M (in CBSD; protein expression is comparable to wild-type; significant decrease of enzyme activity).
CBS	354	354	V -> M (in CBSD).
CBS	355	355	A -> P (in CBSD).
CBS	361	361	A -> T (in CBSD).
CBS	369	369	R -> C (in CBSD; when linked with C-491 severe form).
CBS	370	370	C -> Y (in CBSD).
CBS	371	371	V -> M (in CBSD).
CBS	376	376	D -> N (in CBSD; has significantly decreased levels of enzyme activity).
CBS	379	379	R -> Q (in CBSD; exhibits an activity lower than 4% of the wild-type enzyme; absent capacity to form multimeric quaternary structure).
CBS	379	379	R -> W (in CBSD).
CBS	384	384	K -> E (in CBSD; severe form).
CBS	384	384	K -> N (in CBSD; moderate form).
CBS	391	391	M -> I (in CBSD).
CBS	434	434	T -> N (in CBSD).
CBS	435	435	I -> T (in CBSD; does not affect activity; does not affect tetramer formation; impaired stimulation by S- adenosylmethionine).
CBS	439	439	R -> Q (in CBSD; linked with K-143).
CBS	454	454	V -> E (in CBSD).
CBS	456	456	L -> P (in CBSD; severe; exhibits an activity lower than 4% of the wild-type enzyme; absent capacity to form multimeric quaternary structure).
CBS	466	466	S -> L (in CBSD; increased activity; does not affect tetramer formation; impaired stimulation by S-adenosylmethionine).
CBS	491	491	R -> C (in CBSD; linked with C-368).
CBS	526	526	Q -> K (in CBSD; has significantly decreased levels of enzyme activity).
CBS	534	534	V -> D (in CBSD; linked with S-306).
CBS	539	539	L -> S (in CBSD).
CBS	548	548	R -> Q (presents 60% of the wild-type activity; dramatically reduced capacity to form multimeric quaternary structure).
CRYAA	21	21	R -> L (in congenital cataract; associated with macular hypoplasia and a generally hypopigmented fundus).
CRYAA	49	49	R -> C (in ADC; nuclear cataract).
CRYAA	105	105	D -> H (in a breast cancer sample; somatic mutation).
CRYAA	116	116	R -> C (in ADC; zonular central nuclear cataract; reduced chaperone-like activity and increased membrane-binding capacity).
CRYAA	116	116	R -> H (in ADC; reverse phase-high- performance liquid chromatography suggests an increase hydrophobicity of the mutant protein; loss of chaperone activity of the mutant is seen in DL- dithiothreitol-induced insulin aggregation assay; fast protein liquid chromatography purification shows that the mutant protein has increased binding affinity to lysozyme).
SIK1	211	211	G -> S (in a glioblastoma multiforme sample; somatic mutation).
SIK1	469	469	G -> D (in a metastatic melanoma sample; somatic mutation).
CSTB	4	4	G -> R (in EPM1).
AIRE	15	15	R -> C (in APECED).
AIRE	15	15	R -> L (in APECED; enzymatic activity of approximately 30% of that of the wild- type).
AIRE	16	16	T -> M (in APECED; enzymatic activity of approximately 10% of that of the wild- type).
AIRE	21	21	A -> V (in APECED).
AIRE	22	23	Missing (in APECED; lack of alpha- galactosidase enzymatic activity; lack of homodimerization).
AIRE	28	28	L -> P (in APECED; abolishes association with cytoplasmic tubular structures and homodimerization).
AIRE	29	29	L -> P (in APECED).
AIRE	77	77	F -> S (in APECED; lack of alpha- galactosidase enzymatic activity; lack of homodimerization).
AIRE	78	78	W -> R (in APECED; lack of alpha- galactosidase enzymatic activity; lack of homodimerization).
AIRE	80	80	V -> L (in APECED).
AIRE	83	83	K -> E (in APECED).
AIRE	85	85	Y -> C (in APECED).
AIRE	90	90	Y -> C (in APECED).
AIRE	93	93	L -> R (in APECED).
AIRE	228	228	G -> W (in APECED; changes the subcellular localization and in addition disrupts the transactivating capacity of the wild-type AIRE; acts with a dominant negative effect by binding to the wild- type AIRE thus preventing the protein from forming the complexes needed for transactivation).
AIRE	301	301	V -> M (in APECED; no effect on protein structure or on interaction with histone H3).
AIRE	305	305	G -> S.
AIRE	311	311	C -> Y (in APECED; impairs zinc binding and folding of the PHD-type 1 zinc finger).
AIRE	326	326	P -> L (in APECED; no significant effect on structure, but may alter protein interactions).
AIRE	326	326	P -> Q (in APECED; alters folding of the PHD-type 1 zinc finger).
AIRE	539	539	P -> L (in APECED).
KRTAP10-2	241	241	R -> G.
KRTAP10-4	159	159	I -> V.
KRTAP10-6	81	81	C -> CPSCCA.
KRTAP10-8	64	64	S -> N (in a colorectal cancer sample; somatic mutation).
KRTAP10-8	159	159	S -> F (in a breast cancer sample; somatic mutation).
ITGB2	128	128	D -> Y (in LAD1).
ITGB2	239	239	A -> T (in LAD1).
ITGB2	300	300	D -> V (in LAD1).
ITGB2	716	716	G -> A (in LAD1).
COL6A1	121	121	K -> R (in BM).
COL6A1	272	272	G -> D (in BM).
COL6A1	274	274	P -> L (in BM).
COL6A1	275	275	G -> R (in BM).
COL6A1	281	281	G -> R (in UCMD).
COL6A1	284	284	G -> R (in UCMD; fibroblasts with the mutation assembled and secreted normal collagen VI microfibrils; cell adhesion of heterozygous Arg-284 fibroblasts is markedly decreased but can be rescued by the addition of normal collagen VI).
COL6A1	290	290	G -> R (in BM and UCMD).
COL6A1	305	305	G -> V (in BM).
COL6A1	341	341	G -> D (in BM).
COL6A1	341	341	G -> V (in BM).
COL6A1	571	571	K -> T (in BM).
COL6A1	881	881	T -> M.
COL6A2	106	106	E -> K (in BM).
COL6A2	271	271	G -> S (in BM).
COL6A2	283	283	G -> R (in UCMD).
COL6A2	489	489	R -> Q.
COL6A2	498	498	R -> H (in UCMD).
COL6A2	518	518	P -> S.
COL6A2	531	531	G -> R (in UCMD).
COL6A2	621	621	D -> N (in BM).
COL6A2	700	700	G -> S (in BM).
COL6A2	724	724	R -> C.
COL6A2	777	777	C -> R (in BM).
COL6A2	784	784	R -> H (in UCMD).
COL6A2	804	804	V -> G.
COL6A2	837	837	L -> P (in UCMD; prevents collagen VI assembly).
COL6A2	853	853	R -> Q (in BM).
COL6A2	876	876	R -> S (in UCMD).
COL6A2	895	895	S -> R.
COL6A2	897	897	Missing (in UCMD; results in severe collagen VI matrix deficiencies).
COL6A2	932	932	P -> L (in BM; results in reduced intracellular collagen VI assembly and secretion).
FTCD	299	299	R -> P (in FIGLU-URIA; mild phenotype; 57% wild-type activity).
FTCD	438	438	A -> E.
MCM3AP	409	409	L -> V (in a colorectal cancer sample; somatic mutation).
MMP11	166	166	D -> N (in a colorectal cancer sample; somatic mutation).
MYO18B	234	234	G -> V (in a lung small cell carcinoma sample; somatic mutation).
MYO18B	347	347	K -> N (in a lung small cell carcinoma sample; somatic mutation).
MYO18B	379	379	R -> Q (in a lung small cell carcinoma sample; somatic mutation).
MYO18B	389	389	W -> C (in a lung adenocarcinoma sample; somatic mutation).
MYO18B	590	590	T -> M (in a lung large cell carcinoma sample; somatic mutation).
MYO18B	835	835	A -> G (in a lung squamous cell carcinoma sample; somatic mutation).
MYO18B	1095	1095	R -> L (in a lung adenocarcinoma sample; somatic mutation).
MYO18B	1195	1195	R -> Q (in a lung small cell carcinoma sample; somatic mutation).
MYO18B	1238	1238	P -> Q (in a lung large cell carcinoma sample; somatic mutation).
MYO18B	1238	1238	P -> T (in a lung adenocarcinoma sample; somatic mutation).
MYO18B	1708	1708	E -> K (in a lung adenocarcinoma sample; somatic mutation).
MYO18B	1715	1715	E -> D (in a lung adenocarcinoma sample; somatic mutation).
MYO18B	1970	1970	A -> E (in a lung small cell carcinoma sample; somatic mutation).
MYO18B	2295	2295	G -> C (in a lung small cell carcinoma sample; somatic mutation).
MYO18B	2381	2381	R -> H (in a lung adenocarcinoma sample; somatic mutation).
MYO18B	2554	2554	D -> E (in a lung large cell carcinoma sample; somatic mutation).
MTMR3	221	221	V -> L (in a breast cancer sample; somatic mutation).
SLC5A1	28	28	D -> G (in GGM).
SLC5A1	28	28	D -> N (in GGM).
SLC5A1	135	135	R -> W (in GGM; loss of activity).
SLC5A1	318	318	G -> R (in GGM).
SLC5A1	468	468	A -> V (in GGM).
MYH9	93	93	N -> K (in MHA).
MYH9	95	95	A -> T (in MHA).
MYH9	96	96	S -> L (in EPS).
MYH9	373	373	K -> N (in MHA and SBS).
MYH9	702	702	R -> C (in APSM, EPS, FTNS, MHA and SBS).
MYH9	702	702	R -> H (in APSM and EPS).
MYH9	705	705	R -> H (in DFNA17).
MYH9	810	810	K -> N (in a breast cancer sample; somatic mutation).
MYH9	910	910	K -> Q (in FTNS).
MYH9	1066	1072	Missing (in MHA and SBS).
MYH9	1114	1114	S -> P (in APSM).
MYH9	1155	1155	T -> I (in MHA and FTNS).
MYH9	1165	1165	R -> C (in FTNS and SBS).
MYH9	1165	1165	R -> L (in FTNS, MHA and SBS).
MYH9	1205	1207	Missing (in SBS).
MYH9	1400	1400	R -> W (in a EPS patient; might contribute to pathogenicity; when associated with L-96).
MYH9	1424	1424	D -> H (in FTNS and MHA).
MYH9	1424	1424	D -> N (in FTNS, MHA, SBS and MPSD; affects protein stability).
MYH9	1424	1424	D -> Y (in MHA).
MYH9	1816	1816	I -> V (in EPS).
MYH9	1841	1841	E -> K (in FTNS, SBS, MHA and EPS).
ATP6V1E1	50	50	R -> G (in a colorectal cancer sample; somatic mutation).
GNB1L	296	296	A -> T (in a breast cancer sample; somatic mutation).
PPM1F	296	296	R -> Q (in a colorectal cancer sample; somatic mutation).
PPM1F	417	417	Q -> K (in a breast cancer sample; somatic mutation).
ADRBK2	104	104	R -> K (in a lung bronchoalveolar carcinoma sample; somatic mutation).
CRYBB1	129	129	S -> R (in CAMIS; significantly decreased thermal stability of CRYBB1/CRYBA1- crystallin heteromer but not CRYBB1- crystallin homomer).
CHEK2	17	17	A -> S (in an osteogenic sarcoma sample; somatic mutation; might influence susceptibility to breast cancer; does not cause protein abrogation in familial colorectal cancer).
CHEK2	59	59	T -> K (in multiple cancers).
CHEK2	64	64	E -> K (in prostate cancer; somatic mutation).
CHEK2	137	137	R -> Q (might influence susceptibility to breast cancer; does not cause protein abrogation in familial colorectal cancer).
CHEK2	145	145	R -> P (in prostate cancer; somatic mutation).
CHEK2	145	145	R -> W (in colon cancer and LFS2; does not cause protein abrogation in familial colorectal cancer).
CHEK2	167	167	G -> R (in prostate cancer; somatic mutation).
CHEK2	180	180	R -> C (in prostate cancer; somatic mutation).
CHEK2	180	180	R -> H (in prostate cancer; somatic mutation).
CHEK2	181	181	R -> C (in prostate cancer; somatic mutation).
CHEK2	181	181	R -> H (in prostate cancer; somatic mutation).
CHEK2	239	239	E -> K (in prostate cancer; germline mutation).
CHEK2	251	251	I -> F (in prostate cancer; germline mutation).
CHEK2	318	318	R -> H (in prostate cancer; somatic mutation).
CHEK2	323	323	T -> P (in prostate cancer; somatic mutation).
CHEK2	327	327	Y -> C (in prostate cancer; somatic mutation).
CHEK2	428	428	S -> F (increases breast cancer risk approximately 2-fold among Ashkenazi Jewish women).
CHEK2	476	476	T -> K (in prostate cancer; somatic mutation).
NEFH	796	796	Missing (in ALS).
NF2	46	46	L -> R (in vestibular schwannoma; loss of ability to interact with the CUL4A-RBX1- DDB1-VprBP/DCAF1 E3 ubiquitin-protein ligase complex).
NF2	62	62	F -> S (in NF2; loss of ability to interact with the CUL4A-RBX1-DDB1-VprBP/ DCAF1 E3 ubiquitin-protein ligase complex).
NF2	77	77	M -> V (in NF2).
NF2	79	79	K -> E (in vestibular schwannoma).
NF2	96	96	Missing (in NF2 and in sporadic meningioma).
NF2	106	106	E -> G (in NF2).
NF2	117	117	L -> I (in sporadic meningioma).
NF2	119	119	Missing (in sporadic meningioma).
NF2	122	129	Missing (in sporadic meningioma).
NF2	133	133	C -> R (in NF2).
NF2	141	141	L -> P (in NF2; loss of ability to interact with the CUL4A-RBX1-DDB1-VprBP/ DCAF1 E3 ubiquitin-protein ligase complex).
NF2	197	197	G -> C (in NF2).
NF2	219	219	V -> M (in vestibular schwannoma).
NF2	220	220	N -> Y (in NF2).
NF2	234	234	L -> R (in NF2 and in retinal hamartoma; severe).
NF2	273	273	I -> F (in breast ductal carcinoma).
NF2	339	339	L -> F (in sporadic meningioma).
NF2	351	351	R -> H.
NF2	352	352	T -> M (in NF2).
NF2	360	360	L -> P (in NF2).
NF2	364	364	K -> I (in melanoma).
NF2	413	413	K -> E (in NF2).
NF2	418	418	R -> C (in vestibular schwannoma).
NF2	463	463	E -> K (in a breast cancer sample; somatic mutation).
NF2	533	533	K -> T (in NF2).
NF2	535	535	L -> P (in NF2; late onset).
NF2	538	538	Q -> P (in NF2; mild).
NF2	539	539	L -> H (in NF2).
NF2	579	579	K -> M (in NF2).
LARGE	331	331	S -> F (in MDDGA6).
LARGE	495	495	W -> R (in MDDGA6).
LARGE	509	509	E -> K (in MDDGB6).
TMPRSS6	141	141	Y -> C (in IRIDA).
TMPRSS6	212	212	I -> T (in IRIDA; decreases the total amount of protein produced likely interfering with mRNA stability; demonstrates a reduced inhibitory effect).
TMPRSS6	223	223	R -> H (in a breast cancer sample; somatic mutation).
TMPRSS6	234	234	R -> S (in a breast cancer sample; somatic mutation).
TMPRSS6	271	271	R -> Q (in IRIDA; inactivates the hepcidin promoter as the wild-type protein; appears to be a silent mutation in vitro).
TMPRSS6	304	304	S -> L (in IRIDA).
TMPRSS6	442	442	G -> R (in IRIDA).
TMPRSS6	510	510	C -> S (in IRIDA).
TMPRSS6	521	521	D -> N (in IRIDA).
TMPRSS6	774	774	R -> C (in IRIDA).
GGA1	239	239	G -> S (in a breast cancer sample; somatic mutation).
GGA1	484	484	P -> A (in a breast cancer sample; somatic mutation).
TRIOBP	1019	1019	G -> R (in DFNB28).
PLA2G6	310	310	V -> E (in NBIA2A).
PLA2G6	545	545	K -> T (in NBIA2B).
PLA2G6	632	632	R -> W (in NBIA2B).
PLA2G6	691	691	Missing (in NBIA2A).
PLA2G6	741	741	R -> Q (in PARK14).
PLA2G6	747	747	R -> W (in PARK14).
XPNPEP3	453	453	G -> C (in NPHPL1).
EP300	827	827	L -> P (in a breast cancer sample).
EP300	1013	1013	E -> G (in a breast cancer sample).
EP300	1650	1650	S -> Y (in a pancreatic cancer sample).
PEX26	45	45	L -> P (in IRD).
PEX26	89	89	G -> R (in ZWS).
PEX26	98	98	R -> W (in NALD; affects the interaction with PEX6).
PRODH	8	8	P -> L.
PRODH	30	30	P -> S.
PRODH	58	58	A -> T.
PRODH	167	167	A -> V (associated with susceptibility to SCZD4; moderate reduction of enzymatic activity).
PRODH	185	185	R -> Q (no effect on enzymatic activity).
PRODH	275	275	T -> N.
PRODH	289	289	L -> M (can be associated with HP-1 in a subset of schizophrenia patients; no effect on enzymatic activity).
PRODH	426	426	D -> N (moderate reduction of enzymatic activity).
PRODH	444	444	G -> D.
PRODH	488	488	N -> S (in a breast cancer sample; somatic mutation).
PRODH	521	521	Q -> E (strongly reduced enzymatic activity).
DGCR14	31	31	A -> V.
TSSK2	61	61	M -> V.
TSSK2	197	197	Y -> C.
GP1BB	113	113	Y -> C (in BSS).
GP1BB	133	133	A -> P (in BSS).
TBX1	194	194	H -> Q (in VCFS).
TBX1	337	337	G -> E (in a colorectal cancer sample; somatic mutation).
TRMT2A	604	604	P -> S (in a breast cancer sample; somatic mutation).
RANBP1	16	16	E -> D (in a breast cancer sample; somatic mutation).
ZNF74	623	624	KL -> NF.
SCARF2	258	258	C -> Y (in VDEGS).
SCARF2	494	494	R -> C (in a breast cancer sample; somatic mutation).
MED15	261	262	Missing.
SERPIND1	447	447	E -> K (in HCF2D).
SERPIND1	462	462	P -> L (in HCF2D; Tokushima; impaired secretion of the mutant molecules).
BCR	400	400	S -> P (in a bladder transitional cell carcinoma sample; somatic mutation).
BCR	1091	1091	V -> M.
BCR	1096	1096	T -> A.
BCR	1104	1104	A -> G.
BCR	1106	1106	D -> N.
BCR	1149	1149	A -> T.
BCR	1161	1161	E -> K.
BCR	1187	1187	K -> E.
ADORA2A	392	392	G -> R.
CRYBB3	165	165	G -> R (in CATCN2).
SRRD	44	50	Missing.
CRYBA4	69	69	L -> P (in MCOPCT4; is predicted to disrupt the beta-sheet structure of the protein).
CRYBA4	94	94	F -> S (in CZ2; modeling suggests that this substitution would significantly reduce the intrinsic stability of the crystalline monomer).
XBP1	12	12	D -> V (in a breast cancer sample; somatic mutation).
XBP1	232	232	R -> K (in a breast cancer sample; somatic mutation).
RFPL1	139	139	Missing (in RFPL1S).
THOC5	380	380	T -> K (in a breast cancer sample; somatic mutation).
THOC5	499	499	G -> S (in a breast cancer sample; somatic mutation).
SF3A1	511	511	R -> W (in a colorectal cancer sample; somatic mutation).
TCN2	198	198	M -> T.
TCN2	219	219	I -> L.
SMTN	637	637	R -> Q (in a colorectal cancer sample; somatic mutation).
SMTN	763	763	A -> V (in a colorectal cancer sample; somatic mutation).
FBXO7	378	378	R -> G (in PARK15).
TIMP3	179	179	S -> C (in SFD).
TIMP3	189	189	G -> C (in SFD).
TIMP3	190	190	G -> C (in SFD).
TIMP3	191	191	Y -> C (in SFD).
TIMP3	204	204	S -> C (in SFD).
MB	55	55	E -> K.
MB	134	134	K -> N.
MB	140	140	R -> Q.
MB	140	140	R -> W.
APOL1	188	188	I -> T (in a breast cancer sample; somatic mutation).
NCF4	147	147	L -> I.
RAC2	29	29	P -> L (in a breast cancer sample; somatic mutation).
RAC2	57	57	D -> N (in NEUID; dominant-negative mutant; binds GDP, but not GTP; inhibits oxidase activation and superoxide anion production in vitro).
LGALS2	132	132	E -> Q (in a breast cancer sample; somatic mutation).
H1F0	1	1	M -> MLGKGRQRRRRQRQRQSPVPRPSDRPAGLGLAKPAR RALPTPEPGRKSSDSSLASPGAALQTGPVVRGSGADPEAGF AQPPTRAGPLEGAFNSRTRQATM (in RNA edited version).
MICALL1	817	817	E -> K (in a breast cancer sample; somatic mutation).
POLR2F	60	60	Y -> N (in a breast cancer sample; somatic mutation).
SOX10	135	135	S -> T (in YDBHS).
SOX10	161	161	R -> RLR (in WS4C).
CSNK1E	256	256	R -> L (in a lung adenocarcinoma sample; somatic mutation).
APOBEC3H	15	15	Missing (decreases protein stability).
FAM83F	418	418	A -> V (in a breast cancer sample; somatic mutation).
ADSL	2	2	A -> V (in ADSL deficiency; severe).
ADSL	3	3	A -> V (in ADSL deficiency; severe).
ADSL	26	26	M -> L (in ADSL deficiency; severe).
ADSL	72	72	I -> V (in ADSL deficiency; severe).
ADSL	100	100	P -> A (in ADSL deficiency; moderate).
ADSL	114	114	Y -> H (in ADSL deficiency; severe. Total loss of activity).
ADSL	141	141	R -> W (in ADSL deficiency; severe).
ADSL	194	194	R -> C (in ADSL deficiency; severe).
ADSL	246	246	K -> E (in ADSL deficiency; moderate).
ADSL	268	268	D -> N (in ADSL deficiency; severe. Total loss of activity).
ADSL	303	303	R -> C (in ADSL deficiency; mild).
ADSL	311	311	L -> V (in ADSL deficiency; severe).
ADSL	318	318	P -> L (in ADSL deficiency; severe).
ADSL	364	364	V -> M (in ADSL deficiency; severe).
ADSL	374	374	R -> W (in ADSL deficiency; severe).
ADSL	395	395	S -> R (in ADSL deficiency; severe).
ADSL	396	396	R -> C (in ADSL deficiency; severe).
ADSL	396	396	R -> H (in ADSL deficiency; severe).
ADSL	422	422	D -> Y (in ADSL deficiency; moderate).
ADSL	423	423	L -> V (in ADSL deficiency; moderate).
ADSL	426	426	R -> H (in ADSL deficiency; severe. Most frequent mutation).
ADSL	430	430	D -> N (in ADSL deficiency; mild).
ADSL	438	438	S -> P (in ADSL deficiency; severe).
ADSL	447	447	S -> P (in ADSL deficiency; severe).
ADSL	450	450	T -> S (in ADSL deficiency; moderate).
ADSL	452	452	R -> P (in ADSL deficiency; severe).
MCHR1	25	25	T -> M.
MCHR1	28	28	D -> V.
MCHR1	34	34	G -> R (no changes in receptor binding or functional signaling).
MCHR1	210	210	R -> H.
MCHR1	250	250	Y -> H.
MCHR1	305	305	T -> M.
MCHR1	377	377	P -> S.
MCHR1	411	411	T -> M.
ACO2	697	697	T -> N (in a breast cancer sample; somatic mutation).
SREBF2	273	273	A -> S (in a breast cancer sample; somatic mutation).
SREBF2	347	347	N -> K (in a breast cancer sample; somatic mutation).
TNFRSF13C	64	64	G -> V.
TNFRSF13C	65	72	AGAGEAAL -> V (in CVID4; fails to bind TNFSF13B and fails to induce downstream NF-kappa-B processing).
TNFRSF13C	159	159	H -> Y.
NAGA	160	160	S -> C (in SCHIND; type III).
NAGA	325	325	E -> K (in SCHIND; type I and type III).
NAGA	329	329	R -> Q (in KANZD).
NAGA	329	329	R -> W (in KANZD; loss of activity).
CYB5R3	58	58	R -> Q (in METHB-CYB5R3; type 1; 62% of activity).
CYB5R3	73	73	L -> P (in METHB-CYB5R3; type 1).
CYB5R3	106	106	V -> M (in METHB-CYB5R3; type 1; 77% of activity).
CYB5R3	128	128	S -> P (in METHB-CYB5R3; type 2; Hiroshima).
CYB5R3	149	149	L -> P (in METHB-CYB5R3).
CYB5R3	179	179	A -> V (in METHB-CYB5R3; type 1).
CYB5R3	204	204	C -> R (in METHB-CYB5R3; type 2).
CYB5R3	204	204	C -> Y (in METHB-CYB5R3; type 1).
CYB5R3	256	256	Missing (in METHB-CYB5R3; type 1; retains approximately 38% of residual diaphorase activity).
CYB5R3	273	273	Missing (in METHB-CYB5R3; type 2).
CYB5R3	292	292	G -> D (in METHB-CYB5R3; type 1; retains approximately 58% of residual diaphorase activity).
CYB5R3	299	299	Missing (in METHB-CYB5R3; type2; almost complete loss of activity).
A4GALT	80	80	Missing (in p individuals).
A4GALT	183	183	M -> K (in p individuals; complete loss of activity).
ARFGAP3	290	290	E -> G (in a breast cancer sample; somatic mutation).
UPK3A	202	202	G -> D (in RADYS).
UPK3A	273	273	P -> L (in RADYS; with severe vesicoureteric reflux; normal targeting to the cell surface).
PKDREJ	669	669	A -> G (in a breast cancer sample; somatic mutation).
PKDREJ	1875	1875	T -> I (in a breast cancer sample; somatic mutation).
TRMU	14	14	G -> S.
TRMU	77	77	Y -> H (in AILF).
TRMU	272	272	G -> D (in AILF).
TRMU	279	279	V -> M.
ALG12	67	67	T -> M (in CDG1G).
ALG12	101	101	G -> R (in CDG1G).
ALG12	146	146	R -> Q (in CDG1G).
ALG12	158	158	L -> P (in CDG1G).
MLC1	59	59	G -> E (in MLC1).
MLC1	92	92	P -> S (in MLC1).
MLC1	93	93	S -> L (in MLC1).
MLC1	118	118	T -> R (in MLC1).
MLC1	141	141	N -> K (in MLC1).
MLC1	141	141	N -> S (in MLC1).
MLC1	212	212	G -> R (in MLC1).
MLC1	280	280	S -> L (in MLC1).
MLC1	309	309	L -> M (in a pedigree affected by schizophrenia).
PANX2	147	147	S -> F (in a breast cancer sample; somatic mutation).
HDAC10	584	584	G -> C.
MAPK11	221	221	A -> V (in a lung neuroendocrine carcinoma sample; somatic mutation).
LMF2	68	68	P -> L (in a breast cancer sample; somatic mutation).
SCO2	140	140	E -> K (in FIC).
SCO2	225	225	S -> F (in FIC).
TYMP	44	44	R -> Q (in MTDPS1).
TYMP	145	145	G -> R (in MTDPS1).
TYMP	153	153	G -> S (in MTDPS1).
TYMP	222	222	K -> R (in MTDPS1).
TYMP	289	289	E -> A (in MTDPS1).
TYMP	397	398	Missing (in MTDPS1).
ARSA	18	18	A -> D (in MLD; enzyme activity reduced to 5% of wild-type enzyme).
ARSA	29	29	D -> N (in MLD; infantile-onset; causes a severe reduction of enzyme activity).
ARSA	30	30	D -> H (in MLD; enzyme activity reduced to 2.4% of wild-type enzyme).
ARSA	32	32	G -> S (in MLD; late-infantile form).
ARSA	68	68	L -> P (in MLD; late-infantile form).
ARSA	76	76	L -> P.
ARSA	84	84	R -> Q (in MLD; mild).
ARSA	84	84	R -> W (in MLD; juvenile form).
ARSA	86	86	G -> D (in MLD; severe; no enzyme residual activity; leads to a decreased stability of the mutant enzyme; causes an arrest of the mutant enzyme polypeptide in a prelysosomal compartment).
ARSA	94	94	P -> A (in MLD; adult form).
ARSA	95	95	S -> N (in MLD).
ARSA	96	96	S -> F (in MLD; severe).
ARSA	96	96	S -> L (in MLD; severe; no enzyme residual activity).
ARSA	99	99	G -> D (in MLD; adult type).
ARSA	99	99	G -> V (in MLD; late-infantile form).
ARSA	119	119	G -> R (in MLD; juvenile-onset).
ARSA	122	122	G -> S (in MLD; adult type).
ARSA	135	135	L -> P (in MLD).
ARSA	136	136	P -> L (in MLD; severe late-infantile type; loss of enzymatic activity).
ARSA	136	136	P -> S (in MLD; late-infantile form).
ARSA	137	137	Missing (in MLD).
ARSA	143	143	R -> G (in MLD; juvenile/adult-onset; generates 5% as much activity as the parallel normal control).
ARSA	148	148	P -> L (in MLD; juvenile-onset).
ARSA	152	152	D -> Y (in MLD).
ARSA	153	153	Q -> H (in MLD; late-infantile form; no enzyme residual activity).
ARSA	154	154	G -> D (in MLD).
ARSA	155	155	P -> L (in MLD; juvenile-onset).
ARSA	155	155	P -> R (in MLD).
ARSA	156	156	C -> R (in MLD; adult type; enzyme activity reduced to 50% of wild-type enzyme).
ARSA	167	167	P -> R (in MLD).
ARSA	169	169	D -> N (in MLD).
ARSA	172	172	C -> Y (in MLD; juvenile-onset).
ARSA	179	179	I -> S (in MLD; mild).
ARSA	181	181	L -> Q (in MLD; infantile form).
ARSA	190	190	Q -> H (in MLD; no enzyme residual activity).
ARSA	191	191	P -> T (in MLD; juvenile-onset).
ARSA	201	201	Y -> C (in MLD; juvenile-onset; low amounts of residual enzyme activity; leads to a decreased stability of the mutant enzyme; causes an arrest of the mutant enzyme polypeptide in a prelysosomal compartment).
ARSA	212	212	A -> P (in MLD; enzyme activity reduced to 2.6% of wild-type enzyme).
ARSA	212	212	A -> V (in MLD).
ARSA	217	217	R -> H (in MLD; enzyme activity reduced to 15.6% of wild-type enzyme).
ARSA	219	219	F -> V (in MLD; enzyme activity reduced to less than 1% of normal activity).
ARSA	224	224	A -> V (in MLD).
ARSA	227	227	H -> Y (in MLD; late-infantile form).
ARSA	231	231	P -> T (in MLD).
ARSA	244	244	R -> C (in MLD; juvenile-onset).
ARSA	244	244	R -> H (in MLD; infantile-onset).
ARSA	245	245	G -> R (in MLD; severe; represents 20% of all alleles among Australians and about 85% of all Australians Lebanese alleles).
ARSA	247	247	F -> S (in MLD).
ARSA	250	250	S -> Y (in MLD; infantile-onset).
ARSA	253	253	E -> K (in MLD; late-infantile).
ARSA	255	255	D -> H (in MLD; late-infantile form; no enzyme residual activity; leads to a decreased stability of the mutant enzyme; causes an arrest of the mutant enzyme polypeptide in a prelysosomal compartment).
ARSA	274	274	T -> M (in MLD; severe; 35% of normal activity).
ARSA	281	281	D -> Y (in MLD).
ARSA	282	282	N -> S (in MLD; enzyme activity reduced to 0.6% of wild-type enzyme).
ARSA	288	288	R -> C (in MLD).
ARSA	288	288	R -> H (in MLD; adult form).
ARSA	293	293	G -> D (in MLD; late-onset).
ARSA	293	293	G -> S (in MLD; adult type; causes a severe reduction of enzyme activity).
ARSA	294	294	C -> Y (in MLD; juvenile-onset; causes a severe reduction of enzyme activity).
ARSA	295	295	S -> Y (in MLD; severe).
ARSA	298	298	L -> S (in MLD; late-infantile form; complete loss of enzyme activity).
ARSA	300	300	C -> F (in MLD; late-infantile-onset; enzyme activity reduced to less than 1%; the mutant protein is unstable; results in more rapid enzyme degradation in lysosomes; addition of the cysteine protease inhibitor leupeptin does not increase the amount of the enzyme activity; strongly interferes with the octamerization process of the enzyme at low pH).
ARSA	302	302	K -> N (in MLD; enzyme activity reduced to 2.8% of wild-type enzyme).
ARSA	306	306	Y -> H (in MLD; juvenile-onset).
ARSA	308	308	G -> D (in MLD; late-infantile form).
ARSA	308	308	G -> V (in MLD; late-infantile form; no enzyme residual activity).
ARSA	309	309	G -> S (in MLD; severe; 13% of normal activity).
ARSA	311	311	R -> Q (in MLD; juvenile-onset).
ARSA	312	312	E -> D (in MLD; low amounts of residual enzyme activity; leads to a decreased stability of the mutant enzyme).
ARSA	314	314	A -> T (in MLD; infantile-onset).
ARSA	325	325	G -> S (in MLD; juvenile-onset).
ARSA	327	327	T -> I (in MLD; late-infantile form).
ARSA	335	335	D -> V (in MLD; late-infantile-onset; loss of enzymatic activity).
ARSA	367	367	K -> N (in MLD).
ARSA	370	370	R -> Q (in MLD; mild).
ARSA	370	370	R -> W (in MLD; severe; no enzyme residual activity).
ARSA	376	376	Y -> N (in MLD; enzyme activity reduced to 4.7% of wild-type enzyme).
ARSA	377	377	P -> L (in MLD; severe; high frequency among Habbanite Jews).
ARSA	381	381	D -> E (in MLD; early-infantile form).
ARSA	382	382	E -> K (in MLD; intermediate).
ARSA	384	384	R -> C (in MLD).
ARSA	390	390	R -> Q (in MLD; juvenile-onset).
ARSA	390	390	R -> W (in MLD; late-infantile and juvenile-onset).
ARSA	397	397	H -> Y (in MLD; adult-onset).
ARSA	398	398	Missing (in MLD).
ARSA	406	408	Missing (in MLD; late-infantile-onset).
ARSA	409	409	T -> I (in MLD; mild).
ARSA	425	425	P -> T (in MLD; juvenile-onset; retains about 12% of specific enzyme activity; the mutant protein is unstable; results in more rapid enzyme degradation in lysosomes; addition of the cysteine protease inhibitor leupeptin increases the amount of the enzyme activity; displays a modest reduction in the octamerization process of the enzyme at low pH).
ARSA	428	428	L -> P (in MLD; late-infantile form).
ARSA	429	429	Y -> S (in MLD; adult-onset).
ARSA	464	464	A -> V.
ARSA	469	469	A -> G (in MLD; early-infantile form).
ARSA	489	489	C -> G (in MLD; late-onset).
POTED	172	172	E -> Q.
TGFBR3	635	635	A -> T.
TGFBR3	765	765	G -> R.
DBT	98	98	I -> M (in MSUD2).
DBT	276	276	F -> C (in MSUD2).
PRKCZ	514	514	S -> F (in a colorectal cancer sample; somatic mutation).
PRKCZ	519	519	R -> C (in a colorectal adenocarcinoma sample; somatic mutation).
CAMTA1	1336	1336	T -> I.
PINK1	67	67	L -> F.
PINK1	68	68	R -> P.
PINK1	92	92	C -> F (in PARK6).
PINK1	98	98	R -> W.
PINK1	111	111	I -> S.
PINK1	115	115	Q -> L.
PINK1	124	124	A -> V.
PINK1	125	125	C -> G (in PARK6).
PINK1	126	126	Q -> P (in PARK6; strongly reduces interaction with PARK2).
PINK1	147	147	R -> H (in PARK6; uncertain pathogenicity).
PINK1	168	168	A -> P (in PARK6; has reduced autophosphorylation activity compared to wild-type; localizes to the mitochondria and immunogold experiments reveal that both wild-type and mutant proteins face the mitochondrial intermembrane space).
PINK1	186	186	K -> N.
PINK1	196	196	P -> L (in PARK6).
PINK1	215	215	P -> L (in a glioblastoma multiforme sample; somatic mutation).
PINK1	217	217	A -> D (in PARK6).
PINK1	231	231	E -> G.
PINK1	235	235	N -> I.
PINK1	240	240	E -> K (in PARK6).
PINK1	257	257	T -> I.
PINK1	263	263	R -> G.
PINK1	268	268	L -> V (in PARK6).
PINK1	271	271	H -> Q (in PARK6).
PINK1	276	276	R -> Q.
PINK1	279	279	R -> H (in PARK6).
PINK1	280	280	A -> T (in PARK6; early-onset).
PINK1	296	296	P -> L.
PINK1	309	309	G -> D (in PARK6; fails to maintain mitochondrial membrane potential; has reduced autophosphorylation activity compared to wild-type; strongly reduces interaction with PARK2).
PINK1	313	313	T -> M (in PARK6).
PINK1	317	317	V -> I.
PINK1	318	318	M -> L.
PINK1	322	322	P -> L.
PINK1	347	347	L -> P (in PARK6; strongly reduces interaction with PARK2).
PINK1	362	362	D -> H.
PINK1	369	369	L -> P (in PARK6).
PINK1	386	386	G -> A (in PARK6).
PINK1	388	388	C -> R (in PARK6).
PINK1	395	395	G -> V.
PINK1	399	399	P -> L (in PARK6; digenic inheritance; associated with Ser-39 mutation in PARK7 gene).
PINK1	407	407	R -> Q (in PARK6; early-onset).
PINK1	409	409	G -> V (in PARK6).
PINK1	417	417	E -> G (in PARK6).
PINK1	425	425	P -> S.
PINK1	431	431	Y -> H (may predispose to Parkinson disease development; shows decreased mitochondrial membrane potential under stress conditions).
PINK1	442	442	I -> T.
PINK1	451	451	N -> S (may predispose to Parkinson disease development; shows decreased mitochondrial membrane potential under stress conditions).
PINK1	461	461	L -> S.
PINK1	464	464	R -> H (in PARK6).
PINK1	476	476	E -> K (may predispose to Parkinson disease development; shows decreased mitochondrial membrane potential under stress conditions).
PINK1	489	489	L -> P (in PARK6).
PINK1	501	501	R -> P (may predispose to Parkinson disease development; shows decreased mitochondrial membrane potential under stress conditions).
PINK1	525	525	D -> N.
PINK1	534	534	Q -> QQ (in PARK6).
PINK1	537	537	A -> T.
PINK1	575	575	C -> R (may predispose to Parkinson disease development; shows decreased mitochondrial membrane potential under stress conditions).
EPHB2	199	199	R -> H (in prostate cancer).
EPHB2	289	289	C -> G.
EPHB2	650	650	V -> A (in prostate cancer).
EPHB2	679	679	H -> N (in prostate cancer).
EPHB2	883	883	M -> V (in prostate cancer).
EPHB2	909	909	I -> M (in prostate cancer).
EPB41	214	214	V -> I.
SCP2	155	155	A -> D (in a breast cancer sample; somatic mutation).
LEPR	204	204	K -> R.
LEPR	675	675	S -> T.
LRRC7	235	235	L -> M (in a breast cancer sample; somatic mutation).
CLCA4	877	878	Missing.
NOTCH2	444	444	C -> Y (in ALGS2).
TPM3	8	8	M -> R (in NEM1; decrease in the sensitivity of contraction to activating calcium).
GBA	46	46	K -> E (in a patient with Parkinson disease).
GBA	54	54	V -> L (in GD).
GBA	55	55	C -> S (in GD; neuronopathic and perinatal lethal forms; loss of activity).
GBA	63	63	D -> N (in GD1; very low activity).
GBA	76	76	F -> V (in GD).
GBA	82	82	T -> I (in GD).
GBA	85	85	G -> E (in GD).
GBA	87	87	R -> Q (in GD; 20% of normal activity).
GBA	118	118	K -> N (in GD; mild; 8% of normal activity; increases susceptibility to proteolytic degradation).
GBA	129	129	A -> T (in GD).
GBA	146	146	S -> L (in GD; type 2).
GBA	152	152	G -> E (in GD).
GBA	156	156	N -> D (in GD).
GBA	158	158	I -> S (in GD1; very low activity).
GBA	158	158	I -> T (in GD).
GBA	159	159	R -> Q (in GD; type 2; 13% of normal activity).
GBA	159	159	R -> W (in GD; severe).
GBA	161	161	P -> L (in GD; 16% of normal activity).
GBA	161	161	P -> S (in GD; mild).
GBA	162	162	M -> V (in GD; loss of activity; increases susceptibility to proteolytic degradation).
GBA	166	166	D -> V (in GD; 9% of normal activity; increases susceptibility to proteolytic degradation).
GBA	170	170	R -> C (in GD1 and GD2; also found in a patient with Parkinson disease).
GBA	170	170	R -> L (in GD).
GBA	173	173	T -> I (in GD).
GBA	173	173	T -> P (in GD).
GBA	175	175	A -> E (in GD).
GBA	179	179	D -> H (in GD).
GBA	196	196	K -> Q (in GD; severe).
GBA	198	198	P -> L (in GD).
GBA	198	198	P -> T (in GD).
GBA	200	200	I -> N (in GD; 5% of normal activity).
GBA	200	200	I -> S (in GD).
GBA	201	201	H -> P (in GD).
GBA	209	209	R -> C (in GD).
GBA	209	209	R -> P (in GD).
GBA	213	213	L -> F (in GD; 12% of normal activity).
GBA	215	215	A -> D (in GD).
GBA	217	217	P -> S (in GD; type 2).
GBA	221	221	P -> L (in GD1; very low activity).
GBA	221	221	P -> T (in GD).
GBA	223	223	W -> R (in GD; gene conversion).
GBA	224	224	L -> F (in GD; 4% of normal activity; increases susceptibility to proteolytic degradation).
GBA	228	228	G -> V (in GD).
GBA	229	229	A -> E (in GD; type 2).
GBA	229	229	A -> T (in GD).
GBA	230	230	V -> E (in GD1; very low activity).
GBA	232	232	G -> E (in GD; also found in a patient with Parkinson disease; 7% of normal activity).
GBA	234	234	G -> E (in GD; severe).
GBA	234	234	G -> W (in GD).
GBA	237	237	K -> E (in GD; severe; loss of activity; increases susceptibility to proteolytic degradation).
GBA	241	241	G -> E (in GD).
GBA	241	241	G -> R (in GD; type 1 and type 2; gene conversion).
GBA	244	244	Y -> C (in GD).
GBA	251	251	Y -> H (in GD).
GBA	255	255	F -> Y (in GD; mild).
GBA	270	270	T -> R (in GD).
GBA	276	276	S -> P (in GD).
GBA	290	290	F -> L (in GD; perinatal lethal form).
GBA	294	294	H -> Q (in GD1; also found in Gaucher disease type 2).
GBA	296	296	R -> Q (in GD; type 2; also found in a patient with Parkinson disease).
GBA	298	298	F -> L (in GD; type 2; 4% of normal activity).
GBA	303	303	L -> I (in GD; 5% of normal activity).
GBA	304	304	G -> D (in GD).
GBA	305	305	P -> R (in GD; mild).
GBA	310	310	S -> N (in GD; less than 5% of normal activity).
GBA	324	324	R -> C (in GD; type 1).
GBA	324	324	R -> H (in GD; type 2).
GBA	328	328	P -> L (in GD; mild).
GBA	342	342	K -> I (in GD).
GBA	343	343	Y -> C (in GD; type 2; 16% of normal activity; increases susceptibility to proteolytic degradation).
GBA	348	348	A -> V (in GD).
GBA	350	350	H -> R (in perinatal lethal GD).
GBA	351	351	W -> C (in GD; mild).
GBA	352	352	Y -> H (in GD).
GBA	354	354	D -> H (in GD).
GBA	357	357	A -> D (in GD).
GBA	362	362	T -> I (in GD; 6% of normal activity).
GBA	363	363	L -> P (in GD).
GBA	364	364	G -> R (in GD; type 2).
GBA	380	380	A -> T (in GD).
GBA	381	381	C -> G (in GD; type 2; loss of activity).
GBA	388	388	E -> K (in GD; 12% of normal activity).
GBA	391	391	V -> L (in GD).
GBA	392	392	R -> G (in GD).
GBA	392	392	R -> W (in GD; 5% of normal activity).
GBA	398	398	R -> Q (in GD; mild).
GBA	400	400	M -> I (in GD).
GBA	402	402	Y -> C (in GD; 8% of normal activity; increases susceptibility to proteolytic degradation).
GBA	403	403	S -> T (in GD; mild).
GBA	405	405	S -> G (in GD).
GBA	405	405	S -> N (in GD).
GBA	409	409	N -> S (in GD1; common mutation; associated with susceptibility to Parkinson disease; alters interaction with saposin-C and membranes and thereby reduces enzyme activity; mild).
GBA	410	410	L -> V (in GD; 15% of normal activity; increases susceptibility to proteolytic degradation).
GBA	414	414	V -> L (in GD; mild).
GBA	416	416	G -> S (in GD; mild).
GBA	417	417	W -> G (in GD).
GBA	419	419	D -> A (in GD; type 2; also found in a patient with Parkinson disease).
GBA	419	419	D -> H (in GD; 4% of normal activity).
GBA	419	419	D -> N (in GD).
GBA	421	421	N -> K (in GD; 22% of normal activity).
GBA	426	426	P -> L (in GD).
GBA	428	428	G -> E (in GD; type 2).
GBA	429	429	G -> R (in GD; 17% of normal activity).
GBA	430	430	P -> L (in GD).
GBA	431	431	N -> I (in GD; type 2).
GBA	432	432	W -> R (in GD).
GBA	433	433	V -> L (in GD; severe; 12% of normal activity).
GBA	435	435	N -> T (in GD1; mild).
GBA	436	436	F -> S (in GD; 6% of normal activity; alters protein stability and increases susceptibility to proteolytic degradation).
GBA	437	437	V -> F (in perinatal lethal GD).
GBA	437	437	V -> L (in GD3).
GBA	438	438	D -> N (in GD; type 1 and type 2; 14% of normal activity; increases susceptibility to proteolytic degradation).
GBA	438	438	D -> Y (in GD).
GBA	440	440	P -> L (in GD1).
GBA	441	441	I -> F (in GD; type 3).
GBA	441	441	I -> T (in GD; mild).
GBA	448	448	D -> V (in GD; severe; very low activity; alters protein stability).
GBA	450	450	F -> I (in GD).
GBA	451	451	Y -> H (in GD).
GBA	452	452	K -> Q (in GD).
GBA	454	454	P -> R (in GD; type 2).
GBA	455	455	M -> V (in GD; loss of activity; increases susceptibility to proteolytic degradation).
GBA	456	456	F -> V (in GD).
GBA	457	457	Y -> C (in GD).
GBA	460	460	G -> D (in GD1; associated with R-490; loss of activity).
GBA	464	464	K -> E (in GD; severe).
GBA	482	482	D -> N (in a patient with Parkinson disease).
GBA	483	483	L -> P (in GD1 and GD2; common mutation; associated with susceptibility to Parkinson disease; gene conversion; very low activity; alters protein stability).
GBA	483	483	L -> R (in GD; severe).
GBA	485	485	A -> P (in GD).
GBA	490	490	H -> R (in GD; type 1; associated with D- 460).
GBA	497	497	V -> L.
GBA	500	500	L -> P (in GD; 10% of normal activity; increases susceptibility to proteolytic degradation).
GBA	501	501	N -> K (in GD; type 2).
GBA	502	502	R -> C (in GD; 37% of normal activity; also found in patients with Parkinson disease).
GBA	502	502	R -> P (in GD; loss of activity; increases susceptibility to proteolytic degradation).
GBA	509	509	L -> P.
GBA	513	513	D -> Y (in GD2).
GBA	517	517	G -> S (in GD).
GBA	530	530	T -> I (in GD3).
GBA	535	535	R -> C (in GD; mild).
GBA	535	535	R -> H (in GD; mild).
RASAL2	165	165	R -> W (in a colorectal cancer sample; somatic mutation).
RASAL2	379	379	E -> D (in a breast cancer sample; somatic mutation).
NEK7	275	275	I -> M (in an ovarian serous carcinoma sample; somatic mutation).
HHAT	448	448	G -> E (in a melanoma cell line; abolishes GTP-binding).
HHAT	450	450	N -> S (in a lung cancer cell line).
USH2A	163	163	C -> Y (in USH2A).
USH2A	218	218	V -> E (in USH2A).
USH2A	268	268	G -> R (in USH2A; uncertain pathogenicity).
USH2A	280	280	L -> F (in USH2A).
USH2A	284	284	E -> K (in USH2A).
USH2A	303	303	R -> C (in USH2A).
USH2A	303	303	R -> S (in USH2A).
USH2A	307	307	S -> I (in USH2A; uncertain pathogenicity).
USH2A	319	319	C -> Y (in USH2A).
USH2A	334	334	R -> Q (in USH2A).
USH2A	334	334	R -> W (in USH2A).
USH2A	346	346	N -> H (in USH2A).
USH2A	352	352	T -> I (in USH2A).
USH2A	357	357	N -> T (in USH2A).
USH2A	365	365	L -> F.
USH2A	391	391	S -> I (in USH2A; uncertain pathogenicity).
USH2A	419	419	C -> F (in USH2A).
USH2A	453	453	T -> I (found in a renal cell carcinoma sample; somatic mutation).
USH2A	464	464	R -> C (in USH2A; uncertain pathogenicity).
USH2A	479	479	F -> S.
USH2A	516	516	G -> V (in USH2A; uncertain pathogenicity).
USH2A	517	517	R -> T (in USH2A; uncertain pathogenicity).
USH2A	536	536	C -> R (in USH2A; abolishes interaction with collagen IV).
USH2A	575	575	C -> S (in USH2A; uncertain pathogenicity).
USH2A	587	587	Missing (in USH2A; uncertain pathogenicity).
USH2A	595	595	F -> S.
USH2A	610	610	H -> P (in USH2A).
USH2A	703	703	D -> E.
USH2A	739	739	F -> L (in RP39; uncertain pathogenicity).
USH2A	759	759	C -> F (in RP39 and USH2A).
USH2A	761	761	P -> R (in USH2A).
USH2A	841	841	S -> Y.
USH2A	911	911	T -> N (in RP39; uncertain pathogenicity).
USH2A	1047	1047	L -> V.
USH2A	1059	1059	P -> L (in USH2A; uncertain pathogenicity).
USH2A	1212	1212	P -> L (in USH2A).
USH2A	1349	1349	S -> P.
USH2A	1470	1470	L -> R (in RP39; uncertain pathogenicity).
USH2A	1515	1515	T -> M (in USH2A).
USH2A	1572	1572	L -> F.
USH2A	1757	1757	Y -> C.
USH2A	1833	1833	V -> E (in USH2A).
USH2A	2080	2080	K -> N.
USH2A	2086	2086	T -> N.
USH2A	2249	2249	A -> D (in USH2A).
USH2A	2265	2266	EY -> D (in USH2A).
USH2A	2354	2354	R -> H (in USH2A).
USH2A	2795	2795	A -> S (in USH2A).
USH2A	3124	3124	R -> G (in USH2A; uncertain pathogenicity).
USH2A	3251	3251	C -> R (in USH2A).
USH2A	3267	3267	C -> R (in USH2A).
USH2A	3282	3282	C -> R (in USH2A).
USH2A	3335	3335	I -> M.
USH2A	3472	3472	Y -> YY (in USH2A).
USH2A	3504	3504	P -> T (in USH2A).
USH2A	3521	3521	W -> R (in USH2A).
USH2A	3571	3571	T -> M (in USH2A).
USH2A	3590	3590	P -> L.
USH2A	3895	3895	G -> E (in USH2A).
USH2A	3976	3976	T -> M (in USH2A).
USH2A	4054	4054	S -> I (in USH2A).
USH2A	4115	4115	R -> C (in USH2A; uncertain pathogenicity).
USH2A	4232	4232	P -> R (in USH2A).
USH2A	4337	4337	T -> M (in USH2A).
USH2A	4425	4425	T -> M (in USH2A).
USH2A	4433	4433	V -> L.
USH2A	4439	4439	T -> I (in USH2A).
USH2A	4487	4487	Y -> C (in USH2A).
USH2A	4592	4592	Q -> H (in USH2A).
USH2A	4624	4624	F -> V.
USH2A	4674	4674	R -> G (in RP39).
USH2A	4795	4795	L -> R (in USH2A).
USH2A	4818	4818	P -> L (in USH2A).
USH2A	5031	5031	R -> W.
LYST	1563	1563	R -> H (in CHS).
MTR	61	61	R -> K.
MTR	255	255	C -> Y.
MTR	881	881	Missing (in cblG).
MTR	1173	1173	P -> L (in cblG).
CFHR1	159	159	L -> V.
CFHR5	216	216	N -> S (in a breast cancer sample; somatic mutation).
CFHR5	277	277	Y -> N (in a patient with atypical hemolytic uremic syndrome).
CFHR5	379	379	V -> L (in patients with atypical hemolytic uremic syndrome).
F13B	450	450	C -> F (in FA13BD).
UCHL5	197	197	I -> F.
ZNF281	527	527	I -> T (in a breast cancer sample; somatic mutation).
DDX59	77	77	P -> T (in a breast cancer sample; somatic mutation).
CDK11B	201	201	R -> W.
CDK11B	414	414	S -> L.
CDK11B	452	452	V -> A.
CDK11B	463	463	I -> V.
CDK11B	506	506	G -> S.
CDK11B	601	601	L -> Q.
CDK11B	641	641	K -> N.
NPHP4	3	3	D -> Y (in SLSN4).
NPHP4	91	91	F -> L (in SLSN4).
NPHP4	160	160	R -> L (in a patient with nephronophthisis with extra-renal features; the patient also carries W-735 in the same gene and L-209 in TTC21B).
NPHP4	342	342	R -> C (in NPHP4).
NPHP4	469	469	R -> W (in NPHP4).
NPHP4	627	627	T -> M (in SLSN4).
NPHP4	654	654	A -> G (in NPHP4).
NPHP4	735	735	R -> W (in NPHP4).
NPHP4	754	754	G -> R (in NPHP4; affects interaction with RPGRIP1L).
NPHP4	765	765	V -> I.
NPHP4	766	766	Q -> R (in NPHP4; with color blindness).
NPHP4	776	776	P -> R (in NPHP4).
NPHP4	782	782	H -> Q (in NPHP4).
NPHP4	940	941	Missing.
NPHP4	946	946	T -> A (in SLSN4).
NPHP4	961	961	R -> H (in NPHP4).
NPHP4	1192	1192	R -> W (in NPHP4).
NPHP4	1225	1225	T -> M (in SLSN4).
NPHP4	1284	1284	R -> C (in NPHP4).
NPHP4	1287	1287	Q -> E (in NPHP4; with hearing loss).
PLEKHG5	703	703	F -> S (in DSMA4; stability and intracellular location affected severely impairing the NF-kappa-B transduction pathway).
TNFRSF9	250	250	E -> G (in a colorectal cancer sample; somatic mutation).
KIF1B	34	34	S -> L (in a medulloblastoma sample; somatic mutation; loss of ability to induce apoptosis).
KIF1B	98	98	Q -> L (in CMT2A1).
KIF1B	692	692	E -> V (confers susceptibility to neuroblastoma; found as germline mutation in a neuroblastoma patient; loss of ability to induce apoptosis).
KIF1B	873	873	T -> I (confers susceptibility to neuroblastoma; found as germline mutation in a neuroblastoma patient; loss of ability to induce apoptosis).
KIF1B	1133	1133	Y -> C.
KIF1B	1263	1263	P -> S (confers susceptibility to neuroblastoma; found as germline mutation in a neuroblastoma patient; loss of ability to induce apoptosis).
KIF1B	1527	1527	S -> N (confers susceptibility to pheochromocytoma; found as germline mutation in a pheochromocytoma family; loss of ability to induce apoptosis).
KIF1B	1600	1600	V -> M.
KIF1B	1674	1674	E -> K (in a pheochromocytoma sample; loss of ability to induce apoptosis).
MTOR	8	8	A -> S (in a lung large cell carcinoma sample; somatic mutation).
MTOR	135	135	M -> T (in a metastatic melanoma sample; somatic mutation).
MTOR	2011	2011	M -> V (in an ovarian mucinous carcinoma sample; somatic mutation).
MTOR	2215	2215	S -> Y (in a colorectal adenocarcinoma sample; somatic mutation).
MTOR	2220	2220	L -> F (found in a renal cell carcinoma sample; somatic mutation).
MTOR	2406	2406	V -> A (found in a renal cell carcinoma sample; somatic mutation).
MTOR	2476	2476	P -> L (in a glioblastoma multiforme sample; somatic mutation).
MFN2	94	94	R -> W (in CMT6).
MFN2	206	206	T -> I (in CMT6).
MFN2	276	276	Q -> R (in CMT6).
MFN2	357	357	K -> N (in CMT2A2).
MFN2	361	361	H -> Y (in CMT6).
MFN2	364	364	R -> W (in CMT6).
TNFRSF8	273	273	C -> Y.
ADORA1	170	170	E -> K (in a colorectal cancer sample; somatic mutation).
SPEN	990	990	D -> H (in a breast cancer sample; somatic mutation).
SPEN	1488	1488	R -> I (in a breast cancer sample; somatic mutation).
ARHGEF10L	96	96	A -> V (in a colorectal cancer sample; somatic mutation).
IGSF21	467	467	T -> M (in a colorectal cancer sample; somatic mutation).
UBR4	1394	1394	R -> H (in a breast cancer sample; somatic mutation).
UBR4	4924	4924	G -> R (in a melanoma patient).
ALPL	17	17	S -> F (in HOPS).
ALPL	28	28	Y -> C (in HOPS; infantile; 7% of activity).
ALPL	33	33	A -> V (in HOPS; 7.2% of wild-type activity).
ALPL	40	40	A -> V (in HOPS; 2% of activity).
ALPL	51	51	A -> S (in HOPS).
ALPL	51	51	A -> V (in HOPS).
ALPL	62	62	M -> L (in HOPS; moderate; 27% of activity).
ALPL	62	62	M -> V (in HOPS).
ALPL	63	63	G -> R (in HOPS).
ALPL	63	63	G -> V (in HOPS; loss of activity).
ALPL	68	68	T -> M (in HOPS; childhood-type; severe allele).
ALPL	71	71	R -> C (in HOPS).
ALPL	71	71	R -> H (in HOPS).
ALPL	71	71	R -> P (in HOPS).
ALPL	71	71	R -> S (in HOPS; childhood-type; severe allele).
ALPL	75	75	G -> S (in HOPS; severe; 3.5% of activity).
ALPL	76	76	Q -> R (in HOPS).
ALPL	111	111	A -> T (in HOPS; odonto).
ALPL	114	114	A -> G (in HOPS).
ALPL	120	120	G -> R (in HOPS).
ALPL	128	128	V -> M (in HOPS).
ALPL	129	129	G -> R (in HOPS).
ALPL	132	132	A -> V (in HOPS).
ALPL	134	134	T -> H (in HOPS; requires 2 nucleotide substitutions).
ALPL	134	134	T -> N (in HOPS; 9% of activity).
ALPL	136	136	R -> H (in HOPS; moderate; 33% of activity).
ALPL	148	148	T -> I (in HOPS).
ALPL	152	152	R -> H (in HOPS).
ALPL	162	162	G -> S (in HOPS).
ALPL	162	162	G -> V (in HOPS; severe; 1% of activity).
ALPL	170	170	N -> D (in HOPS).
ALPL	171	171	H -> R (in HOPS).
ALPL	171	171	H -> Y (in HOPS; severe; 2% of activity).
ALPL	176	176	A -> T (in HOPS).
ALPL	177	177	A -> T (in HOPS; adult type; moderate allele).
ALPL	179	179	A -> T (in HOPS).
ALPL	181	181	S -> L (in HOPS; 1% of activity).
ALPL	184	184	R -> W (in HOPS; loss of activity).
ALPL	189	189	D -> E (in HOPS).
ALPL	191	191	E -> G (in HOPS; odonto).
ALPL	191	191	E -> K (in HOPS; moderate; frequent mutation in European countries).
ALPL	201	201	C -> Y (in HOPS).
ALPL	207	207	Q -> P (in HOPS).
ALPL	211	211	N -> D (in HOPS).
ALPL	212	212	I -> F (in HOPS).
ALPL	220	220	G -> A (in HOPS).
ALPL	220	220	G -> V (in HOPS; odonto).
ALPL	223	223	R -> Q (in HOPS).
ALPL	223	223	R -> W (in HOPS; 3% of activity; severe allele).
ALPL	224	224	K -> E (in HOPS; infantile; partial loss of activity).
ALPL	235	235	E -> G (in HOPS).
ALPL	246	246	R -> S (in HOPS; 4% of activity).
ALPL	249	249	G -> V (in HOPS; partial loss of activity).
ALPL	272	272	R -> H (in HOPS; 6.8% of wild-type activity).
ALPL	272	272	R -> L (in HOPS).
ALPL	275	275	L -> P (in HOPS; childhood-type; severe allele).
ALPL	289	289	L -> F (in HOPS).
ALPL	291	291	E -> K (in HOPS; moderate; 8% of activity).
ALPL	292	292	P -> T (in HOPS; 4% of wild-type activity).
ALPL	293	294	Missing (in HOPS).
ALPL	294	294	D -> A (in HOPS).
ALPL	294	294	D -> Y (in HOPS).
ALPL	295	295	M -> T (in HOPS; 8.5% of wild-type activity).
ALPL	297	297	Y -> D (in HOPS; 1.3% of wild-type activity).
ALPL	298	298	E -> K (in HOPS).
ALPL	299	299	L -> P (in HOPS).
ALPL	306	306	D -> V (in HOPS).
ALPL	311	311	E -> K (in HOPS).
ALPL	326	326	G -> R (in HOPS; in a patient carrying also K-291).
ALPL	327	327	F -> G (in HOPS; requires 2 nucleotide substitutions).
ALPL	327	327	F -> L (in HOPS; childhood).
ALPL	327	327	Missing (in HOPS).
ALPL	334	334	G -> D (in HOPS).
ALPL	339	339	G -> R (in HOPS).
ALPL	348	348	A -> T (in HOPS).
ALPL	354	354	E -> D (in HOPS).
ALPL	378	378	D -> V (in HOPS; loss of activity).
ALPL	381	381	H -> R (in HOPS).
ALPL	382	382	V -> I (in HOPS).
ALPL	391	391	R -> C (in HOPS; moderate; 10% of activity).
ALPL	391	391	R -> H (in HOPS; childhood-type; severyye allele).
ALPL	399	399	A -> S (in HOPS).
ALPL	406	406	D -> G (in HOPS; 15% of activity).
ALPL	411	411	T -> A (in HOPS; absence of residual enzymatic activity).
ALPL	414	414	L -> M (in HOPS).
ALPL	417	417	N -> S (in HOPS).
ALPL	423	423	V -> A (in HOPS; 16% of activity).
ALPL	426	426	G -> C (in HOPS; infantile; partial loss of activity).
ALPL	426	426	G -> D (in HOPS).
ALPL	436	436	Y -> H (in HOPS).
ALPL	445	445	S -> P (in HOPS; severe; 2% of activity).
ALPL	450	450	R -> C (in HOPS; severe; 4% of activity).
ALPL	450	450	R -> H (in HOPS).
ALPL	452	452	E -> K (in HOPS).
ALPL	456	456	G -> R (in HOPS; loss of activity).
ALPL	459	459	V -> M (in HOPS; infantile).
ALPL	468	468	A -> T (in HOPS).
ALPL	473	473	G -> S (in HOPS).
ALPL	476	476	E -> K (in HOPS).
ALPL	478	478	N -> I (in HOPS; 9% of activity).
ALPL	489	489	C -> S (in HOPS; 9% of activity).
ALPL	490	490	I -> F (in HOPS; odonto; partial loss of activity).
ALPL	491	491	G -> R (in HOPS).
HSPG2	1532	1532	C -> Y (in SJS1).
RHCE	16	16	W -> C (associated with altered expression of E antigen).
RHCE	36	36	A -> T (in C(X)/Rh9 antigen).
RHCE	41	41	Q -> R (in C(W)/Rh8 antigen).
RHCE	60	60	L -> I.
RHCE	154	154	R -> T (in RhEKH).
RHCE	233	233	Q -> E (in RhEFM).
RHCE	238	238	M -> V (in RhEFM).
PTPRU	830	830	H -> Y (in a colorectal cancer sample; somatic mutation).
PTPRU	835	835	R -> W (in a colorectal cancer sample; somatic mutation).
PTPRU	856	856	R -> C (in a colorectal cancer sample; somatic mutation).
GJA4	71	71	P -> S.
GJA4	128	128	A -> V.
ZMYM4	1410	1410	R -> W (in a colorectal cancer sample; somatic mutation).
STK40	133	133	M -> T (in a colorectal adenocarcinoma sample; somatic mutation).
STK40	211	211	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation).
GRIK3	215	215	R -> H (in a colorectal cancer sample; somatic mutation).
GRIK3	352	352	R -> Q (in RNA edited version).
GRIK3	391	391	D -> H (in a breast cancer sample; somatic mutation).
KCNQ4	274	274	L -> H (in DFNA2A).
KCNQ4	276	276	W -> S (in DFNA2A).
KCNQ4	281	281	L -> S (in DFNA2A).
KCNQ4	285	285	G -> C (in DFNA2A; loss of potassium selectivity of the pore).
HIVEP3	484	484	V -> M (in a colorectal cancer sample; somatic mutation).
EIF2B3	87	87	A -> V (in VWM).
EIF2B3	225	225	R -> Q (in VWM).
TESK2	11	11	G -> A (in a breast infiltrating ductal carcinoma sample; somatic mutation).
MAST2	275	275	K -> E (in an ovarian mucinous carcinoma sample; somatic mutation).
MAST2	655	655	G -> A (in a breast mucinous carcinoma sample; somatic mutation).
MAST2	1703	1703	G -> E.
POMGNT1	176	176	T -> P (in MDDGA3).
POMGNT1	198	198	S -> R (in MDDGA3).
POMGNT1	223	223	E -> K (in MDDGA3; specific activity abolished in the membrane bound form but not the soluble form).
POMGNT1	265	265	R -> H (in MDDGA3; found on the same allele as Q-311; could be a polymorphism).
POMGNT1	269	269	C -> Y (in MDDGA3; specific activity abolished of the membrane bound form but not the soluble form).
POMGNT1	311	311	R -> Q (in MDDGA3 and MDDGB3).
POMGNT1	367	367	R -> H (in MDDGA3).
POMGNT1	425	425	W -> S (in MDDGA3).
POMGNT1	427	427	D -> H (in MDDGA3).
POMGNT1	490	490	C -> Y (in MDDGA3 and MDDGB3).
POMGNT1	550	550	S -> N (in MDDGA3).
POMGNT1	556	556	D -> N (in MDDGC3; normal enzyme activity but altered kinetic properties).
POMGNT1	605	605	R -> P (in MDDGB3).
CD55	52	52	R -> P (in Tc(c) antigen).
CD55	82	82	L -> R (in WES(a) antigen).
CD55	240	240	R -> H (in GUTI(-) antigen).
NRD1	153	153	E -> EE.
HEATR8	183	183	S -> Y (in a breast cancer sample; somatic mutation).
PRKAA2	371	371	P -> T (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation).
PRKAA2	407	407	R -> Q (in a gastric adenocarcinoma sample; somatic mutation).
PRKAA2	523	523	S -> G (in a breast cancer sample; somatic mutation).
OMA1	69	69	H -> Y (in a patient with amyotrophic lateral sclerosis).
OMA1	226	226	L -> V (in a colorectal cancer sample; somatic mutation).
OMA1	272	272	E -> G (in a patient with amyotrophic lateral sclerosis).
OMA1	365	365	D -> Y.
HOOK1	433	433	S -> L (in a breast cancer sample; somatic mutation).
PGM1	68	68	K -> M (in allele PGM1*7+, allele PGM1*7-, allele PGM1*3+ and allele PGM1*3-).
PGM1	115	115	T -> A (in GSD14).
ROR1	144	144	G -> E (in a metastatic melanoma sample; somatic mutation).
ROR1	150	150	F -> L (in an ovarian mucinous carcinoma sample; somatic mutation).
ROR1	301	301	I -> V (in a renal clear cell carcinoma sample; somatic mutation).
ROR1	562	562	E -> D (in a breast cancer sample; somatic mutation).
ROR1	567	567	R -> I (in a colorectal adenocarcinoma sample; somatic mutation).
ROR1	776	776	S -> N (in a colorectal adenocarcinoma sample; somatic mutation).
FPGT-TNNI3K	309	309	F -> L.
FPGT-TNNI3K	430	430	S -> L (in a colorectal adenocarcinoma sample; somatic mutation).
FPGT-TNNI3K	629	629	R -> G (in a colorectal cancer sample; somatic mutation).
FPGT-TNNI3K	798	798	M -> I (in a head & Neck squamous cell carcinoma sample; somatic mutation).
ZZZ3	456	456	P -> S (in a colorectal cancer sample; somatic mutation).
NEXN	131	131	Q -> E (in CMH20; affects interaction with ACTA1 and F-actin).
NEXN	279	279	R -> C (in CMH20; the mutant protein accumulates in the cytoplasm but binding to ACTA1 is not altered).
NEXN	611	611	P -> T (in CMD1CC; affects cardiac Z line integrity; no effect on protein expression and stability).
NEXN	650	650	Missing (in CMD1CC; affects cardiac Z- disk integrity; no effect on protein expression and stability).
NEXN	652	652	Y -> C (in CMD1CC; affects cardiac Z line integrity; no effect on protein expression and stability).
RD3	35	35	G -> R.
RD3	57	57	G -> V (in an individual with cone-rod degeneration).
RD3	68	68	R -> W.
RD3	130	130	K -> M (in an individual with cone-rod dystrophy features).
RD3	167	167	R -> K.
RD3	195	195	D -> V.
CLCA2	754	754	G -> E (in a breast cancer sample; somatic mutation).
ABCA4	11	11	L -> P (in FFM).
ABCA4	13	15	Missing (in STGD1).
ABCA4	18	18	R -> W (in STGD1).
ABCA4	24	24	R -> H (in STGD1).
ABCA4	54	54	C -> Y (in STGD1).
ABCA4	58	58	N -> K (in STGD1).
ABCA4	60	60	A -> E (in STGD1).
ABCA4	60	60	A -> T (in STGD1).
ABCA4	60	60	A -> V (in STGD1).
ABCA4	65	65	G -> E (in STGD1 and CORD3).
ABCA4	68	68	P -> L (in STGD1).
ABCA4	68	68	P -> R (in STGD1).
ABCA4	72	72	G -> R (in STGD1).
ABCA4	75	75	C -> G (in STGD1).
ABCA4	77	77	V -> E (in STGD1).
ABCA4	96	96	N -> D (in STGD1).
ABCA4	96	96	N -> H (in STGD1).
ABCA4	100	100	S -> P (in STGD1).
ABCA4	152	152	R -> Q.
ABCA4	156	156	I -> V (in STGD1).
ABCA4	190	190	Q -> H (in STGD1).
ABCA4	192	192	A -> T (in STGD1).
ABCA4	206	206	S -> R (in STGD1; reduced basal and retinal-stimulated ATP-hydrolysis).
ABCA4	212	212	R -> C (in STGD1 and CORD3; common mutation in southern Europe; reduced ATP- binding capacity).
ABCA4	220	220	R -> C (in STGD1).
ABCA4	224	224	T -> M (in a breast cancer sample; somatic mutation).
ABCA4	230	230	C -> S (in STGD1).
ABCA4	244	244	L -> P (in STGD1).
ABCA4	247	247	N -> S (in STGD1).
ABCA4	249	249	D -> G (in STGD1).
ABCA4	300	300	T -> N (in STGD1).
ABCA4	309	309	P -> R (in STGD1).
ABCA4	328	328	E -> V (in STGD1).
ABCA4	333	333	R -> W (in STGD1).
ABCA4	336	336	S -> C (in STGD1).
ABCA4	339	339	W -> G (in FFM).
ABCA4	340	340	Y -> D (in STGD1).
ABCA4	380	380	N -> K (in STGD1).
ABCA4	407	407	A -> V (in STGD1 and CORD3).
ABCA4	445	445	S -> R (in STGD1).
ABCA4	523	523	D -> E (in STGD1).
ABCA4	525	525	F -> C (in STGD1).
ABCA4	537	537	R -> C (in STGD1).
ABCA4	541	541	L -> P (in STGD1, FFM and CORD3; reduced ATP-binding capacity; abolishes retinal- stimulated ATP hydrolysis).
ABCA4	549	549	A -> P (in STGD1).
ABCA4	550	550	G -> R (in STGD1).
ABCA4	552	552	V -> I.
ABCA4	572	572	R -> P (in STGD1).
ABCA4	572	572	R -> Q (in STGD1).
ABCA4	602	602	R -> Q (in STGD1).
ABCA4	602	602	R -> W (in STGD1).
ABCA4	607	607	G -> R (in STGD1).
ABCA4	607	607	G -> W (in STGD1).
ABCA4	608	608	F -> I (in STGD1).
ABCA4	635	635	Q -> K (in STGD1).
ABCA4	636	636	Q -> H (in STGD1).
ABCA4	643	643	V -> G.
ABCA4	643	643	V -> M (in STGD1).
ABCA4	645	645	D -> N (in STGD1).
ABCA4	653	653	R -> C (in STGD1).
ABCA4	686	686	L -> S (in STGD1).
ABCA4	716	716	T -> M (in STGD1).
ABCA4	764	764	C -> Y (in STGD1).
ABCA4	765	765	S -> N (in STGD1).
ABCA4	765	765	S -> R (in STGD1).
ABCA4	767	767	V -> D (in STGD1).
ABCA4	797	797	L -> P (in STGD1).
ABCA4	818	818	G -> E (in ARMD2 and STGD1; reduced ATP- binding capacity).
ABCA4	821	821	W -> R (in STGD1).
ABCA4	824	824	I -> T (in STGD1).
ABCA4	846	846	D -> H.
ABCA4	849	849	V -> A (in STGD1).
ABCA4	851	851	G -> D (in STGD1; highly reduced ATP- binding capacity).
ABCA4	854	854	A -> T (in STGD1).
ABCA4	863	863	G -> A (in STGD1, FFM and CORD3; frequent mutation in northern Europe in linkage disequilibrium with the polymorphic variant Q-943; reduced ATP-binding capacity and retinal-stimulated ATP hydrolysis).
ABCA4	863	863	Missing (in STGD1 and CORD3; reduced ATP- binding capacity and retinal-stimulated ATP hydrolysis).
ABCA4	873	873	F -> L (in STGD1).
ABCA4	897	897	T -> I (in STGD1).
ABCA4	901	901	T -> A.
ABCA4	914	914	H -> R.
ABCA4	931	931	V -> M (in STGD1).
ABCA4	935	935	V -> A (in STGD1).
ABCA4	943	943	R -> W (in STGD1 and FFM).
ABCA4	957	957	Q -> R (in STGD1).
ABCA4	959	959	T -> I (in STGD1).
ABCA4	965	965	N -> S (in STGD1; reduced retinal- stimulated ATP hydrolysis).
ABCA4	971	971	T -> N (in STGD1; highly reduced ATP- binding capacity; abolishes retinal- stimulated ATP hydrolysis).
ABCA4	972	972	T -> N (in STGD1; could be a rare polymorphism).
ABCA4	974	974	S -> P (in STGD1).
ABCA4	978	978	G -> C (in STGD1).
ABCA4	989	989	V -> A (in STGD1).
ABCA4	991	991	G -> R (in FFM).
ABCA4	1014	1014	L -> R (in STGD1).
ABCA4	1019	1019	T -> A (in STGD1).
ABCA4	1019	1019	T -> M (in STGD1).
ABCA4	1022	1022	E -> K (in STGD1).
ABCA4	1031	1031	K -> E (in STGD1).
ABCA4	1036	1036	E -> K (in STGD1).
ABCA4	1038	1038	A -> V (in STGD1, FFM and CORD3; frequent mutation; reduced ATP-binding and retinal-stimulated ATP hydrolysis).
ABCA4	1055	1055	R -> W (in STGD1).
ABCA4	1063	1063	S -> P (in STGD1).
ABCA4	1071	1071	S -> L (in STGD1; reduced ATP-binding capacity).
ABCA4	1072	1072	V -> A (in STGD1).
ABCA4	1087	1087	E -> D (in STGD1).
ABCA4	1087	1087	E -> K (in STGD1).
ABCA4	1091	1091	G -> E (in FFM).
ABCA4	1097	1097	R -> C (in STGD1).
ABCA4	1108	1108	R -> C (in STGD1 and FFM; reduced ATP- binding capacity).
ABCA4	1108	1108	R -> H (in STGD1).
ABCA4	1108	1108	R -> L (in STGD1).
ABCA4	1112	1112	T -> N (in STGD1).
ABCA4	1122	1122	E -> K (in STGD1 and CORD3).
ABCA4	1129	1129	R -> C (in STGD1; may predispose to develop retinal toxicity after treatment with chloroquine and hydroxychloroquine).
ABCA4	1148	1148	K -> T.
ABCA4	1201	1201	L -> R (in STGD1; may predispose to develop retinal toxicity after treatment with chloroquine and hydroxychloroquine).
ABCA4	1204	1204	D -> N (in STGD1).
ABCA4	1250	1250	L -> P (in STGD1).
ABCA4	1253	1253	T -> M (in FFM; could be a rare polymorphism).
ABCA4	1300	1300	R -> Q (in STGD1).
ABCA4	1314	1314	P -> T.
ABCA4	1380	1380	P -> L (in STGD1; reduced ATP-binding capacity).
ABCA4	1388	1388	L -> P (in STGD1).
ABCA4	1399	1399	E -> K (in STGD1).
ABCA4	1406	1406	H -> Y (in STGD1).
ABCA4	1408	1408	W -> L (in STGD1).
ABCA4	1408	1408	W -> R (in STGD1; reduced retinal- stimulated ATP hydrolysis).
ABCA4	1429	1429	V -> A (in STGD1).
ABCA4	1430	1430	L -> P (in STGD1).
ABCA4	1433	1433	V -> I (in STGD1).
ABCA4	1439	1439	G -> D (in STGD1).
ABCA4	1440	1440	F -> S (in STGD1).
ABCA4	1440	1440	F -> V (in STGD1).
ABCA4	1443	1443	R -> H (in STGD1).
ABCA4	1486	1486	P -> L (in STGD1).
ABCA4	1488	1488	C -> F (in STGD1).
ABCA4	1488	1488	C -> R (in STGD1 and FFM; reduced retinal-stimulated ATP hydrolysis).
ABCA4	1488	1488	C -> Y (in STGD1).
ABCA4	1490	1490	C -> Y (in STGD1 and CORD3; reduced retinal-stimulated ATP hydrolysis).
ABCA4	1508	1508	G -> C (in FFM).
ABCA4	1513	1513	Q -> R (in STGD1).
ABCA4	1525	1525	L -> P (in STGD1).
ABCA4	1526	1526	T -> M (in STGD1; reduced retinal- stimulated ATP hydrolysis).
ABCA4	1532	1532	D -> N (in STGD1).
ABCA4	1537	1537	T -> M (in STGD1).
ABCA4	1598	1598	A -> D (in CORD3).
ABCA4	1631	1631	L -> P (in STGD1).
ABCA4	1637	1637	A -> T (rare polymorphism).
ABCA4	1640	1640	R -> Q (in STGD1, FFM and CORD3).
ABCA4	1640	1640	R -> W (in STGD1 and CORD3).
ABCA4	1652	1652	Y -> D (in STGD1).
ABCA4	1681	1685	Missing (in STGD1; highly reduced ATP- binding capacity).
ABCA4	1689	1689	S -> P (in STGD1).
ABCA4	1693	1693	V -> I (in STGD1).
ABCA4	1696	1696	S -> N (in STGD1).
ABCA4	1703	1703	Q -> K (in STGD1).
ABCA4	1705	1705	R -> L (in STGD1).
ABCA4	1729	1729	L -> P (in STGD1).
ABCA4	1733	1733	M -> T (in STGD1).
ABCA4	1736	1736	S -> P (in STGD1).
ABCA4	1748	1748	G -> R (in STGD1).
ABCA4	1761	1763	Missing (in STGD1; highly reduced ATP- binding capacity).
ABCA4	1763	1763	L -> P (in STGD1).
ABCA4	1776	1776	P -> L (in STGD1).
ABCA4	1780	1780	P -> A (in STGD1).
ABCA4	1794	1794	A -> D (in STGD1).
ABCA4	1799	1799	N -> D (in STGD1).
ABCA4	1805	1805	N -> D (in STGD1).
ABCA4	1817	1817	E -> D.
ABCA4	1820	1820	R -> P (in STGD1).
ABCA4	1838	1838	H -> Y (in STGD1).
ABCA4	1843	1843	R -> W (in STGD1).
ABCA4	1846	1846	I -> T.
ABCA4	1884	1884	V -> E (in STGD1).
ABCA4	1885	1885	E -> K (in STGD1).
ABCA4	1886	1886	G -> E (in STGD1; highly reduced ATP- binding capacity).
ABCA4	1890	1890	Missing (in STGD1).
ABCA4	1896	1896	V -> D (in STGD1).
ABCA4	1921	1921	V -> M.
ABCA4	1940	1940	L -> P (in STGD1 and FFM).
ABCA4	1948	1948	P -> L.
ABCA4	1971	1971	L -> R (in FFM; highly reduced ATP- binding capacity; abolishes basal and retinal-stimulated ATP hydrolysis).
ABCA4	1975	1975	G -> R (in STGD1).
ABCA4	1977	1977	G -> S (in STGD1; highly reduced ATP- binding capacity; inhibition of ATP hydrolysis by retinal).
ABCA4	2027	2027	L -> F (in STGD1 and FFM; highly reduced ATP-binding capacity).
ABCA4	2030	2030	R -> Q (in STGD1 and FFM).
ABCA4	2035	2035	L -> P (in STGD1).
ABCA4	2038	2038	R -> W (in STGD1; highly reduced ATP- binding capacity).
ABCA4	2050	2050	V -> L (in STGD1).
ABCA4	2059	2059	G -> A.
ABCA4	2060	2060	L -> R (in CORD3).
ABCA4	2071	2071	Y -> F (in STGD1).
ABCA4	2077	2077	R -> G (in STGD1).
ABCA4	2077	2077	R -> W (in STGD1; highly reduced ATP- binding capacity).
ABCA4	2096	2096	E -> K (in STGD1; inhibition of ATP hydrolysis by retinal).
ABCA4	2106	2106	R -> C (in STGD1 and FFM; reduced ATP- binding capacity).
ABCA4	2107	2107	R -> C (in STGD1).
ABCA4	2107	2107	R -> H (in STGD1; may predispose to develop retinal toxicity after treatment with chloroquine and hydroxychloroquine).
ABCA4	2128	2128	H -> R (in STGD1).
ABCA4	2131	2131	E -> K (in STGD1).
ABCA4	2139	2139	R -> W (in STGD1).
ABCA4	2146	2146	G -> D (in CORD3).
ABCA4	2149	2149	R -> L (in STGD1).
ABCA4	2150	2150	C -> R (in STGD1).
ABCA4	2150	2150	C -> Y (in STGD1 and CORD3).
ABCA4	2160	2160	K -> R (in STGD1).
ABCA4	2216	2216	A -> V.
ABCA4	2229	2229	L -> P (in STGD1).
ABCA4	2241	2241	L -> V (in STGD1).
ABCA4	2263	2263	R -> L (in STGD1).
ARHGAP29	552	552	S -> C (in a breast cancer sample; somatic mutation).
ABCD3	17	17	G -> D (in a patient with Zellweger syndrome).
SLC44A3	441	441	G -> W (found in a renal cell carcinoma sample; somatic mutation).
CDC14A	493	493	D -> Y (in a colorectal cancer sample; somatic mutation).
COL11A1	565	565	G -> V (in STL2).
COL11A1	625	625	G -> V (in STL2).
COL11A1	676	676	G -> R (in STL2; overlapping phenotype with Marshall syndrome).
COL11A1	921	926	Missing (in STL2; overlapping phenotype with Marshall syndrome).
COL11A1	1027	1027	G -> R (in STL2).
COL11A1	1110	1118	Missing (in STL2).
COL11A1	1313	1315	Missing (in STL2; overlapping phenotype with Marshall syndrome).
COL11A1	1326	1326	A -> V (in a breast cancer sample; somatic mutation).
COL11A1	1328	1328	Q -> K (in a breast cancer sample; somatic mutation).
COL11A1	1328	1328	Q -> L (in a breast cancer sample; somatic mutation).
COL11A1	1513	1513	G -> D (in STL2).
COL11A1	1516	1516	G -> V (in STL2; overlapping phenotype with Marshall syndrome).
KIAA1324	829	829	S -> R (in a breast cancer sample; somatic mutation).
ADORA3	105	105	A -> T (in a colorectal cancer sample; somatic mutation).
KCND3	94	94	V -> M (in a colorectal cancer sample; somatic mutation).
TRIM33	580	580	M -> I (in a glioblastoma multiforme sample; somatic mutation).
TRIM33	811	811	E -> K (in a lung adenocarcinoma sample; somatic mutation).
TRIM33	885	885	P -> S (in a glioblastoma multiforme sample; somatic mutation).
CASQ2	33	33	R -> Q (in CPVT2; reduces calcium- dependent dimerization).
CASQ2	167	167	L -> H (in CPVT2; alters protein folding, reduces calcium-binding and calcium- dependent oligomerization, decreases sarcoplasmic reticulum Ca(2+) storing capacity and reduces the amplitude of I(Ca)-induced Ca(2+) transients and of spontaneous Ca(2+) sparks in permeabilized myocytes).
CASQ2	307	307	D -> H (in CPVT2; reduces calcium-binding and causes 50% decrease in calcium- dependent binding to triadin-1 and junctin).
CD2	217	217	C -> Y (in a breast cancer sample; somatic mutation).
SPAG17	1707	1707	D -> E (in a colorectal cancer sample; somatic mutation).
FMO5	457	457	P -> L.
KCNN3	81	85	Missing.
LMNA	32	32	Missing (in EDMD2).
LMNA	33	33	E -> G (in EDMD2).
LMNA	39	39	N -> S (in MDCL and EDMD2).
LMNA	59	59	L -> R (in CMDHH).
LMNA	63	63	I -> N (in EDMD2).
LMNA	65	65	E -> G (in EDMD2).
LMNA	112	112	Missing (in EDMD2).
LMNA	133	133	R -> L (in FPLD2).
LMNA	140	140	L -> P (in EDMD2).
LMNA	189	189	R -> P (in EDMD2; found also in a patient with limb-girdle muscular dystrophy; sporadic).
LMNA	190	190	R -> Q (in EDMD2).
LMNA	190	190	R -> RR (in EDMD2).
LMNA	196	199	RLQT -> S (in EDMD2).
LMNA	206	206	F -> L (in EDMD2).
LMNA	208	208	Missing (in LGMD1B).
LMNA	215	215	L -> P (in CMD1A).
LMNA	222	222	H -> P (in EDMD2).
LMNA	230	230	D -> N (in FPLD2).
LMNA	232	232	G -> E (in EDMD2).
LMNA	248	248	L -> P (in EDMD2).
LMNA	249	249	R -> Q (in EDMD2).
LMNA	249	249	R -> W (in MDCL and EDMD2; mis-localized in the nucleus; causes nuclear deformations and LMNB1 redistribution).
LMNA	260	260	K -> N (in CMDA1).
LMNA	261	261	Missing (in EDMD2).
LMNA	267	267	Y -> C (in EDMD2).
LMNA	268	268	S -> P (in EDMD2).
LMNA	271	271	L -> P (in EDMD2).
LMNA	294	294	Q -> P (in EDMD2).
LMNA	295	295	S -> P (in EDMD2).
LMNA	298	298	R -> C (in CMT2B1).
LMNA	302	302	L -> P (in MDCL).
LMNA	303	303	S -> P (in EDMD2).
LMNA	317	317	E -> K (in CMD1A).
LMNA	336	336	R -> Q (in EDMD2).
LMNA	343	343	R -> Q (in EDMD2).
LMNA	349	349	R -> L (in CMD1A).
LMNA	355	355	Missing (in EDMD2).
LMNA	358	358	E -> K (in EDMD2 and MDCL; aberrant localization with decreased nuclear rim staining and formation of intranuclear foci; distribution of endogenous LMNA, LMNB1 and LMNB2 are altered in cells expressing this mutant; interacts with itself and with wild-type LMNA and LMNB1; no decrease in the stability compared with wild-type).
LMNA	361	361	E -> K (in EDMD2).
LMNA	371	371	M -> K (in EDMD2; has a dramatically aberrant localization with decreased nuclear rim staining and formation of intranuclear foci; distribution of endogenous LMNA, LMNB1 and LMNB2 are altered in cells expressing this mutant; causes an increased loss of endogenous EMD from the nuclear envelope; interacts with itself and with wild-type LMNA and LMNB1; no decrease in the stability compared with wild-type).
LMNA	377	377	R -> H (in LGMD1B).
LMNA	377	377	R -> L (in EDMD2 and LGMD1B).
LMNA	380	380	L -> S (in MDCL).
LMNA	386	386	R -> K (in EDMD2; has a dramatically aberrant localization with decreased nuclear rim staining and formation of intranuclear foci; distribution of endogenous LMNA, LMNB1 and LMNB2 are altered in cells expressing this mutant; causes an increased loss of endogenous EMD from the nuclear envelope; interacts with itself and with wild-type LMNA and LMNB1; no decrease in the stability compared with wild-type).
LMNA	399	399	R -> C (in FPLD2).
LMNA	435	435	R -> C (in CMD1A).
LMNA	446	446	D -> V (in EDMD2).
LMNA	449	449	G -> D (in EDMD2).
LMNA	453	453	R -> P (in MDCL).
LMNA	453	453	R -> W (in EDMD2; interacts with itself and with wild-type LMNA and LMNB1; no decrease in the stability compared with wild-type).
LMNA	454	454	L -> P (in EDMD2).
LMNA	455	455	R -> P (in MDCL).
LMNA	456	456	N -> D (in MDCL).
LMNA	456	456	N -> I (in EDMD2; mis-localized in the nucleus; does not alter nuclear size or shape).
LMNA	456	456	N -> K (in EDMD2).
LMNA	461	461	D -> Y (in EDMD2).
LMNA	465	465	G -> D (in FPLD2).
LMNA	467	467	W -> R (in EDMD2).
LMNA	469	469	I -> T (in EDMD2).
LMNA	481	481	Y -> H (in LGMD1B).
LMNA	482	482	R -> L (in FPLD2).
LMNA	482	482	R -> W (in FPLD2; interacts with itself and with wild-type LMNA and LMNB1; no decrease in the stability compared with wild-type).
LMNA	486	486	K -> N (in FPLD2; interacts with itself and with wild-type LMNA and LMNB1; no decrease in the stability compared with wild-type).
LMNA	520	520	W -> S (in EDMD2; interacts with itself and with wild-type LMNA and LMNB1; no decrease in the stability compared with wild-type).
LMNA	527	527	R -> C (in HGPS).
LMNA	527	527	R -> H (in MADA).
LMNA	527	527	R -> P (in EDMD2 and FPLD2; interacts with itself and with wild-type LMNA and LMNB1; reduced binding to SUN1; no decrease in the stability compared with wild-type).
LMNA	528	528	T -> K (in EDMD2; interacts with itself and with wild-type LMNA and LMNB1; no decrease in the stability compared with wild-type).
LMNA	528	528	T -> R (in EDMD2).
LMNA	529	529	A -> V (in MADA).
LMNA	530	530	L -> P (in EDMD2; interacts with itself and with wild-type LMNA and LMNB1; reduced binding to SUN1; no decrease in the stability compared with wild-type).
LMNA	541	541	R -> C (in apical left ventricular aneurysm).
LMNA	541	541	R -> H (in EDMD2).
LMNA	541	541	R -> P (in EDMD2; mis-localized in the nucleus; does not alter nuclear size or shape).
LMNA	541	541	R -> S (in EDMD2 and CMD1A; the phenotype is entirely reversed by coexpression of the S-541 mutation and wild-type lamin- C).
LMNA	542	542	K -> N (in HGPS).
LMNA	573	573	S -> L (in CMD1A, FPLD2 and MADA).
LMNA	578	578	E -> V (in an atypical progeroid patient; diagnosed as Werner syndrome).
LMNA	582	582	R -> H (in FPLD2).
LMNA	602	602	G -> S (in EDMD2).
LMNA	608	608	G -> S (in HGPS; reduced binding to SUN1).
LMNA	624	624	R -> H (in EDMD2).
LMNA	644	644	R -> C (in an atypical progeroid patient; diagnosed as Hutchinson-Gilford progeria syndrome).
SPTA1	24	24	I -> S (in EL2; Lograno).
SPTA1	28	28	R -> C (in EL2).
SPTA1	28	28	R -> L (in EL2).
SPTA1	31	31	V -> A (in EL2; Marseille).
SPTA1	34	34	R -> W (in EL2; Genova).
SPTA1	41	41	R -> W (in EL2; Tunis).
SPTA1	45	45	R -> S (in EL2; Clichy).
SPTA1	45	45	R -> T (in EL2; Anastasia).
SPTA1	46	46	G -> V (in EL2; Culoz).
SPTA1	48	48	K -> R (in HPP).
SPTA1	49	49	L -> F (in EL2; Lyon).
SPTA1	151	151	G -> D (in EL2; Ponte de Sor).
SPTA1	154	154	L -> LL (in EL2).
SPTA1	207	207	L -> P (in EL2 and HPP; Saint-Louis).
SPTA1	260	260	L -> P (in EL2; Nigerian).
SPTA1	261	261	S -> P (in EL2).
SPTA1	469	469	H -> P (in EL2; Barcelona).
SPTA1	469	469	Missing (in EL2; Alexandria).
SPTA1	471	471	Q -> P (in EL2).
SPTA1	2025	2025	A -> G (in Cagliari).
KCNJ10	65	65	R -> P (in SESAME).
KCNJ10	77	77	G -> R (in SESAME).
KCNJ10	140	140	C -> R (in SESAME).
KCNJ10	164	164	T -> I (in SESAME).
KCNJ10	167	167	A -> V (in SESAME).
KCNJ10	297	297	R -> C (in SESAME).
DDR2	105	105	R -> S (in a lung large cell carcinoma sample; somatic mutation).
DDR2	113	113	E -> K (in SEMD-SL; abolishes collagen binding).
DDR2	713	713	T -> I (in SEMD-SL; causes retention in an intracellular compartment and thereby abolishes signaling in response collagen binding).
DDR2	726	726	I -> R (in SEMD-SL; causes retention in an intracellular compartment and thereby abolishes signaling in response collagen binding).
DDR2	752	752	R -> C (in SEMD-SL; causes retention in an intracellular compartment and thereby abolishes signaling in response collagen binding).
POU2F1	88	88	S -> F (in a breast cancer sample; somatic mutation).
FMO2	471	471	Y -> YQYRLVGPGQWEGARNAIFTQKQRILKPLKTRALKD SSNFSVSFLLKILGLLAVVVAFFCQLQWS (in allele FMO2*1).
FMO4	37	37	I -> T.
FMO4	339	339	E -> Q.
FMO4	372	372	G -> S.
FMO4	536	536	F -> L.
FMO4	544	544	L -> R.
DARS2	45	45	S -> G (in LBSL).
DARS2	152	152	C -> F (in LBSL).
DARS2	179	179	R -> H (in LBSL).
DARS2	184	184	Q -> K (in LBSL).
DARS2	248	248	Q -> K (in LBSL).
DARS2	263	263	R -> Q (in LBSL).
DARS2	560	560	D -> V (in LBSL).
DARS2	613	613	L -> F (in LBSL).
DARS2	626	626	L -> Q (in LBSL).
DARS2	626	626	L -> V (in LBSL).
DARS2	629	629	Y -> C (in LBSL).
ABL2	99	99	E -> Q (somatic mutation in a breast cancer sample).
ABL2	519	519	R -> I (somatic mutation in a lung squamous cell carcinoma).
LHX4	84	84	R -> C (in CPHD4; has impaired activity on CGA, POU1F1 and TSHB promoters but exhibits normal DNA binding to the CGA pituitary glycoprotein basal element (PGBE) and interaction with the POU1F1 protein).
LHX4	190	190	L -> R (in CPHD4; the mutant protein is inactive in DNA binding and pituitary gene activation assays).
LHX4	210	210	A -> P (in CPHD4; the mutant protein is inactive in DNA binding and pituitary gene activation assays).
LHX4	389	389	P -> T (in CPHD4).
LAMC1	1116	1116	R -> H (in a colorectal cancer sample; somatic mutation).
RGL1	174	174	Y -> S (in a breast cancer sample; somatic mutation).
RGL1	699	699	V -> M (in a breast cancer sample; somatic mutation).
HMCN1	1624	1624	A -> V.
HMCN1	5345	5345	Q -> R (in ARMD1).
PLA2G4A	442	442	H -> Q (in a breast cancer sample; somatic mutation).
CDC73	2	2	A -> S (found in parathyroid adenoma samples; somatic mutation; parathyroid adenoma samples are from a patient with isolated hyperparathyroidism who also carries germline mutation P-91).
CDC73	5	10	Missing (found in a parathyroid carcinoma sample; somatic mutation; parathyroid carcinoma sample is from a patient with hyperparathyroidism-jaw tumor syndrome who also carries a germline mutation causing a splicing defect).
CDC73	34	34	K -> Q (found in a clear cell renal carcinoma sample; somatic mutation; unlike wild-type protein the mutant is defective in suppressing CCND1 expression in vivo).
CDC73	59	59	S -> F (found in a parathyroid carcinoma sample; somatic mutation).
CDC73	63	63	L -> P (found in a kindred with familial hyperparathyroidism).
CDC73	64	64	L -> P (in FIHP; does not affect interaction with the Pfa1 complex).
CDC73	91	91	R -> P (found in a patient with isolated hyperparathyroidism and parathyroid adenomas).
CDC73	95	95	L -> P (found in a parathyroid adenoma sample; somatic mutation; parathyroid adenoma sample is from a patient with familial hyperparathyroidism who also carries a germline frameshift mutation).
CDC73	272	272	N -> S (found in a parathyroid adenoma sample).
CDC73	292	292	R -> K (found in a Wilms tumor sample; somatic mutation).
CDC73	379	379	D -> N (in HPT-JT).
LBR	119	119	P -> L (in PHA).
LBR	372	372	R -> C (in REYNS).
LBR	569	569	P -> R (in PHA).
KCNT2	33	33	V -> I (in a breast cancer sample; somatic mutation).
CFH	78	78	R -> G (in AHUS1).
CFH	127	127	R -> L (in CFH deficiency; with membranoproliferative glomerulonephritis).
CFH	224	224	Missing (in CFH deficiency; with membranoproliferative glomerulonephritis; affects binding of factor H to C3b and shows defective complement regulation).
CFH	325	325	C -> Y (in AHUS1).
CFH	400	400	Q -> K (in AHUS1).
CFH	431	431	C -> S (in CFH deficiency; with membranoproliferative glomerulonephritis).
CFH	536	536	C -> R (in CFH deficiency).
CFH	567	567	R -> G (associated with basal laminar drusen).
CFH	609	609	V -> I (in AHUS1).
CFH	630	630	C -> W (in AHUS1).
CFH	673	673	C -> S (in CFH deficiency; with membranoproliferative glomerulonephritis).
CFH	673	673	C -> Y (in AHUS1).
CFH	850	850	E -> K (in AHUS1).
CFH	893	893	H -> R (in AHUS1).
CFH	915	915	C -> S (in AHUS1).
CFH	950	950	Q -> H (in AHUS1).
CFH	951	951	Y -> H (in AHUS1).
CFH	956	956	T -> M (in AHUS1).
CFH	959	959	C -> Y (in CFH deficiency).
CFH	978	978	W -> C (in AHUS1).
CFH	1007	1007	V -> I.
CFH	1021	1021	Y -> F (in AHUS1).
CFH	1043	1043	C -> R (in AHUS1).
CFH	1076	1076	Q -> E (in CFH deficiency).
CFH	1078	1078	R -> S (associated with basal laminar drusen).
CFH	1119	1119	D -> G (in CFH deficiency).
CFH	1134	1134	V -> G (in AHUS1).
CFH	1142	1142	Y -> D (in AHUS1).
CFH	1157	1157	W -> R (in AHUS1).
CFH	1163	1163	C -> W (in AHUS1).
CFH	1169	1169	I -> L (in AHUS1).
CFH	1183	1183	W -> C (in AHUS1).
CFH	1183	1183	W -> L (in AHUS1).
CFH	1183	1183	W -> R (in AHUS1).
CFH	1184	1184	T -> R (in CFH deficiency).
CFH	1189	1189	L -> R (in AHUS1).
CFH	1194	1194	G -> D (in AHUS1).
CFH	1198	1198	E -> A (in AHUS1).
CFH	1199	1199	F -> S (in AHUS1).
CFH	1210	1210	R -> C (in CFH deficiency).
CFH	1215	1215	R -> G (in AHUS1).
CFH	1215	1215	R -> Q (in CFH deficiency).
CFH	1225	1231	YPTCAKR -> FQS (in AHUS1).
CFH	1226	1226	P -> S (in AHUS1; atypical).
CRB1	27	27	C -> F (in RP12).
CRB1	144	144	F -> V (in LCA8).
CRB1	161	161	A -> V (in RP12).
CRB1	162	162	V -> M (in PPCRA).
CRB1	195	195	C -> F (in RP12).
CRB1	205	205	I -> T.
CRB1	250	250	C -> W (in RP12).
CRB1	289	289	T -> M.
CRB1	383	383	C -> Y (in LCA8).
CRB1	433	433	Y -> C (in RP12).
CRB1	480	480	C -> G (in LCA8).
CRB1	480	480	C -> R (in LCA8).
CRB1	578	578	V -> E (in RP12).
CRB1	584	584	D -> Y (in LCA8).
CRB1	587	587	C -> Y (in RP12).
CRB1	679	679	Q -> E.
CRB1	681	681	C -> Y (in LCA8).
CRB1	710	710	E -> Q (in LCA8).
CRB1	741	741	M -> T (in LCA8).
CRB1	749	749	Missing (in RP12 and LCA8).
CRB1	764	764	R -> C (in RP12 and LCA8).
CRB1	769	769	R -> H.
CRB1	769	769	R -> Q.
CRB1	836	836	P -> T (in RP12).
CRB1	837	837	D -> H (in RP12; located on the same allele as T-1354).
CRB1	846	846	G -> R (in RP12).
CRB1	850	850	G -> S (in RP12).
CRB1	852	852	I -> T (in LCA8).
CRB1	891	891	C -> G (in RP12; without preservation of the paraarteriolar retinal pigment epithelium).
CRB1	894	894	N -> S (in RP12).
CRB1	905	905	R -> Q.
CRB1	948	948	C -> Y (in RP12 and LCA8; without preservation of the paraarteriolar retinal pigment epithelium).
CRB1	959	959	G -> S (in RP12).
CRB1	962	962	Missing (in RP12; without preservation of the paraarteriolar retinal pigment epithelium).
CRB1	986	986	N -> I (in RP12).
CRB1	989	989	I -> T (in LCA8).
CRB1	1025	1025	S -> I (in LCA8).
CRB1	1041	1041	M -> T (in RP12).
CRB1	1071	1071	L -> P (in RP12).
CRB1	1100	1100	I -> R (in LCA8).
CRB1	1100	1100	I -> T (in RP12).
CRB1	1103	1103	G -> R (in LCA8 and RP12).
CRB1	1107	1107	L -> P (in LCA8).
CRB1	1107	1107	L -> R (in LCA8).
CRB1	1165	1165	C -> W (in RP12).
CRB1	1181	1181	C -> R (in RP12).
CRB1	1205	1205	G -> R (in LCA8).
CRB1	1218	1218	C -> F (in LCA8).
CRB1	1317	1317	N -> H (in LCA8).
CRB1	1321	1321	C -> S (in LCA8; also early onset RP without preservation of the paraarteriolar retinal pigment epithelium).
CRB1	1331	1331	R -> H.
CRB1	1354	1354	A -> T (in RP12; located on the same allele as H-837).
CRB1	1383	1383	R -> H (in RP12).
PTPRC	228	228	E -> A (in a breast cancer sample; somatic mutation).
PTPRC	362	363	Missing (in T(-)B(+)NK(+) SCID; associated with lack of surface expression).
PTPRC	863	863	G -> R (in a breast cancer sample; somatic mutation).
CAMSAP2	361	361	I -> L (in a colorectal cancer sample; somatic mutation).
CACNA1S	528	528	R -> G (in HOKPP1).
CACNA1S	528	528	R -> H (in HOKPP1).
CACNA1S	900	900	R -> S (in HOKPP1).
LGR6	725	725	G -> C (in a colorectal cancer sample; somatic mutation).
LGR6	928	928	P -> H (in a colorectal cancer sample; somatic mutation).
PSEN2	122	122	T -> P (in AD4).
PSEN2	130	130	S -> L (in CMD1V).
PSEN2	141	141	N -> I (in AD4; Volga German patients).
PSEN2	148	148	V -> I (in AD4; LOAD; Spanish patients).
PSEN2	239	239	M -> I (in AD4).
DYRK3	239	239	M -> L.
CR1	1408	1408	T -> I.
CR1	1850	1850	H -> D.
IRF6	16	16	A -> V (in VWS).
IRF6	18	18	V -> A (in VWS; abrogates DNA binding).
IRF6	18	18	V -> M (in VWS; abrogates DNA binding).
IRF6	22	22	L -> P (in VWS and PPS; abrogates DNA binding).
IRF6	39	39	P -> A (in VWS).
IRF6	45	45	R -> Q (in VWS).
IRF6	60	60	W -> G (in PPS; abrogates DNA binding).
IRF6	61	61	A -> G (in VWS).
IRF6	64	64	T -> I (in VWS).
IRF6	66	66	K -> T (in PPS).
IRF6	70	70	G -> R (in VWS; does not affect DNA binding).
IRF6	76	76	P -> S (in VWS; abrogates DNA binding).
IRF6	82	82	Q -> K (in PPS).
IRF6	84	84	R -> C (in PPS; abrogates DNA binding).
IRF6	84	84	R -> G (in VWS; abrogates DNA binding).
IRF6	84	84	R -> H (in PPS; abrogates DNA binding).
IRF6	84	84	R -> L (in PPS).
IRF6	88	88	N -> H (in VWS).
IRF6	89	89	K -> E (in PPS; abrogates DNA binding).
IRF6	90	90	S -> G (in VWS).
IRF6	98	98	D -> H (in VWS; abrogates DNA binding).
IRF6	100	100	T -> A (in VWS).
IRF6	250	250	R -> Q (in VWS).
IRF6	251	251	L -> P (in VWS).
IRF6	273	273	Q -> R (in VWS).
IRF6	290	296	FTSKLLD -> L (in VWS).
IRF6	294	294	L -> P (in VWS).
IRF6	297	297	V -> I (in VWS).
IRF6	320	320	K -> E (in VWS).
IRF6	321	321	V -> M (in VWS).
IRF6	325	325	G -> E (in VWS).
IRF6	339	339	R -> I (in VWS).
IRF6	345	345	L -> P (in VWS).
IRF6	347	347	C -> F (in VWS).
IRF6	349	349	E -> V (in VWS).
IRF6	369	369	F -> S (in VWS and OFC6).
IRF6	374	374	C -> W (in VWS).
IRF6	388	388	K -> E (in VWS).
IRF6	396	396	P -> S (in VWS).
IRF6	424	424	S -> L (in PPS; significant decrease of transcriptional activity).
IRF6	430	430	D -> N (in PPS).
RPS6KC1	554	554	L -> I (in a lung neuroendocrine carcinoma sample; somatic mutation).
RPS6KC1	663	663	G -> A (in an ovarian mucinous carcinoma sample; somatic mutation).
RPS6KC1	1003	1003	C -> Y (in a lung adenocarcinoma sample; somatic mutation).
RPS6KC1	1022	1022	E -> K (in a breast infiltrating ductal carcinoma sample; somatic mutation).
PTPN14	159	159	Q -> E (in a breast cancer sample; somatic mutation).
PTPN14	360	360	H -> P (in a breast cancer sample; somatic mutation).
CENPF	1516	1611	Missing.
GJC2	19	19	H -> P (associated with lymphedema in a small family).
GJC2	36	36	I -> M (in SPG44; does not form functional homotypic channels).
GJC2	48	48	S -> L (in LMPH1C).
GJC2	90	90	P -> S (in HLD2).
GJC2	125	125	R -> Q (associated with lymphedema in a small family).
GJC2	149	149	G -> S (associated with lymphedema in a small family).
GJC2	260	260	R -> C (in LMPH1C).
GJC2	272	272	Y -> D (in HLD2).
GJC2	286	286	M -> T (in HLD2).
GJC2	316	316	P -> L (associated with lymphedema in a small family).
RAB3GAP2	1052	1052	G -> C (in MARTS; may cause exon skipping).
MARK1	233	233	Y -> C (in a gastric adenocarcinoma sample; somatic mutation).
MARK1	355	355	N -> T (in an ovarian serous carcinoma sample; somatic mutation).
MARC1	15	15	L -> H.
MARC1	247	247	D -> H.
ADCK3	213	213	R -> W (in CoQ10 deficiency).
ADCK3	272	272	G -> D (in CoQ10 deficiency).
ADCK3	272	272	G -> V (in CoQ10 deficiency).
ADCK3	514	514	Y -> C (in SCAR9).
ADCK3	549	549	G -> S (in SCAR9).
ADCK3	551	551	E -> K (in CoQ10 deficiency).
ADCK3	584	584	Missing (in SCAR9).
CDC42BPA	50	50	E -> K (in a lung neuroendocrine carcinoma sample; somatic mutation).
CDC42BPA	1148	1148	A -> T.
CDC42BPA	1211	1211	R -> H.
CDC42BPA	1317	1317	V -> I.
CDC42BPA	1418	1418	I -> K.
CDC42BPA	1618	1618	T -> A.
OBSCN	1086	1086	A -> S.
OBSCN	1090	1090	A -> T.
OBSCN	1091	1091	S -> T.
OBSCN	1101	1101	A -> P.
OBSCN	1121	1121	G -> R.
OBSCN	1133	1133	L -> V.
OBSCN	1136	1136	A -> V (in a colorectal cancer sample; somatic mutation).
OBSCN	1156	1156	H -> Q.
OBSCN	1248	1248	Q -> H.
OBSCN	1792	1792	R -> H (in a colorectal cancer sample; somatic mutation).
OBSCN	1930	1930	V -> M (in a colorectal cancer sample; somatic mutation).
OBSCN	2090	2090	E -> K (in a colorectal cancer sample; somatic mutation).
OBSCN	2314	2314	S -> F (in a breast cancer sample; somatic mutation).
OBSCN	3389	3389	A -> V.
OBSCN	3426	3426	D -> E.
OBSCN	3834	3834	R -> G.
OBSCN	3983	3983	R -> Q (in a colorectal cancer sample; somatic mutation).
OBSCN	4558	4558	R -> H (in a colorectal cancer sample; somatic mutation).
OBSCN	4810	4810	R -> Q (in a breast cancer sample; somatic mutation).
OBSCN	4823	4823	A -> S.
OBSCN	5071	5071	A -> T (in a breast cancer sample; somatic mutation).
OBSCN	5598	5598	R -> Q.
OBSCN	6473	6473	E -> Q.
TBCE	52	55	Missing (in HRD and KCS1).
B3GALNT2	203	203	N -> S (in a breast cancer sample; somatic mutation).
AGT	242	242	T -> I (associated with susceptibility to hypertension).
AGT	375	375	R -> Q (in RTD).
EGLN1	317	317	P -> R (in ECYT3; marked decrease in enzyme activity).
EGLN1	371	371	R -> H (in ECYT3; decreased interaction with HIF1A and HIF2A and decreased enzyme activity).
AKT3	171	171	G -> R (in a glioblastoma multiforme sample; somatic mutation).
NLRP3	174	174	I -> T (in CINCA).
NLRP3	200	200	V -> M (in FCAS1 and MWS).
NLRP3	262	262	R -> L (in CINCA).
NLRP3	262	262	R -> P (in CINCA).
NLRP3	262	262	R -> W (in FCAS1 and MWS).
NLRP3	266	266	L -> H (in CINCA).
NLRP3	305	305	D -> G (in CINCA).
NLRP3	305	305	D -> N (in CINCA and MWS).
NLRP3	307	307	L -> P (in FCAS1 and MWS).
NLRP3	308	308	Q -> L (in CINCA).
NLRP3	311	311	F -> S (in CINCA).
NLRP3	350	350	T -> M (in MWS and CINCA).
NLRP3	354	354	A -> V (in MWS).
NLRP3	356	356	E -> D (in CINCA).
NLRP3	360	360	H -> R (in CINCA).
NLRP3	407	407	T -> P (in CINCA).
NLRP3	438	438	T -> I (in CINCA).
NLRP3	438	438	T -> N (in CINCA).
NLRP3	441	441	A -> T (in MWS).
NLRP3	441	441	A -> V (in FCAS1).
NLRP3	490	490	R -> K (in FCAS1).
NLRP3	525	525	F -> C (in FCAS1).
NLRP3	525	525	F -> L (in CINCA).
NLRP3	571	571	G -> R (in MWS).
NLRP3	572	572	Y -> C (in CINCA).
NLRP3	575	575	F -> S (in CINCA).
NLRP3	629	629	E -> G (in FCAS1).
NLRP3	634	634	L -> F (in CINCA).
NLRP3	664	664	M -> T (in CINCA).
NLRP3	861	861	Y -> C (in CINCA).
ACTN2	9	9	Q -> R (in CMD1AA).
FH	107	107	N -> T (in MCUL1).
FH	117	117	A -> P (in MCUL1).
FH	180	180	H -> R (in MCUL1).
FH	185	185	Q -> R (in MCUL1).
FH	230	230	K -> R (in FHD and MCUL1).
FH	282	282	G -> V (in MCUL1).
FH	308	308	A -> T (in FHD).
FH	312	312	F -> C (in FHD).
FH	328	328	M -> R (in HLRCC).
FH	425	425	D -> V (in FHD).
EXO1	27	27	V -> A.
EXO1	109	109	E -> K (abrogates exonuclease activity).
EXO1	137	137	A -> S.
EXO1	410	410	L -> R (abrogates exonuclease activity).
EXO1	438	438	F -> C.
EXO1	640	640	P -> A.
EXO1	640	640	P -> S (reduces interaction with MSH2; abrogates interaction with MSH2; when associated with L-770).
EXO1	726	726	H -> P.
EXO1	770	770	P -> L (reduces interaction with MSH2; abrogates interaction with MSH2; when associated with S-640 or E-759).
EXO1	827	827	A -> V.
CD46	13	13	S -> F.
CD46	35	35	C -> Y (in AHUS2).
CD46	59	59	R -> Q.
CD46	165	165	P -> S (in AHUS2; reduced cell surface expression).
CD46	216	216	W -> C (in AHUS2).
CD46	228	228	C -> Y (in a colorectal cancer sample; somatic mutation).
CD46	231	231	P -> R (in AHUS2).
CD46	240	240	S -> P (in AHUS2; no change in cell surface expression but reduced activity).
CD46	271	272	Missing (in AHUS2; no cell surface expression).
CD46	355	355	V -> G.
OR2M5	244	244	H -> N (found in a renal cell carcinoma sample; somatic mutation).
TNNT2	80	80	F -> L (in CMH2).
TNNT2	89	89	I -> N (in CMH2).
TNNT2	102	102	R -> L (in CMH2).
TNNT2	102	102	R -> Q (in CMH2).
TNNT2	102	102	R -> W (in CMH2).
TNNT2	104	104	R -> L (in CMH2).
TNNT2	114	114	A -> V (in CMH2).
TNNT2	120	120	F -> I (in CMH2).
TNNT2	120	120	F -> V (in CMH2).
TNNT2	139	139	R -> K.
TNNT2	140	140	R -> C (in CMH2).
TNNT2	141	141	R -> W (in CMD1D).
TNNT2	151	151	R -> W (in CMD1D).
TNNT2	170	170	Missing (in CMH2).
TNNT2	173	173	E -> K (in CMH2).
TNNT2	189	189	S -> F (in CMH2).
TNNT2	210	210	Missing (in CMD1D).
TNNT2	215	215	R -> L (in CMD1D).
TNNT2	220	220	Missing (in CMD1D).
TNNT2	249	249	S -> T.
TNNT2	263	263	K -> R.
TNNT2	281	281	N -> I (in CMH2).
TNNT2	288	288	R -> C (in CMH2).
TNNT2	288	288	R -> P (in CMH2).
TNNT2	296	296	R -> C (in CMH2).
CAMK1G	443	443	A -> T (in a breast infiltrating ductal carcinoma sample; somatic mutation).
LAMB3	199	199	G -> A (in GABEB; somatic second-site mutation).
LAMB3	207	207	K -> Q (in GABEB; somatic second-site mutation).
LAMB3	210	210	E -> K (in GABEB).
LAMB3	450	450	R -> C (in a colorectal cancer sample; somatic mutation).
LAMB3	679	679	P -> L (in H-JEB).
HSD11B1	148	148	V -> E (in a breast cancer sample; somatic mutation).
TRAF3IP3	529	529	P -> S (in a colorectal cancer sample; somatic mutation).
FLVCR1	121	121	N -> D (in PCARP).
FLVCR1	192	192	C -> R (in PCARP).
FLVCR1	241	241	A -> T (in PCARP).
FLVCR1	493	493	G -> R (in PCARP).
OPTC	182	182	I -> T.
OPTC	229	229	R -> C.
ABCB10	471	471	R -> T (in a breast cancer sample; somatic mutation).
REN	16	16	L -> R (in HNFJ2; affects ER translocation and processing of nascent preprorenin, resulting in abolished prorenin and renin biosynthesis and secretion).
REN	104	104	D -> N (in RTD).
REN	230	230	R -> K (in RTD).
TTLL10	130	130	A -> T (in a colorectal cancer sample; somatic mutation).
SDF4	148	148	A -> T (in a colorectal cancer sample; somatic mutation).
GABRD	177	177	E -> A (in GEFS+5; reduced receptor current amplitudes).
GABRD	220	220	R -> C (in a GEFS+ family; does not affect receptor current amplitudes; could be a rare polymorphism).
PEX10	290	290	H -> Q (in NALD).
PANK4	475	475	E -> K (in a colorectal cancer sample; somatic mutation).
LRRC47	193	193	E -> D (in a colorectal cancer sample; somatic mutation).
CDK18	46	46	G -> S.
CDK18	65	65	G -> R.
CDK18	164	164	T -> M.
CHD5	45	45	V -> M (in a breast cancer sample; somatic mutation).
CHD5	119	119	D -> N (in a breast cancer sample; somatic mutation).
CHD5	667	667	R -> G (in a breast cancer sample; somatic mutation).
ESPN	719	719	S -> R (in DFNB36; irregular microvillar organization).
ESPN	744	744	D -> N (in DFNB36; irregular microvillar organization).
ESPN	774	774	R -> Q (in DFNB36; sporadic case with mild phenotype; could be a rare polymorphism).
ESPN	848	848	Missing (in DFNB36; severe phenotype; severe impairment of microvillar elongation; espin accumulates in the nucleus).
PARK7	26	26	M -> I (in PARK7; does not affect protein stability and degradation; does not interfere with homodimerization).
PARK7	64	64	E -> D (in PARK7; no apparent effect on protein stability; impaired mitochondrial morphology).
PARK7	98	98	R -> Q.
PARK7	104	104	A -> T (in PARK7).
PARK7	149	149	D -> A (in PARK7).
PARK7	150	150	G -> S.
PARK7	163	163	E -> K.
PARK7	171	171	A -> S.
IL10	15	15	G -> R (in a family affected by Crohn disease; decreases secretion thereby reducing the anti-inflammatory effect).
TARDBP	90	90	A -> V.
TARDBP	169	169	D -> G (in ALS10).
TARDBP	267	267	N -> S (in ALS10; also in a patient with frontotemporal dementia).
TARDBP	287	287	G -> S (in ALS10).
TARDBP	290	290	G -> A (in ALS10).
TARDBP	294	294	G -> A (in ALS10).
TARDBP	294	294	G -> V (in ALS10; a patient with bulbar signs and dementia).
TARDBP	295	295	G -> R (in ALS10).
TARDBP	295	295	G -> S (in ALS10; also in patients with frontotemporal lobar degeneration with motor neuron disease).
TARDBP	298	298	G -> S (in ALS10).
TARDBP	315	315	A -> T (in ALS10).
TARDBP	331	331	Q -> K (in ALS10; impedes the development of normal limb and tail buds and increases the number of apoptotic nuclei when expressed in chick embryos; does not affect the interaction with ATNX2).
TARDBP	332	332	S -> N (in ALS10).
TARDBP	335	335	G -> D (in ALS10).
TARDBP	337	337	M -> V (in ALS10; impedes the development of normal limb and tail buds and increases the number of apoptotic nuclei when expressed in chick embryos).
TARDBP	343	343	Q -> R (in ALS10).
TARDBP	348	348	G -> C (in ALS10).
TARDBP	361	361	R -> S (in ALS10).
TARDBP	379	379	S -> C (in ALS10).
TARDBP	379	379	S -> P (in ALS10).
TARDBP	382	382	A -> T (in ALS10).
TARDBP	390	390	N -> D (in ALS10).
TARDBP	390	390	N -> S (in ALS10).
TARDBP	393	393	S -> L (in ALS10).
MASP2	99	99	R -> Q.
MASP2	118	118	R -> C.
MASP2	120	120	D -> G (found in a patient suffering from frequent infections and chronic inflammatory disease; strongly decreases affinity for MBL2 and FCN2).
UBIAD1	75	75	S -> F.
UBIAD1	97	97	A -> T (in SCCD).
UBIAD1	98	98	G -> S (in SCCD).
UBIAD1	102	102	N -> S (in SCCD).
UBIAD1	112	112	D -> G (in SCCD).
UBIAD1	112	112	D -> N (in SCCD).
UBIAD1	118	118	D -> G (in SCCD).
UBIAD1	119	119	R -> G (in SCCD).
UBIAD1	121	121	L -> F (in SCCD).
UBIAD1	122	122	V -> E (in SCCD).
UBIAD1	122	122	V -> G (in SCCD).
UBIAD1	171	171	S -> P (in SCCD).
UBIAD1	175	175	T -> I (in SCCD).
UBIAD1	177	177	G -> R (in SCCD).
UBIAD1	186	186	G -> R (in SCCD).
UBIAD1	188	188	L -> H (in SCCD).
UBIAD1	232	232	N -> S (in SCCD).
UBIAD1	236	236	D -> E (in SCCD).
UBIAD1	240	240	D -> N (in SCCD).
MTHFR	51	51	R -> P (in MTHFRD).
MTHFR	52	52	R -> Q (in MTHFRD).
MTHFR	157	157	R -> Q (in MTHFRD).
MTHFR	227	227	T -> M (in MTHFRD).
MTHFR	251	251	P -> L (in MTHFRD).
MTHFR	323	323	L -> P (in MTHFRD).
MTHFR	324	324	N -> S (in MTHFRD).
MTHFR	325	325	R -> C (in MTHFRD).
MTHFR	335	335	R -> C (in MTHFRD).
MTHFR	339	339	W -> G (in MTHFRD).
MTHFR	357	357	R -> C (in MTHFRD).
MTHFR	377	377	R -> C (in MTHFRD).
MTHFR	387	387	G -> D (in MTHFRD).
MTHFR	428	428	E -> A (common polymorphism; thermolabile; decreased activity).
MTHFR	470	470	E -> A.
MTHFR	572	572	P -> L (in MTHFRD).
MTHFR	586	586	E -> K (in MTHFRD).
NPPA	152	153	Missing (in allele 2).
PLOD1	123	123	Q -> H (in a breast cancer sample; somatic mutation).
PLOD1	367	371	Missing (in EDS6).
PLOD1	446	446	W -> G (in EDS6).
PLOD1	532	532	Missing (in EDS6).
PLOD1	612	612	W -> C (in EDS6).
PLOD1	667	667	A -> T (in EDS6).
PLOD1	678	678	G -> R (in EDS6).
PLOD1	706	706	H -> R (in EDS6).
CTRC	35	35	D -> H.
CTRC	35	35	D -> N.
CTRC	37	37	R -> Q (normal secretion and activity).
CTRC	48	48	Q -> R (reduced secretion and activity).
CTRC	73	73	A -> T (reduced secretion; abolishes activity).
CTRC	80	80	R -> W.
CTRC	217	217	G -> R.
CTRC	217	217	G -> S (reduced secretion and activity).
CTRC	218	218	G -> S.
CTRC	220	220	L -> R.
CTRC	225	225	E -> A.
CTRC	235	235	V -> I (slightly reduced secretion and activity).
CTRC	249	249	P -> L.
CTRC	254	254	R -> W (reduced secretion; normal activity).
CTRC	260	260	D -> N.
C1orf64	52	52	G -> W (in a breast cancer sample; somatic mutation).
C1orf64	100	100	G -> W (in a breast cancer sample; somatic mutation).
CLCNKA	80	80	W -> C (in BS4B; a patient also carrying a mutation in CLCNKB).
EPHA2	721	721	R -> Q (in ARCC2; alters EPHA2 signaling).
EPHA2	777	777	G -> S (in a gastric adenocarcinoma sample; somatic mutation).
EPHA2	940	940	T -> I (in CTPP1).
EPHA2	948	948	G -> W (in CTPP1).
SPATA21	24	24	P -> S (in a breast cancer sample; somatic mutation).
ATP13A2	12	12	T -> M (in a patient with early onset Parkinson disease).
ATP13A2	504	504	G -> R (in a patient with Kufor-Rakeb syndrome).
ATP13A2	533	533	G -> R (in a patient with early onset Parkinson disease).
ATP13A2	746	746	A -> T.
SDHB	29	29	A -> AQ (in pheochromocytoma).
SDHB	40	40	K -> E.
SDHB	43	43	A -> P (in pheochromocytoma).
SDHB	46	46	R -> G (in pheochromocytoma).
SDHB	46	46	R -> Q (in pheochromocytoma and PGL4).
SDHB	53	53	G -> R (in pheochromocytoma).
SDHB	65	65	L -> H (in pheochromocytoma).
SDHB	65	65	L -> P (in pheochromocytoma).
SDHB	87	87	L -> S (in pheochromocytoma).
SDHB	100	100	S -> F (in pheochromocytoma; absence of expression in tumor cells indicating complete loss of SDHB function).
SDHB	101	101	C -> Y (in pheochromocytoma).
SDHB	127	127	I -> N (in pheochromocytoma).
SDHB	131	131	P -> R (in PGL4).
SDHB	132	132	H -> P (in PGL4).
SDHB	192	192	C -> R (in pheochromocytoma).
SDHB	196	196	C -> Y (in pheochromocytoma).
SDHB	197	197	P -> R (in PGL4).
SDHB	230	230	R -> C (in pheochromocytoma).
SDHB	242	242	R -> H (in familial malignant paraganglioma and pheochromocytoma, pheochromocytoma and PGL4).
TMEM206	336	336	K -> N (in a breast cancer sample; somatic mutation).
PADI3	509	509	G -> R (in a breast cancer sample; somatic mutation).
PADI4	89	89	D -> N.
ALDH4A1	16	16	P -> L (in allele ALDH4A1*4).
ALDH4A1	352	352	S -> L (in HP-2; allele ALDH4A1*3).
PLA2G2D	65	65	Q -> H.
PLA2G2D	73	73	H -> R.
PLA2G2D	96	96	H -> R.
PLA2G2D	121	121	R -> C.
PLA2G2D	121	121	R -> L.
RAP1GAP	257	257	C -> R (in a breast cancer sample; somatic mutation).
RAP1GAP	609	609	Y -> C (in a breast cancer sample; somatic mutation).
WNT4	12	12	L -> P (in RKH syndrome; unable to suppress steroidogenesis in an ovarian adenocarcinoma cell line resulting in increased androgen production).
WNT4	83	83	R -> C (in RKH syndrome; with androgen excess, normal kidney size and location; unable to suppress expression of steroidogenic enzymes in ovarian; impairs protein secretion).
WNT4	114	114	A -> V (in SERKAL; reduced transcript levels).
WNT4	216	216	E -> G (in RKH syndrome; unable to suppress expression of steroidogenic enzymes in ovarian and adrenal cell lines).
EPHA8	123	123	N -> K (in a breast infiltrating ductal carcinoma sample; somatic mutation).
EPHA8	179	179	R -> C (in a gastric adenocarcinoma sample; somatic mutation).
EPHA8	198	198	R -> L (in a lung adenocarcinoma sample; somatic mutation).
EPHA8	860	860	P -> L (in a metastatic melanoma sample; somatic mutation).
C1QC	34	34	G -> R (in C1QD).
C1QB	42	42	G -> D (in C1QD).
C1QB	123	123	A -> T (in a breast cancer sample; somatic mutation).
ZNF436	196	196	C -> G (in a breast cancer sample; somatic mutation).
ASAP3	617	617	A -> T (in a colorectal cancer sample; somatic mutation).
RPL11	20	20	L -> H (in DBA7).
RPL11	161	161	Missing (in DBA7).
GALE	25	25	A -> V (in EDG).
GALE	34	34	N -> S (in EDG; peripheral; nearly normal activity towards UDP-galactose).
GALE	40	40	R -> C (in EDG).
GALE	69	69	D -> E (in EDG).
GALE	94	94	V -> M (in EDG; generalized; 30-fold decrease in UDP-galactose epimerization activity; 2-fold decrease in affinity for UDP-galactose; 24% of normal activity with respect to UDP-N- acetylgalactosamine).
GALE	165	165	E -> K (in EDG).
GALE	169	169	R -> W (in EDG).
GALE	183	183	L -> P (in EDG; peripheral; 3-fold decrease in UDP-galactose epimerization activity).
GALE	239	239	R -> W (in EDG).
GALE	302	302	G -> D (in EDG).
GALE	335	335	R -> H (in EDG; 2-fold decrease in UDP- galactose epimerization activity).
HMGCL	37	37	E -> K (in HMGCLD; activity lower than 5% respect to the wild-type).
HMGCL	41	41	R -> Q (in HMGCLD; loss of activity and of proton exchange).
HMGCL	42	42	D -> E (in HMGCLD; reduced activity).
HMGCL	42	42	D -> G (in HMGCLD; loss of activity).
HMGCL	42	42	D -> H (in HMGCLD; loss of activity).
HMGCL	48	48	K -> N (in HMGCLD).
HMGCL	70	70	V -> L (in HMGCLD).
HMGCL	75	75	S -> R (in HMGCLD).
HMGCL	142	142	S -> F (in HMGCLD; activity lower than 5% respect to the wild-type).
HMGCL	165	165	R -> Q (in HMGCLD).
HMGCL	174	174	C -> Y (in HMGCLD; activity lower than 5% respect to the wild-type).
HMGCL	192	192	F -> S (in HMGCLD; activity lower than 5% respect to the wild-type).
HMGCL	200	200	I -> F (in HMGCLD; activity lower than 5% respect to the wild-type).
HMGCL	201	201	S -> Y (in HMGCLD).
HMGCL	203	203	G -> E (in HMGCLD; complete loss of activity).
HMGCL	204	204	D -> N (in HMGCLD).
HMGCL	233	233	H -> R (in HMGCLD; loss of activity).
HMGCL	263	263	L -> P (in HMGCLD).
FUCA1	65	65	G -> D (in FUCA1D; loss of activity).
FUCA1	68	68	S -> L (in FUCA1D).
FUCA1	410	410	L -> R (in FUCA1D; less than 1% of residual activity).
C1orf201	254	254	S -> F (in a breast cancer sample; somatic mutation).
RHD	103	103	S -> C (in a breast cancer sample; somatic mutation).
RHD	110	110	L -> P (in Tar antigen).
RHD	218	218	M -> I.
RHD	223	223	F -> V (in RhDVa(FK) and RhDVa(TT)).
RHD	245	245	V -> L (in RhDVa(TT)).
TMEM50A	141	141	F -> L.
LDLRAP1	202	202	S -> H (in ARH; Lebanon; requires 2 nucleotide substitutions).
SEPN1	273	273	G -> E (in RSMD1).
SEPN1	293	293	H -> R (in RSMD1).
SEPN1	315	315	G -> S (in RSMD1).
SEPN1	340	340	N -> I (in RSMD1).
SEPN1	453	453	W -> S (in RSMD1).
SEPN1	462	462	U -> G (in RSMD1).
SEPN1	463	463	G -> V (in RSMD1).
SEPN1	466	466	R -> Q (in RSMD1).
SEPN1	469	469	R -> Q (in RSMD1).
SEPN1	469	469	R -> W (in RSMD1).
UBXN11	474	474	A -> V.
UBXN11	486	486	C -> CPGPGPGPS.
UBXN11	487	494	Missing.
UBXN11	488	502	Missing.
CD52	40	41	NI -> SM.
DHDDS	42	42	K -> E (in RP59).
HMGN2	7	7	E -> K (in variant H17).
ARID1A	1020	1020	R -> K (found in a clear cell renal carcinoma; somatic mutation).
ARID1A	2089	2089	L -> P (found in a clear cell renal carcinoma case; somatic mutation).
PIGV	256	256	Q -> K (in HPMR).
PIGV	341	341	A -> E (in HPMR).
PIGV	341	341	A -> V (in HPMR).
PIGV	385	385	H -> P (in HPMR).
NR0B2	57	57	R -> W (in early-onset obesity; Japanese population; loss of repressor activity).
NR0B2	189	189	G -> E (in early-onset obesity; Japanese population; strong decrease of repressor activity).
NR0B2	195	195	A -> S (in early-onset obesity; Japanese population; slight decrease of repressor activity).
NR0B2	213	213	R -> C (in early-onset obesity; Japanese population; loss of repressor activity).
NR0B2	216	216	R -> H (no effect on repressor activity).
C1orf172	312	312	R -> H (in a colorectal cancer sample; somatic mutation).
MAP3K6	869	869	P -> T (in a breast cancer sample; somatic mutation).
MAP3K6	925	925	S -> L (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
MAP3K6	968	968	T -> I (in an ovarian endometrioid cancer sample; somatic mutation).
STX12	88	88	P -> R (in a breast cancer sample; somatic mutation).
HCRTR1	167	167	G -> S.
SPOCD1	671	671	R -> W (in a breast cancer sample; somatic mutation).
LCK	28	28	V -> L (in leukemia).
LCK	232	232	P -> PQKP (in leukemia).
LCK	353	353	A -> V (in leukemia).
LCK	447	447	P -> L (in leukemia).
ZBTB8B	181	181	E -> K (in a colorectal cancer sample; somatic mutation).
YARS	41	41	G -> R (in CMTDIC; partial loss of activity).
YARS	153	156	Missing (in CMTDIC).
YARS	196	196	E -> K (in CMTDIC; partial loss of activity).
AK2	103	103	R -> W (in RDYS).
AK2	165	165	D -> G (in RDYS).
GJB4	124	124	R -> Q (may be associated with deafness).
GJB4	137	137	F -> L (in EKV; associated with erythema gyratum repens in some individuals).
GJB4	160	160	R -> C (may be associated with deafness).
GJB4	169	169	C -> W (may be associated with deafness).
GJB3	12	12	G -> D (in EKV).
GJB3	12	12	G -> R (in EKV).
GJB3	42	42	R -> P (in EKV).
GJB3	86	86	C -> S (in EKV).
GJB3	137	137	F -> L (in EKV).
GJB3	141	141	I -> V (in DFNA2B).
GJB3	183	183	E -> K (in DFNA2B).
GJB3	200	200	V -> I.
NCDN	392	392	V -> E (in a colorectal cancer sample; somatic mutation).
NCDN	392	392	V -> L (in a colorectal cancer sample; somatic mutation).
CLSPN	439	439	H -> R (in a breast cancer sample; somatic mutation).
COL8A2	3	3	G -> R.
COL8A2	155	155	R -> Q (in FECD1; identified as a polymorphism in the Japanese population).
COL8A2	304	304	R -> Q (in FECD1).
COL8A2	357	357	G -> R (in FECD1; uncertain pathogenicity).
COL8A2	434	434	R -> H (in FECD1).
COL8A2	455	455	Q -> K (in FECD1 and PPCD2).
COL8A2	502	502	T -> M.
COL8A2	575	575	P -> L (in FECD1; uncertain pathogenicity).
COL8A2	645	645	T -> I.
CSF3R	229	229	P -> H (in a patient with severe congenital neutropenia hyporesponsive to CSF3 treatment; affects CSF3 mediated proliferation and survival of myeloid cells; abrogates receptor signaling by altering ligand binding).
CSF3R	640	640	T -> N (in neutrophilia).
DNALI1	120	120	I -> M (in a colorectal cancer sample; somatic mutation).
EPHA10	150	150	R -> H (in a gastric adenocarcinoma sample; somatic mutation).
EPHA10	630	630	L -> P.
EPHA10	775	775	H -> R (in a breast infiltrating ductal carcinoma sample; somatic mutation).
EPHA10	956	956	A -> T.
NDUFS5	96	96	P -> S (detected in a patient with mitochondrial complex I deficiency; uncertain pathological significance).
MACF1	302	302	E -> V (in a breast cancer sample; somatic mutation).
MACF1	6462	6462	E -> Q (in a breast cancer sample; somatic mutation).
MACF1	7093	7093	G -> E (in a breast cancer sample; somatic mutation).
PPT1	38	38	W -> C (in CLN1).
PPT1	39	39	H -> Q (in CLN1).
PPT1	42	42	G -> E (in CLN1).
PPT1	75	75	T -> P (in CLN1; juvenile onset).
PPT1	79	79	D -> G (in CLN1; juvenile onset).
PPT1	108	108	G -> R (in CLN1; onset in adulthood).
PPT1	109	109	Y -> D (in CLN1).
PPT1	122	122	R -> W (in CLN1; seems to results in intracellular accumulation of the enzyme).
PPT1	177	177	Q -> E (in CLN1).
PPT1	181	181	V -> L (in CLN1).
PPT1	181	181	V -> M (in CLN1).
PPT1	219	219	L -> Q (in CLN1; juvenile onset).
PPT1	247	247	Y -> H (in CLN1).
PPT1	250	250	G -> V (in CLN1).
ZMPSTE24	248	248	P -> L (in MADB; found in compound heterozygotes carrying a null allele; does not affect enzyme activity).
ZMPSTE24	265	265	N -> S (in MADB).
ZMPSTE24	340	340	W -> R (in MADB).
COL9A2	326	326	Q -> W (in IDD; requires 2 nucleotide substitutions).
NFYC	165	165	Q -> H (in a breast cancer sample; somatic mutation).
CLDN19	20	20	G -> D (in HOMG5; perinuclear retention of the mutant protein).
CLDN19	57	57	Q -> E (in HOMG5; the mutant protein inserts correctly into the cell membrane although subsequent analyzes suggested that dimer formation was disrupted).
CLDN19	90	90	L -> P (in HOMG5).
ERMAP	35	35	G -> S (in Sc7 antigen).
ERMAP	81	81	R -> Q (in Sc6 antigen).
ERMAP	103	113	DAQEGSVTLQI -> CPRGKCHSADP (in Sc-3 allele).
ERMAP	114	475	Missing (in Sc-3 allele).
SLC2A1	34	34	N -> I (in GLUT1DS1).
SLC2A1	34	34	N -> S (in GLUT1DS1; 55% of wild-type glucose uptake activity).
SLC2A1	34	34	N -> Y (in GLUT1DS1).
SLC2A1	66	66	S -> F (in GLUT1DS1).
SLC2A1	91	91	G -> D (in GLUT1DS1; significantly decreases the transport of 3-O-methyl-D- glucose).
SLC2A1	93	93	R -> W (in GLUT1DS2).
SLC2A1	95	95	S -> I (in GLUT1DS2).
SLC2A1	96	96	M -> V (in GLUT1DS1).
SLC2A1	126	126	R -> C (in GLUT1DS1 and GLUT1DS2; reduced transporter activity).
SLC2A1	126	126	R -> H (in GLUT1DS1; significantly decreases the transport of 3-O-methyl-D- glucose and dehydroascorbic acid; 57% of wild-type glucose uptake activity).
SLC2A1	126	126	R -> L (in GLUT1DS1; compound heterozygote with V-256).
SLC2A1	130	130	G -> S (in GLUT1DS1; 75% of wild-type glucose uptake activity).
SLC2A1	146	146	E -> K (in GLUT1DS1).
SLC2A1	153	153	R -> C (in GLUT1DS1; 44% of wild-type glucose uptake activity).
SLC2A1	153	153	R -> H (in GLUT1DS2).
SLC2A1	155	155	A -> V (in GLUT1DS1).
SLC2A1	165	165	V -> I (in GLUT1DS2).
SLC2A1	169	169	Missing (in GLUT1DS1; 48% of wild-type glucose uptake activity).
SLC2A1	212	212	R -> C (in GLUT1DS1).
SLC2A1	212	212	R -> H (in GLUT1DS1).
SLC2A1	223	223	R -> P (in GLUT1DS1 and GLUT1DS2; mild phenotype; reduced transporter activity).
SLC2A1	223	223	R -> W (in GLUT1DS1).
SLC2A1	256	256	K -> E (in GLUT1DS1; compound heterozygote with L-126).
SLC2A1	275	275	A -> T (in GLUT1DS2; the mutation decreases glucose transport but does not affect cation permeability).
SLC2A1	282	285	Missing (in GLUT1DS2; accompanied by hemolytic anemia and altered erythrocyte ion concentrations; the mutation decreases glucose transport and causes a cation leak that alteres intracellular concentrations of sodium potassium and calcium).
SLC2A1	295	295	T -> M (in GLUT1DS1; 75% of wild-type glucose uptake activity).
SLC2A1	303	303	V -> L (found in a patient with GLUT1 deficiency syndrome).
SLC2A1	310	310	T -> I (in GLUT1DS1).
SLC2A1	314	314	G -> S (in GLUT1DS2; the mutation decreases glucose transport but does not affect cation permeability).
SLC2A1	317	317	N -> T (in GLUT1DS2).
SLC2A1	324	324	S -> L (in GLUT1DS1 and GLUT1DS2; mild phenotype; reduced transporter activity).
SLC2A1	329	329	E -> Q (in GLUT1DS1).
SLC2A1	333	333	R -> Q (in GLUT1DS1).
SLC2A1	333	333	R -> W (in GLUT1DS1; 43% of wild-type glucose uptake activity).
SLC2A1	382	382	G -> D (in GLUT1DS1).
SLC2A1	405	405	A -> D (in GLUT1DS1).
SLC2A1	485	485	P -> L (in GLUT1DS1).
TMEM125	107	107	R -> L (in a breast cancer sample; somatic mutation).
CDC20	402	402	V -> M.
CDC20	479	479	R -> Q.
ATP6V0B	155	155	V -> M (in a breast cancer sample; somatic mutation).
UROD	25	25	G -> E (in FPCT; insoluble protein).
UROD	46	46	F -> L (in HEP; mild phenotype; strong decrease of activity).
UROD	62	62	P -> L (in HEP).
UROD	80	80	A -> G (in HEP).
UROD	80	80	A -> S (in FPCT; decrease of activity).
UROD	134	134	V -> Q (in FPCT and HEP; requires 2 nucleotide substitutions; nearly normal activity).
UROD	142	142	R -> Q (in FPCT).
UROD	144	144	R -> P (in FPCT; decrease of activity).
UROD	156	156	G -> D (in FPCT; decrease of activity).
UROD	161	161	L -> Q (in FPCT).
UROD	165	165	M -> R (in FPCT; activity < 2%).
UROD	167	167	E -> K (in HEP and FPCT; nearly normal activity).
UROD	168	168	G -> R (in HEP; relative activity of 65% of wild-type towards uroporphyrinogen III).
UROD	170	170	G -> D (in HEP; relative activity of 17% and 60% of wild-type towards uroporphyrinogen I and III respectively).
UROD	193	193	R -> P (in FPCT; insoluble protein).
UROD	195	195	L -> F (in FPCT).
UROD	216	216	L -> Q (in FPCT).
UROD	218	218	E -> K (in FPCT; significant decrease of activity).
UROD	219	219	S -> F (in FPCT).
UROD	220	220	H -> P (in HEP; mild form).
UROD	229	229	F -> L (in FPCT).
UROD	232	232	F -> L (in FPCT; decrease of activity).
UROD	235	235	P -> S (in FPCT).
UROD	260	260	I -> T (in FPCT; decrease of activity).
UROD	281	281	G -> E (in FPTC and HEP).
UROD	281	281	G -> V (in FPCT).
UROD	282	282	L -> R (in FPCT).
UROD	292	292	R -> G (in HEP).
UROD	303	303	G -> S (in FPCT).
UROD	304	304	N -> K (in FPCT).
UROD	311	311	Y -> C (in HEP).
UROD	318	318	G -> R (in FPCT).
UROD	324	324	M -> T (in FPCT).
UROD	332	332	R -> H (in FPCT).
UROD	334	334	I -> T (in FPCT).
MUTYH	125	125	Y -> H (in CAPAR).
MUTYH	128	128	W -> R (in CAPAR).
MUTYH	148	148	G -> IW (in CAPAR; dysfunctional in base excision repair assay).
MUTYH	179	179	R -> C (in CAPAR).
MUTYH	179	179	R -> H (in CAPAR).
MUTYH	182	182	R -> W (in CAPAR; dysfunctional in base excision repair assay).
MUTYH	402	402	P -> S (in GASC; sporadic).
MUTYH	411	411	Q -> R (in GASC; sporadic).
MUTYH	477	477	Missing (in CAPAR; dysfunctional in base excision repair assay).
MUTYH	512	512	S -> F.
MMACHC	27	27	Q -> R (in MMACHC).
MMACHC	116	116	L -> P (in MMACHC).
MMACHC	122	122	H -> R (in MMACHC).
MMACHC	130	130	Y -> H (in MMACHC).
MMACHC	147	147	G -> A (in MMACHC).
MMACHC	147	147	G -> D (in MMACHC).
MMACHC	156	156	G -> D (in MMACHC).
MMACHC	157	157	W -> C (in MMACHC).
MMACHC	161	161	R -> G (in MMACHC).
MMACHC	161	161	R -> Q (in MMACHC).
MMACHC	189	189	R -> S (in MMACHC).
MMACHC	193	193	L -> P (in MMACHC).
MMACHC	206	206	R -> P (in MMACHC).
MMACHC	206	206	R -> W (in MMACHC).
RAD54L	63	63	P -> H (in a colon adenocarcinoma sample).
RAD54L	325	325	G -> R (in a breast cancer sample; invasive ductal).
RAD54L	444	444	V -> E (in a non-Hodgkin lymphoma sample).
FAAH	345	345	A -> D (in a breast cancer sample; somatic mutation).
CYP4B1	345	345	V -> I (in allele CYP4B1*6).
CYP4A11	353	353	S -> G.
CYP4A11	500	519	NGIHLRLRRLPNPCEDKDQL -> MESTCVSGGSLTLVKTR TSFEGLHLPSCLPDPRFCPLPVCPYPVFCLPTFPSSHLPAV PQSACPSLSHLSPGLPTCLSTCLLPTCISCWEKS (in CYP4A11V).
CYP4A22	11	11	R -> C (in allele CYP4A22*2 and CYP4A22*3).
CYP4A22	185	185	V -> F (in allele CYP4A22*10, allele CYP4A22*11, allele CYP4A22*12, allele CYP4A22*13, allele CYP4A22*14 and allele CYP4A22*15).
CYP4A22	276	276	K -> T (in allele CYP4A22*8, allele CYP4A22*11, allele CYP4A22*14 and allele CYP4A22*15).
STIL	1012	1012	P -> R.
FOXE3	49	49	G -> A (in a family with eye development anomalies).
FOXE3	82	82	M -> V (in a family with eye development anomalies).
FOXE3	90	90	R -> L (in ASMD; a patient with Peters anomaly).
FOXE3	196	196	G -> A.
FOXE3	300	300	S -> G.
CDKN2C	72	72	A -> P (in breast cancer; loss of CDK6 interaction).
TXNDC12	201	201	Missing (in COXPD6; higher DNA binding affinity, partially impaired flavin binding and association with increased parthanatos-linked cell death).
ORC1	89	89	F -> S (in MGORS1).
ORC1	105	105	R -> Q (in MGORS1).
ORC1	127	127	E -> G (in MGORS1).
ORC1	666	666	R -> W (in MGORS1).
ORC1	720	720	R -> Q (in MGORS1).
SLC1A7	41	41	R -> C (in a colorectal cancer sample; somatic mutation).
CPT2	113	113	S -> L (in CPT2D; muscular form. Frequent mutation, may be a polymorphism as it found in some 'normal' cDNA seqeuences).
CPT2	151	151	R -> Q (in CPT2D).
CPT2	210	210	Y -> D (in CPT2D).
CPT2	213	213	D -> G (in CPT2D).
CPT2	214	214	M -> T (in CPT2D).
CPT2	227	227	P -> L (in CPT2D).
CPT2	296	296	R -> Q (in CPT2D).
CPT2	448	448	F -> L (in CPT2D).
CPT2	479	479	Y -> F (in CPT2D).
CPT2	503	503	R -> C (in CPT2D).
CPT2	549	549	G -> D (in CPT2D).
CPT2	550	550	Q -> R (in CPT2D).
CPT2	600	600	G -> R (in CPT2D).
CPT2	604	604	P -> S (in CPT2D).
CPT2	631	631	R -> C (in CPT2D; early-onset hepatocardiomuscular form).
DHCR24	294	294	N -> T (in DESMOS).
DHCR24	306	306	K -> N (in DESMOS).
BSND	8	8	R -> L (in BS4A; completely abolishes CLCNKA activation; mutated protein fails to increase surface expression of CLCNKA; intracellular localization; probably retained in the ER).
BSND	8	8	R -> W (in BS4A; completely abolishes CLCNKA activation).
BSND	10	10	G -> S (in BS4A; increases CLCNKA currents over those obtained with wild- type; still activates CLCNKA to an extent similar to that of wild-type; intracellular but some plasma membrane localization as well).
BSND	47	47	G -> R (in BS4A; atypical; might be due to a less severe loss of function).
PCSK9	23	23	L -> LL (this polymoprhism seems to have a modifier effect on LDLR mutation and familial hypercholesterolemia).
PCSK9	57	57	E -> K.
PCSK9	77	77	T -> I.
PCSK9	93	93	R -> C.
PCSK9	106	106	G -> R.
PCSK9	114	114	V -> A.
PCSK9	129	129	D -> G (in FH3).
PCSK9	157	157	N -> K.
PCSK9	215	215	R -> H (in FH3).
PCSK9	218	218	R -> S (in FH3).
PCSK9	219	219	Q -> E.
PCSK9	237	237	R -> W.
PCSK9	239	239	A -> D.
PCSK9	357	357	R -> H (in FH3).
PCSK9	374	374	D -> H (in FH3).
PCSK9	374	374	D -> Y (in FH3).
PCSK9	391	391	H -> N.
PCSK9	417	417	H -> Q.
PCSK9	452	452	G -> D.
PCSK9	469	469	R -> W.
PCSK9	482	482	E -> G.
PCSK9	496	496	R -> W (in FH3).
PCSK9	515	515	F -> L.
PCSK9	522	522	A -> T.
PCSK9	554	554	Q -> E.
PCSK9	616	616	P -> L.
PCSK9	668	668	S -> R.
CYP2J2	192	192	I -> N (in allele CYP2J2*4; significantly reduced metabolism of arachidonic acid only).
CYP2J2	404	404	N -> Y (in allele CYP2J2*6; significantly reduced metabolism of both arachidonic acid and linoleic acid).
C1orf87	151	151	Q -> E (in a breast cancer sample; somatic mutation).
ALG6	170	170	S -> I (in CDG1C).
ALG6	227	227	G -> E (in CDG1C).
ALG6	299	299	Missing (in CDG1C).
ALG6	308	308	S -> R (in CDG1C).
ALG6	333	333	A -> V (in CDG1C).
ALG6	444	444	Missing (in CDG1C).
ALG6	478	478	S -> P (in CDG1C).
IL12RB2	313	313	R -> G.
IL12RB2	720	720	H -> R.
RPE65	22	22	L -> P (in LCA2).
RPE65	36	38	Missing (in LCA2).
RPE65	40	40	G -> S (in LCA2).
RPE65	44	44	R -> Q (in LCA2).
RPE65	68	68	H -> Y (in LCA2).
RPE65	79	79	Y -> H (in RP20).
RPE65	85	85	R -> H (in RP20; uncertain pathogenicity).
RPE65	91	91	R -> Q (in LCA2).
RPE65	91	91	R -> W (in RP20).
RPE65	95	95	E -> Q (in RP20).
RPE65	102	102	E -> K (in RP20).
RPE65	132	132	A -> T (in RP20).
RPE65	144	144	Y -> D (in LCA2).
RPE65	148	148	E -> D (in LCA2).
RPE65	167	167	D -> Y (in RP20).
RPE65	182	182	H -> N (in LCA2).
RPE65	182	182	H -> Y (in LCA2).
RPE65	239	239	Y -> D (in LCA2).
RPE65	287	287	V -> F (in LCA2).
RPE65	294	294	K -> T (in RP20).
RPE65	321	321	N -> K (in LCA2).
RPE65	330	330	C -> Y (in LCA2).
RPE65	341	341	L -> S (in RP20).
RPE65	363	363	P -> T (in LCA2).
RPE65	368	368	Y -> H (in RP20).
RPE65	393	393	A -> E (in LCA2).
RPE65	393	393	A -> G (in LCA2).
RPE65	417	417	E -> Q (in LCA2).
RPE65	431	431	Y -> C (in LCA2).
RPE65	435	435	Y -> C (in LCA2).
RPE65	436	436	G -> V (in RP20).
RPE65	452	452	V -> G (in RP20).
RPE65	470	470	P -> L (in LCA2).
RPE65	473	473	V -> D (in RP20).
RPE65	515	515	R -> W (in RP20; this mutation has been found in compound heterozygosity in LCA2).
RPE65	528	528	G -> V (in RP20).
NUAK2	503	503	K -> R (in an ovarian Endometrioid carcinoma sample; somatic mutation).
NUAK2	541	541	G -> E (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
TLR5	392	858	Missing (in 10% of the population; abolishes flagellin signaling; associated with resistance to SLEB1).
ACADM	53	53	R -> C (in ACADMD).
ACADM	67	67	Y -> H (in ACADMD; mild).
ACADM	78	78	I -> T (in ACADMD).
ACADM	115	116	Missing (in ACADMD).
ACADM	116	116	C -> Y (in ACADMD).
ACADM	121	121	T -> I (in ACADMD).
ACADM	132	132	P -> R (in a breast cancer sample; somatic mutation).
ACADM	149	149	M -> I (in ACADMD).
ACADM	193	193	T -> A (in ACADMD; the thermostability is markedly decreased).
ACADM	195	195	G -> R (in ACADMD).
ACADM	206	206	R -> L (in ACADMD).
ACADM	244	244	C -> R (in ACADMD).
ACADM	245	245	S -> L (in ACADMD).
ACADM	267	267	G -> R (in ACADMD).
ACADM	281	281	R -> T (in ACADMD; mild or benign clinical phenotype).
ACADM	310	310	G -> R (in ACADMD).
ACADM	326	326	M -> T (in ACADMD).
ACADM	329	329	K -> E (in ACADMD; most common variant).
ACADM	336	336	S -> R (in ACADMD).
ACADM	352	352	Y -> C (in ACADMD).
ACADM	375	375	I -> T (in ACADMD).
NID1	1036	1036	F -> S (in a colorectal cancer sample; somatic mutation).
EDARADD	103	103	S -> F.
EDARADD	114	114	D -> Y (in EDA).
EDARADD	122	122	L -> R (in EDA; severely impairs NF- kappa-B activation and acted in a dominant-negative manner).
EDARADD	135	136	Missing (in EDA; impairs the interaction with EDAR and severely inhibits NF-kappa- B activity).
EDARADD	152	152	E -> K (in EDA; may reduce binding to EDAR; impairs NF-kappa-B activation by about 50%).
BCL10	16	16	V -> E (in MALT lymphoma).
BCL10	31	31	K -> E (in MALT lymphoma).
BCL10	45	45	K -> Q (in mesothelioma).
BCL10	52	52	T -> I (in mesothelioma).
BCL10	57	57	C -> R (in MALT lymphoma).
BCL10	58	58	R -> G (in germ cell tumor).
BCL10	58	58	R -> Q (in mesothelioma).
BCL10	64	64	R -> K (in MALT lymphoma).
BCL10	93	93	N -> S (in mesothelioma).
BCL10	101	101	D -> E (in MALT lymphoma).
BCL10	134	134	S -> P (in MALT lymphoma).
BCL10	153	153	M -> V (in mesothelioma).
BCL10	168	168	T -> A (in MALT lymphoma).
BCL10	174	174	L -> S (in MALT lymphoma).
BCL10	210	210	Missing (in follicular lymphoma).
BCL10	218	218	S -> F (in germ cell tumor, mesothelioma and other cancer cell lines).
BCL10	230	230	V -> I (in MALT lymphoma).
ZNHIT6	455	455	L -> H (in a colorectal cancer sample; somatic mutation).
GTF2B	132	132	R -> Q (in a colorectal cancer sample; somatic mutation).
ZNF644	53	53	E -> Q (in a breast cancer sample; somatic mutation).
BRDT	89	89	A -> V (in a gastric adenocarcinoma sample; somatic mutation).
BRDT	288	288	H -> Y (in a lung neuroendocrine carcinoma sample; somatic mutation).
GLMN	393	393	Missing (in GVMs).
RPL5	140	140	G -> S (in DBA6).
RPL5	285	285	A -> V (in DBA6).
AVPR1B	267	267	S -> G.
MARC2	3	3	A -> S.
NUP133	326	326	G -> V (in a breast cancer sample; somatic mutation).
NUP133	448	448	G -> R (in a breast cancer sample; somatic mutation).
AGL	1343	1343	E -> K.
AGL	1448	1448	G -> R (in GSD3; deficient in ability to bind glycogen; unstable due to enhanced ubiquitination; forms aggresomes upon proteasome impairment).
CSF1	496	496	S -> F.
ALX3	168	168	L -> V (in FND1).
ALX3	183	183	R -> W (in FND1).
ALX3	196	196	R -> W (in FND1).
ALX3	203	203	N -> S (in FND1).
KCNA10	200	200	R -> H (in a colorectal cancer sample; somatic mutation).
CHIA	125	125	K -> R.
OVGP1	662	662	L -> H (in a colorectal cancer sample; somatic mutation).
SLC16A1	204	204	K -> E (in SDLT).
SLC16A1	472	472	G -> R (in SDLT).
HIPK1	310	310	G -> C.
HIPK1	1165	1165	L -> V.
BCAS2	139	139	N -> S (in a colorectal cancer sample; somatic mutation).
AMPD1	48	48	P -> L (polymorphism; activity comparable to wild-type).
AMPD1	425	425	R -> H (in AMPDDM; loss of activity).
AMPD1	633	633	P -> H (in a colorectal cancer sample; somatic mutation).
NRAS	12	12	G -> C (in leukemia).
NRAS	13	13	G -> D (in a patient with an autoimmune lymphoproliferative disorder).
NRAS	13	13	G -> R (in colorectal cancer).
NRAS	50	50	T -> I (in NS6; hypermorphic mutation).
NRAS	60	60	G -> E (in NS6; hypermorphic mutation).
NRAS	61	61	Q -> K (in neuroblastoma cell).
VANGL1	25	25	E -> K.
VANGL1	83	83	S -> L (in NTD; uncertain pathogenicity).
VANGL1	153	153	F -> S (in NTD; uncertain pathogenicity).
VANGL1	175	175	R -> Q.
VANGL1	181	181	R -> Q (in NTD; uncertain pathogenicity).
VANGL1	202	202	L -> F (in NTD; uncertain pathogenicity).
VANGL1	239	239	V -> I (in SDAM; abolishes ability to interact with DVL1, DVL2 and DVL3).
VANGL1	251	251	T -> M.
VANGL1	274	274	R -> Q (in NTD; does not abolish ability to interact with DVL1, DVL2 and DVL3).
VANGL1	290	290	Y -> H.
VANGL1	328	328	M -> T (in NTD; does not abolish ability to interact with DVL1, DVL2 and DVL3).
VANGL1	404	404	A -> S (in NTD; uncertain pathogenicity).
VANGL1	468	468	D -> E.
FBXO28	345	345	P -> H (found in a renal cell carcinoma case; somatic mutation).
NVL	359	359	C -> G.
HSD3B2	10	10	A -> V (in AH2; nonsalt-wasting form).
HSD3B2	15	15	G -> D (in AH2; activity abolished).
HSD3B2	82	82	A -> T (in AH2).
HSD3B2	100	100	N -> S (in AH2; nonsalt-wasting form).
HSD3B2	108	108	L -> W (in AH2; activity abolished).
HSD3B2	129	129	G -> R (in AH2; nonsalt-wasting form).
HSD3B2	142	142	E -> K (in AH2; activity abolished).
HSD3B2	155	155	P -> L (in AH2; nonsalt-wasting form).
HSD3B2	173	173	L -> R (in AH2; nonsalt-wasting form).
HSD3B2	186	186	P -> L (in AH2; activity abolished).
HSD3B2	205	205	L -> P (in AH2).
HSD3B2	213	213	S -> G (in AH2; late onset; partial loss of activity).
HSD3B2	216	216	K -> E (in AH2; late onset; partial loss of activity).
HSD3B2	222	222	P -> H (in AH2; nonsalt-wasting form; activity abolished).
HSD3B2	222	222	P -> Q (in AH2; activity abolished).
HSD3B2	222	222	P -> T (in AH2).
HSD3B2	231	238	Missing (in AH2; activity abolished).
HSD3B2	245	245	A -> P (in AH2; loss of 88% of activity).
HSD3B2	253	253	Y -> N (in AH2; activity abolished).
HSD3B2	254	254	Y -> D (in AH2; activity abolished).
HSD3B2	259	259	T -> M (in AH2; activity abolished).
HSD3B2	259	259	T -> R (in AH2; activity abolished).
HSD3B2	294	294	G -> V (in AH2; nonsalt-wasting form; activity abolished).
HSD3B2	341	341	P -> L (in AH2; strongly reduced activity).
PHGDH	135	135	R -> W (in PHGDH deficiency; results in a 2-fold decrease in enzyme activity with 3-phosphohydroxypyruvate, but no change in substrate affinity).
PHGDH	261	261	V -> M (in PHGDH deficiency; results in a four-fold decrease in substrate affinity and a slight increase in maximal enzyme activity with 3-phosphohydroxypyruvate).
PHGDH	373	373	A -> T (in PHGDH deficiency; results in almost undetectable enzyme activity with 3-phosphohydroxypyruvate).
PHGDH	377	377	G -> S (in PHGDH deficiency; results in a 2-fold decrease in enzyme activity with 3-phosphohydroxypyruvate, but no change in substrate affinity).
PHGDH	425	425	V -> M (in PHGDH deficiency; results in almost undetectable enzyme activity with 3-phosphohydroxypyruvate).
PHGDH	490	490	V -> M (in PHGDH deficiency; results in almost undetectable enzyme activity with 3-phosphohydroxypyruvate).
HMGCS2	167	167	Y -> C (in HMGCS deficiency).
HMGCS2	174	174	F -> L (in HMGCS deficiency; reduced peptide level; no enzymatic activity).
HMGCS2	212	212	G -> R (in HMGCS deficiency).
HMGCS2	500	500	R -> H (in HMGCS deficiency).
C4BPA	357	357	Y -> H.
EPHX1	44	44	E -> Q.
EPHX1	260	260	L -> P (in allele EPHX1*1G).
EPHX1	396	396	T -> I (either a rare polymorphism or a sequencing error).
LEFTY2	342	342	S -> N (in LRAM).
PARP1	488	488	E -> V (in a breast cancer sample; somatic mutation).
HFE2	85	85	S -> P (in HFE2A).
HFE2	99	99	G -> R (in HFE2A).
HFE2	101	101	L -> P (in HFE2A).
HFE2	168	168	A -> D (in HFE2A).
HFE2	170	170	F -> S (in HFE2A).
HFE2	172	172	D -> E (in HFE2A).
HFE2	191	191	W -> C (in HFE2A).
HFE2	205	205	S -> R (in HFE2A).
HFE2	222	222	I -> N (in HFE2A).
HFE2	250	250	G -> V (in HFE2A).
HFE2	288	288	R -> W (in HFE2A).
HFE2	320	320	G -> V (in HFE2A).
HFE2	321	321	C -> W (in HFE2A).
GJA5	88	88	P -> S (in FAS; somatic).
GJA5	96	96	A -> S (in FAS).
GJA8	23	23	R -> T (in nuclear progressive cataract).
GJA8	44	44	V -> E (in CAMIS).
GJA8	48	48	E -> K (in CZP1).
GJA8	64	64	V -> G (in CZP1 and nuclear progressive cataract).
GJA8	88	88	P -> S (in CZP1).
GJA8	198	198	R -> Q (in CAMIS).
GJA8	247	247	I -> M (in CZP1).
HIST2H4A	64	64	E -> Q (in a breast cancer sample; somatic mutation).
HIST2H2AB	53	53	A -> T (in a breast cancer sample; somatic mutation).
ACTA1	3	3	D -> Y (in NEM3; some patients have core lesions on muscle biopsy).
ACTA1	17	17	G -> R (in MPCETM).
ACTA1	27	27	D -> N (in NEM3).
ACTA1	37	37	V -> L (in NEM3).
ACTA1	40	40	P -> L (in NEM3).
ACTA1	42	42	H -> Y (in NEM3; severe).
ACTA1	43	43	Q -> R (in NEM3).
ACTA1	44	44	G -> V (in NEM3).
ACTA1	45	45	V -> F (in NEM3).
ACTA1	66	66	I -> N (in NEM3).
ACTA1	68	68	T -> I (in NEM3).
ACTA1	74	74	E -> K (in NEM3).
ACTA1	75	75	H -> L (in NEM3).
ACTA1	75	75	H -> R (in NEM3).
ACTA1	77	77	I -> L (in NEM3).
ACTA1	79	79	T -> A (in NEM3).
ACTA1	85	85	E -> K (in NEM3).
ACTA1	96	96	L -> P (in NEM3; autosomal recessive).
ACTA1	116	116	A -> T (in NEM3).
ACTA1	117	117	N -> S (in NEM3; autosomal dominant).
ACTA1	117	117	N -> T (in NEM3).
ACTA1	118	118	R -> H (in NEM3).
ACTA1	134	134	M -> V (in NEM3; autosomal dominant).
ACTA1	136	136	V -> A (in NEM3).
ACTA1	138	138	I -> M (in NEM3; autosomal recessive).
ACTA1	140	140	A -> P (in NEM3).
ACTA1	142	142	L -> P (in NEM3).
ACTA1	148	148	G -> D (in NEM3).
ACTA1	150	150	T -> N (in NEM3).
ACTA1	156	156	D -> N (in NEM3).
ACTA1	165	165	V -> L (in MPCETM).
ACTA1	165	165	V -> M (in NEM3; results in sequestration of sarcomeric and Z line proteins into intranuclear aggregates; there is some evidence of muscle regeneration suggesting a compensatory effect).
ACTA1	172	172	A -> G (in NEM3).
ACTA1	181	181	D -> G (in NEM3).
ACTA1	181	181	D -> H (in NEM3).
ACTA1	181	181	D -> N (in NEM3).
ACTA1	184	184	G -> D (in NEM3; mild).
ACTA1	185	185	R -> C (in NEM3; severe).
ACTA1	185	185	R -> D (in NEM3; requires 2 nucleotide substitutions).
ACTA1	185	185	R -> G (in NEM3; autosomal dominant; severe).
ACTA1	185	185	R -> S (in NEM3).
ACTA1	198	198	R -> L (in NEM3).
ACTA1	199	199	G -> S (in NEM3).
ACTA1	223	223	L -> P (in CFTD).
ACTA1	226	226	E -> G (in NEM3).
ACTA1	226	226	E -> Q (in NEM3).
ACTA1	227	227	N -> V (in NEM3; requires 2 nucleotide substitutions).
ACTA1	229	229	M -> I (in NEM3).
ACTA1	229	229	M -> T (in NEM3).
ACTA1	229	229	M -> V (in NEM3).
ACTA1	243	243	E -> K (in NEM3).
ACTA1	248	248	Q -> K (in NEM3).
ACTA1	248	248	Q -> R (in NEM3).
ACTA1	253	253	G -> D (in NEM3).
ACTA1	258	258	R -> H (in NEM3; severe).
ACTA1	258	258	R -> L (in NEM3).
ACTA1	261	261	E -> V (in NEM3; autosomal recessive).
ACTA1	265	265	Q -> L (in NEM3; severe).
ACTA1	270	270	G -> C (in NEM3; autosomal dominant).
ACTA1	270	270	G -> D (in NEM3).
ACTA1	270	270	G -> R (in NEM3).
ACTA1	271	271	M -> R (in NEM3; autosomal dominant).
ACTA1	274	274	A -> E (in NEM3).
ACTA1	281	281	Y -> H (in NEM3).
ACTA1	282	282	N -> K (in NEM3; severe).
ACTA1	285	285	M -> K (in NEM3).
ACTA1	288	288	D -> G (in NEM3; severe).
ACTA1	294	294	D -> V (in CFTD; results in decreased motility due to abnormal interactions between actin and tropomyosin with tropomyosin stabilized in the 'off' position; the mutant protein incorporates into actin filaments and does not result in increased actin aggregation or disruption of the sarcomere).
ACTA1	334	334	P -> S (in CFTD).
ACTA1	336	336	E -> A (in NEM3).
ACTA1	338	338	K -> E (in NEM3).
ACTA1	338	338	K -> I (in NEM3).
ACTA1	350	350	S -> L (in NEM3).
ACTA1	359	359	I -> L (in NEM3; autosomal dominant; severe).
ACTA1	372	372	V -> F (in NEM3; severe).
ACTA1	374	374	R -> S (in NEM3).
ACTA1	375	375	K -> E (in NEM3).
ACTA1	375	375	K -> Q (in NEM3).
PRPF3	493	493	P -> S (in RP18).
PRPF3	494	494	T -> M (in RP18; reduces phosphorylation; impairs binding to PRPF4; impairs self- association; affects interaction with the U4/U5/U6 tri-snRNP complex; does not affect global pre-mRNA splicing).
ECM1	167	167	F -> I (in LiP).
MCL1	231	231	M -> L.
CTSK	79	79	G -> E (in PKND).
CTSK	146	146	G -> R (in PKND).
CTSK	277	277	A -> V (in PKND).
VPS72	318	318	I -> V (in a breast cancer sample; somatic mutation).
RFX5	149	149	R -> Q (in BLS2).
THEM4	38	38	S -> C.
TCHH	1400	1400	R -> P (found in a renal cell carcinoma sample; somatic mutation).
SPRR3	98	105	Missing.
SPRR1B	23	23	Q -> H (in clone 15B).
SPRR1B	61	61	V -> L (in clone 41D).
SPRR1B	80	80	A -> P (in clone 15B).
S100A9	20	20	H -> R.
S100A5	54	54	D -> G.
NPR1	182	182	A -> V.
NPR1	270	270	F -> C (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
NPR1	755	755	V -> M.
CRTC2	379	379	R -> C.
HAX1	130	130	L -> R (in SCN3).
HAX1	141	141	F -> L (in SCN3; mild form).
HAX1	172	172	V -> I (in SCN3).
CHRNB2	287	287	V -> L (in ENFL3).
CHRNB2	287	287	V -> M (in ENFL3; approximately 10-fold increase in acetylcholine sensitivity).
ADAR	806	806	E -> V (in a breast cancer sample; somatic mutation).
ADAR	966	966	C -> F (in DSH).
ADAR	1155	1155	R -> W (in DSH).
DPM3	85	85	L -> S (in CDG1O; affects interaction with DPM1).
THBS3	955	955	R -> G (in a breast cancer sample; somatic mutation).
FAM189B	358	358	S -> F (in a breast cancer sample; somatic mutation).
PKLR	37	37	G -> E (in PKHYP).
PKLR	40	40	R -> W (in PKRD).
PKLR	48	53	Missing (in PKRD).
PKLR	73	73	L -> P (in PKRD).
PKLR	80	80	S -> P (in PKRD).
PKLR	86	86	R -> P (in PKRD).
PKLR	90	90	I -> N (in PKRD).
PKLR	95	95	G -> R (in PKRD).
PKLR	107	107	M -> T (in PKRD).
PKLR	111	111	G -> R (in PKRD).
PKLR	115	115	A -> P (in PKRD; Val de Marne).
PKLR	120	120	S -> F (in PKRD; Beaujon).
PKLR	130	130	S -> Y (in PKRD; Conakry).
PKLR	131	131	Missing (in PKRD).
PKLR	134	134	V -> D (in PKRD).
PKLR	153	153	I -> T (in PKRD).
PKLR	154	154	A -> T (in PKRD).
PKLR	155	155	L -> P (in PKRD).
PKLR	159	159	G -> V (in PKRD).
PKLR	163	163	R -> C (in PKRD; Linz).
PKLR	163	163	R -> L (in PKRD).
PKLR	165	165	G -> V (in PKRD).
PKLR	172	172	E -> Q (in PKRD; Sassari).
PKLR	219	219	I -> T (in PKRD).
PKLR	221	221	D -> DD (in PKRD).
PKLR	222	222	G -> A (in PKRD; Katsushika).
PKLR	263	263	G -> R (in PKRD).
PKLR	263	263	G -> W (in PKRD).
PKLR	272	272	L -> V (in PKRD).
PKLR	275	275	G -> R (in PKRD).
PKLR	281	281	D -> N (in PKRD).
PKLR	287	287	F -> V (in PKRD).
PKLR	288	288	V -> L (in PKRD; Moriguchi).
PKLR	293	293	D -> N (in PKRD).
PKLR	295	295	A -> V (in PKRD).
PKLR	310	310	I -> N (in PKRD; Dordrecht).
PKLR	314	314	I -> T (in PKRD; Hong Kong).
PKLR	315	315	E -> K (in PKRD).
PKLR	320	320	V -> L (in PKRD).
PKLR	331	331	D -> E (in PKRD; Parma).
PKLR	331	331	D -> N (in PKRD).
PKLR	332	332	G -> S (in PKRD; loss of catalytical activity).
PKLR	335	335	V -> M (in PKRD).
PKLR	336	336	A -> S (in PKRD).
PKLR	337	337	R -> P (in PKRD).
PKLR	337	337	R -> Q (in PKRD).
PKLR	339	339	D -> H (in PKRD).
PKLR	341	341	G -> A (in PKRD).
PKLR	341	341	G -> D (in PKRD).
PKLR	342	342	I -> F (in PKRD).
PKLR	348	348	K -> N (in PKRD; Kamata).
PKLR	348	348	Missing (in PKRD; Brescia).
PKLR	352	352	A -> D (in PKRD).
PKLR	354	354	Missing (in PKRD).
PKLR	357	357	I -> T (in PKRD).
PKLR	358	358	G -> E (in PKRD).
PKLR	359	359	R -> C (in PKRD; Aomori).
PKLR	359	359	R -> H (in PKRD).
PKLR	361	361	N -> D (in PKRD).
PKLR	364	364	G -> D (in PKRD; Tjaereborg; unstability of the protein and decrease in catalytical activity).
PKLR	368	368	V -> F (in PKRD; Osaka).
PKLR	374	374	L -> P (in PKRD).
PKLR	376	376	S -> I (in PKRD).
PKLR	384	384	T -> M (in PKRD; Tokyo/Beirut; most common mutation in Japanese population; no conformational change).
PKLR	385	385	R -> W (in PKRD).
PKLR	387	387	E -> G (in PKRD).
PKLR	390	390	D -> N (in PKRD; Mantova; almost complete inactivation).
PKLR	392	392	A -> T (in PKRD).
PKLR	393	393	N -> K (in PKRD).
PKLR	393	393	N -> S (in PKRD; Paris).
PKLR	394	394	A -> D (in PKRD).
PKLR	394	394	A -> V (in PKRD).
PKLR	401	401	C -> CS (in PKRD).
PKLR	408	408	T -> A (in PKRD; Hirosaki).
PKLR	408	408	T -> I (in PKRD).
PKLR	421	421	Q -> K (in PKRD; Fukushima/Maebashi/ Sendai).
PKLR	426	426	R -> Q (in PKRD; Sapporo).
PKLR	426	426	R -> W (in PKRD; Naniwa).
PKLR	427	427	E -> A (in PKRD).
PKLR	427	427	E -> D (in PKRD).
PKLR	431	431	A -> T (in PKRD).
PKLR	458	458	G -> D (in PKRD).
PKLR	459	459	A -> V (in PKRD).
PKLR	460	460	V -> M (in PKRD).
PKLR	468	468	A -> G (in PKRD).
PKLR	468	468	A -> V (in PKRD; Hadano).
PKLR	477	477	T -> A (in PKRD).
PKLR	479	479	R -> H (in PKRD; Amish; no conformational change).
PKLR	485	485	S -> F (in PKRD).
PKLR	486	486	R -> W (in PKRD; frequent mutation; no conformational change).
PKLR	488	488	R -> Q (in PKRD).
PKLR	490	490	R -> W (in PKRD).
PKLR	495	495	A -> T (in PKRD).
PKLR	495	495	A -> V (in PKRD).
PKLR	498	498	R -> C (in PKRD).
PKLR	498	498	R -> H (in PKRD).
PKLR	504	504	R -> L (in PKRD; unstability of the protein).
PKLR	510	510	R -> Q (in PKRD; the most common mutation in European population).
PKLR	511	511	G -> R (in PKRD).
PKLR	531	531	R -> C (in PKRD).
PKLR	532	532	R -> Q (in PKRD).
PKLR	532	532	R -> W (in PKRD; Complete loss in the responsiveness to fructose 1,6- bisphosphate, FBP).
PKLR	552	552	V -> M (in PKRD).
PKLR	557	557	G -> A (in PKRD).
PKLR	559	559	R -> G (in PKRD).
PKLR	566	566	N -> K (in PKRD).
PKLR	569	569	R -> Q (in PKRD).
SEMA4A	345	345	D -> H (in RP35 and CORD10; heterozygous compound with C-350).
SEMA4A	350	350	F -> C (in RP35 and CORD10; heterozygous compound with H-345).
NTRK1	85	85	R -> S.
NTRK1	93	93	L -> P (in CIPA).
NTRK1	107	107	A -> V (in an ovarian serous carcinoma sample; somatic mutation).
NTRK1	213	213	L -> P (in CIPA).
NTRK1	522	522	G -> R (in CIPA).
NTRK1	577	577	G -> R (in CIPA; loss of function).
NTRK1	587	587	M -> V (in CIPA).
NTRK1	649	649	R -> W (in CIPA).
NTRK1	654	654	R -> C (in CIPA).
NTRK1	674	674	D -> Y (in CIPA).
NTRK1	695	695	P -> L (in CIPA).
NTRK1	714	714	G -> S (in CIPA).
NTRK1	780	780	R -> P (in CIPA; loss of function).
INSRR	278	278	E -> Q (in a lung adenocarcinoma sample; somatic mutation).
INSRR	1065	1065	G -> E (in a glioblastoma multiforme sample; somatic mutation).
FCRL5	687	687	S -> C (in a breast cancer sample; somatic mutation).
FCRL3	445	445	H -> N (in a breast cancer sample; somatic mutation).
CD1D	64	64	T -> S.
CD1E	164	164	R -> W (in allele CD1E*03).
CD1E	194	194	L -> P (in allele CD1E*04; impairs localization to late endosomal compartments and lipid antigen presentation).
OR6K3	216	216	V -> M (found in a renal cell carcinoma sample; somatic mutation).
AIM2	304	304	C -> Y.
APCS	141	141	G -> S (in a breast cancer sample; somatic mutation).
APCS	155	155	E -> G.
APCS	158	158	S -> G.
ATP1A2	715	715	G -> R (in FHM2; de novo mutation in a sporadic case).
SLAMF1	81	81	L -> F (in a breast cancer sample; somatic mutation).
PVRL4	185	185	T -> M (in EDSS1).
PPOX	59	59	R -> W (in VP).
PPOX	152	152	R -> C (in VP).
PPOX	168	168	R -> C.
PPOX	232	232	G -> R (in VP).
NDUFS2	228	228	R -> Q (in MT-C1D).
NDUFS2	229	229	P -> Q (in MT-C1D).
NDUFS2	413	413	S -> P (in MT-C1D).
TOMM40L	100	100	D -> N (in a colorectal cancer sample; somatic mutation).
NR1I3	133	133	V -> G.
MPZ	30	30	I -> M (in CMT1B).
MPZ	32	32	V -> F (in CMT1B; severe).
MPZ	34	34	T -> I (in CMT1B).
MPZ	35	35	D -> Y (in CMTDID).
MPZ	39	39	H -> P (in CMT1B; slightly reduces intercellular adhesion; does not affect targeting to the cell membrane).
MPZ	42	42	Missing (in DSS).
MPZ	44	44	S -> F (in CMT2I and CMT1B).
MPZ	50	50	Missing (in CMT1B).
MPZ	51	57	Missing (in CMT1B; affects targeting to the cell membrane; reduces intercellular adhesion).
MPZ	51	51	S -> F (in CMT1B).
MPZ	54	54	S -> C (in CMT1B; severe).
MPZ	54	54	S -> P (in CMT1B).
MPZ	56	56	E -> K (in CMT2).
MPZ	58	58	V -> F (in CMT1B; moderate).
MPZ	60	60	D -> H (in CMT2I).
MPZ	61	61	D -> G (in CMT2; unclassified).
MPZ	62	62	I -> F (in CMT1B).
MPZ	62	62	I -> M (in CMT2I).
MPZ	63	63	S -> C (in DSS).
MPZ	63	63	S -> F (in CMT1B).
MPZ	63	63	Missing (in CMT1B).
MPZ	64	64	Missing (in CMT1B and DSS).
MPZ	65	65	T -> A (in CMT1B).
MPZ	65	65	T -> I (in CMT1B).
MPZ	68	68	Y -> C (in CMT1B; severe/mild).
MPZ	75	75	D -> V (in CMT2J).
MPZ	78	78	S -> L (in CMT1B; severe).
MPZ	78	78	S -> W (in CMT1B).
MPZ	81	81	H -> R (in CMT1B; severe; reduces intercellular adhesion; does not affect targeting to the cell membrane).
MPZ	81	81	H -> Y (in CMT; associated with F-113).
MPZ	82	82	Y -> C (in CMT1B and DSS).
MPZ	89	89	I -> N (in CMT2I; patient carrying also Met-92 and Met-162).
MPZ	90	90	D -> E (in CMT1B).
MPZ	92	92	V -> M (in CMT2I; patient carrying also Asn-89 and Met-162).
MPZ	93	93	G -> E (in CMT1B).
MPZ	96	96	K -> E (in CMT1B).
MPZ	97	97	E -> V (in CMT2J).
MPZ	98	98	R -> C (in CMT1B; severe and DSS).
MPZ	98	98	R -> H (in CMT1B).
MPZ	98	98	R -> P (in CMT1B).
MPZ	98	98	R -> S (in CMT1B).
MPZ	99	99	I -> T (in CMT1B).
MPZ	101	101	W -> C (in CMT1B).
MPZ	103	103	G -> E (in CMT1B).
MPZ	109	109	D -> N (in CMT1B).
MPZ	110	110	G -> D (in DSS).
MPZ	112	112	I -> T (in CMT1B; severe).
MPZ	113	113	V -> F (in CMT; unclassified; associated with Y-81).
MPZ	113	113	V -> I (in CMT2).
MPZ	114	114	I -> T (in DSS; associated on the same allele as His-116 and Asn-128 in one patient).
MPZ	116	116	N -> H (in DSS; associated on the same allele as Thr-114 and Asn-128 in one patient).
MPZ	118	118	D -> DFY (in DSS).
MPZ	118	118	D -> N (in CMT2I).
MPZ	119	119	Y -> C (in CMT2; unclassified).
MPZ	122	122	N -> S (in CMT1B; loss of glycosylation site).
MPZ	123	123	G -> C (in DSS and CMT1B).
MPZ	124	125	Missing (in DSS).
MPZ	124	124	T -> K (in CHN).
MPZ	124	124	T -> M (in CMT1B and CMT2J; CMTJ2 patients present Adie pupil; slightly reduces intercellular adhesion; does not affect targeting to the cell membrane; affects glycosylation).
MPZ	127	127	C -> Y (in DSS).
MPZ	128	128	D -> E (in CMT1B).
MPZ	128	128	D -> N (in DSS; associated on the same allele as Thr-114 and His-116 in one patient).
MPZ	130	130	K -> R (in CMT1B and DSS).
MPZ	131	131	N -> K (in ROULS).
MPZ	132	132	P -> L (in CMT1B; moderate).
MPZ	134	134	D -> E (in CMT1B).
MPZ	134	134	D -> G (in CMT1B).
MPZ	134	134	D -> N (in CMT1B).
MPZ	135	135	I -> L (in CMT1B and DSS).
MPZ	135	135	I -> T (in CMT1B).
MPZ	136	136	V -> E (in DSS).
MPZ	137	137	G -> S (in CMT1B).
MPZ	138	138	K -> N (in CMT1B).
MPZ	139	139	T -> N (in CMT1B).
MPZ	140	140	S -> T (in CMT1B).
MPZ	143	143	T -> M (in CMT1B).
MPZ	145	145	Y -> S (in CMT1B).
MPZ	146	146	V -> F (in CMT1B).
MPZ	162	162	I -> M (in CMT2I; patient carrying also Asn-89 and Met-92).
MPZ	163	163	G -> R (in CMT1B).
MPZ	167	167	G -> A (in CMT1B and DSS; severe).
MPZ	167	167	G -> R (in DSS and CMT).
MPZ	170	170	L -> R (in CMT1B).
MPZ	216	216	T -> ER (in CMT1B; referred to as 'T216ER').
MPZ	221	221	A -> T (in DSS).
MPZ	224	224	D -> Y (in CMT1B; also in two asymptomatic individuals from the same family).
MPZ	227	227	R -> S (in CMT1B).
MPZ	236	236	K -> E (in CMT2I).
MPZ	236	236	Missing (in CMT1B).
MPZ	244	244	R -> L.
HSPA6	65	65	P -> T.
HSPA6	95	95	R -> Q.
HSPA6	159	159	A -> V.
HSPA6	297	297	T -> K.
FCGR3A	66	66	L -> H.
FCGR3B	36	36	S -> R (in allele FCGR3B*01).
FCGR3B	82	82	N -> D (in allele FCGR3B*01).
FCGR3B	106	106	I -> V (in allele FCGR3B*01).
FCGR2B	232	232	I -> T.
FCGR2B	258	258	Y -> D.
C1orf101	653	653	T -> I (in a breast cancer sample; somatic mutation).
ALDH9A1	116	116	C -> S (in allele ALDH9A1*2).
TBX19	128	128	S -> F (in IAD).
SLC19A2	93	93	D -> H (in TRMA).
SLC19A2	143	143	S -> F (in TRMA).
F5	334	334	R -> G (in Hong Kong; does not predispose to clinical thrombosis).
F5	334	334	R -> T (in THR-APCR; Cambridge).
F5	387	387	I -> T (in THR-APCR; Liverpool; mutant protein is expressed with an additional carbohydrate chain).
F5	613	613	C -> R (in THR-APCR; Nijkerk).
F5	775	775	S -> A (in a colorectal cancer sample; somatic mutation).
F5	1730	1730	Y -> C (in FA5D; Seoul 2).
F5	2102	2102	R -> C (in FA5D; impairs both factor V secretion and activity).
F5	2102	2102	R -> H (in THR-APCR).
FMO3	24	24	E -> D (modest increase in catalytic efficiency toward trimethylamine, methimazole, ethylenethiourea and sulindac).
FMO3	32	32	E -> K (in TMAU).
FMO3	52	52	A -> T (in TMAU).
FMO3	61	61	N -> K (loss of activity).
FMO3	61	61	N -> S (in TMAU; more than 90% reduction in catalytic efficiency toward trimethylamine, benzydamine and methyl p- tolyl sulfide).
FMO3	66	66	M -> I (in TMAU; loss of activity; affects FAD binding).
FMO3	153	153	P -> L (in TMAU; 90% reduction in catalytic efficiency toward trimethylamine and benzydamine; 34% reduction in catalytic efficiency toward methyl p-tolyl sulfide; nearly no effect on affinity for these substrates).
FMO3	198	198	D -> E.
FMO3	387	387	R -> L (in TMAU).
FMO3	416	416	K -> N (2-fold decrease in affinity for trimethylamine; 3-fold decrease in catalytic efficiency toward methimazole; 3-fold increase in catalytic efficiency toward sulindac; 30% increase in catalytic efficiency toward ethylenethiourea).
FMO3	434	434	M -> I (in TMAU; profoundly alters enzyme function).
FMO3	492	492	R -> W (in TMAU; loss of activity; affects FAD binding).
FMO3	503	503	G -> R.
FMO1	227	227	S -> T.
MYOC	4	4	F -> S.
MYOC	9	9	C -> S.
MYOC	12	12	G -> R.
MYOC	16	16	P -> L.
MYOC	17	17	A -> S.
MYOC	25	25	C -> R (in GLC1A).
MYOC	48	48	Q -> H (in GLC1A; also in GLC3A; associated with CYP1B1 mutation H-368).
MYOC	53	53	V -> A (in GLC1A).
MYOC	57	57	N -> D.
MYOC	57	57	N -> S.
MYOC	73	73	N -> S.
MYOC	77	77	D -> E.
MYOC	82	82	R -> C (in GLC1A).
MYOC	82	82	R -> H.
MYOC	95	95	L -> P.
MYOC	126	126	R -> W (in GLC1A).
MYOC	158	158	R -> Q (in GLC1A).
MYOC	189	189	R -> Q.
MYOC	203	203	S -> F.
MYOC	215	215	L -> P.
MYOC	244	244	G -> V (in GLC1A; uncertain pathogenicity).
MYOC	245	245	C -> Y (in GLC1A; forms homomultimeric complexes that migrate at molecular weights larger than their wild-type counterparts; these mutant complexes remain sequestered intracellularly).
MYOC	246	246	G -> R (in GLC1A).
MYOC	251	251	V -> A (in GLC1A).
MYOC	252	252	G -> R (in GLC1A).
MYOC	261	261	E -> K (in GLC1A).
MYOC	272	272	R -> G (in GLC1A; could be a polymorphism).
MYOC	274	274	P -> R (in GLC1A).
MYOC	286	286	W -> R (in GLC1A).
MYOC	293	293	T -> K (in GLC1A).
MYOC	300	300	E -> K (in GLC1A; uncertain pathogenicity).
MYOC	323	323	E -> K (in GLC1A).
MYOC	329	329	V -> M.
MYOC	337	337	Q -> E (in GLC1A).
MYOC	337	337	Q -> R (in GLC1A).
MYOC	341	341	S -> P (in GLC1A).
MYOC	342	342	R -> K (in GLC1A).
MYOC	345	345	I -> M (in GLC1A).
MYOC	352	352	E -> K (in GLC1A; could be a rare polymorphism).
MYOC	353	353	T -> I (in GLC1A; uncertain pathogenicity).
MYOC	360	360	I -> N (in GLC1A).
MYOC	361	361	P -> S (in GLC1A).
MYOC	363	363	A -> T (in GLC1A).
MYOC	364	364	G -> V (in GLC1A).
MYOC	367	367	G -> R (in GLC1A).
MYOC	369	369	F -> L (in GLC1A).
MYOC	370	370	P -> L (in GLC1A; severe form).
MYOC	377	377	T -> K (in GLC1A).
MYOC	377	377	T -> M (in GLC1A).
MYOC	380	380	D -> A (in GLC1A; incomplete penetrance).
MYOC	380	380	D -> G (in GLC1A).
MYOC	380	380	D -> H (in GLC1A).
MYOC	380	380	D -> N (in GLC1A).
MYOC	393	393	S -> N (in GLC1A).
MYOC	393	393	S -> R (in GLC1A).
MYOC	402	402	V -> I.
MYOC	414	414	E -> K.
MYOC	422	422	R -> C.
MYOC	422	422	R -> H (in GLC1A).
MYOC	423	423	K -> E (in GLC1A; heterozygote specific phenotype).
MYOC	425	425	S -> P.
MYOC	426	426	V -> F (in GLC1A).
MYOC	427	427	A -> T (in GLC1A).
MYOC	433	433	C -> R (in GLC1A; severe form).
MYOC	434	434	G -> S (in GLC1A).
MYOC	437	437	Y -> H (in GLC1A).
MYOC	438	438	T -> I (in GLC1A).
MYOC	445	445	A -> V (in GLC1A).
MYOC	448	448	T -> P (in GLC1A).
MYOC	450	450	N -> D (in GLC1A).
MYOC	465	465	I -> M (in GLC1A).
MYOC	470	470	R -> C (in GLC1A).
MYOC	470	470	R -> H.
MYOC	471	471	Y -> C (in GLC1A; uncertain pathogenicity).
MYOC	473	473	Y -> C.
MYOC	477	477	I -> N (in GLC1A).
MYOC	477	477	I -> S (in GLC1A).
MYOC	480	480	N -> K (in GLC1A).
MYOC	481	481	P -> L (in GLC1A).
MYOC	481	481	P -> T (in GLC1A).
MYOC	495	495	V -> I.
MYOC	499	499	I -> F (in GLC1A).
MYOC	499	499	I -> S (in GLC1A).
MYOC	500	500	K -> R.
MYOC	502	502	S -> P (in GLC1A).
METTL13	16	16	Y -> C (found in a renal cell carcinoma sample; somatic mutation).
SERPINC1	17	17	Y -> S (in AT3D; type-I).
SERPINC1	23	23	L -> P (in AT3D; type-I; impairs cotranslational processing).
SERPINC1	32	32	C -> R (in AT3D; type-I).
SERPINC1	52	52	M -> T (previously Whitechapel).
SERPINC1	73	73	P -> L (in AT3D; type-II; Basel/ Franconville/Clichy-1/Clichy-2/Dublin-2; lacks heparin-binding ability).
SERPINC1	79	79	R -> C (in AT3D; Tours/Alger/Amiens/ Toyama/Paris-1/Paris-2/Padua-2/Barcelona- 2/Kumamoto/Omura/Sasebo; lacks heparin- binding ability).
SERPINC1	79	79	R -> H (in AT3D; type-II; Rouen-1/Padua- 1/Bligny/Budapest-2; lack of heparin- binding properties).
SERPINC1	79	79	R -> S (in AT3D; type-II; Rouen-2; lack of heparin-binding properties).
SERPINC1	87	87	Missing (in AT3D; type-I).
SERPINC1	89	89	R -> C (in AT3D; type-I).
SERPINC1	90	90	F -> L (in AT3D; type-I; Budapest-6).
SERPINC1	95	95	Y -> C (in AT3D; type-I).
SERPINC1	95	95	Y -> S (in AT3D; type-I).
SERPINC1	98	98	L -> P (in AT3D; type-I).
SERPINC1	108	109	Missing (in AT3D; type-I).
SERPINC1	112	112	P -> T (in AT3D; type-I).
SERPINC1	121	121	M -> K (in AT3D; type-I).
SERPINC1	127	127	C -> R (in AT3D; type-I).
SERPINC1	131	131	L -> F (in AT3D; type-II; Budapest-3/ Budapest-7).
SERPINC1	131	131	L -> V (in AT3D; type-II; Southport).
SERPINC1	133	133	Q -> K (in AT3D; type I).
SERPINC1	138	139	Missing (in AT3D; type-I).
SERPINC1	146	146	K -> E (in AT3D; Dreux; complete loss af heparin binding).
SERPINC1	148	148	S -> P (in AT3D; type-II; Nagasaki; defective heparin binding associated with thrombosis).
SERPINC1	150	150	Q -> P (in AT3D; type-II; Vienna).
SERPINC1	152	154	Missing (in AT3D; type-I).
SERPINC1	152	152	H -> Y (in AT3D; type-I).
SERPINC1	153	153	Missing (in AT3D; type-I).
SERPINC1	158	158	L -> P (in AT3D; type-I).
SERPINC1	160	160	C -> Y (in AT3D; type-I).
SERPINC1	161	161	R -> Q (in AT3D; type-II; Geneva).
SERPINC1	167	167	N -> T.
SERPINC1	178	178	L -> H (in AT3D; type-I).
SERPINC1	179	179	F -> L (in AT3D; type-I).
SERPINC1	190	190	Y -> C (polymorphism in population of Scandinavian origin).
SERPINC1	198	198	Y -> C (in AT3D; type-I and -II; Whitechapel).
SERPINC1	198	198	Y -> H (in AT3D; type-I).
SERPINC1	214	214	S -> F (in AT3D; type-I).
SERPINC1	214	214	S -> Y (in AT3D; type-I).
SERPINC1	218	218	Missing (in AT3D; type-I).
SERPINC1	219	219	N -> D (in AT3D; type-II; Rouen-6; increases affinity for heparin).
SERPINC1	219	219	N -> K (in AT3D; type-II; Glasgow-3).
SERPINC1	223	223	S -> P (in AT3D; type-I).
SERPINC1	243	243	T -> I (in AT3D; type-I).
SERPINC1	251	251	I -> T (in AT3D; type-I).
SERPINC1	257	257	W -> R (in AT3D; type-I).
SERPINC1	261	261	F -> L (in AT3D).
SERPINC1	269	269	E -> K (in AT3D; type-II; Truro, increases affinity for heparin).
SERPINC1	273	307	Missing (in AT3D; type-I).
SERPINC1	283	283	M -> I (in AT3D; type-II).
SERPINC1	283	283	M -> V (in AT3D; type-II).
SERPINC1	302	302	L -> P (in AT3D; type-I).
SERPINC1	316	316	I -> N (in AT3D; type-II; Haslar/ Whitechapel).
SERPINC1	323	323	S -> P (in AT3D).
SERPINC1	334	334	E -> K (in AT3D; type-II).
SERPINC1	344	344	Missing (in AT3D; type-I).
SERPINC1	381	381	S -> P (in AT3D; type-I).
SERPINC1	391	391	R -> Q.
SERPINC1	397	397	S -> P (in AT3D; type-I).
SERPINC1	398	398	D -> H (in AT3D; type-I).
SERPINC1	412	412	S -> R (in AT3D; type-I).
SERPINC1	414	414	A -> T (in AT3D; type-II; Hamilton/ Glasgow-2; reduces interaction with thrombin by 90%).
SERPINC1	416	416	A -> S (in AT3D; type-II; Cambridge-2).
SERPINC1	419	419	A -> V (in AT3D; type-I).
SERPINC1	424	424	G -> D (in AT3D; type-II; Stockholm).
SERPINC1	425	425	R -> C (in AT3D; type-II; Northwick-Park/ Milano-1/Frankfurt-1; deprived of inhibitory activity).
SERPINC1	425	425	R -> H (in AT3D; type-II; Glasgow/ Sheffield/Chicago/Avranches/Kumamoto-2; increases affinity for heparin; deprived of inhibitory activity).
SERPINC1	425	425	R -> P (in AT3D; type-II; Pescara; deprived of inhibitory of activity).
SERPINC1	426	426	S -> L (in AT3D; type-II; Denver/Milano- 2; deprived of inhibitory activity).
SERPINC1	434	434	F -> C (in AT3D; type-II; Rosny).
SERPINC1	434	434	F -> L (in AT3D; type-II; Maisons- Laffite).
SERPINC1	434	434	F -> S (in AT3D; type-II; Torino).
SERPINC1	436	436	A -> T (in AT3D; type-II; Oslo/Paris-3).
SERPINC1	437	437	N -> K (in AT3D; type-II; La Rochelle).
SERPINC1	438	438	R -> G (in AT3D; type-II).
SERPINC1	438	438	R -> M (in AT3D; type-II; Kyoto).
SERPINC1	439	439	P -> L (in AT3D; type-II; Utah; deprived of inhibitory activity).
SERPINC1	439	439	P -> T (in AT3D; type-II; Budapest-5).
SERPINC1	441	441	L -> P (in AT3D; type-II).
SERPINC1	453	453	I -> T (in AT3D; type-I).
SERPINC1	456	456	G -> R (in AT3D; type-I).
SERPINC1	457	457	R -> T (in AT3D; type-II).
SERPINC1	459	461	Missing (in AT3D; type-I).
SERPINC1	459	459	A -> D (in AT3D; type-I).
SERPINC1	461	461	P -> L (in AT3D; type-II; Budapest).
SERPINC1	462	462	C -> F (in AT3D; type-I).
RYR2	164	164	P -> S (in CPVT1).
RYR2	176	176	R -> Q (in ARVD2 and CPVT1).
RYR2	414	414	R -> L (in CPVT1).
RYR2	419	419	I -> F (in CPVT1).
RYR2	420	420	R -> W (in CPVT1).
RYR2	433	433	L -> P (in ARVD2 and CPVT1).
RYR2	2246	2246	S -> L (in CPVT1).
RYR2	2306	2306	V -> I (in CPVT1).
RYR2	2311	2311	E -> D (in CPVT1).
RYR2	2328	2328	P -> S (in CPVT1).
RYR2	2386	2386	N -> I (in ARVD2 and CPVT1).
RYR2	2387	2387	A -> P (in CPVT1).
RYR2	2392	2392	Y -> C (in CPVT1).
RYR2	2403	2403	A -> T (in CPVT1).
RYR2	2474	2474	R -> S (in CPVT1).
RYR2	2504	2504	T -> M (in ARVD2 and CPVT1).
RYR2	3778	3778	L -> F (in CPVT1).
RYR2	3946	3946	G -> S (in CPVT1).
RYR2	4097	4097	N -> S (in CPVT1).
RYR2	4104	4104	N -> K (in CPVT1).
RYR2	4146	4146	E -> K (in CPVT1).
RYR2	4158	4158	T -> P (in CPVT1).
RYR2	4201	4201	Q -> R (in CPVT1).
RYR2	4497	4497	R -> C (in CPVT1).
RYR2	4499	4499	F -> C (in CPVT1).
RYR2	4504	4504	M -> I (in CPVT1).
RYR2	4510	4510	A -> T (in CPVT1).
RYR2	4607	4607	A -> P (in CPVT1).
RYR2	4653	4653	V -> F (in CPVT1).
RYR2	4671	4671	G -> R (in CPVT1).
RYR2	4771	4771	V -> I (in CPVT1).
RYR2	4848	4848	I -> V (in CPVT1).
RYR2	4860	4860	A -> G (in CPVT1; diminishes the response to activation by luminal Ca(2+) but has little effect on the sensitivity of the channel to activation by cytosolic Ca(2+); shows caffeine-induced Ca(2+) release but exhibits no store-overload- induced Ca(2+) release (SOICR); HL1 cardiac cells transfected with the G-4860 mutant displayed attenuated SOICR activity compared to cells transfected with wild-type RYR2).
RYR2	4867	4867	I -> M (in CPVT1).
RYR2	4880	4880	V -> A (in CPVT1).
RYR2	4895	4895	N -> D (in CPVT1).
RYR2	4902	4902	P -> L (in CPVT1).
RYR2	4950	4950	E -> K (in CPVT1).
RYR2	4959	4959	R -> Q (in CPVT1).
NPHS2	20	20	P -> L (in NPHS2).
NPHS2	92	92	G -> C (in NPHS2).
NPHS2	138	138	R -> Q (in NPHS2).
NPHS2	160	160	D -> G (in NPHS2).
NPHS2	180	180	V -> M (in NPHS2).
NPHS2	291	291	R -> W (in NPHS2).
TOR1AIP1	190	190	V -> I (in a breast cancer sample; somatic mutation).
GLUL	324	324	R -> C (in CSGD; reduced glutamine synthetase activity).
GLUL	341	341	R -> C (in CSGD; suggests reduced glutamine synthetase activity).
RNASEL	59	59	G -> S.
RNASEL	406	406	S -> F.
NCF2	19	21	Missing (in CGD2).
NCF2	58	58	Missing (in CGD2).
NCF2	96	96	Missing (in CGD2).
NCF2	160	161	DK -> EV (in CGD2).
NCF2	196	196	Missing (in CGD2).
GLT25D2	475	475	V -> I (in a breast cancer sample; somatic mutation).
ULK4	415	415	T -> M.
ULK4	417	417	S -> P.
ALDH1L1	511	511	A -> V (in a colorectal cancer sample; somatic mutation).
P2RY14	140	140	L -> P (in a colorectal cancer sample; somatic mutation).
GOLIM4	312	312	A -> V (in a breast cancer sample; somatic mutation).
SUMF1	20	20	L -> F (in MSD; loss of activity).
SUMF1	155	155	S -> P (in MSD; loss of activity).
SUMF1	177	177	A -> P (in MSD; loss of activity; decreases its specific enzyme activity to less than 1%; does not affect localization of the protein in the endoplasmic reticulum of MSD fibroblasts; protein stability is almost comparable to wild-type).
SUMF1	179	179	W -> S (in MSD; decreases its specific enzyme activity to less than 3%; does not affect localization of the protein in the endoplasmic reticulum of MSD fibroblasts; protein stability is almost comparable to wild-type).
SUMF1	218	218	C -> Y (in MSD; loss of activity).
SUMF1	224	224	R -> W (in MSD; loss of activity).
SUMF1	259	259	N -> I (in MSD; loss of activity).
SUMF1	266	266	P -> L (in MSD; retains some activity).
SUMF1	279	279	A -> V (in MSD; loss of activity; decreases its specific enzyme activity to about 23%; does not affect localization of the protein in the endoplasmic reticulum of MSD fibroblasts; protein stability is decreased).
SUMF1	336	336	C -> R (in MSD; loss of activity).
SUMF1	345	345	R -> C (in MSD; retains some activity).
SUMF1	348	348	A -> P (in MSD; loss of activity).
SUMF1	349	349	R -> Q (in MSD; loss of activity).
SUMF1	349	349	R -> W (in MSD; loss of activity; decreases its specific enzyme activity to less than 1%; does not affect localization of the protein in the endoplasmic reticulum of MSD fibroblasts; protein stability is severely decreased).
ZNF385D	386	386	A -> T (in a colorectal cancer sample; somatic mutation).
ZNF385D	387	387	H -> Q (in a colorectal cancer sample; somatic mutation).
NEK10	66	66	A -> V (in an ovarian mucinous carcinoma sample; somatic mutation).
NEK10	379	379	E -> K (in a metastatic melanoma sample; somatic mutation).
NEK10	701	701	L -> V.
ITGA9	750	750	R -> C (in a breast cancer sample; somatic mutation).
SCN10A	916	916	R -> W (found in a renal cell carcinoma sample; somatic mutation).
FOXP1	5	5	S -> P.
FOXP1	101	101	M -> V.
FOXP1	215	215	P -> A.
FOXP1	261	261	S -> P.
FOXP1	390	390	T -> S.
FOXP1	445	445	V -> M.
FOXP1	570	570	N -> S.
FOXP1	597	597	N -> T.
FOXP1	613	613	T -> N.
ROBO2	945	945	I -> T (in VUR2).
ROBO2	1236	1236	A -> T (in VUR2).
ROBO1	1055	1055	S -> N (in a breast cancer sample).
GBE1	224	224	L -> P (in GSD4; loss of activity).
GBE1	257	257	F -> L (in GSD4; loss of activity).
GBE1	329	329	Y -> S (in GSD4; non-progressive form; 50% residual activity).
GBE1	515	515	R -> C (in GSD4; loss of activity).
GBE1	515	515	R -> H (in APBD).
GBE1	524	524	R -> Q (in GSD4 and APBD).
GBE1	545	545	H -> R (in GSD4).
GBE1	628	628	H -> R (in GSD4; childhood neuromuscular form; 15 to 25% residual activity).
ARL6	31	31	T -> M (in BBS3; abrogates the GTP- binding ability without affecting GDP- binding/dissociating properties; increased proteasomal degradation).
ARL6	31	31	T -> R (in BBS3; locked in a GDP-bound state that differs from its wild-type counterpart which is mainly GTP-bound; increased proteasomal degradation).
ARL6	89	89	A -> V (in RP55).
ARL6	169	169	G -> A (in BBS3; abrogates the GTP- binding ability; increased proteasomal degradation).
ARL6	170	170	L -> W (in BBS3; abrogates the GTP- binding ability; increased proteasomal degradation).
SEMA5B	42	42	G -> S (in a breast cancer sample; somatic mutation).
SEMA5B	223	223	I -> M (in a breast cancer sample; somatic mutation).
BFSP2	233	233	Missing (in ADC-BFSP2; congenital).
BFSP2	287	287	R -> W (in ADC-BFSP2; juvenile-onset).
CP	63	63	I -> T (retained in the ER due to impaired N-glycosylation; may present a vulnerability factor for iron induced oxidative stress in Parkinson disease).
CP	551	551	T -> I.
CP	793	793	R -> H.
FNDC3B	927	927	P -> S (in a breast cancer sample; somatic mutation).
LEPREL1	613	613	D -> N (in a breast cancer sample; somatic mutation).
WDR53	60	60	S -> C (in a breast cancer sample; somatic mutation).
RPL35A	27	27	Missing (in DBA5).
RPL35A	33	33	V -> I (in DBA5; may result in aberrant splicing).
CHL1	411	411	L -> I (in a colorectal cancer sample; somatic mutation).
CNTN6	108	108	T -> A (in a breast cancer sample; somatic mutation).
CNTN6	314	314	F -> V.
CNTN6	585	585	S -> C (in a breast cancer sample; somatic mutation).
CNTN6	954	954	E -> V (in a patient with amyotrophic lateral sclerosis).
CNTN4	176	176	T -> P (in a colorectal cancer sample; somatic mutation).
CNTN4	420	420	K -> N (in a colorectal cancer sample; somatic mutation).
CAV3	14	14	V -> L (in SIDS).
CAV3	27	27	R -> Q (in HYPCK, RMD, LGMD1C and distal myopathy).
CAV3	28	28	D -> E (in RMD and LGMD1C).
CAV3	29	29	P -> L (in HYPCK).
CAV3	33	33	N -> K (in LGMD1C and distal myopathy).
CAV3	44	44	V -> E (in LGMD1C).
CAV3	46	46	A -> T (in LGMD1C and RMD; decreased surface expression of the CAV3 protein).
CAV3	46	46	A -> V (in RMD).
CAV3	53	53	S -> G (in RMD).
CAV3	56	56	G -> S.
CAV3	57	57	V -> M (in HYPCK).
CAV3	61	61	S -> R (in a patient with mild proximal myopathy).
CAV3	64	66	Missing (in LGMD1C).
CAV3	64	64	T -> P (in LGMD1C).
CAV3	64	64	T -> S (in CMH).
CAV3	72	72	C -> W.
CAV3	78	78	T -> M (in LQT9 and SIDS).
CAV3	79	79	L -> R (in LQT9 and SIDS).
CAV3	85	85	A -> T (in LQT9).
CAV3	97	97	F -> C (in LQT9; increase in late sodium current).
CAV3	97	97	Missing (in HYPCK).
CAV3	105	105	P -> L (in LGMD1C and RMD).
CAV3	126	126	R -> H.
CAV3	141	141	S -> R (in LQT9; increase in late sodium current).
SRGAP3	623	623	L -> I (in a breast cancer sample; somatic mutation).
MTMR14	336	336	R -> Q (in a ADCNM patient; drastically reduced enzymatic activity).
MTMR14	462	462	Y -> C (in a ADCNM patient; reduced enzymatic activity).
FANCD2	126	126	S -> G (in FANCD2).
FANCD2	302	302	R -> W (in FANCD2).
FANCD2	1236	1236	R -> H (in FANCD2; no effect on ubiquitination).
IRAK2	249	249	S -> L (in a lung adenocarcinoma sample; somatic mutation).
IRAK2	421	421	P -> T (in a lung adenocarcinoma sample; somatic mutation).
HRH1	385	385	D -> E (in a colorectal cancer sample; somatic mutation).
PPARG	318	318	V -> M (in diabetes).
PPARG	388	388	F -> L (in FPLD3).
PPARG	425	425	R -> C (in FPLD3).
PPARG	495	495	P -> L (in diabetes).
WNT7A	72	72	E -> K (in LPHAS).
WNT7A	109	109	A -> T (in FUHRS; retains activity that is significant but not comparable to wild-type activity).
WNT7A	222	222	R -> W (in LPHAS).
WNT7A	292	292	R -> C (in LPHAS; results in a loss of function mutation with some residual activity).
DAZL	54	54	T -> A (may be associated with susceptibility to spermatogenic failure in Asian individuals; this substitution may lead to affect the DAZL transcript stability and prevent its translation).
THRB	234	234	A -> T (in GTHR).
THRB	243	243	R -> W (in GTHR).
THRB	268	268	A -> G (in GTHR).
THRB	316	316	R -> H (in PRTH).
THRB	317	317	A -> T (in GTHR).
THRB	320	320	R -> C (in GTHR).
THRB	320	320	R -> H (in GTHR).
THRB	331	331	N -> D (in GTHR).
THRB	335	335	A -> P (in GTHR).
THRB	337	337	Missing (in GTHR).
THRB	338	338	R -> W (in GTHR).
THRB	340	340	Q -> H (in GTHR).
THRB	341	341	L -> P (in GTHR).
THRB	342	342	K -> I (in GTHR).
THRB	345	345	G -> R (in GTHR).
THRB	345	345	G -> S (in GTHR).
THRB	346	346	L -> F (in GTHR).
THRB	348	348	V -> E (in GTHR).
THRB	426	426	T -> I (in GTHR).
THRB	429	429	R -> Q (in PRTH).
THRB	431	431	I -> M (in GTHR).
THRB	438	438	R -> H (in GTHR).
THRB	442	442	M -> V (in GTHR).
THRB	443	443	K -> E (in GTHR).
THRB	446	446	C -> R (in GTHR).
THRB	447	447	P -> T (in GTHR).
THRB	453	453	P -> H (in GTHR).
THRB	453	453	P -> L (in GTHR).
THRB	453	453	P -> S (in GTHR).
THRB	459	459	F -> C (in GTHR).
RARB	90	90	V -> I (in a colorectal cancer sample; somatic mutation).
TGFBR2	61	61	C -> R (in a gastric adenocarcinoma sample; somatic mutation).
TGFBR2	73	73	I -> V (in a colorectal cancer sample; somatic mutation).
TGFBR2	328	328	H -> Y (in a lung neuroendocrine carcinoma sample; somatic mutation).
TGFBR2	336	336	Y -> N (in LDS1B).
TGFBR2	355	355	A -> P (in LDS1B).
TGFBR2	357	357	G -> W (in LDS1B).
TGFBR2	435	435	N -> S (in a breast tumor; signaling of TGF-beta significantly inhibited).
TGFBR2	447	447	V -> A (in a breast tumor; signaling of TGF-beta significantly inhibited).
TGFBR2	449	449	S -> F (in LDS2B; has a negative effect on TGF-beta signaling).
TGFBR2	452	452	L -> M (in a breast tumor; signaling of TGF-beta significantly inhibited).
TGFBR2	460	460	R -> C (in AAT3).
TGFBR2	460	460	R -> H (in AAT3).
TGFBR2	490	490	N -> S (in a gastric adenocarcinoma sample; somatic mutation).
TGFBR2	526	526	E -> Q (in esophageal cancer).
TGFBR2	528	528	R -> C (in LDS1B).
TGFBR2	528	528	R -> H (in LDS1B).
CRTAP	13	13	A -> E (in OI2B; overlapping features with OI type 3).
CRTAP	67	67	L -> P (in OI7).
CRTAP	157	157	K -> E (in OI2B; overlapping features with OI type 3).
FBXL2	226	226	V -> M (in a colorectal cancer sample; somatic mutation).
MLH1	18	18	R -> C (in HNPCC2).
MLH1	19	19	I -> F (in HNPCC2; uncertain pathogenicity).
MLH1	21	21	A -> V (in HNPCC2).
MLH1	25	25	I -> F (in HNPCC2).
MLH1	28	28	P -> L (in HNPCC2).
MLH1	29	29	A -> S (in HNPCC2; could be a polymorphism; has no effect on ex vivo splicing assay).
MLH1	35	35	M -> K (in HNPCC2; uncertain pathogenicity).
MLH1	35	35	M -> N (in MMRCS; requires 2 nucleotide substitutions).
MLH1	35	35	M -> R (in HNPCC2).
MLH1	37	37	E -> ELNH (found in an endometrial cancer sample; somatic mutation).
MLH1	38	38	N -> H (in HNPCC2).
MLH1	41	41	D -> G (in HNPCC2).
MLH1	41	41	D -> H (associated with HNPCC2; has no effect on ex vivo splicing assay).
MLH1	44	44	S -> F (in HNPCC2; the equivalent substitution in yeast causes loss of function in a mismatch repair assay; has no effect on ex vivo splicing assay).
MLH1	45	47	TSI -> CF (in HNPCC2).
MLH1	54	54	G -> E (in CRC; sporadic; somatic mutation).
MLH1	62	62	Q -> K (in HNPCC2; reduced repair efficiency in a yeast mismatch repair assay).
MLH1	63	63	D -> E (in HNPCC2).
MLH1	64	64	N -> S (in HNPCC2).
MLH1	67	67	G -> E (in CRC).
MLH1	67	67	G -> R (in HNPCC2; the equivalent substitution in yeast causes loss of function in a mismatch repair assay; has no effect on ex vivo splicing assay).
MLH1	67	67	G -> W (in HNPCC2).
MLH1	68	68	I -> N (in HNPCC2; the equivalent substitution in yeast causes loss of function in a mismatch repair assay).
MLH1	69	69	R -> K (in HNPCC2; reduced repair efficiency in a mismatch repair assay).
MLH1	71	71	Missing (in HNPCC2).
MLH1	77	77	C -> R (in HNPCC2 and CRC; sporadic; normal interaction with PMS2; loss of function in a mismatch repair assay).
MLH1	77	77	C -> Y (in CRC; sporadic; early onset).
MLH1	80	80	F -> V (in HNPCC2).
MLH1	84	84	K -> E (in HNPCC2).
MLH1	98	98	G -> S (associated with HNPCC2; has no effect on ex vivo splicing assay).
MLH1	101	101	G -> D (in HNPCC2; has no effect on ex vivo splicing assay).
MLH1	101	101	G -> S (associated with HNPCC2; has no effect on ex vivo splicing assay).
MLH1	102	102	E -> K (in HNPCC2; uncertain pathogenicity).
MLH1	106	106	S -> R (in gastric cancer; uncertain pathogenicity).
MLH1	107	107	I -> R (in HNPCC2; normal interaction with PMS2; loss of function in a mismatch repair assay).
MLH1	109	109	H -> Q (in gastric cancer; uncertain pathogenicity).
MLH1	111	111	A -> V (in HNPCC2; uncertain pathogenicity).
MLH1	116	116	T -> K (associated with HNPCC2; has no effect on ex vivo splicing assay).
MLH1	117	117	T -> M (in HNPCC2; fails to interact with PMS2 and EXO1; loss of function in a mismatch repair assay; has no effect on ex vivo splicing assay).
MLH1	117	117	T -> R (in HNPCC2; equivalent substitution in yeast causes loss of function in mismatch repair assay).
MLH1	126	126	Y -> N (associated with HNPCC2; has no effect on ex vivo splicing assay).
MLH1	128	128	A -> P (in HNPCC2).
MLH1	155	155	L -> R (in HNPCC2).
MLH1	182	182	R -> G (in HNPCC2; incomplete).
MLH1	182	182	R -> K (in HNPCC2).
MLH1	185	185	V -> G (in HNPCC2; defective in a mismatch repair assay; has no effect on ex vivo splicing assay).
MLH1	185	185	V -> L (in HNPCC2; could be a polymorphism).
MLH1	193	193	S -> P (in HNPCC2).
MLH1	215	215	N -> S (associated with HNPCC2; has no effect on ex vivo splicing assay).
MLH1	216	216	I -> S (associated with HNPCC2; has no effect on ex vivo splicing assay).
MLH1	217	217	R -> G.
MLH1	226	295	Missing (in HNPCC2).
MLH1	226	226	R -> L (in HNPCC2).
MLH1	234	234	E -> G (in HNPCC2; uncertain pathogenicity).
MLH1	244	244	G -> D (in HNPCC2; defective in a mismatch repair assay).
MLH1	244	244	G -> V (in CRC; sporadic; somatic mutation; could be a polymorphism).
MLH1	247	247	S -> P (in HNPCC2).
MLH1	260	260	L -> F (associated with HNPCC2; has no effect on ex vivo splicing assay).
MLH1	260	260	L -> R (in CRC).
MLH1	262	262	Missing (in HNPCC2).
MLH1	264	264	H -> Y (in HNPCC2).
MLH1	265	265	R -> C (associated with HNPCC2; results in partial exon 10 skipping on ex vivo splicing assay).
MLH1	265	265	R -> H (rare polymorphism; associated with HNPCC2; slightly lower mismatch repair efficiency; results in partial exon 10 skipping on ex vivo splicing assay).
MLH1	268	268	E -> G (in CRC).
MLH1	282	282	A -> G (in HNPCC2).
MLH1	292	292	L -> P (in HNPCC2; uncertain pathogenicity).
MLH1	295	295	S -> T (in HNPCC2).
MLH1	304	304	D -> V (in HNPCC2).
MLH1	309	309	P -> S.
MLH1	320	320	E -> D (associated with HNPCC2; has no effect on ex vivo splicing assay).
MLH1	321	321	S -> I (in HNPCC2; uncertain pathogenicity).
MLH1	325	327	Missing (in colorectal cancer).
MLH1	325	325	R -> Q (in CRC; sporadic; somatic mutation; could be a polymorphism).
MLH1	326	326	V -> A (in HNPCC2; proficient in a mismatch repair assay).
MLH1	329	329	H -> P (in HNPCC2).
MLH1	330	330	Missing (in HNPCC2; results in weak exon 11 skipping on ex vivo splicing assay).
MLH1	338	338	N -> S (in HNPCC2).
MLH1	379	379	Y -> C (in HNPCC2).
MLH1	384	384	V -> D (could be a non-functional polymorphism associated with HNPCC confined to East Asian population).
MLH1	385	385	R -> C (in HNPCC2; uncertain pathogenicity).
MLH1	385	385	R -> P (in HNPCC2; uncertain pathogenicity).
MLH1	441	441	A -> T (in HNPCC2).
MLH1	472	472	R -> I (in CRC; uncertain pathogenicity).
MLH1	474	474	R -> Q (in HNPCC2; has no effect on ex vivo splicing assay; uncertain pathogenicity).
MLH1	474	474	R -> W (associated with HNPCC2; has no effect on ex vivo splicing assay).
MLH1	485	485	D -> E (in HNPCC2).
MLH1	485	485	D -> H (in HNPCC2; uncertain pathogenicity).
MLH1	492	492	A -> T (in HNPCC2 and CRC; sporadic).
MLH1	506	506	V -> A (in HNPCC2).
MLH1	539	539	A -> D (associated with HNPCC2; has no effect on ex vivo splicing assay).
MLH1	542	542	Q -> L (in HNPCC2; type II; equivalent substitution in yeast causes loss of function in a mismatch repair assay).
MLH1	542	542	Q -> P (in HNPCC2).
MLH1	549	549	L -> P (in HNPCC2; has no effect on ex vivo splicing assay).
MLH1	550	550	L -> P (in HNPCC2).
MLH1	551	551	N -> T (in HNPCC2; has no effect on ex vivo splicing assay).
MLH1	559	559	L -> R (in HNPCC2).
MLH1	565	565	I -> F (in HNPCC2).
MLH1	574	574	L -> P (in HNPCC2; type I; abrogates interaction with EXO1).
MLH1	578	578	E -> G (in HNPCC2 and CRC).
MLH1	582	582	L -> V (in HNPCC2; type II).
MLH1	585	585	L -> R (associated with HNPCC2; has no effect on ex vivo splicing assay).
MLH1	586	586	A -> P (in HNPCC2).
MLH1	588	588	L -> P (in HNPCC2).
MLH1	589	589	A -> D (in HNPCC2).
MLH1	596	596	Missing (in HNPCC2).
MLH1	601	601	D -> G (in CRC; uncertain pathogenicity).
MLH1	612	612	Missing (in HNPCC2).
MLH1	616	616	Missing (in HNPCC2 and MMRCS; abrogates interaction with EXO1; has no effect on ex vivo splicing assay).
MLH1	618	618	K -> R (in colorectal cancer).
MLH1	618	618	K -> T (in HNPCC2; type II).
MLH1	618	618	Missing (in HNPCC2).
MLH1	619	619	A -> P (associated with HNPCC2; has no effect on ex vivo splicing assay).
MLH1	622	622	L -> H (in HNPCC2).
MLH1	623	623	A -> P (in HNPCC2; uncertain pathogenicity).
MLH1	626	627	FS -> ST (in HNPCC2).
MLH1	631	631	D -> A (in HNPCC2; uncertain pathogenicity).
MLH1	635	635	N -> K (in gastric cancer; uncertain pathogenicity).
MLH1	636	636	L -> P (in HNPCC2).
MLH1	640	640	P -> L (associated with HNPCC2; has no effect on ex vivo splicing assay).
MLH1	640	640	P -> S (in HNPCC2; has no effect on ex vivo splicing assay).
MLH1	648	648	P -> L (in HNPCC2).
MLH1	648	648	P -> S (in HNPCC2; protein unstable but still functional in mismatch repair).
MLH1	654	654	P -> L (in HNPCC2).
MLH1	656	656	F -> S (associated with HNPCC2; has no effect on ex vivo splicing assay).
MLH1	657	657	Missing (in HNPCC2; uncertain pathogenicity).
MLH1	659	659	R -> L (in HNPCC2).
MLH1	659	659	R -> P (in HNPCC2; interacts only very weakly with PMS2; equivalent substitution in yeast causes almost complete loss of function in a mismatch repair assay; abrogates interaction with EXO1).
MLH1	659	659	R -> Q.
MLH1	662	662	T -> P (in HNPCC2; could be a rare polymorphism).
MLH1	666	666	W -> R (associated with HNPCC2; has no effect on ex vivo splicing assay).
MLH1	681	681	A -> T (in HNPCC2; could be a common polymorphism; equivalent substitution in yeast does not affect mismatch repair; abrogates interaction with EXO1).
MLH1	687	687	R -> W (in HNPCC2; uncertain pathogenicity).
MLH1	689	689	Q -> R (in HNPCC; suspected; could be a polymorphism).
MLH1	719	719	I -> INVFHI (in HNPCC2).
MLH1	724	724	L -> M (in HNPCC2).
MLH1	749	749	L -> P (in colorectal cancer).
MLH1	751	751	K -> R (in HNPCC2; could be a polymorphism).
MLH1	755	755	R -> W (in HNPCC; incomplete).
CTDSPL	121	121	S -> P.
CTDSPL	127	127	N -> S.
CTDSPL	132	132	V -> G.
DLEC1	351	351	P -> R (in a breast cancer sample; somatic mutation).
OXSR1	433	433	P -> S (in a metastatic melanoma sample; somatic mutation).
SCN5A	9	9	G -> V (in LQT3).
SCN5A	27	27	R -> H (in BRS1).
SCN5A	43	43	R -> Q (in LQT3; does not affect baseline kinetics of sodium currents; causes an unusual hyperpolarizing shift of the activation kinetics after lidocaine treatment).
SCN5A	95	95	V -> I (in BRS1).
SCN5A	126	126	K -> E (in BRS1).
SCN5A	138	138	M -> I (found in patients with atrial fibrillation).
SCN5A	161	161	E -> K (in BRS1 and PFHB1A).
SCN5A	187	187	T -> I (in BRS1; loss of function).
SCN5A	212	212	L -> P (in PFHB1A).
SCN5A	225	225	R -> Q (in LQT3).
SCN5A	225	225	R -> W (in PFHB1A).
SCN5A	226	226	A -> V (in BRS1).
SCN5A	230	230	I -> V (in BRS1).
SCN5A	282	282	R -> H (in BRS1).
SCN5A	294	294	V -> M (in BRS1).
SCN5A	298	298	G -> S (in PFHB1A; also in irritable bowel syndrome; results in reduction of whole cell current density and a delay in channel activation kinetics without a change in single-channel conductance).
SCN5A	319	319	G -> S (in BRS1).
SCN5A	325	325	L -> R (in BRS1).
SCN5A	336	336	P -> L (in BRS1; detected in a compound heterozygote also carrying V-1660; the presence of both mutations is necessary for the phenotypic expression of the disease; severe reduction of sodium currents).
SCN5A	351	351	G -> V (in BRS1; 7-fold current reduction).
SCN5A	353	353	T -> I (in BRS1).
SCN5A	356	356	D -> N (in BRS1; loss of function).
SCN5A	369	369	M -> K (in BRS1).
SCN5A	376	376	R -> H (found in patients with atrial fibrillation).
SCN5A	393	393	Missing (in BRS1).
SCN5A	406	406	N -> K (in LQT3).
SCN5A	406	406	N -> S (in BRS1).
SCN5A	428	428	E -> K (found in patients with atrial fibrillation).
SCN5A	445	445	H -> D (found in patients with atrial fibrillation).
SCN5A	470	470	N -> K (found in patients with atrial fibrillation).
SCN5A	481	481	R -> W (found in patients with atrial fibrillation).
SCN5A	512	512	T -> I (in PFHB1A; voltage-dependent activation and inactivation of the Ile- 512 channel is shifted negatively by 8 to 9 mV and had enhanced slow activation and slower recovery from inactivation commpared to the wild-type channel; the double mutant Arg-558/Ile-512 channel shows that Arg-558 eliminates the negative shift induced by Ile-512 but only partially restores the kinetic abnormalities).
SCN5A	514	514	G -> C (in BRS1 and PFHB1A).
SCN5A	532	532	F -> C (in SIDS).
SCN5A	567	567	L -> Q (in BRS1).
SCN5A	586	587	Missing (in LQT3).
SCN5A	619	619	L -> F (in LQT3).
SCN5A	639	639	G -> R (in LQT3).
SCN5A	655	655	E -> K (found in patients with atrial fibrillation).
SCN5A	680	680	R -> H (in LQT3).
SCN5A	681	681	H -> P (in BRS1).
SCN5A	735	735	A -> E (in BRS1).
SCN5A	735	735	A -> V (in BRS1; expresses currents with steady state activation voltage shifted to more positive potentials and exhibit reduced sodium channel current at the end of phase I of the action potential).
SCN5A	752	752	G -> R (in BRS1 and PFHB1A).
SCN5A	814	814	R -> Q (in BRS1).
SCN5A	851	851	F -> L (in BRS1).
SCN5A	878	878	R -> C (in BRS1).
SCN5A	892	892	F -> I (in BRS1).
SCN5A	896	896	C -> S (in BRS1).
SCN5A	910	910	S -> L (in BRS1).
SCN5A	941	941	S -> N (in LQT3; also in SIDS).
SCN5A	965	965	R -> C (in BRS1; steady state inactivation shifted to a more negative potential; slower recovery from inactivation).
SCN5A	997	997	A -> S (in LQT3; also found in patients with atrial fibrillation; sodium current characterized by slower decay and a 2- to 3-fold increase in late sodium current).
SCN5A	1023	1023	R -> H (in BRS1).
SCN5A	1027	1027	R -> Q.
SCN5A	1053	1053	E -> K (in BRS1; also found in patients with atrial fibrillation; abolishes binding to ANK3 and also prevents accumulation of SCN5A at cell surface sites in ventricular cardiomyocytes).
SCN5A	1084	1084	G -> S (in SIDS; may be a rare polymorphism).
SCN5A	1114	1114	D -> N (in LQT3).
SCN5A	1131	1131	T -> I (found in patients with atrial fibrillation).
SCN5A	1225	1225	E -> K (in BRS1).
SCN5A	1232	1232	R -> W (in BRS1 and PFHB1A).
SCN5A	1236	1236	K -> N (in BRS1).
SCN5A	1240	1240	E -> Q (in BRS1).
SCN5A	1262	1262	G -> S (in BRS1).
SCN5A	1275	1275	D -> N (in CMD1E, BRS1, PFHB1A and FAS; in familial atrial standstill is found in association with polymorphisms in the regulatory region of GJA5).
SCN5A	1295	1295	E -> K (in LQT3; causes significant positive shifts in the half-maximal voltage of steady-state inactivation and activation).
SCN5A	1304	1304	T -> M (in LQT3).
SCN5A	1319	1319	G -> V (in BRS1).
SCN5A	1330	1330	A -> P (in LQT3).
SCN5A	1330	1330	A -> T (in LQT3).
SCN5A	1332	1332	P -> L (in LQT3).
SCN5A	1333	1333	S -> Y (in LQT3 and SIDS).
SCN5A	1344	1344	F -> S (in BRS1).
SCN5A	1382	1382	S -> I (in BRS1).
SCN5A	1405	1405	V -> L (in BRS1).
SCN5A	1406	1406	G -> R (in BRS1).
SCN5A	1432	1432	R -> G (in BRS1).
SCN5A	1438	1438	P -> L (in BRS1).
SCN5A	1473	1473	F -> C (in LQT3).
SCN5A	1479	1479	Missing (in BRS1).
SCN5A	1486	1486	F -> L (in LQT3).
SCN5A	1494	1494	Y -> N (in BRS1).
SCN5A	1500	1500	K -> N.
SCN5A	1500	1500	Missing (in BRS1).
SCN5A	1501	1501	L -> V (in LQT3).
SCN5A	1502	1502	G -> S (in BRS1).
SCN5A	1505	1507	Missing (in LQT3).
SCN5A	1507	1509	Missing (in LQT3).
SCN5A	1512	1512	R -> W (in BRS1; significantly affects cardiac sodium channel characteristics; associated with an increase in inward sodium current during the action potential upstroke).
SCN5A	1527	1527	K -> R (in BRS1; asymptomatic patient; associated with P-1569).
SCN5A	1569	1569	A -> P (in BRS1; asymptomatic patient; associated with R-1527).
SCN5A	1595	1595	D -> N (in PFHB1A; significant defect in the kinetics of fast-channel inactivation distinct from mutations reported in LQT3).
SCN5A	1609	1609	S -> W (in LQT3).
SCN5A	1617	1617	Missing (in LQT3 and BRS1).
SCN5A	1620	1620	T -> K (in LQT3 and PFHB1A).
SCN5A	1620	1620	T -> M (in BRS1; arrhythmogenicity revealed only at temperatures approaching the physiologic range).
SCN5A	1623	1623	R -> L (in LQT3).
SCN5A	1623	1623	R -> Q (in LQT3).
SCN5A	1626	1626	R -> P (in LQT3).
SCN5A	1644	1644	R -> C (in LQT3 and BRS1).
SCN5A	1645	1645	T -> M (in LQT3).
SCN5A	1649	1649	A -> V (in BRS1).
SCN5A	1652	1652	M -> R (in LQT3).
SCN5A	1660	1660	I -> V (in BRS1; detected in a compound heterozygote also carrying L-336; the presence of both mutations is necessary for the phenotypic expression of the disease; complete loss of sodium currents due to defective channel trafficking to the plasma membrane).
SCN5A	1705	1705	F -> S (in SIDS; causes a hyperpolarizing shift of steady-state inactivation and delayed recovery from inactivation).
SCN5A	1710	1710	S -> L (in VF1 and BRS1).
SCN5A	1714	1714	D -> G (in BRS1; strong decrease of current density; does not affect ion selectivity properties).
SCN5A	1740	1740	G -> R (in BRS1).
SCN5A	1743	1743	G -> E (in BRS1).
SCN5A	1743	1743	G -> R (in BRS1; yields nearly undetectable currents in transfected cells).
SCN5A	1763	1763	V -> M (in LQT3).
SCN5A	1766	1766	M -> L (in LQT3; affects protein trafficking).
SCN5A	1768	1768	I -> V (in LQT3; increases the rate of recovery from inactivation and the channel availability, observed as a positive shift of the steady-state inactivation curve).
SCN5A	1777	1777	V -> M (in LQT3).
SCN5A	1784	1784	E -> K (in LQT3 and BRS1).
SCN5A	1787	1787	S -> N (in LQT3).
SCN5A	1790	1790	D -> G (in LQT3).
SCN5A	1795	1795	Y -> C (in LQT3; also in a family associating LQT syndrome and atrial fibrillation; slows the onset of activation, but does not cause a marked negative shift in the voltage dependence of inactivation or affect the kinetics of the recovery from inactivation; increases the expression of sustained Na(+) channel activity and promotes entrance into an intermediate or slowly developing inactivated state).
SCN5A	1795	1795	Y -> H (in BRS1; accelerates the onset of activation and causes a marked negative shift in the voltage dependence of inactivation; does not affect the kinetics of the recovery from inactivation; increases the expression of sustained Na(+) channel activity and promotes entrance into an intermediate or slowly developing inactivated state).
SCN5A	1795	1795	Y -> YD (in LQT3 and BRS1; 7.3-mV negative shift of the steady-state inactivation curve and 8.1-mV positive shift of the steady-state activation curve; may reduced sodium current during the upstroke of the action potential).
SCN5A	1819	1819	D -> N (in LQT3; digenic; associated with Gly-100 mutation on the KCNH2 gene).
SCN5A	1825	1825	L -> P (in LQT3; drug-induced LQT syndrome).
SCN5A	1826	1826	R -> C (found in patients with atrial fibrillation).
SCN5A	1826	1826	R -> H (in LQT3; sodium current characterized by slower decay and a 2- to 3-fold increase in late sodium current).
SCN5A	1839	1839	D -> G (in LQT3).
SCN5A	1850	1850	C -> S (in BRS1; decreased I(Na) density; shift of the steady-state inactivation towards negative potentials).
SCN5A	1875	1875	M -> T (in atrial fibrillation; pronounced depolarized shift of the voltage dependence of steady-state inactivation; no persistent sodium current).
SCN5A	1904	1904	S -> L (in LQT3; promotes late sodium currents by increasing the propensity of the channel to reopen during prolonged depolarization).
SCN5A	1924	1924	A -> T (in BRS1; significantly affect cardiac sodium channel characteristics; associated with an increase in inward sodium current during the action potential upstroke).
SCN5A	1935	1935	G -> S (in BRS1).
SCN5A	1951	1951	V -> M (found in patients with atrial fibrillation).
SCN5A	1968	1968	I -> S (in BRS1).
SCN5A	2006	2006	P -> A (in LQT3; causes an increase of persistent sodium current and produces a depolarizing shift in voltage dependence of inactivation).
CX3CR1	57	57	T -> A.
CX3CR1	122	122	V -> I.
RPL14	138	138	A -> S.
RPL14	158	159	Missing.
RPL14	159	159	A -> AA.
RPL14	159	159	A -> AAA.
RPL14	159	159	A -> AAAA.
RPL14	159	159	A -> AAAAA.
RPL14	159	159	A -> AAAAAA.
RPL14	159	159	A -> AAAAAAAA.
SNRK	611	611	G -> S (in an ovarian mucinous carcinoma sample; somatic mutation).
SNRK	748	748	P -> L (in an ovarian serous carcinoma sample; somatic mutation).
SNRK	765	765	I -> M (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
ANO10	510	510	L -> R (in SCAR10).
CCR3	218	218	C -> S (polymorphism found in about 7% of the population; may show reduced activity).
PTH1R	132	132	P -> L (in BOCD).
PTH1R	150	150	R -> C (in ENCHOM; Ollier type; unclear pathogenicity).
PTH1R	223	223	H -> R (in JMC; constitutively activated).
PTH1R	410	410	T -> P (in JMC; constitutively activated).
PTH1R	410	410	T -> R (in JMC; leads to agonist- independent cAMP formation which is less pronounced than that observed with the Pro-410 mutant).
PTH1R	458	458	I -> R (in JMC).
PTPN23	1099	1099	P -> S (in a lung cancer cell line; may be a common polymorphism).
COL7A1	119	119	T -> P (in a breast cancer sample; somatic mutation).
COL7A1	142	142	K -> R (in RDEB).
COL7A1	1347	1347	G -> R (in RDEB; localized type; mild).
COL7A1	1364	1364	P -> T (in a breast cancer sample; somatic mutation).
COL7A1	1366	1366	R -> W (in a breast cancer sample; somatic mutation).
COL7A1	1519	1519	G -> D (in TBDN; compound heterozygous with E-2251; clinically silent when heterozygous with a normal allele).
COL7A1	1522	1522	G -> E (in DDEB).
COL7A1	1557	1557	G -> R (in DDEB).
COL7A1	1595	1595	G -> R (in INDWSF).
COL7A1	1604	1604	G -> R (in RDEB).
COL7A1	1652	1652	G -> R (in RDEB; mitis type).
COL7A1	1703	1703	G -> E (in RDEB).
COL7A1	1772	1772	R -> W (in RDEB).
COL7A1	1776	1776	G -> R (in DDEB).
COL7A1	1782	1782	G -> R (in RDEB; mitis type).
COL7A1	1791	1791	G -> E (in EBP).
COL7A1	1812	1812	G -> R (in RDEB).
COL7A1	1815	1815	G -> R (in INDWSF).
COL7A1	1845	1845	G -> R (in RDEB).
COL7A1	1981	1981	K -> R (in RDEB; mild form).
COL7A1	1982	1982	G -> W (in HS-DEB).
COL7A1	2003	2003	G -> R (in DDEB).
COL7A1	2006	2006	G -> A (in DDEB).
COL7A1	2006	2006	G -> D (in DDEB; interferes with collagen VII folding and secretion).
COL7A1	2008	2008	R -> C (in HS-DEB; also in a milder localized type).
COL7A1	2008	2008	R -> G (in HS-DEB).
COL7A1	2009	2009	G -> R (in RDEB).
COL7A1	2015	2015	G -> E (in DDEB; interferes with collagen VII folding and secretion).
COL7A1	2025	2025	G -> A (in RDEB; mitis type).
COL7A1	2028	2028	G -> A (in DDEB).
COL7A1	2028	2028	G -> R (in DDEB and EBP).
COL7A1	2031	2031	G -> S (in RDEB; severe phenotype).
COL7A1	2034	2034	G -> R (in DDEB and EBDSC; interferes with collagen VII folding and secretion).
COL7A1	2034	2034	G -> W (in DDEB).
COL7A1	2037	2037	G -> E (in P-DEB).
COL7A1	2040	2040	G -> D (in DDEB).
COL7A1	2040	2040	G -> S (in P-DEB).
COL7A1	2040	2040	G -> V (in DDEB).
COL7A1	2043	2043	G -> R (in DDEB).
COL7A1	2043	2043	G -> W (in DDEB; localized type).
COL7A1	2046	2046	G -> V (in DDEB).
COL7A1	2049	2049	G -> E (in HS-DEB).
COL7A1	2055	2055	G -> E (in DDEB).
COL7A1	2063	2063	R -> W (in HS-DEB; also in a mild form).
COL7A1	2064	2064	G -> R (in DDEB).
COL7A1	2069	2069	R -> C (in RDEB).
COL7A1	2070	2070	G -> R (in DDEB).
COL7A1	2073	2073	G -> D (in RDEB; mitis type).
COL7A1	2076	2076	G -> D (in DDEB; also in recessive forms).
COL7A1	2079	2079	G -> E (in DDEB).
COL7A1	2079	2079	G -> R (in DDEB; associated with squamous cell carcinoma).
COL7A1	2132	2132	G -> D (in RDEB).
COL7A1	2192	2192	G -> S (in RDEB).
COL7A1	2207	2207	G -> R (in DDEB).
COL7A1	2221	2221	G -> A (in a patient with recessive dystrophic epidermolysis bullosa).
COL7A1	2242	2242	G -> R (in EBP).
COL7A1	2251	2251	G -> E (in TBDN; compound heterozygous with D-1519; leads to isolated toenail dystrophy when heterozygous with a normal allele).
COL7A1	2263	2263	G -> V (in RDEB).
COL7A1	2287	2287	G -> R (in a compound heterozygote affected by moderately severe dystrophic epidermolysis bullosa; in combination with R-2316; leads to isolated toenail dystrophy when heterozygous with a normal allele).
COL7A1	2296	2296	G -> E (in RDEB).
COL7A1	2316	2316	G -> R (in a compound heterozygote affected by moderately severe dystrophic epidermolysis bullosa; in combination with R-2287).
COL7A1	2348	2348	G -> R (in DDEB/RDEB; mild form).
COL7A1	2366	2366	G -> S (in RDEB; mitis type).
COL7A1	2369	2369	G -> S (in EBP).
COL7A1	2557	2557	G -> R (in RDEB).
COL7A1	2569	2569	G -> R (in RDEB; severe and mitis type).
COL7A1	2575	2575	G -> R (in HS-DEB; also in a mild form).
COL7A1	2622	2622	R -> W (in RDEB).
COL7A1	2623	2623	G -> C (in PR-DEB; dominant).
COL7A1	2653	2653	G -> R (in RDEB; mitis type).
COL7A1	2671	2671	G -> V (in RDEB).
COL7A1	2674	2674	G -> D (in RDEB).
COL7A1	2674	2674	G -> R (in RDEB; mitis type).
COL7A1	2713	2713	G -> D (in DDEB).
COL7A1	2713	2713	G -> R (in EBP).
COL7A1	2740	2740	G -> A (in RDEB).
COL7A1	2749	2749	G -> R (in HS-DEB; also in a mild form).
COL7A1	2775	2775	G -> S (in RDEB; mitis type).
COL7A1	2791	2791	R -> W (in DDEB).
COL7A1	2798	2798	M -> K (in HS-DEB; also in a mild form; the anchoring fibrils may be absent).
DAG1	192	192	T -> M (in MDDGC7; results in impaired interaction with LARGE and incomplete DAG1 glycosylation).
MST1R	1304	1304	R -> G.
RBM6	353	353	S -> F (in a non-small cell lung cancer cell line).
PBRM1	49	49	V -> L (found in a lung cancer cell line).
PBRM1	56	56	T -> A (found in a brain cancer cell line).
PBRM1	57	57	Missing (found in a case of clear cell renal carcinoma; somatic mutation).
PBRM1	66	66	R -> G (found in a colon cancer cell line).
PBRM1	90	90	Q -> E (found in a bladder cancer cell line).
PBRM1	144	144	Y -> F (found in a malignant melanoma cell line).
PBRM1	160	160	E -> A (found in a malignant melanoma cell line).
PBRM1	202	202	R -> C (found in a endometrial cancer cell line).
PBRM1	206	206	E -> K (found in hematopoietic and lymphoid cancer cell lines).
PBRM1	226	226	E -> G (found in hematopoietic and lymphoid cancer cell lines).
PBRM1	228	228	I -> V (found in a breast cancer cell line).
PBRM1	232	232	T -> P (found in a case of clear cell renal carcinoma; somatic mutation).
PBRM1	233	233	I -> T (found in a renal carcinoma cell line).
PBRM1	256	256	A -> T (found in an ovary carcinoma cell line).
PBRM1	340	340	G -> A (found in a malignant melanoma cell line).
PBRM1	523	523	M -> I (found in a case of clear cell renal carcinoma; somatic mutation).
PBRM1	540	540	R -> S (found in a case of clear cell renal carcinoma; somatic mutation).
PBRM1	597	597	A -> D (found in a case of clear cell renal carcinoma; somatic mutation).
PBRM1	621	621	K -> E (found in a case of clear cell renal carcinoma; somatic mutation).
PBRM1	661	661	K -> N (found in a case of clear cell renal carcinoma; somatic mutation).
PBRM1	674	674	D -> E (found in a case of clear cell renal carcinoma; somatic mutation).
PBRM1	678	678	R -> C.
PBRM1	893	893	Y -> C (found in hematopoietic, lymphoid, lung and liver cancer cell lines).
PBRM1	895	895	T -> S (found in a lung cancer cell line).
PBRM1	922	922	E -> Q (found in a breast cancer cell line).
PBRM1	925	925	K -> Q (found in a colon cancer cell line).
PBRM1	1079	1079	P -> Y (requires 2 nucleotide substitutions; found in a colon cancer cell line).
PBRM1	1098	1098	A -> S (found in hematopoietic and lymphoid cancer cell lines).
PBRM1	1120	1120	R -> Q (found in hematopoietic and lymphoid cancer cell lines).
PBRM1	1177	1177	G -> S (found in a kidney cancer cell line).
PBRM1	1204	1204	H -> P (found in a case of clear cell renal carcinoma; somatic mutation).
PBRM1	1209	1214	Missing (found in a case of clear cell renal carcinoma; somatic mutation).
PBRM1	1287	1287	E -> Q (found in a breast cancer cell line).
PBRM1	1414	1414	G -> E (found in a lung cancer cell line).
PBRM1	1503	1503	G -> C (found in a stomach cancer cell line).
PBRM1	1560	1560	Q -> H (found in an endometrial cancer cell line).
PBRM1	1614	1614	I -> N (found in a case of clear cell renal carcinoma; somatic mutation).
PBRM1	1647	1647	R -> C (found in a breast cancer cell line).
PRKCD	494	494	M -> V.
PRKCD	593	593	V -> M.
CACNA1D	1	1	M -> MM (in a NIDDM patient).
APPL1	643	643	E -> Q (in a breast cancer sample; somatic mutation).
FLNB	161	161	F -> C (in LRS1).
FLNB	168	168	G -> S (in LRS1).
FLNB	171	171	L -> R (in BOOMD).
FLNB	188	188	S -> P (in AO1).
FLNB	227	227	E -> K (in LRS1).
FLNB	234	234	L -> V (in LRS1).
FLNB	235	235	S -> P (in BOOMD).
FLNB	361	361	G -> S (in LRS1).
FLNB	363	363	G -> E (in LRS1).
FLNB	566	566	R -> Q (in a breast cancer sample; somatic mutation).
FLNB	663	663	N -> K (in a breast cancer sample; somatic mutation).
FLNB	703	703	T -> K (in a breast cancer sample; somatic mutation).
FLNB	1431	1431	L -> R (in LRS1).
FLNB	1534	1534	A -> G (in a breast cancer sample; somatic mutation).
FLNB	1571	1571	Missing (in LRS1).
FLNB	1592	1592	V -> D (in LRS1).
FLNB	1603	1603	P -> L (in LRS1).
FLNB	1691	1691	G -> S (in LRS1).
FLNB	1834	1834	G -> R (in LRS1).
DNASE1L3	19	19	L -> V (in a breast cancer sample; somatic mutation).
DNASE1L3	82	82	G -> R (in a breast cancer sample; somatic mutation).
DNASE1L3	117	117	Y -> S (in a colorectal cancer sample; somatic mutation).
FAM107A	15	15	L -> M (in ovarian cancer and renal cell carcinoma cell lines).
FAM107A	19	19	P -> L (in renal cell carcinoma cell line).
PRICKLE2	148	148	R -> H (in EPM5; associated with Ile-153; results in increased protein activity compared to wild-type; mutant protein is less active in stimulating calcium release compared to wild-type).
PRICKLE2	153	153	V -> I (in EPM5; associated with His-148; results in increased protein activity compared to wild-type; mutant protein is less active in stimulating calcium release compared to wild-type).
PRICKLE2	605	605	V -> F (in EPM5; results in decreased protein activity compared to wild-type; mutant protein is less active in stimulating calcium release compared to wild-type).
MITF	310	310	R -> K (in WS2A; could be a polymorphism).
MITF	317	317	N -> K (in TIETZS).
MITF	324	324	Missing (in WS2A).
MITF	357	357	S -> P (in WS2A).
MITF	385	385	N -> D (in WS2A).
MITF	405	405	S -> P (in WS2A).
PROK2	32	32	G -> R (in KAL4).
PROK2	73	73	R -> C (in KAL4).
CHMP2B	29	29	I -> V.
CHMP2B	148	148	D -> Y (in FTD3).
CHMP2B	206	206	Q -> H (in amyotrophic lateral sclerosis; CHMP2B-related).
EPHA3	37	37	T -> K (in a colorectal cancer sample; somatic mutation).
EPHA3	85	85	N -> S (in a colorectal cancer sample; somatic mutation).
EPHA3	229	229	S -> Y (in a lung large cell carcinoma sample; somatic mutation).
EPHA3	449	449	S -> F (in a lung neuroendocrine carcinoma sample; somatic mutation).
EPHA3	518	518	G -> L (in a lung squamous cell carcinoma sample; somatic mutation; requires 2 nucleotide substitutions).
EPHA3	621	621	I -> L (in a colorectal cancer sample; somatic mutation).
EPHA3	766	766	G -> E (in a lung adenocarcinoma sample; somatic mutation).
EPHA3	806	806	D -> N (in a colorectal cancer sample; somatic mutation).
ARL13B	79	79	R -> Q (in JBTS8; reduces binding to GTP).
ARL13B	200	200	R -> C (in JBTS8).
EPHA6	703	703	F -> S.
CPOX	135	135	V -> A (in HCP).
CPOX	162	168	Missing (in HCP).
CPOX	189	189	G -> S (in HCP; <5% of activity).
CPOX	197	197	G -> W (in HCP).
CPOX	201	201	E -> K (in HCP).
CPOX	214	214	L -> R (in HCP).
CPOX	249	249	P -> R (in HCP).
CPOX	249	249	P -> S (in HCP).
CPOX	279	279	G -> R (in HCP; a patient carrying also the L-12 mutation in ALAD).
CPOX	280	280	G -> R (in HCP).
CPOX	295	295	H -> D (in HCP).
CPOX	331	331	R -> W (in HCP).
CPOX	390	390	Missing (in HCP).
CPOX	404	404	K -> E (in HCP; harderoporphyria form).
CPOX	427	427	W -> R (in HCP).
CD96	280	280	T -> M (in CLSYN).
BOC	713	713	V -> M (in a breast cancer sample; somatic mutation).
DTX3L	209	209	K -> N (in a breast cancer sample; somatic mutation).
MYLK	128	128	A -> V.
MYLK	133	133	Q -> H.
MYLK	160	160	P -> R.
MYLK	276	276	T -> A.
MYLK	378	378	R -> H.
MYLK	443	443	P -> S.
MYLK	607	607	R -> G.
MYLK	652	652	P -> A.
MYLK	656	656	W -> C.
MYLK	692	692	T -> M.
MYLK	701	701	A -> T.
MYLK	709	709	V -> M.
MYLK	1085	1085	T -> A.
MYLK	1213	1213	V -> M (found in a patient with familial aortic dissections).
MYLK	1399	1399	E -> K (found in a patient with familial aortic dissections).
MYLK	1527	1527	A -> V.
MYLK	1588	1588	P -> L (in an ovarian mucinous carcinoma sample; somatic mutation).
MYLK	1754	1754	A -> T (found in a patient with familial aortic dissections; binding to calmodulin is reduced; significant reduction in kinase activity compared to wild-type protein).
MYLK	1759	1759	S -> P (in AAT7; shows minimal cells endogenous expression; binding to calmodulin is abolished; 6-fold reduction in kinase activity compared to wild-type protein).
KALRN	196	196	S -> L.
KALRN	213	213	R -> W (in a colorectal cancer sample; somatic mutation).
KALRN	1896	1896	S -> C (in a breast cancer sample; somatic mutation).
OSBPL11	184	184	S -> L (in a breast cancer sample; somatic mutation).
UROC1	70	70	L -> P (in UROD).
UROC1	450	450	R -> C (in UROD; loss of activity).
RAB7A	129	129	L -> F (in CMT2B).
RAB7A	157	157	K -> N (in CMT2B).
RAB7A	161	161	N -> T (in CMT2B).
RAB7A	162	162	V -> M (in CMT2B).
IFT122	7	7	W -> C (in CED1).
IFT122	322	322	S -> F (in CED1).
IFT122	502	502	V -> G (in CED1).
PIK3R4	936	936	R -> Q (in a breast cancer sample; somatic mutation).
ATP2C1	201	201	P -> L (in HHD).
ATP2C1	304	304	A -> T (in HHD).
ATP2C1	309	309	G -> C (in HHD; unable to bind manganese, reduced affinity for calcium).
ATP2C1	318	318	L -> P (in HHD).
ATP2C1	341	341	L -> P (in HHD; unstable protein).
ATP2C1	344	344	C -> Y (in HDD; unstable protein).
ATP2C1	411	411	C -> R (in HDD; unstable protein).
ATP2C1	490	490	C -> F (in HHD).
ATP2C1	570	570	T -> I (in HDD; unstable protein).
ATP2C1	580	580	I -> V (in HDD; unable to undergo conformational change necessary for ion transport).
ATP2C1	584	584	L -> P (in HHD).
ATP2C1	641	641	M -> R (in HHD).
ATP2C1	645	645	G -> R (in HHD).
ATP2C1	709	709	T -> M (in HHD).
ATP2C1	742	742	D -> Y (in HDD; unable to bind calcium or manganese).
ATP2C1	744	744	P -> R (in HHD).
ATP2C1	789	789	G -> R (in HDD; unstable protein).
NEK11	108	108	T -> M (in a colorectal adenocarcinoma sample; somatic mutation).
NEK11	492	492	E -> K (in a colorectal adenocarcinoma sample; somatic mutation).
NEK11	617	617	D -> N (in a colorectal adenocarcinoma sample; somatic mutation).
NPHP3	360	360	S -> T (in NPHP3).
NPHP3	386	386	N -> S (in NPHP3).
NPHP3	397	397	R -> H (in NPHP3).
NPHP3	973	973	R -> Q (in RHPD).
NPHP3	1141	1141	L -> P (in NPHP3).
NPHP3	1221	1221	A -> V (in NPHP3).
NPHP3	1252	1252	S -> R (in NPHP3).
NPHP3	1314	1314	S -> T (in NPHP3).
TF	77	77	D -> N (in ATRAF).
TF	319	319	H -> R (in allele TF*CHI).
TF	477	477	A -> P (in ATRAF).
TF	646	646	K -> E (in allele TF*BV).
TF	671	671	G -> E (in allele TF*B2).
RYK	96	96	N -> S.
RYK	224	224	R -> C.
RYK	240	240	V -> I (in an ovarian mucinous carcinoma sample; somatic mutation).
EPHB1	707	707	S -> T (in an ovarian undifferentiated carcinoma sample; somatic mutation).
EPHB1	719	719	I -> V (in a gastric adenocarcinoma sample; somatic mutation).
EPHB1	743	743	R -> Q (in a gastric adenocarcinoma sample; somatic mutation).
PCCB	17	17	L -> M (in PA-2).
PCCB	44	44	R -> P (in PA-2).
PCCB	67	67	R -> S (in PA-2).
PCCB	106	106	S -> R (in PA-2).
PCCB	107	107	V -> M (in PA-2).
PCCB	112	112	G -> D (in PA-2).
PCCB	131	131	G -> R (in PA-2).
PCCB	140	140	K -> KICK (in PA-2).
PCCB	153	153	A -> P (in PA-2).
PCCB	165	165	R -> Q (in PA-2; does not affect either heteromeric or homomeric assembly).
PCCB	165	165	R -> W (in PA-2).
PCCB	168	168	E -> K (in PA-2; common mutation).
PCCB	188	188	G -> R (in PA-2).
PCCB	198	198	G -> D (in PA-2).
PCCB	205	205	V -> D (in PA-2).
PCCB	228	228	P -> L (in PA-2).
PCCB	246	246	G -> V (in PA-2).
PCCB	341	341	Missing (in PA-2).
PCCB	408	408	Missing (in PA-2).
PCCB	410	410	R -> W (in PA-2).
PCCB	430	430	I -> L (in PA-2).
PCCB	435	435	Y -> C (in PA-2).
PCCB	439	439	Y -> C (in PA-2).
PCCB	442	442	M -> T (in PA-2).
PCCB	468	468	A -> T (in PA-2).
PCCB	497	497	A -> V (in PA-2; common mutation; does not affect either heteromeric or homomeric assembly).
PCCB	512	512	R -> C (in PA-2; affects heteromeric and homomeric assembly).
PCCB	519	519	L -> P (in PA-2; affects heteromeric and homomeric assembly).
PCCB	536	536	N -> D (in PA-2; affects heteromeric and homomeric assembly).
MRPS22	170	170	R -> H (in COXPD5).
CLSTN2	193	193	S -> I (in a colorectal cancer sample; somatic mutation).
CLSTN2	765	765	R -> Q (in a colorectal cancer sample; somatic mutation).
TFDP2	64	64	I -> T.
TFDP2	81	81	P -> S.
ATR	1488	1488	A -> P (in a lung squamous cell carcinoma sample; somatic mutation).
ATR	2002	2002	A -> G (in a lung adenocarcinoma sample; somatic mutation).
ATR	2233	2233	S -> I (in a lung large cell carcinoma sample; somatic mutation).
ATR	2438	2438	E -> K (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
ATR	2537	2537	E -> Q (in a breast infiltrating ductal carcinoma sample; somatic mutation).
CLRN1	40	40	C -> G (in USH3).
CLRN1	48	48	N -> K (in USH3).
CLRN1	105	105	S -> P (in USH3).
CLRN1	120	120	M -> K (in USH3).
CLRN1	150	150	L -> P (in USH3).
CLRN1	153	154	IL -> M (in USH3).
IFT80	105	105	H -> Q (in ATD2).
IFT80	549	549	Missing (in ATD2).
IFT80	701	701	A -> P (in ATD2).
SI	117	117	Q -> R (in CSID; missorting of the enzyme to the basolateral membrane).
SI	341	341	L -> P (in CSID; causes loss of anchored SI from the membrane).
SI	577	577	V -> G (in CSID).
SI	594	594	S -> P (in CSID).
SI	620	620	L -> P (in CSID; SI accumulates predominantly in the ER).
SI	694	694	T -> P (in CSID).
SI	1073	1073	G -> D (in CSID).
SI	1098	1098	Q -> P (in CSID; exhibits intracellular accumulation of mannose-rich SI in the Golgi).
SI	1229	1229	C -> Y (in CSID).
SI	1367	1367	R -> G (in CSID).
SI	1745	1745	F -> C (in CSID).
BCHE	32	32	Missing (in BChE deficiency).
BCHE	56	56	F -> I (in BChE deficiency).
BCHE	61	61	Y -> C (in BChE deficiency; enzymatically inactive in the plasma).
BCHE	65	65	P -> S (in BChE deficiency; seems to cause reduced expression of the protein).
BCHE	98	98	D -> H (in BChE deficiency).
BCHE	124	124	N -> Y (in BChE deficiency).
BCHE	143	143	G -> D (in BChE deficiency).
BCHE	153	153	L -> F (in BChE deficiency; seems to cause reduced expression of the protein).
BCHE	156	156	Y -> C (in BChE deficiency).
BCHE	170	170	V -> M (in BChE deficiency; allele H variant).
BCHE	198	198	D -> E (in BChE deficiency; seems to cause reduced expression of the protein).
BCHE	226	226	S -> G (in BChE deficiency; enzymatically inactive in the plasma).
BCHE	227	227	A -> V (in BChE deficiency).
BCHE	229	229	A -> T (in BChE deficiency; enzymatically inactive in the plasma).
BCHE	278	278	T -> P (in BChE deficiency).
BCHE	295	295	K -> R (in BChE deficiency).
BCHE	335	335	L -> P (in BChE deficiency; expressed at very low level).
BCHE	356	356	A -> D (in BChE deficiency).
BCHE	358	358	L -> I (in BChE deficiency; BChE variant form; fluoride-resistant; Japanese type).
BCHE	393	393	G -> R (in BChE deficiency).
BCHE	414	414	R -> C (in BChE deficiency).
BCHE	446	446	F -> S (in BChE deficiency).
BCHE	488	488	E -> K (in BChE deficiency).
BCHE	499	499	W -> R (in BChE deficiency; seems to cause reduced expression of the protein).
BCHE	502	502	F -> L (in BChE deficiency).
BCHE	525	525	E -> V (in BChE deficiency; allele J variant).
BCHE	543	543	R -> C (in BChE deficiency).
BCHE	546	546	Q -> L (in BChE deficiency; seems to cause reduced expression of the protein).
WDR49	10	10	R -> H (in a colorectal cancer sample; somatic mutation).
SERPINI1	49	49	S -> P (in FEN1B; Syracuse).
SERPINI1	52	52	S -> R (in FEN1B; Portland).
PRKCI	118	118	P -> L (in a metastatic melanoma sample; somatic mutation).
PRKCI	130	130	R -> C.
ECT2	802	802	T -> P (in a breast cancer sample; somatic mutation).
SPATA16	283	283	R -> Q (in SPGF6).
SPATA16	286	286	M -> V.
SPATA16	423	423	V -> M.
SPATA16	509	509	A -> V.
SPATA16	526	526	M -> T.
SPATA16	564	564	Q -> R.
PIK3CA	38	38	R -> H (in cancer; shows an increase in lipid kinase activity; may disrupt the interaction between the PI3K-ABD domain and the N-terminal lobe of PI3K/PI4K kinase domain possibly affecting the conformation of the kinase domain).
PIK3CA	88	88	R -> Q (in cancer; may disrupt the interaction between the PI3K-ABD domain and the N-terminal lobe of PI3K/PI4K kinase domain possibly affecting the conformation of the kinase domain).
PIK3CA	106	106	G -> V (in cancer; shows an increase in lipid kinase activity).
PIK3CA	343	343	Y -> C (in cancer).
PIK3CA	420	420	C -> R (in cancer; shows an increase in lipid kinase activity; may increase the affinity for lipid membranes).
PIK3CA	453	453	E -> Q (in cancer; shows an increase in lipid kinase activity; may disrupt the interaction of the C2 PI3K-type domain with the iSH2 region of the p85 regulatory subunit).
PIK3CA	542	542	E -> K (in KERSEB; shows an increase in lipid kinase activity; oncogenic in vivo; occurs in the interface between the PI3K helical domain and the nSH2 (N-terminal SH2) region of the p85 regulatory subunit and may reduce the inhibitory effect of p85; requires interaction with RAS to induce cellular transformation).
PIK3CA	542	542	E -> Q (in cancer).
PIK3CA	542	542	E -> V (in cancer).
PIK3CA	545	545	E -> A (in cancer).
PIK3CA	545	545	E -> G (in KERSEB).
PIK3CA	545	545	E -> K (in KERSEB; shows an increase in lipid kinase activity; oncogenic in vivo; occurs in the interface between the PI3K helical domain and the nSH2 (N-terminal SH2) region of the p85 regulatory subunit and may reduce the inhibitory effect of p85; requires interaction with RAS to induce cellular transformation; enhances invadopodia-mediated extracellular matrix degradation and invasion in breast cancer cells).
PIK3CA	546	546	Q -> E (in cancer).
PIK3CA	546	546	Q -> K (in cancer).
PIK3CA	546	546	Q -> P (in cancer).
PIK3CA	546	546	Q -> R (in cancer).
PIK3CA	1007	1007	G -> R (in cancer).
PIK3CA	1021	1021	Y -> C (in cancer).
PIK3CA	1021	1021	Y -> H (in cancer).
PIK3CA	1021	1021	Y -> N (in cancer).
PIK3CA	1023	1023	R -> Q (in cancer).
PIK3CA	1025	1025	T -> N (in cancer).
PIK3CA	1035	1035	A -> V (in cancer).
PIK3CA	1043	1043	M -> I (in cancer; shows an increase in lipid kinase activity).
PIK3CA	1047	1047	H -> L (in cancer).
PIK3CA	1047	1047	H -> R (in KERSEB; shows an increase in lipid kinase activity; oncogenic in vivo; requires binding to p85 regulatory subunit to induce cellular transformation but not interaction with RAS; may mimic the conformatitonal change triggered by the interaction with RAS; enhances invadopodia-mediated extracellular matrix degradation and invasion in breast cancer cells; increases lipid kinase activity; may alter the interaction of the PI3K/ PI4K kinase domain with the cell membrane).
PIK3CA	1047	1047	H -> Y (in cancer).
PIK3CA	1050	1050	G -> D (in cancer).
PIK3CA	1052	1052	T -> K (in cancer).
PIK3CA	1065	1065	H -> L (in cancer).
PIK3CA	1065	1065	H -> Y (in cancer).
PEX5L	226	226	A -> T (in a colorectal cancer sample; somatic mutation).
MCF2L2	254	254	L -> P (in a colorectal cancer sample; somatic mutation).
MCF2L2	622	622	R -> H (in a colorectal cancer sample; somatic mutation).
MCF2L2	1039	1039	L -> F (in a breast cancer sample; somatic mutation).
EPHB3	168	168	R -> L (in a lung small cell carcinoma sample; somatic mutation).
EPHB3	724	724	R -> W (in a lung neuroendocrine carcinoma sample; somatic mutation).
MAP3K13	746	746	P -> L (in a metastatic melanoma sample; somatic mutation).
DGKG	706	706	E -> K (in a breast cancer sample; somatic mutation).
HRG	103	103	G -> E (in THR-HRG; HRG Tokushima 1; results in increased intracellular degradation and reduced protein secretion).
HRG	241	241	C -> R (in THR-HRG; HRG Tokushima 2; results in increased intracellular degradation and reduced protein secretion).
RFC4	354	354	T -> S (in a breast cancer sample; somatic mutation).
TP63	129	129	S -> L.
TP63	184	184	S -> L (in head and neck cancer).
TP63	187	187	A -> P (in lung carcinoma; somatic mutation).
TP63	193	193	T -> TP (in SHFM4).
TP63	204	204	Q -> L (in cervical cancer).
TP63	232	232	K -> E (in SHFM4).
TP63	233	233	K -> E (in SHFM4).
TP63	243	243	R -> Q (in EEC3).
TP63	243	243	R -> W (in EEC3).
TP63	266	266	R -> Q (in EEC3).
TP63	279	279	P -> H (in colon cancer).
TP63	308	308	C -> Y (in EEC3).
TP63	311	311	S -> N (in EEC3).
TP63	318	318	R -> C (in EEC3).
TP63	318	318	R -> Q (in EEC3).
TP63	319	319	R -> C (in EEC3).
TP63	319	319	R -> H (in EEC3 and SHFM4).
TP63	319	319	R -> S (in EEC3).
TP63	343	343	R -> Q (in EEC3).
TP63	343	343	R -> W (in EEC3).
TP63	345	345	C -> R (in EEC3; abolishes transcription activation).
TP63	347	347	C -> S (in EEC3).
TP63	348	348	P -> S (in EEC3).
TP63	351	351	D -> G (in EEC3).
TP63	351	351	D -> H (in EEC3).
TP63	352	352	R -> G (in EDRH and OFC8).
TP63	549	549	I -> T (in EDRH).
TP63	553	553	L -> F (in AEC).
TP63	560	560	S -> A (in ovarian cancer).
TP63	561	561	C -> G (in AEC).
TP63	580	580	S -> P (in EDRH).
TP63	603	603	D -> H.
ATP13A4	353	353	V -> A.
OPA1	8	8	A -> S (in OPA1).
OPA1	38	43	Missing (in OPA1).
OPA1	80	80	Y -> C (in OPA1).
OPA1	95	95	T -> M (in OPA1).
OPA1	102	102	Y -> C (in OPA1).
OPA1	167	167	P -> L.
OPA1	270	270	E -> K (in OPA1).
OPA1	272	272	L -> P (in OPA1).
OPA1	273	273	D -> A (in OPA1).
OPA1	290	290	R -> Q (in OPA1).
OPA1	290	290	R -> W (in OPA1).
OPA1	293	294	Missing (in OPA1).
OPA1	300	300	G -> E (in OPA1).
OPA1	310	310	Q -> R (in OPA1).
OPA1	324	326	Missing (in OPA1).
OPA1	357	357	A -> T (in OPA1).
OPA1	382	382	I -> M (in OPA1).
OPA1	384	384	L -> F (in OPA1).
OPA1	396	396	L -> P (in OPA1).
OPA1	396	396	L -> R (in OPA1).
OPA1	429	430	Missing (in OPA1).
OPA1	430	430	N -> D (in OPA1).
OPA1	432	432	Missing (in OPA1).
OPA1	438	438	D -> V (in OPA1).
OPA1	445	445	R -> H (in OPA1 and OPA1D).
OPA1	449	449	T -> R (in OPA1).
OPA1	463	463	I -> IFIF (in OPA1).
OPA1	468	468	K -> E (in OPA1).
OPA1	470	470	D -> G (in OPA1).
OPA1	487	487	E -> K (in OPA1).
OPA1	503	503	T -> K (in OPA1).
OPA1	505	505	K -> N (in OPA1).
OPA1	545	545	S -> R (in OPA1).
OPA1	550	550	D -> N.
OPA1	551	551	C -> Y (in OPA1).
OPA1	551	551	Missing (in OPA1).
OPA1	571	571	R -> H (in OPA1).
OPA1	574	574	L -> P (in OPA1).
OPA1	582	582	Y -> C (in OPA1D; patient presenting with ophthalmoplegia, mild myopathy and ataxia).
OPA1	586	589	Missing (in OPA1).
OPA1	590	590	R -> Q (in OPA1).
OPA1	590	590	R -> W (in OPA1).
OPA1	593	593	L -> P (in OPA1).
OPA1	646	646	S -> L (in OPA1).
OPA1	700	701	Missing (in OPA1).
OPA1	728	728	N -> K (in OPA1).
OPA1	768	768	G -> D (in OPA1).
OPA1	781	781	R -> W (in OPA1).
OPA1	785	785	Q -> R (in OPA1).
OPA1	823	823	S -> Y (in OPA1).
OPA1	841	841	Y -> C (in OPA1).
OPA1	882	882	R -> L (in OPA1).
OPA1	887	887	L -> P (in OPA1).
OPA1	907	907	E -> G.
OPA1	932	932	R -> C (in OPA1).
OPA1	939	939	L -> P (in OPA1).
OPA1	949	949	L -> P (in OPA1).
MUC20	130	376	Missing.
MUC20	184	354	Missing.
MUC20	203	354	Missing.
MUC20	241	354	Missing.
MUC20	483	533	Missing.
TNK2	34	34	R -> L (in a lung adenocarcinoma sample; somatic mutation).
TNK2	99	99	R -> Q (in an ovarian mucinous carcinoma sample; somatic mutation; undergoes autoactivation and causes phosphorylation on Tyr-284 leading to activation of AKT1).
TNK2	346	346	E -> K (in an ovarian endometrioid cancer sample; somatic mutation).
TNK2	409	409	M -> I (in a gastric adenocarcinoma sample; somatic mutation).
OGG1	12	12	G -> E (found in a kidney cancer sample; no effect on activity; abolishes mitochondrial localization).
OGG1	131	131	R -> Q (found in a lung cancer sample; loss of activity).
OGG1	232	232	S -> T (found in a kidney cancer sample).
CAMK1	217	217	P -> S (in a metastatic melanoma sample; somatic mutation).
TTLL3	454	454	G -> S (in a colorectal cancer sample, abolishes monoglycylase activity; somatic mutation).
TTLL3	476	476	M -> I (in a colorectal cancer sample, abolishes monoglycylase activity; somatic mutation).
CRELD1	162	162	P -> A (in AVSD2 susceptibility).
VHL	38	38	S -> P (in VHLD; type II).
VHL	52	52	E -> K (in VHLD; type I).
VHL	63	63	L -> P (in pheochromocytoma).
VHL	64	64	R -> P (in pheochromocytoma).
VHL	65	65	S -> A (in pheochromocytoma).
VHL	65	65	S -> L (in VHLD; type I).
VHL	65	65	S -> W (in VHLD; type I).
VHL	66	73	Missing (in VHLD; type I).
VHL	68	68	S -> W (in pheochromocytoma and VHLD; type II).
VHL	70	70	E -> K (in VHLD; type I).
VHL	75	75	Missing (in VHLD).
VHL	76	76	F -> I (in VHLD; type I).
VHL	76	76	F -> L (in VHLD; type I).
VHL	76	76	F -> S (in VHLD; type I).
VHL	76	76	Missing (in VHLD; type I; common mutation).
VHL	78	78	N -> H (in VHLD; type I).
VHL	78	78	N -> T (in VHLD; type I).
VHL	79	79	R -> P (in VHLD).
VHL	80	80	S -> I (in VHLD; type I).
VHL	80	80	S -> R (in VHLD; type I).
VHL	82	84	Missing (in VHLD).
VHL	82	82	R -> P (in VHLD; type I).
VHL	86	86	P -> A (in VHLD; type I).
VHL	86	86	P -> H (in VHLD).
VHL	86	86	P -> L (in VHLD; type I).
VHL	86	86	P -> R (in VHLD; type I).
VHL	86	86	P -> S (in VHLD).
VHL	88	88	W -> R (in VHLD; type I).
VHL	88	88	W -> S (in VHLD; type I).
VHL	89	89	L -> H (in lung cancer).
VHL	91	91	F -> L (in cerebellar hemangioblastoma).
VHL	92	97	Missing (in VHLD; type I).
VHL	93	93	G -> D (in VHLD).
VHL	96	96	Q -> P (in VHLD; type I).
VHL	101	101	L -> G (in VHLD; type I; requires 2 nucleotide substitutions).
VHL	101	101	L -> R (in VHLD; type I).
VHL	104	104	G -> A (in cerebellar hemangioblastoma).
VHL	105	105	T -> P (in VHLD; type I).
VHL	106	106	G -> D (in lung cancer).
VHL	107	107	R -> G (in pheochromocytoma).
VHL	107	107	R -> P (in VHLD; type I).
VHL	111	111	S -> C (in VHLD; type II).
VHL	111	111	S -> N (in VHLD; type I).
VHL	111	111	S -> R (in VHLD; type I).
VHL	112	112	Y -> H (in VHLD; type IIA).
VHL	112	112	Y -> N (in VHLD).
VHL	114	114	G -> C (in VHLD; type II).
VHL	114	114	G -> R (in VHLD; type I-II).
VHL	114	114	G -> S (in VHLD; type II).
VHL	115	115	H -> Q (in VHLD; type II).
VHL	116	116	L -> V (in VHLD).
VHL	117	117	W -> C (in VHLD; type I).
VHL	118	118	L -> R (in VHLD).
VHL	119	119	F -> L (in pheochromocytoma and VHLD; type II).
VHL	119	119	F -> S (in VHLD; type II).
VHL	122	122	A -> I (in pheochromocytoma; requires 2 nucleotide substitutions).
VHL	126	126	D -> Y (in ECYT2).
VHL	128	128	L -> F (in VHLD; type II).
VHL	129	129	L -> LE (in VHLD).
VHL	130	130	V -> L (in ECYT2 and VHLD; type I).
VHL	131	131	N -> K (in VHLD; type I).
VHL	131	131	N -> T (in VHLD; type I).
VHL	135	135	L -> F (in hemangioblastoma).
VHL	136	136	F -> S (in VHLD).
VHL	136	136	F -> Y (in VHLD).
VHL	143	143	D -> E (in VHLD; type II).
VHL	145	145	Q -> H (in VHLD).
VHL	147	147	I -> T (in pheochromocytoma).
VHL	148	148	Missing (in VHLD; type I).
VHL	149	149	A -> T (in VHLD; type II).
VHL	154	154	P -> L (in VHLD; type II).
VHL	155	155	V -> G (in VHLD; type II).
VHL	155	155	V -> M (in VHLD; with RCC).
VHL	156	156	Y -> C (in pheochromocytoma and VHLD; type I).
VHL	156	156	Y -> D (in VHLD; type I).
VHL	156	156	Y -> N (in pheochromocytoma).
VHL	157	157	T -> I (in VHLD; type II).
VHL	157	157	T -> TF (in VHLD; type I).
VHL	158	158	L -> P (in VHLD; type I-II; abolishes release from chaperonin complex and the interaction with Elongin BC complex).
VHL	158	158	L -> V (in VHLD; type I).
VHL	159	159	K -> E (in VHLD; type II).
VHL	161	161	R -> P (in pheochromocytoma and VHLD; type I).
VHL	161	161	R -> Q (in pheochromocytoma and VHLD; type II).
VHL	162	162	C -> F (in VHLD; type I; No effect on interaction with HIF1A nor on HIF1A degradation).
VHL	162	162	C -> R (in VHLD; type I).
VHL	162	162	C -> Y (in VHLD; type I).
VHL	164	164	Q -> H (in VHLD).
VHL	164	164	Q -> R (in VHLD; type II).
VHL	166	166	V -> D (in VHLD; with RCC).
VHL	166	166	V -> F (in VHLD; type IIA).
VHL	167	167	R -> G (in VHLD; type I-II).
VHL	170	170	V -> D (in VHLD; type II).
VHL	170	170	V -> F (in VHLD; type II).
VHL	170	170	V -> G (in VHLD; type I).
VHL	175	175	Y -> D (in VHLD; type I).
VHL	176	176	R -> W (in VHLD).
VHL	177	177	R -> RLRVKPE (in VHLD; type I).
VHL	178	178	L -> P (in VHLD; type I-II; common mutation).
VHL	180	180	I -> V (in VHLD; type I).
VHL	184	184	L -> P (in VHLD; type I).
VHL	184	184	L -> R (in VHLD; type I).
VHL	186	186	E -> K (in VHLD; type I).
VHL	186	186	Missing (in VHLD).
VHL	188	188	L -> P (in VHLD; type I-II).
VHL	188	188	L -> Q (in VHLD; type I).
VHL	198	198	L -> Q (in pheochromocytoma).
VHL	198	198	L -> R (in ECY2 and VHLD; type II).
TSEN2	309	309	Y -> C (in PCH2B).
RAF1	256	256	R -> S (in NS5).
RAF1	257	257	S -> L (in NS5 and LEOPARD2; shows in vitro greater kinase activity and enhanced ERK activation than wild-type).
RAF1	259	259	S -> A (in an ovarian serous carcinoma sample; somatic mutation).
RAF1	259	259	S -> F (in NS5).
RAF1	260	260	T -> I (in hypertrophic cardiomyopathy).
RAF1	260	260	T -> R (in NS5).
RAF1	261	261	P -> A (in NS5; shows in vitro greater kinase activity and enhanced MAPK1 activation than wild-type).
RAF1	261	261	P -> L (in NS5; shows greater kinase activity and enhanced MAPK1 activation than wild-type).
RAF1	261	261	P -> S (in NS5; shows in vitro greater kinase activity and enhanced MAPK1 activation than wild-type).
RAF1	263	263	V -> A (in NS5; shows in vitro greater kinase activity and enhanced MAPK1 activation than wild-type).
RAF1	335	335	Q -> H (in a lung adenocarcinoma sample; somatic mutation).
RAF1	486	486	D -> G (in NS5).
RAF1	486	486	D -> N (in NS5; has reduced or absent kinase activity).
RAF1	491	491	T -> I (in NS5; has reduced or absent kinase activity).
RAF1	491	491	T -> R (in NS5).
RAF1	612	612	S -> T (in NS5).
RAF1	613	613	L -> V (in NS5 and LEOPARD2; shows in vitro greater kinase activity and enhanced MAPK1 activation than wild- type).
TMEM43	358	358	S -> L (in ARVD5).
XPC	334	334	P -> H (in XP-C; severe).
XPC	513	513	M -> I.
XPC	690	690	W -> S (in XP-C; diminishes repair activity and impairs DNA binding).
XPC	697	697	V -> VV (in XP-C; mild).
COLQ	59	59	P -> Q (in CMSE; abrogates binding to T subunit).
COLQ	342	342	D -> E (in CMSE; impairs anchoring to the basal lamina).
COLQ	410	410	R -> Q (in CMSE).
COLQ	430	430	Y -> S (in CMSE).
COLQ	444	444	C -> Y (in CMSE).
BTD	128	128	F -> V (in BTD deficiency).
BTD	228	228	D -> Y (in BTD deficiency).
BTD	323	323	H -> R (in BTD deficiency; partial).
BTD	451	451	G -> D (in BTD deficiency; partial).
BTD	456	456	Q -> H (in BTD deficiency).
BTD	532	532	T -> M (in BTD deficiency).
BTD	538	538	R -> C (in BTD deficiency).
OXSM	106	106	F -> I (in a breast cancer sample; somatic mutation).
EOMES	667	667	E -> Q (in a breast cancer sample; somatic mutation).
GPD1L	83	83	E -> K (in SIDS; decreased enzymatic activity and significant reduction of sodium current when coexpressed with SCN5A in HEK cells).
GPD1L	124	124	I -> V (in SIDS; significant reduction of sodium current when coexpressed with SCN5A in HEK cells).
GPD1L	273	273	R -> C (in SIDS; significant reduction of sodium current when coexpressed with SCN5A in HEK cells).
GPD1L	280	280	A -> V (in BRS2; decreased enzymatic activity and affects SCN5A membrane expression; reduction of sodium current when coexpressed with SCN5A in HEK cells).
CCR4	130	130	L -> V.
CCR4	178	178	C -> S.
GLB1	49	49	R -> C (in GM1G1).
GLB1	49	49	R -> H (in GM1G3).
GLB1	51	51	I -> T (in GM1G3).
GLB1	59	59	R -> C (in GM1G1; protein enzymatically inactive; severe mutation).
GLB1	59	59	R -> H (in GM1G1; with cardiac involvement in some patients; protein enzymatically inactive; severe mutation).
GLB1	68	68	R -> Q (in GM1G2; 7.4% of wild-type enzyme activity).
GLB1	68	68	R -> W (in GM1G2; no enzyme activity).
GLB1	73	73	K -> E (in GM1G3).
GLB1	82	82	T -> M (in GM1G3; mild phenotype).
GLB1	83	83	Y -> C (in MPS4B).
GLB1	83	83	Y -> H (in MPS4B; 2-5% of activity).
GLB1	121	121	R -> S (in GM1G1).
GLB1	123	123	G -> R (in GM1G1).
GLB1	132	132	M -> T (in GM1G1; 4.3% of wild-type enzyme activity).
GLB1	134	134	G -> V (in GM1G1).
GLB1	136	136	P -> S (in GM1G1).
GLB1	147	147	Missing (in GM1G1).
GLB1	148	148	R -> C (in GM1G3).
GLB1	148	148	R -> S (in GM1G1).
GLB1	149	149	S -> F (in MPS4B; 2.0% of wild-type enzyme activity).
GLB1	151	151	D -> V (in GM1G1).
GLB1	151	151	D -> Y (in GM1G1; complete lack of protein; no enzymatic activity).
GLB1	155	155	L -> R (in GM1G2 and GM1G3; 6.7% of wild- type enzyme activity).
GLB1	162	162	L -> S (in GM1G1).
GLB1	173	173	L -> P (in GM1G1).
GLB1	184	184	Q -> R (in GM1G1; no enzymatic activity).
GLB1	190	190	G -> D (in GM1G1; 3.4% of wild-type enzyme activity).
GLB1	198	198	D -> Y (in MPS4B; 17.4% of wild-type enzyme activity).
GLB1	199	199	Y -> C (in GM1G1).
GLB1	201	201	R -> C (in GM1G1 and GM1G2; 8.4% of wild- type enzyme activity; activity severely reduced in transfection with the F-436 polymorphism).
GLB1	201	201	R -> H (in GM1G2; 36.2% of wild-type enzyme activity; also in GM1G1 and a patient with a slowly progressive GM1- gangliosidosis form).
GLB1	208	208	R -> C (in GM1G1).
GLB1	214	214	D -> Y (in GM1G3).
GLB1	216	216	V -> A (in GM1G1).
GLB1	239	239	T -> M (in GM1G1; protein enzymatically inactive; severe mutation; causes a rapid degradation of the protein precursor).
GLB1	240	240	V -> M (in GM1G1).
GLB1	255	255	Q -> H (in GM1G1; 2.4% of wild-type enzyme activity).
GLB1	263	263	P -> S (in GM1G3).
GLB1	264	264	L -> S (in GM1G2).
GLB1	266	266	N -> S (in GM1G3).
GLB1	270	270	Y -> D (in GM1G3; originally classified as Morquio syndrome).
GLB1	272	272	G -> D (in GM1G1).
GLB1	273	273	W -> L (in MPS4B; 8% of activity).
GLB1	281	281	H -> Y (in GM1G1 and GM1G3).
GLB1	316	316	Y -> C (in GM1G1).
GLB1	318	318	N -> H (in GM1G1; uncertain pathogenicity).
GLB1	329	329	T -> I (in GM1G1; 5.0% of wild-type enzyme activity).
GLB1	332	332	D -> E (in GM1G1; 2.3% of wild-type enzyme activity).
GLB1	332	332	D -> N (in GM1G1).
GLB1	333	333	Y -> H (in GM1G2; 3.0% of wild-type enzyme activity; the mutant protein is localized in the lysosomal-endosomal compartment).
GLB1	346	346	K -> N (in GM1G1).
GLB1	347	347	Y -> C (in GM1G1).
GLB1	377	381	Missing (in GM1G1).
GLB1	397	397	P -> A (in MPS4B; 24.0% of wild-type enzyme activity).
GLB1	408	408	Q -> P (in MPS4B; 1.1% of wild-type enzyme activity).
GLB1	420	420	T -> K (in GM1G3).
GLB1	420	420	T -> P (in GM1G1).
GLB1	422	422	L -> R (in GM1G1).
GLB1	434	434	S -> L (in GM1-gangliosidosis; unclassified clinical type).
GLB1	438	438	G -> E (in GM1G3 and MPS4B; mild form; 5.7% of activity).
GLB1	441	441	D -> N (in GM1G1).
GLB1	442	442	R -> Q (in GM1G1).
GLB1	444	444	Y -> C (in MPS4B).
GLB1	457	457	R -> Q (in GM1G3).
GLB1	482	482	R -> C (in MPS4B; loss of activity).
GLB1	482	482	R -> H (in MPS4B and GM1G1; loss of activity).
GLB1	484	484	N -> K (in MPS4B; mild form; 1.9% of activity).
GLB1	491	491	D -> N (in GM1G1).
GLB1	491	491	D -> Y (in GM1G1).
GLB1	494	494	G -> C (in GM1G1).
GLB1	494	494	G -> S (in MPS4B).
GLB1	500	500	T -> A (in MPS4B; mild form; 2.1% of activity).
GLB1	509	509	W -> C (in MPS4B; also in a patient with a slowly progressive form of GM1- gangisidosis; loss of activity).
GLB1	532	532	S -> G.
GLB1	549	549	P -> L (in GM1G1).
GLB1	554	554	G -> E (in GM1-gangliosidosis; unclassified clinical type).
GLB1	578	578	K -> R (in GM1G1).
GLB1	579	579	G -> D (in GM1G1 and GM1G2; protein enzymatically inactive; severe mutation).
GLB1	590	590	R -> C (in GM1G1).
GLB1	590	590	R -> H (in GM1G2).
GLB1	591	591	Y -> C (in GM1G1; with cardiac involvement in some patients; protein enzymatically inactive; severe mutation; causes a rapid degradation of the protein precursor).
GLB1	591	591	Y -> N (in GM1G1; with cardiac involvement in some patients; protein enzymatically inactive; severe mutation; causes a rapid degradation of the protein precursor).
GLB1	595	595	R -> W (reduction of activity).
GLB1	597	597	P -> S (in GM1G1; 2.1% of wild-type enzyme activity).
GLB1	632	632	E -> G (in GM1G2).
DCLK3	108	108	P -> L (in a breast infiltrating ductal carcinoma sample; somatic mutation).
DCLK3	422	422	E -> K (in a colorectal adenocarcinoma sample; somatic mutation).
DCLK3	472	472	S -> N (in a lung large cell carcinoma sample; somatic mutation).
DCLK3	554	554	R -> C (in a lung squamous cell carcinoma sample; somatic mutation).
DCLK3	570	570	G -> R (in a renal clear cell carcinoma sample; somatic mutation).
DCLK3	596	596	V -> A (in a colorectal adenocarcinoma sample; somatic mutation).
MYD88	93	93	L -> P (in MYD88D; results in a loss of function).
MYD88	196	196	R -> C (in MYD88D; results in a loss of function).
ACVR2B	40	40	R -> H (in HTX4).
ACVR2B	494	494	V -> I (in HTX4).
XIRP1	929	929	L -> H (in a breast cancer sample; somatic mutation).
XIRP1	1634	1634	R -> K (in a breast cancer sample; somatic mutation).
SLC25A38	130	130	G -> E (in PRARSA).
SLC25A38	134	134	R -> H (in PRARSA).
SLC25A38	187	187	R -> P (in PRARSA).
SLC25A38	209	209	D -> H (in PRARSA).
CTNNB1	23	23	S -> R (in hepatocellular carcinoma; no effect).
CTNNB1	25	33	Missing (in hepatocellular carcinoma).
CTNNB1	32	32	D -> A (in hepatocellular carcinoma).
CTNNB1	32	32	D -> G (in PTR and hepatocellular carcinoma).
CTNNB1	33	33	S -> F (in PTR, MDB and hepatocellular carcinoma).
CTNNB1	33	33	S -> L (in hepatocellular carcinoma).
CTNNB1	33	33	S -> Y (in colorectal cancer and PTR; enhances transactivation of target genes).
CTNNB1	34	34	G -> E (in PTR).
CTNNB1	34	34	G -> R (in hepatocellular carcinoma).
CTNNB1	35	35	I -> S (in hepatocellular carcinoma).
CTNNB1	37	38	SG -> W (in hepatocellular carcinoma).
CTNNB1	37	37	S -> A (in MDB and hepatocellular carcinoma; enhances transactivation of target genes).
CTNNB1	37	37	S -> C (in PTR, hepatoblastoma and ovarian cancer).
CTNNB1	37	37	S -> F (in PTR).
CTNNB1	37	37	S -> Y (in hepatocellular carcinoma).
CTNNB1	41	41	T -> A (in hepatoblastoma and hepatocellular carcinoma; also in a desmoid tumor; strongly reduces phosphorylation and degradation; abolishes phosphorylation on Ser-33 and Ser-37 and enhances transactivation of target genes).
CTNNB1	41	41	T -> I (in PTR, hepatocellular carcinoma and ovarian cancer).
CTNNB1	45	45	S -> F (in hepatocellular carcinoma).
CTNNB1	45	45	S -> P (in hepatocellular carcinoma).
CTNNB1	45	45	Missing (in colorectal cancer).
CYP8B1	234	234	R -> H.
ABHD5	7	7	E -> K (in CDS).
ABHD5	82	82	H -> R (found in a patient with CDS but without evidence it may cause the disease).
ABHD5	115	115	S -> G (in CDS).
CLEC3B	55	55	A -> S.
CLEC3B	58	58	V -> M.
CXCR6	25	25	D -> A (in STRL33.3).
CCR5	10	10	Y -> D (in INCCR5-71A) (No sulfation and greatly decreased binding CCL4 and CCL5; when associated with D-3; D-10 and D-15. Restored most CCL4 binding; when associated with D-3 and D-15).
CCR5	12	12	I -> L.
CCR5	20	20	C -> S.
CCR5	34	34	P -> L (in TZCCR5-179).
CCR5	42	42	I -> F.
CCR5	62	62	K -> R (in UGCCR5-145B).
CCR5	68	68	Y -> H (in ZWCCR5-7).
CCR5	95	95	D -> N (in MWCCR5-107).
CCR5	97	97	G -> E (in INCCR5-467).
CCR5	122	122	L -> P (in ZWCCR5-7).
CCR5	158	158	F -> S (in UGCCR5-145A).
CCR5	176	176	Y -> C (in KECCR5-116).
CCR5	177	177	T -> A (in INCCR5-45C).
CCR5	178	178	C -> R (found in a HIV-resistant individiual).
CCR5	185	185	S -> N (in UGCCR5-145A).
CCR5	210	210	M -> V (in ZWCCR5-7).
CCR5	214	214	Y -> C (in KECCR5-3B).
CCR5	215	215	S -> L.
CCR5	228	228	Missing.
CCR5	239	239	T -> S (in INCCR5-71A).
CCR5	246	246	L -> P (in UGCCR5-145A).
CCR5	288	288	T -> M (in INCCR5-72A).
CCR5	302	302	E -> G (in TZCCR5-179).
CCR5	303	303	K -> E (in THCCR5-5).
CCR5	306	306	N -> S (in MWCCR5-1567).
CCR5	322	322	K -> R (in THCCR5-5).
CCR5	333	333	E -> G (in THCCR5-2).
CCR5	345	345	E -> G (in UGCCR5-145C).
ALS2CL	280	280	Q -> E (in a breast cancer sample; somatic mutation).
ALS2CL	576	576	L -> F (in a breast cancer sample; somatic mutation).
MYL3	56	56	E -> G (in CMH8).
MYL3	143	143	E -> K (in CMH8; autosomal recessive).
MYL3	149	149	M -> V (in MVC1).
MYL3	154	154	R -> H (in MVC1).
PLXNB1	1891	1891	D -> V (in a breast cancer sample; somatic mutation).
TREX1	73	73	D -> N (in CHBL and AGS1; loss of function).
TREX1	169	169	R -> H (in AGS1 and systemic lupus erythematosus).
TREX1	213	213	A -> V (in systemic lupus erythematosus).
TREX1	255	255	D -> DD (in AGS1; heterozygous compound with H-169).
TREX1	255	255	D -> N (in AGS1; autosomal dominant form; does not affect activity).
TREX1	256	256	V -> D (in AGS1).
TREX1	282	282	G -> S (in systemic lupus erythematosus; associated in cis with P-302).
TREX1	295	295	R -> S (in systemic lupus erythematosus).
TREX1	302	302	A -> P (in systemic lupus erythematosus; associated in cis with S-282).
TREX1	345	345	P -> L (in systemic lupus erythematosus).
TREX1	360	360	Y -> C (in systemic lupus erythematosus).
TREX1	361	361	G -> A (in systemic lupus erythematosus).
PFKFB4	181	181	N -> K (in a breast cancer sample; somatic mutation).
UQCRC1	301	301	N -> S.
SLC25A20	133	133	R -> W (in CACT deficiency).
SLC25A20	231	231	D -> H (in CACT deficiency).
NDUFAF3	77	77	G -> R (in MT-C1D).
NDUFAF3	122	122	R -> P (in MT-C1D).
LAMB2	246	246	R -> Q (in CONPHS; without ocular abnormalities).
LAMB2	246	246	R -> W (in PIERSS).
LAMB2	321	321	C -> R (in CONPHS; with mild ocular abnormalities).
LAMB2	1380	1380	N -> K (in CONPHS; with mild ocular abnormalities; associated with F-1393).
LAMB2	1393	1393	L -> F (in CONPHS; with mild ocular abnormalities; associated with K-1380).
GPX1	7	8	Missing.
GPX1	8	8	Missing.
GPX1	194	194	A -> T.
AMT	42	42	H -> R (in NKH).
AMT	47	47	G -> R (in NKH).
AMT	145	145	N -> I (in NKH).
AMT	211	211	E -> K (in NKH).
AMT	269	269	G -> D (in NKH).
AMT	276	276	D -> H (in NKH).
AMT	320	320	R -> H (in NKH).
MST1	13	13	C -> Y.
MST1	212	212	C -> F.
CAMKV	40	40	R -> W (in a colorectal adenocarcinoma sample; somatic mutation).
CAMKV	60	60	G -> S (in an ovarian serous carcinoma sample; somatic mutation).
CAMKV	274	274	R -> W (in a colorectal adenocarcinoma sample; somatic mutation).
GNAT1	38	38	G -> D (in CSNBAD3; in the Nougaret family descendants).
SEMA3B	348	348	R -> C (in a non-small cell lung cancer cell line).
SEMA3B	397	397	D -> H (in a non-small cell lung cancer cell line).
HYAL1	268	268	E -> K (in MPS9).
RASSF1	53	53	R -> C.
RASSF1	133	133	D -> E.
RASSF1	135	135	S -> F (prevents G1 cell cycle arrest; reduced protein phosphorylation).
RASSF1	329	329	Y -> C.
ZMYND10	407	407	R -> Q (in non-small cell lung cancer cell lines).
MAPKAPK3	28	28	P -> S (in a glioblastoma multiforme sample; somatic mutation).
MAPKAPK3	105	105	E -> A (in an ovarian endometrioid sample; somatic mutation).
RRP9	8	8	R -> G (in a breast cancer sample; somatic mutation).
RRP9	342	342	A -> E (in a breast cancer sample; somatic mutation).
ACY1	197	197	R -> W (in ACY1D; loss of activity).
ACY1	233	233	E -> D (in ACY1D; loss of activity).
ACY1	353	353	R -> C (in ACY1D; loss of activity).
ACY1	378	378	R -> Q (in ACY1D).
ACY1	378	378	R -> W (in ACY1D; slightly reduced activity).
ACY1	381	381	E -> D (in a breast cancer sample; somatic mutation).
ACY1	393	393	R -> H (in ACY1D).
TLR9	901	901	R -> H (in a colorectal cancer sample; somatic mutation).
TLR9	933	933	T -> M (in a colorectal cancer sample; somatic mutation).
BAP1	95	95	A -> D (in a lung cancer sample; impairs deubiquitinase activity).
BAP1	178	178	G -> V (in a lung cancer sample; impairs deubiquitinase activity).
PHF7	369	369	K -> N (in a breast cancer sample; somatic mutation).
TNNC1	8	8	A -> V (in CMH13; increases calcium sensitivity of the myofilaments).
TNNC1	29	29	L -> Q (in CMH13; impairs protein kinase A dependent signaling from cardiac troponin I to troponin C).
TNNC1	84	84	C -> Y (in CMH13; increases calcium sensitivity of the myofilaments).
TNNC1	134	134	E -> D (in CMH13; no changes in calcium sensitivity of the myofilaments).
TNNC1	145	145	D -> E (in CMH13; increases calcium sensitivity of the myofilaments).
TNNC1	159	159	G -> R (in CMD1Z).
NEK4	777	777	R -> K (in a colorectal adenocarcinoma sample; somatic mutation).
ITIH4	86	86	I -> N.
RFT1	67	67	R -> C (in CDG1N).
RFT1	152	152	K -> E (in CDG1N).
RFT1	298	298	E -> K (in CDG1N).
HESX1	6	6	Q -> H (in CPHD5).
HESX1	26	26	I -> T (in CPHD5; the mutated protein is associated with impaired transcriptional repression but not DNA binding).
HESX1	149	149	E -> K (in GHDPA; unable to repress PROP1-mediated activation).
HESX1	170	170	S -> L (in SOD; mild).
HESX1	181	181	T -> A (in GHDPA).
PDHB	31	31	L -> V.
FEZF2	188	188	G -> D (in a patient with amyotrophic lateral sclerosis).
KBTBD8	198	198	S -> C (in a breast cancer sample; somatic mutation).
KBTBD8	405	405	R -> K (in a breast cancer sample; somatic mutation).
POU1F1	24	24	P -> L (in CPHD1).
POU1F1	135	135	F -> C (in CPHD1).
POU1F1	143	143	R -> Q (in CPHD1).
POU1F1	158	158	A -> P (in CPHD1).
POU1F1	172	172	R -> Q (in CPHD1; associated with severe impairment of transactivation; has a greatly reduced DNA-binding affinity as the wild-type protein).
POU1F1	174	174	E -> G (in CPHD1).
POU1F1	179	179	S -> R (in CPHD1; transactivation capacity of this mutant is markedly decreased on the GH1, PRL, TSHB and POU1F1 genes; abolishes the functional interaction of POU1F1 on the PRL promoter with the coactivator CREBBP but not with the transcription factor LHX3; displays normal nuclear accumulation but a markedly decreased binding to a DNA response element).
POU1F1	193	193	W -> R (in CPHD1).
POU1F1	230	230	E -> K (in CPHD1; associated with less severe impairment of transactivation; has a similar DNA-binding affinity as the wild-type protein).
POU1F1	239	239	P -> S (in CPHD1; loss of function).
POU1F1	271	271	R -> W (in CPHD1).
PROS1	15	15	L -> H (in PROS1D).
PROS1	18	18	V -> E (in PROS1D; expresses very low/ undetectable PROS1 levels compared to wild-type; has impaired secretion; intracellular degradation of unsecreted material is found).
PROS1	41	41	R -> H (in PROS1D).
PROS1	50	50	K -> E (in PROS1D).
PROS1	52	52	G -> D (in PROS1D; does not affect PROS1 production but results in 15.2-fold reduced PROS1 activity; has 5.4 fold reduced affinity for anionic phospholipid vesicles (P < 0.0001) and decreased affinity for an antibody specific for the Ca(2+)-dependent conformation of the PROS1 Gla domain).
PROS1	67	67	E -> A (in PROS1D).
PROS1	68	68	A -> D (in PROS1D).
PROS1	72	72	F -> C (in PROS1D).
PROS1	76	76	P -> L.
PROS1	87	87	V -> L (in PROS1D).
PROS1	88	88	C -> Y (in PROS1D).
PROS1	90	90	R -> C (in PROS1D; produces around 50% of PROS1 levels compared to wild-type; has impaired secretion; intracellular degradation of unsecreted material is found).
PROS1	90	90	R -> H (in PROS1D).
PROS1	95	95	G -> E (in PROS1D).
PROS1	95	95	G -> R (in PROS1D; the activated protein cofactor activity is inhibited by C4BPB with a dose dependency similar to that of wild-type PROS1).
PROS1	98	98	T -> S.
PROS1	101	101	R -> C (in PROS1D).
PROS1	111	111	R -> S (in PROS1D).
PROS1	121	121	C -> Y (in PROS1D).
PROS1	129	129	D -> G (in PROS1D).
PROS1	144	144	T -> N (in PROS1D).
PROS1	149	149	W -> C (in PROS1D).
PROS1	157	157	D -> G (in PROS1D).
PROS1	161	161	C -> G (in PROS1D).
PROS1	166	166	N -> Y (in PROS1D).
PROS1	168	168	N -> S.
PROS1	175	175	C -> F (in PROS1D).
PROS1	186	186	C -> Y (in PROS1D).
PROS1	196	196	K -> E (in PROS1D; Tokushima; the specific activity decreases to 58% of that of the wild-type PROS1; the activated protein cofactor activity is inhibited by C4BPB with a dose dependency similar to that of wild-type PROS1).
PROS1	204	204	E -> G (in PROS1D).
PROS1	241	241	C -> S (in PROS1D).
PROS1	243	243	D -> N (in PROS1D).
PROS1	245	245	D -> G (in PROS1D).
PROS1	247	247	C -> G (in PROS1D).
PROS1	249	249	E -> K (in PROS1D).
PROS1	258	258	N -> S (in PROS1D; produces around 30% of PROS1 levels compared to wild-type; has impaired secretion; intracellular degradation of unsecreted material is found).
PROS1	265	265	C -> R (in PROS1D).
PROS1	265	265	C -> W (in PROS1D).
PROS1	266	266	Y -> C (in PROS1D).
PROS1	267	267	C -> S (in PROS1D).
PROS1	300	300	L -> P (in PROS1D).
PROS1	324	324	S -> P (in PROS1D).
PROS1	336	336	G -> D (in PROS1D).
PROS1	336	336	G -> S (in PROS1D).
PROS1	336	336	G -> V (in PROS1D; expresses very low/ undetectable PROS1 levels compared to wild-type; has impaired secretion; intracellular degradation of unsecreted material is found).
PROS1	339	339	L -> P (in PROS1D).
PROS1	351	351	L -> P (in PROS1D).
PROS1	355	355	R -> H (in PROS1D).
PROS1	357	357	G -> R (in PROS1D).
PROS1	364	364	K -> E (in PROS1D).
PROS1	376	376	D -> N (in PROS1D).
PROS1	381	381	G -> D (in PROS1D).
PROS1	381	381	G -> V (in PROS1D).
PROS1	383	383	W -> R (in PROS1D).
PROS1	385	385	M -> V.
PROS1	390	390	E -> K (in PROS1D).
PROS1	446	446	L -> P (in PROS1D).
PROS1	449	449	C -> S (in PROS1D).
PROS1	475	475	C -> R (in PROS1D).
PROS1	482	482	G -> C (in PROS1D).
PROS1	485	485	Y -> C (in PROS1D).
PROS1	501	501	S -> A (in PROS1D).
PROS1	501	501	S -> P (variant Heerlen; could be associated with PROS1D).
PROS1	508	508	V -> G (in PROS1D).
PROS1	508	508	V -> M (in PROS1D).
PROS1	515	515	R -> C (in PROS1D; secretion of the mutant markedly decreased compared with that of the wild-type; intracellular degradation and impaired secretion of the mutant).
PROS1	515	515	R -> P (in PROS1D).
PROS1	521	521	G -> D (in PROS1D).
PROS1	525	525	A -> P (in PROS1D).
PROS1	526	526	L -> S (in PROS1D).
PROS1	532	532	T -> A (in PROS1D).
PROS1	545	545	E -> G (in a colorectal cancer sample; somatic mutation).
PROS1	552	552	L -> S (in PROS1D).
PROS1	559	559	I -> M.
PROS1	561	561	R -> G (in PROS1D).
PROS1	562	562	I -> L (in PROS1D; could be a polymorphism).
PROS1	568	568	C -> Y (in PROS1D).
PROS1	575	575	L -> R (in PROS1D).
PROS1	583	583	N -> H.
PROS1	584	584	L -> Q (in PROS1D).
PROS1	611	611	M -> K (in PROS1D).
PROS1	611	611	M -> T (in PROS1D).
PROS1	616	616	A -> P (in PROS1D).
PROS1	622	622	L -> R (in PROS1D).
PROS1	630	630	T -> I (in PROS1D; the activated protein cofactor activity is inhibited by C4BPB with a dose dependency similar to that of wild-type PROS1).
PROS1	636	636	Y -> C (in PROS1D; shows intracellular degradation and decreased secretion).
PROS1	638	638	G -> D (in PROS1D).
PROS1	639	639	C -> F (in PROS1D).
PROS1	639	639	C -> Y (in PROS1D).
PROS1	640	640	M -> T (in PROS1D).
PROS1	644	644	I -> S (in PROS1D).
PROS1	664	664	H -> P (in PROS1D; expresses very low/ undetectable PROS1 levels compared to wild-type; has impaired secretion; intracellular degradation of unsecreted material is found).
PROS1	665	665	S -> L (in PROS1D).
PROS1	666	666	C -> R (in PROS1D).
PROS1	667	667	P -> L (in PROS1D).
TFG	149	149	A -> S (in a colorectal cancer sample; somatic mutation).
IMPG2	124	124	F -> L (in MACLP-IMPG2).
IMPG2	1013	1013	P -> L.
TMEM39A	247	247	S -> L (in a breast cancer sample; somatic mutation).
PLA1A	110	110	R -> H.
NR1I2	36	36	G -> R (in allele PXR*3).
NR1I2	98	98	R -> C.
NR1I2	122	122	R -> Q (in allele PXR*4; rare polymorphism).
NR1I2	148	148	R -> Q.
NR1I2	381	381	R -> W.
NR1I2	403	403	I -> V.
HGD	25	25	L -> P (in AKU).
HGD	42	42	E -> A (in AKU).
HGD	60	60	W -> G (in AKU).
HGD	62	62	Y -> C (in AKU).
HGD	97	97	W -> G (in AKU).
HGD	122	122	A -> D (in AKU).
HGD	153	153	D -> G (in AKU).
HGD	168	168	E -> K (in AKU; loss of activity).
HGD	189	189	S -> I (in AKU).
HGD	216	216	I -> T (in AKU).
HGD	225	225	R -> H (in AKU).
HGD	227	227	F -> S (in AKU).
HGD	230	230	P -> T (in AKU).
HGD	270	270	G -> R (in AKU).
HGD	291	291	D -> E (in AKU).
HGD	300	300	V -> G (in AKU).
HGD	330	330	R -> S (in AKU).
HGD	368	368	M -> V (in AKU; loss of activity).
HGD	371	371	H -> R (in AKU).
GOLGB1	348	348	Q -> H (in a breast cancer sample; somatic mutation).
GOLGB1	944	944	A -> G (in a breast cancer sample; somatic mutation).
ILDR1	97	97	R -> Q (in DFNB42).
ILDR1	453	453	R -> Q (in DFNB42; uncertain pathological significance).
ILDR1	463	463	R -> C.
CASR	11	11	L -> S (in FHH; demonstrates reduced intracellular and plasma membrane expression and signaling to the MAPK pathway in response to extracellular calcium relative to wild-type; fails to be inserted in the microsomes and does not undergo proper glycosylation).
CASR	13	13	L -> P (in FHH; has a dose-response curve shifted to the right relative to that of wild-type; demonstrates reduced intracellular and plasma membrane expression and signaling to the MAPK pathway in response to extracellular calcium relative to wild-type; fails to be inserted in the microsomes and does not undergo proper glycosylation).
CASR	14	14	T -> A (does not demonstrate reduced intracellular and plasma membrane expression and signaling to the MAPK pathway in response to extracellular calcium relative to wild-type; does not fail to be inserted in the microsomes and does undergo proper glycosylation).
CASR	21	21	G -> R (could be associated with FHH).
CASR	27	27	Q -> R (found in a patient with primary hyperparathyroidism detected at adulthood; mutant CASR is activated by a higher calcium concentrations than the wild-type).
CASR	39	39	P -> A (in FHH).
CASR	47	47	K -> N (in FIH; the EC(50) of the mutant is significantly lower than that of wild- type).
CASR	62	62	R -> M (in FHH and NSHPT; mild).
CASR	66	66	R -> C (in FHH).
CASR	100	100	T -> I (found in a patient with primary hyperparathyroidism detected at adulthood).
CASR	116	116	A -> T (in FIH).
CASR	118	118	N -> K (in FIH; also in sporadic hypoparathyroidism; the mutation shifts the concentration-response curve to the left and increases maximal activity).
CASR	125	125	L -> P (in FIH; shifts the concentration- response curve of calcium ions to the left).
CASR	127	127	E -> A (in ADH).
CASR	128	128	F -> L (in FIH; there is a shift in the dose-response curve so that the extracellular calcium concentration needed to produce half-maximal increase in total inositol phosphate in the cells is significantly lower than the one required for the wild-type receptor).
CASR	131	131	C -> W (in FIH; associated with clinical features of Bartter syndrome).
CASR	138	138	T -> M (in FHH).
CASR	143	143	G -> E (in FHH).
CASR	151	151	T -> M (in FIH; there is a shift in the dose-response curve so that the extracellular calcium concentration needed to produce half-maximal increase in total inositol phosphate in the cells is significantly lower than the one required for the wild-type receptor).
CASR	171	171	S -> N (could be associated with FHH).
CASR	174	174	L -> R (in FHH).
CASR	180	180	F -> C (in FHH; although the mutant receptor is expressed normally at the cell surface it is unresponsive with respect to intracellular signaling (MAPK activation) to increases in extracellular calcium concentrations).
CASR	185	185	R -> Q (in FHH).
CASR	191	191	E -> K (in FIH; there is a shift in the dose-response curve so that the extracellular calcium concentration needed to produce half-maximal increase in total inositol phosphate in the cells is significantly lower than the one required for the wild-type receptor).
CASR	221	221	P -> Q (could be associated with FHH).
CASR	225	225	K -> T (could be associated with FHH).
CASR	227	227	R -> Q (in FHH; impaired in their MAPK response to increasing extracellular calcium concentrations; less markedly impaired relative to wild-type then Leu- 227; when cotransfected with wild-type the curve is right-shifted intermediate to the curve for wild-type).
CASR	250	250	E -> K (could be associated with FHH).
CASR	271	271	S -> F (could be associated with FHH).
CASR	297	297	E -> K (in FHH and NSHPT).
CASR	336	336	Missing (found in a patient with primary hyperparathyroidism detected at adulthood).
CASR	339	339	P -> T (mutation found in a patient with primary hyperparathyroidism detected at adulthood; inactivating mutation; mutant CASR is activated by a higher calcium concentrations than the wild-type).
CASR	354	354	E -> A (in IGE8; patients present juvenile myoclonus epilepsy).
CASR	397	397	G -> R (could be associated with FHH).
CASR	465	465	R -> Q (in FHH; loss-of-function mutation; the quantity of the mutant receptor is higher than that of the wild- type receptor; dose-response curves show that the mutation significantly reduces the sensitivity of the receptor to extracellular calcium concentrations).
CASR	509	509	G -> R (could be associated with FHH).
CASR	553	553	G -> R (in FHH).
CASR	555	555	I -> V (could be associated with FHH).
CASR	557	557	G -> E (in FHH).
CASR	562	562	C -> Y (could be associated with FHH).
CASR	582	582	C -> F (in FHH).
CASR	582	582	C -> Y (in NSHPT).
CASR	604	604	E -> K (in FIH; there is a significant leftward shift in the concentration response curves for the effects of extracellular calcium on both intracellular calcium mobilization and MAPK activity).
CASR	612	612	F -> S (in FIH).
CASR	616	616	L -> V (in FIH; does not affect the total accumulation of inositol phosphates as a function of extracellular calcium concentrations in transfected cells).
CASR	623	623	G -> D (could be associated with FHH).
CASR	650	650	L -> P (found in a patient with primary hyperparathyroidism detected at adulthood).
CASR	670	670	G -> E (in NSHPT).
CASR	670	670	G -> R (could be associated with FHH).
CASR	681	681	Q -> H (in FIH).
CASR	686	686	I -> V (in IGE8; patients present juvenile myoclonus epilepsy).
CASR	689	689	V -> M (found in a patient with primary hyperparathyroidism detected at adulthood).
CASR	697	697	V -> M (in FHH).
CASR	727	727	L -> Q (in FIH; the mutant receptor demonstrates a significant leftward shift in the extracellular calcium/ intracellular signaling dose-response curve versus that for the wild-type receptor).
CASR	728	728	V -> F (could be associated with FHH).
CASR	742	742	W -> R (could be associated with FHH).
CASR	767	767	E -> K (in ADH).
CASR	773	773	L -> R (in hypoparathyroidism; sporadic; the mutation shifts the concentration- response curve to the left and increases maximal activity).
CASR	788	788	F -> C (in FIH; leftward shift in the concentration-response curve for the mutant receptor; cells cotransfected with both the wild-type and the mutant receptor show an EC(50) similar to the mutant; a gain-of-function mutation rendering the receptor more sensitive than normal to activation).
CASR	788	788	F -> L (in FIH; induces a significant shift to the left relative to the wild- type protein in the MAPK response to increasing extracellular calcium concentrations).
CASR	795	795	R -> W (in FHH).
CASR	806	806	F -> S (in FIH; mild shift of the concentration-response curve to tne left but the change in EC(50) does not reach statistical significance).
CASR	820	820	S -> F (in FIH; the concentration- response curve of the mutant receptor is left-shifted and its EC(50) is significantly lower than that of the wild-type).
CASR	843	843	A -> E (in FIH; also in FIH associated with clinical features of Bartter syndrome; shifts the concentration- response curve of calcium ions to the left).
CASR	851	851	C -> S.
CASR	881	881	F -> L (in FHH; mutant CASR has a right- shifted dose-response to extracellular calcium concentrations; activated by a higher calcium concentrations than the wild-type).
CASR	886	886	R -> W (could be associated with FHH).
CASR	898	898	R -> Q (in IGE8).
CASR	988	988	A -> G (in IGE8; patients present juvenile myoclonus epilepsy).
CASR	988	988	A -> V (in IGE8; patients present juvenile myoclonus epilepsy).
UMPS	96	96	R -> G (in ORAC1).
UMPS	109	109	V -> G (in ORAC1).
UMPS	429	429	G -> R (in ORAC1).
GP9	7	7	L -> P (in BSS).
GP9	37	37	D -> G (in BSS).
GP9	71	71	F -> S (in BSS).
GP9	113	113	C -> Y (in BSS).
RHO	4	4	T -> K (in RP4).
RHO	15	15	N -> S (in RP4).
RHO	17	17	T -> M (in RP4).
RHO	23	23	P -> H (in RP4; most common variant, leads to interaction with EDEM1 followed by degradation by the ERAD system).
RHO	23	23	P -> L (in RP4).
RHO	28	28	Q -> H (in RP4).
RHO	40	40	L -> R (in RP4).
RHO	44	44	M -> T (in RP4).
RHO	45	45	F -> L (in RP4).
RHO	46	46	L -> R (in RP4).
RHO	51	51	G -> A.
RHO	51	51	G -> R (in RP4).
RHO	51	51	G -> V (in RP4).
RHO	68	71	Missing (in RP4).
RHO	87	87	V -> D (in RP4).
RHO	89	89	G -> D (in RP4).
RHO	90	90	G -> D (in CSNBAD1).
RHO	94	94	T -> I (in CSNBAD1).
RHO	104	104	V -> I.
RHO	106	106	G -> W (in RP4).
RHO	109	109	G -> R (in RP4).
RHO	110	110	C -> F (in RP4).
RHO	110	110	C -> Y (in RP4).
RHO	114	114	G -> D (in RP4).
RHO	125	125	L -> R (in RP4).
RHO	127	127	S -> F (in RP4).
RHO	131	131	L -> P (in RP4).
RHO	135	135	R -> G (in RP4).
RHO	135	135	R -> L (in RP4).
RHO	135	135	R -> W (in RP4).
RHO	140	140	C -> S (in RP4).
RHO	150	150	E -> K (in RP4; autosomal recessive).
RHO	164	164	A -> E (in RP4).
RHO	164	164	A -> V (in RP4).
RHO	167	167	C -> R (in RP4).
RHO	171	171	P -> L (in RP4).
RHO	171	171	P -> Q (in RP4).
RHO	171	171	P -> S (in RP4).
RHO	178	178	Y -> C (in RP4).
RHO	178	178	Y -> N (in RP4).
RHO	181	181	E -> K (in RP4).
RHO	182	182	G -> S (in RP4).
RHO	186	186	S -> P (in RP4).
RHO	188	188	G -> E (in RP4).
RHO	188	188	G -> R (in RP4).
RHO	190	190	D -> G (in RP4).
RHO	190	190	D -> Y (in RP4).
RHO	209	209	V -> M (effect not known).
RHO	211	211	H -> R (in RP4).
RHO	216	216	M -> K (in RP4).
RHO	220	220	F -> C (in RP4).
RHO	222	222	C -> R (in RP4).
RHO	255	255	Missing (in RP4).
RHO	264	264	Missing (in RP4).
RHO	267	267	P -> L (in RP4).
RHO	267	267	P -> R (in RP4).
RHO	292	292	A -> E (in CSNBAD1).
RHO	297	297	S -> R (in RP4).
RHO	342	342	T -> M (in RP4).
RHO	345	345	V -> L (in RP4).
RHO	345	345	V -> M (in RP4).
RHO	347	347	P -> A (in RP4).
RHO	347	347	P -> L (in RP4; common variant).
RHO	347	347	P -> Q (in RP4).
FOXL2	58	58	S -> L (in BPES; sporadic; nuclear and cytoplasmic aggregation; impaired transactivation activity).
FOXL2	63	63	I -> T (in BPES).
FOXL2	65	65	M -> V (in BPES).
FOXL2	66	66	A -> V (in BPES; nuclear and cytoplasmic aggregation; impaired transactivation activity).
FOXL2	69	69	E -> K (in BPES; sporadic; nuclear aggregation; normal transactivation activity).
FOXL2	80	80	I -> T (in BPES; nuclear and cytoplasmic aggregation; impaired transactivation activity).
FOXL2	84	84	I -> N (in BPES; nuclear and cytoplasmic aggregation; impaired transactivation activity).
FOXL2	85	85	Missing (in BPES; sporadic).
FOXL2	90	90	F -> S (in BPES; nuclear and cytoplasmic aggregation; impaired transactivation activity).
FOXL2	98	98	W -> G (in BPES; nuclear and cytoplasmic aggregation; impaired transactivation activity).
FOXL2	98	98	W -> R (in BPES).
FOXL2	101	101	S -> R (in BPES; nuclear aggregation; impaired transactivation activity).
FOXL2	102	102	I -> T (in BPES; nuclear and cytoplasmic aggregation; impaired transactivation activity).
FOXL2	103	103	R -> C (in BPES; nuclear and cytoplasmic aggregation; normal transactivation activity).
FOXL2	104	104	H -> R (in BPES; diffuse nuclear localization as wild type; normal transactivation activity).
FOXL2	105	105	N -> S (in BPES; type II).
FOXL2	106	106	L -> F (in BPES; sporadic; nuclear and cytoplasmic aggregation; impaired transactivation activity).
FOXL2	106	106	L -> P (in BPES; nuclear and cytoplasmic aggregation; impaired transactivation activity).
FOXL2	108	108	L -> P (in BPES; nuclear aggregation and cytoplasmic mislocalization; impaired transactivation activity).
FOXL2	109	109	N -> K (in BPES; type II; diffuse nuclear localization as wild type; impaired transactivation activity).
FOXL2	134	134	C -> W (in granulosa-cell tumors of the ovary; not commonly found in other tumor types).
FOXL2	187	187	G -> D (in POF3; does not affect nuclear localization; reduces transcriptional activation of OSR2).
FOXL2	193	193	K -> R (in BPES; type II).
FOXL2	215	215	Y -> C (in BPES).
FOXL2	217	217	S -> C (in BPES; diffuse nuclear localization; normal transcriptional activation).
FOXL2	217	217	S -> F (in BPES; diffuse nuclear localization; increased transactivation activity).
FOXL2	234	234	A -> AAAAAA (in BPES; significant higher cytoplasmic retention compared to the wild-type protein).
FOXL2	234	234	A -> AAAAAAAAAAA (in BPES; type II).
FOXL2	234	234	A -> AAAAAAAAAAAA (in BPES).
FOXL2	285	285	P -> S.
GRK7	253	253	S -> F (in a metastatic melanoma sample; somatic mutation).
PLOD2	598	598	R -> H (in BRKS2).
PLOD2	601	601	G -> V (in BRKS2).
PLOD2	608	608	T -> I (in BRKS2).
AGTR1	282	282	T -> M (in RTD).
GYG1	83	83	T -> M (in GSD15; inactivation of the autoglucosylation).
HPS3	397	397	R -> Q (in a colorectal cancer sample; somatic mutation).
HPS3	397	397	R -> W (in HPS3; mild).
GPR87	191	191	D -> Y (in a colorectal cancer sample; somatic mutation).
P2RY12	256	256	R -> Q (in P2RY12D).
P2RY12	265	265	R -> W (in P2RY12D).
SLC33A1	113	113	S -> R (in SPG42).
SLC33A1	400	400	V -> A (in a colorectal cancer sample; somatic mutation).
GFM1	496	496	M -> R (in COXPD1).
B3GALNT1	271	271	G -> R (in an English with P1(k) phenotype).
EIF5A2	42	42	E -> D.
SLC2A2	197	197	V -> I (in NIDDM; abolishes transport activity of the transporter expressed in Xenopus oocytes).
SLC2A2	389	389	L -> P (in FBS).
SLC2A2	417	417	P -> L (in FBS).
GHSR	204	204	A -> E (in ISSA; affects cell-surface expression; impairs constitutive activity but not the ability to respond to ghrelin).
KCNMB3	165	165	N -> S.
KCNMB3	230	230	M -> T.
MFN1	415	415	D -> H (in a colorectal cancer sample; somatic mutation).
FXR1	233	233	A -> T (in a breast cancer sample; somatic mutation).
MCCC1	289	289	A -> V (in MCC1 deficiency; mild form).
MCCC1	325	325	M -> R (in MCC1 deficiency).
MCCC1	532	532	D -> H (in MCC1 deficiency; severe form).
MCCC1	535	535	S -> F (in MCC1 deficiency; asymptomatic form).
HTR3C	128	128	V -> M (in a colorectal cancer sample; somatic mutation).
EIF2B5	73	73	V -> G (in VWM).
EIF2B5	106	106	L -> F (in VWM).
EIF2B5	113	113	R -> H (in VWM; with ovarian failure).
EIF2B5	195	195	R -> C (in VWM; with ovarian failure).
EIF2B5	195	195	R -> H (in VWM; Cree leukoencephalopathy type).
EIF2B5	299	299	R -> H (in VWM).
EIF2B5	315	315	R -> G (in VWM).
EIF2B5	315	315	R -> H (in VWM).
EIF2B5	339	339	R -> P (in VWM).
EIF2B5	339	339	R -> Q (in VWM).
EIF2B5	339	339	R -> W (in VWM).
EIF2B5	386	386	G -> V (in VWM).
EIF2B5	430	430	V -> A (in VWM).
EIF2B5	650	650	E -> K (in VWM).
DVL3	216	216	R -> T (in a breast cancer sample; somatic mutation).
ALG3	171	171	R -> Q (in CDG1D).
EIF4G1	696	696	P -> L (in a colorectal cancer sample; somatic mutation).
FAM131A	260	260	S -> N (in a breast cancer sample; somatic mutation).
CLCN2	48	48	P -> R (reduces channel activity).
CLCN2	68	68	R -> H (reduces channel activity).
CLCN2	199	199	G -> A (no effect).
CLCN2	235	235	R -> Q (confers susceptibility to juvenile myoclonic epilepsy type 8; the mutant channel has accelerated deactivation rates compared to wild-type, but normal activation and peak current).
CLCN2	577	577	R -> Q (confers susceptibility to idiopathic generalized epilepsy type 11; the mutant channel has accelerated deactivation rates compared to wild-type, but normal activation and peak current).
CLCN2	644	644	R -> C (no effect).
CLCN2	646	646	R -> Q (reduces channel activity).
CLCN2	719	719	S -> L (in a patient with childhood absence epilepsy).
CLCN2	725	725	R -> W (slightly faster channel activation).
CLCN2	747	747	R -> H (slightly faster channel activation).
LIPH	108	108	W -> R (in LAH2 and ARWH2).
LIPH	172	205	Missing (in LAH2).
AHSG	276	276	D -> N (in allele AHSG*5).
KNG1	378	380	Missing (in T-kinin peptide).
EIF4A2	181	181	V -> L (in a breast cancer sample; somatic mutation).
ADIPOQ	84	84	G -> R (does not form high molecular weight multimers).
ADIPOQ	90	90	G -> S (does not form high molecular weight multimers).
ADIPOQ	112	112	R -> C (in ADPND; does not assemble into trimers resulting in impaired secretion from the cell).
ADIPOQ	117	117	V -> M.
ADIPOQ	164	164	I -> T (associated with low plasma adiponectin concentration and diabetes mellitus type 2; does not assemble into trimers resulting in impaired secretion from the cell).
ADIPOQ	221	221	R -> S.
ADIPOQ	241	241	H -> P.
RTP1	124	124	R -> S (in a breast cancer sample; somatic mutation).
CLDN16	71	71	M -> R (in HOMG3).
CLDN16	141	141	H -> D (in HOMG3).
CLDN16	145	145	L -> P (in HOMG3).
CLDN16	149	149	R -> L (in HOMG3).
CLDN16	151	151	L -> F (in HOMG3).
CLDN16	151	151	L -> P (in HOMG3).
CLDN16	151	151	L -> W (in HOMG3).
CLDN16	167	167	L -> P (in HOMG3).
CLDN16	191	191	G -> R (in HOMG3).
CLDN16	198	198	G -> A (in HOMG3).
CLDN16	198	198	G -> D (in HOMG3).
CLDN16	209	209	A -> T (in HOMG3).
CLDN16	216	216	R -> T (in HOMG3).
CLDN16	232	232	F -> C (in HOMG3).
CLDN16	233	233	G -> D (in HOMG3).
CLDN16	235	235	S -> F (in HOMG3).
CLDN16	235	235	S -> P (in HOMG3).
CLDN16	239	239	G -> R (in HOMG3).
LRP1B	3157	3157	R -> C (in NSCLC cells).
ABCG5	146	146	E -> Q (in STSL).
ABCG5	389	389	R -> H (in STSL).
ABCG5	419	419	R -> H (in STSL).
ABCG5	419	419	R -> P (in STSL).
ABCG5	437	437	N -> K (in STSL).
ABCG5	523	523	I -> V.
ABCG5	550	550	R -> S (in STSL).
ABCG5	600	600	C -> Y.
ABCG5	622	622	M -> V.
PRKCE	143	143	E -> K (in a colorectal cancer sample; somatic mutation).
FSHR	128	128	S -> Y (in OHSS; displays increase in affinity and sensitivity toward hCG and does not show any constitutive activity nor promiscuous activation by TSH).
FSHR	160	160	I -> T (in ODG1; impairs cell surface expression).
FSHR	189	189	A -> V (in ODG1; very frequent in the Finnish population).
FSHR	224	224	D -> V (in ODG1; FSH binding is barely detectable; impaired targeting to the cell membrane; adenylate cyclase stimulation by FSH is 4 +-2% residual activity).
FSHR	348	348	P -> R (in ODG1).
FSHR	419	419	A -> T (in ODG1).
FSHR	449	449	T -> A (in OHSS; increase of receptor sensitivity to both hCG and TSH together with an increase in basal activity).
FSHR	519	519	P -> T (in ODG1; totally impairs adenylate cyclase stimulation in vitro; alters the cell surface targeting of the receptor which remains trapped intracellularly).
FSHR	545	545	I -> T (in OHSS; displays promiscuous activation by both hCG and TSH together with detectable constitutive activity).
FSHR	567	567	D -> G (in FSHR activation; 1.5-fold increase in basal cAMP production compared to the wild-type receptor indicating that this mutation leads to ligand-independent constitutive activation).
FSHR	573	573	R -> C (in ODG1; alters signal transduction of the receptor; adenylate cyclase stimulation by FSH is 24 +-4% residual activity).
FSHR	591	591	F -> S (in ovarian sex cord tumor; loss of function).
FSHR	601	601	L -> V (in ODG1; binds FSH with a similar affinity than the wild-type receptor; adenylate cyclase stimulation by FSH is 12 +-3% residual activity).
EHBP1	395	395	R -> T (in a breast cancer sample; somatic mutation).
GKN1	118	118	K -> T (in a breast cancer sample; somatic mutation).
CD8A	111	111	G -> S (in CD8 deficiency; prevents CD8 expression).
GLI2	479	479	R -> G (in HPE9).
GLI2	932	932	P -> S (in HPE9).
GLI2	1444	1444	M -> I (in HPE9).
GLI2	1554	1554	P -> L (in HPE9).
KYNU	198	198	T -> A (detected in a boy with xanthurenic aciduria).
MBD5	144	144	T -> I (in a patient with mental retardation; unknown pathological significance).
MBD5	461	461	R -> H (in two patients with mental retardation; unknown pathological significance).
MBD5	654	654	D -> E (in a patient with mental retardation; unknown pathological significance).
MBD5	655	655	A -> T (in a patient with mental retardation; unknown pathological significance).
MBD5	677	677	S -> N.
MBD5	857	857	A -> T (in a patient with mental retardation; unknown pathological significance).
MBD5	1048	1048	T -> I (in a patient with mental retardation; unknown pathological significance).
CYTIP	329	329	P -> S (found in a renal cell carcinoma case; somatic mutation).
TTC21B	60	60	F -> Y (found in a patient with Meckel- Gruber like syndrome also carrying variant C-671 in BBS7; hypomorphic variant in vitro).
TTC21B	66	66	K -> R.
TTC21B	150	150	W -> R (in NPHP12; with extra-renal features; functionally null mutation in vitro).
TTC21B	157	157	K -> E (in BBS; hypomorphic variant in vitro; the patient also carries a frame- shift mutation and variant M-501 in BBS12).
TTC21B	209	209	P -> L (in NPHP12; hypomorphic variant in vitro; also found in a patient with Bardet-Biedl syndrome carrying two variants in BBS4).
TTC21B	222	222	Q -> L (found in a patient with Meckel- Gruber like syndrome also carrying variant V-280 on the same allele and variant G-1183 in RPGRIP1L; hypomorphic variant in vitro).
TTC21B	231	231	T -> S (in ATD4, NPHP12 and BBS; hypomorphic variant in vitro; a patient with Bardet-Biedl syndrome also carries variants L-159 and T-346 in BBS12; also found in a patient with Meckel-Gruber syndrome carrying a homozygous variant in TMEM216).
TTC21B	242	242	D -> N.
TTC21B	255	255	Y -> C (in BBS; the patient also carries a frameshift mutation and variant P-34 in BBS10; hypomorphic variant in vitro).
TTC21B	280	280	M -> V (found in a patient with Meckel- Gruber like syndrome also carrying L-222 on the same allele and variant G-1183 in RPGRIP1L; hypomorphic variant in vitro).
TTC21B	327	327	A -> S (found in a patient with Meckel- Gruber syndrome also carrying a mutation in CC2D2A; hypomorphic variant in vitro).
TTC21B	347	347	Y -> C (found in a patient with Meckel- Gruber syndrome also carrying N-1041 on the same allele; hypomorphic variant in vitro).
TTC21B	411	411	R -> G (in BBS; the patient also carries a homozygous frameshift mutation in BBS7; hypomorphic variant in vitro).
TTC21B	412	412	Q -> R.
TTC21B	424	424	D -> E.
TTC21B	566	566	H -> R (in NPHP12; functionally null mutation in vitro).
TTC21B	591	591	S -> N (in JBTS; hypomorphic variant in vitro).
TTC21B	616	616	R -> C.
TTC21B	624	624	I -> V.
TTC21B	645	645	H -> R.
TTC21B	724	724	S -> T.
TTC21B	753	753	P -> L (in NPHP12; with extra-renal features; functionally null mutation in vitro; also found in a patient with Meckel-Gruber like syndrome carrying variant D-559 in BBS1 and a variant in CC2D2A).
TTC21B	755	755	D -> Y (in ATD4; functionally null mutation in vitro).
TTC21B	795	795	L -> P (in ATD4; functionally null mutation in vitro).
TTC21B	844	844	M -> V (found in a patient with Meckel- Gruber syndrome; functionally null mutation in vitro).
TTC21B	867	867	R -> C (in JBTS; functionally null mutation in vitro).
TTC21B	867	867	R -> H (found in a patient with Meckel- Gruber syndrome also carrying a homozygous variant in CC2D2A; functionally null mutation in vitro).
TTC21B	869	869	Q -> R (found in a patient with Meckel- Gruber like syndrome; hypomorphic variant in vitro).
TTC21B	939	939	R -> Q (hypomorphic variant in vitro).
TTC21B	939	939	R -> W (functionally null mutation in vitro).
TTC21B	1002	1002	L -> V (found in a patient with Meckel- Gruber like syndrome; also found in patients with Bardet-Bied syndrome; also found in a patient with nephronophthisis with extra-renal features; hypomorphic variant in vitro).
TTC21B	1011	1011	M -> V.
TTC21B	1035	1035	Y -> C.
TTC21B	1041	1041	D -> N (found in a patient with Meckel- Gruber syndrome also carrying C-347 on the same allele; functionally null mutation in vitro).
TTC21B	1103	1103	T -> R (in BBS; the patient also carries two mutations in BBS6; hypomorphic variant in vitro).
TTC21B	1167	1167	Y -> C (in NPHP12; hypomorphic variant in vitro).
TTC21B	1186	1186	M -> V (in JBTS; hypomorphic variant in vitro).
TTC21B	1208	1208	I -> S (in BBS; the patients also carries two mutations in BBS1; functionally null mutation in vitro).
TTC21B	1284	1284	D -> H.
TTC21B	1311	1311	R -> G.
ABCB11	186	186	E -> G (in BRIC2).
ABCB11	238	238	G -> V (in PFIC2).
ABCB11	284	284	V -> A.
ABCB11	284	284	V -> L (in PFIC2).
ABCB11	297	297	E -> G (in PFIC2 and BRIC2; reduced transport capacity for taurocholate).
ABCB11	336	336	C -> S (in PFIC2).
ABCB11	415	415	R -> Q.
ABCB11	432	432	R -> T (in BRIC2; reduced transport capacity for taurocholate).
ABCB11	461	461	K -> E (in PFIC2).
ABCB11	482	482	D -> G (in PFIC2).
ABCB11	570	570	A -> T (in BRIC2).
ABCB11	591	591	N -> S (in a patient with intrahepatic cholestasis of pregnancy).
ABCB11	616	616	R -> G.
ABCB11	619	619	T -> A.
ABCB11	676	676	D -> Y (in fluvastatin-induced cholestasis; does not affect transport capacity for taurocholate).
ABCB11	698	698	R -> H.
ABCB11	855	855	G -> R (in ethinylestradiol/gestodene- induced cholestasis; loss of transport capacity for taurocholate).
ABCB11	865	865	A -> V.
ABCB11	923	923	T -> P (in BRIC2).
ABCB11	926	926	A -> P (in BRIC2).
ABCB11	958	958	R -> Q.
ABCB11	982	982	G -> R (in PFIC2).
ABCB11	1004	1004	G -> D (in PFIC2).
ABCB11	1050	1050	R -> C (in BRIC2).
ABCB11	1128	1128	R -> H (in BRIC2).
ABCB11	1153	1153	R -> C (in PFIC2).
ABCB11	1268	1268	R -> Q (in PFIC2).
TLK1	121	121	R -> C.
OLA1	168	168	E -> Q (in a breast cancer sample; somatic mutation).
AGPS	309	309	T -> I (in RCDP3).
AGPS	419	419	R -> H (in RCDP3).
AGPS	469	469	L -> P (in RCDP3).
PRKRA	222	222	P -> L (in DYT16).
CERKL	106	106	R -> S (in RP26).
ZNF804A	324	324	N -> S (in a colorectal cancer sample; somatic mutation).
ALS2CR11	123	123	K -> M (in a colorectal cancer sample; somatic mutation).
BMPR2	60	60	C -> Y (in PPH1).
BMPR2	82	82	Q -> H (in PPH1).
BMPR2	117	117	C -> Y (in PPH1).
BMPR2	118	118	C -> W (in PPH1).
BMPR2	123	123	C -> R (in PPH1).
BMPR2	123	123	C -> S (in PPH1).
BMPR2	182	182	G -> D (in PPH1).
BMPR2	224	224	E -> D.
BMPR2	347	347	C -> Y (in PPH1).
BMPR2	420	420	C -> R (in PPH1).
BMPR2	483	483	C -> R (in PPH1; sporadic).
BMPR2	485	485	D -> G (in PPH1; complete loss of function).
BMPR2	491	491	R -> Q (in PPH1; sporadic).
BMPR2	491	491	R -> W (in PPH1).
BMPR2	512	512	K -> T (in PPH1).
BMPR2	519	519	N -> K (in PPH1).
BMPR2	899	899	R -> P (in PPH1; leads to constitutive activation of the MAPK14 pathway).
MDH1B	48	48	L -> I (found in a renal cell carcinoma sample; somatic mutation).
ERBB4	140	140	T -> I (in a colorectal adenocarcinoma sample; somatic mutation).
ERBB4	303	303	S -> Y (in a lung squamous cell carcinoma sample; somatic mutation).
PNKD	7	7	A -> V (in DYT8).
PNKD	9	9	A -> V (in DYT8).
EPHA4	370	370	G -> E (in a bladder carcinoma NOS sample; somatic mutation).
EPHA4	399	399	S -> F (in a metastatic melanoma sample; somatic mutation).
AGAP1	82	82	S -> G (in an autistic patient).
AGAP1	798	798	R -> G (in an autistic patient).
AGAP1	854	854	P -> T (in a family with an autistic patient).
HDAC4	727	727	P -> R (in a breast cancer sample; somatic mutation).
HDLBP	568	568	K -> N (in a breast cancer sample; somatic mutation).
HDLBP	939	939	D -> V (in a breast cancer sample; somatic mutation).
HSPD1	29	29	D -> G (in HLD4; transfection with the mutant protein impairs cell growth that worsens with increasing temperature).
HSPD1	98	98	V -> I (in SPG13).
STAT1	491	491	P -> A (in a breast cancer sample; somatic mutation).
STAT1	600	600	L -> P (found in an infant who died of a viral-like illness associated with complete STAT1 deficiency).
STAT1	706	706	L -> S (in MSMD; loss of GAF and ISGF3 activation; impairs the nuclear accumulation of GAF but not of ISGF3 in heterozygous cells stimulated by IFNs).
TPO	53	53	A -> P (in TDH2A).
TPO	240	240	D -> N (in TDH2A; loss of activity).
TPO	307	307	N -> T (in TDH2A).
TPO	326	326	A -> T (in TDH2A).
TPO	378	378	E -> K (in TDH2A).
TPO	433	433	V -> M (in TDH2A).
TPO	447	447	I -> F (in TDH2A).
TPO	453	453	Y -> D (in TDH2A).
TPO	458	458	L -> P (in TDH2A).
TPO	491	491	R -> H (in TDH2A).
TPO	493	493	G -> S (in TDH2A).
TPO	499	499	P -> L (in TDH2A).
TPO	527	527	W -> C (in TDH2A).
TPO	533	533	G -> C (in TDH2A; partial defect; expression slightly lower in efficiency and more degenerative than wild-type enzyme).
TPO	574	575	Missing (in TDH2A; partial defect; expressed on the plasma membrane surface at less than half the rate of wild-type enzyme).
TPO	590	590	G -> S (in TDH2A).
TPO	648	648	R -> Q (in TDH2A).
TPO	660	660	Q -> E (in TDH2A).
TPO	665	665	R -> W (in TDH2A; fails to localize to the plasma membrane).
TPO	693	693	R -> W (in TDH2A).
TPO	771	771	G -> R (in TDH2A; fails to localize to the plasma membrane).
TPO	796	796	D -> Y (in TDH2A).
TPO	799	799	E -> K (in TDH2A).
TPO	808	808	C -> R (in TDH2A).
TPO	839	839	V -> I (in TDH2A).
TRAPPC12	717	717	E -> Q (in a breast cancer sample; somatic mutation).
CASP10	14	14	K -> T (found in a colon cancer sample; somatic mutation).
CASP10	21	21	R -> C (found in a multiple myeloma sample; somatic mutation).
CASP10	147	147	M -> T (in GASC; somatic mutation; impairs CASP10-mediated apoptosis).
CASP10	285	285	L -> P (found in a T-acute lymphoblastic leukemia sample; somatic mutation).
CASP10	406	406	I -> L (in ALPS2A; the mutant protein has defective apoptosis and exerts a dominant-negative effect when cotransfected with the wild-type protein).
STRADB	155	155	G -> E (in a metastatic melanoma sample; somatic mutation).
CPSF3	578	578	D -> N (in a breast cancer sample; somatic mutation).
ROCK2	1194	1194	S -> P (in a metastatic melanoma sample; somatic mutation).
LPIN1	56	56	G -> E (in a colorectal cancer sample; somatic mutation).
SMC6	292	292	A -> V (in a breast cancer sample; somatic mutation).
GEN1	275	275	R -> L (in a breast cancer sample; somatic mutation).
GEN1	766	766	C -> R (found in a renal cell carcinoma case; somatic mutation).
WDR12	72	72	M -> V.
WDR12	89	89	Y -> C.
WDR12	286	286	E -> G.
WDR35	626	626	E -> G (in CED2).
WDR35	875	875	A -> T (in CED2).
APOB	490	490	R -> W (in FHBL1; reduced protein secretion).
APOB	2564	2564	F -> C (in a colorectal cancer sample; somatic mutation).
APOB	3319	3319	D -> H.
APOB	3427	3427	T -> K.
APOB	3921	3921	V -> I.
HADHB	59	59	G -> D (in TFP deficiency).
HADHB	61	61	R -> C (in TFP deficiency).
HADHB	61	61	R -> H (in TFP deficiency).
HADHB	117	117	R -> G (in TFP deficiency).
HADHB	119	119	A -> V (in a breast cancer sample; somatic mutation).
HADHB	121	121	L -> P (in TFP deficiency).
HADHB	133	133	T -> P (in TFP deficiency).
HADHB	242	242	D -> G (in TFP deficiency).
HADHB	247	247	R -> H (in TFP deficiency).
HADHB	259	270	Missing (in TFP deficiency).
HADHB	263	263	D -> G (in TFP deficiency).
HADHB	280	280	G -> D (in TFP deficiency).
HADHB	294	294	P -> L (in TFP deficiency).
HADHB	294	294	P -> R (in TFP deficiency).
HADHB	301	301	G -> S (in TFP deficiency).
HADHB	444	444	R -> K (in TFP deficiency).
OTOF	255	255	Q -> H (in NSRAN).
OTOF	490	490	P -> Q (in DFNB9).
OTOF	515	515	I -> T (in DFNB9 and NSRAN; temperature sensitive).
OTOF	773	773	R -> S.
OTOF	794	794	R -> H (in DFNB9).
OTOF	822	822	R -> W (in DFNB9; uncertain pathogenicity).
OTOF	964	964	A -> E (in NSRAN).
OTOF	1011	1011	L -> P (in NSRAN and DFNB9).
OTOF	1083	1083	A -> P.
OTOF	1138	1138	L -> P (in NSRAN).
OTOF	1236	1236	R -> Q.
OTOF	1322	1322	D -> E.
OTOF	1323	1323	E -> K (in a breast cancer sample; somatic mutation).
OTOF	1547	1547	I -> V (in a breast cancer sample; somatic mutation).
OTOF	1625	1625	V -> M.
OTOF	1688	1688	T -> K.
OTOF	1795	1795	F -> C (in NSRAN).
OTOF	1888	1888	G -> D.
OTOF	1939	1939	R -> Q (in NSRAN).
OTOF	1987	1987	P -> R (in NSRAN).
NRBP1	432	432	P -> L (in an ovarian mucinous carcinoma sample; somatic mutation).
ALK	560	560	L -> F (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
ALK	877	877	A -> S (in an ovarian serous carcinoma sample; somatic mutation).
ALK	1091	1091	D -> N (in NBLST3; somatic mutation).
ALK	1128	1128	G -> A (in NBLST3).
ALK	1151	1151	T -> M (in NBLST3).
ALK	1166	1166	M -> R (in NBLST3; somatic mutation).
ALK	1171	1171	I -> N (in NBLST3; somatic mutation).
ALK	1174	1174	F -> C (in NBLST3).
ALK	1174	1174	F -> I (in NBLST3; somatic mutation).
ALK	1174	1174	F -> L (in NBLST3; somatic mutation).
ALK	1174	1174	F -> V (in NBLST3; somatic mutation).
ALK	1192	1192	R -> P (in NBLST3).
ALK	1234	1234	A -> T (in NBLST3; somatic mutation).
ALK	1245	1245	F -> C (in NBLST3; somatic mutation).
ALK	1245	1245	F -> V (in NBLST3; somatic mutation).
ALK	1250	1250	I -> T (in NBLST3; somatic mutation).
ALK	1275	1275	R -> L (observed in neuroblastoma).
ALK	1275	1275	R -> Q (in NBLST3).
ALK	1278	1278	Y -> S (in NBLST3; somatic mutation).
XDH	149	149	R -> C (in XU1).
XDH	763	763	L -> F (in a breast cancer sample; somatic mutation).
XDH	791	791	R -> G (in a breast cancer sample; somatic mutation).
XDH	910	910	T -> M.
SPAST	45	45	P -> Q (rare polymorphism which modifies the phenotype of SPG4 disease).
SPAST	195	195	L -> V (in SPG4).
SPAST	344	344	I -> K (in SPG4; abrogates ATPase activity and promotes microtubule binding).
SPAST	347	347	Q -> K (in SPG4; promotes microtubule binding).
SPAST	361	361	P -> L (in SPG4).
SPAST	362	362	S -> C (in SPG4).
SPAST	370	370	G -> R (in SPG4; promotes microtubule binding and the formation of thick microtubule bundles).
SPAST	378	378	L -> Q (in SPG4).
SPAST	381	381	F -> C (in SPG4; promotes microtubule binding and the formation of thick microtubule bundles).
SPAST	386	386	N -> K (in SPG4; abrogates ATPase activity, promotes microtubule binding and the formation of thick microtubule bundles).
SPAST	386	386	N -> S (in SPG4).
SPAST	388	388	K -> R (in SPG4; abrogates ATPase activity, promotes microtubule binding and the formation of thick microtubule bundles and impairs traffic from the ER to Golgi).
SPAST	390	390	M -> V (in SPG4).
SPAST	399	399	S -> L (in SPG4).
SPAST	404	404	Missing (in SPG4).
SPAST	406	406	I -> V (in SPG4).
SPAST	407	407	S -> R (in SPG4).
SPAST	423	423	V -> L (in a breast cancer sample; somatic mutation).
SPAST	424	424	R -> G (in SPG4).
SPAST	426	426	L -> V (in SPG4; promotes microtubule binding and the formation of thick microtubule bundles).
SPAST	435	435	P -> L (in SPG4).
SPAST	436	436	S -> F (in SPG4).
SPAST	441	441	D -> G (in SPG4).
SPAST	448	448	C -> Y (in SPG4; abrogates binding to the tail of beta-3-tubulin, abolishes microtubule severing and promotes the formation of thick microtubule bundles).
SPAST	459	459	R -> G (in SPG4).
SPAST	460	460	R -> C (in SPG4; promotes microtubule binding and the formation of thick microtubule bundles).
SPAST	460	460	R -> L (in SPG4).
SPAST	485	485	A -> V (in SPG4).
SPAST	489	489	P -> L (in SPG4).
SPAST	493	493	D -> G (in SPG4).
SPAST	499	499	R -> C (in SPG4; abrogates ATPase activity, promotes microtubule binding and the formation of thick microtubule bundles).
SPAST	499	499	R -> H (in SPG4).
SPAST	503	503	R -> L (in SPG4).
SPAST	503	503	R -> W (in SPG4).
SPAST	512	512	E -> D (in SPG4).
SPAST	515	515	Missing (in SPG4).
SPAST	534	534	L -> P (in SPG4).
SPAST	551	551	A -> Y (in SPG4; requires 2 nucleotide substitutions).
SPAST	555	555	D -> N (in SPG4).
SPAST	556	556	A -> V (in SPG4; promotes microtubule binding and the formation of thick microtubule bundles).
SPAST	559	559	G -> D (in SPG4).
SPAST	562	562	R -> G (in SPG4).
SPAST	562	562	R -> Q (in SPG4).
SPAST	584	584	D -> H (in SPG4).
SPAST	607	607	W -> C (in SPG4).
SPAST	614	614	T -> I (in SPG4; variant form with congenital arachnoid cysts).
SPAST	615	615	T -> I (in SPG4).
EIF2AK2	439	439	L -> V (in a lung adenocarcinoma sample; somatic mutation).
PRKD3	716	716	V -> M (in a glioblastoma multiforme sample; somatic mutation).
SOS1	108	108	E -> K (in NS4).
SOS1	266	266	T -> K (in NS4).
SOS1	269	269	M -> R (in NS4).
SOS1	269	269	M -> T (in NS4).
SOS1	309	309	D -> Y (in NS4).
SOS1	337	337	Y -> C (in NS4).
SOS1	432	432	W -> R (in NS4).
SOS1	433	433	E -> K (in NS4).
SOS1	434	434	G -> R (in NS4).
SOS1	441	441	C -> Y (in NS4).
SOS1	477	477	Q -> R (in NS4).
SOS1	497	497	R -> Q (found in a Noonan syndrome patient who also carries a likely pathogenic mutation Ser-261 in RAF1; the mutant protein cannot induce ERK1 phosphorylation).
SOS1	548	548	S -> R (in NS4).
SOS1	550	550	L -> P (in NS4).
SOS1	552	552	R -> G (in NS4; increases the basal level of active RAS; prolonges RAS activation after EGF stimulation and enhances ERK activation).
SOS1	552	552	R -> K (in NS4).
SOS1	552	552	R -> S (in NS4).
SOS1	702	702	Y -> H (in NS4).
SOS1	729	729	W -> L (in NS4; promotes constitutive RAS activation and enhances ERK activation).
SOS1	733	733	I -> F (in NS4).
SOS1	846	846	E -> K (in NS4).
SOS1	977	977	Q -> R.
SOS1	1320	1320	H -> R.
MAP4K3	669	669	T -> S (in a lung squamous cell carcinoma sample; somatic mutation).
LRPPRC	354	354	A -> V (in LSFC).
EPAS1	537	537	G -> W (in ECYT4; gain of function; affects hydroxylation).
MSH2	2	2	A -> T (in HNPCC1).
MSH2	13	13	S -> I (in colorectal cancer).
MSH2	17	17	V -> F (in gastric cancer; uncertain pathogenicity; cryptic acceptor splice site suppressed on ex vivo splicing assay).
MSH2	33	33	T -> P (in HNPCC1; shows slightly reduced mismatch binding or release efficiency).
MSH2	40	40	G -> S (in CRC).
MSH2	44	44	T -> M (in HNPCC1).
MSH2	45	45	A -> V (in HNPCC1).
MSH2	92	92	Missing (in HNPCC1; uncertain pathogenicity; has no effect on ex vivo splicing assay).
MSH2	93	93	L -> F (in HNPCC1).
MSH2	96	96	R -> H.
MSH2	98	98	Y -> C (in HNPCC1; uncertain pathogenicity).
MSH2	102	102	V -> I (in HNPCC1).
MSH2	110	110	K -> T (in HNPCC1; somatic mutation).
MSH2	139	139	N -> S (in HNPCC1).
MSH2	145	145	I -> M (in HNPCC1).
MSH2	161	161	V -> D (in HNPCC1; affects protein stability; associated with an absence of the protein in tumors).
MSH2	162	162	G -> A (in HNPCC1).
MSH2	162	162	G -> R (in HNPCC1; shows a decreased expression level of the MutS alpha complex and is associated with an abnormal subcellular localization pattern; affects protein stability; associated with an absence of the protein in tumors).
MSH2	163	163	V -> D (in HNPCC1).
MSH2	163	163	V -> G (in HNPCC1).
MSH2	164	164	G -> R (in HNPCC1; affects protein stability; associated with an absence of the protein in tumors).
MSH2	167	167	D -> H (in HNPCC1; does not show a decreased expression level of the MutS alpha complex and is not associated with an abnormal subcellular localization pattern; could be a polymorphism).
MSH2	169	169	I -> V (in HNPCC1; uncertain pathogenicity).
MSH2	173	173	L -> P (in HNPCC1; affects protein stability; associated with an absence of the protein in tumors).
MSH2	175	175	L -> P (in HNPCC1).
MSH2	187	187	L -> P (in HNPCC1; affects protein stability; associated with an absence of the protein in tumors).
MSH2	198	198	E -> G (in HNPCC1).
MSH2	199	199	C -> R (in glioma; also associated with HNPCC1; has no effect on ex vivo splicing assay).
MSH2	203	203	G -> R (in CRC; uncertain pathogenicity; somatic mutation).
MSH2	216	216	I -> V (in HNPCC1; could be a polymorphism; shows slightly reduced mismatch binding or release efficiency).
MSH2	246	246	K -> Q (in HNPCC1; uncertain pathogenicity).
MSH2	265	314	Missing (in HNPCC1).
MSH2	283	283	D -> Y (in HNPCC1).
MSH2	305	305	A -> T (in HNPCC1).
MSH2	323	323	S -> C (in HNPCC1; uncertain pathogenicity).
MSH2	323	323	S -> Y (in HNPCC1; uncertain pathogenicity).
MSH2	331	331	N -> D (associated with HNPCC1; has no effect on ex vivo splicing assay).
MSH2	333	333	C -> Y (in HNPCC1; affects protein stability; associated with an absence of the protein in tumors).
MSH2	335	335	T -> I (in HNPCC1; uncertain pathogenicity).
MSH2	336	336	P -> S (in HNPCC1).
MSH2	342	342	V -> I (in colorectal cancer).
MSH2	349	349	P -> L (in HNPCC1).
MSH2	359	359	R -> S (in HNPCC1; shows a decreased expression level of the MutS alpha comp lex and is associated with an abnormal subcellular localization pattern).
MSH2	393	393	K -> M (in HNPCC1).
MSH2	419	419	Q -> K (in CRC; uncertain pathogenicity; the equivalent substitution in yeast partially affects mismatch repair in vitro).
MSH2	440	440	Missing (in HNPCC1).
MSH2	470	470	V -> E (associated with HNPCC1; has no effect on ex vivo splicing assay).
MSH2	492	492	M -> V (in HNPCC1).
MSH2	506	506	D -> Y (in CRC; sporadic; early onset; the equivalent substitution in yeast partially affects mismatch repair in vitro).
MSH2	524	524	R -> P (in HNPCC1; defective in mismatch repair activity).
MSH2	552	552	T -> P (in HNPCC1).
MSH2	554	554	S -> R (in HNPCC1; could be a polymorphism).
MSH2	562	562	E -> V (in HNPCC1).
MSH2	583	583	N -> S (in HNPCC1).
MSH2	596	596	Missing (in HNPCC1; has no effect on ex vivo splicing assay).
MSH2	600	600	A -> V (in HNPCC1).
MSH2	603	603	D -> N (in HNPCC1; affects protein stability; associated with an absence of the protein in tumors).
MSH2	610	610	H -> N (associated with HNPCC1; has no effect on ex vivo splicing assay).
MSH2	619	619	Y -> C (in CRC).
MSH2	629	629	Q -> R (in HNPCC1; uncertain pathogenicity).
MSH2	636	636	A -> P (in HNPCC1; partial functional loss; mainly causes defects in mismatch binding or release efficiency).
MSH2	638	638	R -> G (associated with HNPCC1; has no effect on ex vivo splicing assay).
MSH2	639	639	H -> R (in HNPCC1).
MSH2	641	641	C -> G.
MSH2	645	645	Q -> E (associated with HNPCC1; has no effect on ex vivo splicing assay).
MSH2	647	647	E -> K (in HNPCC1).
MSH2	656	656	Y -> H (in HNPCC1; somatic mutation).
MSH2	660	660	D -> G (in HNPCC1).
MSH2	671	671	N -> Y (in HNPCC1; uncertain pathogenicity).
MSH2	674	674	G -> S (in HNPCC1; somatic mutation).
MSH2	679	679	I -> T (in HNPCC1; somatic mutation).
MSH2	688	688	M -> I (in HNPCC1).
MSH2	692	692	G -> R (in HNPCC1).
MSH2	696	696	P -> L (associated with HNPCC1; has no effect on ex vivo splicing assay).
MSH2	697	697	C -> F (in HNPCC1; the equivalent substitution in yeast causes loss of function in a mismatch repair assay; mainly causes defects in mismatch binding or release efficiency).
MSH2	697	697	C -> R (in HNPCC1; has no effect on ex vivo splicing assay).
MSH2	714	714	A -> V (in HNPCC1; uncertain pathogenicity).
MSH2	723	723	S -> F (in HNPCC1; has no effect on ex vivo splicing assay).
MSH2	729	729	M -> V (in HNPCC1; somatic mutation).
MSH2	732	732	T -> I (in HNPCC1; somatic mutation).
MSH2	745	746	Missing (in HNPCC1; mainly causes defects in mismatch binding or release efficiency).
MSH2	748	748	D -> Y (associated with HNPCC1; has no effect on ex vivo splicing assay).
MSH2	749	749	E -> K (in HNPCC1; mainly causes defects in mismatch binding or release efficiency; the mutant protein is well expressed in tumors).
MSH2	770	770	I -> V.
MSH2	813	813	M -> V (in HNPCC1).
MSH2	824	824	Q -> E (in gastric cancer; uncertain pathogenicity).
MSH2	834	834	A -> T (in HNPCC1; shows no defects; could be a polymorphism).
MSH2	839	839	H -> Q (associated with HNPCC1; has no effect on ex vivo splicing assay).
MSH2	839	839	H -> R (in HNPCC1).
MSH2	845	845	K -> E (in HNPCC1).
MSH2	853	853	E -> A (in HNPCC1; uncertain pathogenicity).
MSH2	868	868	P -> A (in gastric cancer; uncertain pathogenicity).
MSH2	870	870	A -> G (in gastric cancer; uncertain pathogenicity).
MSH2	873	873	C -> G (in gastric cancer; uncertain pathogenicity).
MSH2	886	886	E -> G (in HNPCC1).
MSH2	905	905	T -> R (in HNPCC1; could be a polymorphism).
MSH2	923	923	V -> E (in HNPCC1; could be a polymorphism).
MSH2	931	931	K -> T (in HNPCC1).
CPO	273	273	K -> N (in a colorectal cancer sample; somatic mutation).
EFEMP1	220	220	I -> F.
EFEMP1	345	345	R -> W (in DHRD; misfolded, accumulates in cells due to inefficient secretion; induces the formation of deposits between Bruch's membrane and the retinal pigment epithelium where it accumulates).
BCL11A	142	142	S -> F (in a breast cancer sample; somatic mutation).
PUS10	484	484	T -> I (in a colorectal cancer sample; somatic mutation).
WDPCP	55	55	R -> K (in a patient with Meckel syndrome compound heterozygous for mutations in CC2D2A).
WDPCP	205	205	L -> F (in a patient with Bardet-Biedl syndrome compound heterozygous for mutations in BBS12).
WDPCP	708	708	S -> F.
ETAA1	50	50	E -> D (in a colorectal cancer sample; somatic mutation).
ANTXR1	326	326	A -> T (in HCI susceptibility; expression of FLT1 in hemangioma endothelial cells is markedly reduced compared to controls; low FLT1 expression in hemangioma cells is caused by reduced activity of a pathway involving ITGB1, ANTXR1, KDR and NFATC2IP; the mutation disrupts interaction of these molecules in a dominant-negative manner).
GFPT1	15	15	T -> A (in LGMTA).
GFPT1	15	15	T -> M (in LGMTA).
GFPT1	43	43	D -> V (in LGMTA).
GFPT1	111	111	R -> C (in LGMTA).
GFPT1	121	121	I -> T (in LGMTA).
GFPT1	199	199	V -> F (in LGMTA).
GFPT1	366	366	D -> Y (in LGMTA).
GFPT1	403	403	R -> H (in LGMTA).
GFPT1	452	452	R -> H (in LGMTA).
GFPT1	509	509	M -> T (in LGMTA).
GFPT1	510	510	M -> T (in LGMTA).
GFPT1	514	514	R -> W (in LGMTA).
GFPT1	530	530	R -> W (in LGMTA).
AAK1	533	533	Q -> H.
AAK1	835	835	G -> D.
SNRNP27	81	81	T -> I.
SNRNP27	114	114	S -> F.
ATP6V1B1	81	81	L -> P (in dRTA-D).
ATP6V1B1	123	123	G -> V (in dRTA-D).
ATP6V1B1	124	124	R -> W (in dRTA-D).
ATP6V1B1	157	157	R -> C (in dRTA-D).
ATP6V1B1	161	161	E -> K.
ATP6V1B1	174	174	M -> R (in dRTA-D).
ATP6V1B1	275	275	T -> P (in dRTA-D).
ATP6V1B1	316	316	G -> E (in dRTA-D).
ATP6V1B1	346	346	P -> R (in dRTA-D).
ATP6V1B1	364	364	G -> S (in dRTA-D).
ATP6V1B1	465	465	R -> H (in dRTA-D).
DYSF	52	52	W -> R (in LGMD2B).
DYSF	67	67	V -> D (in MMD1 and LGMD2B; Reduces calcium-sensitive phospholipid binding and interaction with AHNAK and AHNAK2).
DYSF	84	84	A -> V.
DYSF	155	155	G -> R (in LGMD2B).
DYSF	234	234	G -> E (in LGMD2B).
DYSF	253	253	R -> W (in isolated hyperCKemia).
DYSF	266	266	L -> P (in pseudometabolic myopathy).
DYSF	284	284	I -> T (in LGMD2B).
DYSF	299	299	G -> E (in MMD1).
DYSF	299	299	G -> R (in LGMD2B and proximodistal myopathy).
DYSF	299	299	G -> W (in MMD1).
DYSF	335	335	G -> A.
DYSF	340	340	S -> R (in proximodistal myopathy).
DYSF	374	374	V -> L (in MMD1; uncertain pathogenicity).
DYSF	386	390	FRAED -> Y (in MMD1).
DYSF	389	389	E -> Q (in MMD1).
DYSF	390	390	D -> N.
DYSF	426	426	G -> R (in MMD1).
DYSF	426	426	G -> V (in MMD1).
DYSF	456	456	C -> W (in MMD1).
DYSF	519	519	G -> R (in MMD1).
DYSF	555	555	R -> W (in isolated hyperCKemia, LGMD2B and MMD1).
DYSF	618	618	G -> R (in MMD1 and LGMD2B).
DYSF	621	621	G -> R (in LGMD2B).
DYSF	625	625	D -> Y (in LGMD2B).
DYSF	731	731	P -> R (in LGMD2B).
DYSF	791	791	P -> R (in MMD1 and LGMD2B).
DYSF	819	819	R -> Q.
DYSF	930	930	W -> C (in LGMD2B; uncetain pathogenicity).
DYSF	959	959	R -> W (in MMD1 and LGMD2B).
DYSF	1029	1029	P -> L (in MMD1).
DYSF	1038	1038	R -> Q (in LGMD2B; uncertain pathogenicity).
DYSF	1041	1041	R -> C (in MMD1).
DYSF	1065	1065	E -> EAE.
DYSF	1208	1208	I -> M (in LGMD2B).
DYSF	1228	1228	L -> P (in LGMD2B).
DYSF	1276	1276	L -> V (in proximodistal myopathy; could be a polymorphism).
DYSF	1298	1298	I -> V (in MMD1 and LGMD2B).
DYSF	1325	1325	I -> M (in a breast cancer sample; somatic mutation).
DYSF	1325	1325	I -> V.
DYSF	1335	1335	E -> K (in MMD1 and LGMD2B).
DYSF	1341	1341	L -> P (in LGMD2B).
DYSF	1349	1349	L -> V (in a breast cancer sample; somatic mutation).
DYSF	1351	1351	N -> S.
DYSF	1361	1361	C -> R (in MMD1).
DYSF	1505	1505	Y -> C (in LGMD2B).
DYSF	1526	1526	K -> T (in LGMD2B).
DYSF	1543	1543	G -> D (in LGMD2B).
DYSF	1581	1581	R -> H.
DYSF	1662	1662	T -> R (in MMD1).
DYSF	1678	1678	C -> S (in isolated hyperCKemia).
DYSF	1679	1679	G -> E (in MMD1).
DYSF	1693	1693	R -> Q (in MMD1).
DYSF	1693	1693	R -> W (in MMD1).
DYSF	1734	1734	E -> G (in LGMD2B).
DYSF	1748	1748	E -> V (in proximodistal myopathy).
DYSF	1768	1768	R -> W (in LGMD2B and proximodistal myopathy; uncetain pathogenicity).
DYSF	1837	1837	D -> N (in MMD1; could be a polymorphism).
DYSF	1842	1842	G -> D (in MMD1).
DYSF	1857	1857	H -> R (in MMD1).
DYSF	1922	1922	L -> P (in MMD1).
DYSF	1938	1939	Missing (in MMD1).
DYSF	1942	1942	C -> G (in MMD1).
DYSF	1967	1967	G -> S.
DYSF	1970	1970	P -> S (in LGMD2B).
DYSF	2000	2000	R -> Q (in MMD1).
DYSF	2042	2042	R -> C (in MMD1, LGMD2B and proximodistal myopathy).
DYSF	2068	2068	P -> L (in MMD1).
HK2	148	148	L -> F.
HK2	314	314	A -> V.
HK2	353	353	R -> C.
HK2	775	775	R -> Q.
TACR1	192	192	Y -> H (display properties similar to those of the wild-type receptor).
SUCLG1	14	14	M -> L (in MTDPS9; with progressive liver disease and recurrent hepatic failure).
SUCLG1	85	85	G -> A (in MTDPS9).
SUCLG1	170	170	P -> R (in MTDPS9).
TCF7L1	147	147	T -> N (in a breast cancer sample; somatic mutation).
REEP1	20	20	A -> E (in SPG31).
EIF2AK3	566	566	D -> V.
EIF2AK3	588	588	R -> Q (in WRS; in a Pakistani family; probable complete loss of activity).
EIF2AK3	716	716	P -> L.
RPIA	135	135	A -> V (in RPID).
COA5	53	53	A -> P (in MT-C4D).
LONRF2	562	562	R -> W (in a colorectal cancer sample; somatic mutation).
MAP4K4	712	712	S -> T.
SLC9A2	299	299	T -> S (in a breast cancer sample; somatic mutation).
SLC9A2	806	806	R -> Q (in a breast cancer sample; somatic mutation).
EDAR	47	47	C -> Y (in EDA).
EDAR	87	87	C -> R (in EDA).
EDAR	89	89	R -> H (in EDA).
EDAR	98	98	R -> Q (in EDA).
EDAR	110	110	D -> A (in EDA).
EDAR	148	148	C -> R (in EDA).
EDAR	358	358	R -> Q (in EDA).
EDAR	375	375	R -> H (in EDA; the mutant protein does not interact with EDARADD and is functionally inactive).
EDAR	377	377	L -> F (in EDA).
EDAR	382	382	G -> S (in EDA).
EDAR	396	396	Q -> QQ (in EDA).
EDAR	403	403	T -> M (in EDA).
EDAR	408	408	I -> F (in EDA).
EDAR	413	413	T -> P (in EDA).
EDAR	418	418	I -> T (in EDA).
EDAR	420	420	R -> Q (in EDA and ED3; abolishes NF- kappa-B activation and reduces JNK activation).
EDAR	434	434	W -> C (in EDA).
EDAR	434	434	W -> R (in EDA).
NPHP1	342	342	G -> R (in NPHP1; associated with Cogan- type congenital ocular motor apraxia).
BUB1	259	259	Y -> C (in pancreatic cancer; associated with N-265; failure to rescue the spindle-assembly checkpoint activity as a result of a deficient recruitment of MAD2L1 and BUBR1 to kinetochores; efficient restoration of chromosome congression; reduced binding to BUB3; rescue of the ability of kinetochores to bind SGOL1 and CENPF but not MCAK).
BUB1	265	265	H -> N (in pancreatic cancer; associated with C-259; complete rescue of the spindle-assembly checkpoint activity; increased rate of chromosome congression errors).
BUB1	492	492	S -> Y (in colorectal cancer).
BUB1	648	648	P -> R (in colorectal cancer).
MERTK	289	289	E -> K.
MERTK	446	446	A -> G (in a renal clear cell carcinoma sample; somatic mutation).
MERTK	540	540	E -> K (in RP38).
MERTK	661	661	S -> C (in RP38).
MERTK	708	708	A -> S (in a head & Neck squamous cell carcinoma sample; somatic mutation).
MERTK	871	871	I -> T (in RP38).
MERTK	871	871	I -> V.
PAX8	31	31	R -> H (in CHNG2; loss of activity).
PAX8	40	40	Q -> P (in CHNG2; loss of activity).
PAX8	57	57	C -> Y (in CHNG2; loss of activity).
PAX8	62	62	L -> R (in CHNG2; loss of activity).
CCDC93	315	315	H -> R (in a colorectal cancer sample; somatic mutation).
MAP3K2	112	112	M -> I (in a lung large cell carcinoma sample; somatic mutation).
ARHGEF4	100	100	K -> R (in a breast cancer sample; somatic mutation).
ARHGEF4	441	441	T -> R (in a breast cancer sample; somatic mutation).
YSK4	500	500	I -> M (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
LCT	268	268	Q -> H (in COLACD).
LCT	1363	1363	G -> S (in COLACD).
CXCR1	306	306	A -> T.
SLC11A1	30	30	Q -> R.
SLC11A1	318	318	A -> V.
ZEB2	99	99	Missing (in MWIS).
ZEB2	953	953	R -> G (in MWIS).
ZEB2	983	983	D -> N (in a colorectal cancer sample; somatic mutation).
ZEB2	1119	1119	Q -> R (in MWIS).
WNT10A	128	128	R -> Q (in OODD).
WNT10A	143	143	H -> Y (in EDA).
WNT10A	145	145	V -> M (in EDA).
WNT10A	228	228	F -> I (in OODD and EDA).
WNT10A	360	360	R -> C (found in a patient with unclassified form of ectodermal dysplasia).
ACVR2A	306	306	D -> N (in a gastric adenocarcinoma sample; somatic mutation).
ACVR2A	367	367	A -> T (found in a clear cell renal carcinoma case; somatic mutation).
ORC4	174	174	Y -> C (in MGORS2).
DES	46	46	S -> Y (in MFM1; entirely similar expression patterns as the wild-type).
DES	173	179	Missing (in MFM1; severe form).
DES	245	245	E -> D (in MFM1).
DES	342	342	N -> D (in MFM1; unable to form a filamentous network; abolishes binding to MTM1).
DES	359	361	Missing (in MFM1).
DES	360	360	A -> P (in MFM1; heterozygous with Ile- 391 gives a severe childhood-onset; unable to form a filamentous network; abolishes binding to MTM1).
DES	366	366	Missing (in MFM1).
DES	393	393	N -> I (in MFM1; heterozygous with Pro- 358 gives a severe childhood-onset; unable to form a filamentous network).
DES	442	442	T -> I (in MFM1; reveals a severe disturbance of filament-formation competence and filament-filament interactions, indicating an inherent incompaibility of mutant and wild-type protein to form mixed filaments).
DES	449	449	K -> M (in MFM1).
DES	449	449	K -> T (in MFM1; entirely similar expression patterns as the wild-type).
DES	451	451	I -> M (in CMD1I; reveals a severe disturbance of filament-formation competence and filament-filament interactions, indicating an inherent incompaibility of mutant and wild-type protein to form mixed filaments).
DES	454	454	R -> W (in MFM1; reveals a severe disturbance of filament-formation competence and filament-filament interactions, indicating an inherent incompaibility of mutant and wild-type protein to form mixed filaments).
DES	460	460	S -> I (in MFM1; reveals a severe disturbance of filament-formation competence and filament-filament interactions, indicating an inherent incompaibility of mutant and wild-type protein to form mixed filaments).
RIF1	1784	1784	E -> K (in a breast cancer sample; somatic mutation).
RIF1	1955	1955	D -> H (in a breast cancer sample; somatic mutation).
ACVR1C	195	195	I -> T.
ACVR1C	216	216	G -> R.
ACVR1C	267	267	W -> R (in a lung squamous cell carcinoma sample; somatic mutation).
ACVR1C	355	355	I -> V.
ACVR1	115	115	P -> S (in a melanoma sample; somatic mutation).
ACVR1	197	198	PF -> L (in FOP; variant phenotype).
ACVR1	202	202	R -> I (in FOP; with some atypical features).
ACVR1	206	206	R -> H (in FOP).
ACVR1	207	207	Q -> E (in FOP; with some atypical features).
ACVR1	328	328	G -> E (in FOP; variant phenotype).
ACVR1	328	328	G -> R (in FOP; variant phenotype).
ACVR1	328	328	G -> W (in FOP; variant phenotype).
ACVR1	356	356	G -> D (in FOP; variant phenotype).
ACVR1	375	375	R -> P (in FOP; variant phenotype).
GRB14	507	507	H -> Y (in a patient with amyotrophic lateral sclerosis).
SCN2A	188	188	R -> W (in BFIC3; mutant channel inactivates more slowly than wild-type whereas the Na(+) channel conductance is not affected).
SCN2A	223	223	R -> Q (in BFIC3).
SCN2A	252	252	M -> V (in BFIC3).
SCN2A	261	261	V -> M (in BFIC3).
SCN2A	263	263	A -> V (in EIEE11).
SCN2A	328	328	F -> V.
SCN2A	524	524	R -> Q.
SCN2A	575	575	A -> V (there is no significant effetcs on the voltage-dependence of the channel).
SCN2A	892	892	V -> I (in BFIC3).
SCN2A	1003	1003	L -> I (in BFIC3).
SCN2A	1211	1211	E -> K (in EIEE11; markedly altered the voltage-dependence of the channel).
SCN2A	1319	1319	R -> Q (in BFIC3).
SCN2A	1330	1330	L -> F (in BFIC3).
SCN2A	1473	1473	I -> M (in EIEE11; markedly altered the voltage-dependence of the channel).
SCN2A	1563	1563	L -> V (in BFIC3).
SCN2A	1902	1902	R -> T (associated with autism).
CSRNP3	474	474	P -> L (in a colorectal cancer sample; somatic mutation).
SCN1A	944	944	V -> E (in SMEI).
SCN1A	1038	1038	F -> L (associated with autism).
SCN1A	1289	1289	Missing (in SMEI).
SCN1A	1559	1559	Missing (in SMEI).
SCN1A	1649	1649	L -> Q (in FHM3).
SCN1A	1766	1766	Missing (in SMEI).
SCN1A	1807	1810	Missing (in SMEI).
SCN1A	1812	1815	WEKF -> C (in SMEI).
SCN1A	1955	1955	I -> T (associated with autism).
SCN9A	10	10	Q -> R (in PERYTHM; causes a hyperpolarizing shift of -5.3 mV for the midpoint of activation which is smaller than that seen in other mutations causing early-onset erythromelalgia mutations; also causes a faster rate of activation and slower deactivation compared to wild- type; expression of the mutant protein induced hyperexcitability in dorsal root ganglion neurons but the increase is smaller than that produced by Thr-859).
SCN9A	62	62	I -> V (in FEB3B).
SCN9A	149	149	P -> Q (in FEB3B).
SCN9A	216	216	F -> S (in PERYTHM; hyperpolarizes the voltage dependence of activation by 11 mV, accelerates activation, slows deactivation and enhances the response to slow, small depolarizations).
SCN9A	228	228	I -> M.
SCN9A	241	241	S -> T (in PERYTHM).
SCN9A	395	395	N -> K (in PERYTHM).
SCN9A	406	406	E -> K (in PERYTHM).
SCN9A	490	490	S -> N.
SCN9A	519	519	E -> K.
SCN9A	641	641	N -> Y (in GEFS+7).
SCN9A	666	666	K -> R (in GEFS+7; also found in a patient with severe myoclonic epilepsy in infancy).
SCN9A	695	695	I -> M.
SCN9A	710	710	C -> Y (found in a patient with severe myoclonic epilepsy in infancy).
SCN9A	750	750	I -> V.
SCN9A	859	859	I -> T (in PERYTHM; sporadic; activated at more negative potentials; slower inactivation kinetics than wild-type channels).
SCN9A	869	869	L -> F (in PERYTHM; causes a hyperpolarizing shift in channel activation, a depolarizing shift of inactivation and an 18-fold increase in deactivation time compared to wild-type; the mean ramp current amplitude in response to slow depolarization is higher in the mutant channels).
SCN9A	869	869	L -> H (in PERYTHM; activated at more negative potentials; slower inactivation kinetics than wild-type channels).
SCN9A	907	907	R -> Q (in CIPAR; significant reduction in membrane localization of the mutant protein compared to the wild-type; complete loss of function of the sodium channel).
SCN9A	1007	1007	R -> C (in PEPD).
SCN9A	1134	1134	L -> F.
SCN9A	1171	1171	E -> Q (found in a patient with severe myoclonic epilepsy in infancy).
SCN9A	1278	1278	L -> V.
SCN9A	1309	1309	V -> D (in PEPD).
SCN9A	1309	1309	V -> F (in PEPD).
SCN9A	1310	1310	V -> F (in PEPD).
SCN9A	1381	1385	Missing (in CIPAR; significant reduction in membrane localization of the mutant protein compared to the wild-type; complete loss of function of the sodium channel).
SCN9A	1460	1460	F -> V (in PERYTHM; produces a hyperpolarizing shift in channel activation and a depolarizing shift in steady-state activation).
SCN9A	1472	1472	I -> T (in PEPD; reduction in fast inactivation leading to persistent sodium current).
SCN9A	1473	1473	F -> V (in PEPD).
SCN9A	1475	1475	T -> I (in PEPD; reduction in fast inactivation leading to persistent sodium current).
SCN9A	1638	1638	M -> K (in PEPD; reduction in fast inactivation leading to persistent sodium current).
LRP2	103	103	C -> R (found in a renal cell carcinoma sample; somatic mutation).
LRP2	1287	1287	A -> P.
LRP2	2522	2522	Y -> H (in DBS).
LRP2	4272	4272	M -> V (in a colorectal cancer sample; somatic mutation).
GAD1	12	12	S -> C (in CPSQ1).
WIPF1	495	495	A -> G.
CHN1	20	20	L -> F (in DURS2; behaves as a dominant gain-of-function allele that increases CHN1 activity in vitro; appears to enhance membrane translocation and CHN1 activity by destabilizing the closed conformation of CHN1 protein in response to phorbol 12-myristate 13-acetate (PMA)).
CHN1	126	126	I -> M (in DURS2; behaves as a dominant gain-of -function allele that increases CHN1 activity in vitro).
CHN1	143	143	Y -> H (in DURS2; behaves as a dominant gain-of-function allele that increases CHN1 activity in vitro; appears to enhance membrane translocation and CHN1 activity by destabilizing the closed conformation of CHN1 protein in response to phorbol 12-myristate 13-acetate (PMA)).
CHN1	223	223	A -> V (in DURS2; behaves as a dominant gain-of-function allele that increases CHN1 activity in vitro; appears to enhance membrane translocation and CHN1 activity by destabilizing the closed conformation of CHN1 protein in response to phorbol 12-myristate 13-acetate (PMA)).
CHN1	228	228	G -> S (in DURS2; behaves as a dominant gain-of-function allele that increases CHN1 activity in vitro).
CHN1	252	252	P -> Q (in DURS2; behaves as a dominant gain-of-function allele that increases CHN1 activity in vitro; appears to enhance membrane translocation and CHN1 activity by destabilizing the closed conformation of CHN1 protein in response to phorbol 12-myristate 13-acetate (PMA)).
CHN1	313	313	E -> K (in DURS2; behaves as a dominant gain-of-function allele that increases CHN1 activity in vitro).
ATF2	352	352	D -> H (in a breast cancer sample; somatic mutation).
PDE11A	804	804	R -> H.
PDE11A	867	867	R -> G.
COL5A2	833	833	P -> L.
COL5A2	963	963	G -> R (in EDS2).
COL5A2	1230	1230	T -> S.
COL5A2	1432	1432	D -> V.
SLC40A1	64	64	Y -> N (in HFE4).
SLC40A1	77	77	A -> D (in HFE4).
SLC40A1	80	80	G -> S (in iron overload).
SLC40A1	80	80	G -> V (in HFE4).
SLC40A1	144	144	N -> D (in HFE4).
SLC40A1	144	144	N -> H (in HFE4).
SLC40A1	144	144	N -> T (in HFE4).
SLC40A1	157	157	D -> G (in HFE4).
SLC40A1	162	162	Missing (in HFE4).
SLC40A1	174	174	N -> I (in iron overload).
SLC40A1	181	181	D -> V (in HFE4).
SLC40A1	182	182	Q -> H (in HFE4).
SLC40A1	267	267	G -> D (in HFE4).
SLC40A1	270	270	D -> V (in HFE4).
SLC40A1	323	323	G -> V (in HFE4).
SLC40A1	326	326	C -> Y (in iron overload).
SLC40A1	490	490	G -> D (in iron overload).
HIBCH	122	122	Y -> C (in HIBCHD).
STAT4	112	112	E -> Q (in a breast cancer sample; somatic mutation).
MYO1B	385	385	V -> G (in a colorectal cancer sample; somatic mutation).
MYO1B	385	385	V -> I (in a colorectal cancer sample; somatic mutation).
MYO1B	969	969	E -> K (in a melanoma patient).
ALS2	102	102	H -> R.
ALS2	1406	1406	R -> K.
FZD7	24	24	G -> S.
RAPH1	891	891	A -> S (in a breast cancer sample; somatic mutation).
RAPH1	1228	1228	T -> A (in a breast cancer sample; somatic mutation).
PIKFYVE	1103	1103	K -> R (in CFD).
MAP2	277	277	E -> D (in a colorectal cancer sample; somatic mutation).
MAP2	705	705	P -> L (in a colorectal cancer sample; somatic mutation).
CPS1	79	79	G -> E (in CPS1D).
CPS1	123	123	S -> F (in CPS1D; modestly decreases enzyme activity).
CPS1	212	212	Y -> N (in CPS1D).
CPS1	280	280	K -> N (in CPS1D).
CPS1	438	438	A -> P (in CPS1D).
CPS1	457	457	V -> G (in CPS1D).
CPS1	471	471	T -> N (in CPS1D).
CPS1	544	544	T -> M (in CPS1D).
CPS1	587	587	R -> H (in CPS1D).
CPS1	593	593	G -> A (in CPS1D).
CPS1	651	651	E -> K (in CPS1D).
CPS1	674	674	N -> I (in CPS1D).
CPS1	678	678	Q -> P (in CPS1D; results in a poor enzyme expression and solubility; hampers correct enzyme folding).
CPS1	774	774	P -> L (in CPS1D; the enzyme is inactive).
CPS1	780	780	R -> H (in CPS1D).
CPS1	810	810	Q -> R (in CPS1D).
CPS1	843	843	L -> S (in CPS1D).
CPS1	850	850	R -> C (in CPS1D).
CPS1	850	850	R -> H (in CPS1D).
CPS1	875	875	K -> E (in CPS1D).
CPS1	918	918	S -> P (in CPS1D).
CPS1	982	982	G -> D (in CPS1D).
CPS1	1103	1103	Q -> R (in CPS1D).
CPS1	1141	1141	V -> G (in CPS1D).
CPS1	1195	1195	H -> P (in CPS1D).
CPS1	1215	1215	I -> V (in CPS1D).
CPS1	1241	1241	N -> K (in CPS1D).
CPS1	1376	1376	G -> S (polymorphism with no functional consequences).
CPS1	1411	1411	P -> L (in CPS1D; modestly decreases enzyme activity).
CPS1	1453	1453	R -> Q (in CPS1D; the enzyme is inactive).
CPS1	1453	1453	R -> W (in CPS1D; the enzyme is inactive).
CPS1	1491	1491	Y -> H (in CPS1D; triggers a large decrease in the apparent affinity for N- acetyl-L-glutamate (NAG)).
BARD1	153	153	K -> E.
BARD1	564	564	Q -> H (in an ovarian clear cell adenocarcinoma).
BARD1	695	695	V -> L (in a breast cancer sample; somatic mutation).
BARD1	761	761	S -> N (in an uterine cancer sample; somatic mutation).
ABCA12	476	476	A -> V (in a pancreatic ductal adenocarcinoma sample; somatic mutation).
FN1	940	940	D -> N (in a breast cancer sample; somatic mutation).
FN1	973	973	Y -> C (in GFND2).
FN1	1120	1120	R -> P (in a breast cancer sample; somatic mutation).
FN1	1834	1834	W -> R (in GFND2; reduced binding to heparin, endothelial cells and podocytes; impaired capability to induce stress- fiber formation).
FN1	1883	1883	L -> R (in GFND2; reduced binding to heparin, endothelial cells and podocytes; impaired capability to induce stress- fiber formation).
FN1	2380	2380	D -> N (in a colorectal cancer sample; somatic mutation).
SMARCAL1	432	432	L -> V (in a breast cancer sample; somatic mutation).
SMARCAL1	468	468	A -> P (in SIOD).
SMARCAL1	548	548	I -> N (in SIOD).
SMARCAL1	579	579	S -> L (in SIOD).
SMARCAL1	586	586	R -> W (in SIOD; impairs without abolishing annealing helicase activity but still binds selectively to fork DNA relative to ssDNA or dsDNA).
SMARCAL1	644	644	R -> W (in SIOD).
SMARCAL1	645	645	R -> C (in SIOD).
SMARCAL1	647	647	K -> Q (in SIOD).
SMARCAL1	647	647	K -> T (in SIOD).
SMARCAL1	705	705	T -> I (in SIOD).
SMARCAL1	764	764	R -> Q (in SIOD; abolishes annealing helicase activity but still binds selectively to fork DNA relative to ssDNA or dsDNA).
SMARCAL1	820	820	R -> H (in SIOD).
TNS1	1093	1093	F -> L (in a breast cancer sample; somatic mutation).
STK36	660	660	S -> C (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
STK36	767	767	S -> Y (in an ovarian papillary serous adenocarcinoma sample; somatic mutation).
STK36	1138	1138	Q -> K (in an ovarian serous carcinoma sample; somatic mutation).
STK36	1185	1185	P -> S (in an ovarian endometrioid sample; somatic mutation).
STK36	1313	1313	H -> P.
CYP27A1	145	145	G -> E (in CTX).
CYP27A1	395	395	R -> C (in CTX).
CYP27A1	395	395	R -> S (in CTX).
CYP27A1	405	405	R -> Q (in CTX).
CYP27A1	474	474	R -> Q (in CTX).
CYP27A1	474	474	R -> W (in CTX).
CYP27A1	479	479	R -> C (in CTX).
SPEG	1178	1178	E -> D (in a gastric adenocarcinoma sample; somatic mutation).
SPEG	1903	1903	R -> W (in an ovarian mucinous carcinoma sample; somatic mutation).
SPEG	2742	2742	V -> M (in a gastric adenocarcinoma sample; somatic mutation).
PAX3	45	45	F -> L (in WS1).
PAX3	47	47	N -> H (in WS3).
PAX3	47	47	N -> K (in CDHS).
PAX3	48	48	G -> R (in WS1).
PAX3	50	50	P -> L (in WS1; important hearing loss).
PAX3	56	56	R -> L (in WS1; associated with meningomyelocele).
PAX3	59	59	I -> F (in WS1).
PAX3	59	59	I -> N (in WS1).
PAX3	60	60	V -> M (in WS1).
PAX3	62	62	M -> V (in WS1).
PAX3	63	67	Missing (in WS1).
PAX3	73	73	S -> L (in WS1).
PAX3	78	78	V -> M (in WS1).
PAX3	81	81	G -> A (in WS1; originally classified as Waardenburg syndrome type 2).
PAX3	84	84	S -> F (in WS3).
PAX3	85	85	K -> E (in WS1).
PAX3	99	99	G -> D (in WS1).
PAX3	238	238	F -> S (in WS1).
PAX3	265	265	V -> F (in WS1).
PAX3	266	266	W -> C (in WS1).
PAX3	270	270	R -> C (in WS1 and WS3).
PAX3	271	271	R -> C (in WS1).
PAX3	271	271	R -> G (in WS1).
PAX3	271	271	R -> H (in WS1; associated with Lys-273 in one family).
PAX3	273	273	R -> K (associated with His-271 in one Waardenburg syndrome type I family).
PAX3	391	391	Q -> H (in WS1).
COL4A4	116	116	G -> E (in BFH).
COL4A4	441	446	Missing (in APSAR).
COL4A4	570	570	E -> Q.
COL4A4	897	897	G -> E (in BFH).
COL4A4	931	931	A -> T.
COL4A4	960	960	G -> R (in BFH).
COL4A4	1030	1030	G -> V (in APSAR).
COL4A4	1132	1132	P -> L (in BFH).
COL4A4	1201	1201	G -> S (in APSAR).
COL4A4	1402	1402	P -> S.
COL4A4	1572	1572	P -> L (in APSAR).
COL4A3	297	297	G -> E (in APSAR).
COL4A3	407	407	G -> R (in APSAR).
COL4A3	532	532	G -> D (in APSAR).
COL4A3	640	640	G -> R (in APSAR).
COL4A3	739	739	G -> R (in APSAR).
COL4A3	853	853	G -> R (in APSAR).
COL4A3	985	985	G -> V (in BFH).
COL4A3	1015	1015	G -> E (in BFH).
COL4A3	1167	1167	G -> R (in APSAD; in isolated microhematuria at heterozygosity).
COL4A3	1207	1207	G -> E (in APSAR; in isolated microhematuria at heterozygosity).
COL4A3	1215	1215	R -> Q (in APSAR; could be a polymorphism).
COL4A3	1216	1216	G -> R (in APSAR).
COL4A3	1277	1277	G -> S (in APSAR).
COL4A3	1330	1330	I -> T (in APSAR; could be a polymorphism).
COL4A3	1334	1334	G -> E (in APSAR).
COL4A3	1347	1347	D -> E (in APSAR; could be a polymorphism).
COL4A3	1474	1474	L -> P.
COL4A3	1495	1495	Q -> R.
COL4A3	1661	1661	R -> C (in APSAR).
MFF	29	29	E -> K (in a colorectal cancer sample; somatic mutation).
PID1	43	43	T -> THFQTMLKSKLNVLTLKKEPLPAVIFHEPEAIELCT TTPLMKTRTHSGCK (in variant with duplicated exon 2).
SP110	8	8	M -> T (in a breast cancer sample; somatic mutation).
SP110	683	683	G -> S (in a breast cancer sample; somatic mutation).
SP100	471	471	S -> P (in HeLa cells).
GIGYF2	56	56	N -> S (may be associated with PARK11).
GIGYF2	112	112	T -> A (in PARK11).
GIGYF2	278	278	I -> V (in PARK11).
GIGYF2	335	335	S -> T (in PARK11).
GIGYF2	457	457	N -> T (in PARK11).
GIGYF2	606	606	D -> E (in PARK11).
GIGYF2	1171	1171	H -> R.
GIGYF2	1211	1211	Missing.
GIGYF2	1212	1212	Q -> QQ.
GIGYF2	1242	1242	V -> I (in PARK11).
INPP5D	685	685	V -> E (in one patient with acute myeloid leukemya; somatic mutation).
SAG	84	84	R -> C.
SAG	125	125	T -> M.
SAG	364	364	P -> L.
SAG	378	378	V -> I.
SAG	384	384	R -> C.
UGT1A1	15	15	L -> R (in CN2; mutant protein rapidly degraded by the proteasome owing to its mislocalization in the cell).
UGT1A1	34	34	P -> Q (in CN2).
UGT1A1	39	39	H -> D (in CN1).
UGT1A1	170	170	Missing (in CN1 and CN2; has nearly normal activity at pH 7.6 and is inactive at pH 6.4).
UGT1A1	171	171	Missing (in CN2).
UGT1A1	175	175	L -> Q (in CN2; has low residual bilirubin glucuronidation activity of about 4.6% of that of the wild-type protein).
UGT1A1	177	177	C -> R (in CN1).
UGT1A1	191	191	S -> F (in CN2; has low residual bilirubin glucuronidation activity of about 5.3% of that of the wild-type protein).
UGT1A1	209	209	R -> W (in CN2; has low residual bilirubin glucuronidation activity of about 2.9% of that of the wild-type protein).
UGT1A1	229	229	P -> Q (in CN2 and GILBS; displays 2-fold decrease in biluribin affinity and 61% of wild-type bilirubin glucuronidation activity).
UGT1A1	276	276	G -> R (in CN1).
UGT1A1	279	279	N -> Y (in CN2).
UGT1A1	291	291	E -> V (in CN1).
UGT1A1	292	292	A -> V (in CN1).
UGT1A1	294	294	I -> T (in GILBS and CN2; 40-55% normal activity; normal Km for bilirubin; when homozygous far less repressive and generates the mild Gilbert phenotype).
UGT1A1	308	308	G -> E (in CN1; no enzyme activity).
UGT1A1	331	331	Q -> R (in CN2; has no residual bilirubin glucuronidation activity).
UGT1A1	336	336	R -> L (in CN1 and CN2).
UGT1A1	336	336	R -> Q (in CN1).
UGT1A1	336	336	R -> W (in CN2; has very low residual bilirubin glucuronidation activity of about 0.4% of that of the wild-type protein).
UGT1A1	354	354	W -> R (in CN2).
UGT1A1	357	357	Q -> R (in CN1).
UGT1A1	368	368	A -> T (in CN1).
UGT1A1	370	370	I -> V (in CN2).
UGT1A1	375	375	S -> F (in CN1; no enzyme activity).
UGT1A1	376	376	H -> R (in CN1 and CN2).
UGT1A1	377	377	G -> V (in CN1 and CN2).
UGT1A1	381	381	S -> R (in CN1).
UGT1A1	387	387	P -> H (in CN2; has no residual bilirubin glucuronidation activity).
UGT1A1	387	387	P -> S (in CN1).
UGT1A1	395	395	G -> V (in CN1; has no residual bilirubin glucuronidation activity).
UGT1A1	401	401	A -> P (in CN1).
UGT1A1	402	402	K -> T (in CN1; has no residual bilirubin glucuronidation activity; N-glycosylation does take place at this new additional site).
UGT1A1	403	403	R -> C (in CN2).
UGT1A1	428	428	K -> E (in CN1).
UGT1A1	443	443	L -> P (in CN2; has no residual bilirubin glucuronidation activity).
UGT1A1	461	461	W -> R (in CN1 and CN2).
UGT1A1	478	478	A -> D (in CN2).
UGT1A1	486	486	Y -> D (in CN2, GILBS and TNHBB; displays less than 10% of wild-type bilirubin glucuronidation activity).
COL6A3	411	411	L -> V.
COL6A3	491	491	D -> H.
COL6A3	492	492	T -> S.
COL6A3	807	807	A -> T.
COL6A3	830	830	A -> S.
COL6A3	1014	1014	K -> E (in BM).
COL6A3	1064	1064	R -> Q (in UCMD).
COL6A3	1386	1386	E -> K (in BM).
COL6A3	1395	1395	R -> Q (in UCMD).
COL6A3	1467	1467	N -> D (in BM).
COL6A3	1576	1576	R -> Q.
COL6A3	1632	1632	R -> Q.
COL6A3	1674	1674	D -> N (in UCMD).
COL6A3	1679	1679	G -> E (in BM).
COL6A3	1726	1726	L -> R (in BM).
COL6A3	1985	1985	V -> M (in BM).
COL6A3	2047	2047	G -> D (in BM).
COL6A3	2056	2056	G -> R (in BM).
COL6A3	2080	2080	G -> D (in BM).
COL6A3	2431	2431	D -> V.
COL6A3	2453	2453	E -> K.
MLPH	35	35	R -> W (in GS3; abolishes RAB27A binding).
LRRFIP1	68	68	S -> C (in a breast cancer sample; somatic mutation).
PRSS56	176	176	R -> G (in MCOP6).
PRSS56	309	309	W -> S (in MCOP6).
CHRND	80	80	E -> K (in FCCMS; reduced adult and fetal AChR expression and a reduced probability of both adult and fetal AChR being in the open state).
CHRND	95	95	F -> L (in MUPSL).
CHRND	271	271	P -> Q (in FCCMS; burst duration was decreased and disassociation of ACh was increased resulting in brief channel opening episodes; shows abnormal association with alpha CHRNA1 subunit resulting in a decreased number of fully assembled AChRs).
CHRND	289	289	S -> F (in SCCMS; delayed closure of AchR ion channels, increasing the propensity for open-channel block, as well as a reduced rate of channel opening).
CHRND	398	398	D -> E (in a breast cancer sample; somatic mutation).
CHRNG	107	107	V -> G (in MUPSE and MUPSL).
CHRNG	239	239	R -> C (in MUPSE and MUPSL).
KCNJ13	162	162	R -> W (in SVD; overexpression produces a non-selective cation current that depolarizes transfected cells and increases their fragility).
WDR69	129	129	T -> M (in a breast cancer sample; somatic mutation).
IHH	46	46	P -> L (in ACFD).
IHH	95	95	E -> K (in BDA1).
IHH	100	100	D -> E (in BDA1).
IHH	131	131	E -> K (in BDA1).
IHH	190	190	V -> A (in ACFD).
PER2	662	662	S -> G (in FASPS; reduced in vitro phosphorylation by CSNK1E).
PER2	823	823	L -> V (in a breast cancer sample; somatic mutation).
GPC1	337	337	A -> D (in a breast cancer sample; somatic mutation).
RNPEPL1	247	247	V -> M (in a colorectal cancer sample; somatic mutation).
CAPN10	202	202	R -> H.
CAPN10	276	276	E -> G (in a colorectal cancer sample; somatic mutation).
CAPN10	341	341	A -> V.
CAPN10	529	529	A -> S.
CAPN10	613	613	S -> N.
AGXT	9	9	T -> N (in HP1).
AGXT	41	41	G -> R (in HP1; protein destabilization and loss of activity in the presence of L-11).
AGXT	41	41	G -> V (in HP1).
AGXT	82	82	G -> E (in HP1; abolishes catalytic activity by interfering with pyridoxal phosphate binding).
AGXT	82	82	G -> R (in HP1).
AGXT	95	95	E -> EE (in HP1).
AGXT	108	108	W -> R (in HP1).
AGXT	112	112	A -> D (in HP1).
AGXT	116	116	G -> R (in HP1).
AGXT	139	139	Missing (in HP1).
AGXT	152	152	F -> I (in HP1; protein destabilization and loss of activity in the presence of L-11).
AGXT	153	153	L -> V (in HP1).
AGXT	156	156	G -> R (in HP1).
AGXT	158	158	S -> L (in HP1).
AGXT	161	161	G -> R (in HP1).
AGXT	170	170	G -> R (in HP1; causes mistargeting when associated with L-11).
AGXT	173	173	C -> Y (in HP1).
AGXT	183	183	D -> N (in HP1).
AGXT	187	187	S -> F (in HP1).
AGXT	190	190	G -> R (in HP1).
AGXT	195	195	M -> R (in HP1).
AGXT	201	201	D -> E (in HP1).
AGXT	205	205	S -> P (in HP1).
AGXT	218	218	S -> L (in HP1).
AGXT	233	233	R -> C (in HP1).
AGXT	233	233	R -> H (in HP1).
AGXT	233	233	R -> L (in HP1).
AGXT	243	243	D -> H (in HP1).
AGXT	244	244	I -> T (in HP1; prevalent mutation in the Canary islands; protein misfolding and loss of activity when associated with P- 11).
AGXT	253	253	C -> R (in HP1).
AGXT	279	279	I -> M (in HP1).
AGXT	279	279	I -> T.
AGXT	280	280	A -> V.
AGXT	287	287	S -> T (in HP1).
AGXT	289	289	R -> C (in HP1).
AGXT	296	296	Missing (in HP1).
AGXT	298	298	L -> P (in HP1).
AGXT	326	326	V -> I.
AGXT	336	336	V -> D (in HP1).
AGXT	350	350	G -> D (in HP1).
PASK	11	11	E -> K (in a metastatic melanoma sample; somatic mutation).
PASK	1301	1301	P -> S.
CDK15	93	93	K -> E (in a renal clear cell carcinoma sample; somatic mutation).
CDK15	276	276	E -> D (in a breast infiltrating ductal carcinoma sample; somatic mutation).
IDH1	132	132	R -> C (in colorectal cancer and glioma samples; glioblastoma multiforme; somatic mutation; abolishes magnesium binding and alters enzyme activity so that isocitrate is no longer converted to alpha- ketoglutarate but instead alpha- ketoglutarate is converted to R(-)-2- hydroxyglutarate).
IDH1	132	132	R -> G (in a glioma sample; glioblastoma multiforme; somatic mutation).
IDH1	132	132	R -> H (in a glioma sample; glioblastoma multiforme; somatic mutation; abolishes magnesium binding and alters enzyme activity so that isocitrate is no longer converted to alpha-ketoglutarate but instead alpha-ketoglutarate is converted to R(-)-2-hydroxyglutarate).
IDH1	132	132	R -> L (in a glioma sample; glioblastoma multiforme; somatic mutation; abolishes magnesium binding and alters enzyme activity so that isocitrate is no longer converted to alpha-ketoglutarate but instead alpha-ketoglutarate is converted to R(-)-2-hydroxyglutarate).
IDH1	132	132	R -> S (in a glioma sample; glioblastoma multiforme; somatic mutation; abolishes magnesium binding and alters enzyme activity so that isocitrate is no longer converted to alpha-ketoglutarate but instead alpha-ketoglutarate is converted to R(-)-2-hydroxyglutarate).
KLF11	347	347	A -> S (in MODY7; increased repression activity; no alteration in binding affinity to mSin3A).
MYCN	393	393	R -> H (in MODED).
MYCN	393	393	R -> S (in MODED).
MYCN	394	394	R -> H (in MODED).
MATN3	11	11	P -> S.
MATN3	70	70	R -> H (in EDM5).
MATN3	105	105	F -> S (in EDM5).
MATN3	120	120	T -> M (in EDM5; retained and accumulates within the cell).
MATN3	121	121	R -> W (in EDM5; retained and accumulates within the cell).
MATN3	128	128	A -> P (in EDM5; bilateral hereditary microepiphyseal dysplasia).
MATN3	134	134	E -> K (in EDM5; retained and accumulates within the cell).
MATN3	192	192	I -> N (in EDM5; retained and accumulates within the cell).
MATN3	194	194	V -> D (in EDM5; retained and accumulates within the cell).
MATN3	195	195	T -> K (in EDM5).
MATN3	218	218	Y -> N (in EDM5).
MATN3	304	304	C -> S (in SEMD-MATN3).
C2orf44	454	454	P -> S (in a breast cancer sample; somatic mutation).
TP53I3	180	180	M -> K (in a breast cancer sample; somatic mutation).
POMC	7	7	S -> T.
POMC	9	9	S -> L.
POMC	97	99	Missing.
POMC	106	106	D -> N.
POMC	214	214	E -> G.
POMC	236	236	R -> Q.
HADHA	282	282	V -> D (in TFP deficiency; mild phenotype with slowly progressive myopathy and sensorimotor polyneuropathy).
HADHA	305	305	I -> N (in TFP deficiency; mild phenotype with slowly progressive myopathy and sensorimotor polyneuropathy).
HADHA	342	342	L -> P (in LCHAD deficiency).
HADHA	510	510	E -> Q (in AFLP and LCHAD deficiency; loss of activity).
KHK	40	40	G -> R (in FRUCT).
KHK	43	43	A -> T (in FRUCT).
KHK	159	159	R -> G (either a polymorphism or a cloning artifact).
CAD	177	177	R -> Q (in a colorectal cancer sample; somatic mutation).
CAD	735	735	Y -> C (in a colorectal cancer sample; somatic mutation).
MPV17	50	50	R -> Q (in MTDPS6; may cause protein instability and decay).
MPV17	50	50	R -> W (in MTDPS6).
MPV17	166	166	N -> K (in MTDPS6).
EIF2B4	228	228	A -> V (in VWM).
EIF2B4	306	306	R -> G.
EIF2B4	357	357	R -> Q (in VWM).
EIF2B4	374	374	R -> C (in VWM).
EIF2B4	465	465	C -> R (in VWM; with ovarian failure).
EIF2B4	489	489	Y -> H (in VWM; with ovarian failure).
ZNF513	339	339	C -> R (in RP58; cannot bind to promoters of retinal-specific genes).
C2orf71	201	201	I -> F (in RP54; induces proteasomal degradation).
C2orf71	227	227	E -> K.
C2orf71	247	247	V -> A.
C2orf71	252	252	A -> D.
C2orf71	258	258	R -> I.
C2orf71	312	312	S -> N.
C2orf71	320	320	R -> C.
C2orf71	372	372	D -> N (in RP54).
C2orf71	378	378	E -> K.
C2orf71	612	612	L -> P (in RP54).
C2orf71	615	615	V -> D (in RP54).
C2orf71	628	628	A -> T.
C2orf71	648	648	A -> P.
C2orf71	688	688	C -> Y.
C2orf71	867	867	P -> L.
C2orf71	954	954	P -> S.
C2orf71	955	955	R -> Q.
C2orf71	959	959	A -> T.
C2orf71	1020	1020	Q -> R.
C2orf71	1089	1089	Missing.
C2orf71	1160	1160	A -> T.
C2orf71	1177	1177	R -> Q.
C2orf71	1225	1225	S -> SS.
C2orf71	1247	1247	G -> S.
SRD5A2	55	55	L -> Q (in PPSH).
SRD5A2	85	85	G -> D (in PPSH).
SRD5A2	115	115	G -> D (in PPSH).
SRD5A2	123	123	G -> R (in PPSH).
SRD5A2	126	126	Q -> R (in PPSH).
SRD5A2	145	145	R -> W (in PPSH).
SRD5A2	157	157	Missing (in PPSH).
SRD5A2	158	158	G -> R (in PPSH).
SRD5A2	181	181	P -> L (in PPSH).
SRD5A2	183	183	G -> S (in PPSH).
SRD5A2	196	196	G -> S (in PPSH).
SRD5A2	197	197	E -> D (in PPSH).
SRD5A2	200	200	E -> K (in PPSH).
SRD5A2	207	207	A -> D (in PPSH).
SRD5A2	212	212	P -> R (in PPSH).
SRD5A2	228	228	A -> T (in PPSH).
SRD5A2	231	231	H -> R (in PPSH).
SRD5A2	235	235	Y -> F (in PPSH).
SRD5A2	245	245	S -> Y (in PPSH).
SRD5A2	246	246	R -> W (in PPSH).
QPCT	71	71	Q -> R.
CYP1B1	28	28	S -> W (in POAG).
CYP1B1	52	52	P -> L.
CYP1B1	57	57	W -> C (in POAG; juvenile onset; allele CYP1B1*11).
CYP1B1	77	77	L -> P (in GLC3A).
CYP1B1	115	115	A -> P (in GLC3A).
CYP1B1	132	132	M -> R (in GLC3A).
CYP1B1	144	144	Q -> H.
CYP1B1	144	144	Q -> P (in GLC3A).
CYP1B1	144	144	Q -> R (in GLC3A).
CYP1B1	145	145	R -> W (in POAG).
CYP1B1	184	184	G -> S.
CYP1B1	189	189	A -> P (associated with ocular hypertension susceptibility).
CYP1B1	192	192	D -> V (in GLC3A).
CYP1B1	193	193	P -> L (in GLC3A).
CYP1B1	203	203	N -> S (in GLC3A; reduces enzymatic activity).
CYP1B1	215	215	S -> I (in GLC3A).
CYP1B1	232	232	G -> R (in GLC3A and POAG; adult-onset).
CYP1B1	239	239	S -> R (in GLC3A).
CYP1B1	269	271	Missing (in GLC3A and POAG).
CYP1B1	320	320	V -> L (in GLC3A).
CYP1B1	330	330	A -> F (in GLC3A; requires 2 nucleotide substitutions; uncertain pathogenicity).
CYP1B1	330	330	A -> S (associated with ocular hypertension susceptibility).
CYP1B1	343	343	Missing (in GLC3A; reduces enzymatic activity and also the abundance of the enzyme).
CYP1B1	345	345	L -> F (in POAG).
CYP1B1	355	358	Missing (in GLC3A).
CYP1B1	364	364	V -> M (in GLC3A).
CYP1B1	388	388	A -> T (in GLC3A).
CYP1B1	390	390	R -> C (in GLC3A).
CYP1B1	390	390	R -> S (in GLC3A).
CYP1B1	399	399	I -> S (in GLC3A).
CYP1B1	409	409	V -> F (in POAG).
CYP1B1	422	422	V -> G.
CYP1B1	423	423	N -> Y (in GLC3A and POAG; juvenile- onset).
CYP1B1	444	444	R -> Q (in GLC3A).
CYP1B1	445	445	F -> C (in GLC3A).
CYP1B1	466	466	G -> D (in GLC3A).
CYP1B1	499	499	E -> G (in GLC3A).
CYP1B1	515	515	S -> L (in POAG; uncertain pathogenicity).
CYP1B1	518	518	V -> A.
CYP1B1	523	523	R -> T (in POAG; juvenile-onset).
CYP1B1	530	530	D -> G (in POAG).
ABCG8	184	184	R -> H (in STSL).
ABCG8	231	231	P -> T (in STSL).
ABCG8	263	263	R -> Q (in STSL).
ABCG8	405	405	R -> H (in STSL).
ABCG8	501	501	L -> P (in STSL).
ABCG8	543	543	R -> S (in STSL).
ABCG8	570	570	Missing (in STSL).
ABCG8	572	572	L -> P (in STSL).
ABCG8	574	574	G -> E (in STSL).
ABCG8	574	574	G -> R (in STSL).
ABCG8	596	596	L -> R (in STSL).
ABCG8	641	641	Y -> F.
SLC3A1	122	122	P -> S (in CSNU1).
SLC3A1	128	128	P -> Q (in CSNU1).
SLC3A1	151	151	Y -> C (in CSNU1).
SLC3A1	181	181	R -> Q (in CSNU1).
SLC3A1	216	216	T -> M (in CSNU1).
SLC3A1	253	253	N -> K (in CSNU1).
SLC3A1	268	268	E -> K (in CSNU1; reduction in amino acid transport activity).
SLC3A1	341	341	T -> A (in CSNU1; reduction in amino acid transport activity).
SLC3A1	362	362	R -> C (in CSNU1).
SLC3A1	362	362	R -> H (in CSNU1).
SLC3A1	365	365	R -> W (in CSNU1).
SLC3A1	398	398	G -> R (in CSNU1).
SLC3A1	452	452	R -> W (in CSNU1).
SLC3A1	461	461	Y -> H (in CSNU1).
SLC3A1	467	467	M -> K (in CSNU1).
SLC3A1	467	467	M -> T (in CSNU1; loss of 80% of amino acid transport activity).
SLC3A1	481	481	G -> V (in CSNU1).
SLC3A1	482	482	E -> K (in CSNU1).
SLC3A1	508	508	P -> A (in CSNU1).
SLC3A1	510	510	Q -> R (in CSNU1).
SLC3A1	582	582	Y -> H (in CSNU1).
SLC3A1	584	584	R -> T (in CSNU1).
SLC3A1	599	599	F -> S (in CSNU1).
SLC3A1	600	600	G -> E (in CSNU1).
SLC3A1	615	615	P -> T (in CSNU1).
SLC3A1	648	648	F -> S (in CSNU1).
SLC3A1	652	652	T -> R (in CSNU1).
SLC3A1	678	678	L -> P (in CSNU1).
SIX3	69	69	G -> D (in HPE2).
SIX3	92	92	V -> G (in HPE2).
SIX3	105	105	I -> V (in HPE2).
SIX3	173	173	H -> P (in HPE2).
SIX3	202	202	T -> I (in HPE2).
SIX3	226	226	L -> V (in HPE2).
SIX3	231	231	P -> R (in HPE2).
SIX3	250	250	V -> A (in HPE2).
SIX3	257	257	R -> P (in HPE2).
SIX3	257	257	R -> W (in HPE2).
EPCAM	66	66	C -> Y (in DIAR5).
MSH6	20	20	A -> V (in colorectal/endometrial cancer).
MSH6	54	54	G -> A (in CRC; uncertain pathogenicity).
MSH6	99	99	K -> N (in CRC; uncertain pathogenicity).
MSH6	128	128	R -> L (no impairment of heterodimerization with MSH2 and of in vitro mismatch repair capacity).
MSH6	285	285	S -> I (in CRC).
MSH6	295	295	K -> R (in multiple colorectal adenoma).
MSH6	340	340	F -> S (in CRC, breast cancer and leukemia).
MSH6	449	449	L -> P (in colorectal/endometrial cancer; uncertain pathogenicity).
MSH6	492	492	M -> V (in HNPCC5).
MSH6	503	503	S -> C.
MSH6	509	509	V -> A.
MSH6	522	522	Q -> R (in CRC; uncertain pathogenicity).
MSH6	566	566	G -> R (in CRC; partial functional loss).
MSH6	619	619	E -> D (in CRC; uncertain pathogenicity).
MSH6	623	623	P -> L (no impairment of heterodimerization with MSH2 and of in vitro mismatch repair capacity).
MSH6	685	685	G -> A (in CRC).
MSH6	698	698	Q -> E (in suspected HNPCC; could be a polymorphism).
MSH6	725	725	I -> M (in CRC; uncertain pathogenicity).
MSH6	772	772	R -> Q (in CRC).
MSH6	772	772	R -> W (in HNPCC5).
MSH6	787	787	A -> V (in CRC; uncertain pathogenicity).
MSH6	800	800	V -> A (in CRC; somatic mutation).
MSH6	800	800	V -> L (may be a rare polymorphism).
MSH6	803	803	D -> G (in CRC).
MSH6	850	850	Y -> C (in suspected HNPCC5 and CRC).
MSH6	901	901	R -> H (in colorectal/endometrial cancer).
MSH6	976	976	R -> H (in CRC; sporadic).
MSH6	1021	1021	A -> D (in CRC; uncertain pathogenicity).
MSH6	1031	1031	D -> V (in CRC; somatic mutation).
MSH6	1076	1076	R -> C (in CRC; uncertain pathogenicity).
MSH6	1087	1087	P -> T (in CRC).
MSH6	1095	1095	R -> H (in CRC; uncertain pathogenicity).
MSH6	1100	1100	T -> M (in CRC; uncertain pathogenicity).
MSH6	1158	1158	C -> R (in CRC; somatic mutation).
MSH6	1163	1163	E -> V (in HNPCC5).
MSH6	1193	1193	E -> K (found in an endometrial cancer sample; displays marked impairment of heterodimerization with MSH2 and of in vitro mismatch repair capacity).
MSH6	1213	1213	D -> V.
MSH6	1219	1219	T -> I (in CRC; uncertain pathogenicity).
MSH6	1248	1248	H -> D (in CRC; uncertain pathogenicity).
MSH6	1260	1260	V -> I.
MSH6	1284	1284	T -> M (in CRC).
MSH6	1354	1354	L -> Q (in CRC; uncertain pathogenicity).
LHCGR	18	18	Q -> QLQ (may be associated with earlier age of onset of breast cancer and poor prognosis).
LHCGR	131	131	C -> R (in LHR; Leydig cell hypoplasia type 2).
LHCGR	144	144	V -> F (in LHR; Leydig cell hypoplasia type 1; exhibits a marked impairment of human chorionic gonadotropin binding; shows the absence of the glycosylated cell surface form; the mutant receptor is retained in the endoplasmic reticulum; mutant receptors do not migrate to the cell surface).
LHCGR	152	152	I -> T (in LHR; reveals a marked impairment of human chorionic gonadotropin binding and signal transduction).
LHCGR	284	284	N -> S.
LHCGR	306	306	S -> N.
LHCGR	343	343	C -> S (in LHR; Leydig cell hypoplasia type 1; completely devoided of hormone- induced cAMP reporter gene activation; although initial translocation to the endoplasmic reticulum is normal translocation is halted or misrouted and the mutant does not reach the cell surface and cannot bind hormone).
LHCGR	354	354	E -> K (in LHR; Leydig cell hypoplasia type 1).
LHCGR	368	368	L -> P (in FMPP; cells expressing the mutation display up to a 12-fold increase in basal cAMP production compared with cells expressing the same number of cell surface wild-type receptor indicating constitutive activation of the mutant receptor).
LHCGR	373	373	A -> V (in FMPP).
LHCGR	398	398	M -> T (in FMPP).
LHCGR	457	457	L -> R (in FMPP).
LHCGR	502	502	L -> P (in LHR; Leydig cell hypoplasia type 1; shows reduced cAMP production and ligand binding; receptor trafficking is not affected by the mutation).
LHCGR	542	542	I -> L (in FMPP).
LHCGR	543	543	C -> R (in LHR; Leydig cell hypoplasia type 1; completely devoided of hormone- induced cAMP reporter gene activation; although initial translocation to the endoplasmic reticulum is normal translocation is halted or misrouted and the mutant does not reach the cell surface and cannot bind hormone).
LHCGR	564	564	D -> G (in FMPP).
LHCGR	564	564	D -> N (in a breast cancer sample; somatic mutation).
LHCGR	568	568	A -> V (in FMPP).
LHCGR	571	571	M -> I (in FMPP).
LHCGR	572	572	A -> V (in FMPP).
LHCGR	575	575	I -> L (in FMPP).
LHCGR	577	577	T -> I (in FMPP).
LHCGR	578	578	D -> E (in FMPP).
LHCGR	578	578	D -> G (in FMPP).
LHCGR	578	578	D -> H (in Leydig cell tumor; somatic mutation; causes receptor activation and precocious puberty).
LHCGR	578	578	D -> Y (in FMPP).
LHCGR	581	581	C -> R (in FMPP).
LHCGR	593	593	A -> P (in LHR; Leydig cell hypoplasia type 1; abolishes signal transduction).
LHCGR	608	609	Missing (in LHR; Leydig cell hypoplasia type 1).
LHCGR	616	616	S -> Y (in LHR; Leydig cell hypoplasia type 1; micropenis).
LHCGR	625	625	I -> K (in LHR; Leydig cell hypoplasia type 2).
RTN4	429	429	L -> V (in a colorectal cancer sample; somatic mutation).
PEX13	326	326	I -> T (in NALD).
AHSA2	248	248	M -> T (in a breast cancer sample; somatic mutation).
PLEK	92	92	W -> R.
FIGLA	4	4	A -> E.
FIGLA	140	140	Missing (in POF6; one individual with premature ovarian failure).
CD207	264	264	W -> R (in BIRGD; abolishes mannose- binding ability).
CYP26B1	181	181	V -> M.
CYP26B1	185	185	A -> V.
CYP26B1	191	191	R -> H.
CYP26B1	227	227	D -> N.
CYP26B1	473	473	R -> C.
CYP26B1	479	479	V -> I.
SPR	150	150	R -> G (in DRDSPRD).
SPR	163	163	P -> L (in DRDSPRD).
DGUOK	142	142	R -> K (in MTDPS3).
DGUOK	227	227	E -> K (in MTDPS3).
DGUOK	250	250	L -> S (in MTDPS3; significant reduction of activity).
DCTN1	59	59	G -> S (in HMN7B; shows a modestly reduced affinity for microtubules which has been suggested to impair axonal transport; the effect is identical to that of complete loss of the CAP-Gly domain).
DCTN1	71	71	G -> A (in PERRYS).
DCTN1	71	71	G -> E (in PERRYS).
DCTN1	71	71	G -> R (in PERRYS; diminishes microtubule binding and lead to intracytoplasmic inclusions).
DCTN1	72	72	T -> P (in PERRYS).
DCTN1	74	74	Q -> P (in PERRYS; diminishes microtubule binding and lead to intracytoplasmic inclusions).
DCTN1	163	163	A -> P.
DCTN1	571	571	M -> T (in susceptibility to amyotrophic lateral sclerosis).
DCTN1	785	785	R -> W (in susceptibility to amyotrophic lateral sclerosis).
DCTN1	1101	1101	R -> K (in susceptibility to amyotrophic lateral sclerosis).
DCTN1	1249	1249	T -> I (in susceptibility to amyotrophic lateral sclerosis; uncertain pathogenicity).
MOGS	486	486	R -> T (in CDGIIb; loss of activity).
MOGS	652	652	F -> L (in CDGIIb; loss of activity).
HTRA2	72	72	L -> P.
HTRA2	141	141	A -> S (polymorphism; associated with a 2.15-fold increased risk of PD; reduced protease activity).
HTRA2	399	399	G -> S (in PARK13; reduced protease activity).
HTRA2	404	404	R -> W (could be associated with an increased risk of developing PD).
GGCX	299	299	F -> S (in PXEL-MCFD).
GGCX	394	394	L -> R (in VKCFD1; affects glutamate binding).
GGCX	476	476	R -> C (in PXEL-MCFD).
GGCX	476	476	R -> H (in PXEL-MCFD).
GGCX	485	485	R -> P (in VKCFD1).
GGCX	493	493	W -> S (in PXEL-MCFD).
GGCX	558	558	G -> R (in PXEL-MCFD).
SFTPB	228	228	A -> I (requires 2 nucleotide substitutions).
SFTPB	228	228	A -> R (requires 2 nucleotide substitutions).
SFTPB	236	236	R -> C (in SMDP1).
KDM3A	187	187	D -> H (in a breast cancer sample; somatic mutation).
BCS1L	35	35	G -> R (in BJS; with mild mitochondrial complex III deficiency).
BCS1L	45	45	R -> C (in MT-C3D).
BCS1L	50	50	T -> A (in MT-C3D).
BCS1L	73	73	R -> C (in MT-C3D).
BCS1L	99	99	P -> L (in MT-C3D).
BCS1L	114	114	R -> W (in BJS).
BCS1L	144	144	R -> Q (in GRACILE).
BCS1L	155	155	R -> P (in MT-C3D; abolishes interaction with LETM1).
BCS1L	183	183	R -> C (in MT-C3D; causes a decreased incorporation of the Rieske iron-sulfur protein UQCRFS1 into complex III).
BCS1L	183	183	R -> H (in BJS).
BCS1L	184	184	R -> C (in MT-C3D and BJS; with mild mitochondrial complex III deficiency; causes a decreased incorporation of the Rieske iron-sulfur protein UQCRFS1 into complex III).
BCS1L	277	277	S -> N (in MT-C3D).
BCS1L	302	302	Q -> E (in BJS).
BCS1L	306	306	R -> H (in BJS).
BCS1L	327	327	V -> A (in GRACILE).
BCS1L	353	353	V -> M (in MT-C3D).
BCS1L	368	368	F -> I (in MT-C3D).
NHEJ1	57	57	R -> G (in NHEJ1-SCID; fails to translocate to the nucleus).
NHEJ1	123	123	C -> R (in NHEJ1-SCID).
ABCB6	69	69	R -> G (in a breast cancer sample; somatic mutation).
TEKT4	272	272	C -> S (in a breast cancer sample; somatic mutation).
KCNIP3	170	170	A -> S (in a breast cancer sample; somatic mutation).
KCNIP3	179	179	D -> Y (in a breast cancer sample; somatic mutation).
ADRA2B	301	303	Missing (common polymorphism; frequency in Caucasians 0.31 and in African- Americans 0.12; impaired phosphorylation and desensitization by GRKs).
ADRA2B	379	379	V -> G.
TMEM127	90	90	V -> M (in a pheochromocytoma sample arising from adrenal medulla).
SNRNP200	681	681	R -> C (in RP33; uncertain pathogenicity).
SNRNP200	681	681	R -> H (in RP33; uncertain pathogenicity).
SNRNP200	683	683	V -> L (in RP33; uncertain pathogenicity).
SNRNP200	689	689	Y -> C (in RP33; uncertain pathogenicity).
SNRNP200	1087	1087	S -> L (in RP33).
SNRNP200	1090	1090	R -> L (in RP33).
SNRNP200	1736	1736	F -> L (in a colorectal cancer sample; somatic mutation).
CNNM4	134	134	V -> L (in a breast cancer sample; somatic mutation).
CNNM4	196	196	S -> P (in JALIS).
CNNM4	200	200	S -> Y (in JALIS).
CNNM4	236	236	R -> Q (in JALIS).
CNNM4	324	324	L -> P (in JALIS).
ZAP70	337	337	L -> R (in STD).
ZAP70	448	448	G -> E (in a head and neck squamous cell carcinoma sample; somatic mutation).
ZAP70	465	465	R -> C (in STD).
ZAP70	465	465	R -> H (in STD).
ZAP70	507	507	A -> V (in STD).
ZAP70	518	518	S -> R (in STD).
ZAP70	541	541	K -> KLEQ (in STD).
ZAP70	564	564	C -> R (in STD).
CNGA3	48	48	P -> L.
CNGA3	162	162	D -> V (in ACHM2).
CNGA3	163	163	P -> L (in ACHM2).
CNGA3	181	181	Y -> C (in ACHM2).
CNGA3	182	182	N -> Y (in ACHM2).
CNGA3	186	186	L -> F (in ACHM2).
CNGA3	191	191	C -> Y (in ACHM2).
CNGA3	194	194	E -> K (in ACHM2).
CNGA3	223	223	R -> W (in ACHM2).
CNGA3	224	224	T -> R (in ACHM2).
CNGA3	228	228	E -> K (in ACHM2; the dose-response relationship for cGMP-activation is not significantly different from that of wild-type CNGA3; the dose-response relationship of the mutant CNGA3 + CNGB3 is similar to that of the wild-type protein; the channel density into the cell membrane is considerably improved by decreasing the cultivation temparature).
CNGA3	249	249	F -> S (in ACHM2).
CNGA3	260	260	D -> N (in ACHM2).
CNGA3	263	263	Y -> D (in ACHM2).
CNGA3	267	267	G -> D (in ACHM2).
CNGA3	277	277	R -> C (in ACHM2).
CNGA3	277	277	R -> H (in ACHM2; does not form functional homomeric or heteromeric channels; cell surface expression levels is significantly reduced).
CNGA3	283	283	R -> Q (in ACHM2; does not reveal any detectable calcium influx upon agonist application at 37 degrees Celsius; the channel function could be restored by incubating the transfected cells at 27 degrees Celsius; the dose-response relationship for cGMP-activation is not significantly different from that of wild-type CNGA3; the dose-response relationship of the mutant CNGA3 + CNGB3 is similar to that of the wild-type protein; a substantial reduction of macroscopic cGMP maximum current to only one-third of the mean value for wild-type CNGA3 + CNGB3 is observed for the mutant CNGA3 + CNGB3; the channel density into the cell membrane is considerably improved by decreasing the cultivation temparature).
CNGA3	283	283	R -> W (in ACHM2).
CNGA3	291	291	T -> R (in ACHM2; does not reveal any detectable calcium influx upon agonist application at 37 degrees Celsius; the channel function could be restored by incubating the transfected cells at 27 degrees Celsius; the K(1/2) value is shifted toward a higher cGMP concentration by a factor of 1.8; no positive influence of the CNGB3 subunit in the cGMP sensitivity is observed; a substantial reduction of macroscopic cGMP maximum current to only one-third of the mean value for wild-type CNGA3 + CNGB3 is observed for the mutant CNGA3 + CNGB3; the channel density into the cell membrane is considerably improved by decreasing the cultivation temparature).
CNGA3	312	312	Missing (in ACHM2).
CNGA3	341	341	S -> P (in ACHM2).
CNGA3	369	369	T -> S (in ACHM2).
CNGA3	372	372	P -> S (in ACHM2).
CNGA3	380	380	F -> S (in ACHM2).
CNGA3	401	401	S -> P (in ACHM2).
CNGA3	406	406	M -> T (in ACHM2).
CNGA3	410	410	R -> W (in ACHM2).
CNGA3	427	427	R -> C (in ACHM2).
CNGA3	436	436	R -> W (in ACHM2).
CNGA3	439	439	R -> W (in ACHM2; does not reveal any detectable calcium influx upon agonist application at 37 degrees Celsius; the channel function could be restored by incubating the transfected cells at 27 degrees Celsius; the dose-response relationship for cGMP-activation is shifted toward a lower cGMP concentration; the dose-response relationship of the mutant CNGA3 + CNGB3 is similar to that of the wild-type protein; coexpression of the CNGB3 subunit compensate completely for the slightly higher apparent cGMP sensitivity of homomers; the channel density into the cell membrane is considerably improved by decreasing the cultivation temparature).
CNGA3	469	469	A -> T (in ACHM2; the dose-response relationship for cGMP-activation is shifted toward a lower cGMP concentration; the left shift in the dose-response relationship of the mutant CNGA3 is less distinctive than in homomeric channels with this mutation indicating a partial rescue effect of the CNGB3 subunit; is in large part located in the cell membrane at 37 and 27 degrees Celsius).
CNGA3	471	471	N -> S (in ACHM2; mutant CNGA3 alone or together with the CNGB3 subunit exhibit an increase in apparent affinity for cGMP and an increase in the relative agonist efficacy of cAMP compared with cGMP; cell surface expression levels is unchanged).
CNGA3	485	485	D -> V (in ACHM2).
CNGA3	510	510	C -> S (in ACHM2).
CNGA3	513	513	G -> E (in ACHM2).
CNGA3	516	516	G -> E (in ACHM2).
CNGA3	522	522	I -> T (in ACHM2).
CNGA3	525	525	G -> D (in ACHM2).
CNGA3	529	529	V -> M (in ACHM2).
CNGA3	547	547	F -> L (in ACHM2; does not reveal any detectable calcium influx upon agonist application at 37 degrees Celsius; the channel function could be restored by incubating the transfected cells at 27 degrees Celsius; the dose-response relationship for cGMP-activation is shifted toward a lower cGMP concentration; a substantial reduction of macroscopic cGMP maximum current to only one-third of the mean value for wild-type CNGA3 + CNGB3 is observed for the mutant CNGA3 + CNGB3; is in large part located in the cell membrane at 37 and 27 degrees Celsius).
CNGA3	548	548	G -> R (in ACHM2).
CNGA3	557	557	G -> R (in ACHM2; the K(1/2) value is shifted toward a higher cGMP concentration by a factor of 3.0; no positive influence of the CNGB3 subunit in the cGMP sensitivity is observed; average cGMP maximum current is decreased to half of the mean wild-type value for the mutant CNGA3 + CNGB3).
CNGA3	563	563	R -> H (in ACHM2; mutant CNGA3 alone or together with the CNGB3 subunit exhibit an increase in apparent affinity for cGMP and an increase in the relative agonist efficacy of cAMP compared with cGMP; cell surface expression levels is significantly reduced).
CNGA3	565	565	T -> M (in ACHM2).
CNGA3	569	569	R -> H (in ACHM2).
CNGA3	573	573	Y -> C (in ACHM2).
CNGA3	590	590	E -> K (in ACHM2; the dose-response relationship for cGMP-activation is shifted toward a lower cGMP concentration).
CNGA3	593	593	E -> K (in ACHM2).
RNF149	7	7	E -> K (in a breast cancer sample; somatic mutation).
IL18R1	317	317	Missing.
MFSD9	59	59	G -> A (in a breast cancer sample; somatic mutation).
MFSD9	84	84	V -> A (in a breast cancer sample; somatic mutation).
GPR45	7	7	S -> C (in a breast cancer sample; somatic mutation).
RANBP2	585	585	T -> M (associated with ANE1).
RANBP2	653	653	T -> I (associated with ANE1).
RANBP2	656	656	I -> V (associated with ANE1).
D2HGDH	147	147	I -> S (in D2HGA1; severe phenotype; loss of catalytic activity).
D2HGDH	375	375	D -> Y (in D2HGA1).
D2HGDH	436	436	G -> V.
D2HGDH	439	439	N -> D (in D2HGA1; mild phenotype; altered catalytic activity).
D2HGDH	444	444	V -> A (in D2HGA1; severe phenotype; altered catalytic activity).
DDX18	41	41	G -> R (in a breast cancer sample; somatic mutation).
NDUFS1	241	241	R -> W (in MT-C1D).
NDUFS1	252	252	D -> G (in MT-C1D).
SERPINE2	204	204	K -> N (in a breast cancer sample; somatic mutation).
GYPC	8	8	N -> S (in Webb (WB) antigen).
GYPC	14	14	L -> F (in Duch (DH(a)) antigen).
GYPC	23	23	A -> S (in Ahonen (AN(a)) antigen).
ATIC	426	426	K -> R (in AICAR; loss of transformylase activity).
BIN1	35	35	K -> N (in ARCNM; abolishes membrane tubulation).
BIN1	151	151	D -> N (in ARCNM; abolishes membrane tubulation).
ERCC3	99	99	F -> S (in XP-B; combined with features of Cockayne syndrome; mild).
ERCC3	119	119	T -> P (in TTDP; mild).
ERCC3	418	418	K -> Q (in a breast cancer sample; somatic mutation).
PROC	14	14	W -> G (in patients with PROC deficiency).
PROC	32	32	R -> C (in ADPROCD).
PROC	38	38	R -> W (in patients with PROC deficiency).
PROC	42	42	R -> C (in patients with PROC deficiency).
PROC	42	42	R -> H (in Malakoff; low anticoagulant activity).
PROC	42	42	R -> S (in ADPROCD; type II; Osaka-10; alters proteolytic processing so that S- 42 is the N-terminus of the mature protein).
PROC	43	43	A -> T.
PROC	49	49	E -> D (in patients with PROC deficiency).
PROC	51	51	R -> C (in patients with PROC deficiency).
PROC	57	57	R -> G (in Yonago; defective anticoagulant activity).
PROC	57	57	R -> Q (in patients with PROC deficiency).
PROC	57	57	R -> W (in ADPROCD).
PROC	62	62	E -> A (in ADPROCD; Vermont-1).
PROC	76	76	V -> M (in ADPROCD; Vermont-1).
PROC	89	89	G -> C (in patients with PROC deficiency).
PROC	108	108	H -> N (in patients with PROC deficiency; La Jolla-1).
PROC	109	109	G -> R (in patients with PROC deficiency).
PROC	114	118	Missing (in patients with PROC deficiency).
PROC	114	114	G -> R (in ADPROCD).
PROC	118	118	F -> L (in patients with PROC deficiency).
PROC	119	124	Missing (in patients with PROC deficiency; St Louis-2).
PROC	120	125	Missing (in patients with PROC deficiency; St Louis-3).
PROC	144	145	NG -> K (in ARPROCD; neonatal purpura fulminans).
PROC	145	145	G -> R (in ADPROCD).
PROC	147	147	C -> Y (in patients with PROC deficiency).
PROC	149	149	H -> P (in patients with PROC deficiency).
PROC	161	161	S -> R (in patients with PROC deficiency).
PROC	178	178	A -> P (in ARPROCD; Clamart).
PROC	183	183	C -> R (in patients with PROC deficiency).
PROC	189	189	R -> W (in patients with PROC deficiency; La Jolla-3).
PROC	194	194	R -> C (in patients with PROC deficiency).
PROC	210	210	P -> L (in ADPROCD).
PROC	220	220	R -> P (in patients with PROC deficiency).
PROC	220	220	R -> Q (in ADPROCD; Vermont-3).
PROC	220	220	R -> W (in ADPROCD).
PROC	226	226	Q -> H (in patients with PROC deficiency).
PROC	243	243	I -> T (in ADPROCD).
PROC	244	244	H -> Y (in patients with PROC deficiency).
PROC	253	253	H -> Q (in patients with PROC deficiency).
PROC	265	265	L -> F (in patients with PROC deficiency).
PROC	271	271	R -> Q (in Marseille; low anticoagulant activity).
PROC	271	271	R -> W (in patients with PROC deficiency).
PROC	272	272	R -> C (in ADPROCD).
PROC	281	281	D -> DLD (in patients with PROC deficiency).
PROC	289	289	P -> L (in ARPROCD).
PROC	294	294	S -> N (in Paris; low anticoagulant activity).
PROC	298	298	N -> D (in patients with PROC deficiency).
PROC	301	301	A -> T (in patients with PROC deficiency).
PROC	301	301	A -> V (in patients with PROC deficiency).
PROC	309	309	A -> T (in patients with PROC deficiency).
PROC	312	312	S -> L (in patients with PROC deficiency).
PROC	312	312	S -> P (in a patient with PROC deficiency; sporadic case).
PROC	321	321	P -> L (in ADPROCD).
PROC	324	324	G -> R (in ADPROCD).
PROC	328	328	R -> C (in ADPROCD).
PROC	328	328	R -> H (in ARPROCD; Muenchen).
PROC	334	334	G -> S (in ARPROCD).
PROC	340	340	T -> M (in ADPROCD; Vermont-2).
PROC	343	343	G -> D (in patients with PROC deficiency).
PROC	363	363	Missing (in patients with PROC deficiency).
PROC	367	367	V -> A (in ARPROCD; neonatal purpura fulminans).
PROC	369	369	P -> L (in ADPROCD; Osaka-6).
PROC	385	385	M -> I (in patients with PROC deficiency).
PROC	388	388	A -> T (in patients with PROC deficiency).
PROC	388	388	A -> V (in patients with PROC deficiency).
PROC	392	392	G -> R (in ADPROCD; Osaka-9).
PROC	394	394	R -> W (in patients with PROC deficiency).
PROC	401	401	D -> N (in ADPROCD; La Jolla-2/Osaka-7 and -8).
PROC	418	418	G -> D (in ARPROCD; Hong Kong-2).
PROC	423	423	G -> S (in ADPROCD).
PROC	426	426	C -> Y (in ADPROCD).
PROC	433	433	G -> S (in patients with PROC deficiency; Purmerend).
PROC	436	436	T -> N (in ADPROCD).
PROC	441	441	Y -> H (in ADPROCD; Osaka-4).
PROC	444	444	W -> C (in ADPROCD).
PROC	445	445	I -> M (in patients with PROC deficiency).
RAB6C	159	159	A -> T.
CFC1	112	112	R -> C (in HTX2; complete loss of activity; abnormal cell surface localization).
CFC1	189	189	R -> C.
IRS1	608	608	T -> R (may contribute to insulin resistance by impairing metabolic signaling through PI3K-dependent pathways).
IRS1	723	723	Missing (in NIDDM).
IRS1	1043	1043	S -> Y (in NIDDM).
IRS1	1095	1095	C -> Y (in NIDDM).
SLC19A3	23	23	G -> V (in BBGD).
SLC19A3	422	422	T -> A (in BBGD).
MMADHC	108	108	S -> SLAEPLS (in MMADHC; cblD variant 2).
MMADHC	182	182	T -> N (in MMADHC; cblD variant 1).
MMADHC	204	232	Missing (in MMADHC; cblD original).
MMADHC	249	249	Y -> C (in MMADHC; cblD variant 1).
MMADHC	259	259	L -> P (in MMADHC; cblD variant 1).
GALNT5	507	507	E -> D (in a breast cancer sample; somatic mutation).
GALNT5	692	692	L -> F (in a breast cancer sample; somatic mutation).
GPR35	29	29	V -> I.
SCN3A	43	43	Missing.
SCN3A	606	606	S -> T.
SCN3A	1813	1813	L -> S.
SLC25A12	590	590	Q -> R (in AGC1D; the mutant protein is unable to transport aspartate or glutamate although it is able to integrate normally into the inner mitochondrial membrane).
HAT1	317	317	A -> P (in a colorectal cancer sample; somatic mutation).
CHRNA1	177	177	V -> L (in FCCMS; mutant channel shows an approximately 30-fold decrease of ACh binding affinity for the second of 2 closed-state binding sites but only a 2- fold decrease in gating efficiency).
CHRNA1	198	198	G -> S (in SCCMS).
CHRNA1	201	201	V -> M (in SCCMS).
CHRNA1	254	254	R -> L (in MUPSL).
CHRNA1	262	262	N -> K (in SCCMS).
CHRNA1	278	278	F -> V (in FCCMS; markedly reduced protein expression).
CHRNA1	294	294	V -> F (in SCCMS; causes increased channel opening in absence of ACh; prolonged opening in presence of ACh; increased affinity for ACh and enhanced desensitization).
CHRNA1	299	299	T -> I (in SCCMS).
CHRNA1	301	301	F -> L (in FCCMS; fewer and shorter ion channel activations with decreased channel opening rate and increased channel closing rate).
CHRNA1	314	314	S -> I (in SCCMS).
CHRNA1	330	330	V -> I (in FCCMS; abnormally slow channel opening and closing resulting in abnormally brief current).
CHRNA1	463	463	C -> W (in SCCMS; increases the rate of channel opening and slows the rate of channel closing but has no effect on agonist binding).
HOXD13	57	63	Missing (in BDSD; does not affect capacity to transactivate EPHA7 promoter).
HOXD13	57	58	Missing.
HOXD13	57	57	A -> AAAAAAAAAA (in SPD1 and in syndactyly type 5).
HOXD13	325	325	Q -> R (in SDTY5; impairs capacity to transactivate EPHA7 promoter).
HOXD11	245	245	G -> D.
HOXD10	319	319	M -> K (in CVT; also in Charcot-Marie- Tooth disease-like foot deformities).
HOXD9	269	269	Missing.
DFNB59	54	54	T -> I (in DFNB59).
DFNB59	183	183	R -> W (in DFNB59).
CRYGD	15	15	R -> C (in ADC; progressive punctate cataract with early onset; forms disulfide-linked oligomers).
CRYGD	24	24	P -> T (in CCA3 and lamellar cataract; lowered solubility).
CRYGD	37	37	R -> S (in a patient with cataract; very low solubility; crystallizes spontaneously).
CRYGD	43	43	W -> R (in ADC; much less stable than the wild-type protein; more prone to aggregate when subjected to environmental stresses such as heat and UV irradiation).
CRYGD	59	59	R -> H (in CACA; lowered solubility; crystallizes easily).
CRYGD	102	102	M -> V.
CRYGD	107	107	E -> A (in CCP).
CRYGC	5	5	T -> P (in CCL; interactions between Pro- 5 mutants themselves were unchanged versus wild-type CRYGC indicating that homogeneous interaction sites or domains differ from those used in heterogeneous interactions).
CRYGC	48	48	R -> H.
CRYGC	169	169	R -> W (in ADC; congenital lamellar cataract).
CRYGB	73	73	S -> I.
NEUROD1	111	111	R -> L (in MODY6).
DIRC1	51	51	S -> A.
COL3A1	169	169	L -> F (in AAA).
COL3A1	183	183	G -> C (in EDS4).
COL3A1	183	183	G -> D (in EDS4).
COL3A1	183	183	G -> S (in EDS4).
COL3A1	192	192	G -> V (in EDS4).
COL3A1	201	201	G -> R (in EDS4).
COL3A1	204	204	G -> D (in EDS4).
COL3A1	204	204	G -> S (in EDS4).
COL3A1	210	210	G -> D (in EDS4).
COL3A1	219	219	G -> C (in EDS4).
COL3A1	225	225	G -> V (in EDS4).
COL3A1	228	228	G -> E (in EDS4).
COL3A1	240	240	G -> R (in EDS4).
COL3A1	243	243	G -> V (in EDS4).
COL3A1	249	249	G -> D (in EDS4).
COL3A1	249	249	G -> V (in EDS4).
COL3A1	252	252	G -> D (in EDS4).
COL3A1	252	252	G -> R (in EDS4).
COL3A1	252	252	G -> V (in EDS4).
COL3A1	255	255	G -> V (in EDS4).
COL3A1	264	264	G -> R (in EDS4).
COL3A1	267	267	G -> V (in EDS4).
COL3A1	297	297	G -> R (in EDS4).
COL3A1	303	303	G -> R (in fibromuscular dysplasia and aortic aneurysm).
COL3A1	321	321	G -> V (in EDS4).
COL3A1	327	327	G -> D (in EDS4).
COL3A1	345	345	G -> R (in EDS4).
COL3A1	417	417	G -> R (in EDS4).
COL3A1	420	420	G -> S (in a colorectal cancer sample; somatic mutation).
COL3A1	444	444	G -> R (in EDS4).
COL3A1	489	489	G -> E (in EDS4).
COL3A1	501	501	G -> R (in EDS4).
COL3A1	519	519	G -> V (in EDS4).
COL3A1	540	540	G -> R (in EDS4).
COL3A1	549	549	G -> E (in EDS4).
COL3A1	552	552	G -> E (in EDS4).
COL3A1	567	567	G -> E (in EDS4).
COL3A1	582	582	G -> S (in EDS4).
COL3A1	588	588	G -> D (in EDS4).
COL3A1	635	635	P -> L.
COL3A1	636	636	G -> R (in EDS4).
COL3A1	657	657	G -> E (in EDS4).
COL3A1	660	660	G -> D (in EDS4).
COL3A1	666	666	G -> D (in EDS4).
COL3A1	699	699	G -> R (in EDS4).
COL3A1	726	726	G -> R (in EDS4).
COL3A1	738	738	G -> S (in EDS4).
COL3A1	738	738	G -> V (in EDS4).
COL3A1	744	744	G -> V (in EDS4).
COL3A1	756	756	G -> E (in EDS4).
COL3A1	762	762	G -> C (in EDS4).
COL3A1	786	786	G -> R (in AAA).
COL3A1	804	804	G -> S (in EDS3).
COL3A1	828	828	G -> R (in EDS4).
COL3A1	828	828	G -> W (in EDS4).
COL3A1	830	838	Missing (in EDS4).
COL3A1	852	852	G -> C (in EDS4).
COL3A1	879	879	G -> V (in EDS4).
COL3A1	882	882	G -> D (in EDS4).
COL3A1	900	900	G -> D (in EDS4).
COL3A1	903	903	G -> E (in EDS4).
COL3A1	909	909	G -> D (in EDS4).
COL3A1	909	909	G -> V (in EDS4).
COL3A1	918	918	G -> E (in EDS4).
COL3A1	924	924	G -> C (in EDS4).
COL3A1	936	936	G -> R (in EDS4).
COL3A1	936	936	G -> S (in EDS4).
COL3A1	939	939	G -> D (in EDS4).
COL3A1	942	942	G -> E (in EDS4).
COL3A1	957	957	G -> S (in EDS4; severe variant).
COL3A1	960	960	G -> V (in EDS4; severe variant).
COL3A1	966	966	G -> V (in EDS4).
COL3A1	972	972	G -> A (in EDS4).
COL3A1	984	984	G -> T (in EDS4; requires 2 nucleotide substitutions).
COL3A1	996	996	G -> E (in EDS4).
COL3A1	999	999	G -> R (in EDS4).
COL3A1	1011	1011	G -> E (in EDS4).
COL3A1	1014	1014	G -> E (in EDS4).
COL3A1	1032	1032	G -> V (in EDS4).
COL3A1	1035	1035	G -> C (in EDS4).
COL3A1	1044	1044	G -> D (in EDS4).
COL3A1	1050	1050	G -> D (in EDS4; mild variant).
COL3A1	1050	1050	G -> V (in EDS4).
COL3A1	1071	1071	G -> V (in EDS4).
COL3A1	1077	1077	G -> V (in EDS4).
COL3A1	1089	1089	G -> D (in EDS4).
COL3A1	1098	1098	G -> D (in EDS4).
COL3A1	1098	1098	G -> V (in EDS4).
COL3A1	1101	1101	G -> E (in EDS4).
COL3A1	1104	1104	G -> A (in EDS4).
COL3A1	1161	1161	G -> V (in EDS4).
COL3A1	1164	1164	G -> E (in EDS4).
COL3A1	1164	1164	G -> R (in EDS4).
COL3A1	1164	1164	G -> S (in spondyloepiphyseal dysplasia).
COL3A1	1167	1167	G -> V (in EDS4).
COL3A1	1170	1170	G -> D (in EDS4).
COL3A1	1170	1170	G -> V (in EDS4).
COL3A1	1173	1173	G -> E (in EDS4).
COL3A1	1173	1173	G -> R (in EDS4; Gottron type acrogeria).
COL3A1	1176	1176	G -> V (in EDS4; severe).
COL3A1	1179	1179	G -> R (in EDS4).
COL3A1	1182	1182	G -> E (in EDS4).
COL3A1	1185	1185	G -> D (in EDS4; severe variant).
COL3A1	1185	1185	G -> V (in EDS4).
COL3A1	1188	1188	G -> E (in EDS4; severe variant).
COL3A1	1188	1188	G -> R (in EDS4).
COL3A1	1434	1434	R -> C (in a colorectal cancer sample; somatic mutation).
TXNDC15	248	248	S -> P (in a breast cancer sample; somatic mutation).
ARHGAP26	417	417	N -> S (in JMML).
CTNND2	275	275	G -> C.
CTNND2	482	482	A -> T.
CTNND2	810	810	G -> R.
CTNND2	1159	1159	P -> S (in a colorectal cancer sample; somatic mutation).
MAST4	923	923	Q -> R.
MAST4	1957	1957	R -> W.
MAST4	2201	2201	P -> L.
MAST4	2293	2293	S -> C.
MAST4	2470	2470	E -> D (in a lung squamous cell carcinoma sample; somatic mutation).
GPR98	2379	2379	G -> A.
GPR98	2803	2803	A -> T.
GPR98	3217	3217	A -> V.
GPR98	5344	5344	E -> G.
GPR98	5437	5437	T -> A.
ADAMTS19	360	360	L -> I (in a breast cancer sample; somatic mutation).
CSNK1A1	297	297	D -> H (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
SGCD	150	150	S -> A (in CMD1L).
SGCD	261	261	E -> K (in LGMD2F).
HRH2	217	217	N -> D.
HRH2	231	231	K -> R.
HRH2	268	268	V -> M.
TBC1D9B	1086	1086	P -> Q (in a breast cancer sample; somatic mutation).
SLC6A3	121	121	G -> S (in a breast cancer sample; somatic mutation).
SLC6A3	368	368	L -> Q (in DYTPRI; loss of function).
SLC6A3	395	395	P -> L (in DYTPRI; loss of function).
SLC6A3	544	544	R -> S (in a breast cancer sample; somatic mutation).
FASTKD3	22	22	L -> V (in a breast cancer sample; somatic mutation).
DNAH5	1716	1716	R -> L (in CILD3).
DNAH5	2264	2264	S -> N (in CILD3).
DNAH5	2347	2347	E -> K (in CILD3).
DNAH5	2501	2501	R -> P (in CILD3).
DNAH5	2843	2843	F -> S (in CILD3).
DNAH5	3409	3409	W -> S (in CILD3).
DNAH5	3519	3519	G -> R (in KTGS).
DNAH5	3843	3843	S -> L (in CILD3).
DNAH5	4205	4205	G -> V (in CILD3).
TRIO	1978	1978	V -> M (in a metastatic melanoma sample; somatic mutation).
ANKH	5	5	P -> L (in CCAL2).
ANKH	5	5	P -> T (in CCAL2).
ANKH	48	48	M -> T (in CCAL2).
ANKH	292	292	W -> R (in CMDJ).
ANKH	331	331	C -> R (in CMDJ).
ANKH	375	375	Missing (in CMDJ).
ANKH	376	376	Missing (in CMDJ).
ANKH	377	377	Missing (in CMDJ).
ANKH	380	380	P -> PA (in CMDJ).
ANKH	490	490	Missing (in CCAL2; sporadic).
CDH10	371	371	V -> L (in a breast cancer sample; somatic mutation).
SLC45A2	58	58	P -> A (in OCA4).
SLC45A2	58	58	P -> S (in OCA4).
SLC45A2	157	157	D -> N (in OCA4).
SLC45A2	188	188	G -> V (in OCA4).
SLC45A2	202	202	W -> C (in OCA4).
SLC45A2	221	221	Missing (in OCA4).
SLC45A2	317	317	Y -> C (in OCA4).
SLC45A2	477	477	A -> T (in OCA4).
SLC45A2	486	486	A -> V (in OCA4).
UGT3A2	515	515	R -> H (in a colorectal cancer sample; somatic mutation).
NIPBL	1206	1206	I -> V.
NIPBL	1206	1206	Missing (in CDLS1).
NIPBL	1246	1246	A -> G (in CDLS1).
NIPBL	1311	1311	C -> R (in CDLS1).
NIPBL	1312	1312	L -> P (in CDLS1).
NIPBL	1348	1348	L -> R (in CDLS1).
NIPBL	1647	1647	E -> K (in a breast cancer sample; somatic mutation).
NIPBL	1789	1789	R -> L (in CDLS1).
NIPBL	1803	1803	D -> V (in CDLS1).
NIPBL	1856	1856	R -> T (in CDLS1).
NIPBL	1897	1897	Missing (in CDLS1).
NIPBL	2081	2081	G -> A (in CDLS1).
NIPBL	2090	2090	S -> I (in CDLS1).
NIPBL	2150	2150	L -> P (in CDLS1).
NIPBL	2298	2298	R -> C (in CDLS1).
NIPBL	2298	2298	R -> H (in CDLS1).
NIPBL	2312	2312	G -> R (in CDLS1).
NIPBL	2381	2381	G -> A (in CDLS1).
NIPBL	2390	2390	A -> T (in CDLS1).
NIPBL	2430	2430	Y -> C (in CDLS1).
NIPBL	2440	2440	Y -> H (in CDLS1).
LIFR	279	279	S -> P (in SWS).
LIFR	1068	1068	F -> L (in a colorectal cancer sample; somatic mutation).
OSMR	618	618	G -> A (in PLCA1).
OSMR	691	691	I -> T (in PLCA1).
C9	119	119	C -> G (in C9D).
PRKAA1	16	16	Q -> R (in a breast cancer sample; somatic mutation).
OXCT1	58	58	T -> M.
OXCT1	133	133	V -> E (in SCOTD).
OXCT1	215	215	A -> V (in SCOTD; partial loss of activity).
OXCT1	219	219	G -> E (in SCOTD).
OXCT1	221	221	V -> M (in SCOTD).
OXCT1	226	226	S -> N (in SCOTD; loss of activity).
OXCT1	324	324	G -> E (in SCOTD).
OXCT1	327	327	L -> P (in SCOTD; partial loss of activity).
OXCT1	404	404	V -> F (in SCOTD; loss of activity).
OXCT1	405	405	S -> P (in SCOTD; loss of activity).
OXCT1	456	456	C -> F (in SCOTD).
OXCT1	468	468	R -> C (in SCOTD; partial loss of activity; the mutant retains half of the activity of the wild-type at 30 degrees).
GHR	56	56	C -> S (in LARS).
GHR	58	58	S -> L (in LARS).
GHR	62	62	E -> K (in ISSA).
GHR	68	68	W -> R (in LARS).
GHR	89	89	R -> K (in LARS).
GHR	114	114	F -> S (in LARS; loss of ability to bind ligand).
GHR	143	143	V -> A (in LARS).
GHR	149	149	P -> Q (in LARS; disrupts GH binding).
GHR	162	162	V -> D (in LARS).
GHR	162	162	V -> I (found in a patient with idiopathic short stature; unknown pathological significance).
GHR	170	170	D -> H (in LARS; abolishes receptor homodimerization).
GHR	171	171	I -> T (in LARS; almost completely abolishes GH-binding at cell surface: 53% binding to membrane fractions).
GHR	172	172	Q -> P (in LARS; almost completely abolishes GH-binding at cell surface and in membrane fractions).
GHR	173	173	V -> G (in LARS; almost completely abolishes GH-binding at cell surface: 26% binding to membrane fractions).
GHR	179	179	R -> C (in LARS and ISSA).
GHR	226	226	Y -> C (in LARS).
GHR	229	229	R -> G (in LARS).
GHR	244	244	S -> I (in LARS).
GHR	262	262	D -> N (in LARS).
NIM1	21	21	R -> W.
NIM1	64	64	E -> Q.
NIM1	260	260	L -> I.
NIM1	320	320	M -> I.
NIM1	333	333	P -> S (in a lung neuroendocrine carcinoma sample; somatic mutation).
NIM1	411	411	P -> T (in a lung large cell carcinoma sample; somatic mutation).
PARP8	777	777	S -> A (in a colorectal cancer sample; somatic mutation).
ERBB2IP	1207	1207	K -> E.
CDK7	163	163	G -> A.
OCLN	219	219	F -> S (in BLCPMG).
GTF2H2	151	151	I -> M.
GTF2H2	236	236	V -> L.
MCCC2	155	155	R -> Q (in MCC2 deficiency; mild form).
MCCC2	173	173	S -> L (in MCC2 deficiency; severe form).
MCCC2	193	193	R -> C (in MCC2 deficiency; mild form).
MCCC2	218	218	A -> T (in MCC2 deficiency).
MCCC2	268	268	R -> T (in MCC2 deficiency; asymptomatic form).
MCCC2	310	310	P -> R (in MCC2 deficiency; mild form).
MCCC2	339	339	V -> M (in MCC2 deficiency; severe form).
MCCC2	437	437	I -> V (in MCC2 deficiency; mild form).
MAP1B	326	326	R -> Q (in a colorectal cancer sample; somatic mutation).
MAP1B	574	574	V -> M (in a colorectal cancer sample; somatic mutation).
COL4A3BP	67	67	G -> E (in LY-A cell line; destroyes the phosphatidylinositol 4-phosphate-binding activity).
AP3B1	390	410	Missing (in HPS2).
AP3B1	580	580	L -> R (in HPS2).
ARSB	65	65	S -> F (in MPS6; intermediate form).
ARSB	86	86	Missing (in MPS6; severe form; low protein levels and activity).
ARSB	92	92	T -> M (in MPS6; mild form).
ARSB	95	95	R -> Q (in MPS6; mild/severe form).
ARSB	116	116	P -> H (in MPS6; severe form).
ARSB	117	117	C -> R (in MPS6; severe form).
ARSB	137	137	G -> V (in MPS6; intermediate form).
ARSB	142	142	M -> I (in MPS6).
ARSB	144	144	G -> R (in MPS6; severe form; severe reduction of activity).
ARSB	146	146	W -> L (in MPS6).
ARSB	146	146	W -> R (in MPS6).
ARSB	146	146	W -> S (in MPS6).
ARSB	152	152	R -> W (in MPS6; intermediate form).
ARSB	160	160	R -> Q (in MPS6; intermediate form).
ARSB	192	192	C -> R (in MPS6; mild form; severe reduction of activity).
ARSB	210	210	Y -> C (in MPS6; mild/intermediate).
ARSB	236	236	L -> P (in MPS6; mild form).
ARSB	239	239	Q -> R (in MPS6).
ARSB	302	302	G -> R (in MPS6; severe form).
ARSB	312	312	W -> C (in MPS6; severe form; low protein levels and activity).
ARSB	315	315	R -> Q (in MPS6; intermediate form).
ARSB	321	321	L -> P (in MPS6; intermediate form; severe reduction of activity).
ARSB	393	393	H -> P (in MPS6; mild/severe form).
ARSB	399	399	F -> L (in MPS6).
ARSB	405	405	C -> Y (in MPS6; mild form).
ARSB	484	484	R -> G (in MPS6).
ARSB	498	498	L -> P (in MPS6; mild/severe form).
ARSB	521	521	C -> Y (in MPS6; severe form; severe reduction of activity).
ARSB	531	531	P -> R (in MPS6; mild form).
MSH3	57	65	Missing.
MSH3	62	62	A -> AAAA.
RASGRF2	114	114	R -> H (in a colorectal cancer sample; somatic mutation).
RASGRF2	538	538	D -> N (in a breast cancer sample; somatic mutation).
RASGRF2	1216	1216	D -> E (in a breast cancer sample; somatic mutation).
HAPLN1	333	333	R -> H (in a colorectal cancer sample; somatic mutation).
RASA1	398	398	R -> L (in basal cell carcinomas).
RASA1	400	400	K -> E (in basal cell carcinomas).
RASA1	401	401	I -> V (in basal cell carcinomas).
RASA1	540	540	C -> Y (in CMAVM).
CAST	592	592	E -> G.
FER	404	404	E -> Q (in an ovarian Endometrioid carcinoma sample; somatic mutation).
FER	460	460	W -> C (in a lung small cell carcinoma sample; somatic mutation).
CAMK4	150	150	E -> G (in a lung adenocarcinoma sample; somatic mutation).
CAMK4	469	469	I -> M (in a lung large cell carcinoma sample; somatic mutation).
APC	99	99	R -> W (in FAP; could be a rare polymorphism).
APC	171	171	S -> I (in FAP).
APC	414	414	R -> C (in FAP).
APC	722	722	S -> G (in FAP).
APC	784	784	S -> T (in FAP).
APC	817	817	G -> C (in gastric cancer).
APC	880	880	I -> T (in colorectal carcinoma and gastric cancer; from a patient with MMRCS).
APC	890	890	V -> I (in colorectal carcinoma; from a patient with MMRCS).
APC	906	906	S -> Y (in colorectal tumor).
APC	911	911	E -> G (in FAP and colorectal tumor).
APC	942	942	N -> D (in gastric cancer).
APC	1027	1027	Y -> C (in colorectal tumor).
APC	1057	1057	E -> G (in non-FAP).
APC	1118	1118	N -> D.
APC	1171	1171	R -> C (in FAP; could be a polymorphism).
APC	1171	1171	R -> H (in gastric cancer).
APC	1176	1176	P -> L (in FAP).
APC	1184	1184	A -> P (in FAP).
APC	1197	1197	F -> S (in gastric cancer).
APC	1254	1254	I -> F (in a colorectal cancer sample; somatic mutation).
APC	1259	1259	I -> T (in gastric cancer).
APC	1292	1292	T -> M.
APC	1296	1296	A -> V (in MDB; sporadic).
APC	1304	1304	I -> V.
APC	1312	1312	G -> E (in gastric cancer).
APC	1313	1313	T -> A (in FAP and colorectal tumor).
APC	1326	1326	V -> A (in gastric cancer).
APC	1348	1348	R -> W (in FAP).
APC	1395	1395	S -> C (in hepatoblastoma).
APC	1422	1422	D -> H (in colorectal tumor).
APC	1472	1472	V -> I (in MDB; sporadic).
APC	1495	1495	S -> G (in MDB; sporadic).
APC	1508	1508	A -> V (in colorectal carcinoma from a patient with MMRCS).
APC	2621	2621	S -> C (in FAP).
APC	2738	2738	I -> T (in FAP).
APC	2839	2839	L -> F (in FAP).
MCC	267	267	R -> L (in a colorectal cancer sample).
MCC	490	490	S -> L (in a colorectal cancer sample).
MCC	506	506	R -> Q (in colorectal cancer samples; somatic mutation).
MCC	698	698	A -> V (in colorectal cancer samples; somatic mutation).
SNCAIP	706	706	E -> Q.
FBN2	391	391	E -> K (in CCA).
FBN2	594	594	T -> S.
FBN2	681	681	R -> H.
FBN2	754	754	G -> S (in CCA).
FBN2	1057	1057	G -> D (in CCA).
FBN2	1091	1091	N -> S (in CCA).
FBN2	1093	1093	I -> T (in CCA).
FBN2	1115	1115	D -> H (in CCA; the underlying nucleotide substitution also causes low level in- frame mis-splicing of exon 25).
FBN2	1122	1122	S -> P (in CCA).
FBN2	1142	1142	C -> F (in CCA).
FBN2	1142	1142	C -> R (in CCA).
FBN2	1146	1146	Y -> C (in CCA).
FBN2	1156	1156	C -> F (in CCA).
FBN2	1161	1161	E -> K (in CCA).
FBN2	1179	1179	G -> C (in CCA).
FBN2	1198	1198	C -> Y (in CCA).
FBN2	1240	1240	C -> R (in CCA).
FBN2	1246	1246	C -> F (in CCA).
FBN2	1253	1253	C -> Y (in CCA).
FBN2	1257	1257	C -> W (in CCA).
FBN2	1268	1268	C -> R (in CCA).
FBN2	1384	1384	C -> F (in CCA).
FBN2	1384	1384	C -> Y (in CCA).
FBN2	1408	1408	D -> N (in CCA).
FBN2	1425	1425	C -> R (in CCA).
FBN2	1434	1434	C -> S (in CCA).
FBN2	1772	1772	W -> G.
FBN2	2062	2062	E -> V (found in a renal cell carcinoma case; somatic mutation).
FBN2	2266	2266	F -> L.
SLC22A5	12	12	G -> S (in CDSP).
SLC22A5	15	15	G -> W (in CDSP).
SLC22A5	17	17	F -> L (in CDSP).
SLC22A5	19	19	R -> P (in CDSP; carnitine transport is reduced to less than 5% of normal).
SLC22A5	32	32	N -> S (in CDSP).
SLC22A5	46	46	P -> S (in CDSP; carnitine transport is reduced to less than 5% of normal).
SLC22A5	66	66	T -> P (associated with CDSP; unclassified misssense variant).
SLC22A5	75	75	R -> P (associated with CDSP; unclassified misssense variant).
SLC22A5	83	83	R -> L (in CDSP).
SLC22A5	96	96	G -> A (associated with CDSP; unclassified misssense variant).
SLC22A5	122	122	D -> Y (in CDSP).
SLC22A5	123	123	V -> G (associated with CDSP; unclassified misssense variant).
SLC22A5	142	142	A -> S (in CDSP).
SLC22A5	143	143	P -> L (associated with CDSP; unclassified misssense variant).
SLC22A5	169	169	R -> Q (in CDSP).
SLC22A5	169	169	R -> W (in CDSP; abolishes carnitine transport).
SLC22A5	177	177	M -> V (associated with CDSP; unclassified misssense variant).
SLC22A5	179	179	M -> L (in CDSP).
SLC22A5	186	186	L -> P (in CDSP).
SLC22A5	211	211	Y -> C (in CDSP).
SLC22A5	214	214	A -> V (in CDSP).
SLC22A5	227	227	R -> H (in CDSP).
SLC22A5	230	230	F -> L (associated with CDSP; unclassified misssense variant).
SLC22A5	232	232	T -> M (in CDSP; markedly reduced carnitine transport compared to the wild- type protein).
SLC22A5	234	234	G -> R (in CDSP).
SLC22A5	240	240	A -> T (associated with CDSP; unclassified misssense variant).
SLC22A5	242	242	G -> V (in CDSP; abolishes carnitine transport).
SLC22A5	257	257	R -> W (in CDSP).
SLC22A5	264	264	T -> R (in CDSP).
SLC22A5	282	282	R -> Q (in CDSP).
SLC22A5	283	283	W -> C (in CDSP; reduces L-carnitine uptake).
SLC22A5	283	283	W -> R (in CDSP).
SLC22A5	301	301	A -> D (in CDSP; has 2-3% residual carnitine transport of the value measured in cells expressing the wild-type protein).
SLC22A5	312	312	I -> V (associated with CDSP; unclassified misssense variant).
SLC22A5	351	351	W -> R (in CDSP; abolishes carnitine transport).
SLC22A5	355	355	S -> L (in CDSP).
SLC22A5	358	358	Y -> N (associated with CDSP; unclassified misssense variant).
SLC22A5	362	362	S -> L (in CDSP).
SLC22A5	398	398	P -> L (in CDSP).
SLC22A5	399	399	R -> Q (in CDSP; carnitine transport is reduced to less than 5% of normal).
SLC22A5	399	399	R -> W (in CDSP).
SLC22A5	440	440	T -> M (in CDSP).
SLC22A5	442	442	A -> I (in CDSP; requires 2 nucleotide substitutions).
SLC22A5	443	443	F -> V (in CDSP).
SLC22A5	446	446	V -> F (in CDSP).
SLC22A5	447	447	Y -> C (in CDSP).
SLC22A5	452	452	E -> K (in CDSP).
SLC22A5	455	455	P -> R (in CDSP).
SLC22A5	467	467	S -> C (in CDSP; reduces L-carnitine uptake).
SLC22A5	468	468	T -> R (in CDSP; markedly reduced carnitine transport compared to the wild- type protein).
SLC22A5	471	471	R -> C (in CDSP).
SLC22A5	478	478	P -> L (in CDSP; loss of carnitine transport but stimulated organic cation transport).
SLC22A5	481	481	V -> F.
SLC22A5	481	481	V -> I.
SLC22A5	488	488	R -> C (in CDSP).
SLC22A5	507	507	L -> S (in CDSP).
SLC22A5	508	508	F -> L.
SLC22A5	530	530	M -> V.
AFF4	757	757	S -> T (found in a clear cell renal carcinoma case; somatic mutation).
SAR1B	11	11	G -> D (in CMRD).
SAR1B	37	37	G -> R (in CMRD; loss of GDP/GTP- binding).
SAR1B	75	75	D -> G (in CMRD).
TGFBI	113	113	V -> I (in granular corneal dystrophy; unclassified form; with centrifuge pattern of opacities).
TGFBI	123	123	D -> H (in granular corneal dystrophy; unclassified form; Hanoi).
TGFBI	124	124	R -> C (in CDL1).
TGFBI	124	124	R -> H (in ACD; most common mutation in Japanese).
TGFBI	124	124	R -> L (in CDRB).
TGFBI	124	124	R -> S (in CDGG1; late-onset; mild ocular irritation and reduction in visual acuity).
TGFBI	125	126	Missing (associated with Leu-124 in atypical granular dystrophy; French granular variant).
TGFBI	269	269	L -> F.
TGFBI	501	501	P -> T (in CDL3A).
TGFBI	505	505	V -> D (in CDL1).
TGFBI	509	509	L -> R (in EBMD).
TGFBI	518	518	L -> P (in CDL1).
TGFBI	518	518	L -> R (in CDL1; severe phenotype; delayed age of onset).
TGFBI	527	527	L -> R (in CDL1; late-onset; found also in sporadic cases).
TGFBI	538	538	T -> R (in CDL1; delayed age of onset).
TGFBI	539	539	V -> D (in lattice corneal dystrophy; unclassified form).
TGFBI	540	540	F -> S (in CDL3A).
TGFBI	540	540	Missing (in CDRB).
TGFBI	544	544	N -> S (in CDL; late-onset).
TGFBI	546	546	A -> D (in CDL1; associated with Q-551).
TGFBI	546	546	A -> T (in CDL3A).
TGFBI	551	551	P -> Q (in CDL1; associated with D-546).
TGFBI	555	555	R -> Q (in CDTB; originally thought to cause CDRB).
TGFBI	555	555	R -> W (in CDGG1; common mutation in Europe and United States; rare in Japan).
TGFBI	569	569	L -> R (in CDL1).
TGFBI	572	572	H -> R (in CDL1; late-onset).
TGFBI	572	572	Missing (in CDL1; late-onset and unilateral phenotype).
TGFBI	594	594	G -> V (in lattice corneal dystrophy; unclassified form).
TGFBI	622	622	N -> H (in asymmetric lattice corneal dystrophy).
TGFBI	622	622	N -> K (in CDL3A).
TGFBI	623	623	G -> D (in CDL1; delayed age of onset).
TGFBI	624	625	Missing (in lattice corneal dystrophy; unclassified form).
TGFBI	626	626	H -> P (in CDL1).
TGFBI	626	626	H -> R (in CDL1; delayed age of onset).
TGFBI	631	631	V -> D (in CDL).
TGFBI	666	666	R -> S (in EBMD; low penetrance in one family).
MYOT	33	33	S -> I (in a colorectal cancer sample; somatic mutation).
MYOT	39	39	S -> F (in SBM).
MYOT	55	55	S -> F (in LGMD1A and MFM3).
MYOT	60	60	S -> C (in MFM3).
MYOT	60	60	S -> F (in MFM3).
MYOT	95	95	S -> I (in MFM3).
ARAP3	471	471	R -> W (in a colorectal cancer sample; somatic mutation).
ARAP3	1085	1085	I -> M (in a breast cancer sample; somatic mutation).
ARAP3	1428	1428	T -> P (in a breast cancer sample; somatic mutation).
NR3C1	29	29	F -> L.
NR3C1	112	112	L -> F.
NR3C1	233	233	D -> N.
NR3C1	421	421	C -> Y (in a glucocorticoid resistant leukemia cell line).
NR3C1	477	477	R -> H (in GCRES).
NR3C1	559	559	I -> N (in GCRES; interferes with translocation to the nucleus and thereby strongly reduces transcription activation. Is equally impaired in nuclear export. Acts as dominant negative mutant).
NR3C1	571	571	V -> A (in pseudohermaphroditism; female with hypokalemia due to glucocorticoid resistance; 6-fold reduction in binding affinity compared with the wild-type receptor).
NR3C1	641	641	D -> V (in GCRES).
NR3C1	679	679	G -> S (in GCRES; has 50% binding affinity).
NR3C1	729	729	V -> I (in GCRES).
NR3C1	747	747	I -> M (in GCRES; alters interaction with NCOA2 and strongly reduces transcription activation; acts as dominant negative mutant).
NR3C1	753	753	L -> F (in two glucocorticoid resistant leukemia cell lines lacking the normal allele).
STK32A	89	89	S -> F (in a metastatic melanoma sample; somatic mutation).
STK32A	316	316	M -> I (in a lung neuroendocrine carcinoma sample; somatic mutation).
JAKMIP2	315	315	R -> C (in a colorectal cancer sample; somatic mutation).
SH3TC2	169	169	Y -> H (in MNMN).
SH3TC2	529	529	R -> Q (in CMT4C; homozygous in 2 unrelated Turkish patients; also found in 1 of 320 Turkish control chromosomes).
SH3TC2	657	657	E -> K (in CMT4C; homozygous in a Turkish patient).
SH3TC2	658	658	R -> C (in CMT4C; heterozygous in one German patient with affected sibling).
PDE6A	102	102	R -> H (in RP43).
PDE6A	102	102	R -> S (in RP43).
PDE6A	277	277	V -> A.
PDE6A	293	293	P -> L.
PDE6A	344	344	S -> R (in RP43).
PDE6A	391	391	V -> M.
PDE6A	569	569	Q -> K (in RP43).
PDE6A	573	573	S -> P (in RP43).
PDE6A	827	827	K -> Q.
PDE6A	850	850	G -> V.
GLRA1	272	272	I -> N (in STHE).
GLRA1	278	278	P -> T (in STHE).
GLRA1	280	280	R -> H (in STHE).
GLRA1	294	294	Q -> H (in STHE).
GLRA1	299	299	R -> L (in STHE; decreased potency of glycine to activate the channel).
GLRA1	299	299	R -> Q (in STHE; decreased potency of glycine to activate the channel).
GLRA1	304	304	K -> E (in STHE).
GLRA1	307	307	Y -> C (in STHE).
GLRA1	428	428	R -> H (in STHE).
ITK	19	19	R -> K (in a metastatic melanoma sample; somatic mutation).
ITK	23	23	P -> L (in a metastatic melanoma sample; somatic mutation).
ITK	451	451	R -> Q (in a gastric adenocarcinoma sample; somatic mutation).
ADAM19	133	133	R -> Q (in a colorectal cancer sample; somatic mutation).
ADAM19	298	298	A -> T (in a colorectal cancer sample; somatic mutation).
ADAM19	609	609	H -> Q (in a pancreatic ductal adenocarcinoma sample; somatic mutation).
NIPAL4	142	142	G -> V (in ARCII).
NIPAL4	176	176	A -> D (in ARCII; frequent mutation).
NIPAL4	208	208	S -> F (in ARCII).
NIPAL4	230	230	G -> R (in ARCII).
NIPAL4	237	237	H -> N (in ARCII).
NIPAL4	297	297	G -> R (in ARCII).
STK10	277	277	K -> E (in a testicular germ cell tumor; somatic mutation).
SH3PXD2B	43	43	R -> W (in FTHS).
UIMC1	353	353	M -> T (common polymorphism not associated with susceptibility to breast cancer).
NSD1	1616	1616	H -> L (in SOTOSS).
NSD1	1637	1637	L -> P (in SOTOSS).
NSD1	1674	1674	C -> W (in SOTOSS).
NSD1	1687	1687	I -> N (in SOTOSS).
NSD1	1792	1792	G -> V (in SOTOSS).
NSD1	1925	1925	C -> R (in SOTOSS).
NSD1	1955	1955	G -> D (in SOTOSS).
NSD1	1984	1984	R -> Q (in SOTOSS; loss of enzyme activity).
NSD1	1997	1997	Y -> C (in WES).
NSD1	2005	2005	R -> Q (in SOTOSS; strongly reduced enzyme activity).
NSD1	2017	2017	R -> Q (in SOTOSS; loss of enzyme activity).
NSD1	2017	2017	R -> W (in SOTOSS).
NSD1	2143	2143	H -> Q (in WES).
NSD1	2183	2183	C -> S (in WES).
SLC34A1	48	48	A -> F (in NPHLOP1; causes hypophosphatemic urolithiasis; results in lower phosphate current, decreases affinity for phosphate and decreases phosphate uptake compared to wild-type; shows a dominant-negative effect; requires 2 nucleotide substitutions).
SLC34A1	147	147	V -> M (in NPHLOP1; causes hypophosphatemic osteoporosis; results in lower phosphate current, decreases affinity for phosphate and decreases phosphate uptake compared to wild-type; shows a dominant-negative effect).
SLC34A1	160	160	V -> VILVTVLV (in FRTS2; loss of function in the homozygous state).
MAPK9	13	13	V -> M (in a colorectal adenocarcinoma sample; somatic mutation).
MAPK9	56	56	K -> N (in a head & Neck squamous cell carcinoma sample; somatic mutation).
SDHA	524	524	A -> V (in LS).
SDHA	554	554	R -> W (in LS).
SDHA	555	555	G -> E (in MT-C2D and CMD1GG).
PDCD6	123	123	G -> C (in a breast cancer sample; somatic mutation).
SLC6A19	57	57	R -> C (in HND; abolishes transport activity).
SLC6A19	173	173	D -> N (in HND; population allele frequency among Europeans is 0.007; reduces transport activity by 50% but does not completely inactivates the transporter).
SLC6A19	240	240	R -> Q.
SLC6A19	242	242	L -> P (in HND; completely abolishes the transport activity).
SLC6A19	501	501	E -> K (in HND; completely abolishes the transport activity).
SLC6A18	79	79	G -> S.
SLC6A18	496	496	G -> R.
TERT	55	55	L -> Q (in idiopathic pulmonary fibrosis susceptibility; impaired telomerase acivity).
TERT	65	65	P -> A (associated with acute myeloid leukemia).
TERT	202	202	A -> T (in AA susceptibility; severe and moderate; shorter telomeres).
TERT	279	279	A -> T.
TERT	299	299	V -> M (associated with acute myeloid leukemia).
TERT	441	441	Missing (in AA susceptibility; associated with susceptibility to acute myeloid leukemia).
TERT	522	522	R -> K (associated with acute myeloid leukemia).
TERT	570	570	K -> N (in AA susceptibility; abolishes telomerase catalytic activity but no effect on binding to TERC).
TERT	631	631	R -> Q (in AA susceptibility).
TERT	682	682	G -> D (in AA susceptibility; non-severe; abolishes telomerase catalytic activity but little effect on binding to TERC).
TERT	694	694	V -> M (in AA susceptibility; moderate).
TERT	721	721	P -> R (in a family with autosomal recessive DKC; no effect on telomerase catalytic activity and little effect on binding to TERC).
TERT	726	726	T -> M (in AA susceptibility; very severe; no effect on telomerase catalytic activity but shortened telomeres).
TERT	772	772	Y -> C (in AA susceptibility; moderate).
TERT	785	785	P -> L (in AA susceptibility).
TERT	811	811	R -> C (in a family with autosomal recessive DKC; 50% reduction in telomerase activity).
TERT	865	865	R -> H (in idiopathic pulmonary fibrosis susceptibility).
TERT	901	901	R -> W (in a family with autosomal recessive DKC; severe phenotype overlapping with Hoyeraal-Hreidarsson syndrome; very short telomeres and greatly reduced telomerase activity).
TERT	902	902	K -> N (in ADDKC; abolishes telomerase catalytic activity but no effect on binding to TERC).
TERT	979	979	R -> W (in ADDKC; shortened telomeres but no effect on telomerase catalytic activity nor on binding to TERC).
TERT	1090	1090	V -> M (in AA susceptibility; severe).
TERT	1110	1110	T -> M (in idiopathic pulmonary fibrosis susceptibility; impaired telomerase acivity).
TERT	1127	1127	F -> L (in ADDKC; severe; shortened telomeres but no effect on telomerase catalytic activity nor on binding to TERC).
CLPTM1L	313	313	K -> N (in a breast cancer sample; somatic mutation).
MTRR	81	81	Missing (in cblE).
MTRR	83	83	V -> M (in cblE).
MTRR	156	156	A -> T (in cblE).
MTRR	432	432	C -> R (in cblE).
MTRR	514	514	G -> R (in cblE).
MTRR	581	581	G -> R (in cblE).
MTRR	603	603	Missing (in cblE).
CCT5	147	147	H -> R (in HSNSP).
PRDM9	335	335	Y -> H (common polymorphism; may be a genetic risk for patients with azoospermia caused by meiotic arrest).
AMACR	52	52	S -> P (in AMACRD and CBAS4; inactive enzyme).
AMACR	107	107	L -> P (in CBAS4; inactive enzyme).
DNAJC21	214	214	D -> N (in a breast cancer sample; somatic mutation).
IL7R	132	132	P -> S (in T(-)/B(+)/NK(+) SCID).
SLC1A3	290	290	P -> R (in EA6).
GDNF	21	21	P -> S (in HSCR3; could be a polymorphism).
GDNF	150	150	D -> N (in HSCR3; could be a polymorphism).
GDNF	154	154	T -> S (in HSCR3; sporadic form).
GDNF	211	211	I -> M (in HSCR3).
C7	220	220	R -> Q (in C7D).
C7	379	379	G -> R (in C7D).
C7	521	521	R -> S (in C7D).
C7	682	682	E -> Q (in C7D).
C7	687	687	R -> H (in C7D).
FBXO4	8	8	S -> R (in esophagus cancer samples).
FBXO4	12	12	S -> L (in esophagus cancer sample; impairs homodimerization and reduces ubiquitin ligase activity).
FBXO4	13	13	P -> S (in esophagus cancer sample).
FBXO4	23	23	L -> Q (in esophagus cancer samples).
FBXO4	76	76	P -> T (in esophagus cancer samples; impairs interaction with SKP1).
SEPP1	112	112	P -> S.
SEPP1	278	278	R -> Q.
SEPP1	314	314	S -> P.
SEPP1	368	368	R -> C.
C5orf34	266	266	S -> R (in a breast cancer sample; somatic mutation).
FGF10	106	106	C -> F (in LADDS).
FGF10	156	156	I -> R (in LADDS).
MOCS2	7	7	V -> F (in MOCOD type B; in a patient with mild form of the disease; impairs interaction with MOCS2B).
HSPB3	7	7	R -> S (in HMN2C).
IL6ST	415	415	T -> I (in a colorectal cancer sample; somatic mutation).
MAP3K1	92	92	S -> N.
MAP3K1	189	189	L -> P (in SRXY6; increases phosphorylation of the downstream target MAPK3/MAPK1 compared to wild-type and enhances binding of RHOA to the mutant MAP3K1 complex).
MAP3K1	189	189	L -> R (in SRXY6; increases phosphorylation of the downstream targets MAPK14 and MAPK3/MAPK1 compared to wild- type and enhances binding of RHOA to the mutant MAP3K1 complex).
MAP3K1	211	211	V -> VIQ (in SRXY6).
MAP3K1	443	443	C -> S.
MAP3K1	616	616	G -> R (in SRXY6).
PLK2	14	14	S -> T (in an ovarian Endometrioid carcinoma sample; somatic mutation).
PLK2	92	92	G -> S (in a lung adenocarcinoma sample; somatic mutation).
ERCC8	160	160	A -> T (in CSA).
ERCC8	160	160	A -> V (in CSA).
ERCC8	194	194	W -> C (in CSA).
ERCC8	202	202	L -> S (in CSA).
ERCC8	205	205	A -> P (in CSA).
ERCC8	266	266	D -> G (in CSA).
PIK3R1	409	409	R -> Q (in a patient with severe insulin resistance; lower insulin-stimulated lipid kinase activity compared with wild- type).
CENPH	2	2	E -> K (in a colorectal cancer sample; somatic mutation).
SMN2	2	2	A -> G (in SMA2 and SMA3).
SMN2	30	30	D -> N (in SMA2).
SMN2	44	44	D -> V (in SMA3).
SMN2	95	95	G -> R (in SMA3; reduces SMN binding to Sm proteins).
SMN2	111	111	A -> G (in SMA2; reduces SMN binding to Sm proteins).
SMN2	116	116	I -> F (in SMA1).
SMN2	136	136	Q -> E (in SMA1).
SMN2	245	245	P -> L (in SMA3).
SMN2	262	262	S -> G (in SMA3).
SMN2	262	262	S -> I (in SMA3).
SMN2	272	272	Y -> C (in SMA1).
SMN2	274	274	T -> I (in SMA2 and SMA3).
SMN2	275	275	G -> S (in SMA3).
SMN2	279	279	G -> C (in SMA2 and SMA3).
SMN2	279	279	G -> V (in SMA1).
NAIP	535	535	V -> M.
CARTPT	61	61	L -> F (cosegregates with obesity phenotype in a large family).
CARTPT	66	66	S -> T.
HEXB	255	255	S -> R (in GM2G2).
HEXB	309	309	C -> Y (in GM2G2; adult type; severe; almost complete absence of activity).
HEXB	456	456	Y -> S (in GM2G2).
HEXB	504	504	P -> S (in GM2G2).
HEXB	505	505	R -> Q (in GM2G2).
HEXB	534	534	C -> Y (in GM2G2; infantile type).
HEXB	543	543	A -> T (in GM2G2).
DMGDH	109	109	H -> R (in DMGDHD).
ACOT12	190	190	L -> H (found in a clear cell renal carcinoma case; somatic mutation).
TTC37	860	878	Missing (found in a patient with THE syndrome).
TTC37	1077	1077	A -> D (found in a patient with THE syndrome).
TTC37	1270	1270	P -> A (found in a patient with THE syndrome).
TTC37	1485	1485	L -> R (found in a patient with THE syndrome).
PCSK1	213	213	Missing (in PC1 deficiency).
PCSK1	307	307	S -> L (in PC1 deficiency; in vitro the mutation markedly impairs the catalytic activity of the enzyme; however intracellular trafficking of this mutant enzyme appears normal; retains some autocatalytic activity even though it is completely inactive on other substrates).
PCSK1	483	483	G -> R (in PC1 deficiency; prevents processing of pro-PCSK1 and leads to its retention in the endoplasmic reticulum).
RIOK2	216	216	I -> T (in a renal clear cell carcinoma sample; somatic mutation).
ST8SIA4	92	92	E -> G (in a colorectal cancer sample; somatic mutation).
WDR36	25	25	L -> P (possible disease-susceptibility mutation).
WDR36	163	163	A -> V (possible disease-susceptibility mutation).
WDR36	216	216	Y -> P (possible disease-susceptibility mutation; requires 2 nucleotide substitutions).
WDR36	355	355	N -> S (in GLC1G).
WDR36	529	529	R -> Q (in GLC1G).
TSSK1B	50	50	A -> T.
TRIM36	428	428	K -> R.
FEM1C	434	434	D -> N (in a breast cancer sample; somatic mutation).
FEM1C	462	462	D -> N (in a breast cancer sample; somatic mutation).
CDO1	143	143	E -> Q (in a colorectal cancer sample; somatic mutation).
HSD17B4	16	16	G -> S (in DBPD).
PPIC	160	160	H -> L.
ALDH7A1	199	199	A -> V (in PDE).
ALDH7A1	427	427	E -> Q (in PDE).
IRF1	8	8	M -> L (in GASC; somatic mutation; produces a protein with markedly reduced transcriptional activity but unaltered DNA-binding activity).
IRF1	11	11	W -> R (in GASC; the mutation abolishes DNA binding and transactivating activities).
GDF9	67	67	K -> E (in some patients with premature ovarian failure).
GDF9	186	186	S -> Y (in a patient with premature ovarial failure).
GDF9	216	216	V -> M (in two patients with premature ovarial failure).
PITX1	130	130	E -> K (in CCF; reduces the ability to transactivate a luciferase reporter gene; suppresses wild-type activity in a dose- dependent manner).
HSPA9	184	184	H -> Y.
NDUFA2	50	50	D -> N (in a breast cancer sample; somatic mutation).
PCDHB15	719	719	A -> V (in a breast cancer sample; somatic mutation).
PCDHB15	758	758	G -> V (in a breast cancer sample; somatic mutation).
TAF7	178	178	S -> R.
POU4F3	223	223	L -> P (in DFNA15; whereas wild-type protein is located in the nucleus part of the mutant protein is also present in the cytoplasm; mutant protein shows greatly reduced capability for binding to DNA as well as transcriptionally activating reporter gene expression).
POU4F3	289	289	L -> F (in DFNA15; whereas wild-type protein is located in the nucleus part of the mutant protein is also present in the cytoplasm; mutant protein shows greatly reduced capability for binding to DNA as well as transcriptionally activating reporter gene expression).
SPINK1	14	14	L -> P (in PCTT).
SPINK1	55	55	P -> S.
SCGB3A2	33	33	K -> N (in a breast cancer sample; somatic mutation).
ADRB2	34	34	V -> M.
ADRB2	159	159	I -> F.
ADRB2	159	159	I -> L.
ADRB2	375	375	K -> R.
SLC26A2	255	255	G -> E (in AO2).
SLC26A2	279	279	R -> W (in AO2).
SLC26A2	340	340	Missing (in ACG1B).
SLC26A2	425	425	N -> D (in ACG1B).
SLC26A2	454	454	Q -> P (in diatrophic dysplasia; broad bone-platyspondylic variant).
SLC26A2	653	653	C -> S (in EDM4).
SLC26A2	678	678	G -> V (in ACG1B).
SLC26A2	715	715	A -> V (in AO2).
CSF1R	693	693	P -> H (in a lung squamous cell carcinoma sample; somatic mutation).
PDGFRB	589	589	Y -> H (in a gastric adenocarcinoma sample; somatic mutation).
PDGFRB	882	882	T -> I (in a breast infiltrating ductal carcinoma sample; somatic mutation).
TCOF1	53	53	W -> R (in TCS1).
TCOF1	516	516	P -> L.
TCOF1	1030	1030	R -> K (in a colorectal cancer sample; somatic mutation).
TCOF1	1432	1432	D -> G.
IRGM	17	17	E -> D.
IRGM	94	94	T -> K.
GM2A	88	88	Missing (in GM2GAB).
GM2A	138	138	C -> R (in GM2GAB).
GM2A	169	169	R -> P (in GM2GAB).
SLC36A2	87	87	G -> V (in HG and IG; partially inactivating mutation; results in a 3- fold increase of Km value for proline and a 5-fold increase of Km for glycine).
HAVCR1	157	157	P -> PMTTTVP.
HAVCR1	157	157	P -> PMTTVP.
HAVCR1	195	195	Missing.
GABRA6	180	180	P -> H (in a colorectal cancer sample; somatic mutation).
GABRA1	322	322	A -> D (in EJM5).
GABRG2	79	79	N -> S (found in a patient with generalized tonic-clonic seizures).
GABRG2	177	177	R -> G (in FEB8).
GABRG2	328	328	K -> M (in GEFS+3).
GABRP	416	416	H -> R (in a breast cancer sample; somatic mutation).
NKX2-5	7	7	L -> P (in ASD-AVCD; somatic mutation).
NKX2-5	15	15	K -> I (in ASD-AVCD).
NKX2-5	19	19	N -> S (in ASD-AVCD; somatic mutation).
NKX2-5	21	21	E -> Q (in TOF and ASD-AVCD).
NKX2-5	22	22	Q -> P (in ASD-AVCD).
NKX2-5	45	45	S -> P (in ASD-AVCD; somatic mutation).
NKX2-5	51	51	F -> L (in ASD-AVCD; somatic mutation).
NKX2-5	63	63	A -> V (in ASD-AVCD).
NKX2-5	69	69	L -> P (in ASD-AVCD; somatic mutation).
NKX2-5	77	77	P -> L (in ASD-AVCD; somatic mutation).
NKX2-5	114	114	C -> R (in ASD-AVCD; somatic mutation).
NKX2-5	114	114	C -> S (in ASD-AVCD; somatic mutation).
NKX2-5	118	118	K -> R (in ASD-AVCD; somatic mutation).
NKX2-5	119	119	A -> S (in CHNG5; exhibits a significant functional impairment with reduction of transactivation properties and dominant- negative effect which was associated with reduced DNA binding).
NKX2-5	124	124	K -> R (in ASD-AVCD; somatic mutation).
NKX2-5	126	126	E -> V (in ASD-AVCD; somatic mutation).
NKX2-5	127	127	A -> E (in ASD-AVCD).
NKX2-5	133	133	P -> S (in ASD-AVCD; somatic mutation).
NKX2-5	135	135	A -> T (in ASD-AVCD; somatic mutation).
NKX2-5	142	142	R -> C (in ASD-AVCD).
NKX2-5	144	144	L -> P (in ASD-AVCD; somatic mutation).
NKX2-5	161	161	R -> P (in CHNG5; exhibits a significant functional impairment with reduction of transactivation properties and dominant- negative effect which was associated with reduced DNA binding).
NKX2-5	178	178	T -> M (in ASD-AVCD).
NKX2-5	183	183	K -> E (in ASD-AVCD; somatic mutation).
NKX2-5	187	187	Q -> H (in ASD-AVCD).
NKX2-5	188	188	N -> K (in ASD-AVCD).
NKX2-5	189	189	R -> G (in ASD-AVCD).
NKX2-5	190	190	R -> C (in ASD-AVCD).
NKX2-5	191	191	Y -> C (in ASD-AVCD).
NKX2-5	192	192	K -> R (in ASD-AVCD; somatic mutation).
NKX2-5	192	192	K -> T (in ASD-AVCD; somatic mutation).
NKX2-5	194	194	K -> R (in ASD-AVCD; somatic mutation).
NKX2-5	205	205	V -> E (in ASD-AVCD; somatic mutation).
NKX2-5	216	216	R -> C (in TOF and ASD-AVCD).
NKX2-5	219	219	A -> V (in ASD-AVCD and TOF; somatic mutation).
NKX2-5	226	226	D -> N (in ASD-AVCD; somatic mutation).
NKX2-5	248	248	Y -> H (in ASD-AVCD; somatic mutation).
NKX2-5	275	275	P -> T (in ASD-AVCD).
NKX2-5	279	279	S -> F (in ASD-AVCD; somatic mutation).
NKX2-5	279	279	S -> P (in ASD-AVCD; somatic mutation).
NKX2-5	281	281	A -> V (in ASD-AVCD; somatic mutation).
NKX2-5	286	286	A -> V (in ASD-AVCD; somatic mutation).
NKX2-5	294	294	N -> H (in ASD-AVCD; somatic mutation).
NKX2-5	299	299	D -> G (in ASD-AVCD; somatic mutation).
NKX2-5	305	305	S -> G (in ASD-AVCD; somatic mutation).
NKX2-5	320	320	G -> S (in ASD-AVCD; somatic mutation).
NKX2-5	322	322	R -> Q (in ASD-AVCD; somatic mutation).
NKX2-5	323	323	A -> T (in ASD-AVCD).
MSX2	148	148	P -> H (in CRS2; gain of function).
MSX2	154	154	L -> P (in PFM1).
MSX2	159	160	Missing (in PFM1; loss of function).
MSX2	172	172	R -> H (in PFM1; loss of function).
DRD1	81	81	K -> R.
CDHR2	1004	1004	P -> L (in an acute myeloid leukemia sample; somatic mutation).
HK3	480	480	R -> W (in a colorectal cancer sample; somatic mutation).
HK3	499	499	A -> V (in a breast cancer sample; somatic mutation).
FGFR4	550	550	V -> M (in breast pleomorphic lobular sample; somatic mutation).
FGFR4	712	712	P -> T (in a lung adenocarcinoma sample; somatic mutation).
FGFR4	772	772	S -> N (in a lung neuroendocrine carcinoma sample; somatic mutation).
F12	53	53	Y -> C (in FA12D; Tenri; inactive).
F12	142	142	R -> P (in FA12D; CRM-negative phenotype; low levels of accumulation in the cell; not secreted).
F12	328	328	T -> K (in HAE3).
F12	328	328	T -> R (in HAE3).
F12	372	372	R -> P (in FA12D; Locarno; inactive).
F12	411	411	A -> T (in FA12D; Shizuoka; CRM-negative phenotype; transcribed and synthesized at wild-type levels; not secreted).
F12	414	414	L -> M (in FA12D; CRM-negative phenotype).
F12	417	417	R -> Q (in FA12D; CRM-negative phenotype).
F12	440	440	Q -> K (in FA12D; CRM-negative phenotype; accumulation in the cell; low secretion).
F12	461	461	D -> N (in FA12D; CRM-positive phenotype).
F12	505	505	W -> C (in FA12D; CRM-negative phenotype; transcribed and synthesized at wild-type levels; not secreted).
F12	589	589	G -> R (in FA12D; CRM-positive phenotype).
F12	590	590	C -> S (in FA12D; Washington D.C.; inactive).
GRK6	31	31	R -> Q (in a gastric adenocarcinoma sample; somatic mutation).
GRK6	275	275	I -> M (in a breast infiltrating ductal carcinoma sample; somatic mutation).
DBN1	278	278	E -> K (in a breast cancer sample; somatic mutation).
DBN1	640	640	E -> Q (in a breast cancer sample; somatic mutation).
PDLIM7	450	450	K -> N (in a breast cancer sample; somatic mutation).
B4GALT7	186	186	A -> D (in EDSP).
B4GALT7	206	206	L -> P (in EDSP).
PROP1	73	73	R -> C (in CPHD2; familial; no detectable DNA binding observed with the mutant protein in electromobility shift assays; whereas in vitro translated PROP1 and the mutant proteins were similar in their expression and electrophoretic properties).
PROP1	73	73	R -> H (in CPHD2; familial).
PROP1	88	88	F -> S (in CPHD2; impairs binding of the mutated protein to DNA target sequences).
PROP1	99	99	R -> Q (in CPHD2; displays a significant decrease in DNA binding on a paired-box response element (PRDQ9) and trans- activation of a luciferase reporter gene).
PROP1	117	117	F -> I (in CPHD2; familial).
PROP1	120	120	R -> C (in CPHD2; familial).
PROP1	125	125	R -> W (in CPHD2).
GRM6	150	150	G -> S (in CSNB1B).
GRM6	191	191	S -> F (in a breast cancer sample; somatic mutation).
GRM6	781	781	E -> K (in CSNB1B).
RUFY1	267	267	C -> F (in a breast cancer sample; somatic mutation).
C5orf60	70	70	Missing.
SQSTM1	117	117	A -> V.
SQSTM1	274	274	E -> Q.
SQSTM1	387	387	P -> L (in PDB).
SQSTM1	392	392	P -> L (in PDB; no effect on polyubiquitin-binding).
SQSTM1	399	399	S -> P (in PDB).
SQSTM1	404	404	M -> T (in PDB).
SQSTM1	404	404	M -> V (in PDB; loss of polyubiquitin- binding).
SQSTM1	411	411	G -> S (in PDB; no effect on polyubiquitin-binding).
SQSTM1	425	425	G -> R (in PDB; loss of polyubiquitin- binding).
FLT4	378	378	R -> C (in a renal clear cell carcinoma sample; somatic mutation).
FLT4	857	857	G -> R (in LMPH1A; loss of kinase activity).
FLT4	1010	1010	T -> I (in a metastatic melanoma sample; somatic mutation).
FLT4	1035	1035	H -> R (in LMPH1A; loss of kinase activity).
FLT4	1041	1041	R -> P (in LMPH1A; loss of kinase activity).
FLT4	1044	1044	L -> P (in LMPH1A; loss of kinase activity).
FLT4	1075	1075	R -> Q.
FLT4	1114	1114	P -> L (in LMPH1A; loss of kinase activity).
FLT4	1137	1137	P -> S (in juvenile hemangioma).
LEF1	113	113	G -> R (in a colorectal cancer sample; somatic mutation).
HTT	18	18	Q -> QQQ.
STK32B	35	35	G -> E (in a metastatic melanoma sample; somatic mutation).
WFS1	58	58	A -> V (in WFS).
WFS1	107	107	G -> R.
WFS1	110	110	Y -> N (in WFS).
WFS1	126	126	A -> T (in WFS).
WFS1	133	133	A -> T (in WFS).
WFS1	169	169	E -> K (in WFS).
WFS1	292	292	P -> S (in WFS).
WFS1	296	296	I -> S (in WFS).
WFS1	326	326	A -> V.
WFS1	350	350	Missing (in WFS).
WFS1	354	354	Missing (in WFS).
WFS1	414	414	Missing (in WFS).
WFS1	415	415	Missing (in WFS).
WFS1	437	437	G -> R (in WFS).
WFS1	443	443	S -> I (in WFS).
WFS1	457	457	R -> S (in WFS).
WFS1	461	463	Missing (in WFS).
WFS1	468	468	Missing (in WFS).
WFS1	508	512	Missing (in WFS).
WFS1	540	540	Missing (in WFS).
WFS1	567	568	Missing (in WFS).
WFS1	629	629	R -> W (in WFS).
WFS1	634	634	K -> T (in DFNA6).
WFS1	653	653	R -> C (in a patient with type 2 diabetes).
WFS1	669	669	Y -> C (in WFS).
WFS1	674	674	G -> R.
WFS1	684	684	A -> V.
WFS1	690	690	C -> R (in WFS).
WFS1	700	700	W -> C (in WFS).
WFS1	708	708	R -> C.
WFS1	736	736	G -> S (in WFS).
WFS1	737	737	E -> K.
WFS1	779	779	V -> M (in DFNA6).
WFS1	780	780	G -> R (in WFS).
WFS1	802	802	I -> V.
WFS1	829	829	L -> P (in DFNA6).
WFS1	864	864	E -> K (in Wolfram-like syndrome; autosomal dominant).
WFS1	871	871	V -> M.
WFS1	885	885	P -> L (in WFS; mild form).
NCAPG	265	265	M -> T (in a colorectal cancer sample; somatic mutation).
GRXCR1	38	38	P -> L (in DFNB25).
GRXCR1	51	51	G -> E.
GRXCR1	64	64	G -> S (in DFNB25).
GRXCR1	91	91	G -> V.
GRXCR1	138	138	R -> C (in DFNB25).
GRXCR1	153	153	F -> V (in DFNB25).
TEC	563	563	R -> K (in a lung adenocarcinoma sample; somatic mutation).
PDGFRA	829	829	G -> R (in a glioblastoma multiforme sample; somatic mutation).
PDGFRA	996	996	E -> K (in a metastatic melanoma sample; somatic mutation).
PDGFRA	1071	1071	D -> N (in a lung neuroendocrine carcinoma sample; somatic mutation).
KIT	550	558	Missing (in GIST; somatic mutation).
KIT	551	555	Missing (in GIST; somatic mutation).
KIT	559	560	Missing (in GIST; somatic mutation).
KIT	559	559	V -> A (in GIST).
KIT	559	559	V -> D (in GIST; somatic mutation).
KIT	559	559	Missing (in GIST).
KIT	583	583	E -> K (in PBT).
KIT	584	584	F -> L (in PBT).
KIT	601	601	G -> R (in PBT).
KIT	656	656	L -> P (in PBT).
KIT	664	664	G -> R (in PBT).
KIT	737	737	D -> N (in a colorectal adenocarcinoma sample; somatic mutation).
KIT	791	791	R -> G (in PBT).
KIT	796	796	R -> G (in PBT; with sensorineural deafness).
KIT	804	804	R -> W (in a colorectal adenocarcinoma sample; somatic mutation).
KIT	812	812	G -> V (in PBT).
KIT	816	816	D -> F (in mastocytosis; requires 2 nucleotide substitutions; somatic mutation; constitutively activated).
KIT	816	816	D -> V (in mast cell leukemia and mastocytosis; somatic mutation; constitutively activated; loss of interaction with MPDZ).
KIT	816	816	D -> Y (in acute myeloid leukemia, mastocytosis and a germ cell tumor of the testis; somatic mutation; constitutively activated).
KIT	820	820	D -> G (in mast cell disease; systemic).
KIT	822	822	N -> K (in a germ cell tumor of the testis; somatic mutation).
KIT	829	829	A -> P (in a germ cell tumor of the testis; somatic mutation).
KIT	839	839	E -> K (in mastocytosis; somatic mutation; dominant negative mutation; loss of autophosphorylation).
KIT	847	847	T -> P (in PBT).
KIT	893	896	Missing (in PBT; severe).
LPHN3	247	247	A -> S.
LPHN3	770	770	T -> M.
LPHN3	915	915	L -> V.
SLC4A4	342	342	R -> S (in pRTA-OA; mistargeting and altered function).
SLC4A4	471	471	S -> L (in pRTA-OA; mistargeting to the apical membrane and altered function).
SLC4A4	529	529	T -> S (in pRTA-OA; mistargeting and altered function).
SLC4A4	554	554	R -> H (in pRTA-OA; mistargeting and altered function).
SLC4A4	843	843	A -> V (in pRTA-OA; altered function).
SLC4A4	925	925	R -> C (in pRTA-OA; altered function).
CDKL2	98	98	L -> I (in an ovarian papillary serous adenocarcinoma sample; somatic mutation).
CDKL2	149	149	R -> Q (in an ovarian mucinous carcinoma sample; somatic mutation).
ABCG2	206	206	I -> L.
ABCG2	316	316	T -> P.
ABCG2	431	431	F -> L.
ABCG2	489	489	F -> L.
ABCG2	590	590	N -> Y.
ABCG2	620	620	D -> N.
GRID2	209	209	T -> N (in a colorectal cancer sample; somatic mutation).
ALPK1	320	320	L -> M.
ALPK1	339	339	K -> E (in an ovarian mucinous carcinoma sample; somatic mutation).
ALPK1	383	383	K -> E.
ANK2	685	685	G -> E (in a breast cancer sample; somatic mutation).
ANK2	1234	1234	G -> R (in a colorectal cancer sample; somatic mutation).
ANK2	1425	1425	E -> G (in LQT4; loss of function).
ANK2	3620	3620	T -> K (in a colorectal cancer sample; somatic mutation).
ANK2	3707	3707	L -> I (in LQT4; loss of function).
ANK2	3711	3711	T -> N (in LQT4; loss of function).
ANK2	3873	3873	R -> W (in LQT4; loss of function).
ANK2	3898	3898	E -> K (in LQT4; loss of function).
FSTL5	92	92	L -> I (in a colorectal cancer sample; somatic mutation).
NEIL3	58	58	N -> NN.
PDE6B	74	74	R -> C (in RP40; autosomal recessive).
PDE6B	166	166	E -> K.
PDE6B	212	212	Y -> H.
PDE6B	219	219	Y -> H (in RP40; autosomal recessive).
PDE6B	228	228	L -> H (in RP40; autosomal recessive and autosomal dominant).
PDE6B	228	228	L -> I.
PDE6B	258	258	H -> N (in CSNBAD2).
PDE6B	527	527	L -> P (in RP40; autosomal recessive).
PDE6B	535	535	I -> N (in RP40; autosomal recessive).
PDE6B	552	552	R -> Q (in RP40; autosomal recessive).
PDE6B	557	557	H -> Y (in RP40; autosomal dominant).
PDE6B	576	576	G -> D (in RP40; autosomal recessive).
PDE6B	699	699	L -> R (in RP40; autosomal recessive).
PDE6B	854	854	L -> R (in RP40; autosomal recessive).
GAK	144	144	S -> L.
GAK	877	877	Q -> R.
GAK	962	962	G -> D (in a lung neuroendocrine carcinoma sample; somatic mutation).
GRK4	425	425	L -> P.
EVC2	283	283	I -> R (in EVC).
EVC2	630	630	A -> S (in a colorectal cancer sample; somatic mutation).
EVC2	950	950	R -> W (in EVC).
EVC2	994	994	L -> V (in a colorectal cancer sample; somatic mutation).
EVC	307	307	S -> P (in WAD).
EVC	403	403	G -> S.
EVC	953	953	D -> G.
EVC	965	965	Missing.
JAKMIP1	251	251	K -> R.
JAKMIP1	375	375	A -> V (in a colorectal cancer sample; somatic mutation).
ABLIM2	227	227	G -> R (in a pancreatic ductal adenocarcinoma sample; somatic mutation).
ABLIM2	274	274	K -> M (in a pancreatic ductal adenocarcinoma sample; somatic mutation).
SLC2A9	22	22	S -> N.
SLC2A9	191	191	E -> D.
SLC2A9	216	216	G -> R.
SLC2A9	275	275	T -> M.
SLC2A9	281	281	D -> H.
SLC2A9	300	300	R -> H.
CC2D2A	721	721	P -> S (in JBTS9).
CC2D2A	800	800	K -> E.
CC2D2A	1096	1096	Q -> H (in JBTS9).
CC2D2A	1114	1114	T -> M (in MKS6 and JBTS9).
CC2D2A	1116	1116	T -> M (in COACHS).
CC2D2A	1122	1122	P -> S (in JBTS9).
CC2D2A	1528	1528	R -> C (in JBTS9 and COACHS).
CC2D2A	1551	1551	L -> P (in JBTS9).
CC2D2A	1556	1556	D -> V (in JBTS9).
PROM1	31	31	A -> G.
PROM1	31	31	A -> S.
PROM1	373	373	R -> C (in CORD12, STGD4 and MCDR2; affects the interaction with CDHR1 and actin).
SLIT2	636	636	S -> P.
SLIT2	1277	1277	S -> F.
GBA3	106	106	D -> N (rare polymorphism).
RFC1	692	692	E -> D.
RFC1	955	955	Q -> K.
RFC1	1146	1146	S -> L.
N4BP2	283	283	P -> A (in a breast cancer sample; somatic mutation).
COX7B2	27	27	H -> Q.
GABRA4	516	516	S -> R (in a breast cancer sample; somatic mutation).
CNGA1	32	32	R -> Q.
CNGA1	118	118	D -> N.
CNGA1	320	320	S -> F (in RP49).
KDR	2	2	Q -> R (in a lung adenocarcinoma sample; somatic mutation).
KDR	248	248	A -> G (in a renal clear cell carcinoma sample; somatic mutation).
KDR	275	275	R -> L (in a colorectal cancer sample; somatic mutation).
KDR	873	873	G -> R (in a colorectal cancer sample; somatic mutation).
KDR	1147	1147	P -> S (in HCI; somatic mutation).
IGFBP7	78	78	R -> G (in RNA edited version).
IGFBP7	95	95	K -> R (in RNA edited version).
EPHA5	417	417	R -> Q (in a lung adenocarcinoma sample; somatic mutation).
EPHA5	503	503	E -> K (in a lung large cell carcinoma sample; somatic mutation).
EPHA5	582	582	G -> E (in a lung adenocarcinoma sample; somatic mutation).
EPHA5	856	856	T -> I (in a lung squamous cell carcinoma sample; somatic mutation).
EPHA5	1032	1032	N -> S (in a lung large cell carcinoma sample; somatic mutation).
UGT2B4	40	40	K -> N.
UGT2B4	78	78	P -> T.
UGT2B4	80	80	S -> P.
UGT2B4	109	109	F -> L.
UGT2B4	277	277	V -> I.
UGT2B4	396	396	F -> L.
UGT2B4	511	511	C -> R.
GC	445	445	R -> C (in allele GC*2A9).
EREG	42	42	G -> A (in a breast cancer sample; somatic mutation).
AREG	80	80	D -> V.
AREG	81	81	Y -> C.
PPEF2	120	120	S -> R.
BMP2K	68	68	V -> M (in a lung squamous cell carcinoma sample; somatic mutation).
BMP2K	212	212	D -> V.
BMP2K	288	288	R -> H.
ANTXR2	45	45	L -> P (in ISH).
ANTXR2	105	105	G -> D (in JHF).
ANTXR2	189	189	I -> T (in ISH).
ANTXR2	218	218	C -> R (in ISH).
ANTXR2	293	293	V -> VQ (in JHF).
ANTXR2	329	329	L -> R (in JHF).
ANTXR2	381	381	Y -> C (in JHF).
PRKG2	716	716	W -> R (in a colorectal adenocarcinoma sample; somatic mutation).
PTPN13	1419	1419	L -> P.
AFF1	1204	1204	Q -> K (in a breast cancer sample; somatic mutation).
PKD2	24	24	P -> L.
PKD2	190	190	A -> T.
PKD2	306	306	R -> Q (in ADPKD2).
PKD2	322	322	R -> Q (in ADPKD2).
PKD2	322	322	R -> W (in ADPKD2).
PKD2	356	356	A -> P (in ADPKD2).
PKD2	384	384	A -> P (in ADPKD2).
PKD2	414	414	W -> G (in ADPKD2).
PKD2	420	420	R -> G (in ADPKD2).
PKD2	479	479	Missing (in ADPKD2; somatic mutation).
PKD2	482	482	F -> C.
PKD2	504	512	Missing (in ADPKD2; somatic mutation).
PKD2	511	511	D -> V (in ADPKD2).
PKD2	632	632	C -> R (in ADPKD2).
PKD2	684	684	Missing (in ADPKD2; somatic mutation).
PKD2	807	807	R -> Q (in ADPKD2).
SNCA	30	30	A -> P (in PARK1).
SNCA	46	46	E -> K (in PARK1 and DLB; significant increase in binding to negatively charged phospholipid liposomes).
SNCA	53	53	A -> T (in PARK1; no effect on osmotic stress-induced phosphorylation).
BMPR1B	31	31	R -> H (in a gastric adenocarcinoma sample; somatic mutation).
BMPR1B	297	297	D -> N (in a metastatic melanoma sample; somatic mutation).
BMPR1B	486	486	R -> Q (in brachydactyly type C and BDA2; with also additional features of symphalangism-1).
ADH1C	166	166	P -> S.
MTTP	95	95	Q -> H.
MTTP	168	168	V -> I (rare polymorphism).
MTTP	540	540	R -> H (in ABL; loss of activity).
MTTP	590	590	S -> I (in ABL).
MTTP	746	746	G -> E (in ABL).
MTTP	780	780	N -> Y (in ABL; loss of activity).
TET2	34	34	L -> F.
TET2	123	123	R -> H.
TET2	145	145	S -> N (in a chronic myelomonocytic leukemia sample; somatic mutation).
TET2	174	174	P -> H.
TET2	308	308	A -> T (in chronic myelomonocytic leukemia and acute myeloid leukemia samples).
TET2	312	312	N -> S (in an acute myeloid leukemia sample; somatic mutation).
TET2	355	355	G -> D.
TET2	399	399	P -> L (in myelodysplastic/ myeloproliferative disorders; a patient positive for mutation F-617 in JAK2).
TET2	429	429	G -> R.
TET2	460	460	S -> F (in a chronic myelomonocytic leukemia sample; somatic mutation).
TET2	666	666	D -> G (in a chronic myelomonocytic leukemia sample; somatic mutation).
TET2	817	817	S -> T (in myelodysplastic/ myeloproliferative disorders).
TET2	867	867	Y -> H.
TET2	941	941	P -> S (in a chronic myelomonocytic leukemia sample; somatic mutation).
TET2	949	949	H -> R.
TET2	1073	1073	E -> V.
TET2	1084	1084	Q -> P.
TET2	1135	1135	C -> Y (in a myeloproliferative disorder; somatic mutation).
TET2	1167	1167	R -> T (in a myelodysplatic/ myeloproliferative disorder and a chronic myelomonocytic leukemia sample).
TET2	1175	1175	I -> V (in a refractory anemia with ringed sideroblasts sample).
TET2	1204	1204	S -> C (in a myeloproliferative disorder; somatic mutation).
TET2	1214	1214	R -> W (in a myelodysplastic syndrome; somatic mutation in a chronic myelomonocytic leukemia sample).
TET2	1237	1239	Missing (in a polycythemia vera sample; somatic mutation).
TET2	1242	1242	D -> R.
TET2	1242	1242	D -> V (in myeloproliferative disorders).
TET2	1245	1245	Y -> S (in a myeloproliferative disorder; somatic mutation).
TET2	1261	1261	R -> C (in a myeloproliferative disorder; somatic mutation).
TET2	1261	1261	R -> H (in a chronic myelomonocytic leukemia sample; somatic mutation).
TET2	1261	1261	R -> L (in a myelodysplastic syndrome).
TET2	1285	1285	Missing (in a myelodysplastic syndrome; somatic mutation).
TET2	1287	1287	F -> L (in myelodysplastic/ myeloproliferative disorders).
TET2	1291	1291	W -> R (in a myelodysplastic syndrome; somatic mutation).
TET2	1299	1299	K -> E (in a refractory anemia sample).
TET2	1299	1299	K -> N (in chronic myelomonocytic leukemia samples).
TET2	1302	1302	R -> G (in primary myelofibrosis and chronic myelomonocytic leukemia samples).
TET2	1318	1318	E -> G (in chronic myelomonocytic leukemia samples).
TET2	1367	1367	P -> S (in a chronic myelomonocytic leukemia sample).
TET2	1396	1396	C -> W (in a myelodysplastic syndrome).
TET2	1398	1398	L -> R (in a myelodysplastic syndrome; somatic mutation).
TET2	1417	1417	V -> F (in a chronic myelomonocytic leukemia sample; somatic mutation).
TET2	1701	1701	M -> I.
TET2	1718	1718	V -> L (in refractory anemia with ringed sideroblasts; somatic mutation in an acute myeloid leukemia sample).
TET2	1723	1723	P -> S.
TET2	1757	1757	H -> D (in a chronic myelomonocytic leukemia sample; somatic mutation).
TET2	1778	1778	H -> R.
TET2	1811	1811	C -> R (in a chronic myelomonocytic leukemia sample; somatic mutation).
TET2	1828	1828	Q -> L (in a myeloproliferative disorder; somatic mutation).
TET2	1869	1869	G -> W (in an essential thrombocythemia sample).
TET2	1872	1872	L -> P (in a refractory anemia with excess blasts sample).
TET2	1873	1873	I -> T (in myelodysplastic syndromes, myeloproliferative disorders and chronic myelomonocytic leukemia; somatic mutation in acute myeloid leukemia and chronic myelomonocytic leukemia samples).
TET2	1875	1875	C -> R (in a myelodysplastic syndrome; somatic mutation).
TET2	1881	1881	H -> Q (in a myelodysplastic syndrome; somatic mutation).
TET2	1881	1881	H -> R (in a myeloproliferative disorder; somatic mutation; also in a patient with systemic mastocytosis associated with chronic myelomonocytic leukemia).
TET2	1896	1896	R -> M (in a primary acute myeloid leukemia sample; somatic mutation).
TET2	1896	1896	R -> S (in a myeloproliferative disorder; somatic mutation).
TET2	1898	1898	S -> F (in a secondary acute myeloid leukemia sample; somatic mutation).
TET2	1900	1900	V -> A.
TET2	1911	1916	Missing (in a myelodysplastic syndrome; somatic mutation).
TET2	1913	1913	G -> D (in myelodysplastic syndromes; refractory cytopenia with multilineage dysplasia and ringed sideroblasts; somatic mutation in a patient).
TET2	1919	1919	A -> V (in a myeloproliferative disorder; somatic mutation).
TET2	1926	1926	R -> H (in a chronic myelomonocytic leukemia sample; somatic mutation).
TET2	1941	1941	P -> S (in a chronic myelomonocytic leukemia sample; somatic mutation).
TET2	1962	1962	P -> L (in a myelodysplastic syndrome).
TET2	1966	1966	R -> H (in a chronic myelomonocytic leukemia sample; somatic mutation).
TET2	1974	1974	R -> M (in a chronic myelomonocytic leukemia sample; somatic mutation).
TET2	2000	2000	R -> K.
ARHGEF38	67	67	K -> N (in a breast cancer sample; somatic mutation).
TBCK	66	66	R -> L.
TBCK	151	151	I -> M.
TBCK	265	265	D -> N.
TBCK	425	425	T -> M.
TBCK	471	471	M -> I.
TBCK	503	503	R -> I (in a colorectal adenocarcinoma sample; somatic mutation).
TBCK	692	692	R -> C.
TBCK	806	806	I -> V (in a head & Neck squamous cell carcinoma sample; somatic mutation).
HADH	40	40	A -> T (in HADH deficiency).
HADH	57	57	D -> E (in HADH deficiency).
HADH	258	258	P -> L (in HHF4; loss of activity).
OSTC	9	9	F -> L (in a breast cancer sample; somatic mutation).
EGF	1070	1070	P -> L (in HOMG4; affects basolateral sorting of pro-EGF preventing the hormone to stimulate EGFR; lack of TRPM6 activation).
ENPEP	887	887	R -> T (in a breast cancer sample; somatic mutation).
PITX2	100	100	L -> Q (in RIEG1).
PITX2	108	108	R -> H (in RDC).
PITX2	110	110	P -> L (in RIEG1).
PITX2	110	110	P -> R (in RIEG1).
PITX2	114	114	T -> P (in RIEG1).
PITX2	115	115	R -> H (in IRID2).
PITX2	128	134	Missing (in RIEG1; more than 100-fold reduction in DNA binding activity as well as no detectable transactivation activity).
PITX2	129	129	V -> L (in RIEG1; more than 200% increase in transactivation activity).
PITX2	130	130	R -> W (in IRID2).
PITX2	134	134	K -> E (in RIEG1).
PITX2	136	136	R -> C (in RIEG1).
PITX2	137	137	R -> P (in RIEG1).
PITX2	151	151	L -> V (in RIEG1).
PITX2	154	154	N -> T (in RIEG1).
NDST3	264	264	H -> Q (in a colorectal cancer sample; somatic mutation).
MYOZ2	48	48	S -> P (in CMH16).
MYOZ2	246	246	I -> M (in CMH16).
MFSD8	52	52	G -> R (in CLN7).
MFSD8	121	121	Y -> C (in CLN7).
MFSD8	139	139	R -> H (in CLN7).
MFSD8	157	157	A -> P (in CLN7; due to a deletion- insertion mutation at nuleotide level).
MFSD8	294	294	T -> K (in CLN7).
MFSD8	310	310	G -> D (in CLN7; lysosomal localization).
MFSD8	429	429	G -> D (in CLN7; lysosomal localization).
MFSD8	447	447	P -> L (in CLN7).
MFSD8	465	465	R -> W (in CLN7).
GAB1	83	83	Y -> C (in a breast cancer sample; somatic mutation).
GAB1	387	387	T -> N (in a breast cancer sample; somatic mutation).
GYPA	23	23	T -> N (in M(g) antigen).
GYPA	46	46	D -> E (in Ny(a) antigen).
GYPA	47	47	T -> K (in ENEH/Hut antigen).
GYPA	47	47	T -> M (in ENEH/Vw antigen).
GYPA	50	50	R -> W (in Or antigen).
GYPA	73	73	P -> S (in Os(a) antigen).
GYPA	76	76	E -> K (in Ri(a) antigen).
GYPA	82	82	Q -> K (in ENAV/MARS antigen).
GYPA	84	84	A -> P (in ENEP/HAG antigen).
HHIP	341	341	V -> I.
NR3C2	7	7	H -> Q (in a colorectal cancer sample; somatic mutation).
NR3C2	241	241	A -> V (high frequency in healthy individuals; found in a patient with sporadic pseudohypoaldosteronism type I; reduces transcription transactivation upon aldosterone binding).
NR3C2	633	633	G -> R (in AD-PHA1; reduces transcription transactivation upon aldosterone binding).
NR3C2	645	645	C -> S (in AD-PHA1).
NR3C2	659	659	R -> S (in AD-PHA1).
NR3C2	759	759	P -> S (in AD-PHA1).
NR3C2	769	769	L -> P (in AD-PHA1).
NR3C2	770	770	N -> K (in AD-PHA1).
NR3C2	776	776	Q -> R (in AD-PHA1; reduces aldosterone binding).
NR3C2	805	805	S -> P (in AD-PHA1).
NR3C2	815	815	S -> R (in AD-PHA1).
NR3C2	818	818	S -> L (in AD-PHA1; abolishes translocation to the nucleus and transcription transactivation upon aldosterone binding).
NR3C2	924	924	L -> P (in AD-PHA1; abolishes transcription transactivation upon aldosterone binding).
NR3C2	972	972	E -> G (in AD-PHA1; reduces affinity for aldosterone and transcription transactivation).
NR3C2	979	979	L -> P (in AD-PHA1; loss of aldosterone binding and transcription transactivation).
LRBA	2038	2038	Q -> H (in a breast cancer sample; somatic mutation).
LRBA	2274	2274	G -> R (in a breast cancer sample; somatic mutation).
LRBA	2701	2701	T -> K (in a breast cancer sample; somatic mutation).
FBXW7	117	117	E -> K (in a breast cancer sample; somatic mutation).
FBXW7	465	465	R -> C (in a acute lymphoblastic leukemia cell line).
FBXW7	465	465	R -> H (in a colorectal cancer sample; somatic mutation).
FBXW7	505	505	R -> L (in an ovarian cancer cell line).
FBXW7	582	582	S -> L (in a colorectal cancer sample; somatic mutation).
GLRB	251	251	G -> D (in STHE).
GK	185	185	S -> N.
GK	232	232	N -> H.
GK	294	294	N -> D (in GKD).
GK	382	382	A -> T.
GK	446	446	D -> V (in GKD).
GK	509	509	W -> R (in GKD).
CPE	297	297	R -> Q (in a colorectal cancer sample; somatic mutation).
TLL1	182	182	M -> L (in ASD6).
TLL1	238	238	V -> A (in ASD6).
TLL1	629	629	I -> V (in ASD6).
TLL1	688	688	L -> V (in a breast cancer sample; somatic mutation).
NEK1	25	25	E -> K (in a lung large cell carcinoma sample; somatic mutation).
NEK1	294	294	A -> P (in a lung adenocarcinoma sample; somatic mutation).
NEK1	745	745	K -> N.
ADAM29	31	31	P -> L (in a colorectal cancer sample; somatic mutation).
ADAM29	205	205	V -> I (in a colorectal cancer sample; somatic mutation).
KLKB1	123	123	G -> R (in PKK deficiency; reduces the binding activity of Apple domain 2 to HMW kininogen).
KLKB1	208	208	H -> P.
KLKB1	548	548	C -> Y (in PKK deficiency).
IDUA	16	19	Missing (in MPS1H).
IDUA	51	51	G -> D (in MPS1H).
IDUA	75	75	A -> T (in MPS1H).
IDUA	79	79	A -> V (in MPS1H/S; reduction of activity and protein levels).
IDUA	82	82	H -> P (in MPS1H/S).
IDUA	82	82	H -> Q (reduction of protein levels).
IDUA	89	89	R -> Q (in MPS1S; in Japanese 21% of alleles).
IDUA	89	89	R -> W (in MPS1S).
IDUA	116	116	G -> R.
IDUA	133	133	M -> I (in MPS1H).
IDUA	182	182	E -> K (in MPS1H).
IDUA	208	208	G -> D (in MPS1H).
IDUA	218	218	L -> P (in MPS1H).
IDUA	238	238	L -> Q (in MPS1H/S).
IDUA	260	260	S -> F (in MPS1H/S).
IDUA	279	279	V -> A.
IDUA	300	300	A -> T (in IDUA pseudodeficiency).
IDUA	315	315	D -> Y (in MPS1).
IDUA	327	327	A -> P (in MPS1H and MPS1H/S).
IDUA	346	346	L -> R (in MPS1H/S; 0.4% of normal activity).
IDUA	349	350	Missing (in MPS1H).
IDUA	349	349	D -> N (in MPS1H).
IDUA	349	349	D -> Y (in MPS1H).
IDUA	350	350	N -> I (in MPS1S).
IDUA	363	363	R -> C (in MPS1H/S; loss of activity).
IDUA	366	366	T -> P (in MPS1H).
IDUA	380	380	Q -> R (in MPS1H/S).
IDUA	383	383	R -> H (in MPS1S; 2-3% of normal activity).
IDUA	388	388	T -> R (in MPS1H).
IDUA	396	396	L -> LALL (in MPS1H).
IDUA	423	423	S -> R (in MPS1S; significant reduction of activity and protein levels).
IDUA	445	445	Missing (in MPS1S).
IDUA	454	454	V -> I.
IDUA	490	490	L -> P (in MPS1H/S).
IDUA	492	492	R -> P (in MPS1S).
IDUA	496	496	P -> L (in MPS1H/S).
IDUA	504	504	M -> T (in MPS1H/S).
IDUA	533	533	P -> R (in MPS1H and MPS1H/S; in 3% of the MPS1H patients).
IDUA	602	602	F -> I (in MPS1H/S; reduction of activity and protein levels).
IDUA	619	619	R -> G (in MPS1H/S; 1.5% of normal activity).
IDUA	626	626	W -> R (in MPS1H/S).
IDUA	628	628	R -> P (in MPS1H/S).
FGFR3	79	79	T -> S (in a lung adenocarcinoma sample; somatic mutation).
FGFR3	228	228	C -> R (in a colorectal adenocarcinoma sample; somatic mutation).
FGFR3	248	248	R -> C (in KERSEB, bladder cancer, keratinocytic non-epidermolytic nevus and TD1; severe and lethal; also found as somatic mutation in one patient with multiple myeloma).
FGFR3	249	249	S -> C (in KERSEB, bladder cancer, cervical cancer and TD1).
FGFR3	322	322	E -> K (in colorectal cancer).
FGFR3	338	338	T -> M.
FGFR3	370	370	G -> C (in KERSEB, bladder cancer, keratinocytic non-epidermolytic nevus and TD1).
FGFR3	371	371	S -> C (in KERSEB and TD1).
FGFR3	373	373	Y -> C (in KERSEB and TD1).
FGFR3	375	375	G -> C (in ACH).
FGFR3	513	513	D -> N (in LADDS).
FGFR3	538	538	I -> V (in hypochondroplasia).
FGFR3	540	540	N -> S (in hypochondroplasia; mild).
FGFR3	540	540	N -> T (in hypochondroplasia).
FGFR3	621	621	R -> H (in CATSHL syndrome).
FGFR3	646	646	D -> N.
FGFR3	650	650	K -> E (in KERSEB, TD2 and bladder cancer samples; bladder transitional cell carcinoma; somatic mutation).
FGFR3	650	650	K -> M (in KERSEB, ACH and TD1).
FGFR3	650	650	K -> Q (in hypochondroplasia and bladder cancer; in hypochondroplasia the form is milder than that seen in individuals with the K-540 or M-650 mutations).
SH3BP2	415	415	R -> P (in CRBM).
SH3BP2	415	415	R -> Q (in CRBM).
SH3BP2	418	418	P -> H (in CRBM).
SH3BP2	418	418	P -> L (in CRBM).
SH3BP2	418	418	P -> R (in CRBM).
DOK7	180	180	G -> A (in LGM).
ADRA2C	322	325	Missing.
MSX1	61	61	M -> K (in STHAG1).
MSX1	78	78	E -> V (in OFC5; cleft palate only).
MSX1	91	91	G -> D (in OFC5; cleft palate only).
MSX1	114	114	V -> G (in OFC5; cleft palate only).
MSX1	151	151	R -> S (in OFC5; unilateral cleft palate).
MSX1	196	196	R -> P (in STHAG1; severely impairs DNA- binding).
C4orf50	150	150	A -> P (in a breast cancer sample; somatic mutation).
SH3TC1	719	719	R -> H (in a colorectal cancer sample; somatic mutation).
SH3TC1	1130	1130	A -> T (in a colorectal cancer sample; somatic mutation).
DRD5	351	351	N -> D.
DRD5	453	453	S -> C.
BOD1L1	246	246	S -> I (in a breast cancer sample; somatic mutation).
QDPR	14	14	L -> P (in HPABH4C; severe).
QDPR	17	17	G -> R (in HPABH4C; severe).
QDPR	17	17	G -> V (in HPABH4C; severe).
QDPR	18	18	G -> D (in HPABH4C; severe).
QDPR	23	23	G -> D (in HPABH4C; severe).
QDPR	36	36	W -> R (in HPABH4C).
QDPR	51	51	S -> T.
QDPR	66	66	Q -> R (in HPABH4C; severe).
QDPR	74	74	L -> P (in HPABH4C).
QDPR	108	108	W -> G (in HPABH4C).
QDPR	123	123	T -> TT (in HPABH4C).
QDPR	145	145	P -> L (in HPABH4C).
QDPR	149	149	G -> R (in HPABH4C).
QDPR	150	150	Y -> C (in HPABH4C; mild).
QDPR	151	151	G -> S (in HPABH4C; mild).
QDPR	158	158	H -> Y (in HPABH4C; severe).
QDPR	170	170	G -> S (in HPABH4C).
QDPR	212	212	F -> C (in HPABH4C; mild).
QDPR	218	218	G -> GITG (in HPABH4C; mild).
SEPSECS	239	239	A -> T (in PCH2D; abrogates enzyme activity).
SEPSECS	334	334	Y -> C (in PCH2D; abrogates enzyme activity).
ANAPC4	155	155	I -> V (in a colorectal cancer sample; somatic mutation).
SLC34A2	106	106	G -> R (in PALM).
TLR1	248	248	N -> S (may confer susceptibility to leprosy).
UCHL1	93	93	I -> M (in PARK5; impaired enzymatic hydrolase activity; has about a 50% reduction in catalytic activity compared to wild-type protein).
PHOX2B	100	100	R -> L (confers susceptibility to neuroblastoma; found as germline mutation in a neuroblastoma family).
PHOX2B	141	141	R -> Q (in CCHS).
PHOX2B	143	143	Q -> R (in CCHS).
PHOX2B	197	197	G -> D (confers susceptibility to neuroblastoma).
PHOX2B	241	241	A -> AAAAAAAAAAA (in CCHS).
PHOX2B	254	258	Missing.
PHOX2B	255	259	Missing.
SGCB	11	11	Q -> E (in DMD-like).
SGCB	91	91	R -> C (in LGMD2E).
SGCB	91	91	R -> L (in LGMD2E).
SGCB	108	108	L -> R (in LGMD2E).
SGCB	114	114	S -> F (in LGMD2E or DMD-like).
SGCB	119	119	I -> F (in LGMD2E).
SGCB	139	139	G -> D (in DMD-like).
SGCB	167	167	G -> S (in LGMD2E).
SGCB	182	182	T -> A (in DMD-like).
SGCB	184	184	Y -> C (in DMD-like).
NOA1	579	579	Q -> R (in a breast cancer sample; somatic mutation).
GNRHR	10	10	N -> K (in IHH; is able to bind GnRH but with a reduced affinity in vitro).
GNRHR	90	90	E -> K (in IHH; virtual abolition of GnRH agonist binding and agonist-stimulated phosphoinositide turnover; impairs GnRHR- effector coupling).
GNRHR	106	106	Q -> R (in IHH and FEUNS; decreases but does not eliminate GnRH binding).
GNRHR	129	129	A -> D (in IHH; complete loss of function).
GNRHR	139	139	R -> H (in IHH; completely eliminates detectable GnRH-binding activity and prevents GnRH-induced stimulation of inositol phosphate accumulation in vitro).
GNRHR	168	168	S -> R (in IHH; complete loss of the receptor-mediated signaling response).
GNRHR	171	171	A -> T (in IHH; complete loss of ligand binding and receptor activation; specific receptor binding of radioisotope-labeled GnRH ligand is undetectable in transfected cells).
GNRHR	217	217	S -> R (in IHH; altered hormone binding).
GNRHR	262	262	R -> Q (in IHH; minimal effects upon receptor affinity but expression decreased; altered activation of phospholipase C).
STATH	25	34	Missing (in statherin variants SV2 and SV3).
STATH	62	62	Missing (in statherin variants SV1 and SV3).
ODAM	269	269	E -> D (in a colorectal cancer sample; somatic mutation).
AMTN	78	78	G -> S (in a colorectal cancer sample; somatic mutation).
AMBN	11	11	M -> T (in ameloblastoma).
AMBN	354	354	L -> P.
AMBN	396	397	RT -> GA (in an ameloblastoma sample).
AMBN	439	439	H -> R (in an ameloblastoma sample).
ALB	23	23	R -> C (in Redhill/Malmo-I/Tradate; associated with T-344 in Redhill).
ALB	23	23	R -> H (in Fukuoka-2/Lille/Taipei/Varese/ Komagome-3).
ALB	24	24	R -> L (in Jaffna).
ALB	24	24	R -> P (in Takefu/Honolulu-1).
ALB	24	24	R -> Q (in Christchurch/Honolulu-2).
ALB	25	25	D -> V (in Bleinheim/Iowa city-2).
ALB	27	27	H -> Q (in Nagasaki-3).
ALB	27	27	H -> Y (in Larino).
ALB	73	73	F -> Y.
ALB	84	84	E -> K (in Torino).
ALB	87	87	D -> N (in Malmo-95/Dalakarlia).
ALB	90	90	L -> P (in FDH).
ALB	106	106	E -> K (in Vibo Valentia).
ALB	121	121	E -> G.
ALB	138	138	R -> G (in Yanomama-2).
ALB	143	143	E -> K (in Nagoya).
ALB	146	146	V -> E (in Tregasio).
ALB	152	152	H -> R (in Komagome-2).
ALB	201	201	C -> F (in Hawkes bay).
ALB	242	242	R -> H (in FDH).
ALB	242	242	R -> P (in FDH).
ALB	249	249	K -> Q (in Tradate-2).
ALB	264	264	K -> E (in Herborn).
ALB	292	292	Q -> R (in Malmo-10).
ALB	293	293	D -> G (in Nagasaki-1).
ALB	300	300	K -> N (in Caserta).
ALB	337	337	K -> N (in Canterbury/New Guinea/ Tagliacozzo/Cuneo/Cooperstown).
ALB	338	338	D -> G (in Bergamo).
ALB	338	338	D -> V (in Brest).
ALB	342	342	N -> K (in Malmo-47).
ALB	344	344	A -> T (in Redhill; associated with C- 23).
ALB	345	345	E -> K (in Roma).
ALB	357	357	E -> K (in Sondrio).
ALB	378	378	E -> K (in Hiroshima-1).
ALB	382	382	E -> K (in Coari I/Porto Alegre).
ALB	383	383	K -> N (in Trieste).
ALB	389	389	D -> H (in Parklands).
ALB	389	389	D -> V (in Iowa city-1).
ALB	396	396	K -> E (in Naskapi/Mersin/Komagome-1).
ALB	399	399	D -> N (in Nagasaki-2).
ALB	400	400	E -> K (in Tochigi).
ALB	400	400	E -> Q (in Malmo-5).
ALB	406	406	E -> K (in Hiroshima-2).
ALB	420	420	E -> K.
ALB	434	434	R -> C (in Liprizzi).
ALB	503	503	E -> K (in Dublin).
ALB	518	518	D -> N (in Casebrook).
ALB	525	525	E -> K (in Manaus-1/Adana/Lambadi/ Vancouver).
ALB	529	529	E -> K (in Ortonovo).
ALB	557	557	V -> M (in Maddaloni).
ALB	560	560	K -> E (in Castel di Sangro).
ALB	565	565	K -> E (in Maku).
ALB	574	574	D -> A (in Malmo-61).
ALB	574	574	D -> G (in Mexico).
ALB	584	584	K -> E (in Church bay).
ALB	587	587	D -> N (in Fukuoka-1/Paris-2).
ALB	589	589	E -> K (in Osaka-1).
ALB	594	594	E -> K (in Osaka-2/Phnom Phen/albumin B/ Verona).
ALB	596	609	GKKLVAASQAALGL -> PTMRIRERK (in Venezia).
ALB	597	597	K -> E (in Gent/Milano Fast).
ALB	598	598	K -> N (in Vanves).
ALB	599	609	LVAASQAALGL -> TCCCKSSCLRLITSHLKASQPTMRIR ERK (in Kenitra).
G3BP2	434	434	P -> L (in a breast cancer sample; somatic mutation).
COQ2	247	247	Y -> C (in coenzyme Q10 deficiency).
HPSE	260	260	N -> S (in some hepatocellular carcinoma).
HELQ	565	565	D -> N (in a breast cancer sample; somatic mutation).
CDS1	204	204	K -> T (in a breast cancer sample; somatic mutation).
DSPP	6	6	Y -> D (in DTDP2; causes a failure of translocation of the encoded proteins into the endoplasmic reticulum and is therefore likely to lead to a loss of function of both DSP and DPP).
DSPP	15	15	A -> V (in DGI2).
DSPP	17	17	P -> S (in DGI2).
DSPP	18	18	V -> F (in DFNA39/DGI1 and DGI3).
DMP1	117	117	D -> N (in one individual with tumoral calcinosis).
DMP1	272	272	R -> H.
RG9MTD2	82	82	P -> Q (in a breast cancer sample; somatic mutation).
NFKB1	489	489	T -> I.
NFKB1	506	506	M -> V.
NFKB1	566	566	T -> I.
NFKB1	578	578	R -> K.
NFKB1	711	711	H -> Q.
NFKB1	901	901	A -> T.
CFI	64	64	P -> L (in AHUS3).
CFI	119	119	G -> R (in AHUS3).
CFI	183	183	H -> R (in AHUS3).
CFI	243	243	G -> D (in CFI deficiency).
CFI	287	287	G -> R (in AHUS3).
CFI	317	317	R -> W (in AHUS3).
CFI	340	340	I -> T (in AHUS3).
CFI	416	416	I -> L (in AHUS3).
CFI	418	418	H -> L (in CFI deficiency).
CFI	519	519	D -> N (in AHUS3).
CFI	522	522	K -> T (in AHUS3).
CFI	524	524	D -> V (in AHUS3).
BBS7	66	66	I -> F (in BBS7).
BBS7	211	211	T -> I (in BBS7).
BBS7	323	323	H -> R (in BBS7).
BBS7	671	671	Y -> C (in a patient with Meckel-Gruber like syndrome also carrying Y-60 in TTC21B).
IL2	21	21	Missing (in FT-IL2-A and FT-IL2-B).
IL2	22	22	Missing (in FT-IL2-B).
BBS12	39	39	I -> T.
BBS12	113	113	Missing (in BBS12; significantly reduces the interaction with MKKS; shows significantly decreased interaction with BBS7; the interaction with BBS10 is not affected by this mutation).
BBS12	159	159	P -> L (in BBS12; pathogenicity uncertain; significantly reduces the interaction with MKKS; the interaction with BBS10 is not affected by this mutation).
BBS12	170	170	I -> V.
BBS12	289	289	A -> P (in BBS12; significantly reduces the interaction with MKKS; shows significantly decreased interaction with BBS7; the interaction with BBS10 is not affected by this mutation).
BBS12	346	346	I -> T (in BBS12; significantly reduces the interaction with MKKS; shows significantly decreased interaction with BBS7; the interaction with BBS10 is not affected by this mutation).
BBS12	501	501	T -> M (in BBS12; significantly reduces the interaction with MKKS; shows significantly decreased interaction with BBS7; the interaction with BBS10 is not affected by this mutation).
BBS12	540	540	G -> V (in BBS12; significantly reduces the interaction with MKKS; shows significantly decreased interaction with BBS7; the interaction with BBS10 is not affected by this mutation).
OTUD4	216	216	A -> T.
MMAA	89	89	L -> P (in MMAA).
MMAA	145	145	R -> Q (in MMAA).
MMAA	207	207	Y -> C (in MMAA).
MMAA	218	218	G -> E (in MMAA).
MMAA	359	359	R -> G (in MMAA).
MMAA	359	359	R -> Q (in MMAA).
EDNRA	136	136	I -> L (in a breast cancer sample; somatic mutation).
TLR2	677	677	R -> W.
FGB	39	102	Missing (in New York-1).
FGB	44	44	R -> C (in Christchurch-2, Seattle-1 and Ijmuiden).
FGB	45	45	G -> R (in Ise).
FGB	74	74	R -> C (in Nijmegen).
FGB	98	98	A -> T (in Naples and Milano-2; associated with defective thrombin binding and thrombophilia).
FGB	196	196	R -> C (in congenital afibrinogenemia; variant Longmont).
FGB	365	365	A -> T (in Pontoise-2).
FGB	383	383	L -> R (in congenital afibrinogenemia; abolishes fibrinogen secretion).
FGB	430	430	G -> D (in congenital afibrinogenemia; abolishes fibrinogen secretion).
FGA	26	26	D -> N (in Lille-1).
FGA	31	31	G -> V (in Rouen-1).
FGA	35	35	R -> C.
FGA	35	35	R -> H.
FGA	37	37	P -> L (in Kyoto-2).
FGA	38	38	R -> G (in Aarhus-1).
FGA	38	38	R -> N (in Munich-1; requires 2 nucleotide substitutions).
FGA	38	38	R -> S (in Detroit-1).
FGA	39	39	V -> D (in Canterbury).
FGA	66	66	S -> T.
FGA	160	160	R -> S (in Lima).
FGA	453	453	S -> N (in Caracas-2).
FGA	545	545	E -> V (in AMYL8).
FGA	573	573	R -> C (in Dusart/Paris-5).
FGA	573	573	R -> L (in AMYL8).
FGG	301	301	R -> C (in Tochigi/Osaka-2/Milano-5/ Villajoyosa).
FGG	301	301	R -> H (in Bergamo-2/Essen/Haifa/Osaka-3/ Perugia/Saga/Barcelona-3/Barcelona-4).
FGG	318	318	G -> V (in Baltimore-1; impaired polymerization).
FGG	334	334	N -> I (in Baltimore-3; impaired polymerization).
FGG	334	334	N -> K (in Kyoto-1; causes accelerated cleavage by plasmin).
FGG	335	335	G -> D (in Hillsborough; prolonged thrombin clotting time).
FGG	336	336	M -> T (in Asahi; impaired polymerization).
FGG	345	346	Missing (in Vlissingen; defective calcium binding and impaired polymerization).
FGG	355	355	Q -> R (in Nagoya-1; impaired polymerization).
FGG	356	356	D -> V (in Milano-1; impaired polymerization).
FGG	356	356	D -> Y (in Kyoto-3; impaired polymerization).
FGG	363	363	N -> K (in Bern-1; impaired polymerization).
FGG	377	377	G -> VMCGEALPMLKDPCYS (in Paris-1; impaired polymerization).
FGG	384	384	S -> C (in Milano-7; impaired polymerization).
FGG	401	401	R -> G (in Osaka-5).
LRAT	173	173	P -> L.
LRAT	175	175	S -> R (in LCA14; loss of function).
ETFDH	565	565	V -> L (in a colorectal cancer sample; somatic mutation).
ANP32C	140	140	Y -> H.
FBXO8	269	269	L -> I (in a breast cancer sample; somatic mutation).
HPGD	140	140	A -> P (in COA; inactive).
HPGD	193	193	S -> P (in ICNC).
HPGD	217	217	Y -> C.
AGA	12	12	V -> L (in AGU; could be a polymorphism).
AGA	60	60	G -> D (in AGU; German).
AGA	72	72	S -> P (in AGU; Arab. Specifically prevents the proteolytic activation cleavage of AGA in the endoplasmic reticulum).
AGA	100	100	G -> E (in AGU; Canadian).
AGA	101	101	A -> V (in AGU; Italian).
AGA	135	135	F -> S (in AGU; Canadian).
AGA	161	161	R -> Q (in AGU; Finnish).
AGA	163	163	C -> S (in AGU; Finnish. Most frequent mutation; >98% of Finnish AGU alleles).
AGA	252	252	G -> E (in AGU; Finnish).
AGA	252	252	G -> R (in AGU; Italian).
AGA	257	257	T -> I (in AGU; Finnish).
AGA	302	302	G -> R (in AGU; Turkish).
AGA	306	306	C -> R (in AGU; American white).
SLC25A4	90	90	A -> D (in PEOA2).
SLC25A4	98	98	L -> P (in PEOA2).
SLC25A4	114	114	A -> P (in PEOA2).
SLC25A4	123	123	A -> D (in hypertrophic cardiomyopathy; sporadic patient with mild myopathy, exercise intolerance and lactic acidosis but no ophthalmoplegia).
SLC25A4	289	289	V -> M (in PEOA2; also found in a sporadic case affected by PEO).
TLR3	554	554	P -> S (in HSE2; causes TLR3 deficiency and predisposition to herpes simplex encephalitis).
CYP4V2	44	44	W -> R (in BCD).
CYP4V2	61	61	G -> S (in BCD).
CYP4V2	79	79	E -> D (in BCD).
CYP4V2	111	111	I -> T (in BCD).
CYP4V2	123	123	M -> V (in BCD).
CYP4V2	331	331	H -> P (in BCD).
CYP4V2	341	341	S -> P (in BCD).
CYP4V2	372	372	V -> I.
CYP4V2	443	443	R -> Q.
CYP4V2	508	508	R -> H (in BCD).
F11	34	34	D -> H (in FA11D).
F11	46	46	C -> F (in FA11D).
F11	56	56	C -> R (in FA11D; autosomal dominant; secretion of the mutant protein is impaired).
F11	101	101	K -> R (in FA11D).
F11	151	151	Y -> C (in FA11D).
F11	246	246	W -> C (in FA11D).
F11	255	255	C -> Y (in FA11D; secretion of the mutant protein is impaired).
F11	263	263	G -> E (in FA11D).
F11	266	266	S -> N (in FA11D).
F11	270	270	K -> I (in FA11D; although the mutant protein is synthesized the secretion is reduced).
F11	301	301	F -> L (in FA11D).
F11	320	320	L -> P (in FA11D).
F11	322	322	T -> I (in FA11D).
F11	341	341	E -> K (in FA11D).
F11	404	404	T -> N (in FA11D).
F11	418	418	G -> V (in FA11D; autosomal dominant; mutant is not secreted by transfected fibroblasts; dominant-negative effect).
F11	460	460	F -> V (in FA11D).
F11	493	493	T -> I (in FA11D).
F11	511	511	Y -> H (in FA11D; transfected cells contain reduced amount of mutant protein and display decreased secretion).
F11	538	538	P -> L (in FA11D).
F11	565	565	E -> K (in FA11D).
F11	587	587	W -> S (in FA11D; autosomal dominant; mutant is not secreted by transfected fibroblasts; dominant-negative effect).
F11	618	618	I -> S (in FA11D).
TRIML1	21	21	D -> H (in a breast cancer sample; somatic mutation).
F13A1	40	40	V -> I.
F13A1	682	682	R -> H (in FA13AD).
HLA-DRB5	14	14	K -> V (in allele DRB5*02:02; requires 2 nucleotide substitutions).
HLA-DRB5	28	28	L -> S.
HLA-DRB5	66	66	D -> Y (in allele DRB5*01:14).
HLA-DRB5	87	87	A -> E (in allele DRB5*01:13).
HLA-DRB5	96	96	F -> L (in allele DRB5*02:05).
HLA-DRB5	99	99	D -> N (in allele DRB5*01:09).
HLA-DRB5	99	99	D -> Q (in allele DRB5*01:06, allele DRB5*01:11, allele DRB5*02:02, allele DRB5*02:03, allele DRB5*02:04 and allele DRB5*02:05; requires 2 nucleotide substitutions).
HLA-DRB5	99	99	D -> R (in allele DRB5*01:12; requires 2 nucleotide substitutions).
HLA-DRB5	100	100	R -> A (in allele DRB5*01:06, allele DRB5*01:11, allele DRB5*02:02, allele DRB5*02:03 and allele DRB5*02:04; requires 2 nucleotide substitutions).
HLA-DRB5	100	100	R -> T (in allele DRB5*01:03).
HLA-DRB5	103	103	A -> E (in allele DRB5*01:12).
HLA-DRB5	103	103	A -> L (in allele DRB5*01:04; requires 2 nucleotide substitutions).
HLA-DRB5	107	107	Y -> V (in allele DRB5*01:12; requires 2 nucleotide substitutions).
HLA-DRB5	114	114	V -> A (in allele DRB5*01:06, allele DRB5*02:02, allele DRB5*02:04 and allele DRB5*02:05).
HLA-DRB5	115	115	G -> V (in allele DRB5*01:06, allele DRB5*02:02, allele DRB5*02:04 and allele DRB5*02:05).
HLA-DRB5	154	154	G -> A.
HLA-DRB5	164	164	S -> G (in allele DRB5*02:02).
HLA-DRB5	186	186	T -> I (in allele DRB5*02:02).
HLA-DRB5	232	232	V -> I (in allele DRB5*02:02).
EYS	94	94	P -> Q.
EYS	112	112	V -> I.
EYS	135	135	T -> L (requires 2 nucleotide substitutions).
EYS	136	136	V -> F.
EYS	326	326	S -> N.
EYS	532	532	K -> N.
EYS	551	551	R -> L.
EYS	571	571	Q -> R.
EYS	618	618	G -> S (in RP25).
EYS	631	631	G -> S.
EYS	641	641	E -> V.
EYS	745	745	N -> S (in RP25).
EYS	834	834	V -> I.
EYS	938	938	K -> R.
EYS	1110	1110	T -> S (in RP25).
EYS	1163	1163	N -> K.
EYS	1176	1176	C -> R (in RP25).
EYS	1232	1232	I -> F (in RP25).
EYS	1263	1263	I -> V.
EYS	1325	1325	Q -> E.
EYS	1361	1361	I -> V.
EYS	1365	1365	K -> E.
EYS	1419	1419	L -> S.
EYS	1451	1451	I -> T.
EYS	1484	1484	W -> R (in RP25).
EYS	1515	1515	R -> W.
EYS	1517	1517	S -> G.
EYS	1662	1662	D -> V.
EYS	1664	1664	T -> I.
EYS	1682	1682	D -> Y (in RP25).
EYS	1739	1739	P -> L.
EYS	1747	1747	E -> G (in RP25).
EYS	1748	1748	L -> F.
EYS	1837	1837	W -> S.
EYS	1869	1869	L -> M (in RP25).
EYS	1873	1873	L -> V.
EYS	1902	1902	N -> I.
EYS	1915	1915	S -> G.
EYS	1987	1987	T -> P.
EYS	1993	1993	T -> A.
EYS	1999	1999	I -> V.
EYS	2017	2017	G -> V (in RP25).
EYS	2040	2040	V -> D.
EYS	2139	2139	C -> Y (in RP25).
EYS	2151	2151	N -> S.
EYS	2189	2189	L -> P (in RP25).
EYS	2211	2211	S -> L (in RP25; uncertain pathogenic significance).
EYS	2326	2326	R -> Q.
EYS	2503	2503	E -> K (in RP25).
EYS	2556	2556	S -> C.
EYS	2599	2599	H -> R.
EYS	2757	2757	A -> P.
EYS	2829	2829	A -> T (in RP25).
EYS	2831	2831	T -> I.
EYS	2911	2911	C -> Y (in RP25).
EYS	2928	2928	G -> E (in RP25).
EYS	2945	2945	Q -> E (in RP25).
KCNQ5	191	191	W -> G (in a colorectal cancer sample; somatic mutation).
KCNQ5	244	244	R -> C (in a colorectal cancer sample; somatic mutation).
CD109	1007	1007	Q -> E (in a colorectal cancer sample; somatic mutation).
CD109	1065	1065	N -> K (in a colorectal cancer sample; somatic mutation).
MYO6	442	442	C -> Y (in DFNA22).
PHIP	469	469	V -> I (in a colorectal cancer sample; somatic mutation).
PHIP	1767	1767	R -> I (in a colorectal cancer sample; somatic mutation).
FIG4	41	41	I -> T (in CMT4J).
FIG4	48	48	D -> G.
FIG4	53	53	D -> Y (in ALS11).
FIG4	388	388	R -> G.
FIG4	411	411	I -> V.
FIG4	647	647	Y -> C.
FIG4	902	902	I -> T.
ESR1	6	6	H -> Y (in a breast cancer sample; somatic mutation).
ESR1	160	160	G -> C.
ESR1	264	264	M -> I (in a breast cancer sample; somatic mutation).
ESR1	364	364	V -> E (in estrogen resistance; dominant- negative inhibitor of the wild-type ESR).
ESR1	400	400	G -> V (destabilizes the receptor and decreases its affinity for estradiol at 25 degrees Celsius, but not at 4 degrees Celsius).
ESR1	411	411	D -> RNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVC LKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIH LMAKAGLTLQQQHQRLAQLLLILSHIRHM (in a 80 kDa form found in a breast cancer line; contains an in-frame duplication of exons 6 and 7).
ARID1B	814	814	G -> A (in a breast cancer sample; somatic mutation).
MAP3K4	1413	1413	E -> Q (in an ovarian serous carcinoma sample; somatic mutation).
MAP3K4	1492	1492	A -> V.
PARK2	15	15	V -> M (in PARK).
PARK2	33	33	R -> Q (in PARK).
PARK2	37	37	P -> L (in PARK2).
PARK2	42	42	R -> P (in PARK; early-onset; induces a conformational change in the PSMD4- binding site of Ubl resulting in impaired proteasomal binding).
PARK2	46	46	A -> P (in PARK; early-onset; sporadic).
PARK2	92	92	A -> V (in PARK2).
PARK2	100	100	Q -> H.
PARK2	161	161	K -> N (in PARK2 and PARK; severely compromises the mitochondrial localization and fails to stabilize BCL2).
PARK2	211	211	K -> N (in PARK; early and late onset; severely compromises the mitochondrial localization).
PARK2	211	211	K -> R (in PARK; early onset).
PARK2	212	212	C -> Y (in PARK2).
PARK2	240	240	T -> M (in PARK; late onset).
PARK2	240	240	T -> R (in PARK2; impairs the ability to ubiquitinate SNCAIP and BCL2; loss of UBE2L3 binding; severely compromises the mitochondrial localization).
PARK2	253	253	C -> Y (in PARK; late onset).
PARK2	271	271	R -> S.
PARK2	280	280	D -> N (in PARK; does not affect PINK-1 dependent localization to depolarized mitochondria).
PARK2	284	284	G -> R (in PARK2).
PARK2	311	311	Q -> R (in a patient with Parkinson disease; unknown pathological significance).
PARK2	328	328	G -> E (in PARK; does not affect PINK-1 dependent localization to depolarized mitochondria).
PARK2	334	334	R -> C (in PARK).
PARK2	339	339	A -> S.
PARK2	351	351	T -> P (in PARK2; impairs folding of IBR domain).
PARK2	371	371	A -> T (in a patient with Parkinson disease; unknown pathological significance).
PARK2	415	415	T -> N (in PARK2 and PARK; impairs the ability to ubiquitinate SNCAIP; does not affect turnover of CDCRE1; impairs PINK1- dependent localization to dysfunctional depolarized mitochondria).
PARK2	430	430	G -> D (in PARK; early onset; impairs PINK1-dependent localization to dysfunctional depolarized mitochondria; impaired E3 ubiquitin-protein ligase toward ZNF746).
PARK2	431	431	C -> F (in PARK2; impaired E3 ubiquitin- protein ligase toward ZNF746 and BCL2).
PARK2	437	437	P -> L (in PARK; early and late onset and impaired E3 ubiquitin-protein ligase toward BCL2).
PARK2	441	441	C -> R (in PARK).
PRPF4B	584	584	I -> V.
PRPF4B	658	658	F -> L (in a breast cancer sample; somatic mutation).
BMP6	343	343	A -> D (in a colorectal cancer sample; somatic mutation).
BMP6	476	476	P -> L (in a colorectal cancer sample; somatic mutation).
GCM2	47	47	R -> L (in FIH; autosomal recessive form; abolishes normal DNA binding ability of the protein).
GCM2	63	63	G -> S (in FIH; the mutation causes loss- of-function; abolishes transactivation capacity despite normal subcellular localization, protein stability and DNA- binding specificity).
GCM2	110	110	R -> W (in FIH; abolishes DNA binding ability).
GCM2	282	282	Y -> D.
GCM2	382	382	V -> M (does not affect expression level, transactivational capacity and DNA binding ability).
GCM2	502	502	N -> H (in FIH; exerts a dominant- negative effect to abolish transactivation capacity).
GMPR	234	234	A -> T.
ALDH5A1	93	93	C -> F (in SSADH deficiency; 3% of activity).
ALDH5A1	176	176	G -> R (in SSADH deficiency; <1% of activity).
ALDH5A1	223	223	C -> Y (in SSADH deficiency; 5% of activity).
ALDH5A1	233	233	T -> M (in SSADH deficiency; 4% of activity).
ALDH5A1	237	237	A -> S (65% of activity).
ALDH5A1	255	255	N -> S (in SSADH deficiency; 17% of activity).
ALDH5A1	268	268	G -> E (in SSADH deficiency; <1% of activity).
ALDH5A1	335	335	N -> K (in SSADH deficiency; 1% of activity).
ALDH5A1	382	382	P -> L (in SSADH deficiency; 2% of activity).
ALDH5A1	382	382	P -> Q (in SSADH deficiency).
ALDH5A1	406	406	V -> I.
ALDH5A1	409	409	G -> D (in SSADH deficiency; <1% of activity).
ALDH5A1	487	487	V -> E (in SSADH deficiency).
ALDH5A1	533	533	G -> R (in SSADH deficiency; <1% of activity).
GRM4	797	797	V -> I.
LHFPL5	127	127	Y -> C (in DFNB67).
LHFPL5	165	165	T -> M (in DFNB67).
LHFPL5	176	176	R -> L (in DFNB67).
MAPK14	51	51	A -> V (in a gastric adenocarcinoma sample; somatic mutation).
MAPK14	322	322	P -> R (in a lung adenocarcinoma sample; somatic mutation).
KIF6	386	386	A -> E (in a breast cancer sample; somatic mutation).
FOXP4	464	464	A -> T (in a breast cancer sample; somatic mutation).
PTK7	933	933	A -> V (in a colorectal adenocarcinoma sample; somatic mutation).
TTBK1	806	806	S -> F (in a lung large cell carcinoma sample; somatic mutation).
TTBK1	855	855	P -> S (in a metastatic melanoma sample; somatic mutation).
RUNX2	53	53	Q -> L (in CLCD).
RUNX2	78	83	Missing.
RUNX2	84	84	A -> AAAAAAAAAAA (in CLCD associated with brachydactyly of hands and feet).
RUNX2	113	113	L -> R (in CLCD).
RUNX2	118	118	S -> N (in CLCD).
RUNX2	118	118	S -> R (in CLCD).
RUNX2	121	121	F -> C (in CLCD).
RUNX2	123	123	C -> R (in CLCD).
RUNX2	131	131	R -> C (in CLCD).
RUNX2	131	131	R -> G (in CLCD).
RUNX2	131	131	R -> S (in CLCD).
RUNX2	133	133	Missing (in CLCD).
RUNX2	136	136	L -> P (in CLCD).
RUNX2	156	156	V -> D (in CLCD).
RUNX2	156	156	V -> G (in CLCD).
RUNX2	169	169	R -> P (in CLCD).
RUNX2	169	169	R -> Q (in CLCD).
RUNX2	175	175	M -> K (in CLCD).
RUNX2	175	175	M -> R (in CLCD; abolishes DNA binding).
RUNX2	175	175	M -> V (in CLCD).
RUNX2	187	187	F -> S (in CLCD).
RUNX2	190	190	R -> Q (in CLCD; abolishes DNA binding).
RUNX2	190	190	R -> W (in CLCD; has severely impaired DNA binding and transactivation).
RUNX2	191	191	S -> N (in CLCD; abolishes DNA binding).
RUNX2	193	193	R -> C (in CLCD).
RUNX2	193	193	R -> Q (in CLCD).
RUNX2	197	197	F -> S (in CLCD; retains heterodimerization activity together with a trace potential for DNA binding; retains a low but still substantial transactivation activity).
RUNX2	199	199	L -> F (in CLCD; abolishes DNA binding).
RUNX2	200	200	T -> A (in CLCD; mild; associated also with isolated dental anomalies; normal DNA binding).
RUNX2	200	200	T -> I (in CLCD).
RUNX2	201	201	I -> K (in CLCD).
RUNX2	205	205	T -> R (in CLCD).
RUNX2	209	209	Q -> H (in CLCD).
RUNX2	209	209	Q -> R (in CLCD).
RUNX2	211	211	A -> P (in CLCD).
RUNX2	218	218	K -> E (in CLCD).
RUNX2	218	218	K -> N (in CLCD; has severely impaired DNA binding and transactivation).
RUNX2	218	218	K -> Q (in CLCD).
RUNX2	220	220	T -> I (in CLCD; has severely impaired DNA binding and transactivation).
RUNX2	225	225	R -> L (in CLCD).
RUNX2	225	225	R -> Q (in CLCD; interferes with nuclear localization; abolishes DNA binding).
RUNX2	225	225	R -> W (in CLCD; interferes with nuclear localization; has severely impaired DNA binding and transactivation).
RUNX2	228	228	R -> G (in CLCD).
RUNX2	233	233	K -> R (in CLCD).
RUNX2	287	287	D -> N (in CLCD).
RUNX2	362	362	A -> V (in CLCD).
RUNX2	420	420	T -> I (in CLCD).
RUNX2	420	420	T -> N (in CLCD).
RUNX2	511	511	G -> S (in CLCD; could be a polymorphism).
MUT	69	69	I -> V.
MUT	86	86	P -> L (in MMAM; mut0).
MUT	87	87	G -> E (in MMAM; mut0).
MUT	93	93	R -> H (in MMAM; mut0).
MUT	94	94	G -> R (in MMAM; mut0).
MUT	94	94	G -> V (in MMAM; mut- and mut0).
MUT	95	95	P -> R (in MMAM; mut0).
MUT	105	105	W -> R (in MMAM; mut0).
MUT	108	108	R -> C (in MMAM; mut0).
MUT	108	108	R -> G (in MMAM; mut-).
MUT	108	108	R -> H (in MMAM; mut0).
MUT	109	109	Q -> R (in MMAM; mut0).
MUT	137	137	A -> V (in MMAM; mut0).
MUT	145	145	G -> S (in MMAM; mut0).
MUT	148	148	S -> L (in MMAM).
MUT	156	156	D -> N (in MMAM; mut-).
MUT	158	158	G -> V (in MMAM; mut0).
MUT	174	174	F -> S (in MMAM; mut0).
MUT	186	186	M -> V (in MMAM; mut-).
MUT	189	189	N -> K (in MMAM; mut-).
MUT	191	191	A -> E (in MMAM; mut- and mut0).
MUT	197	197	A -> E (in MMAM; mut0).
MUT	203	203	G -> R (in MMAM; mut0).
MUT	215	215	G -> C (in MMAM; mut- and mut0).
MUT	215	215	G -> S (in MMAM; mut0).
MUT	218	218	Q -> H (in MMAM; mut0).
MUT	219	219	N -> Y (in MMAM; mut0).
MUT	228	228	R -> Q (in MMAM; mut0).
MUT	230	230	T -> I (in MMAM; mut-).
MUT	231	231	Y -> N (in MMAM; mut-).
MUT	262	262	S -> N (in MMAM; mut0).
MUT	265	265	H -> Y (in MMAM; mut-).
MUT	281	281	L -> S (in MMAM; mut0).
MUT	291	291	G -> E (in MMAM; mut0).
MUT	293	293	Q -> P (in MMAM; mut0).
MUT	305	305	L -> S (in MMAM; mut0).
MUT	306	306	S -> F (in MMAM; mut0).
MUT	312	312	G -> V (in MMAM; mut0).
MUT	316	316	Y -> C (in MMAM; mut-).
MUT	324	324	A -> T (in MMAM; mut-).
MUT	328	328	L -> F (in MMAM; mut0).
MUT	328	328	L -> P (in MMAM; mut0).
MUT	346	346	Missing (in MMAM; mut0).
MUT	347	347	L -> R (in MMAM; mut0).
MUT	350	350	H -> Y (in MMAM; mut0).
MUT	368	368	V -> D (in MMAM).
MUT	369	369	R -> C (in MMAM; mut0).
MUT	369	369	R -> H (in MMAM; mut- and mut0).
MUT	370	370	T -> P (in MMAM; mut0).
MUT	377	377	A -> E (in MMAM; mut0).
MUT	383	383	Q -> H (in MMAM; mut0).
MUT	383	383	Q -> P (in MMAM; mut0).
MUT	386	386	H -> N (in MMAM; mut0).
MUT	388	388	N -> H (in MMAM; mut0).
MUT	389	389	Missing (in MMAM; mut0).
MUT	412	412	Missing (in MMAM; mut0).
MUT	426	426	G -> R (in MMAM; mut-).
MUT	427	427	G -> D (in MMAM; mut0).
MUT	518	518	L -> P (in MMAM; mut0).
MUT	535	535	A -> P (in MMAM; mut0).
MUT	560	560	C -> Y (in MMAM; mut0).
MUT	566	566	T -> R (in MMAM; mut0).
MUT	573	573	F -> S (in MMAM; mut-).
MUT	587	587	Y -> C (in MMAM; mut-).
MUT	615	615	P -> R (in MMAM; mut0).
MUT	615	615	P -> T (in MMAM; mut0).
MUT	616	616	R -> C (in MMAM; mut0).
MUT	617	617	L -> R (in MMAM).
MUT	621	621	K -> N (in MMAM; mut0).
MUT	623	623	G -> R (in MMAM; mut0).
MUT	624	624	Q -> R (in MMAM).
MUT	626	626	G -> C (in MMAM; mut-).
MUT	627	627	H -> R (in MMAM; mut0).
MUT	630	630	G -> E (in MMAM; mut0).
MUT	633	633	V -> G (in MMAM; mut-).
MUT	637	637	G -> E (in MMAM; mut-).
MUT	637	637	G -> R (in MMAM; mut0).
MUT	638	638	F -> I (in MMAM; mut0).
MUT	640	640	D -> Y (in MMAM; mut0).
MUT	642	642	G -> R (in MMAM; mut-).
MUT	648	648	G -> D (in MMAM; mut-).
MUT	669	669	V -> E (in MMAM; mut0).
MUT	678	678	H -> R (in MMAM; mut-).
MUT	684	684	E -> EL (in MMAM; mut-).
MUT	685	685	L -> R (in MMAM; mut-).
MUT	694	694	R -> W (in MMAM; mut- and mut0).
MUT	700	700	M -> K (in MMAM; mut-).
MUT	703	703	G -> R (in MMAM; mut0).
MUT	717	717	G -> V (in MMAM; mut-; interfers with the binding of the cofactor to the apoenzyme).
TFAP2D	214	214	V -> F (in a breast cancer sample; somatic mutation).
PKHD1	17	17	A -> V (in ARPKD).
PKHD1	19	19	R -> H (in a colorectal cancer sample; somatic mutation).
PKHD1	25	25	I -> V.
PKHD1	222	222	I -> V (in ARPKD).
PKHD1	223	223	G -> S (in ARPKD).
PKHD1	253	253	F -> L (in ARPKD).
PKHD1	307	307	I -> T (in ARPKD).
PKHD1	326	326	G -> V (in ARPKD).
PKHD1	372	372	F -> L (in ARPKD).
PKHD1	387	387	Missing (in ARPKD).
PKHD1	457	457	E -> D.
PKHD1	473	473	I -> S (in ARPKD).
PKHD1	486	486	Y -> H (in ARPKD).
PKHD1	488	488	R -> P.
PKHD1	496	496	R -> P (in ARPKD).
PKHD1	656	656	W -> C (in ARPKD).
PKHD1	703	703	D -> N (in ARPKD).
PKHD1	732	732	V -> F.
PKHD1	739	739	P -> L (in ARPKD).
PKHD1	752	752	T -> M.
PKHD1	757	757	I -> L (in ARPKD).
PKHD1	760	760	R -> H (in ARPKD).
PKHD1	805	805	P -> L (in ARPKD).
PKHD1	830	830	N -> S.
PKHD1	852	852	W -> R.
PKHD1	899	899	T -> P (in ARPKD).
PKHD1	997	997	M -> K (in ARPKD).
PKHD1	1030	1030	A -> E (in ARPKD).
PKHD1	1081	1081	R -> C (in a colorectal cancer sample; somatic mutation).
PKHD1	1096	1096	L -> R (in a colorectal cancer sample; somatic mutation).
PKHD1	1122	1122	G -> S (in ARPKD).
PKHD1	1123	1123	G -> S (in ARPKD).
PKHD1	1150	1150	A -> P.
PKHD1	1204	1204	C -> Y.
PKHD1	1249	1249	C -> W (in ARPKD).
PKHD1	1283	1283	S -> L.
PKHD1	1389	1389	P -> T (in ARPKD).
PKHD1	1407	1407	L -> R (in ARPKD).
PKHD1	1472	1472	C -> Y (in ARPKD).
PKHD1	1486	1486	P -> L (in ARPKD).
PKHD1	1584	1584	S -> I (in ARPKD).
PKHD1	1624	1624	R -> W (in ARPKD).
PKHD1	1781	1781	T -> I (in ARPKD).
PKHD1	1789	1789	V -> L (in ARPKD).
PKHD1	1806	1806	E -> K (in a colorectal cancer sample; somatic mutation).
PKHD1	1833	1833	S -> L (in ARPKD).
PKHD1	1838	1838	Y -> C (in ARPKD).
PKHD1	1867	1867	S -> N (in ARPKD).
PKHD1	1917	1917	Q -> R (in ARPKD).
PKHD1	1942	1942	D -> G (in ARPKD).
PKHD1	1971	1971	G -> D (in ARPKD).
PKHD1	1995	1995	E -> G (in ARPKD).
PKHD1	1998	1998	I -> T (in ARPKD).
PKHD1	2032	2032	V -> L (in ARPKD).
PKHD1	2134	2134	L -> P (in ARPKD).
PKHD1	2303	2303	I -> F (in ARPKD).
PKHD1	2331	2331	I -> K (in ARPKD).
PKHD1	2422	2422	C -> G (in ARPKD).
PKHD1	2615	2615	A -> G.
PKHD1	2688	2688	C -> F (in ARPKD).
PKHD1	2761	2761	D -> Y (in ARPKD).
PKHD1	2772	2772	L -> P (in ARPKD).
PKHD1	2861	2861	S -> G (in ARPKD).
PKHD1	2863	2863	Y -> C (in ARPKD).
PKHD1	2869	2869	T -> K.
PKHD1	2938	2938	T -> M.
PKHD1	2957	2957	I -> T (in ARPKD).
PKHD1	2962	2962	D -> G (in ARPKD).
PKHD1	2983	2983	S -> L (in ARPKD).
PKHD1	3018	3018	S -> F (in ARPKD).
PKHD1	3036	3036	V -> G (in ARPKD).
PKHD1	3072	3072	A -> V.
PKHD1	3081	3081	I -> V (in ARPKD).
PKHD1	3088	3088	D -> N.
PKHD1	3107	3107	R -> P.
PKHD1	3124	3124	H -> Y (in ARPKD).
PKHD1	3143	3143	R -> I.
PKHD1	3167	3167	I -> L (in ARPKD).
PKHD1	3175	3175	N -> D (in ARPKD).
PKHD1	3175	3175	N -> S (in ARPKD).
PKHD1	3177	3177	I -> T (in ARPKD).
PKHD1	3289	3289	S -> I.
PKHD1	3293	3293	D -> V (in ARPKD).
PKHD1	3346	3346	C -> R (in ARPKD).
PKHD1	3440	3440	V -> D.
PKHD1	3468	3468	I -> V (in ARPKD).
PKHD1	3471	3471	V -> G (in ARPKD).
PKHD1	3482	3482	R -> C (in ARPKD).
PKHD1	3502	3502	E -> V (in ARPKD).
PKHD1	3505	3505	S -> R.
PKHD1	3529	3529	E -> Q (in ARPKD).
PKHD1	3551	3551	E -> K.
PKHD1	3553	3553	I -> T (in ARPKD).
PKHD1	3622	3622	C -> Y (in ARPKD).
PKHD1	3783	3783	P -> S (in ARPKD).
PKHD1	3842	3842	R -> L.
EFHC1	77	77	P -> T (in EJM1; associated with H-221; reduces substantially the cell death effect; reduces partly the calcium influx; binds to CACNA1E).
EFHC1	174	174	I -> V (associated with susceptibility to JAE1).
EFHC1	210	210	D -> N (in EJM1; reduces substantially the cell death effect; reduces partly the calcium influx; binds to CACNA1E).
EFHC1	221	221	R -> H (in EJM1; associated with T-77; reduces substantially the cell death effect; reduces partly the calcium influx; binds to CACNA1E).
EFHC1	229	229	F -> L (in EJM1; uncertain pathological significance; reduces substantially the cell death effect; reduces significantly the calcium influx; binds to CACNA1E).
EFHC1	253	253	D -> Y (in EJM1; reduces substantially the cell death effect; reduces partly the calcium influx; binds to CACNA1E).
EFHC1	259	259	C -> Y (associated with susceptibility to JAE1).
EFHC1	353	353	R -> W (in EJM1).
EFHC1	394	394	A -> S (in a sporadic case of unclassified epilepsy).
HCRTR2	293	293	I -> V.
COL19A1	361	361	G -> D (in a breast cancer sample; somatic mutation).
COL19A1	1019	1019	K -> N (in a breast cancer sample; somatic mutation).
RIMS1	820	820	R -> H (in CORD7).
SLC17A5	39	39	R -> C (in SD; frequent mutation in Finland).
SLC17A5	136	136	K -> E (in SD).
SLC17A5	183	183	H -> R (in ISSD).
SLC17A5	268	272	Missing (in ISSD).
SLC17A5	334	334	P -> R (in ISSD).
SLC17A5	371	371	G -> V (in ISSD).
BCKDHB	206	206	H -> R (in MSUD1B).
BCKDHB	278	278	G -> S (in MSUD1B).
EPHA7	170	170	E -> K (in a colorectal adenocarcinoma sample; somatic mutation).
EPHA7	232	232	G -> R (in a metastatic melanoma sample; somatic mutation).
EPHA7	371	371	R -> W (in a colorectal cancer sample; somatic mutation).
EPHA7	903	903	P -> S (in a metastatic melanoma sample; somatic mutation).
MCHR2	63	63	R -> K (no changes in receptor binding or functional signaling).
MCHR2	152	152	R -> Q (no changes in receptor binding or functional signaling).
GRIK2	187	187	E -> Q (in a breast cancer sample; somatic mutation).
GRIK2	567	567	I -> V (in RNA edited version).
GRIK2	571	571	Y -> C (in RNA edited version).
GRIK2	621	621	Q -> R (in RNA edited version).
ATG5	58	58	K -> M (in a colorectal cancer sample; somatic mutation).
PDSS2	382	382	S -> L (in coenzyme q10 deficiency).
SEC63	568	568	Missing (in PCLD).
REV3L	389	389	S -> T.
REV3L	2607	2607	S -> T.
FYN	243	243	V -> L (in a lung squamous cell carcinoma sample; somatic mutation).
FYN	410	410	G -> R (in a metastatic melanoma sample; somatic mutation).
KPNA5	45	45	F -> L (in a breast cancer sample; somatic mutation).
KPNA5	316	316	R -> S (in a breast cancer sample; somatic mutation).
ROS1	419	419	Y -> H (in a gastric adenocarcinoma sample; somatic mutation).
ROS1	865	865	Q -> H (in a lung large cell carcinoma sample; somatic mutation).
ROS1	2003	2003	K -> R (in a colorectal adenocarcinoma sample; somatic mutation).
ROS1	2138	2138	F -> S (in a gastric adenocarcinoma sample; somatic mutation).
ROS1	2203	2203	D -> N.
ROS1	2213	2213	D -> E.
CEP85L	345	345	S -> F (in a breast cancer sample; somatic mutation).
GJA1	2	2	G -> V (in ODDD).
GJA1	7	7	L -> V (in ODDD).
GJA1	11	11	L -> P (in ODDD).
GJA1	17	17	Y -> S (in ODDD).
GJA1	18	18	S -> P (in ODDD).
GJA1	21	21	G -> R (in ODDD; involvement of only the fourth and fifth fingers; SDTY3).
GJA1	22	22	G -> E (in ODDD; involvement of only the fourth and fifth fingers; SDTY3).
GJA1	23	23	K -> T (in ODDD).
GJA1	27	27	S -> P (in ODDD).
GJA1	31	31	I -> M (in ODDD).
GJA1	40	40	A -> V (in ODDD).
GJA1	41	41	V -> L (in ectodermal and oculodentodigital dysplasia; with skin hyperkeratosis; associated with GJB2 variant His-127).
GJA1	49	49	Q -> K (in ODDD).
GJA1	49	49	Q -> P (in ODDD).
GJA1	49	49	Q -> QQ (in ODDD).
GJA1	52	52	F -> FF (in ODDD).
GJA1	59	59	P -> H (in ODDD).
GJA1	69	69	S -> Y (in ODDD).
GJA1	76	76	R -> H (in HSS; overlapping features with oculodentodigital dysplasia).
GJA1	76	76	R -> S (in ODDD).
GJA1	90	90	L -> V (in ODDD).
GJA1	95	95	H -> R (in ODDD).
GJA1	96	96	V -> A (in ODDD).
GJA1	96	96	V -> E (in ODDD).
GJA1	98	98	Y -> C (in ODDD).
GJA1	102	102	K -> N (in ODDD).
GJA1	106	106	L -> P (in ODDD).
GJA1	110	110	E -> D (in ODDD).
GJA1	113	113	L -> P (in ODDD).
GJA1	130	130	I -> T (in ODDD).
GJA1	134	134	K -> E (in ODDD).
GJA1	134	134	K -> N (in ODDD).
GJA1	138	138	G -> R (in ODDD).
GJA1	147	147	M -> T (in ODDD).
GJA1	154	154	T -> A (in ODDD).
GJA1	154	154	T -> N (in ODDD).
GJA1	169	169	Missing (in ODDD).
GJA1	194	194	H -> P (in ODDD; atypical form of ODDD characterized by the predominance of the ocular involvement and by the absence of hand and/or foot syndactyly and absence of any neurologic signs).
GJA1	201	201	S -> F (in ODDD).
GJA1	202	202	R -> H (in ODDD).
GJA1	216	216	V -> L (in ODDD).
GJA1	220	220	S -> Y (in ODDD).
GJA1	251	251	S -> T (in congenital heart malformations).
GJA1	253	253	A -> P (in congenital heart malformations).
GJA1	326	326	T -> A.
GJA1	352	352	E -> G (in heart malformations).
GJA1	364	364	S -> P (in heart malformations; shows abnormalities in the regulation of cell- cell communication as compared with cells expressing normal GJA1).
GJA1	365	365	S -> N (in heart malformations).
GJA1	373	373	S -> G.
GJA1	376	376	R -> Q (in HLHS; in one individual with atrioventricular septal defect; associated with Gln-362; abolishes phosphorylation by PKA and PKC).
LAMA2	527	527	C -> Y (in MDC1A).
LAMA2	545	545	L -> Q.
LAMA2	862	862	C -> R (in MDC1A).
LAMA2	1160	1160	P -> A (in a breast cancer sample; somatic mutation).
LAMA2	2564	2564	L -> P (in MDC1A).
LAMA2	2586	2586	Y -> H.
LAMA2	2614	2614	E -> K.
EYA4	152	152	L -> R (in a colorectal cancer sample; somatic mutation).
EYA4	301	301	D -> N (in a colorectal cancer sample; somatic mutation).
AHI1	49	49	I -> N.
AHI1	443	443	V -> D (in JBTS3).
AHI1	723	723	R -> Q (in JBTS3).
AHI1	761	761	S -> L.
AHI1	856	856	T -> S.
AHI1	1123	1123	S -> F.
AHI1	1140	1140	P -> S.
PEX7	14	14	T -> P (in RD).
PEX7	217	217	G -> R (in RCDP1; could be a polymorphism).
PEX7	218	218	A -> V (in RCDP1).
PEX3	138	138	G -> E (in ZWS).
EPM2A	25	25	S -> P (in EPM2; atypical form; does not affect glycogen binding).
EPM2A	28	28	E -> K (in EPM2; does not affect glycogen binding).
EPM2A	32	32	W -> G (in EPM2; affects phosphatase activity; abolishes glycogen binding; reduced binding to Lafora bodies; disrupts the interaction with PPP1R5; significant protein amount targeted to the nucleus).
EPM2A	46	46	A -> P (does not affect glycogen binding).
EPM2A	84	84	F -> L (in EPM2; affects phosphatase activity and glycogen binding; disrupts the interaction with PPP1R5).
EPM2A	88	88	F -> L (in EPM2; does not affect glycogen binding).
EPM2A	91	91	R -> P (in EPM2; atypical form; learning difficuties with childhood-onset).
EPM2A	108	108	R -> C (in EPM2; loss of phosphatase activity; reduced self-interaction capacity; disrupts the interaction with PPP1R5).
EPM2A	114	114	E -> D.
EPM2A	140	140	K -> N (in EPM2).
EPM2A	148	148	N -> Y (in EPM2).
EPM2A	171	171	R -> H (in EPM2; results in ubiquitin- positive perinuclear aggregates; may affect proper folding).
EPM2A	187	187	T -> A (in EPM2).
EPM2A	194	194	T -> I (in EPM2; results in ubiquitin- positive perinuclear aggregates; loss of phosphatase activity; affects glycogen binding; reduced self-interaction capacity; disrupts the interaction with PPP1R5).
EPM2A	210	210	E -> K (in EPM2).
EPM2A	240	240	G -> S (in EPM2; very slight loss of phosphatase activity; does not affect glycogen binding; disrupts the interaction with PPP1R5).
EPM2A	279	279	G -> S (in EPM2; results in ubiquitin- positive perinuclear aggregates; loss of phosphatase activity; affects glycogen binding; disrupts the interaction with PPP1R5).
EPM2A	293	293	Q -> L (in EPM2; results in ubiquitin- positive perinuclear aggregates; may affect proper folding; loss of phosphatase activity; affects glycogen binding; disrupts the interaction with PPP1R5).
EPM2A	294	294	Y -> N (in EPM2; results in ubiquitin- positive perinuclear aggregates; loss of phosphatase activity; affects glycogen binding; disrupts the interaction with PPP1R5).
EPM2A	301	301	P -> L (in EPM2; loss of phosphatase activity; affects glycogen binding; disrupts the interaction with PPP1R5).
SHPRH	438	438	Q -> R (in an ovarian cancer cell line).
SHPRH	460	460	S -> F (in a melanoma cell line).
SHPRH	1028	1028	N -> Y (in a melanoma cell line).
SHPRH	1222	1222	V -> D (found in a renal cell carcinoma sample; somatic mutation).
GRM1	696	696	R -> W (in a colorectal cancer sample; somatic mutation).
TAB2	208	208	P -> S (in CHTD2).
TAB2	230	230	Q -> K (in CHTD2).
MTHFD1L	444	444	L -> R (in a colorectal cancer sample; somatic mutation).
AKAP12	240	240	E -> K (in a colorectal cancer sample; somatic mutation).
SYNE1	3671	3671	V -> M (in a colorectal cancer sample; somatic mutation).
SYNE1	4210	4210	E -> D (in a colorectal cancer sample; somatic mutation).
SYNE1	4223	4223	R -> H (in a colorectal cancer sample; somatic mutation).
SYNE1	5507	5507	L -> R (in a colorectal cancer sample; somatic mutation).
SYNE1	8095	8095	R -> H (in EDMD4).
SYNE1	8387	8387	V -> L (in EDMD4).
SYNE1	8461	8461	E -> K (in EDMD4).
SYNE1	8468	8468	R -> H (in a colorectal cancer sample; somatic mutation).
GTF2H5	21	21	L -> P (in TTDP).
SLC22A1	189	189	S -> L (no changes in the MPP uptake. No changes in the MPP uptake; when associated with V-408).
SLC22A1	220	220	G -> V (no MPP uptake. Reduction of the MPP uptake; when associated with V-408).
SLC22A1	420	420	Missing (no changes in the MPP uptake. No changes in the MPP uptake; when associated with V-408).
LPA	4193	4193	W -> R (loss of lysine-sepharose binding).
QKI	336	336	R -> Q (in a colorectal cancer sample; somatic mutation).
PDE10A	303	303	L -> P.
RPS6KA2	311	311	E -> K (in a metastatic melanoma sample; somatic mutation).
RPS6KA2	732	732	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation).
FOXC1	79	79	P -> L (in Rieger syndrome).
FOXC1	79	79	P -> R (in ARS).
FOXC1	79	79	P -> T (in ARS).
FOXC1	82	82	S -> T (in ARS).
FOXC1	86	86	L -> F (in ARS; does not affect nuclear localization of the protein; reduces DNA binding and significantly reduces transactivation).
FOXC1	87	87	I -> M (in ARS).
FOXC1	91	91	I -> S (in ARS).
FOXC1	91	91	I -> T (in ARS).
FOXC1	112	112	F -> S (in IGDA and PAN).
FOXC1	115	115	Y -> S (in ARS).
FOXC1	126	126	I -> M (in ARS; with glaucoma).
FOXC1	127	127	R -> H (in ARS).
FOXC1	130	130	L -> F (in RIEG3; expressed at levels similar to those of wild-type protein; migrates at an apparent reduced molecular weight compared with wild-type; has significantly impaired capacity to localize to the nucleus, binds DNA and transactivates reporter genes).
FOXC1	131	131	S -> L (in ARS; with glaucoma).
FOXC1	149	149	G -> D (in ARS).
FOXC1	161	161	M -> K (in ARS; localized correctly to the nucleus; displays reduced DNA binding ability; disrupts FOXC1's transactivation ability).
FOXC1	161	161	M -> V (in ARS).
FOXC1	165	165	G -> R (in ARS; localized correctly to the nucleus; maintains wild-type levels of DNA binding; disrupts FOXC1's transactivation ability).
FOXC1	169	169	R -> P (in ARS; localized correctly to the nucleus; displays reduced DNA binding ability; disrupts FOXC1's transactivation ability).
MYLK4	30	30	E -> Q (in a breast infiltrating ductal carcinoma sample; somatic mutation).
MYLK4	78	78	A -> S (in a breast infiltrating ductal carcinoma sample; somatic mutation).
MYLK4	217	217	H -> L (in a lung squamous cell carcinoma sample; somatic mutation).
RIPK1	64	64	A -> V (in a colorectal adenocarcinoma sample; somatic mutation).
RIPK1	81	81	V -> I (in a colorectal adenocarcinoma sample; somatic mutation).
RIPK1	220	220	A -> V (in a colorectal adenocarcinoma sample; somatic mutation).
TUBB2A	62	62	R -> W (in a colorectal cancer sample; somatic mutation).
TUBB2B	172	172	S -> P (in PMGA; affects microtubules assembly).
TUBB2B	210	210	I -> T (in PMGA).
TUBB2B	228	228	L -> P (in PMGA).
TUBB2B	265	265	F -> L (in PMGA; affects microtubules assembly).
TUBB2B	312	312	T -> M (in PMGA).
PXDC1	203	203	E -> Q (in a breast cancer sample; somatic mutation).
DSP	287	287	N -> K (in SFWHS).
DSP	299	299	S -> R (in ARVD8).
DSP	445	445	I -> V (in ARVD8).
DSP	1255	1255	R -> K (in ARVD8).
DSP	1505	1505	A -> V.
DSP	1526	1526	N -> K.
DSP	1537	1537	R -> C.
DSP	1833	1833	E -> V.
DSP	2375	2375	G -> R (in a case of recessive arrhythmogenic right ventricular cardiomyopathy with skin abnormalities and woolly hair).
TFAP2A	249	249	L -> P (in BOFS).
TFAP2A	254	254	R -> G (in BOFS).
TFAP2A	255	255	R -> G (in BOFS).
TFAP2A	262	262	G -> E (in BOFS).
MAK	272	272	R -> P (in a breast infiltrating ductal carcinoma sample; somatic mutation).
RNF182	43	43	V -> A (in a colorectal cancer sample; somatic mutation).
RNF182	58	58	P -> L (in a colorectal cancer sample; somatic mutation).
NHLRC1	22	22	S -> R (in EPM2; does not significantly alters the subcellular location as compared to the wild-type).
NHLRC1	33	33	F -> S (in EPM2).
NHLRC1	67	67	E -> Q (in EPM2).
NHLRC1	68	68	C -> Y (in EPM2).
NHLRC1	87	87	L -> P (in EPM2).
NHLRC1	126	126	L -> P (in EPM2; the mutant protein targeted exclusively nucleus as compared to predominantly cytoplasmic and partially nuclear localization of the wild-type protein).
NHLRC1	146	146	D -> N (in EPM2).
NHLRC1	153	153	I -> M (in EPM2).
NHLRC1	160	160	C -> R (in EPM2).
NHLRC1	198	198	I -> N (in EPM2).
NHLRC1	219	219	W -> R (in EPM2).
NHLRC1	233	233	D -> A (in EPM2).
NHLRC1	245	245	D -> N (in EPM2).
NHLRC1	253	253	R -> K (in EPM2).
NHLRC1	264	264	P -> H (in EPM2).
NHLRC1	279	279	L -> P (in EPM2; significantly alters the distribution of the protein; a great majority of cells expressing the mutant form formed perinuclear inclusion when compared with the wild-type form).
NHLRC1	294	295	Missing (in EPM2).
NHLRC1	302	302	Q -> P (in EPM2; loss of interaction with EPM2A).
NHLRC1	308	308	D -> A (in EPM2).
TPMT	180	180	Y -> F (allele TPMT*6).
HIST1H4A	64	64	E -> Q (in a breast cancer sample; somatic mutation).
HIST1H4B	64	64	E -> Q (in a breast cancer sample; somatic mutation).
HFE	6	6	R -> S (in HFE).
HFE	43	43	G -> D (in HFE; associated with D-63 in one patient).
HFE	66	66	R -> C (in HFE).
HFE	176	176	A -> V (in HFE; uncertain pathological significance).
HFE	224	224	R -> G (in HFE).
HFE	224	224	R -> Q.
HFE	277	277	E -> K (rare polymorphism).
HFE	283	283	Q -> P (in HFE; destabilizing effect on the tertiary structure of the protein; prevents the normal interaction between HFE and B2M and between HFE and TFRC; decreases the capacity of HFE to reduce transferrin-mediated iron uptake).
HFE	295	295	V -> A (in HFE).
HFE	330	330	R -> M (in HFE).
HIST1H4C	64	64	E -> Q (in a breast cancer sample; somatic mutation).
HIST1H1E	128	128	A -> V (in a colorectal cancer sample; somatic mutation).
HIST1H4D	64	64	E -> Q (in a breast cancer sample; somatic mutation).
HIST1H4E	64	64	E -> Q (in a breast cancer sample; somatic mutation).
HIST1H4F	64	64	E -> Q (in a breast cancer sample; somatic mutation).
HIST1H4H	64	64	E -> Q (in a breast cancer sample; somatic mutation).
HIST1H4I	64	64	E -> Q (in a breast cancer sample; somatic mutation).
HIST1H2BM	110	110	H -> Y (in a colorectal cancer sample; somatic mutation).
HIST1H4J	64	64	E -> Q (in a breast cancer sample; somatic mutation).
HIST1H4K	64	64	E -> Q (in a breast cancer sample; somatic mutation).
HIST1H1B	86	86	G -> D (in a colorectal cancer sample; somatic mutation).
HIST1H4L	64	64	E -> Q (in a breast cancer sample; somatic mutation).
ZSCAN16	137	137	R -> Q (in a colorectal cancer sample; somatic mutation).
ZNF192	163	163	P -> L.
OR5V1	136	136	L -> P (found in a renal cell carcinoma sample; somatic mutation).
OR12D3	250	250	F -> L (in a breast cancer sample; somatic mutation).
OR2H1	63	63	D -> N (in allele 6M1-16*02).
OR2H2	30	30	L -> S.
OR2H2	220	220	T -> A.
ZFP57	166	166	R -> H (in TNDM1).
ZFP57	193	193	H -> N (in TNDM1).
ZFP57	374	374	H -> D (in TNDM1).
HLA-A	41	41	R -> S (in allele A*01:02).
HLA-A	80	80	G -> R (in allele A*01:07).
HLA-A	91	91	M -> V (in allele A*01:07).
HLA-A	100	100	A -> E (in allele A*01:07).
HLA-A	114	114	D -> A (in allele A*01:07).
HLA-A	121	121	I -> M (in allele A*01:03).
HLA-A	180	180	R -> L (in allele A*01:06).
HLA-A	182	182	V -> A (in allele A*01:06).
HLA-E	104	104	G -> R (in allele E*0102).
DDR1	496	496	S -> A (in a lung squamous cell carcinoma sample; somatic mutation).
MUC22	1712	1712	N -> D.
PSORS1C1	34	34	E -> Q.
CDSN	143	143	Missing (in allele 2.11).
CDSN	150	150	S -> N (in allele 2.21, allele 2.22 and allele 2.23).
CDSN	153	153	Missing.
CDSN	253	253	Missing (in allele 1.32).
PSORS1C2	84	84	P -> L.
CCHCR1	733	733	A -> V.
POU5F1	322	322	T -> A.
POU5F1	357	357	M -> L.
HLA-C	138	138	N -> D (in allele Cw*05:04).
HLA-C	140	140	F -> S (in allele Cw*05:04).
HLA-C	201	201	K -> E (in allele Cw*0502).
HLA-C	207	208	EH -> DP (in allele Cw*05:03).
HLA-C	218	218	V -> I (in allele Cw*05:03).
HLA-C	223	223	A -> V (in allele Cw*05:03).
MICA	253	253	W -> S (in allele MICA*056).
MICA	291	291	S -> G (in allele MICA*054).
MICA	300	383	VLVLQSHWQTFHVSAVAAAAIFVIIIFYVRCCKKKTSAAEG PELVSLQVLDQHPVGTSDHRDATQLGFQPLMSDLGSTGSTE GA -> CWCFRVIGRHSMFLLLLLLLLLLLLFLLLLFSTSV VVRRKHQLQRVQSS (in allele MICA*015 and allele MICA*017).
MICA	318	383	AAIFVIIIFYVRCCKKKTSAAEGPELVSLQVLDQHPVGTSD HRDATQLGFQPLMSDLGSTGSTEGA -> GCCYFCYYYFLC PLL (in allele MICA*008, allele MICA*023, allele MICA*028 and allele MICA*053).
MICA	319	319	A -> AA (in allele MICA*010, allele MICA*016, allele MICA*019, allele MICA*027, allele MICA*033, allele MICA*048, allele MICA*054 and allele MICA*056).
MICA	319	319	A -> AAA (in allele MICA*004, allele MICA*006, allele MICA*009, allele MICA*011, allele MICA*026, allele MICA*047 and allele MICA*049).
MICA	319	319	A -> AAAA (in allele MICA*050).
MICA	319	319	A -> AAAAA (in allele MICA*055).
MICA	319	319	A -> AAAAAA (in allele MICA*002, allele MICA*041, allele MICA*046 and allele MICA*052).
MICA	319	319	A -> AAAAAAA (in allele MICA*020).
MICA	328	328	V -> I (in allele MICA*052).
MICA	356	356	T -> M (in allele MICA*049).
MICA	373	373	D -> A (in allele MICA*004, allele MICA*006, allele MICA*010, allele MICA*011, allele MICA*016, allele MICA*019, allele MICA*048 and allele MICA*049).
MICA	377	377	T -> A (in allele MICA*011).
MICA	383	383	A -> T (in allele MICA*018).
MCCD1	53	53	T -> M.
LTA	125	125	T -> P (in allele 8.1).
PRRC2A	1087	1087	T -> I (in a breast cancer sample; somatic mutation).
PRRC2A	1152	1152	R -> H (in a breast cancer sample; somatic mutation).
GPANK1	314	314	T -> N (found in a clear cell renal carcinoma case; somatic mutation).
HSPA1L	268	268	A -> T.
HSPA1L	294	294	D -> G.
HSPA1A	95	95	I -> V.
HSPA1A	467	467	A -> V.
HSPA1B	95	95	I -> V.
HSPA1B	467	467	A -> V.
NEU1	54	54	V -> M (in SIALIDOSIS; type 1; mild mutation as residual activity is still measurable).
NEU1	68	68	G -> V (in SIALIDOSIS; type 2; less than 10% of activity).
NEU1	80	80	P -> L (in SIALIDOSIS; type 2; no enzyme activity; retained in the endoplasmic reticulum / Golgi or rapidly degraded in the lysosomes).
NEU1	91	91	L -> R (in SIALIDOSIS; type 2).
NEU1	182	182	S -> G (in SIALIDOSIS; type 1; normally processed).
NEU1	219	219	G -> A (in SIALIDOSIS; type 1; unable to reach the lysosomes).
NEU1	227	227	G -> R (in SIALIDOSIS; type 1 and juvenile type 2; catalytically inactive; retained in pre-lysosomal compartments).
NEU1	231	231	L -> H (in SIALIDOSIS; type 1; unable to reach the lysosomes).
NEU1	240	240	W -> R (in SIALIDOSIS; type 2; no enzyme activity; retained in the endoplasmic reticulum / Golgi or rapidly degraded in the lysosomes).
NEU1	243	243	G -> R (in SIALIDOSIS; type 1; no enzyme activity and no transport to the lysosome).
NEU1	260	260	F -> Y (in SIALIDOSIS; infantile type 2; catalytically inactive; rapid intralysosomal degradation).
NEU1	270	270	L -> F (in SIALIDOSIS; type 2; reduction in enzyme activity; rapid intralysosomal degradation).
NEU1	270	270	L -> P (in SIALIDOSIS).
NEU1	294	294	R -> S (in SIALIDOSIS; type 1; mild mutation as residual activity is still measurable).
NEU1	298	298	A -> V (in SIALIDOSIS; type 2; less than 10% of activity; rapid intralysosomal degradation; impaired enzyme folding).
NEU1	316	316	P -> S (in SIALIDOSIS; type 1; no enzyme activity; retained in the endoplasmic reticulum / Golgi or rapidly degraded in the lysosomes).
NEU1	328	328	G -> S (in SIALIDOSIS; type 1; reduction in enzyme activity).
NEU1	335	335	P -> Q (in SIALIDOSIS; type 2; unable to reach the lysosomes).
NEU1	341	341	R -> G (in SIALIDOSIS; type 2; affects substrate binding or catalysis).
NEU1	363	363	L -> P (in SIALIDOSIS; infantile type 2; unable to reach the lysosomes).
NEU1	370	370	Y -> C (in SIALIDOSIS; infantile type 2; catalytically inactive).
NEU1	400	400	Y -> YHY (in SIALIDOSIS; type 1; mild mutation as residual activity is still measurable).
SLC44A4	347	347	A -> T (in a colorectal cancer sample; somatic mutation).
SLC44A4	411	411	T -> M (in a colorectal cancer sample; somatic mutation).
CFB	28	28	W -> Q (in allele FA; requires 2 nucleotide substitutions).
CFB	28	28	W -> R (in allele S).
CFB	166	166	S -> P (in AHUS4).
CFB	203	203	R -> Q (in AHUS4).
CFB	242	242	I -> L (in AHUS4).
CFB	286	286	F -> L (in AHUS4; gain-of-function mutation that results in enhanced formation of the C3bBb).
CFB	323	323	K -> E (in AHUS4; gain-of-function mutation that results in enhanced formation of the C3bBb).
CFB	323	323	K -> Q (in AHUS4).
CFB	458	458	M -> I (in AHUS4).
CFB	533	533	K -> R (in AHUS4).
CFB	736	736	A -> S (in allele FA).
SKIV2L	183	183	L -> V (in a breast cancer sample; somatic mutation).
SKIV2L	765	765	M -> I (in a colorectal cancer sample; somatic mutation).
STK19	89	89	D -> N (in a metastatic melanoma sample; somatic mutation).
C4B	1201	1201	S -> T (in allotype C4B).
CYP21A2	9	9	L -> LL (in allele CYP21A2*2).
CYP21A2	30	30	P -> L (in AH3; non-classic form; 50% activity; 10% of non-classic AH3 Texan patients).
CYP21A2	30	30	P -> Q (in AH3; does not affect membrane binding; enzyme function abolished).
CYP21A2	56	56	G -> R (in AH3; loss of activity).
CYP21A2	62	62	H -> L (in AH3; non-classic form; simple virilizing form when associated with a second mild mutation such as S-453 or L- 30; activity is significantly reduced in association with S-453).
CYP21A2	64	64	G -> E (in AH3; no activity).
CYP21A2	77	77	I -> T (in AH3; simple virilizing form).
CYP21A2	90	90	G -> V (in AH3).
CYP21A2	98	98	K -> R.
CYP21A2	102	102	K -> R (in allele CYP21A2*3).
CYP21A2	105	105	P -> L (in AH3).
CYP21A2	107	107	L -> R (in AH3; loss of activity).
CYP21A2	121	121	K -> Q (in AH3; non-classic form; reduced activity; decreased affinity for 17- hydroxyprogesterone and progesterone).
CYP21A2	142	142	L -> P (in AH3; loss of activity).
CYP21A2	167	167	L -> P (in AH3; salt wasting form; loss of activity).
CYP21A2	169	169	C -> Y (in AH3).
CYP21A2	172	172	I -> N (in AH3; simple virilizing form; 1-4% activity).
CYP21A2	196	196	Missing (in AH3; moderate).
CYP21A2	211	211	V -> L (in AH3; non-classic form; pathogenicity uncertain).
CYP21A2	230	230	I -> T (in AH3).
CYP21A2	233	233	R -> K (in AH3).
CYP21A2	236	236	I -> N (in AH3; salt wasting form).
CYP21A2	261	261	L -> P (in AH3).
CYP21A2	281	281	V -> G (in AH3; salt wasting form).
CYP21A2	283	283	M -> L (in AH3).
CYP21A2	291	291	G -> C (in AH3).
CYP21A2	291	291	G -> R (in AH3).
CYP21A2	291	291	G -> S (in AH3; salt wasting form; less then 1% activity).
CYP21A2	292	292	G -> D (in AH3; salt wasting form; less then 1% activity).
CYP21A2	300	300	L -> F (in AH3; salt wasting form).
CYP21A2	301	301	S -> Y (in AH3).
CYP21A2	304	304	V -> M (in hyperandrogenism; due to 21- hydroxylase deficiency; non-classic type; residual activity of 46% for conversion of 17-hydroxyprogesterone and 26% for conversion of progesterone compared with the normal enzyme).
CYP21A2	317	317	L -> M (in AH3).
CYP21A2	320	320	E -> K (in AH3; simple virilizing form; 4% activity).
CYP21A2	339	339	R -> H (in AH3; non-classic form; 50% activity).
CYP21A2	341	341	R -> P (in AH3; simple virilizing form).
CYP21A2	341	341	R -> W (in AH3; non-classic form; mild).
CYP21A2	354	354	R -> C (in AH3; salt wasting form).
CYP21A2	354	354	R -> H (in AH3; salt wasting form).
CYP21A2	356	356	R -> P (in AH3; salt wasting form; 0.15% activity).
CYP21A2	356	356	R -> Q (in AH3; simple virilizing form; mild; 0.65% activity).
CYP21A2	356	356	R -> W (in AH3; salt wasting form).
CYP21A2	362	362	A -> V (in AH3; no activity).
CYP21A2	363	363	L -> W (in AH3).
CYP21A2	365	365	H -> Y (in AH3).
CYP21A2	369	369	R -> W (in AH3).
CYP21A2	375	375	G -> S (in hyperandrogenism; due to 21- hydroxylase deficiency; almost completely abolished enzyme activity).
CYP21A2	380	380	E -> D (in AH3; salt wasting form).
CYP21A2	408	408	R -> C (in AH3; very low residual activity).
CYP21A2	424	424	G -> S (in AH3; very low activity).
CYP21A2	426	426	R -> H (in AH3; exhibit only low enzyme activity toward 17-hydroxyprogesterone).
CYP21A2	435	435	R -> C (in AH3).
CYP21A2	479	479	R -> L (in AH3).
CYP21A2	482	482	P -> S (in AH3; reduced enzyme activity to 70% of normal).
CYP21A2	483	483	R -> P (in AH3; moderate; 1-2% of activity).
CYP21A2	483	483	R -> Q (in AH3).
CYP21A2	483	483	R -> W (in AH3; salt wasting form).
TNXB	29	29	R -> W (in EDS3).
TNXB	1195	1195	V -> M (in EDS3).
TNXB	4033	4033	L -> I.
PRRT1	94	94	A -> T (in a breast cancer sample; somatic mutation).
AGER	100	100	Q -> R.
NOTCH4	317	317	E -> Q.
HLA-DQA1	70	70	C -> K (in allele DQA1*02:01; requires 2 nucleotide substitutions).
HLA-DQA1	70	70	C -> Q (in allele DQA1*03:01, allele DQA1*03:02 and allele DQA1*03:03; requires 2 nucleotide substitutions).
HLA-DQA1	70	70	C -> R (in allele DQA1*01:01, allele DQA1*01:02, allele DQA1*01:03, allele DQA1*01:04, allele DQA1*01:05, allele DQA1*01:06 and allele DQA1*01:07).
HLA-DQA1	73	73	V -> D.
HLA-DQA1	73	73	V -> L (in allele DQA1*02:01, allele DQA1*03:01, allele DQA1*03:02 and allele DQA1*03:03).
HLA-DQA1	75	75	R -> H (in allele DQA1*02:01).
HLA-DQA1	76	76	Q -> R (in allele DQA1*02:01, allele DQA1*03:01, allele DQA1*03:02 and allele DQA1*03:03).
HLA-DQA1	78	78	R -> RR (in allele DQA1*03:01, allele DQA1*03:02 and allele DQA1*03:03).
HLA-DQA1	83	83	F -> G (in allele DQA1*01:01, allele DQA1*01:02, allele DQA1*01:03, allele DQA1*01:04, allele DQA1*01:05, allele DQA1*01:06 and allele DQA1*01:07; requires 2 nucleotide substitutions).
HLA-DQA1	91	91	L -> A (in allele DQA1*01:01, allele DQA1*01:02, allele DQA1*01:03, allele DQA1*01:04, allele DQA1*01:05, allele DQA1*01:06 and allele DQA1*01:07; requires 2 nucleotide substitutions).
HLA-DQA1	91	91	L -> T (in allele DQA1*04:01, allele DQA1*04:02, allele DQA1*04:04, allele DQA1*06:01 and allele DQA1*06:02; requires 2 nucleotide substitutions).
HLA-DQA1	97	97	S -> I (in allele DQA1*01:01, allele DQA1*01:02, allele DQA1*01:03, allele DQA1*01:04, allele DQA1*01:05, allele DQA1*01:06, allele DQA1*01:07, allele DQA1*02:01, allele DQA1*03:01, allele DQA1*03:02, allele DQA1*03:03, allele DQA1*04:01, allele DQA1*04:02, allele DQA1*04:04, allele DQA1*06:01 and allele DQA1*06:02).
HLA-DQA1	98	98	L -> M (in allele DQA1*01:01, allele DQA1*01:02, allele DQA1*01:03, allele DQA1*01:04, allele DQA1*01:05, allele DQA1*01:06 and allele DQA1*01:07).
HLA-DQA1	98	98	L -> V (in allele DQA1*03:01, allele DQA1*03:02 and allele DQA1*03:03).
HLA-DQA1	101	101	R -> C (in allele DQA1*01:07).
HLA-DQA1	124	124	L -> V (in allele DQA1*05:06).
HLA-DQA1	152	152	S -> A (in allele DQA1*01:03).
HLA-DQA1	160	160	T -> I (in allele DQA1*04:02).
HLA-DQA1	161	161	S -> I (in allele DQA1*05:08).
HLA-DQA1	161	161	S -> R (in allele DQA1*06:02).
HLA-DQA1	175	175	Y -> H (in allele DQA1*04:04).
HLA-DQA1	182	182	A -> D (in allele DQA1*03:02 and allele DQA1*03:03).
HLA-DQA1	182	182	A -> S (in allele DQA1*05:03, allele DQA1*05:06 and allele DQA1*05:07).
HLA-DQA1	185	185	S -> I (in allele DQA1*01:01, allele DQA1*01:02, allele DQA1*01:03, allele DQA1*01:04, allele DQA1*01:05, allele DQA1*01:07, allele DQA1*02:01, allele DQA1*03:01, allele DQA1*03:02, allele DQA1*03:03, allele DQA1*04:01, allele DQA1*04:02, allele DQA1*04:04, allele DQA1*06:01 and allele DQA1*06:02).
HLA-DQA1	197	197	K -> E (in allele DQA1*02:01, allele DQA1*03:01, allele DQA1*03:02, allele DQA1*03:03, allele DQA1*04:01, allele DQA1*04:02, allele DQA1*04:04, allele DQA1*06:01 and allele DQA1*06:02).
HLA-DQA1	197	197	K -> Q (in allele DQA1*01:01, allele DQA1*01:02, allele DQA1*01:03, allele DQA1*01:04, allele DQA1*01:05 and allele DQA1*01:07).
HLA-DQA1	230	230	G -> C (in allele DQA1*05:07).
HLA-DQB1	27	27	T -> A (in allele DQB1*04:01).
HLA-DQB1	28	28	P -> S (in allele DQB1*05:01 and allele DQB1*05:02).
HLA-DQB1	35	35	S -> P (in allele DQB1*06:01).
HLA-DQB1	41	41	Y -> L (in allele DQB1*06:01 and allele DQB1*06:35; requires 2 nucleotide substitutions).
HLA-DQB1	58	58	Y -> G (in allele DQB1*03:05, allele DQB1*03:17, allele DQB1*04:01, allele DQB1*04:02, allele DQB1*05:01, allele DQB1*05:02, allele DQB1*05:03, allele DQB1*05:04, allele DQB1*05:05 and allele DQB1*06:23; requires 2 nucleotide substitutions).
HLA-DQB1	58	58	Y -> L (in allele DQB1*02:01, allele DQB1*02:02, allele DQB1*02:03, allele DQB1*02:04, allele DQB1*02:05, allele DQB1*03:02, allele DQB1*03:03, allele DQB1*03:06, allele DQB1*03:07, allele DQB1*03:08, allele DQB1*03:11, allele DQB1*03:12, allele DQB1*03:15, allele DQB1*03:18, allele DQB1*03:20, allele DQB1*03:23, allele DQB1*03:25, allele DQB1*03:26, allele DQB1*04:03, allele DQB1*06:02, allele DQB1*06:03, allele DQB1*06:04, allele DQB1*06:05, allele DQB1*06:06, allele DQB1*06:07, allele DQB1*06:08, allele DQB1*06:09, allele DQB1*06:10, allele DQB1*06:11, allele DQB1*06:12, allele DQB1*06:13, allele DQB1*06:14, allele DQB1*06:15, allele DQB1*06:16, allele DQB1*06:17, allele DQB1*06:18, allele DQB1*06:19, allele DQB1*06:20, allele DQB1*06:21, allele DQB1*06:22, allele DQB1*06:24, allele DQB1*06:25, allele DQB1*06:27, allele DQB1*06:28, allele DQB1*06:29, allele DQB1*06:30, allele DQB1*06:31, allele DQB1*06:32, allele DQB1*06:33, allele DQB1*06:34, allele DQB1*06:36, allele DQB1*06:37, allele DQB1*06:38 and allele DQB1*06:39; requires 2 nucleotide substitutions).
HLA-DQB1	62	62	Y -> H (in allele DQB1*05:01, allele DQB1*05:02, allele DQB1*05:03, allele DQB1*05:05, allele DQB1*06:03, allele DQB1*06:04, allele DQB1*06:07, allele DQB1*06:08, allele DQB1*06:14, allele DQB1*06:17, allele DQB1*06:21, allele DQB1*06:25, allele DQB1*06:27, allele DQB1*06:28, allele DQB1*06:30, allele DQB1*06:31, allele DQB1*06:32, allele DQB1*06:34, allele DQB1*06:36, allele DQB1*06:38 and allele DQB1*06:39).
HLA-DQB1	62	62	Y -> S (in allele DQB1*02:01, allele DQB1*02:02, allele DQB1*02:03, allele DQB1*02:04 and allele DQB1*02:05).
HLA-DQB1	69	69	Y -> I (in allele DQB1*02:01, allele DQB1*02:02, allele DQB1*02:03, allele DQB1*02:04 and allele DQB1*02:05; requires 2 nucleotide substitutions).
HLA-DQB1	87	87	P -> L (in allele DQB1*02:01, allele DQB1*02:02, allele DQB1*02:03, allele DQB1*02:04 and allele DQB1*02:05).
HLA-DQB1	87	87	P -> Q (in allele DQB1*03:16).
HLA-DQB1	89	89	D -> S (in allele DQB1*05:02, allele DQB1*05:04, allele DQB1*05:05, allele DQB1*06:10 and allele DQB1*06:25; requires 2 nucleotide substitutions).
HLA-DQB1	89	89	D -> V (in allele DQB1*05:01, allele DQB1*06:04, allele DQB1*06:05, allele DQB1*06:06, allele DQB1*06:08, allele DQB1*06:09, allele DQB1*06:12, allele DQB1*06:13, allele DQB1*06:17, allele DQB1*06:18, allele DQB1*06:21, allele DQB1*06:22, allele DQB1*06:27, allele DQB1*06:34, allele DQB1*06:36, allele DQB1*06:38 and allele DQB1*06:39).
HLA-DQB1	92	92	Y -> N (in allele DQB1*06:16).
HLA-DQB1	94	94	N -> K (in allele DQB1*06:37).
HLA-DQB1	95	95	S -> R (in allele DQB1*03:15).
HLA-DQB1	99	99	V -> D (in allele DQB1*03:13).
HLA-DQB1	99	99	V -> I (in allele DQB1*02:01, allele DQB1*02:02, allele DQB1*02:03, allele DQB1*02:04, allele DQB1*02:05, allele DQB1*03:06, allele DQB1*03:25, allele DQB1*04:01, allele DQB1*04:02, allele DQB1*04:03, allele DQB1*05:04, allele DQB1*06:01 and allele DQB1*06:35).
HLA-DQB1	102	102	R -> E (in allele DQB1*03:06, allele DQB1*03:25, allele DQB1*04:01, allele DQB1*04:02, allele DQB1*04:03 and allele DQB1*05:04; requires 2 nucleotide substitutions).
HLA-DQB1	103	103	T -> A (in allele DQB1*05:01, allele DQB1*05:02, allele DQB1*05:03, allele DQB1*05:05, allele DQB1*06:17, allele DQB1*06:24 and allele DQB1*06:30).
HLA-DQB1	103	103	T -> D (in allele DQB1*03:06, allele DQB1*03:25, allele DQB1*04:01, allele DQB1*04:02, allele DQB1*04:03 and allele DQB1*05:04; requires 2 nucleotide substitutions).
HLA-DQB1	103	103	T -> K (in allele DQB1*02:01, allele DQB1*02:02, allele DQB1*02:03, allele DQB1*02:04 and allele DQB1*02:05).
HLA-DQB1	106	106	E -> S (in allele DQB1*03:06, allele DQB1*03:25, allele DQB1*04:01, allele DQB1*04:02, allele DQB1*04:03, allele DQB1*05:01, allele DQB1*05:02, allele DQB1*05:03, allele DQB1*05:04 and allele DQB1*05:05; requires 2 nucleotide substitutions).
HLA-DQB1	118	118	E -> A (in allele DQB1*05:01, allele DQB1*05:02, allele DQB1*05:03, allele DQB1*05:05, allele DQB1*06:01, allele DQB1*06:02, allele DQB1*06:03, allele DQB1*06:08, allele DQB1*06:10, allele DQB1*06:11, allele DQB1*06:13, allele DQB1*06:14, allele DQB1*06:16, allele DQB1*06:18, allele DQB1*06:19, allele DQB1*06:20, allele DQB1*06:23, allele DQB1*06:24, allele DQB1*06:27, allele DQB1*06:28, allele DQB1*06:29, allele DQB1*06:30, allele DQB1*06:31, allele DQB1*06:32, allele DQB1*06:33, allele DQB1*06:35 and allele DQB1*06:37).
HLA-DQB1	118	118	E -> G (in allele DQB1*06:04, allele DQB1*06:05, allele DQB1*06:07, allele DQB1*06:09, allele DQB1*06:12, allele DQB1*06:15, allele DQB1*06:17, allele DQB1*06:21, allele DQB1*06:22, allele DQB1*06:25, allele DQB1*06:34, allele DQB1*06:36, allele DQB1*06:38 and allele DQB1*06:39).
HLA-DQB1	119	119	L -> Y (in allele DQB1*05:01, allele DQB1*05:02, allele DQB1*05:03, allele DQB1*05:05, allele DQB1*06:04, allele DQB1*06:05, allele DQB1*06:07, allele DQB1*06:09, allele DQB1*06:12, allele DQB1*06:15, allele DQB1*06:17, allele DQB1*06:21, allele DQB1*06:22, allele DQB1*06:25, allele DQB1*06:34, allele DQB1*06:36, allele DQB1*06:38 and allele DQB1*06:39; requires 2 nucleotide substitutions).
HLA-DQB1	121	121	T -> G (in allele DQB1*05:01, allele DQB1*05:02, allele DQB1*05:03, allele DQB1*05:05, allele DQB1*06:01, allele DQB1*06:02, allele DQB1*06:03, allele DQB1*06:04, allele DQB1*06:05, allele DQB1*06:07, allele DQB1*06:08, allele DQB1*06:09, allele DQB1*06:10, allele DQB1*06:11, allele DQB1*06:12, allele DQB1*06:13, allele DQB1*06:14, allele DQB1*06:15, allele DQB1*06:16, allele DQB1*06:17, allele DQB1*06:18, allele DQB1*06:19, allele DQB1*06:21, allele DQB1*06:22, allele DQB1*06:23, allele DQB1*06:24, allele DQB1*06:25, allele DQB1*06:27, allele DQB1*06:28, allele DQB1*06:29, allele DQB1*06:30, allele DQB1*06:31, allele DQB1*06:32, allele DQB1*06:33, allele DQB1*06:34, allele DQB1*06:35, allele DQB1*06:36, allele DQB1*06:37, allele DQB1*06:38 and allele DQB1*06:39; requires 2 nucleotide substitutions).
HLA-DQB1	157	157	A -> G (in allele DQB1*06:01, allele DQB1*06:02, allele DQB1*06:03, allele DQB1*06:04, allele DQB1*06:09, allele DQB1*06:12, allele DQB1*06:34, allele DQB1*06:36, allele DQB1*06:38 and allele DQB1*06:39).
HLA-DQB1	157	157	A -> S (in allele DQB1*05:01, allele DQB1*05:02 and allele DQB1*05:03).
HLA-DQB1	158	158	Q -> H (in allele DQB1*05:02).
HLA-DQB1	162	162	R -> Q (in allele DQB1*03:22, allele DQB1*06:04, allele DQB1*06:09, allele DQB1*06:12, allele DQB1*06:34, allele DQB1*06:36 and allele DQB1*06:38).
HLA-DQB1	165	165	R -> Q (in allele DQB1*06:38).
HLA-DQB1	165	165	R -> W (in allele DQB1*03:21).
HLA-DQB1	167	167	D -> G (in allele DQB1*02:02).
HLA-DQB1	168	168	Q -> E (in allele DQB1*02:04).
HLA-DQB1	199	199	H -> R (in allele DQB1*02:01, allele DQB1*02:02, allele DQB1*02:04, allele DQB1*03:02, allele DQB1*03:03, allele DQB1*03:05, allele DQB1*03:23, allele DQB1*03:25, allele DQB1*04:01, allele DQB1*04:02, allele DQB1*05:01, allele DQB1*05:02, allele DQB1*05:03, allele DQB1*06:02, allele DQB1*06:03, allele DQB1*06:04, allele DQB1*06:09, allele DQB1*06:12, allele DQB1*06:34, allele DQB1*06:36, allele DQB1*06:38 and allele DQB1*06:39).
HLA-DQB1	200	201	GD -> A (in allele DQB1*03:09).
HLA-DQB1	202	202	V -> I (in allele DQB1*03:24).
HLA-DQB1	214	214	N -> S (in allele DQB1*02:01, allele DQB1*02:02, allele DQB1*02:04, allele DQB1*05:01, allele DQB1*05:02, allele DQB1*05:03, allele DQB1*06:01, allele DQB1*06:02, allele DQB1*06:03, allele DQB1*06:04, allele DQB1*06:09, allele DQB1*06:12, allele DQB1*06:34, allele DQB1*06:36, allele DQB1*06:38 and allele DQB1*06:39).
HLA-DQB1	217	217	T -> I (in allele DQB1*03:02, allele DQB1*03:03, allele DQB1*03:05, allele DQB1*03:19, allele DQB1*03:25, allele DQB1*04:01 and allele DQB1*04:02).
HLA-DQB1	218	218	V -> A (in allele DQB1*06:36).
HLA-DQB1	229	229	S -> N (in allele DQB1*06:01).
HLA-DQB1	235	235	I -> V (in allele DQB1*05:01, allele DQB1*05:02, allele DQB1*05:03, allele DQB1*06:02, allele DQB1*06:03, allele DQB1*06:04, allele DQB1*06:09, allele DQB1*06:12 and allele DQB1*06:36).
HLA-DQB1	253	253	H -> Q (in allele DQB1*05:01, allele DQB1*05:02, allele DQB1*05:03, allele DQB1*06:01, allele DQB1*06:02, allele DQB1*06:03, allele DQB1*06:04, allele DQB1*06:09, allele DQB1*06:12 and allele DQB1*06:36).
TAP2	374	374	A -> T (in allele TAP2*01F, allele TAP2*01G, allele TAP2*01H, allele TAP2*02B and allele TAP2*02D).
TAP2	467	467	V -> I (in allele TAP2*01F and allele TAP2*02D).
TAP2	513	513	A -> S (rare polymorphism).
TAP2	686	686	L -> LQEGQDLYSRLVQQRLMD (in allele TAP2*02:01, allele TAP2*02B, allele TAP2*02C, allele TAP2*02D, allele TAP2*02E, allele TAP2*02F, allele TAP2*03A and allele TAP2*BKY2).
PSMB8	8	8	G -> R (in LMP7C).
PSMB8	30	32	PGH -> RPD (in LPM7C).
PSMB8	75	75	T -> M (in JMPS; markedly decreased chymotrypsin-like activity consistent with a decrease in proteasomal activity and loss of function).
TAP1	67	67	P -> S.
TAP1	719	719	R -> Q (in a lung cancer cell line deficient in MHC class I presentation).
HLA-DMB	162	162	A -> E (in allele DMB*01:02 and allele DMB*01:06).
HLA-DMB	162	162	A -> V (in allele DMB*01:04 and allele DMB*01:05).
BRD2	30	30	G -> E (in a glioblastoma multiforme sample; somatic mutation).
BRD2	49	49	A -> G.
BRD2	558	558	R -> G (in a gastric adenocarcinoma sample; somatic mutation).
BRD2	714	714	P -> L (in a glioblastoma multiforme sample; somatic mutation).
HLA-DPA1	42	42	A -> M (in allele DPA1*02:02, allele DPA1*02:04, allele DPA1*03:01, allele DPA1*03:02 and allele DPA1*03:03; requires 2 nucleotide substitutions).
HLA-DPA1	104	104	L -> A (in allele DPA1*04:01; requires 2 nucleotide substitutions).
HLA-DPA1	221	221	T -> A (in allele DPA1*04:01).
HLA-DPB1	30	30	R -> P (in allele DPB1*75:01).
HLA-DPB1	31	31	A -> L (in allele DPB1*75:01; requires 2 nucleotide substitutions).
HLA-DPB1	32	32	T -> P (in allele DPB1*75:01).
HLA-DPB1	33	33	P -> A (in allele DPB1*75:01).
HLA-DPB1	38	38	F -> D (in allele DPB1*70:01; requires 2 nucleotide substitutions).
HLA-DPB1	38	38	F -> H (in allele DPB1*09:01, allele DPB1*10:01, allele DPB1*14:01, allele DPB1*16:02, allele DPB1*17:01, allele DPB1*22:02, allele DPB1*30:01, allele DPB1*35:01, allele DPB1*45:01, allele DPB1*54:01, allele DPB1*55:01, allele DPB1*58:01, allele DPB1*66:01, allele DPB1*67:01, allele DPB1*76:01, allele DPB1*86:01, allele DPB1*91:01 and allele DPB1*98:01; requires 2 nucleotide substitutions).
HLA-DPB1	40	40	G -> L (in allele DPB1*03:01, allele DPB1*05:02, allele DPB1*06:01, allele DPB1*09:01, allele DPB1*09:02, allele DPB1*10:01, allele DPB1*11:01, allele DPB1*11:02, allele DPB1*13:01, allele DPB1*13:02, allele DPB1*14:01, allele DPB1*14:02, allele DPB1*16:02, allele DPB1*17:01, allele DPB1*17:02, allele DPB1*20:02, allele DPB1*21:01, allele DPB1*20:01, allele DPB1*22:02, allele DPB1*25:01, allele DPB1*26:01, allele DPB1*27:01, allele DPB1*29:01, allele DPB1*30:01, allele DPB1*35:01, allele DPB1*36:01, allele DPB1*37:01, allele DPB1*44:01, allele DPB1*45:01, allele DPB1*52:01, allele DPB1*54:01, allele DPB1*55:01, allele DPB1*56:01, allele DPB1*58:01, allele DPB1*66:01, allele DPB1*67:01, allele DPB1*69:01, allele DPB1*70:01, allele DPB1*74:01, allele DPB1*76:01, allele DPB1*78:01, allele DPB1*79:01, allele DPB1*85:01, allele DPB1*86:01, allele DPB1*87:01, allele DPB1*88:01, allele DPB1*91:01, allele DPB1*92:01, allele DPB1*93:01 and allele DPB1*98:01; requires 2 nucleotide substitutions).
HLA-DPB1	44	44	C -> G (in allele DPB1*26:02).
HLA-DPB1	46	46	A -> T (in allele DPB1*18:02).
HLA-DPB1	68	68	D -> Y (in allele DPB1*24:02).
HLA-DPB1	84	84	A -> E (in allele DPB1*01:02, allele DPB1*02:02, allele DPB1*02:03, allele DPB1*05:01, allele DPB1*08:02, allele DPB1*17:02, allele DPB1*19:01, allele DPB1*21:01, allele DPB1*22:01, allele DPB1*24:01, allele DPB1*30:01, allele DPB1*36:01, allele DPB1*38:01, allele DPB1*47:01, allele DPB1*54:01, allele DPB1*84:01 and allele DPB1*97:01).
HLA-DPB1	113	113	G -> N (in allele DPB1*22:02; requires 2 nucleotide substitutions).
HLA-DPB1	113	113	G -> V (in allele DPB1*15:01, allele DPB1*18:01, allele DPB1*28:01, allele DPB1*34:01, allele DPB1*40:01, allele DPB1*53:01, allele DPB1*62:01 and allele DPB1*74:01).
HLA-DPB1	199	199	T -> I (in allele DPB1*01:01, allele DPB1*03:01, allele DPB1*05:01, allele DPB1*05:02, allele DPB1*06:01, allele DPB1*09:01, allele DPB1*09:02, allele DPB1*13:01, allele DPB1*14:01, allele DPB1*15:01, allele DPB1*18:01, allele DPB1*19:01, allele DPB1*20:01, allele DPB1*26:01, allele DPB1*45:01 and allele DPB1*85:01).
COL11A2	593	593	D -> G.
COL11A2	621	621	P -> T (in DFNB53).
COL11A2	661	661	G -> R (in OSMED).
COL11A2	808	808	G -> E (in DFNA13).
COL11A2	879	879	P -> L.
COL11A2	940	948	Missing (in STL3).
COL11A2	1034	1034	R -> C (in DFNA13).
COL11A2	1441	1441	G -> E (in WZS).
HSD17B8	158	158	V -> L (in a breast cancer sample; somatic mutation).
KIFC1	219	219	R -> Q.
SYNGAP1	201	201	D -> E.
SYNGAP1	749	749	R -> Q.
SYNGAP1	790	790	T -> N.
SYNGAP1	991	991	G -> R.
SYNGAP1	1115	1115	I -> T.
SYNGAP1	1283	1283	P -> L.
SYNGAP1	1310	1310	T -> M.
FANCE	184	184	P -> Q (in FA; uncertain pathological significance).
TULP1	120	127	Missing (in RP14).
TULP1	245	245	A -> V (in RP14).
TULP1	261	261	K -> T (in RP14).
TULP1	368	368	G -> W (in LCA15).
TULP1	378	378	R -> H (in RP14).
TULP1	382	382	F -> S (in RP14).
TULP1	400	400	R -> W (in LCA15).
TULP1	420	420	R -> P (in RP14; no effect on RPE phagocytosis).
TULP1	454	454	T -> M (in RP14).
TULP1	459	459	I -> K (in RP14; no effect on RPE phagocytosis).
TULP1	482	482	R -> W (in RP14).
TULP1	489	489	K -> R (in RP14; abolishes RPE phagocytosis).
TULP1	491	491	F -> L (in RP14; abolishes RPE phagocytosis).
TULP1	496	496	A -> T (in RP14; uncertain pathogenicity).
TULP1	529	529	A -> AFA (in LCA15).
STK38	18	18	E -> K (in a metastatic melanoma sample; somatic mutation).
PIM1	144	144	Y -> H (in a colorectal adenocarcinoma sample; somatic mutation).
PIM1	215	215	E -> Q.
PIM1	226	226	E -> K.
PIM1	233	233	E -> D.
MOCS1	67	67	R -> W (in MOCOD type A).
MOCS1	73	73	R -> W (in MOCOD type A).
MOCS1	80	80	C -> G (in MOCOD type A).
MOCS1	84	84	C -> F (in MOCOD type A).
MOCS1	123	123	R -> W (in MOCOD type A).
MOCS1	126	126	G -> D (in MOCOD type A).
MOCS1	127	127	G -> D (in MOCOD type A).
MOCS1	319	319	R -> Q (in MOCOD type A).
MOCS1	324	324	G -> E (in MOCOD type A).
MOCS1	324	324	G -> R (in MOCOD type A).
TREML1	6	6	L -> V (in a breast cancer sample; somatic mutation).
TREM2	134	134	D -> G (in PLOSL).
TREM2	186	186	K -> N (in PLOSL).
TREM1	97	97	R -> S (in a breast cancer sample; somatic mutation).
GUCA1A	50	50	P -> L (in COD3; some subjects may present a moderately severe cone-rod dystrophy; causes a decrease in the number of bound calcium ions from 3 to 2, without changing the activity profile).
GUCA1A	89	89	E -> K (in COD3; exhibits an about 6-fold shift of ionic calcium concentration at which the guanylate cyclase activity is halfmaximal).
GUCA1A	99	99	Y -> C (in COD3; type 1A; alters calcium ion sensitivity, leading to the constitutive stimulating activity of GC1 at high calcium ion concentration, where normal GUCA1A inhibits it).
GUCA1A	100	100	D -> E (in COD3; exhibits an about 28- fold shift of ionic calcium concentration at which the guanylate cyclase activity is halfmaximal).
GUCA1A	114	114	T -> I (in a patient with an atypical form of retinitis pigmentosa; uncertain pathogenicity).
GUCA1A	143	143	I -> NT (in COD3).
GUCA1A	151	151	L -> F (in COD3).
GUCA1A	155	155	E -> G (in COD3; constitutive activation of GC1).
GUCA1A	159	159	G -> V (in COD3; exhibits an about 18- fold shift of ionic calcium concentration at which the guanylate cyclase activity is halfmaximal).
GUCA1B	155	155	E -> D.
GUCA1B	157	157	G -> R (in RP48).
PRPH2	13	13	R -> W (in RP7; in combination with a null mutation of ROM1).
PRPH2	32	32	I -> V (in some patients with macular dystrophy).
PRPH2	45	45	L -> F (in RP7; in combination with a null mutation of ROM1).
PRPH2	67	67	Missing (in PDREP; also in cone-rod dystrophy).
PRPH2	68	68	G -> R (in PDREP; also in cone-rod dystrophy).
PRPH2	118	118	Missing (in RP7).
PRPH2	126	126	L -> R (in RP7).
PRPH2	142	142	R -> W (in a patient with central areolar choroidal dystrophy).
PRPH2	153	153	K -> R (in RP7).
PRPH2	153	153	Missing (in RP7).
PRPH2	157	157	D -> N (in PDREP).
PRPH2	165	165	C -> Y (in RP7).
PRPH2	167	167	G -> D (in PDREP; butterfly-shaped).
PRPH2	167	167	G -> S (in PDREP; butterfly-shaped).
PRPH2	169	169	Missing (in some patients with macular dystrophy).
PRPH2	172	172	R -> G (in PDREP; butterfly-shaped).
PRPH2	172	172	R -> Q (in some patients with macular dystrophy).
PRPH2	172	172	R -> W (in some patients with macular dystrophy; also in a family affected by central areolar choroidal dystrophy).
PRPH2	173	173	D -> V (in RP7).
PRPH2	184	184	Y -> S (in cone-rod dystrophy).
PRPH2	185	185	L -> P (in RP7; in combination with a null mutation of ROM1).
PRPH2	193	193	Missing (in PDREP; also in cone-rod dystrophy).
PRPH2	195	195	R -> L (in CACD2).
PRPH2	208	208	G -> D (in RP7).
PRPH2	210	210	P -> R (in PDREP and RP7; also in adult- onset foveomacular dystrophy with choroidal neovascularization).
PRPH2	210	210	P -> S (in RP7).
PRPH2	211	211	F -> L (in RP7).
PRPH2	212	212	S -> G (in RP7).
PRPH2	212	212	S -> T (in AVMD).
PRPH2	213	213	C -> R (in PDREP).
PRPH2	214	214	C -> S (in RP7).
PRPH2	216	216	P -> L (in RP7).
PRPH2	216	216	P -> S (in RP7).
PRPH2	219	219	P -> R (in some patients with macular dystrophy).
PRPH2	219	219	Missing (in RP7).
PRPH2	220	220	R -> Q (in PDREP).
PRPH2	220	220	R -> W (in PDREP).
PRPH2	244	244	N -> H (in cone-rod dystrophy).
PRPH2	244	244	N -> K (in RP7; with bulls-eye maculopathy).
PRPH2	266	266	G -> D (in RP7).
PRPH2	268	268	V -> I (in AVMD).
PRPH2	305	305	G -> D (in AVMD).
PRPH2	313	313	P -> L.
GNMT	50	50	L -> P (in GNMT deficiency; 10% wild-type activity).
GNMT	141	141	N -> S (in GNMT deficiency; 0.5% wild- type activity).
GNMT	177	177	H -> N (in GNMT deficiency; 75% wild-type activity, decreases stability of the tetramer).
PEX6	79	79	A -> P.
PEX6	274	274	P -> L (in PBD-CG4; Zellweger spectrum).
PEX6	812	812	R -> Q (in ZWS).
PEX6	812	812	R -> W (in ZWS; atypical).
PEX6	849	849	N -> T (in PBD-CG4; Zellweger spectrum).
PEX6	860	860	R -> Q (in PBD-CG4; Zellweger spectrum).
PEX6	860	860	R -> W (in PBD-CG4; Zellweger spectrum).
CUL7	1014	1014	L -> R (in 3M1).
CUL7	1246	1246	Q -> G (in 3M1; requires 2 nucleotide substitutions).
CUL7	1464	1464	H -> P (in 3M1; impairs the ability to interact with RBX1, thus hampers the assembly of polyubiquitin chains).
SLC22A7	303	303	R -> K.
SLC22A7	507	507	G -> V.
ZNF318	812	812	N -> S (in a breast cancer sample; somatic mutation).
ZNF318	1274	1274	G -> R (in a breast cancer sample; somatic mutation).
POLR1C	279	279	R -> Q (in TCS3).
POLR1C	279	279	R -> W (in TCS3).
POLH	75	75	Missing (in XPV; impairs translesion synthesis).
POLH	111	111	R -> H (in XPV).
POLH	122	122	T -> P (in XPV).
POLH	153	153	G -> D (in a breast cancer sample; somatic mutation).
POLH	263	263	G -> V (in XPV; impairs translesion synthesis).
POLH	361	361	R -> S (in XPV).
POLH	589	589	K -> T (in XPV).
RSPH9	268	268	Missing (in CILD12).
SLC29A1	293	293	A -> T (in a colorectal cancer sample; somatic mutation).
SLC29A1	455	455	I -> V (in a colorectal cancer sample; somatic mutation).
PLA2G7	281	281	Q -> R (in PLA2G7 deficiency; loss of function).
GPR115	674	674	S -> L (in a breast cancer sample; somatic mutation).
RHAG	79	79	S -> N (in RHN).
RHAG	280	280	G -> R (in RHN).
RHAG	380	380	G -> V (in RHN).
TFAP2B	73	73	P -> R (in CHAR).
TFAP2B	236	236	R -> C (in CHAR).
TFAP2B	236	236	R -> S (in CHAR).
TFAP2B	275	275	A -> D (in CHAR).
TFAP2B	285	285	R -> Q (in CHAR).
TFAP2B	300	300	R -> C (in CHAR).
GSTA3	36	36	G -> E.
GSTA3	113	113	R -> Q.
GSTA3	208	208	A -> T.
ICK	115	115	F -> Y (in a renal clear cell carcinoma sample; somatic mutation).
ICK	272	272	R -> Q (in ECO; fails to localize at the nucleus and significantly impairs kinase activity).
GCLC	127	127	R -> C (in HAGGSD).
GCLC	158	158	P -> L (in HAGGSD).
GCLC	370	370	H -> L (in HAGGSD).
GFRAL	195	195	D -> H (in a breast cancer sample; somatic mutation).
RAB23	12	12	M -> K (in CARPS).
RAB23	13	13	Missing.
RAB23	79	79	Missing (in CARPS).
RAB23	85	85	C -> R (in ACPS2).
OGFRL1	47	47	S -> P.
OGFRL1	396	396	Missing.
COX7A2	40	40	E -> D.
ELOVL4	267	267	I -> T.
FAM46A	24	24	G -> GGDFGG.
FAM46A	39	43	Missing.
FAM46A	313	313	T -> A.
DOPEY1	1155	1155	D -> H (in a breast cancer sample; somatic mutation).
CYB5R4	140	140	R -> H.
CYB5R4	187	187	Q -> R.
CYB5R4	223	223	H -> R.
CYB5R4	371	371	D -> Y (in a breast cancer sample; somatic mutation).
CYB5R4	390	390	L -> M (in a breast cancer sample; somatic mutation).
NT5E	358	358	C -> Y (in CAJA).
MANEA	331	331	Y -> C (in a breast cancer sample; somatic mutation).
NDUFAF4	65	65	L -> P (in MT-C1D).
MICAL1	309	309	L -> M (in a breast cancer sample; somatic mutation).
DDO	136	136	F -> L (in a breast cancer sample; somatic mutation).
WISP3	78	78	C -> R (in PPAC).
COL10A1	18	18	G -> E (in SMCD).
COL10A1	18	18	G -> R (in SMCD).
COL10A1	198	198	R -> H.
COL10A1	582	582	Y -> D (in SMCD).
COL10A1	591	591	C -> R (in SMCD).
COL10A1	595	595	G -> E (in SMCD and spondylometaphyseal dysplasia Japanese type).
COL10A1	595	595	G -> R (in SMCD).
COL10A1	597	597	Y -> C (in SMCD).
COL10A1	597	597	Y -> H (in SMCD).
COL10A1	598	598	Y -> D (in SMCD).
COL10A1	600	600	S -> P (in SMCD).
COL10A1	603	603	V -> M.
COL10A1	614	614	L -> P (in SMCD).
COL10A1	617	617	N -> K (in SMCD).
COL10A1	618	618	G -> V (in SMCD).
COL10A1	644	644	L -> R (in SMCD).
COL10A1	648	648	D -> G (in SMCD).
COL10A1	651	651	W -> R (in SMCD).
COL10A1	653	653	Q -> P (in SMCD).
COL10A1	671	671	S -> P (in SMCD).
RSPH4A	87	87	P -> S (in CILD11).
RFX6	181	181	R -> Q (in MIRIS; abolishes DNA-binding).
RFX6	217	217	S -> P (in MIRIS; induces a slight reduction in DNA-binding; in a patient still alive at age 4.5 years).
PLN	9	9	R -> C (in CMD1P; impairs phosphorylation by PKA).
PLN	14	14	Missing (in CMD1P; destabilizes the homopentamer).
HEY2	96	96	T -> A (in a patient with atrioventricular septal defects).
HEY2	98	98	D -> A (in a patient with atrioventricular septal defects).
HEY2	100	100	L -> S (in a patient with atrioventricular septal defects).
ARG1	138	138	G -> V (in ARGIN).
ARG1	235	235	G -> R (in ARGIN).
ARG1	290	290	T -> S (could be a polymorphism).
ENPP1	91	91	L -> P (in OPLL).
ENPP1	266	266	G -> V (in ARHR2; rs121908248).
ENPP1	287	287	S -> F (in OPLL).
ENPP1	342	342	G -> V (in IIAC).
ENPP1	371	371	Y -> F (in IIAC).
ENPP1	579	579	L -> F (in IIAC).
VNN1	63	63	A -> T.
VNN1	146	146	D -> N.
VNN2	112	112	D -> E.
VNN2	349	349	T -> S.
IFNGR1	77	77	C -> Y (in MSMD; fails to bind IFN- gamma).
IFNGR1	87	87	I -> T (in MSMD; impaired response to IFN-gamma).
IFNGR1	99	102	Missing (in MSMD; fails to bind IFN- gamma).
FBXO30	8	8	S -> C (in a colorectal cancer sample; somatic mutation).
LATS1	669	669	M -> I (in a lung adenocarcinoma sample; somatic mutation).
LATS1	806	806	R -> P (in a lung large cell carcinoma sample; somatic mutation).
IYD	101	101	R -> W (in TDH4; strongly reduces activity; does not respond to the increase of flavin mononucleotide concentration).
IYD	105	106	FI -> L (in TDH4; strongly reduces activity; does not respond to the increase of flavin mononucleotide concentration).
IYD	116	116	I -> T (in TDH4; strongly reduces activity; marginally respond to the increase of flavin mononucleotide concentration; reduces protein stability).
EZR	532	532	L -> V.
TCP1	7	7	V -> L (in a breast cancer sample; somatic mutation).
SLC22A2	165	165	M -> I (lower Vmax).
SLC22A2	201	201	T -> M.
PLG	38	38	K -> E (in PLGD; common mutation).
PLG	147	147	L -> P (in PLGD).
PLG	235	235	R -> H (in PLGD; severe type 1 deficiency).
PLG	374	374	V -> F (in PLGD; Nagoya-1).
PLG	532	532	R -> H (in PLGD).
PLG	591	591	S -> P (in PLGD; may be associated with susceptibility to thrombosis).
PLG	620	620	A -> T (in PLGD; type 2 plasminogen deficiency; decreased activity; Nagoya-2/ Tochigi/Kagoshima; may be associated with susceptibility to thrombosis).
PLG	751	751	G -> R (in PLGD; Kanagawa-1; 50% activity).
RNASET2	184	184	C -> R (in LCWM; affects protein trafficking to the extracellular space).
UNC93A	445	445	V -> A.
TCTE3	67	67	I -> V.
TBP	92	95	Missing.
BBS9	141	141	G -> R (in BBS9).
CDK6	199	199	P -> L (in a metastatic melanoma sample; somatic mutation).
CTTNBP2	1213	1213	L -> V.
MAD1L1	29	29	S -> L (in a lymphoid cancer cell line; somatic mutation).
MAD1L1	160	160	N -> S.
MAD1L1	299	299	T -> A (in lung cancer cell line; somatic mutation).
MAD1L1	360	360	R -> Q (in a prostate cancer cell line; somatic mutation).
MAD1L1	500	500	T -> M.
MAD1L1	511	511	E -> K.
MAD1L1	516	516	E -> K (in a breast cancer cell line; somatic mutation).
MAD1L1	556	556	R -> C (in a prostate cancer cell line; somatic mutation).
MAD1L1	556	556	R -> H (in one individual with lung cancer).
MAD1L1	569	569	E -> K (in a breast cancer cell line; somatic mutation).
HDAC9	921	921	P -> T (found in a renal cell carcinoma sample; somatic mutation).
C7orf10	336	336	R -> W (in GA3; healthy individuals who have abnormal quantities of glutaric acid but low 3-hydroxyglutaric acid).
CCM2	198	198	L -> R (in CCM2).
ABCB4	87	87	D -> E.
ABCB4	95	95	P -> S.
ABCB4	138	138	W -> R (in PFIC3).
ABCB4	150	150	R -> K (in ICP).
ABCB4	165	165	F -> I (in GBD1).
ABCB4	301	301	M -> T (in GBD1).
ABCB4	320	320	S -> F (in ICP and GBD1).
ABCB4	346	346	S -> I (in PFIC3).
ABCB4	367	367	I -> V.
ABCB4	395	395	E -> G (in PFIC3).
ABCB4	424	424	T -> A (in PFIC3).
ABCB4	425	425	V -> M (in PFIC3).
ABCB4	450	450	E -> G.
ABCB4	535	535	G -> D (in PFIC3).
ABCB4	541	541	I -> F (in PFIC3).
ABCB4	546	546	A -> D (in ICP; disruption of protein trafficking with subsequent lack of functional protein at the cell surface).
ABCB4	556	556	L -> R (in PFIC3).
ABCB4	564	564	D -> G (in PFIC3).
ABCB4	591	591	L -> Q (in GBD1).
ABCB4	711	711	F -> S (in PFIC3).
ABCB4	742	742	G -> S.
ABCB4	762	762	G -> E (in ICP).
ABCB4	764	764	I -> L (in a heterozygous patient with risperidone-induced cholestasis).
ABCB4	775	775	T -> M.
ABCB4	788	788	R -> Q.
ABCB4	934	934	A -> T (in GBD1).
ABCB4	1082	1082	L -> Q (in a heterozygous patient with amoxicillin/clavulanic acid-induced cholestasis).
ABCB4	1161	1161	Missing (in GBD1).
ABCB4	1168	1168	P -> S (in GBD1).
CDK14	432	432	M -> I (in an ovarian mucinous carcinoma; somatic mutation).
CDK14	463	463	S -> R.
DYNC1I1	373	373	H -> L (found in a renal cell carcinoma case; somatic mutation).
TRRAP	893	893	R -> C (in an ovarian serous carcinoma sample; somatic mutation).
TRRAP	1669	1669	R -> H (in a colorectal adenocarcinoma sample; somatic mutation).
TRRAP	1724	1724	R -> H (in a gastric adenocarcinoma sample; somatic mutation).
TRRAP	1925	1925	A -> V.
TRRAP	1932	1932	P -> L (in a colorectal adenocarcinoma sample; somatic mutation).
TRRAP	1947	1947	R -> L (in an ovarian mucinous carcinoma sample; somatic mutation).
TRRAP	2139	2139	W -> G.
TRRAP	2302	2302	R -> W (in a colorectal adenocarcinoma sample; somatic mutation).
TRRAP	2433	2433	S -> G.
TRRAP	2690	2690	P -> L (in a lung large cell carcinoma sample; somatic mutation).
TRRAP	2750	2750	E -> D.
TRRAP	2801	2801	K -> E.
TRRAP	2931	2931	T -> M (in a colorectal adenocarcinoma sample; somatic mutation).
SRPK2	243	243	G -> D (in a glioblastoma multiforme sample; somatic mutation).
NAMPT	176	176	L -> S (in a colorectal cancer sample; somatic mutation).
COG5	558	558	S -> P.
NRCAM	1093	1093	H -> P (in a breast cancer sample; somatic mutation).
NRCAM	1116	1116	G -> V (in a breast cancer sample; somatic mutation).
FOXP2	553	553	R -> H (in SPCH1).
MET	150	150	H -> Y (found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation).
MET	385	385	C -> Y (found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation).
MET	773	773	P -> L (in gastric cancer).
MET	991	991	P -> S (in gastric cancer; prolonged tyrosine phosphorylation in response to HGF/SF; transforming activity in athymic nude mice).
MET	1092	1092	V -> I (in RCCP; constitutive autophosphorylation).
MET	1094	1094	H -> L (in RCCP; constitutive autophosphorylation; causes malignant transformation in cell lines).
MET	1094	1094	H -> R (in RCCP; causes malignant transformation in cell lines).
MET	1094	1094	H -> Y (in RCCP; constitutive autophosphorylation; causes malignant transformation in cell lines).
MET	1106	1106	H -> D (in RCCP; constitutive autophosphorylation; causes malignant transformation in cell lines).
MET	1131	1131	M -> T (in RCCP; germline mutation).
MET	1173	1173	T -> I (in HCC).
MET	1188	1188	V -> L (in RCCP; germline mutation).
MET	1195	1195	L -> V (in RCCP; somatic mutation).
MET	1220	1220	V -> I (in RCCP; germline mutation).
MET	1228	1228	D -> H (in RCCP; somatic mutation).
MET	1228	1228	D -> N (in RCCP; germline mutation).
MET	1230	1230	Y -> C (in RCCP; germline mutation).
MET	1230	1230	Y -> D (in RCCP; constitutive autophosphorylation; causes malignant transformation in cell lines).
MET	1230	1230	Y -> H (in RCCP; somatic mutation).
MET	1244	1244	K -> R (in HCC).
MET	1250	1250	M -> I (in HCC).
MET	1250	1250	M -> T (in RCCP; somatic mutation).
MET	1294	1294	V -> I (found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation).
GRM8	362	362	F -> Y.
GRM8	368	368	G -> D.
GRM8	430	430	L -> F.
EXOC4	220	220	S -> F (in a colorectal cancer sample; somatic mutation).
EXOC4	599	599	A -> T (in a colorectal cancer sample; somatic mutation).
DGKI	153	153	L -> F.
ATP6V0A4	175	175	G -> D (in RTADR).
ATP6V0A4	237	237	Missing (in RTADR).
ATP6V0A4	449	449	R -> H (in RTADR).
ATP6V0A4	524	524	P -> L (in RTADR).
ATP6V0A4	820	820	G -> R (in RTADR).
HIPK2	792	792	R -> Q.
HIPK2	1027	1027	R -> Q.
BRAF	241	241	T -> M (in a patient with Noonan syndrome).
BRAF	241	241	T -> P (in CFC syndrome and LEOPARD3).
BRAF	241	241	T -> R (in a patient with Noonan syndrome).
BRAF	244	244	T -> P (in CFC syndrome).
BRAF	245	245	L -> F (in CFC syndrome).
BRAF	246	246	A -> P (in CFC syndrome).
BRAF	257	257	Q -> R (in CFC syndrome).
BRAF	262	262	Q -> K (in CFC syndrome).
BRAF	275	275	E -> K (in CFC syndrome).
BRAF	462	462	R -> I (in colorectal cancer).
BRAF	463	463	I -> S (in colorectal cancer).
BRAF	464	464	G -> E (in colorectal cancer).
BRAF	464	464	G -> V (in a colorectal cancer cell line; elevated kinase activity; efficiently induces cell transformation).
BRAF	466	466	G -> A (in melanoma).
BRAF	466	466	G -> E (in melanoma).
BRAF	466	466	G -> V (in LNCR).
BRAF	467	467	S -> A (in CFC syndrome).
BRAF	468	468	F -> S (in CFC syndrome).
BRAF	469	469	G -> A (in NHL; also in a lung adenocarcinoma sample; somatic mutation; elevated kinase activity; efficiently induces cell transformation).
BRAF	469	469	G -> E (in CFC syndrome and colon cancer).
BRAF	469	469	G -> R (in NHL).
BRAF	469	469	G -> V (in a colorectal adenocarcinoma sample; somatic mutation).
BRAF	485	485	L -> F (in CFC syndrome).
BRAF	499	499	K -> E (in CFC syndrome).
BRAF	499	499	K -> N (in CFC syndrome).
BRAF	501	501	E -> G (in CFC syndrome).
BRAF	501	501	E -> K (in CFC syndrome).
BRAF	525	525	L -> P (in CFC syndrome).
BRAF	531	531	W -> C (in NS7).
BRAF	580	580	N -> D (in CFC syndrome).
BRAF	581	581	N -> D (in CFC syndrome).
BRAF	581	581	N -> S (in a colorectal adenocarcinoma sample; somatic mutation).
BRAF	586	586	E -> K (in ovarian cancer).
BRAF	594	594	D -> G (in NHL).
BRAF	595	595	F -> L (in colon cancer and CFC syndrome).
BRAF	596	596	G -> R (in a colorectal adenocarcinoma sample; somatic mutation).
BRAF	596	596	G -> V (in CFC syndrome).
BRAF	597	597	L -> R (in LNCR; also found in an ovarian serous carcinoma sample; somatic mutation).
BRAF	597	597	L -> V (in NS7; also in a lung adenocarcinoma sample; somatic mutation; elevated kinase activity; efficiently induces cell transformation).
BRAF	599	599	T -> R (in CFC syndrome).
BRAF	600	600	V -> D (in a melanoma cell line; requires 2 nucleotide substitutions).
BRAF	600	600	V -> E (in sarcoma, colorectal adenocarcinoma, metastatic melanoma, ovarian serous carcinoma, pilocytic astrocytoma; somatic mutation; most common mutation; constitutive and elevated kinase activity; efficiently induces cell transformation; suppression of mutation in melanoma causes growth arrest and promotes apoptosis).
BRAF	601	601	K -> E (in colorectal cancer).
BRAF	601	601	K -> Q (in CFC syndrome).
BRAF	638	638	D -> E (in CFC syndrome).
BRAF	709	709	Q -> R (in CFC syndrome).
CNTNAP2	114	114	R -> Q.
CNTNAP2	218	218	T -> M.
CNTNAP2	226	226	L -> M.
CNTNAP2	283	283	R -> C.
CNTNAP2	382	382	S -> N.
CNTNAP2	407	407	N -> S.
CNTNAP2	418	418	N -> D.
CNTNAP2	680	680	E -> K.
CNTNAP2	699	699	P -> Q.
CNTNAP2	716	716	Y -> C.
CNTNAP2	731	731	G -> S.
CNTNAP2	779	779	G -> D.
CNTNAP2	869	869	I -> T (associated with susceptibility to autism).
CNTNAP2	906	906	R -> H.
CNTNAP2	1038	1038	D -> N.
CNTNAP2	1102	1102	V -> A.
CNTNAP2	1114	1114	S -> G.
CNTNAP2	1119	1119	R -> H.
CNTNAP2	1129	1129	D -> H.
CNTNAP2	1227	1227	A -> T.
CNTNAP2	1253	1253	I -> T.
CNTNAP2	1278	1278	T -> I.
MLL3	347	347	C -> G (in a colorectal cancer sample; somatic mutation).
MLL3	400	400	D -> N (in a colorectal cancer sample; somatic mutation).
MLL3	478	478	L -> W (in a colorectal cancer sample; somatic mutation).
MLL3	3698	3698	T -> S (in a colorectal cancer sample; somatic mutation).
PTPRN2	716	716	E -> K (in a colorectal cancer sample; somatic mutation).
FAM20C	379	379	G -> E (in RNS).
FAM20C	379	379	G -> R (in RNS).
FAM20C	388	388	L -> R (in RNS).
FAM20C	549	549	R -> W (in RNS).
PMS2	479	479	H -> Q.
PMS2	705	705	E -> K (in MMRCS; could be a rare polymorphism).
ABCB5	230	230	E -> V (in a colorectal cancer sample; somatic mutation).
ABCB5	435	435	A -> T (in a pancreatic ductal adenocarcinoma sample; somatic mutation).
DNAH11	34	34	E -> L (requires 2 nucleotide substitutions).
DNAH11	654	654	S -> C.
DNAH11	2682	2682	I -> V.
KLHL7	150	150	S -> N (in RP42).
KLHL7	153	153	A -> T (in RP42).
KLHL7	153	153	A -> V (in RP42).
KLHL7	255	255	D -> N (in a patient with retinitis pigmentosa; uncertain pathological significance).
KLHL7	423	423	H -> Y.
KLHL7	472	472	K -> Q (in a patient with retinitis pigmentosa; uncertain pathological significance).
STK31	684	684	H -> Y (in a lung neuroendocrine carcinoma sample; somatic mutation).
STK31	860	860	V -> L (in a lung small cell carcinoma sample; somatic mutation).
TAX1BP1	457	457	Q -> R (in a breast cancer sample; somatic mutation).
PLEKHA8	368	368	V -> E (in a breast cancer sample; somatic mutation).
GARS	183	183	L -> P (in HMN5).
GARS	294	294	G -> R (in CMT2D).
CCDC129	105	105	L -> V (in a colorectal cancer sample; somatic mutation).
TBX20	152	152	I -> M (in ASD4).
POU6F2	192	192	Q -> H (in WT5).
GLI3	169	169	P -> L (in a colorectal cancer sample; somatic mutation).
GLI3	440	440	D -> E.
GLI3	515	515	C -> G (in GCPS).
GLI3	520	520	C -> Y (in GCPS).
GLI3	625	625	R -> W (in GCPS).
GLI3	707	707	P -> S (in GCPS).
GLI3	727	727	G -> R (in PAPA1 and PAPB).
GLI3	808	808	I -> M (in GCPS).
GLI3	1304	1304	S -> P (in a colorectal cancer sample; somatic mutation).
CAMK2B	489	489	P -> L (in a colorectal adenocarcinoma sample; somatic mutation).
CAMK2B	510	510	E -> K.
NPC1L1	55	55	V -> L (non-response to ezetimibe treatment).
DDC	47	47	P -> H (in AADCD).
DDC	91	91	A -> V (in AADCD).
DDC	102	102	G -> S (in AADCD).
DDC	147	147	S -> R (in AADCD).
DDC	250	250	S -> F (in AADCD).
DDC	275	275	A -> T (in AADCD).
DDC	309	309	F -> L (in AADCD).
DDC	347	347	R -> Q (in AADCD).
DDC	408	408	L -> I (in AADCD).
GRB10	95	95	P -> S (could be a polymorphism, but may be associated with SRS).
EGFR	709	709	E -> A (found in a lung cancer sample).
EGFR	709	709	E -> K (found in a lung cancer sample).
EGFR	719	719	G -> A (found in a lung cancer sample).
EGFR	719	719	G -> D (found in a lung cancer sample).
EGFR	719	719	G -> S (found in a lung cancer sample; somatic mutation; strongly increased kinase activity).
EGFR	724	724	G -> S (found in a lung cancer sample).
EGFR	734	734	E -> K (found in a lung cancer sample).
EGFR	746	750	Missing (found in a lung cancer sample).
EGFR	746	746	Missing (found in a lung cancer sample).
EGFR	747	749	Missing (found in a lung cancer sample).
EGFR	747	747	L -> F (found in a lung cancer sample).
EGFR	748	748	R -> P (found in a lung cancer sample).
EGFR	752	759	Missing (found in a lung cancer sample).
EGFR	787	787	Q -> R (found in a lung cancer sample).
EGFR	790	790	T -> M (found in a lung cancer sample; increased kinase activity).
EGFR	833	833	L -> V (found in a lung cancer sample).
EGFR	834	834	V -> L (found in a lung cancer sample).
EGFR	858	858	L -> M (found in a lung cancer sample).
EGFR	858	858	L -> R (found in a lung cancer sample; somatic mutation; constitutively activated enzyme with strongly increased kinase activity).
EGFR	861	861	L -> Q (found in a lung cancer sample).
EGFR	873	873	G -> E (found in a lung cancer sample).
PSPH	52	52	M -> T (in PSPHD).
SBDS	44	44	E -> G (in SDS).
SBDS	67	67	K -> E (in SDS).
SBDS	87	87	I -> S (in SDS).
SBDS	126	126	R -> T (in SDS; strongly reduced release of EIF6 from pre-60S ribosome subunits).
SBDS	169	169	R -> C (in SDS).
SBDS	212	212	I -> T (in SDS).
PTPN12	61	61	K -> R (in colon cancer).
CD36	123	123	E -> K (in individuals from a malaria endemic area in West Africa).
CD36	127	127	S -> L.
CD36	174	174	T -> A (in individuals from a malaria endemic area in West Africa).
CD36	232	232	G -> GN (in individuals from a malaria endemic area in West Africa).
CD36	254	254	F -> L (in PG4D; type I).
CD36	271	271	I -> T (in individuals from a malaria endemic area in West Africa).
CD36	413	413	I -> L (in PG4D; type I).
SEMA3A	131	131	A -> T (in a breast cancer sample; somatic mutation).
SEMA3A	396	396	P -> S (found in a renal cell carcinoma sample; somatic mutation).
ABCB1	103	103	F -> L (rare polymorphism).
ABCB1	108	108	E -> K.
ABCB1	887	887	K -> N (in a colorectal cancer sample; somatic mutation).
ABCB1	986	986	M -> V.
ABCB1	999	999	A -> T.
AKAP9	1347	1347	K -> KQ.
AKAP9	1582	1582	S -> L (in LQT11).
AKAP9	2421	2421	M -> I (in a colorectal cancer sample; somatic mutation).
AKAP9	3301	3301	E -> Q (in a breast cancer sample; somatic mutation).
PEX1	590	590	L -> R (in PBD-CG1; Zellweger spectrum).
PEX1	593	593	G -> R (in PBD-CG1; Zellweger spectrum).
PEX1	634	690	Missing (in NALD).
PEX1	798	798	R -> G (in PBD-CG1; Zellweger spectrum).
PEX1	843	843	G -> D (in IRD and NALD).
PEX1	948	948	R -> Q.
PEX1	1237	1237	A -> E (in PBD-CG1; Zellweger spectrum).
SGCE	196	196	L -> R (in DYT11).
SLC25A13	601	601	E -> K (in NICCD).
LMTK2	484	484	D -> H (in a lung large cell carcinoma sample; somatic mutation).
EPHB4	346	346	P -> L (in a metastatic melanoma sample; somatic mutation).
EPHB4	889	889	R -> W (in a gastric adenocarcinoma sample; somatic mutation).
SLC26A4	24	24	R -> G (in Pendred syndrome/deafness individuals).
SLC26A4	28	28	S -> R (in PDS and DFNB4).
SLC26A4	29	29	E -> Q (in PDS).
SLC26A4	78	78	Y -> C (in PDS).
SLC26A4	90	90	S -> L (in DFNB4).
SLC26A4	99	99	T -> M.
SLC26A4	102	102	G -> R (in PDS; fails to localize to cell membrane; abolishes iodide transport).
SLC26A4	104	104	A -> V (in Pendred syndrome/deafness individuals).
SLC26A4	105	105	Y -> C (in PDS).
SLC26A4	106	106	A -> D (in PDS).
SLC26A4	117	117	L -> F (in DFNB4 and PDS; does not affect protein localization to cell membrane; does not affect iodide transport).
SLC26A4	123	123	P -> S (in DFNB4).
SLC26A4	132	132	T -> I (in DFNB4).
SLC26A4	133	133	S -> T (in PDS).
SLC26A4	137	137	S -> P (in PDS).
SLC26A4	138	138	V -> F (in PDS; fails to localize to cell membrane; abolishes iodide transport).
SLC26A4	139	139	G -> A (in PDS).
SLC26A4	144	144	V -> A (found at heterozygosity in a patient with non-syndromic deafness; uncertain pathological significance).
SLC26A4	147	147	M -> V (in DFNB4).
SLC26A4	185	185	R -> T (found at heterozygosity in a patient with non-syndromic deafness; uncertain pathological significance).
SLC26A4	193	193	T -> I (in PDS).
SLC26A4	209	209	G -> V (in DFNB4 and PDS; severely reduces iodide transport without affecting protein localization to cell membrane).
SLC26A4	236	236	L -> P (in PDS and DFNB4; common mutation; fails to localize to cell membrane; abolishes iodide transport).
SLC26A4	239	239	V -> D (in PDS and DFNB4).
SLC26A4	252	252	S -> P (in DFNB4).
SLC26A4	271	271	D -> H (in PDS).
SLC26A4	281	281	V -> I (in DFNB4).
SLC26A4	335	335	F -> L (in PDS and DFNB4).
SLC26A4	369	369	K -> E (in DFNB4).
SLC26A4	372	372	A -> V (in DFNB4).
SLC26A4	384	384	E -> G (in PDS and PDS/DFNB4).
SLC26A4	391	391	S -> N (in PDS).
SLC26A4	392	392	N -> Y (in DFNB4).
SLC26A4	402	402	V -> M (in PDS and DFNB4).
SLC26A4	409	409	R -> H (in PDS).
SLC26A4	409	409	R -> P (in DFNB4).
SLC26A4	410	410	T -> M (in DFNB4 and PDS; fails to localize to cell membrane; abolishes iodide transport).
SLC26A4	411	411	A -> P (in PDS).
SLC26A4	421	421	Q -> R (in Pendred syndrome/deafness individuals).
SLC26A4	429	429	Missing (in Pendred syndrome/deafness individuals).
SLC26A4	445	445	L -> W (in PDS and DFNB4).
SLC26A4	446	446	Q -> R (in DFNB4 and PDS; fails to localize to cell membrane; abolishes iodide transport).
SLC26A4	455	455	I -> F (in DFNB4).
SLC26A4	457	457	N -> K (in DFNB4).
SLC26A4	480	480	V -> D (in PDS; retains residual transport function).
SLC26A4	490	490	I -> L (in DFNB4).
SLC26A4	497	497	G -> S (in DFNB4).
SLC26A4	508	508	T -> N (in PDS).
SLC26A4	514	514	Q -> R (in PDS).
SLC26A4	530	530	Y -> H (in PDS).
SLC26A4	530	530	Y -> S (in PDS and DFNB4).
SLC26A4	552	552	S -> I (in PDS).
SLC26A4	556	556	Y -> C (in PDS; partially affects protein localization to cell membrane; abolishes iodide transport).
SLC26A4	556	556	Y -> H (in PDS).
SLC26A4	558	558	N -> K (in DFNB4).
SLC26A4	565	565	C -> Y (in PDS).
SLC26A4	653	653	V -> A (in PDS; retains residual transport function).
SLC26A4	666	666	S -> F (in DFNB4).
SLC26A4	667	667	F -> C (in PDS).
SLC26A4	672	672	G -> E (in PDS; partially affects protein localization to cell membrane; abolishes iodide transport).
SLC26A4	676	676	L -> Q (in DFNB4).
SLC26A4	683	683	F -> S (in Pendred syndrome/deafness individuals).
SLC26A4	694	694	S -> P (in PDS).
SLC26A4	721	721	T -> M (in DFNB4 and PDS).
SLC26A4	723	723	H -> R (in DFNB4 and PDS; common mutation in Korea and Japan).
SLC26A4	724	724	D -> N (in PDS).
SLC26A4	775	775	M -> T (in PDS and DFNB4).
SLC26A4	776	776	R -> C (retains its ability to transport iodide in vitro).
DOCK4	87	87	T -> I (in a CNS cancer cell line).
DOCK4	606	606	E -> Q.
DOCK4	1059	1059	K -> T (in a CNS cancer cell line).
DOCK4	1718	1718	P -> L (in prostate and ovarian cancer cell lines; abolishes ability to interact with CRK and to activate Rap1).
DOCK4	1733	1733	P -> A.
DOCK4	1755	1755	S -> P (in colorectal cancer cell line).
DOCK4	1884	1884	V -> M (in a prostate cancer cell line).
DOCK4	1917	1917	P -> L.
ZNF277	332	332	I -> L (in a breast cancer sample; somatic mutation).
ZNF277	445	445	L -> F (in a breast cancer sample; somatic mutation).
IFRD1	39	39	Q -> K (found in a renal cell carcinoma sample; somatic mutation).
TFEC	146	146	L -> V (in a colorectal cancer sample; somatic mutation).
CAV1	132	132	P -> L (in breast cancer; seems to form misfolded oligomers that are retained within the Golgi complex and are not targeted to caveolae or the plasma membrane).
ST7	186	186	A -> T.
ST7	361	361	I -> V.
CFTR	13	13	S -> F (in CF).
CFTR	31	31	R -> L (in CF).
CFTR	42	42	S -> F (in CF).
CFTR	44	44	D -> G (in CF).
CFTR	50	50	S -> Y (in CBAVD).
CFTR	57	57	W -> G (in CF).
CFTR	67	67	P -> L (in CF).
CFTR	74	74	R -> W (in CF).
CFTR	85	85	G -> E (in CF).
CFTR	87	87	F -> L (in CF).
CFTR	91	91	G -> R (in CF).
CFTR	92	92	E -> K (in CF).
CFTR	98	98	Q -> R (in CF).
CFTR	105	105	I -> S (in CF).
CFTR	109	109	Y -> C (in CF).
CFTR	110	110	D -> H (in CF).
CFTR	111	111	P -> L (in CBAVD).
CFTR	117	117	R -> C (in CF).
CFTR	117	117	R -> H (in CF and CBAVD).
CFTR	117	117	R -> L (in CF).
CFTR	117	117	R -> P (in CF).
CFTR	120	120	A -> T (in CF).
CFTR	139	139	H -> R (in CF).
CFTR	141	141	A -> D (in CF).
CFTR	149	149	G -> R (in CBAVD).
CFTR	178	178	G -> R (in CF).
CFTR	192	192	Missing (in CF).
CFTR	193	193	E -> K (in CBAVD and CF).
CFTR	199	199	H -> Q (in CF).
CFTR	199	199	H -> Y (in CF).
CFTR	205	205	P -> S (in CF).
CFTR	206	206	L -> W (in CF).
CFTR	225	225	C -> R (in CF).
CFTR	244	244	M -> K (in CBAVD).
CFTR	258	258	R -> G (in CBAVD).
CFTR	287	287	N -> Y (in CF).
CFTR	297	297	R -> Q (in CF).
CFTR	301	301	Y -> C (in CF).
CFTR	307	307	S -> N (in CF).
CFTR	311	311	F -> L (in CF).
CFTR	311	311	Missing (in CF).
CFTR	314	314	G -> E (in CF).
CFTR	314	314	G -> R (in CF).
CFTR	334	334	R -> W (in CF; mild).
CFTR	336	336	I -> K (in CF).
CFTR	338	338	T -> I (in CF; mild; isolated hypotonic dehydration).
CFTR	346	346	L -> P (in CF; dominant mutation but mild phenotype).
CFTR	347	347	R -> H (in CF).
CFTR	347	347	R -> L (in CF).
CFTR	347	347	R -> P (in CF; MILD).
CFTR	352	352	R -> Q (in CF).
CFTR	359	360	QT -> KK (in CF).
CFTR	359	359	Q -> K (in CF).
CFTR	370	370	K -> KNK (in CF).
CFTR	455	455	A -> E (in CF).
CFTR	456	456	V -> F (in CF).
CFTR	458	458	G -> V (in CF).
CFTR	480	480	G -> C (in CF).
CFTR	492	492	S -> F (in CF).
CFTR	504	504	E -> Q (in CF).
CFTR	506	506	I -> V.
CFTR	507	507	Missing (in CF).
CFTR	508	508	Missing (in CF and CBAVD; most common mutation; 72% of the population; CFTR fails to be properly delivered to plasma membrane).
CFTR	513	513	D -> G (in CBAVD).
CFTR	520	520	V -> F (in CF).
CFTR	544	544	G -> V (in CBAVD).
CFTR	549	549	S -> I (in CF).
CFTR	549	549	S -> N (in CF).
CFTR	549	549	S -> R (in CF).
CFTR	551	551	G -> D (in CF).
CFTR	551	551	G -> S (in CF).
CFTR	553	553	R -> Q (in CF).
CFTR	558	558	L -> S (in CF).
CFTR	559	559	A -> T (in CF).
CFTR	560	560	R -> K (in CF).
CFTR	560	560	R -> S (in CF).
CFTR	560	560	R -> T (in CF).
CFTR	562	562	V -> L (in CF).
CFTR	563	563	Y -> N (in CF).
CFTR	569	569	Y -> C (in CF).
CFTR	569	569	Y -> D (in CF).
CFTR	569	569	Y -> H (in CF).
CFTR	571	571	L -> S (in CF).
CFTR	572	572	D -> N (in CF).
CFTR	574	574	P -> H (in CF).
CFTR	579	579	D -> G (in CF).
CFTR	601	601	I -> F (in CF).
CFTR	610	610	L -> S (in CF).
CFTR	613	613	A -> T (in CF).
CFTR	614	614	D -> G (in CF).
CFTR	618	618	I -> T (in CF).
CFTR	619	619	L -> S (in CF).
CFTR	620	620	H -> P (in CF).
CFTR	620	620	H -> Q (in CF).
CFTR	622	622	G -> D (in oligospermia).
CFTR	628	628	G -> R (in CF).
CFTR	633	633	L -> P (in CF).
CFTR	648	648	D -> V (in CF).
CFTR	651	651	D -> N (in CF).
CFTR	665	665	T -> S (in CF).
CFTR	754	754	V -> M (in CF).
CFTR	766	766	R -> M (in CBAVD).
CFTR	792	792	R -> G (in CBAVD).
CFTR	800	800	A -> G (in CBAVD).
CFTR	822	822	E -> K (in CF).
CFTR	826	826	E -> K (in thoracic sarcoidosis).
CFTR	866	866	C -> Y (in CF).
CFTR	912	912	S -> L.
CFTR	913	913	Y -> C (in CF).
CFTR	917	917	Y -> C (in CF).
CFTR	949	949	H -> Y (in CF).
CFTR	952	952	M -> I (in CF).
CFTR	1005	1005	I -> R (in CF).
CFTR	1006	1006	A -> E (in CF).
CFTR	1013	1013	P -> L (in CF).
CFTR	1028	1028	M -> I (in CF).
CFTR	1052	1052	F -> V (in CF).
CFTR	1061	1061	G -> R (in CF).
CFTR	1065	1065	L -> P (in CF).
CFTR	1065	1065	L -> R (in CF).
CFTR	1066	1066	R -> C (in CF).
CFTR	1066	1066	R -> H (in CF).
CFTR	1066	1066	R -> L (in CF).
CFTR	1067	1067	A -> T (in CF).
CFTR	1070	1070	R -> P (in CF).
CFTR	1070	1070	R -> Q (in CF).
CFTR	1070	1070	R -> W (in CBAVD).
CFTR	1071	1071	Q -> P (in CF).
CFTR	1072	1072	P -> L (in CF).
CFTR	1077	1077	L -> P (in CF).
CFTR	1085	1085	H -> R (in CF).
CFTR	1098	1098	W -> R (in CF).
CFTR	1101	1101	M -> R (in CF).
CFTR	1137	1137	M -> V (in CF).
CFTR	1140	1140	Missing (in CF).
CFTR	1152	1152	D -> H (in CF).
CFTR	1234	1234	I -> V (in CF).
CFTR	1235	1235	S -> R (in CF).
CFTR	1244	1244	G -> E (in CF).
CFTR	1249	1249	G -> E (in CF).
CFTR	1251	1251	S -> N (in CF).
CFTR	1255	1255	S -> P (in CF).
CFTR	1282	1282	W -> R (in CF).
CFTR	1283	1283	R -> M (in CF).
CFTR	1286	1286	F -> S (in CF).
CFTR	1291	1291	Q -> H (in CF).
CFTR	1291	1291	Q -> R (in CF).
CFTR	1303	1303	N -> H (in CF).
CFTR	1303	1303	N -> K (in CF).
CFTR	1349	1349	G -> D (in CF).
CFTR	1364	1364	A -> V (in CBAVD).
CFTR	1397	1397	V -> E (in CF).
TSPAN12	101	101	L -> H (in EVR5).
TSPAN12	188	188	G -> R (in EVR5).
TSPAN12	210	210	M -> R (in EVR5).
TSPAN12	237	237	A -> P (in EVR5).
WNT16	126	126	V -> M (in a colorectal cancer sample; somatic mutation).
SPAM1	5	5	K -> Q (found in a renal cell carcinoma sample; somatic mutation).
SMO	535	535	W -> L (in basal cell carcinoma samples; somatic mutation).
SMO	562	562	R -> Q (in basal cell carcinoma samples; somatic mutation).
PODXL	60	60	T -> R.
BPGM	62	62	R -> Q (in BPGMD).
BPGM	90	90	R -> C (in BPGMD; mutation identified at protein level; marked decrease in synthase and mutase activities; no effect on phosphatase activity).
CREB3L2	100	100	Missing.
AKR1D1	106	106	L -> F (in CBAS2).
AKR1D1	133	133	P -> R (in CBAS2).
AKR1D1	198	198	P -> L (in CBAS2).
AKR1D1	261	261	R -> C (in CBAS2).
TRIM24	320	320	I -> T (in an ovarian serous carcinoma sample; somatic mutation).
TRIM24	403	403	T -> N (in a lung squamous cell carcinoma sample; somatic mutation).
TRIM24	762	762	S -> N.
TBXAS1	82	82	L -> P (in GHDD).
TBXAS1	85	85	R -> W (in a breast cancer sample; somatic mutation).
TBXAS1	124	124	V -> I.
TBXAS1	245	245	N -> S (in allele CYP5A1*4).
TBXAS1	412	412	R -> Q (in GHDD).
TBXAS1	449	449	E -> K (in allele CYP5A1*7).
TBXAS1	465	465	R -> Q (in allele CYP5A1*9).
TBXAS1	481	481	G -> W (in GHDD).
TBXAS1	487	487	L -> P (in GHDD).
TBXAS1	501	501	R -> Q.
ADCK2	418	418	V -> L.
WEE2	332	332	N -> K (in a gastric adenocarcinoma sample; somatic mutation).
WEE2	398	398	R -> H (in an ovarian mucinous carcinoma sample; somatic mutation).
ABCB8	152	152	V -> I.
ABCB8	165	165	I -> T (in a breast cancer sample; somatic mutation).
ABCB8	690	690	A -> G (in a breast cancer sample; somatic mutation).
PRKAG2	302	302	R -> Q (in WPWS and CMH-WPWS).
PRKAG2	350	350	R -> RL (in CMH-WPWS; severe).
PRKAG2	383	383	H -> R (in CMH-WPWS; severe).
PRKAG2	488	488	N -> I (in CMH-WPWS; severe).
PRKAG2	531	531	R -> G (in WPWS; absence of cardiac hypertrophy; onset in childhood).
PRKAG2	531	531	R -> Q (in GSDH; reduction of binding affinities for AMP and ATP; loss of cooperative binding; enhanced basal activity; increased phosphorylation of the alpha-subunit).
SNX8	147	147	A -> G (in a colorectal cancer sample; somatic mutation).
LFNG	38	38	G -> R.
LFNG	188	188	F -> L (in SCDO3; not localized to the correct compartment of the cell; unable to modulate Notch signaling in a cell- based assay; enzymatically inactive).
LFNG	346	346	V -> M.
ACTB	183	183	R -> W (in DYTJ; modifies cell response to latrunculin A).
AIMP2	92	92	I -> V (in a lung cancer cell line; reduced interaction with TP53, loss of TP53 activation and loss of proapoptotic activity).
AIMP2	97	99	EPT -> DLS (in a lung cancer cell line; no effect on proapoptotic activity).
AIMP2	209	209	G -> S (in a lung cancer cell line; no effect on proapoptotic activity).
EIF2AK1	202	202	G -> S (in a lung adenocarcinoma sample; somatic mutation).
ZDHHC4	104	104	P -> S (in a breast cancer sample; somatic mutation).
MEOX2	79	80	Missing.
MEOX2	80	80	Missing.
AHR	517	517	P -> S.
AHR	786	786	M -> V.
TWIST1	119	119	Q -> P (in SCS).
TWIST1	131	131	L -> P (in SCS).
TWIST1	135	135	I -> IAALRKII (in SCS).
TWIST1	139	139	P -> PKIIPTLP (in SCS).
TWIST1	156	156	I -> V (in SCS; variant form with features overlapping Baller-Gerold syndrome).
TWIST1	186	186	A -> T (in CRS1).
TWIST1	188	188	S -> L (in CRS1).
FERD3L	36	36	G -> R (in a colorectal cancer sample; somatic mutation).
FAM126A	53	53	L -> P (in HLD5).
GPNMB	110	110	A -> D (in a breast cancer sample; somatic mutation).
GPNMB	531	531	S -> I (in a breast cancer sample; somatic mutation).
CYCS	42	42	G -> S (in THC4; increases the pro- apoptotic function by triggering caspase activation more efficiently than wild- type; does not affect the redox function).
CYCS	66	66	M -> L (in 10% of the molecules).
HOXA2	186	186	Q -> K (in MHICP).
HOXA3	42	42	D -> N (in a breast cancer sample; somatic mutation).
HOXA3	131	131	A -> T (in a breast cancer sample; somatic mutation).
HOXA4	37	37	G -> D (in a breast cancer sample; somatic mutation).
HOXA13	125	125	A -> AAAAAAA (in HFGS).
HOXA13	129	129	A -> AAAAAAAAA (in HFGS).
HOXA13	371	371	Q -> L (in GUTTS).
HOXA13	372	372	N -> H (in HFGS; severe).
GHRHR	45	45	A -> T (in a colorectal cancer sample; somatic mutation).
GHRHR	144	144	L -> H (in IGHD1B).
GHRHR	176	176	A -> V (in IGHD1B; reduced cAMP response to GHRH).
GHRHR	222	222	A -> E (in IGHD1B).
GHRHR	242	242	F -> C (in IGHD1B).
GHRHR	329	329	K -> E (in IGHD1B).
NT5C3	137	137	D -> V (in P5N deficiency; may alter protein structure).
NT5C3	181	181	L -> P (in P5N deficiency; may alter protein structure and markedly decreases activity).
NT5C3	229	229	N -> S (in P5N deficiency; markedly decreases activity).
NT5C3	280	280	G -> R (in P5N deficiency; markedly decreases activity).
RP9	137	137	H -> L (in RP9).
RP9	170	170	D -> G (in RP9).
RP9	210	210	K -> R.
NME8	289	289	I -> T (in a breast cancer sample; somatic mutation).
MPLKIP	29	29	G -> E (in a breast cancer sample; somatic mutation).
MPLKIP	144	144	M -> V (in TTDN1).
PSMA2	110	110	L -> V (in a colorectal cancer sample; somatic mutation).
PGAM2	89	89	E -> A (in GSD10).
PGAM2	90	90	R -> W (in GSD10).
PGAM2	97	97	G -> D (in GSD10).
GCK	4	4	D -> N.
GCK	11	11	A -> T.
GCK	36	36	R -> W (in MODY2).
GCK	53	53	A -> S (in MODY2).
GCK	70	70	E -> K (in MODY2; large increase in Km for glucose).
GCK	80	80	G -> A (in MODY2).
GCK	80	80	G -> S (in MODY2).
GCK	107	107	M -> T.
GCK	108	108	Y -> H (in MODY2).
GCK	110	110	I -> T (in MODY2).
GCK	119	119	A -> D (in MODY2).
GCK	131	131	S -> P (in MODY2; significant increase in the Km and in the affinity for ATP).
GCK	137	137	H -> R (in MODY2).
GCK	150	150	F -> S (in MODY2).
GCK	164	164	L -> P (in MODY2).
GCK	168	168	T -> P (in MODY2).
GCK	175	175	G -> R (in MODY2).
GCK	182	182	V -> M (in MODY2).
GCK	188	188	A -> T (in MODY2; large increase in Km for glucose).
GCK	203	203	V -> A (in MODY2).
GCK	209	209	T -> M (in MODY2).
GCK	210	210	M -> K (in MODY2).
GCK	210	210	M -> T (in MODY2).
GCK	213	213	C -> R (in MODY2).
GCK	221	221	E -> K (in MODY2).
GCK	226	226	V -> M (in MODY2).
GCK	227	227	G -> C (in MODY2).
GCK	228	228	T -> M (in MODY2).
GCK	256	256	E -> K (in MODY2).
GCK	257	257	W -> R (in MODY2; almost complete loss of activity).
GCK	259	259	A -> T (in MODY2).
GCK	261	261	G -> E (in MODY2).
GCK	261	261	G -> R (in MODY2).
GCK	279	279	E -> Q (in MODY2).
GCK	299	299	G -> R (in MODY2).
GCK	300	300	E -> K (in MODY2).
GCK	300	300	E -> Q (in MODY2).
GCK	309	309	L -> P (in MODY2).
GCK	336	336	S -> L (in MODY2).
GCK	367	367	V -> M (in MODY2).
GCK	382	382	C -> Y (in MODY2).
GCK	384	384	A -> T (in MODY2).
GCK	385	385	G -> V (in MODY2).
GCK	392	392	R -> C (in MODY2).
GCK	414	414	K -> E (in MODY2; large increase in Km for glucose).
GCK	455	455	V -> M (in HHF3).
MYO1G	49	49	V -> M (in allele HA-2M; the HA-2V allele constitute the HA-2 epitope while HA-2M is not recognized by HA-2 cytotoxic T lymphocytes).
IGFBP3	7	7	T -> M (in a colorectal cancer sample; somatic mutation).
IGFBP3	252	252	R -> C (in a colorectal cancer sample; somatic mutation).
PHKG1	48	48	V -> M (in a colorectal adenocarcinoma sample; somatic mutation).
PHKG1	323	323	R -> C.
ERV3-1	236	236	Y -> C.
ERV3-1	522	522	L -> P.
GUSB	30	30	P -> S (in MPS7).
GUSB	38	38	C -> G (in MPS7; very mild phenotype).
GUSB	52	52	S -> F (in MPS7; loss of activity).
GUSB	136	136	G -> R (in MPS7).
GUSB	148	148	P -> S (in MPS7).
GUSB	150	150	E -> K (in MPS7).
GUSB	152	152	D -> G (in MPS7).
GUSB	152	152	D -> N (reduced activity levels without apparent pathogenic consequences).
GUSB	176	176	L -> F (in MPS7).
GUSB	216	216	R -> W (in MPS7).
GUSB	243	243	L -> P (in MPS7).
GUSB	320	320	Y -> C (in MPS7).
GUSB	320	320	Y -> S (in MPS7).
GUSB	339	339	N -> S (in MPS7).
GUSB	350	350	K -> N (in MPS7).
GUSB	351	351	H -> Y (in MPS7).
GUSB	354	354	A -> V (in MPS7).
GUSB	361	369	Missing (in MPS7).
GUSB	362	362	D -> N (in MPS7).
GUSB	364	364	P -> L (in MPS7).
GUSB	374	374	R -> C (in MPS7).
GUSB	382	382	R -> C (in MPS7).
GUSB	382	382	R -> H (in MPS7).
GUSB	408	408	P -> S (in MPS7).
GUSB	415	415	P -> L (in MPS7).
GUSB	435	435	R -> P (in MPS7).
GUSB	477	477	R -> W (in MPS7).
GUSB	495	495	Y -> C (in MPS7).
GUSB	508	508	Y -> C (in MPS7).
GUSB	540	540	E -> K (in MPS7).
GUSB	572	572	G -> D (in MPS7).
GUSB	577	577	R -> L (in MPS7; loss of activity).
GUSB	606	606	K -> N (in MPS7).
GUSB	607	607	G -> A (in MPS7).
GUSB	611	611	R -> W (in MPS7).
GUSB	619	619	A -> V (in MPS7).
GUSB	626	626	Y -> H (in MPS7; very mild phenotype).
GUSB	627	627	W -> C (in MPS7).
ASL	31	31	D -> N (in ARGINSA).
ASL	111	111	R -> W (in ARGINSA).
ASL	113	113	R -> Q (in ARGINSA).
ASL	181	181	T -> S (in a breast cancer sample; somatic mutation).
ASL	186	186	R -> Q (in ARGINSA).
ASL	193	193	R -> Q (in ARGINSA).
ASL	200	200	G -> V (in a breast cancer sample; somatic mutation).
ASL	236	236	R -> W (in ARGINSA).
ASL	335	335	V -> L (in ARGINSA).
ASL	382	382	M -> R (in ARGINSA).
ASL	456	456	R -> W (in ARGINSA).
NCF1	42	42	R -> Q (in CGD1).
NCF1	160	160	T -> S.
NCF1	258	258	K -> E.
NCF1	262	262	G -> S.
POR	178	178	Y -> D (in AHV; complete loss of activity).
POR	225	225	P -> L.
POR	252	252	D -> N.
POR	284	284	A -> P (in AHV; significant reduction of activity).
POR	454	454	R -> H (in AHV; significant reduction of activity).
POR	489	489	V -> E (in AHV; significant reduction of activity).
POR	551	551	R -> Q.
POR	566	566	C -> Y (in IDS and AHV; significant reduction of activity).
POR	575	575	Y -> C (in AHV; with abnormal genitalia).
POR	605	605	V -> F (in IDS; significant reduction of activity).
POR	609	617	LKQDREHLW -> R (in AHV).
HSPB1	127	127	R -> W (in HMN2B).
HSPB1	135	135	S -> F (in CMT2F and HMN2B).
HSPB1	136	136	R -> W (in CMT2F).
HSPB1	151	151	T -> I (in HMN2B).
HSPB1	182	182	P -> L (in HMN2B).
KRIT1	97	97	F -> S (in CCM1).
KRIT1	569	569	K -> E (in CCM1).
ERVW-1	129	129	V -> A.
ERVW-1	477	477	S -> F.
SAMD9	1495	1495	K -> E (in NFTC; loss of punctate cytoplasmic expression).
HEPACAM2	31	31	G -> R (in a breast cancer sample; somatic mutation).
HEPACAM2	114	114	F -> L (found in a renal cell carcinoma sample; somatic mutation).
COL1A2	76	93	Missing (in EDS7B).
COL1A2	181	198	Missing (in OI4).
COL1A2	193	193	G -> S (in OI4).
COL1A2	202	202	G -> R (in OI4).
COL1A2	211	211	G -> D (in OI1).
COL1A2	234	234	R -> C (in OI2A).
COL1A2	247	247	G -> R (in OI1).
COL1A2	253	253	G -> D (in OI2A).
COL1A2	256	256	G -> V (in OI4).
COL1A2	283	283	G -> R (in OI2A).
COL1A2	319	319	G -> R (in OI1).
COL1A2	325	325	G -> E (in OI4).
COL1A2	328	328	G -> S (in OI1, OI3 AND OI4).
COL1A2	331	331	G -> D (in OI3).
COL1A2	334	334	G -> C (in OI2A).
COL1A2	337	337	G -> C (in OI3).
COL1A2	337	337	G -> S (in OI3).
COL1A2	345	345	Missing (in OI3).
COL1A2	349	349	G -> C (in OI3).
COL1A2	358	358	G -> S (in OI3).
COL1A2	397	397	G -> E (in OI2A).
COL1A2	409	409	G -> V (in OI2A).
COL1A2	433	433	G -> E (in OI2A).
COL1A2	454	454	G -> C (in OI2A).
COL1A2	457	457	G -> L (in OI2A; requires 2 nucleotide substitutions).
COL1A2	460	460	G -> S (in OI3).
COL1A2	461	466	Missing (in OI2A).
COL1A2	511	511	G -> D (in OI2A).
COL1A2	517	517	G -> R (in OI3).
COL1A2	526	526	G -> E (in OI2A).
COL1A2	547	547	G -> R (in OI2A).
COL1A2	562	562	G -> C (in OI2A).
COL1A2	562	562	G -> V (in OI2A).
COL1A2	586	586	G -> R (in OI2A).
COL1A2	592	592	G -> S (in OI2A).
COL1A2	601	601	G -> S (in OI).
COL1A2	625	625	G -> D (in OI2A).
COL1A2	634	634	G -> V (in OI4).
COL1A2	637	637	G -> D (in OI2A).
COL1A2	640	640	G -> S (in OI2A).
COL1A2	670	670	G -> D (in OI2A).
COL1A2	676	855	Missing (in OI2A).
COL1A2	676	676	G -> D (in OI3).
COL1A2	676	676	G -> V (in OI3 and OI4).
COL1A2	705	707	Missing (in OI2A).
COL1A2	708	708	R -> Q (in Marfan syndrome).
COL1A2	715	715	G -> D (in OI2A).
COL1A2	730	730	G -> C (in OI2A).
COL1A2	733	733	G -> C (in OI1).
COL1A2	736	736	G -> C (in OI1; mild).
COL1A2	739	739	G -> R (in OI2A).
COL1A2	748	748	G -> V (in OI2A).
COL1A2	751	751	G -> S (in OI4).
COL1A2	754	754	G -> C (in OI4).
COL1A2	754	754	G -> R (in OI2A).
COL1A2	766	766	G -> V (in OI4).
COL1A2	778	778	G -> S (in OI3).
COL1A2	784	784	G -> R (in OI2A).
COL1A2	787	787	G -> C (in OI2A).
COL1A2	790	790	G -> D (in OI2A).
COL1A2	796	796	G -> S (in OI2A).
COL1A2	798	798	P -> PP (in OI2A).
COL1A2	806	811	Missing (in OI2A).
COL1A2	811	811	G -> GPPG (in OI4).
COL1A2	820	820	G -> S (in OI3).
COL1A2	835	835	G -> C (in OI3).
COL1A2	835	835	G -> S (in OI1).
COL1A2	856	856	G -> R (in OI3).
COL1A2	856	856	G -> V (in OI2A).
COL1A2	877	877	G -> C (in OI2A).
COL1A2	892	892	G -> D (in OI3 and OI4).
COL1A2	895	895	G -> D (in OI2A).
COL1A2	949	949	G -> S (in OI3; moderate).
COL1A2	955	955	G -> D (in OI2A).
COL1A2	955	955	G -> S (in OI2A).
COL1A2	973	973	G -> V (in OI3).
COL1A2	982	982	G -> D (in OI2A).
COL1A2	989	989	P -> PVGP (in OI4).
COL1A2	991	991	G -> V (in OI3).
COL1A2	997	997	G -> D (in OI2A).
COL1A2	1003	1003	G -> D (in OI2A).
COL1A2	1012	1012	G -> S (in OI3 and OI4; moderate).
COL1A2	1027	1027	G -> E (in OI2A).
COL1A2	1058	1062	Missing (in OI2A).
COL1A2	1066	1066	G -> D (in OI2A).
COL1A2	1078	1078	G -> C (in OI2A).
COL1A2	1087	1087	G -> D (in OI3).
COL1A2	1094	1096	Missing (in OI4).
COL1A2	1096	1096	G -> A (in OI3).
COL1A2	1101	1101	P -> L.
COL1A2	1102	1102	G -> R (in OI4).
COL1A2	1195	1195	C -> Y (in OI1).
PON1	102	102	I -> V (polymorphism associated with decreased activity that seems to be associated with an increased risk for prostate cancer).
CYP3A4	130	130	R -> Q (in allele CYP3A4*8).
CYP3A4	170	170	V -> I (in allele CYP3A4*9).
CYP3A4	174	174	D -> H (in allele CYP3A4*10).
CYP3A4	363	363	T -> M (in allele CYP3A4*11; unstable form).
CYP3A43	25	88	YGTHSHKLFKKLGIPGPTPLPFLGTILFYLRGLWNFDRECN EKYGEMWGLYEGQQPMLVIMDPD -> LGPIHINFLRSWEF LGQPLCLFWELFCSTLGVFGILTENVMKNTEKCGGCMRGNS PCWSSWIPT (in allele CYP3A43*2).
CYP3A43	89	503	Missing (in allele CYP3A43*2).
GPC2	200	200	D -> N (in a breast cancer sample; somatic mutation).
TSC22D4	329	329	V -> M (in a breast cancer sample; somatic mutation).
TFR2	22	22	V -> I (in HFE3).
TFR2	172	172	M -> K (in HFE3).
TFR2	690	690	Q -> P (in HFE3).
EPO	131	132	SL -> NF (in an hepatocellular carcinoma).
EPO	149	149	P -> Q (in an hepatocellular carcinoma).
PLOD3	223	223	N -> S (in LH3 deficiency).
ZNHIT1	134	134	R -> W (in a colorectal cancer sample; somatic mutation).
SLC26A3	120	120	G -> S (in DIAR1).
SLC26A3	124	124	H -> L (in DIAR1).
SLC26A3	131	131	P -> R (in DIAR1).
SLC26A3	206	206	S -> P (in DIAR1).
SLC26A3	317	317	Missing (in DIAR1).
SLC26A3	468	468	D -> V (in DIAR1).
SLC26A3	527	527	Missing (in DIAR1).
DLD	72	72	K -> E (in DLD deficiency).
DLD	229	229	G -> C (in DLD deficiency; carrier rate among Askenazi Jewish 1:94).
DLD	488	488	P -> L (in DLD deficiency).
DLD	495	495	R -> G (in DLD deficiency; loss of enzyme activity).
PPP1R3A	554	554	G -> A (in a breast cancer sample; somatic mutation).
WNT2	5	5	L -> R.
WNT2	299	299	R -> W.
ING3	20	20	D -> G (in HNSCC).
IQUB	735	735	R -> H (in a colorectal cancer sample; somatic mutation).
PAX4	39	39	R -> Q.
PAX4	45	45	R -> W (associated with PKD susceptbility).
PAX4	129	129	R -> W (in diabetes mellitus type 2).
PAX4	141	141	R -> W (confers susceptibility to ketosis-prone diabetes mellitus).
PAX4	172	172	R -> W (in MODY9; the mutant sequence represses the activity of the insulin and glucagon promoters by only 35% compared to 50% and 57% respectively with wild- type sequence).
PAX4	191	191	R -> C.
PAX4	200	200	R -> H.
PAX4	200	200	R -> S.
LRRC4	579	579	T -> A (in a colorectal cancer sample; somatic mutation).
LEP	49	49	Missing (in 30% the clones).
LEP	105	105	R -> W (in morbid obesity and hypogonadism).
RBM28	351	351	L -> P (in ANES).
IMPDH1	105	105	R -> W (in LCA11; does not alter the enzymatic affinity of the corresponding enzyme; alters the affinity and/or the specificity of single-stranded nucleic acid).
IMPDH1	116	116	T -> M (in RP10; does not alter the enzymatic affinity of the corresponding enzyme; alters the affinity and/or the specificity of single-stranded nucleic acid).
IMPDH1	198	198	N -> K (in LCA11; does not alter the enzymatic affinity of the corresponding enzyme; alters the affinity and/or the specificity of single-stranded nucleic acid).
IMPDH1	224	224	R -> P (in RP10).
IMPDH1	226	226	D -> N (in RP10).
IMPDH1	268	268	V -> I (in RP10).
IMPDH1	285	285	A -> T.
IMPDH1	324	324	G -> D (does not alter the enzymatic affinity of the corresponding enzyme; does not affect the affinity for single- stranded nucleic acid).
IMPDH1	372	372	H -> P (in RP10; alters the affinity and/ or the specificity of single-stranded nucleic acid).
OPN1SW	79	79	G -> R (in CBT).
OPN1SW	214	214	S -> P (in CBT).
OPN1SW	264	264	P -> S (in CBT).
CPA5	338	338	E -> D.
C7orf49	82	82	P -> L (in a colorectal cancer sample; somatic mutation).
TMEM140	112	112	A -> E (in a colorectal cancer sample; somatic mutation).
PRSS1	16	16	A -> V (in PCTT; disrupts signal sequence cleavage site).
PRSS1	22	22	D -> G (in PCTT; increased rate of activation).
PRSS1	23	23	K -> R (in PCTT; increased rate of activation).
PRSS1	29	29	N -> I (in PCTT).
PRSS1	29	29	N -> T (in PCTT).
PRSS1	54	54	N -> S (in PCTT; associated with Ile-29; the double mutant shows increased autocatalytic activation which is solely due to the Ile-29 mutation).
PRSS1	104	104	L -> P (in PCTT).
PRSS1	116	116	R -> C (in PCTT).
PRSS1	122	122	R -> C (in PCTT; suppresses an autocleavage site).
PRSS1	122	122	R -> H (in PCTT; suppresses an autocleavage site which is probably part of a fail-safe mechanism by which trypsin, which is activated within the pancreas, may be inactivated; loss of this cleavage site would permit autodigestion resulting in pancreatitis).
PRSS1	137	137	T -> M (in a colorectal cancer sample; somatic mutation).
PRSS1	139	139	C -> F (in PCTT).
EPHB6	170	170	S -> T.
EPHB6	221	221	A -> V.
EPHB6	282	282	P -> H.
EPHB6	309	309	R -> Q.
EPHB6	332	332	S -> L.
EPHB6	360	360	D -> N (in a colorectal cancer sample; somatic mutation).
EPHB6	603	603	A -> P (in a colorectal cancer sample; somatic mutation).
EPHB6	662	662	A -> V.
EPHB6	719	719	R -> Q (in a colorectal cancer sample; somatic mutation).
EPHB6	743	743	P -> S (in an ovarian mucinous carcinoma sample; somatic mutation).
EPHB6	813	813	R -> H.
EPHB6	875	875	E -> K (in a glioblastoma multiforme sample; somatic mutation).
EPHB6	930	930	D -> G (in a colorectal cancer sample; somatic mutation).
EPHB6	993	993	I -> V.
KEL	180	180	R -> P (in KEL24 antigen).
KEL	248	248	R -> Q (in KEL25 antigen).
KEL	249	249	E -> K (in KEL27 antigen).
KEL	281	281	R -> Q (in KEL21/Kp(c) antigen).
KEL	302	302	V -> A (in KEL17 antigen).
KEL	322	322	A -> V (in KEL22 antigen).
KEL	382	382	Q -> R (in KEL23 antigen).
KEL	406	406	R -> Q (in KEL26 antigen).
KEL	492	492	R -> Q (in KEL19 antigen).
KEL	494	494	E -> V (in KEL10/Ul(a) antigen).
KEL	548	548	H -> R (in KEL12 antigen).
CLCN1	105	105	R -> C (in MCR).
CLCN1	136	136	D -> G (in MCR).
CLCN1	150	150	Y -> C (in MCR).
CLCN1	161	161	F -> V (in THD and MCR).
CLCN1	165	165	V -> G (in MCR).
CLCN1	167	167	F -> L (in MCR).
CLCN1	200	200	G -> R (in THD and MCR).
CLCN1	230	230	G -> E (in THD and MCR).
CLCN1	236	236	V -> L (in MCR).
CLCN1	261	261	Y -> C (in MCR).
CLCN1	285	285	G -> E (in MCR).
CLCN1	286	286	V -> A (in THD).
CLCN1	290	290	I -> M (in THD).
CLCN1	291	291	E -> K (in MCR).
CLCN1	300	300	R -> Q.
CLCN1	307	307	F -> S (in THD).
CLCN1	313	313	A -> T (in THD and MCR).
CLCN1	317	317	R -> Q (in THD).
CLCN1	327	327	V -> I (in MCR).
CLCN1	329	329	I -> T (in MCR).
CLCN1	338	338	R -> Q (in THD and MCR).
CLCN1	413	413	F -> C (in MCR).
CLCN1	415	415	A -> V (in MCR).
CLCN1	480	480	P -> L (in THD).
CLCN1	482	482	G -> R (in MCR).
CLCN1	485	485	M -> V (in MCR).
CLCN1	496	496	R -> S (in MCR).
CLCN1	548	548	E -> K (in a breast cancer sample; somatic mutation).
CLCN1	552	552	Q -> R (in THD, MCR and in myotonia levior).
CLCN1	556	556	I -> N (in THD and MCR; mild form).
CLCN1	563	563	V -> I (in MCR).
CLCN1	708	708	F -> L (in MCR).
EPHA1	703	703	E -> K (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
NOBOX	355	355	R -> H (in POF5).
NOBOX	360	360	R -> Q.
NOBOX	452	452	D -> N.
KCNH2	29	29	F -> L (in LQT2).
KCNH2	33	33	N -> T (in LQT2).
KCNH2	47	47	G -> V (in LQT2).
KCNH2	53	53	G -> R (in LQT2).
KCNH2	56	56	R -> Q (in LQT2).
KCNH2	66	66	C -> G (in LQT2).
KCNH2	70	70	H -> R (in LQT2).
KCNH2	72	72	P -> Q (in LQT2).
KCNH2	78	78	A -> P (in LQT2).
KCNH2	86	86	L -> R (in LQT2).
KCNH2	100	100	R -> G (in LQT2; digenic; associated with the Asn-1819 mutation on the SCN5A gene).
KCNH2	189	189	G -> GGAG.
KCNH2	312	312	R -> C (in LQT2).
KCNH2	347	347	P -> S (in LQT2).
KCNH2	436	436	T -> M (in LQT2).
KCNH2	451	451	P -> L (in LQT2).
KCNH2	470	470	N -> D (in LQT2).
KCNH2	474	474	T -> I (in LQT2).
KCNH2	500	508	Missing (in LQT2).
KCNH2	525	525	K -> N (in long QT syndrome 2/3; located on the same allele as Pro-528).
KCNH2	528	528	R -> P (in long QT syndrome 2/3; located on the same allele as Asn-525).
KCNH2	531	531	R -> Q (in LQT2).
KCNH2	534	534	R -> C (in LQT2).
KCNH2	552	552	L -> S (in LQT2).
KCNH2	558	558	A -> P (in LQT2).
KCNH2	561	561	A -> T (in LQT2).
KCNH2	561	561	A -> V (in LQT2).
KCNH2	564	564	L -> P (in LQT2).
KCNH2	569	569	Y -> H (in LQT2).
KCNH2	572	572	G -> C (in LQT2).
KCNH2	572	572	G -> R (in LQT2; severe form).
KCNH2	582	582	R -> C (in LQT2).
KCNH2	584	584	G -> S (in LQT2).
KCNH2	585	585	W -> C (in LQT2).
KCNH2	588	588	N -> D (in LQT2).
KCNH2	588	588	N -> K (in SQT1).
KCNH2	593	593	I -> T (in LQT2).
KCNH2	601	601	G -> S (in LQT2).
KCNH2	604	604	G -> S (in LQT2).
KCNH2	609	609	D -> N (in LQT2).
KCNH2	611	611	Y -> H (in LQT2).
KCNH2	612	612	V -> L (in LQT2).
KCNH2	613	613	T -> M (in LQT2).
KCNH2	614	614	A -> V (in LQT2).
KCNH2	615	615	L -> V (in LQT2).
KCNH2	626	626	G -> S (in LQT2).
KCNH2	627	627	F -> L (in LQT2).
KCNH2	628	628	G -> S (in LQT2).
KCNH2	629	629	N -> D (in LQT2).
KCNH2	629	629	N -> K (in LQT2).
KCNH2	629	629	N -> S (in LQT2).
KCNH2	630	630	V -> A (in LQT2).
KCNH2	630	630	V -> L (in LQT2).
KCNH2	632	632	P -> S (in LQT2).
KCNH2	633	633	N -> S (in LQT2).
KCNH2	637	637	E -> K (in LQT2).
KCNH2	638	638	K -> E (in LQT2).
KCNH2	638	638	Missing (in LQT2).
KCNH2	640	640	F -> L (in LQT2).
KCNH2	645	645	M -> L (in LQT2).
KCNH2	696	696	R -> C (in long QT syndrome 2/3).
KCNH2	752	752	R -> Q (in LQT2).
KCNH2	752	752	R -> W (in LQT2).
KCNH2	784	784	R -> W (predisposes to LQT2 and torsades de pointes while taking the drug amiodarone; in vitro studies confirmed a significant reduction in potassium currents; the ECG abnormalities reversed on drug withdrawal).
KCNH2	805	805	F -> C (in LQT2).
KCNH2	805	805	F -> S (in LQT2).
KCNH2	818	818	S -> L (in LQT2).
KCNH2	822	822	V -> M (in LQT2).
KCNH2	823	823	R -> W (in LQT2).
KCNH2	861	861	N -> I (in LQT2).
KCNH2	917	917	P -> L (in LQT2).
KCNH2	922	922	R -> W (in LQT2).
KCNH2	948	948	R -> C (in long QT syndrome 2/3).
NOS3	474	474	R -> C (in a colorectal cancer sample; somatic mutation).
NOS3	602	602	R -> Q (in a colorectal cancer sample; somatic mutation).
FASTK	424	424	V -> L (in a lung adenocarcinoma sample; somatic mutation).
RHEB	139	139	E -> K (in a colorectal cancer sample; somatic mutation).
HTR5A	262	262	R -> C (in a colorectal cancer sample; somatic mutation).
SHH	6	6	R -> T (in HPE3).
SHH	17	17	L -> P (in HPE3).
SHH	26	26	P -> L (in HPE3).
SHH	27	27	G -> A (in HPE3).
SHH	39	39	L -> P (in HPE3).
SHH	53	53	E -> K (in HPE3).
SHH	83	83	D -> V (in HPE3).
SHH	84	84	I -> F (in HPE3).
SHH	88	88	D -> V (in HPE3; familial; the same mutation in the mouse sequence moderately reduces Ptch1 binding in vitro and signaling potency in chicken embryo neural plate explant assays compared with wild-type sequence).
SHH	100	100	Q -> H (in HPE3; sporadic; in the mouse sequence does not affect signaling activity in any of Shh signaling assays and causes no apparent defects in cholesterol-mediated autoprocessing reactions).
SHH	102	102	C -> R (in HPE3).
SHH	102	102	C -> Y (in HPE3).
SHH	106	107	Missing (in HPE3).
SHH	109	109	L -> F (in HPE3).
SHH	110	110	A -> D (in HPE3).
SHH	110	110	A -> T (in HPE3).
SHH	111	111	I -> F (in SMMCI).
SHH	111	111	I -> N (in HPE3).
SHH	115	115	N -> K (in HPE3; familial; in the mouse sequence shows no change in activities at different temperatures).
SHH	117	117	W -> G (in HPE3; the same mutation in the mouse sequence causes a failure of Shh processing leading to retention of the immature glycosylated protein within the endoplasmic reticulum of transfected cells; causes a temperature-dependent conformational change that allows Shh to bind Ptch1 at 4 or 32 degrees Celsius but not at 37 degrees Celsius; the mutation drastically reduces signaling potency in chicken embryo neural plate explant assays).
SHH	117	117	W -> R (in HPE3; the same mutation in the mouse sequence causes a failure of Shh processing leading to retention of the immature glycosylated protein within the endoplasmic reticulum of transfected cells; causes a temperature-dependent conformational change that allows Shh to bind Ptch1 at 4 or 32 degrees Celsius but not at 37 degrees Celsius; drastically reduces signaling potency in chicken embryo neural plate explant assays).
SHH	124	124	V -> M (in HPE3).
SHH	136	136	E -> K (in HPE3).
SHH	140	140	H -> P (in HPE3).
SHH	140	140	H -> Q (in HPE3).
SHH	143	143	G -> D (in HPE3).
SHH	144	144	R -> P (in HPE3).
SHH	147	147	D -> N (in HPE3).
SHH	150	150	T -> K (in HPE3).
SHH	150	150	T -> R (in HPE3).
SHH	156	156	S -> R (in HPE3).
SHH	170	170	F -> C (in HPE3).
SHH	171	171	D -> H (in HPE3).
SHH	176	178	Missing (in HPE3).
SHH	183	183	C -> F (in HPE3).
SHH	183	183	C -> R (in HPE3).
SHH	183	183	C -> Y (in HPE3).
SHH	184	184	S -> L (in HPE3).
SHH	188	188	E -> Q (in HPE3; familial).
SHH	196	200	Missing (in HPE3).
SHH	196	196	G -> E (in HPE3).
SHH	197	197	G -> V (in HPE3).
SHH	198	198	C -> F (in HPE3).
SHH	198	198	C -> S (in HPE3).
SHH	218	218	L -> P (in HPE3).
SHH	222	222	D -> N (in HPE3; familial).
SHH	224	224	V -> E (in HPE3).
SHH	226	226	A -> T (in HPE3; familial).
SHH	231	231	G -> V (in HPE3).
SHH	232	232	R -> G (in HPE3).
SHH	234	234	L -> P (in HPE3).
SHH	236	236	S -> N (in HPE3).
SHH	236	236	S -> R (in HPE3; familial).
SHH	241	241	F -> L (in HPE3).
SHH	241	241	F -> V (in HPE3).
SHH	255	255	I -> N (in HPE3).
SHH	263	269	Missing (in HPE3; sporadic).
SHH	267	267	T -> I (in HPE3).
SHH	271	271	L -> P (in HPE3).
SHH	275	275	A -> E (in HPE3).
SHH	280	280	S -> W (in HPE3).
SHH	290	290	G -> D (in HPE3; sporadic).
SHH	296	296	G -> A (in HPE3; uncertain pathogenicity).
SHH	310	310	R -> C (in HPE3).
SHH	321	321	R -> S (in HPE3).
SHH	332	332	V -> A (in HPE3 and SMMCI).
SHH	346	346	A -> V (in HPE3).
SHH	347	347	P -> L (in HPE3).
SHH	347	347	P -> Q (in HPE3).
SHH	347	347	P -> R (in HPE3).
SHH	354	354	I -> T (in HPE3).
SHH	362	362	S -> L (in HPE3).
SHH	363	363	C -> Y (in HPE3).
SHH	364	364	Y -> C (in HPE3).
SHH	373	373	A -> T (in HPE3).
SHH	374	374	H -> R (in HPE3).
SHH	376	376	A -> D (in HPE3).
SHH	377	377	F -> S (in HPE3).
SHH	378	380	Missing (in HPE3; familial).
SHH	381	381	R -> P (in HPE3).
SHH	382	382	L -> P (in HPE3).
SHH	383	383	A -> T (in HPE3; sporadic).
SHH	391	391	A -> T (in HPE3; uncertain pathogenicity).
SHH	401	408	Missing (in ocular coloboma).
SHH	402	409	Missing (in HPE3; uncertain pathogenicity).
SHH	404	408	Missing (in HPE3; familial).
SHH	405	409	Missing (in HPE3; uncertain pathogenicity).
SHH	411	411	G -> GG (in HPE3; uncertain pathogenicity).
SHH	416	416	T -> A (in HPE3; uncertain pathogenicity).
SHH	424	424	P -> A (in HPE3; familial).
SHH	435	435	Y -> N (in HPE3).
SHH	436	436	S -> L (in HPE3; sporadic).
SHH	456	456	G -> R (in HPE3; uncertain pathogenicity).
MNX1	245	245	R -> G (in CURRAS).
MNX1	245	245	R -> H (in CURRAS).
MNX1	246	246	T -> S (in CURRAS).
MNX1	288	288	W -> G (in CURRAS).
MNX1	288	288	W -> L (in CURRAS).
MNX1	290	290	Q -> P (in CURRAS).
MNX1	292	292	R -> W (in CURRAS).
MNX1	293	293	R -> Q (in CURRAS).
MNX1	293	293	R -> W (in CURRAS).
DSCAML1	659	659	V -> I (in a colorectal cancer sample; somatic mutation).
DSCAML1	1702	1702	V -> I (in a colorectal cancer sample; somatic mutation).
SYT9	154	154	V -> M.
SYT9	238	238	I -> V.
SYT9	353	353	L -> V.
SYT9	445	445	D -> N (in a colorectal cancer sample; somatic mutation).
AMPD3	310	310	N -> K (in AMPDDE).
AMPD3	311	311	V -> L (in AMPDDE).
AMPD3	320	320	A -> V (in AMPDDE).
AMPD3	324	324	M -> T (in AMPDDE).
AMPD3	331	331	R -> C (in AMPDDE).
AMPD3	402	402	R -> C (in AMPDDE).
AMPD3	450	450	W -> R (in AMPDDE).
AMPD3	585	585	P -> L (in AMPDDE).
AMPD3	712	712	Q -> P (in AMPDDE).
NELL1	553	553	C -> F (in a colorectal cancer sample; somatic mutation).
LRP5	15	20	Missing (found in a family with osteoporosis pseudoglioma syndrome; impairs protein trafficking to the endoplasmic reticulum and cell membrane).
LRP5	18	20	Missing.
LRP5	20	20	L -> LL.
LRP5	29	29	A -> T (in primary osteoporosis).
LRP5	97	97	A -> V.
LRP5	111	111	D -> Y (in OPTA1).
LRP5	145	145	L -> F (in EVR4).
LRP5	154	154	R -> M (in HBM).
LRP5	171	171	G -> R (in OPTA1).
LRP5	171	171	G -> V (in HBM; also in HBM individuals with enlarged mandible and torus palatinus; no enhancement of DKK1 binding by MESD resulting in impaired inhibition of Wnt signaling by DKK1).
LRP5	173	173	T -> M (in EVR4; an individual with abnormal retinal vasculature and retinal folds).
LRP5	203	203	D -> N (in OPPG).
LRP5	214	214	A -> T (in WENHY).
LRP5	214	214	A -> V (in WENHY).
LRP5	242	242	A -> T (in OPTA1, VBCH2 and WENHY).
LRP5	244	244	T -> M (in OPPG; appears to traffic less well than does the wild-type protein; appears to be postranslationally modified similar to wild-type protein; is unable to transduce Wnt signal; has a significantly reduced ability to transduce Norrin signal).
LRP5	253	253	T -> I (in OPTA1).
LRP5	282	282	M -> V (in HBM; lowered LRP5-mediated Wnt signaling. No effect on DKK1 binding).
LRP5	307	307	S -> F (in OPPG).
LRP5	348	348	R -> W (in OPPG).
LRP5	353	353	R -> Q (in OPPG).
LRP5	356	356	S -> L (in idiopathic osteoporosis and OPPG; appears to traffic comparably than does the wild-type protein; appears to be postranslationally modified similar to wild-type protein; is unable to transduce Wnt signal; has a significantly reduced ability to transduce Norrin signal).
LRP5	390	390	T -> K (in OPPG; is unable to traffic normally; appears to be postranslationally modified similar to wild-type protein; is unable to transduce Wnt signal; has a significantly reduced ability to transduce Norrin signal).
LRP5	400	400	A -> E (in OPPG).
LRP5	404	404	G -> R (in OPPG; appears to traffic less well than does the wild-type protein; appears to be postranslationally modified similar to wild-type protein; has 50% of wild-type activity to transduce Wnt signal; has a significantly reduced ability to transduce Norrin signal).
LRP5	409	409	T -> A (in OPPG).
LRP5	434	434	D -> N (in OPPG; appears to traffic less well than does the wild-type protein; appears to be postranslationally modified similar to wild-type protein; has 50% of wild-type activity to transduce Wnt signal; has a significantly reduced ability to transduce Norrin signal).
LRP5	441	441	E -> K (in EVR4).
LRP5	444	444	R -> C (in EVR4; associated in a EVR1 patient with mutation GLN-417 in FZD4).
LRP5	455	455	S -> L (in idiopathic osteoporosis; shows an inhibitory effect on Wnt signal transduction).
LRP5	460	460	E -> K (in OPPG).
LRP5	478	478	W -> R (in OPPG).
LRP5	494	494	R -> Q (in OPPG).
LRP5	504	504	W -> C (in OPPG).
LRP5	511	511	D -> A (in EVR4).
LRP5	520	520	G -> V (in OPPG; appears to traffic comparably than does the wild-type protein; appears to be postranslationally modified similar to wild-type protein; is unable to transduce Wnt signal; has a significantly reduced ability to transduce Norrin signal).
LRP5	522	522	A -> T (in EVR4).
LRP5	531	531	N -> I (in OPPG).
LRP5	535	535	T -> M (in EVR4; autosomal recessive).
LRP5	550	550	G -> R (in EVR4; autosomal recessive).
LRP5	570	570	R -> Q (in EVR4; autosomal recessive; has significantly reduced Wnt or Norrin signal transduction).
LRP5	570	570	R -> W (in OPPG).
LRP5	610	610	G -> R (in EVR4 and OPPG; appears to traffic less well than does the wild-type protein; appears to be postranslationally modified similar to wild-type protein; has 60% of wild-type activity to transduce Wnt signal; has a significantly reduced ability to transduce Norrin signal).
LRP5	617	617	F -> C (in EVR4; autosomal recessive).
LRP5	683	683	D -> N (in OPPG).
LRP5	733	733	Y -> H (in OPPG).
LRP5	752	752	R -> G (in EVR4; autosomal recessive).
LRP5	798	798	T -> A (in EVR4).
LRP5	805	805	R -> W (in EVR4).
LRP5	1036	1036	R -> Q (in primary osteoporosis).
LRP5	1099	1099	D -> Y (in OPPG).
LRP5	1113	1113	R -> C (in OPPG).
LRP5	1121	1121	N -> D (in EVR4).
LRP5	1168	1168	Y -> H (in EVR4; an individual with total retinal detachment and retinoschisis; is unable to transduce Wnt or Norrin signal transduction).
LRP5	1253	1253	C -> F (in EVR4).
LRP5	1361	1361	C -> G (in EVR4; autosomal dominant; has mildly reduced Wnt or Norrin signal transduction).
LRP5	1401	1401	G -> D (in OPPG).
LRP5	1537	1537	A -> T (could be associated with idiopathic osteoporosis; does not result in a significant alteration of Wnt signal transduction).
LRP5	1540	1540	T -> M.
PDGFD	202	202	D -> Y (in a colorectal cancer sample; somatic mutation).
ACAT1	85	85	Missing (in 3KTD).
ACAT1	93	93	N -> S (in 3KTD; 10% activity).
ACAT1	152	152	G -> A (in 3KTD).
ACAT1	158	158	N -> D (in 3KTD; no activity).
ACAT1	183	183	G -> R (in 3KTD; no activity).
ACAT1	297	297	T -> M (in 3KTD; 10% normal activity).
ACAT1	301	301	A -> P (in 3KTD; 5% normal activity).
ACAT1	312	312	I -> T (in 3KTD; 10% activity).
ACAT1	333	333	A -> P (in 3KTD; no activity).
ACAT1	379	379	G -> V (in 3KTD).
ACAT1	380	380	A -> T (in 3KTD; 7% normal activity).
RDX	578	578	D -> N (in DFNB24).
OPCML	95	95	P -> R (in ovarian cancer; somatic mutation).
DEAF1	186	186	E -> V (in a primary colorectal cancer).
DEAF1	191	191	K -> I (in a primary colorectal cancer).
DEAF1	191	191	K -> N (in a primary colorectal cancer).
DEAF1	199	202	YDSE -> CDND (in a primary colorectal cancer).
DEAF1	202	202	E -> D (in a primary colorectal cancer).
DEAF1	218	218	R -> K (in a primary colorectal cancer).
DEAF1	228	228	I -> S (de novo variant found in a patient with mental retardation).
DEAF1	350	352	DRA -> GQT (in a primary colorectal cancer).
DEAF1	356	356	E -> H (in a primary colorectal cancer; requires 2 nucleotide substitutions).
DEAF1	364	364	S -> N (in a primary colorectal cancer).
DEAF1	367	367	Q -> H (in a primary colorectal cancer).
DEAF1	370	370	V -> L (in a primary colorectal cancer).
DEAF1	397	397	Y -> F (in a primary colorectal cancer).
DEAF1	442	442	V -> A (in a primary colorectal cancer).
DEAF1	449	449	E -> K (in a primary colorectal cancer).
DEAF1	451	452	RS -> GI (in a primary colorectal cancer).
DEAF1	468	468	Q -> H (in a primary colorectal cancer).
DEAF1	479	479	H -> L (in a primary colorectal cancer).
DEAF1	498	498	E -> K (in a primary colorectal cancer).
DEAF1	526	526	T -> N (in a primary colorectal cancer).
DEAF1	530	530	R -> L (in a primary colorectal cancer).
DEAF1	537	538	QH -> HL (in a primary colorectal cancer).
DEAF1	542	542	Q -> H (in a primary colorectal cancer).
DEAF1	545	545	A -> G (in a primary colorectal cancer).
DEAF1	545	545	A -> V (in a primary colorectal cancer).
KCNQ1	71	73	Missing (in LQT1).
KCNQ1	111	111	Y -> C (in LQT1).
KCNQ1	140	140	S -> G (in ATFB3; gain of function).
KCNQ1	157	157	F -> C (in LQT1).
KCNQ1	160	160	E -> K (in LQT1).
KCNQ1	167	168	FG -> W (in LQT1).
KCNQ1	174	174	R -> C (in LQT1).
KCNQ1	174	174	R -> H (in LQT1).
KCNQ1	178	178	A -> P (in LQT1; loss of channel activity).
KCNQ1	178	178	A -> T (in LQT1).
KCNQ1	179	179	G -> S (in LQT1).
KCNQ1	184	184	Y -> S (in LQT1).
KCNQ1	189	189	G -> R (in LQT1; familial sudden death).
KCNQ1	190	190	R -> Q (in LQT1; loss of channel activity).
KCNQ1	194	194	A -> P (in LQT1).
KCNQ1	216	216	G -> R (in LQT1).
KCNQ1	225	225	S -> L (in LQT1).
KCNQ1	242	242	D -> N (in LQT1).
KCNQ1	243	243	R -> C (in LQT1; slower rate of activation and voltage dependence of activation-inactivation shifted to more positive potentials (homomultimers); channels non-functional (heteromultimers)).
KCNQ1	243	243	R -> H (in JLNS1; minor changes of wt current (homomultimers); positive voltage shift of the channel activation (heteromultimers)).
KCNQ1	248	248	W -> R (in LQT1; slower rate of activation and voltage dependence of activation-inactivation shifted to more positive potentials (homomultimers); channels non-functional (heteromultimers)).
KCNQ1	250	250	L -> H (in LQT1).
KCNQ1	254	254	V -> M (in LQT1; associated with M-417 in a patient).
KCNQ1	261	261	E -> D (in JLNS1).
KCNQ1	261	261	E -> K (in LQT1; loss of channel activity and no interaction with wt KVLQT1 or MINK subunits).
KCNQ1	266	266	L -> P (in LQT1).
KCNQ1	269	269	G -> D (in LQT1).
KCNQ1	269	269	G -> S (in LQT1).
KCNQ1	273	273	L -> F (in LQT1; functional channel with reduced macroscopic conductance (homomultimers); alteration of normal KVLQT1 function (mut/wt homomultimers)).
KCNQ1	281	281	Y -> C (in LQT1).
KCNQ1	300	300	A -> T (in LQT1).
KCNQ1	305	305	W -> S (in JLNS1).
KCNQ1	306	306	G -> R (in LQT1).
KCNQ1	307	307	V -> L (in SQT2; gain of function).
KCNQ1	309	309	T -> R (in LQT1).
KCNQ1	310	310	V -> I (in LQT1).
KCNQ1	311	311	T -> I (in LQT1).
KCNQ1	312	312	T -> I (in LQT1; loss of channel activity).
KCNQ1	313	313	I -> M (in LQT1).
KCNQ1	314	314	G -> S (in LQT1).
KCNQ1	315	315	Y -> C (in LQT1).
KCNQ1	315	315	Y -> S (in LQT1).
KCNQ1	317	317	D -> N (in LQT1).
KCNQ1	318	318	K -> N (in LQT1).
KCNQ1	320	320	P -> A (in LQT1).
KCNQ1	325	325	G -> R (in LQT1).
KCNQ1	339	339	Missing (in LQT1).
KCNQ1	341	341	A -> V (in LQT1).
KCNQ1	342	342	L -> F (in LQT1).
KCNQ1	344	344	A -> V (in LQT1).
KCNQ1	345	345	G -> E (in LQT1).
KCNQ1	345	345	G -> R (in LQT1; familial sudden death).
KCNQ1	349	349	S -> W (in LQT1).
KCNQ1	353	353	L -> P (in LQT1).
KCNQ1	366	366	R -> P (in LQT1).
KCNQ1	366	366	R -> Q (in LQT1).
KCNQ1	366	366	R -> W (in LQT1).
KCNQ1	371	371	A -> T (in LQT1).
KCNQ1	373	373	S -> P (in LQT1).
KCNQ1	391	391	T -> I (in LQT1).
KCNQ1	392	392	W -> R (in LQT1).
KCNQ1	417	417	V -> M (in LQT1; associated with M-254 in a patient).
KCNQ1	448	448	P -> R (in LQT1).
KCNQ1	525	525	A -> T (in LQT1).
KCNQ1	533	533	R -> W (in LQT1; minor changes of wt current (homomultimers); positive voltage shift of the channel activation (heteromultimers)).
KCNQ1	539	539	R -> W (in LQT1; minor changes of wt current (homomultimers); positive voltage shift of the channel activation (heteromultimers)).
KCNQ1	555	555	R -> C (in LQT1; associated with a fruste phenotype).
KCNQ1	566	566	S -> F (in LQT1).
KCNQ1	587	587	T -> M (in LQT1).
KCNQ1	589	589	G -> D (in LQT1; reduced cell surface expression and strongly reduced potassium current).
KCNQ1	591	591	R -> H (in LQT1).
KCNQ1	594	594	R -> Q (in LQT1).
NUP98	1669	1669	G -> V (in a breast cancer sample; somatic mutation).
HBG1	73	73	G -> R (in Iwata).
HBG1	74	74	D -> H (in Xin-su).
HBG1	74	74	D -> N (in Forest Park; associated with T-76).
HBG1	80	80	D -> N (in Dammam).
HBG1	81	81	D -> N (in Yamaguchi).
HBG1	81	81	D -> Y (in Victoria jubilee).
HBG1	98	98	H -> R (in Dickinson).
HBG1	122	122	E -> K (in Siena/Hull).
HBG1	129	129	A -> T (in Baskent).
HBG1	135	135	V -> M (in Jiangsu).
TRIM5	31	31	G -> S.
TRIM5	58	58	C -> Y.
TRIM5	110	110	G -> E.
TRIM5	467	467	C -> S.
NLRP14	55	55	R -> E (requires 2 nucleotide substitutions).
NLRP14	86	86	D -> V (associated with spermatogenic failure).
NLRP14	98	98	S -> L.
NLRP14	375	375	A -> T (associated with spermatogenic failure).
NLRP14	397	397	T -> I.
NLRP14	441	441	V -> M.
NLRP14	522	522	D -> Q (associated with spermatogenic failure; requires 2 nucleotide substitutions).
NLRP14	779	779	S -> C (in a breast cancer sample; somatic mutation).
NLRP14	951	951	S -> T.
NLRP14	954	954	L -> S.
NLRP14	1019	1019	M -> I (associated with spermatogenic failure).
STK33	160	160	L -> V (in a lung large cell carcinoma sample; somatic mutation).
NUCB2	402	402	Missing.
ABCC8	7	7	G -> R (in HHF1).
ABCC8	21	21	V -> D (in HHF1).
ABCC8	27	27	F -> S (in HHF1).
ABCC8	70	70	G -> E (in HHF1; altered intracellular trafficking).
ABCC8	74	74	R -> Q (in HHF1).
ABCC8	74	74	R -> W (in HHF1).
ABCC8	86	86	V -> A (in PNDM).
ABCC8	111	111	G -> R (in HHF1; altered intracellular trafficking).
ABCC8	116	116	A -> P (in HHF1).
ABCC8	132	132	F -> L (in PNDM; with neurologic features; reduces the sensitivity of the K(ATP) channel to inhibition by MgATP; increases whole-cell K(ATP) current).
ABCC8	187	187	V -> D (in HHF1; severe; high prevalence in Finland; loss of channel activity).
ABCC8	188	188	N -> S (in HHF1; severe).
ABCC8	213	213	L -> R (in PNDM).
ABCC8	233	233	M -> R (in HHF1).
ABCC8	275	275	R -> Q.
ABCC8	310	310	D -> N (in HHF1).
ABCC8	406	406	N -> D (in HHF1).
ABCC8	418	418	C -> R (in HHF1).
ABCC8	435	435	C -> R (in TNDM2).
ABCC8	495	495	R -> Q (in HHF1).
ABCC8	501	501	E -> K (in HHF1).
ABCC8	503	503	L -> P (in HHF1).
ABCC8	508	508	L -> P (in HHF1).
ABCC8	551	551	P -> R (in HHF1).
ABCC8	582	582	L -> V (in TNDM2).
ABCC8	591	591	F -> L (in HHF1).
ABCC8	673	673	D -> N.
ABCC8	686	686	F -> S (in HHF1).
ABCC8	716	716	G -> V (in HHF1).
ABCC8	719	719	K -> T (in HHF1).
ABCC8	810	810	D -> N.
ABCC8	834	834	R -> C.
ABCC8	841	841	R -> G (in HHF1).
ABCC8	889	889	K -> T (in HHF1).
ABCC8	956	956	S -> F (in HHF1).
ABCC8	1023	1023	H -> Y (in TNDM2; overactive channel).
ABCC8	1130	1130	T -> P (in HHF1).
ABCC8	1138	1138	T -> M (in HHF1).
ABCC8	1147	1147	L -> R (in HHF1).
ABCC8	1182	1182	R -> Q (in TNDM2).
ABCC8	1214	1214	R -> Q (in HHF1; severe).
ABCC8	1214	1214	R -> W (in HHF1).
ABCC8	1295	1295	N -> K (in HHF1).
ABCC8	1336	1336	K -> N (in HHF1).
ABCC8	1342	1342	G -> E (in HHF1; altered intracellular trafficking).
ABCC8	1349	1349	L -> Q (in HHF1).
ABCC8	1352	1352	R -> H (in LIH; partially impairs ATP- dependent potassium channel function).
ABCC8	1360	1360	V -> G.
ABCC8	1360	1360	V -> M (in HHF1).
ABCC8	1378	1378	G -> R (in HHF1).
ABCC8	1379	1379	R -> C (in TNDM2).
ABCC8	1381	1381	G -> S (in HHF1).
ABCC8	1384	1384	K -> Q (in HHF1).
ABCC8	1385	1385	Missing (in HHF1; does not alter surface expression but channels are not functional).
ABCC8	1386	1386	S -> F (in HHF1).
ABCC8	1387	1387	Missing (in HHF1; severe; high frequency in Ashkenazi Jewish patients; defective trafficking and lack of surface expression).
ABCC8	1393	1393	R -> H (in HHF1; severe; loss of channel activity).
ABCC8	1400	1400	G -> R (in HHF1).
ABCC8	1418	1418	R -> H (in HHF1; altered intracellular trafficking).
ABCC8	1424	1424	I -> V (in PNDM; overactive channel).
ABCC8	1436	1436	R -> Q (in HHF1; cannot form a functional channel, due to protein instability or defective transport to the membrane).
ABCC8	1450	1450	L -> P (in HHF1).
ABCC8	1457	1457	A -> T (in HHF1).
ABCC8	1471	1471	D -> H (in HHF1).
ABCC8	1471	1471	D -> N (in HHF1).
ABCC8	1478	1478	G -> R (in HHF1; channels insensitive to metabolic inhibition and to activation by ADP).
ABCC8	1486	1486	R -> K (in HHF1).
ABCC8	1493	1493	R -> Q (in HHF1).
ABCC8	1506	1506	E -> K (in HHF1; mild; dominantly inherited; channels insensitive to metabolic inhibition and to activation by ADP).
ABCC8	1507	1507	A -> AAS (in HHF1).
ABCC8	1543	1543	L -> P (in HHF1; reduced channels surface expression and response to ADP).
ABCC8	1550	1550	V -> D (in HHF1).
ABCC8	1551	1551	L -> V (in HHF1).
IGSF22	7	7	R -> W (found in a renal cell carcinoma sample; somatic mutation).
ANO5	231	231	G -> V (in LGMD2L).
ANO5	356	356	C -> G (in GDD; decreases cell adhesion and changes cell morphology to a round shape).
ANO5	356	356	C -> R (in GDD; decreases cell adhesion and changes cell morphology to a round shape).
ANO5	758	758	R -> C (in MMD3).
RCN1	117	117	F -> L (in a colorectal cancer sample; somatic mutation).
RAG1	244	244	R -> G.
RAG1	314	314	R -> W (in CHIDG; reduced recombination activity).
RAG1	328	328	C -> Y (in OS).
RAG1	396	396	R -> C (in OS).
RAG1	396	396	R -> H (in OS).
RAG1	396	396	R -> L (in OS).
RAG1	401	401	S -> P (in OS).
RAG1	410	410	R -> Q (in OS/T(-)B(-)NK(+) SCID; atypical).
RAG1	429	429	D -> G (in OS).
RAG1	433	433	V -> M (in OS/T(-)B(-)NK(+) SCID; atypical).
RAG1	435	435	M -> V (in OS).
RAG1	444	444	A -> V (in OS/T(-)B(-)NK(+) SCID; atypical).
RAG1	474	474	R -> H (in OS/T(-)B(-)NK(+) SCID; atypical).
RAG1	507	507	R -> W (in OS/T(-)B(-)NK(+) SCID and CHIDG; atypical; reduced recombination activity when associated with H-737).
RAG1	522	522	W -> C (in OS/T(-)B(-)NK(+) SCID; atypical).
RAG1	559	559	R -> S (in OS).
RAG1	561	561	R -> C (in OS).
RAG1	561	561	R -> H (in OS).
RAG1	624	624	R -> C (in OS).
RAG1	624	624	R -> H (in T(-)B(-)NK(+) SCID).
RAG1	669	669	E -> G (in OS).
RAG1	737	737	R -> H (in OS and CHIDG; reduced recombination activity when associated with T-507).
RAG1	753	753	H -> L (in OS/T(-)B(-)NK(+) SCID; atypical).
RAG1	778	778	R -> Q (in CHIDG; reduced recombination activity).
RAG1	841	841	R -> W (in T-CMVA).
RAG1	855	855	N -> I (in immunodeficiency; severe combined).
RAG1	885	885	L -> R (in OS).
RAG1	912	912	Y -> C (in OS).
RAG1	975	975	R -> Q (in OS).
RAG1	975	975	R -> W (in CHIDG; reduced recombination activity).
RAG1	981	981	Q -> P (in T-CMVA).
EXT2	85	85	C -> R (in EXT2).
EXT2	152	152	L -> R (in EXT2).
EXT2	179	179	R -> S (in EXT2).
EXT2	202	202	A -> V (in EXT2).
EXT2	223	223	R -> P (in EXT2).
EXT2	227	227	D -> N (in EXT2; can still form an oligomeric complex).
EXT2	380	380	I -> T (in EXT2).
EXT2	576	576	E -> K (in osteochondroma).
ALX4	35	35	R -> T.
ALX4	218	218	R -> Q (in PFM2).
ALX4	272	272	R -> P (in PFM2).
LRP4	137	137	D -> N (in CLSS; abolishes the antagonistic effect of LRP4 on LRP6- mediated activation of Wnt signaling).
LRP4	160	160	C -> Y (in CLSS; abolishes the antagonistic effect of LRP4 on LRP6- mediated activation of Wnt signaling).
LRP4	449	449	D -> N (in CLSS; abolishes the antagonistic effect of LRP4 on LRP6- mediated activation of Wnt signaling).
LRP4	461	461	T -> P (in CLSS).
LRP4	473	473	L -> F (in CLSS; abolishes the antagonistic effect of LRP4 on LRP6- mediated activation of Wnt signaling).
LRP4	529	529	D -> N (in CLSS; abolishes the antagonistic effect of LRP4 on LRP6- mediated activation of Wnt signaling).
LRP4	1017	1017	C -> R (in CLSS).
PTPRJ	214	214	R -> C (in a colon cancer sample; somatic mutation).
OSBP	278	278	D -> A (in a colorectal cancer sample; somatic mutation).
SDHAF2	78	78	G -> R (in PGL2; abolishes interaction with SDHA and flavination of SDHA).
ZBTB3	424	424	H -> L (in a breast cancer sample; somatic mutation).
ZBTB3	455	455	S -> F (in a breast cancer sample; somatic mutation).
SLC22A9	393	393	A -> V (in a breast cancer sample; somatic mutation).
SLC22A9	487	487	M -> V (in a breast cancer sample; somatic mutation).
SLC22A9	521	521	N -> K (in a colorectal cancer sample; somatic mutation).
SPTBN2	253	253	L -> P (in SCA5).
SPTBN2	532	544	Missing (in SCA5).
SPTBN2	629	634	LAAARR -> W (in SCA5).
SPTBN2	774	774	E -> K (in a colorectal cancer sample; somatic mutation).
PC	156	156	R -> Q (in PC deficiency).
PC	270	270	R -> W (in PC deficiency).
PC	304	304	Y -> C (in PC deficiency).
PC	451	451	R -> C (in PC deficiency; mild).
PC	583	583	R -> L (in PC deficiency).
PC	631	631	R -> Q (in PC deficiency).
PC	1131	1133	Missing (in PC deficiency).
CPT1A	123	123	R -> C (in CPT1AD).
CPT1A	304	304	C -> W (in CPT1AD).
CPT1A	314	314	T -> I (in CPT1AD).
CPT1A	316	316	R -> G (in CPT1AD).
CPT1A	343	343	F -> V (in CPT1AD).
CPT1A	357	357	R -> W (in CPT1AD; decreased stability).
CPT1A	395	395	Missing (in CPT1AD; loss of activity).
CPT1A	454	454	D -> G (in CPT1AD).
CPT1A	465	465	G -> W (in CPT1AD).
CPT1A	479	479	P -> L (in CPT1AD; decreased activity).
CPT1A	484	484	L -> P (in CPT1AD).
CPT1A	498	498	Y -> C (in CPT1AD; decreased activity).
CPT1A	710	710	G -> E (in CPT1AD; loss of activity).
IGHMBP2	17	17	L -> P (in HMN6).
IGHMBP2	192	192	L -> P (in HMN6).
IGHMBP2	196	196	Q -> R (in HMN6; severe reduction of ATPase activity and loss of helicase activity on RNA duplices).
IGHMBP2	213	213	H -> R (in HMN6).
IGHMBP2	216	216	P -> L (in HMN6).
IGHMBP2	221	221	T -> A (in HMN6; severe reduction of ATPase activity and loss of helicase activity on RNA duplices).
IGHMBP2	241	241	C -> R (in HMN6; severe reduction of ATPase activity and loss of helicase activity on RNA duplices).
IGHMBP2	251	251	L -> P (in HMN6).
IGHMBP2	334	334	E -> K (in HMN6).
IGHMBP2	361	361	L -> P (in HMN6).
IGHMBP2	364	364	L -> P (in HMN6).
IGHMBP2	382	382	E -> K (in HMN6; severe reduction of ATPase activity and loss of helicase activity on RNA duplices).
IGHMBP2	386	386	W -> R (in HMN6).
IGHMBP2	426	426	L -> P (in HMN6).
IGHMBP2	445	445	H -> P (in HMN6; severe reduction of ATPase activity and loss of helicase activity on RNA duplices).
IGHMBP2	472	472	L -> P (in HMN6).
IGHMBP2	493	493	T -> I (in HMN6; does not affect activity; reduces protein steady-state levels).
IGHMBP2	514	514	E -> K (in HMN6).
IGHMBP2	565	565	D -> N (in HMN6; does not affect ATPase activity; loss of helicase activity on RNA duplices).
IGHMBP2	572	572	Missing (in HMN6).
IGHMBP2	577	577	L -> P (in HMN6).
IGHMBP2	580	580	V -> I (in HMN6).
IGHMBP2	581	581	R -> S (in HMN6).
IGHMBP2	583	583	N -> I (in HMN6; severe reduction of ATPase activity and loss of helicase activity on RNA duplices).
IGHMBP2	586	586	G -> C (in HMN6).
IGHMBP2	603	603	R -> C (in HMN6).
IGHMBP2	603	603	R -> H (in HMN6; severe reduction of ATPase activity and loss of helicase activity on RNA duplices).
IGHMBP2	637	637	R -> C (in HMN6).
IGHMBP2	974	974	D -> E (in HMN6).
POLD3	194	194	G -> V (found in a renal cell carcinoma sample; somatic mutation).
POLD3	195	195	M -> L (found in a renal cell carcinoma sample; somatic mutation).
SLCO2B1	77	77	E -> K (in a breast cancer sample; somatic mutation).
GDPD4	396	396	N -> K.
CLNS1A	20	20	Q -> H.
CLNS1A	218	218	M -> T.
TYR	19	19	H -> Q (in OCA1A).
TYR	21	21	P -> S (in OCA1A).
TYR	36	36	C -> Y (in OCA1A).
TYR	44	44	S -> G (in OCA1A).
TYR	44	44	S -> R (in OCA1A).
TYR	47	47	G -> D (in OCA1A).
TYR	47	47	G -> V (in OCA1A).
TYR	52	52	R -> I (in OCA1).
TYR	68	68	Q -> H (in OCA1A).
TYR	77	77	R -> Q (in OCA1A).
TYR	77	77	R -> RR (in OCA1A).
TYR	77	77	R -> W (in OCA1A).
TYR	79	79	S -> L (in OCA1A).
TYR	80	80	W -> R (in OCA1A).
TYR	97	97	G -> R (in OCA1A).
TYR	109	109	G -> R (in OCA1A).
TYR	152	152	P -> S (in OCA1B).
TYR	155	155	T -> S (in OCA1A).
TYR	176	176	F -> I (in OCA1A).
TYR	177	177	V -> F (in OCA1A).
TYR	179	179	M -> L (in OCA1A).
TYR	180	180	H -> N (in OCA1A).
TYR	199	199	D -> N (in OCA1A).
TYR	201	201	A -> S (in OCA1A).
TYR	205	205	P -> T (in OCA1A).
TYR	216	216	L -> M (in OCA1A).
TYR	217	217	R -> G (in OCA1A).
TYR	217	217	R -> Q (in OCA1A).
TYR	217	217	R -> S (in OCA1A).
TYR	217	217	R -> W (in OCA1A).
TYR	217	217	Missing (in OCA1A).
TYR	227	227	Missing (in OCA1A).
TYR	236	236	W -> L (in OCA1A).
TYR	236	236	W -> S (in OCA1A).
TYR	239	239	R -> W (in OCA1A).
TYR	240	240	D -> V (in OCA1A).
TYR	243	243	K -> T (in OCA1A).
TYR	253	253	G -> R (in OCA1A).
TYR	256	256	H -> Y (in OCA1A).
TYR	272	272	W -> C (in OCA1A).
TYR	275	275	V -> F (in OCA1B).
TYR	288	288	L -> S (in OCA1A).
TYR	289	289	C -> G (in OCA1A).
TYR	289	289	C -> R (in OCA1A).
TYR	294	294	E -> G (in OCA1A).
TYR	294	294	E -> K (in OCA1A and OCA1B).
TYR	299	299	R -> H (in OCA1A).
TYR	299	299	R -> S (in OCA1A).
TYR	312	312	L -> V (in OCA1).
TYR	313	313	P -> R (in OCA1).
TYR	318	318	V -> E (in OCA1A).
TYR	325	325	T -> A (in OCA1B).
TYR	328	328	E -> Q (in OCA1A).
TYR	329	329	S -> P (in OCA1A).
TYR	332	332	M -> T (in OCA1A).
TYR	339	339	S -> G (in OCA1A).
TYR	340	340	F -> L (in OCA1).
TYR	345	345	E -> G (in OCA1A).
TYR	346	346	G -> E (in OCA1A).
TYR	355	355	A -> E (in OCA1A).
TYR	355	355	A -> P (in OCA1A).
TYR	361	361	S -> R (in OCA1A).
TYR	367	367	H -> Y (in OCA1A).
TYR	370	370	M -> T (in OCA1A).
TYR	371	371	N -> T (in OCA1A).
TYR	371	371	N -> Y (in OCA1A).
TYR	373	373	T -> K (in OCA1A).
TYR	378	378	Q -> K (in OCA1A).
TYR	380	380	S -> P (in OCA1B).
TYR	382	382	N -> K (in OCA1A).
TYR	383	383	D -> N (in OCA1A).
TYR	390	390	H -> D (in OCA1B).
TYR	393	393	V -> F (in OCA1A).
TYR	395	395	S -> N (in OCA1A).
TYR	395	395	S -> R (in OCA1A).
TYR	398	398	E -> A (in OCA1A).
TYR	398	398	E -> V (in OCA1A).
TYR	400	400	W -> L (in OCA1A).
TYR	402	402	R -> G (in OCA1B).
TYR	402	402	R -> L (in OCA1A).
TYR	403	403	R -> S (in OCA1A and OCA1B).
TYR	404	404	H -> N (in OCA1A).
TYR	404	404	H -> P (in OCA-I).
TYR	405	405	R -> L (in OCA1A).
TYR	406	406	P -> L (in OCA1A and OCA1B).
TYR	408	408	Q -> H (in OCA1A).
TYR	409	409	E -> D (in OCA1A).
TYR	416	416	A -> S (in OCA1A).
TYR	417	417	P -> H (in OCA1A).
TYR	419	419	G -> R (in OCA1A).
TYR	422	422	R -> Q (in OCA1A and OCA1B; temperature sensitive variant).
TYR	424	424	S -> F (in OCA1A).
TYR	426	426	M -> K (in OCA1A).
TYR	427	427	V -> G (in OCA1A).
TYR	431	431	P -> L (in OCA1A).
TYR	434	434	R -> I (in OCA1A).
TYR	435	435	N -> D (in OCA1A).
TYR	439	439	F -> V (in OCA1A).
TYR	444	444	D -> G (in OCA1A).
TYR	446	446	G -> S (in OCA1A).
TYR	448	448	D -> N (in OCA1A).
TRPC6	112	112	P -> Q (in FSGS2).
TRPC6	143	143	N -> S (in FSGS2).
TRPC6	270	270	S -> T (in FSGS2).
TRPC6	895	895	R -> C (in FSGS2).
TRPC6	897	897	E -> K (in FSGS2).
BIRC2	453	453	M -> V.
DYNC2H1	209	209	F -> I (in SRPS3).
DYNC2H1	587	587	R -> C (in SRPS3).
DYNC2H1	1240	1240	I -> T (in ATD3).
DYNC2H1	1537	1537	Q -> R (in ATD3).
DYNC2H1	1987	1987	T -> A (in SRPS3).
DYNC2H1	1991	1991	M -> L (in ATD3).
DYNC2H1	2205	2205	R -> H (in SRPS3).
DYNC2H1	2461	2461	G -> V (in SRPS3).
DYNC2H1	3015	3015	D -> G (in ATD3).
DYNC2H1	3762	3762	L -> V (in ATD3).
GUCY1A2	681	681	E -> V (in a colorectal cancer sample; somatic mutation).
GUCY1A2	685	685	N -> T (in a colorectal cancer sample; somatic mutation).
ATM	23	23	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation).
ATM	140	140	D -> H.
ATM	224	224	K -> E (in AT).
ATM	250	250	R -> Q.
ATM	292	292	P -> L (in AT; associated with lymphoma).
ATM	323	323	I -> V (in AT).
ATM	332	332	Y -> C (in B-cell chronic lymphocytic leukemia).
ATM	333	333	S -> F.
ATM	337	337	R -> C (in a colorectal adenocarcinoma sample; somatic mutation).
ATM	337	337	R -> H (in a colorectal adenocarcinoma sample; somatic mutation).
ATM	350	350	A -> T (in B-cell chronic lymphocytic leukemia).
ATM	352	352	I -> T (in B-cell chronic lymphocytic leukemia).
ATM	410	410	V -> A.
ATM	504	504	N -> S.
ATM	540	540	C -> Y (in a colorectal adenocarcinoma sample; somatic mutation).
ATM	570	570	F -> S (in AT).
ATM	705	707	YSS -> FIP (in AT; might be associated with susceptibility to cancer).
ATM	768	768	N -> D (in AT).
ATM	785	785	R -> C (in AT).
ATM	848	848	E -> Q (in a lung adenocarcinoma sample; somatic mutation).
ATM	872	872	P -> S.
ATM	924	924	R -> W.
ATM	935	935	T -> A.
ATM	950	950	L -> R (in AT).
ATM	1001	1001	L -> Q (in AT; associated with T-cell acute lymphoblastic leukemia).
ATM	1082	1082	H -> L (in AT).
ATM	1091	1091	E -> D (in AT).
ATM	1179	1179	S -> F (in a gastric adenocarcinoma sample; somatic mutation).
ATM	1321	1321	M -> I.
ATM	1380	1380	H -> Y.
ATM	1382	1382	P -> S.
ATM	1407	1407	I -> T (in T-prolymphocytic leukemia).
ATM	1420	1420	L -> P (in AT).
ATM	1454	1454	K -> N.
ATM	1463	1463	F -> S (in B-cell non-Hodgkin lymphoma).
ATM	1465	1465	L -> P (in AT).
ATM	1469	1469	I -> M (in a renal papillary cancer sample; somatic mutation).
ATM	1475	1475	Y -> C.
ATM	1566	1566	P -> R (in AT).
ATM	1570	1570	V -> A.
ATM	1650	1650	N -> S.
ATM	1682	1682	D -> H (in T-prolymphocytic leukemia).
ATM	1739	1739	N -> T (in a colorectal adenocarcinoma sample; somatic mutation).
ATM	1743	1743	T -> I (in AT; associated with preleukemic T-cell proliferation).
ATM	1812	1813	AF -> V (in AT).
ATM	1910	1910	L -> H (in T-prolymphocytic leukemia).
ATM	1913	1913	V -> G (in AT).
ATM	1916	1916	M -> I (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
ATM	1945	1945	A -> T (in a colorectal adenocarcinoma sample; somatic mutation).
ATM	1953	1953	T -> R (in B-cell chronic lymphocytic leukemia).
ATM	1961	1961	Y -> C.
ATM	1983	1983	N -> S.
ATM	1991	1991	E -> D (in a renal clear cell carcinoma sample; somatic mutation).
ATM	2016	2016	D -> G (in AT).
ATM	2063	2063	G -> E (in AT).
ATM	2067	2067	A -> D (in AT).
ATM	2139	2139	E -> G (in T-prolymphocytic leukemia; somatic mutation).
ATM	2164	2164	E -> K (in T-prolymphocytic leukemia).
ATM	2218	2218	S -> C (in AT).
ATM	2224	2227	MALR -> IS (in AT).
ATM	2227	2227	R -> C (in AT).
ATM	2246	2252	CIKDILT -> H (in AT).
ATM	2274	2274	A -> T (in B-cell chronic lymphocytic leukemia).
ATM	2307	2307	L -> F.
ATM	2332	2332	L -> P.
ATM	2356	2356	I -> F (in a renal clear cell carcinoma sample; somatic mutation).
ATM	2396	2396	T -> S (in T-prolymphocytic leukemia).
ATM	2408	2408	S -> L (in a colorectal adenocarcinoma sample; somatic mutation).
ATM	2418	2418	K -> KK (in mantle cell lymphoma).
ATM	2420	2420	A -> P (in B-cell chronic lymphocytic leukemia).
ATM	2423	2423	E -> G (in mantle cell lymphoma).
ATM	2424	2424	V -> G (in AT, B-cell chronic lymphocytic leukemia and T-prolymphocytic leukemia; associated with increased risk for breast cancer).
ATM	2427	2428	Missing (in AT; associated with T- prolymphocytic leukemia).
ATM	2438	2438	T -> I.
ATM	2442	2442	Q -> P (in T-prolymphocytic leukemia; also in a lung adenocarcinoma sample; somatic mutation).
ATM	2443	2443	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation).
ATM	2464	2464	C -> R.
ATM	2470	2470	Y -> D (in AT).
ATM	2486	2486	R -> G (in T-prolymphocytic leukemia).
ATM	2491	2491	W -> R (in AT).
ATM	2492	2492	L -> R.
ATM	2546	2548	Missing (in AT, T-prolymphocytic leukemia and T-cell acute lymphoblastic leukemia).
ATM	2554	2554	H -> D (in AT).
ATM	2625	2626	DA -> EP (in AT).
ATM	2625	2625	D -> Q (in AT; requires 2 nucleotide substitutions).
ATM	2656	2656	L -> P (in AT; partial functional loss).
ATM	2662	2662	Missing (in AT).
ATM	2663	2663	Missing (in AT).
ATM	2666	2666	T -> A (in a lung adenocarcinoma sample; somatic mutation).
ATM	2668	2668	E -> G (in AT).
ATM	2695	2695	G -> A (in T-prolymphocytic leukemia and B-cell chronic lymphocytic leukemia).
ATM	2702	2702	I -> R (in AT).
ATM	2719	2719	R -> H.
ATM	2722	2722	L -> R (in T-prolymphocytic leukemia).
ATM	2725	2725	D -> G (in T-prolymphocytic leukemia).
ATM	2725	2725	D -> V (in T-prolymphocytic leukemia).
ATM	2726	2726	A -> V (in AT).
ATM	2732	2732	F -> L (in T-prolymphocytic leukemia).
ATM	2765	2765	G -> S (may contribute to breast cancer).
ATM	2810	2810	Missing (in T-prolymphocytic leukemia).
ATM	2824	2824	C -> Y (in AT).
ATM	2827	2827	F -> C (in AT; mild).
ATM	2829	2829	P -> L (in AT).
ATM	2832	2832	R -> C (in AT and B-cell non-Hodgkin lymphoma).
ATM	2842	2842	P -> R (in a lung adenocarcinoma sample; somatic mutation).
ATM	2849	2849	R -> P (in AT).
ATM	2855	2856	SV -> RI (in AT).
ATM	2855	2855	S -> R (in AT).
ATM	2860	2860	Missing (in AT).
ATM	2867	2867	G -> R (in AT).
ATM	2870	2870	D -> N.
ATM	2871	2872	RH -> S (in T-prolymphocytic leukemia).
ATM	2890	2890	L -> V (in T-prolymphocytic leukemia).
ATM	2904	2904	E -> G (in AT).
ATM	2909	2909	R -> G (in AT).
ATM	3006	3006	A -> P (in T-prolymphocytic leukemia).
ATM	3008	3008	R -> C (in AT, T-prolymphocytic leukemia and mantle cell lymphoma).
ATM	3008	3008	R -> H (in B-cell chronic lymphocytic leukemia).
ATM	3018	3018	K -> N (in B-cell chronic lymphocytic leukemia).
DDX10	566	566	L -> V (in a breast cancer sample; somatic mutation).
ALG9	287	287	Y -> C (in CDG1L; impairs activity).
ALG9	506	506	P -> L.
ALG9	523	523	E -> K (in CDG1L; impairs activity).
ZBTB16	617	617	M -> V (in SGYMR).
SIK3	331	331	H -> L (in a breast cancer sample; somatic mutation).
SIK3	1103	1103	A -> V (in a breast cancer sample; somatic mutation).
BACE1	265	265	V -> A.
CBL	367	367	Q -> P (in NSLL; causes impaired CBL- mediated degradation of cell-surface receptors in a dominant-negative fashion).
CBL	382	382	K -> E (in NSLL; causes impaired CBL- mediated degradation of cell-surface receptors in a dominant-negative fashion).
CBL	390	390	D -> Y (in NSLL; causes impaired CBL- mediated degradation of cell-surface receptors in a dominant-negative fashion).
CBL	420	420	R -> Q (in NSLL; causes impaired CBL- mediated degradation of cell-surface receptors in a dominant-negative fashion as well as constitutive ERK phosphorylation).
TECTA	284	284	R -> H (in a breast cancer sample; somatic mutation).
TECTA	771	771	I -> N (in a breast cancer sample; somatic mutation).
TECTA	813	813	N -> T (in a breast cancer sample; somatic mutation).
TECTA	1057	1057	C -> S (in DFNA12; progressive deafness with late onset).
TECTA	1820	1820	L -> F (in DFNA12; prelingual and stable deafness).
TECTA	1824	1824	G -> D (in DFNA12; prelingual and stable deafness).
TECTA	1837	1837	C -> G (in a family with autosomal dominant deafness; postlingual and progressive; phenotype different from DFNA8/DFNA12).
TECTA	2021	2021	R -> H (in a family with autosomal dominant deafness).
TECTA	2100	2100	S -> T.
SORL1	120	120	L -> S (in a breast cancer sample; somatic mutation).
SORL1	1581	1581	M -> L (in a breast cancer sample; somatic mutation).
SORL1	1972	1972	L -> V (in a colorectal cancer sample; somatic mutation).
VWA5A	757	757	R -> C.
VWA5A	759	759	H -> R.
SIAE	3	3	A -> G (rare variant found in a patient with Crohn disease; probably not involved in disease susceptibility; the mutant enzyme has normal activity and is normally secreted).
SIAE	33	33	N -> S (rare variant found in a patient with rheumatoid arthritis; probably not involved in disease susceptibility; the mutant enzyme has normal activity and is normally secreted).
SIAE	62	62	R -> H (the mutant enzyme has normal activity and is normally secreted).
SIAE	64	64	G -> S (the mutant enzyme has normal activity and is normally secreted).
SIAE	161	161	Q -> K (the mutant enzyme has normal activity and is normally secreted).
SIAE	196	196	C -> F (in AIS6; defective enzyme secretion and activity).
SIAE	212	212	G -> R (in AIS6; defective enzyme secretion and activity).
SIAE	230	230	R -> W (in AIS6; defective enzyme secretion and activity).
SIAE	266	266	C -> G (in AIS6; defective enzyme secretion and activity).
SIAE	309	309	Q -> P (in AIS6; defective enzyme secretion and activity).
SIAE	312	312	T -> M (may predispose to autoimmunity; defective enzyme secretion and activity).
SIAE	314	314	R -> H (defective enzyme secretion and activity).
SIAE	349	349	Y -> C (in AIS6; defective enzyme secretion and activity).
SIAE	393	393	R -> H (in AIS6; defective enzyme secretion and activity).
SIAE	400	400	K -> N (rare variant found in a patient with Crohn disease; probably not involved in disease susceptibility; the mutant protein has normal activity).
SIAE	404	404	F -> S (in AIS6; defective enzyme secretion and activity).
SIAE	447	447	H -> R (the mutant enzyme has normal activity and is normally secreted).
SIAE	456	456	M -> I (the mutant enzyme has normal activity and is normally secreted).
SIAE	462	462	Q -> R (the mutant enzyme has normal activity and is normally secreted).
SIAE	479	479	R -> C (in AIS6; defective enzyme secretion and activity).
PKNOX2	447	447	Missing.
KIRREL3	40	40	R -> W (in MRD4).
KIRREL3	336	336	R -> Q (in MRD4).
KIRREL3	731	731	V -> F (in MRD4).
KCNJ1	72	72	V -> E (in BS2).
KCNJ1	74	74	D -> Y (in BS2).
KCNJ1	99	99	W -> C (in BS2).
KCNJ1	108	108	D -> H (in BS2).
KCNJ1	110	110	P -> L (in BS2).
KCNJ1	115	115	S -> F (in a breast cancer sample; somatic mutation).
KCNJ1	122	122	V -> E (in BS2).
KCNJ1	124	124	N -> K (in BS2).
KCNJ1	167	167	G -> E (in BS2).
KCNJ1	198	198	A -> T (in BS2).
KCNJ1	214	214	A -> V (in BS2).
KCNJ1	219	219	S -> R (in BS2).
KCNJ1	315	315	V -> G (in BS2).
HRAS	12	12	G -> A (in FCSS).
HRAS	12	12	G -> C (in FCSS).
HRAS	12	12	G -> E (in FCSS).
HRAS	12	12	G -> S (in FCSS, OSCC and CMEMS).
HRAS	13	13	G -> C (in FCSS).
HRAS	13	13	G -> D (in FCSS).
HRAS	22	22	Q -> K (in CMEMS).
HRAS	58	58	T -> I (in FCSS).
HRAS	61	61	Q -> L (in melanoma; strongly reduced GTP hydrolysis in the presence of RAF1; increases transformation of cultured cell lines).
HRAS	63	63	E -> K (in CMEMS).
HRAS	117	117	K -> R (in FCSS).
HRAS	146	146	A -> T (in FCSS).
HRAS	146	146	A -> V (in FCSS).
DRD4	265	344	Missing (in allele D4.2).
DRD4	281	328	Missing (in allele D4.4).
DRD4	329	329	P -> A (in allele D4.4).
DRD4	332	332	G -> S (in allele D4.4).
TALDO1	171	171	Missing (in TALDO1 deficiency).
SLC25A22	206	206	P -> L (in EIEE3).
PNPLA2	195	195	P -> L (in NLSDM).
PNPLA2	219	219	L -> F.
PNPLA2	252	252	N -> K.
CD151	178	178	R -> H.
TSPAN4	67	67	I -> M (in a breast cancer sample; somatic mutation).
CTSD	229	229	F -> I (in CLN10).
CTSD	282	282	G -> R.
CTSD	383	383	W -> C (in CLN10).
TNNI2	174	174	R -> Q (in DA2B).
TNNT3	74	74	R -> H (in DA2B).
TH	233	233	R -> H (in ARDRD).
TH	236	236	L -> P (in ARDRD; severe parkinsonian symptoms in early infancy; strongly reduced stability and catalytic activity; rare mutation).
TH	314	314	T -> M (in ARDRD; parkinsonian symptoms in infancy).
TH	412	412	Q -> K (in ARDRD; reduced affinity for L- tyrosine).
CDKN1C	171	174	Missing (in several cancers).
CDKN1C	181	184	Missing (in hepatocellular carcinomas).
CDKN1C	200	203	Missing (in a bladder cancer).
CDKN1C	206	209	Missing (in a breast cancer).
SLC22A18	86	86	R -> C (in a rhabdomyosarcoma sample).
SLC22A18	233	233	S -> F (in lung cancer; somatic mutation).
SLC22A18	309	309	R -> Q.
HBB	7	7	E -> A (in G-Makassar).
HBB	7	7	E -> K (in C).
HBB	9	9	K -> T (in Rio Grande).
HBB	11	11	A -> V (in Iraq-Halabja).
HBB	12	12	V -> I (in Hamilton).
HBB	15	15	L -> P (in Saki; unstable).
HBB	17	17	G -> D (in J-Baltimore/J-Trinidad/J- Ireland/J-Georgia/N-New Haven).
HBB	17	17	G -> R (in D-Bushman).
HBB	20	20	N -> K (in D-Ouleh RABAH).
HBB	22	22	D -> N (in Cocody).
HBB	22	22	D -> Y (in Yusa).
HBB	23	23	E -> G (in G-Taipei).
HBB	23	23	E -> K (in E-Saskatoon; unstable).
HBB	23	23	E -> Q (in D-Iran).
HBB	23	23	E -> V (in D-Granada).
HBB	24	24	V -> D (in Strasbourg; O(2) affinity up).
HBB	24	24	V -> F (in Palmerston North; O(2) affinity up; unstable).
HBB	24	24	V -> G (in Miyashiro; O(2) affinity up; unstable).
HBB	25	25	G -> D (in Moscva; O(2) affinity down; unstable).
HBB	25	25	G -> R (in Riverdale-Bronx; O(2) affinity up; unstable).
HBB	25	25	G -> V (in Savannah; unstable).
HBB	26	26	G -> D (in J-Auckland; unstable; O(2) affinity down).
HBB	26	26	G -> R (in G-Taiwan Ami).
HBB	27	27	E -> K (in E).
HBB	27	27	E -> V (in Henri Mondor; slightly unstable).
HBB	28	28	A -> D (in Volga/Drenthe; unstable).
HBB	28	28	A -> S (in Knossos).
HBB	28	28	A -> V (in Grange-blanche; O(2) affinity up).
HBB	29	29	L -> P (in Genova/Hyogo; unstable).
HBB	29	29	L -> Q (in St Louis).
HBB	30	30	G -> D (in Lufkin; unstable).
HBB	31	31	R -> S (in Tacoma; unstable).
HBB	32	32	L -> P (in Yokohama; unstable).
HBB	33	33	L -> R (in Castilla; unstable).
HBB	33	33	L -> V (in Muscat; slightly unstable).
HBB	35	35	V -> D (in Santander; unstable).
HBB	35	35	V -> F (in Pitie-Salpetriere; O(2) affinity up).
HBB	35	35	V -> L (in Nantes; increased oxygen affinity).
HBB	36	36	Y -> F (in Philly; O(2) affinity up; unstable).
HBB	37	37	P -> R (in Sunnybrook).
HBB	37	37	P -> S (in North Chicago; O(2) affinity up).
HBB	37	37	P -> T (in Linkoping/Finlandia; O(2) affinity up).
HBB	38	38	W -> G (in Howick).
HBB	38	38	W -> R (in Rothschild; O(2) affinity down).
HBB	38	38	W -> S (in Hirose; O(2) affinity up).
HBB	39	39	T -> N (in Hinwil; O(2) affinity up).
HBB	40	40	Q -> E (in Vaasa; unstable).
HBB	40	40	Q -> K (in Alabama).
HBB	40	40	Q -> R (in Tianshui).
HBB	42	42	F -> Y (in Mequon).
HBB	42	42	Missing (in Bruxelles).
HBB	43	43	F -> L (in Louisville; unstable).
HBB	43	43	F -> S (in Hammersmith).
HBB	43	43	Missing (in Bruxelles).
HBB	44	44	E -> Q (in Hoshida/Chaya).
HBB	45	45	S -> C (in Mississippi).
HBB	46	46	F -> S (in Cheverly; unstable).
HBB	47	47	G -> E (in K-Ibadan).
HBB	48	48	D -> A (in Avicenna).
HBB	48	48	D -> G (in Gavello).
HBB	48	48	D -> Y (in Maputo).
HBB	49	49	L -> P (in Bab-Saadoum; slightly unstable).
HBB	50	50	S -> F (in Las Palmas; slightly unstable).
HBB	51	51	T -> K (in Edmonton).
HBB	52	52	P -> R (in Willamette; O(2) affinity up; unstable).
HBB	53	53	D -> A (in Ocho Rios).
HBB	53	53	D -> H (in Summer Hill).
HBB	55	55	V -> D (in Jacksonville; O(2) affinity up; unstable).
HBB	56	56	M -> K (in Matera; unstable).
HBB	57	57	G -> R (in Hamadan).
HBB	58	58	N -> K (in G-ferrara; unstable).
HBB	59	59	P -> R (in Dhofar/Yukuhashi).
HBB	60	60	K -> E (in I-High Wycombe).
HBB	61	61	V -> A (in Collingwood; unstable).
HBB	62	62	K -> E (in N-Seatlle).
HBB	62	62	K -> M (in Bologna; O(2) affinity down).
HBB	62	62	K -> N (in Hikari).
HBB	63	63	A -> D (in J-Europa).
HBB	63	63	A -> P (in Duarte; unstable).
HBB	64	64	H -> Y (in M-Saskatoon; O(2) affinity up).
HBB	66	66	K -> M (in J-Antakya).
HBB	66	66	K -> N (in J-Sicilia).
HBB	66	66	K -> Q (in J-Cairo).
HBB	67	67	K -> T (in Chico; O(2) affinity down).
HBB	68	68	V -> A (in Sydney; unstable).
HBB	68	68	V -> D (in Bristol).
HBB	68	68	V -> M (in Alesha; unstable).
HBB	69	69	L -> H (in Brisbane; O(2) affinity up).
HBB	69	69	L -> P (in Mizuho; unstable).
HBB	70	70	G -> D (in Rambam).
HBB	70	70	G -> R (in Kenitra).
HBB	70	70	G -> S (in City of Hope).
HBB	71	71	A -> D (in Seattle; O(2) affinity down; unstable).
HBB	72	72	F -> S (in Christchurch; unstable).
HBB	74	74	D -> G (in Tilburg; O(2) affinity down).
HBB	74	74	D -> V (in Mobile; O(2) affinity down).
HBB	74	74	D -> Y (in Vancouver; O(2) affinity down).
HBB	75	75	G -> R (in Aalborg; unstable).
HBB	75	75	G -> V (in Bushwick; unstable).
HBB	76	76	L -> P (in Atlanta; unstable).
HBB	76	76	L -> R (in Pasadena; O(2) affinity up; unstable).
HBB	77	77	A -> D (in J-Chicago).
HBB	78	78	H -> D (in J-Iran).
HBB	78	78	H -> R (in Costa Rica).
HBB	78	78	H -> Y (in Fukuyama).
HBB	79	79	L -> R (in Quin-hai).
HBB	80	80	D -> Y (in Tampa).
HBB	81	81	N -> K (in G-Szuhu/Gifu).
HBB	82	82	L -> H (in La Roche-sur-Yon; unstable and O(2) affinity up).
HBB	82	82	L -> R (in Baylor; unstable).
HBB	83	83	K -> M (in Helsinki; O(2) affinity up).
HBB	83	83	K -> N (in Providence).
HBB	84	84	G -> D (in Pyrgos).
HBB	84	84	G -> R (in Muskegon).
HBB	85	85	T -> I (in Kofu).
HBB	87	87	A -> D (in Olomouc; O(2) affinity up).
HBB	88	88	T -> I (in Quebec-Chori).
HBB	88	88	T -> K (in D-Ibadan).
HBB	88	88	T -> P (in Valletta).
HBB	89	89	L -> P (in Santa Ana; unstable).
HBB	89	89	L -> R (in Boras; unstable).
HBB	90	90	S -> N (in Creteil; O(2) affinity up).
HBB	90	90	S -> R (in Vanderbilt; O(2) affinity up).
HBB	91	91	E -> D (in Pierre-Benite; O(2) affinity up).
HBB	91	91	E -> K (in Agenogi; O(2) affinity down).
HBB	92	92	L -> P (in Sabine; unstable).
HBB	92	92	L -> R (in Caribbean; O(2) affinity down; unstable).
HBB	93	93	H -> D (in J-Altgelds Gardens; unstable).
HBB	93	93	H -> N (in Isehara; unstable).
HBB	93	93	H -> P (in Newcastle and Duino; associated with S-104 in Duino; unstable).
HBB	93	93	H -> Q (in Istambul; O(2) affinity up; unstable).
HBB	94	94	C -> R (in Okazaki; O(2) affinity up; unstable).
HBB	95	95	D -> G (in Chandigarh).
HBB	95	95	D -> H (in Barcelona; O(2) affinity up).
HBB	95	95	D -> N (in Bunbury; O(2) affinity up).
HBB	96	96	K -> M (in J-Cordoba).
HBB	96	96	K -> N (in Detroit).
HBB	97	97	L -> P (in Debrousse; unstable; O(2) affinity up).
HBB	97	97	L -> V (in Regina; O(2) affinity up).
HBB	98	98	H -> L (in Wood; O(2) affinity up).
HBB	98	98	H -> P (in Nagoya; O(2) affinity up; unstable).
HBB	98	98	H -> Q (in Malmoe; O(2) affinity up).
HBB	98	98	H -> Y (in Moriguchi).
HBB	99	99	V -> G (in Nottingham; unstable).
HBB	100	100	D -> E (in Coimbra; O(2) affinity up).
HBB	101	101	P -> L (in Brigham; O(2) affinity up).
HBB	101	101	P -> R (in New Mexico).
HBB	102	102	E -> D (in Potomac; O(2) affinity up).
HBB	102	102	E -> G (in Alberta; O(2) affinity up).
HBB	102	102	E -> K (in British Columbia; O(2) affinity up).
HBB	102	102	E -> Q (in Rush; unstable).
HBB	103	103	N -> S (in Beth Israel; O(2) affinity down; unstable).
HBB	103	103	N -> Y (in St Mande; O(2) affinity down).
HBB	104	104	F -> L (in Heathrow; O(2) affinity up).
HBB	105	105	R -> S (in Camperdown and Duino; associated with P-92 in Duino; unstable).
HBB	105	105	R -> T (in Sherwood Forest).
HBB	108	108	G -> R (in Burke; O(2) affinity down; unstable).
HBB	109	109	N -> K (in Presbyterian; O(2) affinity down; unstable).
HBB	110	110	V -> M (in San Diego; O(2) affinity up).
HBB	111	111	L -> P (in Showa-Yakushiji).
HBB	112	112	V -> A (in Stanmore; O(2) affinity down; unstable).
HBB	113	113	C -> F (in Canterbury).
HBB	113	113	C -> R (in Indianapolis).
HBB	113	113	C -> Y (in Yahata).
HBB	115	115	L -> M (in Zengcheng).
HBB	115	115	L -> P (in Durham-N.C./Brescia; causes beta-thalassemia).
HBB	116	116	A -> D (in Hradec Kralove; unstable; causes severe beta-thalassemia).
HBB	116	116	A -> P (in Madrid; unstable).
HBB	117	117	H -> L (in Vexin; increased oxygen affinity).
HBB	117	117	H -> Q (in Hafnia).
HBB	118	118	H -> P (in Saitama; unstable).
HBB	118	118	H -> R (in P-Galveston).
HBB	118	118	H -> Y (in Tsukumi).
HBB	120	120	G -> A (in Iowa).
HBB	121	121	K -> E (in Hijiyama).
HBB	121	121	K -> I (in Jianghua).
HBB	121	121	K -> Q (in Takamatsu).
HBB	122	122	E -> A (in D-Neath).
HBB	122	122	E -> G (in St Francis).
HBB	122	122	E -> K (in O-Arab).
HBB	122	122	E -> Q (in D-Los Angeles/D-Punjab/D- Portugal/D-Chicago/D-Oak Ridge).
HBB	122	122	E -> V (in D-Camperdown/Beograd).
HBB	124	124	T -> I (in Villejuif; asymptomatic variant).
HBB	125	125	P -> Q (in Ty Gard; O(2) affinity up).
HBB	125	125	P -> R (in Khartoum; unstable).
HBB	125	125	P -> S (in Tunis).
HBB	127	127	V -> A (in Beirut).
HBB	127	127	V -> E (in Hofu; unstable).
HBB	127	127	V -> G (in Dhonburi/Neapolis; unstable; beta-thalassemia).
HBB	128	128	Q -> E (in Complutense).
HBB	128	128	Q -> K (in Brest; unstable).
HBB	129	129	A -> D (in J-Guantanamo; unstable).
HBB	130	130	A -> P (in Crete; O(2) affinity up; unstable).
HBB	130	130	A -> V (in La Desirade; O(2) affinity down; unstable).
HBB	131	131	Y -> D (in Wien; unstable).
HBB	131	131	Y -> S (in Nevers).
HBB	132	132	Q -> E (in Camden/Tokuchi/Motown).
HBB	132	132	Q -> K (in Shelby/Leslie/Deaconess; unstable).
HBB	132	132	Q -> P (in Shangai; unstable).
HBB	132	132	Q -> R (in Sarrebourg; unstable).
HBB	133	133	K -> N (in Yamagata; O(2) affinity down).
HBB	133	133	K -> Q (in K-Woolwich).
HBB	134	134	V -> L (in Extredemura).
HBB	135	135	V -> E (in North Shore-Caracas; unstable).
HBB	136	136	A -> E (in Beckman; O(2) affinity down; unstable).
HBB	136	136	A -> P (in Altdorf; O(2) affinity up; unstable).
HBB	137	137	G -> D (in Hope; O(2) affinity down; unstable).
HBB	139	139	A -> P (in Brockton; unstable).
HBB	140	140	N -> D (in Geelong; unstable).
HBB	140	140	N -> K (in Hinsdale; O(2) affinity down).
HBB	140	140	N -> S (in S-Wake; associated with V-6).
HBB	140	140	N -> Y (in Aurora; O(2) affinity up).
HBB	141	141	A -> D (in Himeji; unstable; O(2) affinity down).
HBB	141	141	A -> T (in St Jacques: O(2) affinity up).
HBB	141	141	A -> V (in Puttelange; polycythemia; O(2) affinity up).
HBB	142	142	L -> R (in Olmsted; unstable).
HBB	143	143	A -> D (in Ohio; O(2) affinity up).
HBB	144	144	H -> D (in Rancho Mirage).
HBB	144	144	H -> P (in Syracuse; O(2) affinity up).
HBB	144	144	H -> Q (in Little Rock; O(2) affinity up).
HBB	144	144	H -> R (in Abruzzo; O(2) affinity up).
HBB	145	145	K -> E (in Mito; O(2) affinity up).
HBB	146	146	Y -> C (in Rainier; O(2) affinity up).
HBB	146	146	Y -> H (in Bethesda; O(2) affinity up).
HBB	147	147	H -> D (in Hiroshima; O(2) affinity up).
HBB	147	147	H -> L (in Cowtown; O(2) affinity up).
HBB	147	147	H -> P (in York; O(2) affinity up).
HBB	147	147	H -> Q (in Kodaira; O(2) affinity up).
HBD	3	3	H -> L (in Catania).
HBD	5	5	T -> S (in haplotype T11; Kenya).
HBD	11	11	A -> D (in MUMC/Corleone).
HBD	71	71	A -> G (in Ventimiglia).
HBD	88	88	Q -> K (in Montechiaro).
HBD	134	134	V -> A (in Ninive).
HBD	137	137	G -> D (in Babinga).
HBD	141	141	A -> V (in Bagheria).
HBD	142	142	L -> P (in Pelendri).
HBD	143	143	A -> D (in Fitzroy).
HBD	147	147	H -> R (in Monreale).
SMPD1	49	49	D -> V (in NPDB).
SMPD1	92	92	C -> W (in NPDB).
SMPD1	103	103	L -> P (in NPDA and NPDB; expresses protein level comparable to wild-type SMPD1 expressing cells; retains very low enzyme activity).
SMPD1	130	130	V -> A (in NPDB; expresses protein level comparable to wild-type SMPD1 expressing cells; retains 13% residual enzyme actvity).
SMPD1	137	137	L -> P (in NPDB).
SMPD1	157	157	C -> R (in NPDB; seems to be less active).
SMPD1	166	166	G -> R (in NPDB; also in patients with an intermediate form).
SMPD1	176	176	I -> N (in NPDB).
SMPD1	184	184	P -> L (in NPDA/NPDB; intermediate form).
SMPD1	196	196	A -> P (in NPDB).
SMPD1	200	200	R -> C (in NPDB).
SMPD1	225	225	L -> M (in NPDB; expresses protein level comparable to wild-type SMPD1 expressing cells; retains no enzyme activity).
SMPD1	225	225	L -> P (in NPDB; expresses protein level comparable to wild-type SMPD1 expressing cells; retains no enzyme activity).
SMPD1	228	228	R -> C (in NPDB).
SMPD1	228	228	R -> H (in NPDA/NPDB; intermediate form).
SMPD1	232	232	G -> D (in NPDB).
SMPD1	241	241	A -> V (in NPDA/NPDB; intermediate form).
SMPD1	242	242	G -> R (in NPDB).
SMPD1	244	244	W -> C (in NPDB; expresses protein level comparable to wild-type SMPD1 expressing cells; retains no enzyme activity).
SMPD1	245	245	G -> S (in NPDA and NPDB).
SMPD1	246	246	E -> K (in NPDA).
SMPD1	246	246	E -> Q (in NPDA; 30% residual activity).
SMPD1	248	248	S -> R (in NPDA and NPDB; also found in patients with an intermediate form).
SMPD1	251	251	D -> E (in NPDA/NPDB; intermediate form).
SMPD1	278	278	D -> A (in NPDA/NPDB; intermediate form).
SMPD1	281	281	A -> T (in NPDB; expresses protein level comparable to wild-type SMPD1 expressing cells; retains no enzyme activity).
SMPD1	289	289	R -> H (in NPDB; also in patients with an intermediate form).
SMPD1	292	292	Q -> K (in NPDA/NPDB; intermediate form).
SMPD1	294	294	R -> Q (in NPDA).
SMPD1	302	302	L -> P (in NPDA; in 23% of NPDA Ashkenazi Jewish patients).
SMPD1	313	313	Y -> H (in NPDA).
SMPD1	319	319	H -> Y (in NPDA).
SMPD1	323	323	P -> A (in NPDB).
SMPD1	330	330	P -> R (in NPDB).
SMPD1	341	341	L -> P (in NPDA/NPDB; intermediate form).
SMPD1	357	357	A -> D (in NPDB).
SMPD1	367	367	Y -> C (in NPDA).
SMPD1	371	371	P -> S (in NPDB).
SMPD1	376	376	R -> H (in NPDB; also found in a patient with an intermediate form).
SMPD1	376	376	R -> L (in NPDB).
SMPD1	379	379	S -> P (in NPDB).
SMPD1	382	382	M -> I (in NPDA).
SMPD1	383	383	N -> S (in NPDB).
SMPD1	389	389	N -> T (in NPDA).
SMPD1	390	390	Missing (in NPDA).
SMPD1	391	391	W -> G (in NPDB; low sphingomyelin degradation rates).
SMPD1	413	413	A -> V (in NPDB).
SMPD1	421	421	H -> R (in NPDA).
SMPD1	421	421	H -> Y (in NPDB).
SMPD1	431	431	C -> R (in NPDB).
SMPD1	432	432	L -> P (in NPDB).
SMPD1	435	435	W -> C (in NPDB).
SMPD1	436	436	S -> R (in NPDB).
SMPD1	446	446	Y -> C (in NPDA).
SMPD1	450	450	L -> P (in NPDA).
SMPD1	452	452	A -> V (in NPDB).
SMPD1	456	456	G -> D (in NPDB).
SMPD1	463	463	F -> S (in NPDA).
SMPD1	467	467	Y -> S (in NPDA).
SMPD1	474	474	R -> W (in NPDB; also in a patient with an intermediate form).
SMPD1	475	475	P -> L (in NPDA and NPDB).
SMPD1	480	480	F -> L (in NPDB).
SMPD1	482	482	A -> E (in NPDA).
SMPD1	485	485	A -> V (in NPDB).
SMPD1	486	486	T -> A (in NPDB).
SMPD1	488	488	Y -> N (in NPDB).
SMPD1	494	494	G -> S (in NPDB).
SMPD1	496	496	R -> C (in NPDB).
SMPD1	496	496	R -> H (in NPDA).
SMPD1	496	496	R -> L (in NPDA; in 32% of NPDA Ashkenazi Jewish patients).
SMPD1	505	505	S -> G.
SMPD1	514	514	H -> Q (in NPDB).
SMPD1	515	515	E -> V (in NPDB).
SMPD1	517	517	Y -> C (in NPDA).
SMPD1	533	533	W -> R (in NPDB; also in patients with an intermediate form).
SMPD1	537	537	Y -> H (in NPDA).
SMPD1	549	549	L -> P (in NPDB).
SMPD1	563	563	D -> Y (in NPDB; expresses protein level comparable to wild-type SMPD1 expressing cells; retains 6.8% residual enzyme actvity).
SMPD1	576	576	K -> N (in NPDB).
SMPD1	577	577	G -> S (in NPDA; also in patients with an intermediate form).
SMPD1	592	592	Missing (in NPDA).
SMPD1	600	600	R -> H (in NPDB; expresses protein level comparable to wild-type SMPD1 expressing cells; retains about 10% residual enzyme actvity).
SMPD1	600	600	R -> P (in NPDB; expresses protein level comparable to wild-type SMPD1 expressing cells; retains very low enzyme activity).
SMPD1	608	608	Missing (in NPDB; prevalent among NPDB patients from the North African Maghreb region).
TPP1	153	153	S -> P (in CLN2).
TPP1	175	175	R -> H.
TPP1	278	278	Q -> P (in CLN2).
TPP1	428	428	K -> N (in CLN2).
TPP1	481	481	F -> C (in CLN2).
DCHS1	1583	1583	R -> W (in a colorectal cancer sample; somatic mutation).
RIC3	346	346	G -> V (in a colorectal cancer sample; somatic mutation).
PTH	18	18	C -> R (in FIH; dominant; leads to inefficient processing of the precursor; the expressed mutant hormone is trapped intracellularly in the endoplasmic reticulum resulting in apoptosis; mutant protein-expressing cells also show marked up-regulation of the endoplasmic reticulum stress-responsive hormones HSPA5 and EIF2AK3 and the proapoptotic transcription factor DDIT3).
PTH	23	23	S -> P (in FIH; recessive, might lead to inefficient processing of the precursor).
RRAS2	72	72	Q -> L (in an ovarian cancer sample; somatic mutation).
MYOD1	262	262	E -> K (in a breast cancer sample; somatic mutation).
MYOD1	309	309	A -> V (in a breast cancer sample; somatic mutation).
SAA1	70	70	V -> A (in 2-alpha, 2-beta, 1-beta and 1- gamma).
SAA1	75	75	A -> V (in 2-alpha, 2-beta and 1-beta).
SAA1	78	78	D -> N (in 2-alpha and 2-beta).
SAA1	86	87	FF -> LT (in 2-alpha and 2-beta).
SAA1	90	90	G -> D (in 1-beta).
HPS5	624	624	L -> R (in HPS5).
HPS5	1098	1098	T -> I (in HPS5).
LDHA	222	222	K -> E.
LDHA	315	315	R -> C.
MRGPRX2	78	78	F -> L.
CSRP3	44	44	L -> P (in CMH12).
CSRP3	54	55	SE -> RG (in CMH12).
CSRP3	58	58	C -> G (in CMH12).
HTATIP2	106	106	R -> S (in a hepatocellular carcinoma sample).
HTATIP2	108	108	D -> Y (in a hepatocellular carcinoma sample).
HTATIP2	116	116	A -> T (in a hepatocellular carcinoma sample).
HTATIP2	134	134	G -> V (in a hepatocellular carcinoma sample; reduces protein stability).
HTATIP2	144	144	L -> I (in a hepatocellular carcinoma sample).
SLC6A5	89	89	A -> E (no effect on subcellular location; no effect on glycine transport).
SLC6A5	184	184	Q -> R.
SLC6A5	306	306	L -> V (in STHE; compound heterozygote with S-509; impairment of glycine transport when coexpressed with S-509 in vitro).
SLC6A5	425	425	T -> M (in STHE; no effect on subcellular location; impairs glycine transport).
SLC6A5	482	482	W -> C (in STHE; no effect on subcellular location; impairs glycine transport).
SLC6A5	491	491	Y -> C (in STHE; no effect on subcellular location; impairs glycine transport).
SLC6A5	509	509	N -> S (in STHE; compound heterozygote with V-306; no effect on subcellular location; impairs glycine transport).
SLC6A5	510	510	S -> R (in STHE; results in the formation of large aggregates in the cytoplasm; impairs glycine transport).
SLC6A5	632	632	V -> E (in a breast cancer sample; somatic mutation).
SLC6A5	751	751	V -> A.
SLC17A6	40	40	T -> S (in a breast cancer sample; somatic mutation).
DNAJC24	22	22	N -> D (in a breast cancer sample; somatic mutation).
PAX6	17	17	N -> S (in AN).
PAX6	18	18	G -> W (in AN).
PAX6	19	19	R -> P (in AN).
PAX6	22	26	Missing (in AN).
PAX6	26	26	R -> G (in PAN).
PAX6	29	29	I -> S (in AN).
PAX6	29	29	I -> V (in AN).
PAX6	33	33	A -> P (in AN).
PAX6	37	39	Missing (in AN).
PAX6	42	42	I -> S (in AN; mild).
PAX6	43	43	S -> P (in AN).
PAX6	44	44	R -> Q (in AN).
PAX6	46	46	L -> R (in AN; shows almost no binding efficiency; transcriptional activation ability is about 50% lower than that of the wild-type protein).
PAX6	52	52	C -> R (in AN; shows almost no binding efficiency; transcriptional activation ability is about 50% lower than that of the wild-type protein).
PAX6	53	53	V -> D (in PAN; also found in patients with congenital cataract and foveal hypoplasia).
PAX6	53	53	V -> L (in AN; mild; shows 50% lower DNA- binding and transactivation ability than the wild-type protein).
PAX6	56	56	I -> T (in AN; shows only one-quarter to one-third the binding ability of the normal wild-type protein; exhibits normal transactivation).
PAX6	63	63	T -> P (in AN; mild).
PAX6	64	64	G -> V (in foveal hypoplasia; associated with presenile cataract syndrome).
PAX6	68	68	P -> S (in morning glory disk anomaly; significant impairment of transcriptional activation ability).
PAX6	73	73	G -> D (in AN; shows almost no binding efficiency; transcriptional activation ability is about 80% of that of the wild- type protein).
PAX6	79	79	A -> E (in AN; mild).
PAX6	87	87	I -> K (in AN).
PAX6	87	87	I -> R (in AN; loss of activity).
PAX6	118	118	P -> R (in a family with nystagmus associated with a variant form of aniridia).
PAX6	119	119	S -> R (in AN).
PAX6	125	125	R -> C (in FOVHYP; isolated).
PAX6	126	126	V -> D (in AN; atypical form).
PAX6	128	128	R -> C (in FOVHYP; isolated).
PAX6	178	178	Q -> H (in AN).
PAX6	208	208	R -> Q (in AN; mild).
PAX6	208	208	R -> W (in AN).
PAX6	242	242	R -> T (in AN; the mutant homeodomain binds DNA as well as the wild-type homeodomain; the mutant does not modify the DNA-binding properties of the paired domain; the steady-state levels of the full length mutant protein are higher than those of the wild-type one; a responsive promoter is activated to a higher extend by the mutant protein than by the wild-type protein; the presence of the mutation reduces sensitivity to trypsin digestion).
PAX6	258	258	F -> S (in COI; significant impairment of transcriptional activation ability).
PAX6	292	292	S -> I (in BONH; significant impairment of ability to activate transcription).
PAX6	321	321	A -> T (shows about two-fold higher binding efficiency than the normal wild- type protein; transcriptional activation ability is about 89% of that of the wild- type protein).
PAX6	353	353	S -> A (in AN).
PAX6	363	363	S -> P (in PAN).
PAX6	375	375	P -> Q (in AN; reduced DNA binding ability).
PAX6	378	378	Q -> R (in optic nerve aplasia).
PAX6	381	381	M -> V (in BONH).
PAX6	387	387	G -> D.
PAX6	391	391	T -> A (in BONH).
PAX6	422	422	Q -> R (in AN and ocular anterior segment anomalies; loss of DNA binding ability).
WT1	131	131	A -> T (in a patient with hypospadias).
WT1	223	223	S -> N (in WT1).
WT1	253	253	G -> A (in WT1).
WT1	273	273	S -> G (in mesothelioma).
WT1	281	281	L -> P (in RNA edited version).
WT1	312	312	R -> Q (in NPHS4).
WT1	330	330	C -> Y (in DDS).
WT1	342	342	M -> R (in DDS).
WT1	355	355	C -> G (in WT1).
WT1	355	355	C -> Y (in DDS).
WT1	360	360	C -> G (in DDS).
WT1	360	360	C -> Y (in DDS).
WT1	364	364	F -> L (in NPHS4).
WT1	366	366	R -> C (in WT1, DDS and MEACHS).
WT1	366	366	R -> H (in DDS and WT1).
WT1	366	366	R -> L (in DDS).
WT1	369	369	Q -> P (in DDS).
WT1	373	373	H -> Q (in DDS and WT1).
WT1	373	373	H -> Y (in DDS).
WT1	377	377	H -> R (in DDS).
WT1	377	377	H -> Y (in NPHS4).
WT1	379	379	G -> C (in NPHS4).
WT1	383	383	F -> L (in NPHS4).
WT1	385	385	C -> R (in DDS).
WT1	388	388	C -> F (in DDS).
WT1	388	388	C -> R (in NPHS4).
WT1	388	388	C -> Y (in DDS).
WT1	392	392	F -> L (in FS).
WT1	394	394	R -> L (in WT1).
WT1	394	394	R -> P (in DDS).
WT1	394	394	R -> Q (in DDS).
WT1	394	394	R -> W (in DDS, WT1 and MEACHS).
WT1	396	396	D -> G (in DDS).
WT1	396	396	D -> N (in DDS and NPHS4).
WT1	396	396	D -> Y (in DDS).
WT1	397	397	H -> P (in NPHS4).
WT1	398	398	L -> P (in DDS).
WT1	401	401	H -> Y (in DDS).
WT1	405	405	H -> R (in DDS).
EIF3M	80	80	E -> G (in a breast cancer sample; somatic mutation).
CD44	46	46	R -> P (in In(A) antigen).
RAG2	41	41	C -> W (in OS).
RAG2	77	77	T -> N (in CHIDG; reduced recombination activity).
RAG2	229	229	R -> Q (in T(-)B(-)NK(+) SCID).
RAG2	285	285	M -> R (in OS).
RAG2	451	451	G -> A (in CHIDG; reduced recombination activity).
RAG2	478	478	C -> Y (in T(-)B(-)NK(+) SCID).
API5	276	276	P -> S.
ACCS	393	393	S -> L (in a breast cancer sample; somatic mutation).
MAPK8IP1	59	59	S -> N (in NIDDM).
MDK	21	22	Missing (in 35% of the chains).
F2	72	72	E -> G (in FA2D; Shanghai).
F2	200	200	E -> K (in FA2D; prothrombin type 3).
F2	314	314	R -> C (in FA2D; Barcelona/Madrid).
F2	314	314	R -> H (in FA2D; Padua-1).
F2	380	380	M -> T (in FA2D; Himi-1).
F2	425	425	R -> C (in FA2D; Quick-1).
F2	431	431	R -> H (in FA2D; Himi-2).
F2	461	461	R -> W (in FA2D; Tokushima).
F2	509	509	E -> A (in FA2D; Salakta/Frankfurt).
F2	601	601	G -> V (in FA2D; Quick-2).
DDB2	244	244	K -> E (in XP-E; impairs DNA-binding of the UV-DDB complex).
DDB2	273	273	R -> H (in XP-E; impairs interaction with DDB1 and CUL4A).
MYBPC3	5	5	G -> R (in CMH4).
MYBPC3	59	59	T -> A (in CMH4).
MYBPC3	161	161	P -> S (in CMH4).
MYBPC3	219	219	V -> L (in CMH4).
MYBPC3	228	228	D -> N (in CMH4).
MYBPC3	237	237	Y -> S (in CMH4).
MYBPC3	256	256	V -> I (in CMH4).
MYBPC3	257	257	H -> P (in CMH4).
MYBPC3	258	258	E -> K (in CMH4).
MYBPC3	263	263	G -> R (in CMH4).
MYBPC3	273	273	R -> H (in CMH4).
MYBPC3	278	278	G -> E (in CMH4).
MYBPC3	279	279	G -> A (in CMH4).
MYBPC3	282	282	R -> W (in CMH4).
MYBPC3	352	352	L -> P (in CMH4).
MYBPC3	415	415	G -> S.
MYBPC3	416	416	A -> S (in CMH4).
MYBPC3	450	450	E -> Q (in CMH4).
MYBPC3	457	457	R -> H (in CMH4).
MYBPC3	489	489	G -> R (in CMH4).
MYBPC3	494	494	R -> G (in CMH4).
MYBPC3	494	494	R -> Q (in CMH4).
MYBPC3	501	501	R -> Q (in CMH4).
MYBPC3	501	501	R -> W (in CMH4).
MYBPC3	503	503	Missing (in CMH4).
MYBPC3	522	522	G -> W (in CMH4).
MYBPC3	541	541	E -> Q (in CMH4).
MYBPC3	544	544	L -> M.
MYBPC3	565	565	C -> R (in CMH4).
MYBPC3	603	603	D -> V (in CMH4).
MYBPC3	604	604	D -> N (in CMH4; pathogenicity remains to be determined).
MYBPC3	607	607	P -> L (in CMH4).
MYBPC3	667	667	R -> H (in CMH4).
MYBPC3	667	667	R -> P (in CMH4).
MYBPC3	668	668	L -> H (in CMH4).
MYBPC3	732	732	R -> C (in CMH4).
MYBPC3	754	754	N -> K (in CMH4; destabilizes the structure of Ig-like C2-type domain 5).
MYBPC3	758	758	E -> D (in CMH4).
MYBPC3	791	791	W -> R (in CMH4).
MYBPC3	809	809	R -> H (in CMH4).
MYBPC3	810	810	K -> R (in CMH4).
MYBPC3	810	810	Missing (in CMH4).
MYBPC3	812	812	Missing (in CMH4).
MYBPC3	832	832	A -> T (in CMH4; pathogenicity is uncertain).
MYBPC3	833	833	R -> T (in CMH4).
MYBPC3	833	833	R -> W (in CMH4; pathogenicity is uncertain).
MYBPC3	872	872	P -> H (in CMH4).
MYBPC3	947	947	N -> T (in CMH4).
MYBPC3	997	997	Q -> E (in CMH4; dbNP:11570112).
MYBPC3	997	997	Q -> R (in CMH4).
MYBPC3	1001	1001	R -> Q (in CMH4).
MYBPC3	1002	1002	P -> Q (in CMH4).
MYBPC3	1027	1027	T -> S (in CMH4).
MYBPC3	1112	1112	F -> I (in CMH4).
MYBPC3	1114	1114	V -> I (in CMH4).
MYBPC3	1130	1130	I -> T (in CMH4; pathogenicity is uncertain).
MYBPC3	1154	1154	Missing (in CMH4).
MYBPC3	1193	1193	A -> T (in CMH4).
MYBPC3	1247	1247	G -> R (in CMH4).
MYBPC3	1254	1254	A -> T (in CMH4).
SLC39A13	162	164	Missing (in SCD-EDS).
RAPSN	14	14	L -> P (in CMS-ACHRD).
RAPSN	45	45	V -> M (in CMS-ACHRD; reduced coclustering with acetylcholine receptor).
RAPSN	88	88	N -> K (in CMS-ACHRD).
RAPSN	139	139	F -> S (in FADS).
RAPSN	162	162	E -> K (in CMS-ACHRD; reduced coclustering with acetylcholine receptor).
RAPSN	164	164	R -> C (in CMS-ACHRD; reduced coclustering with acetylcholine receptor).
RAPSN	189	189	A -> V (in FADS).
RAPSN	283	283	L -> P (in CMS-ACHRD; reduced coclustering with acetylcholine receptor).
FOLH1	23	23	A -> T (in a colorectal cancer sample; somatic mutation).
FOLH1	475	475	H -> Y (can be associated with lower folate and higher homocysteine levels).
SERPING1	84	138	Missing (in HAE; type 2).
SERPING1	130	130	C -> Y (in HAE; type 1).
SERPING1	273	273	Missing (in HAE; type 2; TA; creates a new glycosylation site).
SERPING1	345	345	G -> R (in HAE; type 1).
SERPING1	394	394	T -> P (in HAE; type 1).
SERPING1	408	408	D -> V (in HAE; type 1).
SERPING1	429	429	G -> R (in HAE; type 2).
SERPING1	454	454	V -> E (in HAE; type 2; WE).
SERPING1	456	456	A -> E (in HAE; type 2; MA).
SERPING1	458	458	A -> T (in HAE; type 2; MO).
SERPING1	458	458	A -> V (in HAE; type 2).
SERPING1	465	465	A -> V (in HAE; type 2).
SERPING1	466	466	R -> H (in HAE; type 2; AT).
SERPING1	466	466	R -> L (in HAE; type 2).
SERPING1	467	467	T -> P (in HAE; type 2).
SERPING1	473	473	V -> E (in HAE; type 1).
SERPING1	473	473	V -> M (in HAE; type 2).
SERPING1	474	474	Q -> E.
SERPING1	477	477	F -> S (in HAE; type 2).
SERPING1	481	481	L -> P (in HAE; type 2).
SERPING1	481	481	L -> R (in HAE; type 2).
SERPING1	489	489	P -> R (in HAE; type 2).
SERPING1	493	493	G -> E (in HAE; type 1).
SERPING1	498	498	P -> R (in HAE; type 1).
SERPING1	498	498	P -> S (in HAE; type 2).
OR6Q1	172	172	F -> I (found in a renal cell carcinoma sample; somatic mutation).
GIF	46	46	S -> L (in IFD).
MS4A6A	183	183	A -> S.
MS4A5	123	123	L -> R (in a colorectal cancer sample; somatic mutation).
PGA4	28	28	L -> F (in isozyme 5).
PGA4	58	58	E -> K (in isozyme 3A, isozyme 4 and isozyme 5).
PGA4	92	92	V -> L (in isozyme 4 and isozyme 5).
PGA4	222	222	Q -> K.
PGA4	376	376	D -> E.
PGA5	28	28	L -> F (in isozyme 5).
PGA5	58	58	E -> K (in isozyme 3A, isozyme 4 and isozyme 5).
PGA5	92	92	V -> L (in isozyme 4 and isozyme 5).
PGA5	222	222	Q -> K.
PGA5	376	376	D -> E.
TMEM216	66	66	R -> C (in JBTS2).
TMEM216	66	66	R -> H (in JBTS2 and MKS2).
TMEM216	66	66	R -> L (in JBTS2).
TMEM216	70	70	G -> A (in MKS2).
TMEM216	107	107	L -> R (in MKS2).
BEST1	3	3	I -> T (in VMD2).
BEST1	6	6	T -> R (in VMD2).
BEST1	9	9	V -> A (in VMD2).
BEST1	10	10	A -> T (in VMD2).
BEST1	10	10	A -> V (in VMD2).
BEST1	11	11	N -> I (in VMD2).
BEST1	13	13	R -> H (in VMD2).
BEST1	16	16	S -> F (in VMD2).
BEST1	17	17	F -> C (in VMD2).
BEST1	21	21	L -> V (in VMD2).
BEST1	24	24	W -> C (in VMD2).
BEST1	25	25	R -> Q (in VMD2).
BEST1	25	25	R -> W (in VMD2).
BEST1	26	26	G -> R (in VMD2).
BEST1	27	27	S -> R (in VMD2).
BEST1	29	29	Y -> H (in VMD2).
BEST1	30	30	K -> R (in VMD2).
BEST1	41	41	L -> P (in VMD2 and ARB).
BEST1	58	58	Q -> L (in VMD2).
BEST1	67	67	L -> V.
BEST1	73	73	I -> N (in VMD2).
BEST1	80	80	F -> L (in VMD2).
BEST1	82	82	L -> V (in VMD2).
BEST1	86	86	V -> M (in ADVIRC).
BEST1	89	89	V -> A (in VMD2).
BEST1	91	91	T -> I (in VMD2).
BEST1	92	92	R -> C (in VMD2; loss of cloride and bicarbonate anions conduction).
BEST1	92	92	R -> H (in VMD2).
BEST1	92	92	R -> S (in VMD2).
BEST1	96	96	Q -> H (in VMD2).
BEST1	99	99	N -> K (in VMD2).
BEST1	100	100	L -> R (in VMD2).
BEST1	101	101	P -> T (in VMD2).
BEST1	102	102	W -> R (in VMD2).
BEST1	104	104	D -> E (in VMD2).
BEST1	104	104	D -> H (in VMD2).
BEST1	105	105	R -> C (in age-related macular degeneration).
BEST1	113	113	F -> L (in VMD2).
BEST1	133	133	N -> K (in VMD2).
BEST1	135	135	G -> S (in VMD2).
BEST1	140	140	L -> R (in VMD2).
BEST1	140	140	L -> V (in RP50; causes protein mislocalization to the cytoplasm and reduction of channel activity).
BEST1	141	141	R -> H (in VMD2 and ARB; reduced whole- cell conductance).
BEST1	152	152	P -> A (in ARB; reduced whole-cell conductance).
BEST1	195	195	A -> V (in VMD2).
BEST1	201	201	I -> T (in VMD2).
BEST1	205	205	I -> T (in RP50; reduced channel activity).
BEST1	207	207	L -> I (in VMD2).
BEST1	209	209	S -> N (in VMD2).
BEST1	216	216	T -> I (in a sporadic case of age-related macular degeneration).
BEST1	218	218	R -> C (in VMD2).
BEST1	218	218	R -> H (in VMD2).
BEST1	218	218	R -> Q (in VMD2).
BEST1	218	218	R -> S (in VMD2).
BEST1	221	221	C -> W (in VMD2).
BEST1	222	222	G -> V (in a family affected by Leber congenital amaurosis/VMD2).
BEST1	224	224	L -> M (in VMD2).
BEST1	224	224	L -> P (in VMD2).
BEST1	227	227	Y -> C (in RP50).
BEST1	228	228	D -> N (in RP50; causes protein mislocalization to the cytoplasm).
BEST1	231	231	S -> R (in VMD2).
BEST1	235	235	V -> L (in VMD2).
BEST1	235	235	V -> M (in VMD2).
BEST1	236	236	Y -> C (in ADVIRC).
BEST1	237	237	T -> R (in VMD2).
BEST1	239	239	V -> M (in ADVIRC).
BEST1	241	241	T -> N (in VMD2).
BEST1	242	242	V -> M (in VMD2; late-onset of visual disturbance).
BEST1	275	275	V -> I (in age-related macular degeneration).
BEST1	276	276	F -> L (in VMD2).
BEST1	293	293	Q -> K (in VMD2).
BEST1	294	294	L -> V (in VMD2).
BEST1	295	295	I -> T (in VMD2).
BEST1	295	295	Missing (in VMD2).
BEST1	296	296	N -> H (in VMD2).
BEST1	296	296	N -> S (in VMD2).
BEST1	297	297	P -> A (in VMD2).
BEST1	298	298	F -> S (in VMD2).
BEST1	299	299	G -> A (in VMD2).
BEST1	300	300	E -> K (in VMD2).
BEST1	301	301	D -> E (in VMD2).
BEST1	301	301	D -> N (in VMD2).
BEST1	302	304	Missing (in VMD2).
BEST1	302	302	D -> G (in VMD2).
BEST1	302	302	D -> H (in VMD2).
BEST1	302	302	D -> V (in VMD2).
BEST1	303	303	D -> E (in VMD2).
BEST1	305	305	F -> S (in VMD2).
BEST1	306	306	E -> D (in VMD2).
BEST1	306	306	E -> G (in VMD2).
BEST1	307	307	T -> A (in VMD2).
BEST1	307	307	T -> I (in VMD2).
BEST1	308	308	N -> S (in VMD2).
BEST1	310	310	I -> T (in VMD2).
BEST1	311	311	V -> G (in VMD2).
BEST1	312	312	D -> N (in AVMD and ARB; causes protein mislocalization to the cytoplasm).
BEST1	317	317	V -> M (in ARB).
BEST1	325	325	M -> T (in ARB).
BEST1	525	525	E -> A.
BEST1	557	557	E -> K.
BEST1	561	561	T -> A.
BEST1	567	567	L -> F (in a sporadic case of age-related macular degeneration; could be a rare polymorphism).
ROM1	16	16	R -> H.
ROM1	60	60	P -> T.
ROM1	75	75	G -> D.
ROM1	108	108	T -> M.
ROM1	229	229	R -> H.
ROM1	242	242	R -> Q.
ROM1	265	265	A -> T.
ROM1	271	271	M -> T.
BSCL2	88	88	N -> S (in SPG17 and DSMAV).
BSCL2	90	90	S -> L (in SPG17 and DSMAV).
BSCL2	212	212	A -> P (in CGL2).
STX5	79	79	Q -> H (in a breast cancer sample; somatic mutation).
SLC22A6	7	7	L -> P.
SLC22A8	389	389	A -> V.
FKBP2	21	22	TA -> S.
FKBP2	25	25	A -> T.
FKBP2	97	97	C -> Y.
PRDX5	157	157	F -> L (in a breast cancer sample; somatic mutation).
RPS6KA4	236	236	S -> L (in a breast infiltrating ductal carcinoma sample; somatic mutation).
SLC22A12	90	90	R -> H (in RH; strongly reduced urate transport).
SLC22A12	92	92	R -> C.
SLC22A12	138	138	V -> M (in RH; strongly reduced urate transport).
SLC22A12	164	164	G -> S (in RH; reduced urate transport).
SLC22A12	217	217	T -> M (in RH; strongly reduced urate transport).
SLC22A12	226	226	A -> V.
SLC22A12	284	284	R -> G (in some gout patients; uncertain pathological significance).
SLC22A12	290	290	G -> C (in some gout patients; uncertain pathological significance).
SLC22A12	297	297	Q -> E (in some gout patients; uncertain pathological significance).
SLC22A12	298	298	E -> D (in RH; strongly reduced urate transport).
SLC22A12	305	305	I -> S (in some gout patients; uncertain pathological significance).
SLC22A12	312	312	Q -> L.
SLC22A12	313	333	Missing (affects urate transport).
SLC22A12	382	382	Q -> L (in RH; strongly reduced urate transport).
SLC22A12	418	418	L -> R (in RH; strongly reduced urate transport).
SLC22A12	430	430	M -> T (in RH; reduced urate transport).
SLC22A12	477	477	R -> H (in RH).
PYGM	116	116	L -> P (in GSD5).
PYGM	194	194	R -> W (in GSD5).
PYGM	205	205	G -> S (in GSD5).
PYGM	292	292	L -> P (in GSD5; rare mutation).
PYGM	349	349	E -> K (in GSD5).
PYGM	397	397	L -> P (in GSD5).
PYGM	488	488	T -> N (in GSD5).
PYGM	543	543	K -> T (in GSD5).
PYGM	602	602	R -> W (in GSD5).
PYGM	655	655	E -> K (in GSD5).
PYGM	660	660	A -> D (in GSD5).
PYGM	666	666	Q -> E (in GSD5).
PYGM	685	685	N -> Y (in GSD5).
PYGM	686	686	G -> R (in GSD5).
PYGM	687	687	A -> P (in GSD5).
PYGM	704	704	A -> V (in GSD5).
PYGM	709	709	Missing (in GSD5; common in Japanese patients).
PYGM	798	798	W -> R (in GSD5).
SF1	357	357	S -> T.
MEN1	12	12	P -> L (in MEN1; no effect on histone methylation; almost no effect on JUND- binding).
MEN1	22	22	L -> R (in MEN1; no effect on histone methylation; almost no effect on JUND- binding; no repression of JUND transactivation).
MEN1	39	39	L -> W (in MEN1).
MEN1	42	42	G -> D (in MEN1).
MEN1	45	45	E -> G (in MEN1).
MEN1	45	45	E -> K (in MEN1).
MEN1	89	95	Missing (in MEN1).
MEN1	98	98	R -> L (in MEN1).
MEN1	110	110	G -> E (in MEN1).
MEN1	119	119	Missing (in MEN1).
MEN1	135	135	K -> I (in MEN1).
MEN1	139	139	H -> D (in MEN1; almost complete loss of histone methylation; strong decrease in JUND-binding; no repression of JUND transactivation).
MEN1	139	139	H -> P (in MEN1).
MEN1	139	139	H -> R (in MEN1).
MEN1	139	139	H -> Y (in MEN1; familial and sporadic cases; almost no effect on JUND-binding; no repression of JUND transactivation).
MEN1	144	144	F -> V (in MEN1).
MEN1	147	147	I -> F (in MEN1).
MEN1	157	157	L -> W (in parathyroid tumors; somatic).
MEN1	158	158	D -> V (in MEN1 and FIHP).
MEN1	159	159	S -> I (in MEN1).
MEN1	160	160	S -> F (in MEN1).
MEN1	161	161	G -> D (in MEN1 and parathyroid tumor).
MEN1	165	165	A -> P (in MEN1; strong decrease in JUND- binding).
MEN1	165	165	A -> T (in MEN1).
MEN1	167	167	V -> F (in MEN1).
MEN1	169	169	A -> D (in MEN1).
MEN1	170	170	C -> R (in MEN1).
MEN1	171	173	Missing (in MEN1).
MEN1	173	173	L -> P (in MEN1).
MEN1	177	177	D -> Y (in MEN1).
MEN1	181	181	A -> P (in MEN1; loss of JUND-binding).
MEN1	184	184	E -> D (in MEN1).
MEN1	184	184	E -> K (in MEN1).
MEN1	184	184	E -> Q (in MEN1).
MEN1	186	186	H -> R (in MEN1).
MEN1	188	188	W -> R (in MEN1 and parathyroid tumor).
MEN1	188	188	W -> S (in MEN1).
MEN1	189	189	V -> E (in FIHP).
MEN1	220	220	V -> F (found in a parathyroid carcinoma sample; somatic mutation).
MEN1	220	220	V -> M (in MEN1).
MEN1	228	228	L -> P (in MEN1).
MEN1	230	230	G -> R (in MEN1).
MEN1	234	234	R -> L (in MEN1).
MEN1	245	245	V -> F (in MEN1).
MEN1	246	246	C -> F (in MEN1).
MEN1	246	246	C -> R (in MEN1).
MEN1	246	246	C -> Y (in MEN1).
MEN1	247	247	A -> V (in MEN1; almost complete loss of histone methylation; loss of JUND- binding; no repression of JUND transactivation).
MEN1	258	258	S -> P (in MEN1).
MEN1	258	258	S -> W (in parathyroid tumor).
MEN1	260	260	E -> K (in FIHP).
MEN1	264	264	L -> R (in MEN1).
MEN1	265	265	Q -> P (in FIHP).
MEN1	266	266	Q -> QLQ (in MEN1).
MEN1	269	269	L -> P (in MEN1).
MEN1	272	272	L -> P (in FIHP).
MEN1	279	279	E -> A (in parathyroid tumor).
MEN1	282	282	P -> H (in FIHP).
MEN1	286	286	G -> R (in MEN1).
MEN1	289	289	A -> E (in MEN1).
MEN1	289	289	A -> P (in parathyroid tumor).
MEN1	291	291	L -> P (in MEN1; almost no effect on JUND-binding).
MEN1	310	310	G -> D (in FIHP).
MEN1	314	314	A -> P (in MEN1; no effect on histone methylation; almost no effect on JUND- binding).
MEN1	316	316	T -> P (in MEN1).
MEN1	319	319	R -> P (in MEN1).
MEN1	322	322	H -> R (in MEN1).
MEN1	322	322	H -> Y (in MEN1).
MEN1	325	325	P -> L (in MEN1).
MEN1	325	325	P -> R (in MEN1).
MEN1	330	330	A -> P (in MEN1).
MEN1	342	342	A -> P (in MEN1).
MEN1	346	346	W -> R (in MEN1).
MEN1	347	347	A -> P (in MEN1).
MEN1	349	349	T -> R (in MEN1; almost complete loss of histone methylation; almost no effect on JUND-binding).
MEN1	353	353	I -> N (in MEN1).
MEN1	358	358	Y -> D (in MEN1).
MEN1	360	360	R -> W (in MEN1).
MEN1	362	362	D -> H (in MEN1).
MEN1	364	364	E -> K (in MEN1).
MEN1	368	368	Missing (in MEN1).
MEN1	373	373	A -> D (in MEN1).
MEN1	377	377	I -> M (in MEN1).
MEN1	378	378	P -> S (in MEN1).
MEN1	390	390	A -> V (in MEN1).
MEN1	416	416	A -> P (in MEN1 and FIHP).
MEN1	418	418	L -> R (in MEN1).
MEN1	419	419	L -> P (in MEN1).
MEN1	420	420	R -> P (in MEN1).
MEN1	423	426	Missing (in MEN1).
MEN1	423	423	D -> H (in MEN1).
MEN1	423	423	D -> N (in MEN1).
MEN1	423	423	Missing (in MEN1).
MEN1	426	426	C -> Y (in MEN1).
MEN1	428	428	W -> S (in MEN1).
MEN1	432	432	S -> R (in MEN1).
MEN1	441	441	W -> C (in MEN1).
MEN1	441	441	W -> R (in MEN1; no effect on histone methylation; almost no effect on JUND- binding; modest repression of JUND transactivation).
MEN1	449	449	L -> P (in MEN1).
MEN1	452	452	F -> S (in MEN1; sporadic; with Zollinger-Ellison syndrome).
MEN1	476	476	W -> C (in MEN1).
MEN1	532	532	R -> C (in MEN1).
MEN1	545	545	P -> S (in MEN1).
MEN1	549	549	P -> S (in MEN1).
MEN1	557	557	T -> S (in adrenal adenoma; somatic).
MEN1	560	560	S -> N (in MEN1).
MEN1	560	560	S -> R (in MEN1).
CDC42BPG	280	280	S -> F (in a glioblastoma multiforme sample; somatic mutation).
ZNHIT2	59	59	A -> P (in a breast cancer sample; somatic mutation).
SCYL1	495	495	H -> Y (in a metastatic melanoma sample; somatic mutation).
RNASEH2C	69	69	R -> W (in AGS3).
RNASEH2C	143	143	K -> I (in AGS3).
EFEMP2	57	57	E -> K (in ARCL1).
FIBP	359	359	L -> R.
CD248	6	6	L -> F (in a colorectal cancer sample; somatic mutation).
SLC29A2	184	186	SGV -> M.
BBS1	35	35	H -> R (in BBS1).
BBS1	53	53	K -> E (in BBS1).
BBS1	148	148	D -> N (in BBS1).
BBS1	160	160	R -> Q (in BBS1).
BBS1	200	201	Missing (in BBS1).
BBS1	305	305	G -> S (in BBS1).
BBS1	389	389	Missing (in BBS1).
BBS1	390	390	M -> R (in BBS1).
BBS1	434	434	Y -> S (in BBS1).
BBS1	503	503	L -> H (in BBS1).
BBS1	518	518	L -> P (in BBS1).
BBS1	518	518	L -> Q (in BBS1).
BBS1	559	559	G -> D (in a patient with Meckel-Gruber like syndrome also carrying L-753 in TTC21B and a variant in CC2D2A).
RBM4B	93	93	E -> V.
RCE1	326	326	P -> A (in a breast cancer sample; somatic mutation).
ADRBK1	578	578	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation).
CLCF1	197	197	R -> L (in CISS2; incapacity to bind CNTFR alpha; heterozygous compound with a nonsense mutation).
RAD9A	3	3	C -> F.
RPS6KB2	443	443	T -> M (in an ovarian mucinous carcinoma sample; somatic mutation).
CORO1B	411	411	V -> M (in a colorectal cancer sample; somatic mutation).
CABP4	124	124	R -> C (in CSNB2B).
AIP	16	16	R -> H.
AIP	47	54	Missing (in patients with pituitary adenoma; uncertain pathogenicity).
AIP	241	241	K -> E (in patients with pituitary adenoma; uncertain pathogenicity).
AIP	248	248	Missing (in a ACTH-secreting pituitary adenoma patient; uncertain pathogenicity).
AIP	271	271	R -> W (in patients with pituitary adenoma; uncertain pathogenicity).
AIP	304	304	R -> Q (in a ACTH-secreting pituitary adenoma patient).
NDUFV1	214	214	E -> K (in MT-C1D).
NDUFV1	341	341	A -> V (in MT-C1D).
NDUFV1	423	423	T -> M (in LS).
NDUFS8	102	102	R -> H (in LS).
TCIRG1	141	141	A -> P (in OPTB1).
TCIRG1	405	405	G -> R (in OPTB1).
TCIRG1	444	444	R -> L (in OPTB1).
TCIRG1	462	462	Missing (in OPTB1).
TCIRG1	517	517	D -> N (in OPTB1).
TCIRG1	775	775	P -> R (in OPTB1).
FGF3	6	6	L -> P (in LAMM; probably impairs secretion).
FGF3	156	156	S -> P (in LAMM).
FADD	105	105	C -> W (in IEHDCM; reduced folding stability as measured by differential scanning calorimetry of the mutant protein; impairs interaction with FAS).
DHCR7	51	51	P -> S (in SLOS).
DHCR7	68	68	L -> P (in SLOS).
DHCR7	93	93	T -> M (in SLOS).
DHCR7	99	99	L -> P (in SLOS).
DHCR7	107	107	Q -> H (in SLOS).
DHCR7	109	109	L -> P (in SLOS).
DHCR7	113	113	S -> C (in SLOS).
DHCR7	138	138	G -> V (in SLOS).
DHCR7	145	145	I -> L (in SLOS).
DHCR7	147	147	G -> D (in SLOS).
DHCR7	154	154	T -> M (in SLOS).
DHCR7	157	157	L -> P (in SLOS).
DHCR7	169	169	S -> L (in SLOS).
DHCR7	182	182	W -> C (in SLOS).
DHCR7	182	182	W -> L (in SLOS).
DHCR7	183	183	C -> Y (in SLOS).
DHCR7	198	198	K -> E (in SLOS).
DHCR7	235	235	F -> S (in SLOS).
DHCR7	242	242	R -> C (in SLOS).
DHCR7	242	242	R -> H (in SLOS).
DHCR7	244	244	G -> R (in SLOS).
DHCR7	247	247	A -> V (in SLOS).
DHCR7	255	255	F -> L (in SLOS).
DHCR7	281	281	V -> M (in SLOS).
DHCR7	289	289	T -> I (in SLOS).
DHCR7	297	297	I -> T (in SLOS).
DHCR7	311	311	C -> G (in SLOS).
DHCR7	311	311	C -> Y (in SLOS).
DHCR7	324	324	Y -> H (in SLOS).
DHCR7	326	326	V -> L (in SLOS).
DHCR7	344	344	G -> R (in SLOS).
DHCR7	352	352	R -> Q (in SLOS).
DHCR7	352	352	R -> W (in SLOS).
DHCR7	353	353	V -> A (in SLOS).
DHCR7	362	362	R -> C (in SLOS).
DHCR7	380	380	C -> R (in SLOS).
DHCR7	380	380	C -> S (in SLOS).
DHCR7	380	380	C -> Y (in SLOS).
DHCR7	397	397	S -> L (in SLOS).
DHCR7	404	404	R -> C (in SLOS).
DHCR7	404	404	R -> S (in SLOS).
DHCR7	405	405	H -> Y (in SLOS).
DHCR7	408	408	Y -> H (in SLOS).
DHCR7	410	410	G -> R (in SLOS).
DHCR7	410	410	G -> S (in SLOS).
DHCR7	426	426	H -> P (in SLOS).
DHCR7	443	443	R -> C (in SLOS).
DHCR7	446	446	R -> Q (in SLOS).
DHCR7	448	448	E -> K (in SLOS; mild).
DHCR7	448	448	E -> Q (in SLOS).
DHCR7	450	450	R -> L (in SLOS).
FOLR2	236	236	H -> N (in a breast cancer sample; somatic mutation).
INPPL1	632	632	L -> I (associated with susceptibility to NIDDM).
INPPL1	721	721	V -> M.
INPPL1	982	982	N -> S (associated with susceptibility to NIDDM).
PHOX2A	72	72	A -> V (in CFEOM2).
PHOX2A	256	256	P -> Q (may be involved in congenital central hypoventilation syndrome).
KCNE3	4	4	T -> A.
KCNE3	99	99	R -> H (in BRS6; also in a patient suffering from drug-induced torsades de pointes).
SERPINH1	78	78	L -> P (in OI10).
MYO7A	25	25	G -> R (in USH1B).
MYO7A	26	26	A -> E (in USH1B).
MYO7A	67	67	V -> M (in USH1B).
MYO7A	90	90	R -> P (in USH1B).
MYO7A	133	133	H -> D (in USH1B; the deleterious effect remains to be proven).
MYO7A	134	134	I -> N (in USH1B).
MYO7A	163	163	G -> R (in USH1B).
MYO7A	164	164	K -> R (in USH1B).
MYO7A	165	165	T -> M (in USH1B).
MYO7A	198	198	A -> T (in USH1B; is predicted to alter the normal splicing of exon 6).
MYO7A	204	204	T -> A (in USH1B).
MYO7A	205	205	I -> V.
MYO7A	212	212	R -> C (in USH1B; frequent mutation).
MYO7A	214	214	G -> R (in USH1B).
MYO7A	218	219	Missing (in USH1B).
MYO7A	241	241	R -> C (in USH1B).
MYO7A	241	241	R -> S (in USH1B).
MYO7A	244	244	R -> P (in DFNB2).
MYO7A	269	269	Missing (in USH1B).
MYO7A	397	397	A -> D (in USH1B).
MYO7A	450	450	E -> Q (in USH1B).
MYO7A	457	457	A -> V (in USH1B).
MYO7A	468	468	H -> HQ (in USH1B).
MYO7A	503	503	P -> L (in USH1B).
MYO7A	519	519	G -> D (in USH1B; the deleterious effect remains to be proven).
MYO7A	597	597	V -> I (rare polymorphism).
MYO7A	599	599	M -> I (in DFNB2).
MYO7A	651	651	L -> P (in USH1B; atypical).
MYO7A	722	722	G -> R (in DFNA11).
MYO7A	756	756	R -> W (in USH1B).
MYO7A	826	826	A -> T (in USH1B).
MYO7A	853	853	R -> C (in DFNA11; disturb calmodulin/ MYO7A binding; may result in impaired adaptation to environmental stimuli and progressive deterioration of hearing transduction in heterozygotes).
MYO7A	886	888	Missing (in DFNA11).
MYO7A	955	955	G -> S (in USH1B).
MYO7A	968	968	E -> D (in USH1B).
MYO7A	1087	1087	L -> P (in USH1B).
MYO7A	1170	1170	E -> K (in USH1B).
MYO7A	1240	1240	R -> Q (in USH1B).
MYO7A	1288	1288	A -> P (in USH1B).
MYO7A	1327	1327	E -> K (in USH1B).
MYO7A	1343	1343	R -> S (in USH1B).
MYO7A	1346	1346	Missing (in USH1B).
MYO7A	1347	1351	Missing (in USH1B).
MYO7A	1602	1602	R -> Q (in USH1B; atypical).
MYO7A	1628	1628	A -> S (in USH1B).
MYO7A	1666	1666	C -> G.
MYO7A	1719	1719	Y -> C (in USH1B; could be a polymorphism).
MYO7A	1743	1743	R -> W (in USH1B).
MYO7A	1858	1858	L -> P (in USH1B).
MYO7A	1873	1873	R -> W (in USH1B).
MYO7A	1883	1883	R -> Q (in USH1B).
MYO7A	1887	1887	P -> L (in USH1B).
MYO7A	1962	1962	Missing (in USH1B).
MYO7A	1992	1992	F -> I.
MYO7A	2137	2137	G -> E (in USH1B).
MYO7A	2163	2163	G -> S (in USH1B).
MYO7A	2187	2187	G -> D (in USH1B).
ALG8	47	47	T -> P (in CDG1H).
ALG8	275	275	G -> D (in CDG1H).
FZD4	33	33	P -> S (in EVR1).
FZD4	36	36	G -> D (in EVR1).
FZD4	40	40	E -> Q (in EVR1).
FZD4	69	69	H -> Y (in EVR1; minor reduction of its wild-type activity).
FZD4	105	105	M -> T (in EVR1).
FZD4	105	105	M -> V (in EVR1; loss of function).
FZD4	114	114	I -> T (in EVR1).
FZD4	157	157	M -> V (in EVR1; loss of function).
FZD4	168	168	P -> S.
FZD4	181	181	C -> R (in EVR1).
FZD4	203	203	K -> N (in retinopathy of prematurity).
FZD4	204	204	C -> R (in EVR1).
FZD4	204	204	C -> Y (in EVR1).
FZD4	223	223	M -> K (in EVR1).
FZD4	256	256	I -> V (in EVR1).
FZD4	335	335	W -> C (in EVR1).
FZD4	342	342	M -> V (in EVR1).
FZD4	370	370	A -> G (in retinopathy of prematurity).
FZD4	417	417	R -> Q (in EVR1; 48% loss of its wild- type activity; associated in a EVR4 patient with mutation CYS-444 in LPR5).
FZD4	436	436	K -> T (in a colorectal cancer sample; somatic mutation).
FZD4	445	445	T -> P (in EVR1).
FZD4	488	488	G -> D (in EVR1).
FZD4	493	494	Missing (in EVR1; loss of function).
FZD4	497	497	S -> F (in EVR1).
FZD4	525	525	G -> R (in EVR1).
RAB38	111	111	K -> T (in a colorectal cancer sample; somatic mutation).
CTSC	39	39	W -> S (in PLS).
CTSC	67	74	Missing (in PLS).
CTSC	127	127	H -> P (in PLS).
CTSC	129	129	V -> E (in PLS).
CTSC	139	139	G -> R (in PLS).
CTSC	236	236	D -> Y (in PLS).
CTSC	249	249	V -> F (in PLS).
CTSC	252	252	Q -> L (in PLS).
CTSC	272	272	R -> H (in PLS).
CTSC	272	272	R -> P (in PLS).
CTSC	286	286	Q -> R (in HMS and PLS).
CTSC	291	291	C -> Y (in PLS).
CTSC	294	294	Y -> H (in PLS).
CTSC	300	300	G -> D (in PLS).
CTSC	300	300	G -> S (in PLS).
CTSC	301	301	G -> S (in PLS).
CTSC	301	301	G -> V (in PLS).
CTSC	304	304	Y -> N (in PLS).
CTSC	312	312	Q -> R (in PLS).
CTSC	319	319	E -> G (in PLS).
CTSC	339	339	R -> C (in PLS).
CTSC	340	340	Y -> C (in PLS).
CTSC	347	347	Y -> C (in PLS and AP1).
CTSC	401	401	E -> K.
CTSC	405	405	H -> N (in PLS).
CTSC	405	405	H -> R (in PLS).
CTSC	429	429	W -> C (in PLS).
CTSC	447	447	E -> G (in PLS).
MTNR1B	66	66	L -> F.
MED17	371	371	L -> P (in MCPHSBA).
MRE11A	104	104	S -> C (in cancer).
MRE11A	117	117	N -> S (in ATLD).
MRE11A	157	157	M -> V.
MRE11A	237	237	F -> C (in a breast cancer sample; somatic mutation).
MRE11A	302	302	H -> Y (in a breast cancer sample; somatic mutation).
MRE11A	305	305	R -> W (in ovarian cancer).
MRE11A	503	503	R -> H (in cancer).
MRE11A	572	572	R -> Q (in cancer).
MTMR2	283	283	R -> W (in CMT4B1).
MMP10	142	142	E -> Q (in a breast cancer sample; somatic mutation).
MMP13	74	74	F -> S (in MANDP1).
MMP13	75	75	F -> S (in SEMD-MO; abnormal intracellular autoactivation and autodegradation within the ER/Golgi resulting in the secretion of small and inactive fragments).
MMP13	91	91	M -> T (in MANDP1).
MMP13	232	232	H -> N (in MANDP1).
CASP5	75	75	L -> R.
CASP5	298	298	R -> H.
PPP2R1B	8	8	G -> R (in a lung cancer patient).
PPP2R1B	15	15	G -> A (in a colorectal cancer patient).
PPP2R1B	65	65	P -> S (in a lung cancer patient).
PPP2R1B	101	101	L -> P (in a colon adenocarcinoma).
PPP2R1B	343	343	K -> E (in a lung cancer patient).
PPP2R1B	365	365	S -> P (in a colorectal cancer patient).
PPP2R1B	448	448	V -> A (in a colon adenocarcinoma).
PPP2R1B	498	498	V -> E (in a colorectal cancer patient).
PPP2R1B	499	499	L -> I (in a colorectal cancer patient).
PPP2R1B	500	500	V -> G (in a colorectal cancer patient).
PPP2R1B	504	504	D -> G (in a lung cancer patient).
PPP2R1B	545	545	V -> A (in a colon adenocarcinoma).
SDHD	81	81	P -> L (in PGL1 and pheochromocytoma).
SDHD	92	92	D -> Y (in PGL1 and pheochromocytoma).
SDHD	93	93	Missing (in PGL1).
SDHD	102	102	H -> L (in PGL1).
SDHD	114	114	Y -> C (in PGL1).
SDHD	139	139	L -> P (in PGL1).
SDHD	145	145	H -> N (found in an individual with features of CWDLS; associated with increased manganese superoxide dismutase expression; asociated with normal reactive oxygen species; associated with no change in AKT expression but a 1.2- fold increase of MAPK expression).
SDHD	148	148	G -> V (in PGL1).
PTS	16	16	R -> C (in HPABH4A; severe decrease in activity; diminishes phosphorylation by PKG).
PTS	25	25	R -> G (in HPABH4A; severe form).
PTS	25	25	R -> Q (in HPABH4A; abolishes activity; no effect on phosphorylation by PKG).
PTS	26	26	L -> F (in HPABH4A).
PTS	35	35	E -> G (in HPABH4A).
PTS	36	36	N -> K (in HPABH4A).
PTS	47	47	N -> D (in HPABH4A; transient phenotype; due to partial PTS deficiency; total loss of activity).
PTS	52	52	N -> S (in HPABH4A; severe form; common in Chinese population).
PTS	56	56	V -> M (in HPABH4A; mild form).
PTS	57	57	Missing (in HPABH4A).
PTS	67	67	T -> M (in HPABH4A).
PTS	70	70	V -> D (in HPABH4A).
PTS	87	87	P -> L (in HPABH4A).
PTS	87	87	P -> S (in HPABH4A; severe form; common in Chinese population).
PTS	96	96	D -> N (in HPABH4A; severe form).
PTS	97	97	V -> M (in HPABH4A).
PTS	99	99	Y -> C (in HPABH4A).
PTS	100	100	F -> V (in HPABH4A).
PTS	106	106	T -> M (in HPABH4A).
PTS	114	114	I -> V (in HPABH4A).
PTS	116	116	D -> G (in HPABH4A; due to partial PTS deficiency; mild form).
PTS	124	124	V -> L (in HPABH4A).
PTS	129	129	K -> E (in HPABH4A).
PTS	136	136	D -> G (in HPABH4A).
PTS	136	136	D -> V (in HPABH4A).
ANKK1	347	347	K -> T (in a breast infiltrating ductal carcinoma sample; somatic mutation).
ANKK1	717	717	Q -> L (in a lung large cell carcinoma sample; somatic mutation).
ANKK1	736	736	R -> L (in a lung squamous cell carcinoma sample; somatic mutation).
ANKK1	764	764	E -> K (in a lung neuroendocrine carcinoma sample; somatic mutation).
DRD2	154	154	V -> I (in DYT11; the contribution to this phenotype is unclear).
TMPRSS5	31	31	D -> V (in patients with sporadic hearing loss).
TMPRSS5	249	249	A -> V.
TMPRSS5	317	317	A -> S (in patients with sporadic hearing loss; no detectable proteolytic activity in a yeast-based protease assay).
TMPRSS5	337	337	P -> S.
HTR3A	33	33	A -> T.
HTR3A	391	391	P -> R.
HTR3A	409	409	R -> Q.
APOC3	78	78	K -> E (in HYPALIP).
APOC3	94	94	T -> A (in C-III-0; unglycosylated).
APOA1	27	27	P -> H (in Munster-3C).
APOA1	27	27	P -> R.
APOA1	28	28	P -> R (in Munster-3B).
APOA1	61	61	A -> T.
APOA1	84	84	L -> R (in AMYL8).
APOA1	92	92	T -> I.
APOA1	113	113	D -> E.
APOA1	119	119	A -> D (in Hita).
APOA1	127	127	D -> N (in Munster-3A).
APOA1	131	131	Missing (in Marburg/Munster-2).
APOA1	132	132	W -> R (in Tsushima).
APOA1	134	134	E -> K (in Fukuoka).
APOA1	160	160	E -> K (in Norway).
APOA1	163	163	E -> G.
APOA1	167	167	P -> R (in Giessen).
APOA1	168	168	L -> R (in Zaragoza).
APOA1	171	171	E -> V.
APOA1	180	180	V -> E (in Oita; 60% of normal apoA-I and normal HDL cholesterol levels. Rapidly cleared from plasma).
APOA1	189	189	P -> R.
APOA1	222	222	E -> K (in Munster-4).
IL10RA	84	84	T -> I (in IBD28).
IL10RA	141	141	G -> R (in IBD28).
SCN4B	179	179	L -> F (in LQT10; increase in late sodium current).
CXCR5	34	34	E -> K (in a breast cancer sample; somatic mutation).
SLC37A4	20	20	G -> D (in GSD1B).
SLC37A4	24	24	Y -> H (in GSD1B).
SLC37A4	27	27	N -> K (in GSD1B).
SLC37A4	28	28	R -> C (in GSD1B).
SLC37A4	28	28	R -> H (in GSD1B; inactive glucose-6- phosphate transport).
SLC37A4	50	50	G -> R (in GSD1B).
SLC37A4	54	54	S -> R (in GSD1B).
SLC37A4	55	55	S -> R (in GSD1B).
SLC37A4	68	68	G -> R (in GSD1B).
SLC37A4	85	85	L -> P (in GSD1B).
SLC37A4	88	88	G -> D (in GSD1B).
SLC37A4	118	118	W -> R (in GSD1B).
SLC37A4	133	133	Q -> P (in GSD1C).
SLC37A4	149	149	G -> E (in GSD1B).
SLC37A4	150	150	G -> R (in GSD1B).
SLC37A4	153	153	P -> L (in GSD1B).
SLC37A4	176	176	C -> R (in GSD1B).
SLC37A4	183	183	C -> R (in GSD1B).
SLC37A4	191	191	P -> L (in GSD1B).
SLC37A4	229	229	L -> P (in GSD1B).
SLC37A4	235	235	Missing (in GSD1B).
SLC37A4	278	278	I -> N (in GSD1B).
SLC37A4	300	300	R -> H (in GSD1B).
SLC37A4	301	301	H -> P (in GSD1B).
SLC37A4	339	339	G -> C (in GSD1B).
SLC37A4	339	339	G -> D (in GSD1B).
SLC37A4	367	367	A -> T (in GSD1B).
SLC37A4	373	373	A -> D (in GSD1B).
SLC37A4	376	376	G -> S (in GSD1C).
HMBS	18	18	M -> I (in AIP).
HMBS	22	22	R -> C (in AIP).
HMBS	24	24	G -> S (in AIP).
HMBS	26	26	R -> C (in AIP).
HMBS	26	26	R -> H (in AIP).
HMBS	28	28	S -> N (in AIP).
HMBS	31	31	A -> P (in AIP).
HMBS	31	31	A -> T (in AIP).
HMBS	34	34	Q -> K (in AIP).
HMBS	34	34	Q -> P (in AIP; less than 3% of activity).
HMBS	34	34	Q -> R (in AIP).
HMBS	35	35	T -> M (in AIP).
HMBS	42	42	L -> S (in AIP).
HMBS	55	55	A -> S (in AIP).
HMBS	61	61	D -> N (in AIP).
HMBS	61	61	D -> Y (in AIP).
HMBS	78	78	T -> P (in AIP).
HMBS	80	80	E -> G (in AIP).
HMBS	81	81	L -> P (in AIP).
HMBS	85	85	L -> R (in AIP).
HMBS	86	86	E -> V (in AIP).
HMBS	90	90	V -> G (in AIP).
HMBS	92	92	L -> P (in AIP).
HMBS	93	93	V -> F (in AIP; loss of activity).
HMBS	93	93	Missing (in AIP).
HMBS	96	96	S -> F (in AIP).
HMBS	98	98	K -> R (in AIP).
HMBS	99	99	D -> G (in AIP).
HMBS	99	99	D -> H (in AIP).
HMBS	99	99	D -> N (in AIP).
HMBS	111	111	G -> R (in AIP).
HMBS	113	113	I -> T (in AIP).
HMBS	116	116	R -> Q (in AIP).
HMBS	116	116	R -> W (in AIP; loss of activity).
HMBS	119	119	P -> L (in AIP).
HMBS	122	122	A -> G (in AIP).
HMBS	124	124	V -> D (in AIP).
HMBS	149	149	R -> L (in AIP).
HMBS	149	149	R -> Q (in AIP).
HMBS	152	152	Missing (in AIP).
HMBS	167	167	R -> Q (in AIP).
HMBS	167	167	R -> W (in AIP).
HMBS	173	173	R -> Q (in AIP; 0.6% of wild-type activity).
HMBS	173	173	R -> W (in AIP).
HMBS	177	177	L -> R (in AIP).
HMBS	178	178	D -> N (in AIP).
HMBS	201	201	R -> W (in AIP; residual activity).
HMBS	202	202	V -> L (in AIP).
HMBS	209	209	E -> K (in AIP).
HMBS	212	212	M -> V (in AIP; <2% residual activity).
HMBS	216	216	G -> D (in AIP).
HMBS	217	217	Q -> H (in AIP).
HMBS	217	217	Q -> L (in AIP).
HMBS	219	219	A -> D (in AIP).
HMBS	222	222	V -> M (in AIP).
HMBS	223	223	E -> K (in AIP).
HMBS	225	225	R -> G (in AIP).
HMBS	225	225	R -> Q (in AIP).
HMBS	236	236	G -> S (in AIP).
HMBS	238	238	L -> R (in AIP).
HMBS	244	244	L -> P (in AIP).
HMBS	245	245	L -> R (in AIP).
HMBS	247	247	C -> F (in AIP; residual activity).
HMBS	247	247	C -> R (in AIP).
HMBS	248	248	I -> IETLLRCI (in AIP).
HMBS	250	250	E -> A (in AIP).
HMBS	250	250	E -> K (in AIP).
HMBS	250	250	E -> Q (in AIP).
HMBS	250	250	E -> V (in AIP).
HMBS	252	252	A -> T (in AIP).
HMBS	252	252	A -> V (in AIP).
HMBS	254	254	L -> P (in AIP).
HMBS	256	256	H -> N (in AIP).
HMBS	256	256	H -> Y (in AIP).
HMBS	260	260	G -> D (in AIP).
HMBS	261	261	C -> Y (in AIP).
HMBS	267	267	V -> M (in AIP).
HMBS	269	269	T -> I (in AIP).
HMBS	270	270	A -> D (in AIP).
HMBS	270	270	A -> G (in AIP).
HMBS	274	274	G -> R (in AIP).
HMBS	278	278	L -> P (in AIP).
HMBS	280	280	G -> R (in AIP).
HMBS	281	281	Missing (in AIP).
HMBS	329	332	Missing (in AIP).
HMBS	335	335	G -> D (in AIP).
HMBS	335	335	G -> S (in AIP; less than 3% of activity).
HMBS	343	343	L -> P (in AIP).
DPAGT1	9	9	M -> I (in a breast cancer sample; somatic mutation).
C1QTNF5	54	54	R -> G.
C1QTNF5	182	182	I -> T (in NNO2).
C1QTNF5	449	449	G -> S.
C1QTNF5	514	514	Q -> H.
TRIM29	514	514	S -> F (in a breast cancer sample; somatic mutation).
SC5DL	29	29	R -> Q (in LATHST).
SC5DL	46	46	Y -> S (in LATHST).
SC5DL	211	211	G -> D (in LATHST).
SCN3B	10	10	L -> P (in BRS7).
SCN3B	54	54	V -> G (found in a case of idiopathic ventricular fibrillation).
SCN3B	89	89	Q -> L (in a colorectal cancer sample; somatic mutation).
SCN3B	195	195	A -> T (in a colorectal cancer sample; somatic mutation).
ROBO3	5	5	L -> P (in HGPPS).
ROBO3	66	66	I -> L (in HGPPS).
ROBO3	319	319	E -> K (in HGPPS).
ROBO3	361	361	G -> E (in HGPPS).
ROBO3	703	703	R -> P (in HGPPS).
ROBO3	705	705	S -> P (in HGPPS).
EI24	30	30	D -> G (in some patients with early onset breast cancer).
EI24	195	195	P -> W (in some patients with early onset breast cancer; requires 2 nucleotide substitutions).
EI24	196	196	I -> D (in some patients with early onset breast cancer; requires 2 nucleotide substitutions).
EI24	197	197	H -> Y (in some patients with early onset breast cancer).
EI24	199	199	V -> H (in some patients with early onset breast cancer; requires 2 nucleotide substitutions).
EI24	319	319	T -> A (in some patients with early onset breast cancer).
HYLS1	211	211	D -> G (in HLS1; altered subcellular localization, becomes localized to nuclear structures).
FOXRED1	430	430	N -> S (in MT-C1D).
KCNJ5	387	387	G -> R (in LQT13).
ST14	827	827	G -> R (in ARIH).
ADAMTS15	770	770	Q -> R (in a colorectal cancer sample; somatic mutation).
ADAMTS15	878	878	C -> G (in a colorectal cancer sample; somatic mutation).
ACAD8	128	128	M -> I (in IBDD).
ACAD8	134	134	D -> Y (in IBDD).
ACAD8	137	137	G -> R (in IBDD; complete loss of activity).
ACAD8	152	152	M -> T (in IBDD).
ACAD8	203	203	V -> I (in IBDD).
ACAD8	302	302	R -> Q (in IBDD; complete loss of activity).
ACAD8	320	320	A -> T (in IBDD; <20% of wild-type activity).
ACAD8	334	334	R -> C (in IBDD).
ACAD8	385	385	Q -> R (in IBDD).
KIR3DL3	56	56	N -> K (in allele KIR3DL3*00601, allele KIR3DL3*00602, allele KIR3DL3*01501 and allele KIR3DL3*01601).
KIR3DL3	152	152	R -> H (in allele KIR3DL3*007, allele KIR3DL3*030 and allele KIR3DL3*031).
KIR3DL3	231	231	G -> D (in allele KIR3DL3*005).
KIR3DL3	321	321	H -> N (in allele KIR3DL3*00101, allele KIR3DL3*00102, allele KIR3DL3*00103, allele KIR3DL3*00601, allele KIR3DL3*00602, allele KIR3DL3*01302, allele KIR3DL3*01305, allele KIR3DL3*01306, allele KIR3DL3*01307, allele KIR3DL3*017 and allele KIR3DL3*026).
KIR3DL3	324	324	V -> D (in allele KIR3DL3*029).
KIR3DL3	373	373	E -> D (in allele KIR3DL3*027, allele KIR3DL3*029 and allele KIR3DL3*031).
KIR3DL2	40	40	P -> A.
KIR3DL2	228	228	A -> P.
KIR3DL2	252	252	I -> T.
GPR183	338	338	A -> V (in an acute myeloid leukemia sample; somatic mutation).
DCLK1	29	29	G -> C (in a gastric adenocarcinoma sample; somatic mutation).
DCLK1	46	46	T -> M (in a gastric adenocarcinoma sample; somatic mutation).
DCLK1	93	93	R -> Q (in a gastric adenocarcinoma sample; somatic mutation).
DCLK1	291	291	S -> F (in a gastric adenocarcinoma sample; somatic mutation).
FGF14	42	42	G -> C.
FGF14	145	145	F -> S (in SCA27).
TNFSF13B	105	105	A -> T.
COL4A1	498	498	G -> R (in HANAC).
COL4A1	498	498	G -> V (in HANAC).
COL4A1	510	510	G -> R (in HANAC).
COL4A1	519	519	G -> R (in HANAC).
COL4A1	525	525	G -> L (in HANAC; requires 2 nucleotide substitutions).
COL4A1	528	528	G -> E (in HANAC).
COL4A1	562	562	G -> E (in BSVDH).
COL4A1	720	720	G -> D (in BSVDH; diffuse small vessel disease of the brain associated with Axenfeld-Rieger anomaly and leukoencephalopathy).
COL4A1	749	749	G -> S (in PCEPH).
COL4A1	755	755	G -> R (in BSVDH; associated with ocular anomalies of variable severity in some patients).
COL4A1	805	805	G -> R (in BSVDH).
COL4A1	1130	1130	G -> D (in PCEPH).
COL4A1	1236	1236	G -> R (in PCEPH).
COL4A1	1423	1423	G -> R (in PCEPH).
COL4A1	1580	1580	G -> R (in PCEPH).
F7	13	13	L -> P (in FA7D; Morioka).
F7	59	59	R -> RR (in FA7D).
F7	64	64	F -> L (in FA7D).
F7	79	79	E -> Q (in FA7D).
F7	82	82	C -> F (in FA7D).
F7	82	82	C -> R (in FA7D).
F7	84	84	Missing (in FA7D).
F7	85	85	E -> K (in FA7D).
F7	88	88	R -> G (in FA7D).
F7	88	88	R -> P (in FA7D).
F7	117	117	N -> D (in FA7D; exhibits no procoagulant activity and is unable to bind tissue factor).
F7	120	120	S -> P (in FA7D).
F7	121	121	C -> F (in FA7D).
F7	125	125	L -> P (in FA7D).
F7	128	128	Y -> C (in FA7D).
F7	138	138	G -> D (in FA7D).
F7	139	139	R -> K (in FA7D).
F7	139	139	R -> Q (in FA7D; Charlotte).
F7	139	139	R -> W (in FA7D).
F7	151	151	C -> S (in FA7D).
F7	154	154	E -> K (in FA7D).
F7	156	156	G -> S (in FA7D).
F7	157	157	G -> C (in FA7D).
F7	157	157	G -> S (in FA7D).
F7	157	157	G -> V (in FA7D).
F7	160	160	Q -> R (in FA7D).
F7	171	171	S -> F (in FA7D).
F7	177	177	G -> R (in FA7D).
F7	181	181	L -> P (in FA7D).
F7	183	183	D -> N (in FA7D).
F7	186	186	S -> F (in FA7D).
F7	189	189	P -> S (in FA7D).
F7	194	194	P -> L (in FA7D).
F7	194	194	P -> T (in FA7D; Malta-I).
F7	195	195	C -> R (in FA7D).
F7	197	197	K -> E (in FA7D).
F7	198	198	I -> T (in FA7D).
F7	212	212	R -> Q (in FA7D; Charlotte).
F7	216	216	G -> D (in FA7D).
F7	238	238	C -> Y (in FA7D).
F7	240	240	G -> R (in FA7D).
F7	241	241	T -> N (in FA7D).
F7	250	250	S -> F (in FA7D).
F7	251	251	A -> P (in FA7D).
F7	251	251	A -> T (in FA7D).
F7	254	254	C -> R (in FA7D).
F7	254	254	C -> Y (in FA7D).
F7	264	264	L -> P (in FA7D).
F7	266	266	A -> T (in FA7D).
F7	272	272	D -> N (in FA7D).
F7	277	277	D -> N (in FA7D).
F7	283	283	R -> W (in FA7D).
F7	298	298	T -> I (in FA7D).
F7	301	301	H -> Q (in FA7D).
F7	302	302	D -> H (in FA7D).
F7	302	302	D -> N (in FA7D).
F7	304	304	A -> T (in FA7D).
F7	304	304	A -> V (in FA7D; Malta-II).
F7	307	307	R -> C (in FA7D).
F7	307	307	R -> H (in FA7D; Mie).
F7	312	312	V -> M (in FA7D).
F7	314	314	L -> V (in FA7D).
F7	321	321	L -> F (in FA7D).
F7	323	323	L -> R (in FA7D).
F7	325	325	E -> K (in FA7D).
F7	326	326	R -> Q (in FA7D).
F7	332	332	T -> M (in FA7D).
F7	337	337	R -> C (in FA7D).
F7	341	341	V -> F (in FA7D).
F7	343	343	G -> S (in FA7D).
F7	344	344	W -> R (in FA7D).
F7	345	345	G -> S (in FA7D).
F7	350	350	R -> C (in FA7D).
F7	358	358	M -> I (in FA7D).
F7	358	358	M -> V (in FA7D).
F7	360	360	L -> P (in FA7D).
F7	363	363	P -> H (in FA7D).
F7	363	363	P -> R (in FA7D).
F7	364	364	R -> Q (in FA7D; Harrow/Padua).
F7	364	364	R -> W (in FA7D).
F7	367	367	T -> S.
F7	370	370	C -> F (in FA7D).
F7	375	375	R -> W (in FA7D).
F7	384	384	T -> M (in FA7D).
F7	387	387	M -> T (in FA7D).
F7	387	387	M -> V (in FA7D).
F7	388	388	F -> S (in FA7D; reduces tissue factor binding; impairs activation by factor Xa; abolishes amidolytic and coagulant activities).
F7	389	389	C -> G (in FA7D).
F7	391	391	G -> C (in FA7D).
F7	391	391	G -> S (in FA7D).
F7	398	398	D -> E (in FA7D).
F7	401	401	K -> E (in FA7D).
F7	402	402	G -> E (in FA7D).
F7	402	402	G -> R (in FA7D).
F7	403	403	D -> H (in FA7D).
F7	404	404	S -> N (in FA7D).
F7	408	408	H -> Q (in FA7D).
F7	408	408	H -> R (in FA7D).
F7	413	413	R -> G (in FA7D).
F7	414	414	G -> C (in FA7D; results in severely impaired protein secretion).
F7	419	419	T -> M (in FA7D).
F7	422	422	V -> F (in FA7D).
F7	425	425	G -> A (in FA7D).
F7	425	425	G -> C (in FA7D).
F7	429	429	A -> T (in FA7D).
F7	432	432	G -> D (in FA7D).
F7	435	435	G -> E (in FA7D).
F7	437	437	Y -> F (in FA7D).
KLF5	301	301	P -> S (in a colorectal cancer sample; somatic mutation).
LATS2	40	40	G -> E (in a lung adenocarcinoma sample; somatic mutation).
SGCG	69	69	G -> D (in LGMD2C).
SGCG	69	69	G -> R (in LGMD2C).
SGCG	283	283	C -> Y (in LGMD2C).
SACS	168	168	D -> Y (in SACS).
SACS	201	201	T -> K (in SACS).
SACS	308	308	L -> F (in SACS).
SACS	556	556	L -> P (in SACS; associated with Q-2798).
SACS	802	802	L -> P (in SACS).
SACS	991	991	C -> R (in SACS).
SACS	1054	1054	F -> S (in SACS; atypical phenotype without spasticity or hyperreflexia).
SACS	1311	1311	M -> K (in SACS).
SACS	1575	1575	R -> P (in SACS).
SACS	1587	1587	H -> R (in SACS).
SACS	1795	1795	M -> I (in a colorectal cancer sample; somatic mutation).
SACS	1946	1946	W -> R (in SACS).
SACS	2032	2032	Missing (in SACS).
SACS	2703	2703	R -> C (in SACS).
SACS	2798	2798	P -> Q (in SACS; associated with P-556).
SACS	2801	2801	Missing (in SACS).
SACS	3248	3248	W -> R (in SACS).
SACS	3481	3481	L -> P (in SACS).
SACS	3636	3636	R -> Q (in SACS; associated with T-3652).
SACS	3645	3645	L -> P (in SACS).
SACS	3652	3652	P -> T (in SACS; associated with Q-3636).
SACS	3653	3653	F -> S (in SACS).
SACS	4074	4074	A -> P (in SACS).
SACS	4331	4331	R -> Q (in SACS).
SACS	4343	4343	E -> K (in SACS).
SACS	4508	4508	K -> T (in SACS).
SACS	4549	4549	N -> D (in SACS).
RNF6	102	102	R -> K (in an esophageal squamous carcinoma sample; somatic mutation).
RNF6	164	164	I -> T.
RNF6	242	242	A -> T (in an esophageal squamous carcinoma sample; somatic mutation).
RNF6	244	244	G -> D (in an esophageal squamous carcinoma sample; somatic mutation).
RNF6	572	572	R -> Q.
CDK8	189	189	D -> N (in a lung neuroendocrine carcinoma sample; somatic mutation).
CDK8	424	424	R -> C (in a colorectal adenocarcinoma sample; somatic mutation).
FLT1	422	422	L -> I (in a lung adenocarcinoma sample; somatic mutation).
FLT1	781	781	R -> Q (in a glioma low grade oligodendroglioma sample; somatic mutation).
FLT1	1061	1061	L -> V (in a bladder transitional cell carcinoma sample; somatic mutation).
HMGB1	11	11	G -> R (in gastric-carcinoma cell line).
HMGB1	149	149	A -> E (in gastric-carcinoma cell line).
HMGB1	156	156	E -> Q.
HMGB1	190	190	D -> G (in gastric-carcinoma cell line).
BRCA2	25	25	G -> R (in BC; abolishes interaction with PALB2).
BRCA2	31	31	W -> C (in BC; abolishes interaction with PALB2).
BRCA2	31	31	W -> R (in BC; abolishes interaction with PALB2).
BRCA2	32	32	F -> L (in BC).
BRCA2	53	53	K -> R (in BC).
BRCA2	60	60	N -> S (in BC; unknown pathological significance).
BRCA2	64	64	T -> I (in BC).
BRCA2	81	81	F -> L (in BC).
BRCA2	108	108	N -> H.
BRCA2	118	118	R -> H (in one patient with esophageal carcinoma).
BRCA2	192	192	M -> T (in one patient with pancreatic cancer).
BRCA2	201	201	P -> R (in BC).
BRCA2	211	211	V -> A (in BC).
BRCA2	222	222	P -> S (in BC).
BRCA2	225	225	T -> A (in one patient with BC; normal RNA expression and splicing).
BRCA2	315	315	C -> S (in one patient with esophageal carcinoma).
BRCA2	327	327	K -> E (in BC; could be a polymorphism).
BRCA2	355	355	V -> L (in lung cancer).
BRCA2	405	405	G -> R (in BC; unknown pathological significance).
BRCA2	431	431	T -> I (in BC; unknown pathological significance).
BRCA2	448	448	R -> H (in BC; unknown pathological significance).
BRCA2	554	554	C -> W (in BC and pancreas cancer).
BRCA2	582	582	T -> P.
BRCA2	613	613	L -> R (in BC; unknown pathological significance).
BRCA2	630	630	T -> I (in ovarian cancer).
BRCA2	707	707	D -> Y.
BRCA2	728	728	D -> A (in BC).
BRCA2	729	729	I -> M (in BC).
BRCA2	886	886	N -> I.
BRCA2	1036	1036	E -> K (in BC; unknown pathological significance).
BRCA2	1106	1106	S -> R (in BC; unknown pathological significance).
BRCA2	1172	1172	S -> L (in BC; unknown pathological significance).
BRCA2	1179	1179	S -> N (in BC).
BRCA2	1279	1279	N -> S.
BRCA2	1286	1286	Missing.
BRCA2	1290	1290	C -> Y.
BRCA2	1302	1302	Missing (in BC).
BRCA2	1414	1414	T -> M.
BRCA2	1420	1420	D -> Y.
BRCA2	1445	1445	K -> T (in BC; unknown pathological significance).
BRCA2	1513	1513	D -> N.
BRCA2	1522	1522	L -> F (in one patient with BC).
BRCA2	1524	1524	F -> V (in BC; unknown pathological significance).
BRCA2	1529	1529	G -> R (in bladder cancer).
BRCA2	1561	1561	H -> N.
BRCA2	1580	1580	C -> Y (in BC; somatic mutation).
BRCA2	1593	1593	E -> D.
BRCA2	1679	1679	T -> I (in BC).
BRCA2	1690	1690	K -> N (in BC).
BRCA2	1730	1730	N -> Y (in BC).
BRCA2	1771	1771	G -> D (in BC; unknown pathological significance).
BRCA2	1804	1804	V -> A (in BC).
BRCA2	1805	1805	N -> S.
BRCA2	1887	1887	T -> M (in BC).
BRCA2	1901	1901	E -> K (in BC).
BRCA2	1902	1902	D -> N.
BRCA2	1929	1929	I -> V (in BC; unknown pathological significance).
BRCA2	1988	1988	V -> I (in one patient with esophageal carcinoma; somatic mutation).
BRCA2	2031	2031	T -> A (in BC; unknown pathological significance).
BRCA2	2044	2044	G -> V (in one patient with BC).
BRCA2	2072	2072	S -> C (in BC).
BRCA2	2074	2074	H -> N.
BRCA2	2089	2089	E -> D (in BC).
BRCA2	2094	2094	Y -> C (in BC).
BRCA2	2096	2096	P -> L (in BC).
BRCA2	2108	2108	R -> C.
BRCA2	2118	2118	V -> L (in BC; unknown pathological significance).
BRCA2	2128	2128	K -> N (in BC).
BRCA2	2135	2135	N -> H (in BC).
BRCA2	2138	2138	V -> F.
BRCA2	2162	2162	K -> R.
BRCA2	2222	2222	Y -> C (in BC).
BRCA2	2274	2274	G -> V (in BC).
BRCA2	2275	2275	E -> G (in BC; unknown pathological significance).
BRCA2	2293	2293	F -> L (in BC; unknown pathological significance).
BRCA2	2336	2336	R -> H (in FANCD1).
BRCA2	2353	2353	G -> R (in BC; unknown pathological significance).
BRCA2	2415	2415	H -> N (in BC).
BRCA2	2421	2421	Q -> H (in BC).
BRCA2	2440	2440	H -> R.
BRCA2	2456	2456	Q -> E (in BC).
BRCA2	2466	2466	A -> V (polymorphism; was originally thought to be linked to ovarian cancer).
BRCA2	2480	2480	L -> V.
BRCA2	2488	2488	R -> K (in BC; unknown pathological significance).
BRCA2	2490	2490	I -> T.
BRCA2	2502	2502	R -> C (in BC; unknown pathological significance).
BRCA2	2502	2502	R -> H (in ovarian cancer; could be a polymorphism).
BRCA2	2510	2510	L -> P (in FANCD1).
BRCA2	2515	2515	T -> I (in BC; could be a polymorphism).
BRCA2	2626	2626	W -> C (in FANCD1).
BRCA2	2627	2627	I -> F (in BC; unknown pathological significance).
BRCA2	2653	2653	L -> P (in BC; unknown pathological significance).
BRCA2	2659	2659	R -> K (in BC; unknown pathological significance).
BRCA2	2663	2663	E -> V (could be associated with cancer susceptibility; major splicing aberration identified with this mutant; multifactorial likelihood analysis provides evidence for pathogenicity).
BRCA2	2706	2706	N -> S.
BRCA2	2722	2722	T -> R (in BC).
BRCA2	2723	2723	D -> G (could be associated with cancer susceptibility; has abrogated function consistent with pathogenicity; major splicing aberration identified with this mutant).
BRCA2	2723	2723	D -> H (in BC; unknown pathological significance).
BRCA2	2728	2728	V -> I (in BC).
BRCA2	2729	2729	K -> N (in BC).
BRCA2	2748	2748	G -> D (in BC; unknown pathological significance).
BRCA2	2787	2787	R -> H (in ovarian cancer; somatic mutation).
BRCA2	2793	2793	G -> R (in BC; unknown pathological significance).
BRCA2	2835	2835	S -> P.
BRCA2	2842	2842	R -> C (in one patient with esophageal carcinoma; somatic mutation).
BRCA2	2856	2856	E -> A.
BRCA2	2944	2944	I -> F.
BRCA2	2950	2950	K -> N (in BC; unknown pathological significance).
BRCA2	2951	2951	A -> T.
BRCA2	2969	2969	V -> M.
BRCA2	3013	3013	T -> I (in BC; unknown pathological significance).
BRCA2	3052	3052	R -> W (could be associated with cancer susceptibility; has abrogated function consistent with pathogenicity; multifactorial likelihood analysis provides evidence for pathogenicity).
BRCA2	3063	3063	P -> S (in a patient with ovarian cancer; unknown pathological significance).
BRCA2	3076	3076	G -> E.
BRCA2	3095	3095	D -> E (in BC; unknown pathological significance).
BRCA2	3098	3098	Y -> H (in BC and ovarian cancer; could be a polymorphism).
BRCA2	3103	3103	I -> M (in melanoma).
BRCA2	3118	3118	M -> T (in BC).
BRCA2	3124	3124	N -> I (in BC).
BRCA2	3196	3196	K -> E (in BC).
BRCA2	3244	3244	V -> I.
BRCA2	3257	3257	K -> R.
BRCA2	3276	3276	R -> S.
BRCA2	3300	3300	P -> S (in one patient with esophageal carcinoma).
BRCA2	3357	3357	T -> R (in BC).
BRCA2	3374	3374	T -> I.
TRPC4	138	138	E -> K (in a breast cancer sample; somatic mutation).
FREM2	1972	1972	E -> K (in FRASS; may impair calcium- binding in the 2nd Calx-beta domain).
RB1	72	72	E -> Q (in RB).
RB1	137	137	E -> D (in RB; unilateral form).
RB1	185	185	I -> T (in RB).
RB1	310	310	G -> E (in RB; could be a polymorphism).
RB1	358	358	R -> G (in RB).
RB1	358	358	R -> Q (in RB).
RB1	447	447	K -> Q (in RB).
RB1	457	457	M -> R (in RB).
RB1	480	480	Missing (in RB; mild form).
RB1	500	500	R -> G (in RB).
RB1	530	530	K -> R (in RB).
RB1	549	549	H -> Y (in RB).
RB1	567	567	S -> L (in RB).
RB1	616	616	K -> E (in RB).
RB1	635	635	A -> P (in RB).
RB1	654	654	V -> E (in RB).
RB1	657	657	L -> P (in RB).
RB1	661	661	R -> W (in RB; mild form).
RB1	662	662	L -> P (in RB).
RB1	673	673	H -> P (in RB).
RB1	685	685	Q -> P (in RB).
RB1	706	706	C -> Y (in RB).
RB1	712	712	C -> R (in RB).
RB1	803	803	N -> K (in RB).
RNASEH2B	60	60	L -> R (in AGS2; heterozygous compound with T-177).
RNASEH2B	86	86	H -> R (in AGS2; heterozygous compound with T-177; reduces stability of the RNase complex).
RNASEH2B	162	162	K -> T (in AGS2).
RNASEH2B	163	163	T -> I (in AGS2; heterozygous compound with T-177).
RNASEH2B	177	177	A -> T (in AGS2; frequent mutation).
RNASEH2B	185	185	V -> G (in AGS2).
RNASEH2B	219	219	Y -> H (in AGS2; heterozygous compound with a nonsense mutation; reduces stability of the RNase complex).
ATP7B	14	14	A -> D.
ATP7B	41	41	N -> S (in WD).
ATP7B	85	85	G -> V (in WD).
ATP7B	96	96	G -> D.
ATP7B	290	290	V -> L.
ATP7B	390	390	I -> V.
ATP7B	446	446	V -> L.
ATP7B	466	466	L -> V.
ATP7B	486	486	A -> S (in WD).
ATP7B	492	492	L -> S (in WD).
ATP7B	532	532	Y -> H (in WD).
ATP7B	536	536	V -> A (in WD).
ATP7B	565	565	N -> S.
ATP7B	591	591	G -> D (in WD).
ATP7B	604	604	A -> P (in WD).
ATP7B	608	609	FD -> Y (in WD).
ATP7B	616	616	R -> Q (in WD).
ATP7B	616	616	R -> W (in WD).
ATP7B	626	626	G -> A (in WD).
ATP7B	639	639	H -> Y (in WD).
ATP7B	641	641	L -> S (in WD).
ATP7B	642	642	D -> H (in WD).
ATP7B	645	645	M -> R (in WD).
ATP7B	653	653	S -> Y (in WD).
ATP7B	657	657	S -> R (in WD).
ATP7B	665	665	M -> I (in WD).
ATP7B	670	671	Missing (in WD).
ATP7B	690	690	P -> L (in WD).
ATP7B	691	691	G -> R (in WD).
ATP7B	693	693	S -> C (in WD).
ATP7B	703	703	C -> Y (in WD).
ATP7B	708	708	L -> P (in WD).
ATP7B	710	710	G -> A (in WD).
ATP7B	710	710	G -> R (in WD).
ATP7B	710	710	G -> S (in WD).
ATP7B	710	710	G -> V (in WD).
ATP7B	711	711	G -> E (in WD).
ATP7B	711	711	G -> R (in WD).
ATP7B	711	711	G -> W (in WD).
ATP7B	713	713	Y -> C (in WD).
ATP7B	721	721	S -> P (in WD).
ATP7B	723	723	R -> G.
ATP7B	737	737	T -> R (in WD).
ATP7B	741	741	Y -> C (in WD).
ATP7B	744	744	S -> P (in WD).
ATP7B	747	747	I -> F (in WD).
ATP7B	756	756	A -> G (in WD).
ATP7B	760	760	P -> L (in WD).
ATP7B	765	765	D -> G (in WD).
ATP7B	766	766	T -> M (in WD).
ATP7B	766	766	T -> R (in WD).
ATP7B	768	768	P -> H (in WD).
ATP7B	769	769	M -> I (in WD).
ATP7B	769	769	M -> R (in WD).
ATP7B	769	769	M -> V (in WD).
ATP7B	776	776	L -> P (in WD).
ATP7B	776	776	L -> V (possible polymorphism).
ATP7B	778	778	R -> G (in WD).
ATP7B	778	778	R -> Q (in WD).
ATP7B	778	778	R -> W (in WD).
ATP7B	795	795	L -> F (in WD).
ATP7B	795	795	L -> R (in WD).
ATP7B	840	840	P -> L (in WD).
ATP7B	857	857	I -> T (in WD).
ATP7B	861	861	A -> T (in WD).
ATP7B	864	864	V -> I.
ATP7B	869	869	G -> R (in WD).
ATP7B	869	869	G -> V (in WD).
ATP7B	874	874	A -> V (in WD).
ATP7B	875	875	G -> R.
ATP7B	875	875	G -> V (in WD; requires 2 nucleotide substitutions).
ATP7B	890	890	V -> M (in WD).
ATP7B	891	891	G -> V (in WD).
ATP7B	898	898	Q -> R (in WD).
ATP7B	918	918	D -> E (in WD).
ATP7B	918	918	D -> N (in WD).
ATP7B	919	919	R -> G (in WD).
ATP7B	919	919	R -> W (in WD).
ATP7B	921	921	S -> N (in WD).
ATP7B	933	933	T -> P (in WD).
ATP7B	935	935	T -> M (in WD).
ATP7B	943	943	G -> C (in WD).
ATP7B	943	943	G -> D (in WD).
ATP7B	949	949	V -> G (in WD).
ATP7B	969	969	R -> Q (in WD).
ATP7B	971	971	A -> V (in WD).
ATP7B	974	974	T -> M (in WD).
ATP7B	975	975	S -> Y (in WD).
ATP7B	977	977	T -> M (in WD).
ATP7B	985	985	C -> Y (in WD).
ATP7B	988	988	G -> R (in WD).
ATP7B	992	992	P -> H (in WD).
ATP7B	992	992	P -> L (in WD; common mutation).
ATP7B	995	995	V -> A.
ATP7B	996	996	M -> T (in WD).
ATP7B	1000	1000	G -> R (in WD).
ATP7B	1003	1003	A -> T (in WD).
ATP7B	1003	1003	A -> V (in WD).
ATP7B	1004	1004	Q -> P (in WD).
ATP7B	1018	1018	A -> V (in WD).
ATP7B	1029	1029	T -> I (in WD).
ATP7B	1031	1031	T -> I (in WD).
ATP7B	1033	1033	T -> A (in WD).
ATP7B	1033	1033	T -> S (in WD).
ATP7B	1035	1035	G -> V (in WD).
ATP7B	1041	1041	R -> P (in WD).
ATP7B	1041	1041	R -> W (in WD; possibly not disease- causing).
ATP7B	1043	1043	L -> P (in WD).
ATP7B	1052	1052	P -> L (in WD).
ATP7B	1061	1061	G -> E (in WD).
ATP7B	1063	1063	A -> V (in WD; could be a polymorphism).
ATP7B	1064	1064	E -> A (in WD).
ATP7B	1064	1064	E -> K (in WD; marked impairment in copper transport).
ATP7B	1065	1065	A -> P (in WD).
ATP7B	1068	1068	E -> G (in WD; common mutation).
ATP7B	1069	1069	H -> Q (in WD; common mutation).
ATP7B	1083	1083	L -> F (in WD; marked impairment in copper transport).
ATP7B	1089	1089	G -> E (in WD).
ATP7B	1089	1089	G -> V (in WD).
ATP7B	1094	1094	F -> L (in WD).
ATP7B	1095	1095	Q -> P (in WD).
ATP7B	1098	1098	P -> R (in WD).
ATP7B	1099	1099	G -> S (in WD).
ATP7B	1101	1101	G -> R (in WD).
ATP7B	1102	1102	I -> T (in WD).
ATP7B	1104	1104	C -> F (in WD).
ATP7B	1104	1104	C -> Y (in WD).
ATP7B	1106	1106	V -> D (in WD; marked impairment in copper transport).
ATP7B	1106	1106	V -> I (in WD).
ATP7B	1109	1109	V -> M.
ATP7B	1111	1111	G -> D (in WD).
ATP7B	1142	1142	Q -> H (in WD).
ATP7B	1143	1143	T -> N.
ATP7B	1146	1146	V -> M (in WD).
ATP7B	1149	1149	G -> A (in WD).
ATP7B	1151	1151	R -> H (in WD).
ATP7B	1153	1153	W -> C (in WD).
ATP7B	1153	1153	W -> R (in WD).
ATP7B	1164	1164	D -> N (in WD).
ATP7B	1168	1168	A -> S (in WD).
ATP7B	1169	1169	M -> T (in WD).
ATP7B	1169	1169	M -> V (in WD; moderate impairment in copper transport).
ATP7B	1173	1173	E -> G (in WD).
ATP7B	1173	1173	E -> K (in WD).
ATP7B	1176	1176	G -> E (in WD).
ATP7B	1176	1176	G -> R (in WD).
ATP7B	1183	1183	A -> G (in WD).
ATP7B	1183	1183	A -> T (in WD; possibly not disease- causing).
ATP7B	1186	1186	G -> C (in WD).
ATP7B	1186	1186	G -> S (in WD; possibly not disease- causing).
ATP7B	1213	1213	G -> V (in WD).
ATP7B	1216	1217	Missing (in WD).
ATP7B	1216	1216	V -> M (in WD).
ATP7B	1217	1218	Missing (in WD).
ATP7B	1220	1220	T -> M (in WD).
ATP7B	1221	1221	G -> E (in WD).
ATP7B	1222	1222	D -> N (in WD).
ATP7B	1222	1222	D -> V (in WD).
ATP7B	1222	1222	D -> Y (in WD).
ATP7B	1228	1228	R -> T (in WD).
ATP7B	1230	1230	I -> V (in WD).
ATP7B	1232	1232	T -> P (in WD).
ATP7B	1239	1239	V -> G (in WD).
ATP7B	1245	1245	P -> S.
ATP7B	1248	1248	K -> N (in WD).
ATP7B	1252	1252	V -> I (in WD).
ATP7B	1255	1255	L -> I (in WD).
ATP7B	1256	1256	Q -> R (in WD).
ATP7B	1262	1262	V -> F (in WD).
ATP7B	1266	1266	G -> R (in WD; common mutation).
ATP7B	1266	1266	G -> V (in WD).
ATP7B	1267	1267	D -> A (in WD).
ATP7B	1267	1267	D -> V (in WD).
ATP7B	1270	1270	N -> S (in WD).
ATP7B	1271	1271	D -> N (in WD).
ATP7B	1273	1273	P -> L (in WD).
ATP7B	1278	1278	A -> V (in WD; uncertain pathogenicity).
ATP7B	1279	1279	D -> G (in WD).
ATP7B	1279	1279	D -> Y (in WD).
ATP7B	1285	1292	Missing (in WD).
ATP7B	1287	1287	G -> S (in WD).
ATP7B	1296	1296	D -> N (in WD).
ATP7B	1297	1297	V -> I.
ATP7B	1297	1297	Missing (in WD).
ATP7B	1305	1305	L -> P (in WD).
ATP7B	1310	1310	S -> R (in WD).
ATP7B	1322	1322	R -> P (in WD).
ATP7B	1327	1327	L -> V (in WD).
ATP7B	1328	1328	A -> T (in WD).
ATP7B	1331	1331	Y -> S (in WD).
ATP7B	1336	1336	I -> T (in WD).
ATP7B	1341	1341	G -> D (in WD).
ATP7B	1341	1341	G -> S (in WD).
ATP7B	1341	1341	G -> V (in WD).
ATP7B	1352	1352	P -> S (in WD).
ATP7B	1353	1353	W -> R (in WD).
ATP7B	1355	1355	G -> C (in WD).
ATP7B	1355	1355	G -> S (in WD).
ATP7B	1358	1358	A -> S (in WD).
ATP7B	1359	1359	M -> I (in WD).
ATP7B	1363	1363	S -> F (in WD).
ATP7B	1368	1368	L -> P (in WD).
ATP7B	1373	1373	L -> P (in WD).
ATP7B	1373	1373	L -> R (in WD).
ATP7B	1375	1375	C -> S (in WD).
ATP7B	1379	1379	P -> S (in WD).
ATP7B	1407	1407	D -> E.
NEK5	290	290	R -> H.
NEK5	531	531	C -> R.
PCDH20	496	496	V -> M (in a breast cancer sample; somatic mutation).
FARP1	714	714	R -> L (in a breast cancer sample; somatic mutation).
SLC15A1	21	21	V -> I.
SLC15A1	28	28	F -> Y.
LMO7	354	354	T -> A (in a colorectal cancer sample; somatic mutation).
LMO7	785	785	L -> M (in a colorectal cancer sample; somatic mutation).
EDNRB	183	183	A -> G (in WS4A).
EDNRB	276	276	W -> C (in HSCR2).
EDNRB	292	292	F -> L (in WS4A).
EDNRB	319	319	R -> W (in HSCR2; sporadic).
EDNRB	374	374	M -> I (in HSCR2).
EDNRB	383	383	P -> L (in HSCR2; familial).
CLN5	63	63	R -> H (in CLN5).
CLN5	63	63	R -> P (in CLN5).
CLN5	209	209	Y -> D (in CLN5).
CLN5	230	230	D -> N (in CLN5).
CLN5	330	330	W -> C (in CLN5; retained in the endoplasmic reticulum rather than reaching the lysosome).
ABCC4	556	556	Y -> C (40% reduced expression level compared to wild-type; higher transport of 9-(2-phosphonyl-methoxyethyl) adenine than wild-type).
ABCC4	776	776	V -> I (20% reduced expression level compared to wild-type; significant lower activity in 6-mercaptopurine transport than wild-type).
ABCC4	854	854	V -> F (transport properties comparable to wild-type).
ABCC4	866	866	I -> V (transport properties comparable to wild-type).
ABCC4	1142	1142	T -> M (10% reduced expression level compared to wild-type; transport properties comparable to wild-type).
POU4F1	163	163	Missing.
PCCA	75	75	A -> P (in PA-1).
PCCA	77	77	R -> W (in PA-1).
PCCA	138	138	A -> T (in PA-1).
PCCA	164	164	I -> T (in PA-1).
PCCA	197	197	G -> E (in PA-1).
PCCA	229	229	M -> K (in PA-1).
PCCA	297	297	Q -> R (in PA-1).
PCCA	368	368	D -> G (in PA-1).
PCCA	373	373	M -> K (in PA-1; unstable protein).
PCCA	379	379	G -> V (in PA-1).
PCCA	398	398	C -> R (in PA-1).
PCCA	399	399	R -> Q (in PA-1).
PCCA	423	423	P -> L (in PA-1).
PCCA	532	532	Missing (in PA-1).
PCCA	551	551	V -> F.
PCCA	559	559	W -> L (in PA-1).
PCCA	631	631	G -> R (in PA-1).
PCCA	668	668	G -> R (in PA-1).
PCCA	712	712	Missing (in PA-1).
TMTC4	655	655	M -> V (in a breast cancer sample; somatic mutation).
MYO16	1168	1168	L -> H (found in a renal cell carcinoma sample; somatic mutation).
ARHGEF7	790	790	T -> A (found in a clear cell renal carcinoma case; somatic mutation).
GRK1	136	136	E -> Q (in one patient with autosomal dominant retinitis pigmentosa; probably not pathogenic).
GRK1	298	298	T -> M (in patients with autosomal recessive retinitis pigmentosa; unclear pathological significance).
GRK1	330	330	N -> S (in patients with autosomal dominant retinitis pigmentosa; probably not pathogenic).
GRK1	380	380	V -> D (in CSNBO2).
GRK1	391	391	P -> H (in CSNBO2).
GRK1	438	438	R -> H (in one patient with autosomal dominant retinitis pigmentosa; probably not pathogenic).
GRK1	514	514	C -> S (in one patient with autosomal dominant retinitis pigmentosa; probably not pathogenic).
GRK1	522	522	M -> T (in patients with autosomal recessive retinitis pigmentosa; unclear pathological significance).
GRK1	536	536	S -> L (in one patient with autosomal dominant retinitis pigmentosa; probably not pathogenic).
GAS6	41	41	F -> L.
GAS6	231	231	S -> Y.
GAS6	390	390	V -> M.
GAS6	543	543	G -> R.
GAS6	623	623	S -> L.
GAS6	655	655	E -> K.
GAS6	659	659	R -> Q.
GJA3	11	11	"L -> S (in cataract; autosomal dominant congenital/infantile ""ant-egg"" cataract)."
GJA3	32	32	F -> L (in CZP3).
GJA3	45	45	W -> S (in nuclear progressive cataract).
GJA3	59	59	P -> L (in cataract; autosomal dominant nuclear punctate cataract).
GJA3	63	63	N -> S (in CZP3).
GJA3	76	76	R -> H (in CZP3; not fully penetrant mutation).
GJA3	187	187	P -> L (in CZP3).
GJB2	12	12	G -> R (in KID syndrome).
GJB2	32	32	R -> H (in DFNB1A).
GJB2	32	32	R -> L.
GJB2	37	37	V -> I (in DFNB1A; was reported first as a polymorphism).
GJB2	44	44	W -> C (in DFNA3A).
GJB2	44	44	W -> S (in DFNA3A; does not affect protein trafficking; affects the ability to form functional channels; dominant negative effect).
GJB2	45	45	G -> E (in deafness).
GJB2	46	48	DEQ -> E (may contribute to deafness).
GJB2	46	46	D -> E (in DFNA3A; the mutant is targeted to the plasma membrane but failes to transfer ionic calcium or propidium iodide intercellularly suggesting disruption of both ionic and biochemical coupling; heterozygous gap junctions also show dysfunctional intercellular couplings and hemichannel opening confirming the dominant-negative nature of the mutation).
GJB2	50	50	D -> Y (in KID syndrome).
GJB2	54	54	N -> K (in BPS).
GJB2	59	59	G -> A (in PPKDFN; impairs trafficking; localizes intracellularly closed to the nucleus; affects the ability to form functional channels; phenotype can be rescued by coexpression with wild-type protein).
GJB2	59	59	G -> S (in BPS).
GJB2	66	66	D -> H (in VS and PPKDFN; impairs trafficking; localizes intracellularly closed to the nucleus; affects the ability to form functional channels; phenotype can be rescued by coexpression with wild-type protein).
GJB2	71	71	I -> T (in deafness).
GJB2	73	73	H -> R (in PPKDFN; the mutant has a dominant-negative effect on connexin trafficking).
GJB2	75	75	R -> Q (in PPKDFN; the mutant protein completely prevents the formation of functional channels).
GJB2	75	75	R -> W (in PPKDFN and DFNA3A; does not affect protein trafficking; affects the ability to form functional channels; dominant negative effect).
GJB2	77	77	W -> R (in DFNB1A).
GJB2	79	79	L -> P (in DFNB1A).
GJB2	80	80	Q -> K (in DFNB1A).
GJB2	83	83	F -> L.
GJB2	84	84	V -> L (in DFNB1A; sorted to the plasma membrane normally and forms gap junctions that were morphologically and electrically indistinguishable from those of control; the mutation reduces the permeability of GJB2 gap junction channels to inositol 1,4,5-trisphosphate (Ins(1,4,5)P3), resulting in blockade of the Ins(1,4,5)P3-induced inward calcium current in neighboring cells).
GJB2	84	84	V -> M (in DFNB1A; the mutant disrupts cellular communication).
GJB2	86	86	T -> R (in DFNB1A; does not form gap junctions since the mutated protein is confined in the cytoplasm and not transported to the cell membrane; when the mutation is co-expressed with the wild-type protein ionic and biochemical coupling is normal consistent with the recessive nature of the mutation).
GJB2	90	90	L -> P (in DFNB1A).
GJB2	93	93	M -> I (in DFNB1A).
GJB2	95	95	V -> M (in DFNB1A).
GJB2	111	111	I -> T.
GJB2	113	113	S -> R (in DFNB1A).
GJB2	118	118	Missing (in DFNB1A).
GJB2	120	120	Missing (in DFNB1A).
GJB2	123	123	T -> N.
GJB2	127	127	R -> H (very common polymorphism in India).
GJB2	129	129	E -> K (in DFNB1A).
GJB2	143	143	R -> Q (in DFNA3A).
GJB2	143	143	R -> W (in DFNB1A).
GJB2	153	153	V -> I (may contribute to deafness).
GJB2	165	165	R -> W.
GJB2	167	167	V -> M (may contribute to deafness).
GJB2	168	168	K -> R (in a patient with congenital erythrokeratodermia; unknown pathological significance).
GJB2	169	169	C -> Y.
GJB2	178	178	V -> A (in DFNB1A).
GJB2	184	184	R -> P (in DFNB1A).
GJB2	184	184	R -> Q (in DFNA3A).
GJB2	184	184	R -> W (in DFNB1A).
GJB2	191	191	F -> L.
GJB2	197	197	A -> S (in DFNA3A).
GJB2	202	202	C -> F (in DFNA3A).
GJB2	203	203	I -> K (in DFNB1A).
GJB2	203	203	I -> T.
GJB2	214	214	L -> P (in DFNB1A).
GJB6	5	5	T -> M (in DFNA3B).
GJB6	11	11	G -> R (in ED2).
GJB6	37	37	V -> E (in ED2).
GJB6	59	59	G -> R (found in one patient with a syndrome resembling Vohwinkel and Bart- Pumphrey syndromes).
GJB6	139	139	S -> G.
GJB6	199	199	S -> T.
FGF9	99	99	S -> N (in SYNS3; expressed and secreted as efficiently as wild-type; however it induces compromised chondrocyte proliferation and differentiation accompanied by enhanced osteogenic differentiation and matrix mineralization of bone marrow-derived mesenchymal stem cells).
CENPJ	1235	1235	E -> V (in MCPH6).
FAM123A	457	457	A -> T (in a colorectal cancer sample; somatic mutation).
GPR180	32	32	T -> N (in a breast cancer sample; somatic mutation).
POLR1D	47	47	E -> K (in TCS2).
POLR1D	50	50	T -> I (in TCS2).
POLR1D	51	51	L -> R (in TCS2).
POLR1D	52	52	G -> E (in TCS2).
POLR1D	56	56	R -> C (in TCS2).
POLR1D	82	82	L -> S (in TCS2).
POLR1D	99	99	G -> S (in TCS2).
PDX1	18	18	C -> R (in MODY4).
PDX1	59	59	Q -> L (in MODY4).
PDX1	76	76	D -> N (in MODY4; could be a polymorphism).
PDX1	197	197	R -> H (in MODY4).
PDX1	243	243	P -> PP (in MODY4).
FLT3	194	194	V -> M.
FLT3	835	835	D -> E (in acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated).
FLT3	835	835	D -> H (in acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated).
FLT3	835	835	D -> N (in acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated).
FLT3	835	835	D -> V (in acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated).
FLT3	835	835	D -> Y (in acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated).
FLT3	836	836	I -> M (in acute lymphoblastic leukemia patients; somatic mutation).
LIG4	278	278	R -> H (in LIG4S and leukemia; impairs activity).
LIG4	433	433	Missing (in RS-SCID).
LIG4	469	469	G -> E (in LIG4S).
SPACA7	25	25	R -> W (in a colorectal cancer sample; somatic mutation).
ZIC2	36	36	Q -> P (in HPE5; 2-fold increase in luciferase activity).
ZIC2	37	37	D -> N (in HPE5).
ZIC2	128	128	D -> N (in HPE5).
ZIC2	152	152	D -> F (in HPE5; requires 2 nucleotide substitutions; 50% reduction of luciferase activity).
ZIC2	239	239	H -> HH.
ZIC2	239	239	Missing.
ZIC2	272	272	S -> N (in HPE5).
ZIC2	286	286	H -> L (in HPE5).
ZIC2	286	286	H -> Q (in HPE5).
ZIC2	286	286	H -> Y (in HPE5).
ZIC2	291	291	H -> Y (in HPE5).
ZIC2	304	304	W -> R (in HPE5).
ZIC2	314	314	F -> C (in HPE5).
ZIC2	325	325	R -> L (in HPE5).
ZIC2	325	325	R -> S (in HPE5).
ZIC2	327	327	H -> Y (in HPE5).
ZIC2	335	335	C -> F (in HPE5).
ZIC2	373	373	R -> P (in HPE5).
ZIC2	402	402	Y -> N (in HPE5).
ZIC2	403	403	T -> K (in HPE5).
ZIC2	404	404	H -> R (in HPE5).
ZIC2	409	409	R -> W (in HPE5).
ZIC2	415	415	H -> Q (in HPE5).
ZIC2	470	470	A -> AAAAAAAAAAA (in HPE5; near-complete loss of luciferase activity).
KL	193	193	H -> R (in HFTC; impairs the ability to form a ternary complex with FGF23 and FGFR1c; impairs KL-dependent FGF23 signaling).
KL	954	954	P -> L (in a colorectal cancer sample; somatic mutation).
SLC10A2	243	243	L -> P (in PBAM; abolishes taurocholate transport).
SLC10A2	262	262	T -> M (in PBAM; abolishes taurocholate transport).
CSNK1A1L	21	21	R -> W.
IRS2	879	879	G -> S.
IRS2	882	882	G -> A.
SLC25A15	27	27	G -> E (in HHH syndrome).
SLC25A15	27	27	G -> R (in HHH syndrome; incapable of catalyzing homo-exchanges of ornithine, arginine, lysine and citrulline).
SLC25A15	37	37	M -> R (in HHH syndrome; exhibits very low transport activity despite normal insertion in the liposomal membrane).
SLC25A15	70	70	A -> L (in HHH syndrome; requires 2 nucleotide substitutions; uncertain pathogenicity).
SLC25A15	71	71	L -> Q (in HHH syndrome; exhibits very low transport activity despite normal insertion in the liposomal membrane).
SLC25A15	113	113	G -> C (in HHH syndrome; exhibits very low transport activity despite normal insertion in the liposomal membrane).
SLC25A15	126	126	P -> R (in HHH syndrome).
SLC25A15	180	180	E -> K (in HHH syndrome).
SLC25A15	188	188	F -> L (in HHH syndrome; maintains a residual transport activity of 10%).
SLC25A15	188	188	Missing (in HHH syndrome).
SLC25A15	190	190	G -> D (in HHH syndrome; maintains a residual transport activity of 35%).
SLC25A15	216	216	G -> S (in HHH syndrome).
SLC25A15	272	272	T -> I (in HHH syndrome; exhibits very low transport activity despite normal insertion in the liposomal membrane).
SLC25A15	273	273	M -> K (in HHH syndrome; exhibits very low transport activity despite normal insertion in the liposomal membrane).
SLC25A15	275	275	R -> Q (in HHH syndrome).
SLC25A15	283	283	L -> F (in HHH syndrome; exhibits very low transport activity despite normal insertion in the liposomal membrane).
WBP4	113	113	K -> R (in a breast cancer sample; somatic mutation).
TNFSF11	199	199	M -> K (in OPTB2).
ING1	335	335	A -> D (in HNSCC).
ING1	358	358	C -> S (in HNSCC).
ING1	359	359	N -> S (in HNSCC).
COG3	620	620	R -> C (in a breast cancer sample; somatic mutation).
LCP1	24	24	D -> E.
SUCLA2	118	118	G -> R (in MTDPS5).
SUCLA2	284	284	R -> C (in MTDPS5).
ITM2B	266	266	S -> FNLFLNSQEKHY (in CAA-ITM2B2; amyloid ADan).
ITM2B	266	266	S -> SRTVKKNIIEEN (in CAA-ITM2B1; amyloid ABri).
LPAR6	63	63	D -> V (in ARWH1).
LPAR6	188	188	I -> F (in ARWH1).
LPAR6	189	189	E -> K (in ARWH1).
RCBTB1	500	500	T -> I.
ARL11	22	22	S -> L.
ARL11	131	131	P -> L.
ARL11	164	164	E -> K.
F10	47	47	E -> G (in FA10D; St. Louis II; strongly reduced activity; not activated by factor VIIa and tissue factor).
F10	51	51	G -> V (in FA10D).
F10	54	54	E -> G (in FA10D; Ketchikan).
F10	54	54	E -> K (in FA10D; Vorarlberg; converts prothrombin at a normal rate but shows decreased affinity for calcium).
F10	72	72	E -> Q (in FA10D; Tokyo).
F10	91	91	E -> K (in FA10D; Riyadh).
F10	142	142	E -> K (in FA10D; uncertain pathological significance; detected in patients carrying K-54 or P-374; slightly reduced activity).
F10	149	149	C -> Y (in FA10D).
F10	151	151	C -> Y (in FA10D).
F10	289	289	G -> R (in FA10D; may affect splicing).
F10	304	304	E -> K (in FA10D).
F10	322	322	D -> N (in FA10D; Stockton; 50% decrease in specific activity).
F10	327	327	R -> W (in FA10D).
F10	338	338	V -> M (in FA10D).
F10	350	350	E -> K (in FA10D).
F10	358	358	T -> M (in FA10D; Roma).
F10	363	363	G -> S (in FA10D).
F10	366	366	R -> C (in FA10D; San Antonio).
F10	374	374	S -> P (in FA10D; Marseille; decreased cleavage by factor IXa; normal catalytic efficiency for prothrombin).
F10	383	383	P -> S (in FA10D; Friuli).
F10	390	390	C -> F (in FA10D; Padua 4).
F10	404	404	C -> R (in FA10D).
F10	406	406	G -> S (in FA10D; almost complete loss of activity).
F10	420	420	G -> R (in FA10D; Padua 3).
F10	448	448	K -> N (in FA10D; San Giovanni Rotondo).
PCDH8	956	956	K -> N (in a breast cancer sample; somatic mutation).
PTPRD	28	28	R -> Q (in a colorectal cancer sample; somatic mutation).
PTPRD	276	276	L -> P (in a colorectal cancer sample; somatic mutation).
PTPRD	901	901	V -> A (in a colorectal cancer sample; somatic mutation).
DAPK1	461	461	A -> S.
DAPK1	519	519	S -> A.
DAPK1	591	591	P -> L.
DAPK1	622	622	I -> M.
DAPK1	941	941	M -> T.
DAPK1	977	977	R -> W.
DAPK1	978	978	K -> N.
DAPK1	993	993	Y -> C.
DAPK1	994	994	D -> E.
DAPK1	1005	1005	E -> Q.
DAPK1	1007	1007	D -> Y.
DAPK1	1008	1008	L -> P.
DAPK1	1010	1010	R -> C.
DAPK1	1018	1018	T -> A.
ROR2	182	182	C -> Y (in RRS).
ROR2	184	184	R -> C (in RRS).
ROR2	189	189	R -> W (in RRS).
ROR2	366	366	R -> W (in RRS).
ROR2	542	542	V -> M (in a colorectal adenocarcinoma sample; somatic mutation).
ROR2	620	620	N -> K (in RRS).
ASTN2	229	229	A -> V (found in a clear cell renal carcinoma case; somatic mutation).
ASTN2	1293	1293	V -> L (in a breast cancer sample; somatic mutation).
C5	389	389	T -> I.
C5	518	518	F -> S.
ADAMTS13	88	88	V -> M (in TTP; reduces protein secretion and proteolytic activity).
ADAMTS13	96	96	H -> D (in TTP).
ADAMTS13	102	102	R -> C (in TTP).
ADAMTS13	193	193	R -> W (in TTP; low activity).
ADAMTS13	196	196	T -> I (in TTP).
ADAMTS13	234	234	H -> Q (in TTP).
ADAMTS13	250	250	A -> V (in TTP; mild effect on protein secretion; strong reduction of proteolytic activity).
ADAMTS13	268	268	R -> P (in TTP; affects protein secretion).
ADAMTS13	390	390	W -> C (in TTP).
ADAMTS13	398	398	R -> H (in TTP).
ADAMTS13	508	508	C -> Y (in TTP; impairs protein secretion).
ADAMTS13	528	528	R -> G (in TTP).
ADAMTS13	673	673	I -> F (in TTP; impairs protein secretion).
ADAMTS13	692	692	R -> C (in TTP).
ADAMTS13	903	903	S -> L (in a patient with thrombotic thrombocytopenic purpura; probable polymorphism).
ADAMTS13	908	908	C -> Y (in TTP; impairs protein secretion).
ADAMTS13	951	951	C -> G (in TTP).
ADAMTS13	1024	1024	C -> G (in TTP).
ADAMTS13	1095	1095	R -> W (in a patient with thrombotic thrombocytopenic purpura).
ADAMTS13	1123	1123	R -> C (in TTP; impairs protein secretion).
ADAMTS13	1213	1213	C -> Y (in TTP).
ADAMTS13	1239	1239	G -> V (in TTP; impairs protein secretion).
ADAMTS13	1336	1336	R -> W (in TTP; impairs protein secretion and proteolytic activity).
DOCK8	473	473	K -> R (in AR-HIES).
DMRT1	221	221	Y -> S.
DMRT1	281	281	R -> S.
DMRT1	295	295	P -> L.
JAK2	191	191	K -> Q (in an ovarian serous carcinoma sample; somatic mutation).
JAK2	537	539	FHK -> L (in myeloproliferative disorder with erythrocytosis).
JAK2	538	539	HK -> QL (in myeloproliferative disorder with erythrocytosis).
JAK2	539	539	K -> L (in myeloproliferative disorder with erythrocytosis; requires 2 nucleotide substitutions).
JAK2	607	607	K -> N (in AML).
JAK2	617	617	V -> F (in PV and AML; associated with susceptibility to Budd-Chiari syndrome; somatic mutation in a high percentage of patients with essential thrombocythemia or myelofibrosis; leads to constitutive tyrosine phosphorylation activity that promotes cytokine hypersensitivity).
UHRF2	87	87	I -> N (in a colorectal cancer sample; somatic mutation).
GLDC	283	283	A -> P (in NKH).
GLDC	329	329	P -> T (in one non-ketotic hyperglycinemia patient).
GLDC	515	515	R -> S (in NKH).
GLDC	564	564	S -> I (in NKH; common mutation in Finland).
GLDC	756	756	Missing (in NKH).
FREM1	649	649	R -> W (in BNAR).
FREM1	1440	1440	G -> S (in BNAR).
TEK	117	117	K -> N (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation).
TEK	849	849	R -> W (in VMCM; activating effect).
TEK	883	883	P -> A (in an ovarian serous carcinoma sample; somatic mutation).
TEK	897	897	Y -> S (in VMCM; activating effect).
TEK	1124	1124	A -> V (in a renal clear cell carcinoma sample; somatic mutation).
DNAI1	515	515	G -> S (in KTGS).
UNC13B	209	209	P -> S (in a colorectal cancer sample; somatic mutation).
SLC25A51	205	205	T -> M (in a breast cancer sample; somatic mutation).
FXN	106	106	L -> S (in FRDA).
FXN	122	122	D -> Y (in FRDA).
FXN	130	130	G -> V (in FRDA).
FXN	154	154	I -> F (in FRDA; reduces interaction with LYRM4; the interaction is rescued by nickel. Defects in mitochondrial structure, mitochondrial iron deposits, decreased enzymatic activity of some mitochondrial and cytoplasmic iron-sulfur cluster-containing enzymes, increased RNA-binding activity of ACO1 and increased sensitivity to oxidative stress).
FXN	155	155	W -> R (in FRDA; reduces interaction with LYRM4; the interaction is rescued by nickel).
FXN	165	165	R -> C (in FRDA; mild form).
FXN	182	182	L -> F (in FRDA).
FXN	198	198	L -> R (in FRDA).
TJP2	48	48	V -> A (in FHCA).
TMC1	572	572	D -> N (in DFNA36).
TMC1	654	654	M -> V (in DFNB7).
TRPM6	75	75	G -> V (in a lung adenocarcinoma sample; somatic mutation).
TRPM6	141	141	S -> L (in HOMG1; impairs heterodimer formation resulting in intracellular retention).
TRPM6	1007	1007	W -> C (in a lung large cell carcinoma sample; somatic mutation).
VPS13A	161	161	R -> H (in a colorectal cancer sample; somatic mutation).
VPS13A	565	565	F -> L.
VPS13A	898	898	V -> A.
VPS13A	1095	1095	A -> P (in CHAC).
VPS13A	1452	1452	S -> P (in CHAC).
VPS13A	1490	1490	R -> K.
VPS13A	1587	1587	Y -> C.
VPS13A	2460	2460	W -> R (in CHAC).
VPS13A	2486	2486	I -> T.
VPS13A	2721	2721	Y -> C (in CHAC).
VPS13A	3172	3172	P -> L.
SLC28A3	4	4	R -> K.
SLC28A3	67	67	R -> K.
SLC28A3	131	131	L -> F.
SLC28A3	367	367	G -> R (reduced transport of inosine and thymidine).
SLC28A3	418	418	L -> I.
SLC28A3	585	585	R -> H.
SLC28A3	602	602	C -> R (lower concentrative capacity and altered sodium binding capacity).
NTRK2	138	138	L -> F (in a lung adenocarcinoma sample; somatic mutation).
NTRK2	309	309	G -> R.
NTRK2	697	697	M -> I (in a lung carcinoma sample; somatic mutation).
NTRK2	699	699	R -> G (in a lung carcinoma sample; somatic mutation).
NTRK2	718	718	R -> C (in a lung carcinoma sample; somatic mutation).
AGTPBP1	423	423	E -> K (in a colorectal cancer sample; somatic mutation).
AUH	240	240	A -> V (in MGA1).
FBP1	164	164	G -> S (in FBPD).
FBP1	177	177	A -> D (in FBPD).
FBP1	194	194	F -> S (in FBPD).
FBP1	284	284	P -> R (in FBPD).
FBP1	325	325	V -> A.
FANCC	496	496	L -> R (in FA).
FANCC	554	554	L -> P (in FA; loss of activity; loss of CDK1-binding and IFNG-induced STAT1- binding; abnormal EIF2AK2 activation and augmented cell death).
GABBR2	628	628	Y -> F.
GALNT12	3	3	G -> E.
GALNT12	46	46	G -> R.
GALNT12	119	119	E -> V.
GALNT12	261	261	D -> N.
GALNT12	272	272	G -> R.
GALNT12	297	297	R -> W (in CRCS1; germline mutation; partial loss of activity).
GALNT12	303	303	D -> N (in CRCS1; germline mutation; reduction of activity).
GALNT12	341	341	E -> D (in CRCS1; somatic mutation; loss of activity).
GALNT12	373	373	R -> H (in CRCS1; germline mutation; partial loss of activity).
GALNT12	382	382	R -> H (in CRCS1; germline mutation; loss of activity).
GALNT12	479	479	C -> F (in CRCS1; somatic mutation; loss of activity).
GALNT12	491	491	T -> M (in CRCS1; germline mutation; loss of activity).
GALNT12	552	552	R -> K.
INVS	482	482	P -> R (in NPHP2).
INVS	493	493	L -> S (in NPHP2; impairs ability to target DVL1 for degradation).
ABCA1	85	85	P -> L (in HDLD2; Alabama).
ABCA1	210	210	E -> D (in a colorectal cancer sample; somatic mutation).
ABCA1	248	248	P -> A.
ABCA1	255	255	A -> T (in HDLD1; deficient cellular cholesterol efflux).
ABCA1	284	284	E -> K (in HDLD1).
ABCA1	364	364	S -> C.
ABCA1	401	401	K -> Q.
ABCA1	482	482	Y -> C (in HDLD1).
ABCA1	496	496	R -> W (associated with increased plasma HDL cholesterol).
ABCA1	590	590	W -> L (in HDLD1).
ABCA1	590	590	W -> S (in HDLD1).
ABCA1	638	638	R -> Q (associated with reduced plasma HDL cholesterol).
ABCA1	693	693	Missing (in HDLD2).
ABCA1	774	774	T -> S.
ABCA1	776	776	K -> N (associated with increased risk of ischemic heart disease).
ABCA1	815	815	E -> G (associated with reduced plasma HDL cholesterol).
ABCA1	840	840	W -> R (in HDLD1).
ABCA1	917	917	D -> Y (in a colorectal cancer sample; somatic mutation).
ABCA1	929	929	T -> I (in HDLD1).
ABCA1	937	937	A -> V (in HDLD1).
ABCA1	1046	1046	A -> D (in HDLD1).
ABCA1	1065	1065	P -> S.
ABCA1	1068	1068	R -> C (in HDLD1).
ABCA1	1091	1091	M -> T (in HDLD2).
ABCA1	1181	1181	S -> F (associated with reduced plasma HDL cholesterol).
ABCA1	1216	1216	G -> V.
ABCA1	1289	1289	D -> N (in HDLD1).
ABCA1	1341	1341	R -> T (associated with reduced plasma HDL cholesterol).
ABCA1	1376	1376	S -> G.
ABCA1	1379	1379	L -> F (in HDLD1; the mutant protein is retained in the endoplasmic reticulum while the wild-type protein is located at the plasma membrane).
ABCA1	1407	1407	A -> T (in a colorectal cancer sample; somatic mutation).
ABCA1	1477	1477	C -> R (in HDLD1).
ABCA1	1506	1506	S -> L (in HDLD1).
ABCA1	1517	1517	I -> R (in HDLD1).
ABCA1	1611	1611	N -> D (associated with atherosclerosis; deficient cellular cholesterol efflux).
ABCA1	1615	1615	R -> Q (associated with reduced plasma HDL cholesterol).
ABCA1	1670	1670	A -> T (associated with reduced plasma HDL cholesterol).
ABCA1	1680	1680	R -> Q (associated with increased plasma HDL cholesterol).
ABCA1	1680	1680	R -> W (in HDLD1; clinical variant).
ABCA1	1704	1704	V -> D (in HDLD1; the mutant protein is retained in the endoplasmic reticulum while the wild-type protein is located at the plasma membrane).
ABCA1	1731	1731	S -> C.
ABCA1	1800	1800	N -> H (in HDLD1).
ABCA1	1851	1851	R -> Q (in HDLD1).
ABCA1	1893	1894	Missing (in HDLD2).
ABCA1	1897	1897	R -> W (in HDLD2; uncertain pathogenicity).
ABCA1	1901	1901	R -> S (in HDLD1).
ABCA1	1925	1925	R -> Q (in Scott syndrome; shows impaired trafficking of the mutant protein to the plasma membrane).
ABCA1	2009	2009	F -> S (in HDLD2).
ABCA1	2081	2081	R -> W (in HDLD1).
ABCA1	2109	2109	A -> T (in a colorectal cancer sample; somatic mutation).
ABCA1	2150	2150	P -> L (in HDLD2).
ABCA1	2163	2163	F -> S (could be associated with reduced plasma HDL cholesterol).
ABCA1	2196	2196	Q -> H (in HDLD1).
ABCA1	2243	2243	D -> E.
ABCA1	2244	2244	V -> I (could be associated with reduced plasma HDL cholesterol).
FKTN	114	114	A -> T (in MDDGC4).
FKTN	170	170	A -> E (in MDDGA4).
FKTN	176	176	F -> S (in MDDGC4).
FKTN	179	179	R -> T (in CMD1X).
FKTN	225	225	D -> E (in a breast cancer sample; somatic mutation).
FKTN	225	225	D -> N (in a breast cancer sample; somatic mutation).
FKTN	246	246	R -> G (in MDDGB4; detected in a compound heterozygote with very mild phenotype carrying a non-sense mutation).
FKTN	250	250	C -> G (in MDDGA4).
FKTN	307	307	R -> Q (in MDDGB4 and MDDGC4; the mutant protein is expressed and localized correctly within the cell).
FKTN	358	358	Q -> P (in CMD1X).
FKTN	371	371	Y -> C (in MDDGA4).
IKBKAP	696	696	R -> P (in HSAN3; mild phenotype; phosphorylation is reduced).
MUSK	790	790	V -> M (in CMS-ACHRD; does not affect catalytic kinase activity; reduces protein expression and stability).
MUSK	819	819	N -> S (in a lung neuroendocrine carcinoma sample; somatic mutation).
PAPPA	944	944	S -> R.
DBC1	347	347	S -> R (common polymorphism).
DBC1	712	712	P -> T (in a colorectal cancer sample; somatic mutation).
GSN	22	22	S -> L (in a breast cancer sample; somatic mutation).
GSN	201	201	T -> I (in a breast cancer sample; somatic mutation).
GSN	214	214	D -> N (in AMYL5).
GSN	214	214	D -> Y (in AMYL5).
GSN	611	611	S -> N (in a breast cancer sample; somatic mutation).
NDUFA8	140	140	N -> H (in a breast cancer sample; somatic mutation).
STRBP	280	280	G -> R (in a breast cancer sample; somatic mutation).
STXBP1	84	84	V -> D (in EIEE4; may alter protein structure).
STXBP1	180	180	C -> Y (in EIEE4; reduced thermostability; decreased binding to STX1A).
STXBP1	443	443	M -> R (in EIEE4; may alter protein structure).
STXBP1	544	544	G -> D (in EIEE4; may alter protein structure).
SPTAN1	904	904	S -> C (in a breast cancer sample; somatic mutation).
SPTAN1	1017	1017	P -> S (in a breast cancer sample; somatic mutation).
SPTAN1	1794	1794	R -> W (in a breast cancer sample; somatic mutation).
SPTAN1	1918	1918	D -> N (in a breast cancer sample; somatic mutation).
SPTAN1	2202	2202	Missing (in EIEE5; could form a heterodimer with SPTBN1 but the heterodimer is thermally instable; suggests a dominant negative effect).
SPTAN1	2303	2303	R -> RM (in EIEE5; could form a heterodimer with SPTBN1 but the heterodimer is thermally instable; suggests a dominant negative effect).
ABL1	47	47	R -> G (in a lung large cell carcinoma sample; somatic mutation).
ABL1	166	166	R -> K (in a melanoma sample; somatic mutation).
ABL1	852	852	T -> P.
NUP214	424	424	G -> A (in a breast cancer sample; somatic mutation).
NUP214	1378	1378	P -> L (in a breast cancer sample; somatic mutation).
NUP214	1392	1392	A -> V (in a breast cancer sample; somatic mutation).
C9orf171	172	172	R -> W (in a colorectal cancer sample; somatic mutation).
TSC1	51	51	E -> D (in TSC1; could be a polymorphism).
TSC1	68	68	H -> R (in a bladder tumor; somatic mutation; reduced stability; does not affect interaction with TSC2).
TSC1	72	72	L -> P (in TSC1).
TSC1	158	158	F -> C (in a bladder tumor; somatic mutation; reduced stability; does not affect interaction with TSC2).
TSC1	190	190	R -> S.
TSC1	191	191	L -> H (in TSC1; could be a polymorphism).
TSC1	198	199	NF -> I (in TSC1).
TSC1	206	206	H -> D (in a bladder tumor; somatic mutation; reduced stability; does not affect interaction with TSC2).
TSC1	216	216	F -> L (in a bladder tumor; diffuse punctate cytoplasmic distribution in aminoacid-starved conditions; does not affect interaction with TSC2).
TSC1	224	224	M -> R (in TSC1; could be a polymorphism).
TSC1	417	417	T -> I (in TSC1; could be a polymorphism; does not affect interaction with TSC2).
TSC1	500	500	R -> Q (in TSC1).
TSC1	577	577	E -> D.
TSC1	586	589	CKIP -> S (in TSC1).
TSC1	587	587	K -> R.
TSC1	654	654	Q -> E (in TSC1).
TSC1	726	726	A -> E (in TSC1).
TSC1	732	732	H -> Y (in FCDBC; could be a polymorphism).
TSC1	809	809	E -> Q.
TSC1	829	829	S -> R.
TSC1	899	899	T -> S (in TSC1).
TSC1	1035	1035	G -> S.
TSC1	1108	1108	G -> S.
COL5A1	25	25	L -> P (in EDS1 and EDS2; not or less efficiently secreted into the extracellular matrix).
COL5A1	25	25	L -> R (in EDS1 and EDS2; not or less efficiently secreted into the extracellular matrix).
COL5A1	114	114	A -> D (unclassified mutation).
COL5A1	192	192	D -> N (unclassified mutation).
COL5A1	229	229	D -> N (associated with increased risk of cervical artery dissection).
COL5A1	393	393	P -> S (unclassified mutation).
COL5A1	908	908	P -> L (found in a renal cell carcinoma case; somatic mutation).
COL5A1	1486	1486	G -> C (in EDS1 and EDS2).
COL5A1	1489	1489	G -> D (in EDS1).
COL5A1	1639	1639	C -> S (in EDS1).
INPP5E	378	378	R -> C (in JBTS1; slightly reduced activity).
INPP5E	435	435	R -> Q (in JBTS1; severe reduction of activity).
INPP5E	512	512	R -> W (in JBTS1; associated with W-515; severe reduction of activity).
INPP5E	515	515	R -> W (in JBTS1; associated with W-512; severe reduction of activity).
INPP5E	563	563	R -> H (in JBTS1; slightly reduced activity).
INPP5E	580	580	K -> E (in JBTS1; severe reduction of activity).
EHMT1	43	43	A -> V (in a breast cancer sample; somatic mutation).
EHMT1	1173	1173	Y -> F (in a breast cancer sample; somatic mutation).
KCNV2	126	126	L -> Q (in RCD3B).
KCNV2	188	188	W -> C (in RCD3B).
KCNV2	256	256	S -> W (in RCD3B).
KCNV2	259	259	A -> V (in RCD3B).
KCNV2	339	341	Missing (in RCD3B).
KCNV2	459	459	G -> D (in RCD3B).
TYRP1	356	356	R -> Q (in OCA3).
LURAP1L	47	49	Missing.
IFNB1	162	162	C -> Y (in clone PF526, loss of ability to form the essential disulfide bond, loss of antiviral activity).
IFNB1	164	164	W -> C (in a breast cancer sample; somatic mutation).
IFNA2	57	57	H -> R (in alpha-2C).
IFNA2	177	177	S -> L (in a breast cancer sample; somatic mutation).
CDKN2A	14	14	D -> E (in a biliary tract tumor).
CDKN2A	16	16	L -> P (in a biliary tract tumor and a familial melanoma).
CDKN2A	19	19	A -> ATA (in CMM2; loss of CDK4 binding).
CDKN2A	20	20	A -> P (in a lung tumor and melanoma).
CDKN2A	20	20	A -> S (in a biliary tract tumor).
CDKN2A	23	23	G -> D (in a pancreas tumor and a melanoma; loss of CDK4 binding).
CDKN2A	24	24	R -> C (in CMM2).
CDKN2A	24	24	R -> P (in CMM2).
CDKN2A	24	24	R -> Q (found in a patient with multiple primary melanoma; partial loss of CDK4 binding).
CDKN2A	26	26	E -> D (in a biliary tract tumor).
CDKN2A	32	32	L -> P (in CMM2).
CDKN2A	33	33	E -> D (in a biliary tract tumor).
CDKN2A	35	35	G -> A (in CMM2; also found in a biliary tract tumor and a patient with uveal melanoma; partial loss of CDK4 binding).
CDKN2A	35	35	G -> E (in CMM2).
CDKN2A	35	35	G -> V (in CMM2; loss of CDK4 binding).
CDKN2A	48	48	P -> L (in CMM2 and a head and neck tumor; somatic mutation).
CDKN2A	49	49	I -> S (in a biliary tract tumor).
CDKN2A	49	49	I -> T.
CDKN2A	50	50	Q -> R (in CMM2).
CDKN2A	53	53	M -> I (in CMM2).
CDKN2A	56	56	S -> I (possible polymorphism).
CDKN2A	57	57	A -> V (in pancreas carcinoma; somatic mutation; partial loss of CDK4 binding).
CDKN2A	59	59	V -> G (in CMM2).
CDKN2A	60	60	A -> T.
CDKN2A	61	62	EL -> DV.
CDKN2A	62	62	L -> P (in CMM2).
CDKN2A	66	66	H -> Y (in non-small cell lung carcinoma).
CDKN2A	67	71	Missing (in melanoma; loss of CDK4 binding).
CDKN2A	67	67	G -> R (in CMM2; partial loss of CDK4 binding).
CDKN2A	68	68	A -> L (in CMM2; requires 2 nucleotide substitutions).
CDKN2A	68	68	A -> T (in an esophagus tumor).
CDKN2A	68	68	A -> V.
CDKN2A	69	69	E -> G (found in some patients with melanoma; partial loss of CDK4 binding).
CDKN2A	69	69	E -> K (in a bladder tumor).
CDKN2A	69	69	E -> V (in a lung tumor).
CDKN2A	71	71	N -> K (in CMM2).
CDKN2A	71	71	N -> S.
CDKN2A	72	72	C -> G (in an esophagus tumor).
CDKN2A	74	74	D -> N (in a bladder tumor).
CDKN2A	74	74	D -> V (in a biliary tract tumor).
CDKN2A	74	74	D -> Y (in CMM2; loss of CDK4 binding).
CDKN2A	77	77	T -> P (in CMM2; loss of CDK4 binding).
CDKN2A	80	80	R -> L (in a head and neck tumor).
CDKN2A	80	80	R -> P (in CMM2; loss of CDK4 binding).
CDKN2A	81	81	P -> T (in CMM2; loss of CDK4 binding).
CDKN2A	83	83	H -> N (in a lung tumor).
CDKN2A	83	83	H -> Y (in a pancreas and a head and neck tumor).
CDKN2A	84	84	D -> E (in a bladder tumor).
CDKN2A	84	84	D -> H (in non-small cell lung carcinoma).
CDKN2A	84	84	D -> N (in an esophagus, a head and neck and a lung tumor).
CDKN2A	85	85	A -> T.
CDKN2A	87	87	R -> P (in CMM2; impairs the function).
CDKN2A	87	87	R -> W (in CMM2; partial loss of CDK4 binding).
CDKN2A	88	88	E -> D (in a biliary tract tumor).
CDKN2A	89	89	G -> D (in CMM2; somatic mutation).
CDKN2A	89	89	G -> S (in CMM2).
CDKN2A	93	93	T -> A (in non-small cell lung carcinoma).
CDKN2A	94	94	L -> Q (in CMM2).
CDKN2A	95	95	V -> A (in non-small cell lung carcinoma).
CDKN2A	97	97	L -> R (in CMM2; loss of CDK4 binding).
CDKN2A	98	98	H -> P (in CMM2).
CDKN2A	98	98	H -> Q (in CMM2).
CDKN2A	99	99	R -> P (in CMM2; loss of CDK4 binding).
CDKN2A	99	99	R -> Q (in non-small cell lung carcinoma).
CDKN2A	100	100	A -> L (in CMM2; requires 2 nucleotide substitutions).
CDKN2A	100	100	A -> P.
CDKN2A	101	101	G -> W (in CMM2 and FAMMMPC; impairs the function).
CDKN2A	102	102	A -> E (in LFS; somatic mutation).
CDKN2A	104	105	Missing.
CDKN2A	107	107	R -> C (in CMM2).
CDKN2A	107	107	R -> H.
CDKN2A	108	108	D -> H (in a bladder tumor).
CDKN2A	108	108	D -> Y (in a head and neck tumor).
CDKN2A	112	112	R -> RR (in CMM2).
CDKN2A	114	114	P -> L (in non-small cell lung carcinoma).
CDKN2A	114	114	P -> S (found in some patients with melanoma; loss of CDK4 binding).
CDKN2A	117	117	L -> M (in CMM2; somatic mutation).
CDKN2A	118	118	A -> T (in CMM2).
CDKN2A	119	119	E -> Q (in a biliary tract tumor).
CDKN2A	120	120	E -> A (in non-small cell lung carcinoma).
CDKN2A	120	120	E -> K (in non-small cell lung carcinoma).
CDKN2A	122	122	G -> R (in CMM2).
CDKN2A	122	122	G -> S (in a biliary tract tumor).
CDKN2A	124	124	R -> H (in an esophagus tumor).
CDKN2A	126	126	V -> D (in CMM2; impairs the function).
CDKN2A	132	132	A -> P (in non-small cell lung carcinoma).
CDKN2A	134	134	A -> V (in non-small cell lung carcinoma).
CDKN2A	142	142	H -> Y (in non-small cell lung carcinoma).
CDKN2A	144	144	R -> C (in squamous cell carcinoma).
CDKN2A	150	150	G -> V (in non-small cell lung carcinoma).
CDKN2B	47	47	G -> E (in lung adenocarcinoma).
CDKN2B	50	50	A -> V (in lung adenocarcinoma).
DMRTA1	342	342	R -> C (in a colorectal cancer sample; somatic mutation).
TAF1L	47	47	G -> A (in a lung small cell carcinoma sample; somatic mutation).
TAF1L	171	171	Q -> E.
TAF1L	750	750	L -> F (in a lung adenocarcinoma sample; somatic mutation).
TAF1L	762	762	L -> I (in a lung adenocarcinoma sample; somatic mutation).
TAF1L	794	794	E -> D (in a lung adenocarcinoma sample; somatic mutation).
TAF1L	1549	1549	H -> Y (in a glioblastoma multiforme sample; somatic mutation).
TAF1L	1824	1824	H -> Q (in a lung adenocarcinoma sample; somatic mutation).
APTX	211	211	K -> Q (in AOA; it probably does not greatly affect the protein; heterozygous).
APTX	212	212	A -> V (in AOA; heterozygous).
APTX	213	213	R -> H (in AOA).
APTX	215	215	H -> R (in AOA).
APTX	220	220	P -> L (in AOA).
APTX	237	237	L -> P (in AOA).
APTX	277	277	V -> G (in AOA; abolishes DNA-binding and enzymatic activity towards Ap(4)A).
APTX	281	281	D -> G (in AOA; heterozygous).
APTX	293	293	W -> R (in AOA; heterozygous).
SIGMAR1	211	211	R -> Q.
GALT	28	28	D -> Y (in GALCT).
GALT	32	32	I -> N (in GALCT; mild).
GALT	38	38	Q -> P (in GALCT).
GALT	44	44	V -> L (in GALCT).
GALT	44	44	V -> M (in GALCT; reduced enzyme activity).
GALT	45	45	S -> L (in GALCT).
GALT	51	51	R -> L (in GALCT).
GALT	51	51	R -> Q (in GALCT).
GALT	55	55	G -> C (in GALCT).
GALT	67	67	R -> C (in GALCT).
GALT	74	74	L -> P (in GALCT; reduced enzyme activity).
GALT	81	81	A -> T (in GALCT).
GALT	97	97	N -> S (in GALCT).
GALT	98	98	D -> N (in GALCT).
GALT	113	113	D -> N (in GALCT).
GALT	114	114	H -> L (in GALCT).
GALT	117	117	F -> S (in GALCT).
GALT	118	118	Q -> H (in GALCT).
GALT	123	123	R -> G (in GALCT).
GALT	123	123	R -> Q (in GALCT).
GALT	125	125	V -> A (in GALCT).
GALT	127	127	K -> E (in GALCT).
GALT	129	129	M -> T (in GALCT).
GALT	130	130	C -> Y (in GALCT).
GALT	132	132	H -> Y (in GALCT).
GALT	135	135	S -> L (in GALCT; frequent mutation in African Americans; about 5% of normal activity).
GALT	135	135	S -> W (in GALCT).
GALT	138	138	T -> M (in GALCT; mild).
GALT	139	139	L -> P (in GALCT).
GALT	142	142	M -> K (in GALCT; 4% of normal activity).
GALT	142	142	M -> V (in GALCT).
GALT	143	143	S -> L (in GALCT).
GALT	148	148	R -> G (in GALCT).
GALT	148	148	R -> Q (in GALCT).
GALT	148	148	R -> W (in GALCT; unstable protein).
GALT	150	150	V -> L (in GALCT).
GALT	151	151	V -> A (in GALCT; approximatively 3% of normal activity).
GALT	154	154	W -> G (in GALCT).
GALT	167	167	W -> R (in GALCT).
GALT	171	171	F -> S (in GALCT; reduced enzyme activity).
GALT	179	179	G -> D (in GALCT).
GALT	183	183	P -> T (in GALCT).
GALT	184	184	H -> Q (in GALCT).
GALT	188	188	Q -> R (in GALCT; most common mutation; accounts for approximately 70% of GALCT alleles tested; 10% of normal activity).
GALT	192	192	S -> N (in GALCT).
GALT	194	194	F -> L (in GALCT).
GALT	195	195	L -> P (in GALCT; no enzymatic activity).
GALT	198	198	I -> M (in GALCT).
GALT	198	198	I -> T (in GALCT).
GALT	199	199	A -> T (in GALCT).
GALT	201	201	R -> H (in GALCT).
GALT	203	203	E -> K (in GALCT).
GALT	204	204	R -> P (in GALCT).
GALT	209	209	Y -> C (in GALCT).
GALT	209	209	Y -> S (in GALCT).
GALT	212	212	Q -> H (in GALCT).
GALT	217	217	L -> P (in GALCT).
GALT	226	226	L -> P (in GALCT).
GALT	229	229	K -> N (in GALCT).
GALT	231	231	R -> H (in GALCT; 15% of normal activity).
GALT	249	249	W -> R (in GALCT).
GALT	251	251	Y -> C (in GALCT).
GALT	251	251	Y -> S (in GALCT).
GALT	252	252	Q -> H (in GALCT).
GALT	258	258	R -> C (in GALCT).
GALT	259	259	R -> W (in GALCT; mild).
GALT	262	262	R -> P (in GALCT).
GALT	263	263	Missing (in GALCT).
GALT	272	272	R -> G (in GALCT).
GALT	282	282	L -> V (in GALCT).
GALT	285	285	K -> N (in GALCT; severe; 25-40% of the European population).
GALT	289	289	L -> R (in GALCT).
GALT	291	291	E -> K (in GALCT).
GALT	294	294	F -> Y (in GALCT).
GALT	308	308	E -> K (in GALCT).
GALT	317	317	Q -> H (in GALCT).
GALT	317	317	Q -> R (in GALCT).
GALT	319	319	H -> Q (in GALCT).
GALT	320	320	A -> T (in GALCT).
GALT	323	323	Y -> D (in GALCT).
GALT	323	323	Y -> H (in GALCT).
GALT	324	324	P -> S (in GALCT).
GALT	325	325	P -> L (in GALCT).
GALT	328	328	R -> H (in GALCT).
GALT	329	329	S -> F (in GALCT).
GALT	330	330	A -> V (in GALCT; mild).
GALT	333	333	R -> G (in GALCT).
GALT	333	333	R -> Q (in GALCT).
GALT	333	333	R -> W (in GALCT; no enzymatic activity).
GALT	334	334	K -> R (in GALCT).
GALT	336	336	M -> L (in GALCT).
GALT	344	344	Q -> K (in GALCT).
GALT	350	350	T -> A (in GALCT; mild).
VCP	95	95	R -> G (in IBMPFD; strongly reduced affinity for ADP and increased affinity for ATP).
VCP	155	155	R -> C (in IBMPFD; also in one patient without evidence of Paget disease of the bone).
VCP	155	155	R -> H (in IBMPFD; strongly reduced affinity for ADP and increased affinity for ATP).
VCP	155	155	R -> P (in IBMPFD).
VCP	159	159	R -> H (in IBMPFD; without frontotemporal dementia).
VCP	191	191	R -> Q (in IBMPFD).
VCP	232	232	A -> E (in IBMPFD).
FANCG	71	71	L -> P (in FA; associated with a mild clinical phenotype; disruption of HES1- binding; no effect on FANCA-binding).
FANCG	607	607	A -> T (in a colorectal cancer sample; somatic mutation).
PIGO	686	686	L -> M (in a colorectal cancer sample; somatic mutation).
TESK1	539	539	H -> Y (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation).
TPM2	91	91	R -> G (in DA1).
TPM2	117	117	E -> A (in NEM4).
TPM2	147	147	Q -> P (in NEM4).
NPR2	297	297	T -> M (in AMDM; markedly deficient activity).
NPR2	338	338	Y -> C (in AMDM).
NPR2	409	409	A -> T (in AMDM).
NPR2	413	413	G -> E (in AMDM; markedly deficient activity).
NPR2	708	708	Y -> C (in AMDM).
NPR2	776	776	R -> W (in AMDM).
NPR2	957	957	R -> C (in AMDM).
NPR2	959	959	G -> A (in AMDM).
GNE	27	27	P -> S (in IBM2).
GNE	36	36	P -> L (in IBM2).
GNE	132	132	H -> Q (in NM).
GNE	162	162	R -> C (in IBM2).
GNE	171	171	M -> V (in IBM2).
GNE	176	176	D -> V (in NM).
GNE	177	177	R -> C (in NM).
GNE	200	200	I -> F (in IBM2).
GNE	206	206	G -> S (in IBM2; moderate phenotype with unusual involvement of quadriceps).
GNE	216	216	V -> A (in IBM2).
GNE	225	225	D -> N (in IBM2).
GNE	246	246	R -> Q (in IBM2).
GNE	246	246	R -> W (in IBM2).
GNE	263	263	R -> L (in SIALURIA; strong reduction of feedback inhibition by CMP-Neu5Ac).
GNE	266	266	R -> Q (in SIALURIA; abolishes feedback inhibition by CMP-Neu5Ac).
GNE	266	266	R -> W (in sialuria).
GNE	303	303	C -> V (in IBM2; requires 2 nucleotide substitutions).
GNE	306	306	R -> Q (in NM).
GNE	331	331	V -> A (in NM).
GNE	378	378	D -> Y (in IBM2 and NM).
GNE	460	460	A -> V (in NM and IBM2).
GNE	472	472	I -> T (in NM).
GNE	519	519	N -> S (in IBM2).
GNE	524	524	A -> V (in IBM2).
GNE	528	528	F -> C (in IBM2).
GNE	557	557	I -> T (in IBM2).
GNE	572	572	V -> L (in NM and IBM2).
GNE	576	576	G -> E (in IBM2).
GNE	587	587	I -> T (in IBM2).
GNE	600	600	A -> T (in IBM2).
GNE	630	630	A -> T (in NM).
GNE	631	631	A -> T (in IBM2).
GNE	631	631	A -> V (in NM and IBM2).
GNE	675	675	Y -> H (in IBM2).
GNE	696	696	V -> M (in IBM2).
RNF38	206	206	A -> T.
MELK	460	460	T -> M (in an ovarian mucinous carcinoma sample; somatic mutation).
FRMPD1	572	572	G -> D (in a breast cancer sample; somatic mutation).
PRKACG	251	251	I -> N.
PSAT1	100	100	D -> A (in PSATD; reduced Vmax).
SECISBP2	540	540	R -> Q (in ATHYHM).
SPTLC1	133	133	C -> W (in HSAN1A).
SPTLC1	133	133	C -> Y (in HSAN1A).
SPTLC1	144	144	V -> D (in HSAN1A).
SPTLC1	239	239	R -> W (in a breast cancer sample; somatic mutation).
SPTLC1	387	387	G -> A (in HSAN1A).
SUSD3	140	140	S -> T (in a breast cancer sample; somatic mutation).
BARX1	48	48	A -> T.
PTCH1	175	175	L -> P (in BCNS; sporadic BCC).
PTCH1	230	230	T -> P (in BCNS).
PTCH1	376	376	F -> S (in BCNS).
PTCH1	393	393	A -> T (in HPE7).
PTCH1	443	443	A -> G (in HPE7).
PTCH1	505	506	FL -> LR (in BCNS).
PTCH1	509	509	G -> R (in BCNS; could be a rare polymorphism).
PTCH1	509	509	G -> V (in BCNS).
PTCH1	513	513	D -> Y (in BCNS).
PTCH1	751	751	V -> G (in HPE7).
PTCH1	815	815	I -> IPNI (in BCNS).
PTCH1	816	816	Missing (in BCNS).
PTCH1	827	827	S -> G (in HPE7).
PTCH1	829	829	V -> M (in squamous cell carcinoma).
PTCH1	908	908	V -> G (in HPE7).
PTCH1	1069	1069	G -> R (in BCNS).
PTCH1	1083	1083	V -> VV (in BCNS).
PTCH1	1114	1114	R -> W (in BCNS and BCC).
PTCH1	1132	1132	S -> P (in BCNS).
PTCH1	1132	1132	S -> Y (in BCNS).
PTCH1	1242	1242	E -> K (in squamous cell carcinoma).
PTCH1	1438	1438	E -> D (in BCNS; sporadic NBCCS).
HSD17B3	56	56	A -> T (in MPH; Cambridge-2. Affects NADPH cofactor binding).
HSD17B3	65	65	S -> L (in MPH).
HSD17B3	80	80	R -> Q (in MPH; Gaza).
HSD17B3	80	80	R -> W (in MPH).
HSD17B3	130	130	N -> S (in MPH; Cambridge-1. Complete loss of activity).
HSD17B3	176	176	Q -> P (in MPH).
HSD17B3	203	203	A -> V (in MPH).
HSD17B3	205	205	V -> E (in MPH).
HSD17B3	208	208	F -> I (in MPH).
HSD17B3	215	215	E -> D (in MPH).
HSD17B3	235	235	M -> V (in MPH).
HSD17B3	268	268	C -> Y (in MPH; complete loss of activity).
HSD17B3	282	282	P -> L (in MPH).
TDRD7	618	618	Missing (in CATC4).
XPA	78	78	Missing.
XPA	94	94	P -> L (in XP-A).
XPA	108	108	C -> F (in XP-A; severe form).
XPA	130	130	R -> K (in XP-A).
XPA	185	185	Q -> H (in XP-A).
XPA	244	244	H -> R (in XP-A; mild form).
FOXE1	65	65	A -> V (in BLS).
FOXE1	102	102	R -> C (in congenital hypothyroidism; with absence of thyroid agenesis; complete loss of DNA binding and transcriptionally inactive).
FOXE1	179	179	A -> AAA.
TGFBR1	24	26	Missing (in allele TGFBR1*6A; could be a tumor susceptibility allele).
TGFBR1	26	26	A -> AA (in allele TGFBR1*10A; rare polymorphism).
TGFBR1	139	139	I -> V.
TGFBR1	200	200	T -> I (in LDS1A).
TGFBR1	232	232	K -> E (in LDS2A).
TGFBR1	241	241	S -> L (in LDS1A).
TGFBR1	267	267	N -> H (in a patient with Marfan syndrome).
TGFBR1	318	318	M -> R (in LDS1A).
TGFBR1	400	400	D -> G (in LDS1A).
TGFBR1	487	487	R -> P (in LDS1A and LDS2A).
TGFBR1	487	487	R -> Q (in LDS2A and AAT5).
TGFBR1	487	487	R -> W (in LDS2A).
ALDOB	74	74	I -> T (in HFI; affects proper folding).
ALDOB	120	121	Missing (in HFI).
ALDOB	135	135	C -> R (in HFI; America; partial activity).
ALDOB	148	148	W -> R (in one subject with fructose intolerance; rare variant; America).
ALDOB	175	175	A -> D (in HFI; frequent mutation).
ALDOB	178	178	C -> R (in HFI).
ALDOB	185	185	P -> R (in HFI).
ALDOB	222	222	V -> F (in HFI; affects proper folding).
ALDOB	229	229	L -> P (in HFI; affects proper folding).
ALDOB	257	257	L -> P (in HFI; Italy).
ALDOB	284	284	L -> P (in HFI).
ALDOB	304	304	R -> Q (in HFI; 100-fold decrease in catalytic efficiency for substrates FBP and F1P).
ALDOB	304	304	R -> W (in HFI; Turkey; 4800-fold decrease in catalytic efficiency for FBP and inactive with F1P).
ALDOB	335	335	N -> K (in HFI; frequent mutation).
ALDOB	338	338	A -> V (in HFI; Turkey and South Europe).
ACTL7A	45	45	R -> C.
SLC46A2	366	366	A -> V (in dnSNP:16917454).
ALAD	12	12	F -> L (in an asymptomatic patient with ALAD deficiency; hexamer with almost no residual activity; also found in a hereditary coproporphyria patient carrying the R-279 mutation in CPOX).
ALAD	133	133	G -> R (in AHP; mixture of about 50% hexamer and 50% octamer; about 10% residual activity).
ALAD	153	153	V -> M (in AHP; about 95% octamer; about 40% residual activity).
ALAD	240	240	R -> W (in AHP; mixture of about 80% hexamer and 20% octamer; about 4% residual activity).
ALAD	274	274	A -> T (in AHP; mixture of about 14% hexamer and 86% octamer; about 20% enzyme residual activity).
ALAD	275	275	V -> M (in AHP; mainly octamer; reduced activity).
POLE3	83	83	T -> A.
ORM1	38	38	Q -> R (in allele ORM1*S).
TRIM32	130	130	P -> S (in BBS11).
TRIM32	394	394	R -> H (in LGMD2H).
TRIM32	487	487	D -> N (in LGMD2H).
TRIM32	588	588	Missing (in LGMD2H).
TLR4	834	834	Q -> H.
TRAF1	139	139	M -> T.
RAB14	4	4	A -> T.
OR1N1	190	190	T -> N (in a breast cancer sample; somatic mutation).
CRB2	46	46	P -> L.
CRB2	97	97	V -> L.
CRB2	116	116	P -> L.
CRB2	187	187	E -> D.
CRB2	351	351	A -> T.
CRB2	534	534	R -> Q.
CRB2	610	610	R -> W.
CRB2	746	746	H -> Q.
CRB2	1110	1110	T -> M.
NR5A1	15	15	V -> M (in SRXY3; without adrenal failure).
NR5A1	33	33	C -> S (in SRXY3; without adrenal failure; markedly impaired transcriptional activity).
NR5A1	35	35	G -> E (in SRXY3; with adrenal failure).
NR5A1	78	78	M -> I (in SRXY3; without adrenal failure).
NR5A1	84	84	R -> H (in SRXY3; without adrenal failure; markedly impaired transcriptional activity).
NR5A1	91	91	G -> S (in SRXY3; without adrenal failure).
NR5A1	92	92	R -> Q (in SRXY3; with adrenal failure).
NR5A1	123	123	G -> A (in POF7; activity levels similar to wild-type).
NR5A1	129	129	P -> L (in POF7; loss of activity).
NR5A1	231	233	Missing (in POF7).
NR5A1	255	255	R -> L (in ACIWOD).
NR5A1	293	293	D -> N (in POF7; without adrenal failure; partial loss of activity).
NR5A1	437	437	L -> Q (in SRXY3; without adrenal failure).
LMX1B	36	36	C -> R (in NPS).
LMX1B	36	36	C -> S (in NPS).
LMX1B	54	54	H -> N (in NPS).
LMX1B	54	54	H -> Q (in NPS).
LMX1B	54	54	H -> Y (in NPS).
LMX1B	57	57	C -> R (in NPS).
LMX1B	58	58	L -> W (in NPS).
LMX1B	60	60	C -> F (in NPS).
LMX1B	60	60	C -> G (in NPS).
LMX1B	60	60	C -> W (in NPS).
LMX1B	60	60	C -> Y (in NPS).
LMX1B	63	63	C -> R (in NPS).
LMX1B	80	80	C -> W (in NPS).
LMX1B	83	83	D -> G (in NPS).
LMX1B	95	95	C -> F (in NPS).
LMX1B	95	95	C -> Y (in NPS).
LMX1B	114	114	H -> Y (in NPS).
LMX1B	117	117	C -> Y (in NPS).
LMX1B	120	120	C -> S (in NPS).
LMX1B	123	123	C -> F (in NPS).
LMX1B	123	123	C -> Y (in NPS).
LMX1B	142	142	C -> W (in NPS).
LMX1B	213	213	A -> P (in NPS).
LMX1B	218	218	S -> P (in NPS).
LMX1B	226	226	R -> P (in NPS).
LMX1B	229	229	L -> P (in NPS).
LMX1B	230	230	A -> V (in NPS).
LMX1B	243	243	W -> C (in NPS).
LMX1B	246	246	N -> K (in NPS).
CDK9	231	231	G -> A.
ENG	8	8	L -> P (in HHT1).
ENG	49	49	V -> F (in HHT1).
ENG	52	52	G -> V (in HHT1).
ENG	53	53	C -> R (in HHT1).
ENG	107	107	L -> R (in HHT1).
ENG	149	149	W -> C (in HHT1).
ENG	160	160	A -> D (in HHT1).
ENG	192	198	Missing (in HHT1).
ENG	207	207	Missing (in HHT1).
ENG	221	221	L -> P (in HHT1).
ENG	232	233	Missing (in HHT1).
ENG	263	263	I -> T (in HHT1).
ENG	263	263	Missing (in HHT1).
ENG	306	306	L -> P (in HHT1).
ENG	412	412	C -> S (in HHT1).
ENG	413	413	G -> V (in HHT1).
ENG	504	504	V -> M (in HHT1).
ENG	615	615	S -> L (in HHT1).
AK1	40	40	G -> R (in hemolytic anemia).
AK1	64	64	G -> R (in hemolytic anemia).
AK1	140	140	Missing (in hemolytic anemia).
AK1	164	164	Y -> C (in hemolytic anemia).
SLC27A4	92	92	A -> T (in IPS).
SLC27A4	247	247	S -> P (in IPS).
SLC27A4	300	300	Q -> R (in IPS).
SLC27A4	374	374	R -> C (in IPS).
SLC27A4	583	583	R -> H (in IPS).
GLE1	144	144	T -> TPFQ (in LCCS1; allele Fin(Major); does not affect subcellular localization).
GLE1	569	569	R -> H (in LCCS1).
GLE1	617	617	V -> M (in LAAHD).
GLE1	684	684	I -> T (in LAAHD).
DOLK	99	99	C -> S (in CDG1M; 2% residual activity; fails to complement the temperature- sensitive phenotype of DK1-deficient yeast cells).
DOLK	441	441	Y -> S (in CDG1M; 4% residual activity; fails to complement the temperature- sensitive phenotype of DK1-deficient yeast cells).
TOR1A	264	264	D -> H.
TOR1A	303	303	Missing (in DYT1).
ASS1	14	14	G -> S (in CTLN1).
ASS1	18	18	S -> L (in CTLN1).
ASS1	19	19	C -> R (in CTLN1).
ASS1	40	40	Q -> L (in CTLN1).
ASS1	69	69	V -> A (in CTLN1).
ASS1	79	79	S -> P (in CTLN1).
ASS1	86	86	R -> C (in CTLN1).
ASS1	86	86	R -> H (in CTLN1).
ASS1	95	95	R -> S (in CTLN1).
ASS1	96	96	P -> H (in CTLN1).
ASS1	96	96	P -> S (in CTLN1).
ASS1	117	117	G -> D (in CTLN1).
ASS1	117	117	G -> S (in CTLN1).
ASS1	118	118	A -> T (in CTLN1).
ASS1	119	119	T -> I (in CTLN1).
ASS1	124	124	D -> N (in CTLN1).
ASS1	127	127	R -> Q (in CTLN1).
ASS1	127	127	R -> W (in CTLN1; severe clinical course).
ASS1	157	157	R -> C (in CTLN1).
ASS1	157	157	R -> H (in CTLN1).
ASS1	160	160	L -> P (in CTLN1).
ASS1	179	179	W -> R (in CTLN1; mild).
ASS1	180	180	S -> N (in CTLN1).
ASS1	190	190	Y -> D (in CTLN1).
ASS1	191	191	E -> K (in CTLN1).
ASS1	191	191	E -> Q (in CTLN1).
ASS1	192	192	A -> V (in CTLN1).
ASS1	202	202	A -> E (in CTLN1).
ASS1	206	206	L -> P (in CTLN1).
ASS1	263	263	V -> M (in CTLN1; mild clinical course).
ASS1	265	265	R -> C (in CTLN1; severe clinical course).
ASS1	265	265	R -> H (in CTLN1).
ASS1	269	269	V -> M (in CTLN1).
ASS1	270	270	E -> Q (in CTLN1).
ASS1	272	272	R -> C (in CTLN1).
ASS1	277	277	K -> T (in CTLN1).
ASS1	279	279	R -> Q (in CTLN1).
ASS1	280	280	G -> R (in CTLN1).
ASS1	283	283	E -> K (in CTLN1).
ASS1	284	284	T -> I (in CTLN1; mild clinical course).
ASS1	291	291	Y -> S (in CTLN1).
ASS1	296	296	D -> G (in CTLN1).
ASS1	302	302	M -> V (in CTLN1).
ASS1	304	304	R -> W (in CTLN1).
ASS1	307	307	R -> C (in CTLN1).
ASS1	310	310	K -> Q (in CTLN1).
ASS1	310	310	K -> R (in CTLN1).
ASS1	324	324	G -> S (in CTLN1).
ASS1	324	324	G -> V (in CTLN1).
ASS1	341	341	S -> F (in CTLN1).
ASS1	345	345	V -> G (in CTLN1).
ASS1	347	347	G -> R (in CTLN1; severe clinical course).
ASS1	359	359	Y -> D (in CTLN1; mild clinical course).
ASS1	362	362	G -> V (in CTLN1; mild).
ASS1	363	363	R -> G (in CTLN1).
ASS1	363	363	R -> L (in CTLN1).
ASS1	363	363	R -> Q (in CTLN1).
ASS1	363	363	R -> W (in CTLN1).
ASS1	389	389	T -> I (in CTLN1).
ASS1	390	390	G -> R (in CTLN1).
POMT1	65	65	G -> R (in MDDGB1).
POMT1	105	105	R -> C (in MDDGA1; severe Walker-Warburg syndrome).
POMT1	105	105	R -> H (in MDDGA1; severe Walker-Warburg syndrome).
POMT1	140	140	Missing (in MDDGB1).
POMT1	200	200	A -> P (in MDDGC1; a common founder mutation).
POMT1	207	207	G -> V (in MDDGA1; severe Walker-Warburg syndrome).
POMT1	285	285	L -> F.
POMT1	421	421	Missing (in MDDGA1; associated with the loss of function of alpha dystroglycan as a matrix receptor).
POMT1	428	428	V -> D (in MDDGA1).
POMT1	522	522	R -> K.
POMT1	537	537	S -> R (in MDDGA1 and MDDGB1).
POMT1	582	582	W -> C (in MDDGB1).
POMT1	590	590	Q -> H (in MDDGB1).
POMT1	669	669	A -> T (in MDDGB1).
SETX	274	274	M -> I (in SCAR1).
SETX	305	305	W -> C (in SCAR1).
SETX	413	413	P -> L (in SCAR1).
SETX	603	603	N -> D (in SCAR1; atypical; associated with K-653).
SETX	653	653	Q -> K (in SCAR1; atypical; associated with D-603).
SETX	1294	1294	R -> C (in SCAR1).
SETX	1756	1756	F -> S (in SCAR1; heterozygous in a British family).
SETX	2136	2136	R -> H (in ALS4).
SETX	2368	2368	P -> R (in SCAR1).
GFI1B	231	231	R -> H (in a colorectal cancer sample; somatic mutation).
RALGDS	496	496	R -> L (in a colorectal cancer sample; somatic mutation).
ABO	80	81	CR -> W.
ABO	223	223	E -> D (in allele B106).
ABO	230	230	G -> R (in group B transferase; lower- level protein expression and intracellular cytoplasmic mislocation).
ABO	288	288	M -> R.
ABO	291	291	D -> N (in allele B104).
ABO	346	346	K -> M (in allele Bw08).
ABO	352	352	R -> G (in allele A107).
ABO	352	352	R -> W (in allele A106 and allele B3).
SURF1	89	89	N -> K (in a breast cancer sample; somatic mutation).
SURF1	124	124	G -> R (in LS).
SURF1	202	202	D -> H.
SURF1	246	246	I -> T (in LS).
SURF1	274	274	Y -> D (in LS).
C9orf96	139	139	G -> D (in a glioblastoma multiforme sample; somatic mutation).
DBH	101	101	V -> M (in DBH deficiency).
DBH	114	114	D -> E (in DBH deficiency).
DBH	345	345	D -> N (in DBH deficiency).
BRD3	36	36	T -> N (in a renal clear cell carcinoma sample; somatic mutation).
BRD3	161	161	A -> T (in a gastric adenocarcinoma sample; somatic mutation).
FCN2	80	80	P -> L (in a colorectal cancer sample; somatic mutation).
FCN1	175	175	Y -> C (in a colorectal cancer sample; somatic mutation).
SOHLH1	31	31	C -> R (found in men with non-obstructive azoospermia; does not have any significant effect on its transactivation).
SOHLH1	177	177	P -> T (found in men with non-obstructive azoospermia; does not have any significant effect on its transactivation).
LHX3	111	111	Y -> C (in CPHD3).
LHX3	210	210	A -> V (in CPHD3; associated with diminished DNA binding and pituitary gene activation).
AGPAT2	136	136	G -> R (in CGL1).
AGPAT2	140	140	Missing (in CGL1).
AGPAT2	228	228	L -> P (in CGL1).
AGPAT2	239	239	A -> V (in CGL1).
MAMDC4	244	244	P -> T (in a breast cancer sample; somatic mutation).
MAMDC4	1174	1174	R -> W (in a breast cancer sample; somatic mutation).
SSNA1	17	17	K -> N (in a breast cancer sample; somatic mutation).
NDOR1	522	522	V -> I (in allele NDOR1*1; shows a decrease in affinity for NADPH and a reduction in ferricyanide reductase activity).
SLC34A3	138	138	S -> F (in HHRH).
SLC34A3	192	192	S -> L (in HHRH).
SLC34A3	196	196	G -> R (in HHRH).
SLC34A3	237	237	D -> N.
SLC34A3	353	353	R -> L (in HHRH).
SLC34A3	413	413	A -> E (in HHRH).
SLC34A3	468	468	R -> W (in HHRH).
NOXA1	274	476	Missing (in NOXA1truncated, a cDNA isolated from Caco-2 cells treated with butyrate).
NELF	480	480	T -> A (in IHH; sporadic case; could be a rare polymorphism).
DNAH9	771	771	R -> L (in a breast cancer sample; somatic mutation).
DNAH9	2653	2653	D -> H (in a breast cancer sample; somatic mutation).
DNAH9	3664	3664	T -> N (in a breast cancer sample; somatic mutation).
NOS2	679	679	A -> S (in a breast cancer sample; somatic mutation).
ACACA	1687	1687	R -> Q (in a colorectal cancer sample; somatic mutation).
ACACA	2271	2271	A -> V (rare polymorphism; frequency <0.004; may play a role in breast cancer susceptibility).
JUP	19	19	T -> I (in ARVD12).
JUP	39	39	S -> SS (in ARVD12; affects the structure and distribution of mechanical and electrical cell junctions).
JUP	142	142	R -> H.
JUP	648	648	V -> I.
GFAP	78	78	D -> E (in ALEXD; adult form).
GFAP	88	88	R -> S (in ALEXD).
GFAP	416	416	R -> W (in ALEXD).
MAPT	5	5	R -> H (in FTD; reduces the ability of tau to promote microtubule assembly and promotes fibril formation in vitro).
MAPT	5	5	R -> L (in PSNP1; delays assembly initiation and lowers the mass of microtubules formed; but the assembly rate is increased compared to normal tau).
MAPT	17	17	T -> M.
MAPT	30	30	T -> A.
MAPT	285	285	D -> N (risk factor for PSNP1).
MAPT	289	289	V -> A (risk factor for PSNP1).
MAPT	574	574	K -> T (in PIDB; reduces the ability to promote microtubule assembly by 70%).
MAPT	583	583	L -> V (in FTD; less able to promote microtubule assembly than wild-type tau).
MAPT	589	589	G -> V (in FTD).
MAPT	596	596	N -> K (in FTD; with parkinsonism).
MAPT	597	597	Missing (in FTD).
MAPT	613	613	N -> H (in FTD; reduced the ability of tau to promote microtubule assembly without having a significant effect on tau filament formation; effects at both the RNA and the protein level).
MAPT	613	613	Missing (in PSNP1/atypical PSNP1; heterozygosity may be a risk factor for both a PSNP1-like syndrome and Parkinson disease; reduced the ability of tau to promote microtubule assembly without having a significant effect on tau filament formation; effects at both the RNA and the protein level).
MAPT	617	617	V -> I.
MAPT	618	618	P -> L (in FTD; most common mutation; reduction in the ability to promote microtubule assembly; accelerates aggregation of tau into filaments).
MAPT	618	618	P -> S (in FTD and CBD; reduction in the ability to promote microtubule assembly).
MAPT	620	620	G -> V (in PSNP1).
MAPT	622	622	S -> N (in FTD; minimal parkinsonism; very early age of onset).
MAPT	634	634	K -> M (in FTD).
MAPT	637	637	S -> F (in PIDB; markedly reduced ability of tau to promote microtubule assembly).
MAPT	654	654	V -> M (in FTD; ultrastructural and biochemical characteristics indistinguishable from Alzheimer disease; accelerates aggregation of tau into filaments).
MAPT	659	659	E -> V (in FTD).
MAPT	669	669	S -> L (in fatal respiratory hypoventilation; unusual apparent autosomal recessive inheritance; reduced binding to microtubules as well as increased fibrillization and aggregation).
MAPT	686	686	K -> I (in PIDB; 90% reduction in the rate of microtubule assembly).
MAPT	706	706	G -> R (in PIDB; in vitro the mutation reduces the ability of tau to promote microtubule assembly by 25 to 30%).
MAPT	723	723	R -> W (in FTD/Alzheimer disease; accelerates aggregation of tau into filaments; reduces tau phosphorylation in cells compared to both the wild-type and other mutant forms).
BRIP1	255	255	Q -> H (in FANCJ).
BRIP1	299	299	M -> I (in BC; early onset; reduces helicase efficiency on longer substrates).
BRIP1	349	349	A -> P (in FANCJ).
BRIP1	419	419	R -> W.
BRIP1	647	647	W -> C (in FANCJ; associated with C-707).
BRIP1	707	707	R -> C (in FANCJ; associated with C-647).
BRIP1	1034	1034	P -> L (in a patient with ovarian cancer; unknown pathological significance).
PRPF8	2301	2301	P -> T (in RP13; no effect on interaction with SNRNP200 and EFTUD2).
PRPF8	2304	2304	F -> L (in RP13).
PRPF8	2309	2309	H -> P (in RP13; no effect on interaction with SNRNP200 and EFTUD2).
PRPF8	2309	2309	H -> R (in RP13; no effect on interaction with SNRNP200 and EFTUD2).
PRPF8	2310	2310	R -> G (in RP13; reduces interaction with SNRNP200 and EFTUD2).
PRPF8	2310	2310	R -> K (in RP13; reduces interaction with SNRNP200 and EFTUD2).
PRPF8	2314	2314	F -> L (in RP13; reduces interaction with EFTUD2, but not with SNRNP200).
PRPF8	2334	2334	Y -> N (in RP13).
SMYD4	601	601	A -> P (found in a renal cell carcinoma sample; somatic mutation).
ITGAE	360	360	D -> E.
ITGAE	1041	1041	C -> S.
P2RX1	351	351	Missing (in one patient presenting with severe bleeding; somatic mutation; results in a non-functional channel).
PLD2	807	807	Q -> E (in a breast cancer sample; somatic mutation).
PITPNM3	626	626	Q -> H (in CORD5).
NTN1	351	351	R -> H (in a neuroblastoma sample).
NTN1	489	489	K -> E (in a neuroblastoma sample).
MAP2K4	142	142	Q -> L (in a lung squamous cell carcinoma sample; somatic mutation).
MAP2K4	154	154	R -> W (in a colorectal adenocarcinoma sample; somatic mutation).
MAP2K4	234	234	N -> I (in an ovarian serous carcinoma sample; somatic mutation).
MAP2K4	251	251	S -> N (in a metastatic melanoma sample; somatic mutation).
MAP2K4	279	279	A -> T (in a colorectal adenocarcinoma sample; somatic mutation).
COX10	196	196	T -> K (in MT-C4D).
COX10	204	204	N -> K (in MT-C4D).
COX10	225	225	P -> L (in MT-C4D).
COX10	258	258	L -> H.
COX10	336	336	D -> G (in MT-C4D; associated with Leigh syndrome).
COX10	336	336	D -> V (in MT-C4D; associated with Leigh syndrome).
PEMT	3	3	R -> W.
PEMT	194	194	G -> R.
KSR1	225	225	S -> P.
KSR1	357	357	V -> A.
KSR1	661	661	Q -> H.
NLK	343	343	A -> T (in a glioblastoma multiforme sample; somatic mutation).
NF1	31	31	H -> R (in NF1).
NF1	74	74	A -> D (in mismatch repair deficient cancer cells).
NF1	80	80	Y -> C.
NF1	82	82	S -> F (in NF1).
NF1	93	93	C -> Y (in NF1).
NF1	117	117	I -> S (in NF1).
NF1	145	145	L -> P (in NF1).
NF1	157	157	I -> N (in NF1).
NF1	176	176	D -> E (in mismatch repair deficient cancer cells; polymorphism).
NF1	186	186	D -> V (in NF1; reduced splicing enhancement).
NF1	194	194	L -> R (in NFNS).
NF1	216	216	L -> P (in NF1).
NF1	324	324	C -> R (in NF1).
NF1	337	337	E -> V (in NF1).
NF1	338	338	D -> G (in NF1).
NF1	357	357	L -> P (in NF1).
NF1	489	489	Y -> C (in NF1).
NF1	491	491	Y -> C (in NF1).
NF1	508	508	L -> P (in NF1).
NF1	532	532	L -> P (in NF1).
NF1	549	549	L -> P (in NF1).
NF1	574	574	S -> R (in NF1).
NF1	578	578	L -> R (in NF1).
NF1	581	581	I -> T (in NF1).
NF1	583	583	K -> R (in NF1).
NF1	604	604	L -> V (in NF1).
NF1	629	629	G -> R (in NF1).
NF1	665	665	S -> F (in NF1; unknown pathological significance).
NF1	695	695	L -> P (in NF1).
NF1	712	712	H -> R (in mismatch repair deficient cancer cells).
NF1	763	763	L -> P (in NF1).
NF1	765	765	R -> H.
NF1	777	777	W -> S (in NF1).
NF1	780	780	T -> K (in NF1).
NF1	781	781	H -> P (in NF1).
NF1	784	784	W -> C (in NF1).
NF1	784	784	W -> R (in NF1).
NF1	844	844	L -> F (in NF1).
NF1	844	844	L -> P (in NF1).
NF1	844	844	L -> R (in NF1; sporadic).
NF1	847	847	L -> P (in NF1).
NF1	848	848	G -> E (in NF1).
NF1	873	873	R -> C (in NF1).
NF1	898	898	L -> P (in NF1; sporadic).
NF1	920	920	L -> P (in NF1; patient with cafe-au-lait spots; may be a distinct form of NF1).
NF1	968	968	M -> R (in NF1).
NF1	991	991	Missing (in NF1).
NF1	1035	1035	M -> R (in NF1).
NF1	1073	1073	M -> V (in NF1).
NF1	1147	1147	L -> P (in NF1).
NF1	1156	1156	N -> S (in NF1).
NF1	1166	1166	G -> D (in NF1).
NF1	1187	1187	L -> I (in a colorectal cancer sample; somatic mutation).
NF1	1193	1193	F -> C (in NF1).
NF1	1196	1196	L -> R (in NF1).
NF1	1204	1204	R -> G (in NF1).
NF1	1204	1204	R -> W (in NF1).
NF1	1243	1243	L -> P (in NF1; with neurofibromatous neuropathy).
NF1	1250	1250	R -> P (in NF1).
NF1	1276	1276	R -> G (in NF1).
NF1	1276	1276	R -> P (in NF1; complete loss of GAP activity).
NF1	1276	1276	R -> Q (in NF1 and mismatch repair deficient cancer cells).
NF1	1411	1411	L -> F (in NFNS).
NF1	1412	1412	R -> S (in NF1; significant reduction of GAP activity).
NF1	1430	1430	K -> E (in NF1).
NF1	1440	1440	K -> Q (in NF1).
NF1	1440	1440	K -> R (in NF1).
NF1	1444	1444	K -> E (in NF1 and NFNS; significant reduction of intrinsic GAP activity).
NF1	1444	1444	K -> N (in NF1).
NF1	1444	1444	K -> R (in NF1).
NF1	1446	1446	L -> P (in NF1).
NF1	1451	1451	N -> T (in NFNS).
NF1	1453	1453	V -> L (in NFNS).
NF1	1459	1459	Missing (in NFNS).
NF1	1489	1489	S -> G (in NF1).
NF1	1605	1605	I -> V (in NF1).
NF1	1611	1611	R -> W (in NF1).
NF1	1733	1733	L -> LGHEQQKLPAATLAL (in NF1).
NF1	1785	1785	A -> S (in NF1).
NF1	1951	1951	P -> L (in a colorectal cancer sample; somatic mutation).
NF1	1952	1952	W -> R (in NF1).
NF1	1953	1953	L -> P (in NF1).
NF1	1953	1953	Missing (in NF1).
NF1	2001	2001	G -> R (in NF1).
NF1	2012	2012	D -> N (in NF1).
NF1	2088	2088	L -> P (in FSNF; null mutation; 50% reduction of protein level; no cafe-au- lait macules).
NF1	2164	2164	L -> M (in NF1).
NF1	2192	2192	Y -> N (in NF1).
NF1	2221	2221	P -> A (in NF1).
NF1	2357	2357	E -> K (in NF1).
NF1	2387	2388	Missing (in NF1).
NF1	2507	2507	T -> I (in NF1).
NF1	2631	2631	T -> A (in NF1).
NF1	2745	2745	G -> R (in a breast cancer sample; somatic mutation).
ERBB2	755	755	L -> P (in a lung adenocarcinoma sample; somatic mutation).
ERBB2	774	774	M -> MAYVM (in a lung adenocarcinoma sample; somatic mutation).
ERBB2	779	779	S -> SVGS (in a lung adenocarcinoma sample; somatic mutation).
IKZF3	277	277	E -> Q (found in a renal cell carcinoma sample; somatic mutation).
KRTAP1-3	34	34	C -> S.
KRTAP1-3	41	50	Missing (in allele KAP1.1).
KRTAP1-3	53	88	Missing (in allele KAP1.9).
KRTAP1-3	92	92	G -> R.
FKBP10	107	117	Missing (in OI6).
STAT5B	630	630	A -> P (in LTD2; affects activation by growth hormone or interferon-gamma).
STAT3	382	382	R -> L (in AD-HIES).
STAT3	382	382	R -> Q (in AD-HIES; loss of function).
STAT3	382	382	R -> W (in AD-HIES; loss of function).
STAT3	384	384	F -> L (in AD-HIES).
STAT3	384	384	F -> S (in AD-HIES).
STAT3	389	389	T -> I (in AD-HIES; loss of function).
STAT3	423	423	R -> Q (in AD-HIES).
STAT3	437	437	H -> Y (in AD-HIES; loss of function).
STAT3	463	463	Missing (in AD-HIES; loss of function).
STAT3	611	611	S -> N (in AD-HIES).
STAT3	621	621	F -> V (in AD-HIES).
STAT3	622	622	T -> I (in AD-HIES).
STAT3	637	637	V -> L (in AD-HIES).
STAT3	637	637	V -> M (in AD-HIES).
STAT3	644	644	Missing (in AD-HIES).
STAT3	657	657	Y -> C (in AD-HIES).
BRCA1	10	10	E -> K (in BC and BROVCA1).
BRCA1	11	11	V -> A (unclassified).
BRCA1	18	18	M -> T (in BC; unknown pathological significance).
BRCA1	21	21	I -> V (unclassified).
BRCA1	22	22	L -> S (in BC).
BRCA1	23	23	E -> K (in BC and BROVCA1).
BRCA1	30	30	L -> F (in a breast cancer sample; somatic mutation).
BRCA1	64	64	C -> G (in BC; no interaction with BAP1).
BRCA1	71	71	R -> K (in BC; unknown pathological significance).
BRCA1	227	227	E -> K (in ovarian cancer; could be a polymorphism).
BRCA1	239	239	H -> R.
BRCA1	271	271	V -> M (in BC).
BRCA1	346	346	P -> S (in BC; could be a polymorphism).
BRCA1	369	369	Missing (in BC).
BRCA1	465	465	Y -> D (in BC).
BRCA1	507	507	R -> I (unclassified).
BRCA1	552	552	G -> V (in BC).
BRCA1	656	656	N -> I.
BRCA1	749	749	D -> Y (in BC).
BRCA1	758	758	L -> F (in a breast cancer sample; somatic mutation).
BRCA1	772	772	V -> A (rare polymorphism).
BRCA1	778	778	G -> C (in a breast cancer sample; somatic mutation).
BRCA1	820	820	K -> E (rare polymorphism).
BRCA1	826	826	T -> K (in BC).
BRCA1	835	835	H -> Y (in BROVCA1; unknown pathological significance).
BRCA1	856	856	Y -> H (in a patient with sporadic breast cancer; unknown pathological significance).
BRCA1	866	866	R -> Q (in BC; unknown pathological significance).
BRCA1	888	888	H -> Y (in BC; unknown pathological significance).
BRCA1	892	892	L -> S (in BC).
BRCA1	960	960	G -> D (in BC).
BRCA1	1025	1025	T -> I (in BC).
BRCA1	1047	1047	V -> A (in BC).
BRCA1	1060	1060	E -> A.
BRCA1	1139	1139	S -> I (in BC; unknown pathological significance).
BRCA1	1150	1150	P -> S (in BC).
BRCA1	1187	1187	S -> I (in BC and BROVCA1).
BRCA1	1200	1200	Q -> H (in BC and BROVCA1).
BRCA1	1204	1204	R -> I (in BC).
BRCA1	1207	1207	K -> N (in BC).
BRCA1	1210	1210	E -> G (in BC; unknown pathological significance).
BRCA1	1217	1217	S -> Y (in BC and BROVCA1).
BRCA1	1219	1219	E -> D (unclassified).
BRCA1	1226	1226	F -> L (in BROVCA1).
BRCA1	1243	1243	R -> G (in BROVCA1).
BRCA1	1297	1297	S -> P (in BC; unknown pathological significance).
BRCA1	1347	1347	R -> G.
BRCA1	1411	1411	M -> T (in ovarian cancer; unknown pathological significance; decreased interaction with PALB2).
BRCA1	1431	1431	S -> P.
BRCA1	1443	1443	R -> G (rare polymorphism).
BRCA1	1495	1495	R -> M (in BC; unknown pathological significance).
BRCA1	1561	1561	T -> I (unclassified).
BRCA1	1606	1606	K -> E (unclassified).
BRCA1	1623	1623	A -> G (could be associated with cancer susceptibility; major splicing aberration identified with this mutant).
BRCA1	1628	1628	M -> V (unclassified).
BRCA1	1637	1637	P -> L (rare polymorphism).
BRCA1	1665	1665	V -> M.
BRCA1	1685	1685	T -> A (in BC; unknown pathological significance).
BRCA1	1685	1685	T -> I (could be associated with cancer susceptibility; multifactorial likelihood analysis provides evidence for pathogenicity).
BRCA1	1689	1689	M -> R (in BC; unknown pathological significance).
BRCA1	1690	1690	K -> Q (in some patients with sporadic breast cancer; unknown pathological significance).
BRCA1	1692	1692	D -> N (in ovarian cancer; could be a polymorphism).
BRCA1	1697	1697	C -> R (in ovarian cancer).
BRCA1	1699	1699	R -> W (in ovarian cancer).
BRCA1	1706	1706	G -> E (in BC; unknown pathological significance).
BRCA1	1708	1708	A -> E (in BC; abolishes ACACA binding).
BRCA1	1713	1713	V -> G.
BRCA1	1715	1715	S -> R (in BC; unknown pathological significance).
BRCA1	1738	1738	G -> R (in BC; unknown pathological significance).
BRCA1	1749	1749	P -> R (in ovarian cancer; could be a polymorphism; abolishes ACACA binding and strongly reduces BRIP1 binding).
BRCA1	1764	1764	L -> P (in BC; unknown pathological significance).
BRCA1	1766	1766	I -> S (in BC; unknown pathological significance).
BRCA1	1775	1775	M -> K (in BC; strongly reduced transcription transactivation; abolishes interaction with BRIP1 and RBBP8).
BRCA1	1775	1775	M -> R (in BC; alters protein stability and abolishes ACACA and BRIP1 binding).
BRCA1	1786	1786	L -> P (in BROVCA1; unknown pathological significance).
BRCA1	1788	1788	G -> V (in BC; unknown pathological significance).
SLC4A1	72	72	E -> D.
SLC4A1	73	73	L -> M.
SLC4A1	130	130	G -> R (in SPH4; Fukoka).
SLC4A1	147	147	P -> S (in SPH4; Mondego).
SLC4A1	285	285	A -> D (in SPH4; Boston).
SLC4A1	400	408	Missing (in EL4).
SLC4A1	429	429	E -> D (in NFLD+ antigen).
SLC4A1	432	432	R -> W (in ELO antigen).
SLC4A1	455	455	G -> E (in SPH4; Benesov).
SLC4A1	455	455	G -> R (in SPH4; Yamagata).
SLC4A1	480	480	E -> K (in FR(a+) antigen).
SLC4A1	490	490	R -> C (in SPH4; Bicetre I).
SLC4A1	490	490	R -> H (in SPH4; Pinhal).
SLC4A1	518	518	R -> C (in SPH4; Dresden).
SLC4A1	548	548	P -> L (in RB(A) antigen).
SLC4A1	551	551	K -> N (in TR(A) antigen).
SLC4A1	552	552	T -> I (in WARR antigen).
SLC4A1	555	555	Y -> H (in VG(a) antigen).
SLC4A1	557	557	V -> M (in WD(a) antigen).
SLC4A1	561	561	P -> A (in NFLD+ antigen).
SLC4A1	561	561	P -> S (in BOW antigen).
SLC4A1	565	565	G -> A (in WU antigen).
SLC4A1	566	566	P -> A (in KREP antigen).
SLC4A1	566	566	P -> S (in PN(a) antigen).
SLC4A1	569	569	N -> K (in BP(a) antigen).
SLC4A1	589	589	R -> C (in AD-dRTA; reduced red cell sulfate transport and altered glycosylation of the red cell band 3 N- glycan chain).
SLC4A1	589	589	R -> H (in AD-dRTA).
SLC4A1	589	589	R -> S (in AD-dRTA).
SLC4A1	602	602	R -> P (in AR-dRTA; with hemolytic anemia).
SLC4A1	609	609	G -> R (in AD-dRTA; detected subapically and at the apical membrane as well as at the basolateral membrane in contrast to the normal basolateral appearance of wild-type protein).
SLC4A1	613	613	S -> F (in AD-dRTA; markedly increased red cell sulfate transport but almost normal red cell iodide transport).
SLC4A1	646	646	R -> Q (in SW(a+) antigen).
SLC4A1	646	646	R -> W (in SW(a+) antigen).
SLC4A1	656	656	R -> C (in HG(a) antigen).
SLC4A1	656	656	R -> H (in MO(a) antigen).
SLC4A1	658	658	E -> K (in WR(a) antigen).
SLC4A1	663	663	M -> K (in SPH4; Tambau).
SLC4A1	663	663	Missing (in SPH4; Osnabruck II).
SLC4A1	687	687	L -> P (in SPH4).
SLC4A1	701	701	G -> D (in AR-dRTA).
SLC4A1	705	705	D -> Y (in SPH4).
SLC4A1	707	707	L -> P (in SPH4; Most).
SLC4A1	714	714	G -> R (in SPH4; Okinawa).
SLC4A1	731	731	S -> P (in SPH4).
SLC4A1	734	734	H -> R (in SPH4).
SLC4A1	760	760	R -> Q (in SPH4; Prague II).
SLC4A1	760	760	R -> W (in SPH4; Hradec Kralove).
SLC4A1	771	771	G -> D (in SPH4; Chur).
SLC4A1	773	773	S -> P (in AR-dRTA; with normal red cell morphology).
SLC4A1	783	783	I -> N (in SPH4; Napoli II).
SLC4A1	808	808	R -> C (in SPH4; Jablonec).
SLC4A1	808	808	R -> H (in SPH4; Nara).
SLC4A1	834	834	H -> P (in SPH4; Birmingham).
SLC4A1	837	837	T -> A (in SPH4; Tokyo).
SLC4A1	837	837	T -> M (in SPH4; Philadelphia).
SLC4A1	837	837	T -> R (in SPH4; Nagoya).
SLC4A1	850	850	Missing (in AR-dRTA).
SLC4A1	858	858	A -> D (in AD-dRTA).
SLC4A1	868	868	P -> L (in acanthocytosis; due to band 3 high transport).
MAP3K14	514	514	G -> K (in a lung neuroendocrine carcinoma sample; somatic mutation; requires 2 nucleotide substitutions).
MAP3K14	852	852	T -> I (in an ovarian mucinous carcinoma sample; somatic mutation).
ARL17B	170	170	L -> I.
CDC27	270	270	G -> A (in a breast cancer sample; somatic mutation).
ITGB3	119	119	R -> W (in GT).
ITGB3	141	141	Y -> C (in GT).
ITGB3	143	143	L -> W (in GT).
ITGB3	145	145	D -> N (in GT).
ITGB3	145	145	D -> Y (in GT; type B).
ITGB3	150	150	M -> V (in GT; may confer constitutive activity to the alpha-IIb/(mutated)beta-3 receptor).
ITGB3	166	166	T -> I (associated with neonatal thrombocytopenia; alloantigen Duv(a+); does not affect significantly the integrin function).
ITGB3	188	188	S -> L (in GT; type II).
ITGB3	222	222	L -> P (in GT; variant form).
ITGB3	240	240	R -> Q (in GT; type B).
ITGB3	240	240	R -> W (in GT; variant Strasbourg-1).
ITGB3	242	242	R -> Q (in GT).
ITGB3	243	243	D -> V (in GT).
ITGB3	288	288	L -> P (in GT).
ITGB3	321	321	M -> L (in GT).
ITGB3	330	330	I -> N (in GT; not expressed on the surface and absent inside the transfected cells).
ITGB3	400	400	C -> Y (in GT).
ITGB3	433	433	P -> A (in alloantigen MO(+); in a case of neonatal alloimmune thrombocytopenia).
ITGB3	532	532	C -> Y (in GT).
ITGB3	568	568	C -> R (in GT; type I).
ITGB3	586	586	C -> F (in GT).
ITGB3	586	586	C -> R (in GT; gain-of-function mutation; constitutively binds ligand-induced binding sites antibodies and the fibrinogen-mimetic antibody PAC-1).
ITGB3	598	598	G -> S (in GT).
ITGB3	601	601	C -> R (in GT).
ITGB3	605	605	G -> S (in GT; type II).
ITGB3	662	662	R -> C (in alloantigen SR(A)).
ITGB3	778	778	S -> P (in GT; variant Strasbourg-1).
C17orf57	286	286	Q -> H (in a breast cancer sample; somatic mutation).
HLF	253	253	I -> F (in fusion protein; decreases DNA- binding activity).
DGKE	99	99	L -> R (in a breast cancer sample; somatic mutation).
TEX14	321	321	K -> E (in a gastric adenocarcinoma sample; somatic mutation).
TEX14	443	443	S -> C.
TEX14	559	559	I -> M.
PPM1E	44	44	E -> EPE.
PPM1E	231	231	L -> S (in a breast cancer sample; somatic mutation).
PPM1E	320	320	R -> G (in a breast cancer sample; somatic mutation).
TRIM37	76	76	L -> P (in MUL; decreased ubiquitination and abolishes the formation of perinuclear aggregates).
TRIM37	109	109	C -> S (in MUL; no effect on E3 ubiquitin-protein ligase activity).
TRIM37	322	322	G -> V (in MUL; no effect on ubiquitination but affects subcellular localization).
TLK2	54	54	E -> D.
TLK2	95	95	A -> G.
TLK2	108	108	A -> G.
TLK2	109	109	R -> L.
TLK2	173	173	F -> L (in a gastric adenocarcinoma sample; somatic mutation).
TLK2	262	262	R -> Q.
ERN1	244	244	N -> S (in a renal clear cell carcinoma sample; somatic mutation).
ERN1	474	474	L -> R (in a lung adenocarcinoma sample; somatic mutation).
ERN1	635	635	R -> W (in a gastric adenocarcinoma sample; somatic mutation).
ERN1	700	700	N -> S.
ERN1	769	769	S -> F (in a glioblastoma multiforme sample; somatic mutation).
ERN1	830	830	P -> L (in an ovarian serous carcinoma sample; somatic mutation).
RGS9	299	299	W -> R (in PERRS).
PRKCA	98	98	P -> S (in a colorectal adenocarcinoma sample; somatic mutation).
PRKCA	467	467	D -> N (in a glioblastoma multiforme sample; somatic mutation).
CD300E	27	27	T -> A (in a colorectal cancer sample; somatic mutation).
SLC9A3R1	225	225	E -> K (in NPHLOP2; the mutant expressed in cultured renal cells increases the generation of cAMP by PTH and inhibits phosphate transport).
SLC25A19	125	125	G -> S (in SNBPP; affects function as shown by complementation studues in yeast).
SLC25A19	177	177	G -> A (in MCPHA).
SEPT9	76	76	R -> C.
SEPT9	106	106	R -> W (in HNA).
SEPT9	111	111	S -> F (in HNA).
CSNK1D	44	44	T -> A (in FASPS).
CSNK1D	97	97	S -> C (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation).
DOC2B	209	209	R -> L (in a patient with amyotrophic lateral sclerosis).
TUSC5	3	3	H -> Y.
TUSC5	15	15	P -> S.
TUSC5	18	18	A -> T.
TUSC5	34	34	E -> D.
INPP5K	315	315	S -> F (in a breast cancer sample; somatic mutation).
SERPINF2	27	27	A -> V.
SERPINF2	176	176	Missing (in APLID; variant Okinawa; probably blocks intracellular transport of alpha-2-plasmin inhibitor).
SERPINF2	411	411	V -> M (in APLID).
DPH1	7	7	A -> V (in breast and ovarian cancer).
DPH1	34	34	A -> D (in breast and ovarian cancer).
DPH1	389	389	S -> R (in breast and ovarian cancer).
PAFAH1B1	31	31	F -> S (in LIS1).
PAFAH1B1	149	149	H -> R (in LIS1; abrogates interaction with NDE1 and reduces neuronal migration in vitro).
PAFAH1B1	169	169	S -> P (in SBH; abrogates interaction with NDE1 and reduces neuronal migration in vitro).
PAFAH1B1	277	277	H -> P (in LIS1).
OR1E1	143	143	A -> T.
OR1E2	168	168	H -> D (in a colorectal cancer sample; somatic mutation).
ASPA	16	16	I -> T (in CAND; <0.5% residual enzyme activity).
ASPA	21	21	H -> P (in CAND).
ASPA	24	24	E -> G (in CAND).
ASPA	27	27	G -> R (in CAND; 3% residual enzyme activity).
ASPA	57	57	A -> T (in CAND).
ASPA	68	68	D -> A (in CAND).
ASPA	114	114	D -> E (in CAND; <0.5% residual enzyme activity).
ASPA	114	114	D -> Y (in CAND).
ASPA	123	123	G -> E (in CAND; about 25% residual enzyme activity).
ASPA	143	143	I -> T (in CAND; in a Japanese patient).
ASPA	152	152	C -> R (in CAND; loss of activity).
ASPA	152	152	C -> W (in CAND).
ASPA	152	152	C -> Y (in CAND; <0.5% residual enzyme activity).
ASPA	168	168	R -> C (in CAND; undetectable enzyme activity).
ASPA	168	168	R -> H (in CAND).
ASPA	176	177	Missing (in CAND).
ASPA	181	181	P -> T (in CAND).
ASPA	183	183	P -> H (in CAND).
ASPA	186	186	V -> F (in CAND).
ASPA	195	195	M -> R (in CAND).
ASPA	231	231	Y -> C (in CAND).
ASPA	244	244	H -> R (in CAND).
ASPA	249	249	D -> V (in CAND).
ASPA	274	274	G -> R (in CAND).
ASPA	280	280	P -> L (in CAND).
ASPA	280	280	P -> S (in CAND).
ASPA	287	287	A -> T (in CAND).
ASPA	295	295	F -> S (in CAND).
ASPA	310	310	C -> G.
CTNS	67	73	Missing (in CTNSJAN).
CTNS	110	110	G -> V (in CTNS; atypical).
CTNS	133	133	I -> F (in CTNS).
CTNS	139	139	S -> F (in CTNS; atypical).
CTNS	154	154	S -> SPCS (in CTNSJAN).
CTNS	158	158	L -> P (in CTNS).
CTNS	169	169	G -> D (in CTNS).
CTNS	177	177	N -> T (in CTNSJAN).
CTNS	182	182	W -> R (in CTNS).
CTNS	197	197	G -> R (in CTNSANN).
CTNS	200	200	P -> L (in CTNSJAN).
CTNS	205	205	D -> N (in CTNS).
CTNS	205	205	Missing (in CTNS).
CTNS	222	222	Q -> R (in CTNS).
CTNS	270	270	Missing (in CTNS).
CTNS	280	280	K -> R (in CTNSJAN).
CTNS	288	288	N -> K (in CTNS).
CTNS	298	298	S -> N (in CTNS).
CTNS	305	305	D -> G (in CTNS).
CTNS	305	305	D -> Y (in CTNS).
CTNS	308	308	G -> R (in CTNS).
CTNS	323	323	N -> K (in CTNSJAN).
CTNS	338	338	L -> P (in CTNS).
CTNS	339	339	G -> R (in CTNS).
CTNS	343	346	Missing (in CTNS).
CTNS	346	349	Missing (in CTNS).
CTNS	346	346	D -> N (in CTNS; atypical).
CTNS	349	349	F -> FDVEF (in CTNS).
ATP2A3	674	674	R -> H (in a breast cancer sample; somatic mutation).
CYB5D2	7	7	R -> G (in a colorectal cancer sample; somatic mutation).
CYB5D2	7	7	R -> P (in a colorectal cancer sample; somatic mutation).
SPNS3	507	507	A -> T (in a colorectal cancer sample; somatic mutation).
CXCL16	123	123	I -> T.
MINK1	1010	1010	E -> V (in a gastric adenocarcinoma sample; somatic mutation).
MINK1	1200	1200	I -> V.
CHRNE	13	13	G -> R (in FCCMS; impaired association with alpha CHRNA1 subunit of AChR).
CHRNE	141	141	P -> L (in FCCMS; marked decrease in rate of AChR channel opening; reduction in frequency of open channel state and resistance to desensitization by ACh).
CHRNE	163	163	S -> L (in FCCMS; fails to assemble with alpha CHRNA1 subunit of AChR).
CHRNE	167	167	R -> L (in CMS-ACHRD; significantly reduced AChR expression).
CHRNE	265	265	P -> L (in CMS-ACHRD; prolongs burst open duration 2-fold by slowing the rate of channel closing).
CHRNE	284	284	T -> P (in SCCMS; markedly prolonged channel openings in presence of agonist; as well as opening in the absence of agonist).
CHRNE	289	289	L -> F (in SCCMS; slows rate of AChR channel closure and increases apparent affinity for ACh; causes pathologic channel openings even in the absence of ACh resulting in a leaky channel).
CHRNE	331	331	R -> W (in CMS-ACHRD; shortens burst duration 2-fold by slowing the rate of channel opening and speeding the rate of ACh dissociation; has a mild fast-channel kinetic effect on the AChR by shortening the long burst and increasing the decay of the endplate current).
CHRNE	431	431	A -> P (in FCCMS; causes an increase in distributions of rates for channel opening and closing increasing the range of activation kinetics).
ENO3	156	156	G -> D (in GSD13; when associated with E- 374).
ENO3	374	374	G -> E (in GSD13; when associated with D- 156).
ZNF232	123	123	A -> V (in a colorectal cancer sample; somatic mutation).
AIPL1	239	239	C -> R (in LCA4; no significant effect on interaction with NUB1).
ALOX12	298	298	A -> T.
ACADVL	130	130	Missing (in ACADVLD).
ACADVL	158	158	T -> N (in ACADVLD).
ACADVL	159	159	Q -> R (in ACADVLD).
ACADVL	174	174	V -> M (in ACADVLD).
ACADVL	185	185	G -> S (in ACADVLD).
ACADVL	213	213	A -> P (in ACADVLD).
ACADVL	218	218	E -> K (in ACADVLD).
ACADVL	243	243	L -> R (in ACADVLD).
ACADVL	247	247	K -> E (in ACADVLD).
ACADVL	247	247	K -> T (in ACADVLD).
ACADVL	260	260	T -> M (in ACADVLD).
ACADVL	278	278	Missing (in ACADVLD).
ACADVL	281	281	A -> D (in ACADVLD).
ACADVL	283	283	V -> A (in ACADVLD).
ACADVL	290	290	G -> D (in ACADVLD).
ACADVL	294	294	G -> E (in ACADVLD).
ACADVL	299	299	K -> N (in ACADVLD).
ACADVL	299	299	Missing (in ACADVLD).
ACADVL	317	317	V -> A (in ACADVLD).
ACADVL	352	352	M -> V (in ACADVLD).
ACADVL	366	366	R -> C (in ACADVLD).
ACADVL	366	366	R -> H (in ACADVLD).
ACADVL	381	381	Missing (in ACADVLD).
ACADVL	382	382	K -> Q (in ACADVLD).
ACADVL	405	405	D -> H (in ACADVLD).
ACADVL	450	450	R -> H (in ACADVLD).
ACADVL	453	453	R -> Q (in ACADVLD).
ACADVL	454	454	D -> N (in ACADVLD).
ACADVL	456	456	R -> H (in ACADVLD).
ACADVL	458	458	F -> L (in ACADVLD).
ACADVL	459	459	R -> W (in ACADVLD).
ACADVL	463	463	G -> E (in ACADVLD).
ACADVL	469	469	R -> Q (in ACADVLD).
ACADVL	469	469	R -> W (in ACADVLD).
ACADVL	490	490	A -> P (in ACADVLD).
ACADVL	502	502	L -> P (in ACADVLD).
ACADVL	602	602	L -> I (in ACADVLD).
ACADVL	613	613	R -> W (in ACADVLD).
ACADVL	615	615	R -> Q (in ACADVLD).
DVL2	282	282	I -> T (found in a renal cell carcinoma case; somatic mutation).
SLC2A4	383	383	V -> I (in NIDDM).
SLC2A4	385	385	I -> T.
ACAP1	114	114	K -> R (in a breast cancer sample; somatic mutation).
ACAP1	129	129	R -> Q (in a colorectal cancer sample; somatic mutation).
TNK1	339	339	R -> K (in a lung adenocarcinoma sample; somatic mutation).
TNK1	514	514	T -> K.
TNK1	539	539	R -> C.
TNK1	546	546	S -> C.
TNK1	598	598	V -> M.
FGF11	163	163	R -> G.
CHRNB1	285	285	L -> M (in SCCMS).
CHRNB1	289	289	V -> M (in SCCMS).
CHRNB1	449	451	Missing (in CMS-ACHRD; impairs AChR assembly by disrupting a specific interaction between beta and delta subunits).
MPDU1	73	73	G -> E (in CDG1F).
MPDU1	74	74	L -> S (in CDG1F).
MPDU1	119	119	L -> P (in CDG1F).
TP53	5	5	Q -> H (in a sporadic cancer; somatic mutation).
TP53	6	6	S -> L (in a sporadic cancer; somatic mutation).
TP53	7	7	D -> H (in a sporadic cancer; somatic mutation).
TP53	8	8	P -> S (in a sporadic cancer; somatic mutation).
TP53	10	10	V -> I (in a sporadic cancer; somatic mutation).
TP53	11	11	E -> K (in sporadic cancers; somatic mutation).
TP53	11	11	E -> Q (in sporadic cancers; somatic mutation).
TP53	15	15	S -> R (in a sporadic cancer; somatic mutation).
TP53	16	16	Q -> L (in a sporadic cancer; somatic mutation).
TP53	17	17	E -> D (in a sporadic cancer; somatic mutation).
TP53	24	24	K -> N (in a sporadic cancer; somatic mutation).
TP53	28	28	E -> A (in a sporadic cancer; somatic mutation).
TP53	29	30	NN -> KD (in a sporadic cancer; somatic mutation).
TP53	31	31	V -> I (in sporadic cancers; somatic mutation).
TP53	33	33	S -> T (in a sporadic cancer; somatic mutation).
TP53	34	34	P -> L (in a sporadic cancer; somatic mutation).
TP53	35	35	L -> F (in sporadic cancers; somatic mutation).
TP53	36	36	P -> L (in a sporadic cancer; somatic mutation).
TP53	37	37	S -> P (in a sporadic cancer; somatic mutation).
TP53	37	37	S -> T (in a sporadic cancer; somatic mutation).
TP53	39	39	A -> P (in a sporadic cancer; somatic mutation).
TP53	39	39	A -> V (in a sporadic cancer; somatic mutation).
TP53	42	42	D -> Y (in a sporadic cancer; somatic mutation).
TP53	43	43	L -> S (in a sporadic cancer; somatic mutation).
TP53	44	44	M -> I (in a sporadic cancer; somatic mutation).
TP53	44	44	M -> T (in a sporadic cancer; somatic mutation).
TP53	44	44	M -> V (in a sporadic cancer; somatic mutation).
TP53	45	45	L -> M (in a sporadic cancer; somatic mutation).
TP53	46	46	S -> F (in sporadic cancers; somatic mutation).
TP53	46	46	S -> P (in sporadic cancers; somatic mutation).
TP53	47	47	P -> L (in sporadic cancers; somatic mutation).
TP53	48	48	D -> G (in a sporadic cancer; somatic mutation).
TP53	49	49	D -> H (in sporadic cancers; somatic mutation).
TP53	49	49	D -> N (in a sporadic cancer; somatic mutation).
TP53	49	49	D -> Y (in sporadic cancers; somatic mutation).
TP53	52	52	Q -> H (in a sporadic cancer; somatic mutation).
TP53	53	53	W -> C (in sporadic cancers; somatic mutation).
TP53	53	53	W -> G (in a sporadic cancer; somatic mutation).
TP53	54	54	F -> L (in a sporadic cancer; somatic mutation).
TP53	54	54	F -> Y (in a sporadic cancer; somatic mutation).
TP53	56	56	E -> K (in sporadic cancers; somatic mutation).
TP53	56	56	E -> V (in a sporadic cancer; somatic mutation).
TP53	58	58	P -> Q (in a sporadic cancer; somatic mutation).
TP53	58	58	P -> T (in a sporadic cancer; somatic mutation).
TP53	59	59	G -> C (in sporadic cancers; somatic mutation).
TP53	59	59	G -> D (in sporadic cancers; somatic mutation).
TP53	59	59	G -> N (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	60	60	P -> L (in sporadic cancers; somatic mutation).
TP53	60	60	P -> Q (in a sporadic cancer; somatic mutation).
TP53	60	60	P -> S (in a sporadic cancer; somatic mutation).
TP53	61	61	D -> G (in sporadic cancers; somatic mutation).
TP53	61	61	D -> N (in sporadic cancers; somatic mutation).
TP53	62	62	E -> D (in a sporadic cancer; somatic mutation).
TP53	63	63	A -> T (in a sporadic cancer; somatic mutation).
TP53	63	63	A -> V (in a sporadic cancer; somatic mutation).
TP53	65	65	R -> T (in a sporadic cancer; somatic mutation).
TP53	66	66	M -> I (in a sporadic cancer; somatic mutation).
TP53	66	66	M -> R (in a sporadic cancer; somatic mutation).
TP53	67	67	P -> L (in sporadic cancers; somatic mutation).
TP53	67	67	P -> R (in a sporadic cancer; somatic mutation).
TP53	67	67	P -> S (in sporadic cancers; somatic mutation).
TP53	68	68	E -> G (in sporadic cancers; somatic mutation).
TP53	68	68	E -> Q (in a sporadic cancer; somatic mutation).
TP53	69	69	A -> D (in a sporadic cancer; somatic mutation).
TP53	69	69	A -> G (in sporadic cancers; somatic mutation).
TP53	69	69	A -> T (in a sporadic cancer; somatic mutation).
TP53	69	69	A -> V (in a sporadic cancer; somatic mutation).
TP53	70	70	A -> T (in a sporadic cancer; somatic mutation).
TP53	71	71	P -> T (in a sporadic cancer; somatic mutation).
TP53	72	72	P -> C (in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions).
TP53	72	72	P -> G (in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions).
TP53	72	72	P -> H (in sporadic cancers; somatic mutation).
TP53	72	72	P -> L (in a sporadic cancer; somatic mutation).
TP53	73	73	V -> E (in a sporadic cancer; somatic mutation).
TP53	73	73	V -> L (in sporadic cancers; somatic mutation).
TP53	73	73	V -> M (in sporadic cancers; somatic mutation).
TP53	74	74	A -> T (in a sporadic cancer; somatic mutation).
TP53	75	75	P -> L (in sporadic cancers; somatic mutation).
TP53	75	75	P -> R (in sporadic cancers; somatic mutation).
TP53	75	75	P -> S (in a sporadic cancer; somatic mutation).
TP53	76	76	A -> G (in a sporadic cancer; somatic mutation).
TP53	76	76	A -> T (in a sporadic cancer; somatic mutation).
TP53	77	77	P -> A (in sporadic cancers; somatic mutation).
TP53	78	78	A -> V (in sporadic cancers; somatic mutation).
TP53	79	79	A -> G (in a sporadic cancer; somatic mutation).
TP53	79	79	A -> T (in a sporadic cancer; somatic mutation).
TP53	79	79	A -> V (in sporadic cancers; somatic mutation).
TP53	80	80	P -> L (in a sporadic cancer; somatic mutation).
TP53	80	80	P -> S (in a sporadic cancer; somatic mutation).
TP53	81	81	T -> I (in sporadic cancers; somatic mutation).
TP53	82	82	P -> L (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	82	82	P -> S (in sporadic cancers; somatic mutation).
TP53	83	83	A -> E (in a sporadic cancer; somatic mutation).
TP53	83	83	A -> V (in sporadic cancers; somatic mutation).
TP53	84	84	A -> G (in sporadic cancers; somatic mutation).
TP53	84	84	A -> V (in sporadic cancers; somatic mutation).
TP53	85	85	P -> L (in sporadic cancers; somatic mutation).
TP53	85	85	P -> S (in sporadic cancers; somatic mutation).
TP53	86	86	A -> V (in a sporadic cancer; somatic mutation).
TP53	87	87	P -> Q (in sporadic cancers; somatic mutation).
TP53	88	88	A -> T (in a sporadic cancer; somatic mutation).
TP53	88	88	A -> V (in sporadic cancers; somatic mutation).
TP53	89	89	P -> L (in sporadic cancers; somatic mutation).
TP53	89	89	P -> S (in sporadic cancers; somatic mutation).
TP53	90	90	S -> F (in sporadic cancers; somatic mutation).
TP53	90	90	S -> Y (in a sporadic cancer; somatic mutation).
TP53	91	91	W -> C (in a sporadic cancer; somatic mutation).
TP53	92	92	P -> A (in a sporadic cancer; somatic mutation).
TP53	92	92	P -> L (in a sporadic cancer; somatic mutation).
TP53	92	92	P -> S (in a sporadic cancer; somatic mutation).
TP53	93	93	L -> M (in a sporadic cancer; somatic mutation).
TP53	93	93	L -> P (in a sporadic cancer; somatic mutation).
TP53	94	94	S -> L (in sporadic cancers; somatic mutation).
TP53	94	94	S -> T (in sporadic cancers; somatic mutation).
TP53	95	95	S -> F (in sporadic cancers; somatic mutation).
TP53	95	95	S -> T (in a sporadic cancer; somatic mutation).
TP53	96	96	S -> C (in a sporadic cancer; somatic mutation).
TP53	96	96	S -> F (in sporadic cancers; somatic mutation).
TP53	96	96	S -> P (in a sporadic cancer; somatic mutation).
TP53	97	97	V -> A (in a sporadic cancer; somatic mutation).
TP53	97	97	V -> F (in a sporadic cancer; somatic mutation).
TP53	97	97	V -> I (in familial cancer not matching LFS; germline mutation and in a sporadic cancer; somatic mutation).
TP53	98	98	P -> L (in sporadic cancers; somatic mutation).
TP53	98	98	P -> S (in sporadic cancers; somatic mutation).
TP53	99	99	S -> F (in sporadic cancers; somatic mutation).
TP53	99	99	S -> P (in a sporadic cancer; somatic mutation).
TP53	100	100	Q -> R (in a sporadic cancer; somatic mutation).
TP53	101	101	K -> N (in a sporadic cancer; somatic mutation).
TP53	101	101	K -> R (in sporadic cancers; somatic mutation).
TP53	102	102	T -> I (in sporadic cancers; somatic mutation).
TP53	104	104	Q -> H (in sporadic cancers; somatic mutation).
TP53	104	104	Q -> L (in a sporadic cancer; somatic mutation).
TP53	105	105	G -> C (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	105	105	G -> D (in sporadic cancers; somatic mutation).
TP53	105	105	G -> R (in sporadic cancers; somatic mutation).
TP53	105	105	G -> S (in a sporadic cancer; somatic mutation).
TP53	105	105	G -> V (in sporadic cancers; somatic mutation).
TP53	106	106	S -> G (in a sporadic cancer; somatic mutation).
TP53	106	106	S -> R (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	107	107	Y -> C (in a sporadic cancer; somatic mutation).
TP53	107	107	Y -> D (in sporadic cancers; somatic mutation).
TP53	107	107	Y -> H (in a sporadic cancer; somatic mutation).
TP53	108	108	G -> D (in a sporadic cancer; somatic mutation).
TP53	108	108	G -> S (in sporadic cancers; somatic mutation).
TP53	109	109	F -> C (in sporadic cancers; somatic mutation).
TP53	109	109	F -> L (in a sporadic cancer; somatic mutation).
TP53	109	109	F -> S (in sporadic cancers; somatic mutation).
TP53	110	110	R -> C (in sporadic cancers; somatic mutation).
TP53	110	110	R -> G (in a sporadic cancer; somatic mutation).
TP53	110	110	R -> H (in sporadic cancers; somatic mutation).
TP53	110	110	R -> L (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	110	110	R -> S (in a sporadic cancer; somatic mutation).
TP53	111	111	L -> M (in a sporadic cancer; somatic mutation).
TP53	111	111	L -> P (in sporadic cancers; somatic mutation).
TP53	111	111	L -> Q (in sporadic cancers; somatic mutation).
TP53	111	111	L -> R (in sporadic cancers; somatic mutation).
TP53	112	112	G -> D (in sporadic cancers; somatic mutation).
TP53	112	112	G -> S (in sporadic cancers; somatic mutation).
TP53	113	113	F -> C (in sporadic cancers; somatic mutation).
TP53	113	113	F -> G (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	113	113	F -> I (in a sporadic cancer; somatic mutation).
TP53	113	113	F -> L (in sporadic cancers; somatic mutation).
TP53	113	113	F -> S (in sporadic cancers; somatic mutation).
TP53	113	113	F -> V (in sporadic cancers; somatic mutation).
TP53	115	115	H -> Y (in sporadic cancers; somatic mutation).
TP53	116	116	S -> C (in sporadic cancers; somatic mutation).
TP53	116	116	S -> F (in a sporadic cancer; somatic mutation).
TP53	116	116	S -> P (in a sporadic cancer; somatic mutation).
TP53	117	117	G -> E (in sporadic cancers; somatic mutation).
TP53	117	117	G -> R (in sporadic cancers; somatic mutation).
TP53	118	118	T -> A (in a sporadic cancer; somatic mutation).
TP53	118	118	T -> I (in sporadic cancers; somatic mutation).
TP53	118	118	T -> R (in a sporadic cancer; somatic mutation).
TP53	119	119	A -> D (in a sporadic cancer; somatic mutation).
TP53	119	119	A -> T (in a sporadic cancer; somatic mutation).
TP53	120	120	K -> E (in sporadic cancers; somatic mutation).
TP53	120	120	K -> M (in sporadic cancers; somatic mutation).
TP53	120	120	K -> Q (in a sporadic cancer; somatic mutation).
TP53	120	120	K -> R (in sporadic cancers; somatic mutation).
TP53	121	121	S -> F (in sporadic cancers; somatic mutation).
TP53	122	122	V -> L (in a sporadic cancer; somatic mutation).
TP53	123	123	T -> I (in a sporadic cancer; somatic mutation).
TP53	123	123	T -> N (in a sporadic cancer; somatic mutation).
TP53	124	124	C -> G (in a sporadic cancer; somatic mutation).
TP53	124	124	C -> R (in sporadic cancers; somatic mutation).
TP53	124	124	C -> S (in sporadic cancers; somatic mutation).
TP53	124	124	C -> W (in a sporadic cancer; somatic mutation).
TP53	124	124	C -> Y (in a sporadic cancer; somatic mutation).
TP53	125	125	T -> A (in a sporadic cancer; somatic mutation).
TP53	125	125	T -> K (in sporadic cancers; somatic mutation).
TP53	125	125	T -> M (in sporadic cancers; somatic mutation).
TP53	125	125	T -> P (in a sporadic cancer; somatic mutation).
TP53	125	125	T -> R (in sporadic cancers; somatic mutation).
TP53	126	126	Y -> C (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	126	126	Y -> D (in sporadic cancers; somatic mutation).
TP53	126	126	Y -> F (in a sporadic cancer; somatic mutation).
TP53	126	126	Y -> G (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	126	126	Y -> H (in sporadic cancers; somatic mutation).
TP53	126	126	Y -> N (in sporadic cancers; somatic mutation).
TP53	126	126	Y -> S (in sporadic cancers; somatic mutation).
TP53	127	127	S -> C (in a sporadic cancer; somatic mutation).
TP53	127	127	S -> F (in sporadic cancers; somatic mutation).
TP53	127	127	S -> P (in sporadic cancers; somatic mutation).
TP53	127	127	S -> T (in sporadic cancers; somatic mutation).
TP53	127	127	S -> Y (in sporadic cancers; somatic mutation).
TP53	128	128	P -> A (in sporadic cancers; somatic mutation).
TP53	128	128	P -> L (in sporadic cancers; somatic mutation).
TP53	128	128	P -> R (in sporadic cancers; somatic mutation).
TP53	128	128	P -> S (in sporadic cancers; somatic mutation).
TP53	129	129	A -> D (in sporadic cancers; somatic mutation).
TP53	129	129	A -> G (in a sporadic cancer; somatic mutation).
TP53	129	129	A -> T (in sporadic cancers; somatic mutation).
TP53	129	129	A -> V (in sporadic cancers; somatic mutation).
TP53	130	130	L -> F (in sporadic cancers; somatic mutation).
TP53	130	130	L -> H (in sporadic cancers; somatic mutation).
TP53	130	130	L -> I (in a sporadic cancer; somatic mutation).
TP53	130	130	L -> P (in sporadic cancers; somatic mutation).
TP53	130	130	L -> R (in sporadic cancers; somatic mutation).
TP53	130	130	L -> V (in sporadic cancers; somatic mutation).
TP53	131	131	N -> D (in a sporadic cancer; somatic mutation).
TP53	131	131	N -> H (in sporadic cancers; somatic mutation).
TP53	131	131	N -> I (in sporadic cancers; somatic mutation).
TP53	131	131	N -> K (in sporadic cancers; somatic mutation).
TP53	131	131	N -> S (in sporadic cancers; somatic mutation).
TP53	131	131	N -> T (in a sporadic cancer; somatic mutation).
TP53	131	131	N -> Y (in sporadic cancers; somatic mutation).
TP53	132	133	KM -> NL (in a sporadic cancer; somatic mutation).
TP53	132	132	K -> E (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	132	132	K -> L (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	132	132	K -> M (in sporadic cancers; somatic mutation).
TP53	132	132	K -> N (in sporadic cancers; somatic mutation).
TP53	132	132	K -> Q (in sporadic cancers; somatic mutation).
TP53	132	132	K -> R (in sporadic cancers; somatic mutation).
TP53	132	132	K -> T (in sporadic cancers; somatic mutation).
TP53	132	132	K -> W (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	133	133	M -> I (in sporadic cancers; somatic mutation).
TP53	133	133	M -> K (in sporadic cancers; somatic mutation).
TP53	133	133	M -> L (in sporadic cancers; somatic mutation).
TP53	133	133	M -> R (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	133	133	M -> V (in sporadic cancers; somatic mutation).
TP53	134	134	F -> C (in sporadic cancers; somatic mutation).
TP53	134	134	F -> I (in sporadic cancers; somatic mutation).
TP53	134	134	F -> L (in sporadic cancers; somatic mutation).
TP53	134	134	F -> S (in sporadic cancers; somatic mutation).
TP53	134	134	F -> V (in sporadic cancers; somatic mutation).
TP53	135	135	C -> F (in sporadic cancers; somatic mutation).
TP53	135	135	C -> G (in sporadic cancers; somatic mutation).
TP53	135	135	C -> R (in sporadic cancers; somatic mutation).
TP53	135	135	C -> S (in sporadic cancers; somatic mutation).
TP53	135	135	C -> T (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	135	135	C -> W (in sporadic cancers; somatic mutation).
TP53	135	135	C -> Y (in sporadic cancers; somatic mutation; decreased E6-mediated binding to E6-AP).
TP53	136	136	Q -> E (in sporadic cancers; somatic mutation).
TP53	136	136	Q -> H (in sporadic cancers; somatic mutation).
TP53	136	136	Q -> K (in a sporadic cancer; somatic mutation).
TP53	136	136	Q -> P (in sporadic cancers; somatic mutation).
TP53	136	136	Q -> R (in sporadic cancers; somatic mutation).
TP53	137	137	L -> M (in sporadic cancers; somatic mutation).
TP53	137	137	L -> P (in sporadic cancers; somatic mutation).
TP53	137	137	L -> Q (in sporadic cancers; somatic mutation).
TP53	137	137	L -> V (in sporadic cancers; somatic mutation).
TP53	138	138	A -> D (in sporadic cancers; somatic mutation).
TP53	138	138	A -> S (in LFS; germline mutation).
TP53	138	138	A -> T (in sporadic cancers; somatic mutation).
TP53	138	138	A -> V (in sporadic cancers; somatic mutation).
TP53	139	139	K -> E (in sporadic cancers; somatic mutation).
TP53	139	139	K -> N (in sporadic cancers; somatic mutation).
TP53	139	139	K -> Q (in sporadic cancers; somatic mutation).
TP53	139	139	K -> R (in sporadic cancers; somatic mutation).
TP53	139	139	K -> T (in sporadic cancers; somatic mutation).
TP53	140	140	T -> A (in sporadic cancers; somatic mutation).
TP53	140	140	T -> I (in sporadic cancers; somatic mutation).
TP53	140	140	T -> N (in a sporadic cancer; somatic mutation).
TP53	140	140	T -> P (in a sporadic cancer; somatic mutation).
TP53	140	140	T -> S (in sporadic cancers; somatic mutation).
TP53	141	141	C -> A (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	141	141	C -> F (in sporadic cancers; somatic mutation).
TP53	141	141	C -> G (in sporadic cancers; somatic mutation).
TP53	141	141	C -> R (in sporadic cancers; somatic mutation).
TP53	141	141	C -> S (in sporadic cancers; somatic mutation).
TP53	141	141	C -> W (in sporadic cancers; somatic mutation).
TP53	141	141	C -> Y (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	142	142	P -> A (in sporadic cancers; somatic mutation).
TP53	142	142	P -> F (in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions).
TP53	142	142	P -> H (in sporadic cancers; somatic mutation).
TP53	142	142	P -> L (in sporadic cancers; somatic mutation).
TP53	142	142	P -> R (in a sporadic cancer; somatic mutation).
TP53	142	142	P -> S (in sporadic cancers; somatic mutation).
TP53	142	142	P -> T (in sporadic cancers; somatic mutation).
TP53	143	143	V -> A (in sporadic cancers; somatic mutation; strong DNA binding ability at 32.5 degrees Celsius; strong reduction of transcriptional activity at 37.5 degrees Celsius).
TP53	143	143	V -> E (in sporadic cancers; somatic mutation).
TP53	143	143	V -> G (in sporadic cancers; somatic mutation).
TP53	143	143	V -> L (in sporadic cancers; somatic mutation).
TP53	143	143	V -> M (in sporadic cancers; somatic mutation).
TP53	144	144	Q -> H (in sporadic cancers; somatic mutation).
TP53	144	144	Q -> K (in sporadic cancers; somatic mutation).
TP53	144	144	Q -> L (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	144	144	Q -> P (in sporadic cancers; somatic mutation).
TP53	144	144	Q -> R (in sporadic cancers; somatic mutation).
TP53	145	145	L -> M (in sporadic cancers; somatic mutation).
TP53	145	145	L -> P (in sporadic cancers; somatic mutation).
TP53	145	145	L -> Q (in sporadic cancers; somatic mutation).
TP53	145	145	L -> R (in sporadic cancers; somatic mutation).
TP53	145	145	L -> V (in sporadic cancers; somatic mutation).
TP53	146	146	W -> C (in a sporadic cancer; somatic mutation).
TP53	146	146	W -> G (in sporadic cancers; somatic mutation).
TP53	146	146	W -> L (in sporadic cancers; somatic mutation).
TP53	146	146	W -> R (in sporadic cancers; somatic mutation).
TP53	146	146	W -> S (in sporadic cancers; somatic mutation).
TP53	147	147	V -> A (in sporadic cancers; somatic mutation).
TP53	147	147	V -> D (in sporadic cancers; somatic mutation).
TP53	147	147	V -> E (in sporadic cancers; somatic mutation).
TP53	147	147	V -> F (in a sporadic cancer; somatic mutation).
TP53	147	147	V -> G (in sporadic cancers; somatic mutation).
TP53	147	147	V -> I (in sporadic cancers; somatic mutation).
TP53	148	148	D -> A (in a sporadic cancer; somatic mutation).
TP53	148	148	D -> E (in sporadic cancers; somatic mutation).
TP53	148	148	D -> G (in a sporadic cancer; somatic mutation).
TP53	148	148	D -> N (in sporadic cancers; somatic mutation).
TP53	148	148	D -> V (in sporadic cancers; somatic mutation).
TP53	148	148	D -> Y (in sporadic cancers; somatic mutation).
TP53	149	149	S -> F (in sporadic cancers; somatic mutation).
TP53	149	149	S -> P (in sporadic cancers; somatic mutation).
TP53	149	149	S -> T (in sporadic cancers; somatic mutation).
TP53	150	150	T -> A (in a sporadic cancer; somatic mutation).
TP53	150	150	T -> I (in sporadic cancers; somatic mutation).
TP53	150	150	T -> K (in sporadic cancers; somatic mutation).
TP53	150	150	T -> N (in a sporadic cancer; somatic mutation).
TP53	150	150	T -> P (in a sporadic cancer; somatic mutation).
TP53	150	150	T -> R (in a sporadic cancer; somatic mutation).
TP53	151	151	P -> A (in sporadic cancers; somatic mutation).
TP53	151	151	P -> H (in sporadic cancers; somatic mutation).
TP53	151	151	P -> L (in sporadic cancers; somatic mutation).
TP53	151	151	P -> R (in sporadic cancers; somatic mutation).
TP53	151	151	P -> T (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	152	152	P -> A (in sporadic cancers; somatic mutation).
TP53	152	152	P -> L (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	152	152	P -> Q (in sporadic cancers; somatic mutation).
TP53	152	152	P -> R (in sporadic cancers; somatic mutation).
TP53	152	152	P -> S (in sporadic cancers; somatic mutation).
TP53	152	152	P -> T (in sporadic cancers; somatic mutation).
TP53	153	153	P -> A (in sporadic cancers; somatic mutation).
TP53	153	153	P -> F (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	153	153	P -> H (in a sporadic cancer; somatic mutation).
TP53	153	153	P -> L (in sporadic cancers; somatic mutation).
TP53	153	153	P -> R (in a sporadic cancer; somatic mutation).
TP53	153	153	P -> S (in sporadic cancers; somatic mutation).
TP53	153	153	P -> T (in sporadic cancers; somatic mutation).
TP53	154	154	G -> A (in sporadic cancers; somatic mutation).
TP53	154	154	G -> C (in a sporadic cancer; somatic mutation).
TP53	154	154	G -> D (in sporadic cancers; somatic mutation).
TP53	154	154	G -> I (in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions).
TP53	154	154	G -> S (in sporadic cancers; somatic mutation).
TP53	154	154	G -> V (in a brain tumor with no family history; germline mutation and in sporadic cancers; somatic mutation).
TP53	155	155	T -> A (in sporadic cancers; somatic mutation).
TP53	155	155	T -> I (in sporadic cancers; somatic mutation).
TP53	155	155	T -> M (in a sporadic cancer; somatic mutation).
TP53	155	155	T -> N (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	155	155	T -> P (in sporadic cancers; somatic mutation).
TP53	155	155	T -> S (in sporadic cancers; somatic mutation).
TP53	156	156	R -> C (in sporadic cancers; somatic mutation).
TP53	156	156	R -> G (in sporadic cancers; somatic mutation).
TP53	156	156	R -> H (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	156	156	R -> L (in sporadic cancers; somatic mutation).
TP53	156	156	R -> P (in sporadic cancers; somatic mutation).
TP53	156	156	R -> S (in sporadic cancers; somatic mutation).
TP53	157	157	V -> A (in sporadic cancers; somatic mutation).
TP53	157	157	V -> D (in sporadic cancers; somatic mutation).
TP53	157	157	V -> F (in sporadic cancers; somatic mutation).
TP53	157	157	V -> G (in sporadic cancers; somatic mutation).
TP53	157	157	V -> I (in sporadic cancers; somatic mutation).
TP53	157	157	V -> L (in sporadic cancers; somatic mutation).
TP53	158	158	R -> C (in sporadic cancers; somatic mutation).
TP53	158	158	R -> F (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	158	158	R -> G (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	158	158	R -> H (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	158	158	R -> L (in sporadic cancers; somatic mutation).
TP53	158	158	R -> P (in sporadic cancers; somatic mutation).
TP53	158	158	R -> Q (in a sporadic cancer; somatic mutation).
TP53	158	158	R -> S (in sporadic cancers; somatic mutation).
TP53	158	158	R -> Y (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	159	159	A -> D (in sporadic cancers; somatic mutation).
TP53	159	159	A -> F (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	159	159	A -> G (in sporadic cancers; somatic mutation).
TP53	159	159	A -> P (in sporadic cancers; somatic mutation).
TP53	159	159	A -> S (in sporadic cancers; somatic mutation).
TP53	159	159	A -> T (in sporadic cancers; somatic mutation).
TP53	159	159	A -> V (in sporadic cancers; somatic mutation).
TP53	160	161	MA -> IP (in a sporadic cancer; somatic mutation).
TP53	160	161	MA -> IS (in sporadic cancers; somatic mutation).
TP53	160	161	MA -> IT (in a sporadic cancer; somatic mutation).
TP53	160	160	M -> I (in sporadic cancers; somatic mutation).
TP53	160	160	M -> K (in sporadic cancers; somatic mutation).
TP53	160	160	M -> T (in a sporadic cancer; somatic mutation).
TP53	160	160	M -> V (in sporadic cancers; somatic mutation).
TP53	161	161	A -> D (in sporadic cancers; somatic mutation).
TP53	161	161	A -> F (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	161	161	A -> G (in sporadic cancers; somatic mutation).
TP53	161	161	A -> P (in sporadic cancers; somatic mutation).
TP53	161	161	A -> S (in sporadic cancers; somatic mutation).
TP53	161	161	A -> T (in sporadic cancers; somatic mutation).
TP53	161	161	A -> V (in sporadic cancers; somatic mutation).
TP53	162	162	I -> F (in sporadic cancers; somatic mutation).
TP53	162	162	I -> M (in sporadic cancers; somatic mutation).
TP53	162	162	I -> N (in a breast cancer with no family history; germline mutation and in sporadic cancers; somatic mutation).
TP53	162	162	I -> S (in sporadic cancers; somatic mutation).
TP53	162	162	I -> T (in sporadic cancers; somatic mutation).
TP53	162	162	I -> V (in sporadic cancers; somatic mutation).
TP53	163	163	Y -> C (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	163	163	Y -> D (in sporadic cancers; somatic mutation).
TP53	163	163	Y -> F (in a sporadic cancer; somatic mutation).
TP53	163	163	Y -> H (in sporadic cancers; somatic mutation).
TP53	163	163	Y -> N (in sporadic cancers; somatic mutation).
TP53	163	163	Y -> S (in sporadic cancers; somatic mutation).
TP53	164	164	K -> E (in sporadic cancers; somatic mutation).
TP53	164	164	K -> M (in sporadic cancers; somatic mutation).
TP53	164	164	K -> N (in sporadic cancers; somatic mutation).
TP53	164	164	K -> Q (in sporadic cancers; somatic mutation).
TP53	164	164	K -> R (in sporadic cancers; somatic mutation).
TP53	164	164	K -> T (in sporadic cancers; somatic mutation).
TP53	165	165	Q -> E (in sporadic cancers; somatic mutation).
TP53	165	165	Q -> H (in a sporadic cancer; somatic mutation).
TP53	165	165	Q -> L (in sporadic cancers; somatic mutation).
TP53	165	165	Q -> P (in sporadic cancers; somatic mutation).
TP53	165	165	Q -> R (in sporadic cancers; somatic mutation).
TP53	166	166	S -> A (in sporadic cancers; somatic mutation).
TP53	166	166	S -> G (in a sporadic cancer; somatic mutation).
TP53	166	166	S -> L (in sporadic cancers; somatic mutation).
TP53	166	166	S -> P (in sporadic cancers; somatic mutation).
TP53	166	166	S -> T (in sporadic cancers; somatic mutation).
TP53	167	168	QH -> HD (in a sporadic cancer; somatic mutation).
TP53	167	168	QH -> YL (in a sporadic cancer; somatic mutation).
TP53	167	167	Q -> H (in sporadic cancers; somatic mutation).
TP53	167	167	Q -> K (in LFS; germline mutation and in a sporadic cancer; somatic mutation).
TP53	167	167	Q -> L (in sporadic cancers; somatic mutation).
TP53	167	167	Q -> R (in sporadic cancers; somatic mutation).
TP53	168	169	HM -> LI (in a sporadic cancer; somatic mutation).
TP53	168	168	H -> D (in sporadic cancers; somatic mutation).
TP53	168	168	H -> L (in sporadic cancers; somatic mutation).
TP53	168	168	H -> N (in sporadic cancers; somatic mutation).
TP53	168	168	H -> P (in sporadic cancers; somatic mutation).
TP53	168	168	H -> Q (in sporadic cancers; somatic mutation).
TP53	168	168	H -> R (in sporadic cancers; somatic mutation).
TP53	168	168	H -> V (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	168	168	H -> Y (in sporadic cancers; somatic mutation).
TP53	169	170	MT -> IS (in a sporadic cancer; somatic mutation).
TP53	169	169	M -> I (in sporadic cancers; somatic mutation).
TP53	169	169	M -> K (in sporadic cancers; somatic mutation).
TP53	169	169	M -> T (in sporadic cancers; somatic mutation).
TP53	169	169	M -> V (in sporadic cancers; somatic mutation).
TP53	170	170	T -> A (in sporadic cancers; somatic mutation).
TP53	170	170	T -> K (in a sporadic cancer; somatic mutation).
TP53	170	170	T -> M (in sporadic cancers; somatic mutation).
TP53	170	170	T -> P (in a sporadic cancer; somatic mutation).
TP53	170	170	T -> S (in sporadic cancers; somatic mutation).
TP53	171	171	E -> A (in a sporadic cancer; somatic mutation).
TP53	171	171	E -> D (in sporadic cancers; somatic mutation).
TP53	171	171	E -> G (in sporadic cancers; somatic mutation).
TP53	171	171	E -> K (in sporadic cancers; somatic mutation).
TP53	171	171	E -> Q (in a sporadic cancer; somatic mutation).
TP53	171	171	E -> V (in sporadic cancers; somatic mutation).
TP53	172	172	V -> A (in sporadic cancers; somatic mutation).
TP53	172	172	V -> D (in sporadic cancers; somatic mutation).
TP53	172	172	V -> F (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	172	172	V -> G (in sporadic cancers; somatic mutation).
TP53	172	172	V -> I (in sporadic cancers; somatic mutation).
TP53	173	173	V -> A (in sporadic cancers; somatic mutation).
TP53	173	173	V -> E (in sporadic cancers; somatic mutation).
TP53	173	173	V -> G (in sporadic cancers; somatic mutation).
TP53	173	173	V -> L (in sporadic cancers; somatic mutation).
TP53	173	173	V -> M (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	173	173	V -> W (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	174	174	R -> G (in LFS; germline mutation and in a sporadic cancer; somatic mutation).
TP53	174	174	R -> K (in sporadic cancers; somatic mutation).
TP53	174	174	R -> M (in sporadic cancers; somatic mutation).
TP53	174	174	R -> S (in sporadic cancers; somatic mutation).
TP53	174	174	R -> T (in a sporadic cancer; somatic mutation).
TP53	174	174	R -> W (in sporadic cancers; somatic mutation).
TP53	175	175	R -> C (in sporadic cancers; somatic mutation).
TP53	175	175	R -> G (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	175	175	R -> L (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	175	175	R -> P (in sporadic cancers; somatic mutation).
TP53	175	175	R -> Q (in a sporadic cancer; somatic mutation).
TP53	175	175	R -> S (in sporadic cancers; somatic mutation).
TP53	176	177	CP -> FS (in a sporadic cancer; somatic mutation).
TP53	176	176	C -> F (in sporadic cancers; somatic mutation).
TP53	176	176	C -> G (in sporadic cancers; somatic mutation).
TP53	176	176	C -> R (in sporadic cancers; somatic mutation).
TP53	176	176	C -> S (in sporadic cancers; somatic mutation).
TP53	176	176	C -> W (in sporadic cancers; somatic mutation).
TP53	176	176	C -> Y (in sporadic cancers; somatic mutation).
TP53	177	177	P -> A (in a sporadic cancer; somatic mutation).
TP53	177	177	P -> F (in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions).
TP53	177	177	P -> H (in sporadic cancers; somatic mutation).
TP53	177	177	P -> I (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	177	177	P -> L (in sporadic cancers; somatic mutation).
TP53	177	177	P -> R (in sporadic cancers; somatic mutation).
TP53	177	177	P -> S (in sporadic cancers; somatic mutation).
TP53	177	177	P -> T (in a sporadic cancer; somatic mutation).
TP53	178	179	HH -> QS (in a sporadic cancer; somatic mutation).
TP53	178	178	H -> D (in sporadic cancers; somatic mutation).
TP53	178	178	H -> HPHP (in a Burkitt lymphoma).
TP53	178	178	H -> L (in a sporadic cancer; somatic mutation).
TP53	178	178	H -> N (in sporadic cancers; somatic mutation).
TP53	178	178	H -> P (in sporadic cancers; somatic mutation).
TP53	178	178	H -> Q (in sporadic cancers; somatic mutation).
TP53	178	178	H -> R (in sporadic cancers; somatic mutation).
TP53	178	178	H -> Y (in sporadic cancers; somatic mutation).
TP53	179	179	H -> D (in sporadic cancers; somatic mutation).
TP53	179	179	H -> L (in sporadic cancers; somatic mutation).
TP53	179	179	H -> N (in sporadic cancers; somatic mutation).
TP53	179	179	H -> P (in sporadic cancers; somatic mutation).
TP53	179	179	H -> Q (in sporadic cancers; somatic mutation).
TP53	179	179	H -> R (in sporadic cancers; somatic mutation).
TP53	179	179	H -> Y (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	180	180	E -> A (in a sporadic cancer; somatic mutation).
TP53	180	180	E -> D (in sporadic cancers; somatic mutation).
TP53	180	180	E -> G (in a sporadic cancer; somatic mutation).
TP53	180	180	E -> K (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	180	180	E -> Q (in sporadic cancers; somatic mutation).
TP53	180	180	E -> V (in a sporadic cancer; somatic mutation).
TP53	181	181	R -> C (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	181	181	R -> G (in sporadic cancers; somatic mutation).
TP53	181	181	R -> H (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	181	181	R -> L (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	181	181	R -> P (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	181	181	R -> S (in sporadic cancers; somatic mutation).
TP53	182	182	C -> R (in sporadic cancers; somatic mutation).
TP53	182	182	C -> S (in sporadic cancers; somatic mutation).
TP53	182	182	C -> Y (in sporadic cancers; somatic mutation).
TP53	183	183	S -> L (in sporadic cancers; somatic mutation).
TP53	183	183	S -> P (in sporadic cancers; somatic mutation).
TP53	184	184	D -> G (in sporadic cancers; somatic mutation).
TP53	184	184	D -> H (in sporadic cancers; somatic mutation).
TP53	184	184	D -> N (in sporadic cancers; somatic mutation).
TP53	184	184	D -> V (in sporadic cancers; somatic mutation).
TP53	184	184	D -> Y (in sporadic cancers; somatic mutation).
TP53	185	185	S -> C (in a sporadic cancer; somatic mutation).
TP53	185	185	S -> G (in sporadic cancers; somatic mutation).
TP53	185	185	S -> I (in sporadic cancers; somatic mutation).
TP53	185	185	S -> N (in a sporadic cancer; somatic mutation).
TP53	185	185	S -> R (in sporadic cancers; somatic mutation).
TP53	185	185	S -> T (in a sporadic cancer; somatic mutation).
TP53	186	186	D -> E (in a sporadic cancer; somatic mutation).
TP53	186	186	D -> G (in sporadic cancers; somatic mutation).
TP53	186	186	D -> H (in sporadic cancers; somatic mutation).
TP53	186	186	D -> N (in sporadic cancers; somatic mutation).
TP53	186	186	D -> V (in sporadic cancers; somatic mutation).
TP53	186	186	D -> Y (in a sporadic cancer; somatic mutation).
TP53	187	187	G -> C (in sporadic cancers; somatic mutation).
TP53	187	187	G -> D (in sporadic cancers; somatic mutation).
TP53	187	187	G -> N (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	187	187	G -> R (in sporadic cancers; somatic mutation).
TP53	187	187	G -> S (in sporadic cancers; somatic mutation).
TP53	187	187	G -> V (in sporadic cancers; somatic mutation).
TP53	188	188	L -> P (in a sporadic cancer; somatic mutation).
TP53	188	188	L -> V (in sporadic cancers; somatic mutation).
TP53	189	189	A -> D (in a sporadic cancer; somatic mutation).
TP53	189	189	A -> G (in sporadic cancers; somatic mutation).
TP53	189	189	A -> P (in sporadic cancers; somatic mutation).
TP53	189	189	A -> S (in a sporadic cancer; somatic mutation).
TP53	189	189	A -> T (in sporadic cancers; somatic mutation).
TP53	189	189	A -> V (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	190	190	P -> A (in sporadic cancers; somatic mutation).
TP53	190	190	P -> H (in a sporadic cancer; somatic mutation).
TP53	190	190	P -> L (in sporadic cancers; somatic mutation).
TP53	190	190	P -> R (in sporadic cancers; somatic mutation).
TP53	190	190	P -> S (in sporadic cancers; somatic mutation).
TP53	190	190	P -> T (in sporadic cancers; somatic mutation).
TP53	191	191	P -> H (in sporadic cancers; somatic mutation).
TP53	191	191	P -> L (in sporadic cancers; somatic mutation).
TP53	191	191	P -> R (in sporadic cancers; somatic mutation).
TP53	191	191	P -> S (in sporadic cancers; somatic mutation).
TP53	191	191	P -> T (in sporadic cancers; somatic mutation).
TP53	192	193	QH -> HN (in a sporadic cancer; somatic mutation).
TP53	192	193	QH -> HY (in a sporadic cancer; somatic mutation).
TP53	192	192	Q -> H (in sporadic cancers; somatic mutation).
TP53	192	192	Q -> K (in a sporadic cancer; somatic mutation).
TP53	192	192	Q -> L (in sporadic cancers; somatic mutation).
TP53	192	192	Q -> P (in sporadic cancers; somatic mutation).
TP53	192	192	Q -> R (in sporadic cancers; somatic mutation).
TP53	193	193	H -> D (in sporadic cancers; somatic mutation).
TP53	193	193	H -> L (in sporadic cancers; somatic mutation).
TP53	193	193	H -> N (in sporadic cancers; somatic mutation).
TP53	193	193	H -> P (in sporadic cancers; somatic mutation).
TP53	193	193	H -> Q (in sporadic cancers; somatic mutation).
TP53	193	193	H -> R (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	193	193	H -> Y (in sporadic cancers; somatic mutation).
TP53	194	194	L -> F (in sporadic cancers; somatic mutation).
TP53	194	194	L -> H (in sporadic cancers; somatic mutation).
TP53	194	194	L -> I (in sporadic cancers; somatic mutation).
TP53	194	194	L -> P (in sporadic cancers; somatic mutation).
TP53	194	194	L -> R (in sporadic cancers; somatic mutation).
TP53	194	194	L -> V (in sporadic cancers; somatic mutation).
TP53	195	195	I -> F (in sporadic cancers; somatic mutation).
TP53	195	195	I -> L (in a sporadic cancer; somatic mutation).
TP53	195	195	I -> N (in sporadic cancers; somatic mutation).
TP53	195	195	I -> S (in sporadic cancers; somatic mutation).
TP53	195	195	I -> T (in sporadic cancers; somatic mutation).
TP53	195	195	I -> V (in a sporadic cancer; somatic mutation).
TP53	195	195	I -> Y (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	196	196	R -> G (in sporadic cancers; somatic mutation).
TP53	196	196	R -> L (in sporadic cancers; somatic mutation).
TP53	196	196	R -> P (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	196	196	R -> Q (in sporadic cancers; somatic mutation).
TP53	196	196	R -> S (in a sporadic cancer; somatic mutation).
TP53	197	197	V -> E (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	197	197	V -> G (in sporadic cancers; somatic mutation).
TP53	197	197	V -> L (in sporadic cancers; somatic mutation).
TP53	197	197	V -> M (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	198	198	E -> D (in a sporadic cancer; somatic mutation).
TP53	198	198	E -> G (in sporadic cancers; somatic mutation).
TP53	198	198	E -> K (in sporadic cancers; somatic mutation).
TP53	198	198	E -> Q (in sporadic cancers; somatic mutation).
TP53	198	198	E -> V (in a sporadic cancer; somatic mutation).
TP53	199	199	G -> A (in a sporadic cancer; somatic mutation).
TP53	199	199	G -> E (in sporadic cancers; somatic mutation).
TP53	199	199	G -> R (in sporadic cancers; somatic mutation).
TP53	199	199	G -> V (in sporadic cancers; somatic mutation).
TP53	200	200	N -> D (in sporadic cancers; somatic mutation).
TP53	200	200	N -> I (in sporadic cancers; somatic mutation).
TP53	200	200	N -> K (in a sporadic cancer; somatic mutation).
TP53	200	200	N -> P (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	200	200	N -> S (in sporadic cancers; somatic mutation).
TP53	200	200	N -> T (in a sporadic cancer; somatic mutation).
TP53	201	202	LR -> FC (in a sporadic cancer; somatic mutation).
TP53	201	201	L -> F (in sporadic cancers; somatic mutation).
TP53	201	201	L -> P (in a sporadic cancer; somatic mutation).
TP53	201	201	L -> S (in a sporadic cancer; somatic mutation).
TP53	202	202	R -> C (in sporadic cancers; somatic mutation).
TP53	202	202	R -> G (in sporadic cancers; somatic mutation).
TP53	202	202	R -> H (in sporadic cancers; somatic mutation).
TP53	202	202	R -> L (in sporadic cancers; somatic mutation).
TP53	202	202	R -> P (in sporadic cancers; somatic mutation).
TP53	202	202	R -> S (in sporadic cancers; somatic mutation).
TP53	203	204	VE -> LV (in a sporadic cancer; somatic mutation).
TP53	203	203	V -> A (in sporadic cancers; somatic mutation).
TP53	203	203	V -> E (in sporadic cancers; somatic mutation).
TP53	203	203	V -> L (in sporadic cancers; somatic mutation).
TP53	203	203	V -> M (in sporadic cancers; somatic mutation).
TP53	203	203	V -> W (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	204	204	E -> A (in sporadic cancers; somatic mutation).
TP53	204	204	E -> D (in sporadic cancers; somatic mutation).
TP53	204	204	E -> G (in sporadic cancers; somatic mutation).
TP53	204	204	E -> K (in sporadic cancers; somatic mutation).
TP53	204	204	E -> Q (in a sporadic cancer; somatic mutation).
TP53	204	204	E -> V (in a sporadic cancer; somatic mutation).
TP53	205	205	Y -> C (in sporadic cancers; somatic mutation).
TP53	205	205	Y -> D (in sporadic cancers; somatic mutation).
TP53	205	205	Y -> F (in sporadic cancers; somatic mutation).
TP53	205	205	Y -> H (in sporadic cancers; somatic mutation).
TP53	205	205	Y -> N (in sporadic cancers; somatic mutation).
TP53	205	205	Y -> S (in sporadic cancers; somatic mutation).
TP53	206	206	L -> F (in a sporadic cancer; somatic mutation).
TP53	206	206	L -> M (in a sporadic cancer; somatic mutation).
TP53	207	208	DD -> EY (in a sporadic cancer; somatic mutation).
TP53	207	207	D -> E (in sporadic cancers; somatic mutation).
TP53	207	207	D -> G (in sporadic cancers; somatic mutation).
TP53	207	207	D -> H (in sporadic cancers; somatic mutation).
TP53	207	207	D -> N (in sporadic cancers; somatic mutation).
TP53	207	207	D -> V (in a sporadic cancer; somatic mutation).
TP53	207	207	D -> Y (in a sporadic cancer; somatic mutation).
TP53	208	208	D -> E (in sporadic cancers; somatic mutation).
TP53	208	208	D -> G (in sporadic cancers; somatic mutation).
TP53	208	208	D -> H (in a sporadic cancer; somatic mutation).
TP53	208	208	D -> I (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	208	208	D -> N (in sporadic cancers; somatic mutation).
TP53	208	208	D -> V (in sporadic cancers; somatic mutation).
TP53	208	208	D -> Y (in a sporadic cancer; somatic mutation).
TP53	209	209	R -> I (in sporadic cancers; somatic mutation).
TP53	209	209	R -> K (in sporadic cancers; somatic mutation).
TP53	209	209	R -> S (in a sporadic cancer; somatic mutation).
TP53	209	209	R -> T (in sporadic cancers; somatic mutation).
TP53	210	210	N -> D (in sporadic cancers; somatic mutation).
TP53	210	210	N -> H (in sporadic cancers; somatic mutation).
TP53	210	210	N -> I (in a sporadic cancer; somatic mutation).
TP53	210	210	N -> K (in a sporadic cancer; somatic mutation).
TP53	210	210	N -> S (in sporadic cancers; somatic mutation).
TP53	210	210	N -> T (in a sporadic cancer; somatic mutation).
TP53	210	210	N -> Y (in a familial cancer not matching LFS; germline mutation).
TP53	211	211	T -> A (in sporadic cancers; somatic mutation).
TP53	211	211	T -> I (in sporadic cancers; somatic mutation).
TP53	211	211	T -> N (in sporadic cancers; somatic mutation).
TP53	211	211	T -> P (in a sporadic cancer; somatic mutation).
TP53	211	211	T -> S (in sporadic cancers; somatic mutation).
TP53	212	212	F -> I (in sporadic cancers; somatic mutation).
TP53	212	212	F -> L (in sporadic cancers; somatic mutation).
TP53	212	212	F -> S (in sporadic cancers; somatic mutation).
TP53	212	212	F -> V (in a sporadic cancer; somatic mutation).
TP53	212	212	F -> Y (in sporadic cancers; somatic mutation).
TP53	213	213	R -> G (in sporadic cancers; somatic mutation).
TP53	213	213	R -> L (in sporadic cancers; somatic mutation).
TP53	213	213	R -> P (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	213	213	R -> Q (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	213	213	R -> W (in sporadic cancers; somatic mutation).
TP53	214	214	H -> D (in sporadic cancers; somatic mutation).
TP53	214	214	H -> P (in a sporadic cancer; somatic mutation).
TP53	214	214	H -> Q (in sporadic cancers; somatic mutation).
TP53	214	214	H -> R (in sporadic cancers; somatic mutation).
TP53	214	214	H -> Y (in sporadic cancers; somatic mutation).
TP53	215	215	S -> C (in sporadic cancers; somatic mutation).
TP53	215	215	S -> G (in sporadic cancers; somatic mutation).
TP53	215	215	S -> I (in sporadic cancers; somatic mutation).
TP53	215	215	S -> K (in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions).
TP53	215	215	S -> N (in sporadic cancers; somatic mutation).
TP53	215	215	S -> R (in sporadic cancers; somatic mutation).
TP53	215	215	S -> T (in sporadic cancers; somatic mutation).
TP53	216	216	V -> A (in sporadic cancers; somatic mutation).
TP53	216	216	V -> E (in sporadic cancers; somatic mutation).
TP53	216	216	V -> G (in sporadic cancers; somatic mutation).
TP53	216	216	V -> L (in sporadic cancers; somatic mutation).
TP53	216	216	V -> M (in sporadic cancers; somatic mutation).
TP53	216	216	V -> W (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	217	217	V -> A (in sporadic cancers; somatic mutation).
TP53	217	217	V -> E (in sporadic cancers; somatic mutation).
TP53	217	217	V -> G (in sporadic cancers; somatic mutation).
TP53	217	217	V -> I (in a sporadic cancer; somatic mutation).
TP53	217	217	V -> L (in sporadic cancers; somatic mutation).
TP53	218	218	V -> A (in sporadic cancers; somatic mutation).
TP53	218	218	V -> E (in sporadic cancers; somatic mutation).
TP53	218	218	V -> G (in sporadic cancers; somatic mutation).
TP53	218	218	V -> L (in sporadic cancers; somatic mutation).
TP53	218	218	V -> M (in sporadic cancers; somatic mutation).
TP53	219	219	P -> C (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	219	219	P -> H (in a sporadic cancer; somatic mutation).
TP53	219	219	P -> L (in sporadic cancers; somatic mutation).
TP53	219	219	P -> R (in a sporadic cancer; somatic mutation).
TP53	219	219	P -> S (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	219	219	P -> T (in sporadic cancers; somatic mutation).
TP53	220	220	Y -> C (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	220	220	Y -> D (in sporadic cancers; somatic mutation).
TP53	220	220	Y -> F (in a sporadic cancer; somatic mutation).
TP53	220	220	Y -> H (in sporadic cancers; somatic mutation).
TP53	220	220	Y -> N (in sporadic cancers; somatic mutation).
TP53	220	220	Y -> S (in a brain tumor with no family history; germline mutation and in sporadic cancers; somatic mutation).
TP53	221	221	E -> A (in sporadic cancers; somatic mutation).
TP53	221	221	E -> D (in sporadic cancers; somatic mutation).
TP53	221	221	E -> G (in sporadic cancers; somatic mutation).
TP53	221	221	E -> K (in sporadic cancers; somatic mutation).
TP53	221	221	E -> Q (in sporadic cancers; somatic mutation).
TP53	222	222	P -> A (in a sporadic cancer; somatic mutation).
TP53	222	222	P -> L (in sporadic cancers; somatic mutation).
TP53	222	222	P -> Q (in sporadic cancers; somatic mutation).
TP53	222	222	P -> R (in a sporadic cancer; somatic mutation).
TP53	222	222	P -> S (in sporadic cancers; somatic mutation).
TP53	222	222	P -> T (in sporadic cancers; somatic mutation).
TP53	223	223	P -> A (in a sporadic cancer; somatic mutation).
TP53	223	223	P -> H (in sporadic cancers; somatic mutation).
TP53	223	223	P -> L (in sporadic cancers; somatic mutation).
TP53	223	223	P -> R (in a sporadic cancer; somatic mutation).
TP53	223	223	P -> S (in a sporadic cancer; somatic mutation).
TP53	223	223	P -> T (in a sporadic cancer; somatic mutation).
TP53	224	224	E -> D (in sporadic cancers; somatic mutation).
TP53	224	224	E -> G (in sporadic cancers; somatic mutation).
TP53	224	224	E -> K (in sporadic cancers; somatic mutation).
TP53	224	224	E -> V (in a sporadic cancer; somatic mutation).
TP53	225	225	V -> A (in sporadic cancers; somatic mutation).
TP53	225	225	V -> D (in a sporadic cancer; somatic mutation).
TP53	225	225	V -> F (in sporadic cancers; somatic mutation).
TP53	225	225	V -> G (in a sporadic cancer; somatic mutation).
TP53	225	225	V -> I (in sporadic cancers; somatic mutation).
TP53	225	225	V -> L (in a sporadic cancer; somatic mutation).
TP53	226	226	G -> A (in sporadic cancers; somatic mutation).
TP53	226	226	G -> D (in sporadic cancers; somatic mutation).
TP53	226	226	G -> N (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	226	226	G -> S (in sporadic cancers; somatic mutation).
TP53	226	226	G -> V (in sporadic cancers; somatic mutation).
TP53	227	227	S -> C (in sporadic cancers; somatic mutation).
TP53	227	227	S -> F (in sporadic cancers; somatic mutation).
TP53	227	227	S -> P (in a sporadic cancer; somatic mutation).
TP53	227	227	S -> T (in LFS; germline mutation and in a sporadic cancer; somatic mutation).
TP53	228	228	D -> A (in sporadic cancers; somatic mutation).
TP53	228	228	D -> E (in sporadic cancers; somatic mutation).
TP53	228	228	D -> G (in sporadic cancers; somatic mutation).
TP53	228	228	D -> H (in sporadic cancers; somatic mutation).
TP53	228	228	D -> N (in sporadic cancers; somatic mutation).
TP53	228	228	D -> P (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	228	228	D -> V (in sporadic cancers; somatic mutation).
TP53	228	228	D -> Y (in sporadic cancers; somatic mutation).
TP53	229	229	C -> G (in a sporadic cancer; somatic mutation).
TP53	229	229	C -> N (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	229	229	C -> R (in sporadic cancers; somatic mutation).
TP53	229	229	C -> S (in sporadic cancers; somatic mutation).
TP53	229	229	C -> Y (in sporadic cancers; somatic mutation).
TP53	230	230	T -> A (in sporadic cancers; somatic mutation).
TP53	230	230	T -> I (in sporadic cancers; somatic mutation).
TP53	230	230	T -> N (in sporadic cancers; somatic mutation).
TP53	230	230	T -> P (in sporadic cancers; somatic mutation).
TP53	230	230	T -> S (in sporadic cancers; somatic mutation).
TP53	231	231	T -> A (in sporadic cancers; somatic mutation).
TP53	231	231	T -> I (in sporadic cancers; somatic mutation).
TP53	231	231	T -> N (in sporadic cancers; somatic mutation).
TP53	231	231	T -> S (in sporadic cancers; somatic mutation).
TP53	232	232	I -> F (in sporadic cancers; somatic mutation).
TP53	232	232	I -> L (in sporadic cancers; somatic mutation).
TP53	232	232	I -> N (in sporadic cancers; somatic mutation).
TP53	232	232	I -> S (in sporadic cancers; somatic mutation).
TP53	232	232	I -> T (in sporadic cancers; somatic mutation).
TP53	232	232	I -> V (in sporadic cancers; somatic mutation).
TP53	233	233	H -> D (in LFS; germline mutation and in a sporadic cancer; somatic mutation).
TP53	233	233	H -> L (in sporadic cancers; somatic mutation).
TP53	233	233	H -> P (in a sporadic cancer; somatic mutation).
TP53	233	233	H -> Q (in sporadic cancers; somatic mutation).
TP53	233	233	H -> R (in sporadic cancers; somatic mutation).
TP53	233	233	H -> Y (in sporadic cancers; somatic mutation).
TP53	234	234	Y -> C (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	234	234	Y -> D (in sporadic cancers; somatic mutation).
TP53	234	234	Y -> F (in a sporadic cancer; somatic mutation).
TP53	234	234	Y -> H (in sporadic cancers; somatic mutation).
TP53	234	234	Y -> K (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	234	234	Y -> N (in sporadic cancers; somatic mutation).
TP53	234	234	Y -> Q (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	234	234	Y -> S (in sporadic cancers; somatic mutation).
TP53	235	235	N -> D (in an adrenocortical carcinoma with no family history; germline mutation and in sporadic cancers; somatic mutation).
TP53	235	235	N -> H (in a sporadic cancer; somatic mutation).
TP53	235	235	N -> I (in sporadic cancers; somatic mutation).
TP53	235	235	N -> M (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	235	235	N -> S (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	235	235	N -> T (in sporadic cancers; somatic mutation).
TP53	235	235	N -> Y (in sporadic cancers; somatic mutation).
TP53	236	236	Y -> C (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	236	236	Y -> D (in sporadic cancers; somatic mutation).
TP53	236	236	Y -> F (in a sporadic cancer; somatic mutation).
TP53	236	236	Y -> H (in sporadic cancers; somatic mutation).
TP53	236	236	Y -> N (in sporadic cancers; somatic mutation).
TP53	236	236	Y -> S (in sporadic cancers; somatic mutation).
TP53	237	237	M -> I (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	237	237	M -> K (in sporadic cancers; somatic mutation).
TP53	237	237	M -> L (in sporadic cancers; somatic mutation).
TP53	237	237	M -> R (in sporadic cancers; somatic mutation).
TP53	237	237	M -> T (in sporadic cancers; somatic mutation).
TP53	237	237	M -> V (in sporadic cancers; somatic mutation).
TP53	238	238	C -> F (in sporadic cancers; somatic mutation).
TP53	238	238	C -> G (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	238	238	C -> H (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	238	238	C -> R (in sporadic cancers; somatic mutation).
TP53	238	238	C -> S (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	238	238	C -> W (in sporadic cancers; somatic mutation).
TP53	238	238	C -> Y (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	239	239	N -> D (in sporadic cancers; somatic mutation).
TP53	239	239	N -> H (in a sporadic cancer; somatic mutation).
TP53	239	239	N -> I (in a sporadic cancer; somatic mutation).
TP53	239	239	N -> K (in sporadic cancers; somatic mutation).
TP53	239	239	N -> S (in sporadic cancers; somatic mutation).
TP53	239	239	N -> T (in sporadic cancers; somatic mutation).
TP53	239	239	N -> Y (in sporadic cancers; somatic mutation).
TP53	240	240	S -> C (in sporadic cancers; somatic mutation).
TP53	240	240	S -> G (in sporadic cancers; somatic mutation).
TP53	240	240	S -> I (in sporadic cancers; somatic mutation).
TP53	240	240	S -> N (in sporadic cancers; somatic mutation).
TP53	240	240	S -> P (in a sporadic cancer; somatic mutation).
TP53	240	240	S -> R (in sporadic cancers; somatic mutation).
TP53	240	240	S -> T (in sporadic cancers; somatic mutation).
TP53	241	241	S -> A (in sporadic cancers; somatic mutation).
TP53	241	241	S -> C (in sporadic cancers; somatic mutation).
TP53	241	241	S -> P (in sporadic cancers; somatic mutation).
TP53	241	241	S -> T (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	241	241	S -> Y (in sporadic cancers; somatic mutation).
TP53	242	242	C -> F (in sporadic cancers; somatic mutation).
TP53	242	242	C -> G (in sporadic cancers; somatic mutation).
TP53	242	242	C -> R (in sporadic cancers; somatic mutation).
TP53	242	242	C -> S (in sporadic cancers; somatic mutation).
TP53	242	242	C -> W (in sporadic cancers; somatic mutation).
TP53	242	242	C -> Y (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	243	244	MG -> IC (in a sporadic cancer; somatic mutation).
TP53	243	244	MG -> IS (in a sporadic cancer; somatic mutation).
TP53	243	243	M -> I (in sporadic cancers; somatic mutation).
TP53	243	243	M -> K (in sporadic cancers; somatic mutation).
TP53	243	243	M -> L (in sporadic cancers; somatic mutation).
TP53	243	243	M -> R (in sporadic cancers; somatic mutation).
TP53	243	243	M -> T (in sporadic cancers; somatic mutation).
TP53	243	243	M -> V (in sporadic cancers; somatic mutation).
TP53	244	244	G -> A (in sporadic cancers; somatic mutation).
TP53	244	244	G -> C (in sporadic cancers; somatic mutation).
TP53	244	244	G -> E (in a sporadic cancer; somatic mutation).
TP53	244	244	G -> R (in sporadic cancers; somatic mutation).
TP53	244	244	G -> S (in sporadic cancers; somatic mutation).
TP53	244	244	G -> V (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	245	245	G -> A (in sporadic cancers; somatic mutation).
TP53	245	245	G -> C (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	245	245	G -> D (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	245	245	G -> E (in a sporadic cancer; somatic mutation).
TP53	245	245	G -> F (in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions).
TP53	245	245	G -> H (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	245	245	G -> L (in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions).
TP53	245	245	G -> N (in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions).
TP53	245	245	G -> R (in sporadic cancers; somatic mutation).
TP53	245	245	G -> V (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	246	246	M -> I (in sporadic cancers; somatic mutation).
TP53	246	246	M -> K (in sporadic cancers; somatic mutation).
TP53	246	246	M -> L (in sporadic cancers; somatic mutation).
TP53	246	246	M -> R (in sporadic cancers; somatic mutation).
TP53	246	246	M -> T (in sporadic cancers; somatic mutation).
TP53	246	246	M -> V (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	247	248	NR -> IP (in a sporadic cancer; somatic mutation).
TP53	247	248	NR -> KW (in sporadic cancers; somatic mutation).
TP53	247	247	N -> D (in sporadic cancers; somatic mutation).
TP53	247	247	N -> F (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	247	247	N -> I (in sporadic cancers; somatic mutation).
TP53	247	247	N -> K (in sporadic cancers; somatic mutation).
TP53	247	247	N -> S (in sporadic cancers; somatic mutation).
TP53	247	247	N -> T (in sporadic cancers; somatic mutation).
TP53	247	247	N -> Y (in sporadic cancers; somatic mutation).
TP53	248	248	R -> C (in a sporadic cancer; somatic mutation).
TP53	248	248	R -> G (in sporadic cancers; somatic mutation).
TP53	248	248	R -> L (in sporadic cancers; somatic mutation).
TP53	248	248	R -> P (in sporadic cancers; somatic mutation).
TP53	248	248	R -> W (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	249	250	RP -> SA (in a sporadic cancer; somatic mutation).
TP53	249	250	RP -> SS (in sporadic cancers; somatic mutation).
TP53	249	249	R -> G (in sporadic cancers; somatic mutation).
TP53	249	249	R -> I (in a sporadic cancer; somatic mutation).
TP53	249	249	R -> K (in sporadic cancers; somatic mutation).
TP53	249	249	R -> M (in sporadic cancers; somatic mutation).
TP53	249	249	R -> N (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	249	249	R -> T (in sporadic cancers; somatic mutation).
TP53	249	249	R -> W (in sporadic cancers; somatic mutation).
TP53	250	250	P -> A (in sporadic cancers; somatic mutation).
TP53	250	250	P -> F (in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions).
TP53	250	250	P -> H (in sporadic cancers; somatic mutation).
TP53	250	250	P -> L (in sporadic cancers; somatic mutation).
TP53	250	250	P -> N (in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions).
TP53	250	250	P -> Q (in sporadic cancers; somatic mutation).
TP53	250	250	P -> S (in sporadic cancers; somatic mutation).
TP53	250	250	P -> T (in sporadic cancers; somatic mutation).
TP53	251	251	I -> F (in sporadic cancers; somatic mutation).
TP53	251	251	I -> L (in sporadic cancers; somatic mutation).
TP53	251	251	I -> M (in LFS; germline mutation).
TP53	251	251	I -> N (in sporadic cancers; somatic mutation).
TP53	251	251	I -> S (in sporadic cancers; somatic mutation).
TP53	251	251	I -> T (in sporadic cancers; somatic mutation).
TP53	251	251	I -> V (in sporadic cancers; somatic mutation).
TP53	252	252	L -> F (in sporadic cancers; somatic mutation).
TP53	252	252	L -> H (in a sporadic cancer; somatic mutation).
TP53	252	252	L -> I (in sporadic cancers; somatic mutation).
TP53	252	252	L -> P (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	252	252	L -> V (in a sporadic cancer; somatic mutation).
TP53	253	253	T -> A (in sporadic cancers; somatic mutation).
TP53	253	253	T -> I (in sporadic cancers; somatic mutation).
TP53	253	253	T -> N (in sporadic cancers; somatic mutation).
TP53	253	253	T -> P (in sporadic cancers; somatic mutation).
TP53	253	253	T -> S (in sporadic cancers; somatic mutation).
TP53	254	254	I -> D (in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions).
TP53	254	254	I -> F (in a sporadic cancer; somatic mutation).
TP53	254	254	I -> L (in a sporadic cancer; somatic mutation).
TP53	254	254	I -> M (in a sporadic cancer; somatic mutation).
TP53	254	254	I -> N (in sporadic cancers; somatic mutation).
TP53	254	254	I -> S (in sporadic cancers; somatic mutation).
TP53	254	254	I -> T (in sporadic cancers; somatic mutation).
TP53	254	254	I -> V (in sporadic cancers; somatic mutation).
TP53	255	255	I -> F (in sporadic cancers; somatic mutation).
TP53	255	255	I -> M (in sporadic cancers; somatic mutation).
TP53	255	255	I -> N (in sporadic cancers; somatic mutation).
TP53	255	255	I -> S (in sporadic cancers; somatic mutation).
TP53	255	255	I -> T (in sporadic cancers; somatic mutation).
TP53	255	255	I -> V (in sporadic cancers; somatic mutation).
TP53	256	256	T -> I (in a brain tumor with no family history; germline mutation and in sporadic cancers; somatic mutation).
TP53	256	256	T -> K (in sporadic cancers; somatic mutation).
TP53	256	256	T -> P (in sporadic cancers; somatic mutation).
TP53	256	256	T -> S (in sporadic cancers; somatic mutation).
TP53	257	257	L -> P (in sporadic cancers; somatic mutation).
TP53	257	257	L -> R (in sporadic cancers; somatic mutation).
TP53	257	257	L -> V (in sporadic cancers; somatic mutation).
TP53	258	258	E -> A (in sporadic cancers; somatic mutation).
TP53	258	258	E -> D (in sporadic cancers; somatic mutation).
TP53	258	258	E -> G (in sporadic cancers; somatic mutation).
TP53	258	258	E -> K (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	258	258	E -> L (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	258	258	E -> Q (in sporadic cancers; somatic mutation).
TP53	258	258	E -> V (in sporadic cancers; somatic mutation).
TP53	259	259	D -> A (in a sporadic cancer; somatic mutation).
TP53	259	259	D -> E (in sporadic cancers; somatic mutation).
TP53	259	259	D -> G (in sporadic cancers; somatic mutation).
TP53	259	259	D -> H (in sporadic cancers; somatic mutation).
TP53	259	259	D -> N (in sporadic cancers; somatic mutation).
TP53	259	259	D -> P (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	259	259	D -> S (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	259	259	D -> V (in sporadic cancers; somatic mutation).
TP53	259	259	D -> Y (in sporadic cancers; somatic mutation).
TP53	260	260	S -> A (in sporadic cancers; somatic mutation).
TP53	260	260	S -> C (in sporadic cancers; somatic mutation).
TP53	260	260	S -> F (in sporadic cancers; somatic mutation).
TP53	260	260	S -> P (in sporadic cancers; somatic mutation).
TP53	260	260	S -> T (in a sporadic cancer; somatic mutation).
TP53	260	260	S -> Y (in sporadic cancers; somatic mutation).
TP53	261	261	S -> C (in a sporadic cancer; somatic mutation).
TP53	261	261	S -> G (in sporadic cancers; somatic mutation).
TP53	261	261	S -> I (in sporadic cancers; somatic mutation).
TP53	261	261	S -> N (in a sporadic cancer; somatic mutation).
TP53	261	261	S -> R (in sporadic cancers; somatic mutation).
TP53	262	263	GN -> PD (in a sporadic cancer; somatic mutation).
TP53	262	262	G -> C (in a sporadic cancer; somatic mutation).
TP53	262	262	G -> D (in sporadic cancers; somatic mutation).
TP53	262	262	G -> H (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	262	262	G -> S (in sporadic cancers; somatic mutation).
TP53	262	262	G -> V (in sporadic cancers; somatic mutation).
TP53	263	263	N -> D (in sporadic cancers; somatic mutation).
TP53	263	263	N -> H (in sporadic cancers; somatic mutation).
TP53	263	263	N -> I (in sporadic cancers; somatic mutation).
TP53	263	263	N -> K (in a sporadic cancer; somatic mutation).
TP53	263	263	N -> S (in a sporadic cancer; somatic mutation).
TP53	264	264	L -> I (in sporadic cancers; somatic mutation).
TP53	264	264	L -> P (in a sporadic cancer; somatic mutation).
TP53	264	264	L -> Q (in a sporadic cancer; somatic mutation).
TP53	264	264	L -> R (in sporadic cancers; somatic mutation).
TP53	264	264	L -> V (in a sporadic cancer; somatic mutation).
TP53	265	265	L -> M (in sporadic cancers; somatic mutation).
TP53	265	265	L -> P (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	265	265	L -> Q (in sporadic cancers; somatic mutation).
TP53	265	265	L -> R (in sporadic cancers; somatic mutation).
TP53	266	266	G -> A (in sporadic cancers; somatic mutation).
TP53	266	266	G -> E (in sporadic cancers; somatic mutation).
TP53	266	266	G -> R (in sporadic cancers; somatic mutation).
TP53	266	266	G -> V (in sporadic cancers; somatic mutation).
TP53	267	267	R -> G (in sporadic cancers; somatic mutation).
TP53	267	267	R -> H (in a sporadic cancer; somatic mutation).
TP53	267	267	R -> P (in sporadic cancers; somatic mutation).
TP53	267	267	R -> Q (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	268	268	N -> F (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	268	268	N -> H (in sporadic cancers; somatic mutation).
TP53	268	268	N -> I (in sporadic cancers; somatic mutation).
TP53	268	268	N -> K (in a sporadic cancer; somatic mutation).
TP53	268	268	N -> S (in sporadic cancers; somatic mutation).
TP53	268	268	N -> Y (in a sporadic cancer; somatic mutation).
TP53	269	269	S -> C (in sporadic cancers; somatic mutation).
TP53	269	269	S -> G (in sporadic cancers; somatic mutation).
TP53	269	269	S -> I (in a sporadic cancer; somatic mutation).
TP53	269	269	S -> N (in sporadic cancers; somatic mutation).
TP53	269	269	S -> R (in sporadic cancers; somatic mutation).
TP53	269	269	S -> T (in a sporadic cancer; somatic mutation).
TP53	270	270	F -> C (in sporadic cancers; somatic mutation).
TP53	270	270	F -> I (in sporadic cancers; somatic mutation).
TP53	270	270	F -> L (in sporadic cancers; somatic mutation).
TP53	270	270	F -> S (in sporadic cancers; somatic mutation).
TP53	270	270	F -> V (in sporadic cancers; somatic mutation).
TP53	270	270	F -> Y (in sporadic cancers; somatic mutation).
TP53	271	271	E -> A (in sporadic cancers; somatic mutation).
TP53	271	271	E -> D (in sporadic cancers; somatic mutation).
TP53	271	271	E -> G (in sporadic cancers; somatic mutation).
TP53	271	271	E -> K (in sporadic cancers; somatic mutation).
TP53	271	271	E -> P (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	271	271	E -> Q (in sporadic cancers; somatic mutation).
TP53	271	271	E -> R (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	271	271	E -> V (in an osteosarcoma with no family history; germline mutation and in sporadic cancers; somatic mutation).
TP53	272	272	V -> A (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	272	272	V -> E (in sporadic cancers; somatic mutation).
TP53	272	272	V -> G (in sporadic cancers; somatic mutation).
TP53	272	272	V -> L (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	272	272	V -> M (in sporadic cancers; somatic mutation).
TP53	273	273	R -> C (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	273	273	R -> G (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	273	273	R -> L (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	273	273	R -> N (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	273	273	R -> P (in sporadic cancers; somatic mutation).
TP53	273	273	R -> Q (in sporadic cancers; somatic mutation).
TP53	273	273	R -> S (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	273	273	R -> Y (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	274	274	V -> A (in sporadic cancers; somatic mutation).
TP53	274	274	V -> D (in sporadic cancers; somatic mutation).
TP53	274	274	V -> F (in sporadic cancers; somatic mutation).
TP53	274	274	V -> G (in sporadic cancers; somatic mutation).
TP53	274	274	V -> I (in sporadic cancers; somatic mutation).
TP53	274	274	V -> L (in sporadic cancers; somatic mutation).
TP53	275	275	C -> F (in sporadic cancers; somatic mutation).
TP53	275	275	C -> G (in sporadic cancers; somatic mutation).
TP53	275	275	C -> R (in sporadic cancers; somatic mutation).
TP53	275	275	C -> S (in sporadic cancers; somatic mutation).
TP53	275	275	C -> W (in sporadic cancers; somatic mutation).
TP53	275	275	C -> Y (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	276	276	A -> D (in sporadic cancers; somatic mutation).
TP53	276	276	A -> G (in sporadic cancers; somatic mutation).
TP53	276	276	A -> P (in sporadic cancers; somatic mutation).
TP53	276	276	A -> S (in sporadic cancers; somatic mutation).
TP53	276	276	A -> T (in sporadic cancers; somatic mutation).
TP53	276	276	A -> V (in sporadic cancers; somatic mutation).
TP53	277	277	C -> F (in sporadic cancers; somatic mutation).
TP53	277	277	C -> G (in sporadic cancers; somatic mutation).
TP53	277	277	C -> R (in sporadic cancers; somatic mutation).
TP53	277	277	C -> S (in sporadic cancers; somatic mutation).
TP53	277	277	C -> W (in sporadic cancers; somatic mutation).
TP53	277	277	C -> Y (in an osteosarcoma with no family history; germline mutation and in sporadic cancers; somatic mutation).
TP53	278	278	P -> F (in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions).
TP53	278	278	P -> H (in sporadic cancers; somatic mutation).
TP53	278	278	P -> L (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	278	278	P -> R (in sporadic cancers; somatic mutation).
TP53	278	278	P -> S (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	278	278	P -> T (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	279	279	G -> E (in sporadic cancers; somatic mutation).
TP53	279	279	G -> R (in sporadic cancers; somatic mutation).
TP53	279	279	G -> V (in sporadic cancers; somatic mutation).
TP53	279	279	G -> W (in sporadic cancers; somatic mutation).
TP53	280	280	R -> G (in sporadic cancers; somatic mutation).
TP53	280	280	R -> I (in sporadic cancers; somatic mutation).
TP53	280	280	R -> K (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	280	280	R -> P (in a sporadic cancer; somatic mutation).
TP53	280	280	R -> S (in sporadic cancers; somatic mutation).
TP53	280	280	R -> T (in sporadic cancers; somatic mutation).
TP53	281	282	DR -> EW (in sporadic cancers; somatic mutation).
TP53	281	281	D -> A (in sporadic cancers; somatic mutation).
TP53	281	281	D -> E (in sporadic cancers; somatic mutation).
TP53	281	281	D -> G (in a brain tumor with no family history; germline mutation and in sporadic cancers; somatic mutation).
TP53	281	281	D -> H (in sporadic cancers; somatic mutation).
TP53	281	281	D -> N (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	281	281	D -> R (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	281	281	D -> V (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	281	281	D -> Y (in sporadic cancers; somatic mutation).
TP53	282	282	R -> G (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	282	282	R -> H (in a sporadic cancer; somatic mutation).
TP53	282	282	R -> L (in sporadic cancers; somatic mutation).
TP53	282	282	R -> P (in sporadic cancers; somatic mutation).
TP53	282	282	R -> Q (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	283	283	R -> C (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	283	283	R -> G (in sporadic cancers; somatic mutation).
TP53	283	283	R -> H (in a brain tumor with no family history; germline mutation and in sporadic cancers; somatic mutation).
TP53	283	283	R -> L (in sporadic cancers; somatic mutation).
TP53	283	283	R -> P (in sporadic cancers; somatic mutation).
TP53	283	283	R -> S (in a sporadic cancer; somatic mutation).
TP53	284	284	T -> A (in sporadic cancers; somatic mutation).
TP53	284	284	T -> I (in sporadic cancers; somatic mutation).
TP53	284	284	T -> K (in sporadic cancers; somatic mutation).
TP53	284	284	T -> P (in sporadic cancers; somatic mutation).
TP53	285	285	E -> A (in a sporadic cancer; somatic mutation).
TP53	285	285	E -> D (in sporadic cancers; somatic mutation).
TP53	285	285	E -> G (in sporadic cancers; somatic mutation).
TP53	285	285	E -> K (in sporadic cancers; somatic mutation).
TP53	285	285	E -> Q (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	285	285	E -> V (in sporadic cancers; somatic mutation).
TP53	286	286	E -> A (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	286	286	E -> D (in sporadic cancers; somatic mutation).
TP53	286	286	E -> G (in sporadic cancers; somatic mutation).
TP53	286	286	E -> K (in sporadic cancers; somatic mutation).
TP53	286	286	E -> L (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	286	286	E -> Q (in sporadic cancers; somatic mutation).
TP53	286	286	E -> V (in sporadic cancers; somatic mutation).
TP53	287	287	E -> A (in a sporadic cancer; somatic mutation).
TP53	287	287	E -> D (in sporadic cancers; somatic mutation).
TP53	287	287	E -> G (in sporadic cancers; somatic mutation).
TP53	287	287	E -> K (in sporadic cancers; somatic mutation).
TP53	287	287	E -> V (in sporadic cancers; somatic mutation).
TP53	288	288	N -> D (in a sporadic cancer; somatic mutation).
TP53	288	288	N -> K (in sporadic cancers; somatic mutation).
TP53	288	288	N -> S (in sporadic cancers; somatic mutation).
TP53	288	288	N -> T (in sporadic cancers; somatic mutation).
TP53	288	288	N -> Y (in sporadic cancers; somatic mutation).
TP53	289	289	L -> F (in sporadic cancers; somatic mutation).
TP53	289	289	L -> H (in sporadic cancers; somatic mutation).
TP53	289	289	L -> P (in sporadic cancers; somatic mutation).
TP53	289	289	L -> R (in a sporadic cancer; somatic mutation).
TP53	289	289	L -> V (in sporadic cancers; somatic mutation).
TP53	290	290	R -> C (in sporadic cancers; somatic mutation).
TP53	290	290	R -> L (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	291	291	K -> E (in sporadic cancers; somatic mutation).
TP53	291	291	K -> M (in sporadic cancers; somatic mutation).
TP53	291	291	K -> N (in sporadic cancers; somatic mutation).
TP53	291	291	K -> Q (in sporadic cancers; somatic mutation).
TP53	291	291	K -> R (in sporadic cancers; somatic mutation).
TP53	291	291	K -> T (in sporadic cancers; somatic mutation).
TP53	292	292	K -> E (in sporadic cancers; somatic mutation).
TP53	292	292	K -> G (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	292	292	K -> I (in LFS; germline mutation and in a sporadic cancer; somatic mutation).
TP53	292	292	K -> N (in sporadic cancers; somatic mutation).
TP53	292	292	K -> Q (in a sporadic cancer; somatic mutation).
TP53	292	292	K -> R (in sporadic cancers; somatic mutation).
TP53	292	292	K -> T (in sporadic cancers; somatic mutation).
TP53	293	293	G -> A (in a sporadic cancer; somatic mutation).
TP53	293	293	G -> R (in sporadic cancers; somatic mutation).
TP53	293	293	G -> V (in sporadic cancers; somatic mutation).
TP53	293	293	G -> W (in a brain tumor with no family history; germline mutation and in sporadic cancers; somatic mutation).
TP53	294	294	E -> A (in a sporadic cancer; somatic mutation).
TP53	294	294	E -> D (in sporadic cancers; somatic mutation).
TP53	294	294	E -> G (in sporadic cancers; somatic mutation).
TP53	294	294	E -> K (in sporadic cancers; somatic mutation).
TP53	294	294	E -> Q (in sporadic cancers; somatic mutation).
TP53	294	294	E -> V (in sporadic cancers; somatic mutation).
TP53	295	295	P -> H (in a sporadic cancer; somatic mutation).
TP53	295	295	P -> L (in sporadic cancers; somatic mutation).
TP53	295	295	P -> R (in a sporadic cancer; somatic mutation).
TP53	295	295	P -> S (in sporadic cancers; somatic mutation).
TP53	296	296	H -> C (in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions).
TP53	296	296	H -> D (in sporadic cancers; somatic mutation).
TP53	296	296	H -> L (in sporadic cancers; somatic mutation).
TP53	296	296	H -> N (in sporadic cancers; somatic mutation).
TP53	296	296	H -> P (in a sporadic cancer; somatic mutation).
TP53	296	296	H -> Q (in sporadic cancers; somatic mutation).
TP53	296	296	H -> R (in a sporadic cancer; somatic mutation).
TP53	296	296	H -> Y (in sporadic cancers; somatic mutation).
TP53	297	297	H -> D (in a sporadic cancer; somatic mutation).
TP53	297	297	H -> N (in a sporadic cancer; somatic mutation).
TP53	297	297	H -> P (in sporadic cancers; somatic mutation).
TP53	297	297	H -> R (in sporadic cancers; somatic mutation).
TP53	297	297	H -> Y (in sporadic cancers; somatic mutation).
TP53	298	298	E -> A (in a sporadic cancer; somatic mutation).
TP53	298	298	E -> D (in sporadic cancers; somatic mutation).
TP53	298	298	E -> K (in sporadic cancers; somatic mutation).
TP53	298	298	E -> Q (in sporadic cancers; somatic mutation).
TP53	298	298	E -> V (in sporadic cancers; somatic mutation).
TP53	299	299	L -> P (in sporadic cancers; somatic mutation).
TP53	299	299	L -> Q (in sporadic cancers; somatic mutation).
TP53	299	299	L -> R (in a sporadic cancer; somatic mutation).
TP53	299	299	L -> V (in a sporadic cancer; somatic mutation).
TP53	300	300	P -> A (in sporadic cancers; somatic mutation).
TP53	300	300	P -> L (in sporadic cancers; somatic mutation).
TP53	300	300	P -> R (in a sporadic cancer; somatic mutation).
TP53	300	300	P -> S (in sporadic cancers; somatic mutation).
TP53	301	301	P -> A (in sporadic cancers; somatic mutation).
TP53	301	301	P -> L (in sporadic cancers; somatic mutation).
TP53	301	301	P -> Q (in sporadic cancers; somatic mutation).
TP53	301	301	P -> S (in sporadic cancers; somatic mutation).
TP53	301	301	P -> T (in a sporadic cancer; somatic mutation).
TP53	302	302	G -> A (in a sporadic cancer; somatic mutation).
TP53	302	302	G -> E (in sporadic cancers; somatic mutation).
TP53	302	302	G -> R (in a sporadic cancer; somatic mutation).
TP53	302	302	G -> V (in a sporadic cancer; somatic mutation).
TP53	303	303	S -> C (in sporadic cancers; somatic mutation).
TP53	303	303	S -> I (in sporadic cancers; somatic mutation).
TP53	303	303	S -> N (in sporadic cancers; somatic mutation).
TP53	303	303	S -> T (in sporadic cancers; somatic mutation).
TP53	304	304	T -> A (in sporadic cancers; somatic mutation).
TP53	304	304	T -> I (in sporadic cancers; somatic mutation).
TP53	304	304	T -> N (in a sporadic cancer; somatic mutation).
TP53	304	304	T -> S (in a sporadic cancer; somatic mutation).
TP53	305	305	K -> E (in a sporadic cancer; somatic mutation).
TP53	305	305	K -> M (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	305	305	K -> N (in sporadic cancers; somatic mutation; loss of nuclear localization).
TP53	305	305	K -> R (in sporadic cancers; somatic mutation).
TP53	305	305	K -> T (in a sporadic cancer; somatic mutation).
TP53	306	306	R -> P (in LFS; germline mutation and in a sporadic cancer; somatic mutation).
TP53	306	306	R -> Q (in sporadic cancers; somatic mutation).
TP53	307	307	A -> P (in a sporadic cancer; somatic mutation).
TP53	307	307	A -> S (in sporadic cancers; somatic mutation).
TP53	307	307	A -> T (in sporadic cancers; somatic mutation).
TP53	308	308	L -> M (in sporadic cancers; somatic mutation).
TP53	308	308	L -> V (in a sporadic cancer; somatic mutation).
TP53	309	309	P -> R (in a sporadic cancer; somatic mutation).
TP53	309	309	P -> S (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	310	310	N -> I (in a sporadic cancer; somatic mutation).
TP53	310	310	N -> T (in sporadic cancers; somatic mutation).
TP53	311	311	N -> H (in sporadic cancers; somatic mutation).
TP53	311	311	N -> K (in a sporadic cancer; somatic mutation).
TP53	311	311	N -> T (in sporadic cancers; somatic mutation).
TP53	312	312	T -> I (in sporadic cancers; somatic mutation).
TP53	312	312	T -> S (in sporadic cancers; somatic mutation).
TP53	313	313	S -> C (in a sporadic cancer; somatic mutation).
TP53	313	313	S -> I (in a sporadic cancer; somatic mutation).
TP53	313	313	S -> N (in a sporadic cancer; somatic mutation).
TP53	313	313	S -> R (in a sporadic cancer; somatic mutation).
TP53	314	314	S -> F (in a sporadic cancer; somatic mutation).
TP53	315	315	S -> C (in a sporadic cancer; somatic mutation).
TP53	315	315	S -> F (in a sporadic cancer; somatic mutation).
TP53	315	315	S -> P (in a sporadic cancer; somatic mutation).
TP53	316	316	P -> L (in a sporadic cancer; somatic mutation).
TP53	316	316	P -> T (in a sporadic cancer; somatic mutation).
TP53	317	317	Q -> H (in a kidney cancer with no family history; germline mutation and in a sporadic cancer; somatic mutation).
TP53	317	317	Q -> K (in sporadic cancers; somatic mutation).
TP53	317	317	Q -> L (in a sporadic cancer; somatic mutation).
TP53	317	317	Q -> P (in a sporadic cancer; somatic mutation).
TP53	317	317	Q -> R (in sporadic cancers; somatic mutation).
TP53	318	318	P -> L (in sporadic cancers; somatic mutation).
TP53	319	319	K -> E (in sporadic cancers; somatic mutation).
TP53	319	319	K -> N (in a sporadic cancer; somatic mutation).
TP53	319	319	K -> R (in a sporadic cancer; somatic mutation).
TP53	320	320	K -> N (in sporadic cancers; somatic mutation).
TP53	321	321	K -> E (in kidney cancer; germline mutation).
TP53	321	321	K -> R (in a sporadic cancer; somatic mutation).
TP53	322	322	P -> L (in sporadic cancers; somatic mutation).
TP53	322	322	P -> R (in sporadic cancers; somatic mutation).
TP53	323	323	L -> G (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	323	323	L -> M (in a sporadic cancer; somatic mutation).
TP53	323	323	L -> P (in a sporadic cancer; somatic mutation).
TP53	323	323	L -> R (in a sporadic cancer; somatic mutation).
TP53	323	323	L -> V (in a sporadic cancer; somatic mutation).
TP53	324	324	D -> E (in sporadic cancers; somatic mutation).
TP53	324	324	D -> S (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions).
TP53	324	324	D -> Y (in a sporadic cancer; somatic mutation).
TP53	325	325	G -> A (in a sporadic cancer; somatic mutation).
TP53	325	325	G -> E (in sporadic cancers; somatic mutation).
TP53	326	326	E -> G (in a sporadic cancer; somatic mutation).
TP53	327	327	Y -> H (in a sporadic cancer; somatic mutation).
TP53	327	327	Y -> S (in a sporadic cancer; somatic mutation).
TP53	328	328	F -> L (in a sporadic cancer; somatic mutation).
TP53	328	328	F -> S (in sporadic cancers; somatic mutation).
TP53	328	328	F -> V (in a sporadic cancer; somatic mutation).
TP53	329	329	T -> I (in a sporadic cancer; somatic mutation).
TP53	329	329	T -> S (in a sporadic cancer; somatic mutation).
TP53	330	330	L -> H (in sporadic cancers; somatic mutation).
TP53	330	330	L -> P (in a sporadic cancer; somatic mutation).
TP53	330	330	L -> R (in sporadic cancers; somatic mutation).
TP53	331	331	Q -> H (in sporadic cancers; somatic mutation).
TP53	331	331	Q -> P (in sporadic cancers; somatic mutation).
TP53	331	331	Q -> R (in sporadic cancers; somatic mutation).
TP53	332	332	I -> V (in a sporadic cancer; somatic mutation).
TP53	334	334	G -> V (in sporadic cancers; somatic mutation).
TP53	334	334	G -> W (in a sporadic cancer; somatic mutation).
TP53	335	335	R -> G (in a sporadic cancer; somatic mutation).
TP53	335	335	R -> H (in a sporadic cancer; somatic mutation).
TP53	335	335	R -> L (in a sporadic cancer; somatic mutation).
TP53	337	337	R -> C (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	337	337	R -> H (in LFS; germline mutation and in sporadic cancers; somatic mutation).
TP53	337	337	R -> L (in sporadic cancers; somatic mutation).
TP53	337	337	R -> P (in sporadic cancers; somatic mutation).
TP53	338	338	F -> I (in a sporadic cancer; somatic mutation).
TP53	338	338	F -> L (in a sporadic cancer; somatic mutation).
TP53	339	339	E -> Q (in a sporadic cancer; somatic mutation).
TP53	341	341	F -> C (in sporadic cancers; somatic mutation).
TP53	342	342	R -> L (in a sporadic cancer; somatic mutation).
TP53	342	342	R -> P (in sporadic cancers; somatic mutation).
TP53	342	342	R -> Q (in sporadic cancers; somatic mutation).
TP53	343	343	E -> G (in sporadic cancers; somatic mutation).
TP53	344	344	L -> P (in LFS; germline mutation and in a sporadic cancer; somatic mutation).
TP53	344	344	L -> R (in a sporadic cancer; somatic mutation).
TP53	346	346	E -> A (in a sporadic cancer; somatic mutation).
TP53	347	347	A -> G (in a sporadic cancer; somatic mutation).
TP53	347	347	A -> T (in sporadic cancers; somatic mutation).
TP53	348	348	L -> F (in a sporadic cancer; somatic mutation).
TP53	348	348	L -> S (in a sporadic cancer; somatic mutation).
TP53	349	349	E -> D (in a sporadic cancer; somatic mutation).
TP53	352	352	D -> H (in a sporadic cancer; somatic mutation).
TP53	353	353	A -> T (in a sporadic cancer; somatic mutation).
TP53	354	354	Q -> E (in a sporadic cancer; somatic mutation).
TP53	354	354	Q -> K (in a sporadic cancer; somatic mutation).
TP53	354	354	Q -> R (in sporadic cancers; somatic mutation).
TP53	356	356	G -> A (in a sporadic cancer; somatic mutation).
TP53	356	356	G -> W (in a sporadic cancer; somatic mutation).
TP53	358	358	E -> D (in a sporadic cancer; somatic mutation).
TP53	358	358	E -> K (in a sporadic cancer; somatic mutation).
TP53	360	360	G -> V (in a sporadic cancer; somatic mutation).
TP53	363	363	R -> K (in a sporadic cancer; somatic mutation).
TP53	364	364	A -> P (in a sporadic cancer; somatic mutation).
TP53	364	364	A -> T (in a sporadic cancer; somatic mutation).
TP53	364	364	A -> V (in a sporadic cancer; somatic mutation).
TP53	365	365	H -> R (in a sporadic cancer; somatic mutation).
TP53	365	365	H -> Y (in a familial cancer not matching LFS; germline mutation and in a sporadic cancer; somatic mutation).
TP53	370	370	K -> Q (in a sporadic cancer; somatic mutation).
TP53	376	376	S -> A (in a sporadic cancer; somatic mutation).
TP53	376	376	S -> T (in a sporadic cancer; somatic mutation).
TP53	379	379	R -> H (in sporadic cancers; somatic mutation).
TP53	385	385	F -> L (in a sporadic cancer; somatic mutation).
TP53	389	389	G -> W (in a sporadic cancer; somatic mutation).
TP53	392	392	S -> L (in a sporadic cancer; somatic mutation).
EFNB3	166	166	R -> Q.
TRAPPC1	129	129	R -> G (in a melanoma).
GUCY2D	52	52	A -> S (in LCA1; could be a rare polymorphism).
GUCY2D	105	105	C -> Y (in LCA1; does not affect basal activity; reduces GCAP-1 induced activity).
GUCY2D	325	325	L -> P (in LCA1; does not affect basal activity; reduces GCAP-1 induced activity).
GUCY2D	362	362	A -> S (in LCA1).
GUCY2D	431	431	G -> D (in a metastatic melanoma sample; somatic mutation).
GUCY2D	507	507	V -> M.
GUCY2D	565	565	F -> S (in LCA1; loss of activity).
GUCY2D	573	573	I -> V (in LCA1).
GUCY2D	837	839	ERT -> DCM (in CORD6).
GUCY2D	838	838	R -> C (in CORD6).
GUCY2D	838	838	R -> H (in CORD6).
GUCY2D	858	858	P -> S (in LCA1; severely impairs basal and GCAP-1 induced activity).
GUCY2D	954	954	L -> P (in LCA1; severely impairs basal and GCAP-1 induced activity).
ALOX12B	426	426	L -> P (in NCIE).
ALOX12B	578	578	H -> Q (in NCIE).
ALOXE3	396	396	R -> S (in NCIE).
ALOXE3	500	500	V -> F (in NCIE).
HES7	25	25	R -> W (in SCDO4).
HES7	58	58	I -> V (in SCDO4).
HES7	186	186	D -> Y (in SCDO4).
PER1	696	696	E -> Q (in a breast cancer sample; somatic mutation).
PER1	985	985	N -> S (in a breast cancer sample; somatic mutation).
PER1	1060	1060	S -> L (in a colorectal cancer sample; somatic mutation).
AURKB	52	52	A -> V.
AURKB	179	179	T -> M.
PIK3R5	28	28	R -> C (in a colorectal cancer sample; somatic mutation).
MYH1	640	640	G -> S.
MYH1	1306	1306	S -> L (in a breast cancer sample; somatic mutation).
MYH1	1445	1445	A -> T (in a breast cancer sample; somatic mutation).
MYH1	1566	1566	Q -> K (found in a renal cell carcinoma sample; somatic mutation).
MYH1	1598	1598	V -> M (in a breast cancer sample; somatic mutation).
MYH2	706	706	E -> K (in IBM3).
MYH2	970	970	V -> I (in one patient with familial myopathy; unknown pathological significance).
MYH2	1061	1061	L -> V.
MYH3	178	178	T -> I (in DA2A and DA2B).
MYH3	261	261	S -> F (in DA2B).
MYH3	292	292	S -> C (in DA2B).
MYH3	375	375	E -> K (in DA2B).
MYH3	498	498	E -> G (in DA2A).
MYH3	517	517	D -> Y (in DA2B).
MYH3	583	583	Y -> S (in DA2A).
MYH3	672	672	R -> C (in DA2A).
MYH3	672	672	R -> H (in DA2A).
MYH3	769	769	G -> V (in DA2B).
MYH3	825	825	V -> D (in DA2A).
MYH3	838	838	K -> E (in DA2B).
MYH3	841	841	Missing (in DA2B).
MYH3	1622	1622	D -> A (in DA2B).
SCO1	174	174	P -> L (in MT-C4D).
ELAC2	211	211	R -> Q (in CaP).
ELAC2	487	487	G -> R (in CaP).
ELAC2	622	622	E -> V (in CaP; in a Finnish family; higher frequency in CaP cases).
ELAC2	627	627	S -> L.
ELAC2	781	781	R -> H (in CaP; in one family with high frequency of CaP; does not affect the enzymatic activity).
ELAC2	806	806	G -> R (in CaP).
PMP22	12	12	H -> Q (in DSS).
PMP22	16	16	L -> P (in CMT1A and DSS).
PMP22	19	19	L -> P (in DSS).
PMP22	22	22	S -> F (in HNPP and CMT1A).
PMP22	23	23	T -> R (in CMT1E).
PMP22	25	26	Missing (in CMT1A).
PMP22	28	28	W -> R (in CMT1E).
PMP22	30	30	V -> M (in HNPP).
PMP22	37	37	D -> V (in CMT1A; with focally folded myelin sheaths).
PMP22	65	65	V -> F (in CMT1A).
PMP22	67	67	A -> P (in CMT1E).
PMP22	67	67	A -> T (in HNPP).
PMP22	69	69	M -> K (in DSS).
PMP22	71	71	L -> P (in DSS).
PMP22	72	72	S -> L (in DSS and CMT1A).
PMP22	72	72	S -> P (in DSS).
PMP22	72	72	S -> W (in DSS).
PMP22	76	76	S -> I (in DSS).
PMP22	79	79	S -> C (in CMT1A).
PMP22	79	79	S -> P (in DSS).
PMP22	80	80	L -> P (in DSS).
PMP22	80	80	L -> R (in DSS).
PMP22	84	84	Missing (in DSS).
PMP22	93	93	G -> R (in CMT1A).
PMP22	100	100	G -> E (in DSS).
PMP22	100	100	G -> R (in DSS).
PMP22	105	105	L -> R (in CMT1A and DSS).
PMP22	107	107	G -> V (in CMT1A).
PMP22	109	109	C -> R (in DSS).
PMP22	115	118	Missing (in CMT1E).
PMP22	118	118	T -> M (in CMT1A).
PMP22	137	137	I -> V.
PMP22	147	147	L -> R (in CMT1A).
PMP22	149	149	S -> R (in DSS).
PMP22	150	150	G -> C (in DSS).
PMP22	150	150	G -> D (in DSS).
ZNF624	558	558	C -> S (in a colorectal cancer sample; somatic mutation).
TNFRSF13B	56	56	H -> N (found in a renal cell carcinoma sample; somatic mutation).
TNFRSF13B	181	181	A -> G (in CVID2).
TNFRSF13B	202	202	R -> H (in CVID2).
FLCN	79	79	S -> W (in a sporadic colorectal carcinoma; somatic mutation).
FLCN	238	238	A -> V (in a renal cell carcinoma cell line).
FLCN	320	320	R -> Q (in a primary colorectal cancer).
FLCN	392	392	R -> G (in a primary colorectal cancer; somatic mutation).
FLCN	444	444	A -> S (in a primary clear-cell renal cell carcinoma; somatic mutation).
ATPAF2	94	94	W -> R (in MC5DN1).
MYO15A	2111	2111	N -> Y (in DFNB3; family from Bengkala).
MYO15A	2113	2113	I -> F (in DFNB3; Indian family).
MYO15A	2205	2205	T -> I (associated with moderately severe sensorineural hearing loss (DFNB3) in a Smith-Magenis syndrome patient).
MYO15A	2716	2716	Q -> H (in DFNB3).
TOP3A	596	596	C -> Y.
MAPK7	535	535	R -> H.
ALDH3A2	45	45	I -> F (in SLS; severe loss of activity).
ALDH3A2	64	64	V -> D (in SLS; severe loss of activity).
ALDH3A2	106	106	L -> R (in SLS; severe loss of activity).
ALDH3A2	114	114	P -> L (in SLS; severe loss of activity).
ALDH3A2	121	121	P -> L (in SLS; severe loss of activity).
ALDH3A2	184	184	T -> M (in SLS; severe loss of activity).
ALDH3A2	184	184	T -> R (in SLS; severe loss of activity).
ALDH3A2	185	185	G -> A (in SLS; severe loss of activity).
ALDH3A2	214	214	C -> Y (in SLS; 4% of activity).
ALDH3A2	226	226	C -> W (in SLS).
ALDH3A2	228	228	R -> C (in SLS; severe loss of activity).
ALDH3A2	237	237	C -> Y (in SLS; severe loss of activity).
ALDH3A2	245	245	D -> N (in SLS; severe loss of activity; originally thought to be a neutral polymorphism).
ALDH3A2	266	266	K -> N (in SLS; mild reduction of activity; the underlying nucleotide substitution affects transcript stability).
ALDH3A2	279	279	Y -> N (in SLS; severe loss of activity).
ALDH3A2	314	315	AP -> GAKSTVGA (in SLS; 8% of activity).
ALDH3A2	315	315	P -> S (in SLS; common mutation in Europeans; severe loss of enzymatic activity).
ALDH3A2	328	328	M -> I (in SLS).
ALDH3A2	365	365	S -> L (in SLS; severe loss of activity).
ALDH3A2	386	386	N -> S (in SLS).
ALDH3A2	406	406	G -> R (in SLS).
ALDH3A2	411	411	H -> Y (in SLS; severe loss of activity).
ALDH3A2	412	412	G -> R (in SLS).
ALDH3A2	415	415	S -> N (in SLS; severe loss of activity).
ALDH3A2	419	419	F -> S (in SLS; severe loss of activity).
ALDH3A2	423	423	R -> H (in SLS; severe loss of activity).
ALDH3A2	447	447	K -> E (in SLS; severe loss of activity).
ULK2	627	627	G -> E (in a metastatic melanoma sample; somatic mutation).
ULK2	662	662	A -> V (in a metastatic melanoma sample; somatic mutation).
MAP2K3	26	26	R -> T.
MAP2K3	175	175	R -> W (in colon cancer).
MAP2K3	215	215	L -> V (in colon cancer).
KCNJ18	140	140	T -> M (in TTPP2).
KCNJ18	205	205	R -> H (in TTPP2; hypermorphic; longer time required for half-maximal current degradation).
KCNJ18	354	354	T -> M (in TTPP2; small decrease in current density).
KCNJ18	366	366	K -> R (in TTPP2; hypermorphic; longer time required for half-maximal current degradation).
SLC46A1	113	113	R -> C (in HFM; loss-of-function mutation; targeted to the plasma membrane but has significantly impaired folate transport activity).
SLC46A1	113	113	R -> S (in HFM; abolishes folate uptake).
SLC46A1	147	147	G -> R (in HFM; reduces folate uptake to 13% of normal levels).
SLC46A1	318	318	S -> R (in HFM; abolishes folate uptake).
SLC46A1	376	376	R -> W (in HFM; abolishes folate uptake).
SLC46A1	425	425	P -> R (in HFM; reduces folate uptake to 3.5% of normal levels).
FOXN1	283	283	A -> V.
PIGS	159	159	M -> I (in a breast cancer sample; somatic mutation).
SEZ6	300	300	V -> M.
SEZ6	330	330	A -> V.
SEZ6	592	592	V -> A.
SEZ6	736	736	Y -> N.
SEZ6	756	756	L -> V.
SLC6A4	425	425	I -> V (polymorphism linked with susceptibility to obsessive-compulsive disorder; increased serotonin transport capacity).
RNF135	115	115	R -> K.
RNF135	286	286	R -> H (in an individual with overgrowth, learning disability, dysmorphic features).
RNF135	415	415	W -> C.
CCL11	7	7	L -> P (in clone 34).
CCL11	51	51	R -> S (in clone 34).
CCL11	79	79	K -> R (in clone 53).
LIG3	717	717	D -> N (in a colorectal cancer sample; somatic mutation).
NLE1	319	319	Q -> K (in a breast cancer sample; somatic mutation).
UNC45B	496	496	D -> H (in a breast cancer sample; somatic mutation).
PEX12	34	34	R -> S (in PBD-CG3; Zellweger spectrum).
PEX12	178	178	Missing (in PBD-CG3; Zellweger spectrum).
PEX12	349	349	Missing (in PBD-CG3; Zellweger spectrum).
RASL10B	52	52	V -> M (in a breast cancer sample; somatic mutation).
C17orf66	330	330	I -> M (in a breast cancer sample; somatic mutation).
CCL5	24	24	S -> F.
HNF1B	36	36	S -> F (in RCAD; gain-of-function mutation).
HNF1B	61	61	V -> G (in RCAD).
HNF1B	76	76	G -> C (in RCAD).
HNF1B	110	110	V -> G (in RCAD).
HNF1B	112	112	R -> P (in RCAD).
HNF1B	136	136	Q -> E (in RCAD).
HNF1B	148	148	S -> L (in RCAD).
HNF1B	148	148	S -> W (in RCAD).
HNF1B	151	151	S -> P (in RCAD).
HNF1B	153	153	H -> N (in RCAD).
HNF1B	156	156	K -> E (in RCAD; has diminished transcriptional activity by loss of DNA binding activity).
HNF1B	164	164	K -> Q (in RCAD).
HNF1B	165	165	R -> H (in RCAD).
HNF1B	235	235	R -> Q (in RCAD).
HNF1B	241	241	A -> T (in RCAD).
HNF1B	260	260	E -> D (in RCAD; insignificant differences in transactivation ability between wild-type and mutated HNF1B).
HNF1B	276	276	R -> G (in RCAD).
HNF1B	276	276	R -> Q (in RCAD).
HNF1B	285	285	G -> D (in RCAD).
HNF1B	295	295	R -> C (in RCAD).
HNF1B	295	295	R -> H (in RCAD).
HNF1B	295	295	R -> P (in RCAD).
HNF1B	370	370	G -> S (in RCAD).
HNF1B	465	465	S -> R (in NIDDM; 22% reduction in activity).
CACNB1	339	339	P -> L (in a colorectal cancer sample; somatic mutation).
CDK12	912	912	R -> H (in a colorectal adenocarcinoma sample; somatic mutation).
TCAP	13	13	Missing (rare polymorphism; could be asssociated with CMD1N).
TCAP	70	70	R -> W (in CMD1N).
TCAP	87	87	R -> Q (in CMD1N).
TCAP	90	90	P -> L (in CMD1N).
TCAP	132	132	E -> Q (in CMD1N; impairs the interaction with MLP, TTN and MYOZ2).
TCAP	137	137	T -> I (in CMH; augments the ability to imteract with TTN and MYOZ2).
TCAP	153	153	R -> H (in CMH).
GSDMB	245	245	D -> G (in a breast cancer sample; somatic mutation).
CDC6	323	323	T -> R (in MGORS5).
TOP2A	450	450	R -> Q (in teniposide (VM-26) resistant cells).
TOP2A	487	487	R -> K (in amsacrine resistant cells).
TNS4	642	642	R -> C (in a colorectal cancer sample; somatic mutation).
KRT10	126	126	G -> S.
KRT10	150	150	M -> T (in a patient with epidermal nevi hyperkeratotic type due to genetic mosaicism).
KRT10	156	156	R -> C (in BCIE).
KRT10	156	156	R -> P (in BCIE).
KRT10	160	160	Y -> N (in BCIE; severe phenotype).
KRT10	446	446	I -> T (in AEI).
KRT10	487	487	H -> Y.
KRT12	135	135	R -> I (in MECD).
KRT12	399	399	L -> LISNLEAQLL (in MECD).
KRT20	4	4	S -> R (in a colorectal cancer sample; somatic mutation).
KRT20	214	214	G -> C (found in a renal cell carcinoma sample; somatic mutation).
KRTAP1-1	12	58	PSCSTSGTCGSSCCQPSCCETSSCQPRCCETSCCQPSCCQT SFCGFP -> R (in allele KAP1.6).
KRTAP1-1	19	110	Missing (in allele KAP1.7).
KRTAP4-9	66	77	Missing (in allele KAP.9-v1).
KRTAP4-11	44	78	Missing (in allele KAP4.14).
KRTAP4-12	105	144	Missing (in allele KAP4.12-v1).
KRTAP4-6	65	65	C -> CCCPS (in allele KAP4.15).
KRTAP4-5	80	84	Missing (in allele KAP4.5-v1).
KRTAP4-4	40	104	Missing (in allele KAP4.4-v1).
KRTAP4-4	40	99	Missing (in allele KAP4.13).
KRTAP4-3	64	64	C -> CCCLTTCCRTTCCRPSCCISSCCRPSCCISSCCKPS (in allele KAP3-v1).
KRTAP4-3	104	133	Missing (in allele KAP3-v2).
KRTAP4-1	83	101	Missing (in allele KAP4.10).
KRT13	108	108	M -> T (in WSN).
KRT13	111	111	L -> P (in WSN).
KRT13	112	112	N -> S (in WSN).
KRT13	115	115	L -> P (in WSN).
KRT13	119	119	L -> P (in WSN).
KRT9	157	157	M -> R (in EPPK).
KRT9	160	160	L -> V (in EPPK).
KRT9	161	161	N -> H (in EPPK).
KRT9	161	161	N -> I (in EPPK).
KRT9	163	163	R -> P (in EPPK).
KRT9	167	167	Y -> WL (in EPPK).
KRT14	123	123	N -> K (in DM-EBS).
KRT14	125	125	R -> G (in DM-EBS).
KRT14	125	125	R -> S (in DM-EBS).
KRT14	128	128	Missing (in DM-EBS).
KRT14	247	247	A -> D (in K-EBS).
KRT14	272	272	M -> T (in K-EBS).
KRT14	375	375	Missing (in WC-EBS).
KRT14	411	411	Missing (in WC-EBS).
KRT14	415	415	Y -> C (in WC-EBS).
KRT14	415	415	Y -> H (in K-EBS).
KRT14	416	416	R -> P (in DM-EBS).
KRT14	417	417	R -> P (in DM-EBS).
KRT14	419	419	L -> Q (in DM-EBS).
KRT14	422	422	E -> K (in WC-EBS).
KRT16	104	107	Missing (in UPVN; somatic mutation).
KRT16	130	130	Missing (in PC1).
KRT17	88	88	M -> T (in PC2 and SM).
KRT17	92	92	N -> D (in PC2).
KRT17	92	92	N -> H (in SM).
KRT17	92	92	N -> S (in PC2).
KRT17	94	98	Missing (in PC2).
KRT17	94	94	R -> C (in PC2 and SM).
KRT17	94	94	R -> H (in SM).
KRT17	94	94	R -> P (in PC2).
KRT17	95	95	L -> P (in PC2).
KRT17	95	95	L -> Q (in PC2).
KRT17	97	97	Missing (in PC2).
KRT17	98	98	Y -> D (in PC2).
KRT17	99	99	L -> P (in PC2).
KRT17	102	102	V -> M (in PC2).
KRT17	109	109	N -> D (in PC2).
HAP1	437	437	R -> W.
HAP1	441	441	M -> T (may influence the age-at-onset of Huntington disease; decreases binding to mutated HTT; influences HTT degradation).
RAB5C	40	40	R -> H (in a colorectal cancer sample; somatic mutation).
KCNH4	797	797	G -> R (in a colorectal cancer sample; somatic mutation).
HCRT	16	16	L -> R (in NRCLP1; early-onset; impaired trafficking and processing).
PTRF	14	14	P -> T (in a breast cancer sample; somatic mutation).
NAGLU	35	35	L -> F (in MPS3B; no enzyme activity; synthesizes a polypeptide with a molecular size similar to that of the wild-type).
NAGLU	38	38	R -> W (in MPS3B; decreases the enzyme activity markedly).
NAGLU	48	48	F -> C (in MPS3B).
NAGLU	48	48	F -> L (in MPS3B; associated with a partially degraded polypeptide in a 16- hour chase experiment suggesting that L- 48 NAGLU affects the processing and stability of the gene; some L-48 NAGLU is being correctly sorted to the lysosomal compartment).
NAGLU	69	69	G -> S (in MPS3B).
NAGLU	77	77	V -> G (in MPS3B; decreases the enzyme activity markedly).
NAGLU	79	79	G -> C (in MPS3B).
NAGLU	79	79	G -> S (in MPS3B).
NAGLU	82	82	G -> D (in MPS3B; no enzyme activity; synthesizes a polypeptide with a molecular size similar to that of the wild-type).
NAGLU	92	92	Y -> H (in MPS3B).
NAGLU	100	100	H -> R (in MPS3B).
NAGLU	115	115	P -> S (in MPS3B).
NAGLU	130	130	R -> C (in MPS3B; does not yield active enzyme).
NAGLU	140	140	Y -> C (in MPS3B).
NAGLU	142	142	Missing (in MPS3B).
NAGLU	153	153	E -> K (in MPS3B).
NAGLU	154	154	I -> R (in MPS3B; does not yield active enzyme).
NAGLU	156	156	W -> C (in MPS3B; no enzyme activity; synthesizes a polypeptide with a molecular size similar to that of the wild-type).
NAGLU	227	227	H -> P (in MPS3B).
NAGLU	234	234	R -> C (in MPS3B).
NAGLU	241	241	V -> M (in MPS3B).
NAGLU	242	242	L -> P (in MPS3B; no enzyme activity).
NAGLU	243	243	P -> L (in MPS3B).
NAGLU	246	246	A -> P (in MPS3B; produces 12.7% residual enzyme activity).
NAGLU	248	248	H -> R (in MPS3B).
NAGLU	268	268	W -> R (in MPS3B).
NAGLU	277	277	C -> F (in MPS3B).
NAGLU	280	280	L -> P (in MPS3B).
NAGLU	292	292	G -> R (in MPS3B).
NAGLU	309	309	Y -> C (in MPS3B; does not yield active enzyme).
NAGLU	314	314	F -> L (in MPS3B).
NAGLU	334	334	V -> F (in MPS3B).
NAGLU	335	335	Y -> C (in MPS3B; decreases the enzyme activity markedly).
NAGLU	358	358	P -> L (in MPS3B).
NAGLU	410	410	F -> S (in MPS3B).
NAGLU	412	412	G -> E (in MPS3B; does not yield active enzyme).
NAGLU	414	414	H -> R (in MPS3B; no enzyme activity).
NAGLU	437	437	T -> I (in MPS3B).
NAGLU	446	446	E -> K (in MPS3B; no enzyme activity).
NAGLU	452	452	E -> K (in MPS3B).
NAGLU	455	455	Y -> C (in MPS3B).
NAGLU	474	474	W -> G (in MPS3B).
NAGLU	482	482	R -> Q (in MPS3B; no enzyme activity).
NAGLU	482	482	R -> W (in MPS3B).
NAGLU	501	501	V -> G (in MPS3B; no enzyme activity; synthesizes a polypeptide with a molecular size similar to that of the wild-type).
NAGLU	516	516	P -> L (in MPS3B; no enzyme activity).
NAGLU	520	520	R -> W (in MPS3B; no enzyme activity; synthesizes a polypeptide with a molecular size similar to that of the wild-type).
NAGLU	521	521	P -> L (in MPS3B; accounts for approximately 6% of mutations in Australasian patients with MPS3B).
NAGLU	534	534	S -> Y (in MPS3B; no enzyme activity; synthesizes a polypeptide with a molecular size similar to that of the wild-type).
NAGLU	560	560	L -> P (in MPS3B).
NAGLU	561	561	L -> R (in MPS3B).
NAGLU	565	565	R -> P (in MPS3B; does not yield active enzyme).
NAGLU	565	565	R -> Q (in MPS3B).
NAGLU	565	565	R -> W (in MPS3B; accounts for approximately 6% of the mutant alleles in Australasian patients with MPS3B).
NAGLU	591	591	L -> P (in MPS3B).
NAGLU	612	612	S -> G (in MPS3B).
NAGLU	617	617	L -> F (in MPS3B).
NAGLU	643	643	R -> C (in MPS3B; accounts for approximately 20% of MPS3B alleles in a Dutch patient group).
NAGLU	643	643	R -> H (in MPS3B).
NAGLU	649	649	W -> C (in MPS3B; no enzyme activity; synthesizes a polypeptide with a molecular size similar to that of the wild-type).
NAGLU	650	650	G -> E (in MPS3B).
NAGLU	658	658	Y -> F (in MPS3B).
NAGLU	664	664	A -> V (in MPS3B).
NAGLU	674	674	R -> C (in MPS3B).
NAGLU	674	674	R -> H (in MPS3B).
NAGLU	676	676	R -> P (in MPS3B).
NAGLU	682	682	L -> R (in MPS3B).
NAGLU	705	705	E -> K (in MPS3B).
HSD17B1	238	238	A -> V.
WNK4	434	434	E -> D (in an ovarian mucinous carcinoma sample; somatic mutation).
WNK4	562	562	E -> K (in PHAII).
WNK4	564	564	D -> A (in PHAII).
WNK4	565	565	Q -> E (in PHAII).
WNK4	813	813	P -> L.
WNK4	992	992	P -> S (in a metastatic melanoma sample; somatic mutation).
WNK4	1013	1013	L -> P.
WNK4	1185	1185	R -> C (in PHAII).
BECN1	103	103	A -> V.
BECN1	403	403	I -> T.
G6PC	5	5	M -> R (in GSD1A).
G6PC	16	16	T -> A (in GSD1A).
G6PC	16	16	T -> R (in GSD1A; complete loss of activity and reduced enzyme stability).
G6PC	20	20	Q -> R (in GSD1A).
G6PC	38	38	D -> V (in GSD1A).
G6PC	54	54	Q -> P (in GSD1A).
G6PC	63	63	W -> R (in GSD1A).
G6PC	65	65	A -> P (in GSD1A).
G6PC	68	68	G -> R (in GSD1A).
G6PC	76	76	K -> N (in GSD1A; loss of catalytic activity).
G6PC	77	77	W -> R (in GSD1A).
G6PC	81	81	G -> R (in GSD1A).
G6PC	83	83	R -> I (in GSD1A).
G6PC	108	108	T -> I (in GSD1A).
G6PC	110	110	E -> K (in GSD1A).
G6PC	111	111	T -> I (in GSD1A).
G6PC	113	113	P -> L (in GSD1A).
G6PC	116	116	P -> L (in a breast cancer sample; somatic mutation).
G6PC	119	119	H -> L (in GSD1A).
G6PC	122	122	G -> D (in GSD1A).
G6PC	124	124	A -> T (in GSD1A).
G6PC	156	156	W -> L (in GSD1A).
G6PC	166	166	V -> A (in GSD1A).
G6PC	166	166	V -> G (in GSD1A; complete loss of activity).
G6PC	170	170	R -> Q (in GSD1A; loss of catalytic activity).
G6PC	177	177	F -> C (in GSD1A).
G6PC	178	178	P -> A (in GSD1A).
G6PC	178	178	P -> S (in GSD1A).
G6PC	179	179	H -> P (in GSD1A).
G6PC	184	184	G -> E (in GSD1A).
G6PC	184	184	G -> V (in GSD1A).
G6PC	188	188	G -> D (in GSD1A).
G6PC	188	188	G -> R (in GSD1A; complete loss of activity).
G6PC	188	188	G -> S (in GSD1A).
G6PC	209	209	Y -> C (in GSD1A; complete loss of activity and reduced enzyme stability).
G6PC	211	211	L -> P (in GSD1A).
G6PC	222	222	G -> R (in GSD1A).
G6PC	236	236	W -> R (in GSD1A).
G6PC	241	241	A -> T (in GSD1A).
G6PC	255	255	T -> I (in GSD1A).
G6PC	257	257	P -> L (in GSD1A).
G6PC	264	264	N -> K (in GSD1A).
G6PC	265	265	L -> P (in GSD1A).
G6PC	266	266	G -> V (in GSD1A).
G6PC	270	270	G -> R (in GSD1A).
G6PC	270	270	G -> V (in GSD1A).
G6PC	270	270	G -> W (in GSD1A).
G6PC	295	295	R -> C (in GSD1A).
G6PC	298	298	S -> P (in GSD1A).
G6PC	322	322	F -> L (in GSD1A).
G6PC	327	327	Missing (in GSD1A).
G6PC	338	338	V -> F (in GSD1A).
G6PC	341	341	I -> N (in GSD1A).
G6PC	345	345	L -> R (in GSD1A).
SOST	21	21	V -> L (in CDD; affects protein secretion).
SOST	21	21	V -> M (in CDD; de novo mutation; affects protein secretion).
SOST	167	167	C -> R (in SOST; leads to retention of the mutant protein in the endoplasmic reticulum; leads to a complete loss of function of the protein).
NAGS	200	200	C -> R (in NAGSD; markedly decreases activity).
NAGS	279	279	A -> P (in NAGSD).
NAGS	410	410	S -> P (in NAGSD; markedly decreases activity).
NAGS	430	430	L -> P (in NAGSD; markedly decreases activity).
NAGS	484	484	W -> R (in NAGSD; markedly decreases activity).
NAGS	518	518	A -> T (in NAGSD; markedly decreases activity).
G6PC3	116	116	M -> K (in SCN4; the patient also carries mutation Thr-166 in ELANE).
G6PC3	116	116	M -> V (in DURSS).
G6PC3	185	185	L -> P (in SCN4).
G6PC3	189	189	R -> Q (in SCN4).
G6PC3	253	253	R -> H (in SCN4; the mutant protein has no phosphatase activity in vitro; electron microscopic studies show enlarged rough endoplasmic reticulum consistent with increased stress).
G6PC3	260	260	G -> R (in SCN4; loss of function).
G6PC3	262	262	G -> R (in SCN4).
ASB16	173	173	T -> P (found in a clear cell renal carcinoma case; somatic mutation).
GRN	9	9	A -> D (in UP-FTD; no significant difference in the total mRNA between cases and controls; although the mutant protein is expressed it is not secreted and appears to be trapped within an intracellular compartment).
GRN	19	19	R -> W.
GRN	55	55	R -> W.
GRN	69	69	A -> T.
GRN	119	119	Missing.
GRN	120	120	S -> Y.
GRN	182	182	T -> M.
GRN	221	221	C -> S.
GRN	275	275	P -> L.
GRN	376	376	D -> N.
GRN	398	398	S -> L.
GRN	433	433	R -> Q.
GRN	564	564	R -> H.
ITGA2B	86	86	L -> P (in GT; cells co-transfected with mutated alpha-IIb and wild-type beta-3 scarcely expressed the alpha-IIb/beta-3 complex).
ITGA2B	139	139	A -> V (in GT).
ITGA2B	161	161	C -> W (in GT).
ITGA2B	174	174	Y -> H (in GT; abolishes the binding function of alpha-IIb/beta-3 for soluble ligands without disturbing alpha-IIb/ beta-3 expression; functional defect is likely caused by its allosteric effect rather than by a defect in the ligand- binding site itself).
ITGA2B	176	176	P -> A (in GT; impairs surface expression of alpha-IIb/beta-3 and abrogates ligand binding to the activated integrin).
ITGA2B	176	176	P -> L (in GT; impairs surface expression of alpha-IIb/beta-3).
ITGA2B	202	202	F -> C (in GT; associated with abrogation of alpha-IIb/beta-3 complex formation).
ITGA2B	207	207	T -> I (in GT).
ITGA2B	214	214	L -> P (in GT; disrupts the structural conformation and the ligand binding properties of the heterodimeric complex; in addition the mutation appears to confer susceptibility to proteolysis).
ITGA2B	222	222	F -> L (in GT).
ITGA2B	267	267	G -> E (in GT).
ITGA2B	273	273	G -> D (in GT; alters the heterodimer conformation thus impairing their intracellular transport).
ITGA2B	320	320	F -> S (in GT; type I; impairs surface expression of alpha-IIb/beta-3).
ITGA2B	329	329	V -> F (in GT; expression of mutant subunit alpha-IIb/bet-3 is 28% of control; mutant pro-alpha-IIb subunit is retained in the endoplasmic reticulum).
ITGA2B	355	355	E -> K (in GT; type I; impairs surface expression of alpha-IIb/beta-3).
ITGA2B	358	358	R -> H (in GT; type II).
ITGA2B	380	380	G -> D (in GT).
ITGA2B	405	405	I -> T (in GT; expression of mutant subunit alpha-IIb/bet-3 is 11% of control; mutant pro-alpha-IIb subunit is retained in the endoplasmic reticulum).
ITGA2B	412	412	G -> R (in GT).
ITGA2B	449	449	G -> D (in GT; type I).
ITGA2B	456	457	Missing (in GT; alteres the conformation of heterodimers such that they were neither recognized by the heterodimer- specific antibody A2A9 nor able to undergo further intracellular processing or transport to the cell surface).
ITGA2B	581	581	A -> D (in GT).
ITGA2B	596	596	I -> T (in GT; type I).
ITGA2B	705	705	C -> R (in GT; type II; the rate of subunit maturation and the surface exposure of ghlycoprotein IIb/beta-3 are strongly reduced).
ITGA2B	752	752	L -> V (in GT).
ITGA2B	755	755	R -> P (in GT).
ITGA2B	778	778	Q -> P (in GT; type II).
ITGA2B	847	847	L -> P (in GT).
ITGA2B	943	943	P -> L (in GT; marked reduction in the rate of surface expression).
ITGA2B	982	982	V -> M (in GT; much reduced surface expression of alpha-IIb/beta-3 and a block in the maturation of pro-alpha- IIb).
ITGA2B	989	989	A -> T.
ITGA2B	1026	1026	R -> Q (in GT).
ADAM11	693	693	S -> R (in a pancreatic ductal adenocarcinoma sample; somatic mutation).
SPPL2C	626	626	M -> V.
STH	7	7	Q -> R.
ARL17A	170	170	L -> I.
PNPO	50	50	E -> K.
PNPO	229	229	R -> W (in PNPO deficiency; strong activity decrease).
HOXB1	27	27	A -> AHSA (in allele HOXB1*B).
HOXB13	41	41	T -> M.
B4GALNT2	459	459	P -> H (in a colorectal cancer sample; somatic mutation).
PHB	88	88	V -> A (in a breast cancer sample; somatic mutation).
PHB	105	105	R -> H (in a breast cancer sample; somatic mutation).
SGCA	30	30	P -> L (in LGMD2D).
SGCA	31	31	L -> P (in LGMD2D).
SGCA	34	34	R -> C (in LGMD2D).
SGCA	34	34	R -> H (in LGMD2D).
SGCA	62	62	Y -> H (in LGMD2D).
SGCA	68	68	G -> E (in LGMD2D).
SGCA	74	74	R -> W (in LGMD2D).
SGCA	89	89	L -> P (in LGMD2D).
SGCA	91	91	G -> R (in LGMD2D).
SGCA	93	93	A -> V (in LGMD2D).
SGCA	97	97	D -> G (in LGMD2D).
SGCA	98	98	R -> C (in LGMD2D).
SGCA	98	98	R -> H (in LGMD2D).
SGCA	103	103	I -> T (in LGMD2D).
SGCA	124	124	I -> T (in LGMD2D).
SGCA	136	136	A -> APGAQP (in LGMD2D; associated with G-137).
SGCA	137	137	E -> K (in LGMD2D).
SGCA	158	158	L -> F (in LGMD2D).
SGCA	173	173	L -> P (in LGMD2D).
SGCA	175	175	V -> A (in LGMD2D).
SGCA	196	196	V -> I (in LGMD2D).
SGCA	205	205	P -> H (in LGMD2D).
SGCA	228	228	P -> Q (in LGMD2D).
SGCA	242	242	V -> A (in LGMD2D).
SGCA	247	247	V -> M (in LGMD2D).
SGCA	284	284	R -> C (in LGMD2D).
COL1A1	22	22	G -> R (in OI2A).
COL1A1	146	146	P -> T (in a patient with osteogenesis imperfecta type 2; rare variant of unknown pathological significance).
COL1A1	194	194	G -> R (in OI1).
COL1A1	197	197	G -> R (in OI4).
COL1A1	200	200	G -> V (in OI1; patient diagnosed with OI1/OI4).
COL1A1	203	203	G -> V (in OI3).
COL1A1	205	205	P -> A.
COL1A1	221	221	G -> C (in OI1; mild form).
COL1A1	224	224	G -> C (in OI1; mild phenotype).
COL1A1	242	242	G -> D (in OI).
COL1A1	257	257	G -> R (in OI4).
COL1A1	263	263	G -> R (in OI1; mild form).
COL1A1	263	263	G -> V (in OI1; mild form).
COL1A1	266	266	G -> E (in OI1).
COL1A1	272	272	G -> C (in OI1).
COL1A1	275	275	G -> D (in OI2A).
COL1A1	287	287	G -> S (in OI1).
COL1A1	288	288	E -> K (in a patient with osteogenesis imperfecta type 1 carrying also mutation Glu-1219; unknown pathological significance).
COL1A1	288	288	E -> V (in a patient with osteogenesis imperfecta type 2; rare variant of unknown pathological significance).
COL1A1	312	312	R -> C (in EDS1).
COL1A1	320	320	G -> V (in OI1).
COL1A1	332	332	G -> R (in OI3; mild to moderate form).
COL1A1	338	338	G -> C (in OI4).
COL1A1	349	349	V -> F (in OI1).
COL1A1	350	350	G -> R (in OI3).
COL1A1	353	353	G -> C (in OI4).
COL1A1	353	353	G -> D (in OI2A).
COL1A1	353	353	G -> S (in OI4).
COL1A1	356	356	G -> C (in OI4; mild form).
COL1A1	368	368	G -> V (in OI2A).
COL1A1	383	383	G -> C (in OI4).
COL1A1	389	389	G -> C (in OI; moderate form).
COL1A1	389	389	G -> R (in OI2A).
COL1A1	390	390	A -> T (in a patient with osteogenesis imperfecta type 2; rare variant of unknown pathological significance).
COL1A1	398	398	G -> A (in OI4).
COL1A1	398	398	G -> D (in OI2A).
COL1A1	401	401	G -> C (in OI4).
COL1A1	404	404	G -> C (in OI; moderate form).
COL1A1	422	422	G -> C (in OI2A).
COL1A1	425	425	G -> S (in OI2A; lethal form).
COL1A1	434	434	G -> V (in OI2A).
COL1A1	455	455	G -> D (in OI2A).
COL1A1	470	470	G -> V (in OI2A).
COL1A1	509	509	G -> V (in OI2A).
COL1A1	527	527	G -> C (in OI4).
COL1A1	530	530	G -> S (in OI2A, OI3 and OI4; mild to lethal form).
COL1A1	533	533	G -> D (in OI2A).
COL1A1	548	548	G -> A (in OI2A).
COL1A1	555	555	P -> R (in OI1).
COL1A1	560	560	G -> C (in OI4).
COL1A1	560	560	G -> R (in OI2A).
COL1A1	560	560	G -> S (in OI4).
COL1A1	569	569	G -> R (in OI2A).
COL1A1	574	574	R -> C (in a patient with isolated osteopenia and vascular rupture).
COL1A1	581	581	G -> R (in OI2A).
COL1A1	593	593	G -> C (in OI3 and OI4).
COL1A1	593	593	G -> S (in OI2A and OI3; moderate to lethal form).
COL1A1	602	602	G -> R (in OI2A).
COL1A1	605	605	G -> D (in OI2A).
COL1A1	614	614	G -> R (in OI2A).
COL1A1	647	647	G -> S (in OI1).
COL1A1	656	656	G -> S (in OI2A).
COL1A1	683	683	G -> S (in OI4).
COL1A1	701	701	G -> C (in OI4).
COL1A1	704	704	G -> C (in OI3).
COL1A1	719	719	G -> D (in OI2A).
COL1A1	719	719	G -> S (in OI3).
COL1A1	722	722	G -> S (in OI1).
COL1A1	728	728	G -> R (in OI2A).
COL1A1	734	734	G -> V (in OI2A).
COL1A1	737	737	G -> D (in OI2A).
COL1A1	740	740	G -> R (in OI2A).
COL1A1	743	743	G -> S (in OI2A).
COL1A1	743	743	G -> V (in OI2A).
COL1A1	764	764	G -> V (in OI2A).
COL1A1	767	767	G -> S (in OI3; severe).
COL1A1	776	776	G -> S (in OI2A).
COL1A1	809	809	G -> S (in OI2A).
COL1A1	815	815	G -> V (in OI2A).
COL1A1	821	821	G -> S (in OI3).
COL1A1	824	824	G -> R (in OI2A).
COL1A1	833	833	G -> D (in OI2A).
COL1A1	839	839	G -> S (in OI2A; mild to moderate form).
COL1A1	842	842	G -> R (in OI2A).
COL1A1	845	845	G -> R (in OI2A).
COL1A1	848	848	G -> R (in OI2A).
COL1A1	851	851	G -> D (in OI2A).
COL1A1	855	855	N -> H (in a patient with osteogenesis imperfecta type 2; rare variant of unknown pathological significance).
COL1A1	866	866	G -> S (in OI3 and OI2A).
COL1A1	869	869	G -> C (in OI2A).
COL1A1	875	875	G -> S (in OI2A).
COL1A1	884	884	G -> S (in OI2A and OI3; extremely severe form).
COL1A1	896	896	G -> C (in OI2A).
COL1A1	896	896	G -> D (in OI2A).
COL1A1	906	906	G -> S (in a patient with mild osteogenesis imperfecta; uncertain pathological significance).
COL1A1	926	926	G -> C (in OI2A).
COL1A1	947	947	G -> C (in OI2A).
COL1A1	977	977	G -> D (in OI2A).
COL1A1	980	980	G -> V (in OI2A).
COL1A1	1001	1001	G -> C (in OI2A).
COL1A1	1010	1010	G -> S (in OI4).
COL1A1	1014	1014	R -> C (in CAFFD).
COL1A1	1022	1022	G -> S (in OI3; severe form).
COL1A1	1022	1022	G -> V (in OI2A).
COL1A1	1025	1025	G -> R (in OI2A).
COL1A1	1040	1040	G -> S (in OI2A and OI3; moderate to lethal form).
COL1A1	1043	1043	G -> S (in OI2A).
COL1A1	1046	1048	Missing (in OI2A).
COL1A1	1049	1049	G -> S (in OI3).
COL1A1	1052	1052	G -> GAPG (in OI2A).
COL1A1	1055	1055	G -> D (in OI2A).
COL1A1	1058	1058	G -> S (in OI3 and OI4; mild form).
COL1A1	1061	1061	G -> D (in OI2A).
COL1A1	1061	1061	G -> S (in OI4).
COL1A1	1066	1066	R -> C (in a patient with overlapping features of osteogenesis imperfecta and Ehlers-Danlos syndrome; pathogenic mutation; affects dimer formation, helix stability and organization of collagen fibrils).
COL1A1	1076	1076	G -> S (in OI3; severe form).
COL1A1	1079	1079	G -> S (in OI1 and OI2A; mild to moderate form).
COL1A1	1082	1082	G -> C (in OI2A).
COL1A1	1088	1088	G -> A (in OI2A).
COL1A1	1091	1091	G -> S (in OI2A).
COL1A1	1093	1093	R -> C (in a patient with isolated osteopenia and vascular rupture).
COL1A1	1094	1094	G -> S (in OI2A).
COL1A1	1100	1100	G -> D (in OI2A).
COL1A1	1106	1106	G -> A (in OI2A).
COL1A1	1124	1124	G -> C (in OI2A).
COL1A1	1142	1142	G -> S (in OI2A).
COL1A1	1151	1151	G -> S (in OI3).
COL1A1	1151	1151	G -> V (in OI2A).
COL1A1	1154	1154	G -> R (in OI2A).
COL1A1	1157	1157	G -> D (in OI1).
COL1A1	1166	1166	G -> C (in OI2A).
COL1A1	1172	1172	G -> D (in OI2A).
COL1A1	1181	1181	G -> S (in OI2A).
COL1A1	1184	1184	G -> V (in OI2A).
COL1A1	1187	1187	G -> S (in OI2A and OI3; extremely severe form).
COL1A1	1187	1187	G -> V (in OI2A).
COL1A1	1195	1195	G -> C (in OI1; mild form).
COL1A1	1219	1219	D -> E (in OI1).
COL1A1	1277	1277	D -> H (in OI2A; impaired pro-alpha chain association).
COL1A1	1312	1312	W -> C (in OI2A).
COL1A1	1337	1338	Missing (in OI2A; impaired pro-alpha chain association).
COL1A1	1356	1356	R -> H.
COL1A1	1388	1388	L -> R (in OI2A; impaired pro-alpha chain association).
COL1A1	1413	1413	D -> N (in OI2A).
COL1A1	1464	1464	L -> P (in OI3).
NOG	35	35	P -> A (in BDB2).
NOG	35	35	P -> R (in SYM1 and TCC).
NOG	36	36	A -> P (in BDB2).
NOG	48	48	E -> K (in BDB2).
NOG	167	167	R -> G (in BDB2).
NOG	184	184	C -> Y (in SYM1; sporadic; de novo mutation).
NOG	187	187	P -> S (in BDB2).
NOG	189	189	G -> C (in SYM1).
NOG	204	204	R -> L (in TCC).
NOG	205	205	W -> C (in SYM1).
NOG	217	217	W -> G (in SYNS1).
NOG	220	220	I -> N (in SYM1).
NOG	222	222	Y -> C (in SYM1 and TCC).
NOG	222	222	Y -> D (in SYM1).
NOG	223	223	P -> L (in SYM1).
NOG	232	232	C -> W (in SYNS1).
SRSF1	89	89	P -> S (in a breast cancer sample; somatic mutation).
EPX	286	286	R -> H (in EPD).
EPX	326	326	R -> H.
EPX	326	326	R -> L.
MKS1	123	123	R -> Q.
MKS1	166	166	R -> W (in MKS1; uncertain pathogenicity).
MKS1	286	286	D -> G.
MKS1	371	371	Missing (in BBS13).
MKS1	450	450	I -> T.
MKS1	492	492	C -> W (in BBS13).
MPO	173	173	Y -> C (in MPD; affects proteolytic processing and secretion).
MPO	447	447	R -> Q (in a colorectal cancer sample; somatic mutation).
MPO	569	569	R -> W (in MPD; suppress post- translational processing).
RAD51C	3	3	G -> R.
RAD51C	125	125	G -> V (in BROVCA3).
RAD51C	126	126	A -> T.
RAD51C	138	138	L -> F (in BROVCA3).
RAD51C	159	159	D -> N.
RAD51C	169	169	V -> A.
RAD51C	258	258	R -> H (in FANCO; possibly hypomorphic allele).
RAD51C	264	264	G -> S.
RAD51C	264	264	G -> V.
RAD51C	366	366	R -> Q.
RPS6KB1	225	225	M -> I.
RPS6KB1	272	272	R -> C.
RPS6KB1	276	276	W -> C.
RPS6KB1	289	289	G -> E (in a colorectal cancer sample; somatic mutation).
RPS6KB1	398	398	S -> A.
CA4	14	14	R -> W (in RP17; abolishes interaction with SLC4A4. Impaired SLC4A4 cotransporter activity stimulation).
CA4	219	219	R -> S (in RP17; no catalytic activity. Impaired SLC4A4 cotransporter activity stimulation).
TBX4	35	35	A -> V.
ACE	1228	1228	P -> L (no effect on activity; increases secretion; rate of solubilization is 2.5- fold higher than wild-type).
PSMC5	60	60	R -> Q (in a colorectal cancer sample; somatic mutation).
CSH2	104	105	IS -> L (in CSH2).
CSH1	104	105	IS -> L (in CSH2).
GH1	16	16	L -> P (in IGHD1B; suppresses secretion).
GH1	37	37	D -> N (in IGHD1B).
GH1	42	42	R -> C (in IGHD1B; reduced secretion).
GH1	53	53	T -> I (in IGHD1B; reduced ability to activate the JAK/STAT pathway).
GH1	67	67	K -> R (in IGHD1B; reduced ability to activate the JAK/STAT pathway).
GH1	73	73	N -> D (in IGHD1B; reduced ability to activate the JAK/STAT pathway).
GH1	79	79	C -> S (in short stature; idiopathic autosomal; affects binding affinity of GH for GHR and the potency of GH to activate the JAK2/STAT5 signaling pathway).
GH1	97	97	S -> F (in IGHD1B; reduced ability to activate the JAK/STAT pathway).
GH1	100	100	E -> K (in IGHD1B).
GH1	103	103	R -> C (in KWKS; loss of activity; no difference in the binding affinity or bioactivity between wild-type and mutant; no difference found in the extent of subcellular localization within endoplasmic reticulum Golgi or secretory vesicles between wild-type and mutant; reduced capability of the mutant to induce GHR/GHBP gene transcription rate when compared to wild-type).
GH1	117	117	Q -> L (in IGHD1B; reduced secretion).
GH1	134	134	S -> C (in IGHD1B).
GH1	134	134	S -> R (in IGHD1B; reduced ability to activate the JAK/STAT pathway).
GH1	138	138	D -> G (in KWKS; loss of activity).
GH1	201	201	T -> A (in IGHD1B; reduced ability to activate the JAK/STAT pathway).
GH1	205	205	I -> M (in short stature; idiopathic autosomal).
GH1	209	209	R -> H (in IGHD2).
CD79B	137	137	G -> S (in AGM6).
SCN4A	135	135	M -> V.
SCN4A	141	141	I -> V (in MYOSCN4A; causes a hyperpolarizing shift of the activation curve; enhances channel slow inactivation).
SCN4A	222	222	R -> W (in HOKPP2).
SCN4A	225	225	R -> W (in MYOSCN4A).
SCN4A	246	246	S -> L.
SCN4A	270	270	Q -> K (in PMC).
SCN4A	445	445	V -> M (in MYOSCN4A).
SCN4A	452	452	E -> K (in MYOSCN4A; variable phenotype ranging from mild to severe myotonia).
SCN4A	669	669	R -> H (in HOKPP2).
SCN4A	671	671	F -> S (in MYOSCN4A).
SCN4A	672	672	R -> C (in HOKPP2).
SCN4A	672	672	R -> G (in HOKPP2).
SCN4A	672	672	R -> H (in HOKPP2).
SCN4A	672	672	R -> S (in HOKPP2).
SCN4A	675	675	R -> G (in NKPP).
SCN4A	675	675	R -> Q (in NKPP).
SCN4A	675	675	R -> W (in NKPP).
SCN4A	693	693	I -> T (in PMC).
SCN4A	704	704	T -> M (in HYPP and PMC).
SCN4A	715	715	A -> T (in MYOSCN4A).
SCN4A	781	781	V -> I (in HYPP and NKPP).
SCN4A	804	804	S -> F (in PMC).
SCN4A	804	804	S -> N (in MYOSCN4A).
SCN4A	861	861	A -> D.
SCN4A	1129	1129	R -> Q (in NKPP and HOKPP2; detected in a family where three affected members manifested hypokalemic periodic paralysis whereas five other patients had normokalemic periodic paralysis).
SCN4A	1132	1132	R -> Q (in HOKPP2).
SCN4A	1135	1135	R -> H (in HOKPP2).
SCN4A	1152	1152	A -> D (in PMC).
SCN4A	1156	1156	A -> T (in PMC, MYOSCN4A and HYPP).
SCN4A	1158	1158	P -> S (in HOKPP2).
SCN4A	1160	1160	I -> V (in MYOSCN4A; acetazolamide- responsive myotonia).
SCN4A	1293	1293	V -> I (in PMC; without cold paralysis).
SCN4A	1297	1297	N -> K (in MYOSCN4A; unusually severe and lethal phenotype with neonatal onset).
SCN4A	1306	1306	G -> A (in PMC).
SCN4A	1306	1306	G -> E (in MYOSCN4A and PMC; severe).
SCN4A	1306	1306	G -> V (in MYOSCN4A and PMC).
SCN4A	1310	1310	I -> N (in MYOSCN4A).
SCN4A	1313	1313	T -> M (in PMC).
SCN4A	1433	1433	L -> R (in PMC and HYPP).
SCN4A	1436	1436	L -> P (in PMC).
SCN4A	1442	1442	V -> E (in CMS-SCNA4).
SCN4A	1448	1448	R -> C (in PMC).
SCN4A	1448	1448	R -> H (in PMC).
SCN4A	1448	1448	R -> L (in PMC).
SCN4A	1456	1456	G -> E (in PMC).
SCN4A	1473	1473	F -> S (in PMC; accelerates deactivation from the inactivated state and enhances the remobilization of gating charge).
SCN4A	1476	1476	M -> I (in MYOSCN4A; highly variable severity).
SCN4A	1481	1481	A -> D (in MYOSCN4A; fluctuating cold- induced and exercise-induced stiffness).
SCN4A	1589	1589	V -> M (in PMC).
SCN4A	1592	1592	M -> V (in HYPP and NKPP).
SCN4A	1705	1705	F -> I (in PMC; increases the extent of charge immobilization in response to strong depolarization).
POLG2	451	451	G -> E (in PEOA4; affects stimulation of the catalytic subunit).
PRKAR1A	9	9	S -> N (in CNC1; exhibits increased PKA activity which is attributed to decreased binding to cAMP and/or the catalytic subunit).
PRKAR1A	74	74	R -> C (in CNC1; exhibits increased PKA activity which is attributed to decreased binding to cAMP and/or the catalytic subunit).
PRKAR1A	146	146	R -> S (in CNC1; exhibits increased PKA activity which is attributed to decreased binding to cAMP and/or the catalytic subunit).
PRKAR1A	183	183	D -> Y (in CNC1; exhibits increased PKA activity which is attributed to decreased binding to cAMP and/or the catalytic subunit).
PRKAR1A	213	213	A -> D (in CNC1; exhibits increased PKA activity which is attributed to decreased binding to cAMP and/or the catalytic subunit).
PRKAR1A	289	289	G -> W (in CNC1; exhibits increased PKA activity which is attributed to decreased binding to cAMP and/or the catalytic subunit).
KCNJ2	67	67	R -> W (in LQT7).
KCNJ2	71	71	D -> V (in LQT7; loss of function and dominant-negative effect in current).
KCNJ2	95	98	Missing (in LQT7).
KCNJ2	172	172	D -> N (in SQT3; gain of function).
KCNJ2	186	186	P -> L (in LQT7).
KCNJ2	216	216	N -> H (in LQT7).
KCNJ2	218	218	R -> W (in LQT7; loss of function and dominant-negative effect in current).
KCNJ2	300	300	G -> V (in LQT7).
KCNJ2	302	302	V -> M (in LQT7).
KCNJ2	314	315	Missing (in LQT7).
SOX9	76	76	A -> E (in CMD1; dimerization and the resulting capacity to activate promoters via dimeric binding sites is lost; other features of the protein function remain unaltered).
SOX9	108	108	P -> L (in CMD1).
SOX9	112	112	F -> L (in CMD1; loss of DNA binding).
SOX9	112	112	F -> S (in CMD1).
SOX9	113	113	M -> T (in CMD1).
SOX9	113	113	M -> V (in CMD1; residual DNA binding and transactivation of regulated genes).
SOX9	119	119	A -> V (in CMD1; almost no loss of DNA binding).
SOX9	143	143	W -> R (in CMD1).
SOX9	152	152	R -> P (in CMD1).
SOX9	154	154	F -> L (in CMD1; 5% of wild-type DNA binding actvity; transcriptional activation is only reduced to 26% of wild-type activity).
SOX9	158	158	A -> T (in CMD1; 17% of wild-type DNA binding activity; shows a 2-fold reduction in nuclear import efficiency; transcriptional activation is only reduced to 62% of wild-type activity).
SOX9	165	165	H -> Q (in CMD1; residual DNA binding and transactivation of regulated genes).
SOX9	170	170	P -> L (in CMD1).
SOX9	170	170	P -> R (in CMD1).
SOX9	173	173	K -> E (in CMD1).
SOX9	354	356	Missing (in CMD1).
USH1G	48	48	L -> P (in USH1G).
USH1G	458	458	D -> V (in USH1G; atypical form with mild retinitis pigmentosa and normal vestibular function; also found in patients with autosomal recessive non- syndromic deafness).
OTOP2	392	392	A -> V (in a colorectal cancer sample; somatic mutation).
GGA3	574	574	P -> L (in a breast cancer sample; somatic mutation).
TSEN54	93	93	S -> P (in PCH4; associated with S-307 on the other allele).
TSEN54	307	307	A -> S (in PCH2A and PCH4; associated with P-93 on the other allele).
ITGB4	38	38	C -> R (in EB-PA; mild form).
ITGB4	61	61	C -> Y (in EB-PA; lethal form).
ITGB4	98	98	R -> H.
ITGB4	131	131	D -> Y (in EB-PA; lethal form).
ITGB4	156	156	L -> P (in EB-PA; mild form).
ITGB4	245	245	C -> G (in EB-PA; lethal form).
ITGB4	252	252	R -> C (in EB-PA; mild form).
ITGB4	273	273	G -> D (in EB-PA; lethal form).
ITGB4	283	283	R -> C (in EB-PA).
ITGB4	325	325	V -> D (in EB-PA).
ITGB4	336	336	L -> P (in EB-PA; mild form).
ITGB4	562	562	C -> R (in EB-PA; mild form).
ITGB4	844	844	R -> L.
ITGB4	931	931	G -> D (in GABEB).
ITGB4	1216	1216	H -> Q.
ITGB4	1225	1225	R -> H (in EB-PA; mild form).
ITGB4	1281	1281	R -> W (in EB-PA; mild form; abolishes interaction with PLEC and reduces interaction with COL17A1).
GALK1	28	28	P -> T (in GALCT2; founder Romani mutation).
GALK1	32	32	V -> M (in GALCT2).
GALK1	36	36	G -> R (in GALCT2).
GALK1	44	44	H -> Y (in GALCT2).
GALK1	68	68	R -> C (in GALCT2).
GALK1	184	184	I -> M.
GALK1	198	198	A -> V (in GALCT2; mild deficiency; Osaka).
GALK1	239	239	R -> Q (in GALCT2).
GALK1	274	274	G -> D.
GALK1	288	288	T -> M (in GALCT2).
GALK1	338	338	V -> A.
GALK1	346	346	G -> S (in GALCT2).
GALK1	349	349	G -> S (in GALCT2).
GALK1	384	384	A -> P (in GALCT2).
ACOX1	178	178	G -> C (in pseudo-NALD).
ACOX1	278	278	M -> V (in pseudo-NALD).
CDK3	106	106	S -> N (in a glioblastoma multiforme sample; somatic mutation).
PRCD	2	2	C -> Y (in RP36).
PRCD	17	17	R -> C.
PRCD	30	30	V -> M (in RP36; may be a common polymorphism).
CANT1	299	299	P -> L (in DBQD).
CANT1	300	300	R -> C (in DBQD).
CANT1	300	300	R -> H (in DBQD).
GAA	103	103	C -> G (in GSD2; infantile form; severe; loss of activity; shows enzyme localization primarily in the ER-Golgi compartment suggesting that mutation could affect the normal processing and stability of the enzyme).
GAA	191	191	Y -> C (in GSD2; extremely low residual enzymatic activity).
GAA	208	208	L -> P (in GSD2).
GAA	219	219	G -> R (in GSD2; infantile form; severe; loss of activity).
GAA	224	224	R -> W (in GSD2; infantile; mild partial loss of activity).
GAA	237	237	A -> V (in GSD2).
GAA	262	262	E -> K (in GSD2; infantile; severe).
GAA	285	285	P -> R (in GSD2; juvenile form; mild; partial loss of activity).
GAA	292	292	Y -> C (in GSD2; juvenile form; mild; partial loss of activity).
GAA	293	293	G -> R (in GSD2; infantile form; severe; almost complete loss of activity).
GAA	299	299	L -> R (in GSD2; infantile form).
GAA	308	308	H -> L (in GSD2).
GAA	308	308	H -> P (in GSD2; infantile form; severe; complete loss of activity).
GAA	309	309	G -> R (in GSD2; severe).
GAA	312	312	L -> R (in GSD2; infantile form; severe; loss of activity).
GAA	318	318	M -> T (in GSD2; severe).
GAA	324	324	P -> L (in GSD2).
GAA	330	330	W -> G (in GSD2; infantile form; severe).
GAA	355	355	L -> P (in GSD2; infantile form; severe; loss of activity).
GAA	361	361	P -> L (in GSD2; juvenile form; severe).
GAA	374	374	C -> R (in GSD2; infantile form; severe; loss of activity).
GAA	375	375	R -> L (in GSD2; extremely low residual enzymatic activity).
GAA	377	377	G -> R (in GSD2; severe).
GAA	401	401	Q -> R (in GSD2; extremely low residual enzymatic activity).
GAA	402	402	W -> R (in GSD2; severe).
GAA	404	404	D -> N (in GSD2; severe).
GAA	405	405	L -> P (in GSD2; infantile form; severe; loss of activity).
GAA	408	408	M -> V (in GSD2; juvenile form; severe).
GAA	437	437	R -> C (in GSD2; juvenile form; severe).
GAA	445	445	A -> P (in GSD2).
GAA	455	455	Y -> F (in GSD2; juvenile form; almost complete loss of activity).
GAA	457	457	P -> L (in GSD2; juvenile form).
GAA	459	459	Missing (in GSD2; infantile form; severe).
GAA	478	478	G -> R (in GSD2; severe; loss of activity).
GAA	481	481	W -> R (in GSD2; severe; loss of activity).
GAA	489	489	D -> N (in GSD2; severe).
GAA	519	519	M -> T (in GSD2; severe; loss of activity).
GAA	519	519	M -> V (in GSD2).
GAA	521	521	E -> K (in GSD2; severe).
GAA	522	522	P -> A (in GSD2; no residual enzymatic activity).
GAA	529	529	S -> V (in GSD2; mild; requires 2 nucleotide substitutions).
GAA	545	545	P -> L (in GSD2; mild; partial loss of activity).
GAA	549	549	G -> R (in GSD2; juvenile form; mild; partial loss of activity).
GAA	552	552	L -> P (in GSD2; infantile/juvenile form; severe; loss of activity).
GAA	566	566	S -> P (in GSD2; infantile form).
GAA	575	575	Y -> S (in GSD2; juvenile form).
GAA	576	576	G -> A.
GAA	579	579	E -> K (in GSD2; infantile form; severe; loss of activity).
GAA	585	585	R -> M (in GSD2).
GAA	599	599	S -> Y (in GSD2; no residual enzymatic activity).
GAA	600	600	R -> C (in GSD2; juvenile form; loss of activity).
GAA	600	600	R -> H (in GSD2; infantile form).
GAA	607	612	Missing (in GSD2).
GAA	607	607	G -> D (in GSD2; infantile form; severe; loss of activity).
GAA	612	612	H -> Q (in GSD2).
GAA	615	615	G -> R (in GSD2; infantile/adult form).
GAA	619	619	S -> R (in GSD2; loss of function of the mutant enzyme).
GAA	638	638	G -> W (in GSD2).
GAA	645	645	D -> H (in GSD2; almost complete loss of activity).
GAA	645	645	D -> N (in GSD2).
GAA	647	647	C -> W (in GSD2).
GAA	648	648	G -> S (in GSD2).
GAA	660	660	R -> H (in GSD2; loss of function of the mutant enzyme).
GAA	672	672	R -> Q (in GSD2).
GAA	672	672	R -> T (in GSD2).
GAA	672	672	R -> W (in GSD2).
GAA	675	675	Missing (in GSD2; infantile form).
GAA	702	702	R -> C (in GSD2; no enzymatic activity; shows enzyme localization primarily in the ER-Golgi compartment suggesting that mutation could affect the normal processing and stability of the enzyme).
GAA	768	768	P -> R (in GSD2; infantile form).
GAA	880	880	A -> D (in GSD2; infantile form; severe; loss of activity).
GAA	901	901	L -> Q (in GSD2; infantile form; severe).
GAA	903	903	Missing (in GSD2; infantile form; severe; loss of activity).
GAA	925	925	N -> NGVPVSN (in GSD2).
GAA	949	949	V -> D (in GSD2).
SGSH	32	32	D -> E (in MPS3A).
SGSH	32	32	D -> G (in MPS3A).
SGSH	40	40	Y -> N (in MPS3A; intermediate).
SGSH	42	42	N -> K (in MPS3A; does not yield active enzyme; the reduction in 62 kDa precursor and 56 kDa mature forms suggests an increased degradation of the mutant enzyme).
SGSH	44	44	A -> T (in MPS3A; severe).
SGSH	66	66	S -> W (in MPS3A; intermediate/severe; common mutation in Italy).
SGSH	74	74	R -> C (in MPS3A; intermediate/severe; the mutant is enzymatically inactive; rapid degradation rather than decrease in synthesis is responsible for the low steady state level of the mutant protein in cells; the majority of newly synthesized protein probably occurs in the endoplasmic reticulum).
SGSH	74	74	R -> H (in MPS3A).
SGSH	79	79	T -> P (in MPS3A; severe).
SGSH	84	85	Missing (in MPS3A).
SGSH	84	84	H -> Y (in MPS3A).
SGSH	85	85	Q -> R (in MPS3A).
SGSH	88	88	M -> T (in MPS3A).
SGSH	90	90	G -> R (in MPS3A).
SGSH	106	106	S -> R (in MPS3A; shows 3.3% activity of the expressed wild-type enzyme; rapid degradation rather than decrease in synthesis is responsible for the low steady state level of the mutant protein in cells).
SGSH	122	122	G -> R (in MPS3A; intermediate).
SGSH	128	128	P -> L (in MPS3A; intermediate).
SGSH	131	131	V -> M (in MPS3A).
SGSH	139	139	T -> M (in MPS3A).
SGSH	146	146	L -> P (in MPS3A; severe).
SGSH	150	150	R -> Q (in MPS3A; severe).
SGSH	150	150	R -> W (in MPS3A).
SGSH	163	163	L -> P (in MPS3A; the mutant is enzymatically inactive; rapid degradation rather than decrease in synthesis is responsible for the low steady state level of the mutant protein in cells; the mutant protein shows instability in the lysosomes).
SGSH	179	179	D -> N (in MPS3A; severe).
SGSH	182	182	R -> C (in MPS3A; intermediate).
SGSH	191	191	G -> R (in MPS3A; the mutant is enzymatically inactive; rapid degradation rather than decrease in synthesis is responsible for the low steady state level of the mutant protein in cells; the majority of newly synthesized protein probably occurs in the endoplasmic reticulum).
SGSH	193	193	F -> L (in MPS3A).
SGSH	206	206	R -> P (in MPS3A; the mutant enzyme retains 8% residual activity).
SGSH	226	226	V -> A.
SGSH	227	227	P -> R (in MPS3A; severe).
SGSH	234	234	A -> G (in MPS3A).
SGSH	235	235	D -> N (in MPS3A; does not yield active enzyme; the reduction in 62 kDa precursor and 56 kDa mature forms suggests an increased degradation of the mutant enzyme).
SGSH	235	235	D -> V (in MPS3A).
SGSH	245	245	R -> H (in MPS3A; severe; common mutation in Western Europe and Australia).
SGSH	251	251	G -> A (in MPS3A).
SGSH	273	273	D -> N (in MPS3A).
SGSH	288	288	P -> S (in MPS3A).
SGSH	293	293	P -> S (in MPS3A; does not yield active enzyme; the reduction in 62 kDa precursor and 56 kDa mature forms suggests an increased degradation of the mutant enzyme).
SGSH	293	293	P -> T (in MPS3A).
SGSH	298	298	S -> P (in MPS3A; associated with a slowly progressive clinical phenotype; rapidly degraded but small amounts of the mutant protein are correctly transported to the lysosome; low but significant residual enzymatic activity).
SGSH	300	300	E -> V (in MPS3A).
SGSH	304	304	R -> L.
SGSH	307	307	Q -> P (in MPS3A).
SGSH	321	321	T -> A (in MPS3A).
SGSH	322	322	I -> S (in MPS3A).
SGSH	354	354	A -> P (in MPS3A).
SGSH	355	355	E -> K (in MPS3A).
SGSH	364	364	S -> R (in MPS3A).
SGSH	369	369	E -> K (in MPS3A; intermediate).
SGSH	374	374	Y -> H (in MPS3A).
SGSH	377	377	R -> C (in MPS3A; severe; does not yield active enzyme; the reduction in 62 kDa precursor and 56 kDa mature forms suggests an increased degradation of the mutant enzyme).
SGSH	377	377	R -> H (in MPS3A).
SGSH	380	380	Q -> R (in MPS3A).
SGSH	381	381	H -> HQR (in MPS3A).
SGSH	386	386	L -> R (in MPS3A).
SGSH	387	387	V -> M.
SGSH	389	389	N -> K (in MPS3A).
SGSH	403	403	Missing (in MPS3A; the mutant is enzymatically inactive; rapid degradation rather than decrease in synthesis is responsible for the low steady state level of the mutant protein in cells).
SGSH	432	435	YRAR -> W (in MPS3A).
SGSH	433	433	R -> Q (in MPS3A; severe).
SGSH	433	433	R -> W (in MPS3A; the mutant is enzymatically inactive; rapid degradation rather than decrease in synthesis is responsible for the low steady state level of the mutant protein in cells; the majority of newly synthesized protein probably occurs in the endoplasmic reticulum).
SGSH	436	438	Missing (in MPS3A).
SGSH	447	447	E -> K (in MPS3A).
SGSH	486	486	V -> F (in MPS3A).
ENDOV	114	114	K -> R.
ENDOV	141	141	H -> Y.
AATK	81	81	S -> F (in an ovarian mucinous carcinoma sample; somatic mutation).
AATK	97	97	L -> V (in a lung adenocarcinoma sample; somatic mutation).
AATK	104	104	M -> V (in an ovarian mucinous carcinoma sample; somatic mutation).
ACTG1	118	118	K -> M (in DFNA20).
ACTG1	264	264	P -> L (in DFNA20).
ACTG1	332	332	P -> A (in DFNA20).
ACTG1	370	370	V -> A (in DFNA20; restricts cell growth at elevated temperature or under hyperosmolar stress as measured in growth assays with yeast expressing the mutation).
PDE6G	27	27	P -> H.
HGS	7	7	T -> S.
PYCR1	119	119	R -> G (in ARCL2B).
PYCR1	119	119	R -> H (in ARCL2B).
PYCR1	179	179	A -> T (in ARCL2B).
PYCR1	189	189	A -> V.
PYCR1	206	206	G -> R (in ARCL2B).
PYCR1	206	206	G -> W (in ARCL2B).
PYCR1	251	251	R -> H (in ARCL2B).
PYCR1	257	257	A -> T (in ARCL2B).
PYCR1	266	266	R -> Q (in ARCL2B; may cause skipping of exon 6).
UTS2R	146	146	S -> R (in a breast cancer sample; somatic mutation).
TSPY3	79	79	E -> EVEVVAE.
TSPY3	195	195	P -> R.
TSPY3	216	216	I -> F.
TSPY1	79	79	E -> EVEVVAE.
TSPY1	195	195	P -> R.
TSPY1	216	216	I -> F.
SRY	3	3	S -> L (in SRXY1).
SRY	18	18	S -> N (in SRXY1; partial; also in two patients with a Turner syndrome phenotype).
SRY	60	60	V -> A (in SRXY1).
SRY	60	60	V -> L (in SRXY1).
SRY	62	62	R -> G (in SRXY1).
SRY	64	64	M -> I (in SRXY1; alters interaction with DNA and DNA bending).
SRY	64	64	M -> R (in SRXY1).
SRY	67	67	F -> V (in SRXY1).
SRY	68	68	I -> T (in SRXY1).
SRY	76	76	R -> S (in SRXY1).
SRY	78	78	M -> T (in SRXY1).
SRY	87	87	N -> Y (in SRXY1).
SRY	90	90	I -> M (in SRXY1).
SRY	91	91	S -> G (in SRXY1).
SRY	95	95	G -> E (in SRXY1).
SRY	95	95	G -> R (in SRXY1).
SRY	101	101	L -> H (in SRXY1).
SRY	106	106	K -> I (in SRXY1).
SRY	108	108	P -> R (in SRXY1).
SRY	109	109	F -> S (in SRXY1).
SRY	113	113	A -> T (in SRXY1).
SRY	125	125	P -> L (in SRXY1).
SRY	127	127	Y -> C (in SRXY1).
SRY	127	127	Y -> F (in SRXY1).
SRY	131	131	P -> R (in SRXY1).
SRY	133	133	R -> W (in SRXY1).
MID1	266	266	C -> R (in OS-I).
MID1	295	295	L -> P (in OS-I).
MID1	391	392	LC -> R (in OS-I).
MID1	438	438	Missing (in OS-I).
MID1	534	534	V -> VFIDSGRHL (in OS-I).
MID1	536	536	I -> T (in OS-I).
IL1RAPL1	379	379	K -> R.
IL1RAPL1	618	618	Q -> H.
IL1RAPL1	637	637	T -> S.
IL1RAPL1	643	643	I -> V.
DMD	18	18	K -> N (in CMD3B).
DMD	32	62	Missing (in BMD).
DMD	54	54	L -> R (in DMD).
DMD	118	118	W -> R (in a patient with Becker muscular dystrophy).
DMD	165	165	D -> V (in one patient with Becker muscular dystrophy).
DMD	168	168	A -> D (in BMD).
DMD	171	171	A -> P (in BMD).
DMD	231	231	Y -> N (in BMD).
DMD	279	279	T -> A (in CMD3B).
DMD	334	334	L -> F (in a colorectal cancer sample; somatic mutation).
DMD	495	534	Missing (in BMD).
DMD	645	645	D -> G (in DMD).
DMD	773	773	K -> E (in DMD).
DMD	1219	1219	E -> Q (in a breast cancer sample; somatic mutation).
DMD	1470	1470	R -> H (in a breast cancer sample; somatic mutation).
DMD	2164	2164	A -> V (in a colorectal cancer sample; somatic mutation).
DMD	2191	2191	R -> W.
DMD	2299	2299	N -> T.
DMD	2305	2366	Missing (in DMD).
DMD	3228	3228	F -> L (in CMD3B).
DMD	3313	3313	C -> F (in one patient with Duchenne muscular dystrophy).
DMD	3335	3335	D -> H (in DMD).
DMD	3340	3340	C -> Y (in DMD).
DMD	3421	3421	A -> V (in BMD).
ARHGEF9	55	55	G -> A (in STHEE; affects dendritic gephrin clustering and trafficking of GABA-A receptors to synapses).
EDA	54	54	H -> Y (in ED1).
EDA	55	55	L -> R (in ED1).
EDA	60	60	C -> R (in ED1).
EDA	61	61	Y -> H (in ED1).
EDA	63	63	E -> K (in ED1).
EDA	65	65	R -> G (in STHAGX1).
EDA	69	69	R -> L (in ED1).
EDA	118	118	P -> L (in a colorectal cancer sample; somatic mutation).
EDA	153	153	R -> C (in ED1; abolishes proteolytic processing).
EDA	155	155	R -> C (in ED1; abolishes proteolytic processing).
EDA	156	156	R -> C (in ED1; abolishes proteolytic processing).
EDA	156	156	R -> G (in ED1).
EDA	156	156	R -> H (in ED1; abolishes proteolytic processing).
EDA	156	156	R -> S (in ED1).
EDA	158	158	K -> N (in ED1; abolishes proteolytic processing).
EDA	183	194	Missing (in ED1).
EDA	184	189	Missing (in ED1).
EDA	185	196	Missing (in ED1).
EDA	189	189	G -> E (in ED1).
EDA	191	196	Missing (in ED1).
EDA	192	197	Missing (in ED1).
EDA	198	198	G -> A (in ED1).
EDA	207	207	G -> R (in ED1).
EDA	207	207	G -> V (in ED1).
EDA	209	209	P -> L (in ED1).
EDA	211	211	T -> R (in ED1).
EDA	218	223	Missing (in ED1).
EDA	218	218	G -> D (in ED1).
EDA	224	224	G -> A (in ED1).
EDA	252	252	H -> L (in ED1).
EDA	252	252	H -> Y (in ED1).
EDA	255	255	G -> C (in ED1).
EDA	255	255	G -> D (in ED1; mild).
EDA	266	266	L -> R (in ED1).
EDA	269	269	G -> V (in ED1).
EDA	274	274	W -> G (in ED1).
EDA	274	274	W -> R (in ED1).
EDA	291	291	G -> R (in ED1).
EDA	291	291	G -> W (in ED1).
EDA	293	293	L -> P (in ED1).
EDA	296	296	L -> V (in ED1).
EDA	298	298	D -> H (in ED1).
EDA	298	298	D -> Y (in ED1).
EDA	299	299	G -> D (in ED1).
EDA	299	299	G -> S (in ED1).
EDA	302	302	F -> S (in ED1).
EDA	306	306	Q -> H (in ED1).
EDA	307	307	V -> G (in ED1).
EDA	320	320	Y -> C (in ED1).
EDA	323	323	V -> G (in ED1).
EDA	332	332	C -> Y (in ED1).
EDA	338	338	T -> M (in STHAGX1).
EDA	343	343	Y -> C (in ED1).
EDA	346	346	C -> Y (in ED1).
EDA	349	349	A -> T (in ED1).
EDA	356	356	A -> D (in ED1).
EDA	356	356	A -> V (in ED1).
EDA	357	357	R -> P (in ED1).
EDA	358	358	Q -> E (in ED1).
EDA	360	360	I -> N (in ED1).
EDA	372	372	N -> D (in ED1).
EDA	373	373	M -> I (in ED1).
EDA	374	374	S -> R (in ED1).
EDA	378	378	T -> M (in ED1).
EDA	378	378	T -> P (in ED1).
EDA	381	381	G -> R (in ED1).
PCDH11X	42	42	D -> G (in a colorectal cancer sample; somatic mutation).
PCDH19	81	81	L -> R (in EIEE9).
PCDH19	121	121	D -> N (in EIEE9; disease features overlapping with Dravet syndrome).
PCDH19	141	141	A -> ASEA (in EIEE9).
PCDH19	146	146	T -> R (in EIEE9).
PCDH19	199	199	E -> Q (in EIEE9; disease features overlapping with Dravet syndrome).
PCDH19	203	203	H -> P (in EIEE9; disease features overlapping with Dravet syndrome; associated with Cys-206).
PCDH19	206	206	F -> C (in EIEE9; disease features overlapping with Dravet syndrome; associated with Pro-203).
PCDH19	206	206	F -> Y (in EIEE9).
PCDH19	249	249	E -> D (in EIEE9).
PCDH19	276	276	S -> P (in EIEE9).
PCDH19	340	340	N -> S (in EIEE9; disease features overlapping with Dravet syndrome).
PCDH19	341	341	D -> E (in EIEE9).
PCDH19	377	377	D -> H (in EIEE9; disease features overlapping with Dravet syndrome).
PCDH19	404	404	T -> I (in EIEE9; disease features overlapping with Dravet syndrome).
PCDH19	414	414	E -> Q (in EIEE9; disease features overlapping with Dravet syndrome).
PCDH19	441	441	V -> E (in EIEE9).
PCDH19	543	543	L -> P (in EIEE9; disease features overlapping with Dravet syndrome).
PCDH19	557	557	N -> K (in EIEE9).
PCDH19	561	561	P -> R (in EIEE9).
PCDH19	567	567	P -> L (in EIEE9).
PCDH19	618	618	D -> N (in EIEE9).
PCDH19	958	958	R -> Q.
PCDH19	1107	1107	R -> G.
IL1RAPL2	606	606	F -> L (in a breast cancer sample; somatic mutation).
ODZ1	342	342	L -> F (in a breast cancer sample; somatic mutation).
ODZ1	1216	1216	V -> I (in a breast cancer sample; somatic mutation).
ODZ1	1482	1482	F -> V (in a colorectal cancer sample; somatic mutation).
ODZ1	2235	2235	Q -> H (in a breast cancer sample; somatic mutation).
ODZ1	2396	2396	L -> F (in a colorectal cancer sample; somatic mutation).
ZDHHC9	148	148	R -> W (in MRXSZ).
ZDHHC9	150	150	P -> S (in MRXSZ).
FHL1	122	122	W -> S (in SPM).
FHL1	123	123	H -> Y (in RBM; X-linked severe early- onset; the mutant protein initiates aggregation of the FHL1 protein, forms reducing bodies and traps wild-type FHL1 into the inclusion bodies; consistent with a dominant-negative effect).
FHL1	128	128	T -> TI (in XMPMA).
FHL1	132	132	C -> F (in RBM; X-linked severe early- onset; the mutant protein initiates aggregation of the FHL1 protein, forms reducing bodies and traps wild-type FHL1 into the inclusion bodies; consistent with a dominant-negative effect).
FHL1	153	153	C -> R (in RBM; X-linked childhood- onset).
FHL1	153	153	C -> Y (in RBM; X-linked childhood- onset).
FHL1	224	224	C -> W (in XMPMA).
SPANXC	59	59	V -> F.
PDZD4	39	39	R -> C (in a breast cancer sample; somatic mutation).
F8	19	19	S -> R (in HEMA).
F8	22	22	R -> T (in HEMA; severe).
F8	24	24	Y -> C (in HEMA).
F8	25	25	Y -> C (in HEMA; mild).
F8	26	26	L -> P (in HEMA; severe).
F8	26	26	L -> R (in HEMA; severe).
F8	30	30	E -> V (in HEMA; mild).
F8	33	33	W -> G (in HEMA; moderate).
F8	35	35	Y -> C (in HEMA; mild/severe).
F8	35	35	Y -> H (in HEMA; severe).
F8	41	41	G -> C (in HEMA; severe/moderate).
F8	48	48	R -> C (in HEMA; severe).
F8	48	48	R -> K (in HEMA).
F8	67	67	K -> E (in HEMA; severe).
F8	67	67	K -> N (in HEMA).
F8	69	69	L -> P (in HEMA; moderate-severe).
F8	72	72	E -> K (in HEMA; moderate).
F8	75	75	D -> E (in HEMA; moderate).
F8	75	75	D -> Y (in HEMA; moderate-severe).
F8	83	83	P -> R (in HEMA).
F8	84	85	Missing (in HEMA; severe).
F8	85	85	Missing (in HEMA; moderate).
F8	89	89	G -> D (in HEMA; severe).
F8	89	89	G -> V (in HEMA; mild).
F8	92	92	G -> A (in HEMA).
F8	97	97	A -> P (in HEMA).
F8	98	98	E -> K (in HEMA; severe).
F8	101	101	D -> G (in HEMA; severe).
F8	101	101	D -> H (in HEMA; severe sporadic).
F8	101	101	D -> V (in HEMA).
F8	111	111	A -> T (in HEMA; severe).
F8	111	111	A -> V (in HEMA; moderate).
F8	113	113	H -> R (in HEMA; mild).
F8	113	113	H -> Y (in HEMA).
F8	117	117	L -> F (in HEMA; mild).
F8	121	121	G -> S (in HEMA).
F8	129	129	E -> V (in HEMA; severe).
F8	130	130	G -> R (in HEMA; severe).
F8	135	135	D -> Y (in HEMA; severe sporadic).
F8	137	137	T -> A (in HEMA; severe).
F8	137	137	T -> I (in HEMA; moderate).
F8	138	138	S -> R (in HEMA; mild).
F8	141	141	E -> K (in HEMA; severe familial).
F8	145	145	D -> H (in HEMA; moderate).
F8	147	147	V -> D (in HEMA; severe).
F8	155	155	Y -> H (in HEMA; moderate).
F8	159	159	V -> A (in HEMA; moderate).
F8	163	163	N -> K (in HEMA; moderate).
F8	164	164	G -> D (in HEMA; moderate).
F8	172	172	C -> W (in HEMA).
F8	176	176	S -> P (in HEMA).
F8	179	179	S -> P (in HEMA; moderate).
F8	181	181	V -> E (in HEMA; mild).
F8	181	181	V -> M (in HEMA; mild/moderate).
F8	185	185	K -> T (in HEMA; mild).
F8	186	186	D -> G (in HEMA; mild).
F8	186	186	D -> N (in HEMA).
F8	186	186	D -> Y (in HEMA; severe).
F8	189	189	S -> L (in HEMA; moderate).
F8	191	191	L -> F (in HEMA).
F8	193	193	G -> R (in HEMA; severe familial).
F8	195	195	L -> P (in HEMA).
F8	198	198	C -> G (in HEMA; severe).
F8	202	202	S -> N (in HEMA; mild).
F8	202	202	S -> R (in HEMA; mild).
F8	214	214	F -> V (in HEMA).
F8	217	217	L -> H (in HEMA; moderate).
F8	219	219	A -> D (in HEMA).
F8	219	219	A -> T (in HEMA).
F8	220	220	V -> G (in HEMA; mild).
F8	222	222	D -> V (in HEMA; moderate).
F8	223	223	E -> K (in HEMA; severe).
F8	224	224	G -> W (in HEMA; moderate).
F8	252	252	T -> I (in HEMA; moderate).
F8	253	253	V -> F (in HEMA; severe).
F8	254	254	N -> I (in HEMA; severe).
F8	255	255	G -> V (in HEMA; severe).
F8	261	261	L -> P (in HEMA).
F8	262	262	P -> L (in HEMA; moderate).
F8	263	263	G -> S (in HEMA).
F8	266	266	G -> E (in HEMA; severe).
F8	267	267	C -> Y (in HEMA; moderate).
F8	275	275	H -> L (in HEMA; mild).
F8	278	278	G -> R (in HEMA; severe).
F8	280	280	G -> D (in HEMA).
F8	284	284	E -> K (in HEMA; moderate).
F8	285	285	V -> G (in HEMA; mild).
F8	291	291	E -> G (in HEMA; mild).
F8	291	291	E -> K (in HEMA; mild).
F8	294	294	T -> I (in HEMA; moderate).
F8	295	295	F -> L (in HEMA; moderate).
F8	297	297	V -> A (in HEMA; mild).
F8	301	301	R -> C (in HEMA; severe/mild).
F8	301	301	R -> L (in HEMA; severe).
F8	302	302	Missing (in HEMA).
F8	303	303	A -> E (in HEMA; mild).
F8	303	303	A -> P (in HEMA; mild).
F8	307	307	I -> S (in HEMA; moderate).
F8	312	312	F -> S (in HEMA; mild/moderate).
F8	314	314	T -> I (in HEMA; moderate).
F8	315	315	A -> V (in HEMA).
F8	320	320	Missing (in HEMA; severe).
F8	323	323	G -> E (in HEMA; severe).
F8	326	326	L -> P (in HEMA).
F8	327	327	L -> V (in HEMA; mild).
F8	329	329	C -> F (in HEMA).
F8	331	331	I -> V (in HEMA; mild).
F8	339	339	M -> T (in HEMA; moderate).
F8	340	340	E -> K (in HEMA).
F8	345	345	V -> A (in HEMA).
F8	345	345	V -> L (in HEMA; severe).
F8	348	348	C -> R (in HEMA; severe).
F8	348	348	C -> S (in HEMA; moderate).
F8	348	348	C -> Y (in HEMA; mild/severe).
F8	365	365	Y -> C (in HEMA; mild).
F8	391	391	R -> C (in HEMA; Okayama; moderate/ severe; abolishes the normal cleavage by thrombin).
F8	391	391	R -> P (in HEMA; severe; abolishes the normal cleavage by thrombin).
F8	394	394	A -> S (in HEMA).
F8	401	401	W -> G (in HEMA).
F8	405	405	I -> F (in HEMA).
F8	412	412	W -> G (in HEMA).
F8	412	412	W -> R (in HEMA; severe).
F8	427	427	K -> I (in HEMA; mild).
F8	431	431	L -> S (in HEMA; moderate).
F8	437	437	R -> P (in HEMA; severe).
F8	437	437	R -> W (in HEMA; mild).
F8	438	438	I -> F (in HEMA; not severe).
F8	439	439	G -> D (in HEMA; severe).
F8	439	439	G -> S (in HEMA; moderate).
F8	439	439	G -> V (in HEMA; severe).
F8	442	442	Y -> C (in HEMA).
F8	450	450	Y -> D (in HEMA; severe).
F8	454	454	T -> I (in HEMA; mild).
F8	455	455	F -> C (in HEMA; mild-moderate/severe).
F8	466	466	G -> E (in HEMA; severe sporadic).
F8	470	470	P -> L (in HEMA; mild).
F8	470	470	P -> R (in HEMA; mild).
F8	470	470	P -> T (in HEMA; mild sporadic).
F8	474	474	G -> E (in HEMA).
F8	474	474	G -> R (in HEMA; severe).
F8	474	474	G -> V (in HEMA).
F8	475	475	E -> K (in HEMA; moderate).
F8	477	477	G -> V (in HEMA; moderate).
F8	478	478	D -> N (in HEMA).
F8	479	479	T -> R (in HEMA).
F8	484	484	F -> C (in HEMA).
F8	488	488	A -> G (in HEMA; moderate).
F8	490	490	R -> G (in HEMA).
F8	496	496	P -> R (in HEMA).
F8	513	513	G -> S (in HEMA; moderate).
F8	513	513	G -> V (in HEMA).
F8	522	522	I -> Y (in HEMA; requires 2 nucleotide substitutions).
F8	529	529	K -> E (in HEMA; moderate).
F8	532	532	W -> G (in HEMA).
F8	540	540	P -> T (in HEMA).
F8	541	541	T -> S (in HEMA; mild).
F8	550	550	R -> G (in HEMA; mild).
F8	553	553	S -> P (in HEMA; severe).
F8	554	554	S -> C (in HEMA; moderate).
F8	554	554	S -> G (in HEMA; mild).
F8	556	556	V -> D (in HEMA; moderate).
F8	560	560	R -> T (in HEMA; mild).
F8	561	561	D -> G (in HEMA; severe).
F8	561	561	D -> H (in HEMA).
F8	561	561	D -> Y (in HEMA; severe).
F8	567	567	I -> T (in HEMA; mild).
F8	569	569	P -> R (in HEMA).
F8	577	577	S -> F (in HEMA; mild).
F8	578	578	V -> A (in HEMA; mild).
F8	579	579	D -> A (in HEMA; mild).
F8	579	579	D -> H (in HEMA; mild).
F8	583	583	N -> S (in HEMA; mild).
F8	584	584	Q -> H (in HEMA; mild).
F8	584	584	Q -> K (in HEMA; moderate).
F8	584	584	Q -> R (in HEMA).
F8	585	585	I -> R (in HEMA; moderate-severe).
F8	585	585	I -> T (in HEMA; severe/moderate).
F8	586	586	M -> V (in HEMA; mild).
F8	588	588	D -> G (in HEMA).
F8	588	588	D -> Y (in HEMA).
F8	594	594	L -> Q (in HEMA; mild).
F8	596	596	S -> P (in HEMA; severe).
F8	601	601	N -> D (in HEMA).
F8	601	601	N -> K (in HEMA).
F8	602	602	R -> G (in HEMA; mild familial).
F8	603	603	S -> I (in HEMA).
F8	603	603	S -> R (in HEMA; severe).
F8	604	604	W -> C (in HEMA; severe).
F8	605	605	Y -> H (in HEMA).
F8	605	605	Y -> S (in HEMA; severe).
F8	609	609	N -> I (in HEMA; moderate).
F8	612	612	R -> C (in HEMA; mild/moderate; secretion impaired).
F8	631	631	N -> K (in HEMA; severe).
F8	631	631	N -> S (in HEMA).
F8	633	633	M -> I (in HEMA; mild).
F8	635	635	S -> N (in HEMA; mild).
F8	637	637	N -> D (in HEMA; severe sporadic/ moderate).
F8	637	637	N -> I (in HEMA).
F8	637	637	N -> S (in HEMA; mild; secretion impaired).
F8	639	639	Y -> C (in HEMA; moderate).
F8	644	644	L -> V (in HEMA; mild).
F8	650	650	L -> F (in HEMA; mild).
F8	653	653	V -> A (in HEMA; mild).
F8	653	653	V -> M (in HEMA; severe).
F8	659	659	L -> P (in HEMA).
F8	663	663	A -> V (in HEMA; mild).
F8	664	664	Q -> P (in HEMA; moderate-severe).
F8	671	671	Missing (in HEMA; severe).
F8	677	677	F -> L (in HEMA; moderate).
F8	681	681	M -> I (in HEMA; mild).
F8	682	682	V -> F (in HEMA).
F8	683	683	Y -> C (in HEMA; severe).
F8	683	683	Y -> N (in HEMA; mild).
F8	686	686	T -> R (in HEMA).
F8	698	698	F -> L (in HEMA).
F8	699	699	M -> T (in HEMA; mild).
F8	699	699	M -> V (in HEMA; severe).
F8	701	701	M -> I (in HEMA; mild).
F8	705	705	G -> V (in HEMA; moderate).
F8	710	710	G -> W (in HEMA).
F8	713	713	N -> I (in HEMA; mild).
F8	717	717	R -> L (in HEMA; mild).
F8	717	717	R -> W (in HEMA; mild).
F8	720	720	G -> D (in HEMA; severe/moderate).
F8	720	720	G -> S (in HEMA).
F8	721	721	M -> I (in HEMA; severe).
F8	721	721	M -> L (in HEMA; mild).
F8	723	723	A -> T (in HEMA; moderate).
F8	725	725	L -> Q (in HEMA; severe).
F8	727	727	V -> F (in HEMA; severe).
F8	742	742	Y -> C (in HEMA; mild).
F8	947	947	P -> R (in HEMA).
F8	1012	1012	V -> L (in HEMA).
F8	1066	1066	H -> Y (in HEMA).
F8	1336	1336	Q -> K (in HEMA).
F8	1460	1460	N -> K (in HEMA).
F8	1610	1610	A -> S (in HEMA).
F8	1698	1698	I -> T (in HEMA; mild).
F8	1699	1699	Y -> C (in HEMA; severe).
F8	1701	1701	E -> K (in HEMA; mild).
F8	1705	1705	Q -> H (in HEMA; mild sporadic).
F8	1708	1708	R -> C (in HEMA; East Hartford; severe/ moderate/mild; abolishes thrombin cleavage at the light chain).
F8	1714	1714	T -> S (in HEMA; moderate).
F8	1715	1715	R -> G (in HEMA; mild).
F8	1720	1720	A -> V (in HEMA).
F8	1723	1723	E -> K (in HEMA; severe).
F8	1727	1727	D -> V (in HEMA; mild).
F8	1728	1728	Y -> C (in HEMA; moderate).
F8	1740	1740	R -> G (in HEMA; mild).
F8	1751	1751	K -> Q (in HEMA).
F8	1762	1762	F -> L (in HEMA).
F8	1768	1768	R -> H (in HEMA).
F8	1769	1769	G -> R (in HEMA; mild).
F8	1771	1771	L -> P (in HEMA).
F8	1775	1775	L -> F (in HEMA; mild).
F8	1775	1775	L -> V (in HEMA; moderate).
F8	1777	1777	L -> P (in HEMA; moderate).
F8	1779	1779	G -> E (in HEMA; severe/moderate).
F8	1779	1779	G -> R (in HEMA; severe).
F8	1780	1780	P -> L (in HEMA; moderate).
F8	1782	1782	I -> R (in HEMA; severe sporadic).
F8	1788	1788	D -> H (in HEMA; mild).
F8	1791	1791	M -> T (in HEMA; severe).
F8	1798	1798	A -> P (in HEMA; severe).
F8	1799	1799	S -> H (in HEMA; requires 2 nucleotide substitutions).
F8	1800	1800	R -> C (in HEMA; moderate).
F8	1800	1800	R -> G (in HEMA; mild).
F8	1800	1800	R -> H (in HEMA; moderate/severe).
F8	1801	1801	P -> A (in HEMA; mild).
F8	1802	1802	Y -> C (in HEMA; moderate).
F8	1803	1803	S -> Y (in HEMA; severe).
F8	1804	1804	F -> S (in HEMA; severe).
F8	1808	1808	L -> F (in HEMA; mild).
F8	1848	1848	E -> G (in HEMA; mild).
F8	1853	1853	A -> T (in HEMA; moderate/severe).
F8	1858	1858	S -> C (in HEMA; moderate).
F8	1864	1864	K -> E (in HEMA).
F8	1865	1865	D -> N (in HEMA; severe).
F8	1865	1865	D -> Y (in HEMA; severe).
F8	1867	1867	H -> P (in HEMA; mild).
F8	1869	1869	G -> D (in HEMA; severe).
F8	1869	1869	G -> V (in HEMA; severe).
F8	1872	1872	G -> E (in HEMA; severe sporadic).
F8	1875	1875	L -> P (in HEMA).
F8	1876	1876	V -> L (in HEMA; mild).
F8	1877	1877	C -> R (in HEMA).
F8	1877	1877	C -> Y (in HEMA).
F8	1882	1882	L -> P (in HEMA).
F8	1888	1888	R -> I (in HEMA; severe).
F8	1894	1894	E -> G (in HEMA; moderate).
F8	1901	1901	I -> F (in HEMA; mild).
F8	1904	1904	E -> D (in HEMA).
F8	1907	1907	S -> C (in HEMA; moderate).
F8	1907	1907	S -> R (in HEMA; severe).
F8	1908	1908	W -> L (in HEMA; mild).
F8	1909	1909	Y -> C (in HEMA; moderate).
F8	1939	1939	A -> T (in HEMA; severe).
F8	1939	1939	A -> V (in HEMA; second mutation; could be a polymorphism).
F8	1941	1941	N -> D (in HEMA; severe/moderate).
F8	1942	1942	G -> A (in HEMA; moderate).
F8	1945	1945	M -> V (in HEMA; moderate).
F8	1951	1951	L -> F (in HEMA; mild).
F8	1960	1960	R -> L (in HEMA; moderate).
F8	1963	1963	L -> P (in HEMA; severe).
F8	1965	1965	S -> I (in HEMA).
F8	1966	1966	M -> I (in HEMA; mild).
F8	1966	1966	M -> V (in HEMA; mild).
F8	1968	1968	S -> R (in HEMA; mild).
F8	1971	1971	N -> T (in HEMA).
F8	1973	1973	H -> L (in HEMA; mild).
F8	1979	1979	G -> V (in HEMA; moderate).
F8	1980	1980	H -> P (in HEMA).
F8	1980	1980	H -> Y (in HEMA; mild).
F8	1982	1982	F -> I (in HEMA; mild).
F8	1985	1985	R -> Q (in HEMA; mild).
F8	1994	1994	L -> P (in HEMA; moderate).
F8	1998	1998	Y -> C (in HEMA; mild).
F8	2000	2000	G -> A (in HEMA; moderate-severe).
F8	2004	2004	T -> R (in HEMA; sporadic).
F8	2007	2007	M -> I (in HEMA; mild).
F8	2013	2013	G -> R (in HEMA).
F8	2015	2015	W -> C (in HEMA; moderate).
F8	2016	2016	R -> P (in HEMA; severe familial).
F8	2016	2016	R -> W (in HEMA; severe/moderate/mild).
F8	2018	2018	E -> G (in HEMA; moderate).
F8	2022	2022	G -> D (in HEMA; severe).
F8	2028	2028	G -> R (in HEMA).
F8	2030	2030	S -> N (in HEMA; mild).
F8	2035	2035	V -> A (in HEMA).
F8	2036	2036	Y -> C (in HEMA; moderate).
F8	2038	2038	N -> S (in HEMA; mild/moderate).
F8	2040	2040	C -> Y (in HEMA).
F8	2045	2045	G -> E (in HEMA; mild).
F8	2045	2045	G -> V (in HEMA; severe sporadic).
F8	2051	2051	I -> S (in HEMA; severe).
F8	2056	2056	I -> N (in HEMA; severe).
F8	2058	2058	A -> P (in HEMA; moderate).
F8	2065	2065	W -> R (in HEMA; moderate).
F8	2067	2067	P -> L (in HEMA; severe sporadic).
F8	2070	2070	A -> V (in HEMA; mild).
F8	2082	2082	S -> N (in HEMA; severe).
F8	2088	2088	S -> F (in HEMA; severe).
F8	2093	2093	D -> G (in HEMA; mild).
F8	2093	2093	D -> Y (in HEMA; severe familial).
F8	2101	2101	H -> D (in HEMA).
F8	2105	2105	T -> N (in HEMA; moderate).
F8	2106	2106	Q -> E (in HEMA; mild).
F8	2106	2106	Q -> P (in HEMA).
F8	2106	2106	Q -> R (in HEMA; mild).
F8	2107	2107	G -> S (in HEMA; severe).
F8	2109	2109	R -> C (in HEMA; mild).
F8	2117	2117	I -> F (in HEMA).
F8	2117	2117	I -> S (in HEMA; mild-moderate; affinity for VWF reduced 8-fold).
F8	2119	2119	Q -> R (in HEMA; moderate).
F8	2120	2120	F -> C (in HEMA).
F8	2120	2120	F -> L (in HEMA; mild).
F8	2124	2124	Y -> C (in HEMA; mild).
F8	2135	2135	R -> P (in HEMA; severe).
F8	2138	2138	S -> Y (in HEMA; moderate; affinity for VWF reduced 80-fold).
F8	2141	2141	T -> N (in HEMA; severe).
F8	2143	2143	M -> V (in HEMA).
F8	2145	2145	F -> C (in HEMA; mild).
F8	2148	2148	N -> S (in HEMA; moderate).
F8	2157	2157	N -> D (in HEMA; mild).
F8	2162	2162	P -> L (in HEMA; severe).
F8	2169	2169	R -> C (in HEMA; mild).
F8	2169	2169	R -> H (in HEMA; severe/mild; affinity for VWF reducced 3-fold).
F8	2172	2172	P -> L (in HEMA).
F8	2172	2172	P -> Q (in HEMA; moderate).
F8	2172	2172	P -> R (in HEMA; severe).
F8	2173	2173	T -> A (in HEMA; mild).
F8	2173	2173	T -> I (in HEMA; mild).
F8	2174	2174	H -> D (in HEMA).
F8	2178	2178	R -> C (in HEMA; mild/moderate).
F8	2178	2178	R -> H (in HEMA; mild).
F8	2178	2178	R -> L (in HEMA; mild).
F8	2182	2182	R -> C (in HEMA; severe/moderate).
F8	2182	2182	R -> H (in HEMA; severe/moderate).
F8	2182	2182	R -> P (in HEMA; moderate/severe).
F8	2183	2183	M -> R (in HEMA; moderate).
F8	2183	2183	M -> V (in HEMA; mild).
F8	2185	2185	L -> S (in HEMA; severe).
F8	2185	2185	L -> W (in HEMA).
F8	2192	2192	S -> I (in HEMA; mild).
F8	2193	2193	C -> G (in HEMA).
F8	2196	2196	P -> R (in HEMA).
F8	2198	2198	G -> V (in HEMA; severe sporadic).
F8	2200	2200	E -> D (in HEMA).
F8	2204	2204	I -> T (in HEMA; mild).
F8	2209	2209	I -> N (in HEMA; moderate).
F8	2211	2211	A -> P (in HEMA; moderate).
F8	2220	2220	A -> P (in HEMA; mild).
F8	2223	2223	Missing (in HEMA; severe/moderate).
F8	2224	2224	P -> L (in HEMA).
F8	2224	2224	Missing (in HEMA; moderate).
F8	2228	2228	R -> G (in HEMA; severe).
F8	2228	2228	R -> L (in HEMA; moderate).
F8	2228	2228	R -> P (in HEMA; moderate-severe).
F8	2228	2228	R -> Q (in HEMA; severe/moderate).
F8	2229	2229	L -> F (in HEMA).
F8	2242	2242	V -> M.
F8	2248	2248	W -> C (in HEMA; moderate).
F8	2248	2248	W -> S (in HEMA; moderate).
F8	2251	2251	V -> A (in HEMA; mild).
F8	2251	2251	V -> E (in HEMA).
F8	2262	2262	V -> VQ (in HEMA; moderate).
F8	2264	2264	T -> A (in HEMA).
F8	2265	2265	Q -> R (in HEMA; moderate).
F8	2279	2279	F -> C (in HEMA; severe sporadic).
F8	2279	2279	F -> I (in HEMA).
F8	2281	2281	I -> T (in HEMA; severe).
F8	2286	2286	D -> G (in HEMA).
F8	2290	2290	W -> L (in HEMA).
F8	2304	2304	G -> V (in HEMA).
F8	2307	2307	D -> A (in HEMA; moderate/mild).
F8	2319	2319	P -> L (in HEMA; mild/severe).
F8	2319	2319	P -> S (in HEMA; mild).
F8	2323	2323	R -> C (in HEMA; severe/moderate; may cause reduced phospholipid binding).
F8	2323	2323	R -> G (in HEMA; moderate).
F8	2323	2323	R -> H (in HEMA; mild; may cause reduced phospholipid binding).
F8	2323	2323	R -> L (in HEMA; mild).
F8	2326	2326	R -> G (in HEMA).
F8	2326	2326	R -> L (in HEMA; severe/moderate; may cause reduced phospholipid binding).
F8	2326	2326	R -> P (in HEMA; severe sporadic).
F8	2326	2326	R -> Q (in HEMA; moderate/mild; may cause reduced phospholipid binding).
F8	2330	2330	Q -> P (in HEMA; severe).
F8	2332	2332	W -> R (in HEMA; severe).
F8	2336	2336	I -> F (in HEMA).
F8	2339	2339	R -> T (in HEMA; moderate).
F8	2344	2344	G -> C (in HEMA; moderate).
F8	2344	2344	G -> D (in HEMA).
F8	2344	2344	G -> S (in HEMA).
F8	2345	2345	C -> S (in HEMA).
F8	2345	2345	C -> Y (in HEMA).
GYG2	194	194	G -> R (found in a renal cell carcinoma case; somatic mutation).
ARSE	12	12	R -> S (in CDPX1).
ARSE	80	80	I -> N (in CDPX1).
ARSE	111	111	R -> P (in CDPX1).
ARSE	117	117	G -> R (in CDPX1).
ARSE	137	137	G -> V (in CDPX1).
ARSE	245	245	G -> R (in CDPX1).
ARSE	481	481	T -> M (in CDPX1).
ARSE	492	492	C -> Y (in CDPX1).
NLGN4X	214	214	G -> S (in a colorectal cancer sample; somatic mutation).
STS	341	341	S -> L (in IXL; loss of activity).
STS	372	372	W -> R (in IXL; loss of activity).
STS	372	372	W -> S (in IXL; loss of activity).
STS	380	380	G -> R (in IXL).
STS	444	444	H -> R (in IXL; loss of activity).
STS	446	446	C -> Y (in IXL; loss of activity).
STS	560	560	Q -> P (in IXL).
KAL1	134	134	C -> G (in KAL1).
KAL1	163	163	C -> R (in KAL1).
KAL1	163	163	C -> Y (in KAL1).
KAL1	163	163	Missing (in KAL1).
KAL1	172	172	C -> R (in KAL1).
KAL1	262	262	R -> P (in KAL1).
KAL1	267	267	N -> K (in KAL1; loss of effect on the migratory activity of GnRH neurons; complete loss of FGFR1-binding).
KAL1	304	304	N -> S (in KAL1).
KAL1	396	396	S -> L (in KAL1).
KAL1	517	517	F -> L (in KAL1; loss of effect on the migratory activity of GnRH neurons; Reduced FGFR1-binding).
KAL1	539	539	E -> K (in KAL1).
KAL1	571	571	W -> R (in KAL1).
KAL1	666	666	K -> M.
KAL1	668	668	R -> H.
GPR143	5	5	R -> C (in OA1; results in altered glycosylation pattern and subcellular localization consistent with proteiin retention in the endoplasmic reticulum; lacks G protein-activation abilities).
GPR143	35	35	G -> D (in OA1; results in altered glycosylation pattern and subcellular localization consistent with protein retention in the endoplasmic reticulum).
GPR143	39	39	L -> R (in OA1).
GPR143	78	78	D -> N (in OA1; results in altered glycosylation pattern and subcellular localization consistent with protein retention in the endoplasmic reticulum).
GPR143	78	78	D -> V (in OA1).
GPR143	80	80	Missing (in OA1).
GPR143	81	81	G -> V (in OA1).
GPR143	84	84	G -> D (in OA1; results in altered glycosylation pattern and subcellular localization consistent with protein retention in the endoplasmic reticulum).
GPR143	84	84	G -> R (in OA1).
GPR143	89	89	S -> F (in NYS6).
GPR143	116	116	C -> G (in OA1).
GPR143	116	116	C -> R (in OA1).
GPR143	116	116	C -> S (in OA1; results in altered glycosylation pattern and subcellular localization consistent with protein retention in the endoplasmic reticulum).
GPR143	116	116	C -> W (in OA1).
GPR143	118	118	G -> E (in OA1; results in altered glycosylation pattern and subcellular localization consistent with protein retention in the endoplasmic reticulum).
GPR143	124	124	Q -> R (in OA1).
GPR143	132	132	W -> R (in OA1).
GPR143	133	133	W -> R (in OA1; results in altered glycosylation pattern and subcellular localization consistent with protein retention in the endoplasmic reticulum).
GPR143	134	134	L -> P (in OA1).
GPR143	138	138	A -> V (in OA1).
GPR143	152	152	S -> N (in OA1).
GPR143	166	166	T -> N (in OA1).
GPR143	173	173	A -> D (in OA1; results in altered glycosylation pattern and subcellular localization consistent with protein retention in the endoplasmic reticulum).
GPR143	185	185	E -> K (in OA1).
GPR143	186	186	R -> P (in OA1).
GPR143	186	186	R -> W (in OA1).
GPR143	229	229	G -> V (in OA1; not delivered at the cell surface of melanocytic and non- melanocytic cells).
GPR143	232	232	T -> K (in OA1; abnormal distribution of melanosomes; Not delivered at the cell surface of melanocytic and non- melanocytic cells).
GPR143	233	233	E -> K (in OA1).
GPR143	235	235	E -> K (in OA1; not delivered at the cell surface of melanocytic and non- melanocytic cells).
GPR143	244	244	I -> V (in OA1; not delivered at the cell surface of melanocytic and non- melanocytic cells).
GPR143	261	261	I -> N (in OA1; results in altered glycosylation pattern and subcellular localization consistent with protein retention in the endoplasmic reticulum).
GPR143	271	271	E -> G (in OA1).
GPR143	290	290	Missing (in OA1; results in altered glycosylation pattern and subcellular localization consistent with protein retention in the endoplasmic reticulum).
GPR143	292	292	W -> C (in OA1).
GPR143	292	292	W -> G (in OA1; results in altered glycosylation pattern and subcellular localization consistent with protein retention in the endoplasmic reticulum).
SHROOM2	1245	1245	D -> H (in a breast cancer sample; somatic mutation).
HCCS	217	217	R -> C (in MCOPS7).
OFD1	74	74	S -> F (in OFD1).
OFD1	79	79	A -> T (in OFD1).
OFD1	138	138	G -> S (in OFD1).
OFD1	358	360	KDD -> FSY (in OFD1).
OFD1	435	435	S -> R (in OFD1).
ACE2	638	638	N -> S.
NHS	844	844	A -> T (in a breast cancer sample; somatic mutation).
CDKL5	40	40	A -> V (in EIEE2; causes mislocalization of the protein in the cytoplasm).
CDKL5	72	72	I -> N (in EIEE2).
CDKL5	72	72	I -> T (in EIEE2).
CDKL5	127	127	H -> R (in EIEE2).
CDKL5	152	152	C -> F (in EIEE2; affect activity; causes mislocalization of the protein in the cytoplasm).
CDKL5	175	175	R -> S (in EIEE2; affect activity; does not affect the cellular distribution of the protein).
CDKL5	178	178	R -> P (in EIEE2).
CDKL5	180	180	P -> L (in EIEE2).
CDKL5	220	220	L -> P (in EIEE2; causes mislocalization of the protein in the cytoplasm).
CDKL5	288	288	T -> I (in EIEE2).
CDKL5	291	291	C -> Y (in EIEE2).
CDKL5	368	368	N -> H (in a colorectal cancer sample; somatic mutation).
CDKL5	374	374	A -> T (in a metastatic melanoma sample; somatic mutation).
CDKL5	399	399	N -> T (in EIEE2).
CDKL5	444	444	R -> C.
CDKL5	574	574	P -> Q (in an ovarian serous carcinoma sample; somatic mutation).
CDKL5	718	718	V -> M (in EIEE2).
CDKL5	793	793	V -> A (in EIEE2; uncertain pathogenicity).
CDKL5	923	923	R -> C.
MAP3K15	192	192	A -> T.
MAP3K15	199	199	S -> N.
MAP3K15	226	226	D -> H.
MAP3K15	255	255	R -> S (in a lung squamous cell carcinoma sample; somatic mutation).
MAP3K15	456	456	S -> G.
MAP3K15	494	494	R -> C.
MAP3K15	562	562	S -> L (in a lung adenocarcinoma sample; somatic mutation).
MAP3K15	677	677	R -> Q (in a metastatic melanoma sample; somatic mutation).
MAP3K15	838	838	G -> S.
MAP3K15	993	993	S -> L.
MAP3K15	1029	1029	N -> H.
MAP3K15	1247	1247	W -> R (in a colorectal adenocarcinoma sample; somatic mutation).
MAP3K15	1251	1251	Q -> E.
SH3KBP1	382	382	P -> L.
MAP7D2	32	32	A -> P (in a breast cancer sample; somatic mutation).
RPS6KA3	75	75	G -> V (in CLS).
RPS6KA3	82	82	V -> F (in CLS).
RPS6KA3	114	114	R -> W (in CLS).
RPS6KA3	127	127	H -> Q (in CLS).
RPS6KA3	154	154	D -> Y (in CLS).
RPS6KA3	225	225	A -> V (in CLS).
RPS6KA3	227	227	S -> A (in CLS).
RPS6KA3	416	416	I -> V (in a breast cancer sample; somatic mutation).
RPS6KA3	431	431	G -> D (in CLS).
RPS6KA3	483	483	Y -> C (in a gastric adenocarcinoma sample; somatic mutation).
RPS6KA3	608	608	L -> F (in a glioblastoma multiforme sample; somatic mutation).
CNKSR2	46	46	R -> H (in a colorectal cancer sample; somatic mutation).
MBTPS2	87	87	M -> I (in IFAPS; does not affect subcellular localization; impairs activity).
MBTPS2	226	226	W -> L (in IFAPS; does not affect subcellular localization; impairs activity).
MBTPS2	227	227	H -> L (in IFAPS; does not affect subcellular localization; impairs activity).
MBTPS2	429	429	R -> H (in IFAPS; does not affect subcellular localization; impairs activity).
MBTPS2	475	475	F -> S (in IFAPS; does not affect subcellular localization; impairs activity).
MBTPS2	508	508	N -> S (in KFSDX; sterol responsiveness is reduced by half).
PHEX	77	77	C -> S (in HYP).
PHEX	80	80	F -> S (in HYP; sporadic).
PHEX	85	85	C -> F (in HYP; sporadic).
PHEX	85	85	C -> R (in HYP).
PHEX	85	85	C -> Y (in HYP).
PHEX	138	138	L -> P (in HYP).
PHEX	141	141	S -> P (in HYP; sporadic).
PHEX	142	142	C -> F (in HYP).
PHEX	160	160	L -> R (in HYP).
PHEX	166	166	R -> C (in HYP).
PHEX	237	237	D -> G (in HYP; sporadic).
PHEX	252	252	F -> S (in HYP).
PHEX	253	253	M -> I (in HYP).
PHEX	317	317	Y -> F (in HYP).
PHEX	341	341	Missing (in HYP; sporadic).
PHEX	444	444	W -> WN (in HYP).
PHEX	530	530	W -> C (in HYP).
PHEX	534	534	P -> L (in HYP).
PHEX	555	555	L -> P (in HYP).
PHEX	567	567	R -> P (in HYP; sporadic).
PHEX	573	573	A -> D (in HYP; sporadic).
PHEX	579	579	G -> R (in HYP).
PHEX	579	579	G -> V (in HYP).
PHEX	621	621	Q -> R (in HYP).
PHEX	651	651	R -> P (in HYP).
PHEX	680	680	N -> K (in HYP; sporadic).
PHEX	680	680	Missing (in HYP).
PHEX	693	693	C -> Y (in HYP; sporadic).
PHEX	720	720	A -> T (in HYP).
PHEX	731	731	F -> Y (in HYP).
PHEX	733	733	C -> S (in HYP; sporadic).
PHEX	746	746	C -> W (in HYP; sporadic).
PHEX	749	749	W -> R (in HYP).
ACOT9	305	305	N -> H (in a pancreatic ductal adenocarcinoma sample; somatic mutation).
PDK3	219	219	E -> A (in a head & Neck squamous cell carcinoma sample; somatic mutation).
PRRG1	60	60	F -> I (in a breast cancer sample; somatic mutation).
SRPX	23	23	Missing.
RPGR	43	43	G -> E (in RP3).
RPGR	43	43	G -> R (in RP3).
RPGR	60	60	G -> V (in RP3).
RPGR	75	75	I -> V (in RP3; could be a polymorphism).
RPGR	98	98	H -> Q (in RP3; reduces interaction with PDE6D).
RPGR	99	99	T -> N (in RP3).
RPGR	127	127	R -> G (in RP3).
RPGR	130	130	F -> C (in RP3; reduces interaction with PDE6D).
RPGR	152	152	S -> L (in RP3).
RPGR	173	173	G -> R (in RP3 and RPDSI).
RPGR	215	215	G -> V (in RP3; reduces interaction with PDE6D).
RPGR	235	235	P -> S (in RP3; reduces interaction with PDE6D).
RPGR	250	250	C -> R (in RP3; reduces interaction with PDE6D).
RPGR	250	250	C -> Y (in RP3).
RPGR	258	258	Missing (in RP3).
RPGR	262	262	A -> G (in RP3; could be a polymorphism).
RPGR	267	267	G -> E (in RP3).
RPGR	267	267	G -> R (in RP3).
RPGR	275	275	G -> S (in RP3; reduces interaction with PDE6D).
RPGR	285	285	E -> G (in RP3).
RPGR	289	289	I -> V (in RP3).
RPGR	296	300	Missing (in RP3).
RPGR	302	302	C -> R (in RP3).
RPGR	302	302	C -> Y (in RP3).
RPGR	312	312	D -> N (in RP3).
RPGR	312	312	D -> Y (in RP3).
RPGR	320	320	G -> R (in RP3).
RPGR	431	431	I -> V.
RPGR	436	436	G -> D (in RP3).
RPGR	526	526	Missing.
OTC	26	26	R -> Q (in OTCD).
OTC	39	39	G -> C (in OTCD; late onset).
OTC	40	40	R -> C (in OTCD; late onset).
OTC	40	40	R -> H (in OTCD; late onset).
OTC	43	43	L -> F.
OTC	44	44	T -> I (in OTCD).
OTC	45	45	L -> P (in OTCD).
OTC	45	45	L -> V (in OTCD).
OTC	47	47	N -> I (in OTCD; neonatal).
OTC	50	50	G -> R (in OTCD; late onset).
OTC	55	55	Y -> D (in OTCD; late onset).
OTC	56	56	M -> T (in OTCD; late onset).
OTC	60	60	S -> L (in OTCD).
OTC	63	63	L -> P (in OTCD; late onset).
OTC	79	79	G -> E (in OTCD).
OTC	82	82	Missing (in OTCD).
OTC	83	83	G -> D (in OTCD).
OTC	83	83	G -> R (in OTCD; neonatal).
OTC	87	87	E -> K (in OTCD).
OTC	88	88	K -> N (in OTCD; late onset).
OTC	90	90	S -> R (in OTCD).
OTC	92	92	R -> Q (in OTCD).
OTC	93	93	T -> A (in OTCD; late onset).
OTC	94	94	R -> T (in OTCD).
OTC	100	100	G -> D (in OTCD; late onset).
OTC	101	101	F -> L.
OTC	102	102	A -> E (in OTCD).
OTC	117	117	H -> L (in OTCD).
OTC	117	117	H -> R (in OTCD; late onset).
OTC	125	125	T -> M (in OTCD; neonatal).
OTC	126	126	D -> G (in OTCD; 0.9% of wild-type activity; early onset).
OTC	129	129	R -> H (in OTCD; 2.1% of wild-type activity; early onset).
OTC	139	139	L -> S (in OTCD).
OTC	140	140	A -> P (in OTCD; late onset).
OTC	141	141	R -> P (in OTCD).
OTC	141	141	R -> Q (in OTCD; activity is 100-fold lower; most common point mutation).
OTC	148	148	L -> F (in OTCD).
OTC	159	159	I -> T (in OTCD).
OTC	160	160	I -> S (in OTCD).
OTC	161	161	N -> S (in OTCD).
OTC	162	162	G -> R (in OTCD).
OTC	168	168	H -> Q (in OTCD; late onset).
OTC	168	168	H -> R (in OTCD; late onset).
OTC	172	172	I -> F (in OTCD).
OTC	172	172	I -> M (in OTCD; no activity; early onset).
OTC	174	174	A -> P (in OTCD).
OTC	175	175	D -> V (in OTCD).
OTC	176	176	Y -> C (in OTCD; late onset).
OTC	178	179	Missing (in OTCD; neonatal).
OTC	178	178	T -> M (in OTCD; neonatal).
OTC	180	180	Q -> H (in OTCD).
OTC	181	181	E -> G (in OTCD; neonatal).
OTC	182	182	H -> L (in OTCD).
OTC	183	183	Y -> C (in OTCD).
OTC	183	183	Y -> D (in OTCD; late onset).
OTC	188	188	G -> R (in OTCD; neonatal).
OTC	188	188	G -> V (in OTCD).
OTC	191	191	L -> F (in OTCD).
OTC	192	192	S -> R (in OTCD; neonatal).
OTC	195	195	G -> R (in OTCD; no activity).
OTC	196	196	D -> V (in OTCD; neonatal; 3.7% activity).
OTC	196	196	D -> Y (in OTCD; neonatal).
OTC	197	197	G -> E (in OTCD).
OTC	197	197	G -> R (in OTCD).
OTC	198	198	N -> K (in OTCD).
OTC	201	201	L -> P (in OTCD; neonatal).
OTC	202	202	H -> Y (in OTCD).
OTC	203	203	S -> C (in OTCD).
OTC	206	206	M -> I (in OTCD).
OTC	206	206	M -> R (in OTCD; neonatal).
OTC	207	207	S -> R (in OTCD; neonatal).
OTC	208	208	A -> T (in OTCD; late onset).
OTC	209	209	A -> V (in OTCD; neonatal).
OTC	213	213	M -> K (in OTCD; late onset).
OTC	214	214	H -> Y (in OTCD; neonatal).
OTC	216	216	Q -> E (in OTCD).
OTC	220	220	P -> A (in OTCD; late onset).
OTC	225	225	P -> L (in OTCD).
OTC	225	225	P -> R (in OTCD; neonatal).
OTC	225	225	P -> T (in OTCD; late onset).
OTC	242	242	T -> I (in OTCD; late onset).
OTC	244	244	L -> Q (in OTCD; late onset).
OTC	247	247	T -> K (in OTCD; neonatal/late onset).
OTC	255	255	H -> P (in OTCD).
OTC	262	262	T -> K (in OTCD; mild).
OTC	263	263	D -> G (in OTCD).
OTC	263	263	D -> N (in OTCD).
OTC	264	264	T -> A (in OTCD; late onset 8.9% activity).
OTC	264	264	T -> I (in OTCD; late onset).
OTC	265	265	W -> L (in OTCD; mild).
OTC	267	267	S -> R (in OTCD).
OTC	268	268	M -> T (in OTCD; late onset).
OTC	269	269	G -> E (in OTCD; neonatal).
OTC	272	272	Missing (in OTCD; late onset).
OTC	277	277	R -> Q (in OTCD; late onset).
OTC	277	277	R -> W (in OTCD; late onset).
OTC	301	301	L -> F (in OTCD).
OTC	302	302	H -> L (in OTCD; female; late onset).
OTC	302	302	H -> Q (in OTCD; late onset).
OTC	302	302	H -> Y (in OTCD; neonatal).
OTC	303	303	C -> R (in OTCD; neonatal).
OTC	303	303	C -> Y (in OTCD).
OTC	304	304	L -> F (in OTCD).
OTC	305	305	P -> H (in OTCD).
OTC	309	309	Missing (in OTCD; late onset).
OTC	320	320	R -> L (in OTCD).
OTC	326	326	E -> K (in OTCD).
OTC	330	330	R -> G (in OTCD).
OTC	333	333	T -> A.
OTC	336	336	A -> S (in OTCD; late onset).
OTC	337	337	V -> L (in OTCD; late onset).
OTC	339	339	V -> L (in OTCD; neonatal).
OTC	340	340	S -> P (in OTCD; late onset).
OTC	341	341	L -> P (in OTCD).
OTC	343	343	T -> K (in OTCD; late onset).
OTC	345	345	Y -> C (in OTCD; neonatal).
OTC	345	345	Y -> D (in OTCD).
OTC	354	354	F -> C (in OTCD; late onset).
TSPAN7	172	172	P -> H (in MRX58).
CASK	28	28	R -> L (in FGS4; does not reveal significant alterations induced by the mutation substitution; causes a partial skipping of exon 2 of the protein).
CASK	96	96	G -> V (in a lung large cell carcinoma sample; somatic mutation).
CASK	268	268	Y -> H (in MRXCASK).
CASK	396	396	P -> S (in MRXCASK).
CASK	710	710	D -> G (in MRXCASK).
MAOA	15	15	D -> E (in a breast cancer sample; somatic mutation).
KDM6A	1106	1106	L -> R (in a colorectal cancer sample; somatic mutation).
ZNF674	343	343	T -> M.
ZNF674	412	412	P -> L (in MRX92; uncertain pathological significance).
UBA1	539	539	M -> I (in SMAX2).
UBA1	547	547	S -> G (in SMAX2).
ZNF41	153	153	P -> L (in MRX89).
ZNF81	3	3	A -> V.
ZNF81	185	185	S -> L.
ZNF81	499	499	I -> V.
PQBP1	224	224	R -> W (in a colorectal cancer sample; somatic mutation).
CLCN5	30	30	R -> RH (in NPHL2).
CLCN5	57	57	G -> V (in NPHL2; alters targeting to endosomes).
CLCN5	179	179	G -> D (in NPHL2; retained in the endoplasmic reticulum; improperly N- glycosylated and non-functional).
CLCN5	200	200	L -> R (in NPHL2; retained in the endoplasmic reticulum; improperly N- glycosylated and non-functional).
CLCN5	203	203	S -> L (in NPHL2; retained in the endoplasmic reticulum; improperly N- glycosylated and non-functional).
CLCN5	212	212	G -> A (in NPHL2; trafficks normally to the cell surface and to early endosomes; endergoes complex glycosylation at the cell surface like wild-type protein but exhibits significant reductions in outwardly rectifying ion currents).
CLCN5	219	219	C -> R (in NPHL2; retained in the endoplasmic reticulum; improperly N- glycosylated and non-functional).
CLCN5	221	221	C -> R (in NPHL2; retained in the endoplasmic reticulum; improperly N- glycosylated and non-functional).
CLCN5	225	225	L -> P (in NPHL2; retained in the endoplasmic reticulum; improperly N- glycosylated and non-functional).
CLCN5	244	244	S -> L (in XLRH; trafficks normally to the cell surface and to early endosomes; displays complex glycosylation at the cell surface like wild-type protein; exhibits reduced current).
CLCN5	260	260	G -> V (in NPHL2; delayed in processing of the protein and decrease in the stability of the mature complex glycosylated form causing lower cell surface expression; the early endosome distribution is normal; shows abolished current at the plasma membrane).
CLCN5	267	267	E -> A (in NPHL2).
CLCN5	267	267	Missing (in NPHL2).
CLCN5	270	270	S -> G (in NPHL2).
CLCN5	270	270	S -> R (in NPHL2; retained in the endoplasmic reticulum; alters protein stability; associated with an abolishment of chloride current).
CLCN5	272	272	Y -> C (in NPHL2; trafficks normally to the cell surface and to early endosomes and displays complex glycosylation at the cell surface like wild-type protein; exhibits no current).
CLCN5	273	273	F -> L (in NPHL2).
CLCN5	278	278	L -> F (in NPHL2; associated with a marked reduction to about 30% of wild- type chloride currents; no significant differences between the expression of the mutated and wild-type protein).
CLCN5	280	280	R -> P (in LMWPHN; 70% reduction in chloride transport activity and alters targeting to endosomes).
CLCN5	340	340	N -> K (in NPHL2; retained in the endoplasmic reticulum; improperly N- glycosylated and non-fuctional).
CLCN5	462	462	G -> D (in NPHL2).
CLCN5	469	469	L -> P (in NPHL2; retained in the endoplasmic reticulum; improperly N- glycosylated and non-functional).
CLCN5	506	506	G -> E (in NPHL1).
CLCN5	512	512	G -> R (in NPHL2; abolishes the chloride currents).
CLCN5	513	513	G -> E (in NPHL2; causes retention in the endoplasmic reticulum and alters protein stability; total loss of function).
CLCN5	513	513	G -> R (in NPHL2).
CLCN5	516	516	R -> W (in NPHL2; causes retention in the endoplasmic reticulum and alters protein stability; total loss of function).
CLCN5	520	520	S -> P (in NPHL2).
CLCN5	524	524	I -> K (in LMWPHN; causes retention in the endoplasmic reticulum and alters protein stability; total loss of function).
CLCN5	527	527	E -> D (in NPHL2; abolishes the chloride currents; total loss of function).
CLCN5	545	545	S -> N (in NPHL2).
CLCN5	546	546	K -> E (in NPHL2; delayed in processing of the protein and decrease in the stability of the mature complex glycosylated form causing lower cell surface expression; the early endosome distribution is normal; shows abolished current at the plasma membrane).
CLCN5	547	547	W -> G (in NPHL2; delayed in processing of the protein and decrease in the stability of the mature complex glycosylated form causing lower cell surface expression; the early endosome distribution is normal; shows reduced current at the plasma membrane).
CLCN5	657	657	T -> S (in NPHL2).
CCNB3	597	597	K -> T (in a colorectal cancer sample; somatic mutation).
SHROOM4	1089	1089	S -> L (in SDSX).
IQSEC2	349	349	R -> C (in MRX1).
IQSEC2	748	748	R -> Q (in MRX1).
IQSEC2	791	791	Q -> P (in MRX1).
IQSEC2	853	853	R -> W (in MRX1).
HUWE1	2981	2981	R -> H (in MRXS-Turner).
HUWE1	4013	4013	R -> W (in MRXS-Turner).
HUWE1	4187	4187	R -> C (in MRXS-Turner).
PHF8	315	315	F -> S (in MRXSSD; abolishes histone methyltransferase activity).
WNK3	854	854	S -> C (in a lung squamous cell carcinoma sample; somatic mutation).
WNK3	1486	1486	L -> F (in a lung large cell carcinoma sample; somatic mutation).
WNK3	1577	1577	S -> P (in a renal clear cell carcinoma sample; somatic mutation).
ALAS2	159	159	D -> Y (in XLSA).
ALAS2	199	199	Y -> H (in XLSA).
ALAS2	204	204	R -> Q (in XLSA; 15% to 35% activity of wild-type).
ALAS2	388	388	T -> S (in XLSA).
ALAS2	411	411	R -> C (in XLSA; 12% to 25% activity of wild-type).
ALAS2	448	448	R -> Q (in XLSA).
ALAS2	452	452	R -> C (in XLSA).
ALAS2	476	476	I -> N (in XLSA).
ALAS2	560	560	R -> H (in XLSA).
MTMR8	127	127	W -> R (in a breast cancer sample; somatic mutation).
MTMR8	454	454	E -> K (in a breast cancer sample; somatic mutation).
LAS1L	170	170	R -> C (in a colorectal cancer sample; somatic mutation).
AR	2	2	E -> K (in PAIS).
AR	54	54	L -> S (in prostate cancer).
AR	57	57	L -> Q (in prostate cancer).
AR	64	64	Q -> R (in prostate cancer).
AR	74	78	Missing.
AR	112	112	Q -> H (in prostate cancer).
AR	180	180	K -> R (in prostate cancer).
AR	194	194	Q -> R (in AIS).
AR	205	205	S -> R.
AR	214	214	G -> R (in AIS; 20% lower transactivation capacity).
AR	255	255	L -> P (in AIS).
AR	266	266	M -> T (in prostate cancer).
AR	269	269	P -> S (in prostate cancer).
AR	340	340	P -> L (in prostate cancer).
AR	390	390	P -> R (in AIS).
AR	390	390	P -> S (in AIS).
AR	443	443	Q -> R (in AIS; might be a polymorphism).
AR	465	472	Missing.
AR	491	491	G -> S (in AIS).
AR	528	528	D -> G (in prostate cancer).
AR	547	547	L -> F (in PAIS).
AR	548	548	P -> S (in AIS).
AR	559	559	C -> Y (in AIS).
AR	568	568	G -> V (in a patient with isolated hypospadias).
AR	568	568	G -> W (in PAIS).
AR	571	571	Y -> C (in AIS).
AR	573	573	A -> D (in AIS; defective DNA binding and transactivation).
AR	574	574	L -> P (in prostate cancer).
AR	575	575	T -> A (in prostate cancer).
AR	576	576	C -> F (in AIS; lack of DNA binding).
AR	576	576	C -> R (in AIS).
AR	579	579	C -> F (in AIS; reduced transcription and DNA binding).
AR	579	579	C -> Y (in AIS).
AR	580	580	K -> R (in prostate cancer).
AR	581	581	V -> F (in AIS).
AR	582	582	F -> S (in PAIS).
AR	582	582	F -> Y (in PAIS).
AR	582	582	Missing (in AIS).
AR	585	585	R -> K (in AIS).
AR	586	586	A -> V (in prostate cancer; somatic mutation).
AR	587	587	A -> S (in prostate cancer; somatic mutation).
AR	596	596	A -> T (in AIS; abolishes dimerization).
AR	597	597	S -> G (in PAIS; high dissociation rate; associated with P-617 in a PAIS patient; partially restores DNA-binding activity of P-617 mutant receptors).
AR	597	597	S -> T (in a patient with severe hypospadias).
AR	601	601	C -> F (in AIS).
AR	604	604	D -> Y (in PAIS).
AR	607	607	R -> Q (in PAIS and breast cancer).
AR	608	608	R -> K (in PAIS and breast cancer; defective nuclear localization).
AR	610	610	N -> T (in PAIS).
AR	611	611	C -> Y (in AIS).
AR	615	615	R -> H (in AIS and PAIS).
AR	615	615	R -> P (in AIS).
AR	615	615	Missing (in AIS).
AR	616	616	L -> P (in AIS).
AR	616	616	L -> R (in PAIS).
AR	617	617	R -> P (in AIS and PAIS; loss of DNA- binding activity; associated with G-597 in a PAIS patient).
AR	619	619	C -> Y (in prostate cancer; loss of DNA binding; somatic mutation).
AR	629	629	R -> Q (in prostate cancer).
AR	630	630	K -> T (in prostate cancer).
AR	647	647	S -> N (in prostate cancer).
AR	664	664	I -> N (in AIS and PAIS).
AR	670	670	Q -> R (in prostate cancer).
AR	671	671	P -> H (in PAIS).
AR	672	672	I -> T (in prostate cancer).
AR	677	677	L -> P (in AIS).
AR	681	681	E -> K (in AIS).
AR	682	682	P -> T (in PAIS).
AR	683	683	G -> A (in prostate cancer).
AR	684	684	V -> I (in AIS).
AR	686	686	C -> R (in PAIS).
AR	687	687	A -> V (in PAIS).
AR	688	688	G -> E (in AIS).
AR	690	690	Missing (in PAIS).
AR	692	692	Missing (in AIS).
AR	695	695	D -> H (in AIS).
AR	695	695	D -> N (in AIS; almost complete loss of androgen binding and transcription activation).
AR	695	695	D -> V (in AIS).
AR	700	700	L -> M (in AIS).
AR	701	701	L -> F (in AIS).
AR	701	701	L -> H (in AIS and prostate cancer).
AR	702	702	S -> A (in AIS).
AR	703	703	S -> C (in AIS).
AR	703	703	S -> G (in PAIS and AIS).
AR	705	705	N -> S (in AIS).
AR	705	705	N -> Y (in AIS).
AR	707	707	L -> R (in AIS).
AR	708	708	G -> A (in PAIS).
AR	708	708	G -> V (in AIS).
AR	710	710	R -> T (in AIS).
AR	711	711	Q -> E (in PAIS).
AR	712	712	L -> F (in PAIS).
AR	715	715	V -> M (in prostate cancer; gain in function).
AR	717	717	K -> E (in prostate cancer).
AR	720	720	K -> E (in prostate cancer; found in bone metastases).
AR	721	721	A -> T (in prostate cancer; somatic mutation).
AR	722	722	L -> F (in AIS).
AR	723	723	P -> S (in AIS).
AR	724	724	G -> D (in AIS and prostate cancer).
AR	725	725	F -> L (in a patient with severe hypospadias).
AR	726	726	R -> L (in prostate cancer).
AR	727	727	N -> K (in AIS).
AR	728	728	L -> S (in PAIS).
AR	730	730	V -> M (in prostate cancer; increases transcription activation).
AR	732	732	D -> N (in AIS).
AR	732	732	D -> Y (in AIS).
AR	733	733	Q -> H (in PAIS).
AR	737	737	I -> T (in PAIS).
AR	741	741	W -> R (in AIS).
AR	742	742	M -> I (in PAIS).
AR	742	742	M -> V (in PAIS).
AR	743	743	G -> E (in AIS).
AR	743	743	G -> V (in PAIS and AIS).
AR	744	744	L -> F (in AIS and prostate cancer).
AR	745	745	M -> T (in PAIS).
AR	746	746	V -> M (in PAIS).
AR	748	748	A -> D (in PAIS).
AR	748	748	A -> T (in prostate cancer).
AR	748	748	A -> V (in prostate cancer).
AR	749	749	M -> I (in prostate cancer).
AR	749	749	M -> V (in PAIS and AIS).
AR	750	750	G -> D (in AIS; loss of androgen binding).
AR	750	750	G -> S (in prostate cancer).
AR	751	751	W -> R (in AIS).
AR	752	752	R -> Q (in AIS).
AR	754	754	F -> L (in PAIS and prostate cancer).
AR	754	754	F -> V (in AIS).
AR	755	755	T -> A (in prostate cancer).
AR	756	756	N -> S (in PAIS).
AR	757	757	V -> A (in prostate cancer).
AR	758	758	N -> T (in PAIS; 50% reduction in transactivation).
AR	759	759	S -> F (in AIS).
AR	759	759	S -> P (in prostate cancer).
AR	762	762	L -> F (in AIS; loss of androgen binding).
AR	763	763	Y -> C (in PAIS and prostate cancer; partial loss of androgen binding).
AR	763	763	Y -> H (in AIS).
AR	764	764	F -> L (in AIS).
AR	765	765	A -> T (in AIS; loss of androgen binding).
AR	765	765	A -> V (in AIS).
AR	766	766	P -> S (in AIS).
AR	767	767	D -> E (in AIS).
AR	768	768	L -> P (in AIS).
AR	771	771	N -> H (in PAIS).
AR	772	772	E -> A (in PAIS).
AR	772	772	E -> G (in PAIS).
AR	774	774	R -> C (in AIS; loss of androgen binding; frequent mutation).
AR	774	774	R -> H (in AIS and PAIS; almost complete loss of androgen binding).
AR	779	779	R -> W (in AIS).
AR	780	780	M -> I (in PAIS and AIS).
AR	782	782	S -> N (in prostate cancer; somatic mutation).
AR	784	784	C -> Y (in AIS; loss of androgen binding and of transactivation).
AR	787	787	M -> V (in AIS).
AR	788	788	R -> S (in AIS).
AR	790	790	L -> F (in AIS).
AR	791	791	S -> P (in prostate cancer).
AR	793	793	E -> D.
AR	794	794	F -> S (in AIS).
AR	798	798	Q -> E (in PAIS, AIS and prostate cancer; reduced transcription activation).
AR	806	806	C -> Y (in PAIS).
AR	807	807	M -> R (in AIS; loss of transactivation).
AR	807	807	M -> T (in PAIS).
AR	807	807	M -> V (in AIS; 25% androgen binding).
AR	812	812	L -> F (in AIS).
AR	814	814	S -> N (in AIS and PAIS).
AR	820	820	G -> A (in AIS).
AR	821	821	L -> V (in PAIS).
AR	827	827	F -> V (in PAIS).
AR	830	830	L -> P (in prostate cancer).
AR	831	831	R -> L (in AIS).
AR	831	831	R -> Q (in AIS; loss of androgen binding).
AR	834	834	Y -> C (in AIS; loss of androgen binding).
AR	840	840	R -> C (in AIS).
AR	840	840	R -> G (in PAIS).
AR	840	840	R -> H (in AIS).
AR	840	840	R -> S (in PAIS).
AR	841	841	I -> S (in PAIS).
AR	842	842	I -> T (in AIS).
AR	846	846	R -> G (in prostate cancer).
AR	854	854	R -> K (in PAIS).
AR	855	855	R -> C (in AIS).
AR	855	855	R -> H (in AIS; strongly reduced transcription activation).
AR	856	856	F -> L (in AIS).
AR	863	863	L -> R (in AIS).
AR	864	864	D -> G (in AIS).
AR	864	864	D -> N (in AIS; loss of androgen binding).
AR	865	865	S -> P (in AIS).
AR	866	866	V -> E (in AIS).
AR	866	866	V -> L (in PAIS).
AR	866	866	V -> M (in AIS and prostate cancer).
AR	869	869	I -> M (in PAIS).
AR	870	870	A -> G (in PAIS).
AR	870	870	A -> V (in PAIS).
AR	871	871	R -> G (in AIS).
AR	874	874	H -> R (in AIS).
AR	874	874	H -> Y (in prostate cancer; increases affinity for testosterone, androgen sensitivity and transcription activation).
AR	877	877	T -> A (in prostate cancer; alters receptor specificity so that transcription is activated by antiandrogens, such as cyproterone acetate; found in bone metastases).
AR	877	877	T -> S (in prostate cancer).
AR	879	879	D -> Y (in AIS).
AR	880	880	L -> Q (in prostate cancer).
AR	881	881	L -> V (in AIS).
AR	886	886	M -> V (in AIS).
AR	889	889	V -> M (in AIS and PAIS).
AR	890	890	D -> N (in prostate cancer).
AR	891	891	F -> L (in prostate cancer).
AR	892	892	P -> L (in AIS).
AR	895	895	M -> T (in AIS; low androgen binding and transactivation).
AR	896	896	A -> T (in prostate cancer).
AR	898	898	I -> T (in AIS).
AR	902	902	Q -> R (in prostate cancer).
AR	903	903	V -> M (in PAIS).
AR	904	904	P -> H (in AIS).
AR	904	904	P -> S (in AIS).
AR	907	907	L -> F (in AIS; almost complete loss of transcription activation).
AR	909	909	G -> E (in prostate cancer).
AR	909	909	G -> R (in PAIS).
AR	910	910	K -> R (in prostate cancer).
AR	911	911	V -> L (in PAIS).
AR	913	913	P -> S (in PAIS).
AR	916	916	F -> L (in AIS).
AR	917	917	H -> R (in AIS).
AR	919	919	Q -> R (in prostate cancer).
OPHN1	45	45	A -> T.
OPHN1	301	301	T -> M.
STARD8	188	188	G -> S (in a breast cancer sample; somatic mutation).
STARD8	242	242	E -> K (in a breast cancer sample; somatic mutation).
NLGN3	451	451	R -> C (in AUTSX1 and ASPGX1).
TAF1	453	453	G -> D (in a colorectal adenocarcinoma sample; somatic mutation).
TAF1	651	651	E -> K (in a metastatic melanoma sample; somatic mutation).
TAF1	691	691	M -> I (in a lung bronchoalveolar carcinoma sample; somatic mutation).
OGT	538	538	L -> P (found in a renal cell carcinoma sample; somatic mutation).
PHKA1	299	299	D -> V (in GSD9D).
SLC16A2	120	120	S -> F (in MCT8 deficiency).
SLC16A2	150	150	A -> V (in MCT8 deficiency).
SLC16A2	156	156	Missing (in MCT8 deficiency).
SLC16A2	161	161	V -> M (in MCT8 deficiency).
SLC16A2	360	360	L -> W (in MCT8 deficiency).
SLC16A2	397	397	L -> P (in MCT8 deficiency).
SLC16A2	427	427	Missing (in MCT8 deficiency).
SLC16A2	438	438	L -> P (in MCT8 deficiency).
SLC16A2	490	490	G -> R (in MCT8 deficiency).
SLC16A2	494	494	L -> P (in MCT8 deficiency).
ABCB7	315	315	R -> G.
ABCB7	346	346	F -> I.
ABCB7	400	400	I -> M (in ASAT).
ABCB7	411	411	V -> L (in ASAT).
ABCB7	433	433	E -> K (in ASAT; impaired maturation of cytosolic Fe/S proteins).
ATRX	175	175	G -> E (in ATRX).
ATRX	178	198	Missing (in ATRX).
ATRX	179	179	N -> S (in ATRX).
ATRX	190	190	P -> A (in ATRX).
ATRX	190	190	P -> L (in ATRX).
ATRX	190	190	P -> S (in ATRX).
ATRX	192	192	L -> F (in ATRX).
ATRX	194	194	V -> I (in ATRX).
ATRX	200	200	C -> S (in ATRX).
ATRX	219	219	Q -> P (in ATRX).
ATRX	220	220	C -> R (in ATRX).
ATRX	220	220	C -> Y (in MRXSHF1).
ATRX	222	222	W -> S (in ATRX).
ATRX	243	243	C -> F (in ATRX).
ATRX	246	246	R -> C (in ATRX).
ATRX	246	246	R -> L (in ATRX).
ATRX	249	249	G -> C (in ATRX).
ATRX	249	249	G -> D (in ATRX).
ATRX	409	409	L -> S (in MRXSHF1).
ATRX	1538	1538	V -> G (in ATRX; could be a polymorphism).
ATRX	1552	1552	V -> F (in ATRX).
ATRX	1609	1609	H -> R (in ATRX).
ATRX	1614	1614	C -> R (in ATRX).
ATRX	1621	1621	T -> M (in ATRX).
ATRX	1645	1645	L -> S (in ATRX).
ATRX	1650	1650	K -> N (in ATRX).
ATRX	1713	1713	P -> S (in ATRX; without alpha- thalassemia).
ATRX	1742	1742	R -> K (in ATRX; atypical; patients presents spastic paraplegia at birth).
ATRX	1847	1847	Y -> C (in ATRX).
ATRX	2035	2035	D -> V (in ATRX).
ATRX	2050	2050	I -> T (in MRXSHF1; originally reported as Carpenter-Waziri syndrome).
ATRX	2084	2084	Y -> H (in ATRX).
ATRX	2131	2131	R -> Q (in MRXSHF1; originally reported as Juberg-Marsidi syndrome).
ATRX	2163	2163	Y -> C (in ATRX).
ATRX	2271	2271	R -> G (in MRXSHF1).
ATP7A	629	629	A -> P (in MNKD).
ATP7A	706	706	L -> R (in MNKD).
ATP7A	727	727	G -> R (in MNKD).
ATP7A	844	844	R -> H (in MNKD).
ATP7A	853	853	G -> R (in MNKD).
ATP7A	860	860	G -> V (in MNKD).
ATP7A	873	873	L -> R (in MNKD).
ATP7A	876	876	G -> E (in MNKD).
ATP7A	876	876	G -> R (in MNKD).
ATP7A	924	924	Q -> R (in MNKD).
ATP7A	994	994	T -> I (in DSMAX3; demonstrates impaired intracellular trafficking compared to control with some of the mutant protein remaining in the Golgi apparatus after exposure to copper).
ATP7A	1000	1000	C -> R (in MNKD).
ATP7A	1006	1006	L -> P (in MNKD).
ATP7A	1007	1007	A -> V (in MNKD).
ATP7A	1015	1015	G -> D (in MNKD).
ATP7A	1019	1019	G -> D (in MNKD).
ATP7A	1044	1044	D -> G (in MNKD).
ATP7A	1100	1100	L -> P (in MNKD).
ATP7A	1118	1118	G -> D (in MNKD).
ATP7A	1255	1255	G -> R (in MNKD).
ATP7A	1282	1282	K -> E (in MNKD).
ATP7A	1300	1300	G -> E (in MNKD).
ATP7A	1302	1302	G -> R (in MNKD).
ATP7A	1302	1302	G -> V (in MNKD).
ATP7A	1304	1304	N -> K (in MNKD).
ATP7A	1304	1304	N -> S (in OHS; has approximately 33% residual copper transport).
ATP7A	1305	1305	D -> A (in MNKD).
ATP7A	1315	1315	G -> R (in MNKD).
ATP7A	1325	1325	A -> V (in MNKD).
ATP7A	1344	1344	S -> R (in MNKD).
ATP7A	1345	1345	I -> F (in MNKD).
ATP7A	1362	1362	A -> V (in MNKD).
ATP7A	1369	1369	G -> R (in MNKD).
ATP7A	1386	1386	P -> S (in DSMAX3; demonstrates impaired intracellular trafficking compared to control with some mutant protein remaining in the Golgi apparatus after exposure to copper).
ATP7A	1397	1397	S -> F (in MNKD).
BRWD3	1596	1596	K -> E (in MRX93; may be a rare polymorphism).
RPS6KA6	140	140	Y -> C (in a lung large cell carcinoma sample; somatic mutation).
RPS6KA6	258	258	S -> T (in a lung adenocarcinoma sample; somatic mutation).
POF1B	239	239	C -> S.
POF1B	329	329	R -> Q (in POF2B; disrupts binding to nonmuscle actin filaments).
POF1B	434	434	Q -> K.
POF1B	444	444	C -> Y.
CHM	471	471	Q -> L (in CHM).
TAF7L	61	61	E -> K.
TAF7L	350	351	Missing.
NRK	424	424	S -> C (in a breast infiltrating ductal carcinoma sample; somatic mutation).
NRK	880	880	I -> L (in a colorectal adenocarcinoma sample; somatic mutation).
COL4A6	1130	1130	G -> E (in a colorectal cancer sample; somatic mutation).
COL4A5	54	54	G -> D (in APSX; adult type).
COL4A5	114	114	G -> S (in APSX).
COL4A5	129	129	G -> E (in APSX; juvenile type).
COL4A5	129	129	G -> V (in APSX; juvenile type).
COL4A5	174	174	G -> R (in APSX).
COL4A5	177	177	G -> C (in APSX; presenting with dot-and- fleck retinopathy).
COL4A5	177	177	G -> R (in APSX; adult type).
COL4A5	192	192	G -> R (in APSX).
COL4A5	204	204	G -> V (in APSX; juvenile type).
COL4A5	216	216	G -> R (in APSX; juvenile type).
COL4A5	219	219	G -> S (in APSX).
COL4A5	230	230	G -> R (in APSX; juvenile type).
COL4A5	239	239	G -> E (in APSX).
COL4A5	264	264	G -> R (in APSX; adult type).
COL4A5	289	289	G -> V (in APSX; juvenile type).
COL4A5	292	292	G -> R (in APSX).
COL4A5	292	292	G -> V (in APSX; juvenile type).
COL4A5	295	295	G -> D (in APSX).
COL4A5	298	298	G -> S (in APSX).
COL4A5	319	319	G -> R (in APSX; juvenile type).
COL4A5	325	325	G -> E (in APSX).
COL4A5	325	325	G -> R (in APSX; juvenile and adult types).
COL4A5	331	331	G -> V (in APSX).
COL4A5	365	367	Missing (in APSX; juvenile type).
COL4A5	365	365	G -> E (in APSX; juvenile type).
COL4A5	371	371	G -> E (in APSX; juvenile type).
COL4A5	374	374	G -> A (in APSX).
COL4A5	383	383	G -> D (in APSX; juvenile type).
COL4A5	400	400	G -> E (in APSX; adult type).
COL4A5	406	406	G -> V (in APSX; adult type).
COL4A5	409	409	G -> D (in APSX).
COL4A5	412	412	G -> V (in APSX; adult type).
COL4A5	415	415	G -> R (in APSX).
COL4A5	420	420	G -> E (in APSX; juvenile type).
COL4A5	420	420	G -> V (in APSX).
COL4A5	423	423	G -> E (in APSX).
COL4A5	430	430	A -> D.
COL4A5	456	458	Missing (in APSX).
COL4A5	466	466	G -> E (in APSX).
COL4A5	472	472	G -> R (in APSX).
COL4A5	491	491	G -> E (in APSX; juvenile type).
COL4A5	494	494	G -> D (in APSX; adult type).
COL4A5	496	507	Missing (in APSX; juvenile type).
COL4A5	497	497	G -> C (in APSX; adult type).
COL4A5	521	521	G -> C (in APSX).
COL4A5	521	521	G -> S (in APSX).
COL4A5	524	524	G -> D (in APSX; adult type).
COL4A5	545	545	G -> R (in APSX).
COL4A5	545	545	G -> V (in APSX).
COL4A5	558	558	G -> R (in APSX).
COL4A5	561	561	G -> R (in APSX).
COL4A5	567	567	G -> A (in APSX; juvenile type).
COL4A5	573	573	G -> D (in APSX).
COL4A5	579	579	G -> E (in APSX).
COL4A5	579	579	G -> R (in APSX; adult type).
COL4A5	603	603	G -> V (in APSX).
COL4A5	609	609	G -> R (in APSX; juvenile type).
COL4A5	609	609	G -> V (in APSX; juvenile type).
COL4A5	619	619	P -> S.
COL4A5	621	621	G -> C (in APSX).
COL4A5	624	624	G -> D (in APSX).
COL4A5	629	629	G -> D (in APSX).
COL4A5	632	632	G -> D (in APSX).
COL4A5	633	633	E -> K (in APSX).
COL4A5	635	635	G -> D (in APSX).
COL4A5	638	638	G -> A (in APSX).
COL4A5	638	638	G -> S (in APSX; juvenile type).
COL4A5	638	638	G -> V (in APSX).
COL4A5	653	653	G -> R (in APSX; juvenile type).
COL4A5	669	669	G -> A (in APSX; juvenile type).
COL4A5	681	681	G -> D (in APSX).
COL4A5	684	684	G -> V (in APSX; adult type).
COL4A5	687	687	G -> E (in APSX).
COL4A5	722	722	G -> E (in APSX).
COL4A5	739	739	P -> A.
COL4A5	739	739	P -> S (in APSX; juvenile type).
COL4A5	740	740	G -> E (in APSX; juvenile type).
COL4A5	743	743	G -> D (in APSX).
COL4A5	772	772	G -> D (in APSX; juvenile type).
COL4A5	796	796	G -> R (in APSX).
COL4A5	802	807	Missing (in APSX).
COL4A5	802	802	G -> R (in APSX).
COL4A5	808	808	G -> E (in APSX; adult type).
COL4A5	811	811	G -> V (in APSX; juvenile type).
COL4A5	822	824	Missing (in APSX).
COL4A5	822	822	G -> R (in APSX).
COL4A5	852	852	G -> E (in APSX; juvenile type).
COL4A5	852	852	G -> R (in APSX).
COL4A5	864	875	Missing (in APSX).
COL4A5	866	866	G -> E (in APSX; adult type).
COL4A5	869	869	G -> R (in APSX; juvenile type).
COL4A5	872	872	G -> R (in APSX).
COL4A5	878	878	G -> R (in APSX).
COL4A5	898	898	M -> V (in APSX; mild phenotype).
COL4A5	902	902	G -> V (in APSX; juvenile type).
COL4A5	911	911	G -> E (in APSX).
COL4A5	941	941	G -> C (in APSX).
COL4A5	942	942	Missing (in APSX).
COL4A5	947	947	G -> D (in APSX).
COL4A5	953	953	G -> V (in APSX; found on the same allele as variant Glu-1211).
COL4A5	988	992	Missing (in APSX; adult type).
COL4A5	1006	1006	G -> A (in APSX).
COL4A5	1006	1006	G -> V (in APSX).
COL4A5	1015	1015	G -> E (in APSX).
COL4A5	1015	1015	G -> V (in APSX).
COL4A5	1030	1030	G -> S (in APSX).
COL4A5	1036	1036	G -> V (in APSX).
COL4A5	1039	1039	G -> S (in APSX; juvenile type).
COL4A5	1045	1045	G -> E (in APSX).
COL4A5	1066	1066	G -> R (in APSX).
COL4A5	1066	1066	G -> S (in APSX).
COL4A5	1086	1086	G -> D (in APSX).
COL4A5	1104	1104	G -> V (in APSX).
COL4A5	1107	1107	G -> R (in APSX).
COL4A5	1143	1143	G -> D (in APSX; juvenile type).
COL4A5	1143	1143	G -> S (in APSX; adult type).
COL4A5	1158	1158	G -> R (in APSX).
COL4A5	1161	1161	G -> R (in APSX).
COL4A5	1167	1167	G -> S (in APSX).
COL4A5	1170	1170	G -> S (in APSX).
COL4A5	1182	1182	G -> R (in APSX; juvenile type).
COL4A5	1196	1196	G -> R (in APSX).
COL4A5	1205	1205	G -> C (in APSX; juvenile type).
COL4A5	1211	1211	G -> E (in APSX; found on the same allele as variant Val-953).
COL4A5	1211	1211	G -> R (in APSX).
COL4A5	1220	1220	G -> D (in APSX).
COL4A5	1229	1229	G -> D (in APSX; adult type).
COL4A5	1241	1241	G -> C (in APSX).
COL4A5	1244	1244	G -> D (in APSX).
COL4A5	1252	1252	G -> S (in APSX; adult type).
COL4A5	1261	1261	G -> E (in APSX).
COL4A5	1270	1270	G -> S (in APSX).
COL4A5	1333	1333	G -> S (in APSX).
COL4A5	1357	1357	G -> S (in APSX).
COL4A5	1379	1379	G -> V (in APSX; adult type).
COL4A5	1410	1410	R -> C (in APSX; adult and juvenile types).
COL4A5	1421	1421	G -> W (in APSX; adult type).
COL4A5	1422	1422	R -> C (in APSX; juvenile type).
COL4A5	1427	1427	G -> V (in APSX; adult type).
COL4A5	1428	1428	L -> M.
COL4A5	1442	1442	G -> D (in APSX).
COL4A5	1451	1451	G -> S (in APSX).
COL4A5	1486	1486	G -> A (in APSX; adult type).
COL4A5	1488	1488	S -> F (in APSX).
COL4A5	1498	1498	A -> D (in APSX).
COL4A5	1511	1511	R -> H (in APSX; juvenile type; could be a non pathogenic variant).
COL4A5	1517	1517	P -> T (in APSX; juvenile type).
COL4A5	1538	1538	W -> S (in APSX; adult type).
COL4A5	1559	1559	P -> A.
COL4A5	1563	1563	R -> Q (in APSX).
COL4A5	1564	1564	C -> S (in APSX; adult type).
COL4A5	1567	1567	C -> R (in APSX; juvenile type).
COL4A5	1596	1596	G -> D (in APSX).
COL4A5	1597	1685	Missing (in APSX).
COL4A5	1649	1649	L -> R (in APSX; adult type).
COL4A5	1677	1677	R -> P (in APSX).
COL4A5	1677	1677	R -> Q (in APSX).
COL4A5	1678	1678	C -> W (in APSX).
COL4A5	1679	1685	Missing (in APSX).
GUCY2F	10	10	R -> P (in a breast cancer sample; somatic mutation).
GUCY2F	568	568	G -> D (in a glioblastoma multiforme sample; somatic mutation).
GUCY2F	1052	1052	K -> R (in a lung adenocarcinoma sample; somatic mutation).
GUCY2F	1055	1055	E -> D (in a lung squamous cell carcinoma sample; somatic mutation).
ACSL4	133	133	R -> C (in a colorectal cancer sample; somatic mutation).
ACSL4	570	570	R -> S (in MRX63).
TMEM164	276	276	Y -> H (in a colorectal cancer sample; somatic mutation).
PAK3	67	67	R -> C (in MRX30).
PAK3	380	380	A -> E (in MRX30).
PAK3	440	440	T -> S (in a colorectal adenocarcinoma sample; somatic mutation).
CAPN6	358	358	G -> R (in a colorectal cancer sample; somatic mutation).
DCX	123	123	T -> I (in LISX1).
DCX	124	124	L -> S (in LISX1).
DCX	128	128	S -> R (in LISX1 and SBHX).
DCX	131	131	K -> N (in SBHX).
DCX	140	140	R -> H (in SBHX).
DCX	140	140	R -> L (in LISX1 and SBHX).
DCX	141	141	N -> D (in LISX1).
DCX	143	143	D -> N (in LISX1 and SBHX).
DCX	148	148	G -> E (in SBHX).
DCX	152	152	A -> S (in LISX1).
DCX	159	159	R -> H (in SBH).
DCX	159	159	R -> L (in SBHX).
DCX	167	167	D -> H (in SBHX).
DCX	170	170	R -> G (in SBHX; mild).
DCX	178	178	L -> R (in SBHX).
DCX	181	181	G -> A (in LISX1 and SBHX).
DCX	183	183	R -> S (in LISX1).
DCX	185	185	I -> T (in SBHX).
DCX	206	206	Y -> D (in SBHX).
DCX	206	206	Y -> H (in LISX1 and SBHX).
DCX	259	259	R -> C (in SBHX).
DCX	259	259	R -> L (in SBHX).
DCX	267	267	R -> C (in SBHX).
DCX	272	272	P -> L (in SBHX).
DCX	272	272	P -> R (in SBHX).
DCX	273	273	R -> W (in LISX1 and SBHX).
DCX	277	277	R -> S (in epilepsy; resistant partial seizures; related to 'cryptogenic' epilepsy).
DCX	281	281	N -> I (in SBHX).
DCX	281	281	N -> K (in SBHX).
DCX	284	284	T -> A (in SBHX).
DCX	284	284	T -> R (in LISX1 and SBHX).
DCX	295	295	I -> T (in SBHX).
DCX	303	303	T -> I (in SBHX).
DCX	304	304	G -> E (in SBHX).
DCX	304	304	G -> V (in SBHX).
DCX	317	317	V -> I (in SBHX).
DCX	324	324	F -> L (in LISX1).
DCX	331	331	I -> N (in SBHX).
DCX	331	331	I -> T (in SBHX).
DCX	332	332	A -> S (in SBHX).
DCX	332	332	A -> V (in SBHX).
DCX	334	334	G -> D (in SBHX).
HTR2C	156	156	I -> V (in RNA edited version).
HTR2C	158	158	N -> S (in RNA edited version).
HTR2C	160	160	I -> V (in RNA edited version).
PLS3	488	488	D -> A (in a breast cancer sample; somatic mutation).
KLHL13	223	223	F -> I (found in a renal cell carcinoma sample; somatic mutation).
CUL4B	213	213	T -> I (in MRXC; could be a rare polymorphism).
CUL4B	572	572	R -> C (in MRXC).
CUL4B	745	745	V -> A (in MRXC).
GRIA3	450	450	R -> Q (in MRX94).
GRIA3	631	631	R -> S (in MRX94; homomers have minimal or no current; heteromers have altered desensitization kinetics).
GRIA3	706	706	M -> T (in MRX94; homomers have minimal or no current; heteromers have altered desensitization kinetics).
GRIA3	833	833	G -> R (in MRX94; reduced receptor expression possibly due to rapid degradation).
OCRL	337	337	R -> P (in OCRL).
OCRL	367	367	Missing (in OCRL).
OCRL	478	479	Missing (in OCRL).
OCRL	495	495	P -> L (in OCRL).
OCRL	500	500	R -> G (in OCRL).
OCRL	533	533	I -> S (in OCRL).
OCRL	742	742	Missing (in OCRL).
OCRL	768	768	I -> N (in OCRL; uncertain pathological significance; abolishes FAM109A-binding; does not affect clathrin-binding).
OCRL	797	797	A -> P (in OCRL; uncertain pathological significance; abolishes FAM109A-, FAM109B- and APPL1-binding; does not affect clathrin-binding).
OCRL	799	799	P -> L (in DD2).
OCRL	801	801	P -> L (in OCRL).
MST4	36	36	G -> W (in a gastric adenocarcinoma sample; somatic mutation).
GPC3	296	296	W -> R (in SGBS1).
PHF6	99	99	C -> F (in BFLS).
PHF6	229	229	H -> R (in BFLS).
PHF6	234	234	K -> E (in BFLS).
PHF6	257	257	R -> G (in BFLS).
MAMLD1	580	580	Q -> R.
MTM1	47	47	Missing (in XCNM).
MTM1	49	49	V -> F (in XCNM; greatly reduced binding to PI(3,5)P2; does not translocate to the late endosome following EGF stimulation; shows normal EGFR degradation).
MTM1	68	68	Y -> D (in XCNM).
MTM1	69	69	R -> C (in XCNM; mild; reduced response to PI5P and reduced binding to PI(3,5)P2).
MTM1	69	69	R -> P (in XCNM).
MTM1	69	69	R -> S (in XCNM; severe).
MTM1	70	70	L -> F (in XCNM; mild; reduced binding to PI(3,5)P2).
MTM1	87	87	L -> P (in XCNM; mild; reduced binding to PI(3,5)P2).
MTM1	157	157	E -> K (in XCNM).
MTM1	179	179	P -> S (in XCNM; mild).
MTM1	180	180	N -> K (in XCNM; very mild).
MTM1	184	184	R -> G (in XCNM; severe; loss of activity; abolishes interaction with DES).
MTM1	184	184	R -> L (in XCNM; reduced activity and response to PI5P).
MTM1	186	186	T -> I (in XCNM).
MTM1	189	189	N -> S (in XCNM).
MTM1	197	197	T -> I (in XCNM).
MTM1	198	198	Y -> N (in XCNM; severe).
MTM1	199	199	P -> S (in XCNM).
MTM1	202	202	L -> S (in XCNM; severe).
MTM1	205	205	P -> L (in XCNM; severe; dramatic decrease in phosphatase activity; abolishes interaction with DES).
MTM1	225	225	I -> T (in XCNM; mild).
MTM1	226	226	P -> T (in XCNM).
MTM1	227	227	V -> M (in XCNM).
MTM1	228	228	L -> P (in XCNM).
MTM1	229	229	S -> P (in XCNM; mild).
MTM1	230	230	W -> C (in XCNM).
MTM1	232	232	H -> R (in XCNM).
MTM1	241	241	R -> C (in XCNM; mild to moderate; abolishes interaction with DES).
MTM1	241	241	R -> L (in XCNM; severe; loss of activity).
MTM1	264	264	I -> S (in XCNM; severe).
MTM1	279	279	A -> G (in XCNM).
MTM1	294	294	Missing (in XCNM; mild).
MTM1	317	317	M -> R (in XCNM; mild).
MTM1	346	346	W -> C (in XCNM; mild).
MTM1	346	346	W -> S (in XCNM).
MTM1	364	364	V -> G (in XCNM).
MTM1	374	374	H -> D (in XCNM).
MTM1	376	376	S -> N (in XCNM; dramatic decrease in phosphatase activity).
MTM1	378	378	G -> E (in XCNM).
MTM1	378	378	G -> R (in XCNM; severe; dramatic decrease in phosphatase activity; does not affect EGFR degradation).
MTM1	389	389	A -> D (in XCNM; severe).
MTM1	391	391	L -> P (in XCNM).
MTM1	397	397	Y -> C (in XCNM; severe; dramatic decrease in phosphatase activity).
MTM1	402	402	G -> A (in XCNM; mild).
MTM1	402	402	G -> R (in XCNM).
MTM1	402	402	G -> V (in XCNM).
MTM1	404	404	E -> K (in XCNM; mild).
MTM1	406	406	L -> P (in XCNM; severe).
MTM1	411	411	W -> C (in XCNM).
MTM1	420	420	S -> SFIQ (in XCNM; severe).
MTM1	421	421	R -> Q (in XCNM; severe; reduced activity and response to PI5P; does not affect interaction with DES).
MTM1	421	421	R -> RFIQ (in XCNM; severe).
MTM1	431	431	D -> N (in XCNM).
MTM1	433	433	D -> N (in XCNM).
MTM1	444	444	C -> Y (in XCNM).
MTM1	469	469	H -> P (in XCNM; loss of activity).
MTM1	470	470	L -> P (in XCNM; severe).
MTM1	481	481	N -> Y (in XCNM; mild).
MTM1	499	499	W -> R (in XCNM; mild).
MTM1	510	510	K -> N (in XCNM; severe).
SLC6A8	87	87	G -> R (in XL-CDS).
SLC6A8	132	132	G -> V (in XL-CDS).
SLC6A8	337	337	C -> W (in XL-CDS).
SLC6A8	381	381	G -> R (in XL-CDS).
SLC6A8	390	390	P -> L (in XL-CDS).
SLC6A8	408	408	Missing (in XL-CDS).
SLC6A8	491	491	C -> W (in XL-CDS).
SLC6A8	554	554	P -> L (in XL-CDS).
SLC6A8	560	560	M -> V.
MECP2	10	10	E -> Q (in RTT).
MECP2	86	86	S -> C.
MECP2	97	97	D -> E (in RTT).
MECP2	97	97	D -> Y (in RTT).
MECP2	100	100	L -> R (in RTT).
MECP2	101	101	P -> H (in RTT).
MECP2	101	101	P -> L (in RTT).
MECP2	101	101	P -> R (in RTT; also in a patient with Angelman syndrome and some typical RTT features).
MECP2	101	101	P -> S (in RTT).
MECP2	101	101	P -> T (in RTT).
MECP2	106	106	R -> Q (in RTT).
MECP2	111	111	R -> G (in RTT).
MECP2	120	120	Y -> D (in RTT).
MECP2	124	124	L -> F (in RTT).
MECP2	128	128	Q -> P (in RTT).
MECP2	133	133	R -> H (in RTT).
MECP2	134	134	S -> C (in RTT).
MECP2	135	135	K -> E (in RTT).
MECP2	137	137	E -> G (in MRXS13).
MECP2	152	152	P -> R (in RTT).
MECP2	155	155	F -> I (in RTT).
MECP2	156	156	D -> G (in RTT).
MECP2	158	158	T -> A (in RTT).
MECP2	161	161	G -> V (in RTT).
MECP2	167	167	R -> W (in MRXS13).
MECP2	181	181	A -> V.
MECP2	196	196	T -> S.
MECP2	197	197	T -> M.
MECP2	201	201	A -> V.
MECP2	203	203	T -> M.
MECP2	210	210	K -> I (in RTT).
MECP2	225	225	P -> L (in MRXS13).
MECP2	225	225	P -> R (in RTT).
MECP2	228	228	T -> S.
MECP2	229	229	S -> L.
MECP2	232	232	G -> A.
MECP2	251	251	P -> L.
MECP2	284	284	K -> E (in MRXS13).
MECP2	287	287	A -> P.
MECP2	291	291	S -> A.
MECP2	302	302	P -> A (in RTT).
MECP2	302	302	P -> H (in RTT).
MECP2	302	302	P -> L (in RTT).
MECP2	302	302	P -> R (in RTT).
MECP2	305	305	K -> R (in RTT).
MECP2	306	306	R -> H (in RTT).
MECP2	322	322	P -> A (in RTT).
MECP2	322	322	P -> L (in RTT).
MECP2	322	322	P -> S (in MRXS13).
MECP2	344	344	R -> W (in RTT).
MECP2	359	359	S -> P.
MECP2	376	376	P -> S (in a RTT patient; could be a polymorphism).
MECP2	388	388	P -> L.
MECP2	388	388	P -> S (in a RTT patient).
MECP2	388	388	Missing.
MECP2	394	394	E -> K.
MECP2	399	399	P -> L (in MRXS13; could be a rare polymorphism).
MECP2	402	402	P -> L.
MECP2	412	412	V -> I.
MECP2	428	428	G -> S (in ENS-MECP2; uncertain pathological significance).
MECP2	439	439	A -> T.
MECP2	444	444	A -> T.
MECP2	453	453	R -> Q (in MRXS13).
MECP2	480	480	P -> S.
SHOX	132	132	L -> V (in LWD).
SHOX	153	153	R -> L (in LWD).
SHOX	168	168	R -> W (in LMD).
SHOX	173	173	R -> C (in LWD).
CSF2RA	196	196	G -> R (in SMDP4).
AMELX	4	4	W -> S (in AIH1).
AMELX	5	8	ILFA -> T (in AIH1).
AMELX	37	37	T -> I (in AIH1).
AMELX	56	56	P -> T (in AIH1).
PIGA	40	40	D -> H (in PNH).
PIGA	48	48	G -> A (in PNH).
PIGA	48	48	G -> D (in PNH).
PIGA	48	48	G -> V (in PNH).
PIGA	128	128	H -> R (in PNH).
PIGA	155	155	S -> F (in PNH).
PIGA	239	239	G -> R (in PNH).
PIGA	297	297	N -> D (in PNH).
BMX	670	670	R -> W (in a lung large cell carcinoma sample; somatic mutation).
RS1	12	12	L -> H (in XLRS1).
RS1	13	13	L -> P (in XLRS1).
RS1	59	59	C -> S (in XLRS1).
RS1	65	65	Y -> C (in XLRS1).
RS1	70	70	G -> A (in XLRS1).
RS1	70	70	G -> S (in XLRS1).
RS1	72	72	E -> D (in XLRS1).
RS1	72	72	E -> K (in XLRS1).
RS1	73	73	S -> P (in XLRS1).
RS1	74	74	G -> V (in XLRS1).
RS1	85	85	Missing (in XLRS1).
RS1	89	89	Y -> C (in XLRS1).
RS1	96	96	W -> R (in XLRS1).
RS1	98	98	A -> E (in XLRS1).
RS1	102	102	R -> Q (in XLRS1).
RS1	102	102	R -> W (in XLRS1).
RS1	103	103	L -> R (in XLRS1).
RS1	108	108	F -> C (in XLRS1).
RS1	109	109	G -> E (in XLRS1).
RS1	109	109	G -> R (in XLRS1).
RS1	109	109	G -> W (in XLRS1).
RS1	110	110	C -> Y (in XLRS1).
RS1	112	112	W -> C (in XLRS1).
RS1	113	113	L -> F (in XLRS1).
RS1	127	127	L -> P (in XLRS1).
RS1	135	135	G -> V (in XLRS1).
RS1	136	136	I -> T (in XLRS1).
RS1	138	138	T -> A (in XLRS1).
RS1	140	140	G -> E (in XLRS1).
RS1	140	140	G -> R (in XLRS1).
RS1	141	141	R -> C (in XLRS1).
RS1	141	141	R -> G (in XLRS1).
RS1	141	141	R -> H (in XLRS1).
RS1	142	142	C -> W (in XLRS1).
RS1	143	143	D -> V (in XLRS1).
RS1	145	145	D -> H (in XLRS1).
RS1	146	146	E -> D (in XLRS1).
RS1	146	146	E -> K (in XLRS1).
RS1	155	155	Y -> C (in XLRS1).
RS1	156	156	R -> G (in XLRS1).
RS1	163	163	W -> C (in XLRS1).
RS1	178	178	G -> D (in XLRS1).
RS1	182	182	R -> C (in XLRS1).
RS1	192	192	P -> L (in XLRS1).
RS1	192	192	P -> R (in XLRS1).
RS1	192	192	P -> S (in XLRS1).
RS1	193	193	P -> L (in XLRS1).
RS1	193	193	P -> S (in XLRS1).
RS1	197	197	R -> C (in XLRS1).
RS1	197	197	R -> H (in XLRS1).
RS1	199	199	I -> T (in XLRS1).
RS1	200	200	R -> C (in XLRS1).
RS1	200	200	R -> H (in XLRS1).
RS1	203	203	P -> L (in XLRS1).
RS1	207	207	H -> Q (in XLRS1).
RS1	209	209	R -> C (in XLRS1).
RS1	209	209	R -> H (in XLRS1).
RS1	213	213	R -> Q (in XLRS1).
RS1	213	213	R -> W (in XLRS1).
RS1	215	215	E -> K (in XLRS1).
RS1	215	215	E -> Q (in XLRS1).
RS1	216	216	L -> P (in XLRS1).
RS1	219	219	C -> G (in XLRS1).
RS1	219	219	C -> R (in XLRS1).
RS1	223	223	C -> R (in XLRS1).
PHKA2	120	120	T -> TYNTAT (in GSD9A).
PHKA2	132	132	H -> P (in GSD9A; type 2).
PHKA2	132	132	H -> Y (in GSD9A; type 2).
PHKA2	141	141	Missing (in GSD9A; type 1).
PHKA2	186	186	R -> C (in GSD9A; type 2).
PHKA2	186	186	R -> H (in GSD9A; type 2).
PHKA2	189	190	Missing (in GSD9A; type 2).
PHKA2	189	189	K -> E (in GSD9A; type 2).
PHKA2	193	193	G -> V (in GSD9A; type 2).
PHKA2	251	251	Missing (in GSD9A; type 2).
PHKA2	295	295	R -> H (in GSD9A; type 1 and type 2).
PHKA2	299	299	D -> G (in GSD9A; type 2).
PHKA2	399	399	P -> S (in GSD9A; type 1).
PHKA2	498	498	P -> L (in GSD9A).
PHKA2	818	825	Missing (in GSD9A; type 1).
PHKA2	869	869	P -> R (in GSD9A).
PHKA2	916	916	R -> W (in GSD9A).
PHKA2	953	954	NL -> I (in GSD9A; type 1).
PHKA2	1070	1070	Missing (in GSD9A).
PHKA2	1111	1111	R -> RTR (in GSD9A; type 2).
PHKA2	1113	1113	M -> I (in GSD9A).
PHKA2	1114	1114	T -> I (in GSD9A; type 2).
PHKA2	1125	1125	E -> K (in GSD9A; type 1).
PHKA2	1205	1205	P -> L (in GSD9A; type 1).
PHKA2	1207	1207	G -> W (in GSD9A; type 1).
PDHA1	10	10	R -> P (in PDHE1 deficiency; affects mitochondrial import of precursor protein).
PDHA1	72	72	R -> C (in PDHE1 deficiency).
PDHA1	113	113	H -> D (in PDHE1 deficiency).
PDHA1	162	162	G -> R (in PDHE1 deficiency).
PDHA1	167	167	V -> M (in PDHE1 deficiency).
PDHA1	199	199	A -> T (in PDHE1 deficiency).
PDHA1	205	205	F -> L (in X-LS; PDHE1 deficiency).
PDHA1	210	210	M -> V (in PDHE1 deficiency).
PDHA1	217	217	P -> L (in PDHE1 deficiency).
PDHA1	231	231	T -> A (in PDHE1 deficiency).
PDHA1	243	243	Y -> N (in PDHE1 deficiency).
PDHA1	258	258	D -> A (in X-LS; PDHE1 deficiency).
PDHA1	263	263	R -> Q (in PDHE1 deficiency).
PDHA1	288	288	R -> H (in PDHE1 deficiency).
PDHA1	292	292	H -> L (in PDHE1 deficiency).
PDHA1	302	302	R -> C (in PDHE1 deficiency; loss of activity; common mutation).
PDHA1	302	302	R -> H (in PDHE1 deficiency).
PDHA1	305	305	E -> EDSYRTRE (in PDHE1 deficiency).
PDHA1	307	307	I -> IPPHSYRTREEI (in PDHE1 deficiency).
PDHA1	311	311	Missing (in PDHE1 deficiency).
PDHA1	313	313	Missing (in PDHE1 deficiency).
PDHA1	378	378	R -> H (in X-LS; PDHE1 deficiency).
YY2	103	103	D -> N (in a breast cancer sample; somatic mutation).
DDX53	141	141	N -> T (found in a renal cell carcinoma case; somatic mutation).
PTCHD1	73	73	L -> F.
PTCHD1	173	173	I -> V.
PTCHD1	195	195	V -> I.
PTCHD1	251	251	P -> L.
PTCHD1	336	337	ML -> II.
PTCHD1	359	359	H -> R.
PTCHD1	470	470	A -> D.
PTCHD1	479	479	E -> G.
ARX	115	115	A -> AAAAAAAA (in EIEE1).
ARX	155	155	A -> AAAAAAAAA (in EIEE1 and PRTS; also found in non-specific mental retardation families; frequent mutation).
ARX	332	332	R -> P (in LISX2).
ARX	353	353	P -> R (in LISX2).
ARX	521	521	A -> T (in LISX2; severe phenotype).
NR0B1	267	267	R -> P (in XL-AHC; impairs transcriptional silencing of the StAR promoter).
NR0B1	269	269	Missing (in XL-AHC; impairs transcriptional silencing of the StAR promoter).
NR0B1	278	278	L -> P (in XL-AHC).
NR0B1	287	287	V -> G (in XL-AHC; the patient presents an inappropriate tall stature and renal ectopy).
NR0B1	295	295	L -> P (in XL-AHC).
NR0B1	297	297	L -> P (in XL-AHC; results in a severe loss of repressor activity).
NR0B1	300	300	A -> P (in XL-AHC).
NR0B1	300	300	A -> V (in XL-AHC).
NR0B1	377	377	E -> K (in XL-AHC).
NR0B1	380	380	Y -> D (in XL-AHC).
NR0B1	381	381	L -> H (in XL-AHC).
NR0B1	385	385	V -> G (in XL-AHC).
NR0B1	425	425	R -> G (in XL-AHC).
NR0B1	425	425	R -> T (in XL-AHC).
NR0B1	439	439	I -> S (in XL-AHC; mild phenotype).
NR0B1	466	466	L -> R (in XL-AHC).
FAM47A	495	507	Missing.
XK	222	222	R -> G (in MLS).
XK	327	327	E -> K (in MLS; atypical without hematologic, neuromuscular, or cerebral involvement; protein seems functional).
CYBB	18	18	W -> C (in XCGD).
CYBB	20	20	G -> R (in XCGD).
CYBB	41	41	Y -> D (in XCGD).
CYBB	54	55	Missing (in XCGD).
CYBB	54	54	R -> M (in XCGD).
CYBB	54	54	R -> S (in XCGD).
CYBB	55	55	A -> D (in XCGD).
CYBB	57	57	A -> E (in XCGD).
CYBB	59	59	C -> R (in XCGD).
CYBB	59	59	C -> W (in XCGD).
CYBB	101	101	H -> R (in XCGD).
CYBB	101	101	H -> Y (in XCGD).
CYBB	119	119	H -> R (in XCGD).
CYBB	156	156	A -> T (in XCGD).
CYBB	178	178	T -> P (in AMCBX2).
CYBB	179	179	G -> R (in XCGD).
CYBB	193	193	S -> F (in XCGD).
CYBB	205	205	F -> I (in XCGD).
CYBB	209	209	H -> Q (in XCGD).
CYBB	209	209	H -> R (in XCGD).
CYBB	209	209	H -> Y (in XCGD).
CYBB	215	215	Missing (in XCGD).
CYBB	222	222	H -> N (in XCGD).
CYBB	222	222	H -> R (in XCGD).
CYBB	222	222	H -> Y (in XCGD).
CYBB	223	223	G -> L (in XCGD; requires 2 nucleotide substitutions).
CYBB	224	224	A -> G (in XCGD).
CYBB	225	225	E -> V (in XCGD).
CYBB	231	231	Q -> P (in AMCBX2).
CYBB	244	244	C -> R (in XCGD).
CYBB	244	244	C -> S (in XCGD).
CYBB	244	244	C -> Y (in XCGD).
CYBB	298	302	Missing (in XCGD).
CYBB	304	304	P -> R (in XCGD; reduces NADPH oxidase activity to 4% of wild-type; translocation to the membrane of the phagosome is only attenuated).
CYBB	307	307	T -> P (in XCGD).
CYBB	309	309	E -> K (in XCGD).
CYBB	315	315	Missing (in XCGD).
CYBB	322	322	G -> E (in XCGD).
CYBB	325	325	I -> F (in XCGD).
CYBB	333	333	S -> P (in XCGD).
CYBB	338	338	H -> Y (in XCGD).
CYBB	339	339	P -> H (in XCGD).
CYBB	342	342	L -> Q (in XCGD).
CYBB	344	344	S -> F (in XCGD).
CYBB	356	356	R -> P (in XCGD).
CYBB	364	364	G -> R.
CYBB	389	389	G -> A (in XCGD).
CYBB	389	389	G -> E (in XCGD).
CYBB	405	405	M -> R (in XCGD).
CYBB	408	408	G -> E (in XCGD).
CYBB	408	408	G -> R (in XCGD).
CYBB	415	415	P -> H (in XCGD).
CYBB	415	415	P -> L (in XCGD).
CYBB	420	420	L -> P (in XCGD).
CYBB	422	422	S -> P (in XCGD).
CYBB	453	453	W -> R (in XCGD).
CYBB	505	505	L -> R (in XCGD).
CYBB	516	516	W -> C (in XCGD).
CYBB	516	516	W -> R (in XCGD).
CYBB	517	517	D -> E.
CYBB	534	534	V -> D (in XCGD).
CYBB	537	537	C -> R (in XCGD).
CYBB	546	546	L -> P (in XCGD).
MED14	1325	1325	F -> L (in a breast cancer sample; somatic mutation).
DDX3X	294	294	R -> T (in a breast cancer sample; somatic mutation).
NYX	29	36	Missing (in CSNB1A).
NYX	31	31	C -> S (in CSNB1A).
NYX	101	101	Missing (in CSNB1A).
NYX	114	118	Missing (in CSNB1A).
NYX	143	143	A -> P (in CSNB1A).
NYX	151	151	P -> L (in CSNB1A).
NYX	155	155	L -> LSVPERLL (in CSNB1A).
NYX	175	175	P -> R (in CSNB1A).
NYX	184	184	L -> P (in CSNB1A).
NYX	187	187	A -> K (in CSNB1A; requires 2 nucleotide substitutions).
NYX	207	207	R -> RLLR (in CSNB1A).
NYX	209	209	R -> RCLR (in CSNB1A).
NYX	213	213	L -> Q (in CSNB1A).
NYX	216	216	N -> S (in CSNB1A).
NYX	232	232	L -> P (in CSNB1A).
NYX	243	246	Missing (in CSNB1A).
NYX	264	264	N -> K (in CSNB1A).
NYX	285	285	L -> P (in CSNB1A).
NYX	298	298	F -> S (in CSNB1A).
NYX	307	307	L -> P (in CSNB1A).
NYX	312	312	N -> S (in CSNB1A).
NYX	347	347	L -> P (in CSNB1A).
NYX	370	370	G -> V (in CSNB1A).
NDP	13	13	L -> R (in ND).
NDP	16	16	L -> P (in ND).
NDP	18	18	I -> K (in EVR2; the patient presented significant phenotypic heterogeneity between the two eyes).
NDP	38	38	R -> C (in ND and EVR2).
NDP	39	39	C -> R (in ND).
NDP	41	41	R -> K (in EVR2).
NDP	41	41	R -> S (in persistent fetal vasculature syndrome).
NDP	42	42	H -> R (in EVR2).
NDP	43	43	H -> Q (in ND).
NDP	43	43	H -> R (in ND).
NDP	44	44	Y -> C (in ND).
NDP	45	45	V -> E (in ND).
NDP	45	45	V -> M (in ND).
NDP	54	54	K -> N (in EVR2).
NDP	55	55	C -> R (in ND).
NDP	58	58	K -> N (in ND and EVR2).
NDP	60	60	V -> E (in ND; reduction of protein amount in the extracellular matrix).
NDP	61	61	L -> F (in ND).
NDP	61	61	L -> I (in EVR2).
NDP	61	61	L -> P (in ND).
NDP	63	63	A -> D (in ND).
NDP	65	65	C -> W (in ND).
NDP	65	65	C -> Y (in ND).
NDP	67	67	G -> E (in ND).
NDP	67	67	G -> R (in ND).
NDP	69	69	C -> S (in ND).
NDP	74	74	R -> C (in ND).
NDP	75	75	S -> C (in ND).
NDP	75	75	S -> P (in ND).
NDP	89	89	F -> L (in ND).
NDP	90	90	R -> C (in ND).
NDP	90	90	R -> P (in ND).
NDP	92	92	S -> P (in ND).
NDP	94	96	HCC -> QCGL (in ND).
NDP	95	95	C -> F (in ND).
NDP	95	95	C -> R (in ND).
NDP	96	96	C -> W (in ND).
NDP	96	96	C -> Y (in ND).
NDP	97	97	R -> P (in ND).
NDP	98	98	P -> L (in ND).
NDP	101	101	S -> F (in ND).
NDP	103	103	L -> V (in EVR2).
NDP	104	104	K -> N (in ND).
NDP	104	104	K -> Q (in ND).
NDP	105	105	A -> T (in ND).
NDP	108	108	L -> P (in retinopathy of prematurity).
NDP	110	110	C -> G (in ND).
NDP	110	110	C -> R (in ND).
NDP	112	112	G -> E (in ND).
NDP	115	115	R -> L (in EVR2).
NDP	118	118	A -> D (in ND).
NDP	120	120	Y -> C (in EVR2).
NDP	121	123	Missing (in ND).
NDP	121	121	R -> G (in EVR2).
NDP	121	121	R -> L (in EVR2).
NDP	121	121	R -> Q (in EVR2 and ND; reduced amount of protein in the extracellular matrix).
NDP	121	121	R -> W (in ND and EVR2).
NDP	123	123	I -> N (in ND).
NDP	126	126	C -> S (in ND).
NDP	128	128	C -> R (in ND).
DUSP21	167	167	R -> C (in a colorectal cancer sample; somatic mutation).
RP2	6	6	Missing (in RP2; loss of membrane association; enhances interaction with ARL3).
RP2	67	67	C -> Y (in RP2).
RP2	86	86	C -> Y (in RP2).
RP2	95	95	P -> L (in RP2; uncertain pathogenicity).
RP2	108	108	C -> G (in RP2).
RP2	118	118	R -> C (in RP2).
RP2	118	118	R -> H (in RP2; reduces affinity for ARL3 800-fold; loss of stimulation of tubulin GTPase activity; no effect on subcellular location).
RP2	137	137	Missing (in RP2).
RP2	138	138	E -> G (in RP2; reduces affinity for ARL3 150-fold and inhibits the GTP-hydrolysis rate of ARL3).
RP2	188	188	L -> P (in RP2).
RP2	253	253	L -> R (in RP2).
RBM10	396	396	R -> H (in a colorectal cancer sample; somatic mutation).
ARAF	331	331	G -> C (in a colorectal adenocarcinoma sample; somatic mutation).
CFP	3	3	T -> I (in a breast cancer sample; somatic mutation).
CFP	100	100	R -> W (in PFD; type II).
CFP	343	343	Q -> R (in PFD; type II).
CFP	414	414	Y -> D (in PFD; type III).
PORCN	60	60	G -> R (in FODH).
PORCN	136	136	S -> F (in FODH).
PORCN	168	168	G -> R (in FODH).
PORCN	228	228	R -> C (in a patient with focal dermal hypoplasia also carrying a frameshift mutation; uncertain pathological significance).
PORCN	252	252	H -> Y (in FODH).
PORCN	258	258	V -> E (in FODH).
PORCN	297	297	S -> L (in FODH).
PORCN	331	331	L -> R (in FODH).
PORCN	341	341	H -> L (in FODH).
PORCN	361	361	E -> V (in FODH).
PORCN	365	365	R -> G (in FODH).
PORCN	365	365	R -> Q (in FODH).
PORCN	385	385	C -> R (in FODH).
PORCN	385	385	C -> Y (in FODH).
PORCN	439	439	W -> R (in FODH).
EBP	110	110	R -> Q (in CDPX2).
EBP	147	147	R -> G (in CDPX2).
WAS	27	27	L -> F (in THC1).
WAS	30	30	Missing (in THC1).
WAS	31	31	E -> K (in WAS).
WAS	43	43	C -> W (in WAS; moderate form).
WAS	45	45	T -> M (in WAS and THC1).
WAS	48	48	T -> I (in THC1).
WAS	52	52	Q -> H (in WAS).
WAS	56	56	A -> V (in THC1).
WAS	58	58	P -> L (in WAS).
WAS	70	70	G -> W (in WAS).
WAS	73	73	C -> R (in WAS; severe form).
WAS	75	75	V -> M (in THC1).
WAS	82	82	S -> P (in WAS; attenuated form).
WAS	83	83	Y -> C (in THC1).
WAS	84	84	F -> L (in WAS; severe form).
WAS	86	86	R -> C (in WAS).
WAS	86	86	R -> H (in WAS).
WAS	86	86	R -> L (in WAS).
WAS	89	89	G -> D (in WAS; mild form).
WAS	97	97	W -> C (in WAS; attenuated form).
WAS	131	131	E -> K (in WAS).
WAS	133	133	E -> K (in WAS; severe form).
WAS	134	134	A -> T (in WAS).
WAS	187	187	G -> C (in WAS).
WAS	236	236	A -> E (in THC1).
WAS	476	476	K -> E (in WAS).
WAS	477	477	R -> K (in THC1).
WAS	481	481	I -> N (in THC1).
GATA1	205	205	V -> M (in XDAT; severe impairment of ZFPM1 binding and erythroid differentiation in vitro).
GATA1	208	208	G -> S (in XDAT; partially disrupts the interaction with ZFPM1).
GATA1	216	216	R -> Q (in XLTT; does not affect ZFPM1 binding; reduced affinity to palindromic GATA sites; supports erythroid maturation less efficiently than wild-type GATA1).
GATA1	218	218	D -> G (in XDAT; partially disrupts the interaction with ZFPM1).
GATA1	218	218	D -> Y (in XDAT; stronger loss of affinity than of G-218-GATA1 for ZFPM1 and disturbed GATA1 self-association).
SLC35A2	252	252	W -> C (in a breast cancer sample; somatic mutation).
PRICKLE3	558	558	E -> D (in a breast cancer sample; somatic mutation).
SYP	2	2	L -> Q.
SYP	158	158	S -> L.
SYP	166	166	D -> N.
SYP	217	217	G -> R (in MRXSYP).
SYP	248	248	D -> N.
SYP	277	277	D -> E (in an individual affected by mental retardation; unknown pathological role).
SYP	293	293	G -> S (in an individual affected by mental retardation; unknown pathological role).
CACNA1F	74	74	C -> R (in CSNB2A).
CACNA1F	150	150	G -> R (in CSNB2A).
CACNA1F	229	229	S -> P (in CSNB2A).
CACNA1F	261	261	G -> R (in CSNB2A).
CACNA1F	369	369	G -> D (in CSNB2A).
CACNA1F	635	635	V -> I (in CSNB2A).
CACNA1F	674	674	G -> D (in CSNB2A).
CACNA1F	746	746	N -> T.
CACNA1F	753	753	F -> C (in CSNB2A).
CACNA1F	756	756	I -> T (in CSNB2A; increases the number of mutant channels open at physiologic membrane potential and allows for persistent Ca(2+) entry due to reduced channel inactivation resulting in a gain- of-function defect).
CACNA1F	860	860	L -> P (in CSNB2A).
CACNA1F	928	928	A -> D (in CSNB2A).
CACNA1F	1018	1018	G -> R (in CSNB2A).
CACNA1F	1060	1060	R -> W (in CSNB2A).
CACNA1F	1079	1079	L -> P (in CSNB2A).
CACNA1F	1375	1375	L -> H (in CSNB2A).
CACNA1F	1499	1499	C -> R (in CSNB2A).
CACNA1F	1500	1500	P -> R (in CSNB2A).
CACNA1F	1508	1508	L -> P (in CSNB2A).
FOXP3	251	251	Missing (in IPEX).
FOXP3	363	363	I -> V (in IPEX).
FOXP3	371	371	F -> C (in IPEX).
FOXP3	384	384	A -> T (in IPEX).
BMP15	5	5	S -> R (no or minor deleterious effect observed).
BMP15	61	61	R -> Q (in POF4).
BMP15	61	61	R -> W (in POF4).
BMP15	68	68	R -> W (in POF4; leads to marked reduction of mature protein production; does not generate a complete recovery of wild-type activity in granulosa cell line transfected with defective mutant and with equal amount of wild-type protein).
BMP15	76	76	R -> C (in POF4).
BMP15	76	76	R -> H (in POF4).
BMP15	138	138	R -> H (in POF4; leads to marked reduction of mature protein production; does not generate a complete recovery of wild-type activity in granulosa cell line transfected with defective mutant and with equal amount of wild-type protein).
BMP15	148	148	L -> P (in POF4; leads to marked reduction of mature protein production; does not generate a complete recovery of wild-type activity in granulosa cell line transfected with defective mutant and with equal amount of wild-type protein).
BMP15	180	180	A -> F (requires 2 nucleotide substitutions).
BMP15	180	180	A -> T (in POF4; uncertain pathogenicity; could be a polymorphism; no or minor deleterious effect detected).
BMP15	196	196	N -> K (in POF4).
BMP15	206	206	R -> H (in POF4).
BMP15	221	221	W -> R (in POF4).
BMP15	235	235	Y -> C (in ODG2; dominant-negative effect; may cause relevant modifications in the conformation of the precursor protein possibly leading to altered processing and impaired activation of latent forms or to abnormal dimerization).
BMP15	243	243	I -> V (in POF4).
BMP15	263	263	L -> LL (no or minor deleterious effect detected).
NUDT11	39	39	S -> N.
KDM5C	87	87	D -> G (in MRXSJ; no effect on subcellular location and enzymatic activity).
KDM5C	388	388	A -> P (in MRXSJ; impairs enzymatic activity and binding to H3-K9Me3).
KDM5C	402	402	D -> Y (in MRXSJ; impairs enzymatic activity).
KDM5C	451	451	S -> R (in MRXSJ).
KDM5C	640	640	C -> Y (de novo mutation found in a patient with mental retardation).
KDM5C	642	642	F -> L (in MRXSJ; impairs enzymatic activity).
KDM5C	698	698	E -> K (in MRXSJ; abolishes function in vivo, but no effect on enzymatic activity or binding to H3-K9Me3).
KDM5C	731	731	L -> F (in MRXSJ; impairs enzymatic activity).
KDM5C	750	750	R -> W (in MRXSJ).
KDM5C	751	751	Y -> C (in MRXSJ; impairs enzymatic activity).
SMC1A	58	62	Missing (in CDLS2).
SMC1A	133	133	F -> V (in CDLS2).
SMC1A	141	141	E -> K (in CDLS2).
SMC1A	196	196	R -> H (in CDLS2).
SMC1A	268	268	Missing (in CDLS2).
SMC1A	306	306	Missing (in CDLS2).
SMC1A	398	398	R -> Q (in CDLS2).
SMC1A	493	493	E -> A (in CDLS2; affects the affinity of SMC hinge dimers for DNA; mutated hinge dimers bind DNA with higher affinity than wild-type proteins).
SMC1A	496	496	R -> C (in CDLS2; affects the affinity of SMC hinge dimers for DNA; mutated hinge dimers bind DNA with higher affinity than wild-type proteins).
SMC1A	496	496	R -> H (in CDLS2; affects the affinity of SMC hinge dimers for DNA; mutated hinge dimers bind DNA with higher affinity than wild-type proteins).
SMC1A	683	683	Missing (in CDLS2).
SMC1A	693	693	R -> G (in CDLS2).
SMC1A	711	711	R -> Q (in CDLS2).
SMC1A	711	711	R -> W (in CDLS2).
SMC1A	781	781	C -> F (in CDLS2).
SMC1A	784	784	I -> T (in CDLS2).
SMC1A	790	790	R -> Q (in CDLS2).
SMC1A	816	816	R -> G (in CDLS2).
SMC1A	832	832	Missing (in CDLS2).
SMC1A	1049	1049	R -> Q (in CDLS2).
SMC1A	1085	1085	Y -> C (in CDLS2).
SMC1A	1122	1122	F -> L (in CDLS2).
SMC1A	1123	1123	R -> W (in CDLS2).
HSD17B10	247	247	N -> S (in MHBD deficiency; intermediate enzyme activity).
FGD1	205	205	S -> I (in AAS).
FGD1	380	380	E -> A (in AAS).
FGD1	443	443	R -> H (in AAS).
FGD1	522	522	R -> H (in AAS).
MAGED2	266	266	Q -> R.
MAGED2	458	458	K -> Q (in a breast cancer sample; somatic mutation).
APEX2	269	269	H -> Y (identified in a patient with mtDNA maintenance disorders).
APEX2	392	392	N -> H (identified in a patient with mtDNA maintenance disorders).
FAM123B	292	292	K -> N.
EFNB1	27	27	P -> R (in CFNS).
EFNB1	54	54	P -> L (in CFNS).
EFNB1	62	62	I -> T (in CFNS).
EFNB1	98	98	L -> S (in CFNS).
EFNB1	111	111	T -> I (in CFNS).
EFNB1	115	115	Q -> P (in CFNS).
EFNB1	119	119	P -> H (in CFNS).
EFNB1	119	119	P -> S (in CFNS).
EFNB1	119	119	P -> T (in CFNS).
EFNB1	137	137	T -> A (in CFNS).
EFNB1	138	138	S -> F (in CFNS).
EFNB1	153	153	C -> S (in CFNS).
EFNB1	153	153	C -> Y (in CFNS).
EFNB1	154	154	R -> H.
EFNB1	155	155	T -> P (in CFNS).
EFNB1	182	182	S -> R (in CFNS).
DLG3	40	40	G -> R (in a colorectal cancer sample; somatic mutation).
SLC7A3	356	356	M -> K (found in a renal cell carcinoma sample; somatic mutation).
IL2RG	39	39	D -> N (in XSCID).
IL2RG	62	62	C -> G (in XSCID).
IL2RG	68	68	E -> G (in XSCID).
IL2RG	68	68	E -> K (in XSCID).
IL2RG	84	84	N -> K (in XSCID).
IL2RG	89	89	Y -> C (in XSCID).
IL2RG	105	105	Y -> C (in XSCID).
IL2RG	114	114	G -> D (in XSCID).
IL2RG	115	115	C -> F (in XSCID).
IL2RG	115	115	C -> R (in XSCID; atypical).
IL2RG	123	123	H -> P (in XSCID).
IL2RG	125	125	Y -> N (in XSCID).
IL2RG	144	144	Q -> P (in XSCID).
IL2RG	153	153	I -> N (in XSCID).
IL2RG	156	156	A -> V (in XSCID).
IL2RG	162	162	L -> H (in XSCID).
IL2RG	172	172	L -> P (in XSCID).
IL2RG	172	172	L -> Q (in XSCID).
IL2RG	182	182	C -> R (in XSCID).
IL2RG	183	183	L -> S (in XSCID).
IL2RG	222	222	R -> C (in XCID).
IL2RG	224	224	R -> W (in XSCID).
IL2RG	226	226	R -> C (in XSCID).
IL2RG	226	226	R -> H (in XSCID).
IL2RG	227	227	F -> C (in XSCID).
IL2RG	230	230	L -> P (in XSCID).
IL2RG	231	231	C -> Y (in XSCID).
IL2RG	232	232	G -> R (in XSCID).
IL2RG	237	237	W -> WQHW (in XSCID).
IL2RG	240	240	W -> C (in XSCID).
IL2RG	241	241	S -> I (in XSCID).
IL2RG	270	270	M -> R (in XSCID).
IL2RG	285	285	R -> Q (in XSCID).
IL2RG	293	293	L -> Q (in XCID).
MED12	961	961	R -> W (in OKS).
MED12	1007	1007	N -> S (in LUJFRYS).
GJB1	3	3	W -> R (in CMTX1).
GJB1	3	3	W -> S (in CMTX1).
GJB1	7	8	YT -> S (in CMTX1).
GJB1	7	7	Y -> C (in CMTX1).
GJB1	8	8	T -> I (in CMTX1).
GJB1	8	8	T -> P (in CMTX1).
GJB1	9	9	L -> W (in CMTX1).
GJB1	11	11	S -> G (in CMTX1).
GJB1	12	12	G -> S (in CMTX1).
GJB1	13	13	V -> L (in CMTX1).
GJB1	13	13	V -> M (in CMTX1).
GJB1	14	14	N -> K (in CMTX1).
GJB1	15	15	R -> Q (in CMTX1).
GJB1	15	15	R -> W (in CMTX1; moderate).
GJB1	16	16	H -> P (in CMTX1).
GJB1	20	21	IG -> NS (in CMTX1).
GJB1	20	20	I -> S (in CMTX1).
GJB1	21	21	G -> D (in CMTX1).
GJB1	22	22	R -> G (in CMTX1; non-functional channel).
GJB1	22	22	R -> P (in CMTX1).
GJB1	22	22	R -> Q (in CMTX1; can be associated with Ile-63).
GJB1	23	23	V -> A (in CMTX1).
GJB1	24	24	W -> C (in CMTX1).
GJB1	25	25	L -> F (in CMTX1).
GJB1	25	25	L -> P (in CMTX1).
GJB1	26	26	S -> L (in CMTX1).
GJB1	26	26	S -> W (in CMTX1; severe).
GJB1	28	28	I -> IIF (in CMTX1).
GJB1	28	28	I -> N (in CMTX1).
GJB1	28	28	I -> T (in CMTX1).
GJB1	29	29	F -> L (in CMTX1).
GJB1	30	30	I -> N (in CMTX1).
GJB1	30	30	I -> T (in CMTX1).
GJB1	34	34	M -> I (in CMTX1; localized in the Golgi apparatus but also forming rare small junction-like plaques).
GJB1	34	34	M -> K (in CMTX1; localized to the endoplasmic reticulum).
GJB1	34	34	M -> T (in CMTX1; functional channel; localized in the Golgi apparatus without reaching the cell membrane).
GJB1	34	34	M -> V (in CMTX1; localized in the Golgi apparatus but also forming rare small gap junction-like plaques).
GJB1	35	35	V -> M (in CMTX1; localized mainly on the cell membrane forming gap junction-like plaques).
GJB1	37	37	V -> M (in CMTX1; localized in the Golgi apparatus but also forming rare small gap junction-like plaques).
GJB1	38	38	V -> M (in CMTX1; localized in the Golgi apparatus without reaching the cell membrane).
GJB1	39	39	A -> P (in CMTX1).
GJB1	39	39	A -> V (in CMTX1).
GJB1	40	40	A -> T (in CMTX1; localized in the Golgi apparatus without reaching the cell membrane).
GJB1	40	40	A -> V (in CMTX1; localized in the Golgi apparatus without reaching the cell membrane).
GJB1	41	41	E -> K (in CMTX1).
GJB1	43	43	V -> M (in CMTX1).
GJB1	44	44	W -> L (in CMTX1).
GJB1	49	49	S -> P (in CMTX1).
GJB1	49	49	S -> Y (in CMTX1).
GJB1	50	50	S -> P (in CMTX1).
GJB1	53	53	C -> S (in CMTX1; suggests a failure to incorporate the mutant protein in the cell membrane).
GJB1	55	55	T -> A (in CMTX1).
GJB1	55	55	T -> I (in CMTX1).
GJB1	55	55	T -> R (in CMTX1).
GJB1	56	56	L -> F (in CMTX1; functional channel).
GJB1	57	57	Q -> H (in CMTX1).
GJB1	58	58	P -> R (in CMT-1).
GJB1	59	59	G -> C (in CMTX1).
GJB1	59	59	G -> R (in CMTX1).
GJB1	60	60	C -> F (in CMTX1; moderate).
GJB1	63	63	V -> I (in CMTX1; can be associated with Gln-22).
GJB1	64	64	C -> F (in CMTX1; moderate).
GJB1	64	64	C -> S (in CMTX1).
GJB1	65	65	Y -> C (in CMTX1).
GJB1	65	65	Y -> H (in CMTX1).
GJB1	66	66	Missing (in CMTX1).
GJB1	69	69	F -> L (in CMTX1).
GJB1	70	70	P -> A (in CMTX1).
GJB1	75	75	R -> P (in CMTX1; localized in the Golgi apparatus without reaching the cell membrane).
GJB1	75	75	R -> Q (in CMTX1; localized in the Golgi apparatus without reaching the cell membrane).
GJB1	75	75	R -> W (in CMTX1; localized in the Golgi apparatus without reaching the cell membrane).
GJB1	77	77	W -> S (in CMTX1).
GJB1	80	80	Q -> R (in CMTX1).
GJB1	81	81	L -> F (in CMTX1).
GJB1	83	83	L -> P (in CMTX1).
GJB1	84	84	V -> I (in CMTX1).
GJB1	85	85	S -> C (in CMTX1; mutant have a higher open probability than hemichannels formed of GJB1 wild-type).
GJB1	85	85	S -> F (in CMTX1).
GJB1	86	86	T -> A (in CMTX1; moderate).
GJB1	86	86	T -> N (in CMTX1).
GJB1	86	86	T -> S (in CMTX1).
GJB1	87	87	P -> A (in CMTX1).
GJB1	87	87	P -> L (in CMTX1).
GJB1	87	87	P -> S (in CMTX1).
GJB1	89	89	L -> P (in CMTX1).
GJB1	90	90	L -> H (in CMTX1).
GJB1	90	90	L -> V (in CMTX1).
GJB1	91	91	V -> M (in CMTX1).
GJB1	93	93	M -> V (in CMTX1).
GJB1	94	94	H -> D (in CMTX1).
GJB1	94	94	H -> Q (in CMTX1; non-functional channel).
GJB1	94	94	H -> Y (in CMTX1).
GJB1	95	95	V -> M (in CMTX1; non-functional channel).
GJB1	100	100	H -> Y (in CMTX1; mild/moderate).
GJB1	102	102	E -> G (in CMTX1; mild phenotype; increased sensitivity to acidification- induced closure).
GJB1	102	102	Missing (in CMTX1).
GJB1	103	103	K -> E (in CMTX1).
GJB1	104	104	K -> T (in CMTX1).
GJB1	107	107	R -> W (in CMTX1).
GJB1	108	108	L -> P (in CMTX1).
GJB1	111	116	Missing (in CMTX1).
GJB1	120	120	V -> E (in CMTX1).
GJB1	120	120	Missing (in CMTX1).
GJB1	124	124	K -> N (in CMTX1).
GJB1	125	125	V -> D (in CMTX1).
GJB1	126	126	H -> Y (in CMTX1).
GJB1	127	127	I -> M (in CMTX1).
GJB1	127	127	I -> S (in CMTX1).
GJB1	128	128	S -> P (in CMTX1).
GJB1	130	130	T -> I (in CMTX1).
GJB1	131	131	L -> P (in CMTX1).
GJB1	133	133	W -> C (in CMTX1; moderate).
GJB1	133	133	W -> R (in CMTX1).
GJB1	135	135	Y -> C (in CMTX1).
GJB1	136	136	V -> A (in CMTX1; demyelinating form; associated with W-359 in the EGR2 gene in a DSS Korean girl).
GJB1	138	138	S -> N (in CMTX1).
GJB1	139	139	V -> M (in CMTX1).
GJB1	141	141	F -> L (in CMTX1).
GJB1	142	142	R -> E (in CMTX1; requires 2 nucleotide substitutions).
GJB1	142	142	R -> Q (in CMTX1).
GJB1	142	142	R -> W (in CMTX1; moderate).
GJB1	143	143	Missing (in CMTX1).
GJB1	146	146	E -> K (in CMTX1).
GJB1	147	147	A -> D (in CMTX1).
GJB1	149	149	F -> I (in CMTX1).
GJB1	149	149	F -> V (in CMTX1; pathogenicity uncertain).
GJB1	151	151	Y -> S (in CMTX1).
GJB1	153	153	F -> S (in CMTX1).
GJB1	156	156	L -> F (in CMTX1).
GJB1	156	156	L -> R (in CMTX1).
GJB1	157	157	Y -> C (in CMTX1).
GJB1	158	158	P -> A (in CMTX1).
GJB1	158	158	P -> R (in CMTX1).
GJB1	158	158	P -> S (in CMTX1).
GJB1	159	159	G -> D (in CMTX1).
GJB1	159	159	G -> S (in CMTX1).
GJB1	160	160	Y -> H (in CMTX1).
GJB1	161	161	A -> P (in CMTX1).
GJB1	164	164	R -> Q (in CMTX1).
GJB1	164	164	R -> W (in CMTX1; moderate).
GJB1	168	168	C -> R (in CMTX1; demyelinating form).
GJB1	168	168	C -> Y (in CMTX1).
GJB1	172	172	P -> A (in CMTX1; suggests a failure to incorporate the mutant protein in the cell membrane).
GJB1	172	172	P -> L (in CMTX1).
GJB1	172	172	P -> R (in CMTX1).
GJB1	172	172	P -> S (in CMTX1).
GJB1	173	173	C -> R (in CMTX1).
GJB1	175	175	N -> D (in CMT-1).
GJB1	177	177	V -> A (in CMTX1).
GJB1	177	177	V -> E (in CMTX1).
GJB1	178	178	D -> Y (in CMTX1).
GJB1	179	179	C -> R (in CMTX1).
GJB1	180	180	F -> L (in CMTX1).
GJB1	180	180	F -> S (in CMTX1).
GJB1	181	181	V -> A (in CMTX1; profoundly impaired in their ability to support the earliest stages of regeneration of myelinated fibers).
GJB1	181	181	V -> M (in CMTX1).
GJB1	182	182	S -> T (in CMTX1).
GJB1	183	183	R -> C (in CMTX1).
GJB1	183	183	R -> H (in CMTX1).
GJB1	183	183	R -> S (in CMTX1).
GJB1	184	184	P -> L (in CMTX1).
GJB1	184	184	P -> R (in CMTX1).
GJB1	185	185	Missing (in CMTX1).
GJB1	186	186	E -> K (in CMTX1; non-functional channel).
GJB1	187	187	K -> E (in CMTX1).
GJB1	189	189	V -> G (in CMTX1).
GJB1	189	189	V -> I (in CMTX1).
GJB1	191	193	Missing (in CMTX1).
GJB1	191	191	T -> A (in CMTX1).
GJB1	192	192	V -> F (in CMTX1).
GJB1	193	193	F -> C (in CMTX1).
GJB1	193	193	F -> L (in CMTX1).
GJB1	194	194	M -> V (in CMTX1).
GJB1	198	198	S -> F (in CMTX1).
GJB1	199	199	G -> R (in CMTX1).
GJB1	201	201	C -> R (in CMTX1; severe).
GJB1	201	201	C -> Y (in CMTX1).
GJB1	203	203	I -> N (in CMTX1).
GJB1	204	204	L -> F (in CMTX1).
GJB1	204	204	L -> V (in CMTX1).
GJB1	205	205	N -> I (in CMTX1; localized to the endoplasmic reticulum).
GJB1	205	205	N -> S (in CMTX1; mild).
GJB1	208	208	E -> G (in CMTX1).
GJB1	208	208	E -> K (in CMTX1; non-detectable levels of hemichannel activation and non- detectable levels of electrical coupling).
GJB1	209	209	Missing (in CMTX1).
GJB1	211	211	Y -> H (in CMTX1).
GJB1	213	214	II -> L (in CMTX1).
GJB1	213	213	I -> V (in CMTX1; localized mainly on the cell membrane forming gap junction-like plaques).
GJB1	215	215	R -> Q (in CMTX1; non-detectable levels of hemichannel activation and non- detectable levels of electrical coupling).
GJB1	215	215	R -> W (in CMTX1; mild/moderate; non- functional channel).
GJB1	219	219	R -> C (in CMTX1; localized mainly on the cell membrane forming gap junction-like plaques).
GJB1	219	219	R -> H (in CMTX1; localized mainly on the cell membrane forming gap junction-like plaques).
GJB1	220	220	R -> G (in CMTX1; localized mainly on the cell membrane forming gap junction-like plaques).
GJB1	230	230	R -> C (in CMTX1; localized mainly on the cell membrane forming gap junction-like plaques).
GJB1	230	230	R -> L (in CMTX1; localized mainly on the cell membrane forming gap junction-like plaques).
GJB1	235	235	F -> C (in CMTX1; the mutation causes abnormal hemichannel opening with excessive permeability of the plasma membrane and decreased cell survival).
GJB1	238	238	R -> H (in CMTX1; localized mainly on the cell membrane forming gap junction-like plaques).
GJB1	239	239	L -> I (in CMTX1; localized mainly on the cell membrane forming gap junction-like plaques).
GJB1	264	264	R -> C (in CMTX1).
GJB1	280	280	C -> G (in CMTX1; forms channels normally).
CXCR3	292	292	R -> Q.
CXCR3	363	363	A -> T.
MAGEE1	640	640	Y -> F (in a breast cancer sample; somatic mutation).
MAGEE1	664	664	T -> N (in a breast cancer sample; somatic mutation).
MAGT1	311	311	V -> G (in MRX95).
PGAM4	40	40	R -> C.
PGAM4	175	175	I -> T.
PGK1	88	88	L -> P (in PGK1D; with congenital non- spherocytic anemia; variant Matsue).
PGK1	158	158	G -> V (in PGK1D; with chronic hemolytic anemia; variant Shizuoka).
PGK1	164	164	D -> V (in PGK1D; with chronic hemolytic anemia and mental retardation; variant Amiens).
PGK1	191	191	Missing (in PGK1D; with chronic hemolytic anemia; variant Alabama).
PGK1	206	206	R -> P (in PGK1D; with chronic hemolytic anemia; variant Uppsala).
PGK1	252	252	E -> A (in PGK1D; with chronic hemolytic anemia; variant Antwerp).
PGK1	266	266	V -> M (in PGK1D; with chronic non- spherocytic hemolytic anemia; variant Tokyo).
PGK1	268	268	D -> N (in Munchen; 21% of activity).
PGK1	285	285	D -> V (in PGK1D; with chronic hemolytic anemia; variant Herlev; 50% of activity).
PGK1	315	315	D -> N (in PGK1D; with rhabdomyolysis; variant Creteil).
PGK1	316	316	C -> R (in PGK1D; with chronic hemolytic anemia; variant Michigan).
PGK1	352	352	T -> N.
TBX22	16	16	V -> A (in a colorectal cancer sample; somatic mutation).
TBX22	51	51	A -> T (in a colorectal cancer sample; somatic mutation).
TBX22	118	118	G -> C (in CPX).
TBX22	121	121	M -> V (in CPX).
TBX22	183	183	P -> L (in CPX).
TBX22	214	214	L -> P (in CPX).
TBX22	260	260	T -> M (in CPX).
TBX22	307	307	D -> N (in a colorectal cancer sample; somatic mutation).
POU3F4	201	202	Missing (in DFNX2).
POU3F4	312	312	A -> V (in DFNX2).
POU3F4	317	317	L -> W (in DFNX2).
POU3F4	323	323	R -> G (in DFNX2; somatic mosaicism in 50% of the peripheral blood lymphocytes).
POU3F4	330	330	R -> S (in DFNX2).
POU3F4	334	334	K -> E (in DFNX2).
ZNF711	139	139	G -> E (in an individual affected by mental retardation; unknown pathological role).
ZNF711	221	221	T -> A.
ZNF711	274	274	H -> R (in an individual affected by mental retardation; unknown pathological role).
ZNF711	524	524	M -> T.
ZNF711	601	601	N -> S (in an individual affected by mental retardation; unknown pathological role).
ZNF711	622	622	E -> D (in an individual affected by mental retardation; unknown pathological role).
SRPX2	72	72	Y -> S (in BPP; affects intracellular processing; increases the interaction with PLAUR).
SRPX2	327	327	N -> S (in RESDX; results in a gain of glycosylation; affects intracellular processing; does not affect interaction with PLAUR).
TIMM8A	66	66	C -> W (in MTS; disrupts the assembly of the heterohexamer with TIMM13).
BTK	11	11	L -> P (in XLA).
BTK	12	12	K -> R (in XLA).
BTK	14	14	S -> F (in XLA).
BTK	19	19	K -> E (in XLA).
BTK	25	25	F -> S (in XLA).
BTK	27	27	K -> R (in XLA).
BTK	28	28	R -> C (in XLA; no effect on phosphorylation of GTF2I).
BTK	28	28	R -> H (in XLA; moderate).
BTK	28	28	R -> P (in XLA).
BTK	33	33	T -> P (in XLA; severe).
BTK	39	39	Y -> S (in XLA).
BTK	40	40	Y -> C (in XLA).
BTK	40	40	Y -> N (in XLA).
BTK	61	61	I -> N (in XLA).
BTK	64	64	V -> D (in XLA).
BTK	64	64	V -> F (in XLA).
BTK	103	103	Q -> QSVFSSTR (in XLA).
BTK	113	113	V -> D (in XLA).
BTK	115	115	S -> F (in XLA).
BTK	117	117	T -> P (in XLA).
BTK	127	127	Q -> H (in XLA).
BTK	154	154	C -> S (in XLA).
BTK	155	155	C -> G (in XLA).
BTK	155	155	C -> R (in XLA).
BTK	184	184	T -> P (in XLA).
BTK	190	190	P -> K (in a lung large cell carcinoma sample; somatic mutation; requires 2 nucleotide substitutions).
BTK	260	280	Missing (in XLA; severe).
BTK	288	288	R -> Q (in XLA).
BTK	288	288	R -> W (in XLA).
BTK	295	295	L -> P (in XLA).
BTK	302	302	G -> E (in XLA).
BTK	302	302	G -> R (in XLA).
BTK	302	302	Missing (in XLA).
BTK	307	307	R -> G (in XLA; loss of activity).
BTK	307	307	R -> T (in XLA).
BTK	308	308	D -> E (in XLA).
BTK	319	319	V -> A (in XLA; moderate).
BTK	334	334	Y -> S (in XLA).
BTK	358	358	L -> F (in XLA).
BTK	362	362	H -> Q (in XLA).
BTK	364	364	H -> P (in XLA).
BTK	365	365	N -> Y (in XLA).
BTK	366	366	S -> F (in XLA).
BTK	369	369	L -> F (in XLA).
BTK	370	370	I -> M (in XLA).
BTK	372	372	R -> G (in XLA).
BTK	408	408	L -> P (in XLA; moderate).
BTK	414	414	G -> R (in XLA).
BTK	418	418	Y -> H (in XLA).
BTK	429	429	I -> N (in XLA).
BTK	430	430	K -> E (in XLA; loss of phosphorylation of GTF2I).
BTK	430	430	K -> R (in XLA).
BTK	445	445	E -> D (in XLA).
BTK	462	462	G -> D (in XLA).
BTK	462	462	G -> V (in XLA).
BTK	476	476	Y -> D (in XLA).
BTK	477	477	M -> R (in XLA).
BTK	502	502	C -> F (in XLA).
BTK	502	502	C -> W (in XLA).
BTK	506	506	C -> R (in XLA).
BTK	506	506	C -> Y (in XLA).
BTK	508	508	A -> D (in XLA).
BTK	509	509	M -> I (in XLA).
BTK	509	509	M -> V (in XLA).
BTK	512	512	L -> P (in XLA).
BTK	512	512	L -> Q (in XLA).
BTK	518	518	L -> R (in XLA).
BTK	520	520	R -> Q (in XLA; severe; prevents activation due to absence of contact between the catalytic loop and the regulatory phosphorylated residue).
BTK	521	521	D -> G (in XLA).
BTK	521	521	D -> H (in XLA; severe).
BTK	521	521	D -> N (in XLA; severe).
BTK	523	523	A -> E (in XLA).
BTK	525	525	R -> G (in XLA).
BTK	525	525	R -> P (in XLA).
BTK	525	525	R -> Q (in XLA; severe; disturbs ATP- binding).
BTK	526	526	N -> K (in XLA).
BTK	535	535	V -> F (in XLA).
BTK	542	542	L -> P (in XLA; growth hormone deficiency).
BTK	544	544	R -> G (in XLA).
BTK	544	544	R -> K (in XLA).
BTK	559	559	F -> S (in XLA).
BTK	562	562	R -> W (in XLA).
BTK	563	563	W -> L (in XLA).
BTK	567	567	E -> K (in XLA; severe).
BTK	578	578	S -> Y (in XLA).
BTK	581	581	W -> R (in XLA).
BTK	582	582	A -> V (in XLA).
BTK	583	583	F -> S (in XLA).
BTK	587	587	M -> L (in XLA; mild).
BTK	589	589	E -> D (in XLA).
BTK	589	589	E -> G (in XLA; moderate; interferes with substrate binding).
BTK	589	589	E -> K (in XLA).
BTK	592	592	S -> P (in XLA).
BTK	594	594	G -> E (in XLA; mild; interferes with substrate binding).
BTK	594	594	G -> R (in XLA).
BTK	598	598	Y -> C (in XLA).
BTK	607	607	A -> D (in XLA; mild).
BTK	613	613	G -> D (in XLA; mild; interferes with substrate binding and/or domain interactions).
BTK	619	619	P -> A (in XLA).
BTK	619	619	P -> S (in XLA).
BTK	619	619	P -> T (in XLA).
BTK	622	622	A -> P (in XLA).
BTK	626	626	V -> G (in XLA).
BTK	630	630	M -> I (polymorphism, 35%).
BTK	630	630	M -> K (in XLA).
BTK	630	630	M -> T (in XLA).
BTK	633	633	C -> Y (in XLA).
BTK	641	641	R -> C (in XLA).
BTK	641	641	R -> H (in XLA; severe).
BTK	644	644	F -> L (in XLA).
BTK	644	644	F -> S (in XLA).
BTK	647	647	L -> P (in XLA).
BTK	652	652	L -> P (in XLA).
GLA	12	14	Missing (in FD; has 4% of wild-type activity).
GLA	20	20	A -> P (in FD; atypical).
GLA	31	31	A -> V (in FD).
GLA	32	32	L -> P (in FD).
GLA	35	35	G -> R (in FD).
GLA	40	40	P -> L (in FD).
GLA	40	40	P -> S (in FD).
GLA	42	42	M -> L (in FD).
GLA	42	42	M -> V (in FD).
GLA	43	43	G -> R (in FD).
GLA	45	46	LH -> RS (in FD).
GLA	46	46	H -> P (in FD; has 36% of wild-type activity).
GLA	46	46	H -> R (in FD).
GLA	46	46	H -> Y (in FD).
GLA	47	47	W -> G (in FD).
GLA	49	49	R -> L (in FD).
GLA	49	49	R -> P (in FD).
GLA	49	49	R -> S (in FD).
GLA	52	52	C -> R (in FD).
GLA	52	52	C -> S (in FD).
GLA	56	56	C -> F (in FD).
GLA	56	56	C -> Y (in FD).
GLA	59	59	E -> K (in FD).
GLA	65	65	S -> T (in FD; does not affect enzyme function).
GLA	72	72	M -> V (in FD; atypical).
GLA	85	85	G -> D (in FD).
GLA	86	86	Y -> C (in FD).
GLA	89	89	L -> P (in FD).
GLA	89	89	L -> R (in FD).
GLA	91	91	I -> T (in FD; mild).
GLA	92	92	D -> H (in FD).
GLA	92	92	D -> Y (in FD).
GLA	93	93	D -> G (in FD).
GLA	93	93	D -> N (in FD; has no enzyme activity).
GLA	94	94	C -> S (in FD).
GLA	94	94	C -> Y (in FD).
GLA	95	95	W -> S (in FD).
GLA	97	97	A -> V (in FD).
GLA	100	100	R -> K (in FD).
GLA	100	100	R -> T (in FD).
GLA	112	117	Missing (in FD).
GLA	112	112	R -> C (in FD).
GLA	112	112	R -> H (in FD; mild).
GLA	112	112	R -> S (in FD).
GLA	113	113	F -> L (in FD; mild).
GLA	113	113	F -> S (in FD).
GLA	120	121	LA -> PT (in FD).
GLA	120	120	L -> V (in FD; has 42% of wild-type activity).
GLA	128	128	G -> E (in FD).
GLA	131	131	L -> P (in FD).
GLA	134	134	Y -> S (in FD).
GLA	135	135	A -> V (in FD).
GLA	138	138	G -> R (in FD).
GLA	142	142	C -> R (in FD).
GLA	142	142	C -> Y (in FD).
GLA	143	143	A -> P (in FD).
GLA	143	143	A -> T (in FD).
GLA	144	144	G -> V (in FD).
GLA	148	148	S -> N (in FD).
GLA	148	148	S -> R (in FD).
GLA	156	156	A -> V (in FD).
GLA	162	162	W -> C (in FD).
GLA	163	163	G -> V (in FD).
GLA	165	165	D -> V (in FD).
GLA	166	166	L -> V (in FD).
GLA	170	170	D -> V (in FD).
GLA	171	171	G -> D (in FD).
GLA	172	172	C -> R (in FD).
GLA	172	172	C -> Y (in FD).
GLA	183	183	G -> D (in FD).
GLA	187	187	M -> V (in FD).
GLA	201	201	S -> F (in FD).
GLA	202	202	C -> Y (in FD).
GLA	205	207	Missing (in FD).
GLA	205	205	P -> T (in FD).
GLA	216	216	Y -> D (in FD).
GLA	219	219	I -> N (in FD).
GLA	219	219	I -> T (in FD; has 46% of wild-type activity).
GLA	223	223	C -> G (in FD).
GLA	224	224	N -> D (in FD).
GLA	224	224	N -> S (in FD).
GLA	226	226	W -> R (in FD).
GLA	230	230	A -> T (in FD).
GLA	231	231	D -> N (in FD).
GLA	234	234	D -> E (in FD).
GLA	235	235	S -> C (in FD).
GLA	236	236	W -> C (in FD).
GLA	236	236	W -> L (in FD).
GLA	242	242	I -> N (in FD).
GLA	244	244	D -> H (in FD).
GLA	244	244	D -> N (in FD).
GLA	247	247	S -> SWTS (in FD).
GLA	258	258	G -> R (in FD).
GLA	259	259	P -> L (in FD).
GLA	259	259	P -> R (in FD).
GLA	260	260	G -> A (in FD).
GLA	261	261	G -> D (in FD).
GLA	263	263	N -> S (in FD).
GLA	264	264	D -> Y (in FD).
GLA	265	265	P -> R (in FD).
GLA	266	266	D -> H (in FD).
GLA	266	266	D -> N (in FD).
GLA	267	267	M -> I (in FD).
GLA	272	272	N -> K (in FD).
GLA	276	276	S -> G (in FD).
GLA	279	279	Q -> H (in FD).
GLA	280	280	Q -> H (in FD).
GLA	284	284	M -> T (in FD).
GLA	285	285	A -> P (in FD).
GLA	287	287	W -> C (in FD).
GLA	287	287	W -> G (in FD).
GLA	288	288	A -> D (in FD).
GLA	289	289	I -> F (in FD).
GLA	296	296	M -> I (in FD; atypical).
GLA	296	296	M -> V (in FD; mild).
GLA	298	298	N -> H (in FD).
GLA	298	298	N -> K (in FD).
GLA	298	298	N -> S (in FD).
GLA	300	300	L -> F (in FD).
GLA	301	301	R -> Q (in FD; mild; does not significantly affect the enzyme activity but the mutant protein levels are decreased presumably in the ER of the cells).
GLA	316	322	Missing (in FD).
GLA	316	316	V -> E (in FD).
GLA	320	320	N -> K (in FD).
GLA	320	320	N -> Y (in FD).
GLA	321	321	Q -> E (in FD).
GLA	328	328	G -> R (in FD).
GLA	328	328	G -> V (in FD).
GLA	338	338	E -> K (in FD).
GLA	340	340	W -> R (in FD).
GLA	341	341	E -> K (in FD).
GLA	356	356	R -> Q (in FD; has 15% of wild-type activity).
GLA	356	356	R -> W (in FD; severe).
GLA	358	358	E -> A (in FD).
GLA	358	358	E -> K (in FD).
GLA	358	358	Missing (in FD).
GLA	360	360	G -> C (in FD; has 6% of wild-type activity).
GLA	363	363	R -> H (in FD).
GLA	373	373	G -> D (in FD).
GLA	373	373	G -> S (in FD).
GLA	377	377	A -> D (in FD).
GLA	378	378	C -> Y (in FD).
GLA	383	383	Missing (in FD; severe; with facial telangiectasias).
GLA	396	396	F -> Y (in RNA edited version).
GLA	404	404	Missing (in FD; mild).
GLA	409	409	P -> A (in FD).
GLA	409	409	P -> T (in FD).
GLA	410	410	T -> A (in FD; mild).
GLA	414	414	L -> S (in FD).
PLP1	15	15	P -> L (in HLD1).
PLP1	31	31	L -> P (in HLD1).
PLP1	32	32	F -> L (in HLD1).
PLP1	32	32	F -> V (in HLD1).
PLP1	33	33	C -> Y (in HLD1).
PLP1	35	35	C -> R (in HLD1).
PLP1	35	35	C -> Y (in HLD1).
PLP1	39	39	A -> T (in HLD1).
PLP1	43	43	T -> I (in HLD1).
PLP1	46	46	L -> P (in HLD1/SPG2).
PLP1	46	46	L -> R (in HLD1).
PLP1	50	50	Y -> C (in HLD1).
PLP1	51	51	F -> S (in HLD1).
PLP1	60	60	Y -> C (in HLD1).
PLP1	74	74	G -> R (in HLD1).
PLP1	76	76	A -> P (in HLD1).
PLP1	116	116	T -> K (in HLD1).
PLP1	117	165	Missing (in HLD1).
PLP1	130	130	H -> Y (in SPG2).
PLP1	137	137	R -> W (in SPG2).
PLP1	140	140	H -> Y (in SPG2).
PLP1	148	148	H -> Y (in HLD1/SPG2).
PLP1	151	151	K -> N (in HLD1).
PLP1	156	156	T -> I (in HLD1).
PLP1	162	162	V -> E (in HLD1).
PLP1	163	163	W -> R (in HLD1).
PLP1	166	166	V -> E (in HLD1).
PLP1	166	166	V -> G (in HLD1/SPG2).
PLP1	169	169	C -> R (in HLD1).
PLP1	170	170	S -> F (in SPG2).
PLP1	170	170	S -> P (in HLD1).
PLP1	172	172	V -> A (in HLD1).
PLP1	173	173	P -> S (in HLD1).
PLP1	175	175	Y -> C (in HLD1).
PLP1	181	181	W -> C (in HLD1).
PLP1	182	182	T -> P (in HLD1).
PLP1	183	183	T -> N (in HLD1).
PLP1	187	187	I -> T (in SPG2).
PLP1	203	203	D -> E (in HLD1).
PLP1	203	203	D -> G (in HLD1).
PLP1	203	203	D -> H (in HLD1).
PLP1	203	203	D -> N (in HLD1).
PLP1	203	203	D -> V (in HLD1).
PLP1	205	205	R -> G (in HLD1).
PLP1	207	207	Y -> C (in HLD1).
PLP1	209	209	V -> D (in HLD1).
PLP1	210	210	L -> H (in HLD1).
PLP1	211	211	P -> L (in HLD1).
PLP1	212	212	W -> R (in HLD1).
PLP1	216	216	P -> A (in HLD1).
PLP1	216	216	P -> L (in SPG2).
PLP1	216	216	P -> S (in HLD1).
PLP1	217	217	G -> S (in HLD1).
PLP1	219	219	V -> F (in HLD1).
PLP1	220	220	C -> Y (in HLD1).
PLP1	221	221	G -> C (in HLD1).
PLP1	224	224	L -> I (in HLD1/SPG2).
PLP1	224	224	L -> P (in HLD1).
PLP1	225	225	L -> P (in HLD1).
PLP1	226	226	S -> P (in SPG2).
PLP1	228	228	C -> Y (in HLD1).
PLP1	234	234	Q -> P (in HLD1).
PLP1	237	237	F -> S (in SPG2).
PLP1	239	239	L -> P (in HLD1).
PLP1	242	242	A -> P (in HLD1).
PLP1	243	243	A -> E (in HLD1).
PLP1	243	243	A -> V (in HLD1).
PLP1	246	246	G -> A (in HLD1).
PLP1	246	246	G -> E (in HLD1).
PLP1	247	247	A -> T (in HLD1).
PLP1	248	248	A -> E (in HLD1).
PLP1	249	249	A -> P (in HLD1).
PLP1	253	253	S -> F (in HLD1).
SERPINA7	43	43	S -> T (in TBG deficiency; San Diego; partial TBG deficiency).
SERPINA7	351	351	H -> Y (in TBG deficiency; Quebec; partial TBG deficiency).
SERPINA7	383	383	P -> L (in TBG deficiency; Kumamoto).
PRPS1	43	43	E -> D (in CMTX5).
PRPS1	52	52	D -> H (in PRPS1 superactivity).
PRPS1	65	65	D -> N (in DFNX1).
PRPS1	87	87	A -> T (in DFNX1).
PRPS1	114	114	N -> S (in PRPS1 superactivity).
PRPS1	115	115	M -> T (in CMTX5).
PRPS1	129	129	L -> I (in PRPS1 superactivity).
PRPS1	133	133	Q -> P (in ARTS).
PRPS1	152	152	L -> P (in ARTS).
PRPS1	183	183	D -> H (in PRPS1 superactivity).
PRPS1	190	190	A -> V (in PRPS1 superactivity).
PRPS1	193	193	H -> Q (in PRPS1 superactivity).
PRPS1	203	203	D -> H (in a breast cancer sample; somatic mutation).
PRPS1	219	219	V -> G (in a breast cancer sample; somatic mutation).
PRPS1	231	231	H -> D (in a colorectal cancer sample; somatic mutation).
PRPS1	290	290	I -> T (in DFNX1).
PRPS1	306	306	G -> R (in DFNX1).
IRS4	20	20	A -> V (in a colorectal cancer sample; somatic mutation).
IRS4	215	215	G -> E (in a colorectal cancer sample; somatic mutation).
IRS4	557	557	G -> R (in a colorectal cancer sample; somatic mutation).
LONRF3	122	122	A -> G (in a breast cancer sample; somatic mutation).
UPF3B	160	160	Y -> D (in MRXS14).
NDUFA1	8	8	G -> R (in MT-C1D).
NDUFA1	37	37	R -> S (in MT-C1D).
NDUFA1	53	53	R -> C (in a colorectal cancer sample; somatic mutation).
LAMP2	321	321	W -> R (in DAND).
C1GALT1C1	152	152	E -> K (in TNSYN; loss capacity to promote Tn synthase activity).
SH2D1A	7	7	Y -> C (in XLP1; reduced protein stability and reduced affinity for SLAMF1).
SH2D1A	8	8	H -> D (in XLP1).
SH2D1A	16	16	G -> D (in XLP1; abolishes interaction with SLAMF1).
SH2D1A	27	27	G -> S (in XLP1).
SH2D1A	28	28	S -> R (in XLP1; reduced protein stability).
SH2D1A	31	31	L -> P (in XLP1; reduced protein stability and reduced affinity for SLAMF1 and FYN).
SH2D1A	32	32	R -> T (in XLP1).
SH2D1A	33	33	D -> Y (in XLP1).
SH2D1A	42	42	C -> W (in XLP1; loss of interaction with CD84 and reduced affinity for SLAMF1).
SH2D1A	49	49	G -> V (in XLP1).
SH2D1A	53	53	T -> I (in XLP1; loss of interaction with CD48 and reduced affinity for SLAMF1 and loss of interaction with nonphosphorylated SLAMF1).
SH2D1A	54	54	Y -> C (in XLP1; reduced protein stability and reduced affinity for SLAMF1 and FYN).
SH2D1A	55	55	R -> L (in XLP1; reduced affinity for SLAMF1 and FYN).
SH2D1A	57	57	S -> P (in one XLP1 patient; unknown pathological significance).
SH2D1A	68	68	T -> I (in XLP1; loss of interaction with CD48 and strongly reduced affinity for SLAMF1).
SH2D1A	84	84	I -> T (in XLP1; reduced protein stability).
SH2D1A	87	87	F -> S (in XLP1; reduced protein stability and reduced affinity for SLAMF1 and FYN).
SH2D1A	99	99	Q -> P (in XLP1; reduced protein stability and strongly reduced affinity for SLAMF1).
SH2D1A	102	102	V -> G (in XLP1; reduced protein stability and strongly reduced affinity for SLAMF1).
BCORL1	832	832	G -> D (in a breast cancer sample; somatic mutation).
AIFM1	201	201	Missing (in COXPD6; higher DNA binding affinity, partially impaired flavin binding and association with increased parthanatos-linked cell death).
RAB33A	102	102	M -> T.
FRMD7	14	14	Missing (in NYS1).
FRMD7	24	24	G -> E (in NYS1).
FRMD7	24	24	G -> R (in NYS1).
FRMD7	24	24	G -> W (in NYS1).
FRMD7	142	142	L -> R (in NYS1).
FRMD7	146	146	R -> W (in NYS1).
FRMD7	221	221	N -> D (in NYS1).
FRMD7	225	225	W -> G (in NYS1).
FRMD7	226	226	A -> T (in NYS1).
FRMD7	229	229	R -> C (in NYS1).
FRMD7	229	229	R -> G (in NYS1).
FRMD7	231	231	L -> V (in NYS1).
FRMD7	261	261	R -> G (in NYS1).
FRMD7	261	261	R -> Q (in NYS1).
FRMD7	266	266	A -> P (in NYS1).
FRMD7	271	271	C -> F (in NYS1).
FRMD7	271	271	C -> Y (in NYS1).
FRMD7	275	275	H -> P (in NYS1).
FRMD7	296	296	G -> R (in NYS1).
FRMD7	301	301	Y -> C (in NYS1).
FRMD7	340	340	S -> L (in NYS1).
USP26	123	123	T -> TT.
USP26	165	165	L -> S.
USP26	364	364	L -> F.
USP26	475	475	H -> Y.
USP26	517	517	L -> F.
USP26	579	579	M -> I.
HPRT1	7	7	G -> D (in GOUT-HPRT; Gravesend).
HPRT1	8	8	V -> G (in LNS; HB).
HPRT1	16	16	G -> D (in LNS; FG).
HPRT1	16	16	G -> S (in GOUT-HPRT; Urangan).
HPRT1	20	20	D -> V (in GOUT-HPRT; Mashad).
HPRT1	23	23	C -> W (in GOUT-HPRT; JS).
HPRT1	28	28	Missing (in LNS).
HPRT1	41	41	L -> P (in LNS; Detroit).
HPRT1	42	42	I -> F (in LNS; Isar).
HPRT1	42	42	I -> T (in LNS; Heapey).
HPRT1	43	44	MD -> RN (in LNS; Salamanca).
HPRT1	45	45	R -> K (in LNS; RJK 2163).
HPRT1	48	48	R -> H (in GOUT-HPRT; AD and DD).
HPRT1	50	50	A -> P (in LNS; LW).
HPRT1	50	50	A -> V (in LNS; 1265).
HPRT1	51	51	R -> G (in GOUT-HPRT; Toronto).
HPRT1	51	51	R -> P (in LNS; Banbury).
HPRT1	52	52	D -> G (in Edinburgh).
HPRT1	53	53	V -> A (in GOUT-HPRT; MG).
HPRT1	53	53	V -> M (in GOUT-HPRT; TE).
HPRT1	54	54	M -> L (in LNS; Japan-1).
HPRT1	57	57	M -> T (in LNS; Montreal).
HPRT1	58	58	G -> R (in GOUT-HPRT; Toowong).
HPRT1	61	61	H -> R (enzyme activity 37% of normal; asymptomatic).
HPRT1	70	70	G -> E (in LNS; New Haven/1510).
HPRT1	71	71	G -> R (in LNS; Yale).
HPRT1	74	74	F -> L (in LNS; Flint/RJK 892/DW/Perth/ 1522).
HPRT1	78	78	L -> V (in GOUT-HPRT; Swan).
HPRT1	80	80	D -> V (in GOUT-HPRT; Arlington).
HPRT1	104	104	S -> R (in GOUT-HPRT; Munich).
HPRT1	110	110	S -> L (in GOUT-HPRT; London).
HPRT1	130	130	V -> D (in LNS; Midland/RJK 896).
HPRT1	131	131	L -> S (in LNS; RJK 1784).
HPRT1	132	132	I -> M (in GOUT-HPRT; Ann-Arbor).
HPRT1	132	132	I -> T (in LNS; Runcorn).
HPRT1	135	135	D -> G (in GOUT-HPRT; Yeronga).
HPRT1	143	143	M -> K (in LNS; RJK 1210).
HPRT1	143	143	M -> MA (in LNS; RW).
HPRT1	161	161	A -> S (in GOUT-HPRT; Milwaukee/RJK 949).
HPRT1	162	162	S -> R (in LNS; Farnham).
HPRT1	168	168	T -> I (in GOUT-HPRT; Brisbane).
HPRT1	176	176	P -> L (in LNS; Marlow).
HPRT1	177	177	D -> V (in LNS; Roanne).
HPRT1	177	177	D -> Y (in LNS; RJK 2185).
HPRT1	179	180	VG -> GR (in GOUT-HPRT; Japan-2).
HPRT1	179	179	Missing (in LNS; Michigan).
HPRT1	183	183	I -> T (in GOUT-HPRT; JF).
HPRT1	188	188	V -> A (in Japan).
HPRT1	194	194	D -> E (in GOUT-HPRT; Moose-Jaw; results in cooperativity and decreased substrate affinities).
HPRT1	194	194	D -> N (in LNS; Kinston/RJK 2188).
HPRT1	195	195	Y -> C (in GOUT-HPRT; Dirranbandi).
HPRT1	199	199	F -> V (in LNS; New Briton/RJK 950).
HPRT1	201	201	D -> G (in GOUT-HPRT; Ashville).
HPRT1	201	201	D -> N (in GOUT-HPRT; RB).
HPRT1	201	201	D -> Y (in LNS; GM).
HPRT1	204	204	H -> D (in LNS; RJK 1874).
HPRT1	204	204	H -> R (in LNS; 779).
HPRT1	206	206	C -> Y (in LNS; Reading/RJK 1727).
MOSPD1	63	63	V -> I (in a breast cancer sample; somatic mutation).
CD40LG	36	36	M -> R (in HIGM1).
CD40LG	38	38	G -> R (in HIGM1).
CD40LG	116	116	G -> R (in HIGM1).
CD40LG	116	116	G -> S (in HIGM1).
CD40LG	123	123	A -> E (in HIGM1).
CD40LG	125	125	H -> R (in HIGM1).
CD40LG	126	126	V -> A (in HIGM1).
CD40LG	126	126	V -> D (in HIGM1).
CD40LG	128	129	SE -> RG (in HIGM1).
CD40LG	140	140	W -> C (in HIGM1).
CD40LG	140	140	W -> G (in HIGM1).
CD40LG	140	140	W -> R (in HIGM1).
CD40LG	143	143	K -> T (in HIGM1).
CD40LG	144	144	G -> E (in HIGM1).
CD40LG	147	147	T -> N (in HIGM1).
CD40LG	155	155	L -> P (in HIGM1).
CD40LG	170	170	Y -> C (in HIGM1).
CD40LG	173	173	A -> D (in HIGM1).
CD40LG	174	174	Q -> R (in HIGM1).
CD40LG	176	176	T -> I (in HIGM1).
CD40LG	195	195	L -> P (in HIGM1).
CD40LG	208	208	A -> D (in HIGM1).
CD40LG	211	211	T -> N (in HIGM1).
CD40LG	219	219	G -> R.
CD40LG	224	224	H -> Y (in HIGM1).
CD40LG	226	226	G -> A (in HIGM1).
CD40LG	227	227	G -> V (in HIGM1).
CD40LG	227	227	Missing (in HIGM1).
CD40LG	231	231	L -> S (in HIGM1).
CD40LG	235	235	A -> P (in HIGM1).
CD40LG	237	237	V -> E (in HIGM1).
CD40LG	254	254	T -> M (in HIGM1).
CD40LG	257	257	G -> D (in HIGM1).
CD40LG	257	257	G -> S (in HIGM1).
CD40LG	258	258	L -> S (in HIGM1).
ZIC3	217	217	P -> A (in a patient with atrial septal defect and pulmonic stenosis not associated with heterotaxy; lacks DNA- binding; does not inhibit transcriptional activation and interaction with GLI3).
ZIC3	253	253	C -> S (in HTX1; increases strongly its cytoplasmic localization; lacks DNA- binding; does not inhibit transcriptional activation and interaction with GLI3).
ZIC3	255	255	W -> G (in HTX1; decreases protein expression and transcriptional activity and increases its cytoplasmic localization).
ZIC3	286	286	H -> R (in HTX1; inreases weakly its cytoplasmic localization; lacks DNA- binding; does not inhibit transcriptional activation and interaction with GLI3).
ZIC3	323	323	T -> M (in HTX1; lacks DNA-binding; does not inhibit transcriptional activation and interaction with GLI3).
ZIC3	405	405	K -> E (in HTX1; lacks DNA-binding; does not inhibit transcriptional activation and interaction with GLI3).
F9	7	7	I -> F.
F9	17	17	I -> N (in HEMB; severe; UK 22).
F9	28	28	C -> R (in HEMB; moderate; HB130).
F9	28	28	C -> Y (in HEMB).
F9	30	30	V -> I (in HEMB).
F9	37	37	A -> T (in warfarin sensitivity; reduced affinity of the glutamate carboxylase for the factor IX precursor).
F9	43	43	R -> L (in HEMB; severe; Bendorf, Beuten, Gleiwitz, etc.).
F9	43	43	R -> Q (in HEMB; severe; San Dimas, Oxford-3, Strasbourg-2, etc.).
F9	43	43	R -> W (in HEMB; severe; Boxtel, Heiden, Lienen, etc.).
F9	45	45	K -> N (in HEMB; severe; Seattle E).
F9	46	46	R -> S (in HEMB; severe; Cambridge).
F9	46	46	R -> T (in HEMB; severe).
F9	48	48	N -> I (in HEMB; severe; Calgary-16).
F9	49	49	S -> P (in HEMB).
F9	52	52	L -> S (in HEMB; severe; Gla mutant).
F9	53	53	E -> A (in HEMB; severe; Oxford-B2; Gla mutant).
F9	54	54	E -> G (in HEMB; severe; HB151; Gla mutant).
F9	55	55	F -> C (in HEMB).
F9	58	58	G -> A (in HEMB; severe; Hong Kong-1).
F9	58	58	G -> R (in HEMB; severe; Los Angeles-4).
F9	62	63	Missing (in HEMB; severe).
F9	66	66	E -> V (in HEMB; moderate).
F9	67	67	E -> K (in HEMB; severe; Nagoya-4; Gla mutant).
F9	71	71	F -> S (in HEMB; severe).
F9	73	73	E -> K (in HEMB; severe; Seattle-3; Gla mutant).
F9	73	73	E -> V (in HEMB; severe; Chongqing; Gla mutant).
F9	75	75	R -> Q (in HEMB; mild).
F9	79	79	E -> D (in HEMB).
F9	84	84	T -> R (in HEMB).
F9	91	91	Y -> C (in HEMB; moderate).
F9	93	93	D -> G (in HEMB; moderate; Alabama).
F9	96	96	Q -> P (in HEMB; severe; New London).
F9	97	97	C -> S (in HEMB).
F9	101	101	P -> R (in HEMB).
F9	102	102	C -> R (in HEMB; severe; Basel).
F9	106	106	G -> D (in HEMB).
F9	106	106	G -> S (in HEMB; mild; Durham).
F9	108	108	C -> S (in HEMB).
F9	110	110	D -> N (in HEMB; severe; Oxford-D1).
F9	112	112	I -> S (in HEMB).
F9	113	113	N -> K (in HEMB; mild).
F9	115	115	Y -> C (in HEMB; severe).
F9	119	119	C -> F (in HEMB; severe).
F9	119	119	C -> R (in HEMB; Iran).
F9	124	124	E -> K (in HEMB).
F9	125	125	G -> E (in HEMB).
F9	125	125	G -> R (in HEMB).
F9	125	125	G -> V (in HEMB).
F9	129	130	Missing (in HEMB).
F9	134	134	C -> Y (in HEMB).
F9	136	136	I -> T (in HEMB; mild).
F9	139	139	G -> D (in HEMB; severe).
F9	139	139	G -> S (in HEMB).
F9	155	155	C -> F (in HEMB; severe).
F9	160	160	G -> E (in HEMB; mild).
F9	167	167	Q -> H (in HEMB; mild).
F9	169	169	S -> C (in HEMB).
F9	170	170	C -> F (in HEMB).
F9	178	178	C -> R (in HEMB).
F9	178	178	C -> W (in HEMB; severe).
F9	191	191	R -> C (in HEMB; moderate; Albuquerque, Cardiff-1, etc.).
F9	191	191	R -> H (in HEMB; moderate; Chapel-Hill, Chicago-2, etc.).
F9	226	226	R -> G (in HEMB; severe; Madrid).
F9	226	226	R -> Q (in HEMB; severe; Hilo and Novara).
F9	226	226	R -> W (in HEMB; severe; Nagoya-1, Dernbach, Deventer, Idaho, etc.).
F9	227	227	V -> D (in HEMB; mild).
F9	227	227	V -> F (in HEMB; Milano).
F9	228	228	V -> F (in HEMB; severe; Kashihara).
F9	228	228	V -> L (in HEMB; mild; Cardiff-2).
F9	241	241	Q -> H (in HEMB).
F9	241	241	Q -> K (in HEMB).
F9	252	252	C -> S (in HEMB; severe; this is the mutation in the index case of the disease, Stephen Christmas).
F9	252	252	C -> Y (in HEMB).
F9	253	253	G -> E (in HEMB; severe).
F9	253	253	G -> R (in HEMB; severe; Luanda).
F9	265	265	A -> T (in HEMB; mild).
F9	268	268	C -> W (in HEMB; moderate).
F9	279	279	A -> T (in HEMB; mild).
F9	283	283	N -> D (in HEMB; severe).
F9	286	286	Missing (in HEMB; severe).
F9	291	291	E -> V (in HEMB; Monschau).
F9	294	294	R -> G (in HEMB; severe).
F9	294	294	R -> Q (in HEMB; mild to moderate; Dreihacken, Penafiel and Seattle-4).
F9	302	302	H -> R (in HEMB).
F9	306	306	N -> S (in HEMB; mild).
F9	316	316	I -> F (in HEMB).
F9	318	318	L -> R (in HEMB).
F9	321	321	L -> Q (in HEMB; severe).
F9	333	333	P -> H (in HEMB; severe).
F9	333	333	P -> T (in HEMB).
F9	342	342	T -> K (in HEMB; mild).
F9	342	342	T -> M (in HEMB; moderate).
F9	344	344	I -> L (in HEMB).
F9	351	351	G -> D (in HEMB).
F9	356	356	W -> C (in HEMB; severe).
F9	357	357	G -> E (in HEMB; severe; Amagasaki).
F9	357	357	G -> R (in HEMB).
F9	362	362	K -> E (in HEMB; moderate).
F9	363	363	G -> W (in HEMB).
F9	366	366	A -> D (in HEMB).
F9	379	379	R -> G (in HEMB; moderate).
F9	379	379	R -> Q (in HEMB; severe; Iceland-1, London and Sesimbra).
F9	382	382	C -> Y (in HEMB).
F9	383	383	L -> F (in HEMB).
F9	383	383	L -> I (in HEMB).
F9	384	384	R -> L (in THR-FIX; factor IX Padua; higher specific activity than wild-type).
F9	387	387	K -> E (in HEMB; mild).
F9	390	390	I -> F (in HEMB; severe).
F9	394	394	M -> K (in HEMB).
F9	395	395	F -> I (in HEMB).
F9	395	395	F -> L (in HEMB).
F9	396	396	C -> F (in HEMB).
F9	396	396	C -> S (in HEMB; severe).
F9	397	397	A -> P (in HEMB; mild; Hong Kong-11).
F9	404	404	R -> T (in HEMB).
F9	407	407	C -> R (in HEMB).
F9	407	407	C -> S (in HEMB; severe).
F9	410	410	D -> H (in HEMB; Mechtal).
F9	411	411	S -> G (in HEMB; Varel).
F9	411	411	S -> I (in HEMB; Schmallenberg).
F9	412	412	G -> E (in HEMB).
F9	413	413	G -> R (in HEMB; moderate to severe).
F9	414	414	P -> T (in HEMB; Bergamo).
F9	419	419	V -> E (in HEMB; moderately severe).
F9	424	424	F -> V (in HEMB).
F9	426	426	T -> P (in HEMB; severe; Barcelos).
F9	430	430	S -> T (in HEMB).
F9	431	431	W -> G (in HEMB).
F9	431	431	W -> R (in HEMB; moderate).
F9	432	432	G -> S (in HEMB; severe).
F9	432	432	G -> V (in HEMB; severe).
F9	433	433	E -> A (in HEMB).
F9	433	433	E -> K (in HEMB).
F9	435	435	C -> Y (in HEMB).
F9	436	436	A -> V (in HEMB; moderately severe; Niigata).
F9	442	442	G -> E (in HEMB).
F9	442	442	G -> R (in HEMB; severe; Angers).
F9	443	443	I -> T (in HEMB; moderately severe; Long Beach, Los Angeles and Vancouver).
F9	445	445	T -> TIYT (in HEMB; severe; Lousada).
F9	449	449	R -> Q (in HEMB; mild).
F9	449	449	R -> W (in HEMB; mild).
F9	450	450	Y -> C (in HEMB; severe).
F9	453	453	W -> R (in HEMB).
F9	454	454	I -> T (in HEMB; Italy).
ATP11C	157	157	T -> I (in a colorectal cancer sample; somatic mutation).
ATP11C	931	931	Q -> P (in a colorectal cancer sample; somatic mutation).
SOX3	43	43	A -> T.
SOX3	248	248	A -> AAAAAAAA (in PHPX; reduced transcriptional activity and impaired nuclear localization).
SOX3	248	248	A -> AAAAAAAAAAAA (in MRXGH).
MAGEC2	6	6	G -> C (in a breast cancer sample; somatic mutation).
SLITRK4	206	206	V -> I (in a colorectal cancer sample; somatic mutation).
SPANXN2	8	8	T -> I.
FMR1	138	138	R -> Q (rare variant found in a developmentally delayed male; unknown pathological significance).
FMR1	304	304	I -> N (in FRAX; alters protein folding and stability; the protein is able to bind RNA, but has reduced affinity for RNA at high salt concentrations).
FMR1	546	546	R -> H.
IDS	41	41	L -> P (in MPS2; mild form; increase in enzyme activity observed in transfected cells).
IDS	41	41	Missing (in MPS2; intermediate form).
IDS	45	45	D -> N (in MPS2).
IDS	48	48	R -> P (in MPS2; mild form).
IDS	54	54	Y -> D (in MPS2; severe form).
IDS	63	63	N -> D (in MPS2; mild/intermediate form).
IDS	68	68	A -> E (in MPS2; severe).
IDS	71	71	S -> N (in MPS2; mild form).
IDS	71	71	S -> R (in MPS2; severe form).
IDS	73	73	L -> F (in MPS2; severe form).
IDS	79	79	A -> E (in MPS2; mild form).
IDS	82	82	A -> E (in MPS2).
IDS	82	82	A -> V (in MPS2; no significant enzyme activity).
IDS	85	85	A -> S (in MPS2; severe form).
IDS	85	85	A -> T (in MPS2; mild to severe forms).
IDS	86	86	P -> L (in MPS2; intermediate to severe forms).
IDS	86	86	P -> Q (in MPS2).
IDS	86	86	P -> R (in MPS2; severe form).
IDS	87	87	S -> N (in MPS2; mild form).
IDS	88	88	R -> C (in MPS2; severe form).
IDS	88	88	R -> G (in MPS2; severe form).
IDS	88	88	R -> H (in MPS2; intermediate/severe form; higher affinity for the artificial substrate; poor transport to lysosomes).
IDS	88	88	R -> L (in MPS2; severe form).
IDS	88	88	R -> P (in MPS2; severe form; total absence of residual activity; poor transport to lysosomes).
IDS	89	89	V -> F (in MPS2).
IDS	92	92	L -> P (in MPS2; severe form).
IDS	94	94	G -> D (in MPS2; mild form).
IDS	95	95	R -> G (in MPS2; intermediate form).
IDS	95	95	R -> T (in MPS2; mild form).
IDS	95	95	Missing (in MPS2; severe form).
IDS	102	102	L -> R (in MPS2; mild form).
IDS	108	108	Y -> C (in MPS2; mild form).
IDS	108	108	Y -> S (in MPS2; mild form).
IDS	115	115	N -> Y (in MPS2).
IDS	117	117	S -> Y (in MPS2; severe form).
IDS	117	117	Missing (in MPS2; severe form; deleterious mutation; results in an inactive enzyme).
IDS	118	118	T -> I (in MPS2; mild to severe forms; greatly reduced activity; poor transport to lysosomes).
IDS	118	118	Missing (in MPS2; severe form).
IDS	120	120	P -> H (in MPS2; mild form).
IDS	120	120	P -> R (in MPS2; severe form).
IDS	121	121	Q -> H (in MPS2; severe form).
IDS	121	121	Q -> R (in MPS2; severe form).
IDS	125	125	E -> V (in MPS2; mild form).
IDS	132	132	S -> W (in MPS2; severe form).
IDS	134	134	G -> R (in MPS2; severe form).
IDS	135	135	K -> N (in MPS2; intermediate form).
IDS	138	138	H -> D (in MPS2; mild/intermediate form).
IDS	140	140	G -> V (in MPS2; no significant enzyme activity).
IDS	143	143	S -> F (in MPS2).
IDS	148	148	D -> H (in MPS2; intermediate form).
IDS	159	159	H -> P (in MPS2; severe form).
IDS	159	159	Missing (in MPS2; intermediate form).
IDS	160	160	P -> R (in MPS2).
IDS	181	181	N -> I (in MPS2; mild form).
IDS	182	182	L -> P (in MPS2; intermediate form).
IDS	184	184	C -> F (in MPS2; mild/intermediate form).
IDS	184	184	C -> W (in MPS2).
IDS	196	196	L -> S (in MPS2; mild/intermediate form).
IDS	198	198	D -> G (in MPS2; mild form).
IDS	205	205	A -> P (in MPS2; intermediate form).
IDS	221	221	L -> P (in MPS2; intermediate form).
IDS	224	224	G -> E (in MPS2; severe form).
IDS	225	225	Y -> D (in MPS2; intermediate form).
IDS	227	227	K -> M (in MPS2; intermediate form).
IDS	227	227	K -> Q (in MPS2; severe form).
IDS	228	228	P -> L (in MPS2).
IDS	228	228	P -> T (in MPS2; severe form).
IDS	229	229	H -> R (in MPS2; intermediate/severe form).
IDS	229	229	H -> Y (in MPS2; severe form).
IDS	231	231	P -> L (in MPS2; mild form).
IDS	252	252	D -> N (in MPS2).
IDS	259	259	L -> P (in MPS2; severe form).
IDS	264	264	Y -> N (in MPS2).
IDS	265	265	N -> I (in MPS2; intermediate form; deleterious mutation; residual activity of 7.5% of the wild-type).
IDS	266	266	P -> H (in MPS2; mild form).
IDS	266	266	P -> R (in MPS2).
IDS	269	269	D -> V (in MPS2).
IDS	293	293	Q -> H (in MPS2; mild form).
IDS	299	299	S -> I (in MPS2; mild form).
IDS	308	308	D -> E (in MPS2; mild form).
IDS	308	308	D -> N (in MPS2; intermediate form).
IDS	309	309	T -> A (in MPS2; severe form).
IDS	313	313	R -> C (in MPS2; could be a polymorphism).
IDS	314	314	L -> P (in MPS2; severe form).
IDS	333	333	S -> L (in MPS2; severe form).
IDS	334	334	D -> G (in MPS2; severe form).
IDS	334	334	D -> N (in MPS2; mild form).
IDS	335	335	H -> R (in MPS2; intermediate form).
IDS	336	336	G -> E (in MPS2; severe from).
IDS	336	336	G -> R (in MPS2; severe form).
IDS	337	337	W -> R (in MPS2; intermediate form).
IDS	339	339	L -> R (in MPS2; severe form).
IDS	340	340	G -> D (in MPS2; mild form).
IDS	341	341	E -> K (in MPS2; severe form).
IDS	342	342	H -> Y (in MPS2; mild form).
IDS	345	345	W -> C (in MPS2; mild form).
IDS	346	346	A -> D (in MPS2; mild/severe form).
IDS	346	346	A -> V (in MPS2; mild/severe form).
IDS	347	347	K -> I (in MPS2).
IDS	347	347	K -> Q (in MPS2; severe form).
IDS	347	347	K -> T (in MPS2; severe form; deleterious mutation confirmed).
IDS	348	348	Y -> H (in MPS2).
IDS	349	349	S -> I (in MPS2; severe form).
IDS	358	358	P -> R (in MPS2; severe form).
IDS	403	403	L -> R (in MPS2; intermediate form).
IDS	410	410	L -> P (in MPS2).
IDS	422	422	C -> R (in MPS2; severe form).
IDS	432	432	C -> Y (in MPS2; severe form).
IDS	434	434	E -> K (in MPS2).
IDS	465	465	Q -> P (in MPS2; severe form).
IDS	467	467	P -> L (in MPS2; severe form).
IDS	468	468	R -> G (in MPS2; mild to severe forms).
IDS	468	468	R -> L (in MPS2; mild to severe forms).
IDS	468	468	R -> Q (in MPS2; severe/intermediate form; greatly reduced activity; poor transport to lysosomes).
IDS	468	468	R -> W (in MPS2; mild to severe forms).
IDS	469	469	P -> H (in MPS2; mild form).
IDS	478	478	D -> G (in MPS2; mild form).
IDS	478	478	D -> Y (in MPS2; severe form).
IDS	480	480	P -> L (in MPS2; mild form).
IDS	480	480	P -> Q (in MPS2; mild form).
IDS	480	480	P -> R (in MPS2; severe form).
IDS	485	485	I -> K (in MPS2).
IDS	485	485	I -> R (in MPS2; severe form).
IDS	488	489	MG -> IA (in MPS2; intermediate form; mutation A-489 confirmed as causative of MPS2).
IDS	490	490	Y -> S (in MPS2; intermediate form).
IDS	491	491	S -> F (in MPS2; mild form).
IDS	502	502	W -> C (in MPS2; severe form).
IDS	502	502	W -> S (in MPS2).
IDS	521	521	E -> K (in MPS2; severe form).
IDS	521	521	E -> V (in MPS2; severe form).
IDS	523	523	Y -> C (in MPS2; mild form).
MAGEA9B	31	31	P -> H.
MAGEA9	31	31	P -> H.
HMGB3	56	56	E -> Q.
GPR50	502	505	Missing (lower fasting circulating triglyceride levels).
FATE1	34	34	I -> T (in fertile and infertile individuals).
FATE1	125	125	S -> R (in fertile and infertile individuals).
CNGA2	97	97	R -> H (in a breast cancer sample; somatic mutation).
CNGA2	399	399	R -> Q (in a breast cancer sample; somatic mutation).
MAGEA4	153	153	G -> D (in a breast cancer sample; somatic mutation).
NSDHL	105	105	A -> V (in CHILD).
NSDHL	182	182	A -> P (in CHILD).
NSDHL	205	205	G -> S (in CHILD).
NSDHL	232	232	Missing (in CKS; temperature-sensitive hypomorphic mutation; able to correctly fold and function at 30 degrees Celsius; impaired function at 37 degrees Celsius due to abnormal folding and protein degradation).
MAGEA1	278	278	K -> T (in a breast cancer sample; somatic mutation).
TREX2	180	180	R -> C.
BGN	266	266	R -> T (in a breast cancer sample; somatic mutation).
BGN	288	288	K -> N (in a breast cancer sample; somatic mutation).
PNCK	262	262	Q -> H.
ABCD1	13	13	N -> T (very rare polymorphism; does not affect ALDP function).
ABCD1	88	88	C -> W (in X-ALD).
ABCD1	90	90	E -> K (in X-ALD).
ABCD1	98	98	S -> L (in X-ALD; CALD type).
ABCD1	99	99	A -> D (in X-ALD; AMN-type).
ABCD1	103	103	S -> R (in X-ALD).
ABCD1	104	104	R -> C (in X-ALD).
ABCD1	104	104	R -> H (in X-ALD; ADO-type).
ABCD1	105	105	T -> I (in X-ALD; ADO-type).
ABCD1	105	105	T -> P (in X-ALD).
ABCD1	107	107	L -> P (in X-ALD; ALD/AMN/ADO-types and asymptomatic).
ABCD1	108	108	S -> L (in X-ALD).
ABCD1	108	108	S -> W (in X-ALD; CALD and AMN-types).
ABCD1	113	113	R -> C (in X-ALD).
ABCD1	113	113	R -> P (in X-ALD).
ABCD1	116	116	G -> R (in X-ALD; CALD-type).
ABCD1	138	141	Missing (in X-ALD; ALD-type).
ABCD1	141	141	A -> T (in X-ALD).
ABCD1	143	143	P -> S (in X-ALD).
ABCD1	148	148	N -> S (in X-ALD; ADO-type).
ABCD1	149	149	S -> N (in X-ALD).
ABCD1	152	152	R -> C (in X-ALD; ADO-type).
ABCD1	152	152	R -> L (in X-ALD).
ABCD1	152	152	R -> P (in X-ALD).
ABCD1	152	152	R -> S (in X-ALD).
ABCD1	161	161	S -> P (in X-ALD).
ABCD1	163	163	R -> H (in X-ALD).
ABCD1	163	163	R -> P (in X-ALD).
ABCD1	174	174	Y -> C (in X-ALD).
ABCD1	174	174	Y -> D (in X-ALD; ALD-type).
ABCD1	174	174	Y -> S (in X-ALD; CALD-type).
ABCD1	178	178	Q -> E (in X-ALD; AMN-type).
ABCD1	181	181	Y -> C (in X-ALD; ALMD-type).
ABCD1	182	182	R -> P (in X-ALD).
ABCD1	189	189	R -> W (in X-ALD).
ABCD1	190	190	L -> P (in X-ALD).
ABCD1	194	194	D -> H (in X-ALD).
ABCD1	198	198	T -> K (in X-ALD).
ABCD1	200	200	D -> N (in X-ALD).
ABCD1	200	200	D -> V (in X-ALD; CALD-type).
ABCD1	207	207	S -> SAAS (in X-ALD).
ABCD1	211	211	L -> P (in X-ALD).
ABCD1	213	213	S -> C (in X-ALD).
ABCD1	214	214	N -> D (in X-ALD).
ABCD1	217	217	K -> E (in X-ALD).
ABCD1	218	218	P -> T (in X-ALD).
ABCD1	220	220	L -> P (in X-ALD).
ABCD1	221	221	D -> G (in X-ALD; CALD and AMN-types).
ABCD1	224	224	V -> E (in X-ALD).
ABCD1	229	229	L -> P (in X-ALD).
ABCD1	254	254	T -> M (in X-ALD; AMN-type).
ABCD1	254	254	T -> P (in X-ALD; AMN-type).
ABCD1	263	263	P -> L (in X-ALD; CALD, AMN and AD- types).
ABCD1	266	266	G -> R (in X-ALD).
ABCD1	271	271	E -> K (in X-ALD).
ABCD1	274	274	R -> W (in X-ALD).
ABCD1	276	276	K -> E (in X-ALD; CALD-type).
ABCD1	277	277	G -> GN (in X-ALD; ADO-type).
ABCD1	277	277	G -> R (in X-ALD; AMN-type).
ABCD1	277	277	G -> W (in X-ALD).
ABCD1	280	280	R -> C (in X-ALD).
ABCD1	285	285	R -> P (in X-ALD).
ABCD1	291	291	E -> D (in X-ALD; ACALD and CALD-types).
ABCD1	291	291	E -> K (in X-ALD).
ABCD1	291	291	Missing (in X-ALD; ALD-type).
ABCD1	294	294	A -> T (in X-ALD; AMN-type).
ABCD1	296	296	Y -> C (in X-ALD).
ABCD1	298	298	G -> D (in X-ALD).
ABCD1	300	300	E -> EVGQ (in X-ALD).
ABCD1	302	302	E -> K (in X-ALD).
ABCD1	322	322	L -> P (in X-ALD).
ABCD1	336	336	K -> M (in X-ALD).
ABCD1	339	339	W -> R (in X-ALD).
ABCD1	342	342	S -> P (in X-ALD; AMN-type).
ABCD1	343	343	G -> D (in X-ALD).
ABCD1	343	343	G -> S (in X-ALD).
ABCD1	389	389	R -> G (in X-ALD; AMN-type).
ABCD1	389	389	R -> H (in X-ALD; does not affect protein stability, homo- and heterodimerization with ALDR and PMP70).
ABCD1	401	401	R -> Q (in X-ALD; ALD and AMN-types; does not affect protein stability, homo- and heterodimerization with ALDR and PMP70).
ABCD1	401	401	R -> W (in X-ALD).
ABCD1	418	418	R -> W (in X-ALD; AMN-type).
ABCD1	427	427	Missing (in X-ALD).
ABCD1	484	484	P -> R (in X-ALD; CALD, AMN and ADO- types; significantly decreases homodimerization and abolishes heterodimerization with ALDR and PMP70).
ABCD1	503	503	L -> P (in X-ALD).
ABCD1	507	507	G -> V (in X-ALD; CALD-types).
ABCD1	512	512	G -> S (in X-ALD; CALD and AS-types; reduced ATPase activity).
ABCD1	514	514	S -> R (in X-ALD).
ABCD1	515	515	S -> F (in X-ALD).
ABCD1	518	518	R -> Q (in X-ALD; CALD-type).
ABCD1	518	518	R -> W (in X-ALD; CALD-type).
ABCD1	522	522	G -> W (in X-ALD; AD-type).
ABCD1	528	528	Missing (in X-ALD; CALD-type).
ABCD1	529	529	G -> S (in X-ALD).
ABCD1	534	534	P -> L (in X-ALD; CALD-type).
ABCD1	540	540	F -> S (in X-ALD).
ABCD1	543	543	P -> L (in X-ALD).
ABCD1	544	544	Q -> R (in X-ALD).
ABCD1	552	552	S -> P (in X-ALD).
ABCD1	554	554	R -> H (in X-ALD).
ABCD1	556	556	Q -> R (in X-ALD; ACALD type).
ABCD1	560	560	P -> L (in X-ALD; CALD-type).
ABCD1	560	560	P -> R (in X-ALD; AMN and ALMD-types).
ABCD1	560	560	P -> S (in X-ALD).
ABCD1	566	566	M -> K (in X-ALD).
ABCD1	591	591	R -> P (in X-ALD).
ABCD1	591	591	R -> Q (in X-ALD; AMN-type; significantly decreases homodimerization and abolishes heterodimerization with ALDR and PMP70).
ABCD1	591	591	R -> W (in X-ALD).
ABCD1	606	606	S -> L (in X-ALD; decreased ATP-binding affinity).
ABCD1	606	606	S -> P (in X-ALD; CALD, AMN and ALMD- types).
ABCD1	608	608	G -> D (in X-ALD; CALD-type).
ABCD1	609	609	E -> G (in X-ALD).
ABCD1	609	609	E -> K (in X-ALD; AMN-type).
ABCD1	616	616	A -> V (in X-ALD).
ABCD1	617	617	R -> C (in X-ALD; ALD-type and asymptomatic).
ABCD1	617	617	R -> G (in X-ALD; ADO and AMN-types with cerebral involvement).
ABCD1	617	617	R -> H (in X-ALD).
ABCD1	626	626	A -> D (in X-ALD).
ABCD1	626	626	A -> T (in X-ALD; CALD and AMN-types).
ABCD1	629	629	D -> H (in X-ALD).
ABCD1	630	630	E -> G (in X-ALD).
ABCD1	631	631	C -> Y (in X-ALD).
ABCD1	632	632	T -> I (in X-ALD).
ABCD1	633	633	S -> I (in X-ALD; asymptomatic).
ABCD1	633	633	S -> R (in X-ALD).
ABCD1	635	635	V -> M (in X-ALD).
ABCD1	636	636	S -> I (in X-ALD).
ABCD1	638	638	D -> Y (in X-ALD).
ABCD1	646	646	A -> P (in X-ALD).
ABCD1	654	654	L -> P (in X-ALD).
ABCD1	657	657	Missing (in X-ALD; CALD-type).
ABCD1	660	660	R -> P (in X-ALD; CALD-type).
ABCD1	660	660	R -> W (in X-ALD; CALD, ALMD and AS- types).
ABCD1	667	667	H -> D (in X-ALD).
ABCD1	668	668	T -> I (in X-ALD).
ABCD1	679	679	W -> R (in X-ALD; AMN-type).
ABCD1	693	693	T -> M (in X-ALD).
SSR4	144	144	G -> R.
L1CAM	9	9	W -> S (in HSAS).
L1CAM	30	30	H -> N.
L1CAM	121	121	G -> S (in HSAS).
L1CAM	179	179	I -> S (in HSAS, MASA and SPG1).
L1CAM	184	184	R -> Q (in HSAS; severe).
L1CAM	184	184	R -> W (in HSAS).
L1CAM	194	194	Y -> C (in HSAS).
L1CAM	202	202	D -> Y (in MASA).
L1CAM	219	219	I -> T (in HSAS).
L1CAM	240	240	P -> L (in HSAS and ACCPX).
L1CAM	264	264	C -> Y (in HSAS; severe).
L1CAM	268	268	G -> D (in MASA).
L1CAM	309	309	E -> K (in MASA).
L1CAM	335	335	W -> C (in HSAS).
L1CAM	335	335	W -> R (in HSAS and MASA; also in a patient with hydrocephalus and Hirschsprung disease).
L1CAM	370	370	G -> R (in HSAS, MASA and SPG1).
L1CAM	386	386	R -> C (in HSAS).
L1CAM	408	408	N -> I (in HSAS).
L1CAM	415	415	A -> P (in HSAS).
L1CAM	421	421	V -> D (in HSAS).
L1CAM	426	426	A -> D (in MASA).
L1CAM	439	443	Missing (in HSAS).
L1CAM	452	452	G -> R (in HSAS; severe).
L1CAM	473	473	R -> C (in HSAS and MASA).
L1CAM	482	482	L -> P (in MASA).
L1CAM	497	497	C -> Y (in HSAS).
L1CAM	526	526	Missing (in HSAS).
L1CAM	542	542	S -> P (in HSAS).
L1CAM	598	598	D -> N (in MASA).
L1CAM	632	632	R -> P (in MASA).
L1CAM	655	655	K -> E (in HSAS).
L1CAM	674	674	S -> C (in MASA; associated with callosal agenesis).
L1CAM	691	691	A -> D (in MASA; associated with callosal agenesis).
L1CAM	691	691	A -> T (in HSAS).
L1CAM	698	698	G -> R (in HSAS and MASA; associated with callosal agenesis).
L1CAM	739	739	R -> W.
L1CAM	741	741	M -> T (in HSAS).
L1CAM	751	751	R -> P (in HSAS).
L1CAM	752	752	V -> M (in MASA; also in a patient with hydrocephalus and Hirschsprung disease).
L1CAM	768	768	V -> F (in HSAS).
L1CAM	770	770	D -> N (in MASA; associated with callosal agenesis).
L1CAM	784	784	Y -> C (in HSAS).
L1CAM	935	935	L -> P (in HSAS).
L1CAM	936	948	Missing (in HSAS).
L1CAM	941	941	P -> L (in HSAS and MASA).
L1CAM	1070	1070	Y -> C (in HSAS).
L1CAM	1194	1194	S -> L (in HSAS and MASA).
L1CAM	1224	1224	S -> L (in HSAS).
L1CAM	1239	1239	G -> E.
AVPR2	43	43	L -> P (in XNDI).
AVPR2	44	44	L -> P (in XNDI).
AVPR2	46	46	I -> K (in XNDI).
AVPR2	53	53	L -> R (in XNDI).
AVPR2	55	55	N -> D (in XNDI).
AVPR2	55	55	N -> H (in XNDI).
AVPR2	59	59	L -> P (in XNDI).
AVPR2	61	61	A -> V.
AVPR2	62	64	Missing (in XNDI).
AVPR2	62	62	L -> P (in XNDI).
AVPR2	64	64	R -> W.
AVPR2	80	80	H -> R (in XNDI).
AVPR2	81	81	L -> F (in XNDI).
AVPR2	83	83	L -> P (in XNDI).
AVPR2	83	83	L -> Q (in XNDI).
AVPR2	84	84	A -> D (in XNDI).
AVPR2	85	85	D -> N (in XNDI).
AVPR2	88	88	V -> M (in XNDI).
AVPR2	92	92	Q -> R (in XNDI).
AVPR2	94	94	L -> Q (in XNDI).
AVPR2	95	95	P -> L (in XNDI).
AVPR2	99	99	W -> R (in XNDI).
AVPR2	104	104	R -> C (in XNDI; binding capacity is 10% of wild-type, but binding affinity is stronger than wild-type).
AVPR2	105	105	F -> V (in XNDI).
AVPR2	106	106	R -> C (in XNDI).
AVPR2	107	107	G -> E (in XNDI).
AVPR2	112	112	C -> R (in XNDI).
AVPR2	112	112	C -> Y (in XNDI).
AVPR2	122	122	G -> D (in XNDI).
AVPR2	122	122	G -> R (in XNDI).
AVPR2	123	123	M -> K (in XNDI).
AVPR2	126	126	S -> F (in XNDI).
AVPR2	127	127	S -> F (in XNDI).
AVPR2	128	128	Y -> S (in XNDI).
AVPR2	130	130	I -> F (in XNDI).
AVPR2	132	132	A -> D (in XNDI).
AVPR2	135	135	L -> P (in XNDI).
AVPR2	137	137	R -> C (in NSIAD; constitutively active).
AVPR2	137	137	R -> H (in XNDI; fails to activate the adenylyl cyclase system).
AVPR2	137	137	R -> L (in NSIAD; constitutively active).
AVPR2	139	139	R -> S.
AVPR2	143	143	R -> P (in XNDI).
AVPR2	163	163	A -> P (in XNDI).
AVPR2	164	164	W -> S (in XNDI).
AVPR2	167	167	S -> L (in XNDI).
AVPR2	167	167	S -> T (in XNDI).
AVPR2	173	173	P -> S (in XNDI).
AVPR2	174	174	Q -> L (in XNDI).
AVPR2	181	181	R -> C (in XNDI).
AVPR2	185	185	G -> C (in XNDI).
AVPR2	191	191	D -> G (in XNDI).
AVPR2	201	201	G -> D (in XNDI).
AVPR2	202	202	R -> C (in XNDI).
AVPR2	203	203	R -> C (in XNDI).
AVPR2	204	204	T -> N (in XNDI).
AVPR2	205	205	Y -> C (in XNDI).
AVPR2	206	206	V -> D (in XNDI).
AVPR2	207	207	T -> N (in XNDI).
AVPR2	209	209	I -> F (in XNDI).
AVPR2	214	214	F -> S (in XNDI).
AVPR2	215	215	V -> M.
AVPR2	217	217	P -> T (in XNDI).
AVPR2	219	219	L -> P (in XNDI).
AVPR2	219	219	L -> R (in XNDI).
AVPR2	247	250	Missing (in XNDI).
AVPR2	247	247	R -> H (in a breast cancer sample; somatic mutation).
AVPR2	252	252	R -> W.
AVPR2	272	272	M -> K (in XNDI).
AVPR2	277	277	V -> A (in XNDI).
AVPR2	277	277	Missing (in CDNI).
AVPR2	280	280	Y -> C (in XNDI).
AVPR2	282	282	L -> P (in XNDI).
AVPR2	285	285	A -> P (in CDNI).
AVPR2	286	286	P -> L (in XNDI).
AVPR2	286	286	P -> R (in XNDI).
AVPR2	286	286	P -> S (in XNDI).
AVPR2	287	287	F -> L (in XNDI).
AVPR2	289	289	L -> P (in XNDI).
AVPR2	292	292	L -> P (in XNDI).
AVPR2	294	294	A -> P (in XNDI).
AVPR2	309	309	L -> P (in XNDI).
AVPR2	309	309	L -> R (in XNDI).
AVPR2	315	315	S -> R (in XNDI).
AVPR2	317	317	N -> K (in XNDI).
AVPR2	318	318	S -> T.
AVPR2	319	319	C -> R (in XNDI).
AVPR2	321	321	N -> D (in XNDI).
AVPR2	321	321	N -> K (in XNDI).
AVPR2	321	321	N -> Y (in XNDI).
AVPR2	322	322	P -> H (in XNDI).
AVPR2	322	322	P -> S (in XNDI).
AVPR2	323	323	W -> R (in XNDI).
AVPR2	323	323	W -> S (in XNDI).
AVPR2	352	352	G -> D.
IRAK1	412	412	V -> M (in a glioblastoma multiforme sample; somatic mutation).
IRAK1	421	421	Q -> H (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
IRAK1	690	690	S -> G (in a lung adenocarcinoma sample; somatic mutation).
OPN1LW	203	203	C -> R (in BCM).
OPN1LW	307	307	P -> L (in BCM).
OPN1LW	338	338	G -> E (in CBP).
OPN1MW	94	94	N -> K (in CBD).
OPN1MW	177	177	W -> R (in COD5; results in protein misfolding and retention in the endoplasmic reticulum).
OPN1MW	203	203	C -> R (in CBD and BCM).
OPN1MW	330	330	R -> Q (in CBD).
FLNA	39	39	A -> G (in PVNH4).
FLNA	102	102	M -> V (in PVNH1).
FLNA	128	128	A -> V (in PVNH4).
FLNA	149	149	S -> F (in PVNH1).
FLNA	170	170	Q -> P (in OPD2).
FLNA	172	172	L -> F (in OPD1).
FLNA	196	196	R -> G (in OPD2).
FLNA	196	196	R -> W (in OPD1).
FLNA	200	200	A -> S (in OPD2).
FLNA	203	203	D -> Y (in OPD1).
FLNA	210	210	C -> F (in OPD2).
FLNA	273	273	A -> P (in OPD2).
FLNA	288	288	G -> R (in CVDX).
FLNA	528	528	V -> M (in PVNH1).
FLNA	555	555	T -> K (in OPD2).
FLNA	637	637	P -> Q (in CVDX).
FLNA	656	656	L -> F (in PVNH1).
FLNA	711	711	V -> D (in CVDX).
FLNA	1184	1184	D -> E (in MNS).
FLNA	1186	1186	S -> L (in FMD).
FLNA	1291	1291	P -> L (in FGS2).
FLNA	1620	1620	Missing (in FMD).
FLNA	1635	1637	Missing (in otopalatodigital spectrum disorder).
FLNA	1645	1645	C -> F (in OPD2).
FLNA	1724	1739	Missing (in TOD).
FLNA	1728	1728	G -> C (in FMD).
EMD	54	54	S -> F (in EDMD1; no loss of binding to F-actin, enhanced rate of actin polymerization and loss of binding to BCLAF1).
EMD	133	133	Q -> H (in EDMD1; loss of binding to F- actin).
EMD	183	183	P -> H (in EDMD1; no loss of binding to F-actin and enhanced rate of actin polymerization).
EMD	183	183	P -> T (in EDMD1).
RPL10	206	206	L -> M (in a family with autism spectrum disorders).
RPL10	213	213	H -> Q (in a family with autism spectrum disorders).
TAZ	94	94	R -> S (in MGA2).
TAZ	118	118	C -> R (in LVNCX).
TAZ	197	197	G -> R (in LVNCX).
GDI1	92	92	L -> P (in MRX41; causes reduced binding and recycling of RAB3A).
GDI1	423	423	R -> P (in MRX48).
G6PD	12	12	V -> L (in Sinnai).
G6PD	32	32	H -> R (in CSNA; Gahoe; class III; frequent in Chinese).
G6PD	35	35	Missing (in CNSHA; Sunderland; class I).
G6PD	44	44	A -> G (in Orissa; class III; frequent in Indian tribal populations).
G6PD	48	48	I -> T (in Aures; class II).
G6PD	58	58	D -> N (in Metaponto; class III).
G6PD	70	70	Y -> H (in Namoru; 4% activity).
G6PD	75	75	L -> P (in Swansea; class I).
G6PD	81	81	R -> C (in Konan/Ube; class III).
G6PD	81	81	R -> H (in Lagosanto; class III).
G6PD	106	106	S -> C (in Vancouver; class I).
G6PD	128	128	L -> P (in Vanua Lava; 4% activity).
G6PD	131	131	G -> V (in Chinese-4).
G6PD	156	156	E -> K (in Ilesha; class III).
G6PD	163	163	G -> D (in Plymouth; class I).
G6PD	163	163	G -> S (in Mahidol; class III; reduced activity; associated with reduced density of Plasmodium vivax but not Plasmodium falciparum in Southeast Asians).
G6PD	165	165	N -> D (in Chinese-3; class II).
G6PD	166	166	R -> H (in Naone; 1% activity).
G6PD	176	176	D -> G (in Shinshu; class I).
G6PD	182	182	R -> W (in Vancouver; class I).
G6PD	198	198	R -> C (in Coimbra; class II).
G6PD	198	198	R -> P (in CNSHA; Santiago; class I).
G6PD	212	212	M -> V (in Sibari; class III).
G6PD	213	213	V -> L (in Minnesota; class I).
G6PD	216	216	F -> L (in Harilaou; class I).
G6PD	227	227	R -> L (in A- type 2; class III).
G6PD	227	227	R -> Q (in Mexico City; class III).
G6PD	242	243	Missing (in Stonybrook; class I).
G6PD	257	257	R -> G (in Wayne; class I).
G6PD	274	274	E -> K (in Corum; class I).
G6PD	278	278	S -> F (in Wexham; class I).
G6PD	279	279	T -> S (in Chinese-1; class II).
G6PD	282	282	D -> H (in Seattle; class III).
G6PD	285	285	R -> H (in Montalbano; class III).
G6PD	291	291	V -> M (in Viangchan/Jammu; class II).
G6PD	317	317	E -> K (in Kalyan/Kerala; class III).
G6PD	322	322	Y -> H (in Rehovot).
G6PD	323	323	L -> P (in A- type 3; class III).
G6PD	342	342	L -> F (in Chinese-5).
G6PD	353	353	P -> S (in Ierapetra; class II).
G6PD	363	363	N -> K (in Loma Linda; class I).
G6PD	385	385	C -> R (in Tomah; class I).
G6PD	386	386	K -> E (in Iowa; class I).
G6PD	387	387	R -> C (in CNSHA; Guadajalara and Mount Sinai; class I).
G6PD	387	387	R -> H (in Beverly Hills; class I).
G6PD	393	393	R -> H (in Nashville/Anaheim; class I).
G6PD	394	394	V -> L (in CNSHA; Alhambra; class I).
G6PD	396	396	P -> L (in Bari; class I).
G6PD	398	398	E -> K (in Puerto Limon; class I).
G6PD	410	410	G -> C (in Riverside; class I).
G6PD	410	410	G -> D (in CNSHA; Japan; class I).
G6PD	416	416	E -> K (in Tokyo; class I).
G6PD	439	439	R -> P (in CNSHA; Pawnee; class I).
G6PD	440	440	L -> F (in Telti/Kobe; class I).
G6PD	447	447	G -> R (in Santiago de Cuba; class I).
G6PD	449	449	Q -> H (in Cassano; class II).
G6PD	454	454	R -> C (in Chinese-II/Maewo/Union; class II, <1% activity).
G6PD	454	454	R -> H (in Andalus; class I).
G6PD	459	459	R -> L (in Canton; class II; frequent in China).
G6PD	459	459	R -> P (in Cosenza; class II).
G6PD	463	463	R -> H (in Kaiping; class II).
G6PD	488	488	G -> V (in Campinas; class I).
IKBKG	57	57	E -> K (in IP; shows the same luciferase activity as the control).
IKBKG	90	90	Missing (in IP; only 46.3% of the activation obtained with the wild-type protein).
IKBKG	113	113	D -> N.
IKBKG	123	123	R -> W (in IP; shows the same luciferase activity as the control).
IKBKG	153	153	L -> R (in EDAID).
IKBKG	173	173	R -> G (in IPD2).
IKBKG	175	175	R -> P (in EDAID).
IKBKG	227	227	L -> P (in EDAID).
IKBKG	288	288	A -> G (in EDAID).
IKBKG	311	311	D -> N (in EDAID).
IKBKG	315	315	E -> A (in AMCBX1).
IKBKG	319	319	R -> Q (in AMCBX1).
IKBKG	323	323	A -> P (in IP; diminishes interaction with TRAF6 and polyubiquitination).
IKBKG	406	406	D -> V (in EDAID).
IKBKG	407	407	M -> V (in IP).
IKBKG	417	417	C -> F (in EDAID).
IKBKG	417	417	C -> R (in EDAID; loss of sumoylation).
IKBKG	417	417	C -> Y (in NEMOID).
DKC1	37	37	Missing (in XDKC).
GPHN	10	10	N -> Y (in STHE; sporadic case).
MLH3	494	494	H -> R.
MLH3	817	817	S -> G (in HNPCC7).
MLH3	981	981	G -> S (in HNPCC7).
MLH3	1007	1007	N -> S (in HNPCC7).
MLH3	1319	1319	G -> R.
MLH3	1394	1394	A -> T (in HNPCC7).
PYGL	339	339	N -> S (in GSD6).
PYGL	377	377	N -> K (in GSD6).
PRKCH	575	575	T -> A (in a aLL TEL/AML1+ sample; somatic mutation).
PRKCH	594	594	T -> I (in a colorectal adenocarcinoma sample; somatic mutation).
MOK	272	272	E -> D (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
EIF5	418	418	K -> M (in a breast cancer sample; somatic mutation).
RPGRIP1	32	32	M -> L.
RPGRIP1	135	135	S -> R.
RPGRIP1	318	318	A -> V (in a patient with primary open angle glaucoma).
RPGRIP1	363	363	R -> T (in a patient with normal tension glaucoma).
RPGRIP1	585	585	P -> S.
RPGRIP1	603	603	C -> S.
RPGRIP1	635	635	A -> G (in a patient with normal tension glaucoma and a patient with primary open angle glaucoma; affects the interaction with NPHP4).
RPGRIP1	638	638	T -> I.
RPGRIP1	746	746	G -> E (in LCA6).
RPGRIP1	764	764	A -> V (does not affect the interaction with NPHP4).
RPGRIP1	806	806	T -> I (in a patient with primary open angle glaucoma who also carries variant K-352 in MYOC; affects the interaction with NPHP4).
RPGRIP1	812	812	R -> H (does not affect the interaction with NPHP4).
RPGRIP1	814	814	R -> L.
RPGRIP1	837	837	A -> G (in a patient with primary open angle glaucoma and a patient with juvenile open angle glaucoma; affects the interaction with NPHP4).
RPGRIP1	838	838	I -> V (in a patient with normal tension glaucoma and a patient with primary open angle glaucoma; affects the interaction with NPHP4).
RPGRIP1	841	841	A -> T.
RPGRIP1	852	852	R -> Q.
RPGRIP1	883	883	G -> D.
MYH6	56	56	G -> R.
MYH6	275	275	I -> N.
MYH6	721	721	R -> W (rare variant that may be associated with sick sinus syndrome in some populations).
MYH6	795	795	R -> Q (in CMH14; late onset).
MYH6	820	820	I -> N (in ASD3).
MYH6	830	830	P -> L (in CMD1EE).
MYH6	1004	1004	A -> S (in CMD1EE).
MYH6	1065	1065	Q -> H (in CMH14).
MYH6	1130	1130	A -> T.
MYH6	1295	1295	E -> Q.
MYH6	1457	1457	E -> K (in CMD1EE).
MYH6	1502	1502	R -> Q.
C14orf21	497	497	S -> Y (in a breast cancer sample; somatic mutation).
C14orf21	626	626	R -> Q (in a breast cancer sample; somatic mutation).
PRKD1	152	152	H -> Y (in a colorectal cancer sample; somatic mutation).
PRKD1	225	225	S -> P.
PRKD1	585	585	P -> S (in a metastatic melanoma sample; somatic mutation).
PRKD1	677	677	R -> M (in a lung bronchoalveolar carcinoma sample; somatic mutation).
PRKD1	857	857	E -> K (in a colorectal cancer sample; somatic mutation).
NUBPL	56	56	G -> R (in MT-C1D).
AKAP6	910	910	K -> M (in a breast cancer sample; somatic mutation).
AKAP6	1192	1192	M -> I (in a breast cancer sample; somatic mutation).
AKAP6	1702	1702	E -> Q (in a breast cancer sample; somatic mutation).
AKAP6	1839	1839	P -> T (in a colorectal cancer sample; somatic mutation).
MIA2	437	437	D -> H (in a breast cancer sample; somatic mutation).
L2HGDH	55	55	G -> D (in L2HGA).
L2HGDH	57	57	G -> R (in L2HGA).
L2HGDH	81	81	K -> E (in L2HGA; alters protein processing and abolishes catalytic activity).
L2HGDH	98	98	H -> R (in L2HGA).
L2HGDH	98	98	H -> Y (in L2HGA).
L2HGDH	176	176	E -> D (in L2HGA; alters protein processing and abolishes catalytic activity).
L2HGDH	178	178	Y -> F.
L2HGDH	302	302	P -> L (in L2HGA).
L2HGDH	434	434	H -> P (in L2HGA).
SAV1	185	185	A -> D (in a colon cancer cell line).
GCH1	15	15	G -> D (in HGCH-3).
GCH1	71	71	L -> Q (in DYT5).
GCH1	74	74	A -> V (in DYT5).
GCH1	79	79	L -> P (in DYT5).
GCH1	83	83	G -> A (in DYT5).
GCH1	88	89	Missing (in DYT5).
GCH1	88	88	R -> P (in DYT5).
GCH1	88	88	R -> W (in DYT5).
GCH1	90	90	G -> V (in DYT5).
GCH1	102	102	M -> K (in DYT5).
GCH1	102	102	M -> R (in DYT5).
GCH1	106	106	T -> I (in DYT5).
GCH1	108	108	G -> D (in GCH1D; phenotype presenting with dystonia and motor delay).
GCH1	115	115	D -> N (in DYT5).
GCH1	134	134	D -> V (in DYT5).
GCH1	135	135	I -> K (in DYT5).
GCH1	141	141	C -> R (in DYT5).
GCH1	141	141	C -> W (in DYT5).
GCH1	144	144	H -> P (in DYT5).
GCH1	153	153	H -> P (in DYT5).
GCH1	163	163	L -> R (in DYT5).
GCH1	176	176	S -> T (in DYT5).
GCH1	178	178	R -> S (in DYT5).
GCH1	180	180	Q -> R (in DYT5).
GCH1	184	184	R -> H (in GCH1D; severe hyperphenylalaninemia).
GCH1	186	186	T -> K (in DYT5).
GCH1	191	191	V -> I (in DYT5).
GCH1	199	199	P -> L (in DYT5).
GCH1	201	201	G -> E (in DYT5).
GCH1	203	203	G -> R (in DYT5).
GCH1	211	211	M -> I (in GCH1D; severe hyperphenylalaninemia).
GCH1	211	211	M -> V (in DYT5).
GCH1	213	213	M -> V (in DYT5).
GCH1	221	221	M -> T (in GCH1D; a patient presenting with dystonia and motor delay; compound heterozygote for an additional deletion).
GCH1	234	234	F -> S (in DYT5).
GCH1	241	241	R -> W (in DYT5).
GCH1	249	249	R -> S (in DYT5).
KTN1	226	226	P -> R (in a breast cancer sample; somatic mutation).
KTN1	1316	1316	T -> P (in a breast cancer sample; somatic mutation).
DACT1	124	124	G -> C (in a colorectal cancer sample; somatic mutation).
DACT1	682	682	S -> L (in a colorectal cancer sample; somatic mutation).
SYNE2	5940	5940	V -> I (in a breast cancer sample; somatic mutation).
SYNE2	6200	6200	Y -> C (in a breast cancer sample; somatic mutation).
SYNE2	6211	6211	T -> M (in EDMD5).
SPTB	202	202	W -> R (in HS; Kissimmee).
SPTB	2018	2018	A -> G (in EL3; Cagliary).
SPTB	2019	2019	S -> P (in EL3; Providence).
SPTB	2023	2023	A -> V (in EL3; Paris).
SPTB	2024	2024	W -> R (in EL3; Linguere).
SPTB	2025	2025	L -> R (in EL3; Buffalo).
SPTB	2053	2053	A -> P (in EL3; Kayes).
SLC8A3	612	612	E -> Q (in a breast cancer sample; somatic mutation).
SIPA1L1	996	996	E -> D (in a breast cancer sample; somatic mutation).
PSEN1	79	79	A -> V (in AD3; no effect on interaction with GFAP).
PSEN1	82	82	V -> L (in AD3; no effect on interaction with GFAP).
PSEN1	92	92	C -> S (in AD3).
PSEN1	96	96	V -> F (in AD3).
PSEN1	105	105	F -> L (in AD3).
PSEN1	113	113	L -> P (in frontotemporal dementia).
PSEN1	115	115	Y -> C (in AD3).
PSEN1	115	115	Y -> H (in AD3).
PSEN1	116	116	T -> N (in AD3).
PSEN1	117	117	P -> L (in AD3).
PSEN1	120	120	E -> D (in AD3).
PSEN1	120	120	E -> K (in AD3).
PSEN1	135	135	N -> D (in AD3).
PSEN1	139	139	M -> I (in AD3).
PSEN1	139	139	M -> K (in AD3).
PSEN1	139	139	M -> T (in AD3).
PSEN1	139	139	M -> V (in AD3).
PSEN1	143	143	I -> F (in AD3).
PSEN1	143	143	I -> T (in AD3).
PSEN1	146	146	M -> I (in AD3).
PSEN1	146	146	M -> L (in AD3).
PSEN1	146	146	M -> V (in AD3).
PSEN1	147	147	T -> I (in AD3).
PSEN1	163	163	H -> R (in AD3).
PSEN1	163	163	H -> Y (in AD3).
PSEN1	165	165	W -> C (in AD3).
PSEN1	166	166	L -> P (in AD3; onset in adolescence).
PSEN1	169	169	S -> L (in AD3).
PSEN1	169	169	S -> P (in AD3).
PSEN1	171	171	L -> P (in AD3).
PSEN1	173	173	L -> W (in AD3).
PSEN1	174	174	L -> M (in AD3).
PSEN1	206	206	G -> A (in AD3).
PSEN1	209	209	G -> R (in AD3).
PSEN1	209	209	G -> V (in AD3).
PSEN1	213	213	I -> T (in AD3).
PSEN1	219	219	L -> P (in AD3).
PSEN1	231	231	A -> T (in AD3).
PSEN1	231	231	A -> V (in AD3).
PSEN1	233	233	M -> L (in AD3).
PSEN1	233	233	M -> T (in AD3).
PSEN1	235	235	L -> P (in A3D).
PSEN1	246	246	A -> E (in AD3).
PSEN1	250	250	L -> S (in AD3).
PSEN1	260	260	A -> V (in AD3).
PSEN1	262	262	L -> F (in AD3).
PSEN1	263	263	C -> R (in AD3).
PSEN1	264	264	P -> L (in AD3).
PSEN1	266	266	G -> S (in AD3).
PSEN1	267	267	P -> S (in AD3).
PSEN1	267	267	P -> T (in AD3).
PSEN1	269	269	R -> G (in AD3).
PSEN1	269	269	R -> H (in AD3).
PSEN1	271	271	L -> V (in AD3).
PSEN1	278	278	R -> T (in AD3).
PSEN1	280	280	E -> A (in AD3).
PSEN1	280	280	E -> G (in AD3).
PSEN1	282	282	L -> R (in AD3).
PSEN1	285	285	A -> V (in AD3).
PSEN1	286	286	L -> V (in AD3).
PSEN1	289	289	S -> C (in AD3).
PSEN1	315	315	Y -> C (found in a renal cell carcinoma sample; somatic mutation).
PSEN1	333	333	D -> G (in CMD1U).
PSEN1	378	378	G -> E (in AD3).
PSEN1	384	384	G -> A (in AD3).
PSEN1	390	390	S -> I (in AD3).
PSEN1	392	392	L -> V (in AD3).
PSEN1	405	405	N -> S (in AD3).
PSEN1	409	409	A -> T (in AD3).
PSEN1	426	426	A -> P (in AD3).
PSEN1	431	431	A -> E (in AD3).
PSEN1	436	436	P -> S (in AD3).
VSX2	200	200	R -> P (in MCOPCTI; loss of DNA binding capacity).
VSX2	200	200	R -> Q (in MCOPCTI; loss of DNA binding capacity).
VSX2	227	227	R -> W (in MCOP2).
DLST	384	384	P -> T.
SPTLC2	359	359	V -> M (in HSAN1C; partial loss of normal activity as measured by reduced formation of sphinganine; affects enzymatic affinity resulting in the accumulation of the alternative metabolite 1-deoxy- sphinganine).
SPTLC2	382	382	G -> V (in HSAN1C; complete loss of normal activity as measured by lack of formation of sphinganine; affects enzymatic affinity resulting in the accumulation of the alternative metabolite 1-deoxy-sphinganine).
SPTLC2	504	504	I -> F (in HSAN1C; partial loss of normal activity as measured by reduced formation of sphinganine; affects enzymatic affinity resulting in the accumulation of the alternative metabolite 1-deoxy- sphinganine).
TSHR	36	36	D -> H (in a patient with Graves disease).
TSHR	41	41	C -> S (in CHNG1).
TSHR	109	109	R -> Q (in CHNG1).
TSHR	162	162	P -> A (in CHNG1).
TSHR	167	167	I -> N (in CHNG1).
TSHR	183	183	K -> R (in HTFG; enhances receptor response to chorionic gonadotropin).
TSHR	197	197	F -> I (in papillary cancer).
TSHR	219	219	D -> E (in papillary cancer).
TSHR	252	252	L -> P (in CHNG1; displays a low expression at the cell surface and a reduced response to bovine TSH in terms of cAMP production).
TSHR	281	281	S -> I (in hyperthyroidism; congenital; due to a toxic adenoma).
TSHR	281	281	S -> N (in HTNA; gain of function; found in toxic thyroid nodules and hyperfunctioning thyroid adenomas).
TSHR	281	281	S -> T (in hyperthyroidism; associated with hyperfunctioning thyroid adenomas).
TSHR	310	310	R -> C (in CHNG1).
TSHR	390	390	C -> W (in CHNG1; persistent hypothyroidism and defective thyroid development; habolishes high affinity hormone binding).
TSHR	410	410	D -> N (in CHNG1; lack of adenylate cyclase activation).
TSHR	425	425	S -> I (in TTNs; 8 to 9 times higher levels of basal cAMP than wild-type TSHR and similar response to maximal TSH stimulation).
TSHR	431	431	G -> S (in HTNA; gain of function; constitutive activation of the G(s)/ adenylyl cyclase system).
TSHR	450	450	R -> H (in CHNG1).
TSHR	453	453	M -> T (in HTNA; sporadic; found in toxic thyroid nodules and hyperfunctioning thyroid adenomas).
TSHR	463	463	M -> V (in HTNA; gain of function).
TSHR	467	467	L -> P (in CHNG1).
TSHR	477	477	T -> I (in CHNG1; severe hypothyroidism).
TSHR	486	486	I -> F (in HTNA; found in thyroid toxic nodules and hyperfunctioning thyroid adenomas; also in hyperfunctioning follicular carcinoma).
TSHR	486	486	I -> M (in HTNA; found in hyperfunctioning thyroid adenomas).
TSHR	498	498	G -> S (in CHNG1).
TSHR	505	505	S -> N (in HTNA; found in toxic thyroid nodules).
TSHR	505	505	S -> R (in HTNA; gain of function).
TSHR	509	509	V -> A (in HTNA; gain of function).
TSHR	512	512	L -> Q (in TTNs; 5 times higher levels of basal cAMP than wild-type TSHR and slightly less response to maximal TSH stimulation).
TSHR	512	512	L -> R (in hyperthyroidism and TTNs; associated with autonomously functioning thyroid nodules; 3.3-fold increase in basal cAMP level).
TSHR	525	525	F -> L (in CHNG1; impairs adenylate cyclase activation).
TSHR	528	528	R -> H.
TSHR	553	553	A -> T (in CHNG1; severe hypothyroidism).
TSHR	568	568	I -> T (in HTNA; found in thyroid toxic nodules and hyperfunctioning thyroid adenomas).
TSHR	593	593	A -> N (in toxic thyroid adenoma; requires 2 nucleotide substitutions; somatic mutation; N-593 and N-593/E-727 constitutively activate the cAMP cascade; double mutant's specific constitutive activity is 2.3-fold lower than the N-593 mutant).
TSHR	597	597	V -> F (in HTNA; 11-fold increase in specific constitutive activity associated with reduction in receptor protein expression).
TSHR	597	597	V -> L (in hyperthyroidism; congenital with severe thyrotoxicosis).
TSHR	600	600	C -> R (in CHNG1).
TSHR	606	606	I -> M.
TSHR	619	619	D -> G (in hyperthyroidism and TTNs; associated with hyperfunctioning thyroid adenomas).
TSHR	623	623	A -> I (in hyperthyroidism; associated with hyperfunctioning thyroid adenomas; gain of function; requires 2 nucleotide substitutions).
TSHR	623	623	A -> V (in hyperthyroidism and TTNs; associated with hyperfunctioning thyroid adenomas; gain of function).
TSHR	629	629	L -> F (in HTNA; also in hyperfunctioning thyroid adenomas and non-adenomatous nodules).
TSHR	630	630	I -> L (in hyperthyroidism; associated with hyperfunctioning thyroid adenomas).
TSHR	631	631	F -> C (in hyperthyroidism; associated with hyperfunctioning thyroid adenomas).
TSHR	631	631	F -> L (in HTNA; gain of function; found in toxic thyroid nodules and hyperfunctioning thyroid adenomas).
TSHR	632	632	T -> A (in HTNA; gain of function; found in toxic thyroid nodules and hyperfunctioning non-adenomatous nodules).
TSHR	632	632	T -> I (in HTNA; gain of function; found in thyroid toxic nodules and hyperfunctioning thyroid adenomas).
TSHR	633	633	D -> A (in hyperthyroidism; associated with hyperfunctioning thyroid adenomas).
TSHR	633	633	D -> E (in HTNA; found in thyroid toxic nodules and hyperfunctioning thyroid adenomas).
TSHR	633	633	D -> Y (in hyperthyroidism and TTNs; associated with hyperfunctioning thyroid adenomas).
TSHR	639	639	P -> A (in TTNs).
TSHR	639	639	P -> S (in HTNA; gain of function).
TSHR	647	647	A -> V (in HTNA; found in non-adenomatous hyperfunctioning nodules).
TSHR	650	650	N -> Y (in HTNA; gain of function).
TSHR	656	656	V -> F (in TTNs).
TSHR	658	661	Missing (in hyperthyroidism; associated with hyperfunctioning thyroid adenomas).
TSHR	670	670	N -> S (in HTNA; gain of function).
TSHR	672	672	C -> Y (in HTNA; gain of function).
TSHR	677	677	L -> V (in thyroid carcinoma; with thyrotoxicosis; gain of function).
TSHR	703	703	A -> G.
TSHR	715	715	N -> D (in papillary cancer).
TSHR	720	720	Q -> E.
TSHR	723	723	K -> M (in papillary cancer).
GTF2A1	30	30	L -> V (in a breast cancer sample; somatic mutation).
GALC	21	21	A -> P.
GALC	41	41	G -> S (in GLD).
GALC	59	59	G -> R (in GLD; infantile; significant reduction of activity).
GALC	68	68	S -> F (in GLD; infantile; significant reduction of activity).
GALC	79	79	R -> H (in GLD).
GALC	82	82	I -> M (in GLD; adult; reduction of activity; when associated with V-2105).
GALC	111	111	G -> D (in GLD).
GALC	111	111	G -> S (in GLD).
GALC	112	112	T -> A (in GLD; adult).
GALC	117	117	M -> L (in GLD; adult).
GALC	130	130	E -> K (in GLD).
GALC	187	187	D -> V (in GLD).
GALC	194	194	G -> A (in GLD).
GALC	250	250	I -> T (in GLD; late infantile).
GALC	263	263	A -> T (in GLD).
GALC	278	278	T -> I (in GLD; infantile; significant reduction of activity).
GALC	284	284	G -> S (in GLD).
GALC	286	286	G -> D (in GLD).
GALC	295	295	N -> T (in GLD).
GALC	303	303	S -> F (in GLD; infantile).
GALC	314	314	Y -> C (in GLD).
GALC	318	318	P -> A (in GLD).
GALC	318	318	P -> R (in GLD).
GALC	323	323	G -> R (in GLD).
GALC	335	335	Y -> C (in GLD; infantile; significant reduction of activity).
GALC	384	384	I -> T (in GLD).
GALC	396	396	R -> L (in GLD).
GALC	396	396	R -> W (in GLD; bilateral cherry red spots).
GALC	400	400	P -> L (in GLD).
GALC	426	426	W -> G (in GLD; infantile; significant reduction of activity).
GALC	490	490	Y -> N (in GLD).
GALC	514	514	F -> S (in GLD).
GALC	529	529	T -> M (in GLD; infantile).
GALC	531	531	R -> C (in GLD).
GALC	531	531	R -> H (in GLD; infantile; significant reduction of activity).
GALC	544	544	D -> N (in GLD; Arab patients).
GALC	553	553	G -> R (in GLD; loss of activity).
GALC	566	566	V -> G (in GLD).
GALC	567	567	Y -> S (in GLD).
GALC	592	592	A -> S (in GLD).
GALC	599	599	I -> S (in GLD; infantile; Druze patients).
GALC	634	634	L -> S (in GLD; adult).
GALC	645	645	L -> R (in GLD; adult).
GALC	668	668	T -> R (in GLD; infantile; significant reduction of activity).
TDP1	493	493	H -> R (in SCAN1; reduces enzyme activity and leads to the accumulation of covalent complexes between TDP1 and DNA).
TDP1	566	566	P -> L (in autosomal recessive or sporadic spinocerebellar ataxia affected Japanese individuals).
FBLN5	363	363	A -> T (in ARMD3).
FBLN5	412	412	G -> E (in ARMD3).
ATXN3	306	306	G -> QQQQQQQQQQQQR.
ATXN3	349	364	Missing (in allele MJD1a).
PRIMA1	22	22	A -> V (in a colorectal cancer sample; somatic mutation).
EVL	188	188	P -> L (in a colorectal cancer sample; somatic mutation).
EVL	247	247	P -> L (in a colorectal cancer sample; somatic mutation).
DYNC1H1	3822	3822	H -> P (de novo variant found in a patient with mental retardation).
CDC42BPB	500	500	K -> E (in a breast infiltrating ductal carcinoma sample; somatic mutation).
CDC42BPB	876	876	R -> W (in a colorectal adenocarcinoma sample; somatic mutation).
CDC42BPB	1315	1315	E -> K (in a lung large cell carcinoma sample; somatic mutation).
MARK3	429	429	V -> A.
AKT1	17	17	E -> K (in breast cancer; also detected in colorectal and ovarian cancer; somatic mutation; alters the PH domain conformation; results in activation of the protein; alters the subcellular location of the protein to the plasma membrane).
BRF1	542	542	V -> M (in a colorectal cancer sample; somatic mutation).
PNP	89	89	E -> K (in PNPD).
PNP	128	128	D -> G (in PNPD).
PNP	174	174	A -> P (in PNPD).
PNP	192	192	Y -> C (in PNPD).
PNP	234	234	R -> P (in PNPD).
ANG	12	12	F -> S (in ALS9).
ANG	20	20	P -> S (in ALS9).
ANG	36	36	Q -> L (in ALS9; reduced ribonucleolytic activity; low angiogenic activity; reduced mitogenic activity; wild type far-UV CD spectra).
ANG	41	41	K -> E (in ALS9; reduced ribonucleolytic activity).
ANG	41	41	K -> I (in ALS9; loss of angiogenic activity; reduced ribonucleolytic activity; retains nuclear translocation).
ANG	52	52	S -> N (in ALS9; loss of angiogenic activity; reduced ribonucleolytic activity; unable to translocate to the nucleus).
ANG	55	55	R -> K (in ALS9; marginally reduced ribonucleolytic activity; wild type far- UV CD spectra).
ANG	63	63	C -> W (in ALS9; reduced ribonucleolytic activity; low angiogenic activity; reduced mitogenic activity; reduced thermal stability).
ANG	64	64	K -> I (in ALS9; reduced ribonucleolytic activity; low angiogenic activity; reduced mitogenic activity; moderate reduction of thermal stability).
ANG	70	70	I -> V (in some ALS9 patients; pathogenicity uncertain; reduced ribonucleolytic activity; moderate reduction of thermal stability).
ANG	136	136	P -> L (in ALS9; loss of angiogenic activity; reduced ribonucleolytic activity; unable to translocate to the nucleus).
ANG	137	137	V -> I (in ALS9).
ANG	138	138	H -> R (in ALS9).
RNASE3	72	72	R -> C.
RNASE2	156	156	H -> N (probably inactive).
SLC7A7	5	5	T -> I (in LPI).
SLC7A7	36	36	Missing (in LPI; failed to induce cationic amino acid transport activity).
SLC7A7	50	50	M -> K (in LPI; failed to induce cationic amino acid transport activity).
SLC7A7	53	53	S -> L (in LPI).
SLC7A7	54	54	G -> V (in LPI; failed to induce cationic amino acid transport activity).
SLC7A7	124	124	L -> P (in LPI).
SLC7A7	140	140	A -> P (in LPI).
SLC7A7	152	152	F -> L (in LPI; moderately reduced cationic amino acid transport activity).
SLC7A7	188	188	T -> I (in LPI; failed to induce cationic amino acid transport activity).
SLC7A7	191	191	K -> E (in LPI).
SLC7A7	238	238	S -> F (in LPI).
SLC7A7	251	251	E -> D (in LPI).
SLC7A7	261	261	L -> P (in LPI).
SLC7A7	333	333	R -> M (in LPI).
SLC7A7	334	334	L -> R (in LPI; failed to induce cationic amino acid transport activity).
SLC7A7	338	338	G -> D (in LPI).
SLC7A7	365	365	N -> Y (in LPI).
SLC7A7	386	386	S -> R (in LPI; failed to induce cationic amino acid transport activity).
SLC7A7	413	413	P -> S (in a breast cancer sample; somatic mutation).
SLC7A7	489	489	S -> P (in LPI).
RBM23	393	393	A -> AA.
ACIN1	1160	1160	R -> Q (in a colorectal cancer sample; somatic mutation).
EFS	361	361	M -> I (in a colorectal cancer sample; somatic mutation).
MYH7	26	26	A -> V (in CMH1).
MYH7	39	39	V -> M (in CMH1).
MYH7	59	59	V -> I (in CMH1).
MYH7	115	115	Y -> H (in CMH1).
MYH7	124	124	T -> I (in CMH1).
MYH7	143	143	R -> G (in CMH1).
MYH7	143	143	R -> Q (in CMH1).
MYH7	143	143	R -> W (in CMH1).
MYH7	146	146	K -> N (in CMH1).
MYH7	148	148	S -> I (in CMH1).
MYH7	162	162	Y -> C (in CMH1).
MYH7	186	186	V -> L (in CMH1).
MYH7	187	187	N -> K (in CMH1).
MYH7	188	188	T -> N (in CMH1).
MYH7	190	190	R -> T (in CMH1).
MYH7	196	196	A -> T (in CMH1).
MYH7	201	201	I -> T (in CMD1S).
MYH7	204	204	R -> H (in CMH1).
MYH7	207	207	K -> Q (in CMH1).
MYH7	211	211	P -> L (in CMH1).
MYH7	222	222	Q -> K (in CMH1).
MYH7	223	223	A -> T (in CMD1S).
MYH7	227	227	L -> V (in CMH1).
MYH7	232	232	N -> S (in CMH1).
MYH7	244	244	F -> L (in CMH1).
MYH7	256	256	G -> E (in CMH1).
MYH7	263	263	I -> M (in CMH1).
MYH7	263	263	I -> T (in CMH1).
MYH7	312	312	F -> C (in CMH1).
MYH7	320	320	V -> M (in CMH1).
MYH7	328	328	E -> G (in CMH1).
MYH7	349	349	M -> T (in CMH1).
MYH7	351	351	K -> E (in CMH1).
MYH7	355	355	A -> T (in CMH1).
MYH7	383	383	K -> N (in CMH1).
MYH7	385	385	A -> V (in CMH1).
MYH7	390	390	L -> V (in CMH1).
MYH7	403	403	R -> L (in CMH1).
MYH7	403	403	R -> Q (in CMH1).
MYH7	404	404	V -> L (in CMH1).
MYH7	404	404	V -> M (in CMH1).
MYH7	406	406	V -> M (in CMH1).
MYH7	407	407	G -> V (in CMH1).
MYH7	411	411	V -> I (in CMH1).
MYH7	412	412	T -> N (in CMD1S).
MYH7	425	425	G -> R (in CMH1).
MYH7	428	428	A -> V (in CMH1).
MYH7	430	430	A -> E (in CMH1).
MYH7	435	435	M -> T (in CMH1).
MYH7	440	440	V -> M (in CMH1).
MYH7	441	441	T -> M (in MPD1).
MYH7	443	443	I -> T (in CMH1).
MYH7	450	450	K -> E (in CMH1).
MYH7	450	450	K -> T (in CMH1).
MYH7	453	453	R -> C (in CMH1).
MYH7	453	453	R -> H (in CMH1).
MYH7	479	479	N -> S (in CMH1).
MYH7	483	483	E -> K (in CMH1).
MYH7	500	500	E -> A (in CMH1).
MYH7	501	501	Y -> C (in CMH1).
MYH7	511	511	I -> F (in CMH1).
MYH7	511	511	I -> T (in CMH1).
MYH7	513	513	F -> C (in CMH1).
MYH7	515	515	M -> R (in CMH1).
MYH7	515	515	M -> V (in CMH1; infrequent).
MYH7	517	517	L -> M (in CMH1).
MYH7	532	532	S -> P (in CMD1S).
MYH7	550	550	A -> V (in CMD1S).
MYH7	571	571	G -> R (in CMH1).
MYH7	576	576	H -> R (in CMH1).
MYH7	584	584	G -> R (in CMH1).
MYH7	584	584	G -> S (in CMH1).
MYH7	587	587	D -> V (in CMH1).
MYH7	595	595	Q -> R (in CMH1).
MYH7	601	601	L -> V (in CMH1).
MYH7	602	602	N -> S (in CMH1).
MYH7	606	606	V -> M (in CMH1; in cis with V-728 gives a more severe phenotype).
MYH7	615	615	K -> N (in CMH1).
MYH7	615	615	K -> Q (in CMH1).
MYH7	642	642	S -> L (in CMD1S).
MYH7	659	659	M -> I (in CMH1).
MYH7	663	663	R -> C (in CMH1).
MYH7	663	663	R -> H (in CMH1).
MYH7	663	663	R -> S (in CMH1).
MYH7	671	671	R -> C (in CMH1).
MYH7	694	694	R -> C (in CMH1).
MYH7	694	694	R -> H (in CMH1).
MYH7	696	696	N -> S (in CMH1).
MYH7	698	698	V -> A (in CMH1).
MYH7	712	712	R -> L (in CMH1).
MYH7	716	716	G -> R (in CMH1).
MYH7	719	719	R -> Q (in CMH1).
MYH7	719	719	R -> W (in CMH1).
MYH7	723	723	R -> C (in CMH1).
MYH7	723	723	R -> G (in CMH1; malignant phenotype).
MYH7	728	728	A -> V (in CMH1; in cis with M-606 gives a more severe phenotype).
MYH7	731	731	P -> L (in CMH1).
MYH7	733	733	G -> E (in CMH1).
MYH7	734	734	Q -> E (in CMH1).
MYH7	734	734	Q -> P (in CMH1).
MYH7	736	736	I -> M (in CMH1).
MYH7	736	736	I -> T (in CMH1).
MYH7	741	741	G -> R (in CMH1).
MYH7	741	741	G -> W (in CMH1).
MYH7	742	742	A -> E (in CMH1).
MYH7	743	743	E -> D (in CMH1).
MYH7	763	763	V -> G (in CMH1).
MYH7	763	763	V -> M (in CMH1).
MYH7	764	764	F -> L (in CMD1S).
MYH7	768	768	G -> R (in CMH1).
MYH7	774	774	E -> V (in CMH1).
MYH7	778	778	D -> E (in CMH1).
MYH7	778	778	D -> G (in CMH1).
MYH7	778	778	D -> V (in CMH1).
MYH7	782	782	S -> N (in CMH1).
MYH7	787	787	R -> C (in CMH1).
MYH7	787	787	R -> H (in CMH1).
MYH7	796	796	L -> F (in CMH1).
MYH7	822	822	M -> L (in CMH1).
MYH7	822	822	M -> T (in CMH1).
MYH7	823	823	G -> E (in CMH1).
MYH7	824	824	V -> I (in CMH1).
MYH7	846	846	E -> Q (in CMH1).
MYH7	847	847	Missing (in CMH1).
MYH7	852	852	M -> T (in CMH1).
MYH7	858	858	R -> C (in CMH1; infrequent).
MYH7	858	858	R -> H (in CMH1).
MYH7	869	869	R -> C (in CMH1).
MYH7	869	869	R -> G (in CMH1).
MYH7	869	869	R -> H (in CMH1).
MYH7	877	877	M -> K (in CMH1).
MYH7	882	882	Q -> E (in CMH1).
MYH7	883	883	Missing (in CMH1).
MYH7	894	894	E -> G (in CMH1).
MYH7	901	901	A -> G (in CMH1).
MYH7	905	905	C -> F (in CMH1).
MYH7	906	906	D -> G (in CMH1).
MYH7	908	908	L -> V (in CMH1).
MYH7	921	921	E -> K (in CMH1).
MYH7	924	924	E -> K (in CMH1).
MYH7	924	924	E -> Q (in CMH1).
MYH7	927	927	E -> K (in CMH1).
MYH7	927	927	Missing (in CMH1).
MYH7	928	928	D -> N (in CMH1).
MYH7	930	930	E -> K (in CMH1).
MYH7	930	930	Missing (in CMH1).
MYH7	931	931	E -> K (in CMH1).
MYH7	935	935	E -> K (in CMH1).
MYH7	949	949	E -> K (in CMH1).
MYH7	953	953	D -> H (in CMH1).
MYH7	1019	1019	T -> N (in CMD1S).
MYH7	1057	1057	G -> D (in CMH1).
MYH7	1057	1057	G -> S (in CMH1).
MYH7	1135	1135	L -> R (in CMH1).
MYH7	1193	1193	R -> S (in CMD1S).
MYH7	1218	1218	E -> Q (in CMH1).
MYH7	1327	1327	N -> K (in CMH1).
MYH7	1356	1356	E -> K (in CMH1).
MYH7	1377	1377	T -> M (in CMH1).
MYH7	1379	1379	A -> T (in CMH1).
MYH7	1382	1382	R -> W (in CMH1).
MYH7	1414	1414	L -> M (in CMH1).
MYH7	1420	1420	R -> W (in CMH1).
MYH7	1426	1426	E -> K (in CMD1S).
MYH7	1454	1454	A -> T (in CMH1).
MYH7	1459	1459	K -> N (in CMH1).
MYH7	1475	1475	R -> C.
MYH7	1500	1500	R -> P (in MPD1).
MYH7	1513	1513	T -> S (in CMH1).
MYH7	1519	1519	S -> C.
MYH7	1555	1555	E -> K (in CMH1).
MYH7	1617	1617	Missing (in MPD1).
MYH7	1634	1634	R -> C (in CMD1S).
MYH7	1663	1663	A -> P (in MPD1).
MYH7	1692	1692	V -> M (probable polymorphism; has been originally reported as a hypertrophic cardiomyopathy mutation).
MYH7	1706	1706	L -> P (in MPD1).
MYH7	1712	1712	R -> W (in CMH1).
MYH7	1729	1729	Missing (in MPD1).
MYH7	1753	1753	E -> K (in CMH1).
MYH7	1768	1768	E -> K (in CMH1).
MYH7	1776	1776	S -> G (in CMH1).
MYH7	1777	1777	A -> T (in CMH1).
MYH7	1854	1854	T -> M (in CMH1).
MYH7	1883	1883	E -> K (in CMH1).
MYH7	1901	1901	H -> L (in MYOMS).
MYH7	1919	1919	K -> N.
MYH7	1929	1929	T -> M (in CMH1).
DHRS2	250	250	A -> V (in a colorectal cancer sample; somatic mutation).
NRL	50	50	S -> T (in RP27; increased transactivation activity).
NRL	160	160	L -> P (in RDCP; severely reduced transcriptional activity).
TINF2	280	280	K -> E (in ADDKC).
TINF2	282	282	R -> H (in ADDKC and ERBMF).
TINF2	282	282	R -> S (in ADDKC).
TGM1	53	53	C -> S (in ARCI-TGM1).
TGM1	94	94	G -> D (in ARCI-TGM1).
TGM1	102	102	D -> V (in LI1).
TGM1	126	126	R -> C (in ARCI-TGM1).
TGM1	126	126	R -> H (in ARCI-TGM1).
TGM1	134	134	Y -> C (in ARCI-TGM1).
TGM1	142	142	R -> C (in ARCI-TGM1).
TGM1	142	142	R -> H (in LI1).
TGM1	142	142	R -> P (in ARCI-TGM1).
TGM1	143	143	R -> C (in LI1 and NCIE).
TGM1	143	143	R -> H (in LI1).
TGM1	144	144	G -> E (in ARCI-TGM1).
TGM1	144	144	G -> R (in ARCI-TGM1).
TGM1	160	160	S -> C (in ARCI-TGM1).
TGM1	205	205	L -> Q (in ARCI-TGM1).
TGM1	209	209	V -> F (in ARCI-TGM1).
TGM1	218	218	G -> S (in LI1).
TGM1	225	225	R -> H (in ARCI-TGM1).
TGM1	225	225	R -> P (in ARCI-TGM1).
TGM1	243	243	I -> S (in ARCI-TGM1).
TGM1	249	249	P -> L (in ARCI-TGM1).
TGM1	264	264	R -> Q (in ARCI-TGM1).
TGM1	264	264	R -> W (in ARCI-TGM1).
TGM1	272	272	S -> P (in ARCI-TGM1).
TGM1	276	276	Y -> N (in ARCI-TGM1).
TGM1	278	278	G -> R (in ARCI-TGM1).
TGM1	285	285	E -> K (in ARCI-TGM1).
TGM1	286	286	R -> Q (in ARCI-TGM1).
TGM1	289	289	N -> T (in LI1).
TGM1	293	293	F -> V (in ARCI-TGM1).
TGM1	304	304	I -> F (in ARCI-TGM1).
TGM1	307	307	R -> G (in ARCI-TGM1).
TGM1	307	307	R -> W (in LI1).
TGM1	315	315	R -> C (in ARCI-TGM1).
TGM1	315	315	R -> H (in ARCI-TGM1).
TGM1	315	315	R -> L (in ARCI-TGM1).
TGM1	323	323	R -> Q (in LI1).
TGM1	323	323	R -> W (in ARCI-TGM1).
TGM1	330	330	N -> H (in ARCI-TGM1).
TGM1	331	331	S -> P (in ARCI-TGM1).
TGM1	342	342	W -> R (in ARCI-TGM1).
TGM1	358	358	S -> R (in ARCI-TGM1).
TGM1	359	359	V -> M (in ARCI-TGM1).
TGM1	365	365	Y -> D (in ARCI-TGM1).
TGM1	366	366	L -> P (in ARCI-TGM1).
TGM1	379	379	V -> L (in LI1 and NCIE).
TGM1	382	382	G -> R (in ARCI-TGM1).
TGM1	383	383	V -> M (in ARCI-TGM1).
TGM1	389	389	R -> H (in NCIE).
TGM1	389	389	R -> P (in ARCI-TGM1).
TGM1	392	392	G -> D (in ARCI-TGM1).
TGM1	396	396	R -> H (in ARCI-TGM1).
TGM1	396	396	R -> L (in NCIE).
TGM1	396	396	R -> S (in ARCI-TGM1).
TGM1	401	401	F -> V (in ARCI-TGM1).
TGM1	430	430	D -> V (in ARCI-TGM1).
TGM1	473	473	G -> S (in ARCI-TGM1).
TGM1	490	490	D -> G (in ARCI-TGM1).
TGM1	520	520	E -> G (in ARCI-TGM1).
TGM1	544	544	Y -> C (in ARCI-TGM1).
TGM1	687	687	R -> C (in ARCI-TGM1).
TGM1	687	687	R -> H (in ARCI-TGM1).
TGM1	764	764	R -> C (in ARCI-TGM1).
FOXG1	109	109	P -> L.
FOXG1	215	215	F -> L (in RTTCV).
FOXG1	244	244	R -> C (in RTTCV; the mutant protein extensively, although not fully, localizes in nuclear speckles, while the wild-type is more widely dispersed throughout the nucleus).
COCH	66	66	V -> G (in DFNA9; affects protein deposition to the extracellular matrix).
COCH	88	88	G -> E (in DFNA9; affects protein deposition to the extracellular matrix).
COCH	109	109	I -> N (in DFNA9; affects protein deposition to the extracellular matrix).
COCH	117	117	W -> R (in DFNA9; does not affect protein deposition to the extracellular matrix).
COCH	119	119	A -> T (in DFNA9).
CFL2	35	35	A -> T (in NEM7; protein is less soluble when expressed in Escherichia coli).
CFL2	47	47	I -> M (in a breast cancer sample; somatic mutation).
NKX2-1	205	205	V -> F (in CHNRD).
NKX2-8	16	16	D -> A.
PAX9	51	51	G -> S (in STHAG3).
FOXA1	72	72	G -> A.
FOXA1	124	124	M -> MM.
FOXA1	185	185	Q -> R.
FOXA1	448	448	S -> N.
SEC23A	382	382	F -> L (in CLSD; loss of function mutation; cargo proteins retained in the endoplasmic reticulum).
FSCB	262	262	T -> R (in a breast cancer sample; somatic mutation).
FSCB	764	764	Q -> K (in a breast cancer sample; somatic mutation).
FSCB	775	775	S -> L (in a breast cancer sample; somatic mutation).
MGAT2	262	262	H -> R (in CDG2A).
MGAT2	290	290	S -> F (in CDG2A).
MGAT2	318	318	N -> D (in CDG2A).
ATL1	66	66	E -> Q (in HSN1D; shows no significant changes in GTPase activity and no changes in endoplasmic reticulum morphology).
ATL1	157	157	L -> W (in SPG3).
ATL1	161	161	A -> P (in SPG3; affects endoplasmic reticulum and Golgi morphology).
ATL1	217	217	R -> Q (in SPG3; alters endoplasmic reticulum morphology).
ATL1	239	239	R -> C (in SPG3; affects endoplasmic reticulum and Golgi morphology).
ATL1	247	247	H -> P (in SPG3).
ATL1	258	258	H -> R (in SPG3).
ATL1	259	259	S -> Y (in SPG3).
ATL1	355	355	N -> K (in HSN1D; the mutant protein has decreased GTPase activity compared to wild-type and causes disruption of endoplasmic reticulum network morphology).
ATL1	408	408	M -> V (in SPG3).
ATL1	415	415	R -> W (in SPG3).
ATL1	436	436	Missing (in SPG3; does not affect GTPase activity; does not affect interaction with SPAST; patients' lymphoblasts show decreased protein levels but normal levels of mRNA).
ABHD12B	282	282	I -> V (in a breast cancer sample; somatic mutation).
NID2	1238	1238	P -> S (in a breast cancer sample; somatic mutation).
BMP4	91	91	S -> C (in OFC11; also found in renal hypodysplasia patients).
BMP4	93	93	E -> G (in MCOPS6).
BMP4	102	102	T -> A.
BMP4	116	116	T -> S (in a renal hypodysplasia patient).
BMP4	150	150	N -> K (in a renal hypodysplasia patient).
BMP4	162	162	R -> Q (in OFC11).
BMP4	168	168	G -> A.
BMP4	225	225	T -> A.
BMP4	226	226	R -> W.
BMP4	287	287	R -> H (in OFC11).
BMP4	346	346	A -> V (in OFC11).
BMP4	367	367	S -> T.
CDKN3	31	31	W -> R (in HCC; patient BX-01).
CDKN3	78	78	F -> L (in HCC; patient T9).
CDKN3	79	79	C -> Y (in HCC; patient BX-01).
CDKN3	91	91	N -> K (in HCC; patient BX-10).
CDKN3	94	94	D -> V (in HCC; patient NT1).
CDKN3	95	95	L -> F (in HCC; patient BX-05).
CDKN3	108	108	I -> V (in HCC; patient T9).
CDKN3	187	187	N -> S (in HCC; patient NT4).
CDKN3	195	195	K -> I (in HCC; patient NT4).
OTX2	89	89	R -> G (in MCOPS5).
OTX2	133	133	P -> T (in MCOPS5).
OTX2	134	134	P -> A (in MCOPS5).
SIX6	165	165	T -> A (in MCOPCT2).
SIX1	17	17	V -> E (in BOS3).
SIX1	73	73	H -> P (in BOS3).
SIX1	106	106	V -> G (in BOS3).
SIX1	110	110	R -> Q (in BOS3).
SIX1	110	110	R -> W (in BOS3; crucial for EYA1-SIX1 interaction).
SIX1	112	112	R -> C (in BOS3).
SIX1	122	122	W -> R (in BOS3).
SIX1	129	129	Y -> C (in BOS3; crucial for EYA1-SIX1 interaction; crucial for SIX1-DNA protein-DNA binding).
SIX1	133	133	Missing (in DFNA23; in addition to deafness the patient had renal anomalies suggesting a branchiootorenal syndrome; crucial for EYA1-SIX1 interaction; crucial for SIX1-DNA protein-DNA binding).
SIX1	249	249	P -> L (in BOR; uncertain pathological significance).
SIX4	23	23	E -> Q (in a breast cancer sample; somatic mutation).
SIX4	446	446	G -> D (in a breast cancer sample; somatic mutation).
SIX4	780	780	D -> E (in a breast cancer sample; somatic mutation).
HSPA2	191	191	C -> S.
HSPA2	496	496	K -> E.
GPX2	37	37	A -> L (requires 2 nucleotide substitutions).
GPX2	176	176	I -> M.
RDH12	47	47	A -> T (in retinal dystrophy; exhibits a profound loss of catalytic activity).
RDH12	51	51	I -> N (in LCA13).
RDH12	55	55	T -> M (in retinal dystrophy; exhibits a profound loss of catalytic activity).
RDH12	65	65	R -> Q.
RDH12	76	76	G -> R (in RP53).
RDH12	101	101	D -> N.
RDH12	125	125	N -> K (in retinal dystrophy; exhibits a profound loss of catalytic activity).
RDH12	126	126	A -> V (in RP53).
RDH12	145	145	G -> E (in retinal dystrophy; exhibits a profound loss of catalytic activity).
RDH12	151	151	H -> D (in LCA13; exhibits a profound loss of catalytic activity).
RDH12	151	151	H -> N (in LCA13).
RDH12	155	155	T -> I (in retinal dystrophy; exhibits a profound loss of catalytic activity).
RDH12	175	175	S -> P (in LCA13).
RDH12	193	193	R -> C (in retinal dystrophy; uncertain pathogenicity).
RDH12	206	206	A -> D (in retinal dystrophy; exhibits a profound loss of catalytic activity).
RDH12	206	206	A -> V (in retinal dystrophy; uncertain pathogenicity).
RDH12	230	230	P -> A (in LCA13).
RDH12	230	230	P -> L (in retinal dystrophy; uncertain pathogenicity).
RDH12	234	234	R -> H (in retinal dystrophy; uncertain pathogenicity; exhibits a loss of catalytic activity).
RDH12	239	239	R -> W (in retinal dystrophy; exhibits a profound loss of catalytic activity).
RDH12	274	274	L -> P (in retinal dystrophy; exhibits a profound loss of catalytic activity).
RDH12	285	285	C -> Y (in retinal dystrophy; exhibits a profound loss of catalytic activity).
ZFYVE26	1164	1164	A -> E (in a breast cancer sample; somatic mutation).
ZFYVE26	1945	1945	R -> Q (in a breast cancer sample; somatic mutation).
MAP3K9	246	246	A -> V (in a metastatic melanoma sample; somatic mutation).
MAP3K9	467	467	R -> C (in a gastric adenocarcinoma sample; somatic mutation).
DNAL1	150	150	N -> S (in CILD16).
ALDH6A1	446	446	G -> R (in MMSDH deficiency).
VRTN	133	133	V -> M (in a colorectal cancer sample; somatic mutation).
NPC2	30	30	V -> M (in NPDC2).
NPC2	39	39	V -> M (in NPDC2; results in the synthesis of functional recombinant proteins correctly targeted to lysosomes).
NPC2	47	47	C -> F (in NPDC2; leads to the synthesis of misfolded recombinant proteins that colocalized with an endoplasmic reticulum marker; normally secreted but unable to correct cholesterol storage in NPC2- deficient cells).
NPC2	93	93	C -> F (in NPDC2; leads to the synthesis of misfolded recombinant proteins that colocalized with an endoplasmic reticulum marker; normally secreted but unable to correct cholesterol storage in NPC2- deficient cells).
NPC2	99	99	C -> R (in NPDC2; leads to the synthesis of misfolded recombinant proteins that colocalized with an endoplasmic reticulum marker; normally secreted but unable to correct cholesterol storage in NPC2- deficient cells).
NPC2	120	120	P -> S (in NPDC2).
RPS6KL1	332	332	R -> W.
EIF2B2	171	171	S -> F (in VWM; with ovarian failure).
EIF2B2	213	213	E -> G (in VWM; with and without ovarian failure).
EIF2B2	273	273	K -> R (in VWM).
EIF2B2	316	316	V -> D (in VWM).
EIF2B2	329	329	G -> V (in VWM).
NEK9	870	870	P -> S (in a lung neuroendocrine carcinoma sample; somatic mutation).
FLVCR2	84	84	R -> H (in PVHH).
FLVCR2	110	112	NIF -> I (in PVHH).
FLVCR2	280	280	P -> R (in PVHH).
FLVCR2	326	326	A -> V (in PVHH).
FLVCR2	352	352	T -> R (in PVHH).
FLVCR2	398	398	L -> V (in PVHH).
FLVCR2	412	412	G -> R (in PVHH).
FLVCR2	430	430	T -> M (in PVHH).
FLVCR2	430	430	T -> R (in PVHH).
POMT2	184	184	T -> M (in MDDGC2).
POMT2	198	198	I -> N (in MDDGA2).
POMT2	246	246	G -> D (in MDDGB2).
POMT2	353	353	G -> S (in MDDGA2).
POMT2	373	373	V -> F (in MDDGA2).
POMT2	413	413	R -> P (in MDDGA2).
POMT2	444	445	IN -> LLWQ (in MDDGA2).
POMT2	482	482	G -> V (in MDDGA2).
POMT2	666	666	Y -> C (in MDDGB2 and MDDGA2).
POMT2	717	717	F -> S (in MDDGB2).
POMT2	726	726	G -> E (in MDDGA2 and MDDGB2).
POMT2	748	748	W -> R (in MDDGB2).
POMT2	748	748	W -> S (in MDDGC2).
TTC8	38	47	Missing (in RP51).
TTC8	197	198	Missing (in BBS8).
GPR68	39	39	N -> S (found in a renal cell carcinoma case; somatic mutation).
TRIP11	1846	1846	T -> I.
SERPINA10	384	384	Q -> P.
SERPINA1	4	4	S -> L (in Z-Wrexham).
SERPINA1	26	26	D -> A (in V-Munich).
SERPINA1	58	58	A -> T (in M5-Karlsruhe).
SERPINA1	69	69	S -> F (in M6-Bonn).
SERPINA1	75	75	Missing (in M-Malton, M-Nichinan and M- Palermo; associated with very low serum levels of AAT; homozygosity for allele M- Malton may be associated with a risk for chronic emphysema or infantile liver cirrhosis).
SERPINA1	84	84	A -> T (in M6-Passau).
SERPINA1	92	92	T -> I (in QO-Lisbon; deficient AAT with very low serum levels).
SERPINA1	109	109	T -> M (in Z-Bristol; deficient AA; disrupts the N-glycosylation site N-107).
SERPINA1	112	112	P -> T (in M5-Berlin).
SERPINA1	172	172	G -> R (in V and M-Nichinan).
SERPINA1	172	172	G -> W (in M2-Obernburg).
SERPINA1	180	180	Q -> E (in L-Frankfurt).
SERPINA1	190	198	QGKIVDLVK -> GFQNAILVR (in Aberrant form).
SERPINA1	228	228	E -> K (in X).
SERPINA1	305	305	Missing (in Basque).
SERPINA1	354	354	S -> F (in S-Munich).
SERPINA1	365	365	D -> N (in P-St.Albans/P-Donauwoerth).
SERPINA1	382	382	M -> R (in Pittsburgh; has antithrombin activity; causes fatal bleeding diathesis).
SERPINA1	386	386	P -> H (in Sao Tome).
SERPINA1	386	386	P -> T (in L-Offenbach).
SERPINA1	387	387	E -> K (in Christchurch).
SERPINA1	393	393	P -> L (in M-Heerlen).
SERPINA1	415	415	P -> H (in Y-Barcelona; associated with V-280).
SERPINA3	167	167	A -> G.
SERPINA3	401	401	M -> V (associated with occlusive- cerebrovascular disease; Isehara-1).
DICER1	839	839	S -> F (in MNG1).
DICER1	1583	1583	L -> R (in PPB).
BCL11B	32	32	E -> V (in a patient with amyotrophic lateral sclerosis).
BCL11B	229	229	P -> S (in a patient with amyotrophic lateral sclerosis).
BCL11B	331	331	S -> P (in a colorectal cancer sample; somatic mutation).
YY1	380	380	D -> Y (de novo variant found in a patient with mental retardation).
WARS	455	455	E -> D (in a breast cancer sample; somatic mutation).
DLK1	347	347	Missing (in clone HDLKAAG).
CINP	177	177	D -> N (in a colorectal cancer sample; somatic mutation).
TNFAIP2	110	110	A -> AA.
TRMT61A	66	66	V -> A.
INF2	13	13	A -> T (in FSGS5).
INF2	42	42	L -> P (in FSGS5).
INF2	184	184	E -> K (in FSGS5).
INF2	186	186	S -> P (in FSGS5).
INF2	198	198	L -> R (in FSGS5).
INF2	214	214	R -> H (in FSGS5).
INF2	218	218	R -> Q (in FSGS5).
INF2	218	218	R -> W (in FSGS5).
INF2	220	220	E -> K (in FSGS5).
ITGA8	567	567	V -> L.
MBL2	24	24	T -> A (in Chinese).
PCDH15	134	134	R -> G (in DFNB23).
PCDH15	262	262	G -> D (in DFNB23).
PCDH15	1342	1342	Q -> K (in USH1F).
PCDH15	1867	1867	Missing (in USH1F).
CDH23	124	124	D -> G (in DFNB12).
CDH23	240	240	P -> L (in DFNB12).
CDH23	247	247	E -> K (in USH1D).
CDH23	301	301	R -> Q (in DFNB12).
CDH23	366	366	A -> T (in USH1D).
CDH23	452	452	N -> S (in DFNB12).
CDH23	480	480	L -> Q (in DFNB12).
CDH23	484	484	A -> P (in USH1D).
CDH23	582	582	R -> Q (in DFNB12).
CDH23	746	746	V -> I.
CDH23	755	755	H -> Y (in USH1D).
CDH23	944	944	S -> G.
CDH23	960	960	E -> K.
CDH23	990	990	D -> N (in DFNB12).
CDH23	1060	1060	R -> W (in DFNB12).
CDH23	1090	1090	V -> I (in USH1D).
CDH23	1186	1186	G -> D (in DFNB12).
CDH23	1206	1206	P -> R (in USH1D).
CDH23	1236	1236	R -> Q.
CDH23	1281	1281	Missing (in USH1D).
CDH23	1282	1282	N -> S.
CDH23	1341	1341	D -> N (in DFNB12).
CDH23	1417	1417	R -> W.
CDH23	1496	1496	Q -> H (in USH1D).
CDH23	1507	1507	R -> Q (in USH1D).
CDH23	1520	1520	I -> M.
CDH23	1574	1574	M -> T.
CDH23	1586	1586	A -> P (in DFNB12).
CDH23	1595	1595	E -> K (in DFNB12).
CDH23	1671	1671	T -> S.
CDH23	1711	1711	V -> I.
CDH23	1716	1716	Q -> P (in DFNB12).
CDH23	1746	1746	R -> Q (in USH1D; mild retinal affection).
CDH23	1788	1788	P -> L (in USH1D).
CDH23	1807	1807	V -> M.
CDH23	1846	1846	D -> N (in DFNB12).
CDH23	1876	1876	S -> N.
CDH23	1887	1887	T -> I.
CDH23	1888	1888	F -> S (in DFNB12).
CDH23	1908	1908	V -> I.
CDH23	1912	1912	R -> W (in USH1D).
CDH23	1930	1930	D -> N (in USH1D).
CDH23	2017	2017	G -> S (in USH1D; most likely affects splicing).
CDH23	2029	2029	R -> W (in DFNB12).
CDH23	2045	2045	D -> N (in DFNB12).
CDH23	2066	2066	R -> Q.
CDH23	2148	2148	D -> N (in DFNB12).
CDH23	2171	2171	R -> C.
CDH23	2202	2202	D -> N (in DFNB12).
CDH23	2227	2227	Q -> P.
CDH23	2376	2376	D -> V (in USH1D).
CDH23	2465	2465	R -> W (in DFNB12).
CDH23	2473	2473	L -> P.
CDH23	2489	2489	R -> H.
CDH23	2517	2517	S -> G (in USH1D).
CDH23	2530	2530	T -> I (in USH1D).
CDH23	2608	2608	R -> H (in DFNB12).
CDH23	2669	2669	I -> V.
CDH23	2744	2744	G -> S (in USH1D; atypical).
CDH23	2771	2771	G -> S (in USH1D).
CDH23	2833	2833	R -> G (in USH1D; atypical).
CDH23	2853	2853	A -> Q (requires 2 nucleotide substitutions).
CDH23	2933	2933	V -> E.
CDH23	2950	2950	I -> N (in DFNB12).
CDH23	2954	2954	D -> N.
CDH23	2956	2956	R -> C (in DFNB12).
CDH23	2962	2962	N -> S.
CDH23	2968	2968	V -> A (in USH1D).
CDH23	3059	3059	P -> T (in DFNB12).
CDH23	3175	3175	R -> C.
CDH23	3175	3175	R -> H (in USH1D).
CDH23	3189	3189	R -> W (in USH1D and USH1DF).
CDH23	3245	3245	S -> F (in USH1D).
KCNMA1	434	434	D -> G (in GEPD; may have a synergistic effect with ethanol in the triggering of symptoms).
PDE6C	29	29	R -> W (in COD4).
PDE6C	157	157	D -> E (rare polymorphism).
PDE6C	323	323	Y -> N (in COD4).
PDE6C	455	455	M -> V (in COD4).
PDE6C	822	822	K -> N (rare polymorphism).
PDE6C	826	826	I -> S (found in a renal cell carcinoma sample; somatic mutation).
PDE6C	834	834	E -> G (rare polymorphism).
CYP2C19	51	51	S -> G (in allele CYP2C19*19).
CYP2C19	132	132	R -> Q (in allele CYP2C19*6; loss of activity).
CYP2C19	161	161	A -> P.
CYP2C19	329	329	R -> H (in allele CYP2C19*18).
CYP2C19	442	442	R -> C (in allele CYP2C19*16; lowered catalytic activity).
LZTS2	121	121	R -> H (in a colorectal cancer sample; somatic mutation).
LZTS2	291	291	G -> R (in a breast cancer sample; somatic mutation).
ACADSB	255	255	L -> F (in SBCADD).
ADAM12	301	301	D -> H (in a breast cancer sample; somatic mutation).
ADAM12	479	479	G -> E (in a breast cancer sample; somatic mutation).
ADAM12	792	792	L -> F (in a breast cancer sample; somatic mutation).
DIP2C	586	586	A -> E (in a breast cancer sample; somatic mutation).
DIP2C	622	622	G -> S (in a colorectal cancer sample; somatic mutation).
DIP2C	1264	1264	V -> M (in a breast cancer sample; somatic mutation).
ADARB2	210	210	T -> M (in a colorectal cancer sample; somatic mutation).
ADARB2	512	512	V -> I (in a colorectal cancer sample; somatic mutation).
PRKCQ	240	240	K -> N (in a colorectal adenocarcinoma sample; somatic mutation).
BEND7	313	313	R -> T (in a breast cancer sample; somatic mutation).
SUV39H2	383	383	D -> H (in a breast cancer sample; somatic mutation).
DCLRE1C	35	35	H -> D (in Omenn syndrome).
DCLRE1C	118	118	G -> V (in RS-SCID).
DCLRE1C	135	135	G -> E (in RS-SCID).
DCLRE1C	140	140	A -> V.
DCLRE1C	153	153	G -> R.
DCLRE1C	329	329	L -> M.
CUBN	786	786	H -> Q (in a breast cancer sample; somatic mutation).
CUBN	1545	1545	N -> Y.
CUBN	1769	1769	V -> I.
CUBN	2153	2153	L -> F.
CUBN	2252	2252	A -> V (in a colorectal cancer sample; somatic mutation).
CUBN	3189	3189	I -> V (in a breast cancer sample; somatic mutation).
CUBN	3258	3258	S -> G (found in a renal cell carcinoma case; somatic mutation).
STAM	212	212	G -> D (in a colorectal cancer sample; somatic mutation).
CACNB2	99	99	A -> G (in a colorectal cancer sample; somatic mutation).
CACNB2	535	535	S -> L (in BRS4; loss of function).
NEBL	187	187	Q -> H.
NEBL	728	728	T -> A.
SPAG6	106	106	V -> L (in a breast cancer sample; somatic mutation).
MYO3A	525	525	N -> K (in an ovarian mucinous carcinoma sample; somatic mutation).
MYO3A	956	956	S -> R (in an ovarian serous carcinoma sample; somatic mutation).
MYO3A	1347	1347	D -> H (in a renal clear cell carcinoma sample; somatic mutation).
PDSS1	308	308	D -> E (in coenzyme q10 deficiency).
WAC	475	475	S -> L (in a colorectal cancer sample; somatic mutation).
ZNF438	381	381	K -> N (in a breast cancer sample; somatic mutation).
ZEB1	78	78	N -> T (in FECD6).
ZEB1	649	649	P -> A (in FECD6).
ZEB1	810	810	Q -> P (in FECD6).
ZEB1	840	840	Q -> P (in FECD6).
ZEB1	905	905	A -> T (in FECD6).
ANKRD30A	227	227	Q -> E (in a breast cancer sample; somatic mutation).
FRMPD2	727	727	R -> W (in a colorectal cancer sample; somatic mutation).
MAPK8	171	171	G -> S (in a renal clear cell carcinoma sample; somatic mutation).
MAPK8	177	177	G -> R (in a glioblastoma multiforme sample; somatic mutation).
ERCC6	134	134	R -> W.
ERCC6	255	255	K -> T.
ERCC6	591	591	P -> A (in a colorectal cancer sample; somatic mutation).
ERCC6	652	652	R -> L (in a colorectal cancer sample; somatic mutation).
ERCC6	670	670	R -> W (in CSB).
ERCC6	680	680	N -> D (in CSB).
ERCC6	686	686	W -> C (in CSB).
ERCC6	687	687	S -> L (in CSB).
ERCC6	851	851	W -> R (in CSB).
ERCC6	871	871	L -> P (in COFS1).
ERCC6	957	957	V -> G (in CSB).
ERCC6	987	987	L -> P (in COFS1).
ERCC6	1038	1038	R -> T (in a breast cancer sample; somatic mutation).
ERCC6	1042	1042	P -> L (in CSB).
ERCC6	1119	1119	E -> Q (in a breast cancer sample; somatic mutation).
ERCC6	1119	1119	E -> V (in a breast cancer sample; somatic mutation).
CHAT	211	211	P -> A (in CMSEA; impaired activity).
CHAT	336	336	I -> T (in CMSEA).
CHAT	392	392	A -> G.
CHAT	420	420	R -> C (in CMSEA; impaired activity).
CHAT	498	498	S -> L (in CMSEA; impaired activity).
CHAT	506	506	V -> L (in CMSEA; impaired activity).
CHAT	560	560	R -> H (in CMSEA; impaired activity).
CCAR1	607	607	E -> K (in a colorectal cancer sample; somatic mutation).
STOX1	18	18	R -> P (in PEE4).
HK1	529	529	L -> S (in HK deficiency).
HK1	680	680	T -> S (in HK deficiency; HK Utrecht).
VCL	277	277	L -> M (in CMH15).
VCL	943	943	P -> A.
VCL	954	954	Missing (in CMD1W).
VCL	975	975	R -> W (in CMD1W; significantly alters metavinculin-mediated cross-linking of actin filaments).
KAT6B	483	483	T -> A (in a breast cancer sample; somatic mutation).
ZMIZ1	551	551	L -> V (in a breast cancer sample; somatic mutation).
LDB3	206	206	T -> I (in CMD1C).
LDB3	345	345	I -> M (in CMD1C).
BMPR1A	58	58	F -> Y (in a renal clear cell carcinoma sample; somatic mutation).
BMPR1A	62	62	Y -> D (in JPS).
BMPR1A	82	82	C -> Y (in JPS).
BMPR1A	124	124	C -> R (in JPS).
BMPR1A	130	130	C -> R (in JPS).
BMPR1A	338	338	A -> D (in CD).
BMPR1A	376	376	C -> Y (in JPS).
BMPR1A	470	470	M -> T (in JPS).
BMPR1A	486	486	R -> Q (in a gastric adenocarcinoma sample; somatic mutation).
ATAD1	107	107	V -> I (in a colorectal cancer sample; somatic mutation).
PTEN	10	10	S -> N (retains phosphatase activity towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the ability to bind phospholipid membranes).
PTEN	15	15	R -> S (in glioma).
PTEN	16	16	Y -> C (loss of phosphatase activity towards Ins(1,3,4,5)P4; retains the ability to bind phospholipid membranes).
PTEN	19	19	D -> N (in malignant melanoma; somatic mutation).
PTEN	20	20	G -> E (reduced phosphatase activity towards Ins(1,3,4,5)P4; retains phosphatase activity towards PtdIns(3,4,5)P3).
PTEN	27	27	Y -> S (loss of phosphatase activity towards Ins(1,3,4,5)P4).
PTEN	33	33	Missing (in CD).
PTEN	34	34	A -> D (in BZS).
PTEN	35	35	M -> R (in CD).
PTEN	36	36	G -> E (in glioma).
PTEN	36	36	G -> R (in endometrial hyperplasia).
PTEN	42	42	L -> R (in glioma; retains phosphatase activity towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the ability to bind phospholipid membranes).
PTEN	47	47	R -> G (in CD).
PTEN	57	57	L -> W (in glioma; loss of protein phosphatase activity).
PTEN	61	61	H -> D (in VATER).
PTEN	61	61	H -> R (loss of phosphatase activity towards Ins(1,3,4,5)P4).
PTEN	67	67	I -> R (in CD).
PTEN	68	68	Y -> H (in CD and BZS; loss of phosphatase activity towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the ability to bind phospholipid membranes).
PTEN	70	70	L -> P (in CD).
PTEN	71	71	C -> Y (in CD; loss of phosphatase activity towards Ins(1,3,4,5)P4).
PTEN	93	93	H -> R (in MCEPHAS).
PTEN	93	93	H -> Y (in CD).
PTEN	105	105	C -> F (in BZS; loss of phosphatase activity towards Ins(1,3,4,5)P4).
PTEN	105	105	C -> Y (in BZS).
PTEN	107	107	D -> Y (in BZS and glioblastoma; loss of phosphatase activity towards Ins(1,3,4,5)P4).
PTEN	112	112	L -> P (in CD and LDD; loss of phosphatase activity towards Ins(1,3,4,5)P4).
PTEN	112	112	L -> R (loss of phosphatase activity towards Ins(1,3,4,5)P4).
PTEN	119	119	V -> L (in multiple cancers).
PTEN	121	121	A -> G (in HNSCC).
PTEN	121	121	A -> P (in glioblastoma; loss of phosphatase activity towards Ins(1,3,4,5)P4).
PTEN	123	123	H -> R (in CD).
PTEN	123	123	H -> Y (in endometrial cancer; loss of protein phosphatase activity).
PTEN	124	124	C -> R (in CD).
PTEN	124	124	C -> S (in CD; phosphatase-dead protein with neither lipid nor protein phosphatase activity).
PTEN	129	129	G -> E (in CD; no lipid phosphatase activity but retains protein phosphatase activity; retains ability to inhibit focal adhesion formation).
PTEN	129	129	G -> R (in glioblastoma; severely reduced protein phosphatase activity; loss of phosphatase activity towards Ins(1,3,4,5)P4).
PTEN	130	130	R -> G (loss of phosphatase activity towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3).
PTEN	130	130	R -> L (in CD and endometrial hyperplasia; loss of phosphatase activity towards Ins(1,3,4,5)P4; retains ability to bind phospholipid membranes).
PTEN	130	130	R -> Q (in CD; loss of phosphatase activity towards Ins(1,3,4,5)P4; retains ability to bind phospholipid membranes).
PTEN	132	132	G -> V (in one patient with clinical findings suggesting hamartoma tumor syndrome).
PTEN	133	133	V -> I (loss of phosphatase activity towards Ins(1,3,4,5)P3).
PTEN	134	134	M -> L (in prostate cancer; no effect on protein phosphatase activity; reduced phosphatase activity towards Ins(1,3,4,5)P3 but retains PtdIns(3,4,5)P3 phosphatase activity).
PTEN	135	135	I -> V (in BZS).
PTEN	136	136	C -> Y (in CD; loss of phosphatase activity towards Ins(1,3,4,5)P3).
PTEN	137	137	A -> AN (in CD).
PTEN	155	155	Y -> C (in CD; loss of phosphatase activity towards Ins(1,3,4,5)P4).
PTEN	158	158	V -> L (in multiple cancers).
PTEN	165	165	G -> E (in CD).
PTEN	165	165	G -> R (in glioblastoma; severely reduced protein phosphatase activity; loss of phosphatase activity towards Ins(1,3,4,5)P4; retains ability to bind phospholipid membranes).
PTEN	165	165	G -> V (in CD).
PTEN	167	167	T -> P (in breast cancer; severely reduced protein phosphatase activity).
PTEN	170	170	S -> N (loss of phosphatase activity towards Ins(1,3,4,5)P4; retains ability to bind phospholipid membranes).
PTEN	170	170	S -> R (in BZS; severely reduced protein phosphatase activity; loss of phosphatase activity towards Ins(1,3,4,5)P4).
PTEN	173	173	R -> C (in endometrial hyperplasia; loss of phosphatase activity towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains ability to bind phospholipid membranes).
PTEN	173	173	R -> H (loss of phosphatase activity towards Ins(1,3,4,5)P4).
PTEN	173	173	R -> P (loss of phosphatase activity towards Ins(1,3,4,5)P4).
PTEN	174	174	Y -> N (loss of phosphatase activity towards Ins(1,3,4,5)P4).
PTEN	191	191	V -> A (in endometrial hyperplasia).
PTEN	217	217	V -> I (in malignant melanoma; somatic mutation).
PTEN	227	227	S -> F (reduced phosphatase activity towards Ins(1,3,4,5)P4 but retains PtdIns(3,4,5)P3 phosphatase activity).
PTEN	234	234	R -> Q (in a patient with glioma and meningioma; not capable of inducing apoptosis; induced increased cell proliferation; led to high constitutive AKT1 activation which could not be increased further by stimulation with insulin).
PTEN	241	241	F -> S (in MCEPHAS).
PTEN	246	246	P -> L (in CD and BZS).
PTEN	251	251	G -> C (loss of phosphatase activity towards Ins(1,3,4,5)P4; retains ability to bind phospholipid membranes).
PTEN	252	252	D -> G (in MCEPHAS).
PTEN	289	289	K -> E (in CD; reduced phosphatase activity towards Ins(1,3,4,5)P4; retains ability to bind phospholipid membranes).
PTEN	319	319	Missing (in glioma; reduced tumor suppressor activity; fails to inactivate AKT/PKB).
PTEN	331	331	D -> G (in CD; reduced phosphatase activity towards Ins(1,3,4,5)P4; retains ability to bind phospholipid membranes).
PTEN	341	341	F -> V (in CD; loss of phosphatase activity towards Ins(1,3,4,5)P4).
PTEN	342	342	K -> N (in CD; reduced phosphatase activity towards Ins(1,3,4,5)P4 but PtdIns(3,4,5)P3 phosphatase activity is similar to wild-type).
PTEN	343	343	V -> E (in CD; loss of phosphatase activity towards Ins(1,3,4,5)P4).
PTEN	345	345	L -> Q (in glioblastoma; reduced tumor suppressor activity; loss of phosphatase activity towards Ins(1,3,4,5)P4; reduced ability to inactivate AKT/PKB; retains ability to bind phospholipid membranes).
PTEN	347	347	F -> L (in CD; reduced phosphatase activity towards Ins(1,3,4,5)P4).
PTEN	348	348	T -> I (in endometrial hyperplasia; reduced phosphatase activity towards PtdIns(3,4,5)P3; mildly reduced tumor suppressor activity; reduced ability to inactivate AKT/PKB).
PTEN	369	369	V -> G (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 phosphatase activity; retains ability to bind phospholipid membranes).
PTEN	401	401	T -> I (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 phosphatase activity; retains ability to bind phospholipid membranes).
ACTA2	39	39	R -> H (in AAT6).
ACTA2	117	117	N -> T (in AAT6).
ACTA2	118	118	R -> Q (in AAT6).
ACTA2	135	135	Y -> H (in AAT6).
ACTA2	145	145	Y -> C (in AAT6).
ACTA2	149	149	R -> C (in AAT6).
ACTA2	154	154	V -> A (in AAT6).
ACTA2	179	179	R -> H (in AAT6; disease phenotype include smooth muscle cells dysfunction in organs throughout the body with decreased contractile function in the iris, bladder and gastrointestinal tract).
ACTA2	185	185	R -> Q (in AAT6).
ACTA2	212	212	R -> Q (in AAT6).
ACTA2	258	258	R -> C (in AAT6).
ACTA2	258	258	R -> H (in AAT6).
ACTA2	292	292	R -> G (in AAT6).
ACTA2	326	326	T -> N (in AAT6).
ACTA2	353	353	T -> N (in AAT6).
LIPA	129	129	H -> P (in CESD).
LIPA	129	129	H -> R (in CESD).
LIPA	200	200	L -> P (in CESD and WOD).
HTR7	92	92	T -> K.
HTR7	279	279	P -> L.
LGI1	26	26	L -> R (in ADLTE; probably affects signal sequence processing and secretion).
LGI1	42	42	C -> G (in ADLTE).
LGI1	42	42	C -> R (in ADLTE).
LGI1	46	46	C -> R (in ADLTE; loss of protein secretion; does not affect glycosylation status of the protein).
LGI1	110	110	A -> D (in ADLTE).
LGI1	122	122	I -> K (in ADLTE).
LGI1	123	123	E -> K (in ADLTE).
LGI1	136	136	R -> W (in ADLTE).
LGI1	145	145	S -> R (in ADLTE; loss of protein secretion; does not affect glycosylation status of the protein).
LGI1	154	154	L -> P (in ADLTE).
LGI1	200	200	C -> R (in ADLTE; loss of protein secretion; does not affect glycosylation status of the protein).
LGI1	232	232	L -> P (in ADLTE; loss of protein secretion).
LGI1	298	298	I -> T (in ADLTE).
LGI1	432	432	V -> E (in ADLTE).
LGI1	473	473	S -> L (in ADLTE).
PLCE1	1484	1484	S -> L (in NPHS3; gives rise to focal segmental glomerulosclerosis rather than diffuse mesangial sclerosis).
HELLS	616	616	H -> R (found in a renal cell carcinoma sample; somatic mutation).
CYP2C9	19	19	L -> I (in allele CYP2C9*7).
CYP2C9	417	417	G -> D.
SORBS1	74	74	R -> W.
SORBS1	195	195	T -> A (in a breast cancer sample; somatic mutation).
ALDH18A1	84	84	R -> Q (in MRJHSL; with metabolic disturbances; reduction of activity).
ALDH18A1	784	784	H -> Y (in MRJHSL; without metabolic disturbances; does not affect proline and ornithine biosynthetic activity).
ABCC2	1150	1150	R -> H (in DJS; protein is properly localized at the plasma membrane, but transport activity is impaired).
ABCC2	1173	1173	I -> F (in DJS; low expression and mislocation to the endoplasmic reticulum).
ABCC2	1382	1382	Q -> R (in DJS).
ABCC2	1392	1393	Missing (in DJS; impaired maturation and intercompartmental trafficking).
WNT8B	53	53	E -> Q (in a colorectal cancer sample; somatic mutation).
CYP17A1	35	35	P -> L (in AH5; 38% 17alpha-hydroxylase activity and 33% 17,20-lyase activity).
CYP17A1	53	53	Missing (in AH5; 10% 17alpha-hydroxylase activity and 13% 17,20-lyase activity).
CYP17A1	64	64	Y -> S (in AH5).
CYP17A1	93	93	F -> C (in AH5).
CYP17A1	96	96	R -> W (in AH5; 25% of both 17alpha- hydroxylase and 17,20-lyase activities).
CYP17A1	106	106	S -> P (in AH5).
CYP17A1	112	112	I -> II (in AH5).
CYP17A1	114	114	F -> V (in AH5).
CYP17A1	116	116	D -> V (in AH5).
CYP17A1	177	177	N -> D (in AH5; 10% 17alpha-hydroxylase and 17,20-lyase activities).
CYP17A1	329	329	Y -> D (in AH5).
CYP17A1	330	330	Missing (in AH5; complete loss of both 17alpha-hydroxylase and 17,20-lyase activities).
CYP17A1	342	342	P -> T (in AH5).
CYP17A1	347	347	R -> C (in AH5).
CYP17A1	347	347	R -> H (in AH5; selectively ablates 17,20-lyase activity, while preserving most 17alpha-hydroxylase activity).
CYP17A1	358	358	R -> Q (in AH5; selectively ablates 17,20-lyase activity, while preserving most 17alpha-hydroxylase activity).
CYP17A1	362	362	R -> C (in AH5).
CYP17A1	373	373	H -> L (in AH5).
CYP17A1	406	406	W -> R (in AH5).
CYP17A1	417	417	F -> C (in AH5; ablates both 17,20-lyase activity and 17alpha-hydroxylase activity; loss of heme-binding and loss of phosphorylation).
CYP17A1	428	428	P -> L (in AH5).
CYP17A1	440	440	R -> H (in AH5).
CYP17A1	487	489	Missing (in AH5).
CYP17A1	496	496	R -> C (in AH5).
CYP17A1	496	496	R -> H (in AH5; 30% 17alpha-hydroxylase activity and 29% 17,20-lyase activity).
CNNM2	568	568	T -> I (in HOMG6; reduced activity; electrophysiological analysis shows that magnesium-sensitive sodium currents are significantly diminished and are blocked by increased extracellular magnesium concentrations).
SLK	405	405	Q -> K (in a lung adenocarcinoma sample; somatic mutation).
SLK	604	604	E -> Q (in an ovarian serous carcinoma sample; somatic mutation).
SORCS1	223	223	K -> N (in a breast cancer sample; somatic mutation).
SMC3	491	491	Missing (in CDLS3; affects the affinity of SMC hinge dimers for DNA; mutated hinge dimers bind DNA with higher affinity than wild-type proteins).
RBM20	634	634	R -> Q (in CMD1DD).
RBM20	636	636	R -> H (in CMD1DD).
RBM20	636	636	R -> S (in CMD1DD).
RBM20	637	637	S -> G (in CMD1DD).
RBM20	638	638	P -> L (in CMD1DD).
SHOC2	2	2	S -> G (in NSLH; creates a N- myristoylation site, resulting in myristoylation of the protein and aberrant targeting to the plasma membrane).
ACSL5	388	388	K -> R (in a colorectal cancer sample; somatic mutation).
ACSL5	466	466	G -> D (in a colorectal cancer sample; somatic mutation).
TCF7L2	465	465	R -> C (in a colorectal cancer sample; somatic mutation).
GFRA1	371	371	L -> R (may be involved in congenital central hypoventilation syndrome).
PNLIPRP1	129	129	S -> C (in a breast cancer sample; somatic mutation).
GRK5	163	163	D -> E (in a lung neuroendocrine carcinoma sample; somatic mutation).
FGFR2	105	105	Y -> C (in CS).
FGFR2	172	172	A -> F (in PS; requires 2 nucleotide substitutions).
FGFR2	203	203	R -> C (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation).
FGFR2	252	253	SP -> FS (in PS).
FGFR2	252	252	S -> F (in APRS; requires 2 nucleotide substitutions).
FGFR2	252	252	S -> L (in CS).
FGFR2	252	252	S -> W (in APRS and PS; common mutation).
FGFR2	253	253	P -> R (in APRS; common mutation).
FGFR2	263	263	P -> L (in CS).
FGFR2	267	267	S -> P (in CS).
FGFR2	268	268	T -> TG (in CS).
FGFR2	272	272	G -> V (in an ovarian serous carcinoma sample; somatic mutation).
FGFR2	273	273	Missing (in PS; type 2).
FGFR2	276	276	F -> V (in CS).
FGFR2	278	278	C -> F (in CS, JWS and PS).
FGFR2	278	278	C -> Y (in CS).
FGFR2	281	281	Y -> C (in CS).
FGFR2	283	283	D -> N (in a lung squamous cell carcinoma sample; somatic mutation).
FGFR2	287	289	Missing (in CS).
FGFR2	288	288	I -> S (in CS).
FGFR2	289	289	Q -> P (in CS and JWS).
FGFR2	290	290	W -> C (in PS; severe; also in a lung squamous cell carcinoma sample; somatic mutation).
FGFR2	290	290	W -> G (in CS).
FGFR2	290	290	W -> R (in CS).
FGFR2	292	292	K -> E (in CS).
FGFR2	301	301	Y -> C (in CS).
FGFR2	314	314	A -> S (in craniosynostosis).
FGFR2	315	315	A -> S (in a non-syndromic craniosynostosis patient with abnormal intrauterine history; confers predisposition to craniosynostosis).
FGFR2	321	321	D -> A (in PS).
FGFR2	328	328	Y -> C (in CS).
FGFR2	331	331	N -> I (in CS).
FGFR2	337	337	A -> ANA (in CS).
FGFR2	337	337	A -> P (in CS).
FGFR2	338	338	G -> E (in CS).
FGFR2	338	338	G -> R (in CS).
FGFR2	340	340	Y -> C (in PS).
FGFR2	340	340	Y -> H (in CS).
FGFR2	341	341	T -> P (in PS and CS).
FGFR2	342	342	C -> F (in CS).
FGFR2	342	342	C -> G (in PS).
FGFR2	342	342	C -> R (in CS, JWS, PS and ABS).
FGFR2	342	342	C -> S (in CS, JWS, PS and ABS).
FGFR2	342	342	C -> W (in CS).
FGFR2	342	342	C -> Y (in CS and PS).
FGFR2	344	344	A -> G (in CS and JWS).
FGFR2	344	344	A -> P (in CS and PS).
FGFR2	347	347	S -> C (in CS).
FGFR2	351	351	S -> C (in CS, PS and ABS).
FGFR2	354	354	S -> C (in CS).
FGFR2	354	354	S -> Y (in CS).
FGFR2	356	358	Missing (in CS).
FGFR2	359	359	V -> F (in CS and PS).
FGFR2	362	362	A -> S (in CS).
FGFR2	372	372	S -> C (in Beare-Stevenson cutis gyrata syndrome).
FGFR2	375	375	Y -> C (in PS and Beare-Stevenson cutis gyrata syndrome).
FGFR2	384	384	G -> R (in CS).
FGFR2	526	526	K -> E (in FSPC).
FGFR2	549	549	N -> H (in CS).
FGFR2	565	565	E -> G (in PS).
FGFR2	612	612	R -> T (in a lung adenocarcinoma sample; somatic mutation).
FGFR2	613	613	G -> R.
FGFR2	628	628	A -> T (in LADDS).
FGFR2	641	641	K -> R (in PS).
FGFR2	648	648	A -> T (in LADDS).
FGFR2	649	650	RD -> S (in LADDS).
FGFR2	659	659	K -> N (in craniosynostosis).
FGFR2	663	663	G -> E (in PS).
FGFR2	678	678	R -> G (in CS).
TACC2	798	798	L -> V (in a breast cancer sample; somatic mutation).
TACC2	1347	1347	A -> S (in a breast cancer sample; somatic mutation).
DMBT1	52	52	S -> W.
DMBT1	60	60	V -> A.
DMBT1	65	65	P -> L.
DMBT1	162	162	G -> E (in a glioma cell line).
DMBT1	337	337	Q -> L.
DMBT1	357	357	P -> S.
DMBT1	364	364	R -> G.
DMBT1	420	420	Q -> H (in a glioma sample; glioblastoma multiforme; somatic mutation).
DMBT1	546	546	N -> S (in a glioma cell line).
DMBT1	607	607	G -> V (in a glioma sample; pilocytic astrocytoma).
DMBT1	649	649	T -> M.
DMBT1	656	656	R -> W.
DMBT1	780	780	T -> M.
DMBT1	1095	1095	S -> P.
DMBT1	1102	1102	S -> T.
DMBT1	1176	1176	R -> W.
DMBT1	1434	1434	R -> W.
DMBT1	1545	1545	V -> M.
DMBT1	1732	1732	H -> S (requires 2 nucleotide substitutions).
DMBT1	1961	1961	T -> P.
DMBT1	2255	2255	V -> M.
OAT	54	54	N -> K (in HOGA).
OAT	55	55	Y -> H (in HOGA).
OAT	89	89	N -> K (in HOGA).
OAT	90	90	Q -> E (in HOGA; mistargeted, accumulates in cytoplasm).
OAT	93	93	C -> F (in HOGA).
OAT	154	154	R -> L (in HOGA; complete loss of activity).
OAT	180	180	R -> T (in HOGA; complete loss of activity).
OAT	184	184	Missing (in HOGA).
OAT	226	226	A -> V (in HOGA).
OAT	241	241	P -> L (in HOGA).
OAT	245	245	Y -> C (in HOGA).
OAT	250	250	R -> P (in HOGA).
OAT	267	267	T -> I (in HOGA).
OAT	270	270	A -> P (in HOGA).
OAT	271	271	R -> K (in HOGA).
OAT	319	319	H -> Y (in HOGA).
OAT	332	332	V -> M (in HOGA).
OAT	353	353	G -> D (in HOGA).
OAT	375	375	G -> A (in HOGA).
OAT	394	394	C -> R (in HOGA).
OAT	402	402	L -> P (in HOGA).
OAT	417	417	P -> L (in HOGA).
DHX32	209	209	P -> R (in a breast cancer sample; somatic mutation).
TCERG1L	437	437	K -> T (in a colorectal cancer sample; somatic mutation).
STK32C	376	376	R -> H (in a colorectal cancer sample; somatic mutation).
KLF6	64	64	W -> R (found in prostate cancer samples; somatic mutation; does not up-regulates CDKN1A in a p53-independent manner and significantly reduces cell proliferation).
KLF6	116	116	S -> P (found in prostate cancer samples; somatic mutation; does not up-regulates CDKN1A in a p53-independent manner and significantly reduces cell proliferation).
KLF6	123	123	A -> D (found in prostate cancer samples; somatic mutation; does not up-regulates CDKN1A in a p53-independent manner and significantly reduces cell proliferation).
KLF6	155	155	S -> R (found in gastric cancer samples; somatic mutation).
KLF6	169	169	L -> P (found in prostate cancer samples; somatic mutation; does not up-regulates CDKN1A in a p53-independent manner and significantly reduces cell proliferation).
KLF6	172	172	P -> T (found in gastric cancer samples; somatic mutation).
KLF6	180	180	S -> L (found in gastric cancer samples; somatic mutation).
KLF6	198	198	R -> K (found in gastric cancer samples; somatic mutation).
NET1	202	202	D -> N (in a breast cancer sample; somatic mutation).
GATA3	274	274	W -> R (in HDR).
GATA3	366	366	R -> L (in a breast cancer sample; somatic mutation).
OPTN	26	26	H -> D (in GLC1E).
OPTN	103	103	E -> D (in GLC1E).
OPTN	201	201	P -> S.
OPTN	213	213	K -> H (requires 2 nucleotide substitutions).
OPTN	216	216	S -> R.
OPTN	357	357	T -> P.
OPTN	478	478	E -> G (in ALS12).
OPTN	486	486	H -> R (in GLC1E; juvenile onset).
PHYH	83	83	N -> Y (in RD).
PHYH	173	173	P -> S (in RD).
PHYH	175	175	H -> R (in RD).
PHYH	177	177	D -> G (in RD; total loss of activity).
PHYH	192	192	A -> AA (in RD).
PHYH	193	193	W -> R (in RD).
PHYH	197	197	E -> Q (in RD).
PHYH	199	199	I -> F (in RD).
PHYH	220	220	H -> Y (in RD).
PHYH	245	245	R -> Q (in RD; partial loss of activity).
PHYH	257	257	F -> S (in RD).
PHYH	269	269	N -> H (in RD).
HSPA14	85	85	A -> V (in a breast cancer sample; somatic mutation).
PTPLA	64	64	E -> Q.
SLC39A12	471	471	P -> T (in a breast cancer sample; somatic mutation).
MTPAP	478	478	N -> D (in SPAX4).
MAP3K8	398	415	CQSLDSALLERKRLLSRK -> GHQVIHEGSSTNDPNNSC (in oncogenic form).
MAP3K8	416	467	Missing (in oncogenic form).
GJD4	269	269	R -> H (in a colorectal cancer sample; somatic mutation).
GJD4	271	271	G -> R (in a colorectal cancer sample; somatic mutation).
ZNF25	21	21	E -> K (in a breast cancer sample; somatic mutation).
ZNF25	81	81	D -> G (in a breast cancer sample; somatic mutation).
RET	20	20	P -> L (in HSCR1; sporadic form).
RET	32	32	S -> L (in HSCR1; familial form).
RET	40	40	L -> P (in HSCR1).
RET	64	64	P -> L (in HSCR1; familial form).
RET	67	67	R -> H (in CCHS).
RET	77	77	R -> C (in HSCR1).
RET	93	93	G -> S (in HSCR1; could be a rare polymorphism).
RET	114	114	R -> H (in CCHS).
RET	142	142	C -> S (in HSCR1; sporadic form).
RET	145	145	V -> G (in a colorectal cancer sample; somatic mutation).
RET	157	157	C -> Y (in HSCR1; could be a polymorphism).
RET	163	163	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation).
RET	174	174	F -> S (in HSCR1; sporadic form).
RET	180	180	R -> P (in HSCR1; sporadic form).
RET	197	197	C -> Y (in HSCR1; sporadic form).
RET	198	198	P -> T (in RADYS; prevents phosphorylation in response to GDNF).
RET	231	231	R -> H (in HSCR1; familial form).
RET	251	251	E -> K (in HSCR1; familial form).
RET	287	287	R -> Q (in HSCR1; sporadic form).
RET	313	313	R -> Q (in HSCR1; sporadic form).
RET	330	330	R -> Q (in HSCR1).
RET	359	359	N -> K (in HSCR1; could be a polymorphism).
RET	360	360	R -> W (in HSCR1).
RET	376	376	V -> A (in RADYS; constitutively phosphorylated; expressed only the immature intracellular form).
RET	393	393	F -> L (in HSCR1; familial form).
RET	394	394	N -> H (in RADYS; prevents phosphorylation in response to GDNF).
RET	394	394	N -> K (in HSCR1).
RET	399	399	P -> L (in HSCR1; sporadic form).
RET	432	432	A -> E (in CCHS).
RET	475	475	R -> Q (in HSCR1; sporadic form).
RET	531	531	C -> CEEC (in MTC; familial form).
RET	593	593	G -> E (in a colorectal cancer sample; somatic mutation).
RET	600	600	R -> Q.
RET	609	609	C -> G (in MEN2A).
RET	609	609	C -> R (in MEN2A).
RET	609	609	C -> W (in HSCR1; familial form).
RET	609	609	C -> Y (in MTC, MEN2A and HSCR1; familial and sporadic forms).
RET	611	611	C -> G (in MTC; familial form).
RET	611	611	C -> R (in MEN2A).
RET	611	611	C -> S (in MEN2A).
RET	611	611	C -> W (in MEN2A and MTC; familial form).
RET	611	611	C -> Y (in MEN2A).
RET	618	618	C -> F (in MEN2A and MTC; familial form).
RET	618	618	C -> G (in MEN2A).
RET	618	618	C -> R (in MEN2A, MTC and HSCR1).
RET	618	618	C -> S (in MEN2A, HSCR1 and MTC; familial and sporadic forms).
RET	618	618	C -> Y (in MEN2A and MTC; familial form).
RET	620	620	C -> F (in MEN2A and MTC; familial form).
RET	620	620	C -> G (in MEN2A and MTC; familial and sporadic forms).
RET	620	620	C -> R (in MEN2A, MTC and HSCR1; familial and sporadic forms).
RET	620	620	C -> S (in MEN2A and MTC; familial form).
RET	620	620	C -> W (in MEN2A and HSCR1).
RET	620	620	C -> Y (in MEN2A).
RET	626	626	Q -> K (in HSCR1; sporadic form).
RET	630	630	C -> F (in MEN2A and MTC; familial form).
RET	630	630	C -> S (in MTC; sporadic form).
RET	630	630	C -> Y (in MTC; familial and sporadic forms).
RET	631	631	D -> G (in thyroid carcinoma; somatic mutation).
RET	632	634	ELC -> DVR (in MEN2A).
RET	634	635	CR -> WG (in MEN2A).
RET	634	634	C -> CHELC (in MEN2A).
RET	634	634	C -> F (in MEN2A and pheochromocytoma).
RET	634	634	C -> G (in MEN2A and pheochromocytoma).
RET	634	634	C -> R (in MEN2A, pheochromocytoma and MTC; familial form; also found as somatic mutation in a sporadic thyroid carcinoma).
RET	634	634	C -> S (in MEN2A, pheochromocytoma and MTC; familial form).
RET	634	634	C -> W (in MEN2A, pheochromocytoma and MTC; familial form).
RET	634	634	C -> Y (in MEN2A, pheochromocytoma and MTC; familial form).
RET	636	636	T -> TCRT (in MEN2A).
RET	639	639	A -> G (in MTC; sporadic form).
RET	640	640	A -> G (in MEN2A).
RET	641	641	A -> G (in MTC; sporadic form).
RET	690	690	S -> P (in HSCR1; sporadic form).
RET	762	762	E -> Q (in HSCR1; sporadic form).
RET	765	765	S -> P (in HSCR1).
RET	767	767	S -> R (in HSCR1; sporadic form).
RET	768	768	E -> D (in MTC; familial and sporadic forms).
RET	778	778	V -> I (in RADYS; constitutively phosphorylated).
RET	790	790	L -> F (in MEN2A and MTC; familial form).
RET	791	791	Y -> F (in HSCR1, pheochromocytoma, MTC and MEN2A; familial form).
RET	804	804	V -> L (in MTC; familial form).
RET	804	804	V -> M (in MTC; familial form).
RET	813	813	R -> Q (in HSCR1; sporadic form).
RET	873	873	R -> Q (in HSCR1; sporadic form).
RET	883	883	A -> F (in MEN2B; somatic mutation in sporadic medullary thyroid carcinoma; requires 2 nucleotide substitutions).
RET	891	891	S -> A (in MTC; familial form).
RET	893	893	F -> L (in HSCR1; sporadic form).
RET	894	894	G -> S (in RADYS; constitutively phosphorylated; expressed only the immature intracellular form).
RET	897	897	R -> Q (in HSCR1; sporadic form).
RET	907	907	K -> E (in HSCR1; sporadic form).
RET	918	918	M -> T (in RADYS, MEN2B and MTC; sporadic form; somatic mutation).
RET	921	921	E -> K (in HSCR1; sporadic form).
RET	922	922	S -> F (in MTC; sporadic form).
RET	922	922	S -> Y (rare polymorphism).
RET	946	946	T -> M (in MEN2B and MTC; familial form).
RET	972	972	R -> G (in HSCR1; familial form).
RET	973	973	P -> L (in HSCR1; familial form).
RET	980	980	M -> T (in HSCR1; sporadic form).
RET	1039	1039	P -> L (in CCHS; with colonic aganglionosis).
RET	1039	1039	P -> Q.
RET	1049	1049	P -> L (in RADYS; prevents phosphorylation in response to GDNF).
RET	1059	1059	Missing (in HSCR1).
RET	1061	1061	L -> P (in HSCR1).
RET	1064	1064	M -> T (in HSCR1; familial form).
RET	1067	1067	P -> S (in RADYS; prevents phosphorylation in response to GDNF).
RET	1112	1112	F -> Y (in a bladder transitional cell carcinoma sample; somatic mutation).
ZNF22	129	129	H -> L (in a breast cancer sample; somatic mutation).
RBP3	530	530	R -> H (in a colorectal cancer sample; somatic mutation).
AGAP8	567	567	Q -> H.
VSTM4	100	100	R -> H (in a colorectal cancer sample; somatic mutation).
NCOA4	94	94	S -> L.
NCOA4	154	154	F -> L.
NCOA4	350	350	C -> R.
NCOA4	561	561	L -> P.
MTRNR2L5	13	13	T -> I (decreased cytoprotective action).
EGR2	268	268	I -> N (in CHN).
EGR2	355	355	D -> V (in CMT1D).
EGR2	359	359	R -> W (in DSS and CMT1D; associated with A-136 in the GJB1 gene in a DSS Korean girl).
EGR2	381	381	R -> C (in CMT1D).
EGR2	381	381	R -> H (in CMT1D).
EGR2	382	383	SD -> RY (in CHN).
EGR2	383	383	D -> Y (in CMT1D).
EGR2	409	409	R -> W (in CMT1D).
NEUROG3	93	93	R -> L (in DIAR4; attenuated NEUROG3 function in vivo).
NEUROG3	107	107	R -> S (in DIAR4; attenuated NEUROG3 function in vivo).
PPA1	57	57	K -> N (in a breast cancer sample; somatic mutation).
NODAL	183	183	R -> Q (in HTX5).
NODAL	260	260	G -> R (in HTX5; decrease in signal transduction).
NODAL	275	275	R -> C (in HTX5; decrease in signal transduction).
NODAL	279	279	E -> K (in a colorectal cancer sample; somatic mutation).
NODAL	284	284	V -> F (in HTX5; decrease in signal transduction).
PRF1	50	50	V -> M (in FHL2).
PRF1	123	123	R -> H.
PRF1	183	183	V -> G (in FHL2).
PRF1	224	224	I -> N (in FHL2).
PRF1	279	279	C -> Y (in FHL2).
PRF1	285	285	Missing (in FHL2).
PRF1	429	429	G -> E (in FHL2).
PCBD1	79	79	T -> I (in hyperphenylalaninemia).
PCBD1	82	82	C -> R (in HPABH4D; mild form).
PCBD1	88	88	R -> Q (in HPABH4D).
PCBD1	97	97	E -> K (in HPABH4D; mild form).
SLC29A3	427	427	G -> S (in HSYN).
SLC29A3	437	437	G -> R (in HSYN).
PSAP	70	70	Missing (in AKRD).
PSAP	215	215	N -> H (in MLD-SAPB; reduces the intracellular activity of the protein significantly).
PSAP	215	215	N -> K (in MLD-SAPB).
PSAP	217	217	T -> I (in MLD-SAPB; juvenile; affects glycosylation at N-215).
PSAP	349	349	L -> P (in AGD).
PSAP	388	388	C -> F (in AGD).
CHST3	222	222	R -> W (in SEDC-JD; severely impairs or abolishes the enzyme function).
CHST3	259	259	L -> P (in SEDC-JD; severely impairs or abolishes the enzyme function).
CHST3	307	307	L -> P (in SEDC-JD).
CHST3	372	372	E -> K (in SEDC-JD).
ECD	281	281	R -> G (could be a rare polymorphism).
USP54	505	505	L -> V (in a breast cancer sample; somatic mutation).
PLAU	214	214	I -> M.
VDAC2	24	24	A -> V.
SFTPA2	12	12	L -> W.
SFTPA2	50	50	V -> L.
SFTPA2	198	198	F -> S (in IPF; rare mutation; the mutant protein is retained in the endoplasmic reticulum and is not secreted).
SFTPA2	231	231	G -> V (in IPF; rare mutation; the mutant protein is retained in the endoplasmic reticulum and is not secreted).
SFTPA1	5	5	P -> L.
SFTPD	123	123	L -> V.
MAT1A	38	38	S -> N (in MATD; abolishes enzyme activity).
MAT1A	55	55	A -> D (in MATD).
MAT1A	199	199	R -> C (in MATD; retains 11% of wild-type activity).
MAT1A	264	264	R -> C (in MATD; has virtually no enzymatic activity).
MAT1A	264	264	R -> H (in MATD; dominant mutation).
MAT1A	305	305	L -> P (in MATD).
MAT1A	322	322	I -> M (in MATD; diminishes but do not completely abolishes enzyme activity; 46% of the level of the wild-type enzyme).
MAT1A	336	336	G -> R (in MATD; retains significant enzymatic activity; 23% of the level of the wild-type enzyme).
MAT1A	344	344	E -> A (in MATD; diminishes but do not completely abolishes enzyme activity; 12% of the level of the wild-type enzyme).
MAT1A	356	356	R -> Q (in MATD).
MAT1A	357	357	P -> L (in MATD).
MAT1A	378	378	G -> S (in MATD).
CDHR1	212	212	A -> T.
CDHR1	532	532	P -> A.
RGR	66	66	S -> R (in RP44).
RGR	132	132	V -> L.
RGR	152	152	H -> N.
RGR	234	234	A -> T.
RGR	241	241	S -> F.
MMRN2	448	448	V -> M (in a colorectal cancer sample; somatic mutation).
GLUD1	270	270	S -> C (in HHF6; diminished sensitivity to GTP).
GLUD1	318	318	R -> K (in HHF6).
GLUD1	318	318	R -> T (in HHF6; diminished sensitivity to GTP).
GLUD1	319	319	Y -> C (in HHF6).
GLUD1	322	322	R -> C (in HHF6; diminished sensitivity to GTP).
GLUD1	322	322	R -> H (in HHF6; diminished sensitivity to GTP).
GLUD1	349	349	E -> A (in HHF6).
GLUD1	498	498	S -> L (in HHF6).
GLUD1	499	499	G -> D (in HHF6).
GLUD1	499	499	G -> S (in HHF6).
GLUD1	501	501	S -> P (in HHF6).
GLUD1	507	507	H -> Y (in HHF6; abolishes inhibition by ATP; no effect on activation by ADP).
MINPP1	41	41	S -> L (in a follicular thyroid carcinoma; somatic mutation).
MINPP1	270	270	Q -> R (in a follicular thyroid adenoma).
PAPSS2	48	48	T -> R (in SEMD-PA; patient with premature pubarche and hyperandrogenism; results in partial loss of activity).
PAPSS2	432	432	R -> K.
FAS	25	25	A -> T (in non-Hodgkin lymphoma; somatic mutation).
FAS	28	28	T -> A (in ALPS1A; associated with autoimmune hepatitis type 2).
FAS	82	82	C -> R (in ALPS1A).
FAS	118	118	N -> S (in squamous cell carcinoma; burn- scar related; somatic mutation).
FAS	121	121	R -> W (in ALPS1A).
FAS	178	178	C -> R (in squamous cell carcinoma; burn- scar related; somatic mutation).
FAS	180	180	L -> F (in non-Hodgkin lymphoma; somatic mutation).
FAS	183	183	P -> L (in non-Hodgkin lymphoma; somatic mutation).
FAS	198	198	T -> I (in non-Hodgkin lymphoma; somatic mutation).
FAS	232	232	Y -> C (in ALPS1A; no effect on interaction with FADD).
FAS	241	241	T -> K (in ALPS1A).
FAS	241	241	T -> P (in ALPS1A).
FAS	249	249	V -> L (in ALPS1A).
FAS	250	250	R -> P (in ALPS1A).
FAS	250	250	R -> Q (in ALPS1A; no effect on interaction with FADD).
FAS	253	253	G -> D (in ALPS1A).
FAS	253	253	G -> S (in ALPS1A).
FAS	255	255	N -> D (in squamous cell carcinoma; burn- scar related; somatic mutation).
FAS	257	257	A -> D (in ALPS1A; loss of interaction with FADD).
FAS	259	259	I -> R (in ALPS1A).
FAS	260	260	D -> G (in ALPS1A).
FAS	260	260	D -> Y (in ALPS1A; loss of interaction with FADD).
FAS	262	262	I -> S (in ALPS1A).
FAS	264	264	N -> K (in non-Hodgkin lymphoma; somatic mutation).
FAS	270	270	T -> I (in ALPS1A).
FAS	270	270	T -> K (in ALPS1A; loss of interaction with FADD).
FAS	272	272	E -> G (in ALPS1A).
FAS	272	272	E -> K (in ALPS1A; also found in non- Hodgkin lymphoma; somatic mutation; loss of interaction with FADD).
FAS	278	278	L -> F (in non-Hodgkin lymphoma; somatic mutation).
FAS	299	299	K -> N (in non-Hodgkin lymphoma; somatic mutation).
FAS	310	310	I -> S (in ALPS1A).
ANKRD1	116	116	T -> M (in TAPVR).
RBP4	59	59	I -> N (in RBP deficiency).
RBP4	93	93	G -> D (in RBP deficiency).
CYP2C8	154	154	E -> D (in clone MP-12).
CYP2C8	193	193	N -> K (in MP-20).
CYP2C8	249	249	K -> R (in clone MP-12).
CYP2C8	390	390	L -> S.
CYP2C8	411	411	H -> L (in clone MP-20).
HPS1	55	55	Missing (in HPS1; mild).
HPS1	630	630	V -> I.
COX15	344	344	S -> P (in LS).
CUTC	77	77	P -> L (in a breast cancer sample; somatic mutation).
CPN1	178	178	G -> D (in CPND).
PAX2	39	40	Missing (in OMN; with bilateral coloboma).
PAX2	75	75	T -> TET (in RCS).
PAX2	76	76	G -> S (in RCS).
PAX2	334	334	A -> V.
C10orf2	303	303	R -> Q (in PEOA3).
C10orf2	303	303	R -> W (in PEOA3; also detected in a case showing digenic inheritance).
C10orf2	315	315	W -> L (in PEOA3).
C10orf2	315	315	W -> S (in PEOA3).
C10orf2	318	318	A -> T (in MTDPS7).
C10orf2	319	319	K -> E (in SANDO; the phenotype highly overlaps with PEOA3).
C10orf2	319	319	K -> T (in PEOA3).
C10orf2	334	334	R -> P (in PEOA3).
C10orf2	335	335	P -> L (in PEOA3).
C10orf2	348	348	G -> R.
C10orf2	354	354	R -> P (in PEOA3).
C10orf2	357	357	R -> P (in PEOA3).
C10orf2	359	359	A -> T (in PEOA3).
C10orf2	360	360	L -> G (in MTDPS7; patients manifest multi-organ failure; requires 2 nucleotide substitutions).
C10orf2	362	362	A -> P (in PEOA3).
C10orf2	363	363	W -> L (in PEOA3).
C10orf2	367	367	I -> T (in PEOA3).
C10orf2	369	369	S -> P (in PEOA3).
C10orf2	369	369	S -> Y (in PEOA3).
C10orf2	370	370	F -> C (in PEOA3).
C10orf2	370	370	F -> L (in PEOA3).
C10orf2	374	374	R -> Q (in PEOA3).
C10orf2	381	381	L -> P (in PEOA3).
C10orf2	426	426	S -> N (in PEOA3).
C10orf2	457	457	T -> I (in MTDPS7; affects helicase activity).
C10orf2	458	458	Q -> H (in PEOA3).
C10orf2	460	460	A -> P (in PEOA3).
C10orf2	474	474	W -> C (in PEOA3).
C10orf2	474	474	W -> S (in PEOA3).
C10orf2	475	475	A -> D (in PEOA3).
C10orf2	475	475	A -> P (in PEOA3).
C10orf2	478	478	F -> I (in PEOA3).
C10orf2	479	479	E -> K (in PEOA3).
C10orf2	508	508	Y -> C (in MTDPS7).
C10orf2	634	634	N -> K.
DPCD	56	56	S -> R.
FGF8	14	14	H -> N (in IHH).
FGF8	26	26	P -> L (in KAL6).
FGF8	40	40	F -> L (in IHH).
FGF8	89	89	K -> E (in IHH).
FGF8	116	116	R -> G (in KAL6).
FGF8	218	218	T -> M (in IHH).
LDB1	299	299	R -> Q (in a colorectal cancer sample; somatic mutation).
PITX3	13	13	S -> N (in ADC).
NFKB2	618	900	Missing (in truncated form EB308).
NFKB2	667	669	AGN -> SAS (in truncated form p80HT).
NFKB2	670	900	Missing (in truncated form p80HT).
NFKB2	703	900	Missing (in truncated form LB40).
INA	110	110	E -> Q (in a breast cancer sample; somatic mutation).
PCGF6	23	23	L -> LPP.
COL17A1	238	238	M -> T.
COL17A1	265	265	S -> C (in GABEB).
COL17A1	627	627	G -> V (in GABEB).
COL17A1	633	633	G -> D (in GABEB).
COL17A1	1303	1303	R -> Q (in GABEB).
GSTO1	155	155	Missing (in allele GSTO1*B).
MXI1	152	152	E -> A (in prostate cancer).
PDCD4	120	120	G -> R (in a breast cancer sample; somatic mutation).
ADRB1	389	389	R -> L.
VWA2	137	137	L -> R (in a colorectal cancer sample; somatic mutation).
KCNK18	34	34	A -> V.
PRDX3	55	55	S -> R.
PRDX3	218	218	A -> T.
BAG3	71	71	R -> W (in CMD1HH).
BAG3	209	209	P -> L (in MFM6).
BAG3	477	477	R -> H (in CMD1HH).
C10orf137	45	45	N -> S (in a colorectal cancer sample; somatic mutation).
C10orf137	95	95	L -> F (in a colorectal cancer sample; somatic mutation).
UROS	3	3	V -> F (in CEP; no residual activity).
UROS	4	4	L -> F (in CEP).
UROS	19	19	Y -> C (in CEP).
UROS	47	47	S -> P (in CEP; less than 3% wild-type activity; severe cutaneous lesions).
UROS	53	53	P -> L (in CEP; no detectable activity; severe phenotype).
UROS	69	69	A -> T (in CEP; less than 2% wild-type activity; moderately-severe phenotype).
UROS	73	73	C -> R (in CEP; frequent mutation in Western countries; no detectable activity; severe phenotype).
UROS	82	82	V -> F (in CEP; high residual activity; mild phenotype).
UROS	99	99	V -> A (in CEP).
UROS	104	104	A -> V (in CEP; residual activity).
UROS	129	129	I -> T (in CEP; no residual activity).
UROS	188	188	G -> R (in CEP; less than 5% wild-type activity).
UROS	188	188	G -> W (in CEP; less than 2% wild-type activity; mild phenotype).
UROS	210	211	EL -> HIQSQAQSQAQDN (in CEP).
UROS	212	212	S -> P (in CEP; no residual activity).
UROS	219	219	I -> S (in CEP; less than 2% wild-type activity; moderately-severe phenotype).
UROS	225	225	G -> S (in CEP).
UROS	228	228	T -> M (in CEP; no detectable activity).
CYP2E1	76	76	R -> H (in allele CYP2E1*2; reduced activity).
ADAMTSL2	113	113	R -> H (in GLPD; leads to the reduced secretion of the mutated protein).
ADAMTSL2	114	114	E -> K (in GLPD).
ADAMTSL2	147	147	P -> L (in GLPD; leads to the reduced secretion of the mutated protein).
ADAMTSL2	811	811	G -> R (in GLPD; leads to the reduced secretion of the mutated protein).
CBFB	100	100	P -> A (in a breast cancer sample; somatic mutation).
SMG1	35	35	A -> T.
SMG1	126	126	R -> C.
SMG1	144	144	S -> C.
SMG1	151	151	N -> Y.
SMG1	160	160	D -> N.
SMG1	167	167	A -> V.
SMG1	320	320	D -> G.
SMG1	465	465	G -> S.
SMG1	546	546	H -> R.
SMG1	588	588	A -> S.
SMG1	612	612	I -> K.
SMG1	753	753	S -> C.
SMG1	809	809	S -> C.
SMG1	812	812	R -> C.
SMG1	829	829	V -> I.
SMG1	832	832	N -> D.
SMG1	952	952	A -> G.
SMG1	969	969	N -> S.
SMG1	1016	1016	F -> L.
SMG1	1029	1029	R -> Q.
SMG1	1072	1072	T -> S.
SMG1	1103	1103	N -> H.
SMG1	1275	1275	P -> R.
SMG1	1292	1292	Q -> P.
SMG1	1332	1332	I -> V.
SMG1	1358	1358	S -> P.
SMG1	1418	1418	R -> T.
SMG1	2171	2171	S -> C (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
SMG1	2258	2258	G -> S.
SMG1	2345	2345	M -> K.
SMG1	2730	2730	Q -> E.
SMG1	2889	2889	G -> S.
SMG1	2899	2899	P -> A.
SMG1	3239	3239	I -> T (in a breast infiltrating ductal carcinoma sample; somatic mutation).
SMG1	3583	3583	K -> Q (in a breast infiltrating ductal carcinoma sample; somatic mutation).
DNAH3	484	484	I -> L (in a colorectal cancer sample; somatic mutation).
DNAH3	1608	1608	S -> F (in a colorectal cancer sample; somatic mutation).
PRKCB	144	144	V -> M (in a colorectal adenocarcinoma sample; somatic mutation).
PRKCB	496	496	V -> M (in a glioblastoma multiforme sample; somatic mutation).
SBK1	92	92	K -> E (in an ovarian mucinous carcinoma sample; somatic mutation).
SBK1	261	261	A -> S.
GPR56	38	38	R -> W (in BFPP).
GPR56	88	88	Y -> C (in BFPP).
GPR56	91	91	C -> S (in BFPP).
GPR56	346	346	C -> S (in BFPP).
GPR56	565	565	R -> W (in BFPP).
WWOX	98	98	P -> L.
WWOX	111	111	T -> S (in a Burkitt lymphoma cell line).
WWOX	120	120	R -> W (in a primary colorectal tumor and a histiocytic lymphoma cell line).
WWOX	272	272	L -> F.
WWOX	291	291	L -> P (found in a esophageal cancer sample; somatic mutation).
WWOX	314	314	R -> H (in a cervical carcinoma cell line).
CDH13	65	65	R -> C (in a patient with amyotrophic lateral sclerosis).
CDH13	103	103	A -> V (in a patient with amyotrophic lateral sclerosis).
CDH13	113	113	G -> R (in a patient with amyotrophic lateral sclerosis).
CDH13	246	246	R -> W (in a patient with amyotrophic lateral sclerosis).
CDH13	367	367	E -> Q (in a patient with amyotrophic lateral sclerosis).
AXIN1	106	106	L -> R (in HCC).
AXIN1	345	345	P -> L (in HCC).
AXIN1	425	425	G -> S (in HCC).
AXIN1	650	650	G -> S (in HCC and in hepatoblastoma).
ABCA3	290	290	L -> M (in a breast cancer sample; somatic mutation).
ABCA3	568	568	N -> D (in SMDP3).
ABCA3	801	801	E -> D (in a breast cancer sample; somatic mutation).
ABCA3	1069	1069	H -> Q (in a breast cancer sample; somatic mutation).
ABCA3	1553	1553	L -> P (in SMDP3).
CREBBP	1278	1278	E -> K (in RSTS1; abolishes acetyltransferase activity).
CREBBP	1378	1378	R -> P (in RSTS1; abolishes acetyltransferase activity and the ability of transactivate CREB).
CREBBP	1447	1447	T -> I (in RSTS1).
CREBBP	1450	1450	Y -> H (in RSTS1).
CREBBP	1470	1470	H -> R (in RSTS1).
CREBBP	1664	1664	R -> H (in RSTS1; abolishes acetyltransferase activity).
ALG1	150	150	S -> R (in CDG1K; impairs activity).
ALG1	342	342	Q -> P (in CDG1K; impairs activity).
ABAT	220	220	R -> K (in GABATD; 25% reduction in activity).
PMM2	9	9	C -> Y (in CDG1A).
PMM2	11	11	F -> C (in CDG1A).
PMM2	15	15	G -> E (in CDG1A).
PMM2	20	20	P -> S (in CDG1A; reduction of activity).
PMM2	32	32	L -> R (in CDG1A).
PMM2	37	37	Q -> H (in CDG1A; partial loss of activity).
PMM2	42	42	G -> R.
PMM2	44	44	V -> A (in CDG1A).
PMM2	44	44	V -> L (in CDG1A).
PMM2	64	64	Y -> C (in CDG1A).
PMM2	65	65	D -> Y (in CDG1A).
PMM2	67	67	V -> M (in CDG1A).
PMM2	69	69	P -> S (in CDG1A).
PMM2	76	76	Y -> C (in CDG1A).
PMM2	93	93	E -> A (in CDG1A).
PMM2	101	101	N -> K (in CDG1A).
PMM2	103	103	C -> F (in CDG1A).
PMM2	104	104	L -> V (in CDG1A).
PMM2	106	106	Y -> C (in CDG1A).
PMM2	108	108	A -> V (in CDG1A).
PMM2	113	113	P -> L (in CDG1A).
PMM2	117	117	G -> R (in CDG1A; loss of activity).
PMM2	119	119	F -> L (in CDG1A; partial loss of activity).
PMM2	120	120	I -> T (in CDG1A).
PMM2	123	123	R -> Q (in CDG1A).
PMM2	131	131	P -> A (in CDG1A).
PMM2	132	132	I -> F (in CDG1A; slightly reduced activity).
PMM2	132	132	I -> N (in CDG1A).
PMM2	132	132	I -> T (in CDG1A).
PMM2	139	139	E -> K (in CDG1A; this mutation seems to disrupt a splicing enhancer sequence and thus results in most cases in a protein with exon 5 skipped; slightly reduced activity).
PMM2	141	141	R -> C (in CDG1A; loss of activity).
PMM2	144	144	F -> L (in CDG1A).
PMM2	148	148	D -> N (in CDG1A).
PMM2	151	151	E -> G (in CDG1A).
PMM2	153	153	I -> T (in CDG1A).
PMM2	157	157	F -> S (in CDG1A).
PMM2	162	162	R -> W (in CDG1A).
PMM2	172	172	F -> V (in CDG1A).
PMM2	175	175	G -> R (in CDG1A).
PMM2	176	176	G -> V (in CDG1A; loss of activity).
PMM2	177	177	Q -> H (in CDG1A; partial loss of activity).
PMM2	183	183	F -> S (in CDG1A).
PMM2	185	185	D -> G (in CDG1A).
PMM2	188	188	D -> G (in CDG1A; severe).
PMM2	192	192	C -> G (in CDG1A; normal activity but lower affinity for alpha-D-mannose 1- phosphate).
PMM2	195	195	H -> R (in CDG1A).
PMM2	206	206	F -> S (in CDG1A).
PMM2	208	208	G -> A (in CDG1A).
PMM2	214	214	G -> S (in CDG1A).
PMM2	216	216	N -> I (in CDG1A).
PMM2	216	216	N -> S (in CDG1A).
PMM2	217	217	D -> E (in CDG1A).
PMM2	218	218	H -> L (in CDG1A).
PMM2	223	223	D -> E (in CDG1A; normal activity but lower affinity for alpha-D-mannose 1- phosphate).
PMM2	223	223	D -> N (in CDG1A).
PMM2	226	226	T -> S (in CDG1A).
PMM2	228	228	G -> C (in CDG1A).
PMM2	228	228	G -> R (in CDG1A).
PMM2	229	229	Y -> S (in CDG1A).
PMM2	231	231	V -> M (in CDG1A).
PMM2	233	233	A -> T (in CDG1A; could be a rare polymorphism).
PMM2	237	237	T -> M (in CDG1A).
PMM2	237	237	T -> R (in CDG1A; loss of activity).
PMM2	238	238	R -> G (in CDG1A).
PMM2	238	238	R -> P (in CDG1A).
PMM2	241	241	C -> S (in CDG1A).
GRIN2A	270	270	K -> E.
CIITA	120	120	K -> IE (in BLS2).
CIITA	469	469	L -> P (in BLS2; mild immunodeficiency; has residual MHC class II trans activation activity).
CIITA	940	963	Missing (in BLS2).
CIITA	962	962	F -> S (in BLS2).
CIITA	964	991	Missing (in BLS2).
CIITA	1027	1027	Missing (in BLS2).
LITAF	23	23	Y -> H (in one EMPD primary tumor; somatic mutation).
LITAF	49	49	T -> M (in CMT1C).
LITAF	112	112	G -> S (in CMT1C).
LITAF	115	115	T -> N (in CMT1C).
LITAF	116	116	W -> G (in CMT1C).
LITAF	122	122	L -> V (in CMT1C).
ERCC4	153	153	R -> P (in XFEPS).
ERCC4	225	225	I -> M (in XP-F).
ERCC4	454	454	R -> W (in XP-F).
ERCC4	490	490	R -> Q (in XP-F).
ERCC4	502	502	E -> K (in XP-F).
ERCC4	513	513	G -> R (in XP-F).
ERCC4	529	529	I -> T (in XP-F).
ERCC4	567	567	T -> A (in XP-F).
ERCC4	605	611	Missing (in XP-F).
ERCC4	608	608	L -> P (in XP-F).
ERCC4	703	703	G -> D.
ERCC4	717	717	I -> T.
ERCC4	799	799	R -> W (in XP-F; mild; significant residual repair activity).
MKL2	390	390	D -> G (found in a renal cell carcinoma sample; somatic mutation).
NOMO1	458	458	K -> N.
NOMO1	1081	1081	E -> K.
NOMO1	1141	1141	I -> F.
NOMO1	1195	1195	R -> G.
MYH11	1241	1264	Missing (in AAT4).
MYH11	1758	1758	R -> Q (in AAT4).
ABCC1	117	117	M -> T.
ABCC1	633	633	R -> Q.
ABCC1	1512	1512	S -> L.
ABCC6	60	62	Missing (in PXE; autosomal recessive).
ABCC6	61	61	G -> D.
ABCC6	64	64	R -> W.
ABCC6	207	207	G -> R.
ABCC6	265	265	R -> G.
ABCC6	319	319	I -> V.
ABCC6	364	364	T -> R (in PXE; autosomal recessive).
ABCC6	411	411	N -> K (in PXE; autosomal dominant).
ABCC6	455	455	A -> P (in PXE; autosomal dominant).
ABCC6	497	497	N -> K.
ABCC6	518	518	R -> Q (in PXE).
ABCC6	568	568	F -> S (in PXE; autosomal dominant).
ABCC6	673	673	L -> P (in PXE; autosomal dominant).
ABCC6	765	765	R -> Q (in PXE; autosomal dominant).
ABCC6	953	953	L -> H.
ABCC6	1114	1114	R -> P (in PXE; autosomal recessive).
ABCC6	1121	1121	S -> W (in PXE; autosomal dominant).
ABCC6	1138	1138	R -> P (in PXE; autosomal dominant).
ABCC6	1203	1203	G -> D (in PXE; autosomal dominant).
ABCC6	1241	1241	W -> C.
ABCC6	1298	1298	V -> F (in PXE; autosomal dominant; abolishes LTC4 and NEM-GS transport).
ABCC6	1301	1301	T -> I (in PXE; autosomal dominant).
ABCC6	1302	1302	G -> R (in PXE; autosomal dominant; abolishes LTC4 and NEM-GS transport).
ABCC6	1303	1303	A -> P (in PXE; autosomal dominant).
ABCC6	1314	1314	R -> Q (in PXE; autosomal dominant).
ABCC6	1314	1314	R -> W (in PXE; autosomal recessive).
ABCC6	1321	1321	G -> S (in PXE; autosomal dominant; abolishes LTC4 and NEM-GS transport).
ABCC6	1347	1347	Q -> H (in PXE; autosomal dominant).
ABCC6	1354	1354	G -> R (in PXE; autosomal recessive).
ABCC6	1424	1424	I -> T (in PXE; autosomal dominant).
ACSM5	159	159	Q -> H.
ERI2	206	206	I -> T (in a colorectal cancer sample; somatic mutation).
EEF2K	291	291	T -> M (in a colorectal adenocarcinoma sample; somatic mutation).
EEF2K	609	609	D -> H.
SCNN1G	58	58	G -> R (in a colorectal cancer sample; somatic mutation).
SCNN1G	178	178	R -> W.
SCNN1G	502	502	A -> P.
SCNN1G	614	614	A -> S.
SCNN1B	37	37	G -> S (in AR-PHA1).
SCNN1B	82	82	S -> C (in BESC1).
SCNN1B	267	267	P -> L (in BESC1; decreased channel activity).
SCNN1B	288	288	N -> S (in BESC1).
SCNN1B	294	294	G -> S (in BESC1; increased channel activity).
SCNN1B	311	311	A -> V (in a colorectal cancer sample; somatic mutation).
SCNN1B	314	314	A -> V (in a breast cancer sample; somatic mutation).
SCNN1B	336	336	A -> P.
SCNN1B	348	348	V -> M (in BESC1).
SCNN1B	369	369	P -> T (in BESC1).
SCNN1B	387	387	L -> V (in a breast cancer sample; somatic mutation).
SCNN1B	434	434	V -> M.
SCNN1B	539	539	E -> K (in BESC1; decreased channel activity).
SCNN1B	563	563	R -> Q (associated with hypertension in South African Black).
SCNN1B	589	589	G -> S.
SCNN1B	597	597	R -> H.
SCNN1B	616	616	P -> L (in LIDDS).
SCNN1B	616	616	P -> S (in LIDDS).
SCNN1B	617	617	P -> S (in LIDDS).
SCNN1B	618	618	P -> R (in LIDDS).
SCNN1B	620	620	Y -> H (in LIDDS; constitutive channel activation).
SCNN1B	624	624	R -> C.
SCNN1B	632	632	E -> G.
ERN2	69	69	V -> I.
ERN2	118	118	R -> C.
ERN2	184	184	R -> C.
ERN2	271	271	R -> Q.
ERN2	318	318	A -> T.
ERN2	410	410	L -> F.
ERN2	487	487	S -> T.
ERN2	504	504	L -> F.
ERN2	858	858	H -> Y.
SLC5A11	526	526	M -> I.
FUS	244	244	R -> C (in ALS6).
FUS	254	254	M -> V (found in a patient with frontotemporal lobar degeneration).
FUS	312	312	K -> Q (in a breast cancer sample; somatic mutation).
FUS	514	514	R -> G (in ALS6).
FUS	514	514	R -> S (in ALS6).
FUS	515	515	G -> C (in ALS6).
FUS	517	517	H -> Q (does not affect protein nuclear localization).
FUS	518	518	R -> K (in ALS6).
FUS	521	521	R -> C (in ALS6; results in aberrant trafficking and cytoplasmic retention of the protein).
FUS	521	521	R -> G (in ALS6; results in aberrant trafficking and cytoplasmic retention of the protein).
FUS	521	521	R -> H (in ALS6; results in aberrant trafficking and cytoplasmic retention of the protein).
FUS	522	522	R -> G (in ALS6).
FUS	524	524	R -> S (in ALS6).
FUS	524	524	R -> T (in ALS6).
FUS	525	525	P -> L (in ALS6).
MYLK3	390	390	G -> R (in a colorectal cancer sample; somatic mutation).
PHKB	118	118	A -> P (in GSD9B).
PHKB	867	867	L -> V (in a breast cancer sample; somatic mutation).
PHKB	877	877	G -> R (in a breast cancer sample; somatic mutation).
FTO	316	316	R -> Q (in GDFD; has no residual normal activity).
SLC6A2	457	457	A -> P (in OI; loss of function).
CETP	168	168	L -> P (in HALP1; reduced secretion into plasma).
CETP	299	299	R -> C (in HALP1; reduced secretion into plasma).
CNGB1	993	993	G -> V (in RP45).
CES2	34	34	R -> W.
CES2	206	206	R -> H.
CTCF	339	339	R -> W (in a Wilms' tumor).
CTCF	344	344	K -> E (in a breast tumor).
CTCF	345	345	H -> R (in a prostate tumor).
CTCF	448	448	R -> Q (in a Wilms' tumor).
CDH3	322	322	N -> I (in EEM).
CDH3	503	503	R -> H (in HJMD).
CDH1	123	123	H -> Y (in a gastric cancer sample).
CDH1	193	193	T -> P (in a diffuse gastric cancer sample).
CDH1	244	244	D -> G (in HDGC).
CDH1	270	270	S -> A (may contribute to prostate cancer).
CDH1	274	277	Missing (found in gastric carcinoma cell lines).
CDH1	282	282	M -> I (in a breast cancer sample; somatic mutation).
CDH1	315	315	N -> S (in lobular breast carcinoma).
CDH1	336	336	E -> D.
CDH1	340	340	T -> A (found in gastric and colorectal cancer samples; cells exhibited decreased aggregation increased invasiveness and non-uniform migration in vitro compared to cells transfected with wild-type sequence).
CDH1	370	370	D -> A (in a diffuse gastric cancer sample).
CDH1	400	400	Missing (in a gastric carcinoma sample; loss of heterozygosity).
CDH1	418	423	Missing (in a gastric carcinoma sample).
CDH1	463	463	E -> Q (in a gastric carcinoma sample).
CDH1	470	470	T -> I.
CDH1	473	473	V -> D (in a diffuse gastric cancer sample).
CDH1	487	487	V -> A (in HDGC).
CDH1	598	598	R -> Q (in a gastric cancer sample).
CDH1	634	634	A -> V (found in a gastric cancer sample; cells exhibited decreased aggregation increased invasiveness and non-uniform migration in vitro compared to cells transfected with wild-type sequence).
CDH1	711	711	L -> V (detected in an endometrial cancer sample).
CDH1	777	777	D -> N (in a breast cancer sample; somatic mutation).
CDH1	838	838	S -> G (in an ovarian carcinoma sample; somatic mutation; loss of heterozygosity).
COG4	729	729	R -> W (in CDG2J; severe defects in glycosylation).
HP	29	87	Missing (in allele HP*1F and allele HP*1S).
HP	129	129	N -> D (in allele HP*1F).
HP	130	130	E -> K (in allele HP*1F).
ZFHX3	3374	3374	A -> V.
ZFHX3	3377	3384	Missing.
ZFHX3	3527	3527	G -> GGG.
MLKL	291	291	L -> P (in a gastric adenocarcinoma sample; somatic mutation).
MLKL	398	398	F -> I (in a gastric adenocarcinoma sample; somatic mutation).
ADAMTS18	382	382	R -> K (in a colorectal cancer sample; somatic mutation).
ADAMTS18	455	455	K -> T (in a colorectal cancer sample; somatic mutation).
GAN	15	15	R -> S (in GAN; no effect on binding to TBCB).
GAN	51	51	A -> P (in GAN).
GAN	52	52	S -> G (in GAN).
GAN	79	79	S -> L (in GAN).
GAN	82	82	V -> F (in GAN; no effect on binding to TBCB).
GAN	86	86	I -> F (in GAN).
GAN	89	89	Y -> C (in GAN).
GAN	138	138	R -> H (in GAN).
GAN	195	195	V -> F (in GAN).
GAN	269	269	R -> Q (in GAN).
GAN	309	309	L -> R (in GAN).
GAN	315	315	P -> L (in GAN).
GAN	368	368	G -> R (in GAN).
GAN	423	423	I -> T (in GAN).
GAN	474	474	G -> R (in GAN).
GAN	486	486	E -> K (in GAN).
GAN	545	545	R -> C (in GAN; complete loss of binding to TBCB).
GAN	545	545	R -> H (in GAN).
GAN	570	570	C -> Y (in GAN).
CBFA2T3	306	306	R -> H (in a colorectal cancer sample; somatic mutation).
CBFA2T3	518	518	E -> K (in a colorectal cancer sample; somatic mutation).
CBFA2T3	534	534	A -> V (in a colorectal cancer sample; somatic mutation).
CDH15	8	8	V -> L (in MRD3; uncertain pathological significance).
CDH15	60	60	R -> C (in MRD3; affects cell-cell adhesion but not surface expression of the protein).
CDH15	92	92	R -> W (in MRD3; affects cell-cell adhesion but not surface expression of the protein).
CDH15	122	122	A -> V (in MRD3; affects cell-cell adhesion but not surface expression of the protein).
HBA2	2	2	V -> E (in Thionville; O(2) affinity down).
HBA2	7	7	D -> G (in Swan River).
HBA2	7	7	D -> V (in Ferndown; O(2) affinity up).
HBA2	7	7	D -> Y (in Woodville; O(2) affinity up).
HBA2	10	10	N -> T (in Broomfield).
HBA2	12	12	K -> E (in Anantharaj).
HBA2	20	20	A -> D (in J-Kurosh).
HBA2	24	24	E -> K (in Chad).
HBA2	25	25	Y -> H (in Luxembourg; unstable).
HBA2	27	27	A -> E (in Shenyang; unstable).
HBA2	27	27	A -> V (in Campinas).
HBA2	28	28	E -> D (in Hekinan).
HBA2	28	28	E -> G (in Fort Worth).
HBA2	28	28	E -> V (in Spanish town).
HBA2	31	31	E -> K (in O-Padova).
HBA2	32	32	R -> K (causes alpha-thalassemia).
HBA2	32	32	R -> S (in Prato; unstable).
HBA2	35	35	L -> R (in Queens/Ogi).
HBA2	38	38	P -> PE (in Catonsville).
HBA2	38	38	P -> R (in Bourmedes).
HBA2	41	41	K -> M (in Kanagawa; O(2) affinity up).
HBA2	42	42	T -> S (in Miyano; O(2) affinity up).
HBA2	44	44	F -> L (in Hirosaki; unstable).
HBA2	45	45	P -> R (in Kawachi; O(2) affinity up).
HBA2	46	46	H -> Q (in Bari).
HBA2	46	46	H -> R (in Fort de France; O(2) affinity up).
HBA2	48	48	D -> A (in Cordele; unstable).
HBA2	48	48	D -> G (in Umi/Michigan; unstable).
HBA2	48	48	D -> H (in Hasharon/Sinai; unstable).
HBA2	48	48	D -> Y (in Kurdistan).
HBA2	49	49	L -> R (in Montgomery).
HBA2	50	50	S -> R (in Savaria).
HBA2	51	51	H -> R (in Aichi; slightly unstable).
HBA2	52	52	G -> D (in J-Abidjan).
HBA2	52	52	G -> R (in Russ).
HBA2	54	54	A -> D (in J-Rovigo; unstable).
HBA2	55	55	Q -> R (in Hikoshima/Shimonoseki).
HBA2	57	57	K -> R (in Port Huron).
HBA2	57	57	K -> T (in Thailand).
HBA2	58	58	G -> R (in L-Persian Gulf).
HBA2	59	59	H -> Q (in Boghe).
HBA2	59	59	H -> Y (in M-Boston/M-Osaka; O(2) affinity down).
HBA2	60	60	G -> V (in Tottori; unstable).
HBA2	61	61	Missing (in Clinic; unstable; causes alpha-thalassemia).
HBA2	62	62	K -> N (in J-Buda).
HBA2	62	62	K -> T (in J-Anatolia).
HBA2	63	63	V -> M (in Evans; unstable).
HBA2	64	64	A -> D (in Pontoise; unstable).
HBA2	65	65	D -> Y (in Persepolis).
HBA2	72	72	A -> E (in J-Habana).
HBA2	72	72	A -> V (in Ozieri).
HBA2	73	73	H -> R (in Daneskgah-Teheran).
HBA2	75	75	D -> A (in Lille).
HBA2	75	75	D -> G (in Chapel Hill).
HBA2	75	75	D -> N (in G-Pest).
HBA2	76	76	D -> A (in Duan).
HBA2	76	76	D -> H (in Q-Iran).
HBA2	77	77	M -> K (in Noko).
HBA2	77	77	M -> T (in Aztec).
HBA2	78	78	P -> R (in Guizhou).
HBA2	79	79	N -> H (in Davenport).
HBA2	79	79	N -> K (in Stanleyville-2).
HBA2	80	80	A -> G (in Singapore).
HBA2	81	81	L -> R (in Ann Arbor; unstable).
HBA2	82	82	S -> C (in Nigeria).
HBA2	83	83	A -> D (in Garden State).
HBA2	85	85	S -> R (in Etobicoke; O(2) affinity up).
HBA2	86	86	D -> V (in Inkster; O(2) affinity up).
HBA2	86	86	D -> Y (in Atago; O(2) affinity up).
HBA2	87	87	L -> R (in Moabit; unstable).
HBA2	88	88	H -> N (in Auckland; unstable).
HBA2	88	88	H -> R (in Iwata; unstable).
HBA2	89	89	A -> S (in Loire; O(2) affinity up).
HBA2	91	91	K -> M (in Handa; O(2) affinity up).
HBA2	93	93	R -> Q (in J-Cape Town; O(2) affinity up).
HBA2	93	93	R -> W (in Cemenelum; O(2) affinity up).
HBA2	95	95	D -> A (in Bassett; markedly reduced oxygen affinity).
HBA2	95	95	D -> Y (in Setif; unstable).
HBA2	96	96	P -> A (in Denmark Hill; O(2) affinity up).
HBA2	96	96	P -> T (in Godavari; O(2) affinity up).
HBA2	98	98	N -> K (in Dallas; O(2) affinity up).
HBA2	100	100	K -> E (in Turriff).
HBA2	104	104	H -> R (in Contaldo; unstable).
HBA2	104	104	H -> Y (in Charolles).
HBA2	110	110	L -> R (in Suan-Dok; unstable; causes alpha-thalassemia).
HBA2	111	111	A -> D (in Petah Tikva; unstable; causes alpha-thalassemia).
HBA2	113	113	H -> D (in Hopkins-II; unstable).
HBA2	114	114	L -> H (in Twin Peaks).
HBA2	115	115	P -> L (in Nouakchott).
HBA2	115	115	P -> R (in Chiapas).
HBA2	115	115	P -> S (in Melusine).
HBA2	116	116	A -> D (in J-Tongariki).
HBA2	117	117	E -> A (in Ube-4).
HBA2	117	117	E -> EHLPAE (in Zaire).
HBA2	118	118	F -> FI (in Phnom Penh).
HBA2	119	119	T -> TEFT (in Grady).
HBA2	121	121	A -> E (in J-Meerut/J-Birmingham).
HBA2	122	122	V -> M (in Owari).
HBA2	123	123	H -> Q (in Westmead).
HBA2	126	126	L -> P (in Quong Sze; causes alpha- thalassemia).
HBA2	126	126	L -> R (in Plasencia; family with moderate microcytosis and hypochromia).
HBA2	127	127	D -> G (in West One).
HBA2	127	127	D -> V (in Fukutomi; O(2) affinity up).
HBA2	127	127	D -> Y (in Monteriore; O(2) affinity up).
HBA2	128	128	K -> N (in Jackson).
HBA2	130	130	L -> P (in Tunis-Bizerte; unstable; causes alpha-thalassemia).
HBA2	131	131	A -> D (in Yuda; O(2) affinity down).
HBA2	131	131	A -> P (in Sun Prairie; unstable).
HBA2	132	132	S -> P (in Questembert; highly unstable; causes alpha-thalassemia).
HBA2	134	134	S -> R (in Val de Marne; O(2) affinity up).
HBA2	136	136	V -> E (in Pavie).
HBA2	137	137	L -> M (in Chicago).
HBA2	137	137	L -> P (in Bibba; unstable; causes alpha- thalassemia).
HBA2	137	137	L -> R (in Toyama).
HBA2	139	139	S -> P (in Attleboro; O(2) affinity up).
HBA2	140	140	K -> E (in Hanamaki; O(2) affinity up).
HBA2	140	140	K -> T (in Tokoname; O(2) affinity up).
HBA2	141	141	Y -> H (in Rouen/Ethiopia; O(2) affinity up).
HBA2	142	142	R -> C (in Nunobiki; O(2) affinity up).
HBA2	142	142	R -> H (in Suresnes; O(2) affinity up).
HBA2	142	142	R -> L (in Legnano; O(2) affinity up).
HBA2	142	142	R -> P (in Singapore).
HBA1	2	2	V -> E (in Thionville; O(2) affinity down).
HBA1	7	7	D -> G (in Swan River).
HBA1	7	7	D -> V (in Ferndown; O(2) affinity up).
HBA1	7	7	D -> Y (in Woodville; O(2) affinity up).
HBA1	10	10	N -> T (in Broomfield).
HBA1	12	12	K -> E (in Anantharaj).
HBA1	20	20	A -> D (in J-Kurosh).
HBA1	24	24	E -> K (in Chad).
HBA1	25	25	Y -> H (in Luxembourg; unstable).
HBA1	27	27	A -> E (in Shenyang; unstable).
HBA1	27	27	A -> V (in Campinas).
HBA1	28	28	E -> D (in Hekinan).
HBA1	28	28	E -> G (in Fort Worth).
HBA1	28	28	E -> V (in Spanish town).
HBA1	31	31	E -> K (in O-Padova).
HBA1	32	32	R -> K (causes alpha-thalassemia).
HBA1	32	32	R -> S (in Prato; unstable).
HBA1	35	35	L -> R (in Queens/Ogi).
HBA1	38	38	P -> PE (in Catonsville).
HBA1	38	38	P -> R (in Bourmedes).
HBA1	41	41	K -> M (in Kanagawa; O(2) affinity up).
HBA1	42	42	T -> S (in Miyano; O(2) affinity up).
HBA1	44	44	F -> L (in Hirosaki; unstable).
HBA1	45	45	P -> R (in Kawachi; O(2) affinity up).
HBA1	46	46	H -> Q (in Bari).
HBA1	46	46	H -> R (in Fort de France; O(2) affinity up).
HBA1	48	48	D -> A (in Cordele; unstable).
HBA1	48	48	D -> G (in Umi/Michigan; unstable).
HBA1	48	48	D -> H (in Hasharon/Sinai; unstable).
HBA1	48	48	D -> Y (in Kurdistan).
HBA1	49	49	L -> R (in Montgomery).
HBA1	50	50	S -> R (in Savaria).
HBA1	51	51	H -> R (in Aichi; slightly unstable).
HBA1	52	52	G -> D (in J-Abidjan).
HBA1	52	52	G -> R (in Russ).
HBA1	54	54	A -> D (in J-Rovigo; unstable).
HBA1	55	55	Q -> R (in Hikoshima/Shimonoseki).
HBA1	57	57	K -> R (in Port Huron).
HBA1	57	57	K -> T (in Thailand).
HBA1	58	58	G -> R (in L-Persian Gulf).
HBA1	59	59	H -> Q (in Boghe).
HBA1	59	59	H -> Y (in M-Boston/M-Osaka; O(2) affinity down).
HBA1	60	60	G -> V (in Tottori; unstable).
HBA1	61	61	Missing (in Clinic; unstable; causes alpha-thalassemia).
HBA1	62	62	K -> N (in J-Buda).
HBA1	62	62	K -> T (in J-Anatolia).
HBA1	63	63	V -> M (in Evans; unstable).
HBA1	64	64	A -> D (in Pontoise; unstable).
HBA1	65	65	D -> Y (in Persepolis).
HBA1	72	72	A -> E (in J-Habana).
HBA1	72	72	A -> V (in Ozieri).
HBA1	73	73	H -> R (in Daneskgah-Teheran).
HBA1	75	75	D -> A (in Lille).
HBA1	75	75	D -> G (in Chapel Hill).
HBA1	75	75	D -> N (in G-Pest).
HBA1	76	76	D -> A (in Duan).
HBA1	76	76	D -> H (in Q-Iran).
HBA1	77	77	M -> K (in Noko).
HBA1	77	77	M -> T (in Aztec).
HBA1	78	78	P -> R (in Guizhou).
HBA1	79	79	N -> H (in Davenport).
HBA1	79	79	N -> K (in Stanleyville-2).
HBA1	80	80	A -> G (in Singapore).
HBA1	81	81	L -> R (in Ann Arbor; unstable).
HBA1	82	82	S -> C (in Nigeria).
HBA1	83	83	A -> D (in Garden State).
HBA1	85	85	S -> R (in Etobicoke; O(2) affinity up).
HBA1	86	86	D -> V (in Inkster; O(2) affinity up).
HBA1	86	86	D -> Y (in Atago; O(2) affinity up).
HBA1	87	87	L -> R (in Moabit; unstable).
HBA1	88	88	H -> N (in Auckland; unstable).
HBA1	88	88	H -> R (in Iwata; unstable).
HBA1	89	89	A -> S (in Loire; O(2) affinity up).
HBA1	91	91	K -> M (in Handa; O(2) affinity up).
HBA1	93	93	R -> Q (in J-Cape Town; O(2) affinity up).
HBA1	93	93	R -> W (in Cemenelum; O(2) affinity up).
HBA1	95	95	D -> A (in Bassett; markedly reduced oxygen affinity).
HBA1	95	95	D -> Y (in Setif; unstable).
HBA1	96	96	P -> A (in Denmark Hill; O(2) affinity up).
HBA1	96	96	P -> T (in Godavari; O(2) affinity up).
HBA1	98	98	N -> K (in Dallas; O(2) affinity up).
HBA1	100	100	K -> E (in Turriff).
HBA1	104	104	H -> R (in Contaldo; unstable).
HBA1	104	104	H -> Y (in Charolles).
HBA1	110	110	L -> R (in Suan-Dok; unstable; causes alpha-thalassemia).
HBA1	111	111	A -> D (in Petah Tikva; unstable; causes alpha-thalassemia).
HBA1	113	113	H -> D (in Hopkins-II; unstable).
HBA1	114	114	L -> H (in Twin Peaks).
HBA1	115	115	P -> L (in Nouakchott).
HBA1	115	115	P -> R (in Chiapas).
HBA1	115	115	P -> S (in Melusine).
HBA1	116	116	A -> D (in J-Tongariki).
HBA1	117	117	E -> A (in Ube-4).
HBA1	117	117	E -> EHLPAE (in Zaire).
HBA1	118	118	F -> FI (in Phnom Penh).
HBA1	119	119	T -> TEFT (in Grady).
HBA1	121	121	A -> E (in J-Meerut/J-Birmingham).
HBA1	122	122	V -> M (in Owari).
HBA1	123	123	H -> Q (in Westmead).
HBA1	126	126	L -> P (in Quong Sze; causes alpha- thalassemia).
HBA1	126	126	L -> R (in Plasencia; family with moderate microcytosis and hypochromia).
HBA1	127	127	D -> G (in West One).
HBA1	127	127	D -> V (in Fukutomi; O(2) affinity up).
HBA1	127	127	D -> Y (in Monteriore; O(2) affinity up).
HBA1	128	128	K -> N (in Jackson).
HBA1	130	130	L -> P (in Tunis-Bizerte; unstable; causes alpha-thalassemia).
HBA1	131	131	A -> D (in Yuda; O(2) affinity down).
HBA1	131	131	A -> P (in Sun Prairie; unstable).
HBA1	132	132	S -> P (in Questembert; highly unstable; causes alpha-thalassemia).
HBA1	134	134	S -> R (in Val de Marne; O(2) affinity up).
HBA1	136	136	V -> E (in Pavie).
HBA1	137	137	L -> M (in Chicago).
HBA1	137	137	L -> P (in Bibba; unstable; causes alpha- thalassemia).
HBA1	137	137	L -> R (in Toyama).
HBA1	139	139	S -> P (in Attleboro; O(2) affinity up).
HBA1	140	140	K -> E (in Hanamaki; O(2) affinity up).
HBA1	140	140	K -> T (in Tokoname; O(2) affinity up).
HBA1	141	141	Y -> H (in Rouen/Ethiopia; O(2) affinity up).
HBA1	142	142	R -> C (in Nunobiki; O(2) affinity up).
HBA1	142	142	R -> H (in Suresnes; O(2) affinity up).
HBA1	142	142	R -> L (in Legnano; O(2) affinity up).
HBA1	142	142	R -> P (in Singapore).
C16orf13	136	136	L -> P.
CACNA1H	161	161	F -> L (in IGE6).
CACNA1H	282	282	E -> K (in IGE6).
CACNA1H	456	456	C -> S (in IGE6).
CACNA1H	499	499	G -> S (in IGE6).
CACNA1H	640	640	P -> L.
CACNA1H	648	648	P -> L (in IGE6).
CACNA1H	684	684	P -> S.
CACNA1H	744	744	R -> Q (in IGE6).
CACNA1H	748	748	A -> V (in IGE6).
CACNA1H	773	773	G -> D (in IGE6).
CACNA1H	784	784	G -> S (in IGE6).
CACNA1H	831	831	V -> M (in IGE6).
CACNA1H	848	848	G -> S (in IGE6).
CACNA1H	1463	1463	D -> N (in IGE6).
CACNA1H	2173	2173	P -> S.
TPSG1	126	126	I -> M (in allele gamma-II).
TPSG1	132	132	S -> T (in allele gamma-II).
TPSG1	204	204	L -> I (in allele gamma-II).
TPSB2	51	53	HGP -> RDR (in beta-III).
TPSAB1	51	53	HGP -> RDR (in beta-III).
CLCN7	132	132	L -> P (in OPTB4).
CLCN7	214	214	N -> S (in OPTB4).
CLCN7	215	215	G -> R (in OPTA2).
CLCN7	227	227	Missing (in OPTB4).
CLCN7	240	240	G -> R (in OPTB4).
CLCN7	249	249	P -> R (in OPTB4).
CLCN7	261	261	I -> F (in OPTB4).
CLCN7	286	286	R -> Q (in OPTA2).
CLCN7	318	318	F -> L (in OPTA2).
CLCN7	332	332	M -> V (in OPTB4).
CLCN7	403	403	R -> Q (in OPTB4).
CLCN7	490	490	L -> F (in OPTA2).
CLCN7	521	521	G -> R (in OPTB4).
CLCN7	526	526	R -> Q (in OPTB4).
CLCN7	526	526	R -> W (in OPTB4).
CLCN7	549	549	L -> P (in OPTB4).
CLCN7	614	614	L -> P (in OPTB4).
CLCN7	651	651	L -> P (in OPTB4).
CLCN7	677	677	G -> V (in OPTA2).
CLCN7	744	744	S -> F (in OPTB4).
CLCN7	758	758	F -> L (in OPTA2).
CLCN7	762	762	R -> Q (in OPTA2 and OPTB4; not detected in the fibroblasts from the patient).
CLCN7	762	762	R -> W (in OPTB4).
CLCN7	766	766	L -> P (in OPTB4).
CLCN7	767	767	R -> P (in OPTB4).
CLCN7	767	767	R -> Q (in OPTB4).
CLCN7	767	767	R -> W (in OPTA2 and OPTB4).
TSC2	258	258	K -> N (in TSC2).
TSC2	304	304	W -> WGMALW (in TSC2).
TSC2	309	309	L -> Q.
TSC2	365	365	Missing (in TSC2).
TSC2	407	407	Y -> D (in TSC2).
TSC2	440	440	G -> S.
TSC2	449	449	M -> I (in TSC2).
TSC2	463	463	I -> V.
TSC2	486	486	N -> I (in TSC2).
TSC2	490	490	I -> V.
TSC2	525	525	N -> S (in TSC2).
TSC2	536	536	A -> V.
TSC2	593	593	H -> R.
TSC2	599	599	K -> M (in TSC2; impairs repression of EIF4EBP1 phosphorylation).
TSC2	607	607	A -> T.
TSC2	611	611	R -> Q (in TSC2 and LAM; impairs phosphorylation at S-1387, S-1418 and S- 1420).
TSC2	611	611	R -> W (in TSC2; impairs phosphorylation at S-1387, S-1418 and S-1420).
TSC2	614	614	A -> D (in TSC2).
TSC2	615	615	F -> S.
TSC2	647	647	D -> N (in TSC2; could be a polymorphism).
TSC2	694	694	Missing (in TSC2).
TSC2	696	696	C -> Y (in TSC2).
TSC2	717	717	L -> R (in TSC2).
TSC2	769	769	V -> E (in TSC2; could be a polymorphism).
TSC2	816	816	P -> L (in TSC2).
TSC2	826	826	L -> M (in TSC2).
TSC2	862	862	A -> V.
TSC2	895	895	M -> V (in TSC2).
TSC2	905	905	R -> Q (in TSC2).
TSC2	905	905	R -> W (in TSC2).
TSC2	963	963	V -> M (in TSC2; could be a polymorphism).
TSC2	1027	1027	L -> P (in TSC2).
TSC2	1084	1084	D -> E (in TSC2).
TSC2	1144	1144	V -> M (in TSC2).
TSC2	1200	1200	R -> W (in TSC2).
TSC2	1227	1227	P -> L (in TSC2).
TSC2	1240	1240	R -> W (in TSC2).
TSC2	1282	1282	S -> G.
TSC2	1295	1295	D -> V (in TSC2).
TSC2	1315	1315	P -> S (in TSC2).
TSC2	1329	1329	R -> H (in TSC2).
TSC2	1341	1341	S -> R.
TSC2	1429	1429	A -> S.
TSC2	1450	1450	P -> R.
TSC2	1497	1497	P -> R (in TSC2).
TSC2	1498	1498	S -> N (in TSC2).
TSC2	1509	1509	Missing (in TSC2; could be a rare polymorphism).
TSC2	1549	1549	Y -> C (in TSC2).
TSC2	1594	1594	L -> M (in TSC2; could be a polymorphism).
TSC2	1614	1614	Missing (in TSC2).
TSC2	1620	1620	H -> Y (in TSC2).
TSC2	1636	1636	D -> N.
TSC2	1643	1643	N -> I (in TSC2).
TSC2	1643	1643	N -> K (in TSC2; Abolishes GAP activity).
TSC2	1650	1650	Y -> C (in TSC2).
TSC2	1651	1651	N -> S (in TSC2; greatly reduces the ability to enhance the RHEB GTPase activity).
TSC2	1653	1653	S -> F (in TSC2).
TSC2	1673	1673	V -> L.
TSC2	1675	1675	P -> L (in TSC2).
TSC2	1681	1681	N -> K (in TSC2; Abolishes GAP activity).
TSC2	1690	1690	D -> Y (in TSC2).
TSC2	1704	1704	S -> T (in TSC2).
TSC2	1709	1709	P -> L (in TSC2).
TSC2	1712	1712	A -> E (in TSC2).
TSC2	1743	1743	R -> P (in TSC2; Abolishes GAP activity).
TSC2	1743	1743	R -> Q (in TSC2).
TSC2	1744	1744	L -> P (in TSC2).
TSC2	1746	1751	Missing (in TSC2).
TSC2	1750	1750	L -> F (in TSC2).
TSC2	1773	1773	H -> P (in TSC2).
TSC2	1783	1783	E -> Q (in TSC2).
TSC2	1787	1787	G -> S.
TSC2	1791	1791	G -> S.
PKD1	13	13	L -> Q (in ADPKD1).
PKD1	36	36	P -> H.
PKD1	61	61	P -> L (in ADPKD1; uncertain pathogenicity).
PKD1	75	75	S -> F (in ADPKD1).
PKD1	87	87	L -> M.
PKD1	88	88	A -> V.
PKD1	97	97	D -> G (in ADPKD1).
PKD1	99	99	S -> I (in ADPKD1; uncertain pathogenicity).
PKD1	139	139	W -> C (in ADPKD1).
PKD1	164	164	Q -> R (in ADPKD1).
PKD1	210	210	C -> G (in ADPKD1).
PKD1	324	324	R -> L (in ADPKD1).
PKD1	381	381	G -> C (in ADPKD1).
PKD1	436	436	C -> R (in ADPKD1).
PKD1	442	442	A -> P (in ADPKD1).
PKD1	572	572	P -> S.
PKD1	594	594	F -> Y (in ADPKD1).
PKD1	690	690	V -> D (in ADPKD1).
PKD1	727	727	L -> P (in ADPKD1).
PKD1	727	727	L -> R (in ADPKD1).
PKD1	738	738	P -> R.
PKD1	845	845	L -> S (in ADPKD1).
PKD1	967	967	W -> R (in ADPKD1).
PKD1	987	987	Q -> H (in ADPKD1).
PKD1	1166	1166	G -> S (in ADPKD1).
PKD1	1168	1168	P -> S.
PKD1	1240	1240	Missing (in ADPKD1).
PKD1	1242	1242	T -> M (in ADPKD1; uncertain pathogenicity).
PKD1	1340	1340	R -> W (in ADPKD1).
PKD1	1399	1399	W -> R.
PKD1	1516	1516	A -> T.
PKD1	1649	1649	T -> M.
PKD1	1667	1667	T -> P (in ADPKD1).
PKD1	1684	1684	S -> L.
PKD1	1786	1786	P -> L (rare polymorphism).
PKD1	1811	1811	E -> K (in ADPKD1).
PKD1	1871	1871	A -> T.
PKD1	1926	1926	A -> V.
PKD1	1943	1943	V -> I.
PKD1	1952	1952	G -> D.
PKD1	1956	1956	V -> E (in ADPKD1).
PKD1	1992	1993	FT -> L (in ADPKD1).
PKD1	1995	1995	R -> H.
PKD1	2083	2083	T -> I (in ADPKD1).
PKD1	2092	2092	Y -> C (in ADPKD1).
PKD1	2185	2185	Y -> D (in ADPKD1).
PKD1	2200	2200	R -> C (in ADPKD1).
PKD1	2220	2224	Missing (in ADPKD1).
PKD1	2250	2250	T -> M (in ADPKD1; could be a rare polymorphism).
PKD1	2260	2260	Missing (in ADPKD1).
PKD1	2329	2329	R -> W (in ADPKD1; could be a rare polymorphism).
PKD1	2336	2336	Y -> D (in ADPKD1).
PKD1	2370	2370	C -> R (in ADPKD1).
PKD1	2373	2373	C -> Y (in ADPKD1).
PKD1	2379	2379	Y -> C.
PKD1	2391	2391	G -> D (in ADPKD1).
PKD1	2392	2392	R -> P (in ADPKD1).
PKD1	2408	2408	R -> C (in ADPKD1).
PKD1	2421	2421	Missing (in ADPKD1).
PKD1	2422	2422	T -> K (in ADPKD1).
PKD1	2423	2423	S -> F (in ADPKD1).
PKD1	2434	2434	R -> W (in ADPKD1).
PKD1	2443	2443	G -> GG (in ADPKD1).
PKD1	2471	2471	P -> L (in ADPKD1).
PKD1	2519	2519	Q -> L (in ADPKD1; could be a polymorphism).
PKD1	2546	2546	H -> Y (in ADPKD1).
PKD1	2569	2569	S -> C (in ADPKD1).
PKD1	2579	2579	Missing (in ADPKD1; could be a polymorphism).
PKD1	2604	2604	D -> N.
PKD1	2613	2613	Missing (in ADPKD1; could be a polymorphism).
PKD1	2646	2646	I -> T (in ADPKD1).
PKD1	2649	2649	T -> I (in ADPKD1; could be a polymorphism).
PKD1	2674	2674	P -> S.
PKD1	2696	2696	L -> R (in ADPKD1).
PKD1	2708	2708	T -> M.
PKD1	2734	2734	P -> T.
PKD1	2735	2735	Q -> L.
PKD1	2752	2752	A -> D (in ADPKD1).
PKD1	2761	2761	R -> P (associated with ADPKD1).
PKD1	2763	2763	L -> V (in ADPKD1).
PKD1	2765	2765	R -> C.
PKD1	2765	2765	R -> RILMR (in ADPKD1).
PKD1	2768	2768	V -> M (in ADPKD1; associated with S- 2858).
PKD1	2771	2771	E -> K (in ADPKD1).
PKD1	2782	2782	V -> M.
PKD1	2785	2785	G -> D (in ADPKD1).
PKD1	2791	2791	R -> Q (in ADPKD1).
PKD1	2802	2802	P -> L (in ADPKD1).
PKD1	2814	2814	G -> R (in ADPKD1; uncertain pathogenicity).
PKD1	2816	2816	L -> P (in ADPKD1).
PKD1	2826	2826	I -> T (in ADPKD1).
PKD1	2858	2858	G -> S (in ADPKD1; associated with M- 2768).
PKD1	2888	2888	R -> G.
PKD1	2889	2889	S -> R (in ADPKD1).
PKD1	2905	2905	V -> I.
PKD1	2921	2921	H -> P (in ADPKD1).
PKD1	2958	2958	S -> L.
PKD1	2966	2966	E -> D.
PKD1	2972	2972	D -> N.
PKD1	2977	2977	T -> N.
PKD1	2978	2978	Missing (in ADPKD1; could be a polymorphism).
PKD1	2985	2985	R -> G (in ADPKD1).
PKD1	2993	2993	L -> P (in ADPKD1).
PKD1	3008	3008	V -> L (in ADPKD1).
PKD1	3008	3008	V -> M.
PKD1	3012	3017	Missing (in ADPKD1).
PKD1	3016	3016	Q -> R (in ADPKD1).
PKD1	3027	3039	Missing (in ADPKD1).
PKD1	3039	3039	R -> C (in ADPKD1).
PKD1	3057	3057	V -> M.
PKD1	3066	3066	F -> L (in ADPKD1).
PKD1	3138	3138	V -> M (in ADPKD1; uncertain pathogenicity).
PKD1	3139	3139	G -> V.
PKD1	3154	3154	L -> P (in ADPKD1).
PKD1	3167	3167	I -> F (in ADPKD1).
PKD1	3188	3188	Missing (in ADPKD1).
PKD1	3193	3193	P -> L.
PKD1	3247	3247	R -> H (in ADPKD1).
PKD1	3285	3285	V -> I (in ADPKD1).
PKD1	3311	3311	H -> R.
PKD1	3355	3355	P -> L (in ADPKD1).
PKD1	3375	3375	V -> M (in ADPKD1).
PKD1	3382	3382	T -> M (in ADPKD1).
PKD1	3435	3435	R -> Q.
PKD1	3510	3510	T -> M (in ADPKD1).
PKD1	3511	3511	L -> V (in ADPKD1; could be a polymorphism).
PKD1	3512	3512	A -> V.
PKD1	3560	3560	G -> R (in ADPKD1).
PKD1	3562	3562	S -> N.
PKD1	3602	3602	G -> S (in ADPKD1).
PKD1	3603	3603	W -> R (in ADPKD1).
PKD1	3632	3632	E -> D (in ADPKD1).
PKD1	3649	3649	P -> L (in ADPKD1).
PKD1	3678	3678	M -> T (in ADPKD1).
PKD1	3682	3682	L -> P (in ADPKD1).
PKD1	3719	3719	R -> Q (in ADPKD1).
PKD1	3726	3726	W -> S (in ADPKD1; uncertain pathogenicity).
PKD1	3748	3752	Missing (in ADPKD1).
PKD1	3750	3750	R -> Q (in ADPKD1).
PKD1	3751	3751	Q -> R (in ADPKD1).
PKD1	3753	3753	R -> W (in ADPKD1).
PKD1	3815	3815	D -> N (in ADPKD1).
PKD1	3852	3852	L -> P (in ADPKD1).
PKD1	3954	3954	A -> P (in ADPKD1; uncertain pathogenicity).
PKD1	3996	3996	F -> FLLF (in ADPKD1).
PKD1	4032	4032	G -> D (in ADPKD1).
PKD1	4058	4058	V -> A.
PKD1	4059	4059	A -> V.
PKD1	4102	4102	G -> E.
PKD1	4106	4106	L -> P.
PKD1	4124	4124	P -> S.
PKD1	4132	4132	Missing (in ADPKD1).
PKD1	4136	4136	R -> G (in ADPKD1).
PKD1	4146	4146	V -> I.
PKD1	4154	4154	R -> C (in ADPKD1).
PKD1	4155	4155	F -> V (in ADPKD1).
PKD1	4190	4190	S -> F.
PKD1	4225	4225	Q -> P (in ADPKD1).
PKD1	4255	4255	P -> S (in ADPKD1).
PKD1	4276	4276	R -> W (in ADPKD1).
TBC1D24	147	147	D -> H (in FIME; signicantly impairs the interaction with ARF6; partially induces neurite overgrowth when overexpressed in primary cortical neurons).
TBC1D24	251	251	F -> L (in FIME; fails to induce neurite overgrowth when overexpressed in primary cortical neurons).
TBC1D24	515	515	A -> V (in FIME; does not affect the interaction with ARF6; fails to induce neurite overgrowth when overexpressed in primary cortical neurons).
AMDHD2	294	294	D -> N (in a colorectal cancer sample; somatic mutation).
PRSS41	286	286	S -> G.
IL32	152	152	D -> N.
MEFV	42	42	R -> W (in arFMF).
MEFV	108	108	S -> R (in arFMF).
MEFV	138	138	G -> A (association with renal amyloidosis).
MEFV	148	148	E -> V (in arFMF).
MEFV	163	163	E -> A (in arFMF).
MEFV	167	167	E -> D (in arFMF).
MEFV	177	177	T -> I (in arFMF).
MEFV	230	230	E -> K (in arFMF).
MEFV	267	267	T -> I (in arFMF).
MEFV	319	319	E -> K (in arFMF).
MEFV	474	474	E -> K (in arFMF).
MEFV	478	478	H -> Y (in adFMF; severe).
MEFV	479	479	F -> L (in arFMF).
MEFV	632	632	G -> S (in arFMF).
MEFV	640	640	I -> M (in arFMF).
MEFV	641	641	I -> F (in arFMF).
MEFV	646	646	P -> L (in arFMF).
MEFV	649	649	L -> P (in arFMF).
MEFV	653	653	R -> H (in arFMF).
MEFV	656	656	E -> A (in arFMF).
MEFV	661	661	D -> N (in arFMF).
MEFV	675	675	S -> N (in arFMF).
MEFV	678	678	G -> E (in arFMF).
MEFV	680	680	M -> L (in arFMF).
MEFV	681	681	T -> I (in arFMF).
MEFV	688	688	Y -> C (in arFMF).
MEFV	692	692	Missing (in arFMF).
MEFV	694	694	M -> L (in arFMF).
MEFV	694	694	M -> V (in arFMF and adFMF; very common mutation particularly in North African Jews; can be associated with amyloidosis development).
MEFV	694	694	Missing (in arFMF and adFMF).
MEFV	695	695	K -> M (in arFMF).
MEFV	695	695	K -> R (in arFMF; reduced penetrance among Ashkenazi Jews).
MEFV	702	702	S -> C (in one patient with familial Mediterranean fever).
MEFV	704	704	V -> I (in arFMF).
MEFV	705	705	P -> S (in arFMF).
MEFV	720	720	I -> M (in arFMF).
MEFV	743	743	F -> L (in arFMF).
MEFV	744	744	A -> S (in arFMF; uncertain pathological significance).
MEFV	758	758	P -> S (in arFMF).
MEFV	761	761	R -> H (in arFMF).
MEFV	780	780	P -> T (in arFMF).
ZNF75A	228	228	Q -> E (in a breast cancer sample; somatic mutation).
DNASE1	31	31	Q -> E (in allele DNASE1*4).
DNASE1	114	114	V -> M (in allele DNASE1*5).
DNASE1	207	207	R -> C (in allele DNASE1*6).
TMEM114	35	35	I -> T (unknown significance; could be a rare polymorphism).
TMEM114	147	147	A -> V.
TMEM114	206	206	F -> L (unknown significance; could be a rare polymorphism).
TNFRSF17	153	153	A -> T.
UMOD	77	77	C -> Y (in HNFJ1).
UMOD	93	97	VCPEG -> AASC (in MCKD2).
UMOD	126	126	C -> R (in HNFJ1).
UMOD	128	128	N -> S (in HNFJ1).
UMOD	148	148	C -> W (in MCKD2/HNFJ1; causes a delay in protein export to the plasma membrane due to a longer retention time in the ER).
UMOD	150	150	C -> S (in MCKD2/HNFJ1; causes a delay in protein export to the plasma membrane due to a longer retention time in the ER).
UMOD	223	223	C -> Y (in HNFJ1).
UMOD	225	225	T -> K (in MCKD2).
UMOD	248	248	C -> W (in MCKD2).
UMOD	255	255	C -> Y (in HNFJ1).
UMOD	300	300	C -> G (in HNFJ1).
UMOD	315	315	C -> R (in GCKDHI; causes a delay in protein export to the plasma membrane due to a longer retention time in the ER).
UMOD	317	317	C -> Y (in MCKD2/HNFJ1; causes a delay in protein export to the plasma membrane due to a longer retention time in the ER).
PDILT	106	106	E -> Q (in a colorectal cancer sample; somatic mutation).
UQCRC2	208	208	F -> Y (in a colorectal cancer sample; somatic mutation).
PLK1	12	12	R -> L (in a lung squamous cell carcinoma sample; somatic mutation).
AQP8	229	229	I -> M (in a breast cancer sample; somatic mutation).
CLN3	101	101	L -> P (in CLN3).
CLN3	170	170	L -> P (in CLN3).
CLN3	295	295	E -> K (in CLN3).
CLN3	330	330	V -> F (in CLN3).
CLN3	334	334	R -> C (in CLN3).
CLN3	334	334	R -> H (in CLN3).
SULT1A2	7	7	I -> T.
SULT1A1	37	37	R -> Q.
TUFM	336	336	R -> Q (in COXPD4).
ATP2A1	789	789	P -> L (in BRM; almost complete loss of Ca(2+) transport activity because of reduced Ca(2+) affinity).
ALDOA	129	129	D -> G (in GSD12; thermolabile).
ALDOA	207	207	E -> K (in GSD12; reduces thermal stability; 3-fold decrease in catalytic efficiency mostly due to reduced substrate affinity).
ALDOA	339	339	C -> Y (in GSD12).
ALDOA	347	347	G -> S (in GSD12; does not affect thermal stability; 4-fold decrease in catalytic efficiency due to reduced enzyme activity).
PHKG2	106	106	V -> E (in GSD9C).
PHKG2	157	157	E -> K (in GSD9C).
PHKG2	189	189	G -> E (in GSD9C).
PHKG2	215	215	D -> N (in GSD9C).
PHKG2	317	317	A -> T.
HSD3B7	19	19	G -> S (in CBAS1).
HSD3B7	147	147	E -> K (in CBAS1; loss of activity).
ZNF668	66	66	A -> T (in a breast cancer sample; somatic mutation).
ZNF668	286	286	G -> S (in a breast cancer sample; somatic mutation).
ZNF668	331	331	T -> R (in a breast cancer sample; somatic mutation).
ZNF668	556	556	R -> Q (in a breast cancer sample; somatic mutation).
ZNF646	1337	1337	N -> I (in a breast cancer sample; somatic mutation).
VKORC1	98	98	R -> W (in VKCFD2).
SLC5A2	654	654	N -> S (in GLYS1).
C16orf58	43	43	G -> E (in a breast cancer sample; somatic mutation).
ORC6	232	232	Y -> S (in MGORS3).
NOD2	157	157	W -> R (associated with Crohn disease).
NOD2	189	189	T -> M.
NOD2	235	235	R -> C (associated with Crohn disease).
NOD2	248	248	L -> R (associated with Crohn disease).
NOD2	291	291	D -> N (associated with Crohn disease).
NOD2	294	294	T -> S (associated with Crohn disease).
NOD2	301	301	A -> V (associated with Crohn disease).
NOD2	311	311	R -> W (associated with Crohn disease and ulcerative colitis).
NOD2	334	334	R -> Q (in BS).
NOD2	334	334	R -> W (in BS).
NOD2	348	348	L -> V (associated with Crohn disease).
NOD2	373	373	R -> C (associated with Crohn disease).
NOD2	382	382	D -> E (in EOS).
NOD2	383	383	E -> K (in BS).
NOD2	414	414	N -> S (associated with Crohn disease).
NOD2	431	431	S -> L (associated with Crohn disease).
NOD2	441	441	E -> K (associated with Crohn disease).
NOD2	469	469	L -> F (in BS).
NOD2	496	496	H -> L (in EOS).
NOD2	605	605	T -> N (in BS).
NOD2	612	612	A -> T (in EOS; associated with Crohn disease).
NOD2	612	612	A -> V (associated with Crohn disease).
NOD2	713	713	R -> C (associated with Crohn disease).
NOD2	755	755	A -> V (associated with Crohn disease and ulcerative colitis).
NOD2	758	758	A -> V (associated with Crohn disease).
NOD2	778	778	E -> K (associated with Crohn disease).
NOD2	793	793	V -> M (associated with Crohn disease).
NOD2	843	843	E -> K (associated with Crohn disease).
NOD2	853	853	N -> S (associated with Crohn disease).
NOD2	863	863	M -> V (associated with Crohn disease).
NOD2	885	885	A -> T (associated with ulcerative colitis).
NOD2	918	918	A -> D (associated with Crohn disease).
NOD2	924	924	G -> D (associated with Crohn disease).
CYLD	747	747	E -> G (in MFT1 and BRSS).
SALL1	150	150	S -> SS.
SALL1	150	150	Missing.
SALL1	164	164	Missing.
SALL1	1265	1265	G -> E.
RPGRIP1L	615	615	T -> P (in JBTS7; affects interaction with NPHP4).
RPGRIP1L	659	659	S -> P (in COACHS).
RPGRIP1L	677	677	T -> I (in a patient with cystic kidney dysplasia, retinitis pigmentosa and cerebellar ataxia without molar tooth sign; affects interaction with NPHP4).
RPGRIP1L	695	695	A -> P (in JBTS7; seems not to affect interaction with NPHP4).
RPGRIP1L	1183	1183	A -> G (in a patient with Meckel-Gruber like syndrome also carrying L-220 and V- 280 in TTC21B).
MMP2	101	101	R -> H (in TWS).
MMP2	210	210	D -> Y.
MMP2	228	228	A -> T (in a colorectal cancer sample; somatic mutation).
MMP2	400	400	Missing (in TWS).
MMP2	404	404	E -> K (in TWS).
MMP2	498	498	T -> M (in a colorectal cancer sample; somatic mutation).
MMP2	644	644	S -> I (in a colorectal cancer sample; somatic mutation).
CES1	18	18	G -> GA.
CES1	143	143	G -> E (5.4-fold decrease in activity with p-nitrophenyl acetate as substrate; no change in affinity for p-nitrophenyl acetate; loss of activity with L- or D- methylphenidate as substrate).
CES1	362	362	Missing.
AMFR	605	605	D -> V (in a breast cancer sample; somatic mutation).
BBS2	23	23	R -> P (in BBS2).
BBS2	75	75	V -> G (in BBS2; in linkage disequilibrium with V-123 in a Bedouin kindred).
BBS2	104	104	D -> A (in BBS2).
BBS2	174	174	D -> E (in BBS2).
BBS2	315	315	R -> Q (in BBS2).
BBS2	315	315	R -> W (in BBS2).
BBS2	349	349	L -> W (in BBS2; has a modifier effect on BBS).
BBS2	558	558	T -> I (in BBS2).
BBS2	632	632	R -> P (in BBS2).
BBS2	643	643	R -> H (in BBS2).
SLC12A3	60	60	T -> M (in GS).
SLC12A3	62	62	D -> N (in GS).
SLC12A3	68	68	E -> K (in GS).
SLC12A3	69	69	H -> N (in GS).
SLC12A3	90	90	H -> Y (in GS).
SLC12A3	145	145	R -> H (in GS).
SLC12A3	153	153	V -> M (in GS).
SLC12A3	154	154	I -> F (in GS).
SLC12A3	158	158	R -> Q (in GS).
SLC12A3	163	163	T -> M (in GS).
SLC12A3	172	172	W -> R (in GS).
SLC12A3	178	178	S -> L (in GS).
SLC12A3	180	180	T -> K (in GS).
SLC12A3	186	186	G -> D (in GS).
SLC12A3	215	215	L -> P (in GS).
SLC12A3	226	226	A -> T (in GS).
SLC12A3	230	230	G -> D (in GS).
SLC12A3	261	261	R -> H (in GS).
SLC12A3	283	283	S -> Y (in GS).
SLC12A3	284	284	K -> R (in GS).
SLC12A3	304	304	T -> P (in GS).
SLC12A3	313	313	A -> V (in GS).
SLC12A3	316	316	G -> V (in GS).
SLC12A3	321	321	R -> W (in GS).
SLC12A3	334	334	R -> W (in GS).
SLC12A3	342	342	G -> A (in GS).
SLC12A3	349	349	P -> L (in GS).
SLC12A3	374	374	G -> V (in GS).
SLC12A3	399	399	R -> C (in GS).
SLC12A3	439	439	G -> S (in GS).
SLC12A3	463	463	G -> E (in GS).
SLC12A3	464	464	A -> T (in GS).
SLC12A3	478	478	K -> E (in GS).
SLC12A3	486	486	D -> N (in GS).
SLC12A3	496	496	G -> C (in GS).
SLC12A3	542	542	L -> P (in GS).
SLC12A3	555	555	S -> L (in GS).
SLC12A3	560	560	P -> H (in GS).
SLC12A3	561	561	Missing (in GS).
SLC12A3	569	569	A -> E (in GS).
SLC12A3	569	569	A -> V (in GS).
SLC12A3	578	578	V -> M (in GS).
SLC12A3	588	588	A -> V (in GS).
SLC12A3	613	613	G -> S (in GS).
SLC12A3	615	615	S -> L (in GS).
SLC12A3	615	615	S -> W (in GS).
SLC12A3	623	623	L -> P (in GS).
SLC12A3	642	642	R -> C (in GS).
SLC12A3	642	642	R -> G (in GS).
SLC12A3	642	642	R -> H (in GS).
SLC12A3	643	643	P -> L (in GS).
SLC12A3	649	649	T -> R (in GS).
SLC12A3	655	655	R -> C (in GS).
SLC12A3	655	655	R -> H (in GS).
SLC12A3	655	655	R -> L (in GS).
SLC12A3	672	672	M -> I (in GS).
SLC12A3	677	677	V -> L (in GS).
SLC12A3	677	677	V -> M (in GS).
SLC12A3	729	729	G -> V (in GS).
SLC12A3	731	731	G -> R (in GS).
SLC12A3	738	738	L -> R (in GS).
SLC12A3	741	741	G -> R (in GS).
SLC12A3	849	849	L -> H (in GS).
SLC12A3	850	850	L -> P (in GS).
SLC12A3	852	852	R -> C (in GS).
SLC12A3	852	852	R -> H (in GS).
SLC12A3	852	852	R -> S (in GS).
SLC12A3	867	867	G -> S (in GS).
SLC12A3	871	871	R -> H (in GS).
SLC12A3	955	955	R -> Q (in GS).
SLC12A3	958	958	R -> G (in GS).
SLC12A3	985	985	C -> Y (in GS).
NLRC5	361	361	M -> I (in a breast cancer sample; somatic mutation).
TK2	53	53	I -> M (in MTDPS2).
TK2	64	64	T -> M (in MTDPS2).
TK2	108	108	T -> M (in MTDPS2; reduction of activity).
TK2	121	121	H -> N (in MTDPS2).
TK2	183	183	R -> W (in MTDPS2).
TK2	192	192	R -> K (in MTDPS2; reduction of activity).
TK2	212	212	I -> N (in MTDPS2).
CES3	129	129	V -> I.
CES3	151	151	A -> T.
CES3	160	160	Y -> H.
CES3	191	191	E -> K.
CES3	213	213	I -> N.
CES3	367	367	R -> W.
CES3	523	523	A -> V.
CES3	555	555	I -> V.
HSF4	19	19	A -> D (in CZ-HSF4; sporadic).
HSF4	73	73	R -> H (in CZ-HSF4).
HSF4	86	86	I -> V (in CZ-HSF4; sporadic).
HSF4	114	114	L -> P (in CZ-HSF4).
EXOC3L1	75	75	Y -> N (in a breast cancer sample; somatic mutation).
EXOC3L1	514	514	A -> D (in a breast cancer sample; somatic mutation).
E2F4	319	319	S -> SSSS.
HSD11B2	114	115	Missing (in AME; reduces enzyme activity by at least 95%).
HSD11B2	179	179	L -> R (in AME; abolishes enzyme activity).
HSD11B2	180	180	S -> F (in AME; reduces enzyme activity).
HSD11B2	186	186	R -> C (in AME).
HSD11B2	208	208	R -> C (in AME; reduces enzyme activity by at least 95%).
HSD11B2	208	208	R -> H (in AME; abolishes enzyme activity).
HSD11B2	213	213	R -> C (in AME; reduces enzyme activity by ca. 90%).
HSD11B2	227	227	P -> L (in hypertension; decreases affinity for cortisol).
HSD11B2	237	237	A -> V (in AME; reduces enzyme activity).
HSD11B2	244	244	D -> N (in AME; associated with R-250).
HSD11B2	250	251	LL -> PS (in AME; abolishes enzyme activity).
HSD11B2	250	250	L -> R (in AME; associated with N-244).
HSD11B2	279	279	R -> C (in AME; decreases enzyme activity by ca. 33%).
HSD11B2	328	328	A -> V (in AME; abolishes enzyme activity).
HSD11B2	337	338	RY -> H (in AME; abolishes enzyme activity).
HSD11B2	337	337	R -> C (in AME).
LCAT	17	17	L -> LLLPPAAPFWL (in LCATD).
LCAT	29	29	N -> I (in LCATD).
LCAT	34	34	P -> L (in FED).
LCAT	34	34	P -> Q (in FED).
LCAT	37	37	T -> M (in LCATD).
LCAT	54	54	G -> S (in LCATD).
LCAT	57	57	G -> R (in LCATD).
LCAT	70	70	V -> E (in FED).
LCAT	95	95	G -> R (in a compound heterozygote carrying H-164; intermediate phenotype between LCATD and FED; reduction of activity).
LCAT	115	115	S -> P.
LCAT	123	123	R -> C (in FED).
LCAT	147	147	T -> I (in FED).
LCAT	159	159	R -> Q (in FED).
LCAT	164	164	R -> C (in LCATD).
LCAT	164	164	R -> H (in LCATD; also in a compound heterozygote carrying R-95 with intermediate phenotype between LCATD and FED; loss of activity).
LCAT	165	165	A -> T.
LCAT	171	171	R -> W (in LCATD).
LCAT	180	180	Y -> N (in LCATD).
LCAT	182	182	R -> C.
LCAT	205	205	S -> N (in LCATD).
LCAT	242	242	K -> N (in LCATD).
LCAT	252	252	N -> K (in LCATD).
LCAT	268	268	R -> H (in LCATD).
LCAT	276	276	M -> K (in FED).
LCAT	298	298	T -> A (in FED and LCATD).
LCAT	298	298	T -> I (in LCATD).
LCAT	317	317	M -> I (in LCATD; partially defective enzyme).
LCAT	331	331	P -> S (in LCATD).
LCAT	333	333	V -> M (in LCATD).
LCAT	371	371	T -> M (in FED).
LCAT	396	396	L -> R (in a patient with LCATD).
LCAT	406	406	F -> V (in LCATD).
CIRH1A	565	565	R -> W (in NAIC).
NIP7	171	171	E -> Q (in a breast cancer sample; somatic mutation).
AARS	329	329	R -> H (in CMT2N).
DHODH	19	19	G -> E (in POADS).
DHODH	135	135	R -> C (in POADS).
DHODH	152	152	G -> R (in POADS).
DHODH	199	199	R -> C (in POADS).
DHODH	202	202	G -> A (in POADS).
DHODH	202	202	G -> D (in POADS).
DHODH	244	244	R -> W (in POADS).
DHODH	284	284	T -> I (in POADS).
DHODH	346	346	R -> W (in POADS).
DHODH	392	392	D -> G (in POADS).
DHX38	1217	1217	T -> A.
FA2H	35	35	D -> Y (in SPG35; patients present spastic paraparesis associated with leukodystrophy and dystonia).
FA2H	53	58	Missing (in SPG35; significantly reduced enzymatic function).
FA2H	154	154	R -> C (in SPG35).
FA2H	235	235	R -> C (in SPG35; significantly reduced enzymatic function).
BCAR1	407	407	S -> T (in a breast cancer sample; somatic mutation).
CHST6	15	15	L -> P (in MCD).
CHST6	22	22	L -> R (in MCD).
CHST6	31	31	P -> S (in MCD).
CHST6	42	42	H -> Y (in MCD).
CHST6	51	51	S -> L (in MCD).
CHST6	52	52	G -> D (in MCD).
CHST6	53	53	S -> L (in MCD).
CHST6	59	59	L -> P (in MCD).
CHST6	61	61	N -> T (in MCD).
CHST6	66	66	V -> L (in MCD).
CHST6	68	68	Y -> H (in MCD).
CHST6	70	70	M -> L (in MCD).
CHST6	72	72	P -> S (in MCD).
CHST6	76	76	V -> M (in MCD).
CHST6	93	93	R -> H (in MCD).
CHST6	97	97	R -> P (in MCD).
CHST6	98	98	S -> W (in MCD).
CHST6	102	102	C -> G (in MCD).
CHST6	102	102	C -> Y (in MCD).
CHST6	104	104	M -> V (in MCD).
CHST6	107	107	F -> S (in MCD).
CHST6	110	110	Y -> C (in MCD).
CHST6	121	121	F -> L (in MCD).
CHST6	122	122	Q -> P (in MCD).
CHST6	127	127	R -> C (in MCD).
CHST6	128	128	A -> V (in MCD).
CHST6	131	131	S -> P (in MCD).
CHST6	152	152	L -> P (in MCD).
CHST6	162	162	R -> G (in MCD).
CHST6	166	166	R -> P (in MCD).
CHST6	177	177	R -> H (in MCD).
CHST6	198	198	V -> E (in MCD).
CHST6	202	202	R -> S (in MCD).
CHST6	204	204	P -> Q (in MCD).
CHST6	205	205	R -> L (in MCD).
CHST6	205	205	R -> Q (in MCD).
CHST6	206	206	A -> T (in MCD).
CHST6	206	206	A -> V (in MCD).
CHST6	210	210	S -> F (in MCD).
CHST6	211	211	R -> Q (in MCD).
CHST6	211	211	R -> W (in MCD; abolishes ability to sulfate keratan).
CHST6	217	217	A -> T (in MCD; abolishes ability to sulfate keratan).
CHST6	221	221	D -> E (in MCD).
CHST6	221	221	D -> Y (in MCD).
CHST6	249	249	H -> P (in MCD).
CHST6	268	268	Y -> C (in MCD).
CHST6	274	274	E -> K (in MCD; abolishes ability to sulfate keratan).
CHST6	276	276	L -> P (in MCD).
CHST6	358	358	Y -> D (in MCD).
TMEM231	6	6	L -> V.
KARS	105	105	L -> H (in CMTRIB; severely affects enzyme activity).
KARS	274	274	I -> M (in CMTRIB).
MAF	288	288	R -> P (in CAPJOM).
MAF	297	297	K -> R (in CCA4).
BCMO1	170	170	T -> M (in ADHVAD; has about 90% decreased enzyme activity compared to wild-type; no evidence for a dominant- negative effect; consistent with a loss- of-function mutation resulting in haploinsufficiency).
DNAAF1	42	117	Missing (in CILD13).
DNAAF1	175	175	L -> R (in CILD13).
ZDHHC7	44	44	D -> N (in a colorectal cancer sample; somatic mutation).
KIAA0182	627	627	R -> W (in a colorectal cancer sample; somatic mutation).
COX4I1	38	38	Y -> F.
IRF8	81	81	R -> K (in a breast cancer sample; somatic mutation).
IRF8	197	197	A -> T (in a breast cancer sample; somatic mutation).
FOXC2	125	125	S -> L (in LYD).
FOXC2	191	191	S -> F.
ZCCHC14	290	290	L -> V (in a breast cancer sample; somatic mutation).
CYBA	25	25	G -> V (in ARCGD).
CYBA	52	52	L -> P (in ARCGD).
CYBA	53	53	E -> V (in ARCGD).
CYBA	90	90	R -> Q (in ARCGD).
CYBA	90	90	R -> W (in ARCGD).
CYBA	94	94	H -> R (in ARCGD).
CYBA	118	118	S -> R (in ARCGD).
CYBA	124	124	A -> V (in ARCGD).
CYBA	125	125	A -> T (in ARCGD).
CYBA	156	156	P -> Q (in ARCGD).
CYBA	193	193	E -> D.
CDT1	66	66	A -> T (in MGORS4).
CDT1	117	117	Q -> H (in MGORS4).
CDT1	453	453	R -> W (in MGORS4).
CDT1	462	462	R -> Q (in MGORS4).
CDT1	468	468	E -> K (in MGORS4).
APRT	65	65	D -> V (in APRTD; Icelandic type).
APRT	110	110	L -> P (in APRTD; Newfoundland type).
APRT	150	150	V -> F (in APRTD).
APRT	153	153	C -> R (in APRTD).
APRT	173	173	Missing (in APRTD).
GALNS	15	15	L -> M (in MPS4A).
GALNS	17	18	Missing (in MPS4A).
GALNS	23	23	G -> R (in MPS4A).
GALNS	36	36	L -> P (in MPS4A).
GALNS	41	41	M -> L (in MPS4A).
GALNS	42	42	G -> E (in MPS4A).
GALNS	47	47	G -> R (in MPS4A; severe form).
GALNS	52	55	Missing (in MPS4A).
GALNS	53	53	S -> F (in MPS4A).
GALNS	60	60	D -> N (in MPS4A; mild form).
GALNS	61	61	R -> W (in MPS4A).
GALNS	69	69	F -> V (in MPS4A).
GALNS	71	74	NFYS -> T (in MPS4A).
GALNS	77	77	P -> R (in MPS4A; severe form).
GALNS	79	79	C -> Y (in MPS4A).
GALNS	80	80	S -> L (in MPS4A; intermediate form).
GALNS	90	90	R -> W (in MPS4A; severe form).
GALNS	94	94	R -> C (in MPS4A; mild/intermediate form).
GALNS	94	94	R -> G (in MPS4A; mild/intermediate form).
GALNS	94	94	R -> L (in MPS4A).
GALNS	96	96	G -> C (in MPS4A).
GALNS	96	96	G -> V (in MPS4A; severe form).
GALNS	97	97	F -> V (in MPS4A; mild form).
GALNS	107	107	A -> T (in MPS4A).
GALNS	111	111	Q -> R (in MPS4A; intermediate form).
GALNS	113	113	I -> F (in MPS4A; severe form; common mutation; found in patients with Irish- British ancestry).
GALNS	116	116	G -> S (in MPS4A).
GALNS	125	125	P -> L (in MPS4A; severe form).
GALNS	135	135	S -> R (in MPS4A; severe form).
GALNS	138	138	V -> A (in MPS4A; mild/severe/ intermediate form).
GALNS	139	139	G -> S (in MPS4A; severe form).
GALNS	141	141	W -> C (in MPS4A).
GALNS	141	141	W -> R (in MPS4A; severe form).
GALNS	150	150	H -> Y (in MPS4A).
GALNS	151	151	P -> L (in MPS4A; severe form).
GALNS	151	151	P -> S (in MPS4A; severe form).
GALNS	155	155	G -> E (in MPS4A).
GALNS	155	155	G -> R (in MPS4A; severe form).
GALNS	156	156	F -> C (in MPS4A; severe form).
GALNS	156	156	F -> S (in MPS4A; mild form).
GALNS	162	162	S -> F (in MPS4A).
GALNS	164	164	N -> T (in MPS4A).
GALNS	166	166	H -> Q (in MPS4A; severe form).
GALNS	167	167	F -> V (in MPS4A).
GALNS	168	168	G -> R (in MPS4A).
GALNS	171	171	D -> A (in MPS4A).
GALNS	178	178	I -> V.
GALNS	179	179	P -> H (in MPS4A; severe form).
GALNS	179	179	P -> L (in MPS4A; severe form).
GALNS	179	179	P -> S (in MPS4A).
GALNS	185	185	E -> G (in MPS4A; severe form).
GALNS	203	203	A -> V (in MPS4A).
GALNS	204	204	N -> K (in MPS4A; mild form).
GALNS	230	230	W -> G (in MPS4A; severe form).
GALNS	233	233	D -> N (in MPS4A).
GALNS	239	239	V -> F (in MPS4A).
GALNS	247	247	G -> D (in MPS4A).
GALNS	253	253	R -> W (in MPS4A).
GALNS	257	257	A -> T (in MPS4A; severe form).
GALNS	259	259	R -> Q (in MPS4A; mild form).
GALNS	260	260	E -> D (in MPS4A).
GALNS	279	287	Missing (in MPS4A; mild form).
GALNS	284	284	F -> V (in MPS4A; severe form).
GALNS	285	285	Missing (in MPS4A).
GALNS	287	287	S -> L (in MPS4A; severe form).
GALNS	290	290	G -> S (in MPS4A; severe form).
GALNS	291	291	A -> D (in MPS4A; mild form).
GALNS	291	291	A -> T (in MPS4A; severe form).
GALNS	295	295	S -> F (in MPS4A; mild form).
GALNS	301	301	G -> C (in MPS4A; severe form).
GALNS	307	307	L -> P (in MPS4A).
GALNS	309	309	G -> R (in MPS4A; severe form).
GALNS	310	310	K -> N (in MPS4A).
GALNS	312	312	T -> S (in MPS4A; mild/intermediate/ severe form).
GALNS	318	318	M -> R (in MPS4A; severe form).
GALNS	325	325	W -> C (in MPS4A).
GALNS	325	325	Missing (in MPS4A).
GALNS	340	340	G -> D (in MPS4A).
GALNS	341	341	S -> R (in MPS4A).
GALNS	343	343	M -> R (in MPS4A; severe form).
GALNS	344	344	D -> E (in MPS4A).
GALNS	344	344	D -> N (in MPS4A; severe form).
GALNS	345	345	L -> P (in MPS4A).
GALNS	346	346	F -> L (in MPS4A; severe form).
GALNS	351	351	A -> V (in MPS4A; severe form).
GALNS	352	352	L -> P (in MPS4A).
GALNS	357	357	P -> L (in MPS4A).
GALNS	361	361	R -> G (in MPS4A).
GALNS	369	369	L -> P (in MPS4A).
GALNS	376	376	R -> Q (in MPS4A; severe form).
GALNS	380	380	R -> S (in MPS4A).
GALNS	380	380	R -> T (in MPS4A).
GALNS	386	386	R -> C (in MPS4A; severe form).
GALNS	386	386	R -> H (in MPS4A).
GALNS	388	388	D -> N (in MPS4A).
GALNS	391	391	M -> V (in MPS4A; severe form).
GALNS	392	392	A -> V (in MPS4A).
GALNS	395	395	L -> P (in MPS4A).
GALNS	395	395	L -> V (in MPS4A; severe form).
GALNS	398	398	H -> D (in MPS4A).
GALNS	401	401	H -> Y (in MPS4A).
GALNS	403	404	Missing (in MPS4A).
GALNS	407	407	N -> H (in MPS4A).
GALNS	409	409	W -> S (in MPS4A; associated with M-67 in a patient).
GALNS	450	450	E -> V (in MPS4A; severe form).
GALNS	452	452	F -> I (in MPS4A).
GALNS	459	459	A -> V.
GALNS	470	470	S -> P (in MPS4A).
GALNS	484	484	P -> S (in MPS4A).
GALNS	487	487	N -> S (in MPS4A).
GALNS	488	488	V -> M.
GALNS	494	494	M -> V (in MPS4A; severe form).
GALNS	510	510	P -> T (in a colorectal cancer sample; somatic mutation).
SPG7	2	2	A -> T.
SPG7	82	82	Missing (might be implicated in the hereditary spastic paraplegia phenotype).
SPG7	284	284	F -> P (requires 2 nucleotide substitutions; might be implicated in the hereditary spastic paraplegia phenotype).
SPG7	294	294	R -> H.
SPG7	349	349	G -> S (in SPG7; function impaired).
SPG7	486	486	R -> Q.
SPG7	510	510	A -> V (in SPG7; function impaired).
SPG7	545	545	F -> L.
SPG7	581	581	Missing (in SPG7).
SPG7	583	583	W -> C (in SPG7; function impaired).
SPG7	603	603	A -> T.
SPG7	635	635	S -> L (might be implicated in the hereditary spastic paraplegia phenotype).
SPG7	650	650	D -> H (might be implicated in the hereditary spastic paraplegia phenotype).
SPG7	692	692	S -> T (in SPG7).
DPEP1	246	246	R -> H (in a colorectal cancer sample; somatic mutation).
CDK10	96	96	P -> L.
ZNF276	275	275	R -> W (may increase breast cancer risk).
FANCA	8	8	N -> K (in FA; could be a polymorphism).
FANCA	210	210	L -> R (in FA).
FANCA	244	244	L -> F (in FA).
FANCA	435	435	R -> C (in FA).
FANCA	492	492	H -> R (in FA).
FANCA	598	598	D -> N (in FA).
FANCA	660	660	L -> P (in FA).
FANCA	761	761	V -> E.
FANCA	817	817	L -> P (in FA).
FANCA	843	843	Y -> D (in FA).
FANCA	845	845	L -> P (in FA).
FANCA	869	869	Q -> P (in FA).
FANCA	951	951	R -> Q.
FANCA	951	951	R -> W.
FANCA	1055	1055	R -> L (in FA).
FANCA	1055	1055	R -> W (in FA).
FANCA	1082	1082	L -> P (in FA).
FANCA	1110	1110	H -> P (in FA; loss of function).
FANCA	1117	1117	R -> G (in FA; loss of function).
FANCA	1128	1128	Q -> E (in FA).
FANCA	1131	1131	T -> A (in FA).
FANCA	1249	1249	L -> P (in FA; possibly hypomorphic allele).
FANCA	1262	1262	F -> L (in FA).
FANCA	1263	1263	Missing (in FA).
FANCA	1302	1302	W -> R (in FA).
FANCA	1324	1324	P -> L (in FA).
FANCA	1359	1359	D -> Y (in FA).
FANCA	1360	1360	M -> I (in FA).
FANCA	1400	1400	R -> H (in FA; possibly hypomorphic allele).
TUBB3	62	62	R -> Q (in CFEOM3A; affects heterodimers formation; results in increased stability and reduced dynamics of microtubules).
TUBB3	262	262	R -> C (in CFEOM3A; affects heterodimers formation; affects microtubules polymerization and depolymerization rates).
TUBB3	262	262	R -> H (in CFEOM3A; severe phenotype with congenital facial weakness, congenital wrist and finger contractures; affects microtubules polymerization and depolymerization rates).
TUBB3	302	302	A -> T (in CFEOM3A; affects heterodimers formation; results in increased stability and reduced dynamics of microtubules).
TUBB3	380	380	R -> C (in CFEOM3A; affects heterodimers formation; results in increased stability and reduced dynamics of microtubules).
TUBB3	410	410	E -> K (in CFEOM3A; severe phenotype with congenital facial weakness; lower extremity weakness and sensory loss in the second to third decade of life in one patient; affects microtubules polymerization and depolymerization rates).
TUBB3	417	417	D -> H (in CFEOM3A; severe phenotype with congenital facial weakness, congenital wrist and finger contractures).
TUBB3	417	417	D -> N (in CFEOM3A; some patients with lower extremity weakness and sensory loss in the second to third decade of life; also found in patients without CFEOM3A who developed polyneuropathy).
MED25	335	335	A -> V (in CMT2B2).
PTPRS	996	996	T -> M (in a colorectal cancer sample; somatic mutation).
TYK2	732	732	H -> R (in a colorectal adenocarcinoma sample; somatic mutation).
ZNF43	244	244	R -> C (in a colorectal cancer sample; somatic mutation).
EML2	484	484	V -> L (in a colorectal cancer sample; somatic mutation).
PRKD2	848	848	G -> E (in a lung adenocarcinoma sample; somatic mutation).
PRKD2	870	870	G -> E (in a gastric adenocarcinoma sample; somatic mutation).
KISS1R	102	102	L -> P (in IHH; absence of inositol phosphate accumulation under kisspeptin challenge; normal affinity for kisspeptin).
KISS1R	223	223	C -> R (in IHH; exhibit profoundly impaired signaling).
KISS1R	297	297	R -> L (in IHH; mild reduction in ligand- stimulated activity across the ligand dose range).
KISS1R	386	386	R -> P (in central precocious puberty; reduced rate of decline in inositol phosphate accumulation after kisspeptin stimulation; prolonged phosphorylation of ERK).
CSNK1G2	189	189	F -> L.
CSNK1G2	194	194	E -> G.
CSNK1G2	196	196	I -> T.
CSNK1G2	206	206	Y -> C.
CSNK1G2	206	206	Y -> H.
CSNK1G2	207	207	R -> S.
CSNK1G2	208	208	E -> Q.
CSNK1G2	217	217	R -> C.
CSNK1G2	223	223	T -> M.
PIP5K1C	253	253	D -> N (in LCCS3; loss of activity).
MATK	354	354	A -> T (in an ovarian mucinous carcinoma sample; somatic mutation).
MATK	503	503	R -> Q (in a colorectal adenocarcinoma sample; somatic mutation).
RFX2	37	37	A -> G (in a breast cancer sample; somatic mutation).
RFX2	110	110	E -> K (in a breast cancer sample; somatic mutation).
C3	549	549	D -> N (in C3D; impairs secretion).
C3	592	592	R -> Q (in AHUS5; leads to impaired binding to the regulator CD46/MCP and resistance to cleavage by factor I).
C3	592	592	R -> W (in AHUS5; leads to impaired binding to the regulator CD46/MCP and resistance to cleavage by factor I).
C3	603	603	F -> V (in AHUS5).
C3	735	735	R -> W (in AHUS5).
C3	1042	1042	R -> L (in AHUS5).
C3	1094	1094	A -> V (in AHUS5; leads to impaired binding to the regulator CD46/MCP and resistance to cleavage by factor I).
C3	1115	1115	D -> N (in AHUS5; leads to impaired binding to the regulator CD46/MCP and resistance to cleavage by factor I).
C3	1158	1158	C -> W (in AHUS5).
C3	1161	1161	Q -> K (in AHUS5; leads to impaired binding to the regulator CD46/MCP and resistance to cleavage by factor I).
C3	1216	1216	D -> N (in C3S).
C3	1320	1320	R -> Q (in C3D; allotype C3'F02'; may inhibit IC3B synthesis).
C3	1464	1464	H -> D (in AHUS5).
INSR	42	42	N -> K (in RMS; impairs transport to the plasma membrane and reduces the affinity to bind insulin).
INSR	55	55	V -> A (in LEPRCH; Verona-1).
INSR	86	86	D -> G (in IRAN type A).
INSR	89	89	L -> P (in IRAN type A).
INSR	113	113	R -> P (in LEPRCH; Atlanta-1; abolishes insulin binding).
INSR	119	119	A -> V (in LEPRCH; markedly impairs insulin binding).
INSR	120	120	L -> Q (in LEPRCH; inhibits receptor processing).
INSR	146	146	I -> M (in LEPRCH; mild).
INSR	167	167	V -> L (in IRAN type A).
INSR	220	220	P -> L (in Ins resistance; severe).
INSR	228	228	C -> R (in a gastric adenocarcinoma sample; somatic mutation).
INSR	236	236	H -> R (in LEPRCH; Winnipeg; in one patient with in RMS heterozygous compound with S-386; may impair receptor processing).
INSR	260	260	L -> P (in LEPRCH; Geldeimalsen).
INSR	279	279	R -> C (in IRAN type A; inhibits receptor internalization).
INSR	279	279	R -> H (in IRAN type A; interferes with receptor processing).
INSR	280	280	C -> Y (in IRAN type A).
INSR	301	301	C -> Y (in LEPRCH).
INSR	308	308	Missing (in LEPRCH; abolishes insulin binding).
INSR	350	350	S -> L (in RMS and LEPRCH).
INSR	362	362	Missing (in LEPRCH).
INSR	386	386	G -> S (in RMS; may impair receptor processing).
INSR	393	393	G -> R (in LEPRCH; Verona-1).
INSR	409	409	F -> V (in IRAN type A).
INSR	439	439	W -> S (in LEPRCH; impairs transport of the receptor to the cell surface).
INSR	458	458	N -> D (in LEPRCH; partially inhibits receptor processing and autophosphorylation; strongly impairs ERK phosphorylation; induces wild-type levels of IRS-1 phosphorylation).
INSR	762	762	R -> S (in IRAN type A).
INSR	858	858	T -> A (in NIDDM).
INSR	925	925	I -> T (in LEPRCH; abolishes insulin binding).
INSR	926	926	R -> W (in LEPRCH; markedly impairs insulin binding).
INSR	937	937	T -> M (in LEPRCH; impaired receptor processing).
INSR	997	997	P -> T (in RMS; reduces insulin binding).
INSR	1020	1020	R -> Q (in IRAN type A).
INSR	1023	1023	I -> F.
INSR	1035	1035	G -> V (in IRAN type A).
INSR	1055	1055	A -> V (in IRAN type A).
INSR	1075	1075	A -> D (in IRAN type A).
INSR	1095	1095	K -> E (in a NIDDM subject).
INSR	1119	1119	R -> W (in LEPRCH).
INSR	1143	1143	I -> T (in RMS; reduces insulin binding).
INSR	1158	1158	R -> Q (in NIDDM).
INSR	1158	1158	R -> W (in RMS; abolishes insulin binding).
INSR	1162	1162	A -> E (in IRAN type A; impairs proteolytic processing).
INSR	1180	1180	M -> I (in a patient with insulin resistance).
INSR	1191	1191	R -> Q (in NIDDM).
INSR	1201	1201	R -> W (in LEPRCH and RMS; reduces insulin binding possibly due to reduced receptor levels on the cell surface).
INSR	1205	1205	P -> L (in IRAN type A; moderate).
INSR	1206	1206	E -> D (in IRAN type A; accelerates degradation of the protein and impairs kinase activity).
INSR	1206	1206	E -> K (in LEPRCH).
INSR	1227	1227	W -> S (in IRAN type A).
PNPLA6	929	929	R -> H (in SPG39).
PNPLA6	1051	1051	M -> V (in SPG39).
ADAMTS10	25	25	A -> T (in ARWMS; shows consistent and significantly diminished protein secretion).
DNM2	368	368	E -> K (in ADCNM).
DNM2	369	369	R -> Q (in ADCNM).
DNM2	369	369	R -> W (in ADCNM; reduced association with the centrosome).
DNM2	465	465	R -> W (in ADCNM; reduced association with the centrosome; COS7 cells show a reduced uptake of transferrin and low- density lipoprotein complex).
DNM2	537	537	G -> C (in CMTIB).
DNM2	555	557	Missing (in CMTDIB; may affect binding to vesicles and membranes in favor of binding to microtubules; may affect receptor-mediated endocytosis).
DNM2	562	562	K -> E (in CMTDIB; with neutropenia; COS7 cells show a reduced uptake of transferrin and low-density lipoprotein complex).
DNM2	570	570	L -> H (in CMTIB).
DNM2	618	618	A -> T (in ADCNM; severe).
DNM2	619	619	S -> L (in ADCNM; severe).
DNM2	619	619	S -> W (in ADCNM; severe).
DNM2	625	625	Missing (in ADCNM; severe; COS7 cells show a reduced uptake of transferrin and low-density lipoprotein complex).
DNM2	650	650	E -> K (in ADCNM; COS7 cells show a reduced uptake of transferrin and low- density lipoprotein complex).
MAST1	269	269	A -> T (in a metastatic melanoma sample; somatic mutation).
MAST1	1240	1240	H -> Y (in an ovarian serous carcinoma sample; somatic mutation).
PKN1	185	185	R -> C (in a metastatic melanoma sample; somatic mutation).
PKN1	197	197	A -> E.
PKN1	873	873	F -> L (in a breast infiltrating ductal carcinoma sample; somatic mutation).
PKN1	921	921	A -> V (in a colorectal adenocarcinoma sample; somatic mutation).
AKAP8	664	664	Q -> H (in a breast cancer sample; somatic mutation).
JAK3	58	58	Missing (in T(-)B(+)NK(-) SCID).
JAK3	100	100	Y -> C (in T(-)B(+)NK(-) SCID).
JAK3	169	169	D -> E (in T(-)B(+)NK(-) SCID).
JAK3	481	481	E -> G (in T(-)B(+)NK(-) SCID).
JAK3	527	527	L -> P (in a gastric adenocarcinoma sample; somatic mutation).
JAK3	582	582	R -> W (in T(-)B(+)NK(-) SCID).
JAK3	586	592	Missing (in T(-)B(+)NK(-) SCID; lack of phosphorylation in response to cytokine stimulation).
JAK3	589	589	G -> S (in T(-)B(+)NK(-) SCID).
JAK3	759	759	C -> R (in T(-)B(+)NK(-) SCID; constitutive phosphorylation).
JAK3	910	910	L -> S (in T(-)B(+)NK(-) SCID).
MAST3	883	883	G -> S.
PEPD	184	184	R -> Q (in PD).
PEPD	276	276	D -> N (in PD).
PEPD	278	278	G -> D (in PD).
PEPD	448	448	G -> R (in PD).
PEPD	452	452	Missing (in PD).
CHST8	247	247	R -> H (in a colorectal cancer sample; somatic mutation).
GPI	5	5	T -> I (in HA-GPID; GPI Matsumoto).
GPI	20	20	H -> P (in HA-GPID; severe form with neurological deficits; GPI Homburg).
GPI	75	75	R -> G (in HA-GPID; GPI Elyria).
GPI	83	83	R -> W (in HA-GPID).
GPI	101	101	V -> M (in HA-GPID; GPI Sarcina).
GPI	159	159	G -> S (in HA-GPID).
GPI	195	195	T -> I (in HA-GPID; GPI Bari and Mola).
GPI	224	224	T -> M (in HA-GPID; GPI Iwate).
GPI	273	273	R -> H (in HA-GPID).
GPI	300	300	A -> P (in HA-GPID).
GPI	339	339	L -> P (in HA-GPID; severe form with neurological deficits; GPI Homburg).
GPI	343	343	Q -> R (in HA-GPID; GPI Narita and Morcone).
GPI	347	347	R -> C (in HA-GPID; GPI Mount Scopus).
GPI	347	347	R -> H (in HA-GPID).
GPI	375	375	T -> R (in HA-GPID; GPI Kinki).
GPI	389	389	H -> R (in HA-GPID; severe form; GPI Calden).
GPI	472	472	R -> H (in HA-GPID).
GPI	487	487	L -> F (in HA-GPID).
GPI	495	495	E -> K (in HA-GPID).
GPI	517	517	L -> V (in HA-GPID; severe form; GPI Calden).
GPI	525	525	I -> T (in HA-GPID).
GPI	539	539	D -> N (in HA-GPID; GPI Fukuoka and Kinki).
ZNF599	178	178	L -> F (de novo variant found in a patient with mental retardation).
WDR62	224	224	W -> S (in MCMMR).
WDR62	526	526	E -> K (in MCMMR).
RYR1	13	13	L -> R (in MHS1).
RYR1	13	13	L -> V (in CCD; autosomal recessive form).
RYR1	35	35	C -> R (in MHS1).
RYR1	44	44	R -> C (in CCD and MHS1).
RYR1	109	109	R -> W (in MMDO).
RYR1	160	160	E -> G (in CCD).
RYR1	163	163	R -> C (in CCD and MHS1; 2-3% of the cases).
RYR1	163	163	R -> L (in MHS1; induces an increase sensitivity to caffeine).
RYR1	165	165	G -> R (in MHS1).
RYR1	166	166	D -> N (in MHS1).
RYR1	177	177	R -> C (in MHS1).
RYR1	178	178	Y -> C (in MHS1).
RYR1	215	215	G -> E (in CCD; autosomal recessive form).
RYR1	226	226	M -> K (in MHS1).
RYR1	227	227	D -> V (in MHS1).
RYR1	328	328	R -> W (in MHS1; has increased sensitivity to both caffeine and halothane).
RYR1	367	367	R -> L (in MHS1).
RYR1	401	401	R -> C (in MHS1).
RYR1	401	401	R -> H (in MHS1).
RYR1	401	401	R -> S (in MHS1).
RYR1	402	402	M -> T (in CFTD).
RYR1	403	403	I -> M (in CCD and MHS1).
RYR1	471	471	R -> C.
RYR1	485	485	M -> V.
RYR1	522	522	Y -> S (in CCD and MHS1).
RYR1	530	530	R -> H (in MHS1).
RYR1	533	533	R -> C (in MHS1).
RYR1	533	533	R -> H (in MHS1).
RYR1	544	544	D -> Y (in MHS1).
RYR1	552	552	R -> W (in MHS1).
RYR1	614	614	R -> L (in MHS1).
RYR1	1043	1043	R -> C (in MHS1).
RYR1	1352	1352	A -> G (in MHS1).
RYR1	1704	1704	G -> S (in CCD; autosomal recessive form).
RYR1	1832	1832	G -> A.
RYR1	2035	2035	H -> L (in CFTD).
RYR1	2101	2101	M -> K.
RYR1	2117	2117	V -> L (in MHS1).
RYR1	2129	2129	D -> E (in MHS1).
RYR1	2163	2163	R -> P (in MHS1).
RYR1	2168	2168	V -> M (in CCD and MHS1; no difference in the thapsigargin-sensitive calcium stores of cells carrying this mutation and the wild-type).
RYR1	2206	2206	T -> R (in MHS1).
RYR1	2214	2214	V -> I (in MHS1).
RYR1	2280	2280	V -> I (in MHS1).
RYR1	2336	2336	R -> H (in MHS1).
RYR1	2342	2342	N -> S (in MHS1).
RYR1	2344	2344	E -> D (in MHS1; uncertain pathogenicity).
RYR1	2346	2346	V -> M (in MHS1).
RYR1	2347	2347	Missing (in MHS1).
RYR1	2348	2348	E -> G (in MHS1).
RYR1	2350	2350	A -> T (in MHS1; reveals an altered calcium dependence and increased caffeine sensitivity).
RYR1	2355	2355	R -> C (in MHS1).
RYR1	2367	2367	A -> T (in MHS1).
RYR1	2404	2404	E -> K (in MHS1).
RYR1	2421	2421	A -> P (in CCD; autosomal recessive form).
RYR1	2423	2423	M -> K (in MMDO and CCD; autosomal recessive form).
RYR1	2428	2428	A -> T (in MHS1; induces an increase sensitivity to caffeine).
RYR1	2431	2431	D -> N (in MHS1).
RYR1	2434	2434	G -> R (in MHS1).
RYR1	2435	2435	R -> L (in MHS1).
RYR1	2437	2437	A -> V (in MHS1).
RYR1	2452	2452	R -> W (in MHS1).
RYR1	2454	2454	R -> C (in MHS1; induces an increase sensitivity to caffeine).
RYR1	2454	2454	R -> H (in CCD and MHS1; severe form; induces an increase sensitivity to caffeine).
RYR1	2458	2458	R -> H (in MHS1).
RYR1	2550	2550	L -> V.
RYR1	2730	2730	D -> G (in MHS1).
RYR1	2880	2880	E -> K (in MHS1).
RYR1	3217	3217	S -> P (in MHS1).
RYR1	3290	3290	E -> K (in MHS1).
RYR1	3326	3326	N -> K (in CFTD).
RYR1	3402	3402	C -> G (in CFTD).
RYR1	3527	3527	P -> S (in CCD; autosomal recessive form).
RYR1	3539	3539	R -> H (in CCD; autosomal recessive form).
RYR1	3772	3772	R -> Q (in CCD; autosomal recessive form).
RYR1	3772	3772	R -> W (in MHS1).
RYR1	3806	3806	G -> R (in MHS1).
RYR1	3916	3916	I -> M (in MHS1).
RYR1	4136	4136	R -> S (in MHS1).
RYR1	4214	4216	Missing (in CCD).
RYR1	4234	4234	V -> L (in MHS1).
RYR1	4501	4501	P -> L (in MHS1).
RYR1	4558	4558	R -> Q (in CCD; autosomal recessive form).
RYR1	4637	4637	T -> A (in CCD).
RYR1	4637	4637	T -> I (in core/rod disease).
RYR1	4638	4638	G -> D (in CCD).
RYR1	4647	4648	Missing (in CCD).
RYR1	4650	4650	L -> P (in CCD; autosomal recessive form).
RYR1	4651	4651	H -> P (in CCD).
RYR1	4668	4668	P -> S.
RYR1	4684	4684	F -> S (in MHS1).
RYR1	4724	4724	K -> Q (in CCD; autosomal recessive form).
RYR1	4737	4737	R -> Q (in MHS1).
RYR1	4737	4737	R -> W (in MHS1).
RYR1	4793	4793	L -> P (in CCD).
RYR1	4796	4796	Y -> C (in CCD).
RYR1	4814	4814	L -> F (in CCD).
RYR1	4824	4824	L -> P (in MHS1).
RYR1	4825	4825	R -> C (in CCD).
RYR1	4826	4826	T -> I (in MHS1).
RYR1	4838	4838	L -> V (in MHS1).
RYR1	4842	4842	V -> M (in CCD; autosomal recessive form).
RYR1	4846	4846	A -> V (in CCD; autosomal recessive form).
RYR1	4849	4849	V -> I (in MHS1 and CCD; autosomal recessive form).
RYR1	4860	4860	Missing (in CCD).
RYR1	4861	4861	R -> C (in CCD).
RYR1	4861	4861	R -> H (in CCD; release of calcium from intracellular stores in the absence of any pharmacological activator of RYR; smaller thapsigargin-sensitive intracellular calcium stores; normal sensitivity of the calcium release to the RYR inhibitor dantrolene).
RYR1	4863	4869	FYNKSED -> Y (in CCD).
RYR1	4864	4864	Y -> C (in CCD).
RYR1	4876	4876	K -> R (in MHS1).
RYR1	4891	4891	G -> R (in CCD).
RYR1	4893	4893	R -> Q (in CCD).
RYR1	4893	4893	R -> W (in CCD; release of calcium from intracellular stores in the absence of any pharmacological activator of RYR; smaller thapsigargin-sensitive intracellular calcium stores; normal sensitivity of the calcium release to the RYR inhibitor dantrolene).
RYR1	4897	4897	G -> V (in CCD).
RYR1	4898	4898	I -> T (in CCD; severe phenotype; also present in some patients with MHS1; no response to the agonists halothane and caffeine).
RYR1	4899	4899	G -> E (in CCD).
RYR1	4899	4899	G -> R (in CCD; release of calcium from intracellular stores in the absence of any pharmacological activator of RYR; smaller thapsigargin-sensitive intracellular calcium stores; normal sensitivity of the calcium release to the RYR inhibitor dantrolene).
RYR1	4906	4906	A -> V (in CCD).
RYR1	4914	4914	R -> G (in CCD).
RYR1	4914	4914	R -> T (in CCD).
RYR1	4927	4928	Missing (in CCD).
RYR1	4938	4938	I -> M (in CCD).
RYR1	4938	4938	I -> T (in MHS1).
RYR1	4939	4939	D -> E (in MHS1).
RYR1	4940	4940	A -> T (in CCD).
RYR1	4942	4942	G -> V (in MHS1).
RYR1	4973	4973	P -> L (in MHS1).
SIX5	158	158	A -> T (in BOR2; affects Eya1 binding and the ability to activate gene transcription).
SIX5	296	296	A -> T (in BOR2).
SIX5	365	365	G -> R (in BOR2).
SIX5	552	552	T -> M (in BOR2; affects Eya1 binding and the ability to activate gene transcription).
LIG1	152	152	K -> E (in a colorectal cancer sample; somatic mutation).
LIG1	566	566	E -> K (found in a patient with a syndrome of immunodeficiency and increased cellular sensitivity to DNA- damaging agents due to LIG1 deficiency; compound heterozygote carrying W-771).
LIG1	612	612	S -> L (in a colorectal cancer sample; somatic mutation).
LIG1	771	771	R -> W (found in a patient with a syndrome of immunodeficiency and increased cellular sensitivity to DNA- damaging agents due to LIG1 deficiency; compound heterozygote carrying K-566).
NUCB1	13	14	LP -> S.
NUCB1	399	399	R -> Q.
TRPM4	7	7	E -> K (in PFHB1B; attenuated desumoylation of TRPM4 resulting in constitutive sumoylation of the channel leading to impaired endocytosis and elevated channel density at the cell surface).
SLC6A16	236	236	E -> K (found in a renal cell carcinoma sample; somatic mutation).
MYH14	120	120	S -> L (in DFNA4).
MYH14	266	266	I -> V.
MYH14	376	376	G -> C (in DFNA4).
MYH14	1559	1559	N -> S.
ZNF480	361	361	H -> Q (in a colorectal cancer sample; somatic mutation).
PRKCG	101	101	H -> Y (in SCA14).
PRKCG	119	119	S -> P (in SCA14).
PRKCG	128	128	G -> D (in SCA14).
PRKCG	141	141	R -> C.
PRKCG	415	415	H -> Q.
PRKCG	523	523	A -> D.
PRKCG	659	659	R -> S.
LILRB3	400	400	Y -> R (requires 2 nucleotide substitutions).
NLRP7	398	398	L -> R (in HYDM).
NLRP7	651	651	P -> S (in HYDM).
NLRP7	693	693	R -> P (in HYDM).
NLRP7	693	693	R -> Q (in HYDM).
NLRP7	693	693	R -> W (in HYDM).
NLRP7	716	716	P -> A (in HYDM).
NLRP7	721	721	R -> W (in HYDM).
NLRP7	761	761	C -> Y (in HYDM).
NLRP7	913	913	N -> S (in HYDM).
NLRP9	425	425	G -> D (in a breast cancer sample; somatic mutation).
NLRP8	126	126	P -> R (in a breast cancer sample; somatic mutation).
NLRP8	375	375	E -> V (in a breast cancer sample; somatic mutation).
NLRP8	1045	1045	Q -> L (in a colorectal cancer sample; somatic mutation).
ZSCAN5A	146	146	E -> Q (in a colorectal cancer sample; somatic mutation).
MADCAM1	253	253	S -> SPESPDTTSQEPPDTTSQEPPDTTS.
BSG	208	208	E -> K (in Ok(A-)).
AZU1	248	248	Missing (in 50% of the molecules).
ELANE	25	25	A -> V (in SCN1).
ELANE	32	32	G -> V (in CH).
ELANE	55	55	C -> Y (in GFI1).
ELANE	57	57	A -> T (in GFI1).
ELANE	60	60	I -> T (in GFI1).
ELANE	71	71	C -> S (in GFI1).
ELANE	85	85	G -> E (in GFI1).
ELANE	98	98	V -> L (in GFI1; located on the same allele as L-101; reduces proteolytic enzyme activity by slightly less than half; together with L-101 shows an additive effect with minimal remaining enzyme activity).
ELANE	101	101	V -> L (in GFI1; located on the same allele as L-98; reduces proteolytic enzyme activity by slightly less than half; together with L-98 shows an additive effect with minimal remaining enzyme activity).
ELANE	123	123	L -> PQL (in GFI1).
ELANE	126	126	S -> L (in GFI1).
ELANE	151	151	C -> S (in GFI1).
ELANE	166	166	A -> T (in SCN1; the patient also carries mutation Lys-116 in G6PC3).
ELANE	177	177	V -> F (in CH).
ELANE	190	199	Missing (in GFI1).
ELANE	191	191	R -> Q (in CH; loss of interaction with NOTCH2NL and loss of NOTCH2NL and NOTCH2 proteolytic cleavage).
ELANE	205	205	P -> R (in GFI1).
ELANE	210	210	G -> V (in GFI1).
ELANE	214	214	G -> R (in GFI1).
CFD	213	213	V -> G (in CFD deficiency).
CFD	214	214	C -> R (in CFD deficiency).
GPX4	120	120	A -> T (in a patient affected by cryptorchidism).
STK11	14	14	E -> K (in cervical cancer; somatic mutation).
STK11	16	16	E -> G (in PJS).
STK11	49	49	Y -> D (in melanoma; sporadic malignant; somatic mutation).
STK11	66	66	V -> M (in cervical carcinoma; somatic mutation).
STK11	67	67	L -> P (in PJS).
STK11	86	86	R -> G (in sporadic cancer; somatic mutation; no effect on kinase activity nor in heterotrimeric complex assembly with STRADA and CAB39).
STK11	87	87	R -> K (in a metastatic melanoma sample; somatic mutation).
STK11	123	123	Q -> R (in sporadic cancer; somatic mutation; no effect on kinase activity nor in heterotrimeric complex assembly with STRADA and CAB39).
STK11	135	135	G -> R (in melanoma; sporadic malignant; somatic mutation).
STK11	157	157	F -> S (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39).
STK11	160	160	L -> P (in cervical cancer; somatic mutation).
STK11	162	164	DGL -> NDM (in PJS).
STK11	163	163	G -> D (in testicular tumors; a tumor with seminoma and teratoma components; associated with severely impaired but detectable kinase activity; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39).
STK11	170	170	Q -> P (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39).
STK11	171	171	G -> S (in colorectal cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39).
STK11	174	174	H -> R (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39).
STK11	176	176	D -> Y (in sporadic cancer; somatic mutation; Loss of kinase activity).
STK11	177	177	I -> N (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39).
STK11	181	181	N -> E (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39; requires 2 nucleotide substitutions).
STK11	194	194	D -> N (in PJS).
STK11	194	194	D -> V (in lung cancer; somatic mutation).
STK11	194	194	D -> Y (in melanoma; sporadic malignant; somatic mutation).
STK11	199	199	E -> K (in colorectal cancer; somatic mutation; impaired kinase activity).
STK11	199	199	E -> Q (in sporadic cancer; somatic mutation; does not affect kinase activity).
STK11	205	205	A -> T (in sporadic cancer; somatic mutation; no effect heterotrimeric complex assembly with STRADA and CAB39).
STK11	208	208	D -> N (in colorectal cancer; somatic mutation; no effect heterotrimeric complex assembly with STRADA and CAB39).
STK11	215	215	G -> D (in colorectal cancer; somatic mutation).
STK11	216	216	S -> F (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39).
STK11	223	223	E -> V (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39).
STK11	230	230	T -> P (in sporadic cancer; somatic mutation; no effect heterotrimeric complex assembly with STRADA and CAB39).
STK11	231	231	F -> L (in cervical cancer; somatic mutation).
STK11	232	232	S -> P (in sporadic cancer; somatic mutation; no effect heterotrimeric complex assembly with STRADA and CAB39).
STK11	239	239	W -> C (in PJS; late onset suggests reduced penetrance).
STK11	245	245	L -> R (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39).
STK11	247	247	Missing (in PJS).
STK11	250	250	T -> P (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39).
STK11	272	272	Y -> H (in sporadic cancer; somatic mutation; no effect on kinase activity nor in heterotrimeric complex assembly with STRADA and CAB39).
STK11	277	277	D -> Y (in sporadic cancer; somatic mutation; no effect on kinase activity nor in heterotrimeric complex assembly with STRADA and CAB39).
STK11	281	281	P -> L (in ovarian carcinoma; somatic mutation).
STK11	285	285	L -> Q (in sporadic cancer; somatic mutation; impairs heterotrimeric complex assembly with STRADA and CAB39).
STK11	297	297	R -> K (in PJS).
STK11	303	306	IRQH -> N (in PJS).
STK11	314	314	P -> H (in colorectal cancer; no effect heterotrimeric complex assembly with STRADA and CAB39).
STK11	315	315	P -> S (in PJS; pathogenicity uncertain; no effect heterotrimeric complex assembly with STRADA and CAB39).
STK11	324	324	P -> L (in gastric carcinoma; no effect heterotrimeric complex assembly with STRADA and CAB39).
STK11	354	354	F -> L (in colorectal cancer; somatic mutation).
STK11	367	367	T -> M (in colorectal cancer; somatic mutation).
NDUFS7	122	122	V -> M (in MT-C1D).
GAMT	20	20	W -> S (in GAMT deficiency).
GAMT	50	50	M -> L (in GAMT deficiency).
GAMT	51	51	H -> P (in GAMT deficiency).
GAMT	54	54	A -> P (in GAMT deficiency).
GAMT	169	169	C -> Y (in GAMT deficiency).
GAMT	197	197	L -> P (in GAMT deficiency; uncertain pathogenicity).
DAZAP1	381	381	S -> T (in a breast cancer sample; somatic mutation).
APC2	562	562	A -> S (in a breast cancer sample; somatic mutation).
APC2	2003	2003	G -> S (in a breast cancer sample; somatic mutation).
TCF3	8	8	A -> V (in a colorectal cancer sample; somatic mutation).
ADAT3	332	332	R -> C (in a breast cancer sample; somatic mutation).
AMH	12	12	V -> G (in PMDS1).
AMH	70	70	L -> P (in PMDS1).
AMH	101	101	G -> V (in PMDS1).
AMH	123	123	R -> W (in PMDS1).
AMH	167	167	Y -> C (in PMDS1).
AMH	185	185	Q -> E.
AMH	194	194	R -> C (in PMDS1).
AMH	325	325	Q -> R.
AMH	477	477	V -> A (in PMDS1).
AMH	506	506	H -> Q (in PMDS1).
AMH	525	525	C -> Y (in PMDS1).
OAZ1	147	147	A -> V.
LMNB2	216	216	R -> W (in a colorectal cancer sample; somatic mutation).
RAX2	87	87	R -> Q (in ARMD6; increased transactivation and DNA-binding activity).
RAX2	137	137	G -> R (in CORD11; decreased interaction with Crx and transactivation activity).
RAX2	140	140	P -> PGP (in CORD11; decreased interaction with Crx and increased transactivation activity).
ATCAY	301	301	S -> R (in ATCAY).
DAPK3	112	112	T -> M (in a colorectal adenocarcinoma sample; somatic mutation).
DAPK3	161	161	D -> N (in an ovarian mucinous carcinoma sample; somatic mutation).
DAPK3	216	216	P -> S (in a lung neuroendocrine carcinoma sample; somatic mutation).
MAP2K2	57	57	F -> C (in CFC syndrome).
FEM1A	500	500	H -> Y (may to be associated with polycystic ovary syndrome (PCOS); may be a common polymorphism).
TICAM1	46	46	M -> I (in a breast cancer sample; somatic mutation).
NRTN	96	96	A -> S (may contribute to Hirschsprung disease in patients carrying a RET mutation).
FUT3	124	124	S -> A (in Le(+)).
FUT3	336	336	D -> A (in Le(-)).
SH2D3A	265	265	E -> G (in a breast cancer sample; somatic mutation).
MCOLN1	106	106	L -> P (in MLIV).
MCOLN1	232	232	T -> P (in MLIV; fails to localize to late endosomes).
MCOLN1	331	331	V -> L (in a breast cancer sample; somatic mutation).
MCOLN1	362	362	D -> Y (in MLIV; affects channel activity).
MCOLN1	403	403	R -> C (in MLIV).
MCOLN1	408	408	Missing (in MLIV; mild psychomotor involvement; does not affect channel activity; affects channel inhibition by low pH; still localizes to late endosomes).
MCOLN1	446	446	V -> L (in MLIV; does not affect channel activity; affects channel inhibition by low pH).
MCOLN1	447	447	L -> P (in MLIV).
MCOLN1	465	465	F -> L (in MLIV; still localizes to late endosomes).
STXBP2	209	209	L -> P (in FHL5).
STXBP2	232	232	Missing (in FHL5; leads to a complete loss of the ability to interact with STX11).
STXBP2	292	292	R -> H (in FHL5; leads to a complete loss of the ability to interact with STX11).
STXBP2	405	405	R -> Q (in FHL5; leads to a complete loss of the ability to interact with STX11).
STXBP2	405	405	R -> W (in FHL5; leads to a complete loss of the ability to interact with STX11).
STXBP2	477	477	P -> L (in FHL5; leads to a complete loss of the ability to interact with STX11).
C19orf59	167	167	I -> V.
MAP2K7	162	162	R -> C (in a colorectal adenocarcinoma sample; somatic mutation).
MAP2K7	162	162	R -> H (in a colorectal adenocarcinoma sample; somatic mutation).
FBN3	935	935	R -> L.
FBN3	938	938	V -> F.
CD320	88	88	Missing (in MMATC).
ANGPTL4	5	5	P -> L.
ANGPTL4	40	40	E -> K (associated with lower plasma levels of triglyceride and higher levels of HDL cholesterol).
ANGPTL4	41	41	M -> I.
ANGPTL4	67	67	S -> R.
ANGPTL4	72	72	R -> L.
ANGPTL4	77	77	G -> R.
ANGPTL4	167	167	E -> K.
ANGPTL4	174	174	P -> S.
ANGPTL4	190	190	E -> Q.
ANGPTL4	196	196	E -> K.
ANGPTL4	230	230	R -> C.
ANGPTL4	233	233	G -> R.
ANGPTL4	237	237	F -> V.
ANGPTL4	251	251	P -> T.
ANGPTL4	291	291	V -> M.
ANGPTL4	293	293	L -> M.
ANGPTL4	296	296	E -> V.
ANGPTL4	307	307	P -> S.
ANGPTL4	308	308	V -> M.
ANGPTL4	336	336	R -> C.
ANGPTL4	338	338	D -> E.
ANGPTL4	349	349	W -> C.
ANGPTL4	361	361	G -> R.
ANGPTL4	361	361	G -> S.
ANGPTL4	371	371	R -> Q.
ANGPTL4	384	384	R -> W.
ACTL9	42	42	A -> D (in a colorectal cancer sample; somatic mutation).
ACTL9	332	332	A -> T (in a colorectal cancer sample; somatic mutation).
OR7D4	52	52	D -> G.
OR7D4	79	79	P -> L (impaired response to androstenone and androstadienone).
OR7D4	88	88	R -> W (impaired response to androstenone and androstadienone; when associated with M-133).
OR7D4	162	162	L -> P.
OR7D4	279	279	A -> D.
ZNF560	186	186	G -> E (in a colorectal cancer sample; somatic mutation).
FBXL12	63	63	L -> H (found in a renal cell carcinoma case; somatic mutation).
OLFM2	86	86	T -> M (in a colorectal cancer sample; somatic mutation).
ICAM4	100	100	Q -> R (in LW(B)).
ICAM4	208	208	V -> L.
ICAM5	140	140	L -> V (in a breast cancer sample; somatic mutation).
ICAM5	188	188	R -> W (in a breast cancer sample; somatic mutation).
ICAM5	488	488	E -> Q (in a breast cancer sample; somatic mutation).
KEAP1	23	23	C -> Y (in a breast cancer sample; somatic mutation).
KEAP1	167	167	V -> F (in a lung adenocarcinoma patient).
KEAP1	236	236	D -> H (in a NSCLC cell line).
KEAP1	284	284	Q -> L (in a lung adenocarcinoma patient).
KEAP1	333	333	G -> C (in a NSCLC cell line; strongly reduces interaction with NFE2L2 and reduces repression of NFE2L2-dependent gene expression).
KEAP1	350	350	G -> S (in a NSCLC cell line).
KEAP1	364	364	G -> C (in a lung adenocarcinoma cell line; also in NSCLC cell lines; may be a polymorphism; strongly reduces interaction with NFE2L2 and reduces repression of NFE2L2-dependent gene expression).
KEAP1	430	430	G -> C (in a lung adenocarcinoma patient; somatic mutation; strongly reduces interaction with NFE2L2 and reduces repression of NFE2L2-dependent gene expression).
KEAP1	522	522	A -> V (in a breast cancer sample; somatic mutation).
TMED1	102	102	D -> N (in a breast cancer sample; somatic mutation).
LDLR	27	27	C -> W (in San Francisco).
LDLR	46	46	C -> S (in FH; Japanese patient).
LDLR	47	48	Missing (in FH; Cape Town-1; retards receptor transport from the endoplasmic reticulum to the cell surface).
LDLR	50	50	A -> S (in FH; German patient).
LDLR	52	52	C -> Y (in Paris-4).
LDLR	56	56	S -> P (in FH).
LDLR	78	78	R -> C (in FH).
LDLR	87	87	W -> G (in FH; French Canadian-4).
LDLR	89	89	C -> Y (in FH).
LDLR	90	90	D -> G (in London-4).
LDLR	90	90	D -> N (in FH).
LDLR	90	90	D -> Y (in FH; Durban-1).
LDLR	92	92	Q -> E (in FH; Spanish patient).
LDLR	95	95	C -> G (in FH; Spanish patient).
LDLR	101	101	E -> K (in FH; Lancashire; 6% of American English).
LDLR	109	109	C -> R (in Munster-1).
LDLR	116	116	C -> R (in FH; Spanish patient).
LDLR	134	134	C -> F (in FH).
LDLR	134	134	C -> W (in FH).
LDLR	140	140	E -> K (in FH; Philippines/Durban-2/ Japan).
LDLR	155	155	C -> G (in Germany).
LDLR	160	160	C -> Y (in FH).
LDLR	168	168	D -> H (in FH; Sephardic/Safed; 10% of the Sephardic Jews).
LDLR	168	168	D -> N (in FH).
LDLR	168	168	D -> Y (in FH; Norwegian patient).
LDLR	172	172	D -> H (may contribute to familial hypercholesterolemia).
LDLR	173	173	C -> R (in Greece-1).
LDLR	173	173	C -> W (in FH; French Canadian patient).
LDLR	175	175	D -> N (in FH; Afrikaner-3; 5-10% of Afrikaners).
LDLR	175	175	D -> Y (in FH).
LDLR	177	177	S -> L (in FH; Puerto Rico).
LDLR	184	184	C -> Y (in FH; Glasco).
LDLR	197	197	C -> F (in Shreveport).
LDLR	197	197	C -> R (in FH; British patient).
LDLR	197	197	C -> Y (in El Salvador-1).
LDLR	218	218	Missing (in FH; Piscataway/Lithuania).
LDLR	221	221	D -> G (in FH; Padova).
LDLR	221	221	D -> N (in FH; German patient).
LDLR	221	221	D -> Y (in FH; Cologne patient).
LDLR	222	222	C -> Y (in FH).
LDLR	224	224	D -> G (in Italy-2).
LDLR	224	224	D -> N (in Portugal).
LDLR	224	224	D -> V (in FH; Cologne patient).
LDLR	226	226	S -> P (in Miami-1).
LDLR	227	227	D -> E (in FH; Afrikaner-1/Maine; 65-70% of Afrikaner Americans).
LDLR	228	228	E -> CK (in Chieti-3).
LDLR	228	228	E -> K (in FH; French Canadian-3/Mexico; 2% of French Canadians).
LDLR	228	228	E -> Q (in Tulsa-2).
LDLR	231	231	C -> G (in FH; Norwegian patient).
LDLR	240	240	E -> K (in Charlotte).
LDLR	248	248	C -> F (in Bretagne-1).
LDLR	248	248	C -> Y (in FH; British patient).
LDLR	253	253	R -> W (may contribute to familial hypercholesterolemia).
LDLR	254	254	Q -> P (in FH).
LDLR	256	256	D -> G (in Nevers).
LDLR	261	261	C -> F (in FH; rare mutation; strongly reduced receptor activity).
LDLR	266	266	D -> E (in Cincinnati-1).
LDLR	270	270	C -> Y (in Miami-2).
LDLR	276	276	C -> R (in FH).
LDLR	276	276	C -> Y (in FH; Syrian patient).
LDLR	277	277	E -> K (in FH; patients from Sweden and La Havana).
LDLR	286	286	S -> R (in Greece-2).
LDLR	288	288	E -> K (in FH; German patient).
LDLR	301	301	D -> A (in FH; Greek patient).
LDLR	302	302	C -> W (in FH; Iraki patient).
LDLR	302	302	C -> Y (in FH; Spanish patient).
LDLR	304	304	D -> E (in Baltimore-1).
LDLR	304	304	D -> N (in Denver-2).
LDLR	313	313	C -> Y (in FH).
LDLR	318	318	C -> F (in FH; Trieste).
LDLR	318	318	C -> R (in FH).
LDLR	318	318	C -> Y (in Mexico-1; leads to a defect in the intracellular transport of the receptor).
LDLR	327	327	H -> Y (in FH).
LDLR	329	329	C -> Y (in FH; Chinese patient).
LDLR	335	335	G -> S (in Paris-6).
LDLR	338	338	C -> S (in FH; Japanese patients).
LDLR	342	342	D -> E (in New York-1).
LDLR	342	342	D -> N (in FH).
LDLR	343	343	G -> S (in Picardie).
LDLR	350	350	R -> P (in FH; British patient).
LDLR	352	352	C -> Y (in Mexico-2).
LDLR	354	354	D -> G (in Munster-2).
LDLR	354	354	D -> V (in Oklahoma).
LDLR	356	356	D -> Y (in FH).
LDLR	357	357	E -> K (in Paris-7).
LDLR	358	358	C -> Y (in FH).
LDLR	364	364	C -> R (in Mexico-3).
LDLR	366	366	Q -> R (in FH).
LDLR	368	368	C -> R (in FH; French Canadian patient).
LDLR	370	370	N -> T (in FH).
LDLR	379	379	C -> R (in Naples-1).
LDLR	379	379	C -> Y (in FH).
LDLR	399	399	A -> D (in FH).
LDLR	401	401	L -> H (in Pori).
LDLR	401	401	L -> V (in FH).
LDLR	403	403	F -> L (in FH; Japanese patient).
LDLR	406	406	R -> Q (may contribute to familial hypercholesterolemia).
LDLR	408	408	E -> K (may contribute to familial hypercholesterolemia; Algeria-1).
LDLR	414	414	L -> R (in FH; Chinese patient).
LDLR	415	415	D -> G (in FH).
LDLR	416	416	R -> Q (in FH; German patient).
LDLR	416	416	R -> W (in FH).
LDLR	423	423	I -> T (in FH; Swedish patient).
LDLR	432	432	L -> V (in FH; German patient).
LDLR	433	433	D -> H (in FH; Osaka-3).
LDLR	434	434	T -> K (in Algeria-3).
LDLR	441	441	I -> M (in Rouen).
LDLR	441	441	I -> N (in Russia-1).
LDLR	443	443	W -> C (in North Platt).
LDLR	451	451	I -> T (in FH).
LDLR	478	478	G -> R (in New York-2).
LDLR	479	479	L -> P (in FH).
LDLR	482	482	D -> H (in FH).
LDLR	483	483	W -> R (in FH).
LDLR	485	485	H -> R (in Milan).
LDLR	487	487	Missing (in FH; Norwegian patient).
LDLR	526	526	P -> S (in Cincinnati-3).
LDLR	564	564	N -> S (in FH; Sicily).
LDLR	568	568	L -> V (in FH; Japanese patient).
LDLR	579	579	D -> N (in FH; Cincinnati-4; less than 2% receptor activity).
LDLR	579	579	D -> Y (in FH).
LDLR	592	592	G -> E (in FH; Sicily).
LDLR	599	599	L -> S (in London-5).
LDLR	608	608	P -> S (in FH).
LDLR	633	633	R -> C (in FH).
LDLR	649	649	P -> L (in FH).
LDLR	677	677	C -> R (in FH; New York-3).
LDLR	682	682	L -> P (in Issoire).
LDLR	699	699	P -> L (may contribute to familial hypercholesterolemia).
LDLR	700	700	D -> E (in FH; Spanish patient).
LDLR	714	714	E -> K (in FH; Japanese patient).
LDLR	792	792	I -> F (in Russia-2).
LDLR	797	797	V -> M (in FH; La Havana patient).
LDLR	799	801	Missing (in FH; Danish patient).
LDLR	820	822	Missing (in FH).
LDLR	826	826	P -> S (in FH).
LDLR	827	827	V -> I (in New York-5).
LDLR	844	844	G -> D (in Turku).
LPPR2	155	155	T -> M (in a colorectal cancer sample; somatic mutation).
EPOR	487	487	N -> S (in ECYT1 and erythroleukemia).
EPOR	488	488	P -> S (in ECYT1).
ZNF442	243	243	C -> S (in a colorectal cancer sample; somatic mutation).
ZNF442	590	590	H -> L (found in a renal cell carcinoma sample; somatic mutation).
MAN2B1	72	72	H -> L (in AM; type II).
MAN2B1	200	200	H -> L (in AM; no residual enzyme activity).
MAN2B1	355	355	T -> P (in AM).
MAN2B1	356	356	P -> R (in AM; type I).
MAN2B1	402	402	E -> K (in AM).
MAN2B1	453	453	S -> Y (in AM).
MAN2B1	714	714	W -> R (in AM).
MAN2B1	750	750	R -> W (in AM; type II).
MAN2B1	801	801	G -> D (in AM; no residual enzyme activity).
MAN2B1	809	809	L -> P (in AM).
RNASEH2A	37	37	G -> S (in AGS4; strongly impairs enzyme activity but not interation with RNASEH2B and RNASEH2C).
KLF1	299	299	H -> Y (in blood group-In(Lu)).
KLF1	325	325	E -> K (in CDA4; has a dominant-negative effect on the transcriptional activation of CD44 and AQP1 promoters).
KLF1	328	328	R -> H (in blood group-In(Lu)).
KLF1	328	328	R -> L (in blood group-In(Lu)).
KLF1	331	331	R -> G (in blood group-In(Lu)).
GCDH	88	88	R -> C (in GA1).
GCDH	94	94	R -> L (in GA1).
GCDH	101	101	G -> R (in GA1).
GCDH	115	115	C -> Y (in GA1).
GCDH	122	122	A -> V (in GA1).
GCDH	128	128	R -> G (in GA1).
GCDH	138	138	R -> G (in GA1; impaired protein stability and loss of activity).
GCDH	139	139	S -> L (in GA1).
GCDH	148	148	V -> I (in GA1).
GCDH	161	161	R -> Q (in GA1).
GCDH	178	178	G -> R (in GA1).
GCDH	179	179	L -> R (in GA1).
GCDH	191	191	M -> T (in GA1).
GCDH	195	195	A -> T (in GA1).
GCDH	227	227	R -> P (in GA1).
GCDH	236	236	F -> L (in GA1).
GCDH	257	257	R -> Q (in GA1).
GCDH	257	257	R -> W (in GA1).
GCDH	263	263	M -> V (in GA1; severe phenotype despite a residual activity of 30% as measured in patient fibroblasts).
GCDH	266	266	M -> V (in GA1).
GCDH	278	278	P -> S (in GA1).
GCDH	283	283	L -> P (in GA1).
GCDH	293	293	A -> T (in GA1).
GCDH	294	294	R -> W (in GA1).
GCDH	295	295	Y -> H (in GA1).
GCDH	298	298	A -> T.
GCDH	298	298	A -> V.
GCDH	305	305	S -> L (in GA1).
GCDH	308	308	C -> S (in GA1).
GCDH	309	309	L -> W (in GA1).
GCDH	313	313	R -> W (in GA1).
GCDH	333	333	Q -> E (in GA1).
GCDH	349	349	A -> T (in GA1).
GCDH	354	354	G -> R (in GA1).
GCDH	354	354	G -> S (in GA1).
GCDH	355	355	R -> C (in GA1).
GCDH	355	355	R -> H (in GA1).
GCDH	365	365	E -> K (in GA1).
GCDH	375	375	C -> R (in GA1).
GCDH	382	382	A -> T (in GA1).
GCDH	383	383	R -> C (in GA1).
GCDH	383	383	R -> H (in GA1).
GCDH	386	386	R -> Q (in GA1).
GCDH	390	390	G -> A (in GA1).
GCDH	390	390	G -> R (in GA1).
GCDH	392	392	N -> D (in GA1).
GCDH	400	400	V -> M (in GA1).
GCDH	402	402	R -> Q (in GA1).
GCDH	402	402	R -> W (in GA1; most common mutation identified; loss of tetramerization and enzyme activity).
GCDH	403	403	H -> R (in GA1).
GCDH	406	406	N -> K (in GA1).
GCDH	407	407	L -> P (in GA1).
GCDH	414	414	E -> K (in GA1; loss of enzyme activity).
GCDH	416	416	T -> I (in GA1).
GCDH	421	421	A -> T (in GA1).
GCDH	421	421	A -> V (in GA1; impaired association of subunits).
GCDH	429	429	T -> M (in GA1).
GCDH	433	433	A -> E (in GA1).
SYDE1	408	408	R -> Q (in a pancreatic ductal adenocarcinoma sample; somatic mutation).
NOTCH3	43	43	C -> G (in CADASIL).
NOTCH3	49	49	C -> F (in CADASIL).
NOTCH3	49	49	C -> Y (in CADASIL).
NOTCH3	54	54	R -> C (in CADASIL).
NOTCH3	60	60	S -> C (in CADASIL).
NOTCH3	65	65	C -> S (in CADASIL).
NOTCH3	67	67	C -> Y (in CADASIL).
NOTCH3	76	76	C -> R (in CADASIL).
NOTCH3	76	76	C -> W (in CADASIL).
NOTCH3	77	82	Missing (in CADASIL).
NOTCH3	80	84	Missing (in CADASIL).
NOTCH3	87	87	C -> R (in CADASIL).
NOTCH3	87	87	C -> Y (in CADASIL).
NOTCH3	90	90	R -> C (in CADASIL).
NOTCH3	93	93	C -> F (in CADASIL).
NOTCH3	93	93	C -> Y (in CADASIL).
NOTCH3	106	106	C -> W (in CADASIL).
NOTCH3	108	108	C -> W (in CADASIL).
NOTCH3	108	108	C -> Y (in CADASIL).
NOTCH3	110	110	R -> C (in CADASIL).
NOTCH3	114	120	Missing (in CADASIL).
NOTCH3	117	117	C -> F (in CADASIL).
NOTCH3	118	118	S -> C (in CADASIL).
NOTCH3	123	123	C -> F (in CADASIL).
NOTCH3	123	123	C -> Y (in CADASIL).
NOTCH3	128	128	C -> Y (in CADASIL).
NOTCH3	133	133	R -> C (in CADASIL).
NOTCH3	134	134	C -> W (in CADASIL).
NOTCH3	141	141	R -> C (in CADASIL).
NOTCH3	142	142	F -> C (in CADASIL).
NOTCH3	144	144	C -> F (in CADASIL).
NOTCH3	144	144	C -> S (in CADASIL).
NOTCH3	144	144	C -> Y (in CADASIL).
NOTCH3	145	145	S -> C (in CADASIL).
NOTCH3	146	146	C -> R (in CADASIL).
NOTCH3	149	149	G -> C (in CADASIL).
NOTCH3	150	150	Y -> C (in CADASIL).
NOTCH3	153	155	Missing (in CADASIL).
NOTCH3	153	153	R -> C (in CADASIL).
NOTCH3	155	155	C -> S (in CADASIL).
NOTCH3	162	162	C -> S (in CADASIL).
NOTCH3	170	170	H -> R.
NOTCH3	171	171	G -> C (in CADASIL).
NOTCH3	174	174	C -> F (in CADASIL).
NOTCH3	174	174	C -> R (in CADASIL).
NOTCH3	174	174	C -> Y (in CADASIL).
NOTCH3	180	180	S -> C (in CADASIL).
NOTCH3	183	183	C -> F (in CADASIL).
NOTCH3	183	183	C -> R (in CADASIL).
NOTCH3	183	183	C -> S (in CADASIL).
NOTCH3	185	185	C -> G (in CADASIL).
NOTCH3	185	185	C -> R (in CADASIL).
NOTCH3	189	189	Y -> C (in CADASIL).
NOTCH3	194	194	C -> F (in CADASIL).
NOTCH3	194	194	C -> R (in CADASIL).
NOTCH3	194	194	C -> S (in CADASIL).
NOTCH3	194	194	C -> Y (in CADASIL).
NOTCH3	201	201	C -> Y (in CADASIL).
NOTCH3	206	206	C -> Y (in CADASIL).
NOTCH3	207	207	R -> C (in CADASIL).
NOTCH3	212	212	C -> S (in CADASIL).
NOTCH3	213	213	R -> K (in CADASIL).
NOTCH3	222	222	C -> G (in CADASIL).
NOTCH3	222	222	C -> Y (in CADASIL).
NOTCH3	224	224	C -> Y (in CADASIL).
NOTCH3	233	233	C -> S (in CADASIL).
NOTCH3	233	233	C -> Y (in CADASIL).
NOTCH3	239	253	Missing (in CADASIL).
NOTCH3	240	240	C -> S (in CADASIL).
NOTCH3	245	245	C -> R (in CADASIL).
NOTCH3	251	251	C -> R (in CADASIL).
NOTCH3	258	258	Y -> C (in CADASIL).
NOTCH3	260	260	C -> Y (in CADASIL).
NOTCH3	319	319	A -> C (in CADASIL; requires 2 nucleotide substitutions).
NOTCH3	332	332	R -> C (in CADASIL).
NOTCH3	335	335	S -> C (in CADASIL).
NOTCH3	337	337	Y -> C (in CADASIL).
NOTCH3	379	379	C -> S (in CADASIL).
NOTCH3	395	395	C -> R (in CADASIL).
NOTCH3	420	420	G -> C (in CADASIL).
NOTCH3	421	421	R -> C (in CADASIL).
NOTCH3	428	428	C -> S (in CADASIL).
NOTCH3	428	428	C -> Y (in CADASIL).
NOTCH3	440	440	C -> G (in CADASIL).
NOTCH3	440	440	C -> R (in CADASIL).
NOTCH3	446	446	C -> S (in CADASIL).
NOTCH3	449	449	R -> C (in CADASIL).
NOTCH3	484	484	C -> F (in CADASIL).
NOTCH3	484	484	C -> Y (in CADASIL).
NOTCH3	495	495	C -> Y (in CADASIL).
NOTCH3	511	511	C -> R (in CADASIL).
NOTCH3	542	542	C -> Y (in CADASIL).
NOTCH3	544	544	R -> C (in CADASIL).
NOTCH3	549	549	C -> Y (in CADASIL).
NOTCH3	558	558	R -> C (in CADASIL).
NOTCH3	578	578	R -> C (in CADASIL).
NOTCH3	607	607	R -> C (in CADASIL).
NOTCH3	728	728	R -> C (in CADASIL).
NOTCH3	775	775	C -> S (in CADASIL).
NOTCH3	953	953	G -> C (in CADASIL).
NOTCH3	984	984	F -> C (in CADASIL).
NOTCH3	985	985	R -> C (in CADASIL).
NOTCH3	1006	1006	R -> C (in CADASIL).
NOTCH3	1015	1015	C -> R (in CADASIL).
NOTCH3	1021	1021	Y -> C (in CADASIL).
NOTCH3	1031	1031	R -> C (in CADASIL).
NOTCH3	1063	1063	D -> C (in CADASIL; requires 2 nucleotide substitutions).
NOTCH3	1133	1133	H -> Q.
NOTCH3	1231	1231	R -> C (in CADASIL).
NOTCH3	1261	1261	C -> R (in CADASIL).
NOTCH3	1261	1261	C -> Y (in CADASIL).
NOTCH3	1515	1515	L -> P (in brain small-vessel-disease; exhibits increased NOTCH3 signaling in a ligand-independent fashion).
CYP4F22	59	59	F -> L (in LI3).
CYP4F22	243	243	R -> H (in LI3).
CYP4F22	372	372	R -> W (in LI3).
CYP4F22	435	435	H -> Y (in LI3).
CYP4F22	436	436	H -> D (in LI3).
TPM4	204	204	E -> Q (in a breast cancer sample; somatic mutation).
AP1M1	303	303	R -> Q (in a breast cancer sample; somatic mutation).
CALR3	82	82	K -> R (in CMH19).
INSL3	24	24	A -> G.
INSL3	43	43	V -> L.
INSL3	49	49	P -> S (could be a rare polymorphism; identified in a male with undermasculinised genitalia and intra- abdominal testes).
INSL3	93	93	P -> L (in CRYPTO).
INSL3	102	102	R -> C (in CRYPTO).
INSL3	102	102	R -> H.
INSL3	110	110	N -> K (in CRYPTO).
SLC5A5	93	93	G -> R (in TDH1).
SLC5A5	102	102	A -> P.
SLC5A5	267	267	Q -> E (in TDH1).
SLC5A5	354	354	T -> P (in TDH1).
SLC5A5	395	395	G -> R (in TDH1).
SLC5A5	536	536	T -> Q (requires 2 nucleotide substitutions).
SLC5A5	543	543	G -> E (in TDH1).
SLC5A5	556	556	S -> Q (requires 2 nucleotide substitutions).
IL12RB1	213	213	R -> W (in MSMD).
CRLF1	76	76	W -> G (in CRISPS).
CRLF1	81	81	R -> H (in CISS1).
CRLF1	374	374	L -> R (in CISS1).
COMP	50	50	E -> D.
COMP	51	51	L -> W.
COMP	109	109	A -> G.
COMP	224	224	R -> G.
COMP	276	276	P -> R (in EDM1).
COMP	285	285	R -> P.
COMP	290	290	D -> N (in PSACH; mild form).
COMP	299	299	G -> R (in PSACH; mild form).
COMP	328	328	C -> R (in PSACH; mild form).
COMP	342	342	D -> Y (in EDM1; Fairbank type).
COMP	348	348	C -> R (in PSACH).
COMP	349	349	D -> V (in PSACH; mild form).
COMP	361	361	D -> V (in EDM1; Fairbank type).
COMP	361	361	D -> Y (in EDM1; binds less calcium).
COMP	367	368	Missing (in EDM1).
COMP	371	371	C -> S (in EDM1; Fairbank type).
COMP	372	372	Missing (in PSACH).
COMP	374	374	Missing (in PSACH; mild form).
COMP	387	387	C -> G (in PSACH; mild form).
COMP	391	394	PNSD -> V (in PSACH).
COMP	408	408	D -> Y (in EDM1).
COMP	420	420	D -> A (in EDM1).
COMP	440	440	G -> E (in PSACH; mild form).
COMP	440	440	G -> R (in PSACH; mild form).
COMP	459	459	Missing (in PSACH; severe form).
COMP	468	468	C -> Y (in PSACH; severe form).
COMP	469	469	Missing (in PSACH; severe form; MUT3 mutant; most common mutation; binds less calcium and causes misfolding of the protein; greatly reduced interaction with ACAN; reduced interaction with collagen).
COMP	472	472	D -> Y (in PSACH; severe form).
COMP	473	473	Missing (in PSACH; severe form).
COMP	482	482	D -> G (in PSACH).
COMP	513	516	Missing (in PSACH; mild form).
COMP	518	518	D -> N (in PSACH; mild form).
COMP	523	523	N -> K (in EDM1; Ribbing type).
COMP	585	585	T -> M (in PSACH; mild form and EDM1).
COMP	585	585	T -> R (in EDM1).
COMP	719	719	G -> D (in PSACH; severe).
TMEM161A	85	85	E -> V (in a breast cancer sample; somatic mutation).
RFXANK	195	195	L -> P (in BLS2).
PBX4	283	283	T -> M (in a colorectal cancer sample; somatic mutation).
TSHZ3	469	469	E -> G.
SLC7A9	10	10	Missing (in CSNU).
SLC7A9	44	44	I -> T (in CSNU; type I).
SLC7A9	52	52	P -> L (in CSNU).
SLC7A9	63	63	G -> R (in CSNU).
SLC7A9	69	69	W -> L (in CSNU).
SLC7A9	70	70	A -> V (in CSNU; mild loss of amino acid transport activity).
SLC7A9	105	105	G -> R (in CSNU; type III; frequent mutation; severe loss of amino acid transport activity).
SLC7A9	123	123	T -> M (in CSNU).
SLC7A9	126	126	A -> T (in CSNU).
SLC7A9	158	158	A -> AA (in CSNU).
SLC7A9	170	170	V -> M (in CSNU; type III; frequent mutation; complete loss of amino acid transport activity).
SLC7A9	182	182	A -> T (in CSNU; type III; frequent mutation; mild loss of amino acid transport activity).
SLC7A9	187	187	I -> F (in CSNU).
SLC7A9	193	193	I -> II (in CSNU).
SLC7A9	195	195	G -> R (in CSNU; type III).
SLC7A9	224	224	A -> V (in CSNU; non-classic type I).
SLC7A9	230	230	W -> R (in CSNU).
SLC7A9	241	241	I -> T (in CSNU).
SLC7A9	244	244	Missing (in CSNU).
SLC7A9	259	259	G -> R (in CSNU; type III).
SLC7A9	261	261	P -> L (in CSNU; types I and III).
SLC7A9	330	330	V -> M (in CSNU; type III).
SLC7A9	331	331	A -> V (in CSNU; non-classic type I).
SLC7A9	333	333	R -> W (in CSNU; frequent mutation; severe loss of amino acid transport activity).
SLC7A9	354	354	A -> T (in CSNU; type III; severe loss of amino acid transport activity).
SLC7A9	379	379	S -> R (in CSNU).
SLC7A9	382	382	A -> T (in CSNU).
WDR88	166	166	D -> H (in a breast cancer sample; somatic mutation).
SLC7A10	112	112	E -> D (in a family with cystinuria).
SCN1B	25	25	D -> N (in a patient with idiopathic epilepsy).
SCN1B	87	87	E -> Q (in a patient presenting with palpitations and complete left bundle branch block on electrocardiogram).
SCN1B	121	121	C -> W (in GEFS+1).
SCN1B	138	138	V -> I.
SCN1B	208	208	K -> I.
SCN1B	211	211	C -> Y.
SCN1B	213	213	G -> D.
HAMP	59	59	R -> G (in HFE2B).
HAMP	70	70	C -> R (in HFE2B).
HAMP	71	71	G -> D (in HFE2B).
HAMP	78	78	C -> Y (in HFE2B).
CD22	34	34	A -> T.
CD22	152	152	Q -> E (observed with a marginally higher frequency in patients with systemic lupus erythematosus).
CD22	203	203	E -> K.
CD22	669	669	R -> C.
FFAR3	44	44	Q -> R.
FFAR3	174	174	R -> W (abolishes activation by propionate).
FFAR3	346	346	S -> N.
DMKN	13	13	A -> D (in a colorectal cancer sample; somatic mutation).
COX6B1	20	20	R -> H (in MT-C4D).
NPHS1	64	64	W -> S (in NPHS1; lack of protein expression on the cell surface).
NPHS1	96	96	L -> V (in NPHS1).
NPHS1	107	107	A -> T (in NPHS1).
NPHS1	107	107	A -> V (in NPHS1).
NPHS1	167	167	P -> L (in NPHS1).
NPHS1	171	171	I -> N (in NPHS1; lack of protein expression on the cell surface).
NPHS1	172	172	Missing (in NPHS1).
NPHS1	173	173	I -> N (in NPHS1; lack of protein expression on the cell surface).
NPHS1	205	207	TPR -> I (in NPHS1).
NPHS1	256	256	R -> W (in NPHS1).
NPHS1	264	264	P -> R (found in patients with nephrotic syndrome; unknown pathological significance).
NPHS1	265	265	C -> R (in NPHS1).
NPHS1	270	270	G -> C (in NPHS1; lack of protein expression on the cell surface).
NPHS1	299	299	R -> C (in NPHS1).
NPHS1	340	340	P -> H (in NPHS1).
NPHS1	347	347	G -> E (in NPHS1).
NPHS1	350	350	S -> P (in NPHS1; lack of protein expression on the cell surface).
NPHS1	366	366	S -> R (in NPHS1; lack of protein expression on the cell surface; the mutant protein is retained in the endoplasmic reticulum).
NPHS1	367	367	R -> C (in NPHS1; lack of protein expression on the cell surface).
NPHS1	368	368	P -> L (in NPHS1).
NPHS1	368	368	P -> S (in NPHS1; lack of protein expression on the cell surface).
NPHS1	376	376	L -> V (in NPHS1; does not affect protein expression on the cell surface).
NPHS1	379	379	R -> W (in NPHS1).
NPHS1	407	407	R -> W (in NPHS1).
NPHS1	412	412	G -> C (in NPHS1).
NPHS1	417	417	C -> F (in NPHS1).
NPHS1	460	460	R -> Q (in NPHS1).
NPHS1	465	465	C -> Y (in NPHS1; lack of protein expression on the cell surface).
NPHS1	519	519	P -> S (in NPHS1).
NPHS1	528	528	C -> F (in NPHS1; lack of protein expression on the cell surface).
NPHS1	558	558	R -> C (in NPHS1).
NPHS1	569	569	S -> R (in NPHS1).
NPHS1	572	572	S -> N (in NPHS1).
NPHS1	575	575	P -> Q (in NPHS1).
NPHS1	586	586	R -> G (in NPHS1).
NPHS1	587	587	L -> R (in NPHS1).
NPHS1	610	610	L -> Q (in NPHS1; lack of protein expression on the cell surface).
NPHS1	617	617	H -> R (found in patients with nephrotic syndrome; unknown pathological significance).
NPHS1	623	623	C -> F (in NPHS1; lack of protein expression on the cell surface).
NPHS1	673	673	N -> K (in NPHS1).
NPHS1	681	681	W -> C (in NPHS1).
NPHS1	709	709	V -> G (in NPHS1).
NPHS1	724	724	S -> C (in NPHS1; does not affect protein expression on the cell surface).
NPHS1	725	725	E -> D (found in patients with nephrotic syndrome; unknown pathological significance).
NPHS1	739	739	A -> V (in NPHS1).
NPHS1	743	743	R -> C (in NPHS1; does not affect protein expression on the cell surface).
NPHS1	802	802	R -> P (in NPHS1; lack of protein expression on the cell surface).
NPHS1	802	802	R -> W (in NPHS1; lack of protein expression on the cell surface).
NPHS1	806	806	A -> D (in NPHS1; lack of protein expression on the cell surface).
NPHS1	819	819	D -> V (in NPHS1).
NPHS1	822	822	V -> M (in NPHS1).
NPHS1	831	831	R -> C (in NPHS1; lack of protein expression on the cell surface).
NPHS1	832	832	L -> P (in NPHS1; the mutant protein is retained in the endoplasmic reticulum).
NPHS1	834	834	V -> F (in NPHS1).
NPHS1	851	851	A -> V (found in patients with nephrotic syndrome; unknown pathological significance).
NPHS1	910	910	S -> P (in NPHS1).
NPHS1	976	976	R -> S (in NPHS1).
NPHS1	1140	1140	R -> C (in NPHS1; does not affect protein expression on the cell surface).
SDHAF1	55	55	R -> P (in MT-C2D).
SDHAF1	57	57	G -> R (in MT-C2D).
ZNF569	29	29	Q -> E (in a breast cancer sample; somatic mutation).
ZNF569	87	87	E -> G (in a breast cancer sample; somatic mutation).
SPINT2	163	163	Y -> C (in DIAR3; has a significantly reduced ability to inhibit trypsin compared to wild-type).
RASGRP4	120	120	Q -> L.
RASGRP4	145	145	V -> A.
RASGRP4	261	261	R -> C.
RASGRP4	335	335	R -> G.
MAP4K1	737	737	S -> F (in a metastatic melanoma sample; somatic mutation).
DLL3	115	115	A -> T.
DLL3	385	385	G -> D (in SCDO1).
DYRK1B	275	275	Q -> R (in a metastatic melanoma sample; somatic mutation).
ZNF546	15	15	L -> V (in a breast cancer sample; somatic mutation).
MAP3K10	107	107	G -> E (in a metastatic melanoma sample; somatic mutation).
PRX	406	406	A -> T.
PRX	495	495	E -> Q.
PRX	935	935	K -> E.
PRX	1259	1259	E -> K.
PRX	1359	1359	Missing.
PRX	1411	1411	R -> C.
LTBP4	311	311	C -> G (in URDS).
CYP2A6	110	110	V -> L (in allele CYP2A6*24, increases phenacetin O-deethylation activity 4 fold).
CYP2A6	128	128	R -> L (in allele CYP2A6*26).
CYP2A6	194	194	K -> E (in allele CYP2A6*15).
CYP2A6	203	203	R -> C (in allele CYP2A6*23; greatly reduced activity toward nicotine C- oxidation as well as reduced coumarin 7- hydroxylation).
CYP2A6	224	224	S -> P.
CYP2A6	438	438	N -> Y (in allele CYP2A6*24).
CYP2B6	139	139	K -> E (in allele CYP2B6*8 and allele CYP2B6*13).
CYP2A13	101	101	R -> Q (in allele CYP2A13*4).
CYP2A13	134	134	T -> TT (in allele CYP2A13*3).
CYP2A13	158	158	D -> E (in allele CYP2A13*3 and allele CYP2A13*8).
CYP2A13	323	323	V -> L (in allele CYP2A13*9).
CYP2A13	453	453	F -> Y (in allele CYP2A13*5).
CYP2A13	494	494	R -> C (in allele CYP2A13*6).
CYP2F1	218	218	D -> N (in allele CYP2F1*3 and in allele CYP2F1*4).
CYP2F1	266	266	Q -> H (in allele CYP2F1*3).
CYP2F1	391	391	L -> P (in allele CYP2F1*5A and in allele CYP2F1*5B).
AXL	295	295	R -> W (in a lung neuroendocrine carcinoma sample; somatic mutation).
AXL	499	499	R -> C (in a gastric adenocarcinoma sample; somatic mutation).
AXL	515	515	S -> G.
TGFB1	81	81	Y -> H (in CE; leads to TGF-beta-1 intracellular accumulation).
TGFB1	218	218	R -> C (in CE; higher levels of active TGF-beta-1 in the culture medium; enhances osteoclast formation in vitro).
TGFB1	218	218	R -> H (in CE).
TGFB1	222	222	H -> D (in CE; sporadic case; higher levels of active TGF-beta-1 in the culture medium).
TGFB1	225	225	C -> R (in CE; higher levels of active TGF-beta-1 in the culture medium).
BCKDHA	159	159	R -> W (in MSUD1A).
BCKDHA	190	190	Q -> K (in MSUD1A).
BCKDHA	253	253	A -> T (in MSUD1A).
BCKDHA	290	290	G -> R (in MSUD1A).
BCKDHA	326	326	I -> T (in MSUD1A).
BCKDHA	409	409	F -> C (in MSUD1A).
BCKDHA	413	413	Y -> C (in MSUD1A).
BCKDHA	438	438	Y -> N (in MSUD1A; impedes assembly of the E1 component).
RPS19	9	14	Missing (in DBA1).
RPS19	15	15	V -> F (in DBA1; affects protein stability; does not localize to the nucleolus).
RPS19	17	17	A -> P (in DBA1).
RPS19	18	19	LA -> E (in DBA1).
RPS19	18	18	L -> P (in DBA1; affects protein stability; does not localize to the nucleolus; affects assembly into a functional ribosomal subunit).
RPS19	18	18	L -> R (in DBA1).
RPS19	21	21	F -> S (in DBA1).
RPS19	47	47	P -> L (in DBA1; affects assembly into a functional ribosomal subunit).
RPS19	52	52	W -> C (in DBA1).
RPS19	52	52	W -> R (in DBA1; affects assembly into a functional ribosomal subunit).
RPS19	55	55	T -> M (in DBA1).
RPS19	56	56	R -> Q (in DBA1; affects assembly into a functional ribosomal subunit).
RPS19	57	57	A -> P (in DBA1; affects protein stability; does not localize to the nucleolus; affects assembly into a functional ribosomal subunit).
RPS19	58	60	Missing (in DBA1).
RPS19	59	59	S -> F (in DBA1).
RPS19	61	61	A -> E (in DBA1; does not localize to the nucleolus; affects assembly into a functional ribosomal subunit).
RPS19	62	62	R -> Q (in DBA1; affects assembly into a functional ribosomal subunit).
RPS19	62	62	R -> W (in DBA1; increased protein degradation; affects assembly into a functional ribosomal subunit).
RPS19	64	64	L -> P (in DBA1).
RPS19	76	76	T -> P (in DBA1).
RPS19	78	83	IYGGRQ -> R (in DBA1).
RPS19	101	101	R -> H (in DBA1; increased protein degradation; affects assembly into a functional ribosomal subunit).
RPS19	120	120	G -> R (in DBA1).
RPS19	127	127	G -> E (in DBA1; affects protein stability; does not localize to the nucleolus; affects assembly into a functional ribosomal subunit).
RPS19	131	131	L -> P (in DBA1).
RPS19	131	131	L -> R (in DBA1).
RPS19	135	135	A -> T (in DBA1).
ARHGEF1	165	165	M -> V (in a colorectal cancer sample; somatic mutation).
ATP1A3	274	274	I -> T (in DYT12).
ATP1A3	277	277	E -> K (in DYT12).
ATP1A3	613	613	T -> M (in DYT12).
ATP1A3	758	758	I -> S (in DYT12).
ATP1A3	780	780	F -> L (in DYT12).
ATP1A3	801	801	D -> Y (in DYT12).
CIC	104	104	E -> K (in a breast cancer sample; somatic mutation).
CIC	492	492	R -> W (de novo variant found in a patient with mental retardation).
CIC	652	652	A -> T (in a breast cancer sample; somatic mutation).
LIPE	146	146	P -> Q (in a breast cancer sample; somatic mutation).
CD177	119	119	L -> F.
CD177	323	323	R -> Q.
CD177	379	379	F -> S.
ETHE1	38	38	Y -> C (in EE).
ETHE1	136	136	T -> A (in EE).
ETHE1	185	185	L -> R (in EE).
XRCC1	350	350	R -> W (in a colorectal cancer sample; somatic mutation).
ZNF155	474	474	H -> R (in a colorectal cancer sample; somatic mutation).
APOE	64	64	Q -> H.
APOE	163	163	R -> H (in E3 Kochi).
APOE	167	167	Missing (in SBHD).
APOC1	71	71	T -> S (polymorphism found only in persons of American Indian or Mexican ancestry; more susceptible to N-terminal truncation and shows greater distribution to the VLDL than the protein with T-71).
APOC4	52	52	G -> D.
APOC4	75	75	P -> Q (in a breast cancer sample; somatic mutation).
CLASRP	213	213	L -> S (in a breast cancer sample; somatic mutation).
MARK4	418	418	R -> C (in a colorectal adenocarcinoma sample; somatic mutation).
ERCC2	47	47	G -> R (in XP-D).
ERCC2	76	76	T -> A (in XP-D).
ERCC2	112	112	R -> H (in TTDP and XP-D).
ERCC2	234	234	D -> N (in XP-D).
ERCC2	259	259	C -> Y (in TTDP).
ERCC2	461	461	L -> V (in XP-D and TTDP).
ERCC2	482	482	Missing (in TTDP).
ERCC2	485	485	L -> P (in XP-D; the corresponding mutation in fission yeast causes complete loss of activity).
ERCC2	487	487	R -> G (in TTDP).
ERCC2	488	493	Missing (in TTDP; mild).
ERCC2	511	511	R -> Q (in XP-D).
ERCC2	541	541	S -> R (in XP-D; mild).
ERCC2	542	542	Y -> C (in XP-D).
ERCC2	582	583	EK -> VSE (in XP-D).
ERCC2	592	592	R -> P (in TTDP).
ERCC2	594	594	A -> P (in TTDP).
ERCC2	601	601	R -> L (in XP-D).
ERCC2	601	601	R -> W (in XP-D).
ERCC2	602	602	G -> D (in XP-D; combined with features of Cockayne syndrome).
ERCC2	616	616	R -> C.
ERCC2	616	616	R -> P (in XP-D and TTDP).
ERCC2	616	616	R -> W (in XP-D and COFS2).
ERCC2	658	658	R -> C (in TTDP).
ERCC2	658	658	R -> G (in TTDP).
ERCC2	658	658	R -> H (in TTDP).
ERCC2	663	663	C -> R (in TTDP).
ERCC2	666	666	R -> W (in XP-D).
ERCC2	673	673	D -> G (in TTDP).
ERCC2	675	675	G -> R (in XP-D/CS; severe form).
ERCC2	681	681	D -> N (in XP-D and COFS2).
ERCC2	683	683	R -> Q (in XP-D; CNS).
ERCC2	713	713	G -> R (in TTDP).
ERCC2	716	730	Missing (in XP-D and TTDP).
ERCC2	722	722	R -> W (in TTDP).
ERCC2	725	725	A -> P (in TTDP).
ERCC1	231	231	F -> L (in COFS4).
OPA3	93	93	G -> S (in OPA3).
OPA3	105	105	Q -> E (in OPA3).
DMPK	438	438	L -> V (in a lung small cell carcinoma sample; somatic mutation).
FOXA3	91	91	G -> R.
NANOS2	68	68	H -> Q.
FKRP	79	79	V -> M (in MDDGC5).
FKRP	114	114	A -> G (in MDDGB5; could be a polymorphism).
FKRP	134	134	R -> W (in MDDGC5).
FKRP	143	146	Missing (in MDDGC5).
FKRP	143	143	R -> S (in MDDGC5).
FKRP	160	160	V -> F (in MDDGC5).
FKRP	182	182	Y -> C (in MDDGC5).
FKRP	217	217	P -> T (in MDDGB5).
FKRP	293	293	T -> I (in MDDGC5).
FKRP	300	300	V -> A (in MDDGC5).
FKRP	300	300	V -> M (in MDDGC5).
FKRP	307	307	Y -> N (in MDDGC5 and MDDGA5; muscle-eye- brain disease).
FKRP	309	309	Y -> C (in MDDGB5).
FKRP	312	312	R -> C (in MDDGC5).
FKRP	315	315	P -> T (in MDDGB5; severe form; brain involvement; mental retardation and cerebellar cysts on cranial MRI).
FKRP	316	316	P -> R (in MDDGB5 and MDDGC5).
FKRP	316	316	P -> S (in MDDGC5).
FKRP	318	318	C -> Y (in MDDGA5; severe Walker-Warburg syndrome).
FKRP	328	328	Y -> S (in MDDGB5).
FKRP	339	339	R -> H (in MDDGB5).
FKRP	339	339	R -> L (in MDDGC5).
FKRP	358	358	P -> L (in MDDGC5).
FKRP	360	360	D -> N (in MDDGC5).
FKRP	401	401	D -> N (in MDDGB5).
FKRP	448	448	P -> L (in MDDGB5; strongly reduced secretion to the medium; localizes mainly to the ER compartment).
FKRP	462	462	P -> S (in MDDGC5).
FKRP	463	463	N -> D (in MDDGB5).
FKRP	465	465	Y -> S (in MDDGB5).
ZNF541	712	712	S -> L (in a breast cancer sample; somatic mutation).
CRX	41	41	R -> Q (in RP).
CRX	41	41	R -> W (in CORD2; exhibits reduced DNA binding, transcriptional synergy and interaction with NRL).
CRX	88	88	K -> N (in LCA7; reduces NRL transactivation and reduces steady state levels of CRX and NRL; altered localization to the cytoplasm).
CRX	90	90	R -> W (in LCA7; reduced DNA-binding ability, transcriptional synergy and interaction with NRL).
CRX	122	122	G -> D (in RP).
CRX	141	141	S -> F (in a breast cancer sample; somatic mutation).
CRX	146	149	Missing (in LCA7).
CRX	158	158	A -> T.
CRX	242	242	V -> M (in CORD2).
PLA2G4C	430	430	R -> C.
GRIN2D	140	140	P -> S (in a breast cancer sample; somatic mutation).
GRIN2D	286	286	G -> R (in a breast cancer sample; somatic mutation).
GRIN2D	527	527	E -> G (in a breast cancer sample; somatic mutation).
FUT1	154	154	Y -> C (in Bombay H-).
FUT1	164	164	L -> H (in para-Bombay).
FUT1	171	171	W -> C (in Bombay H-).
FUT1	259	259	V -> E (in Bombay H-).
FUT1	315	315	A -> V (in Bombay H-).
FUT1	349	349	W -> C (in Bombay H-).
TULP2	149	149	V -> I (found in a renal cell carcinoma sample; somatic mutation).
BAX	11	11	G -> E (in a plasmacytoma cell line).
BAX	67	67	G -> R (in a T-cell acute lymphoblastic leukemia cell line; loss of heterodimerization with Bcl-2 or Bcl- X(L)).
BAX	108	108	G -> V (in a Burkitt lymphoma; loss of homodimerization).
FTL	96	96	A -> T (in NBIA3).
GYS1	464	464	G -> S (in NIDDM).
CGB	18	18	T -> A.
CGB	24	24	P -> M (requires 2 nucleotide substitutions).
CGB	28	28	R -> W.
CGB	30	30	R -> H.
CGB	147	147	S -> C.
CGB5	18	18	T -> A.
CGB5	24	24	P -> M (requires 2 nucleotide substitutions).
CGB5	28	28	R -> W.
CGB5	30	30	R -> H.
CGB5	147	147	S -> C.
CGB8	18	18	T -> A.
CGB8	24	24	P -> M (requires 2 nucleotide substitutions).
CGB8	28	28	R -> W.
CGB8	30	30	R -> H.
CGB8	147	147	S -> C.
NTF4	7	7	C -> Y (in a patient with primary open- angle glaucoma; uncertain pathological significance).
NTF4	84	84	E -> K (in a patient with primary open- angle glaucoma; uncertain pathological significance).
NTF4	88	88	A -> V.
NTF4	89	89	S -> N.
NTF4	90	90	R -> C.
NTF4	90	90	R -> H (in a patient with primary open- angle glaucoma; uncertain pathological significance).
NTF4	114	114	R -> G.
NTF4	133	133	R -> H.
NTF4	140	140	R -> C.
NTF4	206	206	R -> Q (in a patient with primary open- angle glaucoma; uncertain pathological significance).
NTF4	206	206	R -> W (in patients with primary open- angle glaucoma and normal pressure glaucoma; uncertain pathological significance; impaired ligand-mediated TRKB signaling and reduced neurite outgrowth).
NTF4	207	207	T -> I.
NTF4	207	207	T -> S.
NTF4	209	209	R -> G (in a patient with primary open- angle glaucoma; uncertain pathological significance).
HRC	204	204	Missing.
TSKS	19	19	G -> R (in a colorectal cancer sample; somatic mutation).
PNKP	176	176	L -> F (in MCSZ).
PNKP	326	326	E -> K (in MCSZ).
NUP62	391	391	Q -> P (in SNDI).
KCNC3	420	420	R -> H (in SCA13; loss of channel activity).
KCNC3	448	448	F -> L (in SCA13; slow channel closing).
SYT3	474	474	S -> F (in a breast cancer sample; somatic mutation).
SHANK1	569	569	A -> D (in a colorectal cancer sample; somatic mutation).
SHANK1	2026	2026	G -> R (in a colorectal cancer sample; somatic mutation).
KLK15	137	137	A -> T (in a breast cancer sample; somatic mutation).
SIGLEC7	215	215	L -> P (in a colorectal cancer sample; somatic mutation).
ETFB	128	128	D -> N (in GA2B).
ETFB	164	164	R -> Q (in GA2B).
SIGLEC8	282	282	V -> L (found in a renal cell carcinoma sample; somatic mutation).
ZNF432	416	416	L -> V (in a breast cancer sample; somatic mutation).
ZNF432	490	490	C -> Y (in a breast cancer sample; somatic mutation).
PPP2R1A	87	87	H -> R (in lung).
VN1R4	52	52	A -> V (in allele VN1R4*3).
VN1R4	58	58	R -> L (in allele VN1R4*4).
NDUFA3	62	62	N -> D (in a breast cancer sample; somatic mutation).
PRPF31	111	114	Missing (in RP11; high penetrance).
PRPF31	194	194	A -> E (in RP11; mislocation of the protein in the cytoplasm and reduced interaction with PRPF6; the result may be a deficiency in splicing function in the retina).
PRPF31	216	216	A -> P (in RP11; mislocation of the protein in the cytoplasm, but no effect on interaction with PRPF6; the result may be a deficiency in splicing function in the retina).
TSEN34	58	58	R -> W (in PCH2C).
RPS9	137	137	V -> F (in a breast cancer sample; somatic mutation).
KIR2DL1	135	135	P -> L.
KIR2DL1	175	175	P -> T.
KIR2DL1	184	184	D -> N.
KIR2DL1	203	203	H -> R.
KIR2DL1	237	237	K -> E.
KIR2DL1	266	266	R -> C.
NCR1	87	87	D -> Y (in a colorectal cancer sample; somatic mutation).
TNNI3	2	2	A -> V (in CMD2A).
TNNI3	36	36	K -> Q (in CMD1FF).
TNNI3	82	82	P -> S (in CMH7).
TNNI3	141	141	R -> Q (in CMH7).
TNNI3	144	144	L -> Q (in RCM1).
TNNI3	145	145	R -> G (in CMH7).
TNNI3	157	157	A -> V (in CMH7).
TNNI3	162	162	R -> P (in CMH7).
TNNI3	162	162	R -> Q (in CMH7).
TNNI3	166	166	S -> F (in CMH7).
TNNI3	171	171	A -> T (in RCM1).
TNNI3	177	177	Missing (in CMH7).
TNNI3	185	185	N -> K (in CMD1FF).
TNNI3	186	186	R -> Q (in CMH7).
TNNI3	190	190	D -> H (in CMH7 and RCM1).
TNNI3	192	192	R -> H (in RCM1).
TNNI3	196	196	D -> N (in CMH7).
TNNI3	204	204	R -> H (in CMH7).
TNNI3	206	206	K -> Q (in CMH7).
HSPBP1	25	27	Missing.
BRSK1	303	303	R -> W (in a gastric adenocarcinoma sample; somatic mutation).
BRSK1	319	319	V -> I (in a lung large cell carcinoma sample; somatic mutation).
BRSK1	391	391	G -> E (in a metastatic melanoma sample; somatic mutation).
BRSK1	749	749	G -> S.
SBK2	20	20	E -> K.
SBK2	41	41	A -> E.
SBK2	102	102	G -> D.
ZNF471	361	361	F -> C (in a colorectal cancer sample; somatic mutation).
PEG3	594	594	R -> H (in a colorectal cancer sample; somatic mutation).
PEG3	1576	1576	R -> L.
AURKC	52	52	G -> E (in a lung adenocarcinoma sample; somatic mutation).
AURKC	148	148	E -> Q (in a lung squamous cell carcinoma sample; somatic mutation).
AURKC	244	244	H -> Q (in a lung adenocarcinoma sample; somatic mutation).
VN1R1	139	139	I -> T (in allele VN1R1*2).
VN1R1	269	269	A -> D (in allele VN1R1*3).
DCC	168	168	M -> T (in a esophageal carcinoma).
DCC	1039	1039	F -> S (in a colorectal cancer sample; somatic mutation).
DCC	1375	1375	P -> H (in a colorectal carcinoma).
MC4R	11	11	T -> A (in obesity; partial activity).
MC4R	30	30	S -> R (in obesity).
MC4R	36	36	S -> Y (in obesity; shows the same affinity as the wild-type but significant impairment of cAMP-induced activity in response to melanotan II compared with the wild-type receptor).
MC4R	50	50	V -> M (in obesity).
MC4R	58	58	S -> C (in obesity).
MC4R	62	62	N -> S (in obesity; shows a partial cAMP response to alpha-MSH).
MC4R	88	92	Missing (in obesity; the mutant receptor is expressed well on the cell surface but is completely devoid of ligand binding and cAMP generation in response to agonist stimulation).
MC4R	97	97	N -> D (in obesity; completely unable to generate cAMP in response to ligand; shows evidence of impaired cell surface expression).
MC4R	102	102	I -> S (in obesity; shows the same affinity as the wild-type but significant impairment of cAMP-induced activity in response to melanotan II compared with the wild-type receptor).
MC4R	102	102	I -> T (in obesity).
MC4R	106	106	L -> P (in obesity; completely unable to generate cAMP in response to ligand; shows evidence of impaired cell surface expression).
MC4R	125	125	I -> K (in obesity; completely unable to generate cAMP in response to ligand; shows evidence of impaired cell surface expression).
MC4R	170	170	I -> V (in obesity).
MC4R	175	175	A -> T (in obesity; shows a partial cAMP response to alpha-MSH).
MC4R	219	219	A -> V (in obesity; shows significantly impairment of cAMP-induced activity in response to melanotan II compared with the wild-type receptor).
MC4R	226	226	I -> T.
MC4R	253	253	V -> I (in obesity; shows a partial cAMP response to alpha-MSH).
MC4R	271	271	C -> R (in obesity; completely unable to generate cAMP in response to ligand; shows impaired cell surface expression).
MC4R	271	271	C -> Y (in obesity; no activity).
MC4R	274	274	N -> S (in obesity).
MC4R	316	316	I -> S (in obesity; shows reduced cAMP response to alpha-MSH; retains normal affinity for the antagonist AGRP).
MC4R	325	325	L -> F (in obesity; does not bind alpha- MSH).
APCDD1	9	9	L -> R (in HTS; dominant-negative mutant that perturbs the translational processing from the endoplasmic reticulum to the plasma membrane).
CTIF	389	389	V -> L (in a breast cancer sample; somatic mutation).
CTIF	438	438	M -> I (in a breast cancer sample; somatic mutation).
ZNF532	822	822	S -> L (in a breast cancer sample; somatic mutation).
BCL2	7	7	T -> S.
BCL2	59	59	P -> S (in non-Hodgkin lymphoma; somatic mutation).
BCL2	93	93	V -> I (in non-Hodgkin lymphoma; somatic mutation).
SERPINB11	181	181	I -> A (in allele D; requires 2 nucleotide substitutions).
SERPINB11	181	181	I -> T (in allele B and allele C).
METTL4	42	42	S -> F (found in a renal cell carcinoma sample; somatic mutation).
ANKRD29	95	95	V -> M (in a breast cancer sample; somatic mutation).
DSEL	1090	1090	K -> E (in a colorectal cancer sample; somatic mutation).
LPIN2	734	734	S -> L (in MAJEEDS).
ANKRD12	171	171	S -> T.
MC2R	74	74	S -> I (in GCCD1; complete loss of activity).
MC2R	103	103	D -> N (in GCCD1).
MC2R	107	107	D -> N (in GCCD1).
MC2R	120	120	S -> R (in GCCD1).
MC2R	128	128	R -> C (in GCCD1).
MC2R	137	137	R -> P (found in a glucocorticoid deficiency patient carrying also mutation I-74).
MC2R	137	137	R -> W (in GCCD1; partial loss of ACTIVITY).
MC2R	146	146	R -> H (in GCCD1).
MC2R	251	251	C -> F (in GCCD1).
DSG4	125	335	Missing (in LAH1).
DSG2	46	46	R -> Q (in ARVD10).
DSG2	49	49	R -> H (in ARVD10).
DSG2	56	56	V -> M (associated with CMD1BB and ARVD10 although it may not be sufficient by itself to result in cardiomyopathy).
DSG2	158	158	V -> G.
DSG2	335	335	T -> A (in ARVD10).
DSG2	507	507	C -> Y (in ARVD10).
DSG2	713	713	E -> K.
DSG2	812	812	G -> C (in ARVD10).
DSG2	920	920	V -> G.
ROCK1	1193	1193	P -> S (in a lung neuroendocrine carcinoma sample; somatic mutation).
ROCK1	1217	1217	Q -> E.
ROCK1	1262	1262	R -> Q.
ROCK1	1264	1264	C -> R.
TGIF1	157	157	S -> C (in HPE4).
TGIF1	192	192	P -> R (in HPE4).
TGIF1	236	236	Q -> L (in HPE4).
TGIF1	280	280	T -> A (in HPE4).
TGIF1	291	291	S -> F (in HPE4).
TRAPPC8	537	537	R -> Q (in a breast cancer sample; somatic mutation).
DTNA	121	121	P -> L (in LVNC1).
EPG5	1511	1511	A -> T (in a breast cancer sample; somatic mutation).
EPG5	1865	1865	C -> Y (in a breast cancer sample; somatic mutation).
EPG5	2056	2056	R -> W (in a breast cancer sample; somatic mutation).
MYO5B	108	108	V -> G (in DIAR2).
MYO5B	219	219	R -> H (in DIAR2).
MYO5B	656	656	R -> C (in DIAR2).
MOCOS	57	57	A -> P (in XU2).
MOCOS	294	294	T -> I (in XU2).
MOCOS	776	776	R -> C (in XU2).
TCF4	535	535	D -> G (in PTHS; loss of function).
TCF4	572	572	R -> G (in PTHS; loss of function).
TCF4	576	576	R -> Q (in PTHS; loss of function).
TCF4	576	576	R -> W (in PTHS).
TCF4	610	610	A -> V (in PTHS; loss of function).
NEDD4L	355	355	P -> L (common polymorphism; impaired ability to inhibit SCNN).
NEDD4L	497	497	S -> R.
ALPK2	942	942	E -> K (in an ovarian undifferentiated carcinoma sample; somatic mutation).
ALPK2	1476	1476	K -> T (in a melanoma metastatic sample; somatic mutation).
CCBE1	327	327	G -> R (in HLLS; rs121908252).
CDH20	228	228	M -> I (in a breast cancer sample; somatic mutation).
CDH20	416	416	P -> T (in a breast cancer sample; somatic mutation).
CDH20	746	746	Q -> H (in a breast cancer sample; somatic mutation).
KIAA1468	929	929	G -> E (in a colorectal cancer sample; somatic mutation).
TNFRSF11A	21	21	L -> LALLLLCALL (in PDB2).
TNFRSF11A	21	21	L -> LLLCALL (in FEO).
TNFRSF11A	53	53	G -> R (in OPTB7; two patients with osteoclast-poor osteopetrosis).
TNFRSF11A	129	129	R -> C (in OPTB7; a patient with osteoclast-poor osteopetrosis).
TNFRSF11A	170	170	R -> G (in OPTB7; two siblings with osteoclast-poor osteopetrosis).
TNFRSF11A	175	175	C -> R (in OPTB7; two patients with osteoclast-poor osteopetrosis).
TNFRSF11A	244	244	A -> S (in OPTB7; one patient with osteoclast-poor osteopetrosis).
CNDP1	20	20	L -> LL.
SALL3	143	143	R -> H (in a colorectal cancer sample; somatic mutation).
AFG3L2	432	432	N -> T (in SCA28).
AFG3L2	654	654	T -> I (in SCA28).
AFG3L2	666	666	M -> R (in SCA28).
AFG3L2	666	666	M -> T (in SCA28).
AFG3L2	666	666	M -> V (in SCA28).
AFG3L2	671	671	G -> E (in SCA28).
AFG3L2	671	671	G -> R (in SCA28).
AFG3L2	691	691	E -> K (in SCA28).
AFG3L2	694	694	A -> E (in SCA28).
AFG3L2	700	700	E -> K (in SCA28).
AFG3L2	702	702	R -> Q (in SCA28).
FAM210A	82	82	R -> H (in a breast cancer sample; somatic mutation).
FAM210A	140	140	V -> E (in a breast cancer sample; somatic mutation).
DYM	87	87	E -> K (in SMC; does not affect protein localization).
DYM	469	469	N -> Y (in DMC; results in protein mis- localization and aggregation).
DYM	542	542	C -> R (in SMC).
SMAD4	130	130	P -> S (in a colorectal cancer sample; somatic mutation).
SMAD4	330	330	E -> G (in JPS).
SMAD4	351	351	D -> N (in a colorectal cancer sample; somatic mutation).
SMAD4	352	352	G -> R (in JP/HHT and JPS).
SMAD4	361	361	R -> C (in JPS).
SMAD4	361	361	R -> H (in a colorectal cancer sample; somatic mutation).
NPC1	63	63	C -> R (in NPC1).
NPC1	74	74	C -> Y (in NPC1).
NPC1	92	92	Q -> R (in NPC1).
NPC1	113	113	C -> R (in NPC1; partially mislocalized from late endocytic organelles diffusely to the cell periphery; localizes to the endoplasmic reticulum Rab7-negative endosomes and the cell surface; does not clears the lysosomal cholesterol accumulation in NPC1-deficient cells).
NPC1	137	137	T -> M (in NPC1).
NPC1	166	166	P -> S (in NPC1).
NPC1	177	177	C -> G (in NPC1; late infantile form).
NPC1	177	177	C -> Y (in NPC1).
NPC1	231	231	V -> G (in NPC1).
NPC1	237	237	P -> S (in NPC1; late infantile form).
NPC1	242	242	D -> H (in NPC1).
NPC1	242	242	D -> N (in NPC1).
NPC1	247	247	C -> Y (in NPC1).
NPC1	248	248	G -> V (in NPC1).
NPC1	272	272	M -> R (in NPC1).
NPC1	273	273	W -> S (colocalizes with the wild-type protein with Rab7-positive late endosomes; clears the lysosomal cholesterol accumulation in NPC1- deficient cells).
NPC1	333	333	G -> D.
NPC1	372	372	R -> W (in NPC1).
NPC1	378	378	V -> A (in NPC1).
NPC1	380	380	L -> F (in NPC1).
NPC1	381	381	W -> C.
NPC1	388	388	A -> P (in NPC1).
NPC1	389	389	R -> C (in NPC1).
NPC1	401	401	P -> T (in NPC1).
NPC1	404	404	R -> P (in NPC1).
NPC1	404	404	R -> Q (in NPC1).
NPC1	404	404	R -> W (in NPC1).
NPC1	433	433	P -> L (in NPC1).
NPC1	434	434	P -> L (in NPC1).
NPC1	434	434	P -> S.
NPC1	451	451	E -> K (in NPC1).
NPC1	472	472	L -> P.
NPC1	473	473	S -> P (in NPC1; late infantile form).
NPC1	474	474	P -> L (in NPC1).
NPC1	479	479	C -> Y (in NPC1).
NPC1	509	509	Y -> S (in NPC1).
NPC1	510	510	H -> P (in NPC1; late infantile form).
NPC1	512	512	H -> R (in NPC1).
NPC1	518	518	R -> Q (in NPC1; late infantile form; Common in Japanese).
NPC1	518	518	R -> W (in NPC1).
NPC1	521	521	A -> S (in NPC1).
NPC1	537	537	F -> L (in NPC1).
NPC1	543	543	P -> L (in NPC1).
NPC1	574	574	T -> K (in NPC1).
NPC1	576	576	K -> R (in NPC1).
NPC1	605	605	A -> V (in NPC1).
NPC1	612	612	E -> D (in NPC1).
NPC1	615	615	R -> C (in NPC1).
NPC1	615	615	R -> L (in NPC1).
NPC1	631	631	M -> R (in NPC1).
NPC1	640	640	G -> R (in NPC1).
NPC1	652	652	S -> W (in NPC1).
NPC1	660	660	G -> S (in NPC1).
NPC1	664	664	V -> M (in NPC1).
NPC1	666	666	S -> N (in NPC1).
NPC1	670	670	C -> W (in NPC1).
NPC1	673	673	G -> V (in NPC1).
NPC1	684	684	L -> F (in NPC1).
NPC1	691	691	P -> L (in NPC1).
NPC1	695	695	L -> V (in NPC1).
NPC1	700	700	D -> N (in NPC1).
NPC1	703	703	F -> S (in NPC1).
NPC1	724	724	L -> P (in NPC1).
NPC1	727	727	V -> F (in NPC1).
NPC1	734	734	S -> I (in NPC1).
NPC1	742	742	E -> K (in NPC1).
NPC1	745	745	A -> E (in NPC1).
NPC1	754	754	M -> K (in NPC1).
NPC1	757	757	V -> A.
NPC1	763	763	F -> L (in NPC1).
NPC1	767	767	A -> V (in NPC1).
NPC1	775	775	Q -> P (in NPC1).
NPC1	789	789	R -> C (in NPC1).
NPC1	789	789	R -> G (in NPC1).
NPC1	825	825	Y -> C (in NPC1).
NPC1	849	849	S -> I (in NPC1).
NPC1	862	862	Q -> L (in NPC1).
NPC1	865	865	S -> L (in NPC1).
NPC1	871	871	Y -> C (in NPC1).
NPC1	873	873	V -> A.
NPC1	874	874	D -> V (in NPC1).
NPC1	888	888	P -> S (in NPC1).
NPC1	889	889	V -> M (in NPC1; adult form).
NPC1	890	890	Y -> C (in NPC1).
NPC1	899	899	Y -> D (in NPC1).
NPC1	910	910	G -> S (in NPC1).
NPC1	917	917	D -> Y (in NPC1).
NPC1	926	926	A -> T (in NPC1).
NPC1	927	927	A -> V (in NPC1).
NPC1	929	929	L -> P (in NPC1).
NPC1	934	934	R -> Q (in NPC1).
NPC1	940	940	S -> L (in NPC1).
NPC1	942	942	W -> C (in NPC1).
NPC1	943	943	I -> M (in NPC1).
NPC1	944	944	D -> N (in NPC1).
NPC1	945	945	D -> N (in NPC1).
NPC1	948	948	D -> H (in NPC1).
NPC1	948	948	D -> N (in NPC1).
NPC1	948	948	D -> Y (in NPC1).
NPC1	950	950	V -> M (in NPC1; adult form).
NPC1	954	954	S -> L (in NPC1).
NPC1	956	956	C -> Y (in NPC1; late infantile form).
NPC1	958	958	R -> L (in NPC1).
NPC1	958	958	R -> Q (in NPC1).
NPC1	959	959	V -> E (in NPC1).
NPC1	961	966	NITDQF -> S (in NPC1).
NPC1	968	968	N -> S (in NPC1).
NPC1	971	971	V -> G.
NPC1	976	976	C -> R (in NPC1).
NPC1	986	986	G -> S (in NPC1).
NPC1	992	992	G -> A (in NPC1).
NPC1	992	992	G -> R (in NPC1).
NPC1	992	992	G -> W (in NPC1; found in the Nova Scotian clinical variant).
NPC1	996	996	M -> R (in NPC1).
NPC1	1004	1004	S -> L (in NPC1).
NPC1	1007	1007	P -> A (in NPC1).
NPC1	1012	1012	G -> D (in NPC1).
NPC1	1015	1015	G -> V (in NPC1).
NPC1	1016	1016	H -> R (in NPC1).
NPC1	1023	1023	V -> G (in NPC1).
NPC1	1034	1034	G -> R (in NPC1).
NPC1	1036	1036	T -> K (in NPC1).
NPC1	1049	1049	A -> V.
NPC1	1054	1054	A -> T (in NPC1).
NPC1	1059	1059	R -> Q (in NPC1).
NPC1	1061	1061	I -> T (in NPC1; late infantile form).
NPC1	1062	1062	A -> V (in NPC1).
NPC1	1066	1066	T -> N (in NPC1).
NPC1	1087	1087	F -> L (in NPC1).
NPC1	1089	1089	E -> K (in NPC1).
NPC1	1094	1094	I -> T (in NPC1).
NPC1	1097	1097	D -> N (in NPC1).
NPC1	1137	1137	N -> I (in NPC1).
NPC1	1140	1140	G -> V (in NPC1).
NPC1	1142	1142	M -> T (in NPC1).
NPC1	1150	1150	N -> K (in NPC1).
NPC1	1165	1165	V -> M (in NPC1).
NPC1	1167	1167	F -> L (in NPC1).
NPC1	1168	1168	C -> Y (in NPC1).
NPC1	1174	1174	A -> V (in NPC1).
NPC1	1186	1186	R -> H (in NPC1).
NPC1	1189	1189	E -> G (in NPC1).
NPC1	1205	1205	T -> K (in NPC1).
NPC1	1205	1205	T -> R (in NPC1).
NPC1	1212	1212	V -> L (in NPC1).
NPC1	1213	1213	L -> F (in NPC1; juvenile form).
NPC1	1213	1213	L -> V (in NPC1).
NPC1	1216	1216	A -> V (in NPC1).
NPC1	1220	1220	I -> T.
NPC1	1224	1224	F -> L (in NPC1).
NPC1	1236	1236	G -> E (in NPC1).
NPC1	1240	1240	G -> R (in NPC1).
NPC1	1249	1249	S -> G (in NPC1).
ATP8B1	45	45	N -> T (in ICP).
ATP8B1	127	127	L -> P (in PFIC1).
ATP8B1	288	288	L -> S (in PFIC1).
ATP8B1	305	305	F -> I.
ATP8B1	344	344	I -> F (in BRIC1).
ATP8B1	403	403	S -> Y (in PFIC1).
ATP8B1	412	412	R -> P (in PFIC1).
ATP8B1	453	453	S -> Y (in BRIC1).
ATP8B1	454	454	D -> G (in BRIC1).
ATP8B1	456	456	T -> M (in PFIC1).
ATP8B1	500	500	Y -> H (in PFIC1).
ATP8B1	529	529	Missing (in PFIC1).
ATP8B1	535	535	H -> L (in PFIC1).
ATP8B1	554	554	D -> N (in PFIC1).
ATP8B1	600	600	R -> Q (in BRIC1; compound heterozygote with N-70).
ATP8B1	600	600	R -> W (in BRIC1).
ATP8B1	628	628	R -> W (in BRIC1).
ATP8B1	645	699	Missing (in PFIC1).
ATP8B1	688	688	D -> G (in PFIC1).
ATP8B1	694	694	I -> T (in BRIC1).
ATP8B1	733	733	G -> R (in PFIC1).
ATP8B1	795	797	Missing (in BRIC1).
ATP8B1	853	853	F -> S (in PFIC1).
ATP8B1	867	867	R -> C (in ICP).
ATP8B1	886	886	A -> V (in a breast cancer sample; somatic mutation).
ATP8B1	892	892	G -> R (in PFIC1 and BRIC1).
ATP8B1	1040	1040	G -> R (in PFIC1).
ATP8B1	1178	1178	I -> M (in a breast cancer sample; somatic mutation).
DSC2	203	203	R -> C (in ARVD11; fails to undergo complete processing into a mature form; fails to localize at the desmosomes).
DSC2	231	231	I -> T (in ARVD11).
DSC2	275	275	T -> M (in ARVD11; can be processed into a mature form but shows a higher pro- protein to mature protein ratio; only a proportion of the partly functional mutant is incorporated into the desmosomes).
DSC2	340	340	T -> A (in ARVD11).
DSC2	358	358	T -> I.
DSC2	596	596	A -> V.
DSC2	638	638	Q -> H.
DSC2	798	798	R -> Q.
TTR	30	30	C -> R (in AMYL-TTR; amyloid polyneuropathy).
TTR	32	32	L -> P (in AMYL-TTR).
TTR	33	33	M -> I.
TTR	38	38	D -> E (in AMYL-TTR; amyloid polyneuropathy).
TTR	38	38	D -> G (in AMYL-TTR; leptomeningeal amyloidosis).
TTR	40	40	V -> I (in AMYL-TTR; late-onset amyloid polyneuropathy with carpal tunnel syndrome).
TTR	43	43	S -> N (in AMYL-TTR).
TTR	48	48	V -> M (in AMYL-TTR; amyloid polyneuropathy).
TTR	50	50	V -> A (in AMYL-TTR; amyloid polyneuropathy).
TTR	50	50	V -> G (in AMYL-TTR).
TTR	50	50	V -> L (in AMYL-TTR; amyloid polyneuropathy).
TTR	53	53	F -> C (in a patient with amyloidosis).
TTR	53	53	F -> I (in AMYL-TTR; Jewish 'SKO' amyloid polyneuropathy).
TTR	53	53	F -> L (in AMYL-TTR; amyloid polyneuropathy).
TTR	53	53	F -> V (in AMYL-TTR; amyloid polyneuropathy).
TTR	54	54	R -> T (in AMYL-TTR).
TTR	55	55	K -> N (in AMYL-TTR; amyloid polyneuropathy).
TTR	56	56	A -> P (in AMYL-TTR; amyloid polyneuropathy).
TTR	58	58	D -> A (in AMYL-TTR).
TTR	58	58	D -> V (in AMYL-TTR).
TTR	61	61	W -> L (in AMYL-TTR).
TTR	64	64	F -> S (in AMYL-TTR).
TTR	65	65	A -> D (in AMYL-TTR; amyloid cardiomyopathy).
TTR	65	65	A -> S (in AMYL-TTR).
TTR	65	65	A -> T (in AMYL-TTR; amyloid cardiomyopathy).
TTR	67	67	G -> A (in AMYL-TTR; amyloid polyneuropathy).
TTR	67	67	G -> E (in AMYL-TTR).
TTR	67	67	G -> R (in AMYL-TTR; amyloid polyneuropathy).
TTR	67	67	G -> V (in AMYL-TTR; amyloid polyneuropathy with carpal tunnel syndrome).
TTR	69	69	T -> A (in AMYL-TTR; amyloid polyneuropathy).
TTR	69	69	T -> I (in AMYL-TTR).
TTR	70	70	S -> I (in AMYL-TTR; amyloid cardiomyopathy).
TTR	70	70	S -> R (in AMYL-TTR; amyloid polyneuropathy).
TTR	72	72	S -> P (in AMYL-TTR; amyloid polyneuropathy).
TTR	73	73	G -> E (in AMYL-TTR).
TTR	74	74	E -> G (in AMYL-TTR; amyloid polyneuropathy).
TTR	74	74	E -> K (in AMYL-TTR; early-onset amyloid polyneuropathy).
TTR	75	75	L -> P (in AMYL-TTR; amyloid polyneuropathy).
TTR	75	75	L -> Q (in AMYL-TTR).
TTR	78	78	L -> H (in AMYL-TTR; amyloid polyneuropathy).
TTR	78	78	L -> R (in AMYL-TTR; amyloid polyneuropathy).
TTR	79	79	T -> K (in AMYL-TTR; amyloid cardiomyopathy).
TTR	80	80	T -> A (in AMYL-TTR; amyloid polyneuropathy and cardiomyopathy).
TTR	81	81	E -> G (in AMYL-TTR).
TTR	81	81	E -> K (in AMYL-TTR; amyloid polyneuropathy).
TTR	84	84	F -> L (in AMYL-TTR; amyloid polyneuropathy).
TTR	88	88	I -> L (in AMYL-TTR; amyloid cardiomyopathy).
TTR	89	89	Y -> H (in AMYL-TTR; leptomeningeal amyloidosis; vitreous amyloid in some patients).
TTR	90	90	K -> N (in AMYL-TTR; amyloid polyneuropathy).
TTR	91	91	V -> A (in AMYL-TTR; amyloid polyneuropathy).
TTR	93	93	I -> V (in AMYL-TTR; amyloid polyneuropathy).
TTR	94	94	D -> H.
TTR	97	97	S -> Y (in AMYL-TTR; amyloid polyneuropathy).
TTR	98	98	Y -> F (in AMYL-TTR).
TTR	104	104	I -> N (in AMYL-TTR; vitrous amyloid).
TTR	104	104	I -> S (in AMYL-TTR; amyloid polyneuropathy; almost no RBP binding).
TTR	104	104	I -> T (in AMYL-TTR).
TTR	109	109	E -> K (in AMYL-TTR; amyloid polyneuropathy).
TTR	109	109	E -> Q (in AMYL-TTR; amyloid polyneuropathy and cardiomyopathy).
TTR	110	110	H -> N.
TTR	111	111	A -> S (in AMYL-TTR; amyloid polyneuropathy).
TTR	114	114	V -> A (in a patient with amyloidosis).
TTR	117	117	A -> G (in AMYL-TTR; amyloid polyneuropathy).
TTR	117	117	A -> S (in AMYL-TTR).
TTR	121	121	G -> S.
TTR	122	122	P -> R.
TTR	124	124	R -> C.
TTR	124	124	R -> H.
TTR	126	126	T -> N (in AMYL-TTR).
TTR	127	127	I -> M (in AMYL-TTR).
TTR	127	127	I -> V (in AMYL-TTR; amyloid polyneuropathy).
TTR	129	129	A -> T (in HTDE; increased affinity for thyroxine).
TTR	131	131	L -> M (in AMYL-TTR).
TTR	134	134	Y -> C (in AMYL-TTR; amyloid polyneuropathy).
TTR	134	134	Y -> H (in CTS1; amyloid deposit on carpal tunnel; patients show no other abnormalities).
TTR	136	136	Y -> S (in AMYL-TTR; amyloid polyneuropathy).
TTR	136	136	Y -> V (requires 2 nucleotide substitutions).
TTR	140	140	A -> S (in AMYL-TTR).
TTR	142	142	V -> A (in AMYL-TTR).
TTR	144	144	N -> S (in AMYL-TTR).
SETBP1	868	868	D -> A (in SGMFS).
SETBP1	868	868	D -> N (in SGMFS).
SETBP1	870	870	G -> D (in SGMFS).
SETBP1	870	870	G -> S (in SGMFS).
SETBP1	871	871	I -> T (in SGMFS).
SETBP1	1162	1162	R -> W (in a colorectal cancer sample; somatic mutation).
RPRD1A	21	21	Q -> H (in a breast cancer sample; somatic mutation).
NFATC1	315	315	A -> T (in a colorectal cancer sample; somatic mutation).
SLC14A1	74	74	N -> K (in Jk(null)).
SLC14A1	291	291	S -> P (in Jk(null)).
SLC14A1	299	299	G -> E (in Jk(null)).
SLC14A1	319	319	T -> M (in Jk(null)).
PQLC1	175	175	G -> A (in a colorectal cancer sample; somatic mutation).
TCEB3B	498	498	R -> Q (in a colorectal cancer sample; somatic mutation).
SMAD2	133	133	R -> C (in a colorectal carcinoma sample).
SMAD2	300	300	D -> V (in a colorectal cancer sample; somatic mutation).
SMAD2	344	358	Missing (in a colorectal carcinoma sample).
SMAD2	440	440	L -> R (in a colorectal carcinoma sample).
SMAD2	445	445	P -> H (in a colorectal carcinoma sample).
SMAD2	450	450	D -> E (in a colorectal carcinoma sample).
LIPG	96	96	G -> S.
LIPG	312	312	R -> H.
FECH	62	62	P -> R (in EPP).
FECH	71	71	I -> K (in EPP; enzyme totally inactive).
FECH	139	139	Q -> L (in EPP; autosomal recessive EPP; enzyme retains 18% of activity).
FECH	151	151	S -> P (in EPP; enzyme totally inactive).
FECH	178	178	E -> K (in EPP).
FECH	182	182	L -> R (in EPP; enzyme totally inactive).
FECH	186	186	I -> T (in EPP).
FECH	191	191	Y -> H (in EPP; enzyme retains 72% of activity).
FECH	192	192	P -> T (in EPP; enzyme totally inactive).
FECH	236	236	C -> Y (in EPP; enzyme retains 12% of activity).
FECH	260	260	F -> L (in EPP; autosomal recessive EPP; enzyme retains 52% of activity).
FECH	264	264	S -> L (in EPP).
FECH	267	267	M -> I (in EPP; unchanged activity; but increased thermolability).
FECH	283	283	T -> I (in EPP; enzyme almost inactive).
FECH	288	288	M -> K (in EPP; enzyme totally inactive).
FECH	334	334	P -> L (in EPP; autosomal recessive EPP; enzyme retains 19% of activity).
FECH	362	362	V -> G (in EPP).
FECH	379	379	K -> N (in EPP; autosomal recessive EPP; enzyme retains 37% of activity).
FECH	386	386	H -> P (in EPP; loss of activity).
FECH	406	406	C -> S (in EPP; enzyme almost inactive).
FECH	406	406	C -> Y (in EPP; enzyme almost inactive).
FECH	408	411	NPVC -> KSVG (in EPP; no detectable enzymatic activity).
FECH	417	417	F -> S (in EPP; reduced activity).
FECH	417	417	Missing (in EPP; enzyme totally inactive).
RAX	192	192	R -> Q (in MCOP3; does not affect nuclear localization; reduces DNA binding activity).
PDZRN4	784	784	G -> R (in a colorectal cancer sample; somatic mutation).
SCYL2	720	720	T -> S.
SCYL2	863	863	Q -> H (in a lung adenocarcinoma sample; somatic mutation).
SLCO1B3	292	292	I -> M (in a colorectal cancer sample; somatic mutation).
SLCO1B3	647	647	M -> L (in a colorectal cancer sample; somatic mutation).
ABCC9	1513	1513	A -> T (in CMD1O).
SOX5	362	362	Q -> P (in a patient with amyotrophic lateral sclerosis).
SLC11A2	48	48	A -> T (in a colorectal cancer sample; somatic mutation).
SLC11A2	114	114	Missing (in HCMA).
SLC11A2	212	212	G -> V (in HCMA).
SLC11A2	399	399	E -> D (in HCMA; increased skipping of exon 12).
SLC11A2	416	416	R -> C (in HCMA).
SLC11A2	435	435	L -> I.
RASSF3	232	232	R -> H.
TPH2	36	36	L -> P (the property of the variant is indistinguishable from the wild-type).
TPH2	41	41	S -> Y (the property of the variant is indistinguishable from the wild-type).
TPH2	55	55	R -> C (the property of the variant is indistinguishable from the wild-type).
TPH2	303	303	R -> W (in ADHD7; has severely reduced solubility and is completely inactive; loss of function may lead to a reduced serotonin synthesis which in turn makes the mutation carriers susceptible to ADHD and possibly other psychiatric disorders).
TPH2	433	433	R -> G (in RNA edited version).
TPH2	441	441	R -> H (may be due to a rare RNA editing event; functional polymorphism linked with susceptibility to major depressive disorder; 80% loss of function; decreases solubility; decreases thermal stability; reduces catalytic activity).
TPH2	468	468	Q -> R (in RNA edited version).
UTP20	1645	1645	K -> I (in a breast cancer sample; somatic mutation).
UTP20	2452	2452	I -> F (in a breast cancer sample; somatic mutation).
WNK1	419	419	E -> Q (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
WNK1	1199	1199	E -> G (in a colorectal cancer sample; somatic mutation).
WNK1	1799	1799	Q -> E (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation).
WNK1	2190	2190	S -> C (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
WNK1	2362	2362	F -> L (in a lung adenocarcinoma sample; somatic mutation).
DYRK4	70	70	A -> S.
DYRK4	95	95	V -> I.
GALNT8	53	53	Y -> N.
GALNT8	337	337	A -> V.
GALNT8	438	438	D -> G.
VWF	273	273	R -> W (in VWD1 and VWD3; defect in secretion and formation of multimers).
VWF	377	377	W -> C (in VWD3).
VWF	528	528	N -> S (in VWD2).
VWF	550	550	G -> R (in VWD2).
VWF	788	788	C -> Y (in VWD2).
VWF	791	791	T -> M (in VWD2; Normandy type).
VWF	816	816	R -> W (in VWD2; Normandy type).
VWF	857	857	N -> D.
VWF	1060	1060	C -> R (in VWD2).
VWF	1149	1149	C -> R (in VWD1; reduced secretion of homodimers and heterodimers with wild type VWD and increased degradation by the proteasome).
VWF	1266	1266	P -> L (in VWD2).
VWF	1268	1268	H -> D (in VWD2).
VWF	1272	1272	C -> R (in VWD2).
VWF	1306	1306	R -> W (in VWD2).
VWF	1308	1308	R -> C (in VWD2).
VWF	1313	1313	W -> C (in VWD2).
VWF	1314	1314	V -> L (in VWD2).
VWF	1316	1316	V -> M (in VWD2).
VWF	1318	1318	V -> L (in VWD2).
VWF	1324	1324	G -> S (in VWD2).
VWF	1341	1341	R -> Q (in VWD2).
VWF	1374	1374	R -> C (in VWD2).
VWF	1374	1374	R -> H (in VWD2).
VWF	1460	1460	L -> V (in VWD2).
VWF	1461	1461	A -> V (in VWD2).
VWF	1514	1514	F -> C (in VWD2).
VWF	1540	1540	L -> P (in VWD2).
VWF	1570	1570	Y -> C (in a breast cancer sample; somatic mutation).
VWF	1597	1597	R -> G (in VWD2).
VWF	1597	1597	R -> Q (in VWD2).
VWF	1597	1597	R -> W (in VWD2).
VWF	1607	1607	V -> D (in VWD2).
VWF	1609	1609	G -> R (in VWD2).
VWF	1613	1613	S -> P (in VWD2).
VWF	1628	1628	I -> T (in VWD2).
VWF	1638	1638	E -> K (in VWD2).
VWF	1648	1648	P -> S (in VWD2).
VWF	1665	1665	V -> E (in VWD2).
VWF	2063	2063	P -> S (in VWD3).
VWF	2362	2362	C -> F (in VWD3).
VWF	2546	2546	N -> Y (in VWD3).
VWF	2739	2739	C -> Y (in VWD3).
VWF	2773	2773	C -> R (in VWD2).
C1R	131	131	Y -> H.
C1R	163	163	H -> Y.
PRH1	97	97	Q -> QGGQQQQGPPPPQGKPQGPPQQ (in allele PRH1-DB).
PRH1	119	119	R -> C (in allele PRH1-PA; interferes with proteolytic cleavage at Arg-122).
PRH1	163	163	Q -> K (in allele PRH2-3).
PRB4	113	154	Missing (in allele M and allele S).
PRB4	164	184	Missing (in allele S).
ETV6	344	344	Y -> YG (in one individual with AML; somatic mutation; unable to repress transcription).
LRP6	611	611	R -> C (in ADCAD2; impairs Wnt signaling in vitro).
GRIN2B	407	407	S -> N.
GUCY2C	61	61	G -> R (in a metastatic melanoma sample; somatic mutation).
SLCO1B1	152	152	R -> K.
SLCO1B1	156	156	E -> G (decreased transport activity).
SLCO1B1	193	193	L -> R (strongly decreases expression at the plasma membrane; abolishes transport activity).
SLCO1B1	241	241	D -> N.
SLCO1B1	462	462	D -> G.
SLCO1A2	187	187	A -> T.
SLCO1A2	220	220	V -> I (in a colorectal cancer sample; somatic mutation).
FGD4	298	298	M -> R (in fibroblasts from a CMT4H patient; absent from patient's peripheral nerve where splicing defects and aberrant transcripts are detected).
FGD4	298	298	M -> T (in CMT4H).
PKP2	26	26	D -> N (associated with increased susceptibility to arrhythmogenic right ventricular cardiomyopathy).
PKP2	58	58	E -> D.
PKP2	62	62	Q -> K (found in patients with arrhythmogenic right ventricular cardiomyopathy).
PKP2	70	70	S -> I.
PKP2	137	137	E -> K (in ARVD9).
PKP2	140	140	S -> F (in ARVD9; uncertain pathological significance).
PKP2	169	169	S -> G (in ARVD9).
PKP2	195	195	A -> V.
PKP2	276	276	P -> S.
PKP2	338	338	T -> A (in a patient with arrhythmogenic right ventricular cardiomyopathy).
PKP2	372	372	A -> P.
PKP2	424	424	F -> S (in ARVD9).
PKP2	489	489	G -> R.
PKP2	526	526	T -> M.
PKP2	531	531	I -> S.
PKP2	587	587	V -> I (associated with increased susceptibility to arrhythmogenic right ventricular cardiomyopathy).
PKP2	615	615	S -> F (in ARVD9).
PKP2	631	631	Y -> C (in ARVD9).
PKP2	654	654	K -> Q (in ARVD9).
PKP2	673	673	G -> V (in a patient with arrhythmogenic right ventricular cardiomyopathy).
PKP2	787	787	L -> F (in ARVD9).
PKP2	796	796	C -> R (in ARVD9).
KIF21A	356	356	M -> T (in CFEOM1).
KIF21A	947	947	M -> R (in CFEOM1).
KIF21A	947	947	M -> T (in CFEOM1).
KIF21A	947	947	M -> V (in CFEOM1).
KIF21A	954	954	R -> Q (in CFEOM1).
KIF21A	954	954	R -> W (in CFEOM1).
KIF21A	1010	1010	I -> T (in CFEOM1).
ABCD2	244	244	Q -> K (in a pancreatic ductal adenocarcinoma sample; somatic mutation).
LRRK2	712	712	M -> V (in PARK8).
LRRK2	716	716	A -> V.
LRRK2	871	871	K -> E.
LRRK2	930	930	Q -> R (in PARK8; could be a poymorphism).
LRRK2	1067	1067	R -> Q (in PARK8).
LRRK2	1096	1096	S -> C (in PARK8; could be a polymorphism).
LRRK2	1228	1228	S -> T (in PARK8).
LRRK2	1359	1359	K -> I (found in a renal cell carcinoma sample; somatic mutation).
LRRK2	1441	1441	R -> C (in PARK; shows an increase in activity in both autophosphorylation and phosphorylation of a generic substrate).
LRRK2	1550	1550	R -> Q (in an ovarian mucinous carcinoma sample; somatic mutation).
LRRK2	1723	1723	R -> P (in an ovarian serous carcinoma sample; somatic mutation).
LRRK2	1728	1728	R -> H (in PARK8).
LRRK2	1728	1728	R -> L (in PARK8).
LRRK2	1870	1870	L -> F.
LRRK2	1941	1941	R -> H (in PARK8).
LRRK2	2141	2141	T -> M (in PARK8).
LRRK2	2143	2143	R -> H (in PARK8).
LRRK2	2356	2356	T -> I (in PARK8).
LRRK2	2395	2395	E -> K.
LRRK2	2466	2466	L -> H (in PARK8).
CNTN1	794	794	P -> H (in a colorectal cancer sample; somatic mutation).
PPHLN1	173	173	V -> M (in a breast cancer sample; somatic mutation).
PRICKLE1	104	104	R -> Q (in EPM1B; affects interaction with REST).
PRICKLE1	144	144	R -> H (in EPM1B).
PRICKLE1	472	472	Y -> H (in EPM1B).
IRAK4	355	355	M -> V.
MLL2	692	692	P -> T.
MLL2	813	813	P -> L.
MLL2	2382	2382	P -> S.
MLL2	2460	2460	R -> C.
MLL2	2557	2557	P -> L.
MLL2	3398	3398	M -> V.
MLL2	3419	3419	D -> G.
MLL2	4357	4357	R -> S.
MLL2	5109	5109	C -> F (in KABS).
MLL2	5179	5179	R -> H (in KABS).
MLL2	5210	5210	Y -> C (in KABS).
MLL2	5214	5214	R -> H (in KABS).
MLL2	5340	5340	R -> L (in KABS).
MLL2	5428	5428	G -> D (in KABS).
MLL2	5464	5464	T -> M (in KABS).
KRT86	114	114	N -> D (in MLTRX).
KRT86	114	114	N -> H (in MLTRX).
KRT86	402	402	E -> K (in MLTRX).
KRT86	413	413	E -> D (in MLTRX).
KRT86	413	413	E -> K (in MLTRX).
KRT81	402	402	E -> K (in MLTRX).
KRT18	230	230	S -> T.
KRT18	261	261	R -> Q (in CIRRH).
KRT18	340	340	G -> R (in CIRRH).
RARG	430	430	G -> S (in a breast cancer sample; somatic mutation).
HOXC9	87	87	G -> S (in a colorectal cancer sample; somatic mutation).
CDK2	45	45	P -> L (in a glioblastoma multiforme sample; somatic mutation).
ERBB3	104	104	V -> M (in an ovarian mucinous carcinoma sample; somatic mutation).
LRP1	869	869	E -> K (in a colorectal cancer sample; somatic mutation).
LRP1	3760	3760	R -> H (in a colorectal cancer sample; somatic mutation).
TBK1	296	296	D -> H (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
TBK1	410	410	G -> R (in a colorectal adenocarcinoma sample; somatic mutation).
GNS	94	94	S -> I (in MPS3D).
GNS	304	306	Missing (in MPS3D).
GNS	340	340	K -> R (in MPS3D).
GNS	418	418	G -> E (in MPS3D).
MSRB3	89	89	C -> G (in DFNB74; abolishes zinc-binding and enzymatic activity).
IRAK3	22	22	P -> L (may be associated with ASRT5).
IRAK3	111	111	P -> A (may be associated with ASRT5).
IRAK3	134	134	V -> M (may be associated with ASRT5).
IRAK3	400	400	L -> V (may be associated with ASRT5).
IRAK3	429	429	R -> Q (may be associated with ASRT5).
IFNG	29	29	K -> Q.
IFNG	160	160	R -> Q.
KCNMB4	199	199	V -> I.
NAV3	2200	2200	E -> K (in a patient with Sezary syndrome).
CEP290	7	7	W -> C (in JBTS5 and SLSN6).
CEP290	277	277	E -> Q.
CEP290	664	664	D -> G (found in a patient with Joubert syndrome; unknown pathological significance).
CEP290	1566	1566	A -> P.
CEP290	1694	1694	L -> P.
CEP290	2228	2228	N -> K.
ATP2B1	267	267	M -> R (rare polymorphism).
CDK17	214	214	T -> I (found in a renal cell carcinoma sample; somatic mutation).
SLC17A8	211	211	A -> V (in DFNA25).
CHPT1	323	323	Y -> S (in MCF-12A cell line).
PAH	16	16	S -> P (in PKU).
PAH	20	20	Q -> L (in HPA).
PAH	39	39	F -> L (in PKU; haplotype 1).
PAH	39	39	Missing (in PKU; haplotypes 9,21).
PAH	40	40	S -> L (in PKU).
PAH	41	41	L -> F (in PKU).
PAH	41	41	L -> P (in PKU; mild).
PAH	42	42	K -> I (in PKU; haplotype 21).
PAH	46	46	G -> S (in PKU; haplotype 5; significantly reduces phenylalanine binding).
PAH	47	47	A -> V (in non-PKU HPA; haplotype 4; significantly reduces phenylalanine binding).
PAH	48	48	L -> S (in PKU; mild; haplotypes 3,4).
PAH	53	53	R -> H (in PKU).
PAH	55	55	F -> L (in PKU).
PAH	56	56	E -> D (in PKU; haplotype 10).
PAH	63	64	TH -> PN (in PKU; haplotype 1; abolishes phenylalanine binding).
PAH	65	65	I -> N (in PKU).
PAH	65	65	I -> T (in PKU; haplotypes 1,5,9,21,B; abolishes phenylalanine binding).
PAH	67	67	S -> P (in PKU; haplotype 4).
PAH	68	68	R -> S (in PKU; haplotype 1; significantly reduces phenylalanine binding).
PAH	76	76	E -> A (in PKU).
PAH	84	84	D -> Y (in PKU; haplotype 4).
PAH	87	87	S -> R (in non-PKU HPA; haplotype 1).
PAH	92	92	T -> I (in PKU).
PAH	94	94	Missing (in PKU; mild; haplotype 2).
PAH	98	98	L -> S (in non-PKU HPA).
PAH	104	104	A -> D (in PKU; mild; haplotype 1).
PAH	110	110	S -> C (in HPA).
PAH	124	124	T -> I (in PKU; haplotype 28).
PAH	129	129	D -> Y (in PKU).
PAH	143	143	D -> G (in PKU; haplotype 11).
PAH	145	145	D -> V (in PKU).
PAH	146	146	H -> Y (in PKU).
PAH	148	148	G -> S (in PKU; haplotypes 1,2,7).
PAH	151	151	D -> H (in PKU; haplotypes 1,8).
PAH	154	154	Y -> N (in PKU).
PAH	155	155	R -> P (in PKU).
PAH	157	157	R -> N (in PKU; severe; 5% activity; requires 2 nucleotide substitutions).
PAH	158	158	R -> Q (in PKU; haplotypes 1,2,4,7,16, 28).
PAH	158	158	R -> W (in PKU).
PAH	160	160	Q -> P (in PKU).
PAH	161	161	F -> S (in PKU; haplotype 4).
PAH	164	164	I -> T (in PKU; haplotype 1).
PAH	167	167	N -> I (in PKU).
PAH	167	167	N -> S (in HPA).
PAH	169	169	R -> H (in PKU).
PAH	170	170	H -> D (in HPA).
PAH	170	170	H -> R (in PKU).
PAH	171	171	G -> A (in PKU; haplotype 1).
PAH	171	171	G -> R (in PKU).
PAH	173	173	P -> T (in PKU; haplotype 4).
PAH	174	174	I -> T (in PKU; haplotype 1).
PAH	174	174	I -> V (in PKU).
PAH	175	175	P -> A (in PKU).
PAH	176	176	R -> L (in non-PKU HPA).
PAH	176	176	R -> P (in PKU).
PAH	177	177	V -> L (in PKU; haplotype 6).
PAH	178	178	E -> G (in non-PKU HPA).
PAH	183	183	E -> Q (in PKU).
PAH	190	190	V -> A (in PKU; haplotype 3).
PAH	194	194	L -> P (in PKU).
PAH	194	194	Missing (in PKU).
PAH	197	197	Missing (in PKU).
PAH	198	198	Missing (in PKU; haplotype 2).
PAH	201	201	H -> R (in PKU).
PAH	201	201	H -> Y (in non-PKU HPA; haplotype 1).
PAH	204	204	Y -> C (in PKU; mild; haplotypes 3,4).
PAH	205	205	E -> A (in PKU).
PAH	206	206	Y -> D (in PKU).
PAH	207	207	N -> D (in PKU).
PAH	207	207	N -> S (in PKU; severe; haplotype 4).
PAH	211	211	P -> T (in PKU; haplotype 4).
PAH	212	212	L -> P (in PKU).
PAH	213	213	L -> P (in PKU; severe).
PAH	217	217	C -> G (in PKU).
PAH	218	218	G -> V (in PKU; haplotypes 1,2).
PAH	221	221	E -> G (in PKU; haplotype 4).
PAH	222	222	D -> V (in PKU; haplotypes 3,4).
PAH	224	224	I -> M (in PKU; haplotype 4).
PAH	225	225	P -> R (in PKU).
PAH	225	225	P -> T (in PKU; haplotype 1).
PAH	230	230	V -> I (in non-PKU HPA; haplotype 4).
PAH	231	231	S -> F (in PKU).
PAH	231	231	S -> P (in PKU).
PAH	233	233	F -> L (in PKU; haplotypes 2,3).
PAH	238	238	T -> P (in PKU; haplotype 4).
PAH	239	239	G -> S (in PKU).
PAH	240	240	F -> S (in PKU).
PAH	241	241	R -> C (in non-PKU HPA and PKU; haplotype 34).
PAH	241	241	R -> H (in PKU; haplotypes 1,5).
PAH	241	241	R -> L (in PKU).
PAH	242	242	L -> F (in PKU).
PAH	243	243	R -> Q (in non-PKU HPA and PKU; haplotypes 4,7,9).
PAH	244	244	P -> L (in PKU; haplotype 12).
PAH	245	245	V -> A (in non-PKU HPA; haplotypes 3,7).
PAH	245	245	V -> E (in PKU; haplotype 11).
PAH	245	245	V -> L (in PKU).
PAH	246	246	A -> D (in PKU).
PAH	247	247	G -> V (in PKU; haplotype 4).
PAH	248	248	L -> P (in PKU).
PAH	249	249	L -> F (in PKU; haplotype 1).
PAH	252	252	R -> G (in PKU; haplotype 7).
PAH	252	252	R -> Q (in PKU; haplotype 1).
PAH	252	252	R -> W (in PKU; haplotypes 1,6,7,8,42, 69; complete loss of activity).
PAH	255	255	L -> S (in PKU; haplotype 36).
PAH	255	255	L -> V (in PKU; haplotypes 18,21).
PAH	257	257	G -> C (in PKU).
PAH	259	259	A -> T (in PKU; haplotype 3).
PAH	259	259	A -> V (in PKU; haplotypes 7,42).
PAH	261	261	R -> P (in PKU).
PAH	263	263	F -> L (in PKU).
PAH	264	264	H -> L (in PKU).
PAH	265	265	C -> G (in PKU).
PAH	269	269	I -> L (in non-PKU HPA).
PAH	270	270	R -> K (in PKU).
PAH	270	270	R -> S (in PKU; haplotype 1).
PAH	271	271	H -> Y (in PKU).
PAH	273	273	S -> F (in PKU; haplotype 7).
PAH	274	274	K -> E.
PAH	276	276	M -> I (in PKU).
PAH	276	276	M -> V (in PKU; haplotype 4).
PAH	277	277	Y -> C (in PKU).
PAH	277	277	Y -> D (in PKU; haplotype 2).
PAH	278	278	T -> A (in PKU).
PAH	278	278	T -> N (in PKU).
PAH	280	280	E -> K (in PKU; haplotypes 1,2,4,16,38; partial residual activity).
PAH	281	281	P -> L (in PKU; haplotypes 1,4).
PAH	282	282	D -> N (in PKU; haplotype 1).
PAH	283	283	I -> F (in PKU; haplotype 21).
PAH	283	283	I -> N (in PKU; severe).
PAH	297	297	R -> C (in PKU; haplotype 4).
PAH	297	297	R -> H (in PKU).
PAH	299	299	F -> C (in PKU; haplotype 8).
PAH	300	300	A -> S (in PKU; haplotype 1).
PAH	300	300	A -> V (in PKU).
PAH	303	303	S -> P (in PKU; haplotype 5).
PAH	304	304	Q -> R (in PKU).
PAH	306	306	I -> V (in non-PKU HPA; haplotype 4).
PAH	309	309	A -> D (in PKU; haplotype 7).
PAH	309	309	A -> V (in PKU).
PAH	310	310	S -> F (in PKU; haplotype 7).
PAH	311	311	L -> P (in PKU; haplotypes 1,7,10).
PAH	314	314	P -> H (in PKU).
PAH	318	318	I -> T (in PKU; partial loss of activity).
PAH	322	322	A -> G (in PKU; haplotype 12).
PAH	322	322	A -> T (in PKU; haplotype 1).
PAH	325	325	Y -> C (in PKU).
PAH	330	330	E -> D (in PKU).
PAH	331	331	F -> L (in PKU; haplotype 1).
PAH	333	333	L -> F (in PKU).
PAH	334	334	C -> S (in PKU).
PAH	337	337	G -> V (in PKU).
PAH	338	338	D -> Y (in PKU; haplotype 4).
PAH	341	341	K -> R (in PKU).
PAH	341	341	K -> T (in PKU).
PAH	342	342	A -> T (in PKU; haplotype 5).
PAH	343	343	Y -> C (in PKU).
PAH	344	344	G -> R (in PKU).
PAH	344	344	G -> V (in PKU).
PAH	345	345	A -> S (in PKU).
PAH	345	345	A -> T (in PKU; haplotype 7).
PAH	347	347	L -> F (in PKU).
PAH	348	348	L -> V (in PKU; mild haplotype 9).
PAH	349	349	S -> L (in PKU; severe).
PAH	349	349	S -> P (in PKU; haplotypes 1,4).
PAH	350	350	S -> T (in PKU; haplotype 2).
PAH	357	357	C -> G (in PKU).
PAH	362	362	P -> T (in PKU).
PAH	364	368	Missing (in PKU).
PAH	364	364	Missing (in PKU; haplotype 5).
PAH	366	366	P -> H (in PKU).
PAH	372	372	T -> S (in PKU).
PAH	377	377	Y -> C (in PKU; haplotype 4).
PAH	380	380	T -> M (in non-PKU HPA; haplotype 4).
PAH	386	386	Y -> C (in PKU; common mutation).
PAH	387	387	Y -> H (in PKU; haplotype 1).
PAH	388	388	V -> L (in PKU).
PAH	388	388	V -> M (in PKU; haplotypes 1,4).
PAH	390	390	E -> G (in non-PKU HPA; haplotype 4).
PAH	394	394	D -> A (in PKU).
PAH	394	394	D -> H (in PKU).
PAH	395	395	A -> G (in PKU).
PAH	395	395	A -> P (in PKU; haplotype 1).
PAH	399	400	Missing (in PKU; haplotype 7).
PAH	403	403	A -> V (in non-PKU HPA and PKU; haplotype 43).
PAH	407	407	P -> S (in PKU).
PAH	408	408	R -> Q (in PKU; haplotypes 4,12).
PAH	408	408	R -> W (in PKU; haplotypes 1,2,4,5,13,34, 41,44; most common mutation).
PAH	410	410	F -> S (in PKU; mild).
PAH	413	413	R -> P (in non-PKU HPA and PKU; haplotype 4).
PAH	413	413	R -> S (in PKU; haplotype 1).
PAH	414	414	Y -> C (in PKU; haplotype 4).
PAH	415	415	D -> N (in non-PKU HPA; haplotype 1).
PAH	418	418	T -> P (in PKU; haplotype 4).
PAH	430	430	L -> P (in PKU).
PAH	447	447	A -> D (in PKU).
RFX4	687	687	S -> N.
SART3	591	591	V -> M (in DSAP1).
ACACB	193	193	R -> L (in a pancreatic ductal adenocarcinoma sample; somatic mutation).
TRPV4	89	89	T -> I (in MTD; lethal form).
TRPV4	183	183	E -> K (found in a patient with spondyloepiphyseal dysplasia Maroteaux type).
TRPV4	197	197	K -> R (in MTD; lethal form).
TRPV4	199	199	L -> F (in MTD).
TRPV4	269	269	R -> C (in CMT2C).
TRPV4	269	269	R -> H (in CMT2C and DSMAC).
TRPV4	278	278	E -> K (in SMDK).
TRPV4	295	295	T -> A (in MTD).
TRPV4	315	315	R -> W (in CMT2C).
TRPV4	316	316	R -> C (in CMT2C and SPSMA).
TRPV4	331	331	I -> F (in MTD).
TRPV4	331	331	I -> T (in MTD).
TRPV4	333	333	D -> G (in SMDK).
TRPV4	342	342	V -> F (in MTD).
TRPV4	471	471	Missing (in MTD; lethal form).
TRPV4	592	592	F -> L (in MTD).
TRPV4	594	594	R -> H (in SMDK and PSTD).
TRPV4	596	596	L -> P (in SMDK).
TRPV4	600	600	G -> W (in SMDK).
TRPV4	602	602	Y -> C (found in a patient with spondyloepiphyseal dysplasia Maroteaux type).
TRPV4	604	604	I -> M (in MTD; lethal form).
TRPV4	616	616	R -> Q (in BRAC3; this mutation results in a gain of function and a constitutive activation of the channel).
TRPV4	617	617	F -> L (in MTD).
TRPV4	618	618	L -> P (found in a patient with a lethal form of metatropic dysplasia; uncertain pathological significance).
TRPV4	620	620	V -> I (in BRAC3; this mutation results in a gain of function and a constitutive activation of the channel).
TRPV4	625	625	M -> I (in SMDK).
TRPV4	709	709	L -> M (in SMDK).
TRPV4	716	716	A -> S (in SMDK).
TRPV4	775	775	R -> K (in MTD).
TRPV4	777	777	C -> Y (in SMDK).
TRPV4	797	797	E -> K (in MTD and SMDK; also found in a patient with spondyloepiphyseal dysplasia Maroteaux type).
TRPV4	799	799	P -> A (in MTD).
TRPV4	799	799	P -> L (in MTD; also found in a patient with spondyloepiphyseal dysplasia Maroteaux type).
TRPV4	799	799	P -> R (in MTD).
TRPV4	799	799	P -> S (in MTD).
TCHP	44	44	S -> P (in a gastric carcinoma sample).
TCHP	93	93	E -> K (in a pancreatic carcinoma sample).
C12orf76	26	26	A -> T (in a colorectal cancer sample; somatic mutation).
ATP2A2	39	39	N -> T (in DD).
ATP2A2	41	41	Missing (in DD; comedonal type).
ATP2A2	47	47	K -> KMFLTGK (in DD).
ATP2A2	65	65	L -> S (in DD; severe form).
ATP2A2	131	131	R -> Q (in DD).
ATP2A2	160	160	P -> L (in DD).
ATP2A2	186	186	S -> P (in DD).
ATP2A2	211	211	G -> D (in DD; severe form).
ATP2A2	223	223	V -> M (in DD).
ATP2A2	268	268	C -> F (in DD; haemorrhagic lesions).
ATP2A2	310	310	G -> V (in DD).
ATP2A2	318	318	C -> R (in DD; severe form).
ATP2A2	348	348	I -> T (in DD).
ATP2A2	357	357	T -> K (in DD).
ATP2A2	412	412	E -> G (in DD).
ATP2A2	495	495	S -> F (in DD).
ATP2A2	560	560	C -> R (in DD; neuropsychiatric phenotype).
ATP2A2	602	602	P -> L (in AKV; loss of activity).
ATP2A2	675	675	F -> S (in DD; multiple neuropsychiatric features).
ATP2A2	683	683	K -> E (in DD; depression).
ATP2A2	702	702	D -> N (in DD; moderate form).
ATP2A2	745	745	A -> D (in DD; moderate form).
ATP2A2	749	749	G -> R (in DD).
ATP2A2	754	754	Missing (in DD).
ATP2A2	765	765	S -> L (in DD).
ATP2A2	767	767	N -> S (in DD; haemorrhagic lesions and neuropsychiatric phenotype).
ATP2A2	769	769	G -> R (in DD).
ATP2A2	803	803	A -> T (in DD; mild/moderate form).
ATP2A2	838	838	A -> P (in DD; severe form; petit mal epilepsy).
ATP2A2	843	843	V -> F (in DD; depression).
ATP2A2	875	875	C -> G (in DD; retinitis pigmentosa).
ATP2A2	920	920	S -> Y (in DD; mild/moderate/severe form; one patient with epilepsy).
ATP2A2	943	943	H -> R (in DD; learning difficulties).
ATP2A2	975	975	P -> R (in DD).
TBX5	49	49	Q -> K (in HOS).
TBX5	54	54	I -> T (in HOS).
TBX5	80	80	G -> R (in HOS; significant cardiac malformations but only minor skeletal abnormalities; reduced protein stability and strongly reduced affinity for DNA).
TBX5	237	237	R -> Q (in HOS; extensive upper limb malformations; affects transcriptional regulation of MYH6).
TBX5	237	237	R -> W (in HOS; extensive upper limb malformations; strongly reduced affinity for DNA).
MED13L	2023	2023	D -> G (in DTGA1).
KSR2	676	676	R -> S (in a lung adenocarcinoma sample; somatic mutation).
TAOK3	20	20	P -> T (in a lung adenocarcinoma sample; somatic mutation).
TAOK3	392	392	S -> Y (in a lung small cell carcinoma sample; somatic mutation).
CIT	183	183	L -> F.
ANAPC5	617	617	Q -> H (in a breast cancer sample; somatic mutation).
HPD	267	267	I -> F.
HPD	268	268	A -> V (in TYRO3).
HPD	335	335	I -> M (in TYRO3).
CLIP1	1213	1213	M -> I (in a breast cancer sample; somatic mutation).
HCAR1	253	253	D -> E.
SCARB1	167	167	G -> S.
SCARB1	297	297	P -> S (mutation carriers have increased HDL cholesterol levels and a reduction in cholesterol efflux from macrophages).
ULK1	290	290	V -> M (in an ovarian mucinous carcinoma sample; somatic mutation).
ULK1	784	784	S -> C (in a lung adenocarcinoma sample; somatic mutation).
CHFR	166	166	P -> L (in a patient with non small cell lung carcinomas; homozygous).
CHFR	202	202	R -> P (in a patient with non small cell lung carcinomas).
CHFR	270	270	G -> R.
CHFR	536	536	F -> S (in a patient with non small cell lung carcinomas).
CACNA1C	39	39	A -> V (in BRS3; loss of function).
CACNA1C	402	402	G -> S (in TS).
CACNA1C	406	406	G -> R (in TS; causes a nearly complete loss of voltage-dependent channel inactivation).
CACNA1C	490	490	G -> R (in BRS3; loss of function).
CACNA1C	752	752	A -> T.
CACNA1C	878	878	S -> R (found in a clear cell renal carcinoma case; somatic mutation).
CACNA1C	2169	2169	A -> T.
FGF23	71	71	S -> G (in HFTC; only the C-terminal fragment is secreted, whereas the intact protein is retained in the Golgi complex).
FGF23	176	176	R -> Q (in ADHR; partially resistant to cleavage by furin).
FGF23	179	179	R -> Q (in ADHR; C-terminal processing is abolished; reduced proteolysis by PHEX; resistant to cleavage by furin).
AKAP3	831	831	R -> C (in a colorectal cancer sample; somatic mutation).
KCNA1	174	174	V -> F (in EA1).
KCNA1	177	177	I -> R (in EA1).
KCNA1	184	184	F -> C (in EA1; alters voltage dependence and kinetics of activation though not of C-type inactivation).
KCNA1	226	226	T -> A (in EA1).
KCNA1	226	226	T -> M (in EA1).
KCNA1	239	239	R -> S (in EA1).
KCNA1	249	249	F -> I (in EA1).
KCNA1	325	325	E -> D (in EA1; results in non-functional homomeric channels).
KCNA1	329	329	L -> I (in EA1).
KCNA1	342	342	S -> I (in EA1; phenotype without myokymia).
KCNA1	400	400	I -> V (in RNA edited version).
KCNA1	404	404	V -> I (in EA1; yields current amplitudes that were not different from wild-type; coexpression with wild-type partially corrected the alterations in activation parameters).
KCNA1	408	408	V -> A (in EA1; channels have voltage dependence similar to that of wild-type channels but with faster kinetics and increased C-type inactivation).
KCNA5	300	300	G -> S (in a breast cancer sample; somatic mutation).
TNFRSF1A	51	51	H -> Q (in FHF).
TNFRSF1A	59	59	C -> R (in FHF).
TNFRSF1A	59	59	C -> S (in FHF).
TNFRSF1A	62	62	C -> G (in FHF).
TNFRSF1A	62	62	C -> Y (in FHF).
TNFRSF1A	79	79	T -> M (in FHF).
TNFRSF1A	81	81	C -> F (in FHF).
TNFRSF1A	99	99	C -> S (in FHF).
TNFRSF1A	115	115	S -> G (in FHF).
TNFRSF1A	117	117	C -> R (in FHF).
TNFRSF1A	117	117	C -> Y (in FHF).
TNFRSF1A	121	121	R -> P (in FHF).
SCNN1A	327	327	G -> C (in AR-PHA1; results in a significant reduction of channel function as compared to wild-type; significantly lowers both Li+ and Na+ ion currents).
SCNN1A	562	562	S -> L (in AR-PHA1).
MLF2	80	80	F -> C (in a colorectal cancer sample; somatic mutation).
TPI1	42	42	C -> Y (in TPI deficiency).
TPI1	73	73	G -> A (in TPI deficiency).
TPI1	105	105	E -> D (in TPI deficiency; the enzyme becomes thermolabile).
TPI1	123	123	G -> R (in Manchester; thermolabile).
TPI1	155	155	V -> M (in TPI deficiency).
TPI1	171	171	I -> V (in TPI deficiency).
TPI1	232	232	V -> M (in TPI deficiency).
TPI1	241	241	F -> L (in TPI deficiency; Hungary; thermolabile).
ENO2	264	264	P -> A.
ENO2	395	395	T -> A.
ATN1	484	488	Missing.
EMG1	86	86	D -> G (in BWCNS; studies in fibroblasts show a dramatically reduced level of EMG1 protein in a BWCNS-affected patient compared to normal fibroblasts although patient fibroblasts do not have complete EMG1 deficiency; the mutation increases dimerization of EMG1 subunits suggesting that aggregation of EMG1 leads to reduced levels of the protein).
CLSTN3	874	874	H -> Y (in a colorectal cancer sample; somatic mutation).
PEX5	526	526	N -> K (in NALD; strongly affects peroxisomal protein import).
PEX5	600	600	S -> W (in IRD; mildly affects peroxisomal protein import).
GDF3	195	195	R -> Q (in MCOP7).
GDF3	266	266	R -> C (in KFS3 and MCOPCB6).
GDF3	274	274	R -> W (in MCOPCB6).
GDF3	305	305	L -> P (in MCOP7; also detected in a patient with bilateral iris coloboma).
AICDA	24	24	R -> W (in HIGM2).
AICDA	25	25	R -> C.
AICDA	80	80	W -> R (in HIGM2).
AICDA	106	106	L -> P (in HIGM2).
AICDA	139	139	M -> V (in HIGM2).
AICDA	151	151	F -> S (in HIGM2).
MFAP5	61	61	V -> D (in a breast cancer sample; somatic mutation).
KLRC2	102	102	S -> F (in allele NKG2-C*02).
MAGOHB	119	119	E -> K (in a breast cancer sample; somatic mutation).
STYK1	395	395	V -> I (in a glioblastoma multiforme sample; somatic mutation).
TAS2R13	149	149	N -> S (in a breast cancer sample; somatic mutation).
PRH2	97	97	Q -> QGGQQQQGPPPPQGKPQGPPQQ (in allele PRH1-DB).
PRH2	119	119	R -> C (in allele PRH1-PA; interferes with proteolytic cleavage at Arg-122).
PRH2	163	163	Q -> K (in allele PRH2-3).
PRB3	53	53	P -> C (in Gl-8; requires 2 nucleotide substitutions).
PRB3	158	220	Missing (in allele S).
PRB1	93	153	Missing (in allele M).
PRB1	106	319	Missing (in clone CP-5).
PRB1	106	299	Missing (in clone CP-4).
PRB1	134	255	Missing (in allele S).
CDKN1B	69	69	P -> L (found in a patient with multiple endocrine tumors; germline mutation; reduced expression levels; shows impaired binding to CDK2).
HIST4H4	64	64	E -> Q (in a breast cancer sample; somatic mutation).
GYS2	39	39	N -> S (in GSD0).
GYS2	339	339	A -> P (in GSD0).
GYS2	446	446	H -> D (in GSD0).
GYS2	479	479	P -> Q (in GSD0).
GYS2	483	483	S -> P (in GSD0).
GYS2	491	491	M -> R (in GSD0).
LDHB	7	7	K -> E (in LDHB deficiency; slightly decreased activity).
LDHB	35	35	A -> E (in LDHB deficiency).
LDHB	69	69	G -> E (in LDHB deficiency).
LDHB	107	107	R -> W (in GUA1; LDHB deficiency; inactive).
LDHB	129	129	S -> R (in LDHB deficiency).
LDHB	171	171	F -> V (in LDHB deficiency).
LDHB	172	172	R -> H (in LDHB deficiency; unstable).
LDHB	172	172	R -> P (in LDHB deficiency).
LDHB	175	175	M -> L (in LDHB deficiency).
LDHB	223	223	Missing (in LDHB deficiency).
LDHB	322	322	D -> V (in LDHB deficiency).
LDHB	325	325	W -> R (in LDHB deficiency).
KRAS	5	5	K -> E (in NS3).
KRAS	5	5	K -> N (in GASC; found also in a patient with Costello syndrome; exhibits only minor alterations in its in vitro biochemical behavior compared to wild- type protein).
KRAS	10	10	G -> GG (in one individual with AML; expression in 3T3 cell causes cellular transformation; expression in COS cells activates the Ras-MAPK signaling pathway; lower GTPase activity; faster GDP dissociation rate).
KRAS	12	12	G -> A (in a colorectal cancer sample; somatic mutation).
KRAS	12	12	G -> C (in lung carcinoma; somatic mutation).
KRAS	12	12	G -> D (in pancreatic carcinoma, GASC and lung carcinoma; somatic mutation).
KRAS	12	12	G -> R (in lung cancer and bladder cancer; somatic mutation).
KRAS	12	12	G -> S (in lung carcinoma and GASC; somatic mutation).
KRAS	12	12	G -> V (in lung carcinoma, pancreatic carcinoma, colon cancer and GASC; somatic mutation).
KRAS	13	13	G -> D (in a breast carcinoma cell line and GASC; somatic mutation).
KRAS	13	13	G -> R (in pylocytic astrocytoma; somatic mutation; increase activation of the Ras pathway).
KRAS	14	14	V -> I (in NS3; affects activity and impairs responsiveness to GTPase activating proteins; characterized by a strong increase of both intrinsic and guanine nucleotide exchanged factor- catalyzed nucleotide exchange leading to an increased level of the activated state).
KRAS	22	22	Q -> E (in CFC syndrome; exhibits an increase in intrinsic and guanine nucleotide exchange factor catalyzed nucleotide exchange in combination with an impaired GTPase-activating protein- stimulated GTP hydrolysis but functional in interaction with effectors).
KRAS	22	22	Q -> R (in NS3; impairs GTPase-activating protein stimulated GTP hydrolysis with unaffected intrinsic functions and a virtually functional effector interaction).
KRAS	34	34	P -> L (in NS3; characterized by a defective GTPase-activating protein sensitivity and a strongly reduced interaction with effectors).
KRAS	34	34	P -> Q (in NS3).
KRAS	34	34	P -> R (in CFC syndrome; characterized by a defective GTPase-activating protein sensitivity and a strongly reduced interaction with effectors).
KRAS	36	36	I -> M (in NS3).
KRAS	58	58	T -> I (in NS3; affects activity and impairs responsiveness to GTPase activating proteins; exhibits only minor alterations in its in vitro biochemical behavior compared to wild-type protein).
KRAS	59	59	A -> T (in bladder cancer and GASC; somatic mutation).
KRAS	60	60	G -> R (in CFC syndrome; characterized by a defective GTPase-activating protein sensitivity and a strongly reduced interaction with effectors).
KRAS	60	60	G -> S (in NS3).
KRAS	61	61	Q -> R (in a colorectal cancer sample; somatic mutation).
KRAS	117	117	K -> N (in a colorectal cancer sample; somatic mutation).
KRAS	146	146	A -> T (in a colorectal cancer sample; somatic mutation).
BHLHE41	384	384	P -> R (associated with short sleep phenotype).
ASUN	227	227	S -> P (in a colorectal cancer sample; somatic mutation).
STK38L	99	99	G -> A (in a aLL TEL/AML1+ sample; somatic mutation).
PTHLH	44	44	L -> P (in BDE2).
PTHLH	60	60	L -> P (in BDE2).
PTHLH	169	169	S -> T (in a breast cancer sample; somatic mutation).
DNM1L	395	395	A -> D (in one newborn; with microcephaly, abnormal brain development, optic atrophy, hypoplasia, persistent lactic acidemia and a mildly elevated plasma concentration of very-long-chain fatty acids. Defects observed in both mitochondrial and peroxisomal fission).
YARS2	52	52	F -> L (in MLASA2; has a 2-fold reduction in catalytic activity and a reduction in affinity for tRNA-tyr resulting in an overall 9-fold loss of catalytic efficiency).
ALG10B	446	446	I -> V (in some patients with drug- induced cardiac repolarization defects; exerts a greater protective effect, relative to wild-type, against drug blockage of KCNH2 potassium channel).
HDAC7	43	43	V -> M (in a breast cancer sample; somatic mutation).
VDR	33	33	G -> D (in VDDR2A).
VDR	35	35	H -> Q (in VDDR2A).
VDR	45	45	K -> E (in VDDR2A).
VDR	46	46	G -> D (in VDDR2A).
VDR	47	47	F -> I (in VDDR2A).
VDR	50	50	R -> Q (in VDDR2A).
VDR	73	73	R -> Q (in VDDR2A).
VDR	80	80	R -> Q (in VDDR2A).
VDR	274	274	R -> L (in VDDR2A; decreases affinity for ligand by a factor of 1000).
VDR	305	305	H -> Q (in VDDR2A).
VDR	314	314	I -> S (in VDDR2A).
VDR	391	391	R -> C (in VDDR2A).
COL2A1	57	57	C -> Y (in STL1O).
COL2A1	240	240	G -> D (in STL1).
COL2A1	267	267	G -> D (in STL1O).
COL2A1	270	270	G -> R (in STL1).
COL2A1	275	275	R -> C (in spondyloepiphyseal dysplasia; with precocious osteoarthritis).
COL2A1	282	282	G -> D (in STL1).
COL2A1	302	308	Missing (in STL1).
COL2A1	303	303	G -> D (in KD; abnormal allele expressed in the cartilage).
COL2A1	318	318	G -> R (in DRRD).
COL2A1	354	354	G -> R (in spondylometaphyseal dysplasia; congenital type).
COL2A1	375	375	G -> R (in SEDC).
COL2A1	447	447	G -> S (in SEDC).
COL2A1	453	453	G -> A (in STL1).
COL2A1	453	453	G -> D (in ACG2).
COL2A1	453	453	G -> V (in ACG2).
COL2A1	492	492	G -> V (in SEMD-STR).
COL2A1	501	501	G -> R (in STL1).
COL2A1	504	504	G -> C (in SEMD-STR).
COL2A1	510	510	G -> D (in ACG2).
COL2A1	513	513	G -> S (in ACG2).
COL2A1	516	516	G -> D (in ACGA2).
COL2A1	547	547	D -> V (in ACG2).
COL2A1	565	565	R -> C (in STL1).
COL2A1	667	667	L -> F (in DRRD).
COL2A1	717	717	G -> S (in ANFH).
COL2A1	717	717	G -> V (in ACG2).
COL2A1	719	719	R -> C (in OACD; also in mild spondyloepiphyseal dysplasia and precocious osteoarthritis).
COL2A1	771	771	G -> A (in ACG2).
COL2A1	771	771	G -> D (in ACG2).
COL2A1	774	774	G -> S (in SEDC and hypochondrogenesis; lethal).
COL2A1	780	780	G -> R (in ACG2).
COL2A1	795	795	G -> R (in ACG2).
COL2A1	804	804	G -> A (in hypochondrogenesis).
COL2A1	855	855	G -> S (in SEDC).
COL2A1	891	891	G -> R (in ACG2 and SEDC).
COL2A1	894	894	G -> E (in ACG2).
COL2A1	897	897	G -> V (in SEMD-STR).
COL2A1	904	904	R -> C (in EDMMD and STL1).
COL2A1	909	909	G -> C (in SEMD-STR).
COL2A1	948	948	G -> D (in ACG2).
COL2A1	969	969	G -> S (in ACG2).
COL2A1	981	981	G -> S (in ACG2).
COL2A1	989	989	R -> C (in SEDC).
COL2A1	992	992	R -> G (in SEMD-STR).
COL2A1	1005	1005	G -> S (in hypochondrogenesis).
COL2A1	1017	1022	Missing (in hypochondrogenesis).
COL2A1	1017	1017	G -> V (in ACG2).
COL2A1	1053	1053	G -> E (in hypochondrogenesis; lethal).
COL2A1	1065	1065	G -> V (in ACG2).
COL2A1	1110	1110	G -> C (in ACG2).
COL2A1	1113	1113	G -> C (in hypochondrogenesis).
COL2A1	1119	1119	G -> R (in ACG2).
COL2A1	1143	1143	G -> S (in ACG2).
COL2A1	1158	1158	G -> A (in STL1).
COL2A1	1164	1199	Missing (in SEDC).
COL2A1	1170	1170	G -> S (in ANFH and in LCPD).
COL2A1	1173	1173	G -> R (in SEDC).
COL2A1	1176	1176	G -> S (in SEDC).
COL2A1	1184	1184	I -> IGPSGKDGANGIPGPI (in SEDC).
COL2A1	1188	1188	G -> R (in ACG2).
COL2A1	1197	1197	G -> S (in SEDC).
COL2A1	1207	1212	Missing (in KD).
COL2A1	1305	1305	G -> D (in vitreoretinopathy; with phalangeal epiphyseal dysplasia).
COL2A1	1390	1390	T -> N (in PLSD-T; phenotype previously considered as achondrogenesis- hypochondrogenesis type 2).
COL2A1	1391	1391	Y -> C (in PLSD-T).
COL2A1	1439	1439	T -> M (in SEDC).
COL2A1	1448	1448	T -> P (in PLSD-T).
COL2A1	1469	1469	D -> H (in PLSD-T).
COL2A1	1484	1484	Missing (in PLSD-T).
COL2A1	1485	1485	C -> G (in PLSD-T).
PFKM	39	39	R -> L (in GSD7; Ashkenazi).
PFKM	39	39	R -> P (in GSD7; Italian).
PFKM	209	209	G -> D (in GSD7; French Canadian).
PFKM	543	543	D -> A (in GSD7; Italian).
PFKM	686	686	W -> C (in GSD7; Japanese).
H1FNT	108	108	L -> P (in a Japanese man).
H1FNT	136	136	R -> S (in a Japanese man).
WNT10B	77	77	H -> Y.
WNT10B	256	256	C -> Y (associated with obesity; abrogates the ability of WNT10B to activate canonical Wnt signalling and blocks adipogenesis).
WNT10B	285	285	I -> T.
WNT10B	301	301	P -> S.
WNT10B	332	332	R -> W (in SHFM6).
DHH	162	162	L -> P (in GDXYM).
TUBA1A	188	188	I -> L (in LIS3).
TUBA1A	263	263	P -> T (in LIS3).
TUBA1A	264	264	R -> C (in LIS3).
TUBA1A	286	286	L -> F (in LIS3).
TUBA1A	402	402	R -> C (in LIS3).
TUBA1A	402	402	R -> H (in LIS3).
TUBA1A	419	419	S -> L (in LIS3).
MCRS1	441	441	V -> I (in a colorectal cancer sample; somatic mutation).
AQP2	22	22	L -> V (in ANDI).
AQP2	28	28	L -> P (in ANDI).
AQP2	47	47	A -> V (in ANDI).
AQP2	64	64	G -> R (in ANDI).
AQP2	68	68	N -> S (in ANDI).
AQP2	70	70	A -> D (in ANDI).
AQP2	71	71	V -> M (in ANDI).
AQP2	100	100	G -> R (in ANDI).
AQP2	125	125	T -> M (in ANDI).
AQP2	126	126	T -> M (in ANDI).
AQP2	147	147	A -> T (in ANDI).
AQP2	168	168	V -> M (in ANDI).
AQP2	175	175	G -> R (in ANDI).
AQP2	180	180	G -> S (in ANDI).
AQP2	181	181	C -> W (in ANDI).
AQP2	185	185	P -> A (in ANDI).
AQP2	187	187	R -> C (in ANDI; mutant protein does not fold properly and is not functional).
AQP2	187	187	R -> H (in ANDI).
AQP2	190	190	A -> T (in ANDI; mutant protein does not fold properly and is not functional).
AQP2	194	194	V -> I.
AQP2	202	202	W -> C (in ANDI).
AQP2	216	216	S -> P (in ANDI).
AQP2	254	254	R -> L (in ANDI; results in the loss of arginine vasopressin-mediated phosphorylation at S-256).
AQP2	254	254	R -> Q (in ANDI; exerts a dominant- negative effect on wild-type-AQP2 in that it interferes with its trafficking to the apical membrane; is a loss of function instead of a gain of function mutation on dominant nephrogenic diabetes insipidus).
AQP2	258	258	E -> K (in ANDI; retained in the Golgi compartment).
AQP2	262	262	P -> L (in ANDI; mutant protein folds properly and is functional but is retained in intracellular vesicles and does not localize to the ER; upon coexpression with wild-type AQP2 mutant protein interacts with wild-type AQP2 and the resulting heterotetramer properly localizes to the apical membrane).
CELA1	76	76	G -> A (in a breast cancer sample; somatic mutation).
ACVRL1	48	49	GA -> EP (in HHT2).
ACVRL1	48	48	G -> R (in HHT2).
ACVRL1	50	50	W -> C (in HHT2; retained in the cell cytoplasm in the endoplasmic reticulum).
ACVRL1	51	51	C -> Y (in HHT2).
ACVRL1	67	67	R -> Q (in HHT2; retained in the cell cytoplasm in the endoplasmic reticulum).
ACVRL1	67	67	R -> W (in HHT2).
ACVRL1	77	77	C -> W (in HHT2; retained in the cell cytoplasm in the endoplasmic reticulum).
ACVRL1	96	96	N -> D (in HHT2).
ACVRL1	179	179	D -> A (in HHT2; mutant protein is capable of targeting the cell surface appropriately).
ACVRL1	215	215	E -> K (in HHT2).
ACVRL1	223	223	G -> R (in HHT2).
ACVRL1	229	229	K -> R (in HHT2).
ACVRL1	232	232	Missing (in HHT2; mutant protein is capable of targeting the cell surface appropriately).
ACVRL1	233	233	Missing (in HHT2).
ACVRL1	254	254	Missing (in HHT2; retained in the cell cytoplasm in the endoplasmic reticulum).
ACVRL1	285	285	L -> F (in HHT2).
ACVRL1	306	306	A -> P (in HHT2).
ACVRL1	314	314	H -> Y (in HHT2).
ACVRL1	333	333	S -> I (in HHT2; retained in the cell cytoplasm in the endoplasmic reticulum).
ACVRL1	337	337	L -> P (in HHT2).
ACVRL1	347	347	A -> P (in HHT2).
ACVRL1	374	374	R -> Q (in HHT2; retained in the cell cytoplasm in the endoplasmic reticulum).
ACVRL1	376	376	M -> V (in HHT2).
ACVRL1	378	378	P -> L (in HHT2; retained in the cell cytoplasm in the endoplasmic reticulum).
ACVRL1	379	379	E -> K (in HHT2).
ACVRL1	397	397	D -> G (in HHT2).
ACVRL1	407	407	E -> D (in HHT2).
ACVRL1	411	411	R -> P (in HHT2).
ACVRL1	411	411	R -> W (in HHT2).
ACVRL1	424	424	P -> T (in HHT2).
ACVRL1	425	425	F -> L (in HHT2).
ACVRL1	425	425	F -> V (in HHT2).
ACVRL1	425	425	Missing (in HHT2).
ACVRL1	479	479	R -> L (in HHT2).
ACVRL1	482	482	A -> V (in HHT2).
ACVRL1	484	484	R -> W (in HHT2).
ACVRL1	487	487	K -> T (in HHT2; mutant protein is capable of targeting the cell surface appropriately).
KRT83	407	407	E -> K (in MLTRX).
KRT6A	171	171	Missing (in PC1).
KRT5	186	186	V -> M (in K-EBS).
KRT5	311	311	L -> P (in WC-EBS).
KRT5	327	327	M -> K (in WC-EBS).
KRT5	328	328	D -> G (in WC-EBS).
KRT5	331	331	R -> C (in WC-EBS).
KRT5	331	331	R -> H (in WC-EBS).
KRT5	352	352	R -> S (in WC-EBS).
KRT5	404	404	K -> E (in WC-EBS).
KRT5	418	418	E -> K (in K-EBS).
KRT5	438	438	A -> D (in WC-EBS).
KRT5	463	463	L -> P (in K-EBS).
KRT5	467	467	I -> T (in DM-EBS).
KRT5	469	469	T -> P (in DM-EBS).
KRT5	475	475	E -> G (in DM-EBS).
KRT5	475	475	E -> K (in DM-EBS).
KRT5	477	477	E -> K (in DM-EBS).
KRT5	517	517	G -> D (in K-EBS).
KRT74	148	148	N -> K (in ADWH; results in disruption of keratin intermediate filament formation in cultured cells).
KRT73	212	212	R -> H (in a colorectal cancer sample; somatic mutation).
KRT73	248	248	T -> M (in a colorectal cancer sample; somatic mutation).
KRT2	181	181	Q -> P (in IBS).
KRT2	186	186	N -> D (in IBS).
KRT2	465	465	E -> D (in IBS).
KRT2	465	465	E -> K (in IBS).
KRT2	477	477	I -> N (in IBS).
KRT1	155	155	V -> D (in BCIE).
KRT1	176	197	Missing (in palmoplantar keratoderma; and mild ichthyosis largely limited to the flexural areas).
KRT1	188	188	N -> T (in BCIE; severe).
KRT1	312	312	I -> V.
KRT1	330	330	I -> T.
KRT1	459	466	Missing (in palmoplantar keratoderma; and mild ichthyosis largely limited to the flexural areas).
KRT1	537	537	G -> C.
KRT1	560	566	Missing (in allele 1B).
KRT76	168	168	L -> V (in a breast cancer sample; somatic mutation).
KRT8	54	54	Y -> C (in CIRRH).
EIF4B	203	203	P -> R (found in a renal cell carcinoma case; somatic mutation).
AAAS	15	15	Q -> K (in AAAS).
AAAS	160	160	H -> R (in AAAS).
AAAS	263	263	S -> P (in AAAS).
AMHR2	54	54	R -> C (in PMDS2).
AMHR2	142	142	G -> V (in PMDS2).
AMHR2	282	282	H -> Q (in PMDS2).
AMHR2	406	406	R -> Q (in PMDS2).
AMHR2	426	426	D -> G (in PMDS2).
AMHR2	444	452	Missing (in PMDS2).
AMHR2	458	458	V -> A (in PMDS2).
AMHR2	491	491	D -> H (in PMDS2).
AMHR2	504	504	R -> C (in PMDS2).
MAP3K12	409	409	E -> K (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
HOXC11	130	130	P -> S.
MUCL1	46	53	Missing.
NEUROD4	68	68	K -> T.
RDH5	33	33	I -> V.
RDH5	35	35	G -> S (in RPA).
RDH5	73	73	S -> F (in RPA).
RDH5	107	107	G -> R (in RPA; associated with macular dystrophy).
RDH5	132	132	V -> M (in RPA).
RDH5	164	164	V -> F (in RPA).
RDH5	177	177	V -> G (in RPA).
RDH5	238	238	G -> W (in RPA).
RDH5	267	267	C -> W (in RPA).
RDH5	280	280	R -> H (in RPA).
RDH5	281	281	Y -> H (in RPA).
RDH5	294	294	A -> P (in RPA).
RDH5	310	310	L -> EV (in RPA).
SUOX	217	217	R -> Q (in ISOD; 2% of activity).
SUOX	258	258	I -> L (in ISOD).
SUOX	265	265	A -> D (in ISOD).
SUOX	268	268	R -> Q (in ISOD).
SUOX	362	362	G -> S (in ISOD).
SUOX	366	366	R -> H (in ISOD).
SUOX	379	379	K -> R (in ISOD).
SUOX	396	396	Q -> R (in ISOD).
SUOX	427	427	S -> Y (in ISOD).
SUOX	450	450	W -> R (in ISOD).
SUOX	530	530	G -> D (in ISOD).
RPS26	33	33	D -> N (in DBA10).
RPS26	115	115	M -> T (in DBA10).
PAN2	1201	1201	A -> V (in a colorectal cancer sample; somatic mutation).
TIMELESS	129	129	A -> S.
TIMELESS	429	429	A -> D (in a breast cancer sample; somatic mutation).
TIMELESS	471	471	N -> S.
TIMELESS	870	870	M -> V.
TIMELESS	922	922	R -> H.
TIMELESS	924	924	R -> W.
TIMELESS	1008	1008	Q -> E (in a breast cancer sample; somatic mutation).
MIP	134	134	E -> G (in ADC; non-progressive lamellar cataract; loss of activity).
MIP	138	138	T -> R (in ADC; progressive polymorphic and lamellar cataract; loss of activity).
MYO1A	116	116	S -> SS (in DFNA48).
MYO1A	385	385	E -> D (in DFNA48).
MYO1A	674	674	G -> D (in DFNA48).
MYO1A	797	797	S -> F (in DFNA48).
MYO1A	910	910	S -> P (in DFNA48).
INHBE	62	62	R -> T (in a breast cancer sample; somatic mutation).
INHBE	215	215	Q -> H (in a breast cancer sample; somatic mutation).
GLI1	210	210	P -> A (in a breast cancer sample; somatic mutation).
GLI1	514	514	T -> I (in a breast cancer sample; somatic mutation).
GLI1	817	817	E -> Q (in a breast cancer sample; somatic mutation).
GLI1	884	884	D -> A.
DDIT3	115	115	A -> V (in a colorectal cancer sample; somatic mutation).
KIF5A	63	63	Y -> C (in SPG10; complicated form).
KIF5A	198	198	M -> T (in SPG10; complicated form).
KIF5A	204	204	R -> Q (in SPG10; complicated form).
KIF5A	251	251	E -> K (in SPG10; complicated form).
KIF5A	253	253	K -> N (in SPG10; decreases microtubule affinity; reduces gliding velocity; reduces microtubule-dependent ATP turnover).
KIF5A	256	256	N -> S (in SPG10; slightly decreases microtubule affinity; reduces gliding velocity; reduces microtubule-dependent ATP turnover).
KIF5A	256	256	Missing (in SPG10).
KIF5A	257	257	K -> N (in SPG10; complicated form).
KIF5A	276	276	Y -> C (in SPG10).
KIF5A	280	280	R -> C (in SPG10).
KIF5A	280	280	R -> H (in SPG10; complicated form).
KIF5A	280	280	R -> L (in SPG10; pure form).
KIF5A	361	361	A -> V (in SPG10; does not affect microtubule affinity; does not affect gliding velocity; does not affect microtubule-dependent ATP turnover).
SLC26A10	270	270	L -> S (in a colorectal cancer sample; somatic mutation).
AGAP2	339	339	T -> A (in a breast cancer sample; somatic mutation).
AGAP2	455	455	V -> A (in a glioblastoma cell line).
AGAP2	518	518	R -> G (in a sarcoma cell line).
AGAP2	568	568	T -> I (in a neuroblastoma cell line).
AGAP2	651	651	A -> V (in a glioblastoma cell line).
AGAP2	767	767	E -> V (in a glioblastoma cell line).
AGAP2	816	816	D -> Y (in a breast cancer sample; somatic mutation).
AGAP2	939	939	N -> D (in a glioblastoma cell line).
AGAP2	947	947	V -> M (in a sarcoma cell line).
AGAP2	1022	1022	S -> P (in a glioblastoma cell line).
CDK4	24	24	R -> H (in CMM3).
CDK4	41	41	N -> S (in CMM3; sporadic).
CYP27B1	65	65	Q -> H (in VDDR1A).
CYP27B1	189	189	E -> G (in VDDR1A; 22% of wild-type activity).
CYP27B1	189	189	E -> K (in VDDR1A; 11% of wild-type activity).
CYP27B1	321	321	T -> R (in VDDR1A; complete loss of activity).
CYP27B1	323	323	S -> Y (in VDDR1A).
CYP27B1	343	343	L -> F (in VDDR1A; 2.3% of wild-type activity).
CYP27B1	389	389	R -> C (in VDDR1A; complete loss of activity).
CYP27B1	389	389	R -> G (in VDDR1A; complete loss of activity).
CYP27B1	389	389	R -> H (in VDDR1A; complete loss of activity).
CYP27B1	409	409	T -> I (in VDDR1A).
CYP27B1	429	429	R -> P (in VDDR1A).
CYP27B1	453	453	R -> C (in VDDR1A).
CYP27B1	478	478	V -> G (in VDDR1A).
CYP27B1	497	497	P -> R (in VDDR1A).
DYRK2	198	198	P -> L (in a glioblastoma multiforme sample; somatic mutation).
LYZ	74	74	I -> T (in AMYL8).
LYZ	85	85	D -> H (in AMYL8).
BBS10	34	34	R -> P (in BBS10; has moderately reduced ability to interact with BBS7 and BBS9).
BBS10	49	49	R -> W (in BBS10; has moderately reduced ability to interact with BBS7 and BBS9).
BBS10	91	91	C -> W (in BBS10; has moderately reduced ability to interact with BBS7 and BBS9).
BBS10	170	170	L -> S (in BBS10).
BBS10	195	195	C -> W (in BBS10).
BBS10	197	197	Y -> C (in BBS10).
BBS10	240	240	V -> G (in BBS10; has moderately reduced ability to interact with BBS7 and BBS9; severely reduces the interaction with BBS12 (8% of wild-type)).
BBS10	308	308	L -> F (in BBS10; has moderately reduced ability to interact with BBS7 and BBS9).
BBS10	311	311	S -> A (in BBS10; has moderately reduced ability to interact with BBS7 and BBS9; severely reduces the interaction with BBS12 (19% of wild-type)).
BBS10	329	329	S -> L (in BBS10; has moderately reduced ability to interact with BBS7 and BBS9; severely reduces the interaction with BBS12 (15% of wild-type)).
BBS10	363	363	P -> L (in BBS10; has moderately reduced ability to interact with BBS7 and BBS9).
BBS10	414	414	L -> S (in BBS10).
BBS10	579	579	K -> R (in BBS10).
BBS10	613	613	Y -> C (in BBS10).
BBS10	613	613	Y -> H (in BBS10; has moderately reduced ability to interact with BBS7 and BBS9).
BBS10	677	677	G -> V (in BBS10; has moderately reduced ability to interact with BBS7 and BBS9).
BBS10	689	689	T -> P (in BBS10; has moderately reduced ability to interact with BBS7 and BBS9).
PAWR	42	42	P -> L.
PAWR	137	137	G -> A.
MYF6	90	90	A -> D (in ADCNM).
KITLG	36	36	N -> S (in FPH; gain-of-function mutation; sKITLG reveales that the mutant Ser-36 sKITLG increases the content of the melanin by 109% compared with the wild-type sKITLG; tyrosinase activity is significantly increased by the mutant sKITLG compared to wild-type control).
KERA	215	215	T -> K (in CNA2).
KERA	247	247	N -> S (in CNA2).
LUM	199	199	L -> P (found in patients with amyotrophic lateral sclerosis).
HAL	206	206	R -> T (in HISTID).
HAL	208	208	R -> L (in HISTID).
HAL	259	259	P -> L (in HISTID).
HAL	322	322	R -> P (in HISTID).
SLC25A3	72	72	G -> E (in MPCD).
GNPTAB	374	374	F -> L (in MLIIIA; also in MLII).
GNPTAB	399	399	S -> F (in MLIIIA).
GNPTAB	403	403	I -> T (in MLIIIA).
GNPTAB	407	407	D -> A (in MLIIIA).
GNPTAB	442	442	C -> Y (in MLIIIA).
GNPTAB	461	461	C -> G (in MLIIIA).
GNPTAB	662	662	A -> G.
GNPTAB	926	926	Q -> P (in MLIIIA).
GNPTAB	956	956	H -> Y (in MLIIIA).
GNPTAB	1001	1001	L -> P (in MLII).
GNPTAB	1153	1153	N -> S (in MLIIIA).
GNPTAB	1236	1236	K -> M (in MLII; not only impairs lysosomal enzyme targeting but also the availability of intact GNPTG required for phosphotransferase activity and assembly of subunits).
UNG	251	251	F -> S (in HIGM5; fully active and stable when expressed in E. coli; mistargeted to mitochondria rather than the nucleus).
MMAB	96	96	I -> T (in MMAB).
MMAB	191	191	R -> W (in MMAB).
MMAB	193	193	E -> K (in MMAB).
MVK	20	20	H -> P (in HIDS and MEVA).
MVK	20	20	H -> Q (in HIDS).
MVK	39	39	L -> P (in HIDS).
MVK	132	132	V -> I (in HIDS).
MVK	135	135	S -> L (in HIDS).
MVK	148	148	A -> T (in HIDS).
MVK	150	150	S -> L (in HIDS).
MVK	167	167	P -> L (in HIDS).
MVK	171	171	G -> R (in HIDS).
MVK	202	202	G -> R (in HIDS).
MVK	211	211	G -> E (in HIDS).
MVK	215	215	R -> Q (in HIDS).
MVK	243	243	T -> I (in MEVA).
MVK	250	250	V -> I (in HIDS).
MVK	264	264	L -> F (in MEVA).
MVK	265	265	L -> P (in MEVA).
MVK	265	265	L -> R (in HIDS).
MVK	268	268	I -> T (in HIDS and MEVA).
MVK	309	309	G -> S (in HIDS).
MVK	310	310	V -> M (in MEVA and HIDS).
MVK	326	326	G -> R (in HIDS).
MVK	334	334	A -> T (in MEVA).
MVK	356	356	T -> M.
MVK	376	376	G -> V (in HIDS).
MYL2	13	13	A -> T (in MVC2).
MYL2	22	22	E -> K (in CMH10 and MVC2).
MYL2	95	95	P -> A (in MVC2).
MYL2	166	166	D -> V (in CMH10).
ALDH2	496	496	E -> K (in allele ALDH2*3).
NAA25	789	789	S -> R (in a breast cancer sample; somatic mutation).
RPL6	100	100	K -> Q (in a colorectal cancer sample; somatic mutation).
PTPN11	2	2	T -> I (in NS1).
PTPN11	42	42	T -> A (in NS1).
PTPN11	58	58	N -> K (in NS1).
PTPN11	60	60	G -> A (in NS1).
PTPN11	60	60	G -> V (in myelodysplastic syndrome).
PTPN11	61	61	D -> G (in NS1).
PTPN11	61	61	D -> N (in NS1).
PTPN11	61	61	D -> V (in JMML; also in myelodysplastic syndrome).
PTPN11	61	61	D -> Y (in JMML).
PTPN11	62	62	Y -> D (in NS1; also in Noonan patients manifesting juvenile myelomonocytic leukemia).
PTPN11	63	63	Y -> C (in NS1).
PTPN11	69	69	E -> K (in JMML; also in myelodysplastic syndrome).
PTPN11	69	69	E -> Q (in NS1).
PTPN11	71	71	F -> K (in acute myeloid leukemia; requires 2 nucleotide substitutions).
PTPN11	71	71	F -> L (in myelodysplastic syndrome).
PTPN11	72	72	A -> G (in NS1).
PTPN11	72	72	A -> S (in NS1).
PTPN11	72	72	A -> T (in JMML).
PTPN11	72	72	A -> V (in JMML).
PTPN11	76	76	E -> A (in JMML; also in myelodysplastic syndrome).
PTPN11	76	76	E -> D (in NS1).
PTPN11	76	76	E -> G (in JMML).
PTPN11	76	76	E -> V (in JMML).
PTPN11	79	79	Q -> P (in NS1).
PTPN11	79	79	Q -> R (in NS1).
PTPN11	106	106	D -> A (in NS1).
PTPN11	139	139	E -> D (in NS1).
PTPN11	256	256	Q -> R (in NS1).
PTPN11	279	279	Y -> C (in NS1 and LEOPARD1).
PTPN11	279	279	Y -> S (in LEOPARD1).
PTPN11	282	282	I -> V (in NS1).
PTPN11	285	285	F -> L (in NS1).
PTPN11	285	285	F -> S (in NS1).
PTPN11	308	308	N -> D (in NS1; common mutation).
PTPN11	308	308	N -> S (in NS1; some patients also manifest giant cell lesions of bone and soft tissue).
PTPN11	309	309	I -> V (in NS1).
PTPN11	415	415	T -> M (in NS1).
PTPN11	465	465	A -> T (in LEOPARD1).
PTPN11	468	468	G -> A (in LEOPARD1).
PTPN11	472	472	T -> M (in LEOPARD1).
PTPN11	502	502	R -> L (in LEOPARD1).
PTPN11	502	502	R -> W (in LEOPARD1).
PTPN11	505	505	R -> K (in NS1).
PTPN11	506	506	S -> T (in NS1).
PTPN11	507	507	G -> A (in JMML).
PTPN11	507	507	G -> R (in patients with growth retardation, pulmonic stenosis and juvenile myelomonocytic leukemia).
PTPN11	508	508	M -> V (in NS1).
PTPN11	510	510	Q -> P (in LEOPARD1).
PTPN11	510	510	Q -> R (in NS1).
PTPN11	514	514	Q -> P (in LEOPARD1).
PTPN11	564	564	L -> F (in NS1).
TBX3	143	143	L -> P (in UMS).
TBX3	149	149	Y -> S (in UMS).
PEBP1	9	9	S -> N.
HSPB8	67	67	G -> S (in a glioblastoma multiforme sample; somatic mutation).
HSPB8	141	141	K -> E (in HMN2A; strengthen interaction with HSPB1).
HSPB8	141	141	K -> N (in HMN2A and CMT2L; strengthen interaction with HSPB1).
MSI1	160	160	E -> Q (in a breast cancer sample; somatic mutation).
ACADS	46	46	R -> W (in ACADSD).
ACADS	90	90	G -> S (in ACADSD; no detectable activity).
ACADS	92	92	G -> C (in ACADSD).
ACADS	104	104	Missing (in ACADSD; no detectable activity).
ACADS	107	107	R -> C (in ACADSD).
ACADS	325	325	R -> W (in ACADSD; no detectable activity).
HNF1A	12	12	L -> H (in MODY3; abolishes interaction with PCBD1 and DNA).
HNF1A	20	20	G -> R (in MODY3; abolishes interaction with PCBD1 and DNA).
HNF1A	31	31	G -> D (in MODY3; no effect on interaction with PCBD1 and DNA).
HNF1A	48	48	E -> K (in IDDM20).
HNF1A	107	107	L -> R (in MODY3).
HNF1A	117	117	K -> E (in MODY3).
HNF1A	122	122	Y -> C (in MODY3).
HNF1A	127	127	N -> Y (in a hepatocellular carcinoma sample; somatic mutation).
HNF1A	128	128	I -> N (in MODY3).
HNF1A	129	129	P -> T (in MODY3).
HNF1A	131	131	R -> Q (in MODY3; expected to interfere with DNA binding).
HNF1A	131	131	R -> W (in MODY3; expected to interfere with DNA binding).
HNF1A	133	133	V -> M (in MODY3).
HNF1A	142	142	S -> F (in MODY3; reduces transcription activation by about 80%).
HNF1A	143	143	H -> Y (in MODY3; expected to interfere with DNA binding).
HNF1A	158	158	K -> N (in MODY3; expected to interfere with DNA binding).
HNF1A	159	159	R -> Q (in MODY3).
HNF1A	159	159	R -> W (in MODY3).
HNF1A	161	161	A -> T (in MODY3).
HNF1A	165	165	W -> C (in a hepatocellular carcinoma sample; somatic mutation).
HNF1A	191	191	G -> D (in late-onset NIDDM).
HNF1A	200	200	R -> W (in MODY3; expected to interfere with nuclear localization).
HNF1A	203	203	R -> C (in MODY3; expected to interfere with nuclear localization and DNA binding).
HNF1A	203	203	R -> H (in MODY3; expected to interfere with nuclear localization and DNA binding).
HNF1A	205	205	K -> Q (in MODY3; reduces transcription activation by about 50%).
HNF1A	206	206	W -> C (in a hepatic adenoma sample; somatic mutation; expected to interfere with DNA binding).
HNF1A	206	206	W -> L (in a hepatic adenoma sample; somatic mutation; expected to interfere with DNA binding).
HNF1A	229	229	R -> Q (in MODY3).
HNF1A	237	237	N -> S (in a hepatic multiple adenoma sample; somatic mutation).
HNF1A	241	241	C -> G (in IDDM20 and MODY3).
HNF1A	244	244	R -> G (in a hepatic adenoma sample; somatic mutation; expected to interfere with DNA binding).
HNF1A	250	250	Q -> P (in a hepatocellular carcinoma sample; somatic mutation).
HNF1A	254	254	L -> M (in late-onset NIDDM; low penetrance; could be a rare polymorphism).
HNF1A	259	259	V -> D (in MODY3).
HNF1A	260	260	T -> M (in MODY3).
HNF1A	263	263	R -> C (in MODY3; expected to interfere with DNA binding).
HNF1A	268	268	F -> C (in a hepatic adenoma sample; somatic mutation).
HNF1A	271	271	R -> W (in MODY3).
HNF1A	272	272	R -> C (in NIDDM).
HNF1A	272	272	R -> H (in IDDM20 and MODY3).
HNF1A	273	273	K -> E (in a hepatic adenoma sample; somatic mutation).
HNF1A	319	319	G -> S (strong association with NIDDM susceptibility; unique to the Canadian Oji-Cree population).
HNF1A	415	415	G -> R (in IDDM20; loss of function).
HNF1A	432	432	S -> C (in MODY3).
HNF1A	447	447	P -> L (in MODY3).
HNF1A	514	514	H -> R.
HNF1A	519	519	P -> L (in MODY3).
HNF1A	537	537	T -> R (in MODY3; incomplete penetrance).
HNF1A	583	583	R -> G (in IDDM20).
HNF1A	583	583	R -> Q (in late-onset NIDDM; also in an individual with hepatic hyperplasia and familial early-onset diabetes).
HNF1A	594	594	S -> I (in MODY3).
HNF1A	618	618	I -> M (in MODY3).
HNF1A	619	619	E -> K (in MODY3).
HNF1A	620	620	T -> I (in MODY3; incomplete penetrance).
CAMKK2	127	127	P -> L (in a lung neuroendocrine carcinoma sample; somatic mutation).
CAMKK2	182	182	A -> T (in a colorectal adenocarcinoma sample; somatic mutation).
ORAI1	91	91	R -> W (in IDTICED1).
HCAR3	253	253	R -> H.
HCAR3	317	317	M -> I.
HCAR3	350	350	G -> S.
CCDC62	31	31	Q -> E (in a colorectal cancer sample; somatic mutation).
SBNO1	634	634	T -> S (in a breast cancer sample; somatic mutation).
SBNO1	889	889	E -> K (in a breast cancer sample; somatic mutation).
SBNO1	997	997	S -> C (in a breast cancer sample; somatic mutation).
EIF2B1	208	208	N -> Y (in VWM).
PUS1	133	133	D -> N (in a breast cancer sample; somatic mutation).
PUS1	144	144	R -> W (in MLASA1).
VPS13B	866	866	V -> I.
VPS13B	1494	1494	Missing (in COH1).
VPS13B	1739	1744	Missing (in COH1).
VPS13B	1994	1994	I -> V.
VPS13B	2193	2193	L -> R (in COH1; could be a rare polymorphism).
VPS13B	2341	2341	Y -> C (in COH1).
VPS13B	2645	2645	G -> D (in COH1).
VPS13B	2773	2773	S -> L (in COH1).
VPS13B	2820	2820	I -> T (in COH1).
VPS13B	2822	2822	Y -> C.
VPS13B	3001	3001	L -> V (in a breast cancer sample; somatic mutation).
VPS13B	3142	3142	S -> R.
MCPH1	27	27	T -> R (in MCPH1; mild phenotype).
SFTPC	66	66	E -> K (in SMDP2; targeted abnormally to early endosomes and likely to result in a toxic gain of function).
SFTPC	73	73	I -> T (in SMDP2; abnormal trafficking and accumulation of aberrantly processed proSPC within alveoli).
SFTPC	116	116	A -> D (in SMDP2).
SFTPC	188	188	L -> Q (in SMDP2).
NRG1	463	463	M -> K.
RP1	202	202	D -> E (in RP1).
RP1	373	373	T -> I (in RP1).
RP1	408	408	I -> L.
RP1	663	663	K -> N (in RP1; uncertain pathogenicity).
RP1	669	669	A -> T (in RP1).
RP1	706	706	G -> R.
RP1	727	727	C -> W.
RP1	984	984	D -> G (in RP1).
RP1	1370	1370	K -> E (in RP1; uncertain pathogenicity).
RP1	1652	1652	R -> L (in RP1; uncertain pathogenicity).
RP1	1808	1808	L -> P (in RP1; uncertain pathogenicity).
RP1	2033	2033	C -> Y.
TOX	267	267	A -> T (found in a renal cell carcinoma sample; somatic mutation).
ARFGEF1	316	316	G -> E (in a colorectal cancer sample; somatic mutation).
STK3	60	60	V -> L (in an ovarian clear cell carcinoma sample; somatic mutation).
CSMD3	322	322	W -> G (in a colorectal cancer sample; somatic mutation).
CSMD3	2020	2020	S -> C (found in a renal cell carcinoma case; somatic mutation).
CSMD3	3079	3079	R -> H (in a colorectal cancer sample; somatic mutation).
CSMD3	3359	3359	R -> Q (in a colorectal cancer sample; somatic mutation).
KCNQ3	305	305	D -> G (in EBN2; reduces the maximal heteromeric current by approx. 40% with no alteration in voltage dependence of activation or deactivation kinetics).
KCNQ3	309	309	W -> R (in EBN2).
KCNQ3	310	310	G -> V (in EBN2; about 50% reduction of wild-type heteromeric current; ratio of 1:1; or 20%; ratio of 1:1:2).
KCNQ3	468	468	N -> S (has no statistically significant effect on the current or biophysical properties of the heteromeric channel).
ERICH1	365	365	L -> F (in a colorectal cancer sample; somatic mutation).
ARHGEF10	357	357	T -> I (in SNCV).
DLC1	959	959	T -> A.
DLC1	998	998	H -> Q.
DLC1	1025	1025	V -> A.
ZDHHC2	306	306	S -> F (in a hepatocellular carcinoma sample; somatic mutation).
ZDHHC2	356	356	M -> I (in a colorectal cancer sample; somatic mutation).
MTUS1	75	75	Q -> K (in HCC).
MTUS1	186	186	T -> S (in HNSCC cell lines).
MTUS1	425	425	T -> M.
MTUS1	563	563	A -> S (in HCC).
MTUS1	873	873	N -> H (in HCC).
MTUS1	911	911	K -> T.
MTUS1	1105	1105	E -> Q.
MTUS1	1201	1201	Q -> R (in HCC).
DPYSL2	481	481	R -> C (in a colorectal cancer sample; somatic mutation).
ADRA1A	40	40	G -> W (in a breast cancer sample; somatic mutation).
EPHX2	21	21	G -> A.
EPHX2	52	52	R -> Q.
EPHX2	225	225	P -> L.
EPHX2	369	369	M -> V.
EPHX2	403	403	R -> RR.
EPHX2	470	470	E -> G.
ESCO2	539	539	W -> G (in RBS).
WRN	92	92	G -> V (in a colorectal cancer sample; somatic mutation).
WRN	125	125	K -> N (in WRN).
WRN	135	135	K -> E (in WRN).
WRN	172	172	T -> P (no effect on exonuclease activity).
WRN	240	240	N -> K.
WRN	383	383	L -> W.
WRN	724	724	Q -> L.
WRN	1141	1141	S -> L.
WRN	1269	1269	K -> E.
FGFR1	48	48	G -> S (in IHH).
FGFR1	77	77	N -> K.
FGFR1	78	78	R -> C (in KAL2).
FGFR1	97	97	G -> D (in KAL2).
FGFR1	99	99	Y -> C (in KAL2).
FGFR1	101	101	C -> F (in KAL2).
FGFR1	125	125	S -> L (in a breast infiltrating ductal carcinoma sample; somatic mutation).
FGFR1	129	129	D -> A (in KAL2).
FGFR1	167	167	A -> S (in KAL2; with cleft palate, corpus callosum agenesis, unilateral deafness and fusion of fourth and fifth metacarpal bones).
FGFR1	178	178	C -> S (in KAL2; with severe ear anomalies).
FGFR1	224	224	D -> H (in KAL2).
FGFR1	237	237	G -> D (in KAL2).
FGFR1	237	237	G -> S (in IHH/KAL2; also found in a family member with isolated anosmia; may impair proper folding).
FGFR1	245	245	L -> P (in KAL2).
FGFR1	250	250	R -> W (in KAL2).
FGFR1	252	252	P -> R (in PS; seems to be a gain of function).
FGFR1	252	252	P -> T (in a lung bronchoalveolar carcinoma sample; somatic mutation).
FGFR1	254	254	R -> Q (in KAL2).
FGFR1	270	270	G -> D (in KAL2).
FGFR1	273	273	V -> M (in KAL2).
FGFR1	274	274	E -> G (in KAL2; also found in a family member with isolated anosmia).
FGFR1	277	277	C -> Y (in KAL2).
FGFR1	283	283	P -> R (in KAL2).
FGFR1	300	300	I -> T (in TRICEPH).
FGFR1	330	330	N -> I (in OGD).
FGFR1	332	332	S -> C (in KAL2).
FGFR1	339	339	Y -> C (in KAL2).
FGFR1	343	343	A -> V (in KAL2).
FGFR1	346	346	S -> C (in KAL2; also found in a family member with isolated anosmia).
FGFR1	366	366	P -> L (in IHH/KAL2).
FGFR1	374	374	Y -> C (in OGD; elevated basal activity and increased FGF2-mediated activity).
FGFR1	381	381	C -> R (in OGD).
FGFR1	520	520	A -> T (in KAL2).
FGFR1	538	538	I -> V (in KAL2).
FGFR1	607	607	V -> M (in KAL2; with bimanual synkinesis).
FGFR1	621	621	H -> R (in KAL2).
FGFR1	622	622	R -> G (in KAL2; with severe ear anomalies).
FGFR1	622	622	R -> Q (in KAL2).
FGFR1	664	664	V -> L (in a lung large cell carcinoma sample; somatic mutation).
FGFR1	666	666	W -> R (in KAL2; with cleft palate).
FGFR1	685	685	S -> F (in KAL2).
FGFR1	687	687	G -> R (in KAL2).
FGFR1	693	693	I -> F (in KAL2).
FGFR1	703	703	G -> R (in KAL2).
FGFR1	703	703	G -> S (in KAL2).
FGFR1	719	719	M -> R (in KAL2).
FGFR1	722	722	P -> H (in IHH; associated with K-724; also found in a family member with isolated anosmia; reduced tyrosine kinase activity).
FGFR1	722	722	P -> S (in KAL2).
FGFR1	724	724	N -> K (in IHH; associated with H-722; also found in a family member with isolated anosmia; reduced tyrosine kinase activity).
FGFR1	745	745	P -> S (in KAL2).
FGFR1	795	795	V -> I (in KAL2; also found in a family member with isolated anosmia).
ANK1	21	21	R -> T.
ANK1	276	276	L -> R (in SPH1).
ANK1	332	332	D -> H (in a breast cancer sample; somatic mutation).
ANK1	463	463	V -> I (in SPH1).
ANK1	750	750	V -> A.
ANK1	845	845	D -> E.
ANK1	991	991	V -> L.
ANK1	1054	1054	I -> T (in SPH1).
ANK1	1286	1286	E -> D.
ANK1	1392	1392	S -> T.
ANK1	1592	1592	D -> N (in Duesseldorf).
HOOK3	221	221	Q -> R (in a breast cancer sample; somatic mutation).
PRKDC	263	263	K -> N (in a lung adenocarcinoma sample; somatic mutation).
PRKDC	500	500	G -> S (in a metastatic melanoma sample; somatic mutation).
PRKDC	1136	1136	R -> H (in a colorectal adenocarcinoma sample; somatic mutation).
PRKDC	1237	1237	A -> T.
PRKDC	1279	1279	L -> F.
PRKDC	1447	1447	R -> M (in a lung squamous cell carcinoma sample; somatic mutation).
PRKDC	2810	2810	S -> N (in a metastatic melanoma sample; somatic mutation).
PRKDC	2941	2941	G -> A (in a lung neuroendocrine carcinoma sample; somatic mutation).
PRKDC	3584	3584	L -> F.
PRKDC	3800	3800	L -> I.
PRKDC	3932	3932	M -> V.
PRKDC	3936	3936	G -> S.
PRKDC	3937	3937	V -> M.
RB1CC1	1514	1514	R -> C (in a breast cancer sample; somatic mutation).
LYN	385	385	D -> Y (in a breast pleomorphic lobular carcinoma sample; somatic mutation).
FAM110B	214	214	A -> S (in a colorectal cancer sample; somatic mutation).
CHD7	55	55	H -> R (in KAL5).
CHD7	834	834	S -> F (in IHH).
CHD7	1028	1028	I -> V (in CHARGES).
CHD7	1031	1031	W -> G (in CHARGES).
CHD7	1214	1214	Q -> R (in CHARGES).
CHD7	1257	1257	L -> R (in CHARGES).
CHD7	1294	1294	L -> P (in CHARGES).
CHD7	1815	1815	L -> P (in CHARGES).
CHD7	2096	2096	H -> R (in CHARGES).
CHD7	2319	2319	R -> S (in CHARGES).
CHD7	2789	2789	A -> T (in IHH).
CHD7	2880	2880	P -> L (in IHH).
CHD7	2948	2948	K -> E (in KAL5).
CYP7B1	57	57	G -> R (in SPG5A).
CYP7B1	216	216	F -> S (in SPG5A).
CYP7B1	363	363	S -> F (in SPG5A).
CYP7B1	417	417	R -> H (in SPG5A).
ADHFE1	242	242	D -> V (in a breast cancer sample; somatic mutation).
SGK3	92	92	A -> V (in a breast cancer sample; somatic mutation).
SGK3	355	355	L -> P.
PREX2	537	537	V -> I (in a colorectal cancer sample; somatic mutation).
PREX2	1571	1571	A -> E (in a colorectal cancer sample; somatic mutation).
C8orf34	75	75	K -> N (in a colorectal cancer sample; somatic mutation).
EYA1	95	95	P -> S (in BOR1).
EYA1	140	140	G -> S (in BOR1).
EYA1	242	242	S -> G (in BOS1).
EYA1	363	363	E -> K (in anterior segment anomalies).
EYA1	363	363	E -> V (in BOR1).
EYA1	426	426	G -> S (in BOR1; with cataract).
EYA1	429	429	D -> G (in BOR1).
EYA1	440	440	R -> Q (in BOR1).
EYA1	487	487	S -> P (in BOR1).
EYA1	505	505	L -> R (in BOR1).
EYA1	514	514	L -> P (in BOR1).
EYA1	527	527	Y -> C (in BOR1).
EYA1	547	547	R -> G (in anterior segment anomalies; with cataract).
EYA1	569	569	M -> T (in BOR1).
EYA1	583	583	L -> P (in BOR1).
KCNB2	450	450	V -> I (in a colorectal cancer sample; somatic mutation).
CA1	68	68	H -> R (in variant Michigan-1; confers enhanced esterase activity and an additional zinc binding site).
CA1	254	254	G -> R (in Guam).
CA2	18	18	K -> E (in Jogjakarta).
CA2	92	92	Q -> P (in OPTB3; in Czechoslovakia).
CA2	94	94	H -> Y (in OPTB3; partial loss of activity).
CA2	107	107	H -> Y (in OPTB3; frequent mutation).
CA2	144	144	G -> R (in OPTB3; complete loss of activity).
CA2	236	236	P -> H (in Melbourne).
CNGB3	25	25	R -> H.
CNGB3	107	107	G -> R (in ACHM3; uncertain pathogenicity).
CNGB3	148	148	K -> E (in ACHM3).
CNGB3	156	156	S -> F (in ACHM3).
CNGB3	199	199	E -> K (in ACHM3; uncertain pathogenicity).
CNGB3	309	309	P -> L (in ACHM3).
CNGB3	403	403	R -> Q (in macular degeneration).
CNGB3	435	435	S -> F (in ACHM3).
CNGB3	494	494	D -> N (in ACHM3; uncertain pathogenicity).
CNGB3	513	513	D -> Y (in ACHM3; uncertain pathogenicity).
CNGB3	525	525	F -> N (in ACHM3; requires 2 nucleotide substitutions).
CNGB3	558	558	G -> C (in ACHM3).
CNGB3	595	595	L -> F (in ACHM3).
CNGB3	672	672	T -> P (in ACHM3; uncertain pathogenicity).
CNGB3	720	726	Missing (in ACHM3).
NBN	95	95	D -> N (in some childhood acute lymphoblastic leukemia patients; uncertain pathological significance; rare variant).
NBN	150	150	L -> F (in BC).
NBN	171	171	I -> V (in some childhood acute lymphoblastic leukemia patients; uncertain pathological significance; rare variant; associated with aplastic anemia at homozygosity).
NBN	210	210	V -> F.
NBN	574	574	L -> I.
NBN	679	679	Y -> H (found in a renal cell carcinoma sample; somatic mutation).
RUNX1T1	386	386	R -> W (in a colorectal cancer sample; somatic mutation).
RUNX1T1	395	395	R -> W (in a colorectal cancer sample; somatic mutation).
RUNX1T1	471	471	A -> V (in a colorectal cancer sample; somatic mutation).
NDUFAF6	99	99	Q -> R (in MT-C1D).
ZFPM2	30	30	E -> G (in TOF; in one patient with sporadic TOF; does not affect its ability to interact with GATA4).
OXR1	100	100	E -> G.
OXR1	360	360	Q -> P.
OXR1	516	516	K -> R.
ANGPT1	269	269	Missing (in cell line T98G; may be due to exon slippage).
TRPS1	894	894	V -> D (in TRPS3; in heterozygous status has a milder effect causing TRPS1).
TRPS1	901	901	T -> P (in TRPS3; severe).
TRPS1	908	908	R -> P (in TRPS3; severe).
TRPS1	908	908	R -> Q (in TRPS3).
TRPS1	919	919	A -> T (in TRPS3).
TRPS1	952	952	R -> C (in TRPS1; prevents the transport into the nucleus and thus reduces the nuclear TRPS1 concentration consistent with haploinsufficiency).
TRPS1	952	952	R -> H (in TRPS1; prevents the transport into the nucleus and thus reduces the nuclear TRPS1 concentration consistent with haploinsufficiency).
EXT1	27	27	Q -> K (in EXT1; no loss of activity).
EXT1	164	164	D -> H (in EXT1; loss of activity).
EXT1	215	222	MLAKASIS -> I (in isolated osteochondroma; somatic mutation).
EXT1	215	221	Missing (in EXT1).
EXT1	235	239	Missing (in multiple osteochondromas).
EXT1	280	280	R -> G (in EXT1; loss of activity).
EXT1	280	280	R -> S (in EXT1; loss of activity).
EXT1	316	316	N -> S (in chondrosarcoma; no loss of activity).
EXT1	339	339	G -> D (in EXT1; loss of activity).
EXT1	340	340	R -> C (in EXT1; loss of activity; still able to form an oligomeric complex).
EXT1	340	340	R -> H (in EXT1; loss of activity).
EXT1	340	340	R -> L (in EXT1; loss of activity).
EXT1	340	340	R -> S (in EXT1; loss of activity).
EXT1	486	486	A -> V (in EXT1; no loss of activity).
EXT1	496	496	P -> L (in EXT1; no loss of activity).
EXT1	627	627	Missing (in EXT1; loss of activity).
KIAA0196	471	471	N -> D (in SPG8).
KIAA0196	619	619	L -> F (in SPG8; fails to rescue the curly phenotype in a zebrafish model).
KIAA0196	626	626	V -> F (in SPG8; fails to rescue the curly phenotype in a zebrafish model).
NSMCE2	27	27	L -> F (in a breast cancer sample; somatic mutation).
FAM49B	169	169	N -> K.
ADCY8	881	881	F -> L (in a colorectal cancer sample; somatic mutation).
TG	183	183	C -> Y (in TDH3).
TG	985	985	Missing.
TG	1043	1043	H -> Y.
TG	1059	1059	I -> T.
TG	1463	1463	P -> H.
TG	1897	1897	C -> Y (in TDH3).
TG	1979	1979	R -> W (polymorphism associated with AITD3).
TG	2091	2091	D -> E.
TG	2234	2234	A -> D (in TDH3; reduces thyroglobulin synthesis and secretion; promotes thyroglobulin retention within the endoplasmic reticulum).
TG	2336	2336	R -> Q (in TDH3).
TG	2375	2375	G -> R (in TDH3).
KCNK9	236	236	G -> R (in BIBAS; inactive).
PTK2	292	292	H -> P.
PTK2	292	292	H -> Q.
PTK2	793	793	V -> A (in a glioblastoma multiforme sample; somatic mutation).
PTK2	1030	1030	D -> E.
PTK2	1044	1044	K -> E (in a metastatic melanoma sample; somatic mutation).
CLN8	16	16	L -> M (in CLN8; associated with M-170 on the same allele).
CLN8	24	24	R -> G (in CLN8NE).
CLN8	30	30	A -> P (in CLN8).
CLN8	61	61	Missing (in CLN8).
CLN8	155	155	A -> V.
CLN8	158	158	Y -> C (in CLN8).
CLN8	170	170	T -> M (in CLN8; associated with M-16 on the same allele).
CLN8	194	194	Q -> R (in CLN8).
CLN8	204	204	R -> C (in CLN8).
CLN8	237	237	G -> R (in CLN8).
DEFA4	74	74	R -> Q (in a colorectal cancer sample; somatic mutation).
SGK223	122	122	L -> I.
SGK223	137	137	R -> G.
SGK223	139	139	V -> I.
SGK223	402	402	R -> Q.
SGK223	567	567	P -> L.
SGK223	576	576	S -> C.
SGK223	593	593	P -> A.
SGK223	660	660	P -> T.
SGK223	812	812	P -> L.
SGK223	849	849	H -> R.
SGK223	1001	1001	S -> L.
SGK223	1039	1039	V -> M.
SGK223	1111	1111	A -> T.
SGK223	1311	1311	R -> H.
GATA4	52	52	S -> F (in ASD2).
GATA4	296	296	G -> S (in ASD2).
PDGFRL	23	23	H -> Y (in CRC; somatic mutation).
ASAH1	22	22	Q -> H (in FL).
ASAH1	23	23	H -> D (in FL).
ASAH1	36	36	Y -> C (in FL).
ASAH1	96	96	Missing (in FL).
ASAH1	97	97	V -> E (in FL).
ASAH1	182	182	L -> V (in FL).
ASAH1	222	222	T -> K (in FL).
ASAH1	235	235	G -> R (in FL).
ASAH1	254	254	R -> G (in FL).
ASAH1	320	320	N -> D (in FL).
ASAH1	362	362	P -> R (in FL).
NAT1	166	167	RE -> TQ (in allele NAT1*5).
NAT1	205	205	M -> V (in allele NAT1*21).
NAT1	261	261	E -> K (in allele NAT1*24).
NAT1	263	263	I -> V (in allele NAT1*25).
NAT2	145	145	Q -> P (in allele NAT2*17).
NAT2	193	193	T -> M.
LPL	70	70	N -> S (in LPL deficiency; produces an inactive protein which is not secreted into the media).
LPL	96	96	V -> L (in LPL deficiency; gives rise to a 80% decrease in specific catalytic activity).
LPL	98	98	A -> T (in LPL deficiency; decreases the specific activity of the enzyme; reduces the secretion of the mutant protein significantly; the total LPL mass is reduced compared to that of the wild-type construct).
LPL	102	102	R -> S (in LPL deficiency).
LPL	113	113	W -> G (in LPL deficiency).
LPL	113	113	W -> R (in LPL deficiency).
LPL	128	128	T -> A (in LPL deficiency).
LPL	132	132	G -> R (in LPL deficiency; synthesized as a catalytically inactive form).
LPL	163	163	H -> R (in LPL deficiency).
LPL	169	169	G -> E (in LPL deficiency; loss of activity).
LPL	181	181	G -> S (in LPL deficiency).
LPL	181	181	G -> V (in LPL deficiency; synthesized as a catalytically inactive form).
LPL	183	183	D -> G (in LPL deficiency; lacks both triolein and tributyrin esterase activities).
LPL	183	183	D -> H (in LPL deficiency).
LPL	183	183	D -> N (in LPL deficiency; lacks both triolein and tributyrin esterase activities).
LPL	184	184	P -> R (in LPL deficiency; Nijmegen; loss of activity).
LPL	185	185	A -> T (in LPL deficiency; 3.2% of activity).
LPL	186	186	G -> E (in LPL deficiency).
LPL	190	190	E -> G (in LPL deficiency).
LPL	199	199	S -> C (in LPL deficiency; mild hypertriglyceridemia; partial activity).
LPL	201	201	D -> V (in LPL deficiency).
LPL	203	203	A -> T (in LPL deficiency; Bethesda; loss of activity and abnormal heparin binding).
LPL	207	207	D -> E (in LPL deficiency).
LPL	208	208	V -> I (in LPL deficiency; decreases the specific activity of the enzyme; has a mild effect on the secretion of the mutant enzyme; the total LPL mass is reduced compared to that of the wild-type construct).
LPL	210	210	H -> D (in LPL deficiency; complete loss of enzyme activity).
LPL	210	210	H -> Q (in LPL deficiency; loss of activity).
LPL	215	215	G -> E (in LPL deficiency; loss of activity).
LPL	215	215	G -> R (in LPL deficiency).
LPL	220	220	S -> R (in LPL deficiency; 2.0% of activity).
LPL	221	221	I -> T (in LPL deficiency; loss of activity).
LPL	222	222	G -> E (in LPL deficiency).
LPL	225	225	K -> R (in LPL deficiency).
LPL	227	227	V -> A (in LPL deficiency).
LPL	231	231	D -> E (in LPL deficiency; loss of activity).
LPL	232	232	I -> S (in LPL deficiency).
LPL	234	234	P -> L (in LPL deficiency; loss of activity).
LPL	243	243	C -> S (in LPL deficiency; loss of activity).
LPL	252	252	I -> T (in LPL deficiency).
LPL	266	266	C -> W (in LPL deficiency).
LPL	270	270	R -> C (in LPL deficiency).
LPL	270	270	R -> H (in LPL deficiency; loss of activity).
LPL	277	277	D -> N (in LPL deficiency; 5% of full activity).
LPL	278	278	S -> C (in LPL deficiency).
LPL	279	279	L -> V (in LPL deficiency; decreases the specific activity of the enzyme; the total LPL mass is reduced compared to that of the wild-type construct).
LPL	286	286	S -> G (in LPL deficiency).
LPL	286	286	S -> R (in LPL deficiency).
LPL	289	289	Y -> H (in LPL deficiency; no enzyme activity).
LPL	297	297	F -> L (in LPL deficiency and hyperlipidemia; synthesized as a catalytically inactive form; total amount is almost equal to that of the normal enzyme; non-releasable by heparin due to the abnormal structure of the mutant protein).
LPL	303	303	L -> F (in LPL deficiency; approximately 6% of normal LPL activity and 40% of LPL mass are detected in the patient's postheparin plasma; results in the production of a functionally inactive enzyme).
LPL	305	305	C -> R (in LPL deficiency).
LPL	310	310	C -> Y (in LPL deficiency; decreases the specific activity of the enzyme; reduces the secretion of the mutant protein significantly; the total LPL mass is reduced compared to that of the wild-type construct).
LPL	313	313	L -> P (in LPL deficiency).
LPL	325	325	S -> R (in LPL deficiency; has no effect on the specific activity of the enzyme; has a mild effect on the secretion of the mutant enzyme; the total LPL mass is reduced compared to that of the wild-type construct).
LPL	328	328	M -> R (in LPL deficiency).
LPL	328	328	M -> T (in LPL deficiency).
LPL	330	330	L -> F (in LPL deficiency).
LPL	330	330	L -> P (in LPL deficiency).
LPL	361	361	A -> T (in LPL deficiency).
LPL	365	365	S -> F (in LPL deficiency; increases the specific activity of the enzyme; has a mild effect on the secretion of the mutant enzyme; the total LPL mass is reduced compared to that of the wild-type construct).
LPL	392	392	L -> V (in LPL deficiency; loss of activity).
LPL	423	424	Missing (in LPL deficiency; affects the protein folding).
LPL	437	437	E -> K (in LPL deficiency).
LPL	437	437	E -> V (in LPL deficiency).
LPL	445	445	C -> Y (in LPL deficiency; has 48% of normal activity in vitro; decreased levels of activity account for by the lower protein mass levels of the mutants rather than by decreased enzymatic activities).
LPL	448	448	E -> K (in LPL deficiency; results in a moderate reduction in catalytic activity).
LZTS1	119	119	K -> E (in a esophageal cancer sample).
HR	620	620	R -> Q.
HR	633	633	R -> Q (in a colorectal cancer sample; somatic mutation).
HR	1012	1012	D -> N (in ALUNC; affects binding to thyroid hormone receptor).
HR	1136	1136	V -> D (in ALUNC).
BMP1	45	45	D -> H (in a breast cancer sample; somatic mutation).
ENTPD4	341	341	I -> V (found in a renal cell carcinoma case; somatic mutation).
NEFL	8	8	P -> L (in CMT1F).
NEFL	8	8	P -> Q (in CMT1F).
NEFL	336	336	L -> P (in CMT2E).
NEFL	396	396	E -> K (in CMT1F).
NEFL	527	527	Missing (in CMT1F).
CHRNA2	279	279	I -> N (in ENFL4; markedly increases receptor sensitivity to acetylcholine).
PURG	316	316	K -> T (in a breast cancer sample; somatic mutation).
STAR	169	169	E -> G (in AH1; partial loss of activity).
STAR	169	169	E -> K (in AH1; partial loss of activity).
STAR	182	182	R -> L (in AH1; partial loss of activity).
STAR	218	218	A -> V (in AH1; partial loss of activity).
STAR	225	225	M -> T (in AH1).
STAR	272	272	Missing (in AH1; partial loss of activity).
STAR	275	275	L -> P (in AH1; partial loss of activity).
IKBKB	360	360	A -> S (in breast cancer samples; infiltrating ductal carcinoma; somatic mutation).
THAP1	81	81	F -> L (in DYT6; affects DNA-binding).
SGK196	342	342	M -> I (in a lung small cell carcinoma sample; somatic mutation).
HGSNAT	104	104	C -> F (in MPS3C; results in a negligible amount of protein synthesis and very low enzyme activity; retained in the endoplasmic reticulum and loss of intralysosomal proteolytic cleavage).
HGSNAT	165	165	L -> P (in MPS3C; results in a negligible amount of protein synthesis and very low enzyme activity; retained in the endoplasmic reticulum).
HGSNAT	265	265	P -> Q (does not have any clinical significance; does not influence neither stability, nor activity, nor cellular localization of the enzyme).
HGSNAT	280	280	I -> R (in MPS3C).
HGSNAT	290	290	G -> R (in MPS3C; results in a negligible amount of protein synthesis and very low enzyme activity; retained in the endoplasmic reticulum).
HGSNAT	301	301	N -> K (in MPS3C; retained in the endoplasmic reticulum and loss of enzymatic activity).
HGSNAT	311	311	P -> L (in MPS3C; results in a negligible amount of protein synthesis and very low enzyme activity; retained in the endoplasmic reticulum).
HGSNAT	372	372	R -> C (in MPS3C; results in a negligible amount of protein synthesis and very low enzyme activity; retained in the endoplasmic reticulum).
HGSNAT	372	372	R -> H (in MPS3C; Retained in the endoplasmic reticulum and loss of enzymatic activity).
HGSNAT	431	431	W -> C (in MPS3C; associated with T-643 on the same allele in a MPS3C patient; results in a negligible amount of protein synthesis and very low enzyme activity; retained in the endoplasmic reticulum).
HGSNAT	452	452	G -> S (in MPS3C; results in a negligible amount of protein synthesis and very low enzyme activity; retained in the endoplasmic reticulum).
HGSNAT	499	499	E -> K (in MPS3C; results in a negligible amount of protein synthesis and very low enzyme activity; retained in the endoplasmic reticulum).
HGSNAT	509	509	V -> L (does not have any clinical significance; no loss of enzymatic activity).
HGSNAT	510	510	M -> K (in MPS3C; results in a negligible amount of protein synthesis and very low enzyme activity; retained in the endoplasmic reticulum).
HGSNAT	514	514	G -> E (in MPS3C; results in a negligible amount of protein synthesis and very low enzyme activity; retained in the endoplasmic reticulum).
HGSNAT	517	517	A -> E (in MPS3C; results in a negligible amount of protein synthesis and very low enzyme activity; retained in the endoplasmic reticulum).
HGSNAT	546	546	S -> F (in MPS3C; results in a negligible amount of protein synthesis and very low enzyme activity; retained in the endoplasmic reticulum).
HGSNAT	551	551	K -> Q (does not have any clinical significance; no loss of enzymatic activity).
HGSNAT	567	567	S -> C (in MPS3C; results in a negligible amount of protein synthesis and very low enzyme activity; retained in the endoplasmic reticulum).
HGSNAT	569	569	S -> L (in MPS3C; results in a negligible amount of protein synthesis and very low enzyme activity).
HGSNAT	590	590	D -> V (in MPS3C; results in a negligible amount of protein synthesis and very low enzyme activity).
HGSNAT	599	599	P -> L (in MPS3C; results in a negligible amount of protein synthesis and very low enzyme activity).
HGSNAT	643	643	A -> T (associated with C-431 on the same allele in a MPS3C patient; does not have any clinical significance; has a negligible effect on the enzyme expression; no loss of enzymatic activity).
SNAI2	119	119	D -> E (in a patient with neural tube defects).
NPBWR1	19	19	P -> Q (in a breast cancer sample; somatic mutation).
SOX17	17	17	Q -> QTQ (in VUR3).
SOX17	178	178	G -> C (in VUR3).
SOX17	259	259	Y -> N (in VUR3; increased levels of the mutant protein that is associated with increased suppression of CTNNB1 signaling of the Wnt pathway compared to wild- type).
MOS	123	123	A -> T (in a lung adenocarcinoma sample; somatic mutation).
CYP7A1	100	100	F -> S.
CA8	100	100	S -> P (in CMARQ3; affects protein stability owing to accelerated proteasomal degradation).
TTPA	59	59	R -> W (in AVED).
TTPA	101	101	H -> Q (in AVED).
TTPA	120	120	A -> T (in AVED).
TTPA	141	141	E -> K (in AVED).
TTPA	246	246	G -> R (in AVED; mild and slowly progressive form of the disease).
GDAP1	120	120	R -> Q (in CMT4A).
GDAP1	161	161	R -> H (in CMT4A).
GDAP1	310	310	R -> Q (in CMT2RV).
PEX2	55	55	E -> K (in IRD).
FABP4	23	23	E -> D (in a breast cancer sample; somatic mutation).
PSKH2	116	116	S -> I (in a lung adenocarcinoma sample; somatic mutation).
PSKH2	212	212	K -> I (in a lung adenocarcinoma sample; somatic mutation).
TMEM67	54	54	Y -> C (in MKS3; uncertain pathogenicity).
TMEM67	82	82	P -> R (in a patient with Joubert syndrome related disorder without clinically apparent liver disease).
TMEM67	82	82	P -> S (in a patient with Joubert syndrome related disorder without clinically apparent liver disease).
TMEM67	99	99	K -> N (in COACHS).
TMEM67	130	130	P -> R (in COACHS).
TMEM67	172	172	R -> Q (in COACHS).
TMEM67	218	218	G -> A.
TMEM67	242	242	N -> T (in COACHS).
TMEM67	245	245	S -> F (in MKS3; uncertain pathogenicity).
TMEM67	252	252	M -> T (in MKS3 and COACHS; also in a patient with overlaping clinical features with JBTS6).
TMEM67	257	257	M -> V (in COACHS).
TMEM67	261	261	D -> N.
TMEM67	290	290	W -> L (in NPHP11).
TMEM67	296	296	W -> C (in MKS3; uncertain pathogenicity).
TMEM67	320	320	S -> C (is a modifier of Bardet-Biedl syndrome).
TMEM67	349	349	L -> S (in COACHS).
TMEM67	358	358	P -> L (in COACHS).
TMEM67	372	372	T -> K (in COACHS).
TMEM67	376	376	Q -> E (in COACHS).
TMEM67	376	376	Q -> P (in MKS3; leads to endoplasmic reticulum retention and prevents localization at the cell membrane).
TMEM67	437	437	L -> V.
TMEM67	440	440	R -> Q (in MKS3 and COACHS).
TMEM67	441	441	R -> C (in COACHS).
TMEM67	485	485	P -> S (in COACHS).
TMEM67	513	513	Y -> C (in JBTS6, MKS3 and COACHS).
TMEM67	545	545	G -> E (in JBTS6).
TMEM67	590	590	F -> S (in COACHS).
TMEM67	615	615	C -> R (in MKS3, COACHS and NPHP11).
TMEM67	637	637	F -> L (in COACHS).
TMEM67	728	728	S -> G (in COACHS).
TMEM67	782	782	H -> R (in COACHS).
TMEM67	820	820	R -> S (in COACHS).
TMEM67	821	821	G -> R (in NPHP11).
TMEM67	821	821	G -> S (in NPHP11).
TMEM67	833	833	I -> T (in COACHS; also in a patient with overlaping clinical features with JBTS6).
TMEM67	841	841	Q -> P (in COACHS).
TMEM67	942	942	F -> C (in COACHS).
TMEM67	966	966	L -> P (in MKS3).
PDP1	284	284	Missing (in PDP deficiency; low activity).
GDF6	42	42	G -> V (in KFS1).
GDF6	119	119	Q -> R (in MCOP4).
GDF6	199	199	A -> T (found in a patient with microphthalmia isolated with coloboma type 6 carrying a mutation in GDF3).
GDF6	216	216	D -> G (in MCOP4).
GDF6	249	249	A -> E (in KFS1 and MCOP4).
GDF6	253	253	Q -> L (in MCOP4).
GDF6	289	289	L -> P (in KFS1).
GDF6	327	327	P -> H (in MCOP4).
GDF6	424	424	K -> R (in KFS1).
POP1	675	675	E -> Q (in a breast cancer sample; somatic mutation).
RRM2B	64	64	W -> R (in MTDPS8A).
RRM2B	85	85	Missing (in MTDPS8A).
RRM2B	110	110	R -> H (in MTDPS8B).
RRM2B	115	115	V -> L (in colorectal adenocarcinomas cell line; loss of ribonucleotide reductase activity).
RRM2B	121	121	R -> H (in MTDPS8B).
RRM2B	194	194	E -> G (in MTDPS8A).
RRM2B	194	194	E -> K (in MTDPS8A).
RRM2B	224	224	I -> S (in MTDPS8A; without tubulopathy).
RRM2B	236	236	C -> F (in MTDPS8A).
RRM2B	282	282	M -> I (in MTDPS8A; without tubulopathy).
RRM2B	317	317	L -> V (in MTDPS8A; without tubulopathy).
ODF1	219	227	Missing.
DPYS	68	68	T -> R (in DHPD).
DPYS	334	334	Q -> R (in DHPD).
DPYS	360	360	W -> R (in DHPD).
DPYS	435	435	G -> R (in DHPD).
DPYS	490	490	R -> T (in DHPD).
RAD21	481	481	G -> R.
TNFRSF11B	182	182	Missing (in JPD).
ZNF572	512	512	C -> F (in a colorectal cancer sample; somatic mutation).
TRIB1	371	371	F -> L (in a lung large cell carcinoma sample; somatic mutation).
MYC	39	39	E -> D (in a Burkitt lymphoma symple).
MYC	57	57	P -> S (in a Burkitt lymphoma sample).
MYC	59	59	P -> A (in a Burkitt lymphoma sample).
MYC	86	86	N -> T (in a Burkitt lymphoma sample).
SLURP1	15	15	W -> R (in MDM; no expression of the protein).
SLURP1	71	71	R -> H (in MDM; reduced expression of the protein).
SLURP1	77	77	C -> R (in MDM).
SLURP1	99	99	C -> Y (in MDM).
CYP11B1	42	42	P -> S (in AH4; non-classic).
CYP11B1	94	94	P -> L (in AH4).
CYP11B1	133	133	N -> H (in AH4; non-classic).
CYP11B1	318	318	T -> M (in AH4).
CYP11B1	318	318	T -> R (in AH4).
CYP11B1	319	319	T -> M (in AH4; non-classic).
CYP11B1	374	374	R -> Q (in AH4).
CYP11B1	379	379	G -> V (in AH4).
CYP11B1	454	454	R -> C (in AH4).
CYP11B1	494	494	F -> C.
CYP11B2	140	140	N -> NRL (in CMO-1 deficiency; the enzyme is inactive).
CYP11B2	185	185	T -> I (in CMO-2 deficiency).
CYP11B2	198	198	E -> D (in CMO-2 deficiency).
CYP11B2	461	461	L -> P (in CMO-1 deficiency; abolishes the 18-hydroxylase activity required for conversion of 11-deoxycorticosterone to aldosterone).
CYP11B2	498	498	T -> A (in CMO-2 deficiency).
GPIHBP1	56	56	G -> R (no discernible effect on the binding of LPL, chylomicrons or APOA5).
GPIHBP1	115	115	Q -> P (in a patient with chylomicronemia; does not affect expression of the protein at the cell surface; cannot bind LPL or chylomicrons).
PLEC	429	429	L -> LL (in MD-EBS).
PLEC	1003	1005	Missing (in MD-EBS).
PLEC	2110	2110	R -> W (in O-EBS).
CYC1	89	89	L -> V.
SLC39A4	84	84	P -> L (in AEZ; could be a polymorphism).
SLC39A4	95	95	R -> C (in AEZ).
SLC39A4	106	106	N -> K (in AEZ).
SLC39A4	200	200	P -> L (in AEZ).
SLC39A4	303	303	Q -> H (in AEZ).
SLC39A4	309	309	C -> Y (in AEZ; could be a polymorphism).
SLC39A4	330	330	G -> D (in AEZ).
SLC39A4	372	372	L -> P (in AEZ).
SLC39A4	374	374	G -> R (in AEZ).
SLC39A4	410	410	L -> P (in AEZ; could be a polymorphism).
SLC39A4	526	526	G -> R (in AEZ).
SLC39A4	630	630	G -> R (in AEZ).
FOXH1	113	113	S -> T (in colorectal cancer).
FOXH1	125	125	T -> S (in colorectal cancer).
RECQL4	355	355	R -> Q.
RECQL4	441	441	P -> S.
RECQL4	523	523	S -> T.
RECQL4	857	858	Missing.
RECQL4	1021	1021	R -> W (in BGS).
